<SEC-DOCUMENT>0001104659-22-115489.txt : 20221107
<SEC-HEADER>0001104659-22-115489.hdr.sgml : 20221107
<ACCEPTANCE-DATETIME>20221107171146
ACCESSION NUMBER:		0001104659-22-115489
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		30
FILED AS OF DATE:		20221107
DATE AS OF CHANGE:		20221107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COGNITION THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001455365
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268228
		FILM NUMBER:		221366401

	BUSINESS ADDRESS:	
		STREET 1:		2403 SIDNEY STREET
		STREET 2:		SUITE 261
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		412-481-2210

	MAIL ADDRESS:	
		STREET 1:		2500 WESTCHESTER AVE
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COGNITION THERAPUTICS INC
		DATE OF NAME CHANGE:	20090204
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>tm2226999-3_drsa.htm
<DESCRIPTION>S-1
<TEXT>
<html>
  <head>
    <title>tm2226999-3_drsa - none - 18.3437734s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.17pt;">As filed with the Securities and Exchange Commission on November 7, 2022.</font>
        </div>
        <div style="margin-left:20pt; margin-top:1.2pt; text-align:right; width:521.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.17pt;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font>&#8203;</div>
        <div style="margin-top:2.033pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.03333333333333pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.2pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.2pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.7pt; text-align:center; width:541.31pt; line-height:17pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">UNITED STATES</font>
          <br >
          <font style="letter-spacing:-0.32pt;">SECURITIES AND EXCHANGE COMMISSION</font>
        </div>
        <div style="margin-top:1.2pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.17pt;">Washington, D.C. 20549</font><font style="font-weight:normal;letter-spacing:0.17pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541.31pt; line-height:17pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">FORM S-1</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:1.2pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.17pt;">REGISTRATION STATEMENT</font>
          <br >
          <font style="letter-spacing:-0.17pt;">UNDER </font>
          <br >
          <font style="letter-spacing:-0.17pt;">THE SECURITIES ACT OF 1933</font><font style="font-weight:normal;letter-spacing:0.17pt;"> </font>
        </div>
        <div style="margin-top:8.533pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 8.53333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:8.7pt; text-align:center; width:541.31pt; line-height:17pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">COGNITION THERAPEUTICS, INC.</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:1.2pt; text-align:center; width:541.31pt; line-height:8pt;font-size:7pt;">
          <font style="letter-spacing:0.14pt;">(Exact name of registrant as specified in its charter)</font><font style="font-size:8.5pt;">&#8203;<font style="letter-spacing:0.17pt;"> </font></font>
        </div>
        <div style="margin-top:8.523pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 8.52333333333334pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:541.31pt;margin-top:4.69999999999999pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
          <tr style="line-height:9.5pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;font-weight:bold;font-size:8.5pt;">
                <font style="letter-spacing:-0.17pt;">Delaware </font>
              </div>
              <div style="margin-top:1pt; text-align:center; line-height:8pt;">
                <font style="letter-spacing:0.14pt;">(State or other jurisdiction of</font>
                <br >
                <font style="letter-spacing:0.14pt;">incorporation or organization)</font><font style="font-size:8.5pt;">&#8203;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;font-weight:bold;font-size:8.5pt;">
                <font style="letter-spacing:-0.17pt;">2836</font>
              </div>
              <div style="margin-top:1pt; text-align:center; line-height:8pt;">
                <font style="letter-spacing:0.14pt;">(Primary Standard Industrial</font>
                <br >
                <font style="letter-spacing:0.14pt;">Classification Code Number)</font><font style="font-size:8.5pt;">&#8203;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.43pt;">
              <div style="text-align:center;font-weight:bold;font-size:8.5pt;">
                <font style="letter-spacing:-0.17pt;">13-4365359</font>
              </div>
              <div style="margin-top:1pt; text-align:center; line-height:8pt;">
                <font style="letter-spacing:0.14pt;">(I.R.S. Employer</font>
                <br >
                <font style="letter-spacing:0.14pt;">Identification Number)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.17pt;">2500 Westchester Ave.</font>
          <br >
          <font style="letter-spacing:-0.17pt;">Purchase, NY 10577</font>
          <br >
          <font style="letter-spacing:-0.17pt;">(914) 221-6741 </font>
        </div>
        <div style="margin-top:1.19pt; text-align:center; width:541.31pt; line-height:8pt;font-size:7pt;">
          <font style="letter-spacing:0.14pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font><font style="font-size:8.5pt;">&#8203;<font style="letter-spacing:0.17pt;"> </font></font>
        </div>
        <div style="margin-top:8.533pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 8.53333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.7pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.17pt;">Lisa Ricciardi</font>
          <br >
          <font style="letter-spacing:-0.17pt;">President and Chief Executive Officer</font>
          <br >
          <font style="letter-spacing:-0.17pt;">Cognition Therapeutics, Inc.</font>
          <br >
          <font style="letter-spacing:-0.17pt;">2500 Westchester Ave.</font>
          <br >
          <font style="letter-spacing:-0.17pt;">Purchase, NY 10577</font>
          <br >
          <font style="letter-spacing:-0.17pt;">(914) 221-6741 </font>
        </div>
        <div style="margin-top:1.19pt; text-align:center; width:541.31pt; line-height:8pt;font-size:7pt;">
          <font style="letter-spacing:0.14pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font><font style="font-size:8.5pt;">&#8203;<font style="letter-spacing:0.17pt;"> </font></font>
        </div>
        <div style="margin-top:8.533pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 8.5333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.7pt; text-align:center; width:541.31pt; line-height:9.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.17pt;">Copies to:</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.17pt;"> </font>
        </div>
        <table style="width:541.31pt;margin-top:5.19999999999999pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.17pt;">Rachael M. Bushey</font>
                <br >
                <font style="letter-spacing:-0.17pt;">Joseph Walsh</font>
                <br >
                <font style="letter-spacing:-0.17pt;">Troutman Pepper Hamilton Sanders LLP</font>
                <br >
                <font style="letter-spacing:-0.17pt;">3000 Two Logan Square</font>
                <br >
                <font style="letter-spacing:-0.17pt;">Philadelphia, Pennsylvania 19103</font>
                <br >
                <font style="letter-spacing:-0.17pt;">(215) 981-4331</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.65pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.17pt;">Stephen Older</font>
                <br >
                <font style="letter-spacing:-0.17pt;">David Wolpa</font>
                <br >
                <font style="letter-spacing:-0.17pt;">McGuireWoods LLP</font>
                <br >
                <font style="letter-spacing:-0.17pt;">1251 Avenue of the Americas, 20</font><font style=" position:relative; bottom:3.5pt;font-size:6.5pt;letter-spacing:-0.13pt;">th</font><font style="letter-spacing:-0.17pt;"> Floor</font>
                <br >
                <font style="letter-spacing:-0.17pt;">New York, New York 10020</font>
                <br >
                <font style="letter-spacing:-0.17pt;">(212) 548-2100</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.95pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:6.7pt; width:541.31pt; line-height:9.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.17pt;">Approximate date of commencement of proposed sale to the public:</font><font style="letter-spacing:0.17pt;"> As soon as practicable after the effective date of this Registration Statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.17pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933,&#160;check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.17pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.17pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.17pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.17pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </font>
        </div>
        <table style="width:501.31pt;height:30.39pt;margin-left:20pt;margin-top:5.18999999999994pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
          <tr style="line-height:8.5pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.66pt;">
              <div style=" float:left; line-height:8.5pt; text-align:left; width:96pt;white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Large accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8.5pt; text-align:left; margin-left:96pt;">
                <font style="letter-spacing:0.17pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.65pt;">
              <div style=" float:left; line-height:8.5pt; text-align:left; width:120pt;white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8.5pt; text-align:left; margin-left:120pt;">
                <font style="letter-spacing:0.17pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:244.66pt;">
              <div style=" float:left; line-height:8.5pt; text-align:left; width:96pt;white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Non-accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8.5pt; text-align:left; margin-left:96pt;">
                <font style="letter-spacing:0.17pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:244.65pt;">
              <div style=" float:left; line-height:8.5pt; text-align:left; width:120pt;white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Smaller reporting company</font>
                <br >
              </div>
              <div style=" line-height:8.5pt; text-align:left; margin-left:120pt;">
                <font style="letter-spacing:0.17pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.66pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.99pt 0pt 0.96pt 0pt; width:244.65pt;white-space:normal;">
              <div style=" float:left; line-height:8.5pt; text-align:left; width:120pt;white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Emerging growth company</font>
                <br >
              </div>
              <div style=" line-height:8.5pt; text-align:left; margin-left:120pt;">
                <font style="letter-spacing:0.17pt;">&#9746;</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7pt; width:541.31pt; line-height:9.5pt;">
          <font style="letter-spacing:0.17pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.17pt;">The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine.</font><font style="font-weight:normal;letter-spacing:0.17pt;"> </font>
        </div>
        <div style="margin-top:5.033pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 5.0333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.19pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.19000000000005pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow-x:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.83pt;left:48.66pt;height:30.02pt;width:706pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="text-align:justify; width:706pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;font-size:8pt;">
          <font style="letter-spacing:-0.08pt;">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.08pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:87.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;color:#FC0014;">
          <font style="letter-spacing:-0.2pt;">SUBJECT TO COMPLETION, DATED NOVEMBER&#160;7, 2022</font><font style="font-weight:normal;color:#000000;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-weight:bold;color:#FC0014;">
          <font style="letter-spacing:-0.2pt;">PRELIMINARY PROSPECTUS</font><font style="font-weight:normal;color:#000000;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:3.8pt; text-align:center; width:456pt;">
          <img src="lg_cognition-4c.jpg" alt="[MISSING IMAGE: lg_cognition-4c.jpg]" height="67" width="272" >
        </div>
        <div style="margin-top:7.5pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">5,586,592 Shares of Common Stock </font>
        </div>
        <div style="margin-top:10.977pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are offering 5,586,592 shares of our common stock at an assumed public offering price of $1.79 per share, which was the last reported sale price per share of our common stock on the Nasdaq Global Market on November&#160;4, 2022. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;CGTX.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein and may elect to comply with reduced public company reporting requirements in future filings. See &#8220;Prospectus Summary-Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our common stock involves risks. Before deciding whether to invest in our securities, you should consider carefully the risks that we have described on page <a href="#tRIFA">11</a> of this prospectus under the caption &#8220;Risk Factors&#8221; and under similar headings in other documents incorporated by reference into this prospectus.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:53.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:362pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per share</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:362pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:362pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Underwriting discounts and commissions</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:362pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds to us, before expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.51pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">We have agreed to reimburse the underwriters for certain expenses. See &#8220;Underwriting&#8221; on page <a href="#tUNDW">134</a> for additional information regarding underwriting compensation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have granted the underwriters an option for a period of 30&#160;days to purchase up to 837,988 additional shares of common stock on the same terms and conditions as set forth above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain of our affiliated stockholders, including certain of our directors and officers and entities affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of up to approximately $1,765,000 in shares of our common stock in this offering at the public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares in this offering to any or all of these stockholders, or any or all of these stockholders may determine to purchase more, fewer or no shares in this offering. The underwriters will receive the same underwriting discount on any shares purchased by these stockholders as they will on any other shares sold to the public in this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters expect to deliver the shares of our common stock against payment in New York, NY on or about&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2022. </font>
        </div>
        <div style="margin-top:17.7pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:14.91pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">Cantor</font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Co-Manager</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Newbridge Securities Corporation</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2022</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:70.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:248.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:0.2pt;">Prospectus Summary </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU">1</a></font> <a href="#tPRSU"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">Risk Factors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">11</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">Special Note Regarding Forward-Looking Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">62</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">Use of Proceeds </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">64</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIPO"><font style="letter-spacing:0.2pt;">Dividend Policy </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDIPO">65</a></font> <a href="#tDIPO"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCAP"><font style="letter-spacing:0.2pt;">Capitalization </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCAP">66</a></font> <a href="#tCAP"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIL"><font style="letter-spacing:0.2pt;">Dilution </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDIL">67</a></font> <a href="#tDIL"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMDAA"><font style="letter-spacing:0.2pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMDAA">69</a></font> <a href="#tMDAA"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tBUS"><font style="letter-spacing:0.2pt;">Business </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBUS">83</a></font> <a href="#tBUS"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">Description of Capital Stock </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOCS">124</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMUFI"><font style="letter-spacing:0.2pt;">Material U.S. Federal Income Tax Consequences to Non-U.S. Holders </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMUFI">130</a></font> <a href="#tMUFI"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUNDW"><font style="letter-spacing:0.2pt;">Underwriting </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUNDW">134</a></font> <a href="#tUNDW"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">Legal Matters </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">143</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">Experts </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">143</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">Where You Can Find Additional Information </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">143</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOCI"><font style="letter-spacing:0.2pt;">Incorporation of Certain Information by Reference </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOCI">144</a></font>
            </td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Cognition Therapeutics, Inc.&#8221; the &#8220;Cognition Therapeutics&#8221; logo and other trademarks, trade names or service marks of Cognition Therapeutics, Inc. appearing in this prospectus are the property of Cognition Therapeutics, Inc. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> and </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#8482;</font><font style="letter-spacing:0.2pt;"> symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus or any free writing prospectus we may provide to you in connection with this offering in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus and any such free writing prospectus outside the United States.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights information contained elsewhere in this prospectus. This summary is not complete and does not contain all of the information you should consider in making your investment decision. You should carefully read the entire prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. Unless the context otherwise requires, the terms &#8220;Cognition&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references in this prospectus refer to Cognition Therapeutics, Inc.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the sigma 2 receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our lead product candidate, CT1812, is an orally delivered, small molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. We have initially focused on the development of CT1812 for the treatment of Alzheimer&#8217;s disease, or AD, by targeting the accumulation of &beta;-amyloid, or A&beta;, oligomers, which has been linked to the disease. We believe our evidence demonstrates that by binding to the S2R complex, CT1812 displaces A&beta; oligomers from their neuronal receptors. Based on this mechanism, we believe CT1812 has the potential to slow the loss of synapses and cognitive decline observed in AD. CT1812 is the first S2R selective ligand modulator to reach clinical trials and is currently in Phase&#160;2 development for the treatment of AD. The direct healthcare costs to care for patients with AD and other dementias in the U.S. is currently estimated to exceed $300&#160;billion. Approximately 5.8&#160;million people in the U.S. have been diagnosed with AD, and the World Health Organization estimates that AD affects as many as 35&#160;million people globally. Among people with AD, approximately 50% have mild disease, 30% have moderate disease and 20% have severe disease. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are continuing to enroll patients in three ongoing Phase&#160;2 clinical trials with CT1812: SHINE and SEQUEL in mild-to-moderate AD and SHIMMER in dementia with Lewy bodies, or DLB. Preliminary results from an interim analysis of the first 24 patients in Part&#160;A of our ongoing SHINE Phase&#160;2 clinical trial demonstrated a statistically significant decline in the presence of A&beta; monomers and a positive trend on cognitive function as measured by the Alzheimer&#8217;s Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog, in patients receiving CT1812 compared to placebo. We anticipate completing enrollment in 2023 with top-line data in early 2024. Our ongoing SEQUEL Phase&#160;2 clinical trial is also evaluating changes in brain function, as measured by quantitative electroencephalography, or qEEG, in mild-to-moderate AD, and we anticipate completing enrollment in 2022 and reporting topline data thereafter. We have treated over 220 subjects with CT1812 in our clinical trials to date including 90 patients with mild-to-moderate AD. CT1812 has continued to be well tolerated and has been granted Fast Track designation by the U.S. Food and Drug Administration, or FDA, in this indication. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our clinical trials have been funded by approximately $171.0&#160;million in cumulative grants awarded primarily by the National Institute of Aging, or NIA, a division of the National Institutes of Health, or NIH, which includes a grant award of approximately $81.0&#160;million from the NIA to fund our Phase&#160;2 START (COG0203) study of CT1812 in patients with early stage AD. We intend to enroll 540 patients in our START trial with mild cognitive impairment, or MCI, due to AD or mild AD who have elevated levels of A&beta; oligomers as determined by a clinical diagnosis of AD confirmed with amyloid biomarkers positron emission tomography, or PET, imaging and/or cerebrospinal fluid, or CSF, biomarkers. Patients will be randomized to receive CT1812 or a placebo for 18&#160;months. In addition to cognitive and functional measures, such as the Clinical Dementia Rating Scale, or CDR, Sum of Boxes, or SB, and ADAS-Cog, we intend to </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">use a variety of biomarkers to measure target and/or pathway engagement and assess changes in neurodegeneration and disease progression. We are conducting this clinical trial in collaboration with the Alzheimer&#8217;s Clinical Trial Consortium, or ACTC, an NIA-funded clinical trials network designed to accelerate studies for therapeutics for AD and related dementias, and we expect to open sites by the end of 2022. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We intend to expand our CT1812 pipeline to include additional indications such as geographic atrophy, or GA, secondary to dry age-related macular degeneration, or dry AMD. GA is an advanced form of dry AMD. Dry AMD is an eye disease that results in the deterioration of the macula, causing distortion, loss of central vision and eventual blindness, for which there are currently no FDA approved treatments. The S2R complex is expressed in the retina in several cell types including the retinal pigment epithelial cells, or RPE, photoreceptors and retinal ganglion cells. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We have completed a pre-IND meeting with the FDA, and, after the completion of our ongoing preclinical studies, we intend to submit an Investigational New Drug, or IND, application to the FDA by the end of 2022, after which we plan to advance into a Phase&#160;2 clinical trial, leveraging our knowledge of CT1812&#8217;s preclinical and clinical profile to date. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition, we are developing other product candidates in the area of synucleinopathies. Synucleinopathies are a group of degenerative diseases characterized by the abnormal accumulation of the alpha-synuclein protein in neural cell bodies, including Parkinson&#8217;s disease, or PD, and DLB. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The following chart shows the developmental status of our clinical and preclinical product candidates, all of which are wholly owned: </font>
          </div>
          <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
            <img src="tm2226999d3-bc_pipe4c.jpg" alt="[MISSING IMAGE: tm2226999d3-bc_pipe4c.jpg]" height="265" width="608" >
          </div>
          <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">As of November&#160;1, 2022, our intellectual property portfolio contained nine issued U.S. patents, 65 issued foreign patents as well as one pending U.S. provisional application, four pending U.S. patent applications, two pending Patent Cooperation Treaty applications and 26 foreign pending patent applications directed to the composition of matter of, pharmaceutical compositions of, methods of use of, and methods for selecting subsets of patients for treatment with our chemical structures, including our lead CT1812. Our current issued patents relating to CT1812 are projected to begin to expire no earlier than 2035, with the composition of matter patent covering CT1812 set to naturally expire in 2035, subject to adjustment or extension of patent term available in a particular jurisdiction. We will likely be awarded Patent Term Extension, or PTE, when CT1812 is approved as a New Chemical Entity, or NCE, that will extend the term of the CT1812 composition of matter patent by up to five&#160;years, and we anticipate pursuing additional patents to further protect CT1812 and to further extend the patent term associated with CT1812. We expect </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">to file additional patent applications in support of current and new product candidates as well as new platform and core technologies. </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are the exclusive owner of six patent families that include several granted U.S. patents and pending U.S. patent applications, as well as granted patents and pending patent applications in numerous foreign jurisdictions, relating to compositions of matter and pharmaceutical compositions of CT1812, analogs of CT1812, and the use of CT1812 for the treatment in certain diseases, disorders and conditions including AD, dry AMD, PD, and synucleinopathies. </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The first of these patent families is directed to compositions of matter of CT1812, pharmaceutical compositions of CT1812, methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD, and we are the exclusive owner of this patent family in the United States and certain foreign jurisdictions, including Australia, Brazil, Canada, China, the European Union, Hong Kong, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, and South Africa. As of November&#160;1, 2022, this patent family includes granted patents claiming composition of matter of CT1812, pharmaceutical compositions of CT1812, methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD in the United States (three patents), Australia, China, the European Union, Hong Kong, India, Israel, Japan, New Zealand, Mexico, South Korea, Russia and South Africa. This patent family also includes a pending U.S. patent application and pending application in certain foreign jurisdictions including Brazil, Canada, the European Union and Hong Kong. This patent family has a natural expiration date in 2035 subject to any adjustment or extension of patent term that may be available in in a particular jurisdiction such as PTE following approval of the New Drug Application, or NDA, in the United States or extension of patent term via a Supplementary Protection Certificate, or SPC, following European Medicines Agency, or EMA, marketing authorization. Upon approval of the NDA for CT1812 in the United States, the patents in this family claiming compositions of matter of CT1812, pharmaceutical compositions of CT1812, and methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD will be eligible to be listed in the FDA&#8217;s publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. These patents complement the regulatory exclusivity by providing the basis for an additional waiting period prior to the FDA&#8217;s approval of an abbreviated new drug application, or ANDA, or 505(b)(2) applicant. If an ANDA or 505(b)(2) applicant were to file its application referencing the NDA for CT1812 before expiration of our composition of matter, pharmaceutical composition, and method of use patents and the applicant asserted that our patents identified on the Orange Book to be invalid or not be infringed, it may be subject to additional waiting periods prior to the FDA&#8217;s approval (including a statutory 30-month stay if we sue for infringement, or a shorter period if the patent expires or there are certain settlements or judicial decisions in the patent litigation, starting at the end of the five-year NCE regulatory exclusivity period). </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In addition to patent exclusivity, under the provisions of the Hatch-Waxman Act, upon any approval in the United States, we believe that CT1812 will be eligible for five-year NCE regulatory exclusivity, during which time no 505(b)(2) NDA or ANDA can be approved that contains the same active moiety as the chemical entity in the CT1812 NDA. When approved in Europe, CT1812 will also be eligible for 10&#160;years of data and market exclusivity which is extendible for an additional year upon market authorization for one or more new indications during the first eight&#160;years of the data and market exclusivity period. </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We also own four families of pending patent applications directed to methods for selecting subsets of patients with AD for treatment with CT1812, methods of modulating amyloid beta monomer and oligomer levels using CT812, methods of treating dry AMD with CT1812 and methods of treating various neurologic diseases including PD and synucleinopathies with CT1812, as well as a pending provisional application directed to treating certain subsets of AD patients with CT1812. Any of these applications, if issued, will have a natural expiration between 2038 and 2043, subject to any adjustment or extension of patent term that may be available such as PTE following NDA approval in the United States as well as any term limitations based upon earlier expiring patents. </font>
          </div>
          <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Recent Events</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:9.62pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">AAIC</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In August&#160;2022, at the Alzheimer&#8217;s Association International Conference, or AAIC, we presented a proteomic analysis of clinical biomarker data from all participants enrolled in our SPARC study for whom end-of-study (at six&#160;months) and baseline CSF samples were available (n=18). The SPARC study (COG0105) </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">enrolled 23 individuals with mild-to-moderate AD who were randomized to receive oral once-daily treatment with CT1812 or placebo for six&#160;months. The analyses demonstrated the effect of CT1812 on multiple priority AD biomarkers, including YKL-40, a biomarker of inflammation, which is upregulated in AD. Participants treated with CT1812 exhibited a downward shift in YKL-40 towards levels observed in healthy, non-demented individuals, supporting a potential positive impact of CT1812 on disease biology. In addition, CT1812 had a significant impact on CSF levels of clusterin which has been identified as a genetic risk factor for AD by several independent, large-scale genome-wide association studies. We believe the analytic results support the proposed synaptoprotective mechanism of action of CT1812 and role in normalizing cellular processes known to be adversely disrupted in AD. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Preliminary Third Quarter Results</font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Preliminary unaudited operating results for the three and nine months ended September 30, 2022 and certain preliminary financial condition information as of September 30, 2022 are as follows: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Net loss for the three and nine months ended September 30, 2022 is expected to be approximately $6.6 million and $16.2 million, respectively.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The Company ended the third quarter with approximately $46.6 million in cash and cash equivalents and common shares outstanding of 23,969,497 at September 30, 2022. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The above information is preliminary financial information for the three and nine months ended September 30, 2022 and is subject to completion. The unaudited, estimated results for the three and nine months ended September&#160;30, 2022 are preliminary and were prepared by our management, based upon our estimates, a number of assumptions and currently available information, and are subject to revision based upon, among other things, quarter-end closing procedures and/or adjustments, the completion of our interim financial statements and other operational procedures. This preliminary financial information is the responsibility of management and has been prepared in good faith on a consistent basis with prior periods. However, we have not completed our financial closing procedures for the three and nine months ended September 30, 2022, and our actual results could be materially different from this preliminary financial information, which preliminary information should not be regarded as a representation by us, our management, or the underwriters as to our actual results for the nine months ended September 30, 2022. In addition, our independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures with respect to this preliminary financial information and does not express an opinion or any other form of assurance with respect to this preliminary financial information. During the course of the preparation of our financial statements and related notes as of and for the three and nine months ended September 30, 2022, we may identify items that would require us to make material adjustments to this preliminary financial information. As a result, prospective investors should exercise caution in relying on this information and should not draw any inferences from this information. This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with United States generally accepted accounting principles and reviewed by our auditors. See &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements.&#8221; </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our objectives are to develop and advance our portfolio, beginning with our lead product candidate, CT1812, through clinical development for the treatment of age-related degenerative diseases and disorders of the CNS and retina and to leverage our understanding of the S2R complex and its regulation of pathways to pursue indications in other degenerative disorders. The key elements of our strategy include: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Advance clinical development of our lead product candidate, CT1812, in mild-to-moderate AD and earlier stages of the disease</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our lead product candidate, CT1812, has progressed through Phase&#160;1 and into Phase&#160;2 clinical trials. Funding of the Phase&#160;1 and into Phase&#160;2 trials is primarily through the NIA. We are evaluating CT1812 in other AD populations as well and developing CT1812 for patients with earlier symptomatic stages of AD and MCI, which is a slight and noticeable measurable decline in cognitive abilities due to AD. Our START (COG0203) clinical trial in patients with mild dementia associated with early stage AD has been funded by a grant of approximately $81.0&#160;million awarded from the NIA. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Pursue the development of CT1812 for GA secondary to dry AMD</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We plan to evaluate CT1812 as a potential therapy for GA secondary to dry AMD, an advanced form of dry AMD. Dry AMD is an eye disease that results in the deterioration of the macula, causing visual distortion, loss of central vision and eventual blindness. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We have completed a pre-IND meeting with the FDA, and, after the completion of our ongoing preclinical studies, we intend to submit an IND application to the FDA by the end of 2022, after which we plan to advance into a Phase 2 clinical trial, leveraging our knowledge of CT1812&#8217;s preclinical and clinical profile to date. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Leverage our understanding of the S2R complex to develop product candidates for other CNS and degenerative diseases, including synucleinopathies</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We intend to develop and advance other product candidates to treat synucleinopathies, which include PD and DLB. We are initiating a study of CT1812 in patients with DLB and are currently recruiting for patients at approximately 18 sites, with more expected to follow. Data published in February&#160;2021 showed that the S2R complex may play an integral role in the pathology of PD and we believe these results merit further study in a well-controlled Phase&#160;2 clinical trial. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Expand our pipeline through internal development, in-licensing and acquisitions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We intend to leverage our expertise in drug development and business development to evaluate additional product candidates as well as bring forward novel chemical matter using our library generation and Novel Improved Conditioned Extraction screening platform. To achieve this objective, we may supplement our internal development initiatives through selective in-licensing arrangements, as well as investments in strategic collaborations, and partnerships which complement our initiatives. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Optimize the value of CT1812 and other product candidates in major markets.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We currently retain all worldwide rights to CT1812 for all indications. We plan to develop and pursue approval of CT1812 and other future product candidates in major markets. Where appropriate, we may use strategic collaborations or partnerships to accelerate development and maximize the commercial potential of our programs. We and our key opinion leaders believe CT1812 also can be used in combination with other therapeutics targeting AD biologies and thus may have many partnering opportunities. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Continue to pursue non-dilutive funding opportunities</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The majority of our research and clinical efforts have been funded by approximately $171.0&#160;million in cumulative grants awarded primarily by the NIA. This includes awards totaling $10.9&#160;million in support of preclinical studies and $160.1&#160;million for clinical development, the largest of which was the 2020 award of $81.0&#160;million supporting our upcoming Phase&#160;2 START (COG0203) study of CT1812 in early stage AD. These grants are non-dilutive and allow us to collaborate with research institutions in pursuing the development of our product candidates for age-related degenerative diseases. We intend to continue our work with these research institutions and plan to seek additional non-dilutive funding for our clinical development when possible. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risk Factor Summary</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our business and this offering are subject to numerous risks and uncertainties, including those in the section entitled &#8220;Risk Factors,&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, or our 2021 Annual Report, and in our Quarterly Reports on Form 10-Q for the quarters ended March&#160;31, 2022 and June&#160;30, 2022, or our 2022 Quarterly Reports, and in the other documents we file with the Securities and Exchange Commission, or the SEC, which are incorporated by reference in this prospectus. These risks include, but are not limited to, the following: </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to Our Financial Position and Capital Needs; Discovery, Development and Regulatory Approval of Our Product Candidates; and Business and Industry</font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We will need substantial additional capital to meet our financial obligations in the future and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company with no products approved for commercial sale and have incurred significant losses since our inception in 2007. We expect to incur significant losses over for the foreseeable future and may never achieve or maintain profitability. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We have not yet completed Phase&#160;2 clinical trials and have no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">To date, we have partially relied on non-dilutive grants to cover certain of our capital requirements for our clinical trials, and we may fail to continue to receive non-dilutive funding. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of CT1812 and any future product candidates that we may develop or acquire. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We have initially concentrated our research and development efforts on the treatment of AD, a disease that has seen limited success in drug development.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We may not successfully expand our pipeline of product candidates, including by pursuing additional indications for CT1812 or by in-licensing or acquiring additional product candidates for other diseases. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. We have not tested any of our product candidates in pivotal clinical trials and our product candidates may not have favorable results in future clinical trials.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We have conducted, and in the future plan to conduct, clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to Our Intellectual Property</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">If we are unable to obtain and maintain patent protection for our technology and product candidates including our lead product candidate, CT1812, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We may not be able to protect our intellectual property rights throughout the world.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Patent terms may be inadequate to protect our competitive position on our product candidates including our lead product candidate, CT1812, for an adequate amount of time.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our product candidates including our lead product candidate, CT1812.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We may become involved in lawsuits to protect or enforce our patents or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product including our lead product candidate, CT1812. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Related to Commercialization, Manufacturing and Reliance on Third Parties</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The market opportunities for CT1812, if approved, may be smaller than we anticipate.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business, financial condition, results of operations and prospects.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process that is more efficient and cost-effective to commercialize our potential products, which may not be successful.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We rely on third parties in the conduct of all of our clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those drugs and decrease our ability to generate revenue.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates, if approved, effectively in the United States and foreign jurisdictions or generate product revenue. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Relating to Government Regulation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">If we develop a small molecule product candidate that obtains regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Relating to Our Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Concentration of ownership of our common stock among our exiting officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Provisions in our charter documents and Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Relating to this Offering</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Purchasers of common stock in this offering will experience immediate accretion in the net tangible book value of their investment.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">A substantial number of shares of common stock may be sold in the market following this offering, which may depress the market price for our common stock.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We have broad discretion to determine how to use the funds raised in this offering, and may use them in ways that may not enhance our operating results or the price of our common stock. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
            <font style="letter-spacing:0.2pt;">We were incorporated under the laws of the State of Delaware on August&#160;21, 2007. Our principal executive offices are located at 2500 Westchester Ave., Purchase, NY 10577, and our telephone number is (914) 221-6741. Our corporate website address is </font><font style="font-style:italic;letter-spacing:0.2pt;">www.cogrx.com</font><font style="letter-spacing:0.2pt;">. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this prospectus or the registration statement of which it forms a part. We have included our website in this prospectus solely as an inactive textual reference. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company and a Smaller Reporting Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
            <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, enacted in April&#160;2012, and we will remain an emerging growth company until the earliest to occur of: the last day of the fiscal year in which we have more than $1.07&#160;billion in annual revenue; the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700.0&#160;million of equity securities held by non-affiliates; the issuance, in any three-year period, by us of more than $1.0&#160;billion in non-convertible debt securities; and December&#160;31, 2026. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
            <font style="letter-spacing:0.2pt;">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and in the filings we make with the SEC. As a result, the information that we provide to our stockholders may be different than the information you might receive from other public reporting companies that are not emerging growth companies. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
            <font style="letter-spacing:0.2pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies which may make comparison of our financial statements to those of other public companies more difficult. As a result of this election, the information that we provide in this prospectus may be different than the information you may receive from other public companies in which you hold equity interests. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
            <font style="letter-spacing:0.2pt;">We are also a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i)&#160;the market value of our voting and non-voting common stock held by non-affiliates is less than $250&#160;million measured on the last business day of our second fiscal quarter or (ii)&#160;our annual revenue is less than $100&#160;million during the most recently completed fiscal year and the market value of our voting and non-voting common stock held by non-affiliates is less than $700&#160;million measured on the last business day of our second fiscal quarter. Specifically, as a smaller reporting company, we may choose to present only the two </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">most recent fiscal&#160;years of audited financial statements in our annual reports on Form 10-K and have reduced disclosure obligations regarding executive compensation, and, similar to emerging growth companies, if we are a smaller reporting company with less than $100&#160;million in annual revenue, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Common stock to be offered </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">5,586,592 shares </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Common stock to be outstanding after this offering </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">29,557,634 shares, or 30,395,622 shares if the underwriters exercise their option to purchase additional shares in full. </font>
          </div>
          <div style="width:168pt;">
            <div style="white-space:nowrap; margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Option to purchase additional </font>
              <br >
              <font style="letter-spacing:0.2pt;">shares </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We have granted the underwriters an option for a period of 30&#160;days to purchase up to 837,988 additional shares of our common stock from us at the public offering price, less the underwriting discounts and commissions. The number of shares subject to the underwriters&#8217; option will equal 15% of the total number of shares of common stock we are offering. </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of proceeds </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We estimate the net proceeds from this offering will be approximately $9.1 million (or approximately $10.6 million if the underwriters exercise in full their option to purchase up to 837,988 additional shares of common stock), after deducting underwriting discounts and commissions, estimated offering expenses payable by us. We intend to use the net proceeds from this offering for clinical development of our product candidates and for working capital and general corporate purposes. See &#8220;Use of Proceeds&#8221; on page <a href="#tUOP">64</a> of this prospectus. </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Lock-up restrictions </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We, each of our directors and officers, and certain of our affiliated stockholders are subject to certain lock-up restrictions as identified in the section titled &#8220;Underwriting&#8201;&#8212;&#8201;No Sale of Similar Securities.&#8221; </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk factors </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">You should read the section entitled &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">11</a> and the documents incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in our common stock. </font>
          </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Nasdaq Global Market symbol </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;CGTX&#8221;</font>
          </div>
          <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The number of shares of our common stock to be outstanding after this offering is based on 22,597,907 shares of common stock outstanding as of June&#160;30, 2022, and excludes: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">3,350,614 shares of our common stock issuable upon the exercise of outstanding stock options as of June&#160;30, 2022, with a weighted-average exercise price of $3.02 per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">2,350,068 shares of our common stock reserved for future issuance under our 2021 Equity Incentive Plan, or 2021 Plan, plus any future increases in the number of shares of common stock reserved for issuance; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">209,532 shares of our common stock reserved for future issuance under our Employee Stock Purchase Plan, or ESPP, plus any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for issuance under our ESPP. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Except otherwise indicated, the information in this prospectus assumes no exercise of the outstanding options and no exercise by the underwriters of their option to purchase additional shares of our common stock.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, and those discussed under the section entitled &#8220;Risk Factors&#8221; contained in our 2021 Annual Report and our 2022 Quarterly Reports, together with other information in this prospectus, the information and documents incorporated by reference herein, and in any free writing prospectus that we have authorized for use in connection with this offering. The occurrence of any of the events or developments described below could materially and adversely affect our business, financial condition, results of operations and prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Financial Position and Capital Needs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are a clinical-stage biopharmaceutical company with no products approved for commercial sale and have incurred significant losses since our inception in 2007. We expect to incur significant losses over the foreseeable future and may never achieve or maintain profitability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since our inception, we have incurred significant net losses, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses were $11.7&#160;million and $7.8&#160;million for the&#160;years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $94.0&#160;million. Our net losses were $9.6&#160;million and $1.3&#160;million for the six&#160;months ended June&#160;30, 2022 and 2021, respectively. As of June&#160;30, 2022, we had an accumulated deficit of $103.6&#160;million. Our clinical trials have been funded by approximately $171.0&#160;million in cumulative nondilutive grants, awarded primarily by the National Institute of Aging, or NIA, a division of the National Institutes of Health. On October&#160;13, 2021, we closed our initial public offering, or IPO, whereby we received net proceeds of $37.9&#160;million, excluding net proceeds from the overallotment exercise. On November&#160;12, 2021, we received $6.3&#160;million of net proceeds resulting from the exercise of the overallotment option. We have no products approved for commercialization and have never generated any revenue from product sales. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have devoted substantially all of our financial resources and efforts to the development of our product candidates, including conducting preclinical studies and clinical trials. We expect to continue to incur significant expenses and operating losses over the next several&#160;years. We expect that it could be several&#160;years, if ever, before we have a commercialized product. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially for the foreseeable future as we: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conduct our ongoing and planned clinical trials of CT1812, as well as initiate and complete additional clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">pursue regulatory approval of CT1812 for the treatment of mild-to-moderate Alzheimer&#8217;s disease, or AD, dry age-related macular degeneration, or dry AMD, and Parkinson&#8217;s disease, or PD, and dementia with Lewy bodies, or DLB, and other age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seek to discover and develop additional clinical and preclinical product candidates using Novel Improved Conditioned Extraction, or NICE, screening platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintain, expand and protect our intellectual property portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">hire additional clinical, manufacturing and scientific personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">incur additional legal, accounting and other expenses in operating as a public company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">scale up our clinical and regulatory capabilities; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establish a commercialization infrastructure and scale up external manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval, including CT1812. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To become and remain profitable, we must succeed in developing and eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval, and manufacturing, marketing and selling any product candidates for which we may obtain regulatory approval, as well as discovering and developing additional product candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate any revenue or revenue that is significant enough to achieve profitability. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have not yet completed Phase&#160;2 clinical trials and have no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We commenced operations in 2007, and our operations to date have been largely focused on developing our clinical and preclinical product candidates and our Novel, Improved Conditioned Extraction, or NICE, screening platform. To date, we have not yet demonstrated our ability to successfully complete pivotal clinical trials, obtain regulatory approvals, manufacture a product on a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We may also need to transition from a company with a research focus to a company capable of supporting commercial activities. Our inability to adequately address these risks and difficulties or successfully make such a transition could adversely affect our business, financial condition, results of operations and growth prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We will need substantial additional capital to meet our financial obligations in the future and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our operations have required substantial amounts of capital since inception, and we expect our expenses to increase significantly in the foreseeable future. Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. We expect to continue to incur significant expenses and operating losses over the next several&#160;years as we complete our ongoing clinical trials of our product candidates, initiate future clinical trials of our product candidates, seek marketing approval for CT1812 for the treatment of age-related degenerative diseases and disorders of the CNS and retina, such as AD, dry AMD, PD and DLB, and advance any of our other product candidates we may develop or otherwise acquire. In addition, our product candidates, if approved, may not achieve commercial success. Our revenue, if any, will be derived from sales of products that we do not expect to be commercially available for the foreseeable future, if at all. If we obtain marketing approval for CT1812 or any other product candidates that we develop or otherwise acquire, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. We also expect an increase in our expenses associated with creating additional infrastructure to support operations as a public company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of June&#160;30, 2022, we had $45.8&#160;million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents and income from our non-dilutive grants, will be sufficient for us to fund our operating expenses and capital expenditures requirements into the first half of 2024. We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including, but not limited to: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, progress, costs and results of our ongoing and planned clinical trials of CT1812, as well as the associated costs, including any unforeseen costs we may incur as a result of preclinical study or clinical trial delays due to supply chain disruptions or other delays; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, progress, costs and results of preclinical development, laboratory testing and clinical trials for any future product candidates we may decide to pursue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent to which we develop, in-license or acquire other product candidates and technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs we advance them through preclinical and clinical development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability, timing and receipt of any future non-dilutive grants from the NIA, or NIA Grants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number and development requirements of other product candidates that we may pursue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs, timing and outcome of regulatory review of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to establish collaborations to commercialize CT1812 or any of our other product candidates outside the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the additional costs we may incur as a result of operating as a public company, including our efforts to enhance operational systems and hire additional personnel, including enhanced internal controls over financial reporting. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe the net proceeds from this offering will not be sufficient to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of CT1812 and our product candidates. If we receive regulatory approval for any of these product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Further, our ability to raise additional capital may be adversely impacted by recent volatility in the equity markets in the United States and worldwide. If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our growth strategy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">To date, we have partially relied on non-dilutive grants to cover certain of our capital requirements for our clinical trials, and we may fail to continue to receive non-dilutive funding.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To date, we have partially relied on the availability of NIA Grants. Although we have applied for and currently anticipate receiving additional NIA Grants, we cannot be certain that our grant applications will be successful, that additional NIA Grants will be made available to support our clinical trials or that we will continue to satisfy the award criteria of prior NIA Grants that have already been awarded to us. If we fail to continue to receive NIA Grants, our ability to continue our clinical programs for CT1812 may be impaired and delayed, and we may otherwise need to seek additional financing through dilutive methods, such as through equity or debt financings. Such dilutive financings could have an adverse effect on the price of our common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We could be subject to audit and repayment of our non-dilutive NIA Grants.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, in connection with the NIA Grants, we may be subject to routine audits by certain government agencies. As part of an audit, these agencies may review our performance, cost structures and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIA Grant. If any of our expenditures are found to be unallowable or allocated improperly or if we have otherwise violated terms of such NIA Grant, the expenditures may not be reimbursed and/or we may be required to repay funds already disbursed. Any audit by the NIA could require significant financial and management resources and may result in a material adjustment to our results of operations and financial condition and harm our ability to operate in accordance with our business plan. Additionally, negative results in any of our ongoing and planned clinical trials of CT1812 that are funded with NIA Grants may result in our failure to receive additional NIA Grants to fund future clinical trials. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Due to the significant resources required for the development of our product candidates, we must prioritize development of certain product candidates and/or certain disease indications. We may expend our limited resources on candidates or indications that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. We may also reprioritize development of certain product candidates and/or certain disease indications due to limited resources.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are currently focused on developing product candidates to address age-related degenerative diseases and disorders of the CNS and retina. We seek to maintain a process of prioritization and resource allocation among our programs to maintain a balance between aggressively advancing our lead product candidate, CT1812, in identified indications and exploring additional indications or mechanisms as well as developing future product candidates. However, due to the significant resources required for the development of our product candidates, we must focus on specific diseases and disease pathways and decide which product candidates to pursue from time to time and the amount of time and resources to allocate to each such product candidate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, any decision to delay, terminate or collaborate with third parties with respect to certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the market of age-related degenerative diseases and disorders of the CNS and retina or pharmaceutical, biopharmaceutical or biotechnology industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing and cost of, and level of investment in, research, development and, if approved, commercialization activities relating to our product candidates, which may change from time to time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing and status of enrollment for our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of manufacturing our product candidates, as well as building out our supply chain, which may vary depending on the quantity of production and the terms of our agreements with manufacturers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability, timing, and receipt of any future NIA Grants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">future accounting pronouncements or changes in our accounting policies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing of receipt of approvals for our product candidates from regulatory authorities in the United States and internationally; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the level of demand for our product candidates, if approved, which may vary significantly over time. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Discovery, Development and Regulatory Approval of Our Product Candidates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business is heavily dependent on the successful development, regulatory approval and commercialization of CT1812 and any future product candidates that we may develop or acquire.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently have no products approved for sale, and our lead product candidate is in early stages of clinical development. The success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates and, in particular, the advancement of CT1812, currently our only clinical-stage product candidate. However, given our stage of development, it may be many&#160;years, if we succeed at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization. We cannot be certain that our product candidates will receive regulatory approval or be successfully commercialized even if we receive regulatory approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The clinical and commercial success of CT1812 and any future product candidates that we may develop or acquire will depend on a number of factors, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to raise any additional required capital on acceptable terms, or at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to complete an investigational new drug application, or IND, enabling studies and successfully submit INDs or comparable applications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays or difficulties in enrolling and retaining patients in our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether we are required by the U.S. Food and Drug Administration, or FDA, or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our product candidates or any future product candidates or approved products, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability of third parties with whom we contract to manufacture adequate clinical trial and commercial supplies of our product candidates or any future product candidates remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMPs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the convenience of our treatment or dosing regimen; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or any future product candidates, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">supply chain disruptions, which may result in clinical site closures, delays to patient enrollment or changes to trial protocols; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">patient demand for our product candidates, if approved, including patients&#8217; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the FDA or other regulatory agencies may not agree with our clinical development plan and require that we conduct additional clinical trials to support our regulatory submissions. We have not yet conducted an end of Phase&#160;2 meeting with the FDA to discuss the registration pathway for CT1812, and our current clinical development plans for CT1812 in mild-to-moderate AD may change as a result of future interactions with the FDA. For example, the FDA may not accept the results of the ongoing CT1812 clinical trials and may require that we conduct additional trials, including more than one pivotal trial, in order to gain approval in AD. Furthermore, any approval of CT1812 for AD may be limited to CT1812 in combination with the existing standard of care. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates. Even if regulatory </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">approvals are obtained, we may never be able to successfully commercialize any of our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business or achieve profitability. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not successfully expand our pipeline of product candidates, including by pursuing additional indications for CT1812 or by in-licensing or acquiring additional product candidates for other diseases.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A key element of our strategy is to build and expand our pipeline of product candidates, including by developing CT1812 for the treatment of dry AMD and age-related degenerative diseases and disorders of the CNS beyond indications in AD, and by identifying other product candidates using our NICE platform. In addition, we may in-license or acquire additional product candidates for other diseases. We may not be able to identify or develop additional product candidates that are safe, tolerable and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify, in-license or acquire may not be suitable for clinical development. For example, our research methodology may be unsuccessful in identifying potential drug candidates or those we identify may be shown to have harmful side effects or other characteristics that make them unmarketable or unlikely to receive regulatory approval. We have devoted significant resources to discovery efforts through our proprietary NICE platform, and we cannot guarantee that we will be successful in identifying additional potential drug candidates, or that we will be able to successfully identify and in-license new and valuable product candidates from other parties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and development of pharmaceuticals is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are at an early stage of clinical development of our only clinical stage product candidate, CT1812. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our product candidates may not successfully complete preclinical studies or clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it does not meet applicable regulatory criteria; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our competitors may develop therapeutics that render our product candidates obsolete or less attractive; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any of these events occur, we may be forced to abandon our development efforts for a product candidate or candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Failure of a product candidate may occur at any stage of preclinical or clinical development, and we may never succeed in developing marketable products or generating product revenue. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may not be successful in our efforts to further develop our current and future product candidates. Each of our product candidates will require significant clinical development, management of preclinical, clinical and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization and significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical studies that we may conduct may not be acceptable to the FDA or other regulatory authorities or demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical significance or if there are safety </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, to obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our product candidates. We may also rely on collaborators or partners to conduct the required activities to support an application for regulatory approval and to seek approval for one or more of our product candidates. We cannot be sure that any such collaborators or partners will conduct these activities successfully or do so within the timeframe we desire. Even if we or any future collaborators or partners are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may encounter substantial delays in our preclinical studies and clinical trials or may not be able to conduct or complete our preclinical studies or clinical trials on the timelines we expect, if at all.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Clinical trials are expensive and can take many&#160;years to complete, and the outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage and our future clinical trials may not be successful. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">supply chain disruptions, which may result in clinical site closures, delays to patient enrollment or changes to trial protocols; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in obtaining, or failure to obtain, regulatory authorization to commence a trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">imposition of a temporary or permanent clinical hold by the FDA or comparable foreign regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">identifying, recruiting and training suitable clinical investigators; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining institutional review board, or IRB, approval at each trial site; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">new safety findings that present unreasonable risk to clinical trial participants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a negative finding from an inspection of our clinical trial operations or study sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">recruiting an adequate number of suitable patients to participate in a trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">having subjects complete a trial or return for post-treatment follow-up; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">clinical sites deviating from trial protocol or dropping out of a trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">addressing subject safety concerns that arise during the course of a trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">adding a sufficient number of clinical trial sites; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining sufficient supply of product candidates for use in preclinical studies or clinical trials from third-party suppliers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials which could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials or require that we submit additional data or information before allowing a clinical trial to be initiated or continue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">clinical studies of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls or be unable to provide us with sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or a finding that the participants are being exposed to unacceptable health risks; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of clinical trials of our product candidates may be greater than we anticipate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulators may revise the requirements for approving our product candidates or such requirements may not be as we anticipate; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any future collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, we may: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">incur unplanned costs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtain marketing approval in some countries and not in others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">be subject to additional post-marketing testing requirements; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">have the product removed from the market after obtaining marketing approval. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may not be able to initiate or continue clinical trials on a timely basis or at all for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical power for a given trial. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; the severity and difficulty of diagnosing the disease under investigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the patient eligibility and exclusion criteria defined in the protocol; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the proximity of patients to trial sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">competition with other companies for clinical trial sites or patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the design of the trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the existing body of safety and efficacy data with respect to the study drug and safety concerns; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">patient referral practices of physicians; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">risk that enrolled subjects will drop out before completion of the trial, including as a result of contracting health conditions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ability to monitor patients adequately during and after treatment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">availability and efficacy of approved medications or therapies, or other clinical trials, for the disease or condition under investigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to obtain and maintain patient consents. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our product candidates may cause undesirable and unforeseen side effects or have other properties that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Adverse events or other undesirable side effects caused by our product candidates or related to procedures conducted as part of the clinical trials could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Results of our planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted or the Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, early clinical trials may only include a limited number of subjects and limited duration of exposure to our product candidates. In particular, we are pursuing a new approach to inhibiting the synaptic binding and signaling of soluble A&beta; oligomers through the use of small molecule receptor antagonists, like CT1812. As a result, our product candidates may cause unforeseen safety events when evaluated in larger patient populations. Further, clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any of our product candidates receives marketing approval, and we or others later identify undesirable and unforeseen side effects caused by such product, a number of potentially significant negative consequences could result, including but not limited to: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may be required to conduct additional clinical trials or post-approval studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may be required to recall a product or change the way such product is administered to patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we could be sued and held liable for harm caused to patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may be subject to fines, injunctions or the imposition of criminal penalties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the product may become less competitive; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our reputation may suffer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. We have not tested any of our product candidates in pivotal clinical trials and our product candidates may not have favorable results in future clinical trials.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Preclinical and clinical development is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain. We cannot guarantee that any preclinical studies or clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The results from preclinical studies or clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim, topline, or preliminary results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. In particular, while we have conducted certain Phase&#160;2 clinical trials of CT1812 targeting mild-to-moderate AD, we do not know whether CT1812 will perform in future clinical trials as it has performed in these prior trials. The positive results we have observed for CT1812 in past clinical trials may not be predictive of our ongoing and future clinical trials in humans. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. In addition, changes to the design of our current or future clinical trials may be necessary if there are new developments in the field of Alzheimer&#8217;s research. A number of companies in the biopharmaceutical, pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the foregoing reasons, we cannot be certain that any of our ongoing and planned preclinical studies or clinical trials will be successful or acceptable to the FDA or other regulatory authorities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interim &#8220;top-line&#8221; and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may publish interim &#8220;top-line&#8221; or preliminary data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data when we publish such data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have initially concentrated our research and development efforts on the treatment of AD, a disease that has seen limited success in drug development.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Efforts by biopharmaceutical and pharmaceutical companies in treating AD have seen limited success in drug development. Only one disease-modifying therapeutic option has been approved by the FDA. Biogen&#8217;s Aduhelm, a monoclonal antibody administered via infusion, received accelerated approval from the FDA on June&#160;7, 2021. We cannot be certain that our oral, small-molecule approach will lead to the development of approvable or marketable products. With the exception of Aduhelm, the only drugs approved by the FDA to treat patients with AD address the symptoms of the disease. Since 2003, over 500 clinical studies have been completed and only Aduhelm has been approved by the FDA, compared to a success rate of 50% to 80% for all other drug candidates. As a result, the FDA has a limited set of products to rely on in evaluating CT1812. This could result in a longer than expected regulatory review process, increased expected development costs or the delay or prevention of commercialization of CT1812 for the treatment of AD. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have never conducted pivotal clinical trials, and we may be unable to do so for any product candidates we may develop.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will need to successfully complete pivotal clinical trials in order to obtain the approval of the FDA, the European Medicines Agency, or EMA, or other regulatory agencies to market CT1812 or any future product candidate. Carrying out pivotal clinical trials is a complicated process that requires significant financial resources. As an organization, we have not previously conducted any later stage or pivotal clinical trials. In order to do so, we will need to expand our clinical development and regulatory capabilities, and we may be unable to recruit and train qualified personnel. We also expect to continue to rely on third parties to conduct our pivotal clinical trials. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to NDA submission and approval of CT1812 or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing our product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may seek a &#8220;Breakthrough Therapy&#8221; designation for our product candidates if the clinical data support such a designation for one or more product candidates. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, in our case, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">A Fast Track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA granted CT1812 Fast Track designation in October&#160;2017 for the treatment of mild-to-moderate AD, and, in the future, we may seek Fast Track designation for other of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Fast Track designation may not result in a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Many small molecule product candidates that have received Fast Track designation have failed to obtain marketing approval. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ability of the FDA to review and/or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent&#160;years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. On March&#160;18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have conducted, and in the future plan to conduct, clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have conducted clinical trials of our product candidates outside the United States, and plan to continue to do so in the future. For example, we initially conducted our Phase&#160;1b SNAP clinical trial of CT1812 in collaboration with the Karolinska Institute in Sweden. In addition, the Phase&#160;1 single and multiple ascending dose studies of CT1812 in healthy volunteers (COG0101) as well as the first-in-patient study (COG0102) were conducted in Australia. We are also opening additional clinical trial sites in the Netherlands, the Czech Republic and Spain for our SHINE study. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, any comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the data are applicable to the U.S. population and U.S. medical practice; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the trials were performed pursuant to good clinical practice, or GCP, requirements; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if necessary, the FDA is able to validate the data through an on-site inspection. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many foreign regulatory authorities have similar requirements. In addition, foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in product candidates that we may develop not receiving approval or clearance for commercialization in the applicable jurisdiction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are not successful in identifying, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although a substantial amount of our effort will focus on the continued development and potential approval of our current product candidates, a key element of our strategy is to identify, develop and commercialize a portfolio of products that help restore normal cellular damage responses in age-related degenerative diseases and disorders of the CNS and retina. A component of our strategy is to evaluate our product candidates in multiple indications based, in part, on our evaluation of certain biomarkers in a disease area. For example, we intend to evaluate CT1812 and other product candidates discovered through our NICE platform in other diseases beyond indications in AD, such as dry AMD, geographic atrophy, or GA, and synucleinopathies, including PD and DLB. However, we may find that while we have seen promising results in one neurodegenerative disease, that effect is not replicated across other indications with promising similarities. Even if we successfully identify additional product candidates, we may still fail to yield additional product candidates for development and commercialization for many reasons, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the research methodology used may not be successful in identifying potential product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may be unable to identify viable product candidates through our NICE platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">competitors may develop alternatives that render our additional product candidates obsolete; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">additional product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an additional product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an additional product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an additional product candidate may not be accepted as safe and effective by physicians and patients. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We therefore cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop or, if approved, commercialize additional product candidates. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunities may be limited. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if the product candidates that we develop receive regulatory approval in the United States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for our product candidates and adversely affect our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any other jurisdiction does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or any future collaborators&#8217; ability to develop, manufacture, promote and sell product candidates internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from being marketed outside of the jurisdictions in which regulatory approvals have been received. In order to market and sell product candidates in the European Union, or EU, and many other jurisdictions, we and any future collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement before it can be approved for sale in that country. In some cases, the intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other country, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we or any future collaborators fail to comply with the regulatory requirements in international markets or to obtain all required marketing approvals, the target market for a particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and adversely affect our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Business and Industry</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are heavily dependent on the success of CT1812, our lead product candidate, which is still under clinical development, and if CT1812 does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of CT1812, currently our only clinical-stage product candidate. To date, we have invested a significant portion of our efforts and financial resources in the development of CT1812 for the treatment of AD. Our future success is substantially dependent on our ability to successfully complete clinical development for, obtain regulatory approval for and successfully commercialize CT1812, which may never occur. We expect that a substantial portion of our efforts and expenditures over the next few&#160;years will be devoted to CT1812, which will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, building of a commercial organization, substantial investment and significant marketing efforts before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, while inhibition of A&beta; oligomers has been validated as a therapeutic approach, the use of small molecule receptor antagonists, such as CT1812, to inhibit the synaptic binding and signaling of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">soluble A&beta; oligomers is an innovative therapeutic approach, which exposes us to certain risks. For example, we may discover unforeseen safety events or that CT1812 does not possess certain properties required for therapeutic effectiveness. Even if found to be effective in one type of disease, CT1812, or the associated therapeutic approach, may not be effective in other diseases. In addition, given our therapeutic approach, designing preclinical studies and clinical trials to demonstrate its effect is complex and exposes us to risks. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. We are not permitted to market CT1812 in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries. We have not submitted an NDA to the FDA or comparable applications to other regulatory authorities for CT1812 and may not be in a position to do so for several&#160;years, if ever. If we are unable to obtain the necessary regulatory approvals for CT1812, we will not be able to commercialize CT1812 in AD, dry AMD, PD and DLB or other age-related degenerative diseases and disorders of the CNS and retina, and our financial position will be materially adversely affected and we may not be able to generate sufficient revenue to continue our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;1, 2022, we had 19 full-time and 3 part-time employees. We will need to continue to expand our managerial, operational, finance and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize CT1812, our lead product candidate, or any future product candidates. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">manage our clinical trials effectively; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">identify, recruit, retain, incentivize and integrate additional employees, including personnel focused on research and development and, if our product candidates receive marketing approval, sales; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">continue to improve our operational, financial and management controls, reports systems and procedures. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our future financial performance and our ability to develop, manufacture and commercialize CT1812 and our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize CT1812, if approved, and our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to attract and retain senior management and key scientific personnel, our business may be materially and adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon members of our senior management, particularly our President and Chief Executive Officer, Lisa Ricciardi, as well as our senior scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates or any future product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Competition for qualified personnel in the biopharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">decreased demand for our current or future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">injury to our reputation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">withdrawal of clinical trial participants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">costs to defend the related litigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">diversion of management&#8217;s time and our resources; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">substantial monetary awards to trial participants or patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">loss of revenue; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the inability to commercialize our current or any future product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we are unable to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims, the commercialization of our current or any future product candidates we develop could be inhibited or prevented. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may explore strategic collaborations that may never materialize or may fail.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may attempt to broaden the global reach of our platform by selectively collaborating with leading therapeutic companies and other organizations. As a result, we may periodically explore a variety of possible additional strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. In the event we do form such collaborations, we intend to retain significant economic and commercial rights to our programs </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">in key geographic areas that are core to our long-term strategy. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may seek to grow our business through acquisitions of complementary businesses, and the failure to manage acquisitions, or the failure to integrate them with our existing business, could harm our financial condition and operating results.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may consider opportunities to acquire other companies, products or technologies that may enhance our manufacturing capabilities, expand the breadth of our markets or customer base, or advance our business strategies. Potential acquisitions involve numerous risks, including: problems assimilating the acquired service offerings, products or technologies; issues maintaining uniform standards, procedures, quality control and policies; unanticipated costs associated with acquisitions; diversion of management&#8217;s attention from our existing business; risks associated with entering new markets in which we have limited or no experience; increased legal and accounting costs relating to the acquisitions or compliance with regulatory matters; and unanticipated or undisclosed liabilities of any target. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have no current commitments with respect to any acquisition. We do not know if we will be able to identify acquisitions we deem suitable, whether we will be able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully integrate any acquired service offerings, products or technologies. Our potential inability to integrate any business, products or technologies effectively may adversely affect our business, results of operations and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Significant disruptions of information technology systems, breaches of data security and other incidents could materially adversely affect our business, results of operations and financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We collect and maintain information in digital and other forms that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the privacy, security, confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures designed to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may have access to our confidential information. Our internal information technology systems and infrastructure, and those of any future collaborators and our contractors, consultants, vendors and other third parties on which we rely, are vulnerable to damage or unauthorized access or use resulting from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, denial or degradation of service attacks, ransomware, hacking, phishing schemes intended to cause an unauthorized transfer of funds and other social engineering attacks, attachments to emails, persons inside our organization or persons with access to systems inside our organization. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. The prevalent use of mobile devices that access confidential information also increases the risk of lost or stolen devices, security incidents and data security breaches, which could lead to the loss of confidential information or other intellectual property. As a result of the COVID-19 pandemic, we may face increased risks of a security breach or disruption due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. The costs to us to investigate, mitigate and remediate security incidents, breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2021 we were the subject of a phishing scheme involving a fraudulent email and wire instructions, resulting in the loss of approximately $0.5&#160;million in corporate funds. We took immediate action to contain and eradicate the security breach, including the implementation of control enhancements in an effort to prevent a similar situation from occurring again. We also subsequently submitted a claim for the loss under our cyber-security insurance policy whereby we received net proceeds of $0.5&#160;million. We believe this was an isolated event and do not believe our technology systems have been compromised. While we have not experienced any other losses relating to cyber-attacks or other information security breaches such as the one that occurred in November&#160;2021, there can be no assurance (i)&#160;that we will ever recover the funds lost, (ii)&#160;that our insurance carriers will honor our claim and make a payment to us under our cyber-security policy, or (iii)&#160;that we will not suffer additional losses in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, negative publicity and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any security compromise affecting us, our partners or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures and lead to regulatory scrutiny. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, if a computer security breach affects our systems or results in the unauthorized access to or unauthorized use, disclosure, release or other processing of personally identifiable information or clinical trial data, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media and other parties pursuant to privacy and security laws, and our reputation could be materially damaged. We would also be exposed to a risk of loss, governmental investigations or enforcement, or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to or affected by federal, state and foreign data protection laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, or HITECH, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, including Section&#160;5 of the Federal Trade Commission Act, which govern the collection, use, disclosure and protection of health-related and other personal information, may apply to our operations and the operations of any future collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH, and other privacy and data security laws. Depending on the facts and circumstances, we could be subject to significant administrative, civil and criminal penalties if we obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Further, various states have implemented similar privacy laws and regulations. For example, California also recently enacted the California Consumer Privacy Act of 2018, or CCPA. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA also provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA went into effect on January&#160;1, 2020 and grants the California Attorney General the power to bring enforcement actions for violations beginning July&#160;1, 2020. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact our business activities and as a result may increase our compliance costs and potential liability. Many similar privacy laws have been proposed at the federal level and in other states. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Foreign data protection laws, including Regulation&#160;2016/679, known as the General Data Protection Regulation, or GDPR, may also apply to health-related and other personal information data subjects in the European Union or the United Kingdom. The GDPR went into effect on May&#160;25, 2018. Companies that must comply with the GDPR face increased compliance obligations and risk, including robust regulatory enforcement of data protection requirements as well as potential fines for noncompliance of up to &euro;20&#160;million or 4% of annual global revenue of the noncompliance company, whichever is greater. The GDPR imposes numerous requirements for the collection, use, storage and disclosure of personal information of European Union or United Kingdom data subjects, including requirements relating to providing notice to and obtaining consent from data subjects, personal data breach notification, cross-border transfers of personal information, and honoring and providing for the rights of European Union or United Kingdom individuals in relation to their personal information, including the right to access, correct and delete their data. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Compliance with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Failure to comply with U.S. and foreign data protection laws and regulations could result in government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, clinical trial subjects about whom we or any of our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could materially and adversely affect our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. federal and state healthcare fraud and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, other sanctions, imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are unable to obtain and maintain patent protection for our technology and product candidates including our lead product candidate, CT1812, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We rely, and will continue to rely, upon a combination of patents, trademarks, trade secret protection and confidentiality agreements with employees, consultants, collaborators, advisors and other third parties to protect the intellectual property related to our current and future drug development programs and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our technology and product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our current and future drug development programs and product candidates, successfully defend our intellectual property rights against third-party challenges and successfully enforce our intellectual property rights to prevent third-party infringement. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may choose not to seek patent protection for certain innovations or products and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope and, in any event, any patent protection we obtain may be limited. As a result, some of our product candidates are not, and in the future may not be, protected by patents. We generally apply for patents in those countries where we intend to make, have made, use, offer for sale, or sell products and where we assess the risk of infringement to justify the cost of seeking patent protection. However, we do not seek protection in all countries where we intend to sell products and we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. The patent applications that we own may fail to result in issued patents with claims that cover any of our product candidates in the United States or in other foreign countries. We may also inadvertently make statements to regulatory agencies during the regulatory approval process that may be inconsistent with positions that have been taken during prosecution of our patents, which may result in such patents being narrowed, invalidated or held unenforceable, and vice versa that may affect the regulatory approval process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The patents and patent applications that we own may fail to result in issued patents with claims that protect any of our product candidates in the United States or in other foreign countries. We cannot guarantee any current or future patents will provide us with any meaningful protection or competitive advantage. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. The examination process may require us to narrow our claims, which may limit the scope of patent protection that we may obtain. Even if patents do successfully issue based on our patent applications, and even if such patents cover our product candidates, uses of our product candidates, or other aspects related to our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable, any of which could limit our ability to prevent competitors and other third parties from developing and marketing similar products or limit the length of terms of patent protection we may have for our products and technologies. Other companies may also design around technologies we have patented or developed. Any successful opposition to these patents or any other patents owned by us in the future could deprive us of rights necessary for the successful commercialization of any of our product candidates, if approved. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. If any of our patents are challenged, invalidated, circumvented by third parties or otherwise limited or expire prior to the commercialization of our products, and if we do not own or have exclusive rights to other enforceable patents protecting our products or other technologies, competitors and other third parties could market products and use processes that are substantially similar to, or superior to, ours and our business would suffer. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the patent applications we hold with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for any of our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any such outcome could harm our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent&#160;years been the subject of much litigation. The standards that the U.S. Patent and Trademark Office, or USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Patent reform legislation in the United States, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act was signed into law on September&#160;16, 2011 and includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </font><font style="font-style:italic;letter-spacing:0.2pt;">inter partes</font><font style="letter-spacing:0.2pt;"> review, and derivation proceedings. After March&#160;15, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, </font><font style="font-style:italic;letter-spacing:0.2pt;">inter partes</font><font style="letter-spacing:0.2pt;"> review, post-grant review or interference proceedings challenging our owned patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">generally 20&#160;years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not be able to protect our intellectual property rights throughout the world.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We do not have patent rights in certain foreign countries in which a market may exist. Moreover, in foreign jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products and services that are the same as or similar to our products and services, and our competitive position in the international market would be harmed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Patent terms may be inadequate to protect our competitive position on our product candidates including our lead product candidate, CT1812, for an adequate amount of time.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Depending upon the timing, duration and specifics of FDA marketing approval of our drug candidates, one or more of our U.S. patents may be eligible for limited patent term extension, or PTE, under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years beyond the normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the patent. This extension is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. Even if we are able to obtain an extension, the patent term may still expire before or shortly after we receive FDA marketing approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we do not obtain protection under the Hatch-Waxman Amendments by obtaining data exclusivity, our business may be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our commercial success will largely depend on our ability to obtain market exclusivity in the United States and other countries with respect to our drug candidates and their target indications. Depending upon the timing, duration and specifics of FDA marketing approval of our drug candidates, certain of our product candidates may be eligible for marketing exclusivity. The Food, Drug and Cosmetic Act, or FDCA, provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. If market exclusivity is granted for an NCE, during the exclusivity period, the FDA may not accept for review or approve an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four&#160;years if it contains a certification of patent invalidity or non-infringement to one of the patents listed in the Orange Book, with the FDA by the innovator NDA holder. The FDCA also provides three&#160;years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, dosage forms or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and prohibits the FDA from approving an ANDA, or a 505(b)(2) NDA submitted by another company with overlapping conditions associated with the new clinical investigations for the three-year period. Clinical investigation exclusivity does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of an NDA for the same drug. However, an applicant submitting an NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are unable to obtain such marketing exclusivity for our product candidates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products and launch their product earlier than might otherwise be the case. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The validity, scope and enforceability of any patents listed in the Orange Book that cover our product candidates including our lead product candidate CT1812 can be challenged by third parties.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If one of our product candidates is approved by the FDA, one or more third parties may challenge the current patents, or patents that may issue in the future, within our portfolio which could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or a finding of non-infringement. For example, if a third party files an application under Section&#160;505(b)(2) or an ANDA for a generic drug containing any of our product candidates, and relies in whole or in part on studies conducted by or for us, the third party will be required to certify to the FDA that either: (1)&#160;there is no patent information listed in the Orange Book with respect to our NDA for the applicable approved drug candidate; (2)&#160;the patents listed in the Orange Book have expired; (3)&#160;the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4)&#160;the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug. A certification that the new drug will not infringe the Orange Book-listed patents for the applicable approved drug candidate, or that such patents are invalid, is called a paragraph IV certification. If the third party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us once the third party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45&#160;days of receipt of the notice automatically prevents the FDA from approving the third party&#8217;s ANDA until the earliest of 30&#160;months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do not file a patent infringement lawsuit within the required 45-day period, the third party&#8217;s ANDA will not be subject to the 30-month stay of FDA approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, a third party may challenge the current patents, or patents that may issue in the future, within our portfolio which could result in the invalidation of some or all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products. If a third party successfully challenges all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products, we will not be entitled to the 30-month stay of FDA approval upon the filing of an ANDA for a generic drug containing any of our product candidates, and relies in whole or in part on studies conducted by or for us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with our drug candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering any of our product candidates, our competitors might be able to enter the market earlier than anticipated, which would harm our business. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The issuance of a patent does not give us the right to practice the patented invention. A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. Third parties may also have blocking patents that could prevent us from marketing our products or practicing our own patented technology. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our drug candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms. Such a license may not be available, or it may not be available on commercially reasonable terms, in which case our business would be harmed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The risks described elsewhere pertaining to our intellectual property rights also apply to any intellectual property rights that we may in-license, and any failure by us or our potential licensors to obtain, maintain, defend and enforce these rights could harm our business. In some cases we may not have control over the prosecution, maintenance or enforcement of the patents that we may license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our potential licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our product candidates including our lead product candidate, CT1812.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. However, while certain research, development and commercialization activities may be protected by the safe harbor provision of the Hatch Waxman Act, other activities may subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings, </font><font style="font-style:italic;letter-spacing:0.2pt;">inter partes</font><font style="letter-spacing:0.2pt;"> review and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many&#160;years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent was to be held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. Any uncertainties resulting from the initiation and continuation of any litigation could adversely impact our ability to raise additional funds or otherwise harm our business, results of operation, financial condition or cash flows. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could adversely impact the price of our common shares. If securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. The occurrence of any of these events may harm our business, results of operation, financial condition or cash flows. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot provide any assurances that third-party patents do not exist which might be enforced against our drugs or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might harm our ability to develop and market our products.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is or may be relevant to or necessary for the commercialization of our product candidates in any jurisdiction. Patent applications in the United States and elsewhere are not published until approximately 18&#160;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. In addition, U.S. patent applications filed before November&#160;29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Therefore, patent applications covering our products could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">and our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our products that are held to be infringing. We might, if possible, also be forced to redesign products or services so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may become involved in lawsuits to protect or enforce our patents or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Competitors may infringe or otherwise violate our patents or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. As a result, we cannot predict with certainty how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court. Further, even if we prevail against an infringer in U.S. district court, there is always the risk that the infringer will file an appeal and the district court judgment will be overturned at the appeals court and/or that an adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of written description or statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, </font><font style="font-style:italic;letter-spacing:0.2pt;">inter partes</font><font style="letter-spacing:0.2pt;"> review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may not be able to detect or prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could harm the price of our common shares. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product including our lead product candidate, CT1812.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The United States has recently enacted and implemented wide-ranging patent reform legislation. In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and pending patent applications. The United States Supreme Court has ruled on several patent cases in recent&#160;years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we own or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or that we may obtain in the future. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. The United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not be able to protect our intellectual property rights throughout the world, which could impair our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Filing, prosecuting and defending patents covering any of our product candidates throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. We do not have patent rights in certain foreign countries in which a market may exist. Moreover, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products and services that are the same as or similar to our products and services, and our competitive position in the international market would be harmed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because we expect to rely on third parties to manufacture our product candidates and expect to continue to collaborate with third parties on the development of our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Further, adequate remedies may not exist in the event of unauthorized use or disclosure. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may harm our business and results of operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Policing unauthorized use of our intellectual property is difficult, expensive and time-consuming, and we may be unable to determine the extent of any unauthorized use. Moreover, enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be subject to claims that our employees, consultants, independent contractors or we have wrongfully used or disclosed confidential information of their former employers or other third parties.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do and may employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, competitors or potential competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us and to not use the confidential information of their former employer, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">parties. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or product candidates. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Moreover, any such litigation or the threat thereof may harm our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would harm our business, results of operations and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities, and have a harmful effect on the success of our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials and internal research programs. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our product candidates, if approved. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to seeking patents for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to rely on trademarks as one means to distinguish any of our drug candidates that are approved for marketing from the products of our competitors. Once we select new trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our drugs, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks. If we attempt to enforce our trademarks and assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could harm our business, financial condition, results of operations and prospects. For example, the NIA has provided grants to fund certain of our preclinical activities and clinical trials. If the United States or another jurisdiction decides that the NIA grant bestows rights to our patent applications, that could affect our ability to obtain valid and enforceable patent claims protecting our rights as they relate to our lead product candidate, CT1812, our other product candidates and our NICE platform. As a consequence of these and other factors, our patent applications may fail to result in issued patents with claims that cover our product candidates in the United States or in other countries. Such a loss of patent protection could harm our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Once granted, patents may remain open to invalidity challenges including opposition, interference, re-examination, post-grant review, </font><font style="font-style:italic;letter-spacing:0.2pt;">inter partes</font><font style="letter-spacing:0.2pt;"> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others may be able to make product that is similar to product candidates we intend to commercialize that is not covered by the patents that we own; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we, or any collaborators might not have been the first to make or reduce to practice the inventions covered by the issued patents or pending patent applications that we own; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we or any collaborators might not have been the first to file patent applications covering certain of our inventions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">it is possible that our pending patent applications will not lead to issued patents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">issued patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and we may not develop additional proprietary technologies that are patentable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">third parties performing manufacturing or testing for us using our products or technologies could use the intellectual property of others without obtaining a proper license; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may not develop additional proprietary technologies that are patentable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the patents of others may harm our business. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Should any of these events occur, they could significantly harm our business and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Commercialization, Manufacturing and Reliance on Third Parties</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if one or more of our product candidates receive FDA or other regulatory approvals, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. Most of our product candidates target mechanisms for which there are limited or no currently approved products, which may result in slower adoption by physicians, patients and payors. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the clinical indications for which the product is approved and patient demand for approved products that treat those indications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the safety and efficacy of our product as compared to other available therapies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability of coverage and adequate reimbursement from governmental healthcare plans or third party payors for any of our product candidates that may be approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">acceptance by physicians, operators of clinics and patients of the product as a safe and effective treatment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">physician and patient willingness to adopt a new therapy over other available therapies to treat approved indications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">overcoming any biases physicians or patients may have toward particular therapies for the treatment of approved indications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">proper training and administration of our product candidates by physicians and medical staff; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">public misperception regarding the use of our therapies, if approved for commercial sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">patient satisfaction with the results and administration of our product candidates and overall treatment experience, including, for example, the convenience of any dosing regimen; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of treatment with our product candidates in relation to alternative treatments and reimbursement levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payors, physicians and patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the revenue and profitability that our products may offer a physician as compared to alternative therapies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">limitations or warnings contained in the FDA-approved labeling for our products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any FDA requirement to undertake a REMS; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effectiveness of our sales, marketing and distribution efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">adverse publicity about our products or favorable publicity about competitive products; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential product liability claims. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot assure you that our current or future product candidates, if approved, will achieve broad market acceptance among physicians, patients, healthcare payors and others in the medical community. Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be more effective than other commercially available alternatives or successfully commercialized. Any approval we may obtain could be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-marketing testing requirements to maintain approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a REMS. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our reputation, ability to raise additional capital, financial condition, results of operations and business prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The market opportunities for CT1812, if approved, may be smaller than we anticipate.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to initially seek approval for CT1812 for AD, dry AMD, PD and DLB and other age-related degenerative diseases and disorders of the CNS and retina. Our estimates of market potential have been derived from a variety of sources, including scientific literature, patient foundations and market research and may prove to be incorrect. Even if we obtain significant market share for CT1812 after FDA approval, the potential target populations may be too small to consistently generate revenue, and we may never achieve profitability without obtaining marketing approval for additional indications. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We do not currently have nor do we plan to build or acquire the infrastructure or capability internally to manufacture supplies of our product candidates or the materials necessary to produce our product candidates for use in the conduct of our preclinical studies or clinical trials, and we lack the internal resources and the capability to manufacture any of our product candidates on a preclinical, clinical or commercial scale. The facilities used by our contract manufacturers to manufacture our product candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing processes of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for the manufacture of our product candidates. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds these facilities inadequate for the manufacture of our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently rely on third parties at key stages in our supply chain. For instance, the supply chains for our lead product candidate involves several manufacturers that specialize in specific operations of the manufacturing process, specifically, raw materials manufacturing, drug substance manufacturing and drug product manufacturing. As a result, the supply chain for the manufacturing of our product candidates is complicated, and we expect the logistical challenges associated with our supply chain to grow more complex as our product candidates are further developed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We do not have any control over the process or timing of the acquisition or manufacture of materials by our manufacturers. We generally do not begin preclinical or clinical trials unless we believe we have access to a sufficient supply of a product candidate to complete such study. In addition, any significant delay in, or quality control problems with respect to, the supply of a product candidate, or the raw material components thereof, for an ongoing study could considerably delay completion of our preclinical or clinical trials, product testing and potential regulatory approval of our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have not yet engaged any manufacturers for the commercial supply of our product candidates. Although we intend to enter into such agreements prior to commercial launch of any of our product candidates, we may be unable to enter into any such agreement or do so on commercially reasonable terms, which could have a material adverse impact upon our business. Moreover, if there is a disruption to one or more of our third-party manufacturers&#8217; or suppliers&#8217; relevant operations, or if we are unable to enter into arrangements for the commercial supply of our product candidates, we will have no other means of producing our product candidates until they restore the affected facilities or we or they procure alternative manufacturing facilities or sources of supply. Our ability to progress our preclinical and clinical programs could be materially and adversely impacted if any of the third-party suppliers upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory or reputational issues. Additionally, any damage to or destruction of our third-party manufacturers&#8217; or suppliers&#8217; facilities or equipment may significantly impair our ability to manufacture our product candidates on a timely basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, to manufacture our product candidates in the quantities we believe would be required to meet anticipated market demand, our third-party manufacturers would likely need to increase manufacturing capacity and we may need to secure alternative sources of commercial supply, which could involve significant challenges and may require additional regulatory approvals. In addition, the development of commercial-scale manufacturing capabilities may require us and our third-party manufacturers to invest substantial </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">additional funds and hire and retain the technical personnel who have the necessary manufacturing experience. Neither we nor our third-party manufacturers may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all. If our manufacturers or we are unable to purchase the raw materials necessary for the manufacture of our product candidates on acceptable terms, at sufficient quality levels or in adequate quantities, if at all, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of such product candidates, if approved. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process that is more efficient and cost-effective to commercialize our potential products, which may not be successful.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of raw materials. There is no assurance that our third-party manufacturers will be successful in establishing a larger-scale commercial manufacturing process for our product candidates which achieves our objectives for manufacturing capacity and cost of goods. In addition, there is no assurance that our third-party manufacturers will be able to manufacture our product candidates to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of such products or to meet potential future demand. Our failure to properly or adequately scale up manufacturing for commercial scale would adversely affect our business, results of operations and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We rely on third parties in the conduct of all of our clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently do not have the ability to independently conduct clinical trials that comply with the regulatory requirements known as good laboratory practice, or GLP, requirements or GCP requirements, respectively. The FDA and regulatory authorities in other jurisdictions require us to comply with GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our GCP-compliant clinical trials play a significant role in the conduct of these studies and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting preclinical studies, clinical trials or other drug development activities that could harm our competitive position. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLPs or GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or repeated. As a result we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our business, financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The development and commercialization of new drug products is highly competitive. Moreover, the neurodegenerative field is characterized by strong and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of product candidates for the treatment of the diseases and disorders for which we have research programs, including AD, dry AMD, PD and DLB. Companies developing therapeutics for similar indications include large companies with significant financial resources, such as AbbVie, AstraZeneca, Biogen, Celgene, Eli Lilly, GlaxoSmithKline, Johnson &amp; Johnson, Novartis, Pfizer, Roche, Sanofi and Takeda. In addition to competition from other companies targeting neurodegenerative indications, any products we may develop may also face competition from other types of therapies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of age-related degenerative diseases and disorders, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. See &#8220;Risks Related to Our Intellectual Property.&#8221; The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those drugs and decrease our ability to generate revenue.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. Even if we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the cost of the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amounts we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our investment in the development of product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United States, third-party payors, and governmental healthcare plans, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other foreign jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amounts that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates, if approved, effectively in the United States and foreign jurisdictions or generate product revenue.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently do not have a marketing or sales organization. In order to commercialize our product candidates in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If any of our product candidates receive regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of biopharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing our product candidates or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Government Regulation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will have to comply with requirements concerning advertising and promotion for any future products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. We may not promote products for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling or manufacturing process. We could also be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">issue warning letters, untitled letters, or Form 483s; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">impose civil or criminal penalties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suspend or withdraw regulatory approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suspend any of our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refuse to approve pending applications or supplements to approved applications submitted by us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seize or detain products, or require a product recall. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from any future products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The United States government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. In recent&#160;years, Congress has considered reductions in Medicare reimbursement levels for products administered by physicians. The Centers for Medicare &amp; Medicaid Services, or CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some products. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things, the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum Medicaid rebate for both branded and generic products, expanded the 340B program, and revised the definition of average manufacturer price, or AMP, which could increase the amount of Medicaid rebates manufacturers are required to pay to states. The legislation also extended </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Medicaid rebates, previously due only on fee-for-service Medicaid utilization, to include the utilization of Medicaid managed care organizations as well and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of rebates due on those products. On February&#160;1, 2016, CMS issued final regulations to implement the changes to the Medicaid Drug Rebate program under the Affordable Care Act. These regulations became effective on April&#160;1, 2016. Since that time, there have been significant ongoing efforts to modify or eliminate the Affordable Care Act. The Tax Act, enacted on December&#160;22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, as amended, or the Code or the individual mandate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other legislative changes have been proposed and adopted since the passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction, or the Joint Select Committee, to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal&#160;years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which went into effect in April&#160;2013. Subsequent legislation extended the 2% reduction, on average, to 2030 unless additional Congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, the 2% Medicare sequester reductions were suspended from May&#160;1, 2020 through December&#160;31, 2021 due to the COVID-19 pandemic. The sequester will remain in place through 2030. On January&#160;2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. The Inflation Reduction Act of 2022 contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part&#160;D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. The Inflation Reduction Act of 2022 could have the effect of reducing the prices we can charge and reimbursement we receive for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition, results of operations and growth prospects. The effect of Inflation Reduction Act of 2022 on our business and the pharmaceutical industry in general is not yet known. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Affordable Care Act, or ACA, has also been subject to challenges in the courts. On December&#160;14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On December&#160;18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire Affordable Care Act. An appeal was taken to the U.S. Supreme Court. On June&#160;17, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we develop a small molecule product candidate that obtains regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Hatch-Waxman Act, a pharmaceutical manufacturer may file an ANDA seeking approval of a generic version of an approved, small molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA, under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act that references the FDA&#8217;s prior approval of the small molecule innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the Orange Book. If there are patents listed in the Orange Book for a product, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in their applications a paragraph IV certification, challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the patent owner and NDA holder and if, within 45&#160;days of receiving notice, either the patent owner or NDA holder sues for patent infringement, approval of the ANDA or 505(b)(2) NDA is stayed for up to 30&#160;months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, if we choose to develop a small molecule product candidate, and the product is approved, competitors could file ANDAs for generic versions of our small molecule drug products or 505(b)(2) NDAs that reference our small molecule drug products. If there are patents listed for our small molecule drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or in-licensed patents that are listed in the Orange Book are successfully challenged by way of a paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our activities are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil False Claims Act, and laws and regulations pertaining to limitations on and reporting of healthcare provider payments (physician sunshine laws). These laws and regulations are interpreted and enforced by various federal, state and local authorities including CMS, the Office of Inspector General for the U.S. Department of Health and Human Services, the U.S. Department of Justice, individual U.S. Attorney offices within the Department of Justice, and state and local governments. These laws include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the U.S. Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the U.S. False Claims Act (which can be enforced through &#8220;qui tam,&#8221; or whistleblower actions, by private citizens on behalf of the federal government), prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">HIPAA, which imposes criminal liability and amends provisions on the reporting, investigation, enforcement, and penalizing of civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">state laws and regulations, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to certain payments made in the preceding calendar year and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; beginning in 2022, applicable manufacturers are required to report such information regarding payments and transfers of value provided, as well as ownership and investment interests held, during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">similar data protection and healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal data, including the GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the European Union and European Economic Area (including with regard to health data). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Violations of any of these laws or any other governmental regulations that may apply to us, may subject us to significant civil, criminal and administrative sanctions including penalties, damages, fines, imprisonment, and exclusion from government funded healthcare programs, such as Medicare and Medicaid, and/or adverse publicity. Moreover, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical companies for alleged false or misleading statements </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">in connection with the marketing, promotion and/or sale of pharmaceutical products. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation. Generally, future changes in applicable U.S. tax laws and regulations, or their interpretation and application could have an adverse effect on our business, financial conditions and results of operations. We are unable to predict whether such changes will occur and, if so, the ultimate impact on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;&#160;201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The trading price of our common stock could be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In particular, the trading prices for biopharmaceutical companies have been highly volatile as a result of supply chain disruptions and the COVID-19 pandemic. These factors include those discussed in this &#8220;Risk Factors&#8221; section and others such as: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">results from, and any delays in, our current and future clinical trials with CT1812 or any other future clinical development programs, including any delays related to the COVID-19 pandemic; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">announcements of regulatory approval or disapproval of CT1812 or any future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">failure or discontinuation of any of our research and development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the termination of any future collaborations or license agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in the commercialization of CT1812 or any future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">public misperception regarding the use of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">acquisitions and sales of new products or product candidates, technologies or businesses; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">manufacturing and supply issues related to our product candidates for clinical trials or future product candidates for commercialization; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">quarterly variations in our results of operations or those of our competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">changes in coverage and recommendations by securities analysts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">announcements by us or our competitors of new products or product candidates, significant contracts, commercial relationships, acquisitions or capital commitments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">developments with respect to intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our commencement of, or involvement in, litigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">changes in financial estimates or guidance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any major changes in our board of directors or management; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">new legislation or regulation in the United States relating to the sale or pricing of pharmaceuticals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">FDA or other U.S. or foreign regulatory actions affecting us or our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product liability claims or other litigation or public concern about the safety of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">market conditions in the biopharmaceutical sectors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">general economic conditions in the United States and abroad. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the stock markets in general, and the markets for biopharmaceutical stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of our IPO, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion, or (c)&#160;in which </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the prior June&#160;30th, and (2)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Under Section&#160;107(b) of the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Even after we no longer qualify as an emerging growth company, we may, under certain circumstances, still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we sell shares of our common stock in future financings, stockholders may experience dilution and, as a result, our stock price may decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Because we expect our expenses to increase significantly in the foreseeable future and because, based on our current business plans, we believe that the net proceeds from this offering, together with our cash, cash equivalents and non-dilutive grant funding, will be sufficient for us to fund our operating and capital expenditures into the first half of 2024. As a result, we may from time to time issue additional shares of common stock or other securities to raise capital. These issuances may be at a discount from the current trading price of our common stock. Our stockholders would experience dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders will experience additional dilution and, as a result, our stock price may decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Based upon shares of our common stock outstanding as of June 30, 2022, upon the completion of this offering and giving effect to any purchases in this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering will, in the aggregate, beneficially own shares representing 17.1% of our outstanding common stock (or 16.7% if the underwriters exercise in full their option to purchase additional shares). As a result, these persons, acting together, would be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions. The concentration of voting power and transfer restrictions could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in the management of our company in ways with which other stockholders disagree. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, some of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the current market price of our common stock and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. Sales of significant number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate, and make it more difficult for you to sell shares of our common stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our ability to use net operating loss carryforwards and other tax attributes may be limited.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2021, we had federal net operating loss, or NOL, carryforwards of approximately $44.6&#160;million and state NOL carryforwards of approximately $44.6&#160;million available to offset future taxable income. Of the federal NOL carryforwards, $26.2&#160;million begin to expire in 2027, and $18.4&#160;million can be carried forward indefinitely. State NOL carryforwards will begin to expire in 2027. As of December&#160;31, 2021, we had a foreign NOL carryforward of $1.2&#160;million in Australia that can be carried forward indefinitely. As of December&#160;31, 2021, we also had $5.0&#160;million of federal research and development tax credit carryforwards available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2027, if not utilized. Utilization of NOL carryforwards and credits may be subject to an annual limitation due to the &#8220;ownership change&#8221; provisions under Sections&#160;382 and 383 of the Code. An &#8220;ownership change&#8221; is generally defined as a cumulative change in the ownership interest of significant stockholders over a rolling three-year period in excess of 50&#160;percentage points. Similar provisions under state tax law may also apply. If finalized, Treasury Regulations currently proposed under Section&#160;382 of the Code may further limit our ability to utilize our pre-change NOLs or credits if we undergo a future ownership change. We may experience an ownership change in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. Such ownership changes could result in the expiration of our NOL carryforwards and other tax attributes before they can be utilized and, if we are profitable, our future cash flows could be adversely affected due to our increased tax liability. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, under the Tax Cuts and Jobs Act, or the TCJA, as modified by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, NOL carryforwards arising in tax&#160;years beginning after December&#160;31, 2021 are limited to 80% of taxable income. Under the TCJA, federal NOL carryforwards arising in tax&#160;years beginning after December&#160;31, 2017 may be carried forward indefinitely. Under the CARES Act, federal NOL carryforwards arising in tax&#160;years beginning after December&#160;31, 2017 and before January&#160;1, 2021 may be carried back to each of the five tax&#160;years preceding the tax year of such loss and temporarily suspends the 80% limitation mentioned above for this period. The changes in the carryforward and carryback periods as well as the limitation on use of NOL carryforwards may significantly impact our ability to use NOL carryforwards, particularly for tax&#160;years beginning after December&#160;31, 2021, as well as the timing of any such use, and could adversely affect our results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our third amended and restated certificate of incorporation and amended and restated bylaws each contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the exclusive right of our board of directors to elect a director to fill a vacancy, however occurring, including by an expansion of the board of directors, which prevents stockholders from being able to fill vacancies on our board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including voting or other rights or preferences, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the required approval of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are also subject to the anti-takeover provisions contained in Section&#160;203 of the Delaware General Corporation Law, or the DGCL. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three&#160;years or, among other exceptions, the board of directors has approved the transaction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our third amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our third amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the United States District Court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the DGCL, our third amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Our third amended and restated certificate of incorporation and amended and restated bylaws, however, provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. The Supreme Court of Delaware has held that this type of exclusive federal forum provision is enforceable. There may be uncertainty, however, as to whether courts of other jurisdictions would enforce this provision, if applicable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision contained in our third amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General Risk Factors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business is susceptible to general conditions in the global economy and in the global financial markets. Further, the impacts of political unrest, including as a result geopolitical tension, such as a deterioration in the relationship between the U.S. and China or escalation in conflict between Russia and Ukraine, including any additional sanctions, export controls or other restrictive actions that may be imposed by the U.S. and/or other countries against governmental or other entities in, for example, Russia, also could lead to disruption, instability and volatility in the global markets, which may have an adverse impact on our business or ability to access the capital markets. A severe or prolonged economic downturn, including rises in interest rates, inflation, recession or depression, or political disruption could result in a variety of risks to our business, including weakened demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products. In particular, in relation to uncertainty around inflation and the U.S. Federal Reserve&#8217;s measures to slow inflation, the stock market has been exceptionally volatile. Any of the foregoing could materially and adversely affect our business, financial condition, results of operations and prospects, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business. </font>
        </div>
        <div style="margin-top:11.92pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The trading market for our common stock may be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have, and may never obtain, research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of us, the trading price for our stock could be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </font>
        </div>
        <div style="margin-top:11.91pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be subject to securities litigation, which is expensive and could divert our management&#8217;s attention.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management&#8217;s attention from other business concerns. </font>
        </div>
        <div style="margin-top:11.91pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have incurred, and will continue to incur, significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404, which could result in sanctions or other penalties that could materially and adversely affect our business, financial condition, results of operations and prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have incurred, and will continue to incur, significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Market and the rules of the SEC require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to Section&#160;404 and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Beginning with the second annual report that we will be required to file with the SEC, Section&#160;404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404. Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we identify any material weaknesses, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could materially and adversely affect our business, financial condition, results of operations and prospects, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend in part on CROs and other third parties to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Market or other adverse consequences that would materially and adversely affect our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have incurred, and will continue to incur, increased costs and demands upon management as a result of being a public company.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a public company listed in the United States, we incur significant additional legal, accounting and other costs. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and The Nasdaq Stock Market LLC, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:164.14pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to this Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Purchasers of common stock in this offering will experience immediate accretion in the net tangible book value of their investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The public offering price per share of common stock in this offering is higher than the net tangible book value per share of our common stock before giving effect to this offering. Based on an assumed public offering price of $1.79 per share, which represents the last reported sale price of our common stock on the Nasdaq Global Market on November 4, 2022, if you purchase common stock in this offering, you will incur immediate accretion of approximately $0.09 per share, representing the difference between the assumed public offering price per share of common stock and our as adjusted net tangible book value as of June&#160;30, 2022. For a further description of the accretion that you will experience immediately after this offering, see the section in this prospectus entitled &#8220;Dilution.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">A substantial number of shares of common stock may be sold in the market following this offering, which may depress the market price for our common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Sales of a substantial number of shares of our common stock in the public market following this offering could cause the market price of our common stock to decline. A substantial majority of the outstanding shares of our common stock are, and the shares of common stock offered hereby will be, freely tradable without restriction or further registration under the Securities Act. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have broad discretion to determine how to use the funds raised in this offering, and may use them in ways that may not enhance our operating results or the price of our common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Our management will have broad discretion over the use of net proceeds from this offering, and we could spend the net proceeds from this offering in ways our stockholders may not agree with or that do not yield a favorable return, if at all. We currently expect to use the net proceeds from this offering to fund research and development of our product candidates and development programs, including our ongoing Phase&#160;2 trials of CT1812 for the treatment of mild-to-moderate AD and DLB, our planned Phase&#160;2 clinical trials of CT1812 for dry AMD, our IND-enabling studies of compounds in our library for the treatment of neurodegenerative indications such as PD, and the remainder for our other research and development activities, as well as for working capital and other general corporate purposes, including costs and expenses associated with being a public company. However, our use of these net proceeds may differ substantially from our current plans. If we do not invest or apply the net proceeds of this offering in ways that improve our operating results, we may fail to achieve expected financial results, which could cause our stock price to decline.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus, including the information incorporated by reference into this prospectus, contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical or current facts included in this prospectus are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, statements that &#8220;we believe&#8221; or similar statements reflect our beliefs and opinions on the relevant subject. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed in, or implied by these, forward-looking statements and therefore, you should not unduly rely on such statements, including, but not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to raise additional capital to fund our operations and continue the development of our current and future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the clinical nature of our business and our ability to successfully advance our current and future product candidates through our ongoing future clinical trials, preclinical studies and development activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to generate revenue from future product sales and our ability to achieve and maintain profitability; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, and need for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the expected uses of the net proceeds from this offering and our existing cash and cash equivalents and the sufficiency of such resources to fund our planned operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding geopolitical tensions, such as Russia&#8217;s war with Ukraine, on our business, our industry and the economy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent to which the COVID-19 pandemic and measures taken to contain its spread ultimately impact our business, including our ongoing and future clinical trials, preclinical studies and development activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our dependence on the success of CT1812, our lead product candidate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the novelty of our approach to targeting the S2R complex to treat age-related degenerative diseases and disorders, and the challenges we will face due to the novel nature of such approach; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success of competing therapies that are or become available; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the initiation, progress, success, cost, and timing of our ongoing and future clinical trials, preclinical studies and development activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to obtain and maintain regulatory clearance of CT1812 for approved investigational new drug, or IND, applications and any future IND applications for any of our other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:228pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the size and growth of the potential markets for our product candidates and our ability to serve those markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory developments and approval pathways in the United States and foreign countries for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential scope and value of our intellectual property and proprietary rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability, and the ability of any future licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">economic uncertainty resulting from actual or perceived inflation; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">developments relating to our competitors and our industry. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have based these forward-looking statements largely on our current expectations, estimates, forecasts, and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section entitled &#8220;Risk Factors&#8221; in this prospectus and the risk factors set forth in the documents incorporated by reference in this prospectus for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should read this prospectus and the documents incorporated by reference in this prospectus completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:156pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We estimate that the net proceeds to us from this offering will be approximately $9.1 million (or approximately $10.6 million if the underwriters exercise in full their option to purchase up to 837,988 additional shares of common stock), based on an assumed public offering price of $1.79 per share, which was the last reported sale price per share of our common stock on the Nasdaq Global Market on November&#160;4, 2022, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to use the net proceeds of this offering for clinical development of our product candidates and for working capital and other general corporate purposes. We may also use a portion of the net proceeds from this offering to in-license, acquire or invest in complementary businesses, technologies, products or assets. Although we currently have no agreements, commitments or obligations to do so, we evaluate such opportunities and engage in related discussions with third parties from time to time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each $1.00 increase or decrease in the assumed public offering price of $1.79 per share, the last reported sale price per share of our common stock on the Nasdaq Global Market on November 4, 2022, would increase or decrease the net proceeds to us from this offering by $5.3 million, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&#160;million shares of common stock offered by us, would increase or decrease the net proceeds to us by $1.7 million, assuming the assumed public offering price per share remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures and the extent of our preclinical, clinical and future development activities may vary significantly depending on numerous factors, including the progress of our development efforts, the status of and results from our ongoing and planned clinical trials, our ability to take advantage of expedited programs or to obtain regulatory approval for product candidates, the timing and costs associated with the manufacture and supply of product candidates for clinical development or commercialization and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pending the use of the net proceeds from this offering as described above, we intend to invest the net proceeds in a variety of capital preservation instruments, including short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIPO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">DIVIDEND POLICY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We have never declared or paid cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our capital stock in the foreseeable future. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCAP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAPITALIZATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth our cash and our capitalization as of June&#160;30, 2022 on: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an actual basis; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a pro&#160;forma basis, giving further effect to the sale of 5,586,592 shares of our common stock in this offering at an assumed public offering price of $1.79 per share, which was the last reported sale price of our common stock on the Nasdaq Global Market on November 4, 2022, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our capitalization following the closing of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. You should read this information together with our financial statements and the related notes included in our 2021 Annual Report and our 2022 Quarterly Reports and incorporated by reference in this prospectus, and the section of this prospectus entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; </font>
        </div>
        <table style="width:416pt;height:181pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of June&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:297.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except share and per share amounts) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Actual </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:297.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">45,771</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">54,921 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:297.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Stockholders&#8217; equity </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:297.93pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Common stock, par value $0.001 per share; 250,000,000 shares authorized at June&#160;30, 2022; 22,597,907 shares issued and outstanding, actual; 28,184,499 shares issued and outstanding, pro&#160;forma </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">22</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">147,671</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">156,815</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(103,594<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(103,594<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:297.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated other comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:297.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total stockholders&#8217; equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">43,899</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">53,049 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:297.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total capitalization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">43,899</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">53,049</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each $1.00 increase or decrease in the assumed public offering price of $1.79 per share, which was the last reported sale price of our common stock on the Nasdaq Global Market on November 4, 2022, would increase or decrease each of pro&#160;forma cash, additional paid-in capital, total stockholders&#8217; equity and total capitalization by $5.3 million, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&#160;million shares of common stock offered by us would increase or decrease each of pro&#160;forma cash, additional paid-in capital, total stockholders&#8217; equity and total capitalization by $1.7 million, assuming that the assumed public offering price remains the same, and after deducting estimated underwriting discounts and commissions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The foregoing discussion and tables above are based on 22,597,907 shares of common stock outstanding as of June&#160;30, 2022, and excludes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">3,350,614 shares of our common stock issuable upon the exercise of outstanding stock options as of June&#160;30, 2022, with a weighted-average exercise price of $3.02 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">2,350,068 shares of our common stock reserved for future issuance under the 2021 Plan, as well as any future increases in the number of shares of common stock reserved for issuance under the 2021 Plan; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">209,532 shares of our common stock reserved for future issuance under our ESPP, as well as any future increases in the number of shares of common stock reserved for issuance under our ESPP.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock after this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our historical net tangible book value as of June&#160;30, 2022 was $43.9&#160;million, or $1.94 per share of our common stock. Our historical net tangible book value represents our total tangible assets less total liabilities. Historical net tangible book value per share is our historical net tangible book value divided by the number of shares of our common stock outstanding as of June&#160;30, 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After giving effect to the sale of 5,586,592 shares of our common stock to purchase shares of our common stock in this offering at an assumed public offering price of $1.79 per share, which was the last reporting sale price of our common stock on the Nasdaq Global Market on November 4, 2022, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of June&#160;30, 2022 would have been $53.0 million, or $1.88 per share. This represents an immediate decrease in as adjusted net tangible book value of $0.06 per share to our existing stockholders and an immediate increase of $0.09&#160;per share to new investors participating in this offering. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table illustrates this calculation on a per share basis: </font>
        </div>
        <table style="width:416pt;height:95pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:343.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Assumed public offering price per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">1.79 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:343.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Historical net tangible book value per share as of June&#160;30, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">1.94</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:343.26pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Decrease in net tangible book value per share as of June&#160;30, 2022 attributable to </font>
                <br >
                <font style="letter-spacing:0.2pt;">investors purchasing in this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">(0.06<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:343.26pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">As adjusted net tangible book value per share as of June&#160;30, 2022 after giving effect to this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">1.88 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt; width:343.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Increase per share to new investors participating in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">0.09</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each $1.00 increase or decrease in the assumed public offering price of $1.79 per share, the last reported sale price of our common stock on the Nasdaq Global Market on November 4, 2022, would increase or decrease our as adjusted net tangible book value per share after this offering by $0.81 per share. For each $1.00 increase in the assumed public offering price, the dilution per share to new investors participating in this offering would be $0.72 per share, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. For each $1.00 decrease in the assumed public offering price, the accretion per share to new investors participating in this offering would be $0.91 assuming the same. Similarly, an increase of 1.0&#160;million shares of common stock offered by us would increase the as adjusted net tangible book value after this offering by less than $0.01&#160;</font> <font style="letter-spacing:0.2pt;">per share and decrease the dilution per share to new investors participating in this offering by $0.09 per share, and a decrease of 1.0&#160;million shares of common stock offered by us would decrease the as adjusted net tangible book value by $0.01 per share and increase the dilution per share to new investors in this offering by $0.10 per share, assuming that the assumed public offering price remains the same, and after deducting estimated underwriting discounts and commissions. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the underwriters exercise in full their option to purchase up to 837,988 additional shares of common stock from us, the as adjusted net tangible book value per share after giving effect to this offering would be $1.88 per share and accretion to new investors participating in this offering of $0.09 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The foregoing discussion and tables above are based on 22,597,907 shares of common stock outstanding as of June&#160;30, 2022, and excludes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">3,350,614 shares of our common stock issuable upon the exercise of outstanding stock options as of June&#160;30, 2022, with a weighted-average exercise price of $3.02 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">2,350,068 shares of our common stock reserved for future issuance under the 2021 Plan, as well as any future increases in the number of shares of common stock reserved for issuance under the 2021 Plan; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:560pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">209,532 shares of our common stock reserved for future issuance under our ESPP, as well as any future increases in the number of shares of common stock reserved for issuance under our ESPP. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">To the extent that any outstanding options are exercised, new options or other equity awards are issued under our equity incentive plans, or we issue additional shares in the future, there will be further dilution to new investors participating in this offering.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMDAA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following discussion should be read in conjunction with our financial statements and related notes thereto incorporated by reference into this prospectus. In addition to historical information, this discussion contains forward-looking statements that involve risks, uncertainties and assumptions that could cause actual results to differ materially from management&#8217;s expectations. Factors that could cause such differences are discussed in the sections titled &#8220;Special note regarding forward-looking statements&#8221; and &#8220;Risk factors.&#8221; We are not undertaking any obligation to update any forward-looking statements or other statements we may make in the following discussion or elsewhere in this prospectus even though these statements may be affected by events or circumstances occurring after the forward-looking statements or other statements were made. Therefore, no reader of this document should rely on these statements being current as of any time other than the time at which this document is declared effective by the SEC.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since our inception in 2007, we have incurred significant operating losses and devoted substantially all of our time and resources to developing our lead product candidate, CT1812, building our intellectual property portfolio, raising capital and recruiting management and technical staff to support these operations. As of June&#160;30, 2022, we had an accumulated deficit of $103.6&#160;million. We incurred a net loss of $9.6&#160;million and $1.3&#160;million for the six&#160;months ended June&#160;30, 2022 and 2021, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To date, we have funded our operations primarily with proceeds from grants awarded by the National Institute of Aging, or NIA, a division of the National Institutes of Health, or NIH, and proceeds from our initial public offering, or IPO, the sales of convertible promissory notes, convertible preferred stock, simple agreements for future equity, or SAFEs, and stock option exercises. Since our inception, we have received approximately $171.0&#160;million in cumulative grant awards to fund our clinical trials, primarily from the NIA. As of June&#160;30, 2022, we have raised approximately $102.0&#160;million in net proceeds from sales of our equity securities, convertible notes, SAFEs, stock option exercises, and our IPO. As of June&#160;30, 2022, we had cash and cash equivalents of $45.8&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On October&#160;13, 2021, we completed our IPO, pursuant to which we issued and sold 3,768,116 shares of our common stock at a public offering price of $12.00 per share. Additionally, on November&#160;12, 2021, the underwriters exercise of their over-allotment option in full to purchase 565,217 shares of our common stock closed. In connection with the IPO, we received net proceeds of approximately $44.2&#160;million, after deducting underwriting discounts and commissions and other offering related expenses payable by us, which includes net proceeds of approximately $6.3&#160;million from the exercise of the over-allotment option. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA Grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA Grants or raise capital or enter into such agreements or arrangements as and when needed could have a material adverse effect on our business, results of operations and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to raise capital, maintain our research and development efforts, expand our business or continue our operations at planned levels, and as a result we may be forced to substantially reduce or terminate our operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not own or operate manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of CT1812 for preclinical studies and clinical trials, as well as for commercial manufacture if CT1812 obtains marketing approval. We also rely, and expect to continue to rely, on third parties to manufacture, package, label, store, and distribute CT1812, if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise and resources on the development of CT1812. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Impact of COVID-19 on Our Business</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our business has been and could continue to be adversely affected by the effects of the ongoing COVID-19 pandemic, including, but not limited to, our clinical trials. For example, the COVID-19 pandemic may impact patient enrollment in our ongoing and future clinical trials of CT1812. In particular, some sites have in the past or may in the future pause enrollment to focus on, and direct resources to, COVID-19, while at other sites, patients may choose not to enroll or continue participating in the clinical trial as a result of the pandemic. In addition, patient visits to medical providers in the United States have slowed as a result of the COVID-19 pandemic. Further, according to the Centers for Disease Control and Prevention, people who have serious chronic medical conditions are at higher risk of getting very sick from COVID-19. As a result, potential patients in our ongoing and future clinical trials of CT1812 may choose to not enroll, not participate in follow-up clinical visits or drop out of the trial as a precaution against contracting COVID-19. Further, some patients may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupts healthcare services. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our ongoing or planned clinical trials may also be impacted by interruptions or delays in the operations of the FDA and comparable foreign regulatory authorities. For example, we have made certain adjustments to the operation of our trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA and may need to make further adjustments in the future. We have also initiated our clinical trial protocols to enable remote visits to mitigate any potential impacts as a result of the COVID-19 pandemic. Many of these adjustments are new and untested, may not be effective, may affect the integrity of data collected, and may have unforeseen effects on the progress and completion of our clinical trials and the findings from such clinical trials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The spread of COVID 19, including the spread of new strains and variants of COVID-19, and actions taken to reduce such spread may also materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID 19 pandemic may be difficult to assess or predict, there could be a significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">pharmaceutical companies have been highly volatile as a result of the COVID 19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Components of Our Results of Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.62pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Operating Expenses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses consist primarily of direct and indirect costs incurred for our research activities, including development of our drug discovery efforts and the development of our product candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain our research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, facilities, and other expenses consisting of direct and allocated expenses for rent and depreciation, and lab consumables. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific basis because these costs are deployed across multiple programs and, as such, are not separately classified. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot reasonably determine the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. Product candidates in later stages of development generally have higher development costs than those in earlier stages. We expect that our research and development expenses will increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, as we expand our product pipeline, as we maintain, expand, protect and enforce our intellectual property portfolio, and as we incur expenses associated with hiring additional personnel to support our research and development efforts. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses consist primarily of personnel-related costs, including employee salaries, related benefits, and stock-based compensation expense for our employees in the executive, finance and accounting, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. We expense general and administrative costs as incurred. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect that our general and administrative expenses will increase substantially for the foreseeable future as we increase our headcount to support our continued research activities and development of our programs. Following the completion of our IPO on October&#160;13, 2021, we have incurred, and will continue to incur, substantially increased expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and those of any national securities exchange on which our securities are traded, legal, auditing, additional insurance expenses, investor relations activities, and other administrative and professional services. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Income (Expense)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.72pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Grant Income</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Grant income relates to the grants awarded from governmental bodies that are conditional cost reimbursement grants and are recognized as grant income as allowable costs are incurred and the right to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">payment is realized. The grants awarded relate to agreed upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations, research institutions and /or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which we are reimbursed for eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. As of June&#160;30, 2022, the Company has been awarded grants with project periods that extend through May&#160;31, 2025, subject to extension. Our clinical trials&#160;have been funded by approximately $168.9&#160;million in cumulative grants awarded primarily by the NIA, which includes an approximately $81.0&#160;million grant from the NIA to fund our Phase&#160;2 (COG0203) study of CT1812 in patients with early-stage AD, an approximately $30.5&#160;million grant from the NIA to fund our Phase&#160;2 (COG0201) study of CT1812 in patients with mild to moderate AD, and an approximately $29.5 million grant from the NIA to fund our Phase&#160;2 (COG1201) study of CT1812 in patients with dementia with lewy bodies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Fair Value of Derivative Liability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Change in fair value of our derivative liability consists of changes in the fair value of certain conversion and redemption features associated with our convertible notes that are required to be bifurcated and accounted for as free-standing derivative financial instruments. The derivative liability expired unexercised upon the conversion of the convertible notes into Series&#160;B-1 convertible preferred stock in May&#160;2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Fair Value of SAFEs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Change in fair value of our SAFEs consist of fair value adjustments to these instruments based primarily on the changes in the probability of occurrence and estimated timing of future event inputs in the valuation model. Upon the closing of our IPO on October&#160;13, 2021, the SAFEs were converted into 931,485 shares of our common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest Expense, Net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Interest expense, net primarily consists of interest expense from our convertible notes, partially offset by interest income from interest-bearing cash equivalents. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other (Expense) Income, Net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other (expense) income, net consists primarily of research and development tax credits earned in the applicable period, as well as foreign currency transaction gains or losses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Results of Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Comparison of the Six Months Ended June&#160;30, 2022 and 2021</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our results of operations (in thousands): </font>
        </div>
        <table style="width:456pt;height:122pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Six Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">June&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Consolidated Statements of Operations Data:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating Expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">15,616</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,324</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,010</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,243</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">3,767</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">21,626</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">11,567</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">10,059</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(21,626<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,567<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,059<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:182.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Six Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">June&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other income (expense): </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Grant income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">12,289</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">9,338</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,951</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in the fair value of the derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,209</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,209<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in the fair value of SAFEs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1,044<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,044</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other (expense) income, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(237<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">248</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(485<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Gain on debt extinguishment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">443</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(443<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(16<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(894<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">878</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total other income, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">12,036</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,736</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss before income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(9,590<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(1,267<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(8,323<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:311.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">(9,590<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">(1,267<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(8,323<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="20">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.2pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our research and development expenses (in thousands): </font>
        </div>
        <table style="width:416pt;height:121.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:288.55pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Six Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">June&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:288.55pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:288.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Clinical programs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">9,050</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,684</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">7,366</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Personnel </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,362</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,936</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,426</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Manufacturing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,061</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,719</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,658<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Preclinical programs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,036</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">926</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">110</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:288.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Facilities and other costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">59</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">48</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:288.55pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">15,616</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,324</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">6,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses were $15.6&#160;million for the six&#160;months ended June&#160;30, 2022, compared to $9.3&#160;million for the six&#160;months ended June&#160;30, 2021. The increase of $6.3&#160;million was primarily due to the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $7.4&#160;million in clinical programs related to increased Phase 2 trial activity primarily due to increased contract research organization spend; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $1.4&#160;million in personnel costs associated with expanded research and development activities, and equity-based compensation expense; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a decrease of $2.6&#160;million in manufacturing expense related to costs incurred with contract manufacturing organizations for production of pre-clinical and future clinical trial materials associated with our most advanced product candidates due to the timing of the manufacturing of the pre-clinical and clinical trial materials; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $0.1&#160;million in preclinical programs due to increased sponsored research spend under grants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $6.0&#160;million for the six&#160;months ended June&#160;30, 2022, compared to $2.2&#160;million for the six&#160;months ended June&#160;30, 2021. The increase of $3.8&#160;million was primarily due to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $0.9&#160;million in Director &amp; Officer liability insurance and other expenses; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $0.4&#160;million in compensation driven by increased headcount; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:118pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $0.8&#160;million in professional fees driven by increased audit, tax, and legal services; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $1.4&#160;million in equity-based compensation from stock option grants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Income (Expense)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Grant Income</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Grant income was $12.3&#160;million for the six&#160;months ended June&#160;30, 2022, compared to $9.3&#160;million for the six&#160;months ended June&#160;30, 2021. The change in grant income is correlated with the increase in eligible reimbursable costs incurred during 2022 as compared to 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Fair Value of the Derivative Liability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Changes in the fair value derivative liability resulted in a gain of $2.2&#160;million for the six&#160;months ended June&#160;30, 2021. There was no gain or loss for the six&#160;months ended June&#160;30, 2022 as the derecognition of the derivative liability occurred in May&#160;2021 upon the conversion of convertible notes into shares of Series&#160;B-1 convertible preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Fair Value of the SAFEs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Changes in the fair value of the SAFEs resulted in a loss of $1.0&#160;million for the six&#160;months ended June&#160;30, 2021. There was no change in the fair value for the six&#160;months ended June&#160;30, 2022 as the derecognition of the SAFE liability occurred when the SAFEs converted into shares of our common stock upon the closing of our IPO. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Income (Expense), Net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other expense, net was $0.2&#160;million for the six&#160;months ended June&#160;30, 2022, compared to other income, net of $0.2&#160;million for the six&#160;months ended June&#160;30, 2021. Overall, management believes that the change in other expense was not significant in either period. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Gain on Debt Extinguishment</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There was no gain or loss on debt extinguishment for the six&#160;months ended June&#160;30, 2022. Gain on debt extinguishment was $0.4&#160;million for the six&#160;months ended June&#160;30, 2021 as a result of the forgiveness of the Paycheck Protection Program loan on January&#160;21, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest Expense, Net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Interest expense, net was less than $0.1&#160;million for the six&#160;months ended June&#160;30, 2022, compared to interest expense, net of $0.9&#160;million for the six&#160;months ended June&#160;30, 2021. The change of $0.9&#160;million in interest expense, net was the result of the convertible notes outstanding balance during the six&#160;months ended June&#160;30, 2021, which were subsequently converted into shares of our Series&#160;B-1 convertible preferred stock in May&#160;2021. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Comparison of the Years Ended December&#160;31, 2021 and 2020</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our results of operations (in thousands): </font>
        </div>
        <table style="width:456pt;height:285pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Consolidated Statements of Operations Data:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating Expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">18,572</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12,887</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">5,685</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">10,026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">4,520</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,506</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">28,598</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">17,407</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">11,191</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(28,598<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,407<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,191<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other income (expense): </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Grant income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">17,447</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,855</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,592</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in the fair value of the derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,209</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,191</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Change in the fair value of the warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">181</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(181<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Change in the fair value of the Simple Agreements for Future </font>
                <br >
                <font style="letter-spacing:0.2pt;">Equity </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,236<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,236<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other (expense) income, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(88<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">394</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(482<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Gain (loss) on debt extinguishment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">443</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(129<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">572</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(893<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,751<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">858</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:311.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total other income, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">16,882</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">9,568</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">7,314</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:311.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,716<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(7,839<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(3,877<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our research and development expenses (in thousands): </font>
        </div>
        <table style="width:416pt;height:121.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:286.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:286.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:286.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Clinical programs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,679</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,263</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(584<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:286.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Personnel </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,882</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">856</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:286.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Manufacturing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,465</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,798</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:286.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Preclinical programs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,426</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,693</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(267<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:286.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Facilities and other costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">120</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:286.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">18,572</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">12,887</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,685</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses were $18.6&#160;million for the year ended December&#160;31, 2021, compared to $12.9&#160;million for the year ended December&#160;31, 2020. The increase of $5.7&#160;million was primarily due to the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a decrease of $0.6&#160;million in clinical programs related to delays due to COVID 19, resulting in timing and scope changes to clinical studies; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $0.9&#160;million in personnel costs due to increased salaries and bonus expense, increased headcount associated with expanded research and development activities, and equity-based compensation expense; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $5.7&#160;million in manufacturing expense related to costs incurred with contract manufacturing organizations for production of pre-clinical and future clinical trial materials associated with our most advanced product candidates; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a decrease of $0.3&#160;million in preclinical programs due to decreased sponsored research spend under grants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $10.0&#160;million for the year ended December&#160;31, 2021, compared to $4.5&#160;million for the year ended December&#160;31, 2020. The increase of $5.5&#160;million was primarily due to the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $0.5&#160;million in insurance and employee benefits primarily due to the addition of director and officer liability insurance; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $1.0&#160;million in professional fees driven by increased audit, tax, valuation and legal services; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an increase of $4.0&#160;million in equity-based compensation primarily driven by option grants made subsequent to the IPO. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Income (Expense)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Grant Income</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Grant income was $17.4&#160;million for the year ended December&#160;31, 2021, compared to $10.9&#160;million for the year ended December&#160;31, 2020. The change in grant income is correlated with the increase in eligible reimbursable costs incurred during 2021 as compared to 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Fair Value of the Derivative Liability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Changes in the fair value derivative liability resulted in a gain of $2.2&#160;million for the year ended December&#160;31, 2021, compared to a gain of less than $0.1&#160;million for the year ended December&#160;31, 2020. The increase in the gain recorded for the year ended December&#160;31, 2021 relates to the derecognition of the derivative liability in May&#160;2021 upon the conversion of the convertible notes into Series&#160;B-1 convertible preferred stock at that time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Fair Value of the Warrant Liability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Changes in the fair value of warrant liabilities resulted in no gain or loss for the year ended December&#160;31, 2021, compared to a gain of $0.2&#160;million for the year ended December&#160;31, 2020. The decrease of $0.2&#160;million was due to the expiration of warrants to purchase Series&#160;A-1 preferred stock in October&#160;2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Change in Fair Value of the SAFEs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Changes in the fair value of the SAFEs resulted in a loss of $2.2&#160;million for the year ended December&#160;31, 2021. There was no change in fair value for the year ended December&#160;31, 2020 as the SAFEs were entered into in March&#160;2021. The change in fair value was primarily driven by the conversion of the SAFE into common shares and the associated discount applied upon the occurrence of the IPO on October&#160;7, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other (Expense) Income, Net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other expense, net was less than $0.1&#160;million for the year ended December&#160;31, 2021, compared to other income, net of $0.4&#160;million for the year ended December&#160;31, 2020. The decrease was primarily the result of a decrease in research and development incentive income of $0.4&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Gain (Loss) on Debt Extinguishment</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Gain on debt extinguishment was $0.4&#160;million for the year ended December&#160;31, 2021, compared to a loss on debt extinguishment of $0.1&#160;million for the year ended December&#160;31, 2020. The 2020 loss was the result of the execution of the second amendment to the convertible notes on February&#160;27, 2020, which resulted in an extinguishment of the existing notes for accounting purposes. The 2021 gain was the result of the forgiveness of the Paycheck Protection Program loan on January&#160;21, 2021. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest Expense, Net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Interest expense, net was $0.9&#160;million for the year ended December&#160;31, 2021 compared to interest expense, net of $1.8&#160;million for the year ended December&#160;31, 2020. The change of $0.9&#160;million in interest expense, net was the result of a higher overall convertible note balance during 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Capital Resources</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Sources of Liquidity</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To date, we have funded our operations primarily with proceeds from grants awarded by the NIA, and proceeds from the sales of our convertible promissory notes, convertible preferred stock, SAFEs, stock option exercises, and our IPO. Since our inception, we have received grant awards primarily from the NIA in the aggregate amount of approximately $171.0&#160;million. As of June&#160;30, 2022, we have raised approximately $102.0&#160;million in net proceeds from sales of our equity securities, convertible notes and SAFEs, stock option exercises, and our IPO. On March&#160;25, 2021, we completed a SAFE offering with various investors, pursuant to which we received gross proceeds in an aggregate amount equal to $8.9&#160;million. On October&#160;13, 2021, we closed our IPO, selling 3,768,116 shares of our common stock at a public offering price of $12.00 per share. Additionally, on November&#160;12, 2021, the underwriters exercise of their over-allotment option to purchase 565,217 shares of our common stock closed. The net proceeds were approximately $44.2&#160;million, after deducting underwriting discounts and commissions and other offering related expenses payable by the Company, which includes net proceeds of approximately $6.3&#160;million from the exercise of the over-allotment option. As of June&#160;30, 2022, we had $45.8&#160;million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents and income from non-dilutive grants, will be sufficient for us to fund our operating expenses and capital expenditures requirements into the first half of 2024. We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Future Funding Requirements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company. We anticipate that we will need to raise additional funding in the future to fund our operations, including the commercialization of any approved product candidates. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our future funding requirements will depend on many factors, including, but not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, progress, costs and results of our ongoing and planned clinical trials of CT1812, as well as the associated costs, including any unforeseen costs we may incur as a result of preclinical study or clinical trial delays due to the COVID-19 pandemic or other diseases, global or political instability, such as the ongoing conflict between Ukraine and Russia, inflation, or other delays; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, progress, costs and results of preclinical development, laboratory testing and clinical trials for any future product candidates we may decide to pursue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent to which we develop, in-license or acquire other product candidates and technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability, timing, and receipt of any future NIA Grants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:84pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number and development requirements of other product candidates that we may pursue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs, timing and outcome of regulatory review of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to establish collaborations to commercialize CT1812 or any of our other product candidates outside the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the additional costs we may incur as a result of operating as a public company, including our efforts to enhance operational systems and hire additional personnel, including enhanced internal controls over financial reporting. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Until such time as we can generate significant revenue from product sales, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA&#160;Grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA Grants or raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. Adequate funding may not be available when needed or on terms acceptable to us, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic or other diseases, the ongoing conflict between Ukraine and Russia, inflation, and otherwise. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flows from operating activities. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:22.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cash Flows</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our cash flows for the periods indicated (in thousands): </font>
        </div>
        <table style="width:416pt;height:106.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:329.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Six Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">June&#160;30, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:329.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash flows used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(8,345<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,682<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash flows used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(138<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash flows (used in) provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(465<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">7,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:329.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Effect of exchange rate changes on cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:329.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net (decrease) increase in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(8,950<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">6,111</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Operating Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities for the six&#160;months ended June&#160;30, 2022 was $8.3&#160;million, which consisted primarily of our net loss of $9.6&#160;million, offset by the impact of equity-based compensation of $1.9&#160;million and a net change of $0.8&#160;million in our operating assets and liabilities. The net change in our operating assets and liabilities was primarily due to an increase in grant receivables of $1.5&#160;million, an increase in other assets of $1.3&#160;million, offset by an increase in other noncurrent liabilities of $1.7&#160;million, and an increase in deferred grant income of $0.5&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities for the six&#160;months ended June&#160;30, 2021 was $1.7&#160;million, which consisted primarily of our net loss of $1.3&#160;million as well as net non-cash gains of $1.0&#160;million and a net change of $0.6&#160;million in our operating assets and liabilities. The net non-cash gains primarily consisted of amortization of debt discounts of $0.4&#160;million, change in derivative liabilities of $2.2&#160;million, change in fair value of the SAFEs of $1.0&#160;million, a gain on debt extinguishment of $0.4&#160;million, and equity-based compensation of $0.2&#160;million. The net change in our operating assets and liabilities was primarily due to an increase in grant receivables of $1.7&#160;million, an increase in prepaid expenses and other current assets of $0.3&#160;million, a decrease in other receivables of $0.3&#160;million, an increase in accounts payable of $0.4&#160;million, an increase in accrued expenses of $1.3&#160;million, and an increase in other current liabilities of $0.5&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities for the year ended December&#160;31, 2021 was $3.6&#160;million, which consisted primarily of our net loss of $11.7&#160;million partially offset by net non-cash charges of $5.2&#160;million and a net change of $2.8&#160;million in our operating assets and liabilities. The non-cash charges primarily consisted of depreciation and amortization of $0.1&#160;million, amortization of debt discount of $0.4&#160;million, change in fair value of SAFE of $2.2&#160;million, and equity-based compensation of $5.1&#160;million, partially offset by a change in the fair value of the derivative liability of $2.2&#160;million. The net change in our operating assets and liabilities was primarily due to an increase in accounts payable of $2.2&#160;million, an increase in accrued expenses of $1.3&#160;million, and an increase in other current liabilities of $0.5&#160;million, partially offset by an increase in grant receivables of $1.2&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities for the year ended December&#160;31, 2020 was $3.4&#160;million, which consisted primarily of our net loss of $7.8&#160;million partially offset by net non-cash charges of $1.3&#160;million and a net decrease of $3.1&#160;million in our operating assets and liabilities. The non-cash charges primarily consisted of depreciation and amortization of $0.1&#160;million, amortization of debt issuances costs of $0.1&#160;million, amortization of debt discounts of $0.8&#160;million, change in warrant liabilities of $0.2&#160;million, loss on debt extinguishment of $0.1&#160;million, and equity-based compensation of $0.5&#160;million. The net decrease in our net operating assets was primarily due to a net decrease in other receivables of $0.9&#160;million, a decrease in accounts payable of $0.4&#160;million, an increase in accrued expenses of $0.6&#160;million, a decrease in grant receivables of $2.1&#160;million, and an increase in other current liabilities of $0.3&#160;million. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities for the six&#160;months ended June&#160;30, 2022 was $0.1&#160;million related to purchases of fixed assets. We did not use any cash for investing activities for the six&#160;months ended June&#160;30, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the&#160;years ended December&#160;31, 2021 and 2020, we used less than $0.1&#160;million of cash, respectively, for investing activities related to purchases of property and equipment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Financing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in financing activities was $0.5&#160;million for the six&#160;months ended June&#160;30, 2022, and net cash provided by financing activities was $7.8&#160;million for the six&#160;months ended June&#160;30, 2021. The decrease in cash relates primarily to the $8.9&#160;million of SAFEs issued during the six&#160;months ended June&#160;30, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities was $53.2&#160;million and $5.8&#160;million for the&#160;years ended December&#160;31, 2021 and 2020, respectively. The increase in cash provided by financing activities in 2021 relates primarily to proceeds received in connection with the IPO in the amount of $44.2&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contractual Obligations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our contractual obligations as of June&#160;30, 2022 (in thousands): </font>
        </div>
        <table style="width:416pt;height:46.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:223.35pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Less than</font>
                <br >
                <font style="letter-spacing:-0.16pt;">1 Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">1 to 3</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">3 to 5</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">More than 5</font>
                <br >
                <font style="letter-spacing:-0.16pt;">years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:223.35pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease obligations: </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">149</td>
            <td style="padding:0pt;padding-left:5.83pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">193</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">191</td>
            <td style="padding:0pt;padding-left:10.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:223.35pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total: </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.83pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">149</td>
            <td style="padding:0pt;padding-left:5.83pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">193</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">191</td>
            <td style="padding:0pt;padding-left:10.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered into operating leases for office and laboratory facilities under agreements that run through May&#160;31, 2029. The amounts reflected in the table above consist of the future minimum lease payments under the non-cancelable lease arrangements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;1, 2021, we entered into an agreement to lease 2,864 square feet of office space in Purchase, New York. The lease has a term of 89&#160;months and commenced on December&#160;9, 2021. The annual base rent under the lease is less than $0.1&#160;million for the first lease year and is subject to annual increases of between 1.82% and 2.04%. We provided a security deposit in the form of a Letter of Credit in the amount of less than $0.1&#160;million pursuant to the terms of the lease. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, in October&#160;2021, we entered into an insurance premium financing arrangement with a lender. Under the agreement, we financed $1.5&#160;million of certain premiums at a 3.25% annual interest rate. Payments of $0.1&#160;million are due monthly from October&#160;2021 through September&#160;2022. As of June&#160;30, 2022, the outstanding principal of the loan was $0.4&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We enter into contracts in the normal course of business with contract research organizations and other vendors to assist in the performance of our research and development and other services and products for operating purposes. These contracts typically do not contain minimum purchase commitments and generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Critical Accounting Policies and Use of Estimates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Costs, Accrued Research and Development Costs and Related Prepaid Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable advance payments for research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Equity-Based Compensation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We maintain an equity-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The plan allows for the issuance of incentive stock options, non-qualified stock options, restricted stock&#160;units, and other forms of equity awards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We recognize equity-based compensation expense for stock options subject to time-based vesting on a straight-line basis over the requisite service period and account for forfeitures as they occur. To the extent any stock option grants are made subject to the achievement of a performance condition, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. Our stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Term.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The expected term represents the period that the stock-based awards are expected to be outstanding. As we do not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Risk-Free Interest Rate.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#8217; expected term. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Volatility.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Up until October&#160;13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected Dividend Yield.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The expected dividend yield is zero as we have not paid and do not anticipate paying any dividends in the foreseeable future. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Fair Value of Common Stock.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Prior to the IPO, the fair value of the shares of common stock underlying the stock-based awards had historically been determined by the board of directors with input from management. Because there was no public market for the common stock, the board of directors has determined the fair value of the common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having contemporaneous valuations of the common stock performed by a third-party valuation specialist. Subsequent to the IPO, the board of directors will determine the fair value of the shares of common stock underlying the stock-based awards based off of the closing price as reported on the Nasdaq Stock Market LLC on the grant date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See Note 7 to our consolidated financial statements included in our Quarterly Report on Form 10-Q for the six&#160;months ended June&#160;30, 2022 incorporated by reference into this prospectus and elsewhere for more information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:280pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of June&#160;30, 2022, the total unrecognized compensation expense related to unvested time-based vesting awards was $9.0&#160;million, which is expected to be recognized over weighted-average remaining vesting period of approximately 2.5&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent Accounting Pronouncements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">See Note 2 to our consolidated financial statements included in our Quarterly Report on Form 10-Q for the six&#160;months ended June&#160;30, 2022 incorporated by reference into this prospectus and elsewhere for more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Emerging Growth Company Status</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1)&#160;are no longer an emerging growth company or (2)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will remain an emerging growth company until the earliest to occur of: (1)&#160;the last day of the fiscal year in which we have at least $1.07&#160;billion in annual revenue; (2)&#160;the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in Rule&#160;12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0&#160;million as of the last business day of the second fiscal quarter of such year; (3)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period; and (4)&#160;the last day of the fiscal year ending after the fifth anniversary of our IPO.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tBUS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">BUSINESS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the sigma 2 receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our lead product candidate, CT1812, is an orally delivered, small molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. We have initially focused on the development of CT1812 for the treatment of Alzheimer&#8217;s disease, or AD, by targeting the accumulation of &beta;-amyloid, or A&beta;, oligomers, which has been linked to the disease. We believe our evidence demonstrates that by binding to the S2R complex, CT1812 displaces A&beta; oligomers from their neuronal receptors. Based on this mechanism, we believe CT1812 has the potential to slow the loss of synapses and cognitive decline observed in AD. CT1812 is the first S2R selective ligand modulator to reach clinical trials and is currently in Phase&#160;2 development for the treatment of AD. The direct healthcare costs to care for patients with AD and other dementias in the U.S. is currently estimated to exceed $300&#160;billion. Approximately 5.8&#160;million people in the U.S. have been diagnosed with AD, and the World Health Organization estimates that AD affects as many as 35&#160;million people globally. Among people with AD, approximately 50% have mild disease, 30% have moderate disease and 20% have severe disease. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are continuing to enroll patients in three ongoing Phase&#160;2 clinical trials with CT1812: SHINE and SEQUEL in mild-to-moderate AD and SHIMMER in dementia with Lewy bodies, or DLB. Preliminary results from an interim analysis of the first 24 patients in Part&#160;A of our ongoing SHINE Phase&#160;2 clinical trial demonstrated a statistically significant decline in the presence of A&beta; monomers and a positive trend on cognitive function as measured by the Alzheimer&#8217;s Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog, in patients receiving CT1812 compared to placebo. We anticipate completing enrollment in 2023 with top-line data in early 2024. Our ongoing SEQUEL Phase&#160;2 clinical trial is also evaluating changes in brain function, as measured by quantitative electroencephalography, or qEEG, in mild-to-moderate AD, and we anticipate completing enrollment in 2022 and reporting topline data thereafter. We have treated over 220 subjects with CT1812 in our clinical trials to date including 90 patients with mild-to-moderate AD. CT1812 has continued to be well tolerated and has been granted Fast Track designation by the U.S. Food and Drug Administration, or FDA, in this indication. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our clinical trials have been funded by approximately $171.0&#160;million in cumulative grants awarded primarily by the National Institute of Aging, or NIA, a division of the National Institutes of Health, which includes a grant award of approximately $81.0&#160;million from the NIA to fund our Phase&#160;2 START (COG0203) study of CT1812 in patients with early stage AD. We intend to enroll 540 patients in our START trial with mild cognitive impairment, or MCI, due to AD or mild AD who have elevated levels of A&beta; oligomers as determined by a clinical diagnosis of AD confirmed with amyloid biomarkers&#8217; positron emission tomography, or PET, imaging and/or cerebrospinal fluid, or CSF, biomarkers. Patients will be randomized to receive CT1812 or a placebo for 18&#160;months. In addition to cognitive and functional measures, such as the Clinical Dementia Rating Scale, or CDR, Sum of Boxes, or SB, and ADAS-Cog, we intend to use a variety of biomarkers to measure target and/or pathway engagement and assess changes in neurodegeneration and disease progression. We are conducting this clinical trial in collaboration with the Alzheimer&#8217;s Clinical Trial Consortium, or ACTC, an NIA-funded clinical trials network designed to accelerate studies for therapeutics for AD and related dementias, and we expect to open sites by the end of 2022. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We intend to expand our CT1812 pipeline to include additional indications such as geographic atrophy, or GA, secondary to dry age-related macular degeneration, or dry AMD. GA is an advanced form of dry AMD. Dry AMD is an eye disease that results in the deterioration of the macula, causing distortion, loss of central vision and eventual blindness, for which there are currently no FDA approved treatments. The S2R </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">83</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">complex is expressed in the retina in several cell types including the retinal pigment epithelial cells, or RPE, photoreceptors and retinal ganglion cells. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We have completed a pre-IND meeting with the FDA, and, after the completion of our ongoing preclinical studies, we intend to submit an Investigational New Drug, or IND, application to the FDA by the end of 2022, after which we plan to advance into a Phase&#160;2 clinical trial, leveraging our knowledge of CT1812&#8217;s preclinical and clinical profile to date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">In addition, we are developing other product candidates in the area of synucleinopathies. Synucleinopathies are a group of degenerative diseases characterized by the abnormal accumulation of the alpha-synuclein protein in neural cell bodies, including Parkinson&#8217;s disease, or PD, and DLB. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We are developing a pipeline of innovative, small molecule product candidates that are designed to target the S2R complex, a key regulator of the cellular damage response for diseases such as AD, dry AMD, geographic atrophy (an advanced form of dry AMD), or GA, and other conditions for which there is significant unmet medical need. Our current pipeline is summarized below: </font>
        </div>
        <div style="position:relative;margin-top:9.4pt; text-align:center; width:456pt;">
          <img src="tm2226999d3-bc_pipe4c.jpg" alt="[MISSING IMAGE: tm2226999d3-bc_pipe4c.jpg]" height="265" width="608" >
        </div>
        <div style="margin-top:15.81pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Mild to Moderate AD</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We are currently engaged in two ongoing Phase&#160;2 clinical trials, designed to evaluate safety, dosing and potential efficacy for CT1812 as a treatment for mild-to-moderate AD. These trials include evaluations of CT1812&#8217;s ability to engage with the S2R complex enabling the displacement of A&beta; oligomer, its impact in synaptic density and its restoration of synaptic function. In the largest of these trials, our COG0201 SHINE study, we are assessing CT1812&#8217;s ability to alter disease progression and cognition, with a target enrollment of 144 participants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Early-stage AD</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We plan to evaluate CT1812 in a 540-patient Phase&#160;2 COG0203 clinical trial to investigate the potential for CT1812&#8217;s use at an earlier stage of AD. In addition to cognitive and functional measures, such as CDR-SB, ADAS-Cog and volume magnetic resonance imaging, or MRI, we intend to use a variety of biomarkers to measure target and/or pathway engagement and assess changes in neurodegeneration and disease progression. We expect to open sites by the end of 2022. This trial has been funded by a grant of approximately $81.0&#160;million from the NIA. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DLB</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are evaluating CT1812 in a 120-patient Phase&#160;2 COG1201 clinical trial to investigate the potential for CT1812&#8217;s use as a disease-modifying agent in DLB. We are assessing cognitive and functional measures </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">84</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">such as Montreal Cognitive Assessment (MoCA), Cognitive Drug Research Battery (CDR), Clinician Assessment of Fluctuation (CAF), Epworth Sleepiness Scale (ESS), Unified Parkinson&#8217;s Disease Rating Scale&#8201;&#8212;&#8201;Part&#160;III (MDS-UPDRS3), Clinical Global Impression of Change (ADCS-CGIC), ADCS-Activities of Daily Living (ADCS-ADL) and Neuropsychiatric Inventory (NPI). We are currently evaluating sites to commence our trial. The trial has been funded by a grant of approximately $30&#160;million from the NIA. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Geographic Atrophy Secondary to Dry AMD</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are also evaluating the use of CT1812 to treat GA secondary to dry AMD. We believe that human genetic and internal proteomic pathway analyses obtained through our AD trials provides evidence of a relationship between the S2R complex and dry AMD. We are currently engaged in preclinical development activities for this indication, including studies to elucidate the key mechanisms by which CT1812 and the S2R complex alter the biological processes that contribute to dry AMD. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We have completed a pre-IND meeting with the FDA, and, after the completion of our ongoing preclinical studies, we intend to submit an IND application to the FDA by the end of 2022, after which we plan to advance into a Phase 2 clinical trial, leveraging our knowledge of CT1812&#8217;s preclinical and clinical profile to date. We are evaluating candidates for synucleinopathies and dry AMD as potential IND candidates.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Discovery Initiatives</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are pursuing a number of early-stage discovery programs which are built upon our identification of five structurally distinct chemical series. We believe we have identified several structurally distinct compounds that possess advantages for specific disease indications and patient populations. A few of these next-generation S2R modulators have been identified for synucleinopathies and dry AMD and are being assessed as potential IND candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For example, one of our next-generation S2R modulators, CT2074, has shown activity in cell-based dry AMD assays, suggesting the potential to maintain homeostatic functions of RPEs, ameliorate lysosomal dysfunction, and prevent RPE cell death. It has further demonstrated retinal exposures above 80% receptor occupancy with oral administration and favorable PK properties, including high degree of bioavailability and high retina-to-plasma ratio, which we believe may provide us with a suitable next-gen molecule to advance for this indication. Therefore, we believe S2R modulators may present a novel therapeutic approach for these indications and intend to pursue development as described below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our objectives are to develop and advance our portfolio, beginning with our lead product candidate, CT1812, through clinical development for the treatment of age-related degenerative diseases and disorders of the CNS and retina and to leverage our understanding of the S2R complex and its regulation of pathways to pursue indications in other degenerative disorders. The key elements of our strategy include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Advance clinical development of our lead product candidate, CT1812, in mild-to-moderate AD and earlier stages of the disease.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our lead product candidate, CT1812, has progressed through Phase&#160;1 and into Phase&#160;2 clinical trials. Funding of the Phase&#160;1 and into Phase&#160;2 trials is primarily through the NIA. We are evaluating CT1812 in other AD populations as well and developing CT1812 for patients with earlier symptomatic stages of AD and MCI, which is a slight and noticeable measurable decline in cognitive abilities due to AD. Our START (COG0203) clinical trial in patients with mild dementia associated with early stage AD has been funded by a grant of approximately $81.0&#160;million awarded from the NIA. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Pursue the development of CT1812 for GA secondary to dry AMD.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We plan to evaluate CT1812 as a potential therapy for GA secondary to dry AMD. GA is an advanced form of dry AMD. Dry AMD is an eye disease that results in the deterioration of the macula, causing visual distortion, loss of central vision and eventual blindness. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We have completed a pre-IND meeting with the FDA, and, after the completion of our </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">85</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ongoing preclinical studies, we intend to submit an IND application to the FDA by the end of 2022, after which we plan to advance into a Phase 2 clinical trial, leveraging our knowledge of CT1812&#8217;s preclinical and clinical profile to date.</font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Leverage our understanding of the S2R complex to develop product candidates for other CNS and degenerative diseases, including synucleinopathies.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We intend to develop and advance other product candidates to treat synucleinopathies, which include PD and DLB. We are initiating a study of CT1812 in patients with DLB and are currently recruiting for patients at approximately 18 sites, with more expected to follow. Data published in February&#160;2021 showed that the S2R complex may play an integral role in the pathology of PD and we believe these results merit further study in a well-controlled Phase 2 clinical trial. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Expand our pipeline through internal development, in-licensing and acquisitions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We intend to leverage our expertise in drug development and business development to evaluate additional product candidates as well as bring forward novel chemical matter using our library generation and Novel Improved Conditioned Extraction screening platform. To achieve this objective, we may supplement our internal development initiatives through selective in-licensing arrangements, as well as investments in strategic collaborations, and partnerships which complement our initiatives. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Optimize the value of CT1812 and other product candidates in major markets.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We currently retain all worldwide rights to CT1812 for all indications. We plan to develop and pursue approval of CT1812 and other future product candidates in major markets. Where appropriate, we may use strategic collaborations or partnerships to accelerate development and maximize the commercial potential of our programs. We and our key opinion leaders believe CT1812 also can be used in combination with other therapeutics targeting AD biologies and thus may have many partnering opportunities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Continue to pursue non-dilutive funding opportunities.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The majority of our research and clinical efforts have been funded by approximately $171.0&#160;million in cumulative grants awarded primarily by the NIA. This includes awards totaling $10.9&#160;million in support of preclinical studies and $160.1&#160;million for clinical development, the largest of which was the 2020 award of $81.0&#160;million supporting our upcoming Phase&#160;2 START (COG0203) study of CT1812 in early stage AD. These grants are non-dilutive and allow us to collaborate with research institutions in pursuing the development of our product candidates for age-related degenerative diseases. We intend to continue our work with these research institutions and plan to seek additional non-dilutive funding for our clinical development when possible. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Team and Collaborators</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have assembled a management team with extensive experience with CNS and degenerative diseases, significant expertise in the S2R biology domain, as well as drug discovery, clinical development, general management and business development. Collectively, our management team has a track record of managing drug development programs that have received regulatory approval and been successfully commercialized. In addition, our management team has built companies that have initiated innovative technologies and investigational new drug programs. We augment the strengths of our management team with an experienced board of directors and scientific and medical advisory boards. We believe our team, with its deep scientific and drug development background, positions us to become a leader in the development of therapies for age-related degenerative diseases and disorders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since our inception, we have collaborated and worked closely with key healthcare organizations and thought leading institutions in the field of degenerative diseases to develop and advance our therapeutic candidates. To date we have received approximately $171.0&#160;million in cumulative grants awarded primarily from the NIA to support our clinical trials. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Approach to Treating Age-Related Degenerative Diseases of the CNS and Retina</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Age-related degenerative diseases are defined by an age-related decline of cellular function often resulting in cell death. Neurodegenerative diseases, perhaps the most prominent of these degenerative disorders, are a variety of conditions defined by progressive degeneration of nerve cells, or neurons, which </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">86</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">often leads to neuronal death, causing decline in cognition or other functions, resulting in decreased quality of life and shorter life span. The two most common neurodegenerative diseases are AD and PD. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To our knowledge, no other biopharmaceutical company has focused solely on stopping the synaptic binding and signaling of soluble A&beta; oligomers through the use of small molecule receptor modulators, such as CT1812. We believe our deep expertise in oligomer and synaptic biology provides us with a competitive advantage and led to the creation of (1)&#160;proprietary assays that target the critical molecular step causing memory loss and (2)&#160;proprietary chemical libraries yielding highly brain penetrant small molecule drugs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based on this expertise, we are able to discover and optimize small molecule receptor modulators like CT1812 that we believe represent a functionally distinct and promising approach to synaptorestorative AD therapeutics where neurons remain viable and functional. These molecules were designed to displace A&beta; oligomers bound to neuronal receptors at synapses by selectively targeting and clearing A&beta; oligomers from the brain into the CSF. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to neurodegenerative diseases, other degenerative diseases include AMD. AMD is a common eye disease that results in the deterioration of the macula, causing visual distortion, loss of central vision and eventual blindness. It is the leading cause of blindness in people over 60&#160;years of age and afflicts approximately 11&#160;million Americans, including an estimated 12% of all U.S. adults over 80&#160;years of age. We believe that human genetic and internal proteomic pathway analyses obtained through our AD trials provides evidence of a relationship between the S2R complex and dry AMD. We are currently engaged in preclinical development activities for dry AMD, including studies to elucidate the key mechanisms by which CT1812 and the S2R complex alter the biological processes that contribute to dry AMD. We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in dry AMD. We have completed a pre-IND meeting with the FDA and, after the completion of our ongoing preclinical studies, we intend to submit an IND application to the FDA by the end of 2022, after which we plan to advance into a Phase 2 clinical trial, leveraging our knowledge of CT1812&#8217;s preclinical and clinical profile to date. Other S2R modulators are being explored, currently in lead identification studies, prior to lead optimization and candidate selection for IND-enabling studies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Sigma-2 Receptor Complex</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The S2R complex is comprised of transmembrane protein 97, or TMEM97, a four-domain transmembrane protein that forms a complex with progesterone receptor membrane component 1, or PGRMC1. The S2R complex is expressed in the CNS, the retina, as well as peripheral organs, including the pancreas, liver and kidney. Within the brain, the S2R complex is found in several areas, including the cerebellum, cortex, hippocampus and substantia nigra, and is enriched in neurons as compared to glial cells in the adult brain. In the retina, the S2R complex is expressed in several cell types including the RPE cells, photoreceptors and retinal ganglion cells. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The sigma-2 receptor (S2R) complex</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-fc_receptor4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-fc_receptor4clr.jpg]" height="264" width="280" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">87</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Internal and third-party studies suggest that the role of PGRMC1 and TMEM97, the protein components of the S2R complex, regulate cell damage response processes, including cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. In addition, the S2R complex regulates autophagy, the cellular process by which altered cellular proteins are degraded and removed. The aberrant activity of these processes, believed to be triggered by cellular stresses, is a hallmark of the dysfunction related to degenerative diseases. The S2R complex is a key regulator of processes that have been implicated in several age-related degenerative diseases and disorders including AD, retinal diseases, such as dry AMD, and synucleinopathies, such as PD and DLB. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe the array of degenerative disorders which involve protein components of the S2R complex allows for the potential therapeutic use of proprietary S2R modulators in numerous indications. While a fuller understanding of the molecular mechanisms involving the S2R complex remains to be elucidated, evidence suggests that targeting the S2R complex may provide therapeutic benefit to a wide range of age-related degenerative diseases and disorders. We believe modulating the S2R complex to normalize cellular function may provide a restoration of normal cellular processes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Biomarker and Imaging-Driven Evidence</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Biomarkers have become increasingly important in the development of treatments for neurodegenerative diseases for a number of reasons, including monitoring drug activity in patients, assessing changes in disease pathology during treatment and identifying responder populations for clinical studies. Given that biomarker-enabled therapeutics have a higher rate of success at gaining product approval, we elected to employ biomarkers in our programs to mitigate clinical development risk. To that end, in addition to a number of cognitive tests, our clinical trials use a variety of biomarkers to measure target and/or pathway engagement and assess changes in disease progression. For example, in AD, changes in cerebrospinal fluid, or CSF, concentrations of neurogranin and synaptotagmin-1 can be indicative of damage to synapses. In PD and other synucleinopathies, changes in markers such as &alpha;-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain can indicate dysfunction in membrane trafficking and autophagy processes. Quantitative EEG and PET imaging agents as well as vMRI may have utility in several neurodegenerative disorders to measure synaptic function, synaptic density and brain atrophy, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Novel, Improved Conditioned Extracts (NICE) Screening Platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Chemical structures that we are currently evaluating as potential therapeutics for degenerative diseases originate from our NICE screening platform. The NICE screening platform allows us to generate proprietary small molecule libraries derived from natural chemical scaffolds through a proprietary process which we refer to as conditioned extraction. Conditioned extraction, a process pioneered by a cofounder, allows us to eliminate undesirable properties of well characterized, biologically active compounds sourced from natural products, while retaining their biological activity. The resulting molecular configurations are then subjected to proprietary functional </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> screening assays designed to replicate the mature brain and its intricate connections and patterns of electrical signaling. Unlike most other screening assays, such as cells lines derived from immortalized neuronal tumor cells, our use of mature primary neuronal cultures provides us with information-rich measurements more indicative of normal brain function and predicative of functional benefit. We have utilized our NICE screening platform in conjunction with these mature primary neuronal cultures to develop product candidates for our proprietary Early Alzheimer&#8217;s Screening System, or EASSY. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The candidate library produced by the NICE screening platform is predisposed to compounds with attractive drug-like properties such as low molecular weight, low number of reactive hydrogen bonds, lipophilicity and relatively neutral chemistry properties. These characteristics reduce the reactivity of the molecules and related toxicities, while also enhancing their ability to cross the blood-brain and blood-retina barriers. As a result, the NICE screening platform is designed to accelerate drug development time while reducing development risk. We believe these characteristics provide us with a screening platform that is differentiated from other discovery strategies. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">88</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Product Candidates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are leveraging our expertise in the biology of the S2R complex, synaptic function and plasticity, and our understanding of the role of toxic age-related soluble proteins, to construct a pipeline of innovative, differentiated small molecule product candidates that are intended to restore normal cellular damage responses. We intend to develop therapeutics with the potential to overcome diseases associated with age-related toxic protein buildups that disrupt key cellular processes. Our initial product candidates target diseases characterized by dysfunction or dysregulation of the S2R complex that leads to cellular degeneration, as observed in age-related degenerative diseases and disorders, such as AD, GA secondary to dry AMD, PD and DLB as depicted in the illustration below. </font>
        </div>
        <div style="position:relative;margin-top:9.51pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-fc_candid4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-fc_candid4clr.jpg]" height="288" width="573" >
        </div>
        <div style="margin-top:16pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Lead Product Candidate: CT1812</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our lead product candidate, CT1812, is an orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the S2R complex; and through its modulation restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. CT1812 originated from our initial efforts with our NICE screening platform which enables the generation of innovative leads. Leads identified through NICE were then evaluated using proprietary </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> assays designed to better emulate </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> synaptic activity. We believe the use of these assays allows us to identify functionally active structures which may impact neuronal behavior significantly faster than alternate screening approaches. We currently retain worldwide rights to CT1812 for all indications and are developing CT1812 as a potential treatment for a range of diseases including AD, GA secondary to dry AMD and synucleinopathies, such as DLB. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT1812 for the Treatment of Alzheimer&#8217;s Disease (AD)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">CT1812 was designed to selectively target and displace A&beta; oligomers bound to neuronal receptors at synapses by a new and differentiated mechanism of action. CT1812 allosterically modulates, changing the conformation of a key multiprotein regulator of oligomer receptors, the sigma-2 receptor complex. This destabilizes the A&beta; oligomer binding site, increasing the off-rate and thereby displacing bound A&beta; oligomers, which are then cleared from synapses. In our preclinical studies, CT1812 has demonstrated the potential to protect synapses, facilitate their restoration and improve cognitive performance. These preclinical results are currently being validated in our ongoing Phase&#160;2 clinical trials. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview of the Disease</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">AD is a progressive neurodegenerative disorder characterized by cognitive dysfunction, memory loss, dementia and the impairment of daily living activities, along with numerous behavioral and neuropsychiatric </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">89</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">symptoms. In the advanced stages of the disease, an AD patient is unable to recognize faces, use or understand language and displays a lack of awareness for their surroundings. Continued functional decline ultimately results in the patient&#8217;s death. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Due to the size of the affected population and the current lack of effective disease modifying therapies, we believe that AD is one of the most significant unmet medical needs of our time. Nearly six million Americans have been diagnosed with AD and disease prevalence is expected to more than double by 2050. The direct healthcare costs to care for patients with AD and other dementias in the United States is currently estimated to exceed $300&#160;billion and projected to increase to $1 trillion by 2050. Absent the development of meaningful intervention in the course of the disease, the number of people diagnosed with, and dying from, AD is anticipated to escalate appreciably as lifespans lengthen, since prevalence increases significantly with age. The Centers for Disease Control listed AD as the primary cause of death for more than 121,000 Americans in 2019. The disease is equally devastating worldwide, with the World Health Organization estimating that AD affects as many as 35&#160;million people globally. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Currently Approved AD Therapeutics</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Only one disease-modifying therapeutic option has been approved by the FDA. Specifically, Biogen&#8217;s Aduhelm received accelerated approval on June&#160;7, 2021. The FDA allows accelerated approval for drugs to treat serious conditions that fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker thought to predict clinical benefit but is not itself a measure of clinical benefit. After receiving accelerated approval, drug companies are still required to conduct studies to confirm the clinical benefit. If the required studies confirm the drug&#8217;s benefit, then the FDA grants traditional approval of the drug. Aduhelm is a monoclonal antibody administered via infusion reported to reduce A&beta; plaques, which is distinct from our small molecule approach to modulate the S2R, thereby blocking A&beta; oligomers from binding to synapses. The only other therapies approved for AD are indicated to treat the symptoms of AD: acetylcholinesterase inhibitors, or AChEIs, and glutamatergic modulators and an orexin receptor antagonist. AChEIs are designed to slow the degradation of the neurotransmitter acetylcholine, helping to preserve neuronal communication and function temporarily. Glutamatergic modulators are designed to block sustained, low-level activation of the N-methyl-D-aspartate, or NMDA, receptor without inhibiting the normal function of the receptor in memory and cognition. Namenda (memantine), an NMDA receptor antagonist was approved in the United States in 2003. These therapeutic products do not modify or alter the progression of the underlying disease and provide only modest efficacy in treating the symptoms. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Therapeutic Approaches in Development to Treat the Underlying Disease Have Shown Little Success</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Numerous therapeutic approaches have been evaluated to remedy the causes of AD. Those focused on reducing the aberrant production, or removal, of intraneuronal neurofibrillary tangles of tau protein have yielded limited clinical benefit. Development initiatives intended to inhibit hyperphosphorylation of the tau protein and related kinase activity, enhance microtubule stability or block tau aggregation have largely been discontinued due to toxicity or a lack of efficacy. Microglial activation and its role in AD-induced neuroinflammation has emerged as another potential target for therapeutic development as has the proper functioning of processes dictating synaptic plasticity, believed to be of central importance to neuronal activity and continued viability. These efforts have also not yielded meaningful clinical advances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Among the more prevalent and targeted mechanisms implicated in AD, is the accumulation of A&beta; aggregates in the neuronal synapse where disease progression leads to synaptic dysfunction and dysregulation. The accompanying deterioration in neuronal activity ultimately results in neuronal death. As a result, the reduction in the levels of A&beta; aggregates at the synapse has been a prominent objective of a significant number of therapeutic candidates, including active and passive immunotherapies, designed specifically to target A&beta; aggregates. As with other treatment strategies, with the exception of Aduhelm, these approaches have likewise yielded few meaningful treatment advances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe the overarching issue with therapeutic interventions intended to limit A&beta; aggregate concentrations in the brain is that they fail to discriminate between different forms of A&beta; aggregates: fibrils, plaques and oligomers. Accordingly, these efforts may demonstrate success clearing fibrils and the largely inert plaques, but fail to address the specific neurotoxic effects of A&beta; oligomers. We believe that unlike </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">90</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">previously pursued approaches, our strategy of targeting the S2R has the potential to prevent A&beta; oligomer toxicity by acting directly at the synapse, thereby preventing synaptotoxicity, a mechanism we are testing in the clinic currently. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Role of A</font><font style="font-family:Helvetica, Arial Narrow, sans-serif;">&beta;</font><font style="letter-spacing:-0.2pt;"> Oligomers on Synapses and the Downstream Impact to Brain Function and AD</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Synapses are specialized points of contact between neurons, where electrical signaling and communication takes place. It is well established that synapses are routinely sprouted and resorbed as part of the normal process of learning and memory. Each neuron is covered with an estimated 10,000 synapses and these synapses participate in a complex electrical circuit with other neurons. Neurons do not divide or reproduce as part of normal physiological function. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Emerging scientific evidence suggests that A&beta; oligomers, formed over time through the buildup of A&beta; and its aggregates, bind to specific parts of the synaptic structure and interfere with the normal process of memory formation. This ligand-like activity confers to A&beta; oligomers potent synaptotoxic activity. In response, the neuron dismantles and resorbs the synaptic structure to prevent its abnormal function from interfering with what remains of the normal circuit behavior. If a large enough number of synapses are lost, the neuron dies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Synaptic loss, however, is not necessarily permanent and synapses can be regained or sprout again once the oligomers are removed. We have observed this process in our research involving preclinical AD models. This observation leads us to believe that displacement of synaptotoxic A&beta; oligomers may enable synapses to recover and potentially slow cognitive decline. We are further encouraged by the numerous precedents which exist that demonstrate the therapeutic utility of blocking ligand-receptor interactions in the brain with small molecule drugs capable of crossing the blood-brain barrier. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT1812 Uses a Differentiated Mechanism of Action to Selectively Target A&beta; Oligomers</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our proprietary CT1812 clinical candidate employs a novel and fundamentally different mechanism which through alteration of S2R activity selectively facilitates removal of neurotoxic A&beta; oligomers. Experimental evidence suggests that A&beta; oligomers likely occupy binding sites contiguous to the S2R complex. Binding at these locations is believed to produce structural distortions which inhibit the proper functioning of the S2R complex including its role in regulating critical signaling pathways. The preferential binding of CT1812 to the S2R complex produces conformational changes that alters the binding affinity of A&beta; oligomers. CT1812 binding to the S2R complex likely modulates the conformation of the S2R complex, which in turn allosterically alters the conformation of the oligomer binding pocket on the oligomer receptors. Binding pocket destabilization leads to displacement of A&beta; oligomers from the neurons and neuronal synapse. Once displaced, A&beta; oligomers are unable to rebind as long as threshold concentrations of CT1812 are present and are rapidly removed from the synapse. Based on our preclinical studies, we believe that CT1812 not only prevents binding of A&beta; oligomers, displacing them from the S2R complex sites at neuronal synapses, but also slows A&beta; oligomer-induced loss of synapses and restores synaptic activity, which may reverse downstream alterations related to membrane trafficking. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Use of an S2R Targeted Approach is Supported by the A673T Mutation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe the benefit of the mechanism by which CT1812 stops the toxic impact of A&beta; oligomers on cellular function is further supported by an analysis of the A&beta; sequence variant, A673T, which is commonly referred to as the &#8220;Icelandic&#8221; mutation. The A673T mutation is the first variant associated with a mutation in the protein structure of A&beta;, first identified through a genomic analysis of the Icelandic population, and is notable in that carriers of the mutation are four-fold less likely to develop AD. The A673T mutation, which involves the substitution of the amino acid alanine for threonine at position 673 of the precursor molecule, not only produces fewer A&beta; monomers, but our research indicated that the toxic A&beta; oligomers generated have four-fold lower affinity for brain cell synapses. This reduced binding is evidenced in the results of </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> experiments, which are presented below. Whereas wildtype A&beta; oligomer binding is pronounced, the binding of the A673T variant is much lower. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">91</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Binding affinities of wildtype versus mutant A&beta; oligomers to synapses </font>
          <br >
          <font style="font-style:italic;letter-spacing:-0.2pt;">(intensity in arbitrary fluorescent&#160;units)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:38.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:256.07pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:75.52pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Kd (nM) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:100.42pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">B maxa </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:256.07pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">wt A&beta; (1&#8201;&#8211;&#8201;42) oligomers </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:75.52pt;">
              <font style="letter-spacing:0.2pt;">Site 1:442 &#177; 70 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:100.42pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">7.98 &#215; 105 &#177; 0.29 &#215; 105 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:256.07pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">A673T mutant A&beta; (1&#8201;&#8211;&#8201;42) oligomers </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:75.52pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Site 1:1,955 &#177; 502 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:100.42pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">5.98 &#215; 105 &#177; 0.50 &#215; 105</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Kd is a constant used to evaluate and rank the strengths of interactions for ligands and their receptors. The smaller the Kd value, the greater the binding affinity. Bmax refers to the maximum amount of a ligand that can bind specifically to a receptors. Intensity is measured in arbitrary fluorescent&#160;units.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-ph_bindingbwlr.jpg" alt="[MISSING IMAGE: tm2226999d1-ph_bindingbwlr.jpg]" height="216" width="392" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that CT1812 is the only drug currently in clinical trials that mimics the effects of the A673T mutation. As the images presented below suggest, both CT1812 and the A673T mutation similarly reduce the binding of toxic A&beta; oligomers to synapses. We believe that drugs like CT1812 that mimic the protective effects of the A673T mutation are more likely to succeed in the clinical setting in patients with mild-to-moderate AD. </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-ph_synapsesbwlr.jpg" alt="[MISSING IMAGE: tm2226999d1-ph_synapsesbwlr.jpg]" height="200" width="392" >
        </div>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT1812 Trials in AD and DLB</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have completed six clinical trial evaluations of CT1812, in both healthy volunteers and patients with mild-to-moderate AD, with three clinical trials ongoing and one additional trial with topline results currently available and final results expected by the end of 2022. The clinical trials we have conducted to date have enabled us to evaluate the safety profile of CT1812, as well as validate its mechanism through proof-of-concept trials and conduct initial assessments of its therapeutic potential. The following is the status of our completed and ongoing clinical trials. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">92</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:72pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview of our completed, ongoing and planned clinical studies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2226999d3-tbl_trials4c.jpg" alt="[MISSING IMAGE: tm2226999d3-tbl_trials4c.jpg]" height="244" width="608" >
        </div>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">COG0201&#8201;-&#8201;Phase&#160;2 (SHINE) Clinical Trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our COG0201 SHINE study is a randomized, double-blind, placebo-controlled Phase&#160;2 clinical trial designed to enroll up to a total of 144 patients with mild-to-moderate AD to evaluate the safety and potential efficacy of CT1812. Participants are divided in two CT1812 dose groups (100 mg or 300 mg) and one placebo group, dosed daily for six&#160;months. Endpoints include safety and biomarker evidence of disease modification as well as cognitive function, as measured by the ADAS-Cog 11-item version, or ADAS-Cog 11. ADAS-Cog 11 is a globally recognized cognitive scale that is used to assess cognition in patients with AD. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Preliminary results from an interim analysis of the first 24 patients from the COG0201 study demonstrated that CT1812 continued to be generally well tolerated. There were four serious adverse events, or SAEs, which were not drug-related and occurred in a single placebo patient. The patient was discontinued due to one of the SAEs. Treatment emergent adverse events, or TEAEs, were well balanced across all treatment groups. We observed mild and transient elevations of liver enzymes in three patients without any other indications of liver injury. These results were consistent with findings from earlier clinical studies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The preliminary results also demonstrated a significant decline in the presence of A&beta; monomers and a three-point mean improvement in the rate of cognitive decline as measured by ADAS-Cog 11, in patients receiving CT1812 when compared to placebo. These results were observed in patients receiving CT1812 or placebo in addition to background therapies they may have already been receiving for AD. We believe these preliminary results provide promising evidence of CT1812&#8217;s cognitive and biological impact on the 24 patients included in the interim analysis of the SHINE study. These results indicate that patients treated with CT1812 showed relative stability on a measure of cognitive performance compared to the placebo group. A mean difference in the rate of decline of approximately three points was observed between the CT1812 dose groups receiving either 100 mg or 300 mg versus the placebo group based on the ADAS-Cog 11 measurements. After review of these results, which are presented in the graph below, we decided to continue trial enrollment, and are identifying sites and screening patients for this study. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">93</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Results indicate a three-point improvement in cognitive decline in CT1812-treated patients.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-lc_indicate4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-lc_indicate4clr.jpg]" height="204" width="607" >
        </div>
        <div style="text-indent:20pt; margin-top:12.6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Proteomic measurements were also performed of CSF and plasma from these patients, from which we have comprehensive datasets of whole proteome changes observed in AD patients given CT1812 versus placebo for six&#160;months. From this, we identified product candidate pharmacodynamic biomarkers that could reflect processes of target engagement, pathway engagement and/or early disease modification. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The SHINE trial was not powered to detect statistically significant treatment differences. Nevertheless, p-values were calculated at the time of the interim analysis with respect to the clinical and biomarker outcomes to help inform on the potential importance of observed numerical treatment differences. For these interim analyses, p-values&lt;0.05 were considered &#8220;significant&#8221; while p values&gt;0.05 were considered &#8220;non-significant.&#8221; The approximately three-point treatment difference relative to placebo observed for the pooled dose groups that was observed on the ADAS-Cog 11 was non-significant (p&gt;0.05; p=0.1295), while the treatment difference relative to placebo that observed for the reduction in CSF A&beta; 42 protein at the 300mg dose was significant (p&lt;0.05; p=0.0178). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proof-of-Concept Clinical Trials for the Mechanism of CT1812</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have conducted and are continuing to conduct a series of clinical proof-of-concept trials intended to assess target engagement and the impact of CT1812 on synaptic activity. These proof-of-concept trials are presented in more detail below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">COG0202&#8201;-&#8201;Phase&#160;2 (SEQUEL) Trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our COG0202 SEQUEL study is a randomized, double-blind, placebo-controlled Phase&#160;2 clinical trial of 16 patients with mild-to-moderate AD to evaluate the potential efficacy of CT1812 in restoring synaptic function in patients through quantitative EEG measurement, as reflected by relative theta power. The trial is configured as a two-arm crossover trial, in which half of the participants will receive 300 mg of CT1812 daily for 29&#160;days. After a 14-day wash out period, these participants will receive placebo for an additional 29&#160;days. The other half of the participants receive placebo daily for 29&#160;days. After a 14-day wash out period, these participants will receive CT1812 treatment for an additional 29&#160;days. CSF and EEG evaluations are taken periodically throughout the duration of the trial. We anticipate completing enrollment in 2022 and reporting topline data thereafter. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">COG0105&#8201;-&#8201;Phase&#160;1 (SPARC) Trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The COG0105 SPARC study is a randomized, double-blind, placebo-controlled Phase&#160;1 clinical trial of 23 patients with mild-to-moderate AD. The primary objectives of the study were to evaluate CT1812 for safety and tolerability. The secondary objectives were to evaluate potential effects of CT1812 on biologically relevant endpoints using various imaging modalities, including PET imaging and vMRI as well as CSF biomarkers, and cognitive and clinical endpoints. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Participants were randomized to receive treatment with 100 mg or 300 mg of CT1812 or placebo once daily for 24 weeks. A preliminary analysis has been made of safety, clinical laboratory measurements, PET </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">94</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">imaging, functional MRI and vMRI, CSF biomarkers and clinical outcomes in patients treated with CT1812 compared to those in patients receiving placebo. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Seventeen patients completed the study protocol, eleven in the CT1812 arm (six in the 100mg cohort; five in the 300mg cohort) and six in the placebo arm. CT1812 was well-tolerated with similar adverse event rates across treatment arms. Most adverse events were mild-to-moderate in severity with no deaths and no treatment-related SAEs reported. We observed mild and transient elevations of liver enzymes without any other indications of liver injury in two patients in the 300-milligram group. The patients were discontinued from the study and the liver enzyme levels returned to normal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Topline results from the analyses of secondary endpoints demonstrated that after 24-weeks of treatment, there were no significant treatment differences on the ADAS-Cog 11 change from baseline. In addition, there were no significant treatment differences on SV2A signal change compared to baseline. However, vMRI showed a trend (p=0.0641) towards a significant reduction in the loss of composite brain volume in CT1812-treated patients (pooled) compared to placebo. A statistically significant (p&lt;0.05) reduction in loss of brain volume was also observed in three brain regions (hippocampus, prefrontal cortex and pericentral cortex) in treated patients (pooled) compared to placebo, as shown in the table below. </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-lc_volumetric4c.jpg" alt="[MISSING IMAGE: tm2226999d1-lc_volumetric4c.jpg]" height="327" width="304" >
        </div>
        <div style="margin-top:16.6pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">COG0104&#8201;-&#8201;Phase&#160;1 (SNAP) Trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our COG0104 SNAP study was a randomized, double-blind, placebo-controlled Phase&#160;1 clinical trial that enrolled three patients with mild-to-moderate AD to measure the effects of CT1812 on displacement of A&beta; oligomers. Patients were randomized 2:1 to receive a single dose of CT1812 or placebo. Patients enrolled in the trial had an indwelling catheter placed in the lumbar CSF space. CSF samples were collected hourly over a 28-hour period. Five CSF samples were collected before and 24 samples collected after administration of a single 560 mg oral dose of CT1812 or placebo. CSF samples from trial participants were analyzed to measure the concentration of A&beta; oligomers over the trial period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Results of this trial revealed an increase in A&beta; oligomer levels in the CSF over the 24-hour period following treatment with CT1812, but not in the patient administered placebo. These findings were observed using two independent methods, microimmunoelectrode and western blots. This effect of CT1812 was specific to A&beta; oligomers, as no CT1812-related increase in A&beta; 1-40 or 1-42 monomer was observed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe these results provide the early proof of principle of CT1812 target engagement in AD patients. Further, we believe that they corroborate our mechanism of action previously demonstrated in preclinical studies, providing the first evidence that our preclinical studies translate to patients with AD. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">95</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">First evidence of target engagement in humans, which mirrors that found preclinically; and</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          <br >
          <font style="letter-spacing:0.2pt;">we believe this reinforces that our mechanism of action extends to patients with AD</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8.61pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-lc_evidence4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-lc_evidence4clr.jpg]" height="524" width="476" >
        </div>
        <div style="margin-top:14.71pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">COG0102&#8201;-&#8201;Phase&#160;1 Trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our COG0102 study was a randomized, double-blind, placebo-controlled, Phase&#160;1 clinical trial of 19 patients with mild-to-moderate AD. Participants were administered one of three oral doses of CT1812, either 90 mg, 280 mg or 560 mg, once daily for 28&#160;days. The primary endpoint of the trial was safety with a secondary objective of establishing the pharmacokinetic, or PK, profile of CT1812. Also included as exploratory endpoints were measurement of CT1812 in CSF, and protein expression changes in CSF and plasma. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order to gauge the impact of CT1812 on synaptic damage due to AD, we measured concentrations of synaptic proteins, neurogranin and synaptotagmin-1, in CSF samples from these patients using clinically validated standardized assays. Our evaluation of AD protein biomarkers in the CSF revealed that neurogranin levels, shown in the left graph below, in patients treated with CT1812 for 28&#160;days was significantly decreased compared to levels measured in patients administered placebo (p =0.05, analysis of covariance). Neurogranin is a synaptic damage marker that increases in the CSF of AD patients reflecting its decrease in the brain. The lowering of synaptic damage markers in the CSF is consistent with CT1812&#8217;s mechanism of action as observed in our preclinical studies and demonstrates the potential of the drug to slow A&beta; oligomer-induced synapse loss. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Another synaptic damage biomarker that is elevated in the CSF of AD patients is synaptotagmin-1. CSF levels of synaptotagmin-1 were similar at baseline and end of study in patients treated with CT1812, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">96</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">whereas its levels in the placebo group displayed a marked increase over the same time period. This analysis of CT1812&#8217;s impact on synaptotagmin-1 levels is presented in the right graph below. Consistent with our belief that targeting the S2R has the potential to prevent A&beta; oligomer toxicity, we observed a reduction in neurogranin and synaptotagmin in CSF, which are measures of synaptic damage, suggesting that CT1812 may have the ability to protect synapses in AD patients. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Treatment with CT1812 was associated with lower levels of neurogranin and</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          <br >
          <font style="letter-spacing:0.2pt;">synaptotagmin-1 compared to placebo</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-lc_treatmen4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-lc_treatmen4clr.jpg]" height="223" width="392" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CT1812 was well tolerated in the COG0102 study. All AEs were mild-to-moderate. Some of the participants in the highest dose group experienced lymphocytopenia or elevated liver enzymes. These laboratory abnormalities resolved in most patients with continued dosing of CT1812. One trial participant was discontinued from CT1812 prior to study completion because of elevated liver enzymes with subsequent resolution of this abnormality. Lymphocytopenia or elevated liver enzymes were not observed in either the 90 mg or 280 mg dosing cohorts. There were no SAEs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Phase&#160;1 Safety Trials</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to Phase&#160;1 clinical trials conducted in our targeted patient population, we also conducted a series of Phase&#160;1 clinical trials in healthy volunteers designed to evaluate the safety profile of CT1812, as well as determine potential drug-food or drug-drug interactions. These trials and their results, which are summarized below, indicated that CT1812 was generally well-tolerated. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">COG0101&#8201;-&#8201;First in human phase 1 clinical trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our COG0101 study was a randomized, double-blind, placebo-controlled ascending dose Phase&#160;1 multi-cohort clinical trial of 93 healthy volunteers to assess the safety and potential drug-food interactions of CT1812. The trial was conducted in two segments. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The first segment was structured as an ascending single dose trial, in which participants received one dose of CT1812 with increasing doses given to each of six cohorts. In this segment of the trial, eight participants were enrolled per dosing cohort with six participants receiving CT1812 and two receiving placebo. The doses evaluated were 10 mg, 30 mg, 90 mg, 180 mg, 450 mg and 1,120 mg. A seventh cohort of six patients received a single 90-mg dose after receiving a standardized meal. All doses were administered as scheduled. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The second segment was configured as a multiple ascending dose trial, that enrolled 39 healthy volunteers, divided in three cohorts of ten participants, with one additional cohort consisting of nine healthy elderly volunteers. Each participant in this segment of the trial received a single dose of CT1812 each day for 14&#160;days. The doses evaluated in this second segment were 280 mg, 560 mg and 840 mg. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">97</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">CT1812 CSF concentrations correlated to a &gt;80% S2R predicted receptor occupancy in brain</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-lc_correlat4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-lc_correlat4clr.jpg]" height="272" width="336" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following completion of each trial cohort, bioanalytical evaluation of plasma CT1812 PK was conducted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This trial demonstrated that administration of CT1812 in single doses of up to 1,120 mg, administered once, as well as up to 840 mg of CT1812 dosed for 14 consecutive days was well tolerated. Significantly, CT1812 concentrations detected in the CSF correlated to an estimated receptor occupancy in the brain of greater than 80%. There was one SAE in the multiple-dose portion of the study that was deemed unrelated to study drug. There were no SAEs related to the product candidate or TEAEs leading to withdrawal from the study. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">COG0103&#8201;-&#8201;Phase&#160;1 trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our COG0103 study was a Phase&#160;1 clinical trial of 15 healthy volunteers designed to evaluate the potential effects of CT1812 on select CYP isoenzymes: CYP2C19, CYP2C9, CYP2D6 and CYP3A4. This was accomplished by assessing its effects on substrates of these isoenzymes: 20 mg omeprazole, 500 mg tolbutamide, 50 mg dextromethorphan and 4 mg midazolam. The 15 healthy volunteers who participated in the trial received the substrates of these isoenzymes two days prior to the initial dose of CT1812 and PK assessments were performed. A dose of 560 mg of CT1812 was administered to each of the trial participants for the following six consecutive days. The day 6 dose of CT1812 was administered concomitantly with the four-substrate cocktail and PK assessments were repeated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A weak drug interaction was observed between CT1812 and midazolam and dextromethorphan. A lack of any clinically meaningful interaction was observed with coadministration of omeprazole or tolbutamide. Based on the small magnitude of change in PK parameters of the probe drugs observed in this study for the isoenzymes CYP2D6 and CYP3A4, clinically meaningful interactions are unlikely. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Clinical Development Plans and Future Trials</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Our Upcoming COG0203 Phase&#160;2 Clinical Trial Funded by NIA Grant of approximately $81.0&#160;million</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our COG0203 study is a randomized, double-blind, placebo-controlled Phase&#160;2 clinical trial designed to enroll 540 patients with early-stage AD and powered to show a change in the rate of cognitive and functional decline. We intend to enroll patients with MCI, due to AD or mild AD who have elevated levels of A&beta; as determined by PET imaging or as measured in CSF. The trial is being conducted in collaboration with the ACTC and will utilize approximately 50-60 academic sites associated with the consortium, as well as other qualified sites that are not part of the consortium. Patients will be randomized to receive CT1812 or a placebo for 18&#160;months. In addition to a battery of cognitive measures, we intend to use a variety of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">98</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">biomarkers to measure target engagement and assess changes in neurodegeneration and disease progression. We have received a grant of approximately $81.0&#160;million from the NIA to fund this trial. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preclinical Results</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to entering clinical trials, the therapeutic potential of CT1812 was observed in numerous preclinical studies. As is demonstrated in the images below, the addition of A&beta; oligomers to neuronal cell cultures resulted in synaptotoxicity as illustrated by the reduced expression of synaptic markers neurogranin, synaptotagmin and SV2A. The lack of immunoreactivity of these three synaptic proteins can be seen in the middle column of the image below. However, the presence of CT1812 blocked the A&beta; oligomer-induced loss of synapses, as reflected by the presence of synaptic protein expression displayed in the right-hand column below. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">CT1812 prevents A</font><font style="font-family:Helvetica, Arial Narrow, sans-serif;">&beta;</font><font style="letter-spacing:0.2pt;"> oligomer-mediated synaptic damage</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-ph_prevents4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-ph_prevents4clr.jpg]" height="625" width="437" >
        </div>
        <div style="text-indent:20pt; margin-top:12.01pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Results showed that CT1812 also slowed the loss of synapses that is triggered by A&beta; oligomers. A higher resolution image of the cell culture exposed to A&beta; oligomer is shown below, before the addition of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">99</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CT1812, which is presented on the left, and after the addition of CT1812, which is presented on the right. A&beta; oligomers shown in red bind to synaptic receptors and reduce numbers of synapses shown in green. The addition of CT1812 displaces A&beta; oligomer binding and appears to block the effects induced by the A&beta; oligomers, with the synapse numbers remaining at levels similar to normal. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">CT1812 slows loss of synapse numbers in the presence of A</font><font style="font-family:Helvetica, Arial Narrow, sans-serif;">&beta;</font><font style="letter-spacing:0.2pt;"> oligomers</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.6pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-ph_slows4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-ph_slows4clr.jpg]" height="101" width="465" >
        </div>
        <div style="text-indent:20pt; margin-top:13.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The protective benefits of CT1812 observed in these </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> assays are supported by functional </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> assessments of CT1812. In one such preclinical study, the memory of mice was tested based on the subject&#8217;s ability to recall fear-inducing triggers and its performance in a maze. The mice exhibiting symptoms of AD, depicted by the red bars in the image below, performed significantly worse in both the fear and maze tests when compared to normal, non-transgenic mice, represented by the blue bars. However, after administration of CT1812, the AD mice, represented by the solid green bars, were seen to perform at a level similar to that achieved by normal mice. We believe these results are illustrative of CT1812&#8217;s ability to restore synaptic proteins and numbers to normal levels and with it, the animal&#8217;s functional capabilities. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">CT1812 restores functional capabilities in a mouse model of AD</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.7pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-bc_restores4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-bc_restores4clr.jpg]" height="269" width="593" >
        </div>
        <div style="margin-top:17.89pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CT1812 for the Treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (Dry AMD)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that several lines of evidence suggest that modulation of the S2R complex may provide significant therapeutic utility for the treatment of GA secondary to dry AMD. Human genetics points to TMEM97 as a promising therapeutic target for GA secondary to dry AMD, as indicated via several large-scale, independent genome-wide association, or GWA, studies. In addition, unbiased pathway analysis of AD patient proteomic data obtained during our clinical trials provides independent evidence of a relationship between the S2R complex and GA secondary to dry AMD. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are currently engaged in preclinical development activities for this indication, including studies to elucidate the key mechanisms by which CT1812 and the S2R complex alter the biological processes that contribute to dry AMD. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">100</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Early proof-of-concept studies with CT1812 indicate a role of S2R modulators in rescuing key aspects of dry AMD including maintaining homeostatic functions of RPEs, ameliorating lysosomal dysfunction and preventing RPE cell death. PK assessment indicates that we can achieve therapeutic levels (&gt;80% receptor occupancy) of CT1812 in retinal tissue through oral administration. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have completed a pre-IND meeting with the FDA, and, after the completion of our ongoing preclinical studies, we intend to submit an IND application to the FDA by the end of 2022, after which we plan to advance into a Phase 2 clinical trial, leveraging our knowledge of CT1812&#8217;s preclinical and clinical profile to date. We believe that well-characterized clinical endpoints and a defined regulatory path increase the attractiveness of this indication. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview of the Disease</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">AMD is the leading cause of blindness in people over 50&#160;years of age in the United States, afflicting approximately 11&#160;million people in the U.S., including an estimated 12% of all U.S. adults over 80&#160;years of age. Dry AMD is a progressive condition and accounts for up to 90% of all AMD cases. Advanced dry AMD, or GA, affects approximately 2&#160;million people in the U.S. There are no approved therapeutics available for dry AMD. Other treatments in development are primarily invasive, including intravitreal injections, stem cell replacement and gene therapy approaches. We believe the limited treatment options available for patients with dry AMD, coupled with newly implicated biochemical pathways, make GA secondary to dry AMD an attractive target for the development of therapeutics. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There are two types of AMD, the first of which is neovascular, or wet AMD, and non-neovascular, or dry AMD. Dry AMD, which accounts for approximately 90% of all AMD cases, is a progressive condition that involves a dysregulation of cellular processes, among which is the accumulation of lipid deposits, known as drusen, that causes a thickening of the Bruch&#8217;s membrane. This thickening disrupts the cytoarchitecture of the RPE, and this disruption, coupled with oxidative stress and inflammation, leads to the diminished health and function of RPE and photoreceptor cells, with accumulated damage resulting in cell death and visual impairment. </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The anatomy of the eye and the regions impacted by AMD</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-ph_anatomyclr.jpg" alt="[MISSING IMAGE: tm2226999d1-ph_anatomyclr.jpg]" height="239" width="516" >
        </div>
        <div style="margin-top:16.01pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitations of Current Treatments</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Treatments for dry AMD and GA secondary to dry AMD are currently limited to vitamins and over-the-counter zinc. While there are no therapeutics approved by the FDA to treat dry AMD or GA secondary to dry AMD, there is considerable development activity ongoing involving numerous targets. Among the areas of ongoing interest are efforts targeting the complement pathway and its role in inflammation, as mutations in this pathway have been associated with higher risk of dry AMD. In addition, cell and gene therapy approaches are being evaluated to regenerate RPE cells and rescue the loss of photoreceptors. Small molecule visual cycle modulators are also under evaluation to maintain retinal integrity. Most of these approaches require invasive administrations. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">101</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:212pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rationale for S2R Mechanism of Action</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Indications of S2R Involvement in Geographic Atrophy Secondary to Dry AMD</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that several lines of evidence suggest that modulation of the S2R complex may provide significant therapeutic utility for the treatment of GA secondary to dry AMD. First, human genetics point to TMEM97 as a promising therapeutic target, as indicated via several large-scale, independent GWA studies. These studies indicate a genetic mutation known as a single nucleotide polymorphism, or SNP, in the TMEM-VTN locus confers decreased risk for dry AMD. It remains unknown if this mutation confers a change in TMEM97 expression levels. However, knockdown of TMEM97 in </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> models of the disease partially rescues RPE cells from oxidative stress-induced cell death. Investigation of the effects of pharmacological perturbation of the S2R complex signaling is currently ongoing to determine if the rescue of cell death mediated by decreasing TMEM97 expression can be replicated by S2R modulators, such as CT1812. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Unbiased Analysis of Clinical Trial Sample Proteomics Data: Top Disease Ontologies</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unbiased pathway analysis of AD patient proteomic data obtained during the COG0102 and SHINE Part-A clinical trials provides independent evidence of the relationship between the S2R complex and dry AMD. Analyses of CSF were performed to ascertain which predesignated functional disease ontologies may be affected by the administration of CT1812. These analyses identified GA and macular degeneration as two of the top indications affected, with GA presenting the most significant relationship. Subsequent analyses identified several subsets of proteins altered by CT1812 that are involved in dry AMD. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In subsequent analyses examining the overlap of proteins altered in CSF and plasma biofluids of AD patients treated with CT1812 versus placebo, we identified a set of proteins, altered by CT1812 that have been previously shown by other groups to be disrupted in dry AMD or GA, compared to age-matched controls. Subsequent analysis identified several pathways in which these proteins are involved, many of which have known genetic or biological links to processes disrupted in dry AMD. We believe the collective insights provided by these analyses provide early proof of concept that an S2R modulator may be capable of altering AMD relevant proteins and pathways in an aged patient population. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Preclinical Support for Clinical Trials</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that proof-of-concept studies indicate a clear role of S2R modulators in rescuing key aspects of dry AMD. Pathway analysis of transcriptomic data suggest a key role of S2R modulators in regulating pathways involved in cell survival and inflammation. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">102</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:218pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Mechanistic Studies Indicate CT1812 Plays a Role in Cell Survival</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          <br >
          <font style="letter-spacing:0.2pt;">and Inflammatory Pathways in RPE Cells</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-tbl_studies4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-tbl_studies4clr.jpg]" height="439" width="593" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Additional functional studies indicate S2R modulators may ameliorate disruptions in homeostatic functions of RPEs, including ameliorating lysosomal dysfunction and salvaging the ability of RPE cells to recycle photoreceptor outer segments. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">103</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Working Hypothesis of Mechanism of Action in Dry AMD</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.32pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-fc_working4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-fc_working4clr.jpg]" height="392" width="339" >
        </div>
        <div style="text-indent:20pt; margin-top:9.81pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe preclinical studies provide further evidence supporting a clinical trial for CT1812 as a potential treatment for GA secondary to dry AMD. PK assessment indicates that we can achieve therapeutic levels (&gt;80% receptor occupancy) of CT1812 in retinal tissue through oral administration. Moreover, as is illustrated in the graph below, CT1812 levels recorded in the retina were similar to those in the brain, suggesting that the dose(s) used to achieve potential therapeutic levels in the retina needed to achieve efficacy will be similar to the dose(s) for AD. </font>
        </div>
        <div style="margin-top:7.31pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Similarities in CT1812 concentrations following oral administration in the brain and retina</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.32pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-lc_retina4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-lc_retina4clr.jpg]" height="276" width="440" >
        </div>
        <div style="text-indent:20pt; margin-top:9.72pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our next-generation S2R modulator, CT2074, shows good retinal exposures above 80% receptor occupancy with oral administration. This modulator has favorable PK properties, including high degree of bioavailability and high retina-to-plasma ratio, and shows activity in rescuing deficits in AMD assays. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">104</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-lc_study4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-lc_study4clr.jpg]" height="288" width="413" >
        </div>
        <div style="text-indent:20pt; margin-top:10.41pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additional studies have been conducted to elucidate the key mechanisms by which CT1812 and the S2R complex alter the biological processes that contribute to dry AMD. </font><font style="font-style:italic;letter-spacing:0.2pt;">In vivo</font><font style="letter-spacing:0.2pt;"> preclinical studies are evaluating the utility of CT1812 to impede the death of retinal ganglion cells. Not only is it anticipated that these proof-of-concept studies will allow us to further elucidate the mechanism by which the S2R complex modulators act upon the various disease pathologies, but the learnings from this may also inform appropriate patient selection, time of intervention and clinical outcome measurements to enable a successful clinical trial design. </font>
        </div>
        <div style="margin-top:11.12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposed Phase&#160;2 Clinical Trial Design</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that an S2R modulator, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in GA secondary to dry AMD. We have completed a pre-IND meeting with the FDA, and, after the completion of our ongoing preclinical studies, we intend to submit an IND application to the FDA by the end of 2022, after which we plan to advance into a Phase 2 clinical trial, leveraging our knowledge of CT1812&#8217;s preclinical and clinical profile to date.</font>
        </div>
        <div style="text-indent:20pt; margin-top:7.91pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We anticipate eligibility requirements to include individuals 50&#160;years of age or older that have received a diagnosis of GA secondary to dry AMD, with a best corrected visual acuity, or BCVA, score of 24 letters or more, with GA of between 2.5 mm2 and 17.5 mm2. The proposed primary endpoint of the trial is change in GA lesion area using fundus autofluorescence imaging. Proposed secondary endpoints are expected to include change in the square root of the GA lesion area, low luminance visual acuity, or LLVA, and BCVA, low luminance visual acuity deficit and drusen volume as measured by optical coherence tomography. We plan on measuring these outcomes at three-to-six-month intervals. </font>
        </div>
        <div style="margin-top:11.11pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">S2R Modulators for the Treatment of Synucleinopathies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Substantial cellular and clinical biomarker evidence demonstrate that our S2R modulators, including our clinical drug candidate CT1812, have a beneficial impact on the pathways impaired in synucleinopathies, namely the localization of &alpha;-synuclein aggregates in Lewy bodies, which is a chief hallmark of PD and other synucleinopathies. More recently, human genetic evidence has linked SNCA, the gene encoding &alpha;-synuclein, to the pathology of synucleinopathies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.91pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have conducted preclinical studies of S2R ligands in our library, including CT1812, to explore the potential of S2R modulators to rescue the biological processes that are impaired in synucleinopathies. Subject to discussion with the FDA, we intend to conduct clinical studies in DLB, PD and potentially other synucleinopathies as outlined below. </font>
        </div>
        <div style="margin-top:11.12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">An Overview of Synucleinopathies</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Synucleinopathies are a group of neurodegenerative disorders in which the protein alpha-synuclein accumulates abnormally to form inclusions in the cell bodies or axons of neurons or oligodendrocytes. Two </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">105</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">of the primary synucleinopathies are PD and DLB, which each involve motor and cognitive dysfunction. While the cell types and brain structures that are affected in PD and DLB vary markedly between the disorders, synucleinopathies share a characteristic accumulation of &alpha;-synuclein aggregates into fibrils, the major constituent of the Lewy bodies that occur inside brain neurons in these diseases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Increasing evidence suggests that &alpha;-synuclein also aggregates into oligomers, and that oligomers are more toxic than fibrils. &alpha;-synuclein oligomers contribute to neurodegeneration through a variety of mechanisms including disrupting normal autophagy, and inducing synaptic dysfunction and loss. Synaptic dysfunction and loss contribute to the cognitive and motor symptoms of these diseases. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Synucleinopathies are second only to AD in terms of neurodegenerative disease prevalence. In the United States, as many as one million people suffer from PD and an estimated 1.4&#160;million from DLB. According to the Parkinson&#8217;s Foundation and the Lewy Body Dementia Association, the direct healthcare costs for patients with PD and DLB are estimated to be approximately $25&#160;billion and $31.5&#160;billion per year, respectively. For PD, these direct medical costs include an estimated $2.5&#160;billion for medications annually in the United States. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitations of Current Treatments</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Most approved therapeutic products treat the symptoms of the diseases and modulate dopamine. While some existing products provide meaningful symptomatic relief, they have significant side effect risks, fail to address the progression of the disease, and over time gradually lose their effectiveness in treating the symptoms of the disease. There are no currently approved disease-modifying therapeutics for PD or other synucleinopathies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rationale for S2R Mechanism of Action for Synucleinopathies</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&alpha;-synuclein is a protein primarily found in neural tissue that plays a role in neurotransmission. In synucleinopathies such as DLB and PD, &alpha;-synuclein builds up in brain cells and forms oligomers that saturably bind to neurons where they impair critical cellular processes, causing synaptic dysfunction and eventual loss. Our decision to pursue the treatment of synucleinopathies with S2R compounds is based on internal and third-party data, indicating that the S2R components PGRMC1 and TMEM97 regulate cell pathways known to be impaired in synucleinopathies, such as autophagy, vesicle trafficking and lipid synthesis; &alpha;-synuclein oligomers bind directly to PGRMC1; and synucleinopathies share certain mechanistic similarities with AD, including pathologies related to aberrant oligomeric protein formations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As summarized below, we believe our preclinical studies provide compelling evidence supporting the use of CT1812 and our next-generation S2R modulators as potential therapeutics to treat synucleinopathies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As with oligomers of the A&beta; protein in AD, oligomers of &alpha;-synuclein are highly toxic when bound to brains cells and internalized. This binding causes cellular stress, including three major pathway disruptions: upregulation of the autophagy receptor LAMP2A, dysregulation of lipid metabolism and a reduction in membrane trafficking. The S2R complex components, PGRMC1 and TMEM97, directly regulate these processes, activities which are compromised by the binding and internalization of &alpha;-synuclein oligomers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Compounds that bind to S2R and block &alpha;-synuclein binding and/or internalization are therefore expected to be disease-modifying. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preclinical Study Support for Clinical Trials</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The results of </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> studies suggest that S2R modulator, such as CT1812, may have disease modifying effect on the synucleinopathies by reversing pathway disruption and dysregulation caused by &alpha;-synuclein oligomers. In work funded by grants from the Michael J. Fox Foundation, &alpha;-synuclein oligomers were found to bind to brain cells in culture and are internalized, indicated by the red dots in the image to the left below. With the addition of S2R modulator CT1812, the binding and thus internalization of the &alpha;-synuclein oligomers is inhibited as indicated in the image to the right below. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">106</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:219pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">CT1812 blocks the binding and internalization of &alpha;-synuclein oligomers the neuronal synapses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-ph_blocks4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-ph_blocks4clr.jpg]" height="251" width="464" >
        </div>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The potential for S2R modulators to reverse the deleterious cellular effects of &alpha;-synuclein oligomers is also reflected in the </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> analysis of LAMP2A expression presented below. LAMP2A is a critical component of chaperone-mediated autophagy, one of several processes that eliminate damaged cellular proteins. Its expression, noted in orange, is upregulated in the presence of the toxic &alpha;-synuclein oligomer, likely a compensatory mechanism in response to the cellular insult. S2R modulators, which block membrane trafficking deficits caused by &alpha;-synuclein oligomers, are observed to inhibit the upregulation of LAMP2A, as evidenced by the dark and light gray in the below chart. As these antagonists are selective for the S2R complex, their ability to reverse the effects of &alpha;-synuclein on LAMP2A expression provides compelling evidence of the S2R complex&#8217;s importance in the regulation of this autophagy pathway. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">In vitro</font><font style="letter-spacing:0.2pt;"> analysis further illustrates &alpha;-synuclein oligomers&#8217; dose-dependent inhibition of membrane trafficking. Importantly, oligomer-related inhibition was noted to be four-fold higher than that observed with high concentrations of monomeric &alpha;-synuclein, illustrative of the significantly greater toxicity of &alpha;-synuclein oligomers. The addition of CT1812 was observed to reverse the membrane trafficking deficit related to the presence of &alpha;-synuclein oligomer, while having no effect on membrane activity when dosed in its absence. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">107</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">S2R antagonists reverse the effects of &alpha;-synuclein oligomers on LAMP2A expression and trafficking</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.6pt; text-align:center; width:456pt;">
          <img src="tm2226999d1-bc_reverse4clr.jpg" alt="[MISSING IMAGE: tm2226999d1-bc_reverse4clr.jpg]" height="303" width="607" >
        </div>
        <div style="margin-top:18.19pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposed Phase&#160;2 Clinical Trial in Dementia with Lewy bodies (DLB)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are actively enrolling in approximately 18 sites for our Phase&#160;2 clinical trial studying the use of CT1812 to treat patients diagnosed with DLB. The design of this trial is a double-blind, randomized trial involving three dose groups, two active treatment cohorts and a placebo group. We are enrolling 120 patients in a six-month study, with equal participant numbers in each of the three dose groups, with daily (QD) dosing. Eligibility requirements include individuals between 50 and 80&#160;years of age that have received a diagnosis of DLB and have a mini-mental state exam, or MMSE, score of between 18 and 27. Clinical endpoints of the trial include safety and physical activity measurements, cognitive assessments, and PK and pharmacodynamic biomarker analyses compared to baseline measurements recorded at the beginning of the trial. In addition, CSF will be collected and analyzed for &alpha;-synuclein content and established patterns of differential protein expression. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Additional Product Candidates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Many degenerative disorders likely involve a dysfunctional cellular damage response mechanism and significant evidence is emerging which highlights the importance of the S2R complex and its components in regulating this response. The complex likely contains a number of relevant binding sites that may allow for multiple disease intervention approaches, making it an attractive therapeutic target. Accordingly, we are actively engaged in a number of earlier-stage discovery programs which are built upon our identification of five structurally distinct chemical series. From these series we have multiple leads which will be optimize each of our lead series. Each of these leads has demonstrated favorable potency with variable selectivity in early preclinical testing and each of the molecular series possesses distinct bioavailability and PK properties, including differences in half-life and blood-brain and blood-retina permeability. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposed Synucleinopathies Clinical Program</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to additional funding, we plan to study several next-generation S2R modulators derived from chemically distinct series to measure their ability to rescue cell death in synucleinopathies such as PD and DLB. We would also study &alpha;-synuclein pathology and motor deficits in two mechanistically distinct </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> models of synucleinopathies. In parallel, these studies will elucidate the mechanism of action by which S2R modulators are efficacious in PD and DLB and provide essential data to support potential biomarker nomination for PD and DLB. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">108</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Grant Funding</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Historically, we have sought grant funding to strategically advance our programs. To date, we have secured non-dilutive funds from the NIA, the Michael J. Fox Foundation and other groups to pursue our commonly aligned interests of developing therapeutics for neurodegenerative disorders. Taken together, the company has been awarded approximately $171.0&#160;million in cumulative grants for the advancement of our pipeline programs. Of this, approximately $130.6&#160;million in cumulative non-dilutive grants have been awarded by the NIA to fund development of CT1812 for the treatment of AD. </font>
        </div>
        <table style="width:456pt;height:314pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:111.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Funding Org </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:202.66pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Project </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:111.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; line-height:12pt; margin-bottom:-0.500000000000005pt;">
                <font style="letter-spacing:0.2pt;">National Institute on Aging (NIH) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #CCEEFF; min-width:15pt; text-align:right; white-space:nowrap;">2016</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:202.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">COG0101 Ph1b first-in-patient trial for CT1812 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">2,410,669</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:111.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">National Institute on Aging (NIH) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:15pt; text-align:right; white-space:nowrap;">2016</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:202.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">COG0102 Ph1b/2a Clinical Trial for CT1812 </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">2,410,669</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:111.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">National Institute on Aging (NIH) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #CCEEFF; min-width:15pt; text-align:right; white-space:nowrap;">2017</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:202.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">COG0104 Ph1 SNAP Study: CSF Catheter </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">2,527,271</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:111.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">National Institute on Aging (NIH) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:15pt; text-align:right; white-space:nowrap;">2017</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:202.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">COG0105 Ph1 SPARC Study: SV2a PET </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">4,795,774</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:111.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">National Institute on Aging (NIH) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #CCEEFF; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:202.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">COG0201 Ph2 SHINE Study </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">16,848,329</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:111.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; line-height:12pt; margin-bottom:-0.499999999999991pt;">
                <font style="letter-spacing:0.2pt;">National Institute on Aging (NIH) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:15pt; text-align:right; white-space:nowrap;">2019</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:202.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">COG0202 Ph2 SEQUEL Study: qEEG </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">5,445,051</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:111.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">National Institute on Aging (NIH) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #CCEEFF; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:202.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">COG0203 Ph2 Study with ACTC </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">80,974,766</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:111.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">National Institute on Aging (NIH) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:15pt; text-align:right; white-space:nowrap;">2021</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:202.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">COG0108 Study: hAME </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">1,642,783</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:111.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">National Institute on Aging (NIH) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #CCEEFF; min-width:15pt; text-align:right; white-space:nowrap;">2021</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:202.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">COG0201 Ph2 SHINE Amendment </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">13,634,548</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:111.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">National Institute on Aging (NIH) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #FFFFFF; min-width:15pt; text-align:right; white-space:nowrap;">2021</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:202.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">COG1201: Study: DLB </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">29,498,048</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:111.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">NIH and others </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">2010&#8201;&#8211;&#8201;2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:202.66pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Ten Preclinical Programs </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">10,859,971</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:111.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt; width:202.66pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">171,047,879</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of the grants awarded to us relate to agreed upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to CROs, research institutions and/or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which we are reimbursed for our eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIA Grants do not contain payback provisions, the NIA or other government agency may review our performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIA Grant. If any of our expenditures are found to be unallowable or allocated improperly or if we have otherwise violated terms of such NIA Grant, the expenditures may not be reimbursed and/or we may be required to repay funds already disbursed. To date, we have not been found to have breached the terms of any NIA Grant. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We seek to protect and enhance our proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending patent rights, in the United States and internationally, whether developed internally or licensed from third parties. We will also seek to rely on regulatory protection afforded through inclusion in expedited development and review, data exclusivity, market exclusivity and patent term extensions where available. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">109</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Company Owned Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;1, 2022, our intellectual property portfolio contained nine issued U.S. patents, 65 issued foreign patents as well as one pending U.S. provisional application, four pending U.S. patent applications, two pending Patent Cooperation Treaty applications and 26 foreign pending patent applications directed to the composition of matter of, pharmaceutical compositions of, methods of use of, and methods for selecting subsets of patients for treatment with our chemical structures, including our lead CT1812. Our current issued patents relating to CT1812 are projected to begin to expire no earlier than 2035, with the composition of matter patent covering CT1812 set to naturally expire in 2035, subject to adjustment or extension of patent term available in a particular jurisdiction. We will likely be awarded Patent Term Extension, or PTE, when CT1812 is approved as a New Chemical Entity, or NCE, that will extend the term of the CT1812 composition of matter patent by up to five&#160;years, and we anticipate pursuing additional patents to further protect CT1812 and to further extend the patent term associated with CT1812. We expect to file additional patent applications in support of current and new product candidates as well as new platform and core technologies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are the exclusive owner of six patent families that include several granted U.S. patents and pending U.S. patent applications, as well as granted patents and pending patent applications in numerous foreign jurisdictions, relating to compositions of matter and pharmaceutical compositions of CT1812, analogs of CT1812, and the use of CT1812 for the treatment in certain diseases, disorders and conditions including AD, dry AMD, PD, and synucleinopathies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The first of these patent families is directed to compositions of matter of CT1812, pharmaceutical compositions of CT1812, methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD, and we are the exclusive owner of this patent family in the United States and certain foreign jurisdictions, including Australia, Brazil, Canada, China, the European Union, Hong Kong, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, and South Africa. As of November&#160;1, 2022, this patent family includes granted patents claiming composition of matter of CT1812, pharmaceutical compositions of CT1812, methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD in the United States (three patents), Australia, China, the European Union, Hong Kong, India, Israel, Japan, New Zealand, Mexico, South Korea, Russia and South Africa. This patent family also includes a pending U.S. patent application and pending application in certain foreign jurisdictions including Brazil, Canada, the European Union and Hong Kong. This patent family has a natural expiration date in 2035 subject to any adjustment or extension of patent term that may be available in in a particular jurisdiction such as PTE following approval of the New Drug Application, or NDA, in the United States or extension of patent term via a Supplementary Protection Certificate, or SPC, following EMEA marketing authorization. Upon approval of the NDA for CT1812 in the United States, the patents in this family claiming compositions of matter of CT1812, pharmaceutical compositions of CT1812, and methods of using CT1812 for inhibiting amyloid beta effects on a neuronal cell, and methods of using CT1812 to treat AD will be eligible to be listed in the FDA&#8217;s publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. These patents complement the regulatory exclusivity by providing the basis for an additional waiting period prior to the FDA&#8217;s approval of an abbreviated new drug application, or ANDA, or 505(b)(2) applicant. If an ANDA or 505(b)(2) applicant were to file its application referencing the NDA for CT1812 before expiration of our composition of matter, pharmaceutical composition, and method of use patents and the applicant asserted that our patents identified on the Orange Book to be invalid or not be infringed, it may be subject to additional waiting periods prior to the FDA&#8217;s approval (including a statutory 30-month stay if we sue for infringement, or a shorter period if the patent expires or there are certain settlements or judicial decisions in the patent litigation, starting at the end of the five-year NCE regulatory exclusivity period). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to patent exclusivity, under the provisions of the Hatch-Waxman Act, upon any approval in the United States, we believe that CT1812 will be eligible for five-year NCE regulatory exclusivity, during which time no 505(b)(2) NDA or ANDA can be approved that contains the same active moiety as the chemical entity in the CT1812 NDA. When approved in Europe, CT1812 will also be eligible for 10&#160;years of data and market exclusivity which is extendible for an additional year upon market authorization for one or more new indications during the first eight&#160;years of the data and market exclusivity period. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">110</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also own four families of pending patent applications directed to methods for selecting subsets of patients with AD for treatment with CT1812, methods of modulating amyloid beta monomer and oligomer levels using CT812, methods of treating dry AMD with CT1812 and methods of treating various neurologic diseases including PD and synucleinopathies with CT1812, as well as a pending provisional application directed to treating certain subsets of AD patients with CT1812. Any of these applications, if issued, will have a natural expiration between 2038 and 2043, subject to any adjustment or extension of patent term that may be available such as PTE following NDA approval in the United States as well as any term limitations based upon earlier expiring patents. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Additional Product Candidates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are the exclusive owner of three patent families that include several pending U.S. patent applications, as well as pending patent applications in numerous foreign jurisdictions directed to additional product candidates, including CT2168 and CT2074, among others. These patent families have expirations no earlier than 2038 subject to any adjustment or extension of patent term that may be available such as PTE following NDA approval in the United States as well as any term limitations based upon earlier expiring patents. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Manufacturing Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We oversee and manage third party contract manufacturing organizations to support development and manufacture of product candidates for our clinical trials, and, if we receive marketing approval, we will rely on such manufacturers to meet commercial demand. We expect this strategy will enable us to maintain a more efficient infrastructure, avoiding dependence on our own manufacturing facility and equipment, while simultaneously enabling us to focus our expertise on the clinical development and future commercialization of our products. Currently, we rely on and have agreements with a single third-party contract manufacturer to supply the drug substance for CT1812 and with a single third-party contract manufacturer to manufacture clinical trial supplies of CT1812, and we expect to enter into commercial supply agreements with such manufacturers prior to any potential approval of CT1812. We continue to develop a commercial route for CT1812 API and to meet all requirements for our planned clinical trials. We plan to transfer the API manufacture to a larger third-party manufacturer to support the commercial launch of the product, if approved. The current API manufacturer is able to supply all of our needs for the planned clinical studies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CT1812 drug product is manufactured via conventional pharmaceutical processing procedures, employing commercially available excipients and packaging materials. The procedure and equipment employed for manufacture and analysis are consistent with standard organic synthesis or pharmaceutical production, and are transferable to a range of manufacturing facilities, if needed. We have selected a larger third-party drug product manufacturer and will be executing technology transfer of drug product manufacture to a larger manufacturer. We will also maintain the current drug substance and product manufacturer as part of our supply chain strategy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Commercialization Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently have no marketing, sales or distribution capabilities. In order to commercialize any products that are approved for commercial sale, we must either develop a sales and marketing infrastructure or collaborate with third parties that have sales and marketing experience. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may to seek third-party support from established pharmaceutical and biotechnology companies for those products that would benefit from the promotional support of a large sales and marketing force. In these cases, we might seek to promote our products in collaboration with marketing partners or rely on relationships with one or more companies with large established sales forces and distribution systems. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may elect to establish our own sales force to market and sell a product for which we obtain regulatory approval if we expect that the geographic market for a product we develop on our own is limited or that the prescriptions for the product will be written principally by a relatively small number of physicians. If we decide to market and sell any products ourselves, we do not expect to establish direct sales capability until shortly before the products are approved for commercial sale. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">111</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Competition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We face substantial competition from multiple sources, including large and specialty biotechnology and pharmaceutical companies, academic research institutions and governmental agencies and public and private research institutions. Our competitors compete with us on the level of the technologies employed, or on the level of development of product candidates. In addition, many small biotechnology companies have formed collaborations with large, established companies to (i)&#160;obtain support for their research, development and commercialization of products or (ii)&#160;combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the current standard of care treatments for patients with neurodegenerative diseases, numerous commercial and academic preclinical studies and clinical trials are being undertaken by a large number of parties to assess technologies and product candidates in the CNS field. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than we do. Mergers and acquisition activity in the biopharmaceutical sector is likely to result in greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with us in recruiting and retain qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than our proposed product offering. Our competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and treatment cost. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employees and Human Capital Resources</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of November&#160;1, 2022, we had 22 employees, 19 of whom were full-time and 15 of whom were engaged in research and development activities. Seven of our employees hold Ph.D. or M.D. degrees. None of our employees are represented by a labor union. We consider our relationship with our employees to be good. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Facilities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our corporate headquarters is located in the greater New York City area with laboratories in Pittsburgh, PA, where we currently lease approximately 6,686 square feet of laboratory and office space. We believe that our current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Government Regulation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Government authorities in the United States, at the federal, state, and local level, and other countries extensively regulate, among other things, the research, development, nonclinical and clinical testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">112</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">distribution, post-approval monitoring and reporting, marketing, and export and import of products such as those we are developing. Generally, before a new drug can be marketed, considerable data must be generated, which demonstrate the drug&#8217;s quality, safety, and efficacy. Such data must then be organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">U.S. Drug Development Process</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, the approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">completion of nonclinical laboratory tests, animal studies, and formulation studies in accordance with FDA&#8217;s good laboratory requirements and other applicable regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">approval by an independent IRB ethics committee, either centralized or with respect to each clinical site, before each clinical trial may be initiated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">performance of adequate and well-controlled human clinical trials in accordance with GCP requirements to establish the safety and efficacy of the proposed drug for its intended use; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">submission to the FDA of an NDA after completion of all pivotal trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">determination by the FDA within 60&#160;days of its receipt of an NDA to accept the filing for substantive review; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">satisfactory completion of an FDA advisory committee review, if applicable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP requirements to ensure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity, and of selected clinical investigation sites to assess compliance with GCPs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">compliance with any post-approval requirements, including potential requirements to conduct any post-approval studies required by the FDA or the potential requirement to implement a REMS; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">compliance with the Pediatric Research Equity Act, or PREA, which requires either exemption from the requirements or may require conducting clinical research in a pediatric population. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> studies assessing the toxicology, PK, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">113</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the clinical trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which may review data and endpoints at designated check points, make recommendations and/or halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;One</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism, and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;Two</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages, and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&#160;2 clinical trials may be conducted to obtain information prior to beginning; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Phase&#160;Three</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Post-approval clinical trials, sometimes referred to as Phase&#160;4 studies, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&#160;4 clinical trials as a condition of approval of an NDA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA or the sponsor may place a clinical trial on a full or partial clinical hold at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk or concerns related to chemistry, manufacturing and controls. A clinical hold is an order issued by the FDA to delay or suspend an investigation Following the issuance of a clinical hold or a partial clinical hold, a clinical trial may only proceed after FDA has notified the sponsor that any deficiencies have been corrected and FDA is authorizing the trial to proceed. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">114</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. Finally, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a clinical trial may move forward at designated check points based on access to certain data from the clinical trial. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase&#160;2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase&#160;2 clinical trial to discuss Phase&#160;2 clinical results and present plans for the pivotal Phase&#160;3 clinical trials that they believe will support approval of the new drug. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NDA Review and Approval Process</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development nonclinical and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality, and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten&#160;months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes 12&#160;months from the date the NDA is submitted to FDA because the FDA has approximately two&#160;months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60&#160;days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">115</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process, or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase&#160;3 clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies, or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use. It could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may offer conditional approval subject to, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase&#160;4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Expedited Development and Review Programs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. With regard to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. CT1812 was awarded Fast Track designation by the FDA in 2016. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis, or prevention of a disease compared to marketed products. The FDA will </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">116</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six&#160;months of the filing date as compared to ten&#160;months for review of new molecular entity NDAs under its current PDUFA review goals. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive Breakthrough Therapy designation. A sponsor may seek FDA designation of a product candidate as a &#8220;Breakthrough Therapy&#8221; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The Breakthrough Therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as Breakthrough Therapy, the FDA will work to expedite the development and review of such drug. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Fast track designation, priority review, accelerated approval, and Breakthrough Therapy designation do not change the standards for approval, but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Post-Approval Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">117</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">fines, warning letters, or untitled letters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">clinical holds on post-approval or Phase&#160;IV clinical studies, if applicable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product seizure or detention, or refusal to permit the import or export of products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">mandated modification of promotional materials and labeling and the issuance of corrective information. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under PREA, an NDA must contain data to assess the safety and efficacy of the applicant product for indications in applicable pediatric populations. It must also contain information to support dose administration for pediatric populations where the drug may be utilized. FDA has the ability to grant complete waivers, partial waivers, or deferrals for compliance with PREA. PREA requirements may be waived for applications for approval of drug candidates intended to treat, mitigate, prevent, diagnose or cure diseases and other conditions that do not occur in pediatric populations. Generally PREA does not apply for drug candidates which have obtained an orphan designation, unless otherwise regulated by the FDA. Despite this, separate PREA compliance or waivers may still be required for each product indication. Although noncompliance with PREA will generally not be considered for withdrawal of an approval it may be considered by the FDA as the sole basis for enforcement action such as injunction or seizure as non-compliance and may render the drug misbranded. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA closely regulates the marketing, labeling, advertising, and promotion of drug products. A company can make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Marketing Exclusivity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Market exclusivity provisions authorized under the FDCA can delay the submission and approval of certain marketing applications for products containing the same active ingredient. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. The FDCA also permits patent term restoration of up to five&#160;years as compensation for a patent term lost during product development and FDA regulatory review process to the first applicant to obtain approval of an NDA for a new chemical entity in the United States. Patent-term restoration, however, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">118</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. During the NCE exclusivity period, the FDA may not approve or even accept for review an ANDA or an NDA submitted under Section&#160;505(b)(2) (505(b)(2) NDA), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four&#160;years if it contains a certification of patent invalidity or non-infringement to one of the patents listed in the Orange Book, with the FDA by the innovator NDA holder. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the Orange Book. These products may be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA. Any competitor who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must make patent certifications to the FDA that (1)&#160;no patent information on the drug or method of use that is the subject of the application has been submitted to the FDA; (2)&#160;the patent has expired; (3)&#160;the date on which the patent has expired and approval will not be sought until after the patent expiration; or (4)&#160;the patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant has provided a paragraph IV certification the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not approve that application until the earlier of 30&#160;months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#8217;s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many&#160;months or&#160;years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s decision to initiate patent litigation. If the drug has NCE exclusivity and the ANDA is submitted four&#160;years after approval, the 30-month stay is extended so that it expires 7 </font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">1</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;"> years after approval of the innovator drug, unless the patent expires or there is a decision in the infringement case that is favorable to the ANDA applicant before then. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDCA alternatively provides three&#160;years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six&#160;months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. The indications the Company is currently pursuing for its product candidates will not be eligible for pediatric exclusivity because they are age-related degenerative diseases and disorders that do not occur in the pediatric </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">119</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">population. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Healthcare Laws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our activities are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil False Claims Act, and laws and regulations pertaining to limitations on and reporting of healthcare provider payments (physician sunshine laws). These laws and regulations are interpreted and enforced by various federal, state and local authorities including CMS, the Office of Inspector General for the U.S. Department of Health and Human Services, the U.S. Department of Justice, individual U.S. Attorney offices within the Department of Justice, and state and local governments. These laws include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the U.S. civil False Claims Act (which can be enforced through &#8220;qui tam,&#8221; or whistleblower actions, by private citizens on behalf of the federal government), prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal liability and amends provisions on the reporting, investigation, enforcement, and penalizing of civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">state laws and regulations, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to certain payments made in the preceding calendar year and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; beginning in 2022, applicable manufacturers are required to report such information regarding payments and transfers of value provided, as well as ownership and investment interests held, during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">120</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Violations of any of these laws or any other governmental regulations that may apply to us, may subject us to significant civil, criminal and administrative sanctions including penalties, damages, fines, imprisonment, and exclusion from government funded healthcare programs, such as Medicare and Medicaid, and/or adverse publicity. Moreover, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical products. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Corrupt Practices Act</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Foreign Corrupt Practices Act, or the FCPA, generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our industry is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. Violations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Enforcement actions may be brought by the Department of Justice or the SEC, and recent enacted legislation has expanded the SEC&#8217;s power to seek disgorgement in all FCPA cases filed in federal court and extended the statute of limitations in SEC enforcement actions in intent-based claims such as those under the FCPA from five&#160;years to ten&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Coverage and Reimbursement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific details, information on cost-effectiveness, and clinical support for the use of a product to each payor separately. This can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and related services. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. On August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law. This legislation contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">121</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">manufacturers to provide discounts on Part&#160;D drugs. The Inflation Reduction Act of 2022 also caps Medicare beneficiaries&#8217; annual out-of-pocket drug expenses. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. Additional drug pricing proposals could appear in future federal legislation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the state level, there are also new laws and ongoing ballot initiatives that create additional pressure on drug pricing and may affect how pharmaceutical products are covered and reimbursed. A number of states have adopted or are considering various pricing actions, such as those requiring pharmaceutical manufacturers to publicly report proprietary pricing information, limit price increases or to place a maximum price ceiling or cap on certain products. Existing and proposed state pricing laws have added complexity to the pricing of pharmaceutical drug products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, that it will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Healthcare Reform</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The United States government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. In recent&#160;years, Congress has considered reductions in Medicare reimbursement levels for products administered by physicians. CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some products. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things, the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum Medicaid rebate for both branded and generic products, expanded the 340B program, and revised the definition of average manufacturer price, or AMP, which could increase the amount of Medicaid rebates manufacturers are required to pay to states. The legislation also extended Medicaid rebates, previously due only on fee-for-service Medicaid utilization, to include the utilization of Medicaid managed care organizations as well and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of rebates due on those products. On February&#160;1, 2016, CMS issued final regulations to implement the changes to the Medicaid </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">122</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:28pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Drug Rebate program under the Affordable Care Act. These regulations became effective on April&#160;1, 2016. Since that time, there have been significant ongoing efforts to modify or eliminate the Affordable Care Act. The Tax Act, enacted on December&#160;22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, as amended, or the Code, commonly referred to as the individual mandate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other legislative changes have been proposed and adopted since the passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal&#160;years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which went into effect in April&#160;2013. Subsequent legislation extended the 2% reduction, on average, to 2030 unless additional Congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, the 2% Medicare sequester reductions were suspended from May&#160;1, 2020 through December&#160;31, 2021 due to the COVID-19 pandemic. The sequester will remain in place through 2030. On January&#160;2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Affordable Care Act has also been subject to challenges in the courts. On December&#160;14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On December&#160;18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire Affordable Care Act. An appeal was taken to the U.S. Supreme Court. On June&#160;17, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Proceedings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are not currently a party to any material legal proceedings. From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">123</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following description of our capital stock is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our third amended and restated certificate of incorporation, which has been publicly filed with the SEC. See &#8220;Where You Can Find Additional Information and Incorporation of Certain Information by Reference.&#8221;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. The affirmative vote of holders of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our third amended and restated certificate of incorporation, including the provisions relating to amending our amended and restated bylaws, procedures for our stockholder meetings, the classified board, director liability, and exclusive forum for proceedings. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be&#160;entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rights and Preferences</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under our third amended and restated certificate of incorporation, our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Registration Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain holders of shares of our common stock are entitled to certain rights with respect to registration of such shares under the Securities Act. These shares are referred to as registrable securities. The holders of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">124</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">these registrable securities possess registration rights pursuant to the terms of our investors&#8217; rights agreement and are described in additional detail below. The registration of shares of our common stock pursuant to the exercise of the registration rights described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the registration expenses, other than underwriting discounts, selling commissions and stock transfer taxes, of the shares registered pursuant to the demand, piggyback and Form S-3 registrations described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions and limitations, to limit the number of shares the holders may include. The demand, piggyback and Form S-3 registration rights described below will expire no later than four&#160;years after the completion of our initial public offering in October&#160;2021, or with respect to any particular holder, at such time that such holder can sell its shares under Rule&#160;144, or other similar exemption, of the Securities Act during any three-month period. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Demand Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain holders of our common stock are entitled to certain demand registration rights. The holders of a majority of the registrable securities may request that we register all or a portion of their shares, subject to certain specified exceptions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Piggyback Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain holders of our common stock are entitled to rights to notice of this offering and to include their shares of registrable securities in this offering, which we expect the requisite&#160;percentage of holders to waive. In the event that we propose to register any of our securities under the Securities Act in another offering, either for our own account or for the account of other security holders, the holders of registrable securities will be entitled to certain &#8220;piggyback&#8221; registration rights allowing them to include their shares in such registration, subject to specified conditions and limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">S-3 Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain holders of our common stock are entitled to certain Form S-3 registration rights. The holders of at least 10% of registrable securities may request that we register all or a portion of their shares on Form&#160;S-3 if we are qualified to file a registration statement on Form S-3, subject to specified exceptions. Such request for registration on Form S-3 must cover securities with an aggregate offering price which equals or exceeds $1.0&#160;million, net of selling expenses. The right to have such shares registered on Form S-3 is further subject to other specified conditions and limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The investors&#8217; rights agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling holders of registrable securities in the event of either material misstatements or omissions in the applicable registration statement attributable to us or our violation of the Securities Act, and the selling stockholders are obligated to indemnify us for material misstatements or omission in the registration statement attributable to them, subject to certain limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-takeover provisions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certificate of Incorporation and Bylaws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Among other things, our third amended and restated certificate of incorporation and amended and restated bylaws: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that the authorized number of directors may be changed only by resolution of our board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">125</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that our board of directors is classified into three classes of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.69pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.69pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.69pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.69pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">do not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The amendment of any of these provisions would require approval by the holders of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the voting power of all of our then-outstanding common stock entitled to vote generally in the election of directors, voting together as a single class. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The combination of these provisions makes it more difficult for our stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;203 of the Delaware General Corporation Law</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to Section&#160;203 of the DGCL, which&#160;prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three&#160;years after the date that such stockholder became an interested stockholder, with the following exceptions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">126</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those&#160;shares owned (i)&#160;by persons who are directors and also officers and (ii)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the outstanding voting stock that is not owned by the interested stockholder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, Section&#160;203 defines a &#8220;business combination&#8221; to include the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any merger or consolidation involving the corporation and the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, Section&#160;203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three&#160;years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its certificate of incorporation. We have not opted out of these provisions, which may as a result, discourage or prevent mergers or other takeover or change of control attempts of us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Choice of Forum</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our third amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if, the Court of Chancery of the State of Delaware lacks subject&#160;matter jurisdiction, any state court located within the State of Delaware or, if and only if, all such state courts&#160;lack subject matter jurisdiction, the United States District Court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action brought under Delaware statutory or common law: (1)&#160;any derivative claim or action brought on our behalf;&#160;(2)&#160;any claim or cause of action asserting a breach of fiduciary duty by any of our current or former directors, officers or other employees; (3)&#160;any claim or cause of action asserting a claim against us arising out of, or pursuant to, the DGCL, our third amended and restated certificate of incorporation or our amended and restated bylaws; (4)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our third amended and restated certificate of incorporation or our amended and restated bylaws (including&#160;any right, obligation, or remedy thereunder); (5)&#160;any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; or (6)&#160;any claim or cause of action asserting a claim against us or any of our current or former directors, officers or other employees, that is governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#160;having personal jurisdiction over the indispensable parties named as defendants. The aforementioned provision will not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">127</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, our third amended and restated certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum, to the fullest extent permitted by law, for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. The enforceability of similar choice of forum provisions in&#160;other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with one or more actions or proceedings described above, a court could find the choice of&#160;forum provisions contained in our third amended and restated certificate of incorporation to be inapplicable or unenforceable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitations of Liability and Indemnification</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our third amended and restated certificate of incorporation and our amended and restated bylaws&#160;limit our directors&#8217; liability and may indemnify our directors and officers to the fullest extent permitted under the DGCL. The DGCL provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability for: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any breach of the director&#8217;s duty of loyalty to us or our stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any unlawful payment of dividends or unlawful stock repurchases or redemptions as provided in Section&#160;174 of the DGCL; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any transaction from which the director derived an improper benefit. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The DGCL and our amended and restated bylaws provide that we will, in certain situations, indemnify our directors and officers and may indemnify other employees and other agents, to the fullest extent permitted by law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have entered into indemnification agreements with our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, penalties, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. Subject to certain limitations, our indemnification agreements also require us to advance expenses incurred by our directors, officers and key employees for the defense of any action for which indemnification is required or permitted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We maintain a directors&#8217; and officers&#8217; insurance policy pursuant to which our directors and officers are insured against liability for actions taken in their capacities as directors and officers. We believe that these provisions in our third amended and restated certificate of incorporation, our amended and restated bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The limitation of liability and indemnification provisions in our third amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder&#8217;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At present, there is no material pending litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought and we are not aware of any threatened material litigation that may result in claims for indemnification. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or control persons, in the opinion of the SEC, such indemnification is against public policy, as expressed in the Securities Act, and is therefore unenforceable. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">128</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:540pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on the Nasdaq Global Market under the trading symbol &#8220;CGTX.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">129</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMUFI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following is a discussion of the material U.S. federal income tax consequences applicable to non-U.S. holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. All prospective non-U.S. holders of our common stock should consult their tax advisors with respect to the U.S. federal income tax consequences of the ownership and disposition of our common stock, as well as any consequences arising under the laws of any other taxing jurisdiction, including any state, local and non-U.S. tax consequences and any U.S. federal non-income tax consequences. In general, a non-U.S. holder means a beneficial owner of our common stock (other than a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes) that is not a U.S. holder. A U.S. holder is, for U.S. federal income tax purposes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an individual who is a citizen or resident of the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a corporation, or an entity treated as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States or of any state thereof or the District of Columbia; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a trust if (1)&#160;a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons have the authority to control all of the trust&#8217;s substantial decisions or (2)&#160;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing U.S. Treasury Regulations promulgated thereunder, published administrative rulings and judicial decisions, all as in effect as of the date of this prospectus supplement. These laws are subject to change and to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to non-U.S. holders described in this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This discussion is limited to non-U.S. holders that hold shares of our common stock as a capital asset within the meaning of Section&#160;1221 of the Code (generally, for investment). This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder&#8217;s individual circumstances, nor does it address the effect of the alternative minimum tax or Medicare contribution tax on net investment income, the impact of special tax accounting rules under Section&#160;451(b) of the Code, any aspects of U.S. estate or gift tax, or any state, local or non-U.S. taxes. This discussion also does not address all special tax rules applicable to particular non-U.S. holders, such as holders that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below), corporations that accumulate earnings to avoid U.S. federal income tax, tax-exempt organizations, banks, financial institutions, insurance companies, brokers, dealers or traders in securities, commodities or currencies, tax-qualified retirement plans, holders who hold or receive our common stock pursuant to the exercise of employee stock options or otherwise as compensation, holders holding our common stock as part of a hedge, straddle or other risk reduction strategy, conversion transaction or other integrated investment, holders deemed to sell our common stock under the constructive sale provisions of the Code, &#8220;qualified foreign pension funds&#8221; as defined in Section&#160;897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds, controlled foreign corporations, passive foreign investment companies and certain former citizens or long-term residents of the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, this discussion does not address the tax treatment of partnerships (or entities or arrangements that are treated as partnerships for U.S. federal income tax purposes) or persons that hold our common stock through such partnerships or such entities or arrangements. If a partnership, including any entity or arrangement treated as a partnership for U.S. federal income tax purposes, holds shares of our common stock, the U.S. federal income tax treatment of a partner in such partnership will generally depend upon the status of the partner, the activities of the partnership and certain determinations made at the partner level. Such partners and partnerships should consult their tax advisors regarding the tax consequences of the purchase, ownership and disposition of our common stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">130</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There can be no assurance that the U.S. Internal Revenue Service, or the IRS, will not challenge one or more of the tax consequences described herein, and we have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax consequences with respect to the matters discussed below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Distributions on Our Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As described in the section entitled &#8220;Dividend Policy,&#8221; we do not anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, distributions, if any, on our common stock generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder&#8217;s investment, up to such holder&#8217;s adjusted tax basis in the common stock. Any remaining excess will be treated as capital gain from the sale or exchange of such common stock, subject to the tax treatment described below in &#8220;Gain on Sale, Exchange or Other Disposition of Our Common Stock.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the discussions below regarding effectively connected income, dividends paid to a non-U.S. holder will generally be subject to withholding of U.S. federal income tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty. A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. A non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty generally will be required to provide a properly executed IRS Form W-8BEN or W-8BEN-E (or successor form) and satisfy relevant certification and other requirements. Non-U.S. holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dividends that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States (and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States) are generally exempt from the 30% withholding tax if the non-U.S. holder satisfies applicable certification requirements. To claim the exemption, the non-U.S. holder must furnish to us or the applicable withholding agent a valid IRS Form W-8ECI (or applicable successor form), certifying that the dividends are effectively connected with the non-U.S. holder&#8217;s conduct of a trade or business within the United States. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the U.S. federal income tax rates applicable to a &#8220;United States person&#8221; &#8203;(as defined in the Code), which we refer to as a United States person, unless a specific treaty exemption applies. Any U.S. effectively connected income received by a non-U.S. holder that is a corporation, under certain circumstances, also may be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Gain on Sale, Exchange or Other Disposition of Our Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to the discussions below regarding backup withholding and foreign accounts, in general, a non-U.S. holder will not be subject to any U.S. federal income tax on any gain realized upon such holder&#8217;s sale, exchange or other disposition of shares of our common stock unless: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the gain is effectively connected with a U.S. trade or business of the non-U.S. holder (and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed base maintained in the United States by such non-U.S. holder), in which case the non-U.S. holder generally will be taxed at the U.S. federal income tax rates applicable to United States persons and, if the non-U.S. holder is a foreign corporation, the branch profits tax described above in &#8220;Distributions on Our Common Stock&#8221; may also apply; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the non-U.S. holder is a nonresident alien individual who is present in the United States for 183&#160;days or more in the taxable year of the disposition and certain other conditions are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the non-U.S. holder, if any (even though the individual is not considered a </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">131</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">resident of the United States), provided the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses; or </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our common stock constitutes a U.S. real property interest because we are, or have been, at any time during the five-year period preceding such disposition (or the non-U.S. holder&#8217;s holding period, if shorter) a &#8220;U.S. real property holding corporation.&#8221; Even if we are or become a U.S. real property holding corporation, provided that our common stock is &#8220;regularly traded&#8221; &#8203;(as defined by U.S. Treasury Regulations) on an established securities market, our common stock will be treated as a U.S. real property interest only with respect to a non-U.S. holder that holds more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the five-year period ending on the date of the disposition or the period that the non-U.S. holder held our common stock. In such case, such non-U.S. holder generally will be taxed on its net gain derived from the disposition at the U.S. federal income tax rates applicable to United States persons. Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Backup Withholding and Information Reporting</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We must report annually to the IRS and to each non-U.S. holder the gross amount of distributions on our common stock paid to such holder, regardless of whether such distributions constitute dividends or whether any tax was actually withheld. Non-U.S. holders will have to comply with specific certification procedures to establish that the holder is not a United States person in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. U.S. backup withholding generally will not apply to a non-U.S. holder who provides a properly executed IRS Form W-8BEN or W-8BEN-E (or successor form) or otherwise establishes an exemption. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Information reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Non-U.S. holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Copies of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific treaty or agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder may be allowed as a credit against the non-U.S. holder&#8217;s U.S. federal income tax liability, if any, and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Accounts</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sections&#160;1471 through 1474 of the Code (commonly referred to as FATCA) generally impose a U.S. federal withholding tax of 30% on certain payments made to a &#8220;foreign financial institution&#8221; &#8203;(as specifically defined for this purpose), unless such institution enters into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which may include certain equity </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">132</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:360pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners). Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing these withholding and reporting requirements may be subject to different rules. FATCA also generally imposes a 30% withholding tax on certain payments made to a non-financial foreign entity, unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S. owners or information regarding substantial direct and indirect U.S. owners of the entity. The withholding tax under FATCA described above will not apply if the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from the rules. The FATCA withholding provisions described above currently apply to dividends on our common stock. The FATCA withholding provisions also would apply to the gross proceeds of a disposition of our common stock, except that the U.S. Treasury Department has released proposed regulations which, if finalized in their present form, would eliminate such withholding. In its preamble to such proposed regulations, the U.S. Treasury Department stated that taxpayers generally may rely on the proposed regulations until final regulations are issued. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes. Non-U.S. holders are encouraged to consult with their tax advisors regarding the possible implications of FATCA on their investment in our common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISORS REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, NON-U.S. OR U.S. FEDERAL NON-INCOME TAX LAWS.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">133</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUNDW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNDERWRITING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms and conditions set forth in the underwriting agreement, dated&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2022, between us and Cantor Fitzgerald &amp; Co., or Cantor, 499 Park Avenue, New York, New York 10022, as representative of the underwriters named below, or the Representative, and the sole book-running manager of this offering, we have agreed to sell to the underwriters, and the underwriters have agreed, severally and not jointly, to purchase from us, the shares of common stock shown opposite its name below: </font>
        </div>
        <table style="width:416pt;height:51pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 2pt 0pt; width:343.53pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Underwriter </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:60.47pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Shares</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:343.53pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cantor Fitzgerald &amp; Co.</font>  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; width:60.47pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:343.53pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Newbridge Securities Corporation</font>  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:60.47pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:343.53pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total</font>  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3pt double #000000;padding:0pt 0pt 2pt 0pt; width:60.47pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters of officers&#8217; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are purchased. We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise discretionary authority. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Option to Purchase Additional Shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have granted to the underwriters an option, exercisable 30&#160;days from the date of this prospectus supplement, to purchase, from time to time, in whole or in part, up to an aggregate of 837,988 shares from us at the public offering price set forth on the cover page of this prospectus supplement, less underwriting discounts and commissions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Commission and Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriters have advised us that they propose to offer the shares of common stock to the public at the public offering price set forth on the cover page of this prospectus supplement and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share of common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriters may allow, and certain dealers may reallow, a discount from the concession not in excess of $&#8199;&#8199;&#8199;&#8199;&#8199; per share of common stock to certain brokers and dealers. After the initial offering, the Representative may change the offering price and other selling terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase additional shares. </font>
        </div>
        <table style="width:456pt;height:95pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:268pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:268pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Without</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option to </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">With</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option to </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Without</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option to </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">With</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option to </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:268pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:268pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Underwriting discounts and commissions (6%)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:268pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds to us, before expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">134</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $250,000. We have also agreed to reimburse the underwriters for up to $100,000 of certain of their counsels&#8217; fees and expenses, which reimbursed fee is deemed underwriting compensation for this offering by FINRA. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on the Nasdaq Global Market under the trading symbol &#8220;CGTX.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">No Sales of Similar Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We, our officers and our directors and certain of our affiliated stockholders have agreed, subject to certain specified exceptions, not to directly or indirectly, for a period of 90&#160;days after the date of the underwriting agreement: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">1.&nbsp;&nbsp;&nbsp;sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#8220;put equivalent position&#8221; within the meaning of Rule&#160;16a-l(h) under the Exchange Act or otherwise dispose of, any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2.&nbsp;&nbsp;&nbsp;enter into any swap, hedge or other agreement or transaction that transfers, in whole or in part, the economic consequence of ownership of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock, or </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">3.&nbsp;&nbsp;&nbsp;publicly announce an intention to do any of the foregoing for a period of 90&#160;days after the date of this prospectus supplement without the prior written consent of the Representative. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we and each such person agrees that, without the prior written consent of the Representative, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Representative may, in its sole discretion and at any time or from time to time before the termination of the 90-day period release all or any portion of the securities subject to lock-up agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Market Making, Stabilization and Other Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriters may make a market in the common stock as permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriters have advised us that they, pursuant to Regulation&#160;M under the Exchange Act, certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#8220;covered&#8221; short sales or &#8220;naked&#8221; short sales. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Covered&#8221; short sales are sales made in an amount not greater than the underwriter&#8217;s option to purchase additional shares of our common stock in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase additional shares. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">135</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Naked&#8221; short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriters&#8217; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither we, nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, may end any of these activities at any time. These transactions may be effected on the Nasdaq Global Market, in the over-the-counter market or otherwise. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Passive Market Making</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters may also engage in passive market making transactions in our common stock on the NASDAQ in accordance with Rule&#160;103 of Regulation&#160;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#8217;s bid, that bid must then be lowered when specified purchase limits are exceeded. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market in the absence of those transactions. The underwriters are not required to engage in passive market making and, if commenced, may end passive market making activities at any time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Electronic Distribution</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A prospectus in electronic format may be made available by e-mail or on the web sites or through online services maintained by one or more of the underwriters, selling group members (if any) or their affiliates. Other than the prospectus in electronic format, the information on the underwriter&#8217;s web site and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus supplement, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Activities and Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters and certain of their respective affiliates are full service financial institutions engaged in a wide range of activities for their own accounts and the accounts of customers, which may include, among other things, corporate finance, mergers and acquisitions, merchant banking, equity and fixed income sales, trading and research, derivatives, foreign exchange, futures, asset management, custody, clearance and securities lending. The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, in the ordinary course of its business, the underwriters and their respective affiliates may, directly or indirectly, hold long or short positions, trade and otherwise conduct such activities in or with respect to debt or equity securities and/or bank debt of, and/or derivative products. Such investment and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">136</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stamp Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you purchase shares of common stock offered in this prospectus supplement, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Selling Restrictions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Canada</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement constitutes an &#8220;exempt offering document&#8221; as defined in and for the purposes of applicable Canadian securities laws. No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection with the offer and sale of the securities. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this prospectus supplement or on the merits of the securities and any representation to the contrary is an offence. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Canadian investors are advised that this prospectus supplement has been prepared in reliance on section&#160;3A.3 of National Instrument 33-105 </font><font style="font-style:italic;letter-spacing:-0.2pt;">Underwriting Conflicts</font><font style="letter-spacing:-0.2pt;">, or NI 33-105. Pursuant to section 3A.3 of NI 33-105, this prospectus supplement is exempt from the requirement that the issuer and the underwriter(s) provide investors with certain conflicts of interest disclosure pertaining to &#8220;connected issuer&#8221; and/or &#8220;related issuer&#8221; relationships that may exist between the issuer and the underwriter(s) as would otherwise be required pursuant to subsection 2.1(1) of NI 33-105.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Resale Restrictions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The offer and sale of the securities in Canada is being made on a private placement basis only and is exempt from the requirement that the issuer prepares and files a prospectus under applicable Canadian securities laws. Any resale of the securities acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, pursuant to a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus requirements or otherwise under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the securities outside of Canada. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Representations of Purchasers</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each Canadian investor who purchases the securities will be deemed to have represented to the issuer and the underwriter(s) that the investor (i)&#160;is purchasing the securities as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii)&#160;is an &#8220;accredited investor&#8221; as such term is defined in section 1.1 of National Instrument 45-106 </font><font style="font-style:italic;letter-spacing:0.2pt;">Prospectus Exemptions</font><font style="letter-spacing:0.2pt;">, or NI 33-105, or, in Ontario, as such term is defined in section 73.3(1) of the </font><font style="font-style:italic;letter-spacing:0.2pt;">Securities Act</font><font style="letter-spacing:0.2pt;"> (Ontario); and (iii)&#160;is a &#8220;permitted client&#8221; as such term is defined in section 1.1 of National Instrument 31-103 </font><font style="font-style:italic;letter-spacing:0.2pt;">Registration Requirements, Exemptions and Ongoing Registrant Obligations</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Taxation and Eligibility for Investment</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any discussion of taxation and related matters contained in this prospectus supplement does not purport to be a comprehensive description of all of the tax considerations that may be relevant to a Canadian investor when deciding to purchase the securities and, in particular, does not address any Canadian tax considerations. No representation or warranty is hereby made as to the tax consequences to a resident, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">137</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or deemed resident, of Canada of an investment in the securities or with respect to the eligibility of the securities for investment by such investor under relevant Canadian federal and provincial legislation and regulations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Rights of Action for Damages or Rescission</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Securities legislation in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum (such as this prospectus supplement), including where the distribution involves an &#8220;eligible foreign security&#8221; as such term is defined in Ontario Securities Commission Rule&#160;45-501 </font><font style="font-style:italic;letter-spacing:0.2pt;">Ontario Prospectus and Registration Exemptions</font><font style="letter-spacing:0.2pt;"> and in Multilateral Instrument 45-107 </font><font style="font-style:italic;letter-spacing:0.2pt;">Listing Representation and Statutory Rights of Action Disclosure Exemptions</font><font style="letter-spacing:0.2pt;">, as applicable, with a remedy for damages or rescission, or both, in addition to any other rights they may have at law, where the offering memorandum, or other offering document that constitutes an offering memorandum, and any amendment thereto, contains a &#8220;misrepresentation&#8221; as defined under applicable Canadian securities laws. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed under, and are subject to limitations and defences under, applicable Canadian securities legislation. In addition, these remedies are in addition to and without derogation from any other right or remedy available at law to the investor. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Language of Documents</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">Upon receipt of this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. </font><font style="letter-spacing:0.2pt;">Par la r&#233;ception de ce document, chaque investisseur Canadien confirme par les pr&#233;sentes qu&#8217;il a express&#233;ment exig&#233; que tous les documents faisant foi ou se rapportant de quelque mani&#232;re que ce soit &#224; la vente des valeurs mobili&#232;res d&#233;crites aux pr&#233;sentes (incluant, pour plus de certitude, toute confirmation d&#8217;achat ou tout avis) soient r&#233;dig&#233;s en anglais seulement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Australia</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This document does not constitute a prospectus, product disclosure statement or other disclosure document under the Australia&#8217;s Corporations Act 2001 (Cth), or the Corporations Act, of Australia. This document has not been lodged with the Australian Securities &amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this document in Australia: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You confirm and warrant that you are either: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a &#8220;sophisticated investor&#8221; under section 708(8)(a) or (b)&#160;of the Corporations Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a &#8220;sophisticated investor&#8221; under section 708(8)(c) or (d)&#160;of the Corporations Act and that you have provided an accountant&#8217;s certificate to the company which complies with the requirements of section&#160;708(8)(c)(i) or (ii)&#160;of the Corporations Act and related regulations before the offer has been made; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a &#8220;professional investor&#8221; within the meaning of section 708(11)(a) or (b)&#160;of the Corporations Act. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor or professional investor under the Corporations Act any offer made to you under this document is void and incapable of acceptance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You warrant and agree that you will not offer any of the shares issued to you pursuant to this document for resale in Australia within 12&#160;months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">European Economic Area</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In relation to each member state of the European Economic Area, or a Member State, no securities have been offered or will be offered pursuant to the offer described herein in that Member State prior to the publication of a prospectus in relation to the securities which has been approved by the competent authority </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">138</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">in that Member State or, where appropriate, approved in another Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that the securities may be offered to the public in that Member State at any time: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;to any legal entity which is a qualified investor as defined under Article&#160;2 of the Prospectus Regulation; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;to fewer than 150 natural or legal persons (other than qualified investors as defined under Article&#160;2 of the Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;in any other circumstances falling within Article&#160;1(4) of the Prospectus Regulation, </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">provided that no such offer of securities shall require the issuer or any underwriter to publish a prospectus pursuant to Article&#160;3 of the Prospectus Regulation or supplement a prospectus pursuant to Article&#160;23 of the Prospectus Regulation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each person in a Member State who acquires any securities in the offer or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with the issuer and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the case of any securities being offered to a financial intermediary as that term is used in Article&#160;5(1) of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed to and with the issuer and the underwriters that the securities acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Member State to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. Neither the issuer nor the underwriters have authorised, nor do they authorise, the making of any offer of securities through any financial intermediary, other than offers made by the underwriters which constitute the final placement of securities contemplated in this document. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The issuer and the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any securities in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase, or subscribe for, any securities and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In Member States, this document is being distributed only to, and is directed only at, persons who are &#8220;qualified investors&#8221; within the meaning of Article&#160;2(e) of the Prospectus Regulation, or Qualified Investors. This document must not be acted on or relied on in any Member State by persons who are not Qualified Investors. Any investment or investment activity to which this document relates is available in any Member State only to Qualified Investors and will be engaged in only with such persons. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Hong Kong</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No securities have been, may be or will be offered or sold in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong, or the SFO and any rules made thereunder; or in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding UP and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, or the C(WUMP)O, or which do not constitute an offer to the public within the meaning of the C(WUMP)O. No document, invitation or advertisement relating to the securities has been issued or may be issued or will be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">139</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the SFO and any rules made thereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This document has not been and will not be registered with the Registrar of Companies in Hong Kong. Accordingly, this document may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this document and the relevant offering documents and that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Japan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The offering has not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948 of Japan, as amended), or the FIEA, and the Initial Purchaser will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means, unless otherwise provided herein, any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEA and any other applicable laws, regulations and ministerial guidelines of Japan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Singapore</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This document has not been and will not be lodged or registered with the Monetary Authority of Singapore. Accordingly, this document and any other document or material in connection with the offer or sale, or the invitation for subscription or purchase of the securities may not be issued, circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to any person in Singapore other than (i)&#160;to an institutional investor under Section&#160;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&#160;to a relevant person as defined under Section&#160;275(2) of the SFA, or any person pursuant to Section&#160;275(1A) of the SFA, and in accordance with the conditions, specified in Section&#160;275 of the SFA and where (where applicable) Regulation&#160;3 of the Securities and Futures (Classes of Investors) Regulations&#160;2018, or (iii)&#160;otherwise pursuant to, and in accordance with the conditions of any other applicable provision of the SFA. </font><font style="font-weight:bold;letter-spacing:-0.2pt;">In the event that you are not an investor falling within any of the categories set out above, please return this document immediately. You may not forward or circulate this document to any other person in Singapore.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No offer is made to you with a view to the securities being subsequently offered for sale to any other party. There are on-sale restrictions that may be applicable to investors who acquire securities. As such, investors are advised to acquaint themselves with the provisions of the SFA relating to resale restrictions and comply accordingly. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Where the securities are subscribed or purchased under Section&#160;275 of the SFA by a relevant person which is: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a corporation (which is not an accredited investor as defined under Section&#160;4A of the SFA) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">securities or securities-based derivatives contracts (each term as defined in Section&#160;2(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferable within six&#160;months after that corporation or that trust has acquired the securities under Section&#160;275 of the SFA except: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">140</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to an institutional investor under Section&#160;274 of the SFA or to a relevant person defined in Section&#160;275(2) of the SFA, or to any person pursuant to an offer referred to in Section&#160;275(1A) or Section&#160;276(4)(i)(B) of the SFA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">where no consideration is given for the transfer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">where the transfer is by operation of law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">as specified in Section&#160;276(7) of the SFA; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">as specified in Regulation&#160;37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations&#160;2018 of Singapore. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Switzerland</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither this document nor any other offering or marketing material relating to the offering, the issuer or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Israel</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only at, and any offer of the shares is directed only at, investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&#160;million and &#8220;qualified individuals&#8221;, each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">United Kingdom</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In relation to the United Kingdom, no securities have been offered or will be offered pursuant to the offer described herein to the public in the United Kingdom prior to the publication of a prospectus in relation to the securities which has been approved by the United Kingdom Financial Conduct Authority, except that the securities may be offered to the public in the United Kingdom at any time: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;to any legal entity which is a qualified investor as defined under Article&#160;2 of the United Kingdom Prospectus Regulation; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;to fewer than 150 natural or legal persons (other than qualified investors as defined under Article&#160;2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;in any other circumstances falling within Section&#160;86 of the Financial Services and Markets Act&#160;2000 (as amended), or the FSMA.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">141</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:136pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">provided that no such offer of the securities shall require the issuer or any underwriter to publish a prospectus pursuant to Section&#160;85 of the FSMA or supplement a prospectus pursuant to Article&#160;23 of the United Kingdom Prospectus Regulation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each person in the United Kingdom who acquires any securities in the offer or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with the issuer and the underwriters that it is a qualified investor within the meaning of the United Kingdom Prospectus Regulation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the case of any securities being offered to a financial intermediary as that term is used in Article&#160;5(1) of the UK Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed to and with the issuer and the underwriters that the securities acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in the United Kingdom to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. Neither the issuer nor the underwriters have authorised, nor do they authorise, the making of any offer of securities through any financial intermediary, other than offers made by the underwriters which constitute the final placement of securities contemplated in this document. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The issuer and the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the securities in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities and the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United Kingdom, this document is being distributed only to, and is directed only at, persons who are &#8220;qualified investors&#8221; within the meaning of Article&#160;2(e) of the United Kingdom Prospectus Regulation who are also: (i)&#160;persons who fall within the definition of &#8220;investment professionals&#8221; in Article&#160;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order; (ii)&#160;persons falling within Article&#160;49(2) of the Order; or (iii)&#160;persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as &#8220;relevant persons&#8221;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. Any investment or investment activity to which this document relates is available in the United Kingdom only to relevant persons and will be engaged in only with such persons. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any invitation or inducement to engage in investment activity (within the meaning of Section&#160;21 of the FSMA) may only be communicated or caused to be communicated in connection with the issue or sale of the securities in circumstances in which Section&#160;21(1) of the FSMA does not apply. All applicable provisions of the FSMA and the Order must be complied with in respect of anything done by any person in relation to the securities in, from or otherwise involving the United Kingdom. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">142</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:236pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by Troutman Pepper Hamilton Sanders LLP, Philadelphia, Pennsylvania. Certain legal matters in connection with this offering will be passed upon for the underwriters by McGuireWoods LLP, New York, New York. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of Cognition Therapeutics, Inc. at December&#160;31, 2021 and 2020, and for each of the two&#160;years in the period ended December&#160;31, 2021, appearing in this prospectus and registration statement have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have filed with the SEC a registration statement on Form S-1, including exhibits and schedules, under the Securities Act, with respect to the shares of common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits and to the documents incorporated by reference herein. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement or a document incorporated by reference herein. Each of these statements is qualified in all respects by this reference. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may read our SEC filings, including this registration statement, over the Internet at the SEC&#8217;s website at www.sec.gov. Upon the completion of this offering, we will be subject to the information reporting requirements of the Exchange Act and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for review on the web site of the SEC referred to above. We also maintain a website at </font><font style="font-style:italic;letter-spacing:0.2pt;">www.cogrx.com</font><font style="letter-spacing:0.2pt;">, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">143</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIOCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:40pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to &#8220;incorporate by reference&#8221; information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we filed with the SEC (File No.&#160;001&#8209;40886): </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on March&#160;30, 2022, and the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December&#160;31, 2021 from our Definitive Proxy Statement on Schedule&#160;14A, filed with the SEC on April&#160;25, 2022; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our Quarterly Reports on Form 10-Q for the quarters ended March&#160;31, 2022 and June&#160;30, 2022, filed with the SEC on May&#160;11, 2022 and August&#160;9, 2022, respectively; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our Current Reports on Form 8-K filed with the SEC on June&#160;13, 2022 and July&#160;27, 2022; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on October&#160;6, 2021, including any amendments or reports filed for the purposes of updating this description. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information that we have &#8220;furnished&#8221; to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item&#160;2.02 or Item&#160;7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&#160;after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii)&#160;after the date of this prospectus but prior to the termination of the offering. These documents include periodic reports, such as Annual Reports on Form&#160;10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements on Schedule&#160;14A. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to Cognition Therapeutics, Inc., 2500 Westchester Ave., Purchase, New York 10577, Attn: Chief Executive Officer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You also may access these filings on our website at </font><font style="font-style:italic;letter-spacing:0.2pt;">www.cogrx.com</font><font style="letter-spacing:0.2pt;">. We do not incorporate the information on our website into this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus). You may also access these filings at the SEC&#8217;s website at </font><font style="font-style:italic;letter-spacing:0.2pt;">www.sec.gov</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">144</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:98.01pt; text-align:center; width:456pt;">
          <img src="lg_cognition-4c.jpg" alt="[MISSING IMAGE: lg_cognition-4c.jpg]" height="67" width="272" >
        </div>
        <div style="margin-top:76pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">5,586,592 Shares of Common Stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:84.097pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 84.0966666666666pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:31.05pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Preliminary Prospectus </font>
        </div>
        <div style="margin-top:3pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2022</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:19.51pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 19.51pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:67.72pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">Cantor</font><font style="font-weight:normal;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:38.17pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Co-Manager</font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Newbridge Securities Corporation</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:85.117pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 85.1166666666666pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PART II </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INFORMATION NOT REQUIRED IN PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;13.&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the fees and expenses in connection with the issuance and distribution of the securities being registered (excluding the underwriting discount and management fee). Except for the SEC registration fee and the FINRA filing fee, all amounts are estimates. </font>
        </div>
        <table style="width:416pt;height:114pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:366.29pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Item </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.99999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,267 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">FINRA filing fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,813</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">150,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accounting fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">60,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Printing expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">30,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Miscellaneous expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">3,920 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:366.29pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">250,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.7pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;14.&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As permitted by Section&#160;102 of the DGCL, we have adopted provisions in our amended and restated certificate of incorporation and bylaws that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any breach of the director&#8217;s duty of loyalty to us or our stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any transaction from which the director derived an improper personal benefit. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our amended and restated certificate of incorporation also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As permitted by Section&#160;145 of the DGCL, our amended and restated bylaws provide that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may indemnify our directors, officers and employees to the fullest extent permitted by the DGCL, subject to limited exceptions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the DGCL, subject to limited exceptions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the rights provided in our bylaws are not exclusive. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our third amended and restated certificate of incorporation and our amended and restated bylaws provide for the indemnification provisions described above and elsewhere herein. We have entered or will enter into, and intend to continue to enter into, separate indemnification agreements with our directors and officers that may be broader than the specific indemnification provisions contained in the DGCL. These indemnification agreements generally require us, among other things, to indemnify our officers and directors against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">which they could be indemnified. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have purchased and currently intend to maintain insurance on behalf of each and every person who is or was a director or officer of the Company against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;15.&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following list sets forth information as to all unregistered securities we have sold since January&#160;1, 2019 through the date of the prospectus that is a part of this registration statement: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Convertible Notes</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From March&#160;2018 to July&#160;2020, we issued convertible promissory notes in the aggregate principal amount of $13.0&#160;million with an interest rate of 8.0% per annum, pursuant to note purchase agreements entered into with certain holders of our capital stock. On May&#160;1, 2021, the holders of all of our outstanding convertible promissory notes agreed to an acceleration of the date of the automatic conversion from June&#160;30, 2021 to May&#160;1, 2021 for all convertible promissory notes. Accordingly, on May&#160;1, 2021, all of our outstanding convertible promissory notes were converted into 10,926,089 shares of our Series&#160;B-1 convertible preferred stock at a conversion price equal to $1.385 per share. As of the date of this prospectus, no notes are outstanding. Pursuant to the terms of our Series&#160;B-1 convertible preferred stock all shares automatically converted into shares of our common stock upon the closing of our initial public offering in October&#160;2021 on a one-for-one basis, after taking into effect a reverse split effected on October&#160;1, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SAFE Financing</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2021, we entered into simple agreements for future equity, or SAFEs, with various investors, pursuant to which we received gross proceeds in an aggregate amount equal to $8.9&#160;million. The amount invested by the investors in the SAFEs automatically converted into shares of our common stock upon the closing of our initial public offering in October&#160;2021 at a conversion price equal to 80% of the initial public offering price of our common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Awards</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since January&#160;1, 2019, we have granted stock options to employees, officers, directors and consultants, covering an aggregate of 3,602,416 shares of our common stock, having a weighted average exercise price of $5.55 per share, in connection with services provided to us by such parties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since January&#160;1, 2019, we have issued an aggregate of 98,753 shares of our common stock to employees, officers, directors and consultants upon their exercise of stock options, for aggregate cash consideration of approximately $0.1&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exercises of Warrants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since January&#160;1, 2019, we have issued an aggregate of 248,755 shares of our common stock upon the exercise of common stock warrants, for aggregate cash consideration of approximately $0.1&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise stated, the issuances of the above securities were deemed to be exempt from registration under the Securities Act in reliance upon Section&#160;4(a)(2) of the Securities Act or Regulation&#160;D promulgated thereunder, or Rule&#160;701 promulgated under Section&#160;3(b) of the Securities Act as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule&#160;701. Individuals who purchased securities as described above represented their intention to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were affixed to the share certificates issued in such transactions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions or any public offering. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;16.&nbsp;&nbsp;&nbsp;Exhibits and financial statement schedules.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">(a) Exhibits.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The exhibits listed below are filed as part of this registration statement. </font>
        </div>
        <table style="width:456pt;height:590.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:28pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit</font>
                <br >
                <font style="letter-spacing:-0.16pt;">number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:416pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">1.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:416pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2226999d4_ex1-1.htm">Form of Underwriting Agreement.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">3.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921126265/tm2130061d1_ex3-1.htm">Third Amended and Restated Certificate of Incorporation (incorporated by reference to exhibit&#160;3.1 of the Company&#8217;s Current Report on Form 8-K filed on October&#160;14, 2021).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">3.2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921126265/tm2130061d1_ex3-2.htm">Amended and Restated Bylaws (incorporated by reference to exhibit 3.2 of the Company&#8217;s Current Report on Form 8-K filed on October&#160;14, 2021).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">4.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921122299/tm2113659d19_ex4-1.htm">Specimen Common Stock Certificate of Registrant (incorporated by reference to exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">4.2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000155837022004672/cgtx-20211231xex4d1.htm">Description of the Registrant&#8217;s Securities (incorporated herein by reference to Exhibit&#160;4.1 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March&#160;30, 2022).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">5.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:416pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2226999d4_ex5-1.htm">Opinion of Troutman Pepper Hamilton Sanders LLP.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.1&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921097621/tm2113659d10_ex10-1.htm">Form of Indemnification Agreement by and between the Registrant and its individual directors and officers (incorporated by reference to exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-2.htm">Third Amended and Restated Investor Rights Agreement dated as of March&#160;20, 2014, by and among the Registrant and the investors listed therein (incorporated by reference to exhibit 10.2 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.3 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-3.htm">First Amendment dated as of March&#160;23, 2020, to the Third Amended and Restated Investor Rights Agreement dated as March&#160;20, 2014, by and among the Registrant and the investors listed therein (incorporated by reference to exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.4 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-4.htm">Office Lease dated July&#160;1, 2017, by and between the Registrant and RJ Equities LP (incorporated by reference to exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1 (File No.&#160;333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.5 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-5.htm">First Amendment to Office Lease dated July&#160;1, 2017, by and between the Registrant and RJ Equities LP (incorporated by reference to exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.6 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-6.htm">Office Lease dated July&#160;1, 2021, by and between the Registrant and 2500/2700 Westchester Avenue Owner SPE LLC (incorporated by reference to exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.7&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-7.htm">Amended and Restated 2007 Equity Incentive Plan (incorporated by reference to exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.8&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-8.htm">2017 Equity Incentive Plan (incorporated by reference to exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.9&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-9.htm">Amendment to 2017 Equity Incentive Plan (incorporated by reference to exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.10&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-10.htm">Second Amendment to 2017 Equity Incentive Plan (incorporated by reference to exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.11&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921122299/tm2113659d19_ex10-11.htm">2021 Equity Incentive Plan (incorporated by reference to exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.12&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921122299/tm2113659d19_ex10-12.htm">2021 Employee Stock Purchase Plan (incorporated by reference to exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.13&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-13.htm">Form of Restricted Stock Award Agreement (incorporated by reference to exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:650.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:28pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit</font>
                <br >
                <font style="letter-spacing:-0.16pt;">number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:416pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.14&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-14.htm">Form of Stock Option Grant Notice and Award Agreement (incorporated by reference to exhibit 10.14 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.15&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921097621/tm2113659d10_ex10-16.htm">Amended and Restated Employment Agreement by and between the Registrant and Lisa Ricciardi, (incorporated by reference to exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.16&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921097621/tm2113659d10_ex10-21.htm">Form of Restrictive Covenant Agreement (incorporated by reference to exhibit 10.21 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.17&#8226; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921097621/tm2113659d10_ex10-22.htm">Option Agreements for Directors (incorporated by reference to exhibit 10.22 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.18 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-24.htm">Grant Agreement dated August&#160;14, 2016 by and between the Registrant and the National Institute of Aging (incorporated by reference to exhibit 10.25 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.19 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-25.htm">Grant Agreement dated September&#160;12, 2017 by and between the Registrant and the National Institute of Aging (incorporated by reference to exhibit 10.26 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.20 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-26.htm">Grant Agreement dated April&#160;18, 2018 by and between the Registrant and the National Institute of Aging (incorporated by reference to exhibit 10.27 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.21 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-27.htm">Grant Agreement dated September&#160;8, 2018 by and between the Registrant and the National Institute of Aging (incorporated by reference to exhibit 10.28 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.22 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-28.htm">Grant Agreement dated August&#160;28, 2020 by and between the Registrant and the National Institute of Aging (incorporated by reference to exhibit 10.29 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.23 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-29.htm">Grant Agreement dated September&#160;5, 2020 by and between the Registrant and the National Institute of Aging (incorporated by reference to exhibit 10.30 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.24 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-30.htm">Grant Agreement dated September&#160;18, 2020 by and between the Registrant and the National Institute of Aging (incorporated by reference to exhibit 10.31 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.25 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-31.htm">Grant Agreement dated February&#160;3, 2021 by and between the Registrant and the National Institute of Aging (incorporated by reference to exhibit 10.32 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.26 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-32.htm">Grant Agreement dated April&#160;30, 2021 by and between the Registrant and the National Institute of Aging (incorporated by reference to exhibit 10.33 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.27 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-33.htm">Grant Agreement dated May&#160;6, 2021 by and between the Registrant and the National Institute of Aging (incorporated by reference to exhibit 10.34 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.28 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000110465921093246/tm2113659d7_ex10-34.htm">Grant Agreement dated May&#160;10, 2021 by and between the Registrant and the National Institute of Aging (incorporated by reference to exhibit 10.35 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-257999) dated July&#160;29, 2021).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.29* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:416pt;">
              <a style="-sec-extract:exhibit" href="tm2226999d4_ex10-29.htm">Office Lease Agreement, dated August 31, 2022.</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">21.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:416pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1455365/000155837022004672/cgtx-20211231xex21d1.htm">Subsidiaries of Cognition Therapeutics, Inc. (incorporated by reference to exhibit 21.1 of the Company&#8217;s Annual Report on Form 10-K filed on March&#160;30, 2022).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">23.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:416pt;">
              <a style="-sec-extract:exhibit" href="tm2226999d4_23-1.htm">Consent of Ernst &amp; Young LLP, an Independent Registered Public Accounting Firm.</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">23.2* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:416pt;">
              <a style="-sec-extract:exhibit" href="tm2226999d4_ex5-1.htm">Consent of Troutman Pepper Hamilton Sanders LLP (included in Exhibit&#160;5.1).</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:49.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.167pt 0pt 2.167pt 0pt; width:28pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit</font>
                <br >
                <font style="letter-spacing:-0.16pt;">number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.167pt 0pt 2.167pt 0pt; width:416pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">24.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:416pt;">
              <div style="letter-spacing:0.2pt;">
                <a href="#tSIG">Power of Attorney (included on the signature page to this registration statement).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">107* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2226999d4_ex-filingfees.htm">Filing Fee Table.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Filed herewith. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Indicates management contract or compensatory plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:11.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:11.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Financial Statement Schedules.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;17.&nbsp;&nbsp;&nbsp;Undertakings.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i) To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the U.S. Securities and Exchange Commission pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule&#160;424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule&#160;430B or other than prospectuses filed in reliance on Rule&#160;430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. </font><font style="font-style:italic;letter-spacing:0.2pt;">Provided, however</font><font style="letter-spacing:0.2pt;">, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:28pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(5) That for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(6) That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(7) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(8) For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to any charter provision, by law or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSIG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Purchase, State of New York, on this 7</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> day of November, 2022. </font>
        </div>
        <div style="margin-left:220pt; margin-top:12pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">COGNITION THERAPEUTICS, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">By:&nbsp;&nbsp;&nbsp;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:240pt;">
          <font style="letter-spacing:0.2pt;">/s/ Lisa Ricciardi</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Lisa Ricciardi </font> <br ><font style="letter-spacing:0.2pt;">Chief Executive Officer and President </font><br ><font style="letter-spacing:0.2pt;">(</font><font style="font-style:italic;letter-spacing:0.2pt;">Principal Executive Officer</font><font style="letter-spacing:0.2pt;">) </font></div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">POWER OF ATTORNEY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lisa Ricciardi and Andrew Einhorn, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing pursuant to Rule&#160;462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </font>
        </div>
        <table style="width:456pt;height:281.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:51.25pt; white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:12.917pt 0pt 1.833pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Lisa Ricciardi</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Lisa Ricciardi </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt;padding-top:10pt; width:192pt;vertical-align:middle;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Chief Executive Officer, President and Director </font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">(Principal Executive Officer)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:12.917pt 0pt 1.833pt 0pt; width:96pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">November 7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:37pt; white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Andrew Einhorn</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Andrew Einhorn</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt;padding-top:6pt; width:192pt;vertical-align:middle;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Interim Chief Financial Officer </font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">(Principal Financial and Accounting Officer)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">November 7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:37pt; white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Jack A. Khattar</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Jack A. Khattar </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt;padding-top:6pt; width:192pt;vertical-align:middle;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director (Chairman of the Board) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">November 7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:37pt; white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Aaron G. L. Fletcher, Ph.D.</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Aaron G. L. Fletcher, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt;padding-top:6pt; width:192pt;vertical-align:middle;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">November 7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:37pt; white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Brett P. Monia, Ph.D.</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Brett P. Monia, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt;padding-top:6pt; width:192pt;vertical-align:middle;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">November 7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:37pt; white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Ellen B. Richstone</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Ellen B. Richstone </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt;padding-top:6pt; width:192pt;vertical-align:middle;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">November 7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Peggy Wallace</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Peggy Wallace </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt;padding-top:6pt; width:192pt;vertical-align:middle;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">November 7, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2226999d4_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COGNITION THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
[_________] Shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(par value $0.001 per share)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Underwriting Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">November [__], 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: justify">Cantor Fitzgerald &amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: justify; text-indent: 0.25in">As Representative
of the several</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: justify; text-indent: 0.25in">Underwriters listed
in <U>Schedule A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: justify; text-indent: 0.25in">Hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: justify">c/o Cantor Fitzgerald &amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: justify">499 Park Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: justify">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5in 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cognition Therapeutics, Inc.,
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to the several underwriters named in <U>Schedule
A</U> (the &ldquo;<B>Underwriters</B>&rdquo;) an aggregate of [_______] shares (the &ldquo;<B>Firm Shares</B>&rdquo;) of its common stock,
par value $0.001 per share (&ldquo;<B>Common Stock</B>&rdquo;). In addition, the Company has granted to the Underwriters an option to
purchase up to an additional [_________] shares of Common Stock, which are collectively called the &ldquo;<B>Option Shares</B>.&rdquo;
The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the &ldquo;<B>Offered Shares.</B>&rdquo;
Cantor Fitzgerald &amp; Co. (&ldquo;<B>Cantor</B>&rdquo;) has agreed to act as representative of the several Underwriters (in such capacity,
the &ldquo;<B>Representative</B>&rdquo;) in connection with the offering and sale of the Offered Shares. To the extent there are no additional
underwriters listed on <U>Schedule A</U>, the term &ldquo;Representative&rdquo; as used herein shall mean Cantor, as Underwriter, and
the term &ldquo;Underwriters&rdquo; shall mean either the singular or the plural, as the context requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has prepared and filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a registration statement
on Form&#8239;S-1, File No.&#8239;333-[_______]. Such registration statement, as amended or supplemented, including the financial statements,
exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, and the rules and regulations
promulgated thereunder (collectively, the &ldquo;<B>Securities Act</B>&rdquo;), including all documents incorporated or deemed to be incorporated
by reference therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule&#8239;430A or 430B under
the Securities Act, is called the &ldquo;<B>Registration Statement</B>.&rdquo; Any registration statement filed by the Company pursuant
to Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Shares is called the &ldquo;<B>Rule 462(b)
Registration Statement</B>,&rdquo; and from and after the date and time of filing of any such Rule 462(b) Registration Statement the term
&ldquo;Registration Statement&rdquo; shall include the Rule 462(b) Registration Statement. The preliminary prospectus dated November [__],
2022 describing the Offered Shares and the offering thereof is called the &ldquo;<B>Preliminary Prospectus</B>,&rdquo; and the Preliminary
Prospectus and </FONT>any other prospectus in preliminary form that describes the Offered Shares and the offering thereof and is used
prior to the filing of the Prospectus (as defined below) is called a &ldquo;<B>preliminary prospectus</B>.&rdquo; As used herein, the
term &ldquo;<B>Prospectus</B>&rdquo; shall mean the final prospectus in the form first used by the Underwriters to confirm sales of the
Offered Shares or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule
173 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used herein, &ldquo;<B>Applicable Time</B>&rdquo; is [____] p.m.</FONT> (New York time) on November [__], 2022. As used herein, &ldquo;<B>free
writing prospectus</B>&rdquo; has the meaning set forth in Rule 405 under the Securities Act, and &ldquo;<B>Time of Sale Prospectus</B>&rdquo;
means the Preliminary Prospectus, as amended or supplemented immediately prior to the Applicable Time, together with the free writing
prospectuses, if any, identified on <U>Schedule B</U> hereto and the pricing information set forth on <U>Schedule C</U> hereto. As used
herein, <B>&ldquo;Road Show&rdquo;</B> means a &ldquo;road show&rdquo; (as defined in Rule 433 under the Securities Act) relating to the
offering of the Offered Shares contemplated hereby that is a &ldquo;written communication&rdquo; (as defined in Rule 405 under the Securities
Act). As used herein, &ldquo;<B>Section 5(d) Written Communication</B>&rdquo; means each written communication (within the meaning of
Rule 405 under the Securities Act) that is made in reliance on Section 5(d) of the Securities Act by the Company or any person authorized
to act on behalf of the Company to one or more potential investors that are qualified institutional buyers (&ldquo;<B>QIBs</B>&rdquo;)
and/or institutions that are accredited investors (&ldquo;<B>IAIs</B>&rdquo;), as such terms are respectively defined in Rule 144A and
Rule 501(a) under the Securities Act, to determine whether such investors might have an interest in the offering of the Offered Shares;
&ldquo;<B>Section 5(d) Oral Communication</B>&rdquo; means each oral communication, if any, made in reliance on Section 5(d) of the Securities
Act by the Company or any person authorized to act on behalf of the Company made to one or more QIBs and/or one or more IAIs to determine
whether such investors might have an interest in the offering of the Offered Shares; &ldquo;<B>Marketing Materials</B>&rdquo; means any
materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering
of the Offered Shares, including any Road Show or investor presentations made to investors by the Company (whether in person or electronically);
and &ldquo;<B>Permitted Section 5(d) Communication</B>&rdquo; means the Section 5(d) Written Communication(s) and Marketing Materials
listed on <U>Schedule D</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to financial statements and schedules and other information which are &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo;
in, or &ldquo;part of&rdquo; the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary
prospectus, the Time of Sale Prospectus or the Prospectus, and all other references of like import, shall be deemed to mean and include
all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration
Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Time of Sale Prospectus
or the Prospectus, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to amendments or supplements to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Time of Sale Prospectus
or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934, as amended
and the rules and regulations promulgated thereunder (collectively, the &ldquo;<B>Exchange Act</B>&rdquo;), that is or is deemed to be
incorporated by reference in the Registration Statement, the Preliminary Prospectus, any preliminary prospectus or the Prospectus, as
the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to (i)&#8239;the Registration Statement, the Preliminary Prospectus, any preliminary prospectus or the Prospectus, any amendments or supplements
to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic
Data Gathering, Analysis and Retrieval System (&ldquo;<B>EDGAR</B>&rdquo;) and (ii)&#8239;the Prospectus shall be deemed to include any
&ldquo;electronic Prospectus&rdquo; provided for use in connection with the offering of the Offered Shares as contemplated by Section
3(n) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
has only one subsidiary, then all references herein to &ldquo;subsidiaries&rdquo; of the Company shall be deemed to refer to such single
subsidiary, <U>mutatis mutandis</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company hereby confirms
its agreements with the Underwriters as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter as of the date of
this Agreement, the Applicable Time, the First Closing Date (as hereinafter defined) and each Option Closing Date (as hereinafter defined),
if any, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B></FONT><U>Compliance with Registration Requirements</U>. The Registration Statement has become effective under the Securities Act.
The Company has complied, to the Commission&rsquo;s satisfaction, with all requests of the Commission for additional or supplemental information,
if any. No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have
been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. The documents
incorporated or deemed to be incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus,
at the time they were or hereafter are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied
and will comply in all material respects with the requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Disclosure</U>. Each preliminary prospectus and the Prospectus when filed complied in all material respects with the Securities
Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation&#8239;S-T under
the Securities Act) to the copy thereof delivered to the Underwriters for use in connection with the offer and sale of the Offered Shares.
Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective and at all subsequent
times, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.
As of the Applicable Time, the Time of Sale Prospectus did not, and at the First Closing Date and at each, if applicable, Option Closing
Date (as defined in Section 2), the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not,
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading. The Prospectus as of its date (as amended or supplemented) did not,
and at the First Closing Date and each, as applicable, Option Closing Date did not and will not contain any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply
to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus or the Time
of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information relating
to any Underwriter furnished to the Company in writing by the Representative expressly for use therein, it being understood and agreed
that the only such information consists of the information described in Section 9(b) below. There are no contracts or other documents
required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement
which have not been described or filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Free Writing Prospectuses; Road Show</U>. As of the determination date referenced in Rule 164(h) under the Securities Act,
the Company was not, is not or will not be (as applicable) an &ldquo;ineligible issuer&rdquo; in connection with the offering of the
Offered Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Each free writing prospectus that the Company is required
to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements
of the Securities Act. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under
the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material
respects with the requirements of Rule 433 under the Securities Act, including timely filing with the Commission or retention where required
and legending, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the
public offer and sale of the Offered Shares did not, does not and will not include any information that conflicted, conflicts or will
conflict with the information contained in the Registration Statement, the Prospectus or any preliminary prospectus and not superseded
or modified. Except for the free writing prospectuses, if any, identified in <U>Schedule B</U>, and electronic road shows, if any, furnished
to the Representative before first use, the Company has not prepared, used or referred to, and will not, without the Representative&rsquo;s
prior written consent, prepare, use or refer to, any free writing prospectus. Each Road Show, when considered together with the Time
of Sale Prospectus, does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Emerging Growth Company</U>. From the time of initial confidential submission of the Registration Statement to the Commission
(or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Section
5(d) Written Communication or Section 5(d) Oral Communication) through the date hereof, the Company has been and is an &ldquo;emerging
growth company,&rdquo; as defined in Section 2(a) of the Securities Act (an &ldquo;<B>Emerging Growth Company</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Testing-the-Waters Materials</U>. The Company (i) has not alone engaged in any Section 5(d) Written Communication or Section
5(d) Oral Communication other than Permitted Section 5(d) Communications with the consent of the Representatives with entities that are
QIBs or IAIs and (ii) has not authorized anyone other than the Representatives to engage in such Permitted Section 5(d) Communications.
The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Marketing Materials, Section
5(d) Oral Communications and Section 5(d) Written Communications. The Company has not distributed or approved for distribution any Section
5(d) Written Communications other than those listed on <U>Schedule D</U> hereto. Any individual Permitted Section 5(d) Communication
does not conflict with the information contained in the Registration Statement or the Time of Sale Prospectus, complied in all material
respects with the Securities Act, and when taken together with the Time of Sale Prospectus as of the Applicable Time, did not, and as
of the First Closing Date and as of each Option Closing Date, as the case may be, will not, contain any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Distribution of Offering Material By the Company</U>. Prior to the later of (i) the expiration or termination of the option
granted to the several Underwriters in &lrm;Section 2 and (ii) the completion of the Underwriters&rsquo; distribution of the Offered
Shares, the Company has not distributed and will not distribute any offering material in connection with the offering and sale of the
Offered Shares other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed
and consented to by the Representative, and the free writing prospectuses, if any, identified on <U>Schedule B</U> hereto and any Permitted
Section 5(d) Communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Financial Information</U>. The consolidated financial statements of the Company included or incorporated by reference in the
Registration Statement, the Time of Sale Prospectus and the Prospectus, if any, together with the related notes and schedules, present
fairly, in all material respects, the consolidated financial position of the Company and the Subsidiaries (as defined below) as of the
dates indicated and the consolidated results of operations, cash flows and changes in stockholders&rsquo; equity of the Company for the
periods specified and have been prepared in compliance with the requirements of the Securities Act and Exchange Act and in conformity
with GAAP (as defined below) applied on a consistent basis during the periods involved, except as may be expressly stated in the related
notes thereto; there are no financial statements (historical or pro forma) that are required to be included or incorporated by reference
in the Registration Statement, the Time of Sale Prospectus and the Prospectus that are not included or incorporated by reference as required;
the Company and the Subsidiaries (as defined below) do not have any material liabilities or obligations, direct or contingent (including
any off-balance sheet obligations), not described in the Registration Statement (excluding the exhibits thereto), the Time of Sale Prospectus
and the Prospectus; and all disclosures contained or incorporated by reference in the Registration Statement, the Time of Sale Prospectus
and the Prospectus and the Issuer Free Writing Prospectuses, if any, regarding &ldquo;non-GAAP financial measures&rdquo; (as such term
is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K
under the Securities Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and
has been prepared in accordance with the Commission&rsquo;s rules and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Conformity with EDGAR Filing</U>. The Preliminary Prospectus and Final Prospectus delivered to the Underwriter for use in connection
with the sale of the Offered Shares pursuant to this Agreement will be identical to the versions of the Preliminary Prospectus and Final
Prospectus created to be transmitted to the Commission for filing via EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Organization</U>. The Company and each of its subsidiaries (as defined in Rule 405 under the Securities Act) (&ldquo;<B>Subsidiaries</B>&rdquo;)
are duly organized, validly existing as a corporation and in good standing under the Laws of their respective jurisdictions of organization.
The Company and each of its Subsidiaries are duly licensed or qualified as a foreign corporation for transaction of business and in good
standing under the Laws of each other jurisdiction in which their respective ownership or lease of property or the conduct of their respective
businesses requires such license or qualification, and have all corporate power and authority necessary to own or hold their respective
properties and to conduct their respective businesses as described in the Registration Statement, the Time of Sale Prospectus and the
Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or
in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the
assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders&rsquo; equity or results
of operations of the Company and the Subsidiaries taken as a whole, or prevent or materially interfere with the consummation of the transactions
contemplated hereby (a &ldquo;<B>Material Adverse Effect</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Subsidiaries</U>. Except as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company
has no subsidiary that is a &quot;significant subsidiary&quot; of the Company within the meaning of Rule 1.01 of Regulation S-X under
the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Violation or Default</U>. Neither the Company nor any of its Subsidiaries is (i)&#8239;in violation of its charter or by-laws
or similar organizational documents; (ii)&#8239;in default, and no event has occurred that, with notice or lapse of time or both, would
constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage,
deed of trust, loan agreement or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which
the Company or any of its Subsidiaries is bound or to which any of the property or assets of the Company or any of its Subsidiaries are
subject; or (iii)&#8239;in violation of any Law of any Governmental Authority, except, in the case of each of clauses (ii) and (iii)
above, for any such violation or default that would not, individually or in the aggregate, have a Material Adverse Effect. To the Company&rsquo;s
knowledge, no other party under any material contract or other agreement to which it or any of its Subsidiaries is a party is in default
in any respect thereunder where such default would have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(l)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Material Adverse Effect</U>. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Time of Sale Prospectus, the Prospectus and the Free Writing Prospectuses, if any (including any document deemed incorporated by
reference therein), there has not been (i) any Material Adverse Effect or the occurrence of any development that the Company reasonably
expects will result in a Material Adverse Effect, (ii) any transaction which is material to the Company and the Subsidiaries taken as
a whole, (iii) any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company
or any Subsidiary, which is material to the Company and the Subsidiaries taken as a whole, (iv) any material change in the capital stock
or outstanding long-term indebtedness of the Company or any of its Subsidiaries or (v) any dividend or distribution of any kind declared,
paid or made on the capital stock of the Company or any Subsidiary, other than in each case above in the ordinary course of business
or as otherwise disclosed in the Registration Statement or Prospectus (including any document incorporated by reference therein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(m)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Capitalization</U>. The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid
and nonassessable and, other than as disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus, are not
subject to any preemptive rights, rights of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization
as set forth in the Registration Statement and the Prospectus as of the dates referred to therein (other than the grant of additional
options under the Company&rsquo;s existing stock option plans, or changes in the number of outstanding shares of Common Stock of the
Company due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock
outstanding on the date hereof) and such authorized capital stock conforms to the description thereof set forth in the Registration Statement,
the Time of Sale Prospectus and the Prospectus. The description of the securities of the Company in the Registration Statement, the Time
of Sale Prospectus and the Prospectus is complete and accurate in all material respects. Except as disclosed in or contemplated by the
Registration Statement, the Time of Sale Prospectus or the Prospectus, as of the date referred to therein, the Company does not have
outstanding any options to purchase, or any rights or warrants to subscribe for, or any securities or obligations convertible into, or
exchangeable for, or any contracts or commitments to issue or sell, any shares of capital stock or other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(n)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Authorization; Enforceability</U>. The Company has full legal right, power and authority to enter into this Agreement and perform
the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal,
valid and binding agreement of the Company enforceable in accordance with its terms, except to the extent that enforceability may be
limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&rsquo; rights generally and by general
equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(o)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Authorization of the Offered Shares</U>. The Offered Shares have been duly authorized for issuance and sale pursuant to this
Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be duly and validly
issued, fully paid and nonassessable, free and clear of any pledge, lien, encumbrance, security interest or other claim, including any
statutory or contractual preemptive rights, resale rights, rights of first refusal or other similar rights, and will be registered pursuant
to Section 12 of the Exchange Act. The Offered Shares, when issued, will conform to the description thereof set forth in or incorporated
into the Registration Statement, the Time of Sale Prospectus and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(p)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Consents Required</U>. No consent, approval, authorization, order, registration or qualification of or with any Governmental
Authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale by the Company
of the Offered Shares, except for such consents, approvals, authorizations, orders and registrations or qualifications as may be required
under applicable state securities Laws or Laws of the Financial Industry Regulatory Authority Inc. (&ldquo;<B>FINRA</B>&rdquo;) or NASDAQ
(as defined below) in connection with the sale of the Offered Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(q)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Preferential Rights</U>. Except as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus,
(i)&#8239;no person, as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act (each, a &ldquo;<B>Person</B>&rdquo;),
has the right, contractual or otherwise, to cause the Company to issue or sell to such Person any Common Stock or shares of any other
capital stock or other securities of the Company, (ii)&#8239;no Person has any preemptive rights, resale rights, rights of first refusal,
rights of co-sale, or any other rights (whether pursuant to a &ldquo;poison pill&rdquo; provision or otherwise) to purchase any Common
Stock or shares of any other capital stock or other securities of the Company, (iii)&#8239; no Person has the right to act as an underwriter
or as a financial advisor to the Company in connection with the offer and sale of the Common Stock, and (iv)&#8239;no Person has the
right, contractual or otherwise, to require the Company to register under the Securities Act any Common Stock or shares of any other
capital stock or other securities of the Company, or to include any such shares or other securities in the Registration Statement or
the offering contemplated thereby, whether as a result of the filing or effectiveness of the Registration Statement or the sale of the
Offered Shares as contemplated thereby or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(r)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Independent Public Accounting Firm</U>. Ernst &amp; Young LLP (the &ldquo;<B>Accountant</B>&rdquo;), whose report on the consolidated
financial statements of the Company is filed with the Commission as part of the Company&rsquo;s most recent Annual Report on Form 10-K
filed with the Commission and incorporated by reference into the Registration Statement and the Prospectus, are and, during the periods
covered by their report, were an independent registered public accounting firm within the meaning of the Securities Act and the Public
Company Accounting Oversight Board (United States). To the Company&rsquo;s knowledge, the Accountant is not in violation of the auditor
independence requirements of the Sarbanes-Oxley Act of 2002 (the &ldquo;<B>Sarbanes-Oxley Act</B>&rdquo;) with respect to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(s)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Enforceability of Agreements</U>. All agreements between the Company and third parties expressly referenced in the Prospectus
are legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except to the extent that
(i)&#8239;enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&rsquo;
rights generally and by general equitable principles and (ii)&#8239;the indemnification provisions of certain agreements may be limited
by federal or state securities Laws or public policy considerations in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(t)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Litigation</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding
pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s knowledge, any
executive officer or director that is required to be disclosed in the Time of Sale Prospectus, the Prospectus and the Registration Statement
which has not been disclosed therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(u)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Possession of Licenses and Permits</U>. The Company (A) possesses the licenses, permits, certificates, authorizations, consents
and approvals (collectively, &quot;<B>Governmental Licenses</B>&quot;) issued by the appropriate governmental entities necessary to conduct
its business as currently conducted as described in the Time of Sale Prospectus, the Prospectus and the Registration Statement, and (B)
has obtained all necessary Governmental Licenses from other persons necessary to conduct its business, except, in each case of clauses
(A) and (B), (i) as described in the Time of Sale Prospectus, the Prospectus and the Registration Statement or (ii) to the extent that
any failure to possess any Governmental Licenses, provide any notice, make any filing, or obtain any Governmental Licenses would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; none of the Company and subsidiaries is in
violation of, or in default under, any Governmental License, except as would not reasonably be expected to have a Material Adverse Effect.
All of the Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or
the failure of such Governmental Licenses to be in full force and effect would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect. The Company has not received any notice of proceedings relating to the revocation or modification
of any Governmental Licenses which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would
have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(v)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Health Care Authorizations</U>. The Company has submitted and possesses, or qualifies for applicable exemptions to, such valid
and current registrations, listings, approvals, clearances, licenses, certificates, authorizations or permits and supplements or amendments
thereto (collectively, &ldquo;<B>Health Care Authorizations</B>&rdquo;) issued or required by the appropriate local, state, federal,
national, supranational or other foreign regulatory agencies or bodies (collectively, &ldquo;<B>Health Regulatory Agencies</B>&rdquo;)
necessary to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, including,
without limitation, all such Health Care Authorizations required by the FDA, the Australian Therapeutic Goods Administration (&ldquo;<B>TGA</B>&rdquo;),
the Department of Health and Human Services, the European Commission, the EMA or any other Health Regulatory Agencies engaged in the
regulation of Biologics (as defined in the Public Health Service Act of 1944, as amended (42 U.S.C. 6A et seq.)), except as would not
be reasonably expected to result in a Material Adverse Effect. The Company has not received any notice of proceedings, or have any knowledge
of any threatened proceedings, relating to the revocation or modification of, or non-compliance with, any such Health Care Authorization,
except where such revocation, modification or non-compliance would not result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(w)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Compliance with Health Care Laws</U>. The Company is, and has been, in compliance with all applicable Health Care Laws, and
has not engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive
exclusion from Medicare, Medicaid or any other state, federal or national health care program, except where such noncompliance, false
claims liability or civil penalties would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect.
For purposes of this Agreement, &quot;<B>Health Care Laws</B>&quot; means all health care laws applicable to the Company, including,
but not limited to: the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Anti-Kickback Statute (42 U.S.C. Section
1320a-7b(b)), the Civil Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a), the Physician Payments Sunshine Act (42 U.S.C. &sect; 1320a-7h),
the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal
laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud
criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&quot;<B>HIPAA</B>&quot;) (42 U.S.C.
Section 1320d et seq.), the exclusion laws (42 U.S.C. &sect; 1320a-7), Basic Health and Human Services Policy for Protection of Human
Research Subjects &quot;Common Rule&quot; as codified and enforced by the Department of Health and Human Services in 45 C.F.R. part 46
and enforced by FDA under 21 C.F.R. part 50, Laboratory Animal Welfare Act of 1966, HIPAA, as amended by the Health Information Technology
for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.), Medicare (Title XVIII of the Social Security Act), Medicaid (Title
XIX of the Social Security Act), any and all other applicable comparable local, state, federal, national, supranational and foreign health
care laws and the regulations promulgated pursuant to such laws, each as amended from time to time. The Company has not received written
notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator
or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any
Health Care Laws, and, to the knowledge of the Company, no such claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action is threatened. The Company has not received any written notice of adverse filing, warning letter, untitled
letter or other correspondence or notice from the FDA, the European Commission, the EMA, the TGA or any other Health Regulatory Agencies,
or any other court or arbitrator, alleging or asserting material noncompliance with the Health Care Laws. The Company is not a party
to and has no ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring
agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental or regulatory
authority. Additionally, neither the Company, nor, to the knowledge of the Company, any of its employees, officers or directors has been
excluded, suspended or debarred from participation in any U.S. federal health care program or human research study or trial or, to the
knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably
be expected to result in debarment, suspension or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(x)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Research Studies and Trials</U>. (A) The research studies and trials conducted by or, to the Company's knowledge, on behalf
of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time
of Sale Prospectus or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Prospectus
or the Prospectus, as applicable, were and, if still pending, are being, conducted in all material respects in accordance with applicable
experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products
or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA,
National Institute of Health Department of Health and Human Services, the European Commission, the EMA, the TGA and any other Health
Regulatory Agencies to which it is subject; (B) the descriptions of the results of such studies and trials contained in the Registration
Statement, the Time of Sale Prospectus or the Prospectus do not contain any misstatement of a material fact or omit to state a material
fact necessary to make such statements not misleading; (C) the Company has no knowledge of any research studies or trials not described
in the Registration Statement, the Time of Sale Prospectus and the Prospectus the results of which reasonably call into question in any
material respect the results of the research studies and trials described in the Registration Statement, the Time of Sale Prospectus
or the Prospectus; (D) the Company has not received any notices or correspondence from the FDA, the European Commission, the EMA, the
TGA or any Health Regulatory Agency or any institutional review board or comparable authority requiring or threatening the premature
termination, suspension, material modification or clinical hold of any research studies or trials conducted by or on behalf of, or sponsored
by, the Company or in which the Company has participated that are described in the Registration Statement, the Time of Sale Prospectus
or the Prospectus, and, to the Company's knowledge, there are no reasonable grounds for the same; (E) there has not been any violation
of applicable law or regulation by the Company in any of its product development efforts, submissions or reports to the FDA, the European
Commission, the EMA, the TGA or any other Health Regulatory Agency that could reasonably be expected to require investigation, corrective
action or result in enforcement action, except where such violation would not, singly or in the aggregate, result in a Material Adverse
Effect; and (F) the research studies and clinical trials of Company are being conducted in an ethical and human manner under state, national
or supra-national applicable laws that are either equal or more stringent than applicable laws and regulations enforced by the Department
of Health and Human Services and FDA governing human, animal or non-human primate research participants and test subjects and such studies
and the clinical trials are conducted under the auspices of a neutral and independent Institutional Animal Care and Use Committee or
Institutional Review Board and applicable state, national, or supra national agencies responsible for oversight.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(y)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Health Care Products Manufacturing</U>. The manufacture of the Company's products by or, to the knowledge of the Company, on
behalf of the Company is being conducted in compliance with all applicable Health Care Laws, including, without limitation, the FDA's
regulation pertaining to Biologics at 21 CFR Part 600, and, to the extent applicable, the respective counterparts thereof promulgated
by the European Commission, the EMA, TGA or other Health Regulatory Agencies. Except as disclosed in the Registration Statement, the
Time of Sale Prospectus and the Prospectus, the Company has not had any manufacturing site (whether owned by the Company or, to the knowledge
of the Company, that of a third party manufacturer for the Company's products) subject to an FDA, European Commission, EMA, TGA or other
Health Regulatory Agency shutdown or import or export prohibition, nor received any FDA, European Commission, EMA or other Health Regulatory
Agency &quot;warning letters,&quot; or &quot;untitled letters&quot; alleging or asserting material noncompliance with any applicable
Health Care Laws, requests to make material changes to the Company's products, processes or operations, or similar correspondence or
notice from the FDA, the European Commission, the EMA, the TGA or other Health Regulatory Agency alleging or asserting material noncompliance
with any applicable Health Care Laws, other than those that have been satisfactorily addressed and/or closed with the FDA, the European
Commission, the EMA or other Health Regulatory Agency. To the knowledge of the Company, none of the FDA, the European Commission, the
EMA, the TGA or any other Health Regulatory Agency is considering such action</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(z)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Possession of Intellectual Property</U>. The Company owns or possesses all licenses or other rights to use all patents, trademarks,
service marks, trade names, copyrights, software and design licenses, trade secrets, manufacturing processes, other intangible property
rights and know-how as are necessary for the conduct of its business as described in the Time of Sale Prospectus, the Prospectus and
the Registration Statement (collectively, &quot;<B>Intellectual Property</B>&quot;), except where the failure to own or possess such
Intellectual Property would not reasonably be expected to have a Material Adverse Effect. The Company has not received written notice
of any infringement of or conflict with (and the Company does not know of any such infringement of or conflict with) any asserted rights
of others with respect to any Intellectual Property used by the Company that would reasonably be expected to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(aa)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Company IT Systems</U>. The Company owns or has a valid right to access and use all computer systems, networks, hardware, software,
databases, websites and equipment used to process, store, maintain and operate data, information and functions necessary for the conduct
of its business (the &quot;<B>Company IT Systems</B>&quot;), except where the failure to own or have the right to access the Company
IT Systems would not reasonably be expected to have a Material Adverse Effect. The Company IT Systems are adequate for, and operate and
perform in all material respects as required in connection with, the operation of the business of the Company as currently conducted
except as would not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(bb)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Material Defaults</U>. Neither the Company nor any of the Subsidiaries has defaulted on any installment on indebtedness
for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would have a Material
Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since the filing of its last
Annual Report on Form 10-K, indicating that it (i)&#8239;has failed to pay any dividend or sinking fund installment on preferred stock
or (ii)&#8239;has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which
defaults, individually or in the aggregate, would have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(cc)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Certain Market Activities</U>. Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action
designed to or that might cause or result in stabilization or manipulation of the price of the Shares or of any &ldquo;reference security&rdquo;
(as defined in Rule 100 of Regulation M under the Exchange Act (&ldquo;<B>Regulation M</B>&rdquo;)) with respect to the Shares, whether
to facilitate the sale or resale of the Offered Shares or otherwise, and has taken no action which would directly or indirectly violate
Regulation M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(dd)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Broker/Dealer Relationships</U>. Neither the Company nor any of the Subsidiaries (i)&#8239;is required to register as a &ldquo;broker&rdquo;
or &ldquo;dealer&rdquo; in accordance with the provisions of the Exchange Act or (ii)&#8239;directly or indirectly through one or more
intermediaries, controls or is a &ldquo;person associated with a member&rdquo; or &ldquo;associated person of a member&rdquo; (within
the meaning set forth in the FINRA Manual).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ee)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Reliance</U>. The Company has not relied upon the Underwriter or legal counsel for the Underwriter for any legal, tax or
accounting advice in connection with the offering and sale of the Offered Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ff)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Payment of Taxes</U>. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect or where such matters are the result of a pending bona fide dispute with taxing authorities, (A) the Company has accurately prepared
and timely filed all federal, state, foreign and other tax returns or other statements that are or were required to be filed by it, if
any, and has paid or made provision for the payment of all taxes, assessments, governmental or other similar charges, including without
limitation, all sales and use taxes and all taxes which it is obligated to withhold from amounts owing to employees, creditors and third
parties, with respect to the periods covered by such tax returns (whether or not such amounts are shown as due on any tax return), (B)
no deficiency assessment with respect to a proposed adjustment of the Company's federal, state, local or foreign taxes is pending or,
to the Company&rsquo;s knowledge threatened, (C) since the date of the most recent audited financial statements, the Company has not
incurred any liability for taxes other than in the ordinary course of its business, and (D) there is no tax lien, whether imposed by
any federal, state, foreign or other taxing authority, outstanding against the assets, properties or business of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(gg)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Title to Property</U>. The Company has legal and valid title to all assets and properties described as owned by it in the Time
of Sale Prospectus, the Prospectus and the Registration Statement (whether through fee ownership, mineral estates or similar rights of
ownership), in each case free and clear of all liens, except as would not reasonably be expected, individually or in the aggregate, to
have a Material Adverse Effect, and any real property or personal property held under lease by the Company is held under a lease that
is valid, existing and enforceable by the Company with such exceptions as would not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Effect, and the Company has not received any written notice of any material claim that is adverse to the rights
of the Company under any lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(hh)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Environmental Laws</U>. Except as set forth in the Registration Statement, the Time of Sale Prospectus or the Prospectus, (A)
the Company is not in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule
of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree
or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface
water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the
release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum
products, asbestos-containing materials or mold (collectively, &quot;<B>Hazardous Materials</B>&quot;) or to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &quot;<B>Environmental Laws</B>&quot;),
except for those violations that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect,
(B) the Company has all permits, authorizations and approvals required under any applicable Environmental Laws and is in compliance in
all material respects with their requirements, (C) there are no pending or, to the Company&rsquo;s knowledge, threatened administrative,
regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigations
or proceedings relating to any Environmental Law against the Company, and (D) to the Company's knowledge, there are no events or circumstances
that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any
private party or governmental body or agency, against or affecting the Company relating to Hazardous Materials or any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Disclosure Controls</U>. The Company and each of its Subsidiaries maintain systems of internal accounting controls sufficient
to provide reasonable assurance that (i)&#8239;transactions are executed in accordance with management&rsquo;s general or specific authorizations;
(ii)&#8239;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles and to maintain asset accountability; (iii)&#8239;access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization; and (iv)&#8239;the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company&rsquo;s internal control over financial reporting
is effective and the Company is not aware of any material weaknesses in its internal control over financial reporting (other than as
set forth in the Registration Statement, Time of Sale Prospectus or Prospectus). Since the date of the latest audited financial statements
of the Company included in the Prospectus, there has been no change in the Company&rsquo;s internal control over financial reporting
that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting
(other than as set forth in the Registration Statement, Time of Sale Prospectus or Prospectus). The Company has established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) for the Company and designed such disclosure controls and
procedures to ensure that material information relating to the Company and each of its Subsidiaries is made known to the certifying officers
by others within those entities, particularly during the period in which the Company&rsquo;s Annual Report on Form 10-K or Quarterly
Report on Form 10-Q, as the case may be, is being prepared. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the Company&rsquo;s disclosure controls and procedures as of a date within 90 days prior to the filing date of the Form 10-K for the
fiscal year most recently ended (such date, the <B>&ldquo;Evaluation Date</B>&rdquo;). The Company presented in its Form 10-K for the
fiscal year most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date and the disclosure controls and procedures are effective. Since the Evaluation Date,
there have been no significant changes in the Company&rsquo;s internal controls (as such term is defined in Item 307(b) of Regulation
S-K under the Securities Act) or, to the Company&rsquo;s knowledge, in other factors that could significantly affect the Company&rsquo;s
internal controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(jj)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Sarbanes-Oxley</U>. There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or
officers, in their capacities as such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley Act and
the rules and regulations promulgated thereunder. Each of the principal executive officer and the principal financial officer of the
Company (or each former principal executive officer of the Company and each former principal financial officer of the Company as applicable)
has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms,
statements and other documents required to be filed by it or furnished by it to the Commission. For purposes of the preceding sentence,
&ldquo;principal executive officer&rdquo; and &ldquo;principal financial officer&rdquo; shall have the meanings given to such terms in
the Sarbanes-Oxley Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(kk)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Brokers</U>. Neither the Company nor any of the Subsidiaries has incurred any liability for any finder&rsquo;s fees, brokerage
commissions or similar payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to
or pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ll)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Employment Laws Compliance</U>. The Company has not violated, or received any notice of any violation with respect to, any
law, rule, regulation, order, decree or judgment applicable to it and its business, including those relating to transactions with affiliates,
environmental, safety or similar laws, federal or state laws relating to discrimination in the hiring, promotion or pay of employees,
federal or state wages and hours law, the Employee Retirement Income Security Act of 1974, as amended, or the rules and regulations promulgated
thereunder, except for those violations that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(mm)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Investment Company Act</U>. Neither the Company nor any of the Subsidiaries is, or will be, either after receipt of payment
for the Offered Shares or after the application of the proceeds therefrom as described under &ldquo;Use of Proceeds&rdquo; in the Registration
Statement, the Time of Sale Prospectus or the Prospectus, required to register as an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo;
by an &ldquo;investment company,&rdquo; as such terms are defined in the Investment Company Act of 1940, as amended (the &ldquo;<B>Investment
Company Act</B>&rdquo;<B>)</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(nn)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Money Laundering Laws</U>. The Company has not, and to the Company&rsquo;s knowledge, none of the officers or directors of
the Company have, and, to the Company's knowledge, none of the Company&rsquo;s employees or agents purporting to act on behalf of the
Company, as applicable, have made any payment of funds of the Company or received or retained any funds in violation of any law, rule
or regulation relating to the &quot;know your customer&quot; and anti-money laundering laws of any jurisdiction (collectively, the &quot;<B>Money
Laundering Laws</B>&quot;) and no action, suit or proceeding by or before any governmental entity involving the Company with respect
to the Money Laundering Laws is pending or to the Company&rsquo;s knowledge, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(oo)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Off-Balance Sheet Arrangements</U>. There are no transactions, arrangements and other relationships between and/or among the
Company, and/or any of its affiliates and any unconsolidated entity, including any structural finance, special purpose or limited purpose
entity (each, an &ldquo;<B>Off-Balance Sheet Transaction</B>&rdquo;) that could reasonably be expected to affect materially the Company&rsquo;s
liquidity or the availability of or requirements for its capital resources, including those Off-Balance Sheet Transactions described
in the Commission&rsquo;s Statement about Management&rsquo;s Discussion and Analysis of Financial Conditions and Results of Operations
(Release Nos. 33-8056; 34-45321; FR-61), required to be described in the Prospectus which have not been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(pp)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>ERISA</U>. To the knowledge of the Company, each material employee benefit plan, within the meaning of Section 3(3) of the
Employee Retirement Income Security Act of 1974 (&ldquo;<B>ERISA</B>&rdquo;), that is maintained, administered or contributed to by the
Company or any of its affiliates for employees or former employees of the Company and any of its Subsidiaries has been maintained in
material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including ERISA and
the Internal Revenue Code of 1986 (the &ldquo;<B>Code</B>&rdquo;); no prohibited transaction, within the meaning of Section 406 of ERISA
or Section 4975 of the Code, has occurred which would result in a material liability to the Company with respect to any such plan excluding
transactions effected pursuant to a statutory or administrative exemption; and for each such plan that is subject to the funding rules
of Section 412 of the Code or Section 302 of ERISA, no &ldquo;accumulated funding deficiency&rdquo; as defined in Section 412 of the
Code has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes
accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial
assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(qq)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Forward-Looking Statements</U>. Each financial or operational projection or other &ldquo;forward-looking statement&rdquo; (as
defined by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement, the Time of
Sale Prospectus or the Prospectus (i)&#8239;was so included by the Company in good faith and with reasonable basis after due consideration
by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&#8239;is accompanied by
meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward-looking
statement. No such statement was made with the knowledge of an executive officer or director of the Company that is was false or misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(rr)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Margin Rules</U>. Neither the issuance, sale and delivery of the Offered Shares nor the application of the proceeds thereof
by the Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors
of the Federal Reserve System or any other regulation of such Board of Governors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ss)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Insurance</U>. The Company carries, or is covered by, insurance (issued by insurers of recognized financial responsibility)
in such amounts and covering such risks as is appropriate for the conduct of its entire business and the value of its assets, all of
which insurance is in full force and effect in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(tt)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Foreign Corrupt Practices Act</U>. Neither the Company nor any of the directors, employees or officers of the Company or, to
its knowledge, any other person acting on behalf of the Company has, directly or indirectly, given or agreed to give any money, gift
or similar benefit (other than legal price concessions to customers in the ordinary course of business) to any customer, supplier, employee
or agent of a customer or supplier, or official or employee of any governmental agency or instrumentality of any government (domestic
or foreign) or any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position
to help or hinder the business of the Company (or assist it in connection with any actual or proposed transaction) that (i) might subject
the Company to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the past,
might have had a Material Adverse Effect or (iii) if not continued in the future, might have a Material Adverse Effect. The Company has
taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all material
respects with the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(uu)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Conflicts</U>. Neither the execution of this Agreement, nor the issuance, offering or sale of the Offered Shares, nor the
consummation of any of the transactions contemplated herein and therein, nor the compliance by the Company with the terms and provisions
hereof and thereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will
constitute a default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any
property or assets of the Company pursuant to the terms of any contract or other agreement to which the Company may be bound or to which
any of the property or assets of the Company is subject, except (i) such conflicts, breaches or defaults as may have been waived and
(ii) such conflicts, breaches and defaults that would not have a Material Adverse Effect; nor will such action result (x) in any violation
of the provisions of the organizational or governing documents of the Company, or (y) in any material violation of the provisions of
any statute or any order, rule or regulation applicable to the Company or of any Governmental Authority having jurisdiction over the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(vv)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>OFAC</U>. The Company is not, and, to the Company&rsquo;s knowledge, none of its directors, officers agents or employees purporting
to act on behalf of the Company are currently the target of or reasonably likely to become the target of any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&quot;<B>OFAC</B>&quot;); and the Company will not directly
or indirectly use the proceeds of the Offering of the Public Securities hereunder, or lend, contribute or otherwise make available such
proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person
currently the target of any U.S. sanctions administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ww)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&#8239;<U>Statistical and Market-Related Data</U>. All statistical, demographic and market-related data included in the Registration
Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes to be reliable
and accurate or represent the Company&rsquo;s good faith estimates that are made on the basis of data derived from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(xx)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Stock Exchange Listing</U>. The Shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and are listed
on The NASDAQ Global Market (&ldquo;<B>NASDAQ</B>&rdquo;), and the Company has taken no action designed to, or likely to have the effect
of, terminating the registration of the Shares under the Exchange Act or delisting the Shares from NASDAQ, nor has the Company received
any notification that the Commission or NASDAQ is contemplating terminating such registration or listing. To the Company&rsquo;s knowledge,
it is in compliance with all applicable listing requirements of NASDAQ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(yy)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Related-Party Transactions</U>. There are no business relationships or related-party transactions involving the Company or
any of its subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the
Prospectus that have not been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(zz)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>FINRA Matters</U>. All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its
counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company
in connection with the offering of the Offered Shares is true, complete, correct and compliant with FINRA&rsquo;s rules and any letters,
filings or other supplemental information provided to FINRA pursuant to FINRA Rules is true, complete and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(aaa)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Parties to Lock-Up Agreements</U>. The Company has furnished to the Underwriters a letter agreement in the form attached hereto
as <U>Exhibit&#8239;A</U> (the &ldquo;<B>Lock-up Agreement</B>&rdquo;) from each of the persons listed on <U>Exhibit&#8239;B</U>. Such
<U>Exhibit&#8239;B</U> lists under an appropriate caption the directors and executive officers of the Company. If any additional persons
shall become directors or executive officers of the Company prior to the end of the Company Lock-up Period (as defined below), the Company
shall cause each such person, prior to or contemporaneously with their appointment or election as a director or executive officer of
the Company, to execute and deliver to CF&amp;CO a Lock-up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(bbb)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cybersecurity</U>.
The Company and its subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &ldquo;<B>IT Systems</B>&rdquo;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company as currently conducted, free and clear
of known material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have
implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and data, including all &ldquo;Personal Data&rdquo; (defined below) and all sensitive, confidential or regulated data (&ldquo;<B>Confidential
Data</B>&rdquo;) used in connection with their businesses. &ldquo;<B>Personal Data</B>&rdquo; means (i) a natural person&rsquo;s name,
street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver&rsquo;s license
number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify
as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii) &ldquo;personal data&rdquo;
as defined by the European Union General Data Protection Regulation (&ldquo;<B>GDPR</B>&rdquo;) (EU 2016/679); (iv) any information which
would qualify as &ldquo;protected health information&rdquo; under HIPAA; (v) any &ldquo;personal information&rdquo; as defined by the
California Consumer Privacy Act (&ldquo;<B>CCPA</B>&rdquo;); and (vi) any other piece of information that allows the identification of
such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&rsquo;s
health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for
those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal
review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable
laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority,
internal policies and contractual obligations relating to the privacy and security of IT Systems, Confidential Data, and Personal Data
and to the protection of such IT Systems, Confidential Data, and Personal Data from unauthorized use, access, misappropriation or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ccc)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Compliance with Data Privacy Laws</U>. The Company and its subsidiaries are, and at all prior times were, in material compliance
with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, CCPA, and GDPR
(collectively, the &ldquo;<B>Privacy Laws</B>&rdquo;). To ensure compliance with the Privacy Laws, the Company has in place, complies
with, and takes appropriate steps to ensure compliance in all material respects with their policies and procedures relating to data privacy
and security and the collection, storage, use, processing, disclosure, handling, and analysis of Personal Data and Confidential Data
(the &ldquo;<B>Policies</B>&rdquo;). The Company has at all times made all disclosures to users or customers required by applicable laws
and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have been inaccurate or in violation
of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor
any subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of,
any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice;
(ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant
to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.5pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any certificate signed by
any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the Underwriters in connection
with the offering, or the purchase and sale, of the Offered Shares shall be deemed a representation and warranty by the Company to each
Underwriter as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has a reasonable
basis for making each of the representations set forth in this Section 1. The Company acknowledges that the Underwriters and, for purposes
of the opinions to be delivered pursuant to Section 6, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy
and truthfulness of the foregoing representations and hereby consents to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Purchase, Sale and Delivery of the Offered Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>The Firm Shares</U>. Upon the terms herein set forth, the Company agrees to issue and sell to the several Underwriters an aggregate
of [_____] Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject
to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Company the respective number
of Firm Shares set forth opposite their names on <U>Schedule A</U>. The purchase price per Firm Share to be paid by the several Underwriters
to the Company shall be $[__] per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>The First Closing Date</U>. Delivery of certificates for the Firm Shares to be purchased by the Underwriters and payment therefor
shall be made at the offices of McGuireWoods LLP, 1251 6<SUP>th</SUP> Avenue, 20<SUP>th</SUP> Floor, New York 10021 (or such other place
as may be agreed to by the Company and the Representative) at 9:00 a.m. Eastern time, on November [__], 2022 or such other time and date
not later than 5:30 p.m. Eastern time, on November [__], 2022 as the Representative shall designate by notice to the Company (the time
and date of such closing are called the &ldquo;<B>First Closing Date</B>&rdquo;). The Company hereby acknowledges that circumstances under
which the Representative may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to,
any determination by the Company or the Representative to recirculate to the public copies of an amended or supplemented Prospectus or
a delay as contemplated by the provisions of Section 11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>The Option Shares; Option Closing Date</U>. In addition, on the basis of the representations, warranties and agreements herein
contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters
to purchase, severally and not jointly, up to an aggregate of [___] Option Shares from the Company at the purchase price per share to
be paid by the Underwriters for the Firm Shares. The option granted hereunder may be exercised at any time and from time to time in whole
or in part upon notice by the Representative to the Company, which notice may be given at any time within 30 days from the date of this
Agreement. Such notice shall set forth (i) the aggregate number of Option Shares as to which the Underwriters are exercising the option
and (ii) the time, date and place at which certificates for the Option Shares will be delivered (which time and date may be simultaneous
with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the First Closing Date,
the term &ldquo;<B>First Closing Date</B>&rdquo; shall refer to the time and date of delivery of certificates for the Firm Shares and
such Option Shares). Any such time and date of delivery, if subsequent to the First Closing Date, is called an &ldquo;<B>Option Closing
Date,</B>&rdquo; shall be determined by the Representative and shall not be earlier than three or later than five full Business Days after
delivery of such notice of exercise. If any Option Shares are to be purchased, (a) each Underwriter agrees, severally and not jointly,
to purchase the number of Option Shares (subject to such adjustments to eliminate fractional shares as the Representative may determine)
that bears the same proportion to the total number of Option Shares to be purchased as the number of Firm Shares set forth on <U>Schedule
A</U> opposite the name of such Underwriter bears to the total number of Firm Shares and (b) the Company agrees to sell the number of
Option Shares set forth in the paragraph &ldquo;Introductory&rdquo; of this Agreement (subject to such adjustments to eliminate fractional
shares as the Representative may determine). The Representative may cancel the option at any time prior to its expiration by giving written
notice of such cancellation to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Public Offering of the Offered Shares</U>. The Representative hereby advises the Company that the Underwriters intend to offer
for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus,
their respective portions of the Offered Shares as soon after this Agreement has been executed as the Representative, in its sole judgment,
has determined is advisable and practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Payment for the Offered Shares</U>. (i) Payment for the Offered Shares shall be made at the First Closing Date (and, if applicable,
at each Option Closing Date) by wire transfer of immediately available funds to the order of the Company. (ii) It is understood that the
Representative has been authorized, for their own account and the accounts of the several Underwriters, to accept delivery of and receipt
for, and make payment of the purchase price for, the Firm Shares and any Option Shares the Underwriters have agreed to purchase. CF&amp;Co.,
individually and not as the Representative of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares
to be purchased by any Underwriter whose funds shall not have been received by the Representative by the First Closing Date or the applicable
Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter
from any of its obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Delivery of the Offered Shares</U>. The Company shall deliver, or cause to be delivered to the Representative for the accounts
of the several Underwriters certificates for the Firm Shares at the First Closing Date, against the irrevocable release of a wire transfer
of immediately available funds for the amount of the purchase price therefor. The Company shall also deliver, or cause to be delivered
through the facilities of DTC unless the Representative shall otherwise instruct, to the Representative for the accounts of the several
Underwriters, certificates for the Option Shares the Underwriters have agreed to purchase at the First Closing Date or the applicable
Option Closing Date, as the case may be, against the release of a wire transfer of immediately available funds for the amount of the purchase
price therefor. If the Representative so elects, delivery of the Offered Shares may be made by credit to the accounts designated by the
Representative through The Depository Trust Company&rsquo;s full fast transfer or DWAC programs. The certificates for the Offered Shares
shall be registered in such names and denominations as the Representative shall have requested at least two full Business Days prior to
the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the Business
Day preceding the First Closing Date (or the applicable Option Closing Date, as the case may be) at a location in New York City as the
Representative may designate. Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further
condition to the obligations of the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Additional Covenants of the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company further covenants
and agrees with each Underwriter as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Delivery of Registration Statement, Time of Sale Prospectus and Prospectus</U>. The Company shall furnish to the Representative
in New York City, without charge, prior to 10:00 a.m. New York City time on the Business Day next succeeding the date of this Agreement
and during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically
or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares, as many
copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as the
Representative may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Representative&rsquo;s Review of Proposed Amendments and Supplements</U>. During the period when a prospectus relating to the
Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities
Act or any similar rule), the Company (i) will furnish to the Representative for review, a reasonable period of time prior to the proposed
time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and
(ii) will not amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report
filed under the Exchange Act) without the Representative&rsquo;s prior written consent. Prior to amending or supplementing any preliminary
prospectus, the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through incorporation of any report filed
under the Exchange Act), the Company shall furnish to the Representative for review, a reasonable amount of time prior to the time of
filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file
or use any such proposed amendment or supplement without the Representative&rsquo;s prior written consent, which consent shall not be
unreasonably withheld, conditioned or delayed. The Company shall file with the Commission within the applicable period specified in Rule
424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Free Writing Prospectuses</U>. The Company shall furnish to the Representative for review, a reasonable amount of time prior
to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto
prepared by or on behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free
writing prospectus or any amendment or supplement thereto without the Representative&rsquo;s prior written consent, which consent shall
not be unreasonably withheld, conditioned or delayed. The Company shall furnish to each Underwriter, without charge, as many copies of
any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request.
If at any time when a prospectus is required by the Securities Act to be delivered (whether physically or through compliance with Rule
172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares (but in any event if at any time through
and including the First Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus
prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the
Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, the
Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict so that the statements in
such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading,
as the case may be; <U>provided</U>, <U>however</U>, that prior to amending or supplementing any such free writing prospectus, the Company
shall furnish to the Representative for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy
of such proposed amended or supplemented free writing prospectus, and the Company shall not file, use or refer to any such amended or
supplemented free writing prospectus without the Representative&rsquo;s prior written consent, which consent shall not be unreasonably
withheld, conditioned or delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Filing of Underwriter Free Writing Prospectuses</U>. The Company shall not take any action that would result in an Underwriter
or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared
by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Amendments and Supplements to Time of Sale Prospectus</U>. If the Time of Sale Prospectus is being used to solicit offers to
buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition
exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does
not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition
exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if,
in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable
Law, the Company shall (subject to Section 3(b) and Section 3(c)) promptly prepare, file with the Commission and furnish, at its own expense,
to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements
in the Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser,
not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained
in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Notifications and Required Actions</U>. After the date of this Agreement, the Company shall promptly advise the Representative in writing
of: (i) the receipt of any comments of, or requests for additional or supplemental information from, the Commission relating to the Registration
Statement; (ii)&#8239;the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or
supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii) the time
and date that any post-effective amendment to the Registration Statement becomes effective; and (iv) the issuance by the Commission of
any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or
supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the
use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings
to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading
or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission
shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order as soon as reasonably
practicable. Additionally, the Company agrees that it shall comply with all applicable provisions of Rule&#8239;424(b), Rule 433 and Rule
430A under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or
Rule 433 were received in a timely manner by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Amendments and Supplements to the Prospectus and Other Securities Act Matters</U>. If any event shall occur or condition exist
as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule)
to a purchaser, not misleading, or if in the opinion of the Representative or counsel for the Underwriters it is otherwise necessary to
amend or supplement the Prospectus to comply with applicable Law, the Company agrees (subject to Section 3(b) and Section 3(c)) to promptly
prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements
to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus
is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not
misleading or so that the Prospectus, as amended or supplemented, will comply with applicable Law. Neither the Representative&rsquo;s
consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&rsquo;s obligations under
Section 3(b) or Section 3(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Blue Sky Compliance</U>. The Company shall cooperate with the Representative and counsel for the Underwriters to qualify or
register the Offered Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky Laws or Canadian
provincial securities Laws (or other foreign Laws) of those jurisdictions designated by the Representative, shall comply with such Laws
and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered
Shares. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service
of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.
The Company will advise the Representative promptly of the suspension of the qualification or registration of (or any such exemption relating
to) the Offered Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose,
and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best
efforts to obtain the withdrawal thereof as soon as reasonably practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Use of Proceeds</U>. The Company shall apply the net proceeds from the sale of the Offered Shares sold by it in the manner described
under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Time of Sale Prospectus and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Transfer Agent</U>. The Company shall maintain, at its expense, a registrar and transfer agent for the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Earnings Statement</U>. The Company will make generally available to its security holders and to the Representative as soon
as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first
fiscal quarter of the Company commencing after the date of this Agreement that will satisfy the provisions of Section 11(a) of the Securities
Act and the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Continued Compliance with Securities Laws</U>. The Company will comply with the Securities Act and the Exchange Act so as to
permit the completion of the distribution of the Offered Shares as contemplated by this Agreement<B>, </B>the Registration Statement,
the Time of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing, the Company will, during the period
when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance
with Rule 172 under the Securities Act or any similar rule), file on a timely basis with the Commission and NASDAQ all reports and documents
required to be filed under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Listing</U>. The Company will use its best efforts to list, subject to notice of issuance, the Shares on NASDAQ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Company to Provide Copy of the Prospectus in Form That May be Downloaded from the Internet</U>. If requested by the Representative,
the Company shall cause to be prepared and delivered, at its expense, within one Business Day from the effective date of this Agreement,
to CF&amp;CO, an &ldquo;<B>electronic Prospectus</B>&rdquo; to be used in connection with the offering and sale of the Offered Shares.
As used herein, the term &ldquo;<B>electronic Prospectus</B>&rdquo; means a form of Time of Sale Prospectus, and any amendment or supplement
thereto, that meets each of the following conditions: (i) it shall be encoded in an electronic format, satisfactory to CF&amp;CO, that
may be transmitted electronically by CF&amp;CO to offerees and purchasers of the Offered Shares; (ii)&#8239;it shall disclose the same
information as the paper Time of Sale Prospectus, except to the extent that graphic and image material cannot be disseminated electronically,
in which case such graphic and image material shall be replaced in the electronic Prospectus with a fair and accurate narrative description
or tabular representation of such material, as appropriate; and (iii)&#8239;it shall be in or convertible into a paper format or an electronic
format, satisfactory to CF&amp;CO, that will allow investors to store and have continuously ready access to the Time of Sale Prospectus
at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and for on-line
time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the
Commission and in the Registration Statement at the time it was declared effective an undertaking that, upon receipt of a request by an
investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of
the Time of Sale Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Agreement Not to Offer or Sell Additional Shares</U>. During the period commencing on and including the date hereof and continuing
through and including the 90th day following the date of the Prospectus (such period, as extended as described below, being referred to
herein as the &ldquo;<B>Lock-up Period</B>&rdquo;), the Company will not, without the prior written consent of CF&amp;CO (which consent
may be withheld in its sole discretion), directly or indirectly: (i) sell, offer to sell, contract to sell or lend any Shares or Related
Securities (as defined below); (ii) effect any short sale, or establish or increase any &ldquo;put equivalent position&rdquo; (as defined
in Rule 16a-1(h) under the Exchange Act) or liquidate or decrease any &ldquo;call equivalent position &ldquo; (as defined in Rule&#8239;16a-1(b)
under the Exchange Act) of any Shares or Related Securities; (iii) pledge, hypothecate or grant any security interest in; (iv)&#8239;in
any other way transfer or dispose of any Shares or Related Securities; (v)&#8239;enter into any swap, hedge or similar arrangement or agreement
that transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of whether any such
transaction is to be settled in securities, in cash or otherwise; (vi) announce the offering of any Shares or Related Securities; (vii)
file any registration statement under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by
this Agreement with respect to the Offered Shares); or (viii) publicly announce the intention to do any of the foregoing; <U>provided</U>,
<U>however</U>, that the Company may (A) effect the transactions contemplated hereby and (B) issue Shares or options to purchase Shares,
or issue Shares upon exercise of options, pursuant to any equity incentive, employee stock purchase, stock option, stock bonus or other
stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, but only if the holders
of such Shares or options agree in writing with the Underwriters not to sell, offer, dispose of or otherwise transfer any such Shares
or options during such Lock-up Period without the prior written consent of CF&amp;CO (which consent may be withheld in its sole discretion).
For purposes of the foregoing, &ldquo;<B>Related Securities</B>&rdquo; shall mean any options or warrants or other rights to acquire Shares
or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable
or exercisable for, or convertible into, Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Future Reports to the Representative</U>. During the period of five years hereafter, the Company will furnish to the Representative,
c/o Cantor Fitzgerald &amp; Co., at 499 Park Avenue, New York, New York 10022, Attention: Equity Capital Markets, with copies to Cantor
Fitzgerald &amp; Co., 499 Park Avenue, New York, New York 10022, Attention: General Counsel: (i) as soon as practicable after the end
of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal
year and statements of income, stockholders&rsquo; equity and cash flows for the year then ended and the opinion thereon of the Company&rsquo;s
independent public or certified public accountants; (ii) as soon as practicable after the filing thereof, copies of each proxy statement,
Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other report filed by the Company with the Commission,
FINRA or any securities exchange; and (iii) as soon as available, copies of any report or communication of the Company furnished or made
available generally to holders of its capital stock; <U>provided</U>, <U>however</U>, that the requirements of this Section 3(p) shall
be satisfied to the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Investment Limitation</U>. The Company shall not invest or otherwise use the proceeds received by the Company from its sale
of the Offered Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under
the Investment Company Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Stabilization or Manipulation; Compliance with Regulation M</U>. The Company will not take, and will ensure that no affiliate
of the Company will take, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that
might cause or result in stabilization or manipulation of the price of the Shares or any reference security with respect to the Shares,
whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates
to, comply with all applicable provisions of Regulation M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Enforce Lock-Up Agreements</U>. During the Lock-up Period, the Company will enforce all agreements between the Company and any
of its security holders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related Securities
or any of the other actions restricted or prohibited under the terms of the form of Lock-up Agreement. In addition, the Company will direct
the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such &ldquo;lock-up&rdquo;
agreements for the duration of the periods contemplated in such agreements, including &ldquo;lock-up&rdquo; agreements entered into by
the Company&rsquo;s officers and directors and stockholders pursuant to Section 6(j) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Company to Provide Interim Financial Statements</U>. Prior to the First Closing Date and each applicable Option Closing Date,
the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited
interim financial statements of the Company for any period subsequent to the period covered by the most recent financial statements appearing
in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Amendments and Supplements to Permitted Section 5(d)Communications</U>. If at any time following the distribution of any Permitted
Section 5(d) Communication, there occurred or occurs an event or development as a result of which such Permitted Section 5(d) Communication
included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly
notify the Representative and will promptly amend or supplement, at its own expense, such Permitted Section 5(d) Communication to eliminate
or correct such untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Representative, on behalf
of the several Underwriters, may, in its sole discretion, waive in writing the performance by the Company of any one or more of the foregoing
covenants or extend the time for their performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Payment of Expenses</U>. The Company agrees to pay all costs, fees and expenses incurred in connection with the performance
of its obligations hereunder and in connection with the transactions contemplated hereby, including (i) all expenses incident to the issuance
and delivery of the Offered Shares (including all printing and engraving costs), (ii) all fees and expenses of the registrar and transfer
agent of the Shares, (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Offered
Shares to the Underwriters, (iv) all fees and expenses of the Company&rsquo;s counsel, independent public or certified public accountants
and other advisors, (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution
of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of
Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and
each preliminary prospectus, each Permitted Section 5(d) Communication, and all amendments and supplements thereto, and this Agreement,
(vi) all filing fees, reasonable and documented attorneys&rsquo; fees and expenses incurred by the Company or the Underwriters in connection
with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Offered Shares
for offer and sale under the state securities or blue sky Laws or the provincial securities Laws of Canada, and, if requested by the Representative,
preparing and printing a &ldquo;Blue Sky Survey&rdquo; or memorandum and a &ldquo;Canadian wrapper&rdquo;, and any supplements thereto,
advising the Underwriters of such qualifications, registrations and exemptions, in an amount not to exceed [$7,500], (vii) the fees and
expenses of the Underwriters including the fees and expenses of the counsel to the Underwriters, payable upon the execution of this Agreement,
in an amount not to exceed $100,000, (viii) the costs and expenses of the Company relating to investor presentations on any &ldquo;road
show&rdquo;, any Permitted Section 5(d) Communication or any Section 5(d) Oral Communication undertaken in connection with the offering
of the Shares, including expenses associated with the preparation or dissemination of any electronic road show, expenses associated with
the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations
with the prior approval of the Company, travel and lodging expenses of the Representative, employees and officers of the Company and any
such consultants, (ix) the fees and expenses associated with listing the Shares on NASDAQ, and (x) all other fees, costs and expenses
of the nature referred to in Item 13 of Part II of the Registration Statement. Any such amount payable to the Underwriters may be deducted
from the purchase price for the Offered Shares. Except as provided in this Section 4 or in Section 7, Section 9 or Section 10, the Underwriters
shall pay their own expenses, including the fees and disbursements of their counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Covenant of the Underwriters</U>. Each Underwriter severally and not jointly covenants with the Company not to take any action
that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing
prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the
Company under Rule 433(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Conditions of the Obligations of the Underwriters</U>. The respective obligations of the several Underwriters hereunder to purchase
and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Option Shares, each Option Closing
Date, shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in Section 1 as of the
date hereof and as of the First Closing Date as though then made and, with respect to the Option Shares, as of each Option Closing Date
as though then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following
additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Comfort Letter</U>. On the date hereof, the Representative shall have received from Ernst &amp; Young LLP, independent registered
public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to
the Representative, containing statements and information of the type ordinarily included in accountant&rsquo;s &ldquo;comfort letters&rdquo;
to underwriters, delivered according to Statement of Auditing Standards No. 72 (or any successor bulletin), with respect to the audited
and unaudited financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus,
and each free writing prospectus, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Compliance with Registration Requirements; No Stop Order; No Objection from FINRA</U>. For a period from and after the date
of this Agreement and through and including the First Closing Date and, with respect to any Option Shares purchased after the First Closing
Date, each Option Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall have filed the Prospectus with the Commission (including the information required by Rule 430A under the Securities Act)
in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a post-effective
amendment to the Registration Statement containing the information required by such Rule 430A, and such post-effective amendment shall
have become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall
be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Material Adverse Effect or Ratings Agency Change</U>. For the period from and after the date of this Agreement and through
and including the First Closing Date and, with respect to any Option Shares purchased after the First Closing Date, each Option Closing
Date, (a) in the judgment of the Representative there shall not have occurred any Material Adverse Effect, and (b) there shall not have
occurred a downgrading in or withdrawal of the rating assigned to any of the Company&rsquo;s securities (other than asset-backed securities)
by any rating organization or a public announcement by any rating organization that it has under surveillance or review its rating of
any of the Company&rsquo;s securities (other than asset-backed securities), the effect of which, in the case of any such action by a rating
organization described above, would cause a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Opinion of Counsel for the Company</U>. On each of the First Closing Date and each Option Closing Date the Representative shall
have received the opinion and negative assurance letter of Troutman Pepper Hamilton Sanders LLP, counsel for the Company, dated as of
such date, in form and substance reasonably satisfactory to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Opinion of Intellectual Property Counsel</U>. On each of the First Closing Date and each Option Closing Date, the Representative
shall have received the opinion of DLA Piper LLP (US), counsel for the Company with respect to intellectual property matters, dated as
of such date, in form and substance reasonably satisfactory to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Opinion of Counsel for the Underwriters</U>. On each of the First Closing Date and each Option Closing Date the Representative
shall have received the opinion of McGuireWoods LLP, counsel for the Underwriters in connection with the offer and sale of the Offered
Shares, in form and substance satisfactory to the Representative, dated as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Officers&rsquo; Certificate</U>. On each of the First Closing Date and each Option Closing Date, the Representative shall have
received a certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company,
dated as of such date, to the effect set forth in Section 6(b)(ii) and further to the effect that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for the period from and including the date of this Agreement through and including such date, there has not occurred any Material
Adverse Effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the representations, warranties and covenants of the Company set forth in Section&#8239;1 are true and correct with the same force
and effect as though expressly made on and as of such date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied
hereunder at or prior to such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Chief Financial Officer&rsquo;s Certificate</U>. On each of the First Closing Date and each Option Closing Date, the Representative
shall have received a certificate executed by the Chief Financial Officer of the Company, dated as of such date, in the form attached
as <U>Exhibit [_]</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Bring-down Comfort Letter</U>. On each of the First Closing Date and each Option Closing Date the Representative shall have
received from Ernst &amp; Young LLP, independent registered public accountants for the Company, a letter dated such date, in form and
substance satisfactory to the Representative, which letter shall: (i) reaffirm the statements made in the letter furnished by them pursuant
to Section 6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than three Business
Days prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii) cover certain financial information
contained in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Lock-Up Agreements</U>. On or prior to the date hereof, the Company shall have furnished to the Representative an agreement
in the form of <U>Exhibit A</U> hereto from the directors and officers (as defined in Rule 16a-1(f) under the Exchange Act), and each
such agreement shall be in full force and effect on each of the First Closing Date and each Option Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Rule 462(b) Registration Statement</U>. In the event that a Rule 462(b) Registration Statement is filed in connection with the
offering contemplated by this Agreement, such Rule 462(b) Registration Statement shall have been filed with the Commission on the date
of this Agreement and shall have become effective automatically upon such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>NASDAQ</U>. The Company shall have submitted a listing of additional shares notification form to NASDAQ with respect to the
Offered Shares and shall have received no objection thereto from NASDAQ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Additional Documents</U>. On or before each of the First Closing Date and each Option Closing Date, the Representative and counsel
for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling
them to pass upon the issuance and sale of the Offered Shares as contemplated herein, or in order to evidence the accuracy of any of the
representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken
by the Company in connection with the issuance and sale of the Offered Shares as contemplated herein and in connection with the other
transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representative and counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any condition specified
in this Section 6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Representative by notice
from the Representative to the Company at any time on or prior to the First Closing Date and, with respect to the Option Shares, at any
time on or prior to the applicable Option Closing Date, which termination shall be without liability on the part of any party to any other
party, except that Section 4, Section 7, Section 9 and Section 10 shall at all times be effective and shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Reimbursement of Underwriters&rsquo; Expenses</U>. If this Agreement is terminated by the Representative pursuant to Section
6, Section 11 or Section 12, or if the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because
of any refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof,
the Company agrees to reimburse the Representative and the other Underwriters (or such Underwriters as have terminated this Agreement
with respect to themselves), severally, upon demand for all out-of-pocket expenses that shall have been reasonably incurred by the Representative
and the Underwriters in connection with the proposed purchase and the offering and sale of the Offered Shares, including reasonable and
documented fees and disbursements of counsel up to $66,000, printing expenses, travel expenses, postage, facsimile and telephone charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Effectiveness of this Agreement</U>. This Agreement shall become effective upon the execution and delivery hereof by the parties
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Indemnification of the Underwriters</U>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates
and their respective partners, members, directors, officers, employees and agents, and each person, if any, who controls each Underwriter
or any affiliate within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based
upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto),
or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein
not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus,
Time of Sale Prospectus, any free writing prospectus, any Marketing Material, any Section 5(d) Written Communication or the Prospectus
(or any amendment or supplement to the foregoing), or the omission or alleged omission therefrom of a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the
aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any Governmental Authority, commenced or
threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission;
<U>provided</U> that (subject to Section&#8239;9(d)) any such settlement is effected with the written consent of the Company, which consent
shall not unreasonably be delayed, conditioned or withheld; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel), reasonably incurred in investigating,
preparing or defending against any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened,
or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission (whether or
not a party), to the extent that any such expense is not paid under (i)&#8239;or (ii)&#8239;above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided</U></FONT>,
<U>however</U>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out
of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity with the Underwriter
Information (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Indemnification of the Company, its Directors and Officers</U>. Each Underwriter agrees, severally and not jointly, to indemnify
and hold harmless the Company, and its directors, each officer of the Company who signed the Registration Statement and each person, if
any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any and
all loss, liability, claim, damage and expense described in the indemnity contained in Section 9(a), as incurred, but only with respect
to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement, any preliminary prospectus,
the Time of Sale Prospectus, any free writing prospectus, any Section 5(d) Written Communication or the Prospectus (or any amendment or
supplement to the foregoing), in reliance upon and in conformity with information relating to such Underwriter and furnished to the Company
in writing by such Underwriter or Underwriters expressly for use therein. The Company hereby acknowledges that the only information that
the Underwriter or Underwriters has furnished to the Company expressly for use in the Registration Statement, any preliminary prospectus,
the Time of Sale Prospectus, any free writing prospectus, any Section 5(d) Written Communication or the Prospectus (or any amendment or
supplement to the foregoing) are the statements set forth in the third sentence of the third paragraph, the fifth paragraph and the first
sentence of the thirteenth paragraph under the caption &ldquo;Underwriting&rdquo; in the Preliminary Prospectus and Prospectus (the &ldquo;<B>Underwriter
Information</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Notifications and Other Indemnification Procedures</U>. Any party that proposes to assert the right to be indemnified under
this Section 9 will, promptly after receipt of notice of commencement of any action against such party in respect of which a claim is
to be made against an indemnifying party or parties under this Section 9, notify each such indemnifying party of the commencement of such
action, enclosing a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying
party from (i)&#8239;any liability that it might have to any indemnified party otherwise than under this Section 9 and (ii)&#8239;any liability
that it may have to any indemnified party under the foregoing provision of this Section 9 unless, and only to the extent that, such omission
results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified
party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the
extent that it elects by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the
action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the defense of the action,
with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to the indemnified party of
its election to assume the defense, the indemnifying party will not be liable to the indemnified party for any other legal expenses except
as provided below and except for the reasonable costs of investigation subsequently incurred by the indemnified party in connection with
the defense. The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other
charges of such counsel will be at the expense of such indemnified party unless (1)&#8239;the employment of counsel by the indemnified
party has been authorized in writing by the indemnifying party, (2)&#8239;the indemnified party has reasonably concluded (based on advice
of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those
available to the indemnifying party, (3)&#8239;a conflict or potential conflict exists (based on advice of counsel to the indemnified party)
between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense
of such action on behalf of the indemnified party) or (4)&#8239;the indemnifying party has not in fact employed counsel to assume the defense
of such action or counsel reasonably satisfactory to the indemnified party, in each case, within a reasonable time after receiving notice
of the commencement of the action; in each of which cases the reasonable fees, disbursements and other charges of counsel will be at the
expense of the indemnifying party or parties. It is understood that the indemnifying party or parties shall not, in connection with any
proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more
than one separate firm admitted to practice in such jurisdiction (plus local counsel) at any one time for all such indemnified party or
parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly as they are incurred. An
indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No
indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of
any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated by this Section 9 (whether
or not any indemnified party is a party thereto), unless such settlement, compromise or consent (1)&#8239;includes an express and unconditional
release of each indemnified party, in form and substance reasonably satisfactory to such indemnified party, from all liability arising
out of such litigation, investigation, proceeding or claim and (2)&#8239;does not include a statement as to or an admission of fault, culpability
or a failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Settlement Without Consent if Failure to Reimburse</U>. If an indemnified party shall have requested an indemnifying party to
reimburse the indemnified party for reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for
any settlement of the nature contemplated by Section&#8239;9(a)(ii) effected without its written consent if (1)&#8239;such settlement is
entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (2)&#8239;such indemnifying party shall
have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (3)&#8239;such indemnifying
party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Contribution</U>. In order to provide for just and equitable contribution in circumstances in which the indemnification provided
for in the foregoing paragraphs of Section 9 is applicable in accordance with its terms but for any reason is held to be unavailable or
insufficient from the Company or the Underwriters, the Company and the Underwriters will contribute to the total losses, claims, liabilities,
expenses and damages (including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid
in settlement of, any action, suit or proceeding or any claim asserted) to which any indemnified party may be subject in such proportion
as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand.
The relative benefits received by the Company on the one hand and the Underwriters on the other hand shall be deemed to be in the same
proportion as the total net proceeds from the sale of the Offered Shares (before deducting expenses) received by the Company bear to the
total compensation received by the Underwriters (before deducting expenses) from the sale of Offered Shares on behalf of the Company.
If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable Law, the allocation of contribution
shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but
also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, with respect to the statements or omission
that resulted in such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable
considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information
supplied by the Company or the Underwriters, the intent of the parties and their relative knowledge, access to information and opportunity
to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contributions
pursuant to this Section 10 were to be determined by pro rata allocation or by any other method of allocation that does not take into
account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim,
liability, expense, or damage, or action in respect thereof, referred to above in this Section 10 shall be deemed to include, for the
purpose of this Section 10, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim to the extent consistent with Section 9(c). Notwithstanding the foregoing provisions of Section
9 and this Section 10, the Underwriters shall not be required to contribute any amount in excess of the commissions actually received
by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section
10, any person who controls a party to this Agreement within the meaning of the Securities Act, any affiliates of the respective Underwriters
and any officers, directors, partners, employees or agents of the Underwriters or their respective affiliates, will have the same rights
to contribution as that party, and each director of the Company and each officer of the Company who signed the Registration Statement
will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution,
promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be
made under this Section 10, will notify any such party or parties from whom contribution may be sought, but the omission to so notify
will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under this Section
10 except to the extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the
party from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of Section 9(c), no party will
be liable for contribution with respect to any action or claim settled without its written consent if such consent is required pursuant
to Section 9(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Default of One or More of the Several Underwriters</U>. If, on the First Closing Date or any Option Closing Date, any one or
more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on
such date, and the aggregate number of Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to
purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the Representative may make arrangements
satisfactory to the Company for the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such
arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the
number of Firm Shares set forth opposite their respective names on <U>Schedule A</U> bears to the aggregate number of Firm Shares set
forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representative
with the consent of the non-defaulting Underwriters, to purchase the Offered Shares which such defaulting Underwriter or Underwriters
agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date, any one or more of the
several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and
the aggregate number of Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase exceeds
10% of the aggregate number of Offered Shares to be purchased on such date, and arrangements satisfactory to the Representative and the
Company for the purchase of such Offered Shares are not made within 48 hours after such default, this Agreement shall terminate without
liability of any party to any other party except that the provisions of Section 4, Section 7, Section 9 and Section 10 shall at all times
be effective and shall survive such termination. In any such case either the Representative or the Company shall have the right to postpone
the First Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order
that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Agreement,
the term &ldquo;<B>Underwriter</B>&rdquo; shall be deemed to include any person substituted for a defaulting Underwriter under this Section
11. Any action taken under this Section 11 shall not relieve any defaulting Underwriter from liability in respect of any default of such
Underwriter under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Termination of this Agreement</U>. Prior to the purchase of the Firm Shares by the Underwriters on the First Closing Date, this
Agreement may be terminated by the Representative by notice given to the Company if at any time: (i) trading or quotation in any of the
Company&rsquo;s securities shall have been suspended or limited by the Commission or by NASDAQ, or trading in securities generally on
either NASDAQ or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established on
any of such stock exchanges; (ii) a general banking moratorium shall have been declared by any of federal, New York or Delaware authorities;
(iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any
change in the United States or international financial markets, or any substantial change or development involving a prospective substantial
change in United States&rsquo; or international political, financial or economic conditions, as in the judgment of the Representative
is material and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time of
Sale Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv) in the judgment of the Representative there
shall have occurred any change, or any development or event involving a prospective change, in the condition, financial or otherwise,
or in the business, properties, earnings, results of operations or prospects of the Company and its Subsidiaries considered as one enterprise,
whether or not arising in the ordinary course of business; or (v) the Company shall have sustained a loss by strike, fire, flood, earthquake,
accident or other calamity of such character as in the judgment of the Representative may interfere materially with the conduct of the
business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this
Section 12 shall be without liability on the part of (a) the Company to any Underwriter, except that the Company shall be obligated to
reimburse the expenses of the Representative and the Underwriters pursuant to Section 4 or Section 7 hereof or (b) any Underwriter to
the Company; <U>provided</U>, <U>however</U>, that the provisions of Section 9 and Section 10 shall at all times be effective and shall
survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a) the purchase and sale of the Offered
Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts
and commissions, is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on
the other hand, (b) in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter
is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, or its creditors,
employees or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company
with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised
or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering
contemplated hereby except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates
may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e) the Underwriters
have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has
consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Representations and Agreements to Survive Delivery</U>. The respective indemnities, agreements, representations, warranties
and other statements of the Company, its officers and the several Underwriters set forth in or made pursuant to this Agreement will remain
in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of its or their
partners, affiliates, officers, directors or employees or any controlling person, as the case may be, and, anything herein to the contrary
notwithstanding, will survive delivery of and payment for the Offered Shares sold hereunder and any termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Notices</U>. All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed
to the parties hereto as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: left">If to the Representative:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; text-align: left">Cantor Fitzgerald &amp; Co.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">499 Park Avenue</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">New York, NY 10022</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Facsimile: (212) 829-4708</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Attention: General Counsel</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.5in">with a copy to:</TD>
    <TD STYLE="width: 75%; font: 10pt Times New Roman, Times, Serif; text-align: left">McGuireWoods LLP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">1251 6<SUP>th</SUP> Avenue, 20<SUP>th</SUP> Floor</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">New York, New York 10020</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Attention: Stephen Older</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.5in">If to the Company:</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cognition Therapeutics, Inc.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">2500 Westchester Ave.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Purchase, NY 10577</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Attention: Lisa Ricciardi, Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; width: 25%">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%">Email:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 70%">lricciardi@cogrx.com</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.5in">with a copy to:</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Troutman Pepper Hamilton Sanders LLP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">3000 Two Logan Square</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Philadelphia, PA 19103</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Attention: Rachael M. Bushey and Joseph Walsh</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; width: 25%">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%">Email:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 70%"> rachael.bushey@troutman.com</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">joseph.walsh@troutman.com</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each party to this Agreement
may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each
such notice or other communication shall be deemed given (i)&#8239;when delivered personally or by verifiable facsimile transmission (with
an original to follow) on or before 4:30&#8239;p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the
next succeeding Business Day, (ii)&#8239;on the next Business Day after timely delivery to a nationally-recognized overnight courier and
(iii)&#8239;on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested,
postage prepaid).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Electronic Notice</U>. An electronic communication (&ldquo;<B>Electronic Notice</B>&rdquo;) shall be deemed written notice for
purposes of this Section 16 if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice
shall be deemed received at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any
party receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&ldquo;<B>Nonelectronic
Notice</B>&rdquo;) which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic
Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Successors and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the Company and the Underwriters
and their respective successors and the parties referred to in Section 11. References to any of the parties contained in this Agreement
shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights
or obligations under this Agreement without the prior written consent of the other party; <U>provided</U>, <U>however</U>, that the Representative
may assign its rights and obligations hereunder to an affiliate thereof without obtaining the Company&rsquo;s consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Partial Unenforceability</U>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall
not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision
of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Entire Agreement; Amendment; Severability; Waiver</U>. This Agreement (including all schedules and exhibits attached hereto
issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings,
both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may
be amended except pursuant to a written instrument executed by the Company and the Representative. In the event that any one or more of
the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written
by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it
is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or
unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder
of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. No implied waiver
by a party shall arise in the absence of a waiver in writing signed by such party. No failure or delay in exercising any right, power,
or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further
exercise thereof or the exercise of any right, power, or privilege hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.
EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>CONSENT TO JURISDICTION</U>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL
COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY
TRANSACTION CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM
THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT
FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS
AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN
RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE
GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE
PROCESS IN ANY MANNER PERMITTED BY LAW.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be
made by facsimile or electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Construction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the section and exhibit&#8239;headings herein are for convenience only and shall not affect the construction hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>words defined in the singular shall have a comparable meaning when used in the plural, and vice versa;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the words &ldquo;hereof,&rdquo; &ldquo;hereto,&rdquo; &ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words of similar import,
when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>wherever the word &ldquo;include,&rdquo; &ldquo;includes&rdquo; or &ldquo;including&rdquo; is used in this Agreement, it shall
be deemed to be followed by the words &ldquo;without limitation&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>references herein to any gender shall include each other gender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>references herein to any law, statute, ordinance, code, regulation, rule or other requirement of any Governmental Authority shall
be deemed to refer to such law, statute, ordinance, code, regulation, rule or other requirement of any Governmental Authority as amended,
reenacted, supplemented or superseded in whole or in part and in effect from time to time and also to all rules and regulations promulgated
thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if the last day for the giving of any notice or the performance of any act required or permitted under this Agreement is a day
that is not a Business Day, then the time for the giving of such notice or the performance of such action shall be extended to the next
succeeding Business Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B>knowledge</B>&rdquo; means, as it pertains to the Company, the actual knowledge of the officers and directors of the
Company, together with the knowledge which they would have had if they had conducted a reasonable inquiry of the relevant persons into
the relevant subject matter;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B>Governmental Authority</B>&rdquo; means (i) any federal, provincial, state, local, municipal, national or international
government or governmental authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency
or instrumentality, court, tribunal, arbitrator or arbitral body (public or private); (ii) any self-regulatory organization; or (iii)
any political subdivision of any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B>Law</B>&rdquo; means any and all laws, including all federal, state, local, municipal, national or foreign statutes,
codes, ordinances, guidelines, decrees, rules, regulations and by-laws and all judicial, arbitral, administrative, ministerial, departmental
or regulatory judgments, orders, directives, decisions, rulings or awards or other requirements of any Governmental Authority, binding
on or affecting the person referred to in the context in which the term is used and rules, regulations and policies of any stock exchange
on which securities of the Company are listed for trading; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<B>Business Day</B>&rdquo; means any day on which NASDAQ and commercial banks in the City of New York are open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>General Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the parties hereto
acknowledges that it is a sophisticated business person who was adequately represented by counsel during negotiations regarding the provisions
hereof, including the indemnification provisions of Section 9 and the contribution provisions of Section 10, and is fully informed regarding
said provisions. Each of the parties hereto further acknowledges that the provisions of Section 9 and Section 10 hereof fairly allocate
the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate
disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus
and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities Act and the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[<B><I>Signature Page Follows</I></B>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly
sets forth the understanding between the Company and the Underwriters, please so indicate in the space provided below for that purpose,
whereupon this letter shall constitute a binding agreement between the Company and the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">COGNITION THERAPEUTICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Lisa Ricciardi</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: &#8239;&#8239;Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ACCEPTED as of the date first-above written:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CANTOR FITZGERALD &amp; CO.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">For itself and the other several Underwriters
    named in <U>Schedule A</U> to this Agreement.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&#8239;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps">Cognition Therapeutics. Inc..
&ndash; Underwriting Agreement</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0in">&#8239;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 87%; font-size: 10pt"><B>Underwriters</B> </TD><TD STYLE="padding-bottom: 1pt; width: 2%; font-size: 10pt; font-weight: bold">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#8239;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; font-weight: bold; text-align: center"><B>Number of<BR>
</B> <B>Firm Shares</B> <B><BR>
to be<BR>
 Purchased</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cantor Fitzgerald &amp; Co.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;</FONT>]</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">[___] </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;</FONT>]</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&#8239;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#8239;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;</FONT>] </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE B</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><U>Free Writing Prospectuses
Included in the Time of Sale Prospectus</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>[None]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Schedule
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><U>Pricing Information</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Firm Shares: [&#8239;_____&#8239;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Option Shares: [_____&#8239;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Price to Public: $[_____]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Underwriters&rsquo; Discount:
$[_____]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Schedule
D</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Permitted Section 5(d) Communications</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: left"></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Form of Lock-up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[Sent under separate cover]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>Exhibit B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Parties to Lock-up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: left">Anthony Caggiano</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: left">Andrew Einhorn</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: left">Aaron Fletcher</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: left">Jack Khattar</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: left">Brett Monia</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: left">Lisa Ricciardi</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: left">Ellen Richstone</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="text-align: left">Peggy Wallace</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: left">Entities affiliated with BIOS Memory SPV I, LP</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 45; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2226999d4_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Troutman Pepper Hamilton Sanders LLP<BR> 3000 Two Logan Square, Eighteenth and Arch Streets</P>
                                         <P STYLE="margin-top: 0; margin-bottom: 0">Philadelphia, PA 19103-2799</P>
                                         <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                         <P STYLE="margin-top: 0; margin-bottom: 0">troutman.com</P></TD><TD STYLE="text-align: right; width: 50%">&nbsp;<IMG SRC="tm2226999d4_ex5-1img01.jpg" ALT=""></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">November 7, 2022</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cognition Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2500 Westchester Ave.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Purchase, NY 10577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: <U>Registration Statement on Form S-1</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to Cognition Therapeutics, Inc., a Delaware
corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the proposed issuance and sale of up to 5,586,592 shares (the
 &ldquo;<B><I>Shares</I></B>&rdquo;) of common stock, $0.001 par value per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;). The Shares
are included in a registration statement on Form S-1 under the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;),
filed with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) on November 7, 2022 (the &ldquo;<B><I>Registration
Statement</I></B>&rdquo;). The term &ldquo;<B><I>Shares</I></B>&rdquo; shall include any additional shares of Common Stock registered
by the Company pursuant to Rule 462(b) under the Securities Act in connection with the offering contemplated by the Registration Statement.
This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, and
no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related prospectus, other
than as expressly stated herein with respect to the issue of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As such counsel, we have examined such matters of fact and questions
of law as we have considered appropriate for purposes of this letter, including, but not limited to, (a) the Registration Statement and
the prospectus included in the Registration Statement (the &ldquo;<B><I>Prospectus</I></B>&rdquo;), (b) the Company&rsquo;s Third Amended
and Restated Certificate of Incorporation and Amended and Restated Bylaws, each as currently in effect and (c) originals or copies certified
to our satisfaction of such records, documents, certificates, memoranda, opinions and other instruments as in our judgment are necessary
or appropriate to enable us to render the opinion expressed below, and assumed that the Shares will be sold at a price and on terms established
by the Board of Directors of the Company or a duly authorized committee thereof. With your consent, we have relied upon certificates and
other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters.
In our examination of the aforesaid documents, we have assumed the genuineness of all signatures, the legal capacity of all natural persons,
the accuracy and completeness of all documents submitted to us, the authenticity of all original documents, and the conformity to authentic
original documents of all documents submitted to us as copies (including pdfs). We are opining herein as to General Corporation Law of
the State of Delaware (the &ldquo;<B><I>Corporation Act</I></B>&rdquo;), and we express no opinion with respect to any other laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 46%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cognition Therapeutics, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 7, 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="text-align: right; vertical-align: top; width: 54%">
    <IMG SRC="tm2226999d4_ex5-1img01.jpg" ALT=""><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the foregoing
and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly
registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been
issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the form of
underwriting agreement most recently filed as an exhibit to the Registration Statement, the issue and sale of the Shares will have
been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and
nonassessable.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.8pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In rendering the foregoing
opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided
in the Corporation Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is for your benefit
in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable
provisions of the Securities Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference
to our firm in the Registration Statement under the heading &#8220;Legal Matters.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We further consent to the
incorporation by reference of this letter and consent into any registration statement filed pursuant to Rule 462(b) with respect to the
Shares. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section
7 of the Securities Act or the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; width: 50%">Very truly yours, &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Troutman Pepper
    Hamilton Sanders LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt; font-variant: small-caps">Troutman Pepper Hamilton Sanders LLP</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>4
<FILENAME>tm2226999d4_ex10-29.htm
<DESCRIPTION>EXHIBIT 10.29
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.29</B></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>OFFICE LEASE
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">between</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>RJ EQUITIES LP</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">(Landlord)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>COGNITION
THERAPEUTICS,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">(Tenant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Dated: August&nbsp;31,
2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>TABLE OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; width: 8%; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;1.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; width: 1%; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; width: 80%; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>BASIC
    TERMS</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; width: 1%; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; width: 10%; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;2.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PREMISES</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;3.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>TERM AND COMMENCEMENT</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;4.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>CONSTRUCTION OF PREMISES</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;5.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>BASE RENT</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;6.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>RENT ESCALATION</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;7.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>LATE PAYMENT</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;8.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>USE OF PREMISES</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;9.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>COMMON AREAS/PARKING</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;10.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ALTERATIONS</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;11.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>MECHANIC'S LIENS</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;12.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>CONDITION OF PREMISES</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;13.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>UTILITIES AND SERVICES</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;14.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ASSIGNMENT AND SUBLETTING</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>13</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;15.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>RIGHTS RESERVED BY LANDLORD</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>13</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;16.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>REPAIRS</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>14</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;17.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>INDEMNIFICATION AND INSURANCE</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>15</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;18.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>LANDLORD'S LIABILITY</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>16</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;19.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>COMPLIANCE WITH INSURANCE
    REQUIREMENTS</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>17</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;20.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>FIRE OR OTHER CASUALTY</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>17</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;21.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SUBORDINATION</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>18</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;22.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>CONDEMNATION</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>18</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;23.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ESTOPPEL CERTIFICATES</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>19</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;24.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DEFAULT</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>19</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;25.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PROVISIONS RELATED TO
    LANDLORD&rsquo;S REMEDIES</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>20</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;26.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>LANDLORD&rsquo;S DEFAULT;
    RIGHT TO CURE</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>22</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;27.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>WAIVER</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>22</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;28.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>UTILITY DEREGULATION</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>23</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;29.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>TELECOMMUNICATIONS</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>23</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;30.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SURRENDER</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>24</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; width: 8%; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;31.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; width: 1%; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; width: 80%; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>QUIET ENJOYMENT</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; width: 1%; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; width: 10%; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>25</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;32.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>HOLDING OVER</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>25</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;33.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ENVIRONMENTAL COVENANTS,
    REPRESENTATIONS AND WARRANTIES</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>25</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;34.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>TENANT&rsquo;S COMPLIANCE
    WITH LAWS</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>27</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;35.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DISABILITIES ACT</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>27</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;36.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>NOTICE</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>27</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;37.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>BROKERS</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>28</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;38.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>FORCE MAJEURE</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>28</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;39.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>TRANSFER OF LANDLORD'S
    INTEREST</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>28</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;40.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SUCCESSORS</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>29</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;41.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>GOVERNING LAW</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>29</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;42.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SEPARABILITY</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>29</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;43.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>CAPTIONS</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>29</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;44.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>GENDER</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>29</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;45.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXECUTION; COUNTERPARTS</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>29</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;46. </B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><B>ENTIRE AGREEMENT</B></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>30</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;47.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>AUTHORITY</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><B>30</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;48.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SECURITY DEPOSIT</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>30</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;49.</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>OFAC CERTIFICATION</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 3pt; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>31</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 89%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXHIBIT&nbsp;&ldquo;A&rdquo;
    DIAGRAM OF DEVELOPMENT</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>33</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXHIBIT&nbsp;&ldquo;B&rdquo;
    OUTLINE OF PREMISES</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>34</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXHIBIT&nbsp;&ldquo;C&rdquo;
    RULES AND REGULATIONS</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>35</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXHIBIT&nbsp;&ldquo;D&rdquo;
    INTENTIONALLY OMITTED</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>36</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXHIBIT&nbsp;&ldquo;E&rdquo;
    ESTOPPEL CERTIFICATE</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>37</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXHIBIT&nbsp;&ldquo;F&rdquo;
    SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>38</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>OFFICE LEASE
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
Office Lease Agreement (the &quot;Lease&quot;) is made this 31<SUP>st</SUP> day of August, 2022, by and between <B>RJ EQUITIES LP</B>,
a Pennsylvania limited partnership (&quot;Landlord&quot;) and <B>COGNITION THERAPEUTICS,&nbsp;INC.</B>, a Delaware corporation (&ldquo;Tenant&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;1.
BASIC TERMS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">For the purposes of this Lease, the
following terms shall have the meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp; Landlord:</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RJ EQUITIES LP, a Pennsylvania limited
    partnership</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp; Tenant:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COGNITION THERAPEUTICS,&nbsp;INC., a Delaware corporation</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp; Premises:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite&nbsp;230 located on the second floor of the commercial
    building (the &quot;Building&quot;) situated at 2403 Sidney Street, Pittsburgh, PA 15203 (the &quot;Development&quot;) and as outlined
    on the Diagram of Development attached hereto as Exhibit&nbsp;&ldquo;A&rdquo;. The Premises contains approximately 2,980 rentable
    square feet as depicted on the floor plan attached hereto as Exhibit&nbsp;&ldquo;B&rdquo;.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp; Commencement Date:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October&nbsp;1, 2022.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp; Lease Term:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three (3)&nbsp;years and nine (9)&nbsp;months.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp; Termination Date:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30, 2026.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp; Extension Term:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intentionally omitted.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;
    Base Rent:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 27%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Period</B></FONT></TD>
    <TD STYLE="width: 27%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Monthly</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annual</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/1/2022
    - 6/30/2023</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,755.67</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$33,068.04</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/1/2023
    - 6/30/2026</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$4,470.00</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$53,640.00</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: -2in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
    Base Year for Real Estate Taxes:</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) Base Year for Operating Costs:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) Approximate rentable area of the Premises:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,980 sq. ft.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l) Approximate rentable area of the Building:</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">221,000 sq. ft.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m) Tenant's Proportionate Share:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.34%.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n) Security Deposit:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp; Permitted Uses:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office uses.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&nbsp; Notification Addresses:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Landlord:</FONT></TD>
    <TD STYLE="width: 69%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RJ Equities LP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD></TD>
    <TD><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2403 Sidney Street, Suite&nbsp;200</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD></TD>
    <TD><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pittsburgh, PA 15203</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD></TD>
    <TD><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: Ronald J. Tarquinio</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant:</FONT></TD>
    <TD STYLE="width: 69%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cognition Therapeutics,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD></TD>
    <TD><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2403 Sidney Street, Suite&nbsp;261</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pittsburgh, PA 15203</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Attn: President</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;2.
PREMISES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Office
Space</U>. Landlord, for and in consideration of the Rent (as defined below) to be paid and the covenants and agreements to be performed
by Tenant, as hereinafter set forth, does hereby lease, demise and let unto Tenant the Premises, together with a non-exclusive license
(in common with others), to use the common areas of the Building and the Development. Landlord reserves unto itself, however, the use
of the roof, exterior walls and the area above and beneath the Premises, together with the right to install, maintain, use, repair and
replace exterior windows and doors, pipes, ducts, conduits, wires and structural elements leading through the Premises in locations and
in such a manner which shall not materially or adversely interfere with Tenant's use or occupancy thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Current
Lease</U>. Reference is made to that certain Office Lease Agreement dated December&nbsp;20, 2019, between Landlord and Tenant (as amended
from time to time, the &ldquo;Current Lease&rdquo;) for Suite&nbsp;242 in the Building, which Current Lease has a stated Termination
Date (as defined in the Current Lease) of June&nbsp;30, 2023. Landlord and Tenant hereby acknowledge and agree that: (i)&nbsp;the Termination
Date of the Current Lease is hereby modified to be the Commencement Date of this Lease (to the extent the same occurs hereunder &ndash;
if this Lease is terminated prior to the Commencement Date, the Current Lease shall continue unmodified), and (ii)&nbsp;except as expressly
modified by this Lease, all other terms and provisions of the Current Lease shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;3.
TERM AND COMMENCEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Term
and Confirmation</U>. The term of this Lease shall commence on the Commencement Date set forth in Article&nbsp;1(d)&nbsp;and end on the
Termination Date set forth in Article&nbsp;1(f), unless extended or sooner terminated as provided herein, subject to adjustment as provided
below and the other provisions hereof. If the Commencement Date is postponed as provided below, the Termination Date set forth in Article&nbsp;1
shall be adjusted accordingly. Tenant shall execute a confirmation of the Commencement Date and other factual matters in such form as
Landlord may reasonably request within ten (10)&nbsp;days after requested by Landlord following the Commencement Date; any failure to
respond within such time shall be deemed an acceptance of the matters as set forth in Landlord&rsquo;s confirmation. If Tenant disagrees
with Landlord&rsquo;s adjustment of the Commencement Date, Tenant shall pay Rent and perform all other obligations commencing on the
date as determined by Landlord, subject to refund or credit when the matter is resolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Commencement Delays</U>. The Commencement Date, Rent and Tenant&rsquo;s other obligations shall be postponed to the extent Landlord
fails to deliver possession of the Premises in the condition required under Article&nbsp;4 for any reason, including holding over by
prior occupants. If Landlord so fails for a ninety (90) day initial grace period, Tenant shall have the right to terminate this Lease
by notice within ten (10)&nbsp;days. Any such delay in the Commencement Date shall not subject Landlord to liability for loss or damage
resulting therefrom, and Tenant&rsquo;s sole recourse with respect thereto shall be the postponement of Rent or termination of this Lease
in accordance with the preceding sentence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;4.
CONSTRUCTION OF PREMISES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Landlord
shall, prior to the Commencement Date, cause: (i)&nbsp;the interior walls of the Premises to be painted with Building standard paint,
and (ii)&nbsp;the installation of Building standard carpet in the Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;5.
BASE RENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;<U>Base
Rent</U>. Tenant shall pay to Landlord Base Rent, payable in advance without demand on the first day of each calendar month throughout
the Term; provided, that Tenant shall pay Base Rent for the first full calendar month for which Base Rent shall be due (and any initial
partial month) when Tenant executes and delivers this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;<U>Additional
Rent</U>. Whenever under the terms of this Lease any sum of money is required to be paid by Tenant to Landlord in addition to the Base
Rent herein reserved, and said additional amount so to be paid is not designated as &quot;additional rent&quot;, then said amount shall
nevertheless, at the option of Landlord, be deemed &quot;additional rent&quot; and collectible as such, but nothing herein contained
shall be deemed to suspend or delay the payment of any sum at the time the same becomes due and payable hereunder, or limit any other
remedy of Landlord. Nonpayment of additional rent beyond the expiration of applicable notice and/or cure periods shall constitute a default
under this Lease to the same extent, and shall entitle the Landlord to the same remedies, as nonpayment of Base Rent. Where no time limit
for payment is otherwise stated in the specific Lease provision applicable thereto, any such obligation shall be due and payable within
fifteen (15) days following Tenant's receipt of a written statement showing in reasonable detail the basis for the amount claimed. Base
Rent and additional rent are sometimes hereinafter referred to as &ldquo;Rent&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&nbsp;
<U>Payments</U>. All payments of Rent shall be paid when due without any deduction, recoupment, set-off or counterclaim (except as otherwise
set forth in this Lease) at the principal office of the Landlord or at such other place as Landlord may from time to time direct. No
delay by Landlord in providing a statement for Rent shall be deemed a default by Landlord or a waiver of Landlord&rsquo;s right to require
payment of Tenant&rsquo;s obligations for any Rent due under the terms of this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;6.
RENT ESCALATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;
<U>Real Estate Tax Increases</U>. Commencing on January&nbsp;1, 2024, and thereafter through the term of this Lease, Tenant shall pay
to Landlord, as additional rent, Tenant's Proportionate Share of the amount by which Real Estate Taxes incurred by Landlord during any
calendar year following the Base Year for Real Estate Taxes shall exceed the Real Estate Taxes incurred by Landlord during such Base
Year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&ldquo;Real
Estate Taxes&rdquo; shall be deemed to mean the aggregate amount of taxes and assessments levied, assessed or imposed upon the Development
in which the Premises are located. For purposes hereof, Real Estate Taxes shall include, without limitation, real estate taxes, sewer
rents, water rents, assessments (special or otherwise), transit taxes, any tax or excise on rentals or any other tax (however described)
on account of rental received for use and occupancy of all or any part of the Premises, whether such taxes are imposed by the United
States of America, the Commonwealth of Pennsylvania, the county in which the Premises is located or any local governmental municipality,
authority or agency, or any other political subdivision of any of the foregoing. Real Estate Taxes shall also include all reasonable
costs and expenses (including, without limitation, legal fees and court costs) incurred in connection with the protest or the reduction
of any of the aforesaid taxes and or assessments, up to an amount equal to the reduction of any of the aforesaid taxes resulting from
such protest. If at any time during the term hereof, a tax or excise on rents or any other tax, however described, is levied or assessed
by any governmental authority on account of the rents hereunder or the interest of Landlord or Landlord's beneficiaries under this Lease,
then such additional tax shall be included in Real Estate Taxes. Further, any tax assessed or levied by any governmental authority in
lieu of the foregoing Real Estate Taxes shall also be included. For the purpose of determining Real Estate Taxes for any given calendar
year, the amount to be paid for such calendar year shall be (a)&nbsp;with respect to assessments, the amount of the installments (and
any interest) due and payable during such calendar year and (b)&nbsp;with respect to all other Real Estate Taxes, the amount due and
payable during such calendar year, but only to the extent properly allocable to such calendar year. Notwithstanding anything in this
Lease to the contrary, &ldquo;Real Estate Taxes&rdquo; shall not include (i)&nbsp;any capital stock, net income, profit tax, succession,
transfer, franchise, gift, estate or inheritance tax, (ii)&nbsp;any transfer tax or recording charge resulting from a transfer of the
Development or the Building or any interest in the Development or the Building or (iii)&nbsp;any penalties, interest or fines incurred
by Landlord due to nonpayment or late payment of taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;
<U>Operating Cost Increases</U>. Commencing on January&nbsp;1, 2024, and thereafter through the term of this Lease, Tenant shall pay
to Landlord, as additional rent, Tenant's Proportionate Share of the amount by which Operating Costs incurred by Landlord during any
calendar year following the Base Year for Operating Costs shall exceed the Operating Costs incurred by Landlord during such Base Year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;Operating
Costs&rdquo; shall be deemed to mean all costs and expenses of any kind or nature incurred by Landlord in any calendar year in operating,
policing, protecting, lighting, heating, air conditioning, insuring, repairing and maintaining the Building, other structures and improvements
and the land constituting or supporting the Development, all in accordance with accepted principles of sound management of similar properties,
and shall include (without limitation) all costs and expenses of operation, replacement, replacement and maintenance, including by way
of illustration and not limitation: personal property taxes and any tax in addition to or in lieu thereof, assessed against Landlord
or to be collected by Landlord; utilities; supplies; materials; tools; insurance (including, but not limited to, commercial general liability,
casualty, business interruption, rent loss insurance and flood and earthquake insurance); licenses, permits and inspection fees; cost
of services of independent contractors (including property management fees); any tax, assessment, cost or fee incurred by Landlord in
connection with the Development from any neighborhood improvement district or similar program or initiative; cost of compensation (including
employment taxes and fringe benefits) of all persons who perform regular and recurring duties connected with day-to-day operation, maintenance
and repair of the Development, its equipment and the component interior and exterior common areas, ceilings, floors, walks, stairs, stairwells,
elevators, loading docks, trash compactor, malls and landscaped areas including janitorial, gardening, security, parking, operating engineer,
painting, plumbing, electrical, carpentry, heating, ventilation, air conditioning, window washing, signage and advertising; rental expense
or a reasonable allowance for depreciation of personal property used in such maintenance, operation and repair of the Development; those
variable costs, expenses and disbursements which Landlord reasonably determines Landlord would have incurred had the Development been
100% occupied at all times during such calendar year; and amortization of Permitted Capital Expenditures (as hereinafter defined).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Notwithstanding
anything in this Lease to the contrary, &ldquo;Operating Costs&rdquo; shall not include the following: costs to benefit, or relating
to, a specific tenant, such as legal and other related expenses associated with the negotiation or enforcement of leases, and any penalties
or damages from such lawsuits; costs associated with the financing or refinancing of debt or selling of the Building, the Development
or any interest therein, such as points, broker's fees and attorney's fees; executive salaries and compensation of employees of Landlord
above the grade of regional property manager; repairs and/or replacements which are covered by insurance claim or condemnation proceeds;
leasing commissions, legal fees, tenant allowances or fit outs (including permit, license and inspection fees), advertising costs, space
planning costs and promotional material; costs incurred by Landlord in connection with the original construction of the Building or the
correction of latent defects in construction of the Building; depreciation and amortization (except for amortization of Permitted Capital
Expenditures); costs paid to subsidiaries or affiliates of Landlord, to the extent that the costs exceed the reasonable costs that would
have been paid had the services, supplies or materials been provided by unaffiliated parties on a reasonable basis; interest on debt
or amortization payments on any mortgage or deeds of trust or any other borrowings and any ground rent; ground rents or rentals payable
by Landlord pursuant to any over-lease or any compensation paid to clerks, attendants or other persons in commercial concessions operated
by Landlord; costs incurred in managing or operating any &ldquo;pay for&rdquo; parking facilities within the Development; expenses resulting
from the gross negligence or willful misconduct of Landlord or its agents, employees or contractors; any fines or fees for Landlord&rsquo;s
failure to comply with governmental, quasi-governmental, or regulatory agencies&rsquo; rules&nbsp;and regulations, or any costs or expenses
incurred by Landlord due to violation by Landlord, or Landlord&rsquo;s agents, contractors or employees, of either the payment terms
and conditions of any lease or, service contract or other agreement covering the Development or Landlord&rsquo;s obligations as owner
of the Development; costs for sculpture, decorations, painting or other objects of art in excess of amounts typically spent for such
items in office buildings of comparable quality in the competitive area of the Building; costs of any political, charitable or civic
contribution or donations; Capital Items, except for Permitted Capital Expenditures; costs that are properly chargeable to particular
tenants in the Development, including, without limitation, costs and expenses for providing heating and air conditioning service outside
of normal business hours and damages to the Development or any part thereof caused by the act or neglect of another tenant; costs relating
to utilities or other services to tenant spaces for which Tenant pays for such utilities or other services directly; costs properly attributable
(applying generally accepted accounting principles) to other calendar years; costs paid by Landlord if and to the extent such costs are
incurred by Landlord for any work or service furnished to any other tenant in the Development (other than Tenant) to a materially greater
extent and in a materially more favorable manner than furnished generally to the remaining tenants in the Project (including Tenant);
costs incurred with respect to preparation of income tax returns; and costs incurred in cleaning up any environment hazard or condition
in violation of any environmental law. &ldquo;Permitted Capital Expenditures&rdquo; means capital expenditures and capital repairs and
replacements (&ldquo;Capital Items&rdquo;), provided such Capital Items (x)&nbsp;are necessitated by a change in law or regulation occurring
after the Commencement Date; or (y)&nbsp;are reasonably intended to have cost-saving benefits over the Term of the Lease. The foregoing
provision is for definitional purposes only and shall not be construed to impose any obligation upon Landlord to incur such expenses.
No item of Operating Cost shall be included more than once in any given time period and no item of expense charged to Tenant as an Operating
Cost shall be charged to Tenant as Real Estate Taxes or any other type of chargeable expense or cost. The property management fees incurred
by Landlord shall only be chargeable to Tenant to the extent such property management fees do not exceed the property management fees
incurred by other buildings of similar size and quality and located within the geographic area in which the Development is located.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&nbsp;<U>Method
of Payment</U>. Within sixty (60) days after the end of each calendar year (including the last calendar year of the term of this Lease),
Landlord shall furnish Tenant a written statement showing in reasonable detail Landlord's Real Estate Taxes and Operating Costs for the
Base Year and the preceding calendar year and showing Tenant's Proportionate Share of the amount of any increase in such Real Estate
Taxes and/or Operating Costs over the amount thereof for the respective Base Year. Coincidentally with the monthly rent payment due following
Tenant's receipt of such statement, Tenant shall pay to Landlord an amount equal to the sum of (1)&nbsp;Tenant's Proportionate Share
of the increase in Real Estate Taxes and Operating Costs for the preceding calendar year over the amount thereof for the applicable Base
Year; and (2)&nbsp;one-twelfth (1/12th) of such increases for the current calendar year multiplied by the number of rent payments (including
the current one) then elapsed in such calendar year. Thereafter such one-twelfth (1/12th) amount shall be paid monthly with the Base
Rent until subsequently adjusted in accordance with the terms of this Article.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&nbsp;
<U>Tenant&rsquo;s Proportionate Share</U>. &ldquo;Tenant&rsquo;s Proportionate Share&rdquo; of Taxes and Operating Costs shall be the
percentages set forth in Article&nbsp;1, but if the rentable area of the Premises or Building shall change, Tenant&rsquo;s Proportionate
Share shall thereupon become the rentable area of the Premises divided by the rentable area of the Building, subject at all times to
adjustment as provided in this Article. Tenant acknowledges that the &ldquo;rentable area of the Premises&rdquo; under this Lease includes
the usable area, without deduction for columns or projections, multiplied by a load or conversion factor, to reflect a share of certain
areas, which may include lobbies, corridors, mechanical, utility, janitorial, boiler and service rooms and closets, restrooms, and other
public, common and service areas. Except as provided expressly to the contrary herein, the &ldquo;rentable area of the Building&rdquo;
shall include all rentable area of all space leased or available for lease at the Building, which Landlord may reasonably re-determine
from time to time, to reflect re-configurations, additions or modifications to the Building.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&nbsp;<U>Tax
Refunds, Protest Costs, and Expense Adjustments For Prior Years</U>. Landlord shall each year: (i)&nbsp;credit against Real Estate Taxes
any refunds received during such year, (ii)&nbsp;include in Real Estate Taxes any additional amount paid during such year, involving
an adjustment to Real Estate Taxes for a prior year, due to error by the taxing authority, supplemental assessment, or other reason,
(iii)&nbsp;include, in either Real Estate Taxes or Operating Costs, any fees for attorneys, consultants and experts, and other costs
paid during such year in attempting to protest, appeal or otherwise seek to reduce or minimize Real Estate Taxes, by the terms of this
Article, (iv)&nbsp;credit against Operating Costs the cost of any item previously included in Operating Costs, to the extent that Landlord
receives reimbursement from insurance proceeds or a third party during such year (excluding tenant payments for Real Estate Taxes and
Operating Expenses), and (v)&nbsp;make any other appropriate changes to reflect adjustments to Real Estate Taxes or Operating Expenses
for prior years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&nbsp;<U>Payments
After Lease Term Ends</U>. Tenant&rsquo;s obligations to pay Tenant&rsquo;s Proportionate Share of Real Estate Taxes and Operating Costs
(or any other amounts) accruing during, or relating to, the period prior to expiration or earlier termination of this Lease shall survive
the expiration or termination of this Lease for a period of two (2)&nbsp;years. Tenant shall pay the full amount of such estimate and
any additional amount due after the actual amounts are determined, in each case within thirty (30) days after Landlord sends a statement
therefore. If the actual amount is less than the amount Tenant pays as an estimate, Landlord shall refund the difference within thirty
(30) days after such determination is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&nbsp;<U>Audit
Rights</U>. In the event of any dispute as to the amount of Tenant&rsquo;s Proportionate Share of Operating Costs and Real Property Taxes,
Tenant may, by prior written notice (&ldquo;Audit Notice&rdquo;) given within ninety (90) days following receipt of a Landlord&rsquo;s
reconciliation statement (&ldquo;Audit Period&rdquo;), audit Landlord&rsquo;s accounting records with respect to Operating Expenses and
Real Property Taxes relative to the year to which such statement relates. The audit shall be conducted by Tenant, or an accounting firm
engaged by Tenant and reasonably satisfactory to Landlord (billing hourly and not on a contingency fee basis) (&ldquo;Third Party Auditor&rdquo;),
and shall be conducted at the office of Landlord at which its records are kept or, at Landlord&rsquo;s election, the office of Landlord&rsquo;s
property manager (if any). The audit shall be conducted at reasonable times during normal business hours. In no event will Landlord or
its property manager be required to (i)&nbsp;photocopy any accounting records or other items or contracts, (ii)&nbsp;create any ledgers
or schedules not already in existence, (iii)&nbsp;incur any costs or expenses relative to such inspection, or (iv)&nbsp;perform any other
tasks other than making available such accounting records as aforesaid. Neither Tenant nor its auditor may leave the office of Landlord
with originals of any materials supplied by Landlord. Tenant must pay Tenant&rsquo;s Proportionate Share of Operating Costs and Real
Property Taxes when due pursuant to the terms of this Lease and may not withhold payment of Operating Costs, Real Property Taxes or any
other Rent pending results of the audit or during a dispute regarding Operating Costs and Real Property Taxes. The audit must be completed
within ninety (90) days of the date of Tenant&rsquo;s Audit Notice and the results of such audit shall be delivered to Landlord within
forty-five (45) days of the date of Tenant&rsquo;s Audit Notice. If Tenant does not substantially comply with any of the aforementioned
time frames, then the Landlord&rsquo;s statement will be conclusively binding on Tenant. If such audit or review correctly reveals that
Landlord has overcharged Tenant, then within thirty (30) days after the results of such audit are made available to Landlord, the amount
of such overcharge shall be deducted from the installments of Tenant&rsquo;s Share of Operating Costs and Real Property Taxes next becoming
due. If the audit reveals that Tenant was undercharged, then within thirty (30) days after the results of the audit are made available
to Tenant, Tenant agrees to reimburse Landlord the amount of such undercharge. Tenant agrees to keep the results of the audit confidential
and will cause its agents, employees and contractors to keep such results confidential. To that end, Landlord may require Tenant and
its auditor to execute a commercially reasonable confidentiality agreement provided by Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;7.
LATE PAYMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">A late charge of
five (5%) percent shall be due and payable forthwith on the amount of Base Rent and additional rent not received by Landlord from Tenant
on or before the tenth (10<SUP>th</SUP>) day after such payment was due. In addition, Tenant shall pay interest at the Lease Interest
Rate (as defined below) on any sum which is not paid when due, interest to run from the due date until such sum is paid. The &ldquo;Lease
Interest Rate&rdquo; means four (4)&nbsp;percentage points per annum above the prime rate per annum announced from time to time by PNC
Bank, N.A, or its successors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;8.
USE OF PREMISES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant
shall occupy and use the Premises only for the Permitted Uses set forth in Article&nbsp;1. Tenant shall not occupy or use the Premises
for any other purpose or business without the prior written consent of Landlord.</FONT><FONT STYLE="font-size: 10pt">&nbsp;Landlord
has promulgated reasonable Rules&nbsp;and Regulations (&ldquo;Rules&nbsp;and Regulations&rdquo;), which are attached hereto, made part
hereof and marked as Exhibit&nbsp;&ldquo;C&rdquo;. Tenant acknowledges receipt of and shall observe and comply with such Rules&nbsp;and
Regulations. Tenant further acknowledges that Landlord, in Landlord&rsquo;s reasonable discretion, may from time to time adopt, amend,
establish, modify, proscribe or restate such rules&nbsp;and regulations with regard to the operation of the Premises, the Building, and
common areas of the Development; provided that such rules&nbsp;and regulations are generally applicable to all tenants, do not materially
increase the financial burdens of Tenant and do not materially adversely affect Tenant&rsquo;s rights under this Lease. In the event
of any conflict between the provisions of such rules&nbsp;and regulations and this Lease, the provisions of this Lease shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;9.
COMMON AREAS/PARKING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">All parking areas,
driveways, alleys, public corridors and fire escapes, and other areas, facilities and improvements as may be approved by Landlord from
time to time for the general use, in common, of Tenant and other tenants, their employees, agents, invitees and licensees, shall at all
times be subject to the exclusive control and management of Landlord, and Landlord shall have the right from time to time to establish,
modify and enforce reasonable rules&nbsp;and regulations with respect to all such areas, facilities and improvements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Landlord reserves
the right to designate certain parking areas for non-exclusive permitted parking for tenant&rsquo;s employees, for general visitor parking,
and for other designated uses. Tenant shall be allocated fourteen (14) non-exclusive permitted parking spaces for the use of Tenant's
employees, the location of such parking spaces to be designated by Landlord from time to time according to the Landlord's parking policies
and procedures. Landlord agrees to enforce its parking regulations for the mutual benefit of Landlord and tenants of the Development.
Except for claims resulting from Landlord&rsquo;s intentional or grossly negligent acts, Landlord shall not be responsible or liable
for damage or loss sustained to motor vehicles (including any contents) parked in the Development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;10.
ALTERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;Tenant
shall not make any alterations, improvements or additions to the Premises or attach any fixtures or equipment thereto, without the Landlord's
prior written approval, not to be unreasonably withheld. All alterations, improvements or additions made to the Premises or the attachment
of any fixtures or equipment thereto shall be performed at Tenant's sole cost and expense. Tenant may affix pictures and shelving to
the walls without Landlord's consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;All
alterations, improvements or additions to the Premises made by Tenant shall be deemed to have been attached to the Premises and to have
become the property of Landlord upon such attachment, and upon expiration of this Lease or renewal term thereof, Tenant shall not remove
any of such alterations, improvements or additions; provided, however, that Landlord may designate by written notice to Tenant at the
time Tenant requests consent those alterations and additions which shall be removed by Tenant at the expiration or termination of this
Lease, and Tenant shall properly remove the same and repair any damage to the Premises caused by such removal. Notwithstanding anything
in this Lease to the contrary, all furniture, trade fixtures and equipment installed by or for Tenant may be removed by Tenant at any
time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&nbsp;In
performing such alterations, improvements or additions, or in the removal thereof, Tenant shall use due care to cause as little damage
or injury as possible to the Premises and the Building and shall repair all damage or injury that may occur to the Premises or the Building
as a result thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&nbsp;Tenant
agrees in doing any such work in or about the Premises to engage only such labor as will not conflict with or cause strikes or other
labor disturbances among the Development service employees of Landlord. Any contractors employed by Tenant shall be subject to Landlord's
prior written approval, not to be unreasonably withheld. All such contractors shall be required to carry worker's compensation insurance,
commercial general liability insurance and property damage insurance in amounts, form and content, and with companies reasonably satisfactory
to Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&nbsp;Prior
to the commencement by Tenant of any work as set forth in this Article, Tenant shall obtain, at Tenant's sole cost and expense, all necessary
permits, authorizations and licenses required by the various governmental authorities having jurisdiction over the Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;11.
MECHANIC'S LIENS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If any mechanics'
or other lien shall be filed against the Premises or the Development purporting to be for labor or material furnished or to be furnished
at the request of Tenant, then Tenant shall at its expense cause such lien to be discharged by payment, bond or otherwise within thirty
(30) days after notice of filing thereof. As an alternative to causing the lien to be discharged of record, Tenant shall have the right
to contest the validity of any lien or claim if Tenant shall first have posted a bond or other security reasonably satisfactory to Landlord
(such as an undertaking with Landlord's title company to insure that, upon final determination of the validity of such lien or claim,
Tenant shall immediately pay any judgment rendered against Tenant). If Tenant shall fail to take such action within such thirty (30)
day period, Landlord may cause such lien to be discharged by payment, bond or otherwise, without investigation as to the validity thereof
or as to any offsets or defenses thereto and Tenant shall, upon demand, reimburse Landlord for all amounts paid and costs incurred including
reasonable attorney's fees, in having such lien discharged of record. Tenant shall indemnify and hold Landlord harmless from and against
any and all claims, costs, damages, liabilities and expenses (including reasonable attorney's fees) which may be brought or imposed against
or incurred by Landlord by reason of any such lien or its discharge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;12.
CONDITION OF PREMISES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tenant acknowledges
and agrees that, except as expressly set forth in this Lease, there have been no representations or warranties made by or on behalf of
Landlord with respect to the Building, Premises or the Development or with respect to the suitability of any of them for the conduct
of Tenant's business. The taking of possession of the Premises by Tenant shall conclusively establish that the Premises were at such
time in satisfactory condition, order and repair, subject to latent defects which a reasonable inspection of the Premises would not disclose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;13.
UTILITIES AND SERVICES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Utilities</U>:
Separately metered electric and gas service shall be made available to the Premises. Tenant shall pay for the cost of such utility services
directly to the utility provider or to the Landlord, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Building
Services</U>: Landlord shall provide the following to the Premises, the Building or the Development, as applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Janitorial
service four (4)&nbsp;times per week, for office space portions of the Premises only, see Exhibit&nbsp;&quot;D,&quot; Cleaning Specifications;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Water
and sewage for the Permitted Use;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Replacement
standard light globes and/or standard fluorescent tubes and ballasts in the standard ceiling lighting fixtures;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;HVAC,
including maintenance of HVAC equipment and systems;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Passenger
and freight elevator service and maintenance and repair;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Hot
and cold water for drinking, lavatory and toilet purposes at those points of supply provided for nonexclusive general use of tenants
of the Building, and points of supply in the Premises installed by or with Landlord&rsquo;s consent for the exclusive use of Tenant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Maintenance
and repair of interior common areas of the Building, including the public restrooms in the Building; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Maintenance
and repair of exterior common areas of the Development, including but not limited to cleaning of outside exterior windows and doors,
snow removal and landscaping.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&nbsp;
Landlord does not warrant that the utilities or services provided for in this Article&nbsp;shall be free from slow-down, interruption
or stoppage&nbsp;pursuant to voluntary agreement by and between Landlord and governmental bodies and regulatory agencies, or caused by
the maintenance, repair, substitution, renewal, replacement or improvements of any of the equipment involved in the furnishing of any
such utilities or services or caused by strikes, lockouts, labor controversies, fuel shortages, accidents, acts of God or the elements
or any other cause beyond the reasonable control of Landlord; and specifically, no such slow-down, interruption or stoppage&nbsp;of any
of such services shall be construed as an eviction, actual or constructive, of Tenant, nor shall same cause any abatement of Base Rent
or additional rent payable hereunder or in any manner or for any purpose relieve Tenant from any of Tenant's obligations hereunder, unless
same shall make a material portion of the Premises untenantable for a period of three (3)&nbsp;consecutive business days at which point
Base Rent shall be abated until such time as the Premises are no longer untenantable, and in no event shall Landlord be liable for damages
to persons or property or be in default hereunder as a result of such interruption or stoppage&nbsp;of service. Should said disruption
of service or utilities cause significant interference with Tenant&rsquo;s business for a period of sixty (60) days, Tenant shall have
the right to terminate this Lease by written notice to Landlord. Landlord shall provide Tenant with reasonable advance notice of any
anticipated interruptions in utility or Building services, and Landlord shall use reasonable efforts to minimize disruption of Tenant&rsquo;s
use and occupancy in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;14.
ASSIGNMENT AND SUBLETTING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tenant shall not
assign this Lease or sublet the Premises, (whether by operation of law or voluntary agreement) in whole or in part, without the Landlord's
prior written consent, not to be unreasonably withheld. In case of any assignment or subletting, Tenant shall remain primarily liable
on this Lease and shall not be released from the performance of any of the terms, covenants and conditions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, Tenant may assign this Lease, or sublet the Premises or any portion thereof to an affiliate controlling, controlled by
or under common control with Tenant, without Landlord consent, but with notice thereof to Landlord. Tenant may sublet all or a portion
of the Premises without prior consent to third parties and entities related to Tenant either through affiliated or commercial relationships
for office use. Any license, assignment, subleasing or other occupancy agreement shall be subject to all terms, covenants and conditions
of this Lease and no license, assignment, subleasing or other occupancy agreement shall relieve Tenant of any liability hereunder. Upon
Landlord' s request, Tenant shall provide Landlord with copies of all reasonable documentation related to any license, assignment, sublease,
or other occupancy agreement and Tenant shall require any permitted licensee, assignee, sublicensee, or other occupant to obtain and
maintain commercially reasonable insurance naming Landlord as additional insured. Tenant shall provide copies evidencing such insurance
to Landlord upon Landlord's request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;15.
RIGHTS RESERVED BY LANDLORD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Except to the extent
expressly limited herein, Landlord reserves full rights to control the Development, the Building and the Premises (which rights may be
exercised without subjecting Landlord to claims for constructive eviction, abatement of Rent, damages or other claims of any kind), including
more particularly, but without limitation, the following rights for Landlord, its employees or agents; provided however, Landlord shall
use commercially reasonable efforts to exercise such rights in a manner that will first attempt to minimize interference with Tenant&rsquo;s
use and occupancy of the Premises:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;
<U>Access to Premises</U>. To enter the Premises in order to inspect, supply cleaning service or other services to be provided Tenant
hereunder, show the Premises to current and prospective lenders, insurers, purchasers, tenants, brokers and governmental authorities,
and perform any work or take any other actions reserved to Landlord under this Lease or applicable laws. However, Landlord shall: (i)&nbsp;provide
reasonable advance written or oral notice to Tenant&rsquo;s on-site manager or other appropriate person (except in emergencies), (ii)&nbsp;take
reasonable steps to minimize any significant disruption to Tenant&rsquo;s business, and following completion of any work, return Tenant&rsquo;s
leasehold improvements, fixtures, property and equipment to the original locations and condition to the fullest extent reasonably possible,
and (iii)&nbsp;take reasonable steps to avoid materially changing the configuration or reducing the square footage of the Premises, unless
required by laws or other causes beyond Landlord&rsquo;s reasonable control (and in the event of any permanent reduction, the Rent and
other rights and obligations of the parties based on the square footage of the Premises shall be proportionately reduced). Tenant shall
not place partitions, furniture or other obstructions in the Premises which may prevent or impair Landlord&rsquo;s access to the systems
and equipment for the Building or the systems and equipment for the Premises. If Tenant requests that any such access occur before or
after Landlord&rsquo;s regular business hours and Landlord approves, Tenant shall pay all overtime and other additional costs in connection
therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;
<U>Changes to the Development</U>. To: (i)&nbsp;paint and decorate, (ii)&nbsp;perform repairs or maintenance, and (iii)&nbsp;make replacements,
restorations, renovations, alterations, additions and improvements, structural or otherwise in and to the Development or any part thereof,
including any adjacent building, structure, facility, land, street or alley, or change the uses thereof (including changes, reductions
or additions of corridors, entrances, doors, lobbies, parking facilities and other areas, structural support columns and shear walls,
utility lines, pipes, duct work, cables, installations, docks, walks, elevators, stairs, solar tint windows or film, planters, sculptures,
displays, and other amenities and features therein, and changes relating to the connection with or entrance into or use of the Building
or any other adjoining or adjacent building or buildings, now existing or hereafter constructed). In connection with such matters, Landlord
may among other things erect scaffolding, barricades and other structures, open ceilings, close entry ways, restrooms, elevators, stairways,
corridors, parking and other areas and facilities, and take such other actions as Landlord deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;16.
REPAIRS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;Subject
to the provisions of Article&nbsp;6 hereof, Landlord shall perform all maintenance and make all repairs or replacement necessary to maintain
the structural, plumbing, HVAC and electrical systems (including replacement of light bulbs, ballasts and fixtures), exterior doors and
windows, roof, exterior walls, demising walls and floor (but excluding interior ceiling, wall and floor finishes), common areas and utility
lines and connections servicing the Premises, the Building or the Development in good order and condition. Landlord shall commence such
repairs as promptly as the circumstances reasonably permit and thereafter shall diligently pursue the same to completion with reasonable
promptness. Notwithstanding anything contained in this Lease to the contrary, Tenant shall be responsible, at its sole cost and expense,
for any maintenance, repairs and replacements made by the Landlord which are necessitated by the negligent acts, misuse or willful misconduct
of Tenant, its agents, contractors, employees or invitees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;Except
as the Landlord is obligated for repairs as provided hereinabove, Tenant shall make at Tenant's sole cost and expense, all repairs necessary
to maintain the Premises and shall keep the Premises and the fixtures therein in neat, clean, safe and orderly condition. Without limiting
the generality of the foregoing, any maintenance, repairs or replacements of all lab equipment contained in the lab space portion of
the Premises, including without limitation all water treatment systems and vacuum equipment, desired by Tenant shall be the responsibility
of Tenant. If the Tenant refuses or neglects to make such repairs, or fails to diligently prosecute the same to completion, after written
notice from Landlord of the need therefore, Landlord may make such repairs at the expense of Tenant and such expense, along with a fifteen
(15%) percent service charge, shall be collectible as additional rent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&nbsp;Landlord
shall not be liable by reason of any injury to or interference with Tenant's business arising from the making of any repairs in accordance
with this Article&nbsp;16 in or to the Premises or the Building and Development or to any appurtenances or equipment therein; provided
that Landlord shall interfere as little as reasonably practicable with the conduct of Tenant's business in the performance of the foregoing.
There shall be no abatement of Rent because of such repairs, except as provided in Article&nbsp;20 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;17.
INDEMNIFICATION AND INSURANCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;
<U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&nbsp;
Tenant shall indemnify, hold harmless and defend Landlord from and against any and all costs, expenses (including reasonable counsel
fees), liabilities, losses, damages, suits, actions, fines, penalties, claims or demands of any kind and asserted by or on behalf of
any person or governmental authority, arising out of or in any way connected with, and Landlord shall not be liable to Tenant on account
of, (i)&nbsp;any failure by Tenant to perform any of the agreements, terms, covenants or conditions of this Lease required to be performed
by Tenant, (ii)&nbsp;any failure by Tenant to comply with any statutes, ordinances, regulations or orders of any governmental authority
applicable to Tenant&rsquo;s occupancy and use of the Premises, or (iii)&nbsp;any accident, death or personal injury, or damage to or
loss or theft of property, which shall occur in the Premises, except to the extent caused by the negligence or willful misconduct of
Landlord, its agents, employees or contractors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ii)&nbsp;
Landlord shall indemnify, hold harmless and defend Tenant from and against any and all costs, expenses (including reasonable counsel
fees), liabilities, losses, damages, suits, actions, fines, penalties, claims or demands of any kind and asserted by or on behalf of
any person or governmental authority, arising out of or in any way connected with, (i)&nbsp;any failure by Landlord to perform any of
the agreements, terms, covenants or conditions of this Lease required to be performed by Landlord, or (ii)&nbsp;the negligence or willful
misconduct of Landlord or its agents, employees or contractors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;
<U>Required Insurance</U>. Tenant shall maintain at its expense during the term with respect to the Premises and Tenant&rsquo;s use thereof
and of the Building:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&nbsp;Worker&rsquo;s
compensation insurance in the amounts required by statute, and Employer Liability Insurance in at least the following amounts: (a)&nbsp;Bodily
Injury by Accident - $500,000 per accident, (b)&nbsp;Bodily Injury by Disease - $500,000 per employee and (c)&nbsp;Aggregate Limit -
$1,000,000 per policy year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ii)&nbsp;Property
Damage Insurance for the protection of Tenant and Landlord, as their interest may appear, covering all risks of physical loss to Tenant&rsquo;s
alterations or improvements, personal property, business records, fixtures and equipment in amounts not less than the full insurable
replacement cost of such property and full insurable value of such other interests of Tenant, such policies to be in form reasonably
satisfactory to Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(iii)&nbsp;Commercial
general liability insurance in form reasonably satisfactory to Landlord with limits of at least the following amounts: (a)&nbsp;death
or bodily injury - $2,000,000, (b)&nbsp;property damage or destruction (including loss of use thereof) - $2,000,000 per policy year.
Such policy shall include endorsements: (1)&nbsp;for contractual liability covering Tenant&rsquo;s indemnity obligations under this Lease,
and (2)&nbsp;for adding Landlord, Landlord&rsquo;s mortgagee, the management company for the Development, and other parties designated
by Landlord, as additional insureds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certificates, Subrogation and Other Matters</U>. Tenant shall provide Landlord with certificates evidencing the coverage required
hereunder prior to the Commencement Date, or Tenant&rsquo;s entry to the Premises for construction of improvements or any other purpose
(whichever first occurs). Such certificates shall state that such insurance coverage may not be changed, canceled or non-renewed without
at least thirty (30) days&rsquo; prior written notice to Landlord. Tenant shall provide renewal certificates to Landlord at least ten
(10)&nbsp;days prior to expiration of such policies. Tenant&rsquo;s insurance policies shall be primary to all policies of Landlord and
any other additional insureds (whose policies shall be deemed excess and non-contributory). All insurance required hereunder shall be
provided by responsible insurers licensed in the Commonwealth of Pennsylvania, and shall have a general policy holder&rsquo;s rating
of at least A and a financial rating of at least X in the then current edition of Best&rsquo;s Insurance Reports. The parties mutually
hereby waive all rights and claims against each other for all losses covered by their respective insurance policies, and waive all rights
of subrogation for their respective insurers. The parties agree that their respective insurance policies are now, or shall be, endorsed
such that said waiver of subrogation shall not affect the right of the insured to recover thereunder. Landlord disclaims any representations
as to whether the foregoing coverages will be adequate to protect Tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Landlord
Insurance</U>. At all times during the Lease Term, Landlord agrees to maintain in force and effect (i)&nbsp;all-risk fire and extended
coverage insurance on the Building, and (ii)&nbsp;commercial general liability insurance with limits and deductibles consistent with
those maintained by owners of similarly situated buildings in the vicinity of the Building.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;18.
LANDLORD'S LIABILITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Except for claims
arising from the negligent acts or willful misconduct of Landlord or its agents, employees or contractors, Tenant waives all claims against
Landlord and Landlord&rsquo;s partners, members, agents and employees for injury or death to persons, damage to property or any other
interest of Tenant sustained by Tenant or a party claiming by or through Tenant resulting from: (a)&nbsp;any defect in or failure of
structural, plumbing, sprinkling, electrical, heating or air conditioning systems or equipment, or any other systems and equipment of
the Premises or the Building or from the drains, pipes, plumbing or sewer; (b)&nbsp;broken glass; (c)&nbsp;any acts or omissions of the
other tenants or occupants of the Building or of nearby buildings; (d)&nbsp;any acts or omissions of other persons; (e)&nbsp;damage or
loss sustained to motor vehicles (including any contents) parked at or operating within the Development, from any cause; and (f)&nbsp;theft,
Act of God, public enemy, injunction, riot, strike, insurrection, war, court order, or any order of any governmental authorities having
jurisdiction over the Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;19.
COMPLIANCE WITH INSURANCE REQUIREMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tenant agrees that
Tenant will not do or suffer to be done, any act, matter or thing, objectionable to the fire insurance companies whereby the fire insurance
or any other insurance now in force or hereafter to be placed on the Premises or any part thereof, or on the Building of which the Premises
may be a part, shall become void or suspended, or whereby the same shall be rated as a more hazardous risk than at the date when Tenant
receives possession hereunder. In case of a breach of this covenant, in addition to all other remedies of Landlord hereunder, Tenant
agrees to pay to Landlord as additional rent, any and all increases in premiums on insurance carried by Landlord on the Premises or any
part thereof, or on the Building of which the Premises may be a part, caused in any way by the occupancy of Tenant. Notwithstanding the
foregoing, Landlord acknowledges that the Permitted Use shall not constitute a breach of this Article&nbsp;19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;20.
FIRE OR OTHER CASUALTY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;
If the Building and/or Premises are damaged by fire or any other cause to such extent that the same cannot be restored, as reasonably
estimated by Landlord, within one hundred twenty (120) days after the date of such damage or destruction, then Landlord shall, no later
than the sixtieth (60th) day following the damage, give Tenant notice of Landlord&rsquo;s election either to (a)&nbsp;restore the Building
and Premises or (b)&nbsp;terminate this Lease. In the event Landlord elects to terminate this Lease, the Lease shall terminate on the
earlier of the date of such notice or the date upon which Tenant surrenders possession of the Premises. In such event, the Rent and other
charges due hereunder shall be apportioned as of the date of such casualty, and any Rent paid for any period beyond said date shall be
repaid to Tenant. If the time of restoration as estimated by Landlord shall be less than one hundred twenty (120) days, or if Landlord
does not elect to terminate this Lease, as hereinabove provided, Landlord shall restore the Building and the Premises, and Tenant shall
have not right to terminate this Lease except as herein provided. Tenant shall, in such event, restore fixtures and improvements owned
by Tenant to the original condition. Notwithstanding the foregoing, however, if the time of restoration as reasonably estimated by Landlord
exceeds one hundred twenty (120) days, Tenant shall have the right to terminate this Lease upon written notice given to Landlord within
thirty (30) days after the date of Landlord&rsquo;s notice of the estimated restoration period. Landlord shall deliver notice of the
estimated restoration period within sixty (60) days after the date of the casualty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;In
any such case in which use of the Premises is affected by any damage thereto, there shall be an abatement or an equitable reduction in
Rent, depending on the period for which, and the extent to which, the Premises is not reasonably usable for the purposes for which it
is leased hereunder. If the damage results from the fault of Tenant, or Tenant's agents, servants, visitors or licensees, Tenant shall
not be entitled to any abatement or reduction of Rent up to the amount of the deductible paid by Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;21.
SUBORDINATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This Lease shall
be subject and subordinate to the lien of any mortgage, or renewals, modifications, consolidations, replacements or extensions thereof,
which now or hereafter may affect the Premises. Tenant shall, at Landlord's request, execute such agreements and other instruments as
Landlord or any mortgagee of the Premises reasonably shall deem necessary or desirable to subordinate this Lease to the lien of any present
or future mortgage, mortgages or construction loans against the Premises. The subordination of this Lease shall be subject to any current
or future mortgage holder(s)&nbsp;agreement not to disturb Tenant's occupancy so long as Tenant is not then in default of this Lease.
Tenant specifically approves and, upon Landlord's request, agrees to execute an Estoppel Certificate and a Subordination, Nondisturbance
and Attornment Agreement substantially in the forms attached hereto as Exhibits &ldquo;E&rdquo; and &ldquo;F&rdquo;, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;22.
CONDEMNATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;
In the event the Premises, or any part thereof, shall be taken or condemned permanently or temporarily for any public or quasi-public
use or purpose by any competent authority in appropriation proceedings or by any right of eminent domain, the entire compensation award
therefore, including leasehold, reversion and fee, shall belong to the Landlord without any deduction therefrom for any present or future
estate of Tenant. Tenant shall, however, be entitled to claim, prove and receive in such condemnation proceedings such award as may be
allowed for fixtures and other equipment installed by it, and for moving expenses, but only if such award shall be in addition to the
award to Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;
If the entire Building shall be so taken by virtue of eminent domain, this Lease shall terminate on the date when title vests pursuant
to such taking, and the Rent and other charges hereunder shall be apportioned as of said date, and any Rent paid for any period beyond
said date shall be repaid to Tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&nbsp;
If more than twenty percent (20%) of the floor area comprising the Premises shall be so taken, or if a portion of the Building or Development
is taken which materially interferes with Tenant&rsquo;s use of the Premises, either party shall have the right to cancel and terminate
this Lease as of the date of such taking, upon giving notice to the other party within thirty (30) days after notice to Tenant from Landlord
or the condemning authority that such Premises are to be appropriated or taken. In the event that this Lease is not terminated as herein
provided, this Lease shall continue, with an equitable and proportionate adjustment, effective on the date of taking, in Rent and other
charges due hereunder based upon the reduction in floor area.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;23.
ESTOPPEL CERTIFICATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tenant shall, at
any time and from time to time, upon thirty (30) days written request by Landlord, execute, acknowledge and deliver to Landlord a statement
in writing duly executed by Tenant (i)&nbsp;certifying that this Lease is in full force and effect without modification or amendment
(or, if there have been any modifications or amendments, that this Lease is in full force and effect as modified and amended and setting
forth in full all modifications and amendments), (ii)&nbsp;certifying the dates to which Base Rent and additional rent have been paid,
and (iii)&nbsp;either certifying that to the knowledge of Tenant no default exists under this Lease or specifying each such default,
and (iv)&nbsp;certifying such other matters as Landlord and/or any lender may reasonably request; it being the intention and agreement
of Landlord and Tenant that any such statement by Tenant may be relied upon by a prospective purchaser or a prospective mortgagee of
the Building, or current mortgagee of the Building, or by others, in any matter affecting the Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;24.
DEFAULT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
occurrence of any of the following events shall constitute a default by Tenant under this Lease:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)
Failure of Tenant to take possession of the Premises within thirty (30) days following the Commencement Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)
A failure by Tenant to pay any installment of Base Rent hereunder within seven (7)&nbsp;days after the due date (provided, Tenant
shall be afforded one 5-day notice and cure period per 12-month period) or a failure to pay any such other sum herein required to be
paid by Tenant within thirty (30) days after written notice thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)
An abandonment of the Premises by Tenant (provided, the foregoing shall not include temporary vacation or customary work from home
arrangements);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)
An assignment of this Lease or subletting of the Premises in violation of this Lease;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)
A failure by Tenant to pay, when due, any installment of Rent hereunder on two (2)&nbsp;or more occasions within any period of
twelve (12) consecutive months;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">
The failure by Tenant to maintain insurance as required by the provisions of Article&nbsp;17 hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)
A failure by Tenant to observe and perform any other material provision or covenant of this Lease to be observed or performed by
Tenant, where such failure continues for thirty (30) days after written notice thereof from Landlord to Tenant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)
The filing of a petition by or against Tenant for adjudication as a bankrupt or insolvent or for reorganization or for the
appointment pursuant to any local, state or federal bankruptcy or insolvency law of a receiver or trustee of Tenant's property; or
an assignment by Tenant for the benefit of creditors; or the taking possession of the property of Tenant by any local, state or
federal governmental officer or agency or court-appointed official for the dissolution or liquidation of Tenant or for the
operating, either temporary or permanently, of Tenant's business, provided, however, that if any such action is commenced against
Tenant the same shall not constitute a default if Tenant causes the same to be dismissed within sixty (60) days after the filing of
same; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
A default or breach by Tenant beyond the expiration of applicable notice and/or cure periods under any other lease with Landlord in
connection with the Building.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;25.
PROVISIONS RELATED TO LANDLORD&rsquo;S REMEDIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;<U>Remedies</U>.
Upon the occurrence of any event of default set forth above and the expiration of any applicable notice and grace period, Landlord shall
have the rights and remedies hereinafter set forth to the extent permitted by law, which shall be distinct, separate and cumulative with
and in addition to any other right or remedy allowed under law or any other provision of this Lease:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(1)&nbsp;Landlord
may terminate this Lease and Tenant&rsquo;s right of possession, reenter and repossess the Premises by detainer suit, summary proceedings
or other lawful means, and recover from Tenant: (i)&nbsp;any unpaid Rent as of the termination date; (ii)&nbsp;the amount by which: (a)&nbsp;any
unpaid Rent which would have accrued after the termination date during the balance of the term exceeds (b)&nbsp;the reasonable rental
value of the Premises under a lease substantially similar to this Lease, taking into account among other things the condition of the
Premises, market conditions and the period of time the Premises may reasonably remain vacant before Landlord is able to re-lease the
same to a suitable replacement tenant, and Costs of Reletting (as defined in Paragraph (g)&nbsp;below) that Landlord may incur in order
to enter such replacement lease, (iii)&nbsp;any other amounts necessary to compensate Landlord for all damages proximately caused by
Tenant&rsquo;s failure to perform its obligations under this Lease, but excluding consequential, indirect or special damages. For purposes
of computing the amount of rent herein that would have accrued after the termination date, Tenant&rsquo;s obligations for Real Estate
Taxes and Operating Costs shall be projected based upon the average rate of increase in such items from the Commencement Date through
the termination date (or if such period shall be less than three years, then based on Landlord&rsquo;s reasonable estimates). The amounts
computed in accordance with the foregoing subclauses (a)&nbsp;and (b)&nbsp;shall both be discounted in accordance with accepted financial
practice at the rate of four (4%) percent per annum to the then present value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(2)&nbsp;Landlord
may terminate Tenant&rsquo;s right of possession, reenter and repossess the Premises by detainer suit, summary proceedings or other lawful
means, without terminating this Lease, and recover from Tenant: (i)&nbsp;any unpaid Rent as of the date possession is terminated, (ii)&nbsp;any
unpaid rent which thereafter accrues during the term from the date possession is terminated through the time of judgment (or which may
have accrued from the time of any earlier judgment obtained by Landlord), less any consideration received from replacement tenants as
further described and applied pursuant to Paragraph (g)&nbsp;below, and (iii)&nbsp;any other amounts necessary to compensate Landlord
for all damages proximately caused by Tenant&rsquo;s failure to perform its obligations under this Lease, including all Costs of Reletting,
but excluding consequential, indirect or special damages. Tenant shall pay any such amounts to Landlord as the same accrue or after the
same have accrued from time to time upon demand. At any time after terminating Tenant&rsquo;s right to possession as provided herein,
Landlord may terminate this Lease as provided in clause (1)&nbsp;above by notice to Tenant, and Landlord may pursue such other remedies
as may be available to Landlord under this Lease or applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;
<U>Reletting</U>. If this Lease or Tenant&rsquo;s right to possession is terminated or Tenant abandons the Premises, Landlord may: (i)&nbsp;enter
and secure the Premises, change the locks, install barricades, remove any improvements, fixtures or other property of Tenant therein,
perform any decorating, remodeling, repairs, alterations, improvements or additions and take such other actions as Landlord shall determine
in Landlord&rsquo;s sole discretion to prevent damage or deterioration to the Premises or prepare the same for reletting, and (ii)&nbsp;relet
all or any portion of the Premises (separately or as part of a larger space), for any rent, use or period of time (which may extend beyond
the term hereof), and upon any other terms as Landlord shall determine in Landlord&rsquo;s sole discretion. The consideration received
from such reletting shall be applied pursuant to the terms of Paragraph (g)&nbsp;hereof, and if such consideration, as so applied, is
not sufficient to cover all Rent and damages to which Landlord may be entitled hereunder, Tenant shall pay any deficiency to Landlord
as the same accrues or after the same has accrued from time to time upon demand, subject to the other provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&nbsp;
<U>Specific Performance.</U> Landlord shall at all times have the right without prior demand or notice except as required by applicable
law to: (i)&nbsp;seek any declaratory, injunctive or other equitable relief, and specifically enforce this Lease or restrain or enjoin
a violation of any provision hereof, and Tenant hereby waives any right to require that Landlord post a bond or other security in connection
therewith, and (ii)&nbsp;sue for and collect any unpaid Rent which has accrued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&nbsp;
<U>Returned Checks</U>. If Landlord receives two (2)&nbsp;or more checks from Tenant which are returned by Tenant&rsquo;s bank for insufficient
funds, Landlord may require that all checks thereafter be bank certified or cashier&rsquo;s checks (without limiting Landlord&rsquo;s
other remedies). All bank service charges resulting from any returned checks shall be borne by Tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&nbsp;
<U>Landlord&rsquo;s Cure of Tenant Defaults</U>. If Tenant fails to perform any obligation under this Lease beyond the applicable notice
and cure periods set forth herein (except that no notice shall be required in emergencies), Landlord shall have the right (but not the
duty), to perform such obligation on behalf and for the account of Tenant. In such event, Tenant shall reimburse Landlord upon demand,
as additional rent, for all expenses reasonably incurred by Landlord in performing such obligation together with an amount equal to fifteen
(15%) percent thereof for Landlord&rsquo;s overhead, and interest thereon at the Lease Interest Rate from the date of demand. Landlord&rsquo;s
performance of Tenant&rsquo;s obligations hereunder shall not be deemed a waiver or release of Tenant therefrom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&nbsp; <U>Intentionally
Omitted</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&nbsp;
<U>Other Matters</U>. No re-entry or repossession, repairs, changes, alterations and additions, reletting, or any other action or omission
by Landlord shall be construed as an election by Landlord to terminate this Lease or Tenant&rsquo;s right to possession, nor shall the
same operate to release Tenant in whole or in part from any of Tenant&rsquo;s obligations hereunder, unless express notice of such intention
is sent by Landlord to Tenant. Landlord may bring suits for amounts owed by Tenant hereunder or any portions thereof, as the same accrue
or after the same have accrued, and no suit or recovery of any portion due hereunder shall be deemed a waiver of Landlord&rsquo;s right
to collect all amounts to which Landlord is entitled hereunder, nor shall the same serve as any defense to any subsequent suit brought
for any amount not therefor reduced to judgment. Landlord may pursue one or more remedies against Tenant and need not make an election
of remedies except as required by applicable law. All rent and other consideration paid by any replacement tenants shall be applied at
Landlord&rsquo;s option: (i)&nbsp;first, to the Costs of Reletting, (ii)&nbsp;second, to the payment of all costs of enforcing this Lease
against Tenant or any guarantor, (iii)&nbsp;third, to the payment of all interest and service charges accruing hereunder, (iv)&nbsp;fourth,
to the payment of Rent theretofore accrued, and (v)&nbsp;with the residue, if any, to be held by Landlord and applied to the payment
of Rent and other obligations of Tenant as the same become due (and with any remaining residue to be retained by Landlord). &ldquo;Costs
of Reletting&rdquo; shall include without limitation, all costs and expenses incurred by Landlord for any repairs or other matters described
in Paragraph (b)&nbsp;above, brokerage commissions, advertising costs, attorneys&rsquo; fees, any economic incentives given to enter
leases with replacement tenants, and costs of collecting rent from replacement tenants. Landlord shall be under no obligation to observe
or perform any provision of this Lease on its part to be observed or performed which accrues while Tenant is in default hereunder. The
times set forth herein for the curing of defaults by Tenant are of the essence of this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;26.
LANDLORD&rsquo;S DEFAULT; RIGHT TO CURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;If
Landlord shall fail to perform any obligation under this Lease required to be performed by Landlord, Landlord shall not be deemed to
be in default hereunder nor subject to any claims for damages of any kind, unless such failure shall have continued for a period of thirty
(30) days after written notice thereof by Tenant (provided, if the nature of Landlord&rsquo;s failure is such that more time is reasonably
required in order to cure, Landlord shall not be in default if Landlord commences to cure within such thirty (30) day period and thereafter
diligently seeks to cure such failure to completion).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;Upon
the occurrence of any event of default by Landlord after the expiration of any applicable cure and grace period, Tenant shall have all
rights and remedies to the extent permitted by law or in equity, which be distinct, separate and cumulative to the extent permitted by
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;27.
WAIVER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The failure or
delay on the part of Landlord or Tenant to enforce or exercise at any time any of the provisions, rights or remedies in the Lease shall
in no way be construed to be a waiver thereof, nor in any way to affect the validity of this Lease or any part hereof, or the right of
the Landlord or Tenant to thereafter enforce each and every such provision, right or remedy. No waiver of any breach of this Lease shall
be held to be a waiver of any other or subsequent breach. The receipt by Landlord of lesser amount than the Rent due at a time when the
rent is in default under this Lease shall not be construed as a waiver of such default. The receipt by Landlord of a lesser amount than
the Rent due shall not be construed to be other than a payment on account of the Rent then due, nor shall any statement on Tenant's check
or any letter accompanying Tenant's check be deemed an accord and satisfaction and Landlord may accept such payment without prejudice
to Landlord's right to recover the balance of the rent due or to pursue any other remedies provided in this Lease. No act or thing done
by Landlord or Landlord's agents or employees during the term of this Lease shall be deemed an acceptance of a surrender of the Premises,
and no agreement to accept such a surrender shall be valid unless in writing and signed by Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;28.
UTILITY DEREGULATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Landlord has advised
Tenant that various utility companies (each to be referred to herein as a &ldquo;Current Service Provider&rdquo;) are the utility companies
selected by Landlord to provide service for the Development. Notwithstanding the foregoing, if permitted by law, Landlord shall have
the right at any time and from time to time during the term of this Lease to either contract for service from a different company or
companies providing service (each such company shall hereinafter be referred to as an &ldquo;Alternate Service Provider&rdquo;) or continue
to contract for service from the Current Service Provider.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tenant shall cooperate
with Landlord, the Current Service Providers, and any Alternate Service Provider as reasonably necessary, and shall allow Landlord, the
Current Service Providers, and any Alternate Service Provider reasonable access to the Building&rsquo;s lines, feeders, risers, wiring,
and other machinery within the Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Unless caused by
the willful misconduct or negligence of Landlord, its agents or employees, Landlord shall in no way be liable or responsible for any
loss, damage, or expense that Tenant may sustain or incur by reason of any failure, interference, disruption, or defect in the supply
of utility services furnished to the Premises, or of any change in the quality or character of the utility services supplied by the Current
Service Providers or any Alternate Service Provider, and no such change, failure, defect, unavailability, or unsuitability shall constitute
an actual or constructive eviction, in whole or in part, or entitle Tenant to any abatement or diminution of rent, or relieve Tenant
from any of its obligations under this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;29.
TELECOMMUNICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;
<U>Telephone Lines</U>. Subject to Landlord&rsquo;s continuing right of supervision and approval (not to be unreasonably withheld), and
the other provisions hereof, Landlord shall: (i)&nbsp;install telephone lines (&ldquo;Lines&rdquo;) connecting the Premises to Landlord&rsquo;s
terminal block on the floor or floors on which the Premises are located, or (ii)&nbsp;use such Lines as may currently exist and already
connect the Premises to such terminal block. Landlord&rsquo;s predecessor or independent contractor has heretofore connected such terminal
block through riser system Lines to Landlord&rsquo;s main distribution frame (&ldquo;MDF&rdquo;) for the Property. Landlord disclaims
any representations, warranties or understandings concerning the capacity, design or suitability of Landlord&rsquo;s riser Lines, MDF
or related equipment. If there is, or will be, more than one tenant on any floor, at any time, Landlord may allocate, and periodically
reallocate, connections to the terminal block based on the proportion of square feet each tenant occupies on such floor, or the type
of business operations or requirements of such tenants, in Landlord&rsquo;s reasonable discretion. Landlord may arrange for an independent
contractor to review Tenant&rsquo;s request for approval hereunder, monitor or supervise Tenant&rsquo;s installation, connection and
disconnection of Lines, and provide other such services, or Landlord may provide the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;
<U>Installation</U>. Landlord shall install Tenant&rsquo;s Lines and make connections and disconnection at the terminal blocks as described
above, and Landlord shall use an experienced and qualified contractor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&nbsp;
<U>Limitation of Liability</U>. Unless due solely to Landlord&rsquo;s intentional misconduct or negligent acts, Landlord shall have no
liability for damages arising, and Landlord does not warrant that the Tenant&rsquo;s use of the Lines will be free, from the following
(collectively called &ldquo;Line Problems&rdquo;): (i)&nbsp; any eavesdropping, wire-tapping or theft of long distance access codes by
unauthorized parties, (ii)&nbsp;any failure of the Lines to satisfy Tenant&rsquo;s requirements, or (iii)&nbsp;any capacitance, attenuation,
cross-talk or other problems with the Lines, any misdesignation of the Lines in the MDF room or wire closets, or any shortages, failures,
variations, interruptions, disconnections, loss or damage caused by or in connection with the installation, maintenance, replacement,
use or removal of any other Lines or equipment at the Development by or for other tenants at the Development, by any failure of the environmental
conditions at or the power supply for the Development to conform to any requirements of the Lines or any other problems associated with
any Lines or by any other cause. Unless due solely to Landlord&rsquo;s willful misconduct or negligent acts, under no circumstances shall
any Line Problems be deemed an actual or constructive eviction of Tenant, render Landlord liable to Tenant for abatement of any rent
or other charges under the Lease, or relieve Tenant from performance of Tenant&rsquo;s obligations under the Lease. Landlord in no event
shall be liable for damages by reason of loss of profits, business interruption or other consequential damage arising from any Line Problems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;30.
SURRENDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Lease shall
terminate and Tenant shall deliver up and surrender possession of the Premises on the last day of the term hereof, and Tenant waives
the right to any notice of termination or notice to quit and Tenant hereby waives all right to any such notice as may be provided under
any laws now or hereafter in effect in Pennsylvania, including but not limited to the Landlord and Tenant Act of 1951, as amended. Tenant
covenants that upon the expiration or sooner termination of this Lease Tenant shall deliver up and surrender possession of the Premises
in the same condition in which Tenant has agreed to keep the same during the continuance of this Lease and in accordance with the terms
hereof, ordinary wear and tear and damage from casualty or condemnation excepted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;31.
QUIET ENJOYMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Landlord covenants
and agrees that Tenant, upon paying the Rent herein provided for and observing and keeping the covenants, agreements and conditions on
its part to be kept, shall lawfully and quietly hold, occupy and enjoy the Premises during the Lease without hindrance or interruption
by Landlord or anyone claiming by, through or under Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;32.
HOLDING OVER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Unless Landlord
expressly agrees otherwise in writing, Tenant shall pay Landlord 150% of the amount of Rent then applicable prorated on a per diem basis
for each day Tenant shall fail to vacate or surrender possession of the Premises or any part thereof after expiration or earlier termination
of this Lease as required under Article&nbsp;30, together with all damages sustained by Landlord on account thereof. Tenant shall pay
such amounts on demand, and, in the absence of demand, monthly in advance. The foregoing provisions, and Landlord&rsquo;s acceptance
of any such amounts, shall not serve as permission for Tenant to hold-over, nor serve to extend the term (although Tenant shall remain
a tenant at sufferance bound to comply with all provisions of this Lease until Tenant properly vacates the Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;33.
ENVIRONMENTAL COVENANTS, REPRESENTATIONS AND WARRANTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;Tenant
shall comply with all laws, regulations, ordinances and other governmental standards applicable to Tenant's use of the Premises with
respect to hazardous waste, hazardous substances and any and all other environmental matters. Furthermore, Tenant shall procure and maintain
all licenses and permits required by such applicable laws, ordinances or regulations. Tenant covenants and agrees that it shall not release,
emit, or discharge at or from the Premises any hazardous or toxic substances consisting of any hazardous or toxic chemical, waste, byproduct,
pollutants, contamination, compound, product or substance, including, without limitation, asbestos, polychlorinated byphenyls, petroleum
(including crude oil or any fraction thereof), and any material the exposure to, or manufacture, possession, presence, use, generation,
storage, transportation, treatment, release, disposal, abatement, cleanup, removal, remediation or handling of which, is prohibited,
controlled or regulated by federal, state, regional, county, local, governmental, public or private statute, law, regulation, ordinance,
order, consent decree, judgment, permit, license, code, covenant, deed restrictions, common law, treaty, convention or other requirement,
pertaining to protection of the environmental, health or safety of persons, natural resources, conservation, wildlife, waste management,
any hazardous material activity, and pollution (including, without limitation, regulation of releases and disposals to air, land, water
and ground water). These requirements include, without limitation, the Comprehensive Environmental Response, Compensation and Liability
Act of 1980, as amended by the Superfund Amendments and Reauthorization Act of 1986, 42 U.S.C. 9601 et seq., Solid Waste Disposal Act,
as amended by the Resource Conservation and Recovery Act of 1976 and Solid and Hazardous Waste Amendments of 1984, 42 U.S.C. 6901 et
seq., Federal Water Pollution Control Act, as amended by the Clean Water Act of 1977, 33 U.S.C. 1251, et seq., Clean Air Act of 1966,
as amended, 42 U.S.C. 7401 et seq., Toxic Substances Control Act of 1976, 15 U.S.C. 2601 et seq., Occupational Safety and Health Act
of 1970, as amended, 29 U.S.C. 651 et seq., Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. 11001 et seq., National
Environmental Policy Act of 1975, 42 U.S.C. 300(f)&nbsp;et seq., and any similar or implementing Pennsylvania laws, and all amendments,
rules, regulations, guidance documents and publications promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;In
the event Tenant receives any notice of the happening of: (1)&nbsp;any event arising from Tenant&rsquo;s use or occupancy of the Premises
involving an emission, spill, release or discharge at or from the Premises into or upon (i)&nbsp;the air; (ii)&nbsp;soils (whether on
the Premises or neighboring property) or any improvements located thereon; (iii)&nbsp;surface water or ground water; (iv)&nbsp;the sewer
system servicing the Premises, except as allowed under current law, regulation or permit, of any regulated quantities of toxic or hazardous
substances or wastes (intended hereby and hereafter to include any and all such materials listed in any federal, state or local law,
code and ordinances and all rules&nbsp;and regulations promulgated thereunder, as hazardous) (any of which is hereinafter referred to
as &quot;Hazardous Discharge&quot;); or (2)&nbsp;any complaint, order, directive, claim, citation or notice by any governmental authority
or any other person or entity arising from Tenant&rsquo;s use or occupancy of the Premises with respect to (i)&nbsp;air emissions; (ii)&nbsp;spills,
releases or discharges to soils or any improvements located thereon, surface water, ground water or the sewer, septic system or waste
treatment, storage or disposal system servicing the Premises; (iii)&nbsp;solid or liquid waste disposal; (iv)&nbsp;the use, generation,
storage, transportation or disposal of toxic or hazardous substances or wastes; or (v)&nbsp;any other environmental, health or safety
matter relating to any of Tenant's activity upon the Premises, including any improvements located thereon or neighboring property (any
of which is hereinafter referred to as an &quot;Environmental Complaint&quot;), then Tenant shall give immediate notice of same to Landlord,
detailing all relevant facts and circumstances. Tenant shall, upon receipt of notice of a Hazardous Discharge or Environmental Complaint
with respect to the Premises or Tenant&rsquo;s use thereof, and at its sole cost and expense, promptly and completely take all actions
necessary to remove, resolve or minimize the impact of such Hazardous Discharge or Environmental Complaint with respect to the Premises
or Tenant&rsquo;s use thereof, and restore the affected property to its prior condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Without
limitation on the foregoing, and in the event Tenant fails to take the actions set forth herein (to the extent Tenant is obligated to
do so), Landlord shall have the right, but not the obligation, to enter onto the Premises and take any actions as it deems necessary
or advisable to clean up, remove, resolve or minimize the impact or otherwise deal with any Hazardous Discharge or Environmental Complaint
upon Landlord's receipt of any notice from any person or entity asserting the happening of a Hazardous Discharge or Environmental Complaint
on or from or pertaining to the Premises and arising from Tenant&rsquo;s use or occupancy of the Premises. All reasonable costs and expenses
incurred by Landlord in the exercise of any such rights shall be deemed to be additional rent hereunder and shall be immediately payable
by Tenant to Landlord upon demand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&nbsp;Tenant,
its successors and assigns, shall forever indemnify, defend and hold harmless Landlord, its partners, members, directors, officers, employees
and agents, and successors and assigns from and against all damages, punitive damages, liabilities, losses, demands, claims, cost recovery
actions, lawsuit, administrative proceedings, orders, response costs, compliance costs, investigation expenses, consultant fees, attorneys'
fees and litigation expenses, arising from Tenant's use of the Premises, including (1)&nbsp;possession, use and storage of any hazardous
material at the Premises; (2)&nbsp;the operation of any applicable environmental law against the Tenant, Landlord or the Premises, based
on Tenant's activities during the term of this Lease; or (3)&nbsp;the violation at the Premises or by the Tenant of any applicable environmental
law. Tenant and its successors or assigns shall pay all costs and expenses incurred by Landlord, its successors and assigns, to enforce
the provisions of this indemnification, including, without limitation, reasonable attorneys' fees and litigation expenses. This indemnification
shall survive the termination of this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&nbsp;
As between Landlord and Tenant only, Landlord shall be responsible for (i)&nbsp;the remediation of any hazardous materials or substances
located on the Development, the Building, or any part thereof (including the Premises), existing as of the Commencement Date (except
to the extent caused by Tenant or its agents, employees or contractors), (ii)&nbsp;any violations of environmental laws existing as of
the Commencement Date (except to the extent caused by Tenant or its agents, employees or contractors), (iii)&nbsp;the remediation of
any hazardous materials or substances located on the Development, the Building, or any part thereof (including the Premises), existing
as of the Commencement Date and, after the Commencement Date, to the extent caused by Landlord or its agents, employees or contractors,
or other tenants of the Building (i.e. to pursue Landlord&rsquo;s enforcement rights against such other tenants), or (iv)&nbsp;any violations
of environmental laws arising on or after the Commencement Date to the extent caused by Landlord or its agents, employees or contractors
or other tenants of the Building (i.e. to pursue Landlord&rsquo;s enforcement rights against such other tenants).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord
represents and warrants to Tenant, to the best of its knowledge, as of the Commencement Date, it has received no written notice from
any applicable governmental authority regarding the existence of hazardous materials on or about the Premises or the Development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;34.
TENANT&rsquo;S COMPLIANCE WITH LAWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tenant shall comply
with all governmental laws, ordinances and regulations applicable to Tenant's occupancy and use of the Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;35.
DISABILITIES ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tenant shall comply,
at Tenant&rsquo;s sole cost and expense, with the Americans with Disabilities Act of 1990 and similar state and local laws and ordinances,
as well as all regulations issued thereunder, but only if the need for compliance is caused in whole or material part by reason of the
specific nature of Tenant&rsquo;s business operations in the Premises or specific accommodation to Tenant&rsquo;s employees. Except as
set forth in the preceding sentence, Landlord shall cause the Premises and common areas of the Development to comply, at Landlord&rsquo;s
sole cost, or at another tenant&rsquo;s sole cost, or as an Operating Cost subject to pass-through hereunder, with the Americans with
Disabilities Act of 1990 and similar state and local laws and ordinances, as well as all regulations issued thereunder. Tenant shall
promptly advise Landlord in writing, and provide Landlord with copies of any notice received by Tenant alleging violation of any such
law, regulation or ordinance relating to the Premises or the Building or any use thereof or activity therein, or any governmental or
regulatory action or investigation instituted or threatened regarding noncompliance with any such law, regulation or ordinance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;36.
NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Wherever in this
Lease it shall be required or permitted that notice or demand be given or served by either party to this Lease to or on the other party,
such notice or demand shall be deemed to have been duly given or served if in writing and either personally served or forwarded by Federal
Express or comparable delivery service or by registered or certified mail, charges prepaid, and addressed as set forth in Article&nbsp;1
to the applicable Notification Addresses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Each such mailed
notice shall be deemed to have been given to or served upon the party to which addressed (i)&nbsp;on the date of delivery if personally
served, (ii)&nbsp;one business day after the date the same is deposited with the express service, or (iii)&nbsp;three business days after
the date the same is deposited with the postal service, properly addressed in the manner above provided. Either party hereto may change
the address to which such notices shall be delivered or mailed by giving written notice of such change to the other party hereto, as
herein provided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;37.
BROKERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Each party represents
and warrants to the other that TARQUINCoRE, LLC has acted as the only broker or agent in connection with the finding and negotiation
of this Lease. Landlord shall be responsible for payment of commissions or fees due such brokers in accordance with the terms of Landlord's
written listing agreement with such agent. Each party agrees to indemnify and hold harmless the other from and against any claims, suits,
liabilities and expenses incurred by or assessed by reason of any undisclosed brokerage or agency arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;38.
FORCE MAJEURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Neither party shall
be required to perform any term, condition or covenant of this Lease as long as such performance is delayed or prevented by force majeure,
which shall mean Acts of God, strikes, lockouts, material or labor restrictions imposed by governmental authority, civil riot, floods
and other causes not reasonably within the control of such party and which, by the exercise of due diligence, such party is unable, wholly
or in part, to prevent or overcome; provided, however, that such party shall be required to commence and thereafter diligently prosecute
performance of completion to the extent reasonably permitted under the circumstances. Notwithstanding anything herein to the contrary,
the foregoing shall not excuse either party from the payment of any monies due pursuant to the terms of this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;39.
TRANSFER OF LANDLORD'S INTEREST</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Landlord's obligations
hereunder shall be binding upon Landlord only for the period of time that Landlord is in ownership of the Building; and, upon termination
of that ownership, Tenant, except as to any obligations which have then matured or relate to an event occurring prior to the transfer,
any breach occurring prior to the transfer, or any tort or fraud committed prior to the transfer, shall look solely to Landlord's successor
in interest in the Building for the satisfaction of each and every obligation of Landlord hereunder. Tenant agrees to attorn to any transferee
of Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;40.
SUCCESSORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The respective
rights and obligations provided in this Lease shall bind and shall inure to the benefit of the parties hereto and their respective successors
and assigns, provided, however, that no rights shall inure to the benefit of any successors of Tenant whenever, by the express terms
of this Lease, Landlord's written consent for the transfer to such successor is required under Article&nbsp;14 hereof, unless Landlord
shall have granted such consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;41.
GOVERNING LAW</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This Lease shall
be construed, governed and enforced in accordance with the laws of the Commonwealth of Pennsylvania and the exclusive venue for any action
shall be in the Court of Common Pleas of Allegheny County, Pennsylvania.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;42.
SEPARABILITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If any provisions
of this Lease shall be held to be invalid, void or unenforceable, the remaining provisions hereof shall in no way be affected or impaired
and such remaining provisions shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;43.
CAPTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Any headings preceding
the text of the several paragraphs and subparagraphs hereof are inserted solely for convenience of reference and shall not constitute
a part of this Lease, nor shall they affect its meaning, construction or effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;44.
GENDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">As used in this
Lease, the word &quot;person&quot; shall mean and include, where appropriate, any individual, corporation, partnership or other entity;
the plural shall be substituted for the singular, and the singular for the plural, where appropriate; and words of any gender shall mean
to include any other gender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;45.
EXECUTION; COUNTERPARTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This Lease shall
become effective when it has been signed by a duly authorized officer or representative of each of the parties and delivered to the other
party. This Lease may be executed in any number of counterparts, each of which when taken together shall be deemed to be one and the
same instrument. The parties acknowledge and agree that notwithstanding any law or presumption to the contrary, the exchange of copies
of this Lease and signature pages&nbsp;by electronic transmission shall constitute effective execution and delivery of this Lease for
all purposes, and signatures of the parties hereto transmitted electronically shall be deemed to be their original signature for all
purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;46.
ENTIRE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This Lease, including
the Exhibits hereto, contains all the agreements, conditions, understandings, representations and warranties made between the parties
hereto with respect to the subject matter hereof, and may not be modified orally or in any manner other than by an agreement in writing
signed by both parties hereto or their respective successors in interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;47.
AUTHORITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If Tenant is a
corporation, association, partnership or similar legal entity, the Tenant represents and warrants that the individual signing this Lease
is duly authorized to execute and deliver this Lease on behalf of such entity in accordance with the duly adopted authorizing instruments
of such entity which have been adopted or approved in accordance with all legal requirements and the internal bylaws, agreements, or
other organizing documents of the entity, and that this Lease is binding upon such entity in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If Landlord is
a corporation, association, partnership or similar legal entity, The Landlord represents and warrants that the individual signing this
Lease is duly authorized to execute and deliver this Lease on behalf of such entity in accordance with the duly adopted authorizing instruments
of such entity which have been adopted or approved in accordance with all legal requirements and the internal bylaws, agreements, or
other organizing documents of the entity, and that this Lease is binding upon such entity in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;48.
SECURITY DEPOSIT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Upon execution
of this Lease, Tenant shall deposit with Landlord the Security Deposit in the amount set forth in Article&nbsp;1. The Security Deposit
shall be held by Landlord as security for the full and faithful performance by Tenant of all of the terms, covenants and provisions of
this Lease during the term hereof. In no event shall Landlord be obligated to pay, or Tenant is entitled to receive, any interest or
other earnings on the security deposit. Landlord shall not be obligated to hold the Security Deposit in trust or in a separate account
but may freely commingle the security deposit with Landlord&rsquo;s other funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">In the event Tenant
fails to keep and perform any of the terms, covenants or provisions of this Lease, then Landlord, at Landlord&rsquo;s option, may appropriate
and apply the Security Deposit, or so much thereof as may be necessary to pay any Rent or other sums due hereunder for which Tenant shall
be in default of payment. Tenant, upon notice from Landlord, immediately shall remit to Landlord an amount sufficient to restore this
Security Deposit to the amount required to be maintained in accordance with this Article. Upon Tenant&rsquo;s full and complete performance
and compliance with all of the terms, covenants and provisions of this Lease during the lease term, upon the expiration of the term and
Tenant&rsquo;s proper surrender of the Premises, the Security Deposit shall be returned to Tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">In the event of
a sale of the Building, Landlord may deliver the Security Deposit to the purchaser, and upon such delivery, Landlord shall be discharged
from any further liability with respect to the Security Deposit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARTICLE&nbsp;49.
OFAC CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tenant certifies
that: (i)&nbsp;it is not acting, directly or indirectly, for or on behalf of any person, group, entity, or nation named by any Executive
Order or the United States Treasury Department as a terrorist, &ldquo;Specially Designated National and Blocked Person,&rdquo; or other
banned or blocked person, entity, nation, or transaction pursuant to any law, order, rule, or regulation that is enforced or administered
by the Office of Foreign Assets Control; and (ii)&nbsp;it is not engaged in this transaction, directly or indirectly on behalf of, or
instigating or facilitating this transaction, directly or indirectly on behalf of, any such person, group, entity, or nation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF,
the parties, intending to be legally bound, have executed this Lease as of the day and year first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">ATTEST:</FONT></TD>
  <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"><B>COGNITION THERAPEUTICS,&nbsp;INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;</TD>
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">/s/ Lisa Ricciardi</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-size: 10pt">Name: <U>Lisa Ricciardi</U></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-size: 10pt">Title: <U>Chief Executive Officer</U></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">ATTEST:</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"><B>RJ EQUITIES LP</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By: RD Equities, LLC, its General
    Partner</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">/s/ Ronald J. Tarquinio</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Name: Ronald
    J. Tarquinio</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-size: 10pt">Title: Member</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;&quot;A&quot;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Diagram of Development</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;<IMG SRC="tm2226999d4_ex10-29img01.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;&quot;B&quot;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Outline of Premises</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;&quot;C&quot;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Rules&nbsp;and Regulations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>GENERAL:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>OBSTRUCTIONS:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">The streets,
driveways, parking lots, sidewalks, entrances, passages and other common areas provided by Landlord shall not be obstructed by Tenant,
its employees, agents, representatives, vendors and guests or used for any other purpose than ingress and egress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>BATHROOMS:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">The
bathrooms, toilet rooms and other plumbing apparatus shall not be used for any other purposes other than those for which they are
constructed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>GENERAL PROHIBITIONS:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No
                                            cooking, grilling, smoking, gas or other type of flame in the common areas;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No
                                            animals or birds are permitted anywhere on the premises;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No
                                            use of the premises as sleeping rooms;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No
                                            loitering or congregating in the entrances or hallways;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No
                                            making improper loud noises or disturbances of any kind;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Doing
                                            anything to unreasonably disturb or disrupt other tenants in the complex;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Doing
                                            anything to change, damage or destroy the landscaping around the premises;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>SMOKING:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">The complex&rsquo;s
buildings are maintained as <B>smoke free</B> environments. This means <B>no smoking </B>in the building. Smoking is permitted outside
of the buildings where several smoking boxes are provided in four designated areas for cigarette butts. Please use the smoking boxes
for your butts, not the grounds or parking areas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>DOORS:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">Exterior
doors are not to be held open. Holding or propping these doors open for 30 seconds or more will sound off an alarm and automatically
notify police.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>PARKING:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">To insure that
adequate parking spaces are available for our tenants, a specific number of parking passes are provided to each tenant for a specific
parking zone. The passes are to be placed on the rear view mirror of each vehicle and can be transferred from one vehicle to another.
The parking lots are patrolled daily. Vehicles that lack a parking pass or are parked in the wrong zone will be considered in violation
of the parking regulations. Violations are handled as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>First
Violation</U></B></FONT><FONT STYLE="font-size: 10pt">:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A yellow sticker will be placed
under the windshield wiper;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Second
Violation</U></B></FONT><FONT STYLE="font-size: 10pt">:&#8239;&#8239;&#8239;An adhesive yellow sticker will be placed on the windshield;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Third
Violation</U></B></FONT><FONT STYLE="font-size: 10pt">:&#8239;&#8239;&#8239;&#8239;&#8239;The police will be called and the car will be towed, at the owner&rsquo;s
expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">These rules&nbsp;and
regulations are subject to change from time to time at the discretion of the Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;&quot;D&quot;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Cleaning Specifications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Daily Services (4 nights/week) will
consist of the following:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Perform all high dusting where required.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Empty waste receptacles ensuring to
                                            remove waste to building designated location.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Replace liners in receptacles as required.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Spot clean all door glass, doors, door
                                            frames and light switches.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Damp wipe all window sills, ledges
                                            and countertops.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">6.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Wash all tabletops and chair seating
                                            using a food service degreaser.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">7.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Clean and scour sinks in kitchen.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">8.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Spot clean the exterior of all appliances.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">9.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Dust mop and damp mop hard surface
                                            floors.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">10.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Vacuum carpeting traffic lanes and
                                            other soiled areas.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">11.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Vacuum all carpeting, ensuring to
                                            maintain corners, edges and under desks by moving light furniture. (Weekly)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">12.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Damp wipe rosewood baseboards. (Monthly)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">13.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Damp wipe rubber baseboards. (Quarterly)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">14.</FONT></TD><TD><FONT STYLE="font-size: 10pt">Spot clean carpeting as required.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;&quot;E&quot;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">ESTOPPEL CERTIFICATE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>TENANT ESTOPPEL</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">__________
__, 202__</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">________________________<BR>
________________________&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Ladies and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
undersigned certifies to ___________________________ (together with its successors and assigns, the &ldquo;Bank&rdquo;) and the Landlord
(as defined below) as of the date hereof as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;It
is the tenant under a certain Office Lease Agreement dated ______________________ (the &ldquo;Lease&rdquo;) with RJ Equities, LP, a Pennsylvania
limited partnership, as landlord (together with its successors and assigns, &ldquo;Landlord&rdquo;), and the undersigned, as tenant (&ldquo;Tenant&rdquo;),
for premises located at and known as _______________________________________________________ (the &ldquo;Leased Premises&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Lease is in full force and effect. There are no amendments, modifications or supplements to the Lease except the following (if none,
indicate &ldquo;None&rdquo;):<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Lease does not contain any provisions regarding options to purchase and/or lease additional space, rights of first refusal to purchase
and/or lease additional space or any similar provisions regarding acquisition of ownership interests or additional leases space in the
building. If such provisions are contained in the Lease please specify:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
term of the Lease commenced on __________________ and terminates on _____________________. Tenant has taken possession of the Leased
Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
monthly base rent payments currently payable pursuant to the Lease are in the amount of $______________________. Rent has been paid through
_________________________. In addition to the monthly base rent payments, the following amounts are also payable on a monthly basis for
the following purposes, all of which have been paid through _________________________ (if none, indicate &ldquo;None&rdquo;):&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
improvements, if any, required to be made by Landlord under the Lease have been completed and accepted by Tenant. Landlord has not agreed
to grant Tenant any free rent or rent rebate or to make any contribution to tenant improvements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
advance rent has been paid, and to Tenant&rsquo;s knowledge, Tenant has no unsatisfied claims against Landlord, no uncured default exists
under the Lease, and no event has occurred that but for the giving of notice would constitute a default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
prepayment of more than one month&rsquo;s rent shall be made without the Bank&rsquo;s written consent and approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
has all licenses and permits which Tenant must have to operate its business from the Leased Premises, and all are current and have not
been revoked. Since taking possession of the Leased Premises, Tenant has not received any notice that the Leased Premises or Tenant&rsquo;s
use of the Leased Premises violates any applicable law, regulation, ordinance or directive of any governmental authority or agency or
insurance company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
amount of the security deposit is $0.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
undersigned individual hereby certifies that he or she is duly authorized to sign, acknowledge and deliver this letter on behalf of Tenant.
The statements herein contained may be relied upon by the Bank and the Landlord and their respective successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(Print
Name of Tenant)</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 2%; font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 3%">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT&nbsp;&ldquo;F&rdquo;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">SUBORDINATION, NON-DISTURBANCE
AND ATTORNMENT AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>SUBORDINATION,
NON-DISTURBANCE</U></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>AND ATTORNMENT
AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
Subordination, Non-Disturbance and Attornment Agreement (this &ldquo;Agreement&rdquo;) is made as of the _____ day of __________, 20__,
among ___________________________ (the &ldquo;Lender&rdquo;), ___________________________, R.J. Equities LP (the &ldquo;Landlord&rdquo;
or &ldquo;Borrower&rdquo;), a Pennsylvania limited partnership having a place of business at 2403 Sidney Street, Suite&nbsp;200, Pittsburgh,
PA 15203, and _________________________ (the &ldquo;Tenant&rdquo;), having a place of business at ________________.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Introductory
Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Lender
is relying on this Agreement as an inducement to Lender in making and maintaining a loan (the &ldquo;Loan&rdquo;) secured by, among other
things, a Mortgage and Security Agreement dated as of ______________________ (the &ldquo;Mortgage&rdquo;) given by Borrower covering
property commonly known as and numbered ________________________ (the &ldquo;Property&rdquo;). Lender is also the &ldquo;Assignee&rdquo;
under an Assignment of Leases, Rents and Profits (the &quot;Assignment&quot;) dated as of _________________ from Borrower with respect
to the Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Tenant is the tenant under that certain lease (the &ldquo;Lease&rdquo;) dated ________, 20__, made with Landlord covering certain
premises (the &ldquo;Premises&quot;) at the Property as more particularly described in the Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Lender
requires, as a condition to the making and maintaining of the Loan, that the Mortgage be and remain superior to the Lease and that its
rights under the Assignment be recognized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
requires as a condition to the Lease being subordinate to the Mortgage that its rights under the Lease be recognized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Lender,
Landlord, and Tenant desire to confirm their understanding with respect to the Mortgage and the Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, in consideration of the foregoing, the mutual covenants and agreements contained in this Agreement, and other valuable consideration,
the receipt and adequacy of which are hereby acknowledged, and with the understanding by Tenant that Lender shall rely hereon in making
and maintaining the Loan, Lender, Landlord, and Tenant agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Subordination</U>.
                                            The Lease and the rights of Tenant thereunder is subordinate and inferior to the Mortgage
                                            and any amendment, renewal, substitution, extension or replacement thereof and each advance
                                            made thereunder as though the Mortgage, and each such amendment, renewal, substitution, extension
                                            or replacement were executed and recorded, and the advance made, before the execution of
                                            the Lease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Non-Disturbance</U>.
                                            So long as Tenant is not in default (beyond any notice and/or cure period expressed in the
                                            Lease within which Tenant may cure such default) in the payment of rent or in the performance
                                            or observance of any of the terms, covenants or conditions of the Lease on Tenant&rsquo;s
                                            part to be performed or observed: (a)&nbsp;Tenant&rsquo;s occupancy of the Premises shall
                                            not be disturbed by Lender in the exercise of any of its rights under the Mortgage during
                                            the term of the Lease, or any extensions or renewals thereof made in accordance with the
                                            terms of the Lease, and (b)&nbsp;Lender will not join Tenant as a party defendant in any
                                            action or proceeding for the purpose of terminating Tenant&rsquo;s interest and estate under
                                            the Lease because of any default under the Mortgage.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Attornment
                                            and Certificates</U>. In the event Lender succeeds to the interest of Borrower as Landlord
                                            under the Lease, or if the Property or the Premises are sold pursuant to the power of sale
                                            under the Mortgage, Tenant shall attorn to Lender, or a purchaser upon any such foreclosure
                                            sale, and shall recognize Lender, or such purchaser, thereafter as the Landlord under the
                                            Lease. Such attornment shall be effective and self-operative without the execution of any
                                            further instrument. Tenant agrees, however, to execute and deliver at any time and from time
                                            to time, upon the request of any holder(s)&nbsp;of any of the indebtedness or other obligations
                                            secured by the Mortgage, or upon request of any such purchaser, (a)&nbsp;any instrument or
                                            certificate which, in the reasonable judgment of such holder(s), or such purchaser, may be
                                            necessary or appropriate in any such foreclosure proceeding or otherwise to evidence such
                                            attornment and (b)&nbsp;an instrument or certificate regarding the status of the Lease, consisting
                                            of statements, if true (and if not true, specifying in what respect): (i)&nbsp;that the Lease
                                            is in full force and effect, (ii)&nbsp;the date through which rentals have been paid, (iii)&nbsp;the
                                            duration and date of the commencement of the term of the Lease, (iv)&nbsp;the nature of any
                                            amendments or modifications to the Lease, (v)&nbsp;that to Tenant&rsquo;s knowledge no default,
                                            or state of facts, which with the passage of time or notice, or both, would constitute a
                                            default, exists on the part of either party to the Lease, and (vi)&nbsp;the dates on which
                                            payments of additional rent, if any, are due under the Lease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Limitations</U>.
                                            If Lender exercises any of its rights under the Assignment or the Mortgage, or if Lender
                                            shall succeed to the interest of Landlord under the Lease in any manner, or if any purchaser
                                            acquires the Property, or the Premises, upon or after any foreclosure of the Mortgage, or
                                            any deed in lieu thereof, Lender or such purchaser, as the case may be, shall have the same
                                            remedies by entry, action or otherwise in the event of any default by Tenant (beyond any
                                            notice and/or cure period expressed in the Lease within which Tenant may cure such default)
                                            in the payment of rent or in the performance or observance of any of the terms, covenants
                                            and conditions of the Lease on Tenant&rsquo;s part to be paid, performed or observed that
                                            Landlord had or would have had if Lender or such purchaser had not succeeded to the interest
                                            of the present Landlord. From and after any such attornment, Lender or such purchaser shall
                                            be bound to Tenant under all the terms, covenants and conditions of the Lease, and Tenant
                                            shall, from and after such attornment to Lender, or to such purchaser, have the same remedies
                                            against Lender, or such purchaser, for the breach of an agreement contained in the Lease
                                            that Tenant might have had under the Lease against Landlord, if Lender or such purchaser
                                            had not succeeded to the interest of Landlord; <U>provided</U>, <U>however</U>, that Lender
                                            or such purchaser shall only be bound during the period of its ownership, and that in the
                                            case of the exercise by Lender of its rights under the Mortgage, or the Assignment, or any
                                            combination thereof, or a foreclosure, or deed in lieu of foreclosure, all Tenant claims
                                            shall be satisfied only out of the interest, if any, of Lender, or such purchaser, in the
                                            Property, and Lender and such purchaser shall not be: (a)&nbsp;liable for any act or omission
                                            of any prior landlord (including Landlord); or (b)&nbsp;liable for or incur any obligation
                                            with respect to the construction of the Property or any improvements of the Premises or the
                                            Property; or (c)&nbsp;subject to any offsets or defenses which Tenant might have against
                                            any prior landlord (including Landlord), or (d)&nbsp;bound by any rent or additional rent
                                            which Tenant might have paid for more than the then current rental period to any prior landlord
                                            (including Landlord); or (e)&nbsp;bound by any amendment or modification of the Lease, or
                                            any consent to any assignment or sublease, made without Lender&rsquo;s prior written consent;
                                            or (f)&nbsp;bound by or responsible for any security deposit not actually received by Lender;
                                            or (g)&nbsp;liable for any obligation with respect to any breach of warranties or representations
                                            of any nature under the Lease or otherwise, including without limitation, any warranties
                                            or representations respecting use, compliance with zoning, Landlord&rsquo;s title, Landlord&rsquo;s
                                            authority, habitability and/or fitness for any purpose, or possession; or (h)&nbsp;liable
                                            for consequential damages.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Rights Reserved</U>.
                                            Nothing herein contained is intended, nor shall it be construed, to abridge or adversely
                                            affect any right or remedy of: (a)&nbsp;Landlord under the Lease, or any subsequent Landlord,
                                            against Tenant in the event of any default by Tenant (beyond any notice and/or cure period
                                            expressed in the Lease within which Tenant may cure such default) in the payment of rent
                                            or in the performance of observance of any of the terms, covenants or conditions of the Lease
                                            on Tenant&rsquo;s part to be performed or observed; or (b)&nbsp;Tenant to pursue claims under
                                            the Lease against any prior landlord (including Landlord) in the event of any default by
                                            prior landlord whether or not such claim is barred against Lender or a subsequent purchaser.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Notice and
                                            Right to Cure</U>. Tenant agrees to provide Lender with a copy of each notice of default
                                            given to Landlord under the Lease at the same time such notice of default is given to Landlord.
                                            In the event of any default by Landlord under the Lease, Tenant will take no action to terminate
                                            the Lease unless the default remains uncured for a period of sixty (60) days after written
                                            notice thereof shall have been given, postage prepaid, to Landlord at Landlord&rsquo;s address,
                                            and to Lender at the address provided in Section&nbsp;7 below; <U>provided</U>, <U>however</U>,
                                            that if any such default is such that it reasonably cannot be cured within such sixty (60)
                                            day period, such period shall be extended for such additional period of time as shall be
                                            reasonably necessary (including, without limitation, a reasonable period of time to obtain
                                            possession of the Property and to foreclose the Mortgage), if Lender gives Tenant written
                                            notice within such sixty (60) day period of Lender&rsquo;s election to undertake the cure
                                            of the default and if curative action (including, without limitation, action to obtain possession
                                            and foreclosure) is instituted within thirty (30) days thereafter and is thereafter diligently
                                            pursued. Notwithstanding the foregoing, Lender shall have no obligation to cure any default
                                            under the Lease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Notices</U>.
                                            Any notice or communication required or permitted hereunder shall be in writing, and shall
                                            be given or delivered: (a)&nbsp;by United States mail, registered or certified, postage fully
                                            prepaid, return receipt requested, or (b)&nbsp;by recognized courier service or recognized
                                            overnight delivery service; and in any event addressed to the party for which it is intended
                                            at its address set forth below:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 1in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To Lender:</Font></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 43%"></TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To Landlord:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RJ Equities LP</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2403 Sidney Street, Suite&nbsp;200</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pittsburgh, PA 15203</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Ronald J. Tarquinio</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To Tenant:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">or such
other address as such party may have previously specified by notice given or delivered in accordance with the foregoing. Any such notice
shall be deemed to have been given and received on the date delivered or tendered for delivery during normal business hours as herein
provided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>No Oral Change</U>.
                                            This Agreement may not be modified orally or in any manner other than by an agreement in
                                            writing signed by the parties hereto or their respective successors in interest.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Payment of
                                            Rent To Lender</U>. Tenant acknowledges that it has notice that the Lease and the rent and
                                            all sums due thereunder have been assigned to Lender as part of the security for the obligations
                                            secured by the Mortgage. In the event Lender notifies Tenant of a default under the Loan
                                            and demands that Tenant pay its rent and all other sums due under the Lease to Lender, Tenant
                                            agrees that it will honor such demand and pay its rent and all other sums due under the Lease
                                            to Lender, or Lender&rsquo;s designated agent, until otherwise notified in writing by Lender.
                                            Landlord unconditionally authorizes and directs Tenant to make rent payments directly to
                                            Lender following receipt of such notice without any obligation to further inquire as to whether
                                            or not any default exists under the Mortgage or the Assignment and that Landlord shall have
                                            no right or claim against Tenant for or by reason of any payments of rent or other charges
                                            made by Tenant to Lender following receipt of such notice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>No Amendment
                                            or Cancellation of Lease</U>. So long as the Mortgage remains undischarged of record, Tenant
                                            shall not amend, modify, cancel or terminate the Lease, or consent to an amendment, modification,
                                            cancellation or termination of the Lease, or agree to subordinate the Lease to any other
                                            mortgage, without Lender&rsquo;s prior written consent in each instance; provided however,
                                            the foregoing shall not be construed to require Lender&rsquo;s consent for Tenant to exercise
                                            any right to terminate expressly granted in the Lease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">11.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Options</U>.
                                            With respect to any options for additional space provided to Tenant under the Lease, Lender
                                            agrees to recognize the same if Tenant is entitled thereto under the Lease after the date
                                            on which Lender succeeds as landlord under the Lease by virtue of foreclosure or deed in
                                            lieu of foreclosure or Lender takes possession of the Premises; <U>provided</U>, <U>however</U>,
                                            Lender shall not be responsible for any acts of any prior landlord (including Landlord) under
                                            the Lease, or the act of any tenant, subtenant or other party which prevents Lender from
                                            complying with the provisions hereof and Tenant shall have no right to cancel the Lease or
                                            to make any claims against Lender on account thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">12.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Captions</U>.
                                            Captions and headings of sections are not parts of this Agreement and shall not be deemed
                                            to affect the meaning or construction of any of the provisions of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">13.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Counterparts</U>.
                                            This Agreement may be executed in several counterparts each of which when executed and delivered
                                            is an original, but all of which together shall constitute one instrument.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">14.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Governing
                                            Law</U>. This Agreement shall be governed by and construed in accordance with the laws of
                                            the state where the Property is located.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">15.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Parties Bound</U>.
                                            The provisions of this Agreement shall be binding upon and inure to the benefit of Tenant,
                                            Lender and Landlord and their respective successors and assigns; <U>provided</U>, <U>however</U>,
                                            reference to successors and assigns of Tenant shall not constitute a consent by Landlord
                                            or Lender to an assignment or sublease by Tenant, but has reference only to those instances
                                            in which such consent is not required pursuant to the Lease or for which such consent has
                                            been given.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be duly executed as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATTEST:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 46%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 46%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATTEST:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RJ EQUITIES LP</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RD Equities, LLC, its General Partner</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:&nbsp;&nbsp;&nbsp;Ronald J. Tarquinio</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Member</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATTEST:&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LENDER:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 18%"><FONT STYLE="font-size: 10pt">STATE OF __________</FONT></TD>
    <TD STYLE="width: 82%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">) ss:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-size: 10pt">COUNTY OF  ________</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing instrument
was acknowledged before me this____day of_____________, 20_______, by______________, ___________, of_____________, a______, on behalf of
the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notary Public</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">My Commission Expires:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 18%"><FONT STYLE="font-size: 10pt">STATE OF  __________</FONT></TD>
    <TD STYLE="width: 82%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">) ss:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-size: 10pt">COUNTY OF  _________</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing instrument
was acknowledged before me this____day of______________, 20_______, by_______________, ______________, of____________, a______ corporation, on behalf of
the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notary Public</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">My Commission Expires:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 18%"><FONT STYLE="font-size: 10pt">STATE OF  __________</FONT></TD>
    <TD STYLE="width: 82%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">) ss:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-size: 10pt">COUNTY OF  _________</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing instrument
was acknowledged before me this____day of_______________, 20_______, by_____________, _____________, of_____________, a______
corporation, on behalf of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notary Public</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">My Commission Expires:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>tm2226999d4_23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; color: #333333"><B>Consent
of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We&nbsp;consent&nbsp;to the reference to our firm under the caption
 &quot;Experts&quot; in the Registration Statement (Form&nbsp;S-1) and related Prospectus of Cognition Therapeutics,&nbsp;Inc. for the
registration of 5,586,592 shares of its common stock and to the incorporation by reference therein of our report dated March&nbsp;30,
2022, with respect to the consolidated financial statements of Cognition Therapeutics,&nbsp;Inc. included in its Annual Report (Form&nbsp;10-K)
for the year ended December&nbsp;31, 2021, filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%">/S/ ERNST&nbsp;&amp; YOUNG LLP</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">Philadelphia, Pennsylvania</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">November&nbsp;7, 2022</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>tm2226999d4_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B><BR>
Exhibit 107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CALCULATION OF REGISTRATION
FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR>
    <TD STYLE="border: black 1pt solid; vertical-align: bottom; padding-left: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security&nbsp;Type</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security Class&nbsp;Title</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee<BR>
Calculation<BR>
Rule</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum<BR>
Aggregate<BR>
Offering<BR>
Price</B></FONT><B><FONT STYLE="font-size: 10pt"><SUP>(1)(2)</SUP></FONT></B></TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee<BR>
Rate</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount of<BR>
Registration<BR>
Fee</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 2pt">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 12pt; text-align: center; text-indent: -12pt; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, $0.001 par value per share</FONT><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid; width: 4%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule&nbsp;457</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$11,500,000</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: right; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.00011020</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: top; text-align: center; width: 8%">$<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,267.30</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; padding-right: 2pt; width: 1%">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 12pt; text-align: center; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Offering Amounts</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: black 1pt solid; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$11,500,000</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: black 1pt solid; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;$1,267.30</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; padding-right: 2pt">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 12pt; text-align: center; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Fees Previously Paid</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 2pt">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 12pt; text-align: center; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Fee Offsets</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; padding-right: 2pt">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 12pt; text-align: center; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Fee Due</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: black 1pt solid; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;$1,267.30</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; padding-right: 2pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), this Registration Statement shall also cover any additional shares of common stock that become issuable with respect to the shares being registered by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of Cognition Therapeutics, Inc.&rsquo;s (the &ldquo;<B>Registrant</B>&rdquo;) outstanding shares of common stock, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act. The registrant may increase or decrease the size of the offering prior to effectiveness.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</FONT></TD>
    <TD STYLE="text-align: justify">Includes $1,500,000 of common stock issuable upon exercise of the underwriters&rsquo; overallotment option.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>lg_cognition-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_cognition-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ > 'B P$1  (1 0,1 ?_$ ,@  0 " @,! 0$!
M       )"@<( 0(&!00#"P$! 0$  @,! 0            $"!P@%!@D$ Q
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M)1BET2221I_W"N3B7$CBAD_+;93:W#&A3L;(@5%0RN1+>56*K3HR#@Q4G+2
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M]_ Y9/W@K]]DL<Z,1)P]0T- 5 ?>*OQ,X2^X13[?6S^751EYEHGB[^&?CO\
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MC6OK9$T-6(IU,2)(]GUI>J?':M#%23$Y .H( )@ =]!TJ0^AW_N#WPPF=/\
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MC  ](BW:.UP#PW %1^/51'G0F9[7]-B*/P$XMQ<,BFDC+XKAKJ^,0$Q,O,Y
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M,%*2J1I_(/$S,@-CF8276?ZXK[1VIZJ!6>E!".;Y9QVFL=1FZV*G(L'!/,*
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M-@*IU"( 751'ZGM>Q+GR&R1PZ0Q,O)(&N."+/-5][%'6)ZW]DK/)O;359<B
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M#EV,4!UQ@F<JE+!BVY&]E3F<A*R40:T4Z5;OHHCTH.&E3S9B5W(-%W"3"2%
MZ<1;X)9!LN=(0.M&2290.55DX 7&LUB8Q3]I;+XH<Z^./,:L-YO$=W;?M&5
M#SN,K,HRALDU=8I .LG)UH7C@SUDF)MBR$>H]C53 )2.#&*8I<TH:31N$*@
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MQ/6']TR==JO0*G&)B=[8K=.1T!$H#T&,5+UDFX;(J.5>D032()E53?-(4PB
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MN-)NU^F33C%M-1A,Z A[-PUP3[SL&<Z : : : : : : : : : : : : : :
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M<8E@C!XVKS6QY!G2BC")S"KAI4JZB8?+7M%S?-=G18*,$>H&C8?722H @@!
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M79ZJ%I+Z&HE\]RTDDHWWD[\*4G-**NQ<;B7?]1+9C7KY[.- - - - - - -
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M 20LV/<<4UQ:Y!=T\B*=(D<0:UEN,\@N_>O'"2RH)'23+T""@GK?H(Q6=#U
MXMIW$WO+8(IG&^OL\>TGD#@>U2.7,<U<3L*><8,U[7C;$VKB!ACX@H/ZVU%(
MB":*":R:YDP*9RX\QC08*6!K#G3E?A;DQSDRM5.7*F4Y;BGQ7N3ZF8YPGC6D
M72UUK)>5*S,O8.S7#+9JFU<"_:Q4G$N 9,ESH%.U40(F )FDBOF-,,R-U=76
MGX_'X9X'GEEO@C=L2P=HX7X4OF'.3F*[E4+=C*S8]XR63%!G(1DLW2E64W)Q
M%8CF3TC..7._;&7 RXNV::9#]"JJ:A%=*8&]G=AG)W+6.^WM@>3;"PL/(W/.
M+Y*WPJ";HAF[>/BHI*P-3H%4*<J,?(W,#"4X"8HH;AL)=1=6)8T1+GR9N)<5
M\9L\WAJHDT-0\)9+L4<)CBD4CJ I$R\C$"&*HF<557;9--,"F*<QS !1W$-0
MTS1WM)XG@JYVT\7PESC(Z5ALIP-^N5UC)YND\B9J"OLM,IKM9EH]\]J[C)"H
M%036(H I*H&'J#8PZKS(DJ>PTI[07$WC/R#PGF[-.3N/.)[6WO')W)BN.FUC
MHD')-*SCMLPK2\37*VW>H.BQ4#%RD@];IMTN@I/*Z?$"E'1X9$23S)'>XG+U
M7CMVW>1,93H2&J56C,,N\4U:NP3)I$1$,QR HQQE'QL3'-4DVS9!HC9]TTTR
MA_1\/'QT6+]I7@C#<SEE?MU]HRA7.)C&+FXTC"6-XRMQLBB96/7R3D88H =R
M:#3TPNF<;.61Q(.4@.D9PFW.GUE.<#:9L8J)^_B/VU,,)X_BLP<J:G$<E.2^
M88F.O.4KOF5@SO249+V*,;/!J57A9ELK"1$-6D%@:)G3;%6.)! ADFQ6[5O6
MWDB*/4SI6.$N-N+50Y26?A[5W-(R;F*E3+JOUTEAD34:(OD+5)QO1TZY6WKD
MT+7V0V>0\]3YI@2\T4DS)-$TD$\UJ6E*M9D%O$C-W!#C904L:<^.'UN@,]2$
M]8'64LMYUP,UR@E<+!)V!XZ+))6"PL9FQ-V_I')-R-&AT5%4CK@HL=7S5-8O
M(RFEF6"N&&+N)]$QO+7'AY'UYIBW-%C6R.=U5):4DJ^\ESQ["O.$HEI*NW*E
M;:Q_U+Y1XI,C=-@Y!9/R4C=1"QM]3226*-P-0HT T!QL&^^P;^S?8-]@WV\?
MDWT_P!SH!H!H!H!H!H!H!H!H!H!H#H)"F$!'Q$! 2[@ ]([;;AN'@.PC^?0E
M#OH4: : : : : : : : : : : : : : : : : : : B-[N^#\V<D\8X'PWB2
MBS5NAI[D#4Y3*,A&.X]HRK-+BFKYFM*3)GTFQ448IKS/G[)).3%],(@4# 3>
MJAF2K2A+.P9MXYBRCVB8)-6#1NS;)   ";=JB1!%, *!2@!$R '@ !X:AHBY
MDL)98NG=NK><+!1I9OA/#W%R4@:->7#F//#/LCV>:49RT8P:$=*224A^S]G?
M H84")B1M_C/$I37"A,Y8Y'[.[MBK-N=.)I</X,I,Q=I^]Y0H#"R-HAY&L_J
MFH1S]Q-/IB0/)/X])2/:RD<S!0"F,8 -N!1V\"$LL,S[W.KA9.9_XKT7'&)9
M5M6,L\?I>B9!P;(N3)I1I+;C6'/#QL$^=+)*%:-9:,74317, $0?$;*J@*)%
M"B6#$E@:W5_GOW)_JMKCZ2[6UZDLQMVQ(Y[:AR PK^(7THF8K56=)-NX1Q7V
M[!53Z86B=@5 "[]+GI^<"BZ$K+KF2>X3=<@D,&1,CR'CZ&MG;ZKGY*Q0N*?K
M(E13=J/)%W7H&(5L#IPX4?-(@S5HY5,L=!1X10Y#BD(&%A7 JK3$U![36",E
M8,XO2@9FJ3^DY7RIF/)F5KM7Y=:*<RS-W.RC>&C/7+Q"SIJ)W</74'0%!4XE
M!QO\W?H*9(Y8YF*NY/B;/[7//$/E_AK%#WD3%<;)FV#;,(QSLB<P[2L[$B+:
MVUYDHU?'>R<:*(])FC9X^;/4&2I&RJ95C)%D'G4PGRKR'W(.:/&[)]+Q;PXG
M^/\ 1Y2J^FL:&3[-"/<RY/(NZ8IN:)0:5O#HU=HY\T3OY.6.F*K BA&Q2KCY
M8E1$=?3 S/SH4?<9NSB_QVLD+*RQN!\+8"^KT#)BHXEIE.ET.T,R"P$R2ZJL
M2,B<PI]2:H@/_,$1TZE>$37G >2.X?P#Q;7>-RW"RQ<K*O%QY'>&<GXZM"D*
MQ:Q=E ; -5OT>:NV9Q *UF4DUT!6=&8I@0@)D.J3I<"P?O"JO:C<GA+Q=SJI
MES(/-GFD6#2Y(Y&AT:92L>UYVC*UK!.*6JA7"-2B722\BT+-2;OJ.\%L\>)
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M(B$"HM$E3)(F=^0+DR21UC)ECQ94J(W?T*- - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M- - :+\\>)EBYAT?%&/HNX0]2K]0SO0\H7A*6B7$J:SU6J-YI!]7(XK=P@5J
M_>#+ =-17J1W3 #AMJIT(U4WF(4"$(0I0*4A2E*4H  % H  %  V    U"G;
:0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2226999d1-bc_restores4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-bc_restores4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!J@.H P$1  (1 0,1 ?_$ 18  0  !04!
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M".%B@I+"(U.S%18V\=)#=!>B8Y/#)%0EXD2#HV24M";3\D55977_V@ , P$
M A$#$0 _ ,_B@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% <?,<6EQM+>A<
M*"I"%.( )U ^"U#JNWM'#R5*(>"YRWAU?^)%TR]#%KB7[J;RO+<-MET>:M]N
MN&.[99_D,*,_*E1;>E<BY6>QWB#$2E^X-<SSBDM-)/,OT034X)48;=:H](Z4
MNI_8WK;VSMV]>QF11LVVQO<FZVUJ=):=BW*5DF.W)ZQI=DQI*8CC2EQX<DZ*
M923KJ-!PJ'2F@*E=.#[F4N=3?C/] G2/O):>G;?#=?(X.\F1_$<JV8=8]O\
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MCL=G?:?;A070EM2BL+2 02="6FA#>&MU[M!5%U7]9?3]T0;<_LR=2N?2=O,
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MQ'H7ZF.D3/,DND/>K;&S6;;?IB8GRN\GS]Q]YK=+VHV2P7&K<I"XJS:]Q+;
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MVM^WMKG)M4>0F'%M\B6WHZ^MAD@J(6H!13')32332W6G+W<I:?\ %6\+:_\
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MI'#RU!/,<@!H /-PH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#8XVAYMQIQ(6VZA3;B#V*0M)2M
M)]A23I0'!G&[<;>NTZO_ !:IER,(84WW+;#@Y4M-CNM0AEOT4:DZ)[=>VIKA
M0+!U.8CQQ'2I"7'%I4H*2EPI(:2&VVPVWRH3HW]KUXZGF4>/D$ CT H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * T) [2!
M[9H31O0.9/\ /#YXH*/D',G^>'SQ04?(:@@]AU]JA&C2* 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M$/(;=1WK#J5<JDA2==" 011DJNLY&H H!0"@% * 4 H!0"@% * 4 H!0"@%
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M<-1N'$P7)<NNL:?D:[(DM7=5Q4RTAY+JXJ&U)95KZ2-5U"6/07M]I\QQ3=[
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MJ%MLBE@2EH*DK3RI/.@FE6KCT+L)TG;]S.HK938K!%;F[H;D6>Q;<W299+=
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M<;7[=1U+4XXC!L66IQ1)*^:RP5:G52M2.;3M\E&36O0>DU % * 4 H!0"@%
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MX>W6LWN#C$USI8W'7#8S7;NY(N<C"[E&8C0;7EL:=-D/.KMC@1':CMJ4M7,
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M(CQD)D<\IAZ2RI3"TM*994TE2N](Y?2[Y)3_ #PXBC5-(33Q.2J"10"@% *
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M.X';,8E3<A2Y-9G39F5I=L[,:WFSN1$JF1_5Y=P(<4I6H;&B/2]'T[E+5O\
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MJY&FVM#[5W:#UW*?"+Z]<FWKQ/-48KM1:+#8=RM@LDM>6X7N):L*NLRQ;?\
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M1#SSTAWE;U[Q;CTAQUYQ;KQ4HDJ/;PT&@JIZ2%S'::@"@% * 4 H!0"@% *
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MA3"NCIY5R'59GBS**XO)JIM.DE+&FFM,%C@]%<#U6;TJ;DW6T;(+B61J#?<
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MEEN&[HA [U9XI2=#5:W)?A^K25:5T^]TE<-YN*\=U=>18^\>.Y!U16MCJ"V
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MFYC,C:@@::@AWR U<RR#MK1[WX"VMYU2E@M)RT6=ZRXXMEYI^$X.=N8RZE:
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M5B2EQSD20>!/E\GS*KM2K.E1M[3H3U71(H!0"@% * 4 H#@;O$CRW8Z'T!P
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MZA)4!J4@D\/9IL116FNLGZDY10"@% * 4 H!0"@% * 4 H!0"@% 8+7RIO\
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M[<XRJ]33[#*81M7,I'-6[D);3:V4TWA3'3S\FH[159Q"@% * 4 H!0"@% *
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MZ21V.*#RJ40 5%))'83R@>8=E=K9;E&LJU.3'7I)JN8"@% * 4 H!0"@% *
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M]+[D5]I.9.E2T$ ?DW?AQX?[7UPW-[;NMP=QR>'XK\!QW>.=R^C:<W2GQ9>
MA'Q'^EWXN5'.9.\QC!OE_)R_<#RD::?%_LUR+B+(/+.DL-A_!ER=!S6^*]U7
M;#E!MQV:^3+P%I#KVWUV\WLN.)2=O<G<?1 N#,E80S*AK*&X,^,X51)#3#S(
M[YX#B/2[1P(K5F^-Z9+-Y^6RVZ)/0^1+D-1\9;WW=O'/1]%*7B*CP>M5T4+[
M_0:(3VPFW$R*^^ZIZQ\KA6%<A4E3_E*$CL56^MQY:Q;W9Z2TY5VVN;4;IX1=
MMY6V[;=''PE<M=F9L* 4 H!0"@% * 4 H!0"@% <+=/P.X_BF9[CE2])&HP=
M_ E_ET_%*_=!O_\ ;?=VFHA^69SR??#ZP>[1D1TD2H*Q0"@% * 4 H!0"@%
M* 4 H!0"@(;IT;</] KW*IFZ1;YB'H)=A0TT]G\VK%WJLJBL#9(;"R?:3Y1Y
MZHE24JDRC6-3Q/=6/R83E*O-9I?FT&J=/IUUN^53=MZ7)'OHQK?$-G(WI/1Z
M-F,QTXZ'K)N:3V'=G&A\_-KB/IUI#+6G=WK:?_U,7I_'1YWW0H3W_EGK6;M_
MO$95MCY6[#:TIT*N5P'B.&K[QKT+NNUL9*#QJT^UGJK=B3M*NJ+[3G&7Q\8I
MCZCX KX'L]'732JL?IU'3R>LB5Y3N;*Y#F:O2H4 H!0"@% * 4 H!0"@% *
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MQRITLC48/'@2G_ZZ7BE'_P!X%_/_ *6W=IJ(?K#.>1VC[F/=%&%I(A( U)T
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MOXKW9;M*4;MIQ:IBWR]!VIW>K"82GKN,CM#C[;"VFXRWG@VHI2H))4EKFU)
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MX5=YJ.\!'!6I]'4#4<:O+^PVG#10RC*^EV7Z5MRKK.6K@+H4 H!0"@% * 4
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M:R D:CM\GEJNLI=+*=&@H[L_7KTR9EU$VKI4Q7="S9!O@,3NF9NV"S):F)1
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MS2Y'+M1E.[E2$.3:78SWJ(=8S!\[2/L16.Y6KRT&].RCMZDQ5P!0"@% * 4
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M2Y$@1PZ>"N4!WBL!7#1*23Y.RO%<G2^D^3PF=V)^+M'84 A"03J0E()[-2
M3I[)JLEXLW4(% * 4 H!0"@.%R+](;O^+Y/WI56F?^I7?,?8<&9^KS\UF'=U
MV_PJLR/D^,F?UIPJ\T\8>5+I?R3YU>WS[?N?YC_DP*26?>N?=7?LS6H+GE+H
M1YKM>2_.9N\]7$?42Z? 6[3VS;5L5"@(3HU"?8<;/S H$FKK*>NZF3'27I?"
M);6F^Y X4D(8ES^]5Y&^\C6XHYOK@X/GUZ&]G_K$]2?Z*/=_W=$U*[)Z*?H0
M,BV+P@PM>'*RA)]A6B1I6[;.%N*UT1['LI^A:_$[Q39U/;U0=AL$FYS<(DF<
MQ#DQVEQHCK;3Q#S:4((+JVT'5:@-"1VUTN_MX+=UB-W6YTTTU&)\1[YCN3+K
M,M8N26FE,*XEJQ[Q<K/=(D9QK;;,X[[#_JRXBGK*77'62T5@ 73EX<WE-85F
MN+9Z52N'PGX#7.<]I4XI;-N#V=/CO'_9.I3?%.M,EUQPX3E;"DQ7_17)M:3W
MG?(Y6]$7$CFT\G9PK&\SQ=F%-RA%MT:T\]>0QK,>UIVVW*P_)>B7/T%O[JHZ
MDXG4!-L]R:QN[PG;3:996F<Y%4J2_*;)3%:+$ET=ZTMOB#H/2'&L.WMOK-9F
M[;G*J5?C,U1Q=[1'O/.VK[MRA%)+&6EIU=*%8FVOB56;;G%,:QEW!\CNJ;79
MH,1;D)VU%MM;;*%.)T?G-*'(LE)\Q%9/NGB"_"TK<$W%)ZWRF?[A]KEBSE(9
M=6XM1CI<N?S3U_\ C>; PAU3V!98TEA?=O*<DVD!M9/+R*TN1X\W"NYO<37H
MK%<GPOP&6KVPVX*LH6J>>_[AS5L\6[%[B]%@.X)DK:9LEM0G.2;5W++?=+X*
M(G*7Z1(/ &IR7$CS%87*>5R_@._W'[2[&^K<]A06S<2PDWJ?XJ+T&(9$G(($
M&9ZE(CEUE)>:=*%+:<45Z!?*LC7L[":V#NRZLQ!32>A&U,IFUF+<9[+3:/1V
MTA*0.&NGS:R2*HJ%]1F\$'LJ5H!K4@4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H#'F^4R6[8B9X<3ESWSR6X6:/A^\F$YC@5CMZ''3G.?6RQ9I"M.(S6F
M;#?'56Z?;[G+><T,/THZ?ZH1[U<T;7,4RH\'6IC9,>)Q\GZ%O0^]X4N.2)3<
MQAW&XUHM60NVM^R)=C*?N4XI7+4U+BM"6X&%/,/_ &EO1H\R>\G#7H]_W=!3
MBN2OO>YI,L;P2]R=I]S.A+;K..G_ &T7M5LKD&Y._4C$\2B,OMHM,=W>#*>1
MA,5\*FQT(4%\'6P>--6KH*UR5>@O*0W>]2]HXVXA#ZD(4VM"]$!#9 7R*5RK
MU4>!T.FG"H?OA:*K03E02* 4 H!0"@% * P3?E4'\H)X1O[L]T_Y0>EVJEKZ
M"'H729'GB:_R3^Y/[DNUW]O\&K)^#_MZST]XL=X_5F?.OD?"W'\82/LDU]'.
M!?L]?.S[(FH=^>4^A=\VI/%(_F[*S'_%1AWP^LF7_@V?:/N"JGI+S,^IM]'@
M)6H+(4!L1^&Q?KC6-<5_8F8^:?:C(^'_ "WYR[#Z<OAW?P,^G7^\.)^C9M?,
MWVB?U/F/G9=B-S;D^J1Z"M]7OA_-YZQG+^K77VG=/R2(WV'V_I"KB6DX8Z"6
MN*G$09*F9#$1T-'DD2=>X9.H]-WE4A7+[1%0M)4RB;J3ZQ>F+HPM.+9%U([D
M0]I;#NMF7Q!B\F=;K_>D7C)9S4"%(84O%K%D'Q= ]4<:T<EI8;"PK[:>P2]G
MEJ4>,GC@RW%M)XR^T4A?4C=^K#)=KMF-F]O<VLV*;5Y)$^/+I?MRK)D365S,
M,N\2U66[YG=G'KKC%B:DC^MD7E4^$K;0HAL0FTZZ'W:27HHZMZB^=8Y\2ZSH
MUPA.%Q$NV-R$K0T\8JH2G92&4MO<@;$H2$J*@5D\FGHC4$M05.H[K4%1+J[5
M>V?<KCAZSK*I^1U&UOX)/UY^G7+?\HXK/DHL.^+Y^I/!?QS-^](K1/&OJ>O]
M)'GCV]_8D?.C\N)8(1[Q/UJ?<%>>\W]:N_.2[6?.'>GVGF/G[GRV;JMRQ% :
M.#7YU3%T+F*K),T>]ZQ]WC_?$USY/ZRCAS?DKSUVGJ?3Y^VU@_X_7^AY=9]N
M;3#I[YN_V3>ML>8_WIFDX+^ *^[+^P;KT]N3U76?3;=V@I]ZSU<FT.8J+B6T
M)QY)5J>)TNL#L&NOT*QWC7ZA/DV/TT8KQ^__  .8KHV%\N)C&].73?>.HO(,
M@AX_E;ML<2_"9;;3R=T'7'WTM]XTY&4\Z@*6-4H/,1P'&M;[IRMS-7'9M>6T
MO?/-FXMS9K?>\;F7RLHQGM+'K?/CU%;/\4MNP?\ ^0HW]B9W^@5D?\M[SY?>
M,^?LUW__ -S'\R0_BE-U_+N+'3[ M,WY_&/3^6]Y<OO,A>S3B#_N5^;(T<\)
MK=>.VM[]D>.0T.8@VJ:D?-)C@"N',<,[Q=F2KBUR,J7LVW]'QI9B.ROQ622_
M"NW60TIW]D:& &^?3XKG>8GM[G0:5>93A[>,,MLMOU?Q7R%Q+@C>T<O*WZ6-
M7&E:/D**^I'IEN_3Y+L0R7(W[I)NTA$8K;:Y(KBEQY,ALM,^K=^CD9C<IYU'
M50/DTK7._-PY^UGIO%M[/P7\5&F^)N#]Y[LWC2[-3])&N$7JHC))Z ;5+@;#
M[9@NAR*W9'=-$GT></!)YAHD:J]BMX\)Y+,97+1]-6FT]*?(>L>"LM=R^ZK$
M)U:46G@5]UF9FXH!0"@% * 4 H!0"@% * 4!P-W_  &Y_BF7[CE5:RGE,'_P
M*%?_ %QO%)T/O=R;P=/;O6[ONZ5Q.&U<3+:[/9S%.D]*^4NJ!W[V5.O']AUC
MA_\ C;,P>/97J;V"R4,S;3_[J7[DPO?U[9<N2G?,9I;P,=M U]X$^3R@"O9\
M&HVG==**+?N(U]O',[-O9QJT]:Y"2Y%Z<W*L@Z\=-1VD<"!H>RN%J69AZ:W*
MB?>P[QT,<O.Y%7-FJ?,^\;.;MU!'L$'\RNFNY?.J=%*5.@J>5FZ57O,W!*E>
M]03Y>"37897+9BGZR='SE7T:3P2D^HA+6IM12H?T.A!UX>X>-7\;]M)VZIR@
MJ/$[#*7Y6/$EJ:1=@\%Q6OB"[%D_[*K^A*@CVZ\R^WC,1GNR]"/[>W^YD9UN
M&\YW8MZ'7Y1]%&W.$HB]FG<CCY.U5>(9K:OKH\)LC+O]6D<W7,7 H!0"@% *
M 4 H#A<B_2&[_B^3]Z55IG_J5WS'V'!F?J\_-9AW]=_\*C,OQBQ^M2%7FCB_
MRY=+^2?.OV^_;\_GW^Y@4D,^]<^ZN_9FM0W/*70CS5:\E^<S>?JOF>X*YX^H
MET^ X9^6;*MP* V+][\[W:NLGZ]$QTEZ_P ([],<W_/J_P!!6*O0W &F75V1
M/>7W>/(O="[+9D0M?@<?VVO=16[K>A=![&M^J_\ A]XML>**Z&NGC)#WH:*I
M=K2%$$\?6(A[!Q[!6 >T.\[.[(23I6ZODLU=[2Y;.YFZT>TN\60^E7I*M6_.
M.W^XS<CEHE,7RZ=V8SD5 1I%8? Y9%OD*[1YZUCN^Q=WC.D94I7DU*IIO<O#
ME[?RG&-R"<5K3YRLN+X4%EEI21E5S/.D:Z/VW750"N)^**RK+\'W;]/)=>:I
MW;]EMZXL;EKW'X2)+\)>''#)BY+<E]ZH]YSN6\Z <O*1RVM'G]FK;>W!$K"M
M2:@JMZJ<G*\>HZW.>Q.>\-G]9!.#;\5<M-.GD-[/A*M+&OY17+L).BX&@]+\
M5FJLIPS*"5-C0^WI.6Q[$,U8C2W=@\'I7/U&VY^%%"BI6%9%<'!+E-N%)5"\
MKR". M8T&M<F<X<N;-&X\V*.6_[&LVE3TT55ZD_ 6Y-_MF(NQ6YS6'1KB[-*
M$M/.));YHY2RE*4+Y([(U6E7,.'96#9Q3W7O*&7U2Z##+FZ[_!.]_P"'3G)Q
MN3VJZ$\*:UCI,L?:.27K*@G4\(OOOZ)1'DTK>W#4MO*U=:T7?/6FZ)[5I=1[
ML%#F/L)_,K*\%[ID+7B5YS;'5S()_HB/^Q37%8\CK*-9'KF H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0&.Q\INNV.V/P[+;<;CMC'W6R@;[X'&V\QYQ]
MU+D7,7L=SI<&[J@M0YR;O$B0VI"'(SK:V5J=2HI)2G1KYA1TPTF,ZGY0GM?;
MHJ)"/ <Z/V42'I<..ERUX;;BAIJ&'V0W 9Z>"P%2'EEOF'I+UY3P %553*'5
MJNA=V!ER>"/O1:M]N@O;?<RT[;X[LT]DN>;SW=S:/ VX@Q[!&KUNID\UB(U$
M@6K'8J41VSI^!,\=>';0G'!%Y:W#[4Z>Y9:27U%"V4I2)".1O20M*4(2E:B"
MGAKP2.-4DI4P)^A(H#@ILR3&E.M)>3W;T?5I:VT):@O)X:NN<>;O^;F 5V!)
MJ4D1KP)5%WD!24R?ZG=]45(>;"$JCM!#Y0E2)*@A;CCP  24@>EVU*6O3B4R
M;1N%T>>5R,*DZA,-U13#;60U= M<;AS]D=+1YS[-&J=&/O$IU=%I\/@):5.O
M+SBT0U=S&,0-^M(CHD2HUQ3(#A#L-: V&G8@Y1JOM6#IY:4IY6 K5>*ZD2TW
MI<N?ZHN4E3J6 W)@RFVXDZ/(BIY'9#<='.IUB:X2?2*0@)X ZG2&N8JPY54[
M54 P3?E3_P#*#>$8/_?/<_H[A=+M2M#Z U@NDR1O$L:0YX4NXZ%C5)VEVQ\I
M'O;UA"AV>R*RC@_[?L^=WCK]X.N79\Y]:U+>D\QU[PW:0OAVN,MLK;/L *4>
M'EKZ.<$>+N_#]M+LB:EWTDW*NJ*[YN;)/=Z^4:GR<=/8K,Z?KD86O+KSLFW_
M (-GVC[@H]++W->IM]'@)6H+$4!H@#UJ,?*%GW#6,\5O_P +F/F7VHR+<+I/
M\M=A].'PZB5=&/3L3Q(P2,/G39FGNU\T/:(O_P!GO\]V78C<VY?JD>@KB(';
M6+V/5H[IZ @GSZ#6N=\YQ*M,#;++ C/&2E#C'(>]2XE*T*3YE)7JE0]NFLG0
ML2R=XM.R_49U$;18EM1L+M#L5N1#OV8VF%/S?<ZU6K++GMWC\.]66[7NZXU:
MKQMYE[-OO*[+#?;;E,R8;_,\!WJ0@&N>$82=6L?>[M1;W9N"P?AZ#&5V&Z/M
MV=RK_OM<-BK!CV^.X_29O=M]8\TVAW4P:UWW#<L1;V<W;EKL3-RM6<LO,6B3
MB_J;(5:T"*S*[M'*DE!K=NU2M'2IU_TK-.XX1::I709[=A7-3-M,25;TVH,Q
MG)W=VK5RT!R0U*BJMH6&H;?=QDM!Y/VOWRQZ([:X91U):CLHW'AM:WW?VGH)
M<5Y#] 50U1<YR;3U&S4D<>TGC\ZN&'K2N;_5KH-[(U:'L$FN7,:>M%%GR46&
M_%[_ %)8,?\ ;F;][16B>-?4]:^4CSS[>_L)/\:/RXE@='O$?6I]P5Y\S?UN
M[\Y+M9\W]YX[RS'S]SY3-X^?5L62IK-=1YOHTQ*JQY"$\H\-.%7+MQCHY"JU
M-RE5\IO4.9+&NG%U@^;ZM)JC+O9O56E$9A;5*Z-M=IZCT^G3=G"/8R!7Z'EU
MF^Z;DU*VD]:[3=_LF?ZZRM2@_P!Z9IN"@?%//]47EZG_ #-OR=E>KMT0C'+[
M2TU[R/IKNO&";TE/O66%?L/Y@YW3;J3C?*KO #Z7QQ  [4J'96*\<;4=WSE#
MXGZ:,9X\5=PYAM)K87RXF-QTB=2=GZ=<MR"XW^U//)<F0)$06Y#/?%UJ4\M
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M(2HCEUUY0/F5MCA"CLJM*IOL/1O!+KNNPJK"'A+A%9T9T* 4 H!0"@% * 4
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M2U*0X4).FJ>%8/OC+V\MO6%NWY.)YTXPR>7R7'=BQE8*%E-42Z,??,JO:O\
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M.-(JB;QPKH/6O!-'NNQ11PBZO65^UF!G0H!0"@% * 4 H!0"@% * 4!P=T_
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M>\ON\RE*[>4G5*GR(&1$P3ZK$'D,=&OLZ@5O2W%/+JOQ3V)92] ^CO%M'Q/
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M,B2ZV 8KETAI'VKCK(M:E/<O,#Y*F5-DV?PMD\E<@WLQ=U5T4KIZ#'-S_?\
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M2G0TRHEHK2.\1RJ'I D:\->%4X/%:":-:3E* 4 H!0"@% * 4!@J_*G/X?\
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ME61Y7EZ<<W#Z5[/N](Q.3DF0SKOCDZQ7S)]T+-,QJ2S9I7*HQH;9?#FH4D(
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M4RQ[XP)_W,[=/>1$^XLD>4J6RM(/FT^V"M ^T'&WU+Y9H?[P#_\ UJO/#][
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MVU1:]6N[6=59]4NOM-*Y#E% 0G#J/:('N4MZ9%%OUZZ478/!=_E ]A_QLO\
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M>_CB;]@FM <?^K]SY1H;[P'],?E0_>P,?L]I]LUY\S'UB?GR[6?-S>/VA?\
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MGB36L^(^$(_3W*U%1A@G26S\%<QHKC_A7*2WG#Z':A;C*TV]A*"K@M21>O\
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MC$.-%_T$GR6KG>,L_P !3]H/-/W4KC^M;;ZO3? WV5:^;7:?GW^][_7N\/\
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M>[;;VWV6I[JUA:K@_&#2%I!!4>8)'$ZZ5K/AR];L9Q7)M*,91>+I7'1S&C.
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MT^P\QOZK>[M3,0;KM]+JGS$]G+<6/FZXK"%>9N+\+DO.?R3YW>W]5W[=^?\
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M6L;G4<DUV*^N_I4U:'83TKH(M"@4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MR=JL7V-\8GQ&-G\+;+6+;;Y.[B%D0J;%GK^+[)<-VX48N/PXT2.'"TT-4I0
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M]E$F[UF7XC_>F:EBYYK4!YG%#YZ$5ZT6.)]--S.MKW>\4V=9MO9E;+Y@9"G
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MV^CP$K4%D* WM@ZR.!]*$ZVG^B<+K"@A/G64I)T[=!6#<<?9USYE]J,HW/\
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MOT5?!D=A[?1K+YRCLZ5I+R$)J>TTZ4Y#D&>*3I_/?TJ:M5H+V;3>'(1:DH%
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MFHM]KQOR5WS:GAI['YE9@_6HPM>M2YR:?^#9]H^X*J>EE_FO4V^CP$I4%B*
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M.O>J Y3Q\M;TX1MM9>#P6,JKJ/6G![4MU6-F6B&*]TN 5G!F H!0"@% * 4
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M2-2-/,/S*Z6'EHX<OA!U^-WD0G?>D#^;0#4_,K)]W:5U&(<:?4I?-3[QEG^
MG^T%FG[J-Q_6MM]7IS@?[+M>8NT_/O\ >^_KW>'^<N?(1D0DA,LJ)T2EUQ2C
MY  L:DULE>IH?/\ CZ]]+[2R%XPR5*Q;;I*023=)RP/*4);.JO:&AK0_'_J&
MM=%\LT1[?\.&_P J'[R!C[#B ?8KSEFOK-SSY=K/FYO+[1S'S\_E,UK@+(4!
MM>4-.WR?FUR*$DZTP.>$XMI)XU-'2"E@ ]K\?[XFN7)Q?TA=)PYN2:26G;7:
M>J=/O[;.#G_;]?WB76P-S6YUAAK[YO'V3X7+#>C8_P":9J&'$&R*2""KO5G3
MRZ=VW7J+=K5JQ2Y@]KP'T[W6ULIZJE./6*'5[1Y84)"FDX^M*U  D+,^( D>
MR16,<91EF,A+T*VDHTPY=I&(\?2V=RYB3\C8_3B8]'03O%MWL]E=YNV;W21:
MF8JL80%RE#N%RHL^6XN/RF8$DZ@ @C30UJW<L[>1S;EGJPBW%8\SQ]P\[\&;
MWRFXMZW<[GMI0BXRPI2D6WRHO*?QC/3A_OGM_P#G<;_7-9W_ !3<G[?WD;>_
MU?X8^-[R_O$=OQ&NG()X99;4#4\"U&]CC^$&I6\]RTPOX=")7MAX96&VEU+P
MD.7XBO3C(CO,KR^ $N(*26V8BE@:CWH5("2?;KCO;UW.K4G&]C3D1R6_:YPO
MF)JQ*[&*EA5I8>^2B>O[IF,-3:,U1S=RM(*XEN U+9&NHF$Z'VJO\IO;(?1Z
MN["GHUJYGS%_=XYX7=AW(9JVU1O"G(6ENO;>O;?=J[8]><1OAND"V,AN3)CI
M:;99>+#@2TZ&GR M2=2.!X"M=\1;PW;F,\WZ2-4DL>A&A>/N)MR[XSUN[E+R
M?HX4:P6FCU5+Y?A_I:9Z?]K6FBQSG&D^L-A2R^TH+E%((*2D:^P:W-PS<RDL
MDO03C*3;T:3T=P4Z[LL2C1Q<.O65[UDQG(H!0"@% * 4 H!0"@% * 4!PEU_
M KE^*9GN.5.LC48/_@/_ ,NAXI9\@W&NVO\ 9G=^J'Y13/R^L]&^4Q#_ .8#
M94_^YUC]?&:5ZE]@GUF'^:E^Y,(XB\A^;^D8S)^ ;^Y_THKVG;]0_--6;V58
MOHEV$FKM-46O(77VG46?5+NUFVN0Y10$)WL^:/I4MZ9=!1:]<O.1=<\&+AX@
M6Q'XW5]_AUYB]NWV=?\ G[?[F1LOASX/FR^4?1BA?@\?ZVO$,O7=1M2SZI=!
MX!U#@C ,GU'PL):6_P"B5J=0/G&NHWO&2R\FUXM#:/LC_JNQ+5Z9=A\XR6I*
MI<CE(/(Z4*T\B@ 2D^SHH5YBXINV_3-55:R[$?I#^[Q_2^7>KZ/:^7,ACM^9
M6NYQE-^*JGI?,>JISD'CY>VN8N56AH/9\OE]JG04NINU&H'M<?:J&L&RE+61
M%_".?BJ1[C%9%P]ZQ?-OM1JGVF_9B_S$>R1G%>#M_ XVQ^Z9)_;"57IOAKZM
M'H9^<'[Q_P#55WYN/[V9=*OOZ07#V(SVO^=KK*,V_P#H;GS;[#S(_JM[S)&(
M/UX\.J?,"> 5<62DGRC\E(8]VO.'%[_62Z7\E'SE]O\ ]N7,?_<?\F)22P"$
M*U_R1P_,*CI6H+K3EAR(\UVEXCZ61">!KGCZB73X#CFZ25-)#[:MR,6\10@V
M.<4+0.*G4EIM/E4XX.5"![*E'05>Y!TS"KR,Y\OZSJ9>J\(T$OY>UI]L5<7T
MI1Y241;+S >RGD/SJ]"<"^-M*.+?@B>]/N_Z+L=>'R+9D5,?@[8\[ T]G5-;
MFC&3MI)'KV'J5T%L+Q0G(S73IE*99;2EZ;:FVRXI:!S^L1%:)Y.)5RI/;6!<
M:NW8R499IJ$'<23?+LLU-[4[UBQN&=S,.*M;<<7H6@M']&'5'@6Q^.7^)F,/
M*)D5^]P!&39+=8Y1?]7=;3(2RJX7JUJ464*2HZD<#6&;IWINK+S;=Z+BY)X<
MV.LU7P=Q+NC==RX[EW:C/95(I/R:MZ6N4KN1XG&P41T$XYN,H<Y( MN.A6FG
M#4#-@ =/-P!K+LOOK=3=5<C3I9LVQQANF3K&5%S_ -K.8<\4O8!YIM'Y-;GH
M[L?XS:L7<*M0 0>]SH:=GS:NLQOC=LXQV;D7CJZBXN\<[AL)?2+\(UT$JGQ2
M^GQLD*QC=OR\?B7$/_U\*6M[[JBJRO13*8\=\-255FK=.DX.X^)[L1<(LI<6
MP[E-OM1H<IEMRRXESOQ@ZXX9#8&:. MI0V3J2#H.RK#.[]W5LM6[T6\.TZ7/
M^TGABQ%[>8CM84I3EZ2U5U*;J8OO)O(,YQ6+?X\*YPK4'5WV+;HJGG6;;&9_
MJ1%NN=S:+;/(4KU*"%#L/;6!9^[;SF\8W\N]N&OF9JC>W$6ZM_\ $$<WN^[&
M:;BFM::C3O&6!M2TXFR-*4@A/)%.ODT"SK6Z>';D%E5%M;5%VL]5[JA+T"E3
MQ:H]H;<075 *&O+V?-%9-LR2KJ._=R#CLI^-4WQQH@_7'W$U1&M,2E1<<&1Z
MJ)% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * ZS=T +D<\A
MMKUE#33*IQ#\5M82L:,1PIHLJ63JLE6BM!52K3#D[NDI=*JN"J60O%:ZU\PZ
M?[-8MH-O]EM],O.X!M\/+LUV:V@W2R,8[;53)LV;%@WS#L2O\&+,O<*TH@)=
M4XI+:IPYD*'H*C%JCT]V@FB='J>C\)YYX?O7-<=P+Y;^G3;'HGZE=I=L,&V[
MOE\S/<+?.T99@,ES.+-:(PL4J+<<UVMP6)-R3,;C;YSLZ[-!UM4A*'E)2%I"
MB71R] KTU[>7 AYYULP.O;IBW&Z><;Z>>H3;C=W=1K]CO)]O-RME]U9>%8C;
MEYE;XL^[0=P+G@.*83?6W<=CBY-/1Y :0\]RZJ6A6JM60UAHJR\%TX[,1NGC
MI]V&V%M\]<J!T_;';<;.8U,1*C1VLG3@.!V'"E/S[<V5E$D)QQA1/-RH4^KR
M5*KJK7NI[H;2PTKNPZBT5U^> 9LAU][_ ,KJ&SO=W<O$L@<LL&RNX_C-TA-V
MAIF,"@$M.6Z2KG6'==>;34CA4-*N.CET!5TORN2NCN1B2>*;X4VU/A?=<?AO
M6+:S<#-,QE;J]0&*/)5F4J/.,5>&;D[(&*&E18<%*6VUYDKG"B-0D:::&I52
MF>&OI[YFZ>)>AW^*MW47-[EZX#:?;-MV6PWR(6@Y)@JTM:\[NI3J/JO)64<'
MT6_K"6C:[S++>..7;UGSOY/PMR_&4C[(5]&^!/L]_.R[(FH]^:>HVI[4_7?T
MIK,?\9&'KUA,/_!,_-]P54])>9GZO;[M2)2H+$4!%1]1]U'V"JP;C?[.N?-/
MM1D^Y?L[-='@/IG^'I_ UZ<O[P&/T7.KYV\:_P!19KYQ]AN#A'[&_)7:RJ[+
M_P  N7YU9^]MUK_>OU&7G+L9E7#7]0KS>_$^=[U7Z?OA=V-?]],C3_4L6O+?
M'5?X['YF/RYGZ8?NU)O@.=/^_N?N;!X @#0:]O#3YWN5B&/4>K\E7T74NPB'
ML/M5!=K2;!\%\W_%4N:!/RS4>7YGNUTL?6+K[#BL^1UOL(+G9_UKGNUE.[]*
MZ8F)<9_49?,S[$99_@*?M!YI^ZE<OUK;?UZ:X'^R[7S:[3\^OWO?Z\WA_G)_
M(1D.O^_D>T_]F*V9'U2/G[_C/I?:63?%_P#U.;:_GJY_>7JT+Q_ZM>;^F:,^
M\#_3:Z8?O8&/<CWB?K4^X*\Y9GZS<\^7:SYM;S^TLQ\_<^4S=7 60H"7=[4^
MU].KU^3U$6?6(U7_ -S?=F/LTU5D?K'Y2[3CS.G\M=IZST^?MKX/^/W/T/+K
M8^YM-OI[YO;V4^59\S_F&:/@:PNV<?\ )#IY^+:-:]'0=84YCZ:;G=;-><IU
MZR6E-[.Y=)94?61:.1MOZE23<XA)/9V$5TV^8)9*3^%^$Q7VBI1W!?G7'87R
MXF.AT?\ 3=C/4'DF36?,Y+\)Q%]LX;7"5';?86N>ZD.MNO-OAIQM1U2K3T2-
M:U?#*+.;QA:GA'TJZ'BJ]1Y\X5W!8X@WK<RV9DMF,HX-533D\'TET/\ BF-H
M?]^&8_V<MG]SZR_^6\IR6_<7A-K_ .E.XOV=G\V)&;\(_:)U/,,SS%/'33X\
MMGD_\W^S7)'AG*M52M^XO"5+V3;CEBK=C\R)"E>$EM)%CNR$YEF*RTCG"3?+
M6.;B!IJ;?IY:2X6RLHN/ZO'H\)1=]DVY(VW+T=E46E0BGU'%GPKMH$1U+.69
MES!CFT&0VK3WIX:?%I-=SE>&LI#+--V\8<W)TEH_9YNV%KT:V=BE-$2VIUG=
M,N%;"3L>M>,7*=<9EYG1BL7%^/*?6@6^6K5U]AEA+O*4) \R=!Y*UQOWA[*6
M\]-)VZNFI?%7.:IXGX+W;NK><?0>C\>%76*U47*9$/0BQ&G=/.UM\/=)EKL2
MV5); U]%3P.IU)[':W#N#(6<OE%.WLX-K!'I_A;+V;&[K4(-5@J)+NYRMNL@
M,J% * 4 H!0"@% * 4 H!0"@.%N_X'<_Q3,]QRA#,'[P'_Y<[Q3OW1KM_;G>
M"J7Y11/UG6>D?*8_V_\ 93]QUG]?&:5ZD]@?UF'^:E^Y,(XAT/S?TF8RY^ ;
M^Y_THKVI#U$O--6[U=(]4NPDU=I^9[E46O5KNUG46?5HVUR'** @N_XGW140
MTRZ"FUZS\I=I=;\&37^,#V)\WQNK]$PZ\Q^W;[.O?/V_W,C9?#6B/+LR^4?1
MD@_@T;ZW\RO$4_7=7A-IV?5+H/ ^HK]0-W^XN^Z]77[[^I/H-H^R+^IK7SI\
MX%?X7<?Q@O[S'KR5Q5]9?G/O'Z1/N\_TKE_\M:^5,W#L%8E9\KJ/2]_R%TFF
MFO'SU16A<5I@;5#L'F^G52Y12N)H!Q'MBC>#Z!LD=P@N+T&G]:Y/T0Q[E9!P
M]Y<?FWVHU)[3/LQ?/Q[)&<3X.W\#C;+Z_)/[82:]-\-?5H]#/SA?>0_JJ[\W
M'][<+I.0?J>N7YV>^]N5D^;^HW/FWV'F-_5;WF2,0CKV_A1Y5^?V/UKPJ\X<
M8>MEYS^0CYS>WY?^<NO_ 'W_ "HE);?O3]<KW36H):3S7:=8/I8/U7S/<%7,
M?42Z? <,_+-E6X% :#X:)^?8GW]%7>3]>N@N<IZ[J9>M\(?3XWR?7_9>X^U^
M"6ZO0W 'K5T_HH]Y?=]\J[T+Y,#(E:_!XY\OJZ?<%;NMZ(]!Z\M^H?1WBV%X
MI!4.G'*%@HU1/M2CSCB?M\0$)XC17'YU81QWE;>:R$+=S9V5=KBJ_!9J#VKV
MHW^'IV94V93BG7J9:QZ&NF;:S?/%)T[,+;ZT8U^N7>:L1EG008KRM._BNGM&
MOEK -V\/9*[/9>Q1<B1K3@GA'=6=G)7HK9C*OBI4Q70^0N/#PV^G)U"#\7W!
M((3H!=;$D <O !!M&J1IV#R5F%CAK=^%%#3RQ-L+@O<T(T4,*<L? <C#\,_I
MPDI6E<&0.0)T,E^SSQZ6H/(&K8CNSPXDZZ_,KL)<.Y!17D)=3[#C_D'<&:=+
ML(^+RJ,M/5@1G/#"Z:B.,,=ODC6SYO\ Y/\ /777=PY&N&QI^*7"]G'#D5A"
MW^8CKEQ\-CI\@>M2&X+:DIM\:WI*XMM*='%/L@:^I :_;JL+G#>1:;:A1+XI
MTV\/99PU=3E.$-FB6$8K7T%FSJLVDQ#9?>IK#,/8[B&Q!@2'TA#+:2Y(AQWF
MRE+++20.[=]FL;SN0M9#-0MVJ4>."H:4XAX<R'#7%66RF[U%6IO:=$E[M-)E
M>;8?J<8^XL>ZJMD[A\A=,>T]=[K^I+H/26?AU_6#^EK._P##7674/6/H[R.1
M8]X?KC[@JW.PN^5U$:AQB@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% 0'8T=_X=EM[B" Z@. %.NA 4"$GCY* @.VV"^VXT_%:?:=*5+;>!
M=;YD%*D*0APJ2VIM2 I)3H4J&HX\:FK%$2SEBM+VH>A-OI7'5$>2^MUY$J.I
M 06IB'7%HFI"!HGO0OEU.FG,=8'=W<AO:LEHCJ4N-;HD9:N75R,RB,YZ/+H
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M/N;[-S/5WCZ9_AW>ET;].05Q'Y!QAYN!FS0>SV#7SNXV_J+-?./L1M[A%O\
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M.Q\.K[F?H%&GNUG+\A=)S6_+;YCD6/>'ZX^X*MCL;OE=1&H<8H!0"@% * 4
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M<UKRWT'(L\$GZX^X*MCL;GE=1&H<8H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M^W09PYN8 >C_ %./YRKU;RR[7C4+R_Q'NN48UFJ>[V&W]_1TRA&GY>Q=>/\
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MXL%LNE+J$<Q0@K0!WJD@DAK11YCP/;IV4H2L=!K'N$:2^[&;6?6&68S[S2@
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MQ:]'Z9M*+K@G7"N&BIYSW)N+>&^<^UD'#TL9*7C.B6.&A.N*T,K@_BF=TO\
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MKEN2VG7F+6U'8C3G)FN,Y10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MA?L]S?)_L%I_H1O+XJ_X*'\95TS?Y-DW^HK9_=RH_P!/<WR?[ _T(WE\5?\
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M3<AJ_)-W_1&MHO\ G5[X_P#"+$__ (451_+K_P!S^:_"77^LV=_:;P_XEO\
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
:4 H!0"@% * 4 H!0"@% * 4 H!0"@% ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2226999d1-bc_reverse4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-bc_reverse4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!R .0 P$1  (1 0,1 ?_$ /8   $#!0$! 0
M       '" D! @,%!@0*"P$! 0$! 0$! 0$!          $" P0%!@<("1
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M^7ON;6W_  :7]]MM7&Y'=&+#OW(\6"'8&-Z4'_DY%:8V\0[B#1H_^O/*\/\
M_'N6^V[&VHC>2H/%+V![0:&2N@#0!H T : - &@#0!H T : - &@#0!H T :
M - &@#0!H T : - &@#0!H T : - &@#0!H T : - &A'8QJ=@?V8:OR"OXC
M0^E/?W]ZG>S\)*_[[]O[(VU#3LCI.H3^&^GW[]]/_;#Z97(K>(YHOE_LAT(K
M%VA0T : - 4';;CM\G4=@8_( =@!N4=PX#[(<>SAJJH]Y< !QV#CMRB/EX?G
M::%FI4! 0X#N'GU;&="[4*&@#0!H T : - &@#0!H T : - &@#0!H T : -
M &@#0!H T : - (%U'"!<068 [1]6^1_?B>M*M617CB*S3_XI5C['X?ZG(:R
M7(;M>?PL,*?8I;/J);]17-/[/$=47M-\C\S5,*Q?H4- &@#0!H T : - &@#
M0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - )KF'[FEN_P:
M3]^-M 8L.?<<Q7][FC_:W%ZIEB$1GX=,Q^+U+?;?C36=3I_!#QM4R&@#0!H
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M^9H'0S!OL&^V^P;[<0WVX[#YM 5T FN8?N:6[_!I/WXVU5>H,6'N&',5[?\
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M<]3825".-)*Y!05D19 [!/OS)IF5Y>82E$=@K2T">CWB]?T)NK'_ $BV2?\
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M_2+9(_R8MO\ G'TAA-(/Z$W5C_I%LD_Y,6W_ #C:0RRMP?T)NK'_ $BV2?\
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M'DX^3R:F7F:PJX%DZ%AWZ,^E7;L'IWPL/_\ ;2K?HZTS._F.NU"AH T : -
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M T F&:%+ AB?)#FIR24+9VM$MSJO32Y1,C$S3: ?K1<@J!1 X)M'I"*&$.(
M7AJIP(EI<4?+=B+._B%]1/A"9&S37^JZ.Q_GC&64,UL7&0%RNS#;(VL0=+F*
MQ6X]R#M%V5\X77<,T@V'TW)0T<KCQ"M-$]R0WSJ)\2_K<QDC3J6\R39Z;?\
M%W3UAJ7S+&&*9R\F+U:<B9?8R<@/))$ 3K05<9 <PB)N0"^8-9R^WC8N+2[D
M:4?AP8_Z)SW7\]^-5T[JP41<:\K2NDJOPLN]NE<;QK&?DUKW?)152OKI2;Y5
MPBH9^ $5,0GT0P\ VW&K?P]HRFU)GV?H?26S*!WJR@%'Z&DDB"H]HD(HJ<$A
M#SD,H([_ -=JN;NFU]MQE1I7:VV\W6H4- &@#0!H T : - &@#0!H T : -
M&@#0!H T : - 6F[/D#JF7=$"+'_ -X<EOQ I?\ G$PCICKR-9_=CX_ GI3_
M &0_MC^:.M.QG<9]8-";Y>^YK;O\&E_?;;48//AW;^1S%7#_ ,W-'^UJ+WUI
MWJ2HA,;^'1+?B\R_VWXTUC^1K^*'C:T0- &@#0!H"TVW*.X;APW#VQVT0$*Z
ME!*&!<Q!PV+CNRE*!2[CN,:KV;#Y]:4&<I2&Y>%>&W0+T[!L("$%;=_;'(]R
M'Y>N:.F=_!>XD##^KY6M&$5T*&@#0!H T : - &@#0!H T : - &@#0!H T
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M]MQ_%_RGJ^_Z[\KGZK.$L\LLFN;;\SN0[/E]GMZ]1P*Z - &@#0!H T : -
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M &@#0!H T : - &@#0!H T : - &@#0!H T!8?@41]C55R,@38<?^D-RP_\
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M[.1OXZ_2\#-NX7$G1^R9KG9E;'09IGRWE3?UH/64U4@("@F-L0?1\_9J*[?
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MQFY1.HL! /W9 +N<#&$O*43'*',4..WFU88DPFEDP,ELDL=,QE"J+;$ J!B
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M$!$?*.CA4"1[M0H: - 4'L[ 'L[?9'VAT!XWBITD3&3(90PCMY.4O .)MQ[
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M?)/2K.48TQ$Q(D?W8;[!OM][U'XG#M^DR[^.3G%3&CJOW.>'<;SQF[UW4O\
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M*"XHD<B43 783 .BAJ[36OQ#E4CP^ H38Y5$4C$]$H@ <H  ;&*(\X<.&PB
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M2)?"O7S$E&Z:+QQSB*6Y_H>^PB :\WJL<<^UT.SFO'0^W^ ]7GZ+\ACWL/\
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M   B'8(\-.&@+A(4?)[/#@/#CY- '*'F]G;<=OE;[: IW9-]^4.T!V\FX#N
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M_>]S(N :T]!8Y=^4PBQ5 0#M'2'I8SU*SF>1(VW#E1(7@ E* " ;B < 'M$
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MVDSTRX'GY&F2DKB/';IWCUHA'TTYJE! 2OQS1X:19QD:@6.!)M&MY!518J!
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M0<PBI(AS..99H0VQA 3;CL**;;3\"]2<.*>W;XU/H$0)W:QQ!0>) ."!C&
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MY1743$%3$+Z?'@(CJ6X&\8LU--J$L;1))H)&;5 K=N@=))NDW111;E2 =BH
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MQ1$![ [ BA+Q-Y3*FT(D9)ML.W -^P V !\NW .T>.J9+] &@#0!H T : -
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MU.T<1#?<?CK9MM_/\G54-!RFAV'* AYNWLX"&_F'R:R56*@ !P >SR</_AT
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MB9SJ&YESN2" B)0 PF'DW]H_9V<-?+;M'(]-2);Q71,7^@6)1Y0-U\T/CVG
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M\60IBCN;?</E;:RJ4-OCP'8]\&_ IA+N "8 #8!'S\?S-:C34S6^A>4I?=
M@(CY1\VX>0?+I,BPG>8ON1Y3^]Q>/M9E-0JN00>%7_FI77WS<F?SLV;4W#1>
M)] 5._BE6/L?A_J>WU0[C=KUQZK\)_8I;/FP=N#4U\#5L?$<Z^,)&ZYR@ F(
M0QP*("/,!2B82\ $?2 -O9U=>)B81$KXN%TJ]4Z(LH-+G*6ZM1EA7@_5YO'U
M1>7&<KRZ,TP.:7&)(V$J96!4 6$Q0.;8O !'AJN'#0F&YW16M_W&->#WGVP9
M-RQ)U]MU3]0>>L>5_&S.*CH_)>.Y"B0T*^1]<5.5H46K1(ZK)!TD4BPAW@[
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M@BXW.CU"AH T : - &@#0%HD*([B4!'SB&X_(TKX$A3.I02%$  2@;E$!#<
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M!(Q.[4*<<DW,3\Q $0 14*/E'6;'1NSX+W$BI/<A\SR</T="%V@#0!H T :
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M;ODW.^(K33I*&J;<F(+C8(EWDQNM'NRP<$\9QUAC&B*S-O#K*)J*<@!WI]S
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M>M:]^+M@3!MIM&0\D=/]GHCQ%")M'Q7J+CUUC 2;F+BY-8O-0V8I'-[X'Y#
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M64[LI1,?<=B!Y T?&_ 1XKCM!KBUEJBLX7;?0%7B)DGBJ2"1%9 -C_1)!P4
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M);)#4:Q]7DO9[%$1;)MG6?>/E))48MNQ9_%3'G,H*SA- KA4A""8$TQ44/P
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M"3;O$R&YC<0VVU<55\MO SW+8ZU]C^)]"#,P&$P@(&V*4IAY>4P& 3")1
M@[ (<0W[='PL77>>[4*&@#0!H T : - &@#0%I@W*(!VB&VA<7#3-89HIRHE
M*(#R#Q,(  E'T>'9Q[-=L.XL4UE8Y>I[;[O<Z\;G.S]0AI\Z!Y:"KTR8ISD5
M++P["0 45 **A2&=M5N[$XIEYMMM]@W[ UY\L.UDV\L4T?4]-ZO+L]I]OK[F
M,JG3DU7P:$PR1A&F9(ILECRQ5F"3I\XT782$*SCV[1L4O.@9)1L5J@D""I>4
MP<Q>4=A[=>;U&/I.QC51CE-4K?$]GXC\MW_1]SN]SNY9/NY/'IEMREU2FF]9
M7D,'Z'LE6S$-[M/1SF&0</)O&S=$F/+G(J"<V0:J5P[:D3*Z7'OW$E%MD&AD
MRF](0<G'?AKCZ;N)OH?W1LO ^O\ E?2KU_;_ .9Z67VLG+_Z9LZ;X?5&L$LR
M4J@=N"YB*)[&(F=(XASIBIS"7O  PAOZ Z]RR1^2]3V<O3Y?75:-:FV+Q#</
M* ?GZV<2[0!H T : M-V?+U3+T($X\VW_2&9</\ ]0*7_G$PAHKY<OB7-3T>
M)/00>)@\H</E;AI!'H9M0T)ME_AC6W?X-+^^VVH[!&'#O'#F*_O<4</_ ";B
MOT-:);S$(C/PZ9?\7F6^V_&FLZFW]J'>.>;8!+PW 2\_;R#L(\PAQ';AMP 1
MXZ-F3YD_'\_H^RJ?3A7<D4:T7;(1,A0UBIZ\58QID&A Q#FR(6&,L=A<3M=3
M<,%))?O@8*J*)+@F4PICW8;:3<\U[-P:736:/3?OX_$=MX.EHZ?K-C[,1<*U
M:9@G[6]2 7 [Z03FHXSU.0<E*PK<JE)RC,8QJ;8I$$E")D @ 4H 4-DZ$5<I
M\]MMQ-8W63**8"4VZY ,8Q@X%%, (!5/(!P ./LZ5L24A/\ -.1/Y)L57W)7
MO6XF@I=8DI\(IH F<2)F*/? V2 #$$14-P'80$ U-3>E#YV<;^/':K%2LQ6*
MU84AFDU6&E*=XN+6Y1=Y R[^^W:H4]K6;<JJN12,L$>-N%5P7D$ %LH &'@
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M Y5J;ROZGK"FFVR)QH555:,:*KIJ)*F1()R*$23, \H=I$1%,GM!H26[FS$
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M!.(B<#!RFX;<AA\NP:.%*82JFJ1\CYUL?>"7DEM1\BQ4[>:U6[ I"4>)J#6
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MZ*JM&W;-T\_:.+"O[T5& CD#*RUEDU'31@1G',D ]Z#++NY5%,IEE$^)O2$
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M5]8N?0VHFKT;=*IDP$ +TZX43-N E$#$QI5P, @(>?3))I<C*FK>K8F7B@@
M] O4\'D#&SWY?OA'Z)M.4;3:KJ*;T2)$'HRZ30Y!V_HUX+$1$1WW_DOJHCY=
M^W5ZLFYU#;==1U( &VP!P#?S^<?/J&3S^Z6.4>SD'\TG'Y.K2.(G+P(?.K7A
MXJWAG!MV4SJ0#R_!]-#YFLNZ1M?9D3%_HC^?JG/YD17BO_L?01^/]0/YB^I#
M30+[O ES3_8T_P"P+_:AH4OT!:/;\D/S2Z ^?GPN?\X9XE?V;(?OF,U79>/O
M(OOSYX^X^@4_9Y0W';<-_* ]NW';4*088V3*'CN]00\G,/\ 1J@ ,H<1,9
MK>'B;H\1$O>%X#R[>Z$=34KM7<3D';)+)]V<HB42@7@HJ!N4H@( )RF ^_HA
MY>.M22G- FV23 Q2IB4IN3FW.<XF[H"E3WYC&'@4@:2]3,"%=4(<G3;U&*$#
ME.7 V6]C@(CP+09X0]$=RAV>;4A])M5R2&"^!Z<ZOARX:44$3*&LN9]S>P7-
M^2=N(  ;; &K_%/2/B8_EDM))="]A?[,?[0VA="%?P<@W:];I1+P'K>ZA]Q
M=A':^/>T> [:SM[36NVXFG,BF?83$'</* F*(^P82" F /9WU9)!44DQ#82
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MKJ,GU<2_NRFX@ AN7E[1$-N.X"0WH#V^;06H6E;I$*($3*GS#N;D(0@F]L2
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MQ651(H= 5T3J-ES)"<""*9S@(^4>W5>_0RMVIO V[0[!#?4%=;%="AH T :
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M(^;G2,L"W,0AN0QN0X>EP'8"\G,([&#L#5ASP(LL6I1Z!6(7?<X<"\X]H;%
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M\?W?4+)8M)KXB?5;J'@!C6LA.+G1;R19250%5(QE18MS.DTQ1(FF)C\6PAL
M".IA^7[75]5N!]'N_ALNCZ'&24(]*W450D&IYWUQ[[WLGR+!^IZDZ#E7?]R#
M,#;H^Y,+M/VM'^7[4W<<A_XKNN<6E5*/B5+U18P/(BU3&:,1Z9JDJ]"+?@U3
M,Y6*T3-WHHAL4%1X[=ODUYLORW;>3Z4^EWO[#QO\1WE]S74J>.XPN>I#'(O&
M)#-;,[-.D5A8Y1K#2RK1QW*S@IBHJ)(BC[X&.8P 7@KMR>02Z?\ E>W?7X:^
M-S+_ !/>B$UTWOKIX41V\+F?'\E69^SMWIQ:5)I)&F$%DG!9F.1AV@R*Q7K
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M5QSI?<A_5Y-'<F-B[4*&@#0!H T : L$P>B&X;CQ[?8X?+TF U*<7(\O%8(
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MZ:FG]GBQTYBE,(E,4#%'M 2\Q1X?IB[#N&M:F%8L3023 0*B0H\XG] O !$
M+SE$WN1  \FW9J26$7G234#TB;[#P =P !\^VX .@A.Y:*"1MRF13V$0$=B
M #MMV[ &_9Y=4G*QC4*5,ICE2*!@+N4">B;T=Q+RAN!1'?M#RAPXZD-T+]*J
M,*Z^NKFN](N +]DUS+Q9[S'T:Y2^*8*3=KLT)^V0L,NXC6SUN5S'-W2 2XH%
M,FH<"F(.P[@/'4:?(RW],\-N! K;?'1S; 1&%9"!BXJ0 V!L;9>S/ZG&0LDV
M?2UZR/E&K.8B'1=OUIB/%O$8[(;ND"H<@K@??<P"&$XQE7TY[;S?2^MIVB7Q
M3I'LT')N.H;'><O&YP"YI;;(IYFK=)$##SJ5CH%MQNR%S)9$R-(J!'K99KU4
M-9&*17_I.8<[LAN)$CF4*(!I;T[HCEJ,E9T]A]'D1(I/U'940<"1N<J:AUVK
MIH'K.VZB:17:2)UDR)B0>< ,41'8##L( B$2?J-YJ%#0!H T : - &@#0!H
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M+_W-;=_@TO[[;:$=C#A[[CV*?O<4;[68K5=QHQ"(S\.F8_%ZEOMOQIK.IO\
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M3)6[>;<]ZN]5.<JBHIJ''F, F !#3::4#I:;6WA^G@:D?#QZ$F[=N1?I)P(
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M'B;8PF*!A$-R;")!#@/DTHZH5F'8]6H4- &@#0!H T : - &@#0!H T : -
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M@#0%/-[(C^?H0YNVVJ%I5=F+58WR$9 P$>ZE):07,!4F;)HF*BRRG:82[!L
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MQ^15W^XG-?/+YF0EPH8)@JE;:6F[!-$ <#8:Z0J@@(%%41;O-Q* !RAS!Y.
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M P ;F_5<>;8/8UF=1R$*ZCP ,0V80W#<&V_$1X^MI@&W-OL&M*\$4V%9I_\
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M_C(7[]L;Z:OF-#H^H3^&^GW[]]/_ &P^J[D5O$<T7L#Y'YFCN3&Q=J&@T :
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M[&$;:2VXK62@ZVXF[O<)F+J<8\0582[&#BI*<<,DBN(\5T^9TFJ8!4$R8AZ
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M25_'@X\K[;A'6GA/]%<3E/(&5"8U=SDCDB.E&DM6)BU6A>K0J\]".8*>4KK
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MPW3$V^P@;CVB/S=3621HC0+I"=JX*T43%P0%S)'<"8A?7Q1,5IS 8R:9R%6
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M4@I0"[=A=MO,!>&VP\@>78=4GN "@ !L3?;<0$"E#E$=M^4! /-I<6G:2WD
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M[Z&X0:)(&,=,!#GXB &,)0';8=N81'B/'MTD'JU&40/J0^X_9?\ 8O[\3U=
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M;6W_  :7]]MM 8<._<>Q9][JC_:Y%ZNO@1[>0@\;^'3+_B]2WVWXTUC^1O\
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M#AP[.SY0A^8.D -M! ;![/$=^T= &P;[^7^KY&@#E#CP[>WB/E'?0!MV>QH
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MG6/L?A_J>WU"Y7&Z7K\*_"?V*6WZAV_6?Y>!;XQQ'5A[LP>38!UO23)?J -
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M"CS!N.QNW;CV:16Y:08#RX$$4@3547%NHX2(F!>0_*502IG6$!20$13[3B
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M,XY$QJWF<<9'L4E-Q6/:P,!6HVHRT?361$J_ZH0)A2XJ#"+G.]<N'#<-T@
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M/NOTHARAM_JZ$]I0Z8J%$HE 2[CR^B8!#]4 \W$>8P#[0#PU4X<HCQE%2);
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M1Z/=Q]LEV)XL$6\^D/>+.$TDXD@%#F+L!QVU7-WR)RO,\A[22*#=%)H@":0
M44B%(.Q4")))II)[;[$ "AL #QV#55^"+DZ0;I(!*F0##N(!QUDIDT : - &
M@#0&-3L#^S+HAJAH?2G_  [U/_C)7_\ ;6^CN%9'3=0G\-]/_P!_"G?MBNJ[
MDQ^W;@.9#1DQL5U#0: - &@#0!H T : - &@#0!H T : - &@#0!H T : -
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M ]'G$H<P!V]NWDWT(HU+^[)RB0 #80$IM@ .!M]^SV]!0P>IMA2*@*?,F4>
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MLNBY'0]08;3G3[]_"G_MA],K^)+CG0$!#AH16*Z%#0!H T : - &@#0!H T
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M^!E)S3XGH2Y0#T0$.81-P$PE..W$-S"/+L/D]C6:ZW-4TL9P[.W?Y7RN'FT
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MB.I$5+,TU/$9P5($3*K;*.!Y4P.<AD!$!*'NTP*7<1,'Z;6O>8X*Q[FNW(8
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MM-QW)Y&JU4?7^IS=HJGOK--&F0:/)Q\>-:6<Q$5(-$U) JSI0FX[F*U,)1$
M$='P_3S+1+ZK[M3BL?>+2WM$2*<_B";@+I9TZ&3$]24]^4)'(SF[1LO)-QB6
MSJ&%T= B$8!RF(4P"0W$?+I>(K[8YAVEPMM#M;9XE,W3%U*1,X<E?Y<HH;/8
M)_$+=*;4L@XTJDM$P[^^0;)./7?244Y<3S0Z*J*;A-1-3<@F#B!5M<CG&N5O
MCMYBR9KZ[*IC4F':S76+6P9-S[#OYW&-/EEG4,>4C8MHU>O1?BX3;G8KD;/2
M>BL= PF'8"[\-51>1]3I%5M0CG0ZOKUUP=0?3M3*(=YCCI^NM >W8;''/V4'
M='^1H9S2HZU51)I<63D\M&UU>V+)&,VCRF4.4A@4VW 2::EQ&VW$KQ>+Z5,Q
MY+1P.XS7XBJ&"+C/X_K%"E,IQF+(BO5^YRT062>3R]_F3^KQ$&DQB(QT/>'8
MP4LJ\,1!0$EVY"F[H3 4U:;R^),8Z7E;6!2<U^(QB;%=&4G8^193EH;3$97I
MZ#%&0.UH4N_CI5ZZ"^.6J6U?:PKN'48N1>'9 FZ.4ISD-Z!LA*7K$QM\#A3^
M(XO&V!&MS-(C5)&R8<K^5<<!!S0R#3(H2$A3FD[$51\U(_:S$A74K<DLJV:G
M7<^KE.J) (F<P%$U?SV_40VJ4X[6CB)O!^*[*2&7H7&4OA"8KJ%MO61<5T^8
ME%99HC(WS&K:U2$Z#\742W1CX)1A0Y445U3))'/W!2KG%0@*I4HJ4IM6GGS/
M*;QB\?Q,TI$W*DO*TBZPW3\CUV4>EF4(>Q6>VCC\K.D1TJO%ECW+]9&Z+N4>
MZ5,H=M'*FY1*!SD2EETCI>7;7<5<7[A/<P=9.4JMU+=*$IE:"LF#JL2L=0CC
M+U)DX:0/!V!Q5I&OPM5?M)][&@8\8YD'*9FZ[58Z2Q79! YBF*(NIRI+CBGB
M[[^6VHH4]UT0U\A:VK;L>9#IU>-E3'Z5=N--<+MJY<!N%/FY>K0;B7F*C8XZ
M0(2.=E.^;,UT'1'C3B9$J:J(M=MI,IPFULA1<2^(E*WK-Z.&W>(9VL5Q7)^5
M<)1-O>^^AW2EMQ/8+17G<HZ9K1+<GO++C2GBJ*VQ$# HER+' Y!/6H?(DOIE
M6:.KS;U_5'%=FN%=39(VR)Q7;Z;CO-]E8NEBJXZL.16":E3;O&S9NY(U=2/K
M[9P4BI3[(F,8=B@)@-I0U]S]@Z7,Y66TC(:KU+I5_)MUB\CS^1[BR1ZH;-#8
MYD:DYBVT42'C:]=;*#*650ITXG(LPCH@W=E35;*+ 4IRG$.!C<UTCD'.,557
MMR'"0GBU8^=2TU,R]!G8;&)Z[/OJ=D(6LZZ92UHK]O;4A[5)9)*#*2%=J3*J
MO==^*1CII\Q0,4>;1.<8I!6ECE#F=^GGH>2=\6QI7%CT5[B)^ZS<E8JG'GQG
M&R;Q_(FKF0:B-RIELY&D0Y6;QDA'/&1#F/NF51R "<IMBZCB.)I8Y92TH2VC
MGQMP.6K/C(0QI(KC)N,7F-*4D]MU.D;1+'F"I163Z9//:W(U1^+B+02(D[DX
MIRFBJ/(4QN3E.<!#FJ4F<H2FR?%>7ZG<?E1;:ZFX:KQ'3U:9*6M-O+6ZA)IL
M[$2NVAJKB>;RN+Z&DQA18OA8,8<[-?NG)R@Y34*/(<.[+--N14IY[OCR%LZ6
M>N4G4[D"[8L=5QC0;C2H,'DY4Y-RX1N$3(LY2+8O&[^OR8,Y-%J^:.3O6:HM
MRD.T514**A# <]5]MKT([;;3KR&KVKQ":S@6;ZD9: JEIO<O ]1=(PX]AYA^
M9%H2>G**TF&2T6#2MM%4VHHHAN G6 3#^R!V:C<JI5CE*Z=PZQ3KYC6_1A;.
MK=S6DTE**[?Q5GHZ:SM=9O-1V4UL6N&!'*:!G&Z<@D*IMDC\NP@([ (ZME+F
M)(OJ<+=[AN$7XNT2UA':60,>.J7D-Q-5&/J]06"7<MIYA?:%7<F5212>%CN5
M1:3JUE;@FW(IWIW @4/2'N]9;2I=FL<7ECU0TCJR>*B -[ 9_A:U03VM0U)E
MW<1-L[!'SKUI;,L5/%AY%I#O8%I(^]B;FS>MHG!)0!03 XG,GN?6J7T,*6^G
M7Y;>53TAXHCA2V9%@1PK9(V-J5EH&/Z_)S))F.+8K]DAK0U:Q& H]@VJ*+5T
MI>VRAMO_  4HJ]X4GIEFURP^:VGA8X>U^+6_JMM;8<=89?N,[-K)=JW8*@V5
MEEX]J_I6('.?7*$>X0C54W(*XH32?'.5RJ5,5#"/N13!5/I='Y>\L?R5O/W;
M(VDAXK$(]=X8*SH+OXC9O<0U8-.MG+P;-79ZTW9QBI,R44:*47,WB;N( *JK
M3NA;D$PF NZH'E;=K^]AC@J^SCOI?]*V%A\,[)%WR#2<XI7:S+VIW4<^6^K1
MKMTDU;OFL2R09.&K9ZFU103()17$2B*9!.02CQW 1-UDO3TI7MR).";B4-]M
M^/8 @':.W 1$> :&;%V@$$ZD/N/V</8:?OQ/5WHB^(K%/_BE6/L?A_J>WU$:
MRN-UO/X6&%/L4MGU$MVI_(K^SQ',27I(*HCWA0<D,V,HEQ.D1<@I&5 O*;?N
MBG$V^VP;;CPU=:&555/GBZ8.O/)%'QY=YF7B;1FO(-]ZXLM=/6/X(8QU%1L<
MPJM4QU/Q+<Z;.&.X,HJK8E$RN%%R(G$P &XE'>+*:\366$4K"4^'.P\"N^**
MSOJ=<@L8XHGKKDHT>QG+QC^/),'DZ]$!?IZBSXLA)"F.Y7@PK;EZH $5%-$.
M8Y>38PUNHQ4J??[*\S1QGBQ,I.RV2"=XDEZNS^-B.-J%-6-:48,[3D08F"DW
M4,*KZ'CT"HL1M<8542G*  OQ.7R6(J8Q<M+CMR7%A(^*HA&5K'DU<,*VFJ*V
M*6I\;:X^4;3[66K;RZ9)>X]KR+2,<P*+X[E^Y9$<-A.DJ5P*Y"D*(<32SW,U
MDU$JVWF<?E?Q#<?73$/46_F8ZWQ$/AN0K0R4;1'8QV2R)OTHR2%>4BIJKV=W
M',U$U V4/%E(9$IQ > F+>I=+RR\OD18MYK''V_&WO-RCXL,0TRW3<;)XDLS
M.CR>7(W!I;W*(SAWTK9U&=#><D#%%@&9Y5RFROC0PD0(MSJ' H" CRA+)3^F
MW )3EEPOP6TU%NP/X@;[,N:(;$".-'I M]-7R35;5"^^<E -*>UF)F$,RMLB
MDR<1M>N!WE?<G&+>.6C\J!D3BWY%4S'ELNET]XJ\.O&;[>9ZY_Q$Z_%+Y*MT
M53)&T8.PX>^%RME2$+(OHFAML;UF/N5JEYI1E&.V[:):UJ1!<JIQ*F/<*['-
MRF*35-OF%#F*KV\HO/Z"7V[Q3$L>J-&UMQBJ=[;(6A7K'S>'?/7 3>.<AV"S
MU>'FG!T&$B /FDK3'YG*7T(Z* HF433*<AU,UM^A8I'\O/W&RI7B9N+W'#4H
M+&AGN?DIW(<)_):U=OE'$B.,H6LV&S+1J/J@NW!VL9;&AA3(=4VY^&^^P6CL
MQ&2NM=JFGE/%6:,IJ*:-,/6J19G52A[@S9Q]B>3>.K""G*_)<4&L"HI"1,:B
MHFJLN\0;)E3,(BH4 $='O<E2EN&K[4$ R-XSME84E^>E8@CH;)$M183(N/('
M(#R5:1ECJ[F2L;":DG+E4*T5!%B6#*9/==,5!.(!S;:DI7OR)CCEEHXYKR'"
M1OB:WF0M^1J0QZ:K9/R.'YZA4^_2D(K+K1/Q@R"UD7$6YAU4H!Z@YBFX1"PJ
M"DNY  VYE2[AO6UIM^@6.='DMOGM FU*\4/(64\I]+U;I>,8><I>6YS*%4OT
MQ%K29W479*&&-EA2A2&<+ 2,,TO)1%51-P0Y@'E4]$P!?Y8O2:3\2-SADM4J
MQ\-YT/2EUL1.1<60T;TXU6?RB_1JT5D&P1]XG$0G82$MBTRSJ2K@[6"JI2^^
M2U0E=DQ0!0OJ^Y@ #%W)Q:^GAPXAXN[HJ3X\=-I.0E/&HH:U1E,@X]QW(6:B
MUVD5;(5KFW2LM'E@H675MY99%\"\,@*+UBA62J$(8H'V4$1((;;3)_3.S&.+
MG3Y<?TN/6P=UL-<UYXR)A./A(^.?8Z^-+*9;N7YFMH0E*Q),(_F- /@0?.8B
M1,].!':2/< = 0 XB.P'1T*JJNT\=I$HLWBA8\K>19*()"'D\2U;*$)AN]9:
M*]7)"UN]V!U,)L$%5"1HLSQA&5>>KJK=X*)2D+NJ4!#FK58T1BL+I4MNUA .
MAC,^4+9C;,_6AU96&3Q@PQE9KDUF8=%W#A1W%-JC2.GY&=3C58][8&1F)71B
MJ&,^4(=-0H%*!BF$T;QHW)MK--XXK6/U_06_#7BD4V]SR5>N-4^(YX_'267[
M8^%R^>QU4QI831YJ)9I5YZCZL@TL[9=P=,ZBA"F]7'E ..DKQ$-Z1S^=O ZJ
M3\2.H/\ -%*Q5CJ(8V^/N,/"2\'9',@K$I7-O869GK4U!!TBBA95(=)$?7TV
M9GAT_6FXG!'G+WE:>V\BB)G]N7O$0E/%[AV'3T3J 9XU7F(R&ICJ4R-6VBLJ
MG.8VO,<:)1DJ#:68QZ\C&2S=X]<)%*Y;(**&9J\I!Y#\LXZ!?525-731'=4_
MQ.2RN1X_%-RH;6GWAQD@F.W];<OGA9>.D9-C8I"#3=,5T2N6J[Q"K/ Y5"@!
MQ(.VW*("I)>G*.J#S5OQ-#94")@L-XH?W;(B/O\ 25WH"!I8)^ K$'(Q46_?
M1S88]-R_D07F$C$1(DJ<2E,($, ");U)\@\,L,6VH>[;7>-PQQUY2^)<M=6.
M,+=)K7F=<]0-C@\+U%U'.TI8]>KTA8B340LM'-R#[YH_WF4A3IIGW WH&X[$
MDGTK2T%RQ2[2R<S$N>/OC@=6Y\2VDP-SOF38O$^2'=M0PYA:VNZ&]7D$!:QE
M^BW[IFS")/3$9<LI''1*10XF'GW'=(ODBW.Y*]/6J8Z3K\N3)"^EGJO7ZC65
M\*ZJ2U,GL:7I[1[7"O\ UQ-PR?,%GS9=4Z;Y!JL0AEF0@7;F ?((ZB>_<&LI
MA58\Y,W. COO^=_6CM^F+Y?*&J3E8R: - &@#0";Y>^YM;?\&E_?;;0&'#OW
M'<6?>ZH_VN1>J98@\;^'3+_B]2WVWXTUC^1T_@AWSA4$B\YE2I$(!CJ&.'HE
M(0!,8QS"(%(F4 XB.M:&>-((HGWB@Q"=]FZVPQQ+.*S%]3DUTS)6P[>:,S=6
M&M,,@.IJ8;F)%$0=1YE<>._5SIF%$Q#DV54W*)BN^J87F+I--5^4Q^IM\Q>*
M-AK'CJILZQ8*]8"62W'J2\O++.H^"AYAI,+1$A7I>5,9K'0L^D+=5=))VLF=
M1)$>5,V_,!QIM^@Q3:;OMOWJT%Z_B'3+68R#1U\=QZN1*=9&+6&AF,P=XQM]
M3F*TO=X:P1+EL59)8KNIID5$R2RI 6.">P'$":KIN%.-XMKN$DIOB\1EM8VZ
M66Q2^A(JNU*3ML<XD'4DV5FTX'(T-C.P0K1)U%(*+2\?/2I_H:93*\J!A[L2
M@)@GF1RE+UV]AWT9XH,-9'\G2:M0'4WEUS)Q#&@XQ1>.TK#?"/<?O,H2(Q;4
M\;ZTHO!4V*>+N"IIG])L?<"#Z +TL;Z<E>^WE\AM!NN:5Q5UE9IN^:UIBB48
MN$\7*P6,;"P<1CN,R1=6V'8(L"_%[&)2CDZ4I8W"PE*FB8J(=X803*8VB=7B
M,L5CACF[.^Y:"EJ=>*<_(4J:O^*,JXYM,1)Y418Q+15Q&5JV1M*I^0[>E.1@
MSM(D%YV.EH*K%61,R>&)]'#E.;8 %+;K1&6\5"4-MQ[/;R^0N'27XA3SJ5N-
M$KS[%$Y2(W*F.9C)..9YZSFTV\M#U^2/#2R+LS^+;(E7+)-URAN9$P<GN1#C
MIQ6I>EV=(]I@L_B$TZ2GEHA&-(KB&PY.N'3^SRI%OU%3Q>7ZG%6#UN#?,R-'
M!4$7%RK:L&@HH5-(\@JDF50ZABIGTFIG1JO[;5,TB'2'3CL_8-+PMU>1E)5Q
M[/9%')5HN'J75A.$?QRB!Z='P&-<L]0%=AX.>CF%->NE)(\)3$4><'[<Q%U"
M&,F/*)#9>_:YMIMM?R]EIO;@+['^*;&!ZQ697%EAK=TEWV.XS'9Y1M-EJ%VE
M<KEI\G5F#.:4@VT<W=HQ5S34<D%Z8R?JJHG!( $$S<.&OGMX$2FJ_2V^W-'%
MV?Q='C64''].P\YLV6X=#*+2WU8JTL1I!3^'65OL]N:C(%8 U<,7-&IZL@T5
M*L)%#+$2(=4^P'G4ES-=#CJ_B;FK^+U3GI'DQ=J6I0ZS9*Y5W^&I"=4E(X^1
M)R1E&=3L\0",C'-56AJ]<DI% !$I.]09E.&Y3@H).:_QVL8R^F5_+:*7]I?#
M>*G:I:;JE(;].%\&\61&7FB1;J#MS-16J0L_.M'DY%Q[BNINY-DK#5]PL@ND
M<Z2A@]'F -AM(K,Z;;07*]-V[:/CI<<=TS]<\1U"US)UA,QBH1OCT+"N]9M'
MJAI9FQKJ#E1XK-QKHQWL.J5=FJGNNDF!^4!*'I!I2&Z1[]/82V254]=RUKP:
M&SW[J$RQ;/#EN75!!S:[*\2"-JG(2-BX<[]A&0U3R#/P#9N#8A%7;I1]%5\%
MU3=X @"PB   !H[%4=2X[7L+1U8=061<0="D%E:E-SN+Y8*-C-MZXX9JKQ\<
MXN+6#3E9%=NF5,R+@/?97NBJ*E ABEW VP@-EM2MN A=4-<^'%#/,&]?UFQI
MU"W3IMO[.1L\*5[A!M4Y^1;N&CHLQE**HRLJFZE6K!.(D@:2=D6,DBD1(Y$0
M(!Q-L)AR\J[:[4-KM2G+I\%\3F.I3KQR9-6/$G4%AR.EV6/<&9.?,NH&C+L5
MW'OGCBL6]Y&6^U)OU(]HYC8N!@FCA^Z=E37;MFR!SJ"!"&-K2RT>WZG++#*$
M]+\N?!:[](.QJG6!?\W^)-C*#QQ/%+TURF#("V1B4 =E.5V]R2LE>W<Y;%+H
MBBLP9-XYRW]ZE&I5"&!>'/Z0'4$H*S%:N+2]MP</&:="UF%QK:GZ#];QUFN:
M[E&4QSCS';_)[>AV6BU[,<G6"23Q3&XW:5AVKF2E4V+.0(DRI]<GV<Y**J;)
M(1:G?*F02 5@-N8_5E25Y5I_3]1N-]\62&H$,-R=8X=S]!M=,R/:\36R 6DG
M\=;G.,QN3"?@7:K",D$V<BG-45ZER&%%0"BF8""!BB>4XEAO=PK[_@;%'Q24
MTW\SC^>QHXK6<%;=1Z;1\<2;A^@>S263"5QE3%E73A@@5NW?3<^"&XG(4O=B
M)C%#LCI1W"3<O=[_ ((];KQ/'"4DPJ9</V5'*5?L=,@\J8H6C+&I:ZPSO=F1
MK\#+,4R0Z:[I)9$5G7HMUB]TGN(@'I:J4K5O;;]R6=::J;-:R^&_Y"$./&?/
M+4/)=IK.'GY6D75,^HXYLCU*?/"3V2,*8G#)#RNR(>]C4$$.:6C$5A%9$=G
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ME;C"Y.M=HM<SDUD-Y<RUE;+QC!&4D[MB66P<XD 8>]2Q$%&N-GR3,I>80%1
M%!WW$-%QF=MD:;E1IMLQ*6?@I]*R;2I,5[!F(Q:+-0UCKCTENKQ'B$M!Y"+E
M%B98?B<9LJU3MH<_("11%#T!,(^EJM8WK,F%EE68Z6A^G35TOT7I?J]FK%%D
M+!)(6VXRUWFGMC=L7;YQ,RXD[\0.PC8Q$C<A$B@4O=B(;=NHZNI4_I2T0Y,H
M;!M[?S1WT!748$#ZD!_XH+-[(- ^4\3UJ\O@172XBLT_^*58^Q^'^I[?658W
ME]S&ZWG\+#"GV*6SZB6[4_D']GB.8E%O5VKE7O"HBD@HH5=0@J)('*F84UET
MRB4QD$C@!C^D4 * [B <=;XHRDK.Q&)6?#,P'6$*RWJUAO[<8GJ"LO5 PFO?
M^$<L1RE;H^ A)9-%#XN@9:(!C4F94VP*F43/S&,H8!V HZ>E:.2.5DW_ )*&
M<W"^$UT^5Z_4+*->M&4XRS8]=R ^M0]E@!C+A&R5LL-O?PT^U4JSM8[)W,6A
MZDKZNLW6[DP$(<AR\^J\:N93CVZ;;AU/HC&.G:?TXFSLGAD].LYC*>Q8YG,D
MQ2MVR>;+4'-MIV$6L-:O46SIB;9.%?*5=:+1B%C4B/%5%TV756YU2%5*)B\A
MK5;MOU(F[4V^5S7VWPL>FK(+OWWN-TS2E)FI-0I4I+FM=0C5)IA3K;:K56G$
MF@ZH!F2-@C9NSN#%4:I->9N#<#)B8.\4/'ZJ7^)KJ;4Y1[J+7WEEF\,_INMT
M5D"N662R*LYO41"U*5M*D_"HV5G!LQ< P,Z<,:NTKB;=92373 [B/,H8@" *
M<"B6-8T3B!CEFGU)OARWQ<S6CPPL3M8RQ6RFV*^J9!;W9WG;'+-_/5I.,;9C
M@X"M-:N* NJXB4D&YD*/% Y155$PE*<>](!@$IP^<#%1U8O[,G4;YT%=&.=\
M!Y+6R!9G<A2P<.CCDJ,DU(>=A9]19R5?U>IJ,Q2=LBBV,H4JJ3AVAWBGN1$H
M@*L\8]C(HF79/W>_XCG8_P -/!37(^=\A'ELA,HWJ7K]LKV5<3I6B#^(<\C;
MH-U7;.Z0(I759F&3?UU\1N"8/^<G()^8=PV5;WLLK%4^G&_/G-IL></#6P/9
M6+&-LMONMA>5CXDQE+D"OHMFYAZ?CB9FK+7:TV.2#,WF&GOU:9 7:Y2"95)0
MA"F3$@F,A.^WZB7??M0P6CPMNGF??L91K;<E4^YPM^L>16MUJ\]!M;0#^]QM
M;A;+&R"$M69>+]XI)A3FA";,TU $JFRH]A48AYY32)VD]B7A?8 A,H7?*[:Z
MY0BD,F5-I4;W3$;!6?BI.IL@D ;S)4GU1=6!G-+!**=^9%^1)0I2 5,O*.\C
M03TOPV@U,IX473)8RP#:9F,ARIJ[BI?$%<.,U"HG)6%W$LZ24DC)5DO>R;5:
M95%-0O<D$!#F(;;1I91G6=-PEI=$J-=Y[#>&1T]RM5S!29.U9'7ALTW"AW:Z
MN6MA8-+(WL^,DYE."-67[>"*B@S!*?/WZ2K=WSB!/2+Q ;&+EJPQS>,)T>YI
M^/P/=4_#%P-0Y:@V*M6#,QI?'-PM5XK;UU,5GO\ W[R*C46EA=2P-J$T8NF"
M26/V I-D4FZB?T3F.;O"<EHFG,QRUVN93A4Q2;X/3QUW>XTE+\+;">(TJ0OC
MK(.4*:XQ]7HFDA*+2]:=$GX.LO)"2KY;&4U210,6(<6!\(G2!N!RNA 1]$!"
M0J^XUUN834Q$Z;;C/9O"?Z9IRH6?&R@7]A4KYC:-QO98EK8X))5&OU\]D]5/
M'/0K/][RDF2YNP<K+ ND(((=VFGRJ=XC%WG;@/[&IB\;*=W+S%WQYTB4FC9P
MMG4=,2L]8\F2\)*0C*QJ+QK-%I#VV02E9Q@@PC8UNR62!W"M3I*."++$#<.<
M0,.K.[9:&6VKG!?D_L!R&2;);USV-M"VN]P^5[9C4L@S4@9W(%<=S*\;,*<T
M6:7;LD26-XBJW3<%YBJE](HE 1R[+C2/<ES-8M)4T>S?Z0=Q@_HQQ5A[&F5\
M(@XFK=4,L2<Q)W5A9I!!51^QG&AH^5C&";%K'.&3,Z'#F],P\P>EPU8I+LO+
M;Q,MOJ?2W+KQG;@))A#PZ.GO MT0R*PN%SM$TO3CXTDDI>4@)"$E:3&J,!AZ
MTZCHZNMG1$*R5MW:9@7*J(+#SF,.VC6C+BX7T\Q0<@=%>.+5DN!S0Q1=O)_&
M2M<?T>G',6/JL'9:*RD8>%,U7;)LGYV#IC-N@>IK/5".#IH&3,ER&!2-\H+&
MLN9GEMQ&RT7PXX;,F$<\U_J/BG-(MO5-,P4]EFJ8ZF&(1-:1A%K2ZK\?5DE3
MVAY&.7 VQX#Y9RY=E="BB*94>[.!S3><97*LTL9PB8VV0JTMX=&#;CD7(^4U
M[%?DKID?(\)?GDS#2D(S6AK52DKFR:,XYO(UN1109BWR ] X*%4,<4R"!@Y1
MYK15BK]GZ/7PMK.IT3=%MX\$N-SAJ]X0W3K2\@4G)&-<E9GK,M28N9K\\[:V
M.J/OCO$3;R'?.V%@66HZC<%2NX)$3J,RM3$W, [<P;2%,N^W@7K;4)PN!T-[
M\*7IRRT[O,M,V+)]>NMQRT.5I.S5*QUQI,5V?65F%WT54C2U2G(U"ORBLF87
M"3Q"0<AW*7*N38_.>*NQUY0DK*GS\?9P-_;_  M<#7NPV&>DIC(,>O9:?CNG
MOTF,Y"IN 8XO;.FE?<BNI754@6<D>G%SLF!3F .0"!P$OI<N9(\EDGBHKQ'3
M85Z6JA@JQ92L=1D)ER^S!9%;C;#3"[9V 6%XY=/'ZC(&K1D1NR.N\-W:8@<Q
M"\!.;MU4E=7DSDFW6W =&0O+ON.XCMN.VV^V^VX=F^H:]Y?H T : - )OE[[
MFUM_P:7]]MM 8<._<=Q9][JC_:Y%ZIEB#QOX=,Q^+U+?;?C36=3I_!#OEN0H
M\Y^4 !,P")A  Y>T0-ON4"^R(:U-(T,Q6=2+2Q>&'@V7R\_S2>TY)(JODRP9
M@95^,G*^C M,@V5[-RDI(*@M5G:CB/7<V%\DBCWA3D(X*45#"41-(K.WB,FL
MJ.)3G]H]HH>:>C?$6>FT8UL8S\!".(M6!N-.8IQ32-MS-S9&=H6,JX7@CS#:
MQ$L+!%T1RS<I!ZNF<@IB4PB!S?2P32IXB2XBZ/9>Q9JM.2\U8]BJ'$X\QY,=
M/N%!JUB%V>PXP*NU;1MOM95IB>4&Y-HN*2125$C-(B2ABG;F-Z06RV]P;6EG
MM^Q?%>%O@J%2,DE*W%:#7I%KQT_(]F8DJTO6+G:T;Y(/$%20Z!6E@CK*U15;
MN (9(Z20@*)P-OI$6^'[$EN)2IP?S$M4\'3IA;0+=.!N>88BP-+% 6"-R ]M
M5=5ML&6L1OQ9(HT[NG,HP23L$91@<QV9R&(\'E #"40*(A#)Y9?4[\-JBR9/
M\-/IXRZ]DY>Q3>2!D+90H2E.C(S,*#E,M.&N+1EK8*.:NX*2?,O36ZKH52JM
MC&46*FBD I@G82^F('4VY<ODOC9>.M#?1/AW8T7HF*(%>\9 L+C%T1<*ZSM,
M\ZA4I6PQMQB+75I+WS]7KL;'@Z:0]I6;H'101+]!((E,/-S.#N2$X>D^W3;4
M4'$/1%CG!UAQ=9(&S7-ZKAB@V#&>/HV3<Q)HYG6K+).YJ42D?5H-JO(2!Y)X
MH*:P*ID#< Y!U,4E#@UEE,IM=3VISW7.8+T 8/):)68;R-@903^\VG+"5&1?
M,SL6.5+77Y6-F;47OH]:2XC,.9)! RG=E?F(IZ2(=R)XPZ;;6(LJ2XD0S*'A
M\UNOX^D3XD?3DW?J9CK+D#4XVT2,<E'V%?-4K?)^RJS;PC6$:DD&CW*,@LS*
MFHVV[A #%4]+O+#TNGMX1KO+.,SEN]GS;T$ Z4_#0N+S&ZE,S0]L=0HL7,TW
M(U+B_?&%=6V.S?3)NJRK:X>_BC=T1Q62.X-=LW8>J%2%AW8=\H;Z,?+FW$3]
M#W-#PS^&C@[XR,,@A8;@O>(R+RC&34JSE(=,UA>Y?JUPJMU>R;4819(%O>&]
M.RM@1!$$0(D8P'Y1YM+%)SIKP5O,CSR:6">Z..]<MI.7>^$[TLV>E%J5E?9$
METXFE*U*#F1GHM$]?14M,E;6,[$G;UPC0\Y%3TF(<RA5D!(@!5$1'G$TZ845
M@=3>753J:VCEXG?4+P^\88XD<=VA*ZY(G;3CNA6K'D9;[/,5EU*.:S:%;D M
MD5X>J0T",HF>Y.$FXF:J&('=\Y#B B:*%7'2WCM!6VU]<2X]CGX*3O<9]*&)
ML'3]VM2+VT2=DS"#>$M4I-':*KKM$81G"QK!&/A8:*CRG(R;(@=0J&Z@B)C<
M1$=:FLN9C].1'>K22X^/-UX\#DZQTB,Y_IQMG25D*5F@Q6:4L!:S8ZTJPB;(
MM7)R??6M9L_,\:3#4KQM/2SE X^JI?WD0GH ;=4V6Z0T:UZL?%/XV\!5[+TJ
MXUN<$$'.2=WF:X..8O&IH1!ZP7@ 8UYH+*)E@*U@3/5)E$R29S*$<@ESD#=,
M  0U7#B'4RFTZV&4]1_AT,;)'X+C,7LU0E8+-M0O61[7+R[6.FU*Y7!KC%)6
M+.^<1[-5PQA((A")E1<B!T^84Q$1 <M-T=C6$+JEP*Y3?#7P5CACD"(:V.^V
M"JY3K^0:7:(J<?QD@FO"Y2A9>OV5!@O$U^.5154;SZYRJ")Q3,;?L#6G$Q%?
MT]YCZHB:?K-.$G5U'P]\+8ROV&,F8U/.560P3CY/&E"BDGR;J"6@U[/<[.^8
MV)N];*O9!62>WQZ'>)N&XI]X7;W&PVDKCM/@68QBT/VO3D_C1E\QT!8IMG4Z
MOU2&LV3ZO<)!M#,+C48*>@"8^OI((#*M9>3BG=4?3B+M8JA&2_<R2:9VK),I
M2%/SJ'C2NK;4+BW*QLQ.Y[PMNG:T5N5I<W/7EQ1VT7DR,J4;'2\6WD:"7*4?
M/M+>Z8KC!.2N7*IK*\6;>L(*D245*)BG -AD4+UM424[;>X\64?"UZ>LKSEJ
MMEJMF10R-/KXX=Q]_A)>':62EO\ $+EC-4MY78\]<=Q!5DG[1-1X9XR>$6)P
M*">V^KTJ_*:[7TXF5EDXXV<5V1TDAX8W3W*YFQOGTMTR['6^@,(-K*J1]JJ/
MO%DDU6EY&=BW.1VCNCO'BSE%:1,@/O6YB"F;$(4"@H!E#(5]-I'5DV\95:/?
M^AQ,#X3'3;&U <>ELF0G-4C[%ENPJ,'<E%%[XV<*5!42^F*^2KK?O$UJU (I
MMCEW*W6()C=YQ+J0NGI=K[?(LM9K-0\DH_1^=72@H%9\-;!5%B;[!0EDRL:,
MR;@N>Z;91-U/PRI(_'EC2NI%_BH_2JB(Q%C(XR+)'0=NCO$2+"F843%()32+
M1IMYEZHF:I[1RVD3F \([IGK$:U2;W;-*X-<HUO([616L-7<2(V"%4@P9>OF
M:T-)L?8T$CWBH(I@)=M]MM]6&J+=##RKU:RFMW [&+\+G E:2;*5^<O,+,-)
MJ^//?M[/0KQ\M'94@*U5[E$+*C H,S$D(FKH%1 J93)*'.;T@, !85U<S+:A
MVG32;OF#CPM^FT(*X5HCBZ1%<O-1JE&LD)'2C K8*31I:WS\.S9*.81VN@Z2
MD;[+*++<YRF(LF'(7DW-GIQC<='W,^I.\>/A3]UXH5+ISZ2T,29DSIG>:7<J
MV/+R5>AR0AUV;V%A:_3DGP1*C91N5187;\)50%@56$![LNQ"\=ZDS#BD3,?L
M-\C_  BNEYG$Y0IK*PYC1J.4+FQO;JI,[M IL,?VILLJLVG*H/Q//(H+KKGW
M,B^6?(CW)0[OW7,>,S'Z,/-IJTKSX2C927A3]-K*OP</'67,8_$VSVZZQ\BW
MGJXK,MI:\1E<B;"IZ%&-&NFRS.IM.1L1J"HF*;8P\VP6)T;'5DI>,*;[;M_P
M.GK_ (6/3.[KE,K4U(7^Z4RE#WU=@Y^9@@#OE%@6>&E9"$J\,^?)/!*0ID@4
M3(0">B!1$PC71<=O:11-8C:W 7?I$Z,J?T=P,C4:5<<B7.%D?4TVBF1I.M2C
MZ$919'OJK1@XK-6J95!<'DU1<&<$7$W(GW?=;'[R0HA&EEE<>GJ$#0!H#$I_
MK?\ 9ET*-$Z4^,]U/_C(WX/E*-]'?Q)_%'1]0W\-=/?F#.-/W_7GU61#AW!M
MMT3<P J @ !PY2@/IG,.P\@!N781V#CJMUG02NGI=1AN7NK*0C<Q/\"XJQ^V
MR=D:L0[:VV2J*2ZD9+.*R<"H%>0X[(E%1HX<%*8W*Y*(*AN0. Z.D<= OJ3Z
M;J@WF(ZZGF1GN$H&/ITA$..HB>R[31E557 6.BN<8NJ,FB'=.(].-=@L%M.4
MRBC(I#"D E'B.LKZX2UVYAIX]3;^V/UX#(<$>)=FG'U!C(FT52J6F$Q?TR(9
MLL]CE32+>Q+IO355L@F=9O+HQ^Z1I$_,0C0RFXAN ::,U#^FE_@/8O?B'V:O
M3CVO0^'QLMA<Y!QWCB@M >OR,917)\/;K#%&D^Y0 5ED65)4$@D50*.X[[<
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M[7JU"1G\;X9R92<591NC=^^4?1$Y;I.GQ+,6**:1V_<M+-=X]BMS-W7,'>&
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M/AR8*H<K&69F-SD;%$V*J7>5GE%6+UXO+4=C+Q-?!-BC"D.#CU6RNN8 -S
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MG4;/Y8MK^$KB*MRL<Q9%:WZT9I8(.1E8AZV23B'SM\_AW1@9.=UU7+A(X'
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M>0Y+*G6;U?VEL\(A&6+'^([)'QP2Y96'9/)6:R.W=%19E,!MTO4B;"10NP;
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M"^R42@2LLP?+(.EDG$=&.K6JW$B?='3[L"*',<!$;5912B#^Q9*:O<*;B_Q
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M-%$-(@@V*9NN5T5'O2GY52E+.*^W;:Y8?U3=::UX_H<=D3JIG<JYCK6>'T3
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MM#6&@6C&K"5BKM;UKY*LY%$Z;I&V\[E9>R-G214#,I!^NX55.HH50AQ5-L
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MUAM6*C$QR<;'Q:H2]HL[I^Y(V!0IU"JI)B4^Q4R[:699=ZS$#OFK 4%UG)E
M,JY*4JX%*)4Q[LH)D%,IC&,7Z&0N^XCN.X\.S5G0S"TN;$ V#8-991!.I#[C
M]E_V+^_$]:"N*S3_ .*=8^Q^'^I[?4+E]PW6\_A884^Q2V?42WZFI7]GBQR\
MQ$MIV,E(9Z*GJ4K'O8QX5,2E.9K(-5&C@"&,4Y2J=RJ;E$0$ -MN ]FKJ9Q<
M#1PZ!.E\K9NS4QM$R#)%I.-%8^5(5TQ>?&0TC[\O'221&YQD'2<HH0%"&(4
M*3T1$!$;PT!Y8WP^>EV'I4;C^)Q^A'UB&N+B^0K%!P8PPUG=IQZ3F3C%5TUC
MM55$HM$FW$.0@!YQTDD<6=#1>A_IMQJ8GQ$QM"5-N6J2%(-'PJ1R1ZU9EG%A
M=2<<X1?&?**IO'%J?G. GY1,Y,/+QVT*Y:@UC/H,Z:X^L2M/:4&/3@I1_'/4
MD#$247A$89^2:B(N!7.B)F,8QL)G$@4AP5.+IXL(GY3%(2*B@K<N:1N,5B\/
MWI0MZXN+5B.N3RAI-[+CZXDJ4/6Y.%B*]*)_WLHW,+62AX)LBL41$QBE,',
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M?J=%9/$\RV%(Q_?*O1J-*5KJ Q;*9)84^55FR3>+[3"7BOQ;J/LQ$9M 18(
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M?8I;/J);]34K^SQ8ZHONC!Y>&J85B_0H: - &@#0!H T : - &@#0!H T :
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M']=5JRGUIGP0N:DS]7M;/(I8BQ5IZZ%%@;'MBL\6LT8.%9.09/Y=!6F*D=)
M0!25[T-@[L0U'.HC%)I7O.N[;<QJMTZJE^D_J\ZM_4H5>9<6JP8TH40[D':[
M-A&SU^)B"(8SLNY#=!%JR<2I2B8H)%Y0+Y=Q&REI\ACBZO&]N?ZBX*];O4K1
M+IT\5G+M:Q]'5'-*]YH;:XP3J6<1JF0$IB\LJ U"07FG+)V]>M6\&L9,  QS
MN-B<H"79>(LR42<NNX1^4ZY\S99;Y?QG#5FHQP4VM9\H.5FLW-/(RVL(]EA"
MV6=CD*'05> 3O"'>()E3.@H3U1OS (&'F"/*5I^AOH6.6L4\_P!AU_3KE2[X
MQ\*BEY-ID(3(EWK,;(^\4>@]</'4ZM*YQDJTY7.9N)G*JD?"2*BX<HAP0V$-
M@'165*D?W-3](U6%\2"S69M%9,K%>Q_:["PZ<\XW%Q+SQIB*FX^V8ME<S$=5
M!FF$^*)6#0*8!''.F=90#J\ADQ,3DJR@CQZE_P!+^ /O$'ZJ:Q+N'TJGC"2@
MX2.P5D%P2."=+)O8C+<S5Z\_J;-P:TKH,FT:K)K+ LHBMN<P[EVX:M&YF!/3
MA6M=N?L&XY2SPKD$S:\,&,;AZ6H_B/8U@W\K7'[U=.?BE:CAFUR2MI=/7:Z1
M6)V$R=LZ[H$"^JD$0Y1W-KGU>"D[=%8NX%HM_BOYL@8?-;RMQV(;&K#(1,AC
MFP+2<PUBUU'V0E:;(.7+<+(HHZB2-&JA2=TLB(N"F'G$/0#3M+M)R6/U+"^4
M>0]CJLRCG2I=,F#+2C?:C3[UE+*.#(6V32:+\U>3@+Q::8A+1Q533R:S=!>-
MF%$^8ZYP%,X<-^(UM-1MXW,+Z<JK5)^>@G6.^OG(EO=84M$+%Q,K59WJ/6Z=
M;K4F!Y!>8AFD#%U)5O;H](K\YE%9J5LG>'343.0&G*(<1YM2L5-N)X;7%^SY
MU3Y0PAU(U[&4E6XE:FYOQN1OA*>*61([=9X?NK8R/5Y] KX$1@X^*CXMP)4B
MH..\74^B@'*!:VU30RE,_P"6WNO&\CPZB.MC+6:,1=1M;915>;4^J5S*M&R(
MW3>R#*PUV6A,3(3#&5BVYGYS$70GI9)=<ZA#E"/Y1 "F#O!RFNK@SI#Z6[J&
MO9\SKWW5CE:L4[)^++[!XOO*.'H'ITN$"D)I]9*Q-LI75]7G<)*I(6@%D6D2
MG6 <-W!%" 9RY5 Q3%3Y=;4Y30YMK%8Y6RRVL=A(=7=BZI.GKJ_G(N5H-7H%
M3P_GZE6&C&<2#?)5<F*WT^GML5<XIVK.^K_17=C1*F48\>4D=OS"(B(9;33Y
M,UTM9).(E>;<?L)-TA==F3HBG8JPE08>-M9L7Q->/>%[A)N_?&XU.Y7>PG<2
MD!ZLNR%U,-&";M @[*I@=LF D'B!HG26:[N+ZI6VV@Y[+?5GD:U9XZ*(.BKS
M&$8:ZYENN/;G5KU&/2*6CWM+B-\Q/'*@O"@H+XER5;IE%-7<2\-]]M:R;5&J
MLQBEE+6BVYH1&G^(KU!R^/L;V6Q0U'@Y#J&G\GQ^-9A%S*II0K_';.N\M>DV
M[B95%FUF7-A0$%#' 0YS[!Z.LK*R-?UOQ@UV2/%-RG4I:M0$VUQ)[ZW*V5/#
M,U%T*>D7[^DWK(\RE5VEFE14G7^PPA)%LZ,0Q$P$J?$0 =]6<L4HO\/U,]"S
MRBL:\/V/+AKQ#,\26->FK'$1)U2_9FR5B$<GNK;9'$A#PTXFXNEOJPTUL@$P
M*R\FU^*H*DV<&,<9 H<O -W\=MJ[@ZY-4M?2./*[9IG75]:^J#-W0C;4'\/2
M6D)UH6O%,C16"<FA(OFE=2Q.[</GRKJ86*[;/59U0B8 @0H=V/;OJ/+)_3MX
MF\>WT]3;K&R0K?6GF6R6[+W61BE^L6$J6*NC>V3$*Q([63GWTW)1MP*O9XQ$
M52I BF6,1!(P(F]-,WI#V RJDI?29QCJ=%U*/&=XR&T]3>:R]+D'@S)IX^9I
M[+'V([] Y)Q_)O$+NV0G)^YL4H^6</'<[''<)^\(#S%:I;"8=P'AK6D*YF*-
MMT6X?/*^(O:\6-TH*0:U"<8U7/3+##.";2CM&Q3%%-$5!TI8C 9^X(\M2AIQ
M<K8B:)$#*)?L1MQ#3JW6W_$-*.K5/93N',=#76+D[J74L-KFV-/=8NDZK!VF
ML2D-(.G%B3?K#9BST1ZJJ^=HFAB$CF0HG*F4XF45YC&V+RYF9M)7BDM8XZD5
M&7^OMQ>+WTL=4#!9I$U6A9&RA6286K82"MBLIZI_)++HMWR:DBX."+D9L4]P
M;;  FX:W1OQ(U59723\&[<S==2GB<]1E;QK[T0)&<+8L@8_H6;*C?(-*4>0$
M1"OY.YQ\[57*))(#'[X*\@*1BN$Q^B&W W#;#<42VXG3M]J<7U/Z=/FEH2DT
MO)(XO\0[*F$'4BW9XSL.!JEEM%R^<G1C6-FDK1<8X[6/,HKW*9'#1 ! IN=0
M02#TN&MI_537>8C_ //KW44$IZ7NS'#<2B<I2@/84I=Q,;V@W#?4=%J1-N>8
MT_I3_AWJ?_&2O_[:WU'=FM$=+U"?PST^_?PIW]NIJLSJ.(7*54'22@[IF*F'
M*3]D 1$_I>7@.W#52ULS-9B)7"YJ_>]@9=*0]4;+NVY3%1>J-DA=$,/* B+G
ME X$] -^.P\-(^J6H1:],)RT<W)TVMV2QUFR2L>QDYRCJ2(0+X2%]9B7,UZC
M[Z+D'TA#UD8A'?;;W&I4L]*>BD3RB8$Q?CFVS-DJ,"5A.2S@SZ6=+J&?G.+]
M59PH* F @- [W?S^0/)JQ7?.GR%JJE;Z>+-9=<,X[GX@M1?4=%U MIUI8ROQ
MW%V>Q$2>))O6RW=F!)\DB[6**Q@. %4,'+Z7".:VXZI,8M8P\9C3>Q/LPXDP
M?9Z-4<43R4)44(R5;+8^8L7C>+F(I[")* DXJR"H**B^9(FY?0 1%,YNS1+&
MSDE8>>+FGL>U3+2L5X2R)*(Y4C6=;O<XLJYCIV:A"(EB92>CP]6/*.&Y%'9
ML,4"ZR9N<YQ2]8, AQT4_=-"M+'Z6G>AE>=&72],14#$V'%->F(ZD3<[(5MI
M+(&7%I+6)9!:=<+"B+<>:379)&,&P<2:O3I!.IIS.AY3=)_3O!QDTNZQC4X&
M,%--(Z94C*%8LH-NZCXA1L)E"]TWBF[P2I$X\A1#CPU'5QP-*%,NC&&82\-Z
MLM;E(9">9<972J_&:1G4']<;I^L3IGCAXHG!VUT#QZB]CP9NS]\GR)BJX A]
MPY>43Y&:JLPW[M!V"'1_T^PN.+!ANHU1O1Z)-SZ-PO5-A5CF<2<6]%Z\;P4L
MW7[Y5!@^<N".$]@+R SY>/:!JL*VWL*FTIRW\]GKYBYP6+<)W"N7%C64X65K
MU_<)MKP->DR.HY:=J3E0J[(A$S*]P1FX>+E6#F$0-R@/'4I9?L:JJNS]NVXX
M&ZUWI!F*_CR!N\U0/>+#\FC%8^2?3C)@E4EZ]#R-02AV'>J&5*,?$J*,U$N<
M#>CQ[!#5;2QG2#*QRR?37KFV[YG*K=/_ $54V<C[2]JF*H&;R0]E%J<^EWK8
MS"SDL/?SDH2K,%%TDA/)(_WT?NQ4YN7FU,H7+W;,J63RH_J?#X'11'1QTN51
MLHUB<4P==._L<.X4?.E^Z>J2]<,\^+C,IE2!S-VK %NY3*!>5-,-N :J5FJM
M3MX6,O)J<?/WR^=Q27G3'@==\";C&< N:4O<CE1UNU.)7&1'3"PQ3RT&*)Q!
M5V[CK3(D$_:;UL1WX\;,SY^/%#65-O9NGX&F9=(O3PQ4FT4\<10IV=)_'/6*
MJ>Z45%2LNVL<T1FCRE%JC+6:/0=JDWX.! =]@V&:SO\ C6A5,4VYBCTK!.+<
M=/)A>D5U")=R\5$0DJ5$ 43?1<+&,86.9.4A)]$!.,8I%'LX$\FK#5<E>PZE
M'TOGM[C0-.F'"<8>PBTH$>B%A/.'D01Y2$14LB[E].'C$A2,5J:1<.E14 -]
M^\-Y]&T[> 5'5<S8(X>QI'XS_DF2K$:OC)"/*R:UTXBHD*2:R2ZK90$Q3$SI
M!XGW@  %$#$[-$Z,CI6>7(;G;^EWIE7BXRFW*)KI(*X/6Z2C"QO2L[%;5XEH
MHG!0S5\H=,RC6$9M")HMP3.8I6Y1$1Y=1J-:EG++Z8H[G;0'1S@.JGH+2!Q;
M",V%$E7=AJ#%Z9=Z2NV%VW?$?S"!3J$%Q-.$I!R0#AR@"*QPY=6L*=MQ%$TV
MX<Q4ZCAC%.+W=K=4VI!77&0W\A)V).)$2MEIB746=R3X6P$'U1S)+.%7BNXC
MNLH8W8.VB4*M-MO<'DGY\]-?"_F-^R1TVX >QI*/5GU4HV2#PES@J;*"LBM-
MMGU[;S,M:G"485=LLY<S#.;?N%Q*)=R+G./#3A_+@MO$57*-71SO^'@-CZ;O
M#LQ'C5VZI62+;&Y4G&5?KAG>*T7"*+*%F*S-P$A"Y!;10*NW+:05][D')CG,
M8 .[-QXZD5X;:%2^BVVJD>-)]'/37*6R:MDIB.K+S-J=KNIJ36(8LI\8R1"D
M"E( L)N[&3D8L@D,<2"'*N;@.K93I[.,^XDN:.U.*W1S5371O3-TG/G\E!,*
MI7'T]6X$E.D(Q-VV?/8.->2Z%J(U>-$DB':O#3,DFX3$0+OWI#[<=(43MO*W
ME5JYM(GHVZ:H9@Y3B\4Q;5DO)(2,PY*!U'UCEBNF[04I5(X&(Y0 $R)<G*'*
MFD7S:FD[O(B^ZLQNU\%KS''UB$]XV\= QK!C#P$8V=D;QL<4"HHM0%TV9Q0"
M4>5),C,Z9N4 ]$P;>35I#>NU2)Y65I_;X2;)6UUMM8&U53L$*E."T.=&JG=H
MEDW('07<@=(@G[WD[D!/OR#ORCJ4-3.\[U/<")\P 00*01 WI<AAV 2;\-Q#
MLWU'?B51$Z'HT)[CR.E$D4E%5E 322+SG,(AR@4 XB8.'HAMI$N-"N4I+&[@
MKE)-P@?O&ZHE$A@XE$ -R\Q3!^EW#V>.K&C,S24(CU'@(X?LOD#9L/RGB>DP
MC2NA6:=_%*L?8_#_ %/;ZA7<;K>?PL,*?8I:_J);M34O\/$=2'[(;^Q#6M/$
MR9-0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T
M : - &@#0!H!-LP?<TMW^#2?OMMH57,6'?N.XL^]U1_M<B]4PQ!XS\.F8_%Z
MEOMOQIK.IT_@AWZ^_+P^;Y1'L !\X=NJ9&JS?2WA*4G)B>3Q[#!+V"XFOTY-
MII#SK7I$KYLK,*MQ$Q#/W;21=I'4[1[\WGU4JDZGJF<\MTA=/C*09R3'%T:F
MLL6?*Y=LSG9J1Y;),K6>;. "541;/K"?OE0 2[N# .X=FFOU:,2TOIM H%-Q
M!CFGU6S5>OU<J<5;?6F\\W=));S)5D54NXD500(55H=J(D3W+S EMZ0CQ&I.
M=I,IK3]!&FO11TLQT7,5E'#];!"W1#>O62/?IJ+)KPI'3.90CF+P3D]5:M)*
M.;J)' !V[HI?+H^1J:1/GMX'?Q_2QA2 D*/)0U'8QJV+H";AZ>=18[AI'1]E
M@Y&KS[4Y%/HBHR,)..T^8%";][V<=M2&WTWH)6*;5$H.+DNC3IHF&V.&88L@
MTVF-',Y*TEP0#MG<,\FYJ6LDJVC"%$#K,G\W+N5U2[CQ./'4UHDBS-W/,Z.,
MZ6L!!)3?>8JB'Y9BW,,@/E7A!49N+L6.]5++MRE*063QBU>*H@ F.8=A#?CK
M;O'LV\S*;CJK77;=8[VW82Q;D&=A):XTZ#GY.N1\]68!9PU.?U*!L,=(PT]$
M*B*IN^;R#"1<$.3<.)^;R:4>.T/AX? E5E"I#\N/C7S/%3L(XYQJFO'4>O1U
M?D)#D9B]9M><Y(1FL@)(-,YC#ZO&FCX\K/N@'W/'?<=9AVU]QKJ4S.OG^NAK
M*ITOX#IUV0R/5L9UJ!NL,YFW[":BTU"/$_C*[DI"U+J;JF+WDA)SK\3; '%7
MY=2=W:U"-IT\:FLR)TB]/N3E+P_OE&:6%CDHD8O;D9 Q3%77KZD/)0[QL5))
M-=)TU<UIF<AN<=C$[-2&G%Z&IG&MG\MY[FV"L/C5:/2/Y.H@];QU(M9C'J9R
M*+%J#V/52<L;"FJJ8YTI!62; <PF'B(Z1*JI<^?#R(GT_;3'9>\YM3ICZ=+;
MD.U9/=XLAGN2[I$/*O;[4*2K120C5*LI35TU2D-ZN8TA4]F8G$O$I^P1TK,.
M)6WZ$CZ5$[/9G;1&%,6P&,4L1-8!-''\6XW1B3*"W3BW2TR$TU(=4"@4Q@EE
M$U$0Y0YS"4..^D*BL66VW?CJ<NMTC].R:S438[C$'+>M6&ILT43HH>O0=O1G
M"V39N#?BJZ)97PG'CN)A$0U::?L2:5L9E.C_ *?)%N]:N:&D9%^VKC57Z(4R
M@LZ@X9O85J!@;@!"LW4>10 V'B'#;1VX,3YGE7Z2.GMWRQ9\<,UHV4N),B/B
MGY3)!:XB&C89K(+)@@',88ZOM4]MP'8G;Y-2UZFDU?@:L.B/I9$JS#^1^M^I
M2V[QRN(?WV8&TDM+$:I([<OJQ90#+[;#Q..K2*Q.S,ZRY>.C%3O.,<?Y!J,?
M0;; 0\[4$G,,Z=1;E(051:5EVV6K[MH;O![I>*>QJ1BF .'= 'DU/^V*CJI7
MSYFAK/3CAFAS)K37L?0D7)$>IS*2S8HF22GTF#-@QED6_N0D/4H]H4Q_**8:
ML334LW>BORV]YVU@Q[6[;)5N<L4$PG[945EI"ISD@AS.J?)O2+-TY5GN/*)F
MR:H' O 1V[=3IM.\B:F5=^0B[_I#Z:7]SO5Q6Q1$/+ED=@YJE^?H@JS3GTI6
M#2AIF2<-#"LB99U7W)4#J@&QB) 7;<HCHK\_<5Q%%2QMQZ5^GE1U8%7-09++
M/&M8+-=XL0 <1-.?N)BNQSC=(3'CX^25<*I#N&ZBR@;\-6*1I[2K?KIN->IT
MC].I9J]W&.Q8P:2V7*X]I=\3: 9JWL-=DX)W4Y+WP:\ATV:BM>D54#*" [I%
M*.W#4;2O1[3[#+3F5+3V]AZX7I!Z:8^UU*TL<6PIK-C&*;0=<E@340.UC&DC
M)S[9LGW1B)O_ %-_..5"&,&P&4$-N&JTDE--?#>);ES-!1KAAC%^1G-.F[Y5
MHNURE#GW-CHCYT0$UJ_,J^](BI&BAR"+HJT*V. B(B)BE#R:.)73[;\_T$91
M#MI'Q^8DTOT;=.EEJ50QA/XKB7=,I<D[G*Q&NE#E6@I5PHT5<R[5RB"(E5E#
M,TDU"<OI U+QTT<1^YIS.L1;E4QK]'O2P[M+>R)X@J)9Y)]7+*9^HP6 Q KD
MDJ[C)!83N#%!^@Z;J" CQ'E+K+3:EVVL%E6$ZK=\3 YZ)NF14**8F(H-^.,Y
M\DU1BB*K1>L.R/6,D5NR.D(":/(]:$6%(> F.;CQU=&M7[%M)G+S4^WY'0L.
MECI\C<EM<FHXJKB5Y9R;>SQMF004:ECYQ Z8IN&[05#I$DN9L3F4 =S@4O#A
MJJ8MM\ XZIFL1\DC#/=/="LN6$LS.H0R%F<004.<!VF5PI=J>=5R<8MZB*2>
MR*@R"Y1]T @?4:UO[2K)X_39,]BO2U@888]33QW&%C79V#]YZZD!A,#!=PM%
MQ@*\A"E;H.%53 F >CW@^?2&JW).CB"BG2OT[.+BAD$<7UUW9(Y^E*,'"S<R
M@GEFP(A[[)H\_*9UL@F4#<=N[#5I<M;S!M\,]/F#\$15A:8:HL;C^(MKLCB6
M:10* 9<D>BJFV[L%C* T:QQ'ZH]T ;AWPB(\0V6JKID:F9HG7S.3@^DOIF87
M16\1.(ZLE*N5E$FYP8'*#-1Z4B<M( T44.FBH[230 Q]@W!$/-I_W6]KGY!N
M8:?R1[@Z4>GN3IZ].5QI635EVR3B'K-T4%5B0S7OS,6K-P;;NVI#/G(@4 VW
M,.E%5JA5D]\3M8\*_2CC65M]@N-N8DG)V?<0[:.<K+^KIP,55EYE>$KS ^QE
M#M45;*X%0!,/-L3LVXG5P[[>XB?3C*HN.UV.UBEO7$O6 55,518A^X.8-VBA
M0,)D2E NXDV.'RM24Z4-0U5S#&P]*?\ #W4_^,E?_P!M;Z.X5D=-U"<)KI]
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MEVG0S5_K.RH\QIB.JXHR7!PN:LD6G)*ZE3KZ!8"#91,'(0QIC)EF0=O)-<L
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M9%R%:JG3%\(V!>^5#H"<8:N=YR=3[<V39VQXQ@&&/[%"V*/29OQ&2?.+"]>
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M0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T :
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M[A'<1[LFXARB.W: CS" ^<!-QT &01.7E,F4Q1 "["'#8!Y@#;VPTEDA.K*
MW0#FV2(',!2F]$.)2@ % ?8  TUG4I81FU(H94B"15#;<QRE !'E "AOMPX
M : #,FIN\ R"8@L9,ZNY?=F2,0R9C><2&3*(>UH(1>+9 RA%12(*B8"!#B'$
MH"42" >;<HB&@*E02*!2E3* %$1* !V";?F^7OJRR0B@-T0[$B!QYN >4> C
M\D-0H"W0$Q#]T3F3 Q2&VXE*??F /8'F'0%A6;4H\Q4$@$ $-^4.P1$1#VA$
M1T!E%%(=@%,H@7?8! -@WX?F: H*"(CN*9=]RCV>4@@)?UHAI DH#= -]DB
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M&Y3-RCRAMN(:S&WS*W,TH:&*Q+C%*8)/(TBN$LR:#=BB\:1P,TSMFA3E059
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M7_\ S\1UA>TWR-4PK%VA0T : - &@#0!H T : - &@#0!H T : - &@#0!H
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M&=L^XSZT[;@WG?3](RE1267#3R'*H@Z@;5"1["9G&\JB1.0*JP4:,7Z*8"9
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MP_8PU&DJ/0++J^I79J(&.I&,:E)246V0KM89IA+.9!4!$ZFQCAZRH0QD@(5
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MW;WO:XI,'4*I2U)=U681I&.)4R;R3%D4Y3O%4A5*0?2,?@CZV<0\^^F+G:W
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MA3[%+7]1+=J:E_AXCJ0_9#?V(:UIXF3)J - &@#0!H T : - &@#0!H T :
M- &@#0!H T : - &@#0!H T : - &@#0!H T : - )OE[[FUM_P:7]]MM 8<
M._<>Q7][FD?:Y%:NI-'S^ @\;^'3+_B]2WVWXTUC^1O^"'C:J,AJ@- &@#0!
MH T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : -
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M &@#0!H T : - &@#0!H T : 3;+X[8UMP]O^UI?WVVT!@P]PP]BP=Q^YW2
MV]NMQ8AM\C1VXA5?"1"8W\.F7_%ZE^/G_P#'#&FL_P BO[4D/%#\\?S1UHA7
M0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T :
M- &@#0!H T : - &@*#[&A#$<1V)Y=U2E_-T+\AHG2H.T]U.AOV]2-^W ?)]
M%;\ T;K!4J2;7J%,!9WI\366[CFSA44R;DYN=8BH\B8;G3]%7F'8?)MV#K7O
M(DXI:('.F12?)\YPW(8AB 7?G(8IA*81["[[[!MJ<"*\JYY#P$6JDU05:IJ(
MLC%.S34 1]5$I1*4$=A#E I!V#??8-32-#4ZZHPA68GO5UC-DSJ.C=ZZ$2B
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M"9P?G+RM"IB78 .L[>IHH)[B/HG*HH'#COJUC;S(KRK"RT\1^*=9X;#[P0_
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MH T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : -
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MB3OU&?9VFU<C3L#A"LINWL^WG*M:[G(I(BJTB*M$V)K+ W5025.HLN],R.W
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MR& .W65H5ZZL] #OY!#V]'0B*Z%#0!H T : - &@#0!H T : - &@#0!H T
M: - &@#0!H T : - &@#0!H T : - &@#0!H"@CL/M[?(X^70&O._0!P#4A3
MJJ<.<$@*8";B( "G'T2B(#I$\A6=9$CS)EV"Q3!M'LJR6EY:2<J(5^ :J)H/
M)I\S3 R@(B<JYS-DU'"13F*F<2BJ7AQVTXB]-3G.FW'DKC#'4-!V,Z;RV2BG
MOS9G*29R)K2[EJR3>ND^]W7.45DS")CCS#N&^KO6H>CK OQTUN=4X$,*P)G!
M ^P]V!0'Z%SCV][N([[:/V$4SI.@U3*.!I--:1N.#U#46_O5"!+.(Y<\3'6(
MB9W"J1)5..; Y?)I*N5# (J?IQX:CN66E2VVAPL2/7B&P+P>#F8)D, \CVR'
M9J',)>8Y(\6"7=J&$NXF[XVWF'?26E'N"A6GS_0WG/UT?N'!/ZRQZDOB6=I_
M0KWO75^XL$_K;'\[JPMOW$Y!WO73^X<%?K;'^AI'';S).^0[WKI_<."OUMC^
M=TCCMYB> =YUT_N'!/RK'\[IX^S]1MM0.\ZZOW'@K]98OG=2"]66Y!WG75^X
M\%?K+%\[I ZLMR 5.NK]Q8*'_J;%\[JQQ)U/5%.\ZZOW%@K];8_G-(X[>8ZN
M!7O.NC]P8*_6V/YW2N_;S$X[GMX%.\ZZ?(QP4'R+'\[H^?L_42M$5[SKJ\C+
M!(?(L?SND<?9^HF+!WG77^XL%?K;%\[I'$O4P[WKI_<."OUMC_0TCCMYDE;F
M'>]=/[AP5^ML?Z&D<=O,2MS#O>NG]PX*_6V/YW2..WF)X!WG73^X<$_*L?SN
MGC[/U&VU [SKI_<."?E6/YW3Q]GZC;:@=YUT_N'!/RK'\[IX^S]1MM0.\ZZ>
M']XX)[>/"Q]GZW3Q]@VVH'>==.__ 'C@K;VK%\[H-+5#O.NG]Q8+_66+]#2'
MO'5P#O>NKR,L$_)+8]_[72-MF.IZ!WO75Y6."?D%L?SND;;,2]0[WKI_<."O
MUMC^=TCCMYDE;F4[WKI_<."OUMC^=TCCMYB>#*]YUT_N+!0?]38_G=/';S*G
MP#O.ND _[QP4(^U8_G=/$C?"A:*O75^X<%_(+8_G=(X[>99X%>]ZZ?W#@K];
M8_G=(X[>9)X,P*K==8&)RQV#Q*=0I%CI#8TE4TAVW.B?NE/2* C[&^E2PG='
M.JP/7!:[$2#M"F+JQ1UP(B^L%4=V%U:5FIA_OEN*2R#%N!%DA$G%40V'LUI5
MU(V]$.#Q]AR#Q<9)*N,I!TN[6<OW4R^42,^<RJR HN >G2:$%&/,B0O=@)CB
M)QVWU)V^?$*7RVMP%T:$$K<H&2%(P[B<GE[P3&$PEX!Z(CV>QJ>\NXT\Z@\5
M! &I'1A373<$]76,B"CA,Q3(H.S DKLQ5.0I5AV$02$W ?+4]M8X#5/CX>*W
M#,[%AG,E!?R5JP&^*TF+'++2\_2++9'X8[1EUB(MU99G'QL,DH[4>LVC<JP&
M!,PB0?3$ #1+VAMJNFVN[P+T7'7Z9MNZ88$,J3CR$)9O=B ;=V4P#P+OVZS[
MPI3-B1;KL.0HJ,<%%-MQ#EL>_P#::I-'0N*IUU '_>."O:$MC^=T@U+*][UU
M?N'!/ZVQ_.Z1Q(VRG>]=7[AP3^ML?SND<22]P=YUU?N'!7RK'\YI ZN!7O.N
MG]PX)^58_G=/';S+/ .\ZZ?W#@GY5C^=T\?9^HVVH'>==/[AP3\JQ_.Z>/L_
M4;;4#O.NG]PX)^58_G=/'V?J-MJ!WG71^X<%?K;'^AI7>25NV\@[SKH\C'!7
MR2V,/_BZ5W[>996BV\@[SKI_<."?E6/YW3Q]GZCPV\BG>]=/[AP5^ML?SND<
M=O,D\ !7KI_<."ODEL?SND<=O,3P#O>NG]PX*^02QC^<&A4^&WD'?==/[AP7
M_P#)V,-"TW>W]"O>==/[AP3\JQ_.Z>/L_4FVU"G>==7[BP5\JQ_.:>/L_43P
M*]YUT^5C@H?^IL?SNGCMYB5J@[SKH_<&"OUMC^=TKOV\Q..YE.\ZZ?W#@O\
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9I#ZJS^A<4@[OB'H]@:S77;]37*FUN1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2226999d1-fc_candid4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-fc_candid4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!L -> P$1  (1 0,1 ?_$ 0(   $#!0$! 0
M       &!P@! @,$!0D*"P$  @$% 0$               $" P0%!@<("1
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MS)N_+\O_ (S3'[+H;K13@.Y5]>9+^%V7_P 9YC]E4,>)3[(]R/7F2_A=E_\
M&>8_95#'B4=D>Y4]>9-W9=E_\9IC]ET-TE#] [D>O,F_"_+_ .,TS^RZ&Z2F
M_0.Y5]>9+^%V7_QGF/V517B4J<(]RH,WDOX79?\ #DTP/_G5%1F2E3@.Y'KO
M)OPNR[^,LQ^RJ'/2BBKZ\R7\+LP_C/,?LJDQXE2?H'<J#-Y*/_6[+_AR:8'_
M ,ZH8\4BQR"IZ[R;\+LN_C++_LNFQXI,%7UWDWX79=_&:8_9=)CQ3IP'<CUW
MDWX79=_&68_9=.H10Y!4]=Y+^%V7?QEE_P!ET/P=)@J^N\F_"[+?XR2_[+H:
M7$ITX!5":R8?^MV7!_\ >27_ &70Y&)*1;@$>NLEO;Y7Y=[_ ,I9?]ET.6>O
M>A@J>N\F_"[+?XR2_P"RZ&EQ*=. 1Z[R7\+LM_C)+_LNBN9**< JA-Y*/_6[
M+?XR2_[+I8!RD2!D%3UWDWX7Y?\ QFF/V73;I*=. [D>N\F_"[+OAR68'_SN
MANDHIP'<K@FLE$;?*[+?XR2_[+H)(X]Z*< K?7>3?A?E_P#&:8_9=)CQ**<!
MW*\LU-C?Q.09(\,%N4+F?DUN3^:T<U=33KL%[6OI"FW2D6R 5!G<E+]HR6=0
M#R!*R _0=$[Z3'BBF:=3!M]LDQ]VFVEG9Y]%94@"HL]4:@0I@ @\% ?7MV]H
M4GXIZ2IS8MED?E#!N[9J(BHHBFHNDFN184#F /,,8H (\;]H!V4R&#H'#-*C
M7YHF'AQMV_E5'J0.E5N/G<. !<./;V\.SW*$"J1&9YJSQ*)7?. 1,X*0YD&J
MCHC<RVE,QQL<R9S!80 .!1[:;9I/P4(<JWQRV=,=2-=+PR0& H$1?KKW +@(
ME.F5I81 >X.%/)1TUK5(3Y:YI^%V3?O[*_LR@:CF5)H\ J_+7,K<<NR<?>GY
M8/\ SNF'&))0PX!'RUS*UOE;D_[_ ,K^R[TT,%3Y:9C^%N3_ ,8);]ETF0PX
M!5#,\R_"W*/>]?RW[+HP0PX*ORRS*W\+LGOY/7\M?_'*'[D:1P"I\M,Q_"[*
M/W_EOV917I0PX!4^6F9?A=E'\8);]ET-UH8< CY:9C^%N4?Q@EOV70R&' *O
MRUS+\+LH_C!+?LNFA@J?+3,OPNR?^,$M^RZ$,$?+3,?PMR?]_P"6_9="3#@C
MY:9E^%N3_P 8);]ET(8<$?+3,OPMR?\ C!+?LNC%##@%7Y:9C^%N4?Q@EOV7
M0AAT*GRTS+\+<G_C!+?LND"2GI'!5#,\R'_K;E'=_P"GY;O_ /I=!Z4F'!4^
M6F9?A;E'\8);]ETA5-AP"K\L\RO;Y791V_A!+?LNGVE)@SL%4<SS(.S+LH&_
M_K^6_9E(%RU4V P94^6N9?A=E'\8);]ETVZ2GW*GRTS+\+LH_C!+?LNADJ*H
M9IF-A$<MR@>S_K!+>[_Y6/DI,BG (^6>8VO\KLH[;?M_+?LNAJLAAP"I\M,R
M_"W)_P",$M^RZDZ3#@CY:9E^%N3_ ,8);]ET.4,."/EIF7X6Y/\ Q@EOV70A
MAP1\M,Q_"W)_W_EOV70AAP50S/,KW^5^4!;_ -?RW[+J)?)%!DNFWW'SIM80
MR_)3@4=6D\]*"4;" V$!=B%AMV4B">*'Z%([:[?<LJX1C<Q*DQ4>'33CG[B2
M*8'9E L4 0701T:CZ>Q0WI?-'+=*&JI4H"0Q>8F("10"G*(&U%$I@ 2&*(>;
M8Q1OPI=:E[%GI/1"UP'EIE*8WG:3" ^Z!1'Z52(Q4078+S<WAE5Y'/9I!XD9
MXE$.'7A2&$+(@JX6U@&G1?5X4O;?LH.7!.(:B:D#*K,UY5T'(:MC"0A2V*(6
M$P<+6#ZP>^C#),8L5M\3"(@%2P21?@ >2_SZ:%2A"N*&J_&D2R:MII(H0KC=
MOP5$<4A@K0XB'OU+I35;#?32>CH5*:$4(10A%"$4(10A5MPO[M)ZLA5 #6N'
M?V^7A11V35 MWWH+Y)*E-"*$(I=:%<!A+</R7H(=#JWW::$4(5VD?<I.DX1Z
M/PT8HQ1J]RAD:5;3310A%+J0L!#)+I.E6!C)+,S%/J 1 >!B7MYQK\!J+@%!
M+T*]&]B9<TMMW#G54,JN@DFDJ8^F_!!(I>(=O$@T'B@%/'236$% $^D+V MQ
M^8--D8J%?4KE@NG,3$)*J(M6 S:<@!=(<SFC')I<0-J'2")^\.VEF@*+;1-V
MD@*Y#B:*,)NT;FU7$1XB41[0-]=0<4+8'@(A4Q4)($. #Y;_ #J,TU2GFDBC
M-"J "-[4B6*:NT#[GY/@HU!"LII(H0BA"*$*XIM-Z1#H5=?N?/J(#IJRII(H
M0BA"*$(I'@A4I85*:K4DE<7L,/D_+I'$(*I;A?W:'JP35*:2*10JE[?@I2K1
M(X*E2310A7D[?@^I2E@FK*:2*$(H0N:HBV*W*9,QN;?@-Q[>'\T-4WXX*1<5
M*E!TXSSMK-'BEEE%$WY$3)@(E$"@BH5,?2L(7YW=3?(*!+54Y!3N42W[[A\[
MMI E-JNJ"IIY11[36 ?F!1FGBO/WJ&R*1E\M/$-%3D;Q15$EB>:4IA<)MS%$
M-(&$; 0>VUJD62C0IA6Z1C%\./I -QO?R7HR035;=20J@ FO;NJ.H)J[0/N?
MD^"GJ"%9325Q1M<?@^;_ ,%(UHFJ]^ON^?Y*7\.:%;Q&X_#3P25*:$4(10A%
M"$4(10A%"$4(12'!-7D[_@^G2DA5,7O#YE+4PJA6B%C>^/TZ8+]R1P5H]H^_
M0,4#!%/*B$4T*O</OA].C-"K];_/?2I9IJFD?<I:@**+H$+4QQ3!=4H)9"*:
M$4(0%K\>SO\ >[_G4(7*3=(*O'JBZRA/ '!3'S$,)=)R&.9*^DQ-7$A.W75/
M#% =>A^R.>*SV,0\;)*&6EFR)DG1S%3#S05T-?0TW^) /K0^&FSI.7I@G[U!
M<>W@%+)U)CJ9:ROV]'[)7[@:GD4OBO,+/_X<9C_M7D?^EW=3"$D*$*NHWE^<
M%1IP*:!$1[:80J4TE6XWU4FHR%4 U"/&WY=Z1+!-5T>[\[\N@RHA64^A)%-"
MO);X?I5&2,U2PWTWX4^E-4'R>01I]*2I0A5N(]HTF 0JB6P7O0"Z:IQ,( (T
M8)*E-"*$(H0KA+IMQI NFJ"(CVTV9)4H0BA"J'8/P4LT9H^M^'Z5&:,U2FA5
M*/=Y> _D^&D4U>(:.(>]Q_('DI8H0(@(6#B(T -4H5@@( %PIADE4IK>]00Z
M%K!VN \AB_1+43Q34]NG/^"SH/(6._..Z$LU(BDFL']?-^DD_/GHS2."@3U&
M?RAF_P T1OW(:F,2D$PM--5&W=>E4XIH&_"_P4!LDE2FA9+A];:_=P_*\E1K
MG@FJ#K_):CY4*T+=]Z9?))4IH50MWW^"BN2%7S?YKYU*J:KJX]UJ6E)RRH8;
M_!>F R%;30BA"*$(I="%4;W\Z@,R:!MPM?X: ^:2I30BA"*$(H/0A7?6_P ]
M]*EFA ]A?AI9LFK*,*A"R:/=^=^72,CDA4,6UN/;4@70K::2NX7'4(@/Y/?I
M=2:IQL'DXV^G11)4IH63SOKNSO[/R=M1IEBFGLV%M\O&EO["/=;^^6M*N:B?
MJ"]!N^C)'W('L'WA^A2&2DO,[=G^4'(_UT7\X%5%$8)NJ$T=WPC]*A&:O MP
M#C:U1)8H&*-'N_.HU)JH"(>E\'T^RAGP0K1L' H]O;]2GUI( -06[^WX/^&@
MT+H8*VFA'=[G#Z="%=;CYHC^3YE+*J%92'U)JM,ATD4T(H0J5&2:*BA5JHDB
MA"*$*ZWFB/D'ZE+ IJ@]@?#]&@8E)4IH10A%(!D(IH10A%(!D(IH5QNWX*02
M&"IW#[X?3IYIJI?2#X?H4C@FM,/MA/?H&:6:DAT\?PZ_^Q'G^-,:B$?<%.D/
MM ^__5!3^Y/)6*A\<B/\TI]P-2>B6;+S"S[CF^9#Y,LR/_3#P*EA1"2(!<;4
MS1"N*!1OPM;W1J)<)JT;=P6^&]225*$*[N$  1XWO^52S=- ).'!DF[(K91X
MX5(W:I.W9&**[E<X)H(F=*$4*F*JI@*'FB/'L&D7"1+)H-[]]MJNGK;G(-U=
MT\QA\.PR =(Q9I/*)".QLDC,F:.7*\=&FF'C9)X*0Q[H"F3,<5"("<"@%P*Z
MUX>ON0"[#/U-UI9YCG.(8!A<]N'E\ZTB,1Q]G++NWYU6XNCNX2.];R#1)DJX
M0$Z9(]1,Q50.('.82Z0TW%:D5S;O4-=G_:1=,F\^98;@.//MP(K)-R< /N#M
MF3(L"DHB+W!C7$-'3,0EB,H]<((Y!ZP1F&8'49%<@@#M$VD_-(!@$YA&3T4[
MEG!6355P^7CF!V;5->4![)-VC9D=P1)PV33>+@FFY+X58HKGL3D+W2, F*(T
M'#+TZ4/P[L^ML6_9Q3+]0O4)MMTP;>.=SMVW<I#8BT+%$<SC>-4<0[5Y-3;+
M'XQJ\ESJ(,&H2,M(MVS8YS!XARN1$A1.8H" N4&E<BFVP[K=V$SC<S:7::$?
MY@;+-XMM5=S,:!?$'J<8WB483'9M5*4D!7Y3(B:&2( *Q])0 #&$M@$*'SR1
M7H[U*M-\W,5N<Z[0/CU6C]-!VDX<)O#*+*,F\6@32>:.ZCDN<8$] I&U)V-I
M$U-Z.BO85LMU2N 2,*#Q!,06,JLJU5*DJF1 YT5HLYP*66;JK@!!43$"D #&
MXZ!"D#Q?!^OJ035NENKKX+,1-10J*Y *+%?PB:4B)K,57BOFR#%!U;D+NH90
MQ2.B%-K1,<H' @F"X^9H$V. Q?T_9Q6N==-JBW7D@,T*0Z_KA!$HO7T:B1=4
MK5PDR*"*SU-VT!-8!^* O-  $W P@)Q*1(=D%.)A9H@HR2>RR[H\&P=OD6CN
M2BFC,SQ63Y"H<Y$NALX " 50+H#Y_$=(]'0]6JL1'S %5$W;YI' FS<.A<R#
MA%HR5.1+F,VK9XX.DBX<OC )2E*.H#6L!KTP?8@FCXGTP.:RI*Z4V9Y!-1H,
MT*B..G1(9XUDW::BA.4X=E!%)@B(-U1YGQH>8 6\[@/W-Z?O07%!CP],^A6<
M],YW"2#F.<*)K(JL3I23<S/((1TJFT9Y'B[TNM'(H5Y(<YNFX;:T#*MU2@<3
M$,4J?O13T]/6FUWJWCPK8/;7*MUMQ3R\?BF%>.4R,[**7?/V+*)2=N)B2,R
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M D!@N6%>I KT!6 =TK90C8@MR.6+-=4[@$@\1+N2L8@S$!2$)!FY?' JRY!
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MC*^F6&4R5?<?$H.,FGP.,?=-858)9E&O6;9O)F,HB<3DDR )@O:PCIIZN*7
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MDFM?^^3_ *0G]T4IY*)]R@7U%C_[PCAY8B-^Y#0/J*>286_"WNU)JNA'UO\
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M1T?BV.)DDF&,MUR39GSF(<QZIP20YOB4$P76MQ,%C%<4P(@84ZG6F3=3;1I
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MF?8+)8P]S3Y<8]D.W)$CJQ$NQSN,R^!+.-D@</LN.Q1=*1LJA'I*M'82_-*
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M^K.7S_?SJ%VKR?%VFW6U^P[8#L-]9+>DF28E*117.4MUF^2H.\9QV%V\.5I
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MV_@DLL=8[T5/"J&=R!LID!*LF9TIQ15],?-[+/*F"8!%26/#THM;V?J$5O\
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MPYHOA;9TZ+ 8KNGB4-M-AD8ZQA$D&W*M(-\?Q-^E()K FBK(.7*AB+'TKBL
MW[OBGG3#U@]6"A5U6Y0#KVL^X.*]0#TB<#%='.92NT&)2\C(1[8I1BNHM,'
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M<6S7="<RCA4RHB<PU>Q1KIP4M-R-H&^Z&T&[#S:GK(PUC/;K.,/S3#\(*]D
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M"R*9@,CR"D*5,#CXI2VDA0#M)V45S2H:Y+).8'C<U*M,GD\9Q_,\CPN->8Q
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MG?!+&DG7,S?:+;7<D[#),KPJ$S9[@R80S)X] S42D=&50$3$=N6JIA3]>',
MEL%Q]P0JXIW+/.7P%5S5^G[9QO'P45/8-!K,(E5>8AFJ @H$<KD0LW2J0F36
M7((&%BD 6XAHXC2(&-6*&HPR6RCT_P"U</E\;EK3#()')4D"HQ"9Q 4Q0TH:
M->EP4P#I;$[5"T#H2%:Y<5OEVHVS1W 3W.+@$".X>)M5H%G+#?PHMI!!^P4$
MUG8*&.*61N  2J@ "(<.VXGP(9UHO=EMNQ4GV#_;V!DWN2RC#+\L:JF*#:5<
M Z?2D>Z!47R:0>K5'SHP%%0QAYO>-+J10@DK29;/;.J9J.;HX1#$S5M')Q\!
MGC@AREQ1NV)'M_"-2BJFJJ*9F! #2"@"!!I@!F&&'?5!J7[>ZBV7.T6VX;AL
M]T)#!X%QGV$ME(!K+!<S86KY&09*:A*[,8QM&2./15 /.#AVW9Z!5 ))J0Q6
M:#V8VU@<YE<XA<%@XS+7YE97(,I 0$R1LB5</4R-4BN^<H1=05Q/I!72 %U"
M%PU+VHH]$H,=PC$<24R!KB$/#8K)Y6H=65>D*H=A.<P4SG%TNDN9) QSID$0
M44(-R#2#DJ)8?,R6M5$T]VP?\/&GZ3_YRUI%+,+T([ZCDC[D#V#[PTABI+S.
MW9_E!R/]=%_.!4\W41@FZL ^E?3WV[;=]N \;4\W4EB Q7(HM8UZJLQ;<%6C
MDADC'(%KE'F)-@XE)2,I%5QNHC$BO04VT_LQMCELHMD;O;2+DLA@;OV[Q\JB
M6Z28%4="D NFYC%.JDF(@ WX!1JE@$CNH]#]16BCM!M5\EYC$F.)PK.$W.53
M-/H 143 JS4;+ F0P*B0@*&@T@$3%/V]H=TA)(;H&A;N*M>[0;>QNVTUMJ&,
M0T+A3QRQ;)XJR RYU$FCE"Z!C(K.T@T)ID+Q  X5?:XCO5L;8 QHM0.G?9\7
MJ*6+[48XBTF<=B,94YRR!%ED6\6SCW:HE-(-Q(HFLA]<6W'L&C6,F3-N.)2I
MPS ,+Q&-F/D3BL'!QTTX/D,PFJ!QNZ*@CBYD":'27F*HM4Q[#C<;WMP!&X&(
M1X41B[KBX1M/M?MQ)OY7;[#(?#<EE"J)9,HF!E6BY52+)+ 51!82^<1PL'VT
M_ ?FXYNM3;@ N5_W<]GY6<D957;7&W4K,/49E=RHLF1K-2++F%)(KG4>D!-5
MD=R8I0,<AC H-@&PB P.#LD/E?5BNQDVT&UVX<]$S^X6%0\T^Q<J+>%FDO,?
M0W+%0$4FJ:JRZBA""[/YQ4CE\\>/ :0;"J; \'7D5U+>QVQ#J*WLWLWBW =8
M!EY9]P]CH%7/\=R.=EX%%U(S2J:T(^QQ2.8"LB,H4Q1,1<NL@#80X"TF+N0/
M@IW;#=#^V>W'3UMQL?D,:AGL?@'BG<(UES(-H] '[M9^86"*R$6LT1;BN4A2
M+&Y@EMZ5A&D7=-HYLZD;([+;63$K%3LUA4.Y<0+,S!E,& Q7D:W,1=,6S5 R
MPKJD$KHY;D2.'GCQ[;,,2X=(AL@M",V*VRA,?E<>@\-@XW"\N*=*4B0$#/,A
M25+H63D4R.-3<%450 >8DD "8?(-@IAV:C+:#8[9]'!?Q?I;>P+'"HA0XAC:
M1@,")W_B%S'0.5RHFISN8H8VD#6$W&W90SU!2PHU%T!VYP5QAJ&&3.&0!< ;
MJE4:1A!$7"2Q51624T@]5]%P(C]J"@4ITIYNJQNW6(X])/I"'PV!2&>:+0S]
M<@B8^0M723AJJ+TA'Q3H<Q)^>XJ D :QOV#;)1N-@SA5SN8N,&ZBDD^Z?=G$
MR1L,_P  @TT(R1<':%243.A$N,E<FE'7+4(X63.#A<!.;28VD2V-8:CJ8U2_
M-1 HW<4YJT#&NUXE67;PR3Q-B,G%(-DUU 3!NNO%E*?0X=6_4Y#&L)BC\'"I
M&<6=+\R,"1W%)3,=GL#W#?P,WE^(0&3.XU9)7'9)<W)417(JDLF<2+O$U $%
M"D-Z)?J8TG,JET)P4VP))HX\ Q)@8G9NQQX470M54X](4D&XJ@N"(AREM/!4
M+WI@HX]29IATS;*0,@JZQS;''(1 9(V1R#U-5%45I55MZO,7EI/!5$IB&*(@
M!1-P[:0J'""0*G%=9[L3L8Z=3;^2P?$WTKEI3IY$LE Y'I3(N*PJ& =9@"QG
M2@^D?ZJQQ*/=ZUT8[8W!(7!)3!('',45V_>'(=]#HM'S%=TF=-YS+$?O$15$
MA7:I?-2$ U<>T*8XN@%^I<Z.V,VC:X@;#HW X1OMR+@JKB..( X]8E6(X(>W
M/)YH."D&_)'W^^DU60[XX\%LK[,;:O59HKK"()=6133+D E,'VG#5%IK'@*(
MNC!<TDLJ ^G<.S3VC0_*2R]REXV0;C\5?CVS>W,7CDSCF,8G"-<:RI!XXF,?
M6 0]=OI,RSA^(F\0B0H(NGJQ U6X*]H]M'Y0NX=^L(.X)&7K7.8[#;0PN!)X
MFAMOC^.8/'O%7$BQ9'*LZ.NL90X <J+QYYJJZY.()=G?3&T.%>\)G<2? :76
M^39W T,,:X"K@>.1V&S"J&304:@LF=VBJS,V?MRFT2*Y$P 6"("!DBFX#\!^
M5)XMV+(_FQT'O3BQ"2"<<T\,FS;(H()1:3%F50O@T(<@1[<JNM14!,HDB A8
M;=O *1VDAB_>$'<"76NCQ\@TORIZ>\*)O!EKAJY@>_;W:N0RQJD;TZW^7?']
MQ7O^,L:"V2%.D/M0_9?U849I?;V*TY0YJ7=\8I\]$0H* O,+</S<\S,G;IRO
M(AOV>E,/.%N/9:I#BA(ZFA7#I ?1^>-*J L:Z>HH"F5N"P>@HNW(Z @#;4!2
M'$OIV"_$.RE4GJ35ZG+60(V5;M00'BX(@W30%<1O<=1 '1?5Y!I@<4CZUIKL
MF@#R"-R&9H6,P3/I4<HG[C/G@DUR1.'HG*4!JP\=L#3K5L\S4ZG/6@K9P5NL
M*9T4'#SE>L%XY$L8@8B&OPX)LVYA(F< 64U&U7,(AY*1OO4GUI_.*?-ZUD*F
M<5D%6[A\<Z0:3$/)KF*<0[1MQTW$/(-,[C@?6F1< J_<M=%*QA,R8Q1A,&DP
MFC6Q$K<>((@42WL/EJ\9NI7#DXK9*P11<-'"R+14H.FKAVU*BD)#D:+%5Y#8
M;&!AS0,8HF*4W=P'3:I!)UA;-?#$70 R:[1:5+)%:O$2NTDDP273%J4JIA((
M"9>^H"A:UM/&]-DS4H6 &S)LDE%8Z\=N'1G)I:2@6#R917=I)LGQDY1P0[PB
M:\>F*9"@8 3.<Q^(B(4CU*-<UN&3?-$DVB$K,'00Y0LT)&:>3+)DV1MX1JR8
MKJ$19%;I@!3"2P*@4O ND H X*1:5?1UD>*'>$?E%5=L+EJFBS\$LHU38+E(
M@"CDB2(E*H991,YQ - W4'B(\1;)=*UVZ1FJ<61 Z FCVRC<YW+0KD70J)N$
M^88#G 4[<^]KFXE[>/"+)YJJ*)2L@CG",:X8.'+QS,)!%MTE)(5CE.S*5:Z@
MM? @94 &RFOF\--N(S(-5KIMSD Z(G0.U3$? HG:D,9F41OI*J)QUA<1[ )V
MTV.>*/8L3R.,I&K*)D9PT@I),797+1LD! 9MGC%PO'&;I"UUE=HH*I"?4 %!
M6XD-IL8<FB6:Z::J'C7;I"*B6L8[7E'2,<DP:ZB*RJHJN3+.B))@Y !TVNF7
MO\M#!Z(;O6L!5U6Y$'IVKD[-8ZT0JFQ3;FC!.94UB "B@G^W&XE%.]Z#$\4*
M@B=N=HV21B C&D,6(19N(MLH[+95ZH+@DD<043$P.@+I!/L*/G>=P4;G2K?P
M+N>KN*HV8N&C,X-.4@DU;M",0,H"Z+<Q4S@_4Y'F$.#\2)B)?-TZ+")NX-S^
M+UIBS=&4NXJY9PL+4$FS2*3;J"/C4&L>V:J/#>=J,HNB%PN/E*:CQ'IJR2%B
MX^$O6K@*KK!^ LR3RO![+%8) 1VF-P,F9H!P$MRF,%Q5-Z79PXMB*C%7(PTG
M!7 BFD<ZR("@JK<R@-S"BT5.:XG.LS3LFM<QA$H&'S;C;MH#E+V*NI8[15HJ
MNII5,)N:V.=JX)?5P26(8QTPX]PT:>E&;K16CT1;O0: G'OW4BR=D>M$BHD1
M9-G;%=>/,V2%+FE=HMU4A/K*!06OH-IL89-;9D6X.G?A4",8IS(O9,(MF!6Q
M1<O7!G)S/%T2IE?@F<?,UIAIN:WI#0U>A'7BLJRCA=$=;A1)ZD/ZA?LS'9KM
M"@ @!;I'YBE@'N.7LIM5TF'8M4[5%9ZX<+-F)6Q@_43%DQ08),E.-E %$!(K
M81[B$N 6O2TJ3E7H)%2((F3;"Y./Q[I!JFV5<%*/Q)5Q*)CJBCJ-83&'TAM:
MXT#%16:_"WNWJ2,UKB.D5^_B7CV=Y??J+.A3WZ<OX*NOL8[AY/BW=(HS4B*2
M:UK_ *H4#_B"#_3G^I3''I2/!0)ZB..X1P[/\DQOSTA^I3&)*$Q0EMW_ #J8
M+H6J=@V4,+UP4[R7"UGSPXND;?S3-;6!N!C?USO]RD#WI^Q6^&2Y:IB,H5.0
M65;K&>EA68$%5L8YT3G;!;7H44$0N?A1IJZ3EFR68R1#@Y6.FW"3>)%0<O46
MY$45$B%3(4@LBW+8"HD#TQ]'W> U$$DCH52@ @*2J+(S5)018H),D4?!H6+I
M0*<NH# 4X&&X 4/.[*&/%"Q)MTRJ@L8RW-,X%5P=!8[?GI(J:XU P$O;U<4Q
MP(81'TQL!>\9.C-DLPE$"2()NI JLFF"2ZWCUQ$4BE2*"9PN JE $2\!&W *
M6E"LTJ&? ^5\,H=(5$FH>$3*+9D=,Y/!D/J,()@990> %#SQ\WMN]-4LF6%-
MHW(F"9VS%4B<@L_1(JR1.FD)UP712%,P&*8$!* 7X7\@4,@]"%6J;AV[=*HL
MDA>I$16"/8HQYC$(1%,H"HA<3!I0"X6[:-/6FLBIE$$2@S29)2RP@#V3\&D"
M3M,; 9,S(+:+E >(JF[>SA2Z2EFV2VVQUXXB:S0C9LY( *I(@4CB#<.BV.5:
M5Q\ 39R945>)"*F\T#'* ^>(TQATH(JL"MU&Z3,S:)?,2'5M'3L0UG8Q!!XJ
MJ\D48Z.>_J6.%U)JF6*9,OQ93&)8=0FIM7)NKT]*(Z3C[\O5EGBJJF=JO8R3
M(\4"58IB@J]7UN@<MS%7*=($CJE%$#$<G"^HW;V4F8)XXX(=)I\Y=8A3<E<K
MO]2+G%PDW.^&[PS(#@!&8.A$-8$*&K26]](4@ 4+ Q;:T6[4"M$T6:JB[8PL
M4C+)G,=4QM*VHIN)ES#PM0P%<T/W(%+3'H1;9HP<M-8&?JOFB*[MZ "0=/B5
MB&41"Z9>T3]_EJQ_/-@7[5:FQ=SU/VK:*0W%H3DMH1-!1%K#(F+S6HJDT+^'
MD" 3PZ:X%*!R%1 #@4+]@4_SW3_TD>%=I]7<5S5$5B$;&=-F/-C53J1*B39%
M%N@)C*FN]9@ IR*GQIKF,8@C2&^ Q/\ TDS9N'\7<5D="DF=-0C(HNCB /5_
M! (/"C<!*=/0.D! >\QJRWCVL]/>%DI;.\U1+_"5G,*I4P4CF<1'F;E*,>H:
M";">/,?BY.!@Y KF<"1,;ARQ**???@_S%K^#O"QM_9731I-7[2M5%-J"_C/B
M'$J<;N7#AB1XV6$  H:61S"1,0*4H>F/8/EI>-:)H8]X6-GL;@RE_A*WG!0=
M-G;5RBS(5XL5=QZM9I1B9SE%$Y1%)#44;&1+VW[*H 9K-+&#=(H) *+94I$2
M(V7;)K&,#<H$:B)SW'XD+^_?NH;)#*X2@J K.4VR\@GP9O?#)D\(0  "E*EY
MXFL !V'+1IX)B@;)811.9J+0WA1356(LY.#),%ESIG2.43*Z]06,B7MOV4-Q
M2-2ZZ//YKL5'2#95F>,/&J-R()HNC%!#P[=0'X =0H(%$1$N@==^T+4&.:,F
M&"Y*K(CAM'QKA./-%,'2K@&B$:@W%T"JCE04W:I3&!P("Z$-1BC>P<*&+9.A
MATK:,DD,>[CP;M.6]6(NNJ9JD98ZB9T#E$5!#6-C-R]]#%%.U4Y9_P!3F &E
MVZ!&IBG9)G2<MRE(F!'20F JYDR%LF8U^7J-;M&DYC3BA@:K&5L44%8@4(U3
M'GAA4?,%XQNM(G4&XF%E-''FQY!,<UBD2, 7#R4. ,*)UQ&*V[%_-?.&I.4)
M[-@[?+QI8;_$^2W]\M:14?N"]".^EDC[D#WA[GT;A2&*9H%YF;LC_P"\#)!L
M-@=%N/=Z'>/8'94\"D,$W28JJ#=$B1[<?.5 .SCQ+I&X?1I$D53."UR 8';I
MV[,D<7.K25HD5J"0FU\0Y9CZK"?AV=E6/YAJ/ZU;?E[O\3]JRE4/HLV<*%5*
MDLV.HJ4Z@&0<"4RB0E$X:@-H#OMP[*8O<#7K1X-X&NHCM5A$2)*LA00CR-V0
M'$J"D:@J)E3@K=0%1TZ!NK?T1[.VF+Q?&G6D+-T?CQZ5>CRV8 H9JP=R9G3E
MP9Y(LT'(&YY4RD(5%P4XE%(Q1$#:^(CV!;C=^(*5]:S'@.Y/L6)JW4:,T3*"
M3URD_>O6TBB4$T02=NU'7AB,2"/**CJ(4!!6PZ+V"]@?BN?J;M1X+_N5GAW)
MS$0Y,:A&\DR*S,6: BO=8SC4*HZ */.$#6TFXA2%T_B]:9LC,+:T"!6S8J,:
M+,#%"1(M&-UW<@4-(& 7QQ!1#4 #VE4M>@!PZL>]44;M1="0B!$H4H@9*+2T
MIKHJ!;4*4B0@"1)01,)B D &$0OZ--B<Z)9=*LY1A5%V8&/C2 *;8Y8Y$K4C
M<P:3$79 ?ENEM)C64,8H@(@-N%!!=/)LEE3YA09M#N77J>-2'U?&-W"K8/%
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MM2."%A.HB)G)9(XHD:%U )> A;R6$O>-1*.!"T8R2B9(JQHQVHY.B8I'0*"
M\H;G!+38Y^!M!O)V4PF5U*:2NTF\GSPI.$U00$.WOHH4D%+?WJ"6Q36HZ<L(
M%B*4\Y.=41*)=(_FA*4+^<C]< U#'!&)<+%'O&3U %&*ACI<! #?6@8/-^N-
MV@'EJ44'%;]226JL9%T47#TYFY"<1$  .';W"':(UB]9 =;9_;;8Q [RN:2:
MA%T7A6+Y94D?H!^!A*&CF<T$]-E##Q! _D[*!-T'ET,@.\K;9R$++MN1'KJ
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M@E;SS^ERS>3LICU)KJ4TED VKAV7[P'\JHLU4U<">L;7$??'WNRDZ%@<*>#
M+<!OQ[![0OVC3E4( JL#FSH@N$SBW;$ -=AMPO?NU>4.^M+%XG$D+:QR^ &
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M6AUY!F\C !%N[.GK;2#IM8$TV[I?LAA^N[?@K8MCYVAI U6L_LN<>M<XY_\
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M <$Q73O-+M'G4VXC5WRZ,7GLK/)PR#EFS3:K0$[G;YVW_5J:8+ 8Q0(&@XV
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ME G&S&9^EF?I=UC>:>5 +\K4?$$@';5"H;JXI_>FIH@;8N$:-2B//>,'X7$
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M?8 \W3R%IM_FIY*7E%'$7%_)R=0%ZG9  ,DL$:H-C\D!N5(UKUC)>2-T"?\
M4=_^3+_M*QW7ZC;0'3_3.'_J(\/Y5?LQC.187"9-D<KCF:R6Z&;Y.W1F'TGA
MTTX=046@, X533%TFNZ5(X(DX3OJ0*7FB;C80');OR5NX0(/B.8C_9-*OQ[%
M?;?SIL(W8%[0C&4B1XT:O%N&6.:UF.%9PRRGJ'>*8;DK+'<TAIYEB^K%95(L
MF]<-\N2EY %1:IIK&24DVIQ3*!A 5+";B CKD?)6ZC?)(N.2?]DY]N2V.[^H
M?+[EB-L2L@1TG_S$<LF;-<%'9W/\@Z9(3%T8!T9VQGID3E>1+D%3IKS.6."B
M9LJEK3TE=E#B(W#CWUG]EY(W6@-XE0?]D\?YE@]]YYV-^9/]+$?[T3E_*GNQ
M Y)V/B9-SLXU@,D" DF/RAD\03FIN(8+1\F0(3UHY@8Y^=-<[M8E^:D7]5F\
MP;B!L%'R)S  4N&=:G;RX=:<_.NPG,F4HB!:@W %07X)DL*V[RN-V8WMQ17
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M_'XP\4AX_'G!#H_)]PLDS>'9NP214< WY?,*J) "Y2B(]U8Z?DS?2F)1%V(
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M@@ZJ#H'P6L=JR29AX< =!W*7'L "VO<0"K?_ -M;?\,2/YIK,3\RWX!Q*?\
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M0+E$1/SK046\> #'XWDI\4F+B$LF8##. (EM<-/:)1\VG_>[GTG ]2Q=SRY
MRU">DCK]/V)V,PW^P;&\NB]NY)=R^D9F&;SZ'A$VY@.DF[E/2%1XU/JO!GX
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MQV3,8!YQBWL "8?-',;[:79 "0FT8@##!SECQ4-GS396Q*=J5L"=PRD:L9$
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M>/$-UJH+A<GFV!3B0?T7#A2T3S![DR89$*T'@"L=$4S!I"Y#A<Q5. C8/-
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MVP[I.VHR%HWG<^DD(3/)EAEZ:"\;!2;B"AO5BT0R*55V3(6DH](<#N4@)R1
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M2* JX7 01 2\U=MX;6)0. #H  'W;5$1Z**<MU(AB3@!CD"[=Z$VG*;((+*
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M?? P=GP4QDEQZ$C,4"TEDI?S+EF%[=MR./F4Y%**6]@[>%_F5%RFP5AR"8.
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M\5EC&Z:@ HNU$%  YK$7<*<0)?@"J@!>]2GS"[,,[=@1M;$6>4:OQ/O*ZPG
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M,8*-T2(AU"SH>6!2^Y15-O9[E 9*1ND.3;C^0UZ'JC[58X#XQ$?TX/\ P*E
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MM5G,@Q'$=FL#;[@8I@TSX=TWRC+Q0P)!%V:.?K)H,W#5EG<@B%F[HYRF$P"
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M2%1))0+\PJAB^YR] CV"'YH*J:(W1\U0J\06>.*X"[6)>/2R2J6I=@(E*80
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MJDMK\#R3/%&095D&#8:&0+,UU[OY:1@&AO$.6/A6<;'.#O7"ICD:)$2U'$H
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MNZ4=N3&!R"KB17$I@.J)S"4I>)@[>ZTW6WM&)E, ECF7Z:8+=N7^>N:\OD/
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M.W7,=KMY_P!23!^!.3Y!7/+=_<A 1&EM)R/'K6^[,0B2)')US'2 #7(0RES
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M[]3/1081[LC8\=( KJDA,4Q -YA0$VKNKJ=S]+]E<C0BA;Y;3=.4EY5\J_\
MROYGNKPC>M,92D7EO,!HR>UQ!1#^U'W#C<H3:YY%ISD"H^0Y;YGDJD&3&V:3
MJTZ58@1$@292CT#IV,)VP61$1T@?S=;YM^FXM6Y> "^F8IM^ IA)=+VOZ\WM
M_N+.LAM42QWCTF17Z,@.U>W6SNZ^+[HX+CF7P,HUDHF>:.1:.VK]"2U.47[E
MHLU,*!C%$Z:S14HC>]R6MVVXMYA\H7K5V5FX\)@Q-;1%-.-2.Y>H_)OF;;<]
MY;:WEB<#;E"7^X)%Q,Q(;L-?55;F]F6;CP^UN8R.U,2G+9LGB[B6Q"*D%SQ;
MF5E6JAE7D29,6CUPU=(Q3918@@FJ<YA*30' U6UG;B$JC K=KEZU-B"!3B%\
M2N=]9?M>=],PRUK!XUU>)N,%F,FC5,?VCVUWP=XYC>4HOW397%LRR#%$$6#I
M%63AQ:Q[AVV0YA4')TD>*A"[9R^6WC(0(MB9T@X ]/=FL%NH2D\ZD!ST= '6
MG<Z9_;<]6W3]/M\&ZHXV;S&'8HN@R+&-QV$U@VX<"W(_1.H[;Q>5Q^03DV"/
M/!,H DWUD7(8#   !M@/)>7[^ F3&W<Q$H@ \,0Q/?ET+%GF&XVITQ$B#D26
M&;ME6C_%?:%MUNCA^ZF&8YGV#R[*<Q?+6GK"!DF3QLZ1>L?/^/*HU471O\6;
MS0,;L[>-<^O[>[;E*$PVG%;#"8 !%2?0^JJ<)D\YI3FY8E#G'3)<P^<FF<2D
M5 !*%BJEXA]$:P-S<-/3GJ(QZ5?6OF#A=0#W+>WEX7\GP5<6IZAZ<549RRTR
MLD])@.(:SE,4QTB\CTBB41 "F&PB ^6J<;AXT43%<_U EX,&8K<],BJJR97J
M?C4BG.8#):D%E!(IX<2^9V6[K5=PFS$8L.OI[TFXL0_[NY'J(A5""51 R)A(
M#E!PS(YYJ92:3)(&45 &A#& !L & +=E5/%+9OT%O5FBM.([^I,WE/2OT_9O
MF..;@YALWM/E&;8@51+&LKR';;#YK(XMJ=%^D1JG-R44YD^2W/*N54BE5(5-
M58QP#4(B,SN;AQ)Z:^S@@AZ\4^,=%H1NL$#J@F9NT;)M2G,1BU29D.FD5BR
MPH,RF*>Q@(  (%*'UH50F3-WQ*8HNB(5;2M!TW5#?7?8?HJN<NU0./8D5C'[
M>Y5]G&_=)6A 2XI*2Q6N"GZ8']14LQU)<4W>,_RA[B_K'#?H9)2*!B4Y-)-%
M"$4(10A1_CMB\4B-VY;=^+%LUR&:Q)IBSW3'H<]0&LC,OP?'D"K$54U^MQ+R
MA)PT7UCJL&MV]LUS6,>KH99.YS*_<LFS*<C&GW'(NGA2: FV1;G,FMH0*FH<
MR1?CE@3 IW!BB8_%0X":PB(A?MK)V[)E 1ET9<%82OR<D$U?-;0D!02<!*!
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MQ7MCRYYHL\YVD+^WD3:G&)#S?Z@]/>G!*Y:*!SB)I'0 P%%<%R#YW#ZT""'
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MP-_Y9-JV?Z\+'B1'&4(:@"_$@#$=:^FM@LF[@&"I77C$'CHQ4A#T3HE,[*B
M7* @44DP'C;LKUOY(EIV,)$N?#N-T?U:'N7D+S39E;W4K4P(O.#CI-MSZZI<
MZB+7,'8 V^A;N\HUF=[9,8ZI/0='%4K-Z-R/R\4GY$ADE6B@@ D-(-4AOY5'
M!"A;B%_GU&W?C':S'_=MGP*L+UL^/"67BQX?B7@@I'.,7WUWOPUXF9,V&YA&
M9#&$'3J6;S^.QD^LH4Q1$ARE<9*)?-L(=@\;UY0_5>!GOKMR&/YBT>ZPR]A_
MHW*$>6V[5PT.VO?_ .PEESU4EE4G)3 $,T39MQ#Z])TLHUU<-5^+LW$+5RCR
M@)#=PF1],IC_ /&?BNT2,8[:4:?-)SCT?!/CT!LA?2/4V9DJJFU%W$PA1*6P
M.7D>MN*S=I (I@&M!0P /8%S<+U[-_3Z[IMVP2!\FWX\"O&/ZUVQ?W,H0=S+
M>CK<P"@CT:=(.QN^V:[[Y]EN'!,ST%N\_BS*&79IE,LEXU),#%<-S*&'DLP[
M# %>@=GS(6[ (,:1.(/XEXEL>6(\PWEZY<U@"YI^640]'S!X+Z#L7PYE!-!2
M;ZQU*GXB9/O2(7N(4.P*T:&F 9UV+8<KM;2&FV^)X<.I,_U$]..W6^^,,,>W
M%QD,@8-CO%FIQ5:D.Q*N#07?+%8BI?U25NG<-(_:PK9N3\PCMYZP8@Q$2Q!J
M0[8+&\^Y,-UM_"E&33$@X,: L#CUKY>^JSIFP3:'=;=7 -OF#F)AX+;!S/K(
MD,@HHFFX=X0Y4$3(M$TQ+SYON+?C[]>B/*W,K=[96KE*PD<#CK9>(/U*Y!<V
M_--Q;:>F-R <&+@&T#P]R>/V06='V_WFR##GRA'I]PSR9D7!BJ' #1N/K2A@
M*9(2D*(%AA](!X#5#]3N4B[MC=D)"=NS BHSND>Q;Y^E'FFV.91V\9PE&[>N
M _+,86M6?2 I5]7/5_N[M#UG;=XU'3[>-VW1=8K\IB&0>F*I!3$I#EE"B*3P
M '1&IK< 2,/'L'LKC>PV$+T)1N1^21B2*8UKZUVGF/F"6TW^DSB+HH"TOI)8
M#N6[[8S9??\ ZG^ES;Y_L9&I9''XM+1^;OL3259HKS3\T+EK1BJ4K^6C1T'8
MY!?M ;G"XAV5@.9F&RNW(\;D6)!< 1:C=*ZIY7WAO6H7:"/A2!9\3,%^Y2C]
MD9TC272?TL*8MDI'+3,MQ,\D=T\@2659K"1S(X[A>/F2 S(ATR )<,#S3'.<
M+]MA"J7/N>V^878RC*)A&%&C(5<OCT%3Y3R>>QB7$A(SJYB<AP7K,Q*CH.=O
M<$U5UW!BB%A*LX.*BH6L'$#C6AW;HN2^7Z1(][U6T&.@,?J8=V2SKI@;R]_S
MPK(;.Z(1KC^U6&XAJ-%U:N5410A%"%;5NFJU**$5)"M-]=]A^BJKEVJ!Q[$B
ML8_;S*OLX[[I*4%$<$N*2DL'<K^FA_XNI#$(3>XU_*'N+^L<-^ADE!RZE$8E
M.345)%"$4(10A%"$4(5!JC<EDF%6JR2*$(H0BA"*$(H0DM+ (E-8.Q4P#_0E
MJOM*$_S'V+&[]R.[VKQ+R?%(+*?:JK,YF$2ESH[2QYV:ZATB"P$\>ISCD!0Y
M=0JBF01L _:PK/Q;PJ_@]RYWNK O<WTD."6]:]H\?CVT:S+&L&_A$&HH$(5,
MQ!$;H:A#4 B7TCC6O[N1,NG5[ET#E]B-F/A6QIB %<XBS*-UTA(HHBH(@<-2
M=[6+V</<JZ\7^H!+!OBJ-S:F5J46>#]"\-_:P8'#--H&KR/:JIO7.>,45@$4
MQYRIY5H5(  $BCP.H;O[Z[Q^FER>ZU6I ,U@!O\ B&:\I?K+RO;[,1W%AQ-]
MR2[?P'AUKY_.G"5#97=C =PSI""L'-2P."*%,<"$7EGCHHF*AI4$!*D7L'OK
M?_-'(;M^)I(C7'./X2N'^5N<_D-Q"] @7@#D<Y/\%]7?7SOSFFT?3Q,YQMNL
MT?RT6WQ]<!%-P9,X2&61$08P"1XQ$;INA[#UYOV7*+FN<],A(3(QC@P^*]N>
M:O,EJQM(:+D1 Q!^F7XF]R5/LZ^HJ3W^V1ALBRE=K\LDB1+3(6J"3D@MG"[8
M2$*<%EW7G&706#@H8/-JQYQL)VH"1!8"68R99;R5SRUOHF D)7 +;TD/J=L>
MHKT.<A8I!"]@.'8(!]:;RUI.XO"U)SQ]RZ1..IF67D%[P-[EA#M^95P;Y)HR
MI^%'-4%N/=?X;?E5'6^*?AC)4\.;R_0^K1]26A;U5U-%"$4(5 JC"035:K)(
MH0BA"1$S_##&OUC)?XU&TPHRQ'6EO236,_8I^E_HZ:#@D9BO[:9/^NF7W-Q3
M. 2"6]14D4(10A4&J,Y!TU6JR2*$(H0BA"*$*@\ $>/8/9V]G=[M"!BHA=79
M77_=YWC.U(18J^W>6%5;N1 HJE5@WY50&YT "Y#5M?E.5L\PC&0^8"1?_A*T
MK]0A>'*YF!&G3 ?])0.]G7TU;-16T>"YXTP%F7+),/'/I'F(F*5V#Y974&FQ
MK"IQ](>RLEYFO2DX.G1&$FQ>K&M5H7DKE6WIN;D;DKLKM0\6#$MD_K7L<B@X
M*V(8%B((E3,F5)(!L0+"4MN)^P1K1[9BP#.NSB,Q:Q:F2AOOETY;:[IF9N=R
ML&:YDK$LQ5:R+E9J!T3$'G :QC@81!1(#<"UM/)=UH(@)0\24S0B7 9X+F7F
M;D-O< W-S:G,1MAYB4 7#Y%SZE!GV:,/#XT7J4Q^"0\#!0^ZTVTC&-KD9H_*
M?-M:*>DA0$"F);O[*R._!-R/'413K6M>486[(W412V"&!QIJQ:B\1NNU$^2=
M;>X.3-[JMH_.,4=F.F%BZ4,=QUH(V-Y_IC;WZZAY,M$[&>D?^GEF/Q+E7G+G
MEF7,XRU1#[B.4N#+ZA=Q^H'%=I=A2;Q98@H\A641$NT6:"#I1P)GYVZ*>HB*
M*RO$[@OUH=E<IY9RN]?W VEG4,S@">TTR7?N8<VL[3EXW>YTRH!$,2W8*YIV
M^E??;&>H3:>(W)Q@HH1TNJY3*S.FX26:BR>NV0%53<IIJE$XMQ$+@%ZUSS1L
MI[.[*+'0TL2#P?!;9Y4YA;W^TC,$&X3&@!#8MCT*29OC2$&X^E>WO7]RL#RX
M@CIT^];/N[= *_5[EMB!3=G$/=#_ (*N]9"#9.: 1#C8>(]WT@&HW):XLH"V
M8E\E7EB(!VWOY0K%7=G.<]0=GXA7$;@%"MFLHJ:*$(H0BA"*$*@]@^\-"%P7
M:9SILP%J5PD0 *I<Q!\TP%*/]<#NJO!@958E)WZE"'=_H&V!W3WHVGWVF()R
M7/\ :S-XO,H)TFJT!FBHR=M'S@ZI#QBZYA\2Q1&Q5R"-A^"H+UPALU(#-354
M(B H-UDP7+).02.0Y3F*D5% 5"&'3:W%N':/?5+4SEVTCO+_ +4I'UX)2'[O
ML@_/%JB?<B.!ZU&V+_WAY_\ S"E]QB:E]HZDON"D<'V@??\ ZH*/N3R5CCTT
M0_3ON"E()'BD=M_^UTY_MAE/^E5J#BFEY20BA"*$(H0BA"QG,("4 +J U[C>
MVFUO<'MO5&[@$/56F-P&UA'R7JQN2!50)C]UX4N1[<YY%-42N6[_ !N8:>&7
M; N5=XX9*)LQ!,UP,=JZ,DL7@(B8@ &D;&#G_F+:^)MIQB-5GPXT(_B]U"MA
M\N7X6=[;NPF8W?$($GP^6N8Q!(Q&/8ODG+&S\/+I;:#$K)[@8IEC=BBZ]6K)
MOVZK&6!G'RK9'E>,1,X79<TI"GN02@ ''TJX]9Y=HWXF1_O _3PDO1%[F6OE
MA@#7\N?N?[%]=6WC15IMI@[-<HD?EQV#!RNLW$RB;Q2,(JNX.0X@?F"H8U[F
M ?.[:]!^5KPV^VA;P:W(8MC-_0=J\Q>8Y3W.[G<D7,K@#L[-%O<M3<#>3;W:
M&)-,;BY;B^)1ABE.@]G,DB8I)P8RI42$1-(N&B:AC*B!0TF&XC:LGYCY_L]C
M9EKG!M$2/G -9MA[U5Y-R'?;VEBW<D=9'T%J1!Q]R;W;_J>V8WS4+%[;[@8?
MD<Y'R#-\K#1>4P<E(F9-7!U3N0:L7J[H&QDT#"8^@2D#B-PK3]CYIL;S7:LR
MB9DB@N AJ\ LES#RWN=B8SW,2+1J"8$?,&H <WZ5Y\=8F/J;<;ZMMY'S=1/%
M,WCVN(9*+=L<$X_)_5\4K#*O'1 %)U'J8]B:ICN5"I%14.5+C<!'G7G;EAYA
M=,P"=5R)^C4*0(QS'3E@NR_IOS4;+;B#Q$(VI@'6 2]P2/RM0ODY=G3:95,H
M8U"O9^6$0]3LTV@LUOB"Y"LU< Y262=*Z@3,NJZ*32!%Q+R[W&]@YAY:\OW8
M;F!TR $I?[9_!UKKMWS%:CMIG4,0W]3I'0IS="V(.L4V-?Y<Z312<[M9)*[K
M)< 2=1K+.7+C*FV*K''XYV7&4IKPI70@D#CB<$$?0KU+Y.V%RQM[<M)=K-6(
MP'J7DC]3>;QWG,;H$P1"[>(#N!JD'#YNU:491M]E;!IK*=3"7B#B=+?J3?K*
MV$W/ QIFR(EYGF:0<@&JYO0[./#I\;MR%D@ZN&?%UP_D>UA?N2F&!\4RPQ8F
M++V93;)$0$"%* @<>.D!&XE*%ZPIN,0 ?6M^L6H U Q7+E"G+'G ;*E,8&X@
M "705Q=,RO::X)@%[<+^4*R.UF/$#,</5\52YE:C*R6I\LLNA?.-U809YWK"
MZIX1/2<"=,WZF_4P+"*IW&Q1Q.1,#!8Q><8. W'C79O+G-3:V-D$M]0;4WW2
M7DO]0>76KG-M_2+QMPDYB#7P[8]ZAIL*T':G-=FMV8-(R#9:>E(MS$%,+<2*
MSV./\?4 \N0HA>/2FBN=(MPY@$T>9JUAV[SU^7W%B=L:9$V84H<+A+>I>4_T
M]YWO=AS*SN8&X(#<2BYD0/FM@$]@D_2S.GX]I5CGK+)L&R9$OC59.&DP?/=.
MH[Q''&^/F9KIK *AB%.5XH:US:=7:-<EY5RP7K5R<8L0781=C6G9A[EW/S7S
M^_M.:;>1N2G:N1B =9B) :7EG]3N*G3Q*]G.A+<<=P=BL&D5WY%99''WL$_)
MXH'*281LZ[CF"R[;4 &40CXY), -8;#P$ X5SGSEL+EC=&V 1\\:Z6Q@Z]$?
MI?SP<RY3;O>(3<$)Q(UZA_JEI'J  [<<E-UN^3$CUR7PJ7JV1"-33!1/EK-1
M*U$HDX%*B4AWAAT@!@&WN\.4;*QOMW-OZK"1&$BX ==NO[[;6;9(,#AC(8NS
MJB^3,HY06Z*15SK/Q2^+6 $R\YQH.J8Q4S@0I-5[=X=X5L%ODDY0,LF)^FOM
M6&O<[M0N:*2EJT_5TLNJ$VB<[@0%DHU;H@HHNA((KF(J()#RE$2$^*X''B)N
M[LX\,?N=O<VQ)(D(\2#'+)9"S?AN,#$GHD#[$J:NU4!=4$;=P_ %Z;)J@G .
MXW]"-))^@K&54A_1&_9\^J'4I++4@"*H12$@2Q0K##YQ@_F/T7U*KY=JCQZD
MB\8_;W*OLX[[I*T%**7%)26#N5_30_\ %U(8A";W&OY0]Q?UCAOT,DH.74HC
M$IR:BI(H0BA"*$*TPB4HB!=0A;S0'M]X;#2="UE'(ID*84C")CD()2W-IUC:
MXB!>ZJ%RZT7 0L(/;JKIBF!.04IM1E+:M12&[!)YMM?E&K&6YB'=G'2I!]3+
M8(Y*<ZA0+]K#MOZ7SN%7_CQ<@)Z**Y)<%":C !+B-@U7O;OO8M,7@0Y;O08'
M*JO,<P!<I0-_/Z0^;I&EXPR#]J0B,RLE5U%%"$4(7!?$$Y51MV.3!?\ Y-/A
M?X:J[<M-ND^Q6N\MO 'TQ7CH+5$_M:UR'YHF-LT@H0R2IDBDY,8<1 Y"W!4#
MZ@[1"UA[;UG1(^!_PMZEH\K(/.3JP=_6O8:/;BDF<4S>>X63L8X<P4]"0EOQ
M$-8CIOW5@-S\TR/3!;QLH-;)J<ZKK!<+Z *4HCQ#2 A<;!Q[ &J=R<HU)P"N
MXVX&!$6=UX]>U.:)!@FWA70)JMG^\6,LS)<LI"G.\RF#23(:^L#ZA4$ "W&N
M]_I%N[<=P=35EM\3Q,UY;_7?:G\K&>7A[LT#8"VOG_G-MC+Y3N9' S%LIAT0
M7(C- 9B<RB:Z<&HFD!?BQ:@HE-E.!])KAW>=</2V_ELKUH$FVQD/PG(A>*(7
M]Q9W,].OY8]-'8NO77=G)G>Y?L\EWB#E20G%H;"$%UO$G?K\UKN+C#UZ*@ )
ME1%)@<QC (W O$>%>:_R4K7.A8^7PK@,OIZ)=/\ "O5?FGGUNYY(O[X$^/9-
MN+^)6MVV]6HPFZ0'LE-R!P_/\VVR?%YH90\AYB,?*R0M4T_43O(E3-V\<=%4
M%@D/6R8:BJEY>D/-/<+8;S/RTPVYE&-")NT<':O8KK]&O-L-WO9[:5P'_0TD
MW=3MK8 '\5/VKZ)_7X.$4A*@B)_')MEB"\+9)(Z"ZHN!-R>(%$A2VL >=VUQ
M?FO+KFIK>HAPS1/!>M-OS&-VV"T=0DQ^;KK@MH<JC-8$(Y9'OWA)(\. \.%_
M)60'*+V)$F_D*I?WK:.PE;/_ !A=(LHBJB"B!VZQQ*4P)INR*".H+VU% ;6]
M[C5([.5LD2$FZ8M@KVUO+5P Q,2[82!Q6T1=8Q"G,EH$0$1+K$;6&UKZ0[:H
MF(&"OXB$LUN <1[2B'Y/>JEXE';UJDRNO2%WB$,K1. ?\ _4H\7@/6AEI>,*
M"P(B!+F)K((*@(GL!A$ +IOP GEJQAN!*6D<,73^YJ*]!X#@NI$@' JJB1Q!
M2X$,F;0:]BCQO?AP[*O+=TR IZTEN7  XV#X:KOQ25::$BYHELIQU>_H-GR>
MFW;K<L!OJOPMH\E2B%$XA+2HJ2Q'[3A^:3[?)Z=-(X)'8MPE<G#R.F7W-Q0<
M$@EM24EC YA&VGAPXZO+V=U!('6D*E857()' N@QKE,.H@"8 $MK%-8!TB:_
MSJM[E[2&Z"FM4) H@@(D @JF$IP.H!12L!Q 1N7SKZ0\G;5C+<Q! +=ZD*KH
M<PO?;X!O60\:/H4F5!5 !"P -^^]OI<:?B]"&5.>2]K&^ HB'S0X4A>'!)9J
MK(10A ]@VH."%%#K :&6Z>-Y 46/S$MMLO7YJ.I$P\N!D%!+YIQ$ -IMV]];
M'Y3ND;V,LOF'='BM-\[6XWN6S@ U8=/W!,3[-UF1WTN[:N[K%*H@X!1-10ZQ
MC"WD'2>H51TVU6$>SA>JWF:^\I@X")];+&>3]D+>VB02QG[RO0\S<")@"2@D
M()K:3W4"UA$>TQ>VM4VMS4*N6CQZ5O\ . AI$:!TD\J8(J1#Y0HJ)ZF@E*0A
MQ I ,!P$  !* A8?(%9?E%[^I; :DO@L3YBV\3M[IP_IY4X\%XZ] QC,W_52
M4IQTM]X\F$!N)1/JRS.C6,:X\0MV\:VV^-5V.&*X]R@^##=2? ]6&I>/VX4&
M?+<MWDW!7 0$N5Q[ &YTA<Z#H!CVE?QYA)QTETZ>6%O+79O(VUU;$_\ ^/++
M^->4//',YV>:C23_ .:B/J9OE=>G?6)D3A?H1@&Y3)\^4B-OTU"++ Y!1-&7
MA#N1Y1P+K R2@W\G?6K>7=E;N<RNDD'2''R_BU!L<F7>?,_/38Y/MR3I$PU9
M\-)?#-T['LC)\&.S,_ E 52QLLU6(":PD2$)![/NN6FU*4Y6P)B;3<!'5VV#
MLK3O/?+@6''Q!]/$A="_37G8O6IZ")2CX9I-\CW+V!7R5JW(TU@4AUE! 2@Z
M+J( $4-<WF7^M\@5SW9<LF(2;*/X>E=7W7.+8, 6<G\6%#T+?;9"T=)J*(@F
M8J:@E$$URJ#I+:YQTDX!8;_!2W.TN;8?,[MP97NVYK9W()BS#^)_<NRFZ3.0
MBA3 )3@40$#7OJ"_]+6%ENHQFTCF1CP*R<!XL=0P(0HY]$0+VB 6U>Z/N5D;
M!MSAJ$@K.](PGI8XK=UC^8'Y_P!2J'BA5V6)5R5+1KTEYBA4BZS@2YCWL 7#
MB/"D;T1^]#*@.BB*@#RPY1@*I\:7S;@40$>'"^H/FU'QPY#"G2EFLW,OV%&W
MP_4J?B\0FRJ4^J_"UOR>2EXPX(95$;@(>4+4Q=K@AEKD:E3\T%%!3   "&,8
M;?")OI55U%W>JB W%87;(SALL@DOR#*)*)E6Y?,,36%KVUIB(!WA<+T]6>:"
M**A6)RB)_$ 905"J 8Z6H"B5(J0@0HJ^: @6_ >^EJHQR0QXE;Q@O\!BC_3!
M]2@^Y,4!ZU&V*"_4/D'N0"0_,0BJE]HZD9A2-_K'Y/S=)ZNA6./MB/O+?<5*
M!@4C@D?M_P#M=._[8Y3_ *56H.*!@EW2310A%"$4(10A6FOW>0:I76:J830[
M@YU\CP!4PFL)B@  5,>U,Q^.L0_,UA[Q.I@HZB),,$D$\S<2S]3$W:'J^45+
MZP.D $Y9V2('6.(\1,(G!@H%M-N';Y-;YO;N7+9@/I8'UX4ZEE>0WHPN"Y<I
M+48_]&A[RO$+JA3QN%ZZNG*:CVJ,7'9_NNUQ.9 J9=,JXC\XP>-<J'*8ZA2@
M0\XH-R"4WQO9V6YY/;V_SFI@/ZCXG\5%V>U?NQY6(&1E(;<8@#[*X+WQ@\E@
MS13$AI A4EE08MR !0$H-07;% +6L %;#WWK?N4;D"T 3\W4,'7(>=;<6]S(
M'Z21WD/\5\FW71U53?4CN3/8RE*92^VHB7\>UP7PT)BS4\K(EDP710.JR62<
M*$$ZJ5]2Y^%^ ]_!/U!\Y;DQDT[FDV88PMC_ '3BR].^2/)MBW" O6[0N^+(
MD1G=(?PQ@[>ME'C&I_='8'<:'RJ*;SV"9W!,\<E%8ETBQ3;Y=B8Z7DQC;-'4
M^0/(3\>@#8BADT%$CK@)%TA$3AKGDGS#N-QO #.32NV0S1SD<?YE6\[^7=M8
MV[B$&$;QQD:Q XX:5]66W,UM]U?=/F%Y=),R3.)YJU%LU7<W0=N'\ YE<8R.
M-'P+H"H23'(XAX@F=)77R4!N<HF,2O15K9PW^UC*\,RTG+T)# 8/\,5P>QO)
M\HW<X[0AM!,HY O$B3ER V+9G#->6&S6SZ,EUQ[@]..39!,SVWNW..-)Z$4F
MECE3E7JCN>;V5<MEO'K$M&)C90XEN'9VWQ_).0;6&[$ (MJE75.ORK-W/,F]
MERSQI:O&(!(:+?4']2]T6S8T%!,H9!!BPBXMBWB(F.C0$4VS*,;D9H"<5D4S
M_&()IV$3'$=(W'R]NY+RV%NV 8Q#1@,98 %<$\S<RGN-S<F23JNW3A'$RKWK
MSC]E(-W?4]VC?>A^(WX?7OO)67YA9C9LAN/$\"M>\G7#>A(G^/U7&7L @;47
MC?TOI!6IW9&,FZ.A;S9DM62$I6C@@_\ 1W*P>^W3$P#[X:JNME=D;T8YZH\.
M*I;\O8E_)(]P7A1E4.AD7M#]XF#@@*)R_3XN@J4UP P$D-E$P VD;@  EW5T
MGE6XF+8C$EP#D/Q+R_YDM?G_ ##OML?OM1_R6E W",>4==,>094Y /$X#N@T
M6:F 1 R:4H.W\.D4H !2"!59(P^=Y>%=KYWS,W;XA(DZH 8#*1*\Q<GY$!R.
MYN81C'P=P9$UPE&W -VE/#U3$7R_:S8N<3'69KCTO'2YCVU*+2<7A:)3>:!B
M^FW5N/FCQ^9=>4^7Z[V[C, V_P"E(.335XA.'8KCSQS&-SEW)I6Y'7"-VW(L
M"^@;>(->U2&]F#F!HH^4;>F75.:-:.7S<EDS%(#F28.1TB8=?;*=X=]:E^HO
M*+<!.]&($A=AF3_M'BNT?H=SB[$0V4I28V+IJ!CXX^*4WM%.MW=3IZR+&,3V
M[)%H+S\ WG55'39BL4RII*;;&$PNHU\8/BH8.P+7K3_)WE?:;N8G*$#'Q)@@
MRF/]OHZUTSSYYTYCL)FS:G*#VH2^6%L_[A'W#H7CGE7MB^L7'7*>B0P\2)JL
M73EL,5 J.73<AP57*@*N'#8X)W ?/)Q,''O#J.Z\@<KM<O\ 'C:MZQ9D?]2[
M^%^*Y=L/U+YU>YB-O._,VY7H?[=G R_E7U,='F[\KOKL'MQN=(,H]@YRF->.
M9U)0I"<U=C,RL2<Q"(HJ)%*<6 #8N@ \E>=?-VPALM]*S!FU18.2 \ <ZKU-
MY+YC<YERVW>N"IU.6 D6F1@*8*9=P(41,/ .T:U_%;A0+DK2[)(WQSPC4I;_
M &P"_&6'C8;']&WN=M,Q9(2&=%Q7>=8HS&SF:;@(#;MMW7\@=U)I#-/Y3Z%<
M VZ.-IE'E&.(V[+)_P!WJU,NADA( +G?C09.7;=%N!PYAQ*-RI<;F(!>/,,/
M"XT&;T""2G.9O/%MDURB/GA<>P.\0[O>I*3T6^;TQ_2_T=7>7:EQZDC,8_;W
M*OLXW[I*T'%**7%)26#N5_30_P#%U(8A";W&OY0]Q?UCAOT,DH.74HC$IR:B
MI(H0BA"*$+4 %B7N:X  C[G8/N!WU0D95)P0 HV9IN=*1$XM'MGR;,J<B@GR
MU$6RG/ '1B !!505,&@ L-K>EW]V(OW9.P)S]23RQP98_P :<X524,$,K*6;
MHFUI D0!$4FWG6(=#LO;LK'SO2<UQZ!P0)5XEDX#;=:*.FV4=MSMRN3:1-I3
M[P[_ (_RUDO&.:N=-5W29_B(K&1(]/K "")0T6 5-5NU81N-JD+T!Q0TPE.T
MEHY^34V7$2B'#B'9V?FA[Z8O1.9'<E\W!UWJS*H(H0BA"XZMC%< /<[-]R1J
M=GZW4=V/Z0;\(]J\?0#_ /ZYJ!Y-E0'YD4:LY_Z<+3)1']V)],5[!H>8FB =
M[@M_Z!2L'?\ ]3M]RW/9#^D>KWJ]HKS&YA-<1!00OP[BD&J/,GA:,A@P]JI[
M.6H5Q?W+R*]K!<=LMKCD&QFN^6"R)A[+I,<N@'"H=_:4/>KH'Z=\TN;>Z-)+
MZMN< <#+BN$?K3M[=W81!&-K=_Y8.O.R+Q-A-]4^[, JB06V7;?86R(2YP*
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M;%PX,N@4-:J>S2X@&IZ(W'D7[^RN@\MO1-N.5#_F7GCG$;AY]<OQB +@A$U
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M'!(3"=-(!$2@!1[@ *V+:48<&_8K"<GB)8$@GM.*]$8<!)&1@*>D2-:E'O\
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M1?SQ:,T\BHWQ7^\)._YC2^Y15/-0&2D3_6/R?V2G]W:EEV(<!YZ(^3GC_P"
M/2"D>"1NW_[73G^V&4_Z56H.*:7E)"*$(H0BA"*$+7< !B"41 !.4Z91'NY@
M 41#RV\E4;V "G#%19W<3<*[H;?/P(*:6-K N/:8KW4DH;1KL4&]O$6O93T?
M=X8F^2)L%6@S.HO-)]ZVVKDTB!(IOD=W&1V:;]NY(I(1IOD*0S\O.L=-$EEA
MX <H\H?.[;<PW0N7;1B\WZB<\5M^R\.WN=1TZ3%L1TT]:\T?:@/A1WDV&R-Z
MI&+Q4'D\HZ=.D!;M[GFYG!5VKE90HJ!S([P!S$U"(G$1L).-]'YIM[L-5QI?
M>?I(Z5T[D>YL$6[3Q8"V,0<*+J>TTR-TGLQLE"D1*FK/9#AYCI%>:QDT5\%R
MA9NS,D"1=9'#<2*W'6 : #2/:&H\PWE[:S .H28?<1B''J6Z\BVUG>6YF!$K
M>HM\N#2(.?%1Z]F+CR;KJ$S.4DW)?$1VV,7"PRHH ;]2FEL@%(Z F6\SPBTB
MHKI*(@8"B%RWU!9>2]K&Y<&H?[LOM_@%5L'G6<[<"+98^##/_O#3MP[5.#V@
ML0BZZ5\A< ]\<ACFXL>I(/DX[PP"^Q>3<&?2BIBN%@#UFL@94Q3&$4=(@)SW
MO6S^9.6^'MM0&5P_2W!N]:MY;WQO;R-NX-,SHIJ=WQR'T^M\EYD]#DR:!W^R
M!FP(91ME6T$OAJ) =BUYBLYE.!9(,C<"* Y40&+,D"7:8I]0'#3I'5^3;C\M
M/&N@C%ON"VOG.PCNH@D.TP1\KU$2%Z!XM'JM?:AG:N 33+-;!. CW)3@)3+,
MS[Q/2"7T0,94S;1P-YM[\>RNM<GF/&B"6K+/^$KCGF"+6)$1<M&C?Q /Z<%Z
M'IP;IR/3XC,',R<.-PYE:1 -3DL@DE/829M'/-1D+IO0.HF GU@ &-8IN(5U
MKEF\%O;P(-2(_=T+BW-]H+NYG$AP#+[>)JHM[)[4Y!M9@.^3V>*JU<3'4066
MA.2R58+NXX\/EMHM-0%!.**@G*IK*!BW2#S!O<,A<YJ819_N_'T+7_[1"0I$
M:G_#@.'[5,O*T726X&6QC5-TFS98X1\W*F9;ED?"YD""\*0A0(50R:)"\.-B
MAQ[JUC<;P 4+EFQ6Z6OE&KI7$*T<O%-AP66E&Y)-Z\-./4#.C(+*\_$!YLB!
M3)D$%SKJB JF&US=O&I;+>O>%::HYX56-YE 7H2A.H:7K4'UMI=RF74?N9U"
M2;F05PM\=I@[1"->O7BS4J,;CUG@N4%+'*;Y(*71Y90 5 \_S/.Z-RW>_P!&
M,G.EC]W2N5<V\N'<7C(1J9"OA/@&XI#X8T"'ZQ]W\:*5-5O)8M(.(AERRMR$
M=(L\@66031^,*L9%LQY@B4H#;N"UZ[Q/F,;D(F4AK(%7Z?3->;+7)(6.9W+<
M( VP;GRZ</Z9]F."AWD#J3@I;<_')$!YLJZ<SJ[0^I"[5JO..V@E1/J$2)IN
MS6/:W&X!7</)DK%RP)'3XD;=IC3,%_8O/OG+;RM73;?^B;EUP SZ2&?J<]ZU
M,S<JL-O=I-ZV9UVLD[R-?%V@).5"*( U5RI#FDE":#G_ (-!\6!"VU=OF\<!
MY]%J5R8!@_BPX?\ **SWD"P1:MR((B;5QBW_ 'N"<;VB*1%=VT')C@LW-A$&
MP0 2W(B)<KR-4')3B8Q1N*]M( '9V\:J>0MK.]MK%R0:9,GI@="Q_P"M',(;
M?=;J(D- MV])?+QO?4+RKEHY!43>,LX793[_ ).LEA=-V;XNI4-0G,0@D( _
M7 &KMKHGF';FWRJ3.#X%T.W""X7Y0Y@+_/[9<&/YG;R ?![A+>YU]+'1Q"K$
MZ4.G1D@L&@LYELF5QRM(.B_+C<,@QVCF"  477IZC?:O0X^;X>_4B6G>7!EX
MMO\ _I+ZI?HQ*0Y/8G+[K%ZO1^9*E3DB+$(C?)1\Y3D4'F;PBLJW%N5+G."S
M&%F24$YE5P)I533&PE'T>WCPX*3J)D2\BO3T(Z80$12*V)%S%)2&>+';DY@[
M -4FH%$J8%9I8/,%10$P$'@5(P%U6MWVJ6H'YI'"+>JB@(&(:'_,?UK)CJK5
M.>V=4&$3CD5<4E_5*:+\KGQ;X<B 1$-#)N":A[*C8 ,/;[M(B0@&#$Y\:I@O
M*=0<'#84]"D?"S!VL!MT=1:.CCHY8_D'LBU,@ZUBK"MVYDS)IBWY8K%2 FH5
M!X&[!M8<39-0&HZKW(NY)R99)V6<ZIH\:!&$8_W4D)%N1J?G [4D\F6</9 _
M)!$J?,$Q3]AKZO2X7'8MH02">A8ZX!$,*D#BO1N#6 \?%%,83WB6IQ4$HAK-
MR4 $.-[CQ\H]E;988@9T6 N@AR*?-@NX;Z[[#]%5YDK4X]B1.,#_ )=RL/(>
M-^>I*T$9HBES24EB'S@.'9YY0^9H&I<.I1X]:;S&AON%N('D8X=]#)*1]R8Q
M*<BDFBA"*$(H0M(%4S.#F(8##R"ET@(=I3'-VW'MO4;ELF*DV2@AND^41W,R
MB=< 5BG\BLEA$D578(E<K$C5VJ)RK'(F!A6.(>8!3"%[7&M:YA;J:<0LMM<
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M(;II\>M;Z+2-7P/-&<4I(B^D\FC71&H0RY?#-$W^-**&%4JUS?%M5.&DM:_
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M%%7;N22=I10-L(7C!4(D1R,012'60&-$ 5:\_6"PIZ_BNV^GNJ1\4&FH]ZB
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M95GV5):5E,:(IBZX&,?4H=!DW>%X%3$A@ TV \;#P]ZLK^G]GQ9B6(%V;_\
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M;"X<-7)%C"8NHY15._4$=(!7083MV=IXMTM;C$$]U5R3D5J[>WTK.WB]Z1
M[2%=M-DR$;MIU2;>O2BD#4DP\T$TZ"D:2[%J7B)BJ>B]#NK%<QVD+URQ?B 9
M"Z#_ ,.F7[%E-QS*[8V?--E)Q [=O^,&W[G4/)AF4%#W .[O]VO39LQ-B3-C
MT]"\;6-Q*-X.2IO^SL!V3/<Q9LATF/)[?S2@\/1Q]]DKOO*;B(+C[@]]>,/U
MNM@>)A_ZW_JKW_\ _'6YKN6R./+_ /KKW3E&\Q)9=N%))&LEF6!M(IMV!99H
MAB+0X^:F(%#7$G]$1&O' ND;F1&) '8P^"^F'*(B_LK6K&+D=>HCWKFQV/9
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M/,9$MBF24\?J  N CE'@C"'"U]!K>2NJ<MNG7 YLW_27#.<;5^57>$=QJ_\
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MN&LIBB(7=AQ\ZC^TW(UKWQ3&Y@34GN*Y"&TL@Q;-&Y);@V&X\4QL( 0.XO\
M,UD-G PN5JS^Q4^9\P_,6S&#5;CD5YF^U-:.MO.F6<<J.R+AD.41K3SA ?.+
M#9"0"E @D'SM7?<.%;WRJ48MUQ7$O-NUO2MRB*ZQ,T(]_6N(EMG)O.@\K*)1
M4.[>;<%; 76A>R>=!+J#83$]%)(1[>P*V[:[F!O0B342I0\%S?FW(;LN0WIV
MP7GM])J/^8#[EYK^SAQAWF>^0OFPI3+'$V(R+ETD=(I4UW[*7)$I#S5""(^-
M9AP*%POQMVUNW,-W;\"0)&DQ8N#@:'U+A'Z?>6=Q#G%F4X2.B4I ZHD.(O##
M^(?N3\=*\%Z_WYZL,*".=N&:<UG+]86,C%-00>2.12KA\18KXQA5,+ER;3H"
MP  W$;@-7/+>>6MEX&B<8Q%RV!JC,_*!3Z>A=#YKY3O\Q_."Y;NRE*S>+1G;
MC\TB"?JIBZA)EV/)-I2>8F138J1ZYP(1^X;KG.3Q28FT^%.4!-I4&WO5W7D?
MGK:6-J(2G!_#(^BYQXX+P_\ J#^D7,MYS.Y<L6KI?<1-;MG 0 X@J4_LYXI9
M_P!0S%!!L<\0F&8*%5<,7B 6D\>D&Y $RQ40 !Y86\WA?C7&O/'F&SN]K/3(
M:F@?EC(82?,+TK^AGD?=\KYMMQ=A(6!XP^:<#]5K2/I*^F5O@$'RVBAV*!#%
M9L"ZFHA=0R39,AA6U"K8Q3!P]'O[:\N<XA^=OF1<G5/UE?1_R]:&PV@M0  \
M.V.Z+)4-X**9I) FV,7XP+#POPX_F \E6>SV$8G X<0CF$HRNF4JDR'L2WJ^
M4D4(10A%"$4(10A%"$4(10A6'^M^R+^>+0F,%'"(_P!X6>_S"G;^TQ5'P41@
MI&<>4/O_ #M5/-%-*QN/22_Y;[@>@(.(2-V^_:Z<_P!L,H_THM0<4TO*2$4(
M10A%"$4(10A%"%C, &"P&"J$H:*I@NN4^;JKD3*10Z>E=)4=)3"!BI' PIF
M#%X*!POQMY!JTO2$AIZ5$PDSQ)7,4;J@9R<RJ_QX 4H 90"HB4A"7+YP@(CH
MOPMVU83Y:+Y,G^K^'!J*!N2B[F7>5T%$A!$I%+J'+:Z@)Z .-_KB7-\\:RD>
M76HLXA3^$*5S<R?Y=3=!/<N.JU.L=,% (<B;CFE*HW VD@J%,9,IC&'0!@*
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M(2,Q7]M,G_73+[FXH*B$MZ2DBA"*$(H0BA"IQX6'W^';0A A?R_ -J$*P""
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M;$.:XAI$>%[]VD\]VMK;Q$XAOF+,2<QQ73_+&XN[A[9)8PB[@9@\%(?=S:B
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M"X@@;J):A*W*4?/;A>P![EJB.92U$T%O(,>PJ<N5P$0 YNBI+CM"4A,;APR
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MXM7K970G5QM*?<O:K(6LYX%VVG<K@#8QD/)@<P%RTD\89OXL<;?*A+)Y<]5
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M"79[(&JN]K^;4V^B4YV!E'>3,L<QY3)YR91QN*>.<DC'B4%#O#%*]3;B(M
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MDD^Y7SW)4&2MA091V*[@/\/71(<L8F0PF<J)B  J83 -R@)>(<WYI:C.]1@
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MYC"-BW]&N1<TV6RM79M*1!.!P%'RCQ7:.3[FY<M1!9P.^N+FC^Y>Z<>Y.^9
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M6-PZ)?744ZPM\U7>H(,6Y7BR+M4IB',H!P,)A#TAK0?,%_3:G(!Y-<P+=KC
MCBNL>4XB5VW%VCJM,X? T#<.A>AR/3;L<NB*I]J-LSK/T)*&*X+M_BJ:K=M*
MRAIB6YAPC1.X"1F&WB#@(EN<W'4(:AYCNMS=\0@DX@XX_+AU5KQ-5VS86XBT
M)1P:0_Z1]^' 474==+FQ#I9NX-M3MLHY3;1+-=\\P'%GLDNUQ^8'(H-(L@M&
M@Y1",GP!TGQ,!5 N4"F'56,HK\!@P3[M6OAN8(JJ*F5,!C 83 F4US";E)"8
MQ4BF$W8'D#R4$N@!EMTDT4(10A%"$4(10A%"$4(10A%"%8;Z[[#]%3R[5$X]
MB16,?M[E7V<;]TE*$!+BDI+ ?B4_N*)A\PQ!^G0D:ADW,4N9GGF=B5!9R*C'
M$3""29S:"@$^)A,)"GL-C<.R]J>*3LZ6J<P@<+F $ &X$%PH"(&4 ;<L!.4/
M/$ $;=M@&AN#]R;CB%@"<(/. J1#G([.U12(X ZJX$226.<$RIB8IB$4$QB6
M'24MQ&W91,)@LGJ"WR/M20*"BH43%6.0@ 8VHB0 8I@'0'FJ / ;?-IZ)C,I
M:AFK"OE5"MSD:JB"RAB'XF#D@45 U#\6-_0[[=M/3*E4:GPP5AI Q>79(A]8
M"<127!0"H:1$JURIV$#'*(=P<.VK/1-G^;N*EJ;):PS11 HIM7"@+'.DW4 J
M@('4*8"Z5UP3,1L!S'#2(WOQMV4"-SA)^U+4LOK9(HJ%4(-T"77%(_.(DJ;0
M8B(G*0 $QTC:N-AX=E2E;N L!(TX%,2!%67:J]210A%"$FTIT!%(BB!45#MQ
M7.F*UU2 '-L71RR&/<4^WAV^Y58VLV/<K"&\$B 0Q,7QPQ^"Z[-X#L@' I2Z
MDD%@+K QP*N03EU$T@). <+]M4Y08/UJYM7==<F!QXK=J+!5EA4.!> ]E@&_
MOC;LI@.H2DV."BAU4* OM'FR"(@H=*"G7"E^&AHA&.SNE[<1-R$PU6X7\H5L
M7)P?'A("FJ/M6C>:[L1L;D ?G:3=RBBS4NP9 3SDDH6&745 ?1:!%,2J.!+Q
MX)K'*00O:X]O=79^5W(1LP!(>0('7J-/42O./-1*6YNECICI,CPCI#GL) [<
M5TR 3X\!4*4OATD-5P_YR"PF%O:X6/I,4?+YW961W9>!IB?5Q[Z*EL0(S%:Z
M6[:T[!5.=T?<8W<$O]CW)R%(X_F5TL@F"KHC_-(GX#W^X%<E\T'YX_S7?;%=
MP\CAHS'\-GV24^$ALB3WQ^B:N:;S_4(Z1[%U[;C^F!T>];572:*$(H0BA"*$
M(H0BA"*$(H0BA"*$(H0BA"1,T-\LQM/\TUD#7\FEPP"UO=U4PHR2U[/R>Y^5
M24B5I&5N< _-IF'M[+@/S:G3#@J!G6F:;?'Y=5M*9 "+$S@R\BB0QC*B@@BF
MW%RD<QW'(4)SC7 2IC83!>P\*#5E2MWB"1B7S+#TZ$Q>0]=>PF)Y?D>&93-/
M,7?XHW9N)Z2RAL3'<>BP?.6#1H60G)55NQ8BZ<22":/-,7FJJD(6YCEO$ &E
M7ZE+\U FC=_N4G$\QC%V@ODEFA6YHXTBF+I^BT5(F5%1<P/DE"B9@5,A+G,>
MX$"XB'"JPV]QG(-#P4SN+3@ @N*5"I"9E$Y"U1D(9U'2\6MS2EF(24;3$01=
MDIX>5;*R3$%&:;B/>E,D)!/J,8AK@42B%1\+)Z\&KZ%2-ULG'%^_N68,G1%1
M=(Q&B2@758@M(I) ^:$*'-< )T@Y1DU"J )0U^:037[@G^7DSU;.F'6H?F8%
MV;HKCU)M'._&#MYW&<?3<*2+O*BY,>-6BA+)-%0Q*+3F)DR3AKK37(@Q4 X"
M4;"''@%5#8D%$706H:KH9]O3ANV>--\MRR091<-(.8QI&JNY%LT6<KR;1=V@
MFHBXT"@?0B-@N83=M4XVI7"U1V4[U.4Q'!B.M.<SE$'[5F[:V50>HD<)'*<#
M%%%0MRG Q0$# (\/)4##2^JC)B3D::A=:J2K(H0BA"*$(H0K%-.@^JVG0;5<
M0 --AO<1X %N^A";PRD4XYL&5@XE(Q.,2=/TED3RL*Y82!5T$&3$ATE&4J*O
MAS%.D7T"F*(@(& *IW839G(;T[TH$?4')Z"_H%%+=KIHP7+C8Z$&7%MK-O"Y
M,TD,]PF'P:)8QF[P"=4ZL/E;)D]@&2+HB:CE%)=XVDC%(X4$$[&,4U_L+=PW
M8BW]9(R?KZ^I8_F%V'@RG<)$ #3 OEU=:CAU#[9;9YAOPBKEFWFV&9JJ[',,
M.DF&18MBV8HEQ]EGP3["*60DX]T5$B$B@BX3*8NDAP*8I;V&NF>7-O*5MP;P
MB"X<2#]AQCC3!P^2Y=YEW!A,AK9^6ND@MVC ].+43?2W3[LY.L<C=QNU6U$=
MD)2S*1LC:;<XC%Y)%)*-C@R2)-HQR<FKZI6,HH @HGSA,( !+B-=!B96KD9S
MG(B0  J0_%G8.XZER%C=M&$( $$ES26G($L]&+<:T"9ECTU83M%L;G<2]QO
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M8M4BH^:TBK,I:_:,*T S=0H7$1OXA)'C<H\.WN'KW+3$V(.PE71_,Y;U/Q7
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M):0K]QK_  ]"X,Y.QD#'KS<RIX:"(H!0FB67C$A*0X&!\\NFU8&*9(X"!SW
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M@?Q"S8_JQ=Z=+0X>J1@F;&<K+"8ZBW.-<X:C&MJ'B-[T%LDPNT<FL+ 82^Z
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MD^D(!RD;1%-G*,>)$V @!-'QO$P"&FU7F[Y.)6#"D28G[/VJCL.<[G;[R&X
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MD<SRM_D&-N!')W,4NX;'+%%.LD('(50 U#M/+K4)7!KC;T, Y9^FA^-%"@B
MYQR30]0?6INOMSN+NCC+W/I5)7%\)P9Q!JM$G[&+)ETGD^%-GYI%9.2,V@.;
M"RCE+GG$XJ:BE_KEJV+;[79C;@BW;?2=3Z7 JV7S5:E/4I&0!8EZT:O>OH&P
M[())_CT-)3B"!'DND14$(QX$TV;ZD43B'K%%%$BI=2EKZ"W +]_#G1%7&"NW
M:B60)BX.54PJ)E3$Y2D(H8"G\X.*A0TA<-/8-^VAVP0SXK6DF;<T?(E.@@9,
M[%V4Q>20#"4R!P, FL-[A[E*O%-1FZ3&X%VYE&S(XLXV+RZ0AX]@%U"-FT<A
M&#8AP%(H%624 FD" !=/?>P!+(9=Z.("743/)EL"88\T.4H!8 ,JVB5%!X</
M..-Z8J'Z$CB%(H/M0_9?U849H^WL6B<+"V]TS@?_ *J>K4'Y@J<L1V^Q-KCB
MJC6(EGA")"FWS;+#/%G"BB;=I&C+F&0=FY8'$RS=N03I@)1*(@-Q"KN& &;#
MOR5*#" )X]W3V+RXS?I@ZA\AZ@LJR>.FWAXS*^I;:#=*&RE1VY;LX+:_#NG^
M0V\R*$0:-HTS-"4?9B[:ND8LB)HE\@F=X[5*^*0AKZ$@!BP]_!4R "6QP[#5
MTX72-T][B;0]+N[.U^3P3!+,<JG=P4VJD3SDU2HRNW&-Q3&RQF,<N7EOV2AK
M@41]_L#(7Q8\<&$QX>D'HJ2%.-LMA\WI1>=R?01U*HP$3R1?Q0M,#V4Q B[W
M*,J9>L,AQ.#=11G0*,&RRA$E7Z@&77+I72 X&3+JX!>@;(RTB<-8!)J<E PG
M0%V=E([&^COJ$^5^]+W*I;QC-]&X GAA_E9EZ!D&$=M[AT=D(KI-V+5%%R&3
M-5P11)S4'2 ^(<"#D1*$2=D!&491^:3"IZ?@F83-""R8A'H;W]0@&J,,ED(9
M"GLUTYX&VC5)F8,;"\KV]ZH%MSMP<A<G-SCK>O-M')HT3'\08X>:*:8?&TKD
M-K$1NZP(%R,2[AFJ@PD28 ?L3QSG1IU&2>XV0O7^:G/AYLVZG\[6D1F9F.-,
M0NXTZPF]L<);A&PZ(&1AX]FX9J )D^"Y0 Z_$Q9#\I(1P,R108A^C!HY\,G2
M,)8C#V_O2?W(Z<DMM.DC!HV?R)Q@O5 \W!F7N)R2^79@JC-RBLGN,KC$$X1<
M+N&YF;C$5FZPE\"<-38HV-Z0QLV1?W,O#8[<1:A+&5,#B^/K1*+0JXE[E[?[
M>X5\B<-:XRZ>"Y>@<%!.99=0>(-R6 RH%/;X@>ZM7G( 4- JMRP#$Q;YI=:[
MS^!CY),\>^01= 5-9)1%P)SMUDW)>6=)0@W*?FE)8!$HB%QM:]5=IOIVYM$D
M!QE%8[<<NLWHZ+L1*0!&)8OD?<6<9,H+;J=/\OB3Q[G&TR:C-ZN)O%[>*+N5
MT9DH%*"BS--T61*WYBS4AOBSH_;![+VK?N5>99QAX=TR,0#\VF#8^WLR6H[K
MR9M+ESQ(PA%SAKN..GI'6<TU6+97&Y@E++IJ&83$.N#-^B($(7E@#<YM)4SG
M+82NC!Z)1X5T"Y(1H!1EP6V/%B;KD3%>L&BS8ABNX&X.3YE$P63?)J$QE. 6
MCU"1L6_&1&?&:%8YS2,4^.06X1)!\TW'F<;V"M;W_-?RQ&HF+NU <&XK9N4<
MBN\RA(6A$B!#N9?<_ '@G,+T[[M&XEW1$+__ ,NXUV=GX-#6$N^9;L<)R(_E
M@MEL^2;I%86_\4_@E0'3#N<[N1QNV*)>%]&/8W</>_U: >VI7?-5J0^7Q7_E
MA\5L-OR)8C(:H6NR=U6$Z.#/#BAG&>R.90ROG.8(O^J;9R8H^BODF'(0>4QU
MP,(%*U7*56XZ_1)6#W7/[EW#4(D2Q$7<BA^+^M9K;^4MK9#B,"8D%M4V88@G
M$=#>I22P_:_%<*C20\+!MXN-:\M)!10% ?)%.05CE;S1E7$S-%%4YAU/ES&[
M ["EMKE[FUV$S<)D)<6#'LP]62V*WRBR+8M,/"%0*@Q)K0BLL3]1]B=E-F'*
M;"4^DH#J$ $>\!+W>6D;A+OBLC^6$0PP"Z"/+!58I!$1*5(#7$1M;6 !Q$?(
M-6\Y..E5H"() Q8+8JVD'JJBNJY210A%"$P'4I_)%F?V.(?]N(*D<$AB4K\-
M54)MU@"*2/B1<X[C"2J ")3@U-%QY'+DABB!BBV3/JN AVTQQ3+-TKSZ]I[L
MIN?O;LIB0[6,U\K3V]W(B\]?;>1CMVT>YPTB<:S7'G$6NNS22<'(#S(2?%"Z
M32-RRF,.L J6HYX^Y1 8L.'K4CB*8IG<*J\B-NG($C,8E1AGCQLV2+C\FK'R
M2:\%,(MY-PBNY:M%P73UE=64<D$# ( )<M*U*!#SJ35_3]BM!=$B:4;+KX8*
M$?1SM!FF+]+&_D5FN$%+DLYN[U?36+HR!UUYN<CMU)Z4=8>G ME;LEBY2D5,
M"E5,D5'4F"0@ FL7;>FZ 7KD,&&)XAGRQS4(W'B6R]/3U*),CTX;D9!TG]-6
M(M<9R;!<EPW>?/YO(=P&+IPK([$Q[S.=[G;:5E,><O5\9?H/FT\U<%*Y;/2@
M5V3S0["U6AX@C@2*/FC5(Q<5&;9=*=G MHMS\9R7V6<OGNVN3XP3;;']P2;J
MKIL(U2"VR3F]LMVH#%\<>SZSTF1KNGV7R[1$.812XR"?Q@@(@7"1)QS&?I^Y
M7TA32*/Z,/CBG[V^CW&1==V1Y+*=/63XFIARVX$?@N:D109QLZO+RBB4]E;Q
MRTR07,\A-GB&+M$K]!P5J10W(31YJI3IR#UCT"&!'N]Z]3VK)VD@R9+K"=PW
M%RX=O0 I4DTW#I5P#8R12%3%0 <EM\7>Q1X^4ZN/<D') /!^NJ97IY_;CJ?_
M /UF\G__ "^VLI*2>+#_ -MLP_SPI_CLG4C@$AB>M+ZHJ2UP_KGZ8']35HF<
M$S:)-6X>=&*W64.1ABEW #9JW0$)WQ!'1@4 Z?B"  %.0AE" 4PE$H]M[%V
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M\;8D[33(<'AES&%/+F_ R!0X#Q[+CNGA5<O9/J(VXZ@,=?Y5MTM+JQ&)9"K
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MK'V1I"7>%9M$S&U', " C8QOKN' I1HR2S)2>D-Q,3CH-+(59=/U<X4*@@H
M$TF64.*28" B   J=MAH:J;L&";;-L3QS/<<<8[D\(L]9O\ (XUS-1!Y[(8T
M'[QM*,724K"/8F3:OR,3.4@.D3F-B&Y=C)@41 ;L0,>B+8G+H/3WJV-36IIA
MGU##V*.N1=(?29GQ4F$UB*<TRQN?&=7-';A[H8Y)QLO$+N4F\A,FQK+(CUD6
M !55$!<*N.!N)3"(U5CN[T/].1$J,P!'K&:7RUH.JK@9D_L787Z6^G20R7)6
MCC#&,S-Y%C3&*S['U)3()=S+P3*4C9*)EHYW+3!GC59L_CV!!.DHT.()& 1,
M F [/-=Q7YBT?IH ST+MCB>.29$7TL=6:F!B4%$XA QD+%MEV<>S;% J<DY=
M.G-B($3 >8Y<OE '2F%PYEJQOL.:NF=@<>"5D<9)1 54?1444XZS& 1*<P<-
M1C6#WJE+%(*^1_:]]^LW/W$]1349>DG^3O(__B+D?^*P](YJ60789?[QD]_L
MVP_Q2(J8^GL*IGZ@I#A]J'[+^K"EFG]O8K%?31]]7[B>K2.(],E(X) X<HD$
M=.)J&$.;F66%$H%$1.F$LH"H!8IOK3?/J[@"<%%P '*@)D'7"U8=06<[,!CD
M:WP[;%.,7R63>(O4EB&EX;'9T!,H=^DB?47)+AH0-P /=J]M6ON).IL4:N%%
M(UYU2;*Q2,$I(9BS;/<HFYC'&Z"#*756/D./P(9/,,D^3&N  Z$#I5N/FB V
M PF\VKD[#<&9@!\L>)%1EGQ5L)1%2:KB+=9/3XTDQCC;EJ%61:1H*I.HG(%R
MHR62D.&*PYXIMCI965?RKANJB@W:%.L8Y!);48@#&6QO@&<XQ#&H! )&9!)8
M=J8E'Z02=0H^'0LCCJRV1:8I%;FK[J!\D7SR0*>3;M912,3"$?R<#(G#'20:
MN5*,6$G%*MW2I4Q30=E%)0Y%#%(+.SG\T(Q&#XC4U,P6S2$J@DGW/A48LFWW
M0ZX]M\#G,MV_@S*Y%N%@6/8K,C'KL);PA$,JS0<.,JIF0,V.%&(!.<)0*^ =
M1>_40#2M[&=P"X?ID784]1JD;@BX J R=.!ZE]L)E6!Q=]E$;"9U)Q..*2\*
MIXIVQ1?9 V2!%L:=9(.(!XL#H52)@@]/80$37 Q1&9V-V,I29X@D@$A1U @1
M.8&&)[UV<!ZAMH]VIA> PK+"R4S'-9>4<IIMWZ+Q)IC,RGB<HO'E=QC8':",
MNX(F(I J(F'A<+C5&>WNVH R ,"6 ZZU<Y89*8,30/JX\/CV.I4UBE=(H0BA
M"@UN;L%'YZ?Y303((S<./3(#*4,JV(D4J:QU#E$5-/I).5B_;0XF^;EY7(GY
ML5S;<<B&X/C68F.Y=Y!X@'O^*X?2=A^XD)EN\?R^8 F\.XPU)K*IF1$DN#-?
M,R.% ,1X[ W*YA#?6_;>_NIRN !I9K+\GY?=L@F8.MHY@\>"GBFW#24# ;YI
M/RZM#=8_*MICMSI<N_8NA5NKE%"$4(10A%"$4(10A%"$4(3 =1W\D&7_ &&(
M_P#;>#J4L$LTY&VO\G^%_P"RV/\ ^B&=(X#J2CGUI;TE)6A5M#%-75<#!)%-
M"1WQ*( F94I"%]%HW25,13N#64I53=ONAV57&U<$@'0W$#VK':L@6CP8U6VT
M62)J)J21,8+D;M"G$2:[B/B276,0QN%@'1V#\"-DBH=AQ]*JZM2HS = 65)R
MF4JB"*AQ<'U63.DH0!&][@8Y"%[!\M1-N6,OI5V-+ZJLH_=/?[;]3_\ ^L[D
MO_8':NH0Q[_8J)3VXG_S_*/\].O\>D*,AU(&)2UI*2P=ROZ:7_Q=,8I%-&=-
MD;-\S._U<E,F#"B8"F,5L^%2=\%(&TD/RQ8+!S .:Q"]IN%+V(! =0"D^NQZ
M'4 YVJ:8D9=BGOI@/3PLHHT?D-\H=P-J9#=F-R9PJ=TDW,R;Q$"JW%8I01*9
M<I3"!Q !E6G'TK[E$X$# A_B.TU4-/9@[F;R]1>XV5YMNENB[R$NU2DEC:C<
M&KMNGD[EY!<@DF@#Q%8ZB+=3*RJ7*8H?J8?(-9N5W2(QCF?97UX+"PMN)2F2
MPZJ943&/=^]W(KJ"EL499++LLBDO:")8%CV6D512P:,VZB-_W,!(P^:H*_J]
MX+R#=MTV_A73725-QJ*;40".5TL3]K%^GH]RC&VY$26+BOM/O]R>C,G/5=GG
M65U2;?;,YAD<!D<0XVH<XZ[9Y+B0[4MSNMF-MG,A+#CJCHN7?'2<H8QQ\>4!
M454L%C%L_$C&+UTMV]J/"D9' R]0Z1TG'O2CVDR++\ZZL^K7;5^_GGVV6/;[
M&Q.8?92\CDA5''XO!<JB5T;HQO/2-,KM2@9- Y=5PX6$2V,9@5+.,@LZ7SJ^
M"][<:2;MD%&2:C=11BBS:%%N4^CU>W(JC&>>(F(<!03&VD?@"X59W9:B]:U[
M3BF",LDIJI)JP@6"A2D7*XDNB144BG/I()%Q,3O4MR^ <!_(-75B6D'C18W>
M6Q/2"?E#]N"A;NSL 3())QGV!N58S-&ARD(8ZC=-,Y"(%3N *I(&&XMTA^V_
ME76L$UQ6I[SEVN)NV"X? ^@43)S) D,4E8><;*0$RX9L3?)AYYDNJF,FW\X'
M_GQ(END?AJO\6;RA74]QSJS.%)19N$GQR."XUM.2WA,Q,91+YD# /V=JG%M'
MMKBCO;["CNL9;F<#B^-BJ195NJY#5$M!**ZJ*O(.)QOZ(!WUI',>8WI7Y:;C
M6VI0L>H8];KJW).2;7\G;,[0-YHO4.[8DX5JS)W$MJ,'$H:L4:"-C7N)/S7Z
M96"N[[YOFD">H\%MECEEJ,1I@0.L<4JX/"<:A YD7#I-C7$>-NT2@4>S3W5C
MW(+8!9.-F ^8@OTLE8V1$HJ73*F'F@&BW$ U=OG&[*#(\756$2'H %M<L/=^
M=1J5325DJ"FBA"*$(H0BA"*$+ AZ3C]/-]S3IE(>]1AZ?$15:[Q"F "N&_N]
M!$]0E -"N<3 *\!$HB-BAV#1'!(XLH>=0W27D^[N_&%[FPIUH9]A6\.%-DW8
M.&!4E-M%=M9=3*5!15$SDULW(T#S1 1_L9@\\)$.#2BC$Y9BG1CCQZ%%#'>B
M_J(BL19E=1Z*T4UWDW@R.5@Q?PXJRS3-MBX? <,?HZ9BQ0A\YY#PX#YY2-1$
MP%+8U;_O>;[65XF,AK,!5C@)$LK8F9AQB/:D]&=#/4O'3NV#O+\<3W+F\ RW
MH4RN1E&L]BK!-%OL++NY3*H?_*>0(^*#20$KHB8!T^:(W :UVYS"W.4FDP)Q
M -'SZPDU11FJ.E7XMT1=4K-3)6S[:\$@>=//45M1S"YGM\(JSN[O5' [W8RX
MU%RTY1]7XFQ,VU>@2VDX@?A5];WVUTVI7+K:9:A0EV>+4&!=^M2@)/(,'X^M
M\>Q9HCHOZG'6[6!/9?!83U5"XUNHRFE1EX#3F$;DNU.=XUBD<Z'Y6G%,[#,9
M5)T:X):2E 1TAYU7U_FMB5HF,P!$@$@%Q4=[OD%="X#4U)XY_#M6:/Z#>H>
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M2N7-5,N.'M7M9@<"[Q7 8MD\R&?R2T<X=R,M*F0,Y!TX07$Z(-DHU@Y A#*
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MJ)[V4VZ\UM ;:6/W3@X J2NZJ;#)6>((^L&$1NENODFZ\E!H)(9BR7",++Y
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M[0O0 G%P14$.'/1@63YYC@^.Y_'R&/S<)XR-;NB(.B"P*Y<-S&:)O$7+-R=
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M\[R$(=80&_FN$$CB%AXV[ I>U2K_ ,*E.8I3!YP (4=2'I7!74(7.DD17(V
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M$0(  FNC<W$+!VV[:DW&BIX'CZ8*4\>8QD_C2D(XT(F7*0;E QR:@$! QRB
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M-X<H>(>*JG2 A]8*<GQ)0U 8-7;8*D0ZB"U$XIW)2%*I;40X )3D'44;A?M
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M3E]_'CVU<CF%R5"9'M*K1V@#-&(_X %TU>IJ!;MU3DVFZD]!C$UF_$3GYM
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M *O'XJM"VXR50%.W$AS>\FE](:HW+%N[4@.GX9CP5P&3MP*<OOII?5H\& %
M$])>H'K6%0A53D+H5/<AK&Y:0)$&Y; I8W&]^'FCV52G(6S\KZNH(( %0&ZR
MN(].HW9*N%4&KDR9P GA5%43]H  &Y1&X=H]EQJV.]G$=#I$<'22.7)\F72;
MOVA&<2F<IUNPHG(!@.;B1*XW @?75EF / JT^8LG+C&J31#E-S%%J4J9$2%^
6LT%$JEQ$+B(G]T:B2ZE$,NE24E__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2226999d1-fc_receptor4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-fc_receptor4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!C &D P$1  (1 0,1 ?_$ .T  0  !@,! 0
M       $!08'" H" PD!"P$!   ' 0$               $" P0%!P@&"1
M  4# @0#! 4%"0D*"PD  0(#! 4 $082!R$Q$PA!(A11,A4)87%"(Q:!D:$S
M"K'!T5)B<D,D%_#ALL+2<S0E&(*BXE.S-54FMC>21%24E=4V1G8G=V.#9'2D
MM$<H&1$  0,!!00&!@4&"0H& P$  0 1 @,A,1($!4%1809Q@2(R$P?PD:&Q
MP1310E)R(^%BLC.S%?&"DJ+20U,U"&-S@Y.C)#1$="7#5&24M!;"%Q@F_]H
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MCS/</9H&N>[<34Y)/-[,)?2463)VV1_"VJ4F"<V>2Q_'E2HQ!8M0-"3JXD,
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M(ZO1^S*O5(ZZ!"PO^( &&BYA[QEJ'_R@MW;Y<4U^(>PSLNF" ()/NT7MF7(
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MG<VQ3R4VIPV8?_&'4)%*S1(U]%E?N(IDZ*X;O$"()EDT%$P&3(S*G]T50]B
M8X%MK&JM/3X&+$6CAZ7*,=1S ).(X3>'/7T.JG98LVCFC6.CC)14<W;'0.SB
M&I8M,ZIU>J9=(K-1,C>YA-<H%'B:]_;?0ROA@1%PW!GM5"IF<9,I!Y&YR[*K
M*R-RLTHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B*2S@I>E BR8J)G-8YBE(86I> &?><0 OHP'7<.(6X -6M>M*E6I
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M0*!AM8Y^0&H:$!L?K*A@G&TD,JH0 QM13@ Z--AN/&^J_P"X%0P0%P]I5*H
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ML(L2"Q021.:S5+_30N)O#EWS>Y7H9;Y2O0A$"$LP9'%,LQI$7N-ZZ\\HN?\
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MUC8;E+'O;)L_*QN'8R[QA92&P.?3R_"VY\MS7J,Y=-O+MA6,H$^"I@+^(W8
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MWBN.91%JO54I/+L=QQ_CV5L20D9!RB>-S\P]>OHYA'E27R62$WZXAA!V%@$
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M<_%  -NX7%=&9:O#"0"'!ZO6NPV2,TUBI*D32*H@W617<+E21==8NHQ&2BA
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M@B1 % $BJ*^C,0W42N?U!U-0=(0=ZM14$4;D!/2(6 MA#2 52-$2ON?\GH5
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M']95W[V=>URO.N>S B#5J'HA3Q"S;8![2M@'Y2_SE<I[OY3+]D.YC%49'='
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M6X9;U^@E\A#;+(]K>PC#XC(DE$3S\LYSAB"AD3"=GEZ",PBH7HJ' I3I+$$
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M]+*Q)8@6<3MM2>98_EJT9_9RZ4TN4PR'*"J+KF*>'8BLZ8)V,L]L(2<: \-
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MJ?MHKG/S,E*5.0V?,0_926O'V3LT7_=9M/%HJ^K([R5Z[$IQN43(X_++%O\
M:N!F@#73/.8$="S!&ZF?]K!:-\O9"KS%E7N$JL?51F?BOT,]JY5[&;4;F2+E
MB0I&V/$CB"4I;J$:160(6$! H"!0 +7]M<%<Y$_/U3L\>O\ I+OO1X1&FY4;
M? IMU1BJLAY"+C]CY6;59%*1Y&O=90 .)OB2X<0%0"A^J\!KP,I  O:?R++2
MMF Z@-MY-LVVUR<58!1LPC^H9PH0QM1_)'@ "(N0'F8/$*Q54&0)%P ]Z3PB
M8?O%2%66B#;).)Z,CUP;RT_#H)$$PC<R2RX'N N5 X^I#D(U<Y#NU00]W5WE
M;9@_B0 /UO>0JBSR0Q^(VGPUA-0J@MI*:05,F4QK&$[:?/<1]6D8. CR'QK9
M'(U.'S1<7T)_M(KQ/.4Y#*AC;XT?T)+\P-5L1)%$[(;IO8F+DE-1C&$3J3"J
M CYA-8=+8.7"OH!H0!R52!_M/A%<%:X#&O2S#V80/:?I6SOVDN(G!/E;[H9/
MZ]5A)#C.=O8XR)Q$PR,IB\RX(M]X<" *3D"#R&U^5>(UN&+F#+4R'I^.3>;\
M<&]:V7RW6,- S<@6E\M;_(FY7GM\O+&Y?<CNXV=3;'(^9,,Q5RN0ZYC6<(I*
M.6+@#=-(^K4YE@&PB <.?(*]+S)6&5Y:C.Z,:GJ[^]>5T:E\SS!-NU.5/UCL
M;N*WGD&4..Z&>N1G$DWQ<;,P:DTE "=9213$ #IV -+HW@(UPAG:IGK5!R1^
M#=_K%W'EZ>#1:S;*H8_ZM:F/SBH.+QS=#;R.;R@/)=+\:/W213")#*OEL252
M*.H"W$5"&#W;5U3Y:S\/1,T!><K0_9U%R?YDQE4UO+,!A&;KN?\ 24UFA\D4
MR3_MS[D4LB0^'M?[2L8 54_(8P?A5SI#R"GS+QY^%>9UN-4\R1-$.94[1_)7
MI]&\,<OM4-U6P_RUX9]R[HN2]T6;,F;P\Y$OLIEX/'C.!"Z!@A#KH 827&Q%
MG&KWCC<:VW&/@Y&1%AQ;+=V]:AS%0G.VVV>VVQ;*.8X]$XM\K?;N/F")MYN(
M[<8J&7Z.H -*1.U$.RDUQN*.HR[M,!N);CX@'*M8T\W5ES5.!MI1JT_;.3>Y
M;1RV6ICE<5C95G1J ]4!]*UI.SYTD3O1V<;O')C-'.XC<2EX>[Z!YX^4>=_&
MMHZI.4M&IM?XG]-:ZTJ$8ZQ4 O\ #^,%M!?-RSV'Q+;_ ' 6%J8))3#8!J14
MI2"/^N,V^#J<3+%X&2=& >'*N=^4X/KF5%_9G^SFNBN:Z@_<6:-W:A^TIK2^
M=LU&B9V1DBIH)$]0@);^8SL!.K>X7N&@OYZ[WY9IMH5(2O\ DZ)_V:X<UFK&
M>KYG!_YNK%^(J$%6YDD0ZI_K_P 4*O:%)ZQ'YOT+'UFC $W.J4F2"5DH/+U4
M6R<G^DQ))0P"/TW1#E4O-0Q:?5.S! _[0*ZT&G@S='[6.0_F%;@'R1<8''OE
MM[IYLT,#-;.\R%H^DB&-UD"XX;*P1U:@,F75\=.(:?9Q\*^>7G14C+4*=./?
MC4S+]<H-[EW;Y2P,=-GN,,O[!->OO<7*23/$]J&<7-JMUG.-)G/-@)>H;498
MPE$PIJ#8HB >[]BN;-4-K#>/<N@-+!PV[C[U&Y2W=.^ZR  C]TU:@FI=L54X
M$-9OD VL CSX>/A6)RY$J@%P?X+)UWCEKWEA'O7U9'I=WDL5%@<J@L7Q&X*'
M.8KTXN%@ ?,H?@!A#P#WZKZB+8 76_!663+PD3M;XJ/V!35Q;(MW9K*T?A,<
MH]=$(=$1 1,9=@<H<>B%A(B8>=6M$W@[E/F'+-O'N47LI$R.SF&9"PSY$(@N
M:E<1&,I-K#95\V:-$M?4*U,!15U!P%0>'*LQ0. &SO!8JN<9 V J:8U O<<Q
M.4[?I$2%D\B9SRPN N)%0R1N=%DH94R9' "07 CP)POPO59C8-_M4M$ R,M@
M-ZZHW F2>/D[=G;L#.MOVSO-3FUJ=(3/7IW9=*MBNC"!,X +&*!0X^P+VM82
M#C8#:K^C*%D][CV_D76EA^-Y8=DC)QJXML<C'),>NLN42*Q:#V52_5NRB8 4
M,(^837^JL35*S%(X19;:N7PJ#R)LF&81;D^0SD+C1L>D 55(+(K9FJ)A$4WC
M< ZIG: \"*>Y^>TD;?SG5+/AO#([MI/L5TW6"YIEV'-L0;IM,<39^=ME&@!>
M'3 7 %(+@63A:P>J^G]6%93*B4P+L(%YLV\%@JN&$['Q'9?[U.Q@\XFDX[%7
M4"S8-V/367?(AH.)2G,?BH1N54;BB <>=Z]1EHR,L%S$V=2Q\V;%:2K]_!_^
MK7P7KFO\-^'WU&OU/2^F]_W_ 'O'G63;\-GM;X*A:[<5759M4%0^X&'P.=8Z
M]QK)8LLI$2+=R@X1$Z9# *R(HEZ8JZBZS H-O*8+A5.I<VW8G$^G#K5+)[4X
M*T=P4PAB:)I''8CX+$&.HA]RV,H@OIMJ((J:FX<0$ Y\*I,-E_Q4+#:S?'@K
M>H]JVQ"6$2&VO]EV._@5Z!55,, IO2^^UTG*?U'3 Q%&"1N)A_5A01#W=282
M]N[TX*!:=J^Q>/XCC>+1&VF,L(+#GJ<A"0Z[5TY)& F=DH<J(M'!2B8Y(Y(+
M (WZ86J.$LY 5UE)X"0;!)ALXJ$D.US8"6-/I.MO,;$<^:HQ[[3&RA14(W0:
M-@*<3F,"9-,:7W^=@^BC RZ;E>&M*,6+M$VVBWI50S_;;LQDTN3*)+ HI6>2
M0:-O()  2,GJC^XZCJ#J'KGOY^5#''VKCZ/[% 53 F)-F_;;8/:HJ)[>]I(E
MYD3R#V\@44LZ,W5R]%P4P@Z*T,_.R FARC82A,.KWZGO!R\;>N!)F%EOH%;9
MF4S@C-B +]NQW=4K'=E_;-&SSC(V&T^/HRCFXK*B413,(BCJX%4 W$40'WO"
MK4T1B  /K"M+')%ZB6?:QV^HL81!OM;C;(D%&/(2(4L(F@(]^T?,UV'!R-U%
MT9-8G !#[_E4?"&$!COV= ]J;;?3I53[,=M^T6R1\@6VPPF.PTV1A"HY $<7
M2,PMCWQ,K*1<W$UUE3RSA0;6"ZH^4.55J-)W)#$,#TB]"%D.4NDH%#C8.%_[
M@JY$-@4;E2WX6@UW(R9FANN("4?=MYBF+RT:OZ0?&H"G99<I0(JVLOLYB[M^
M^E?2K"_>*=1#S(@4AP.J<PC="X7,H7F;PK :QDI9@4S!R8XMH%[;^A7F4E*)
ME]FSXJ$<[4)^@ L>L="0"_ 5$/=N:P>X >)?&L&-(K2#L7Z8J\\6(M-RI]]M
MED#=XVS 7HN9Y+R@03):1*?J)CXE,/!R?D>DM(KQAB(+GB%,*L)2,-H5.&:/
M<1E)F9E,?7?369D1!)9$@*)M5HX70F,?IG.).JI, (:C<='UU3ED:E =N-LM
MI(V?PJ_R-3M2.)HAGXWJG&T6Q SI7/F2RK-X8QT&Y$S',43" DX)INA"R8&Y
MAXU3%$B5H+=(64E7Q1[!#\744K'L))BAG[\YB;C,2@4K4H>02''IG$2BFH>^
MAZM_3>'YY_",@Y)-3%]"I"M@EX,8@4</Q/'X+FR81[9XPW0<KR"67/'#&"<%
M9&2*"7QU4B"@K$4;+J ('OI^\L%AO>J$M9_<F8A*9B/%J#O"1[I%V'[RM<Z(
MU:'APB,,82;U?D6#O==\N#9+N#814ANAD>12)(1&6R'TK5U% 8'#B3=Z LKC
M3X1*5&5, @'&_C6WN5O,&A3HP!E2[D_J5?M\%J[7M/J3J&I$7D6.-D6_*L,,
M"^1YM#L[NM@FZ.-Y;*0F1XT^?(0T41S$G1567B)-F *&1QRQ=9)0Y?UQ+6_/
MZ[4_,3+FG*..C:!_5UK>UTJ&A:=.G7!(((E*QQ]G@O9/&L:>8SMIE^*3\.@&
M3R;O(0< V507<SZ:/K2-U%?3NG*8&1%R80OHN*P\/9ICFO6HZ]6IF$@12,[
M" ,6&[%OP[]BV13IBE"$B2V$"W@ NR:;R+?92#Q^/CS'>^N=",%8/4 4[J</
MJMU"%\W5*//[=>3%*8&$O?=8JD91\3& + N)SFC]D9V";M#FDL@?MW:#?3<Y
MDTW,$H80 H@ 6*P./$?"IHQ,8&/K20Q5A/</@5"OS.W.TV)P39D879VR2,DE
MI$3HF9-8](@#Y@*7S'4YWY5A-4I'Q\O(7BH=V^*NJ/:IU1]7![P5+][X]*3V
MYQU%%FHJXCRI%5*4 \H@B_ ;W /$P>-;;Y)U..6IQC,Q#4IBZ1OJ [%K#FO3
M9YF31$CVP;#'[)&U:3V<?)>[V<0=.HA;$V:[XPMECJ,YK$U]"0.RZ@ Z&5+)
MB-FYN0CSKIS2.<,M3CWX=\_4J?9"T=G>3<S5FPC./9 ';AL+K-CN>PK+>W3Y
M7\'M=F*?P'-Y>;PN(%LZ40.9^#!HC'RG0.T76;F](=^74/4$/O M>O6Z1K5'
M5=3HUZ4@?#K4G:,@SR'VK[MB\GS1HE?2\O2C.)!D*IME$OA$-W2J1^0[B3W*
M.]-5RJ<5H["]J99\5PF) +ZA7+=NCJ%,8XF UCOU \H!RY^WU'FMJ]./(OA0
M(-268 N/V:I63\M\KBUB((& 9>6T7FI [UMLXB(R&XFYZJ!;1R<1,@V4$HD!
M0?A+NP!KTB/$P> 5\WJ&7D>:LK4^J*4]WV*OTKK#"1IU1[#B_HK4F^< W7;9
MMMZN"1TQ!ADIE!. 6$#$Q42"'*_(?;7?WEI7!Y7K40W_  67!_U50+C3SN@)
MZ[I4[S&OFS9]_+_0LIOE39<QP[M$[QII^X22(GD>(*B935IN&'-0 +$N;D6O
M,ZGIU:KS)3J '"&ELV1 ^*N>7]2I4.6*E(GMR)BW3*1^"\-]F8B;W*WPQ+&0
M4!P\E]S9L (B6QO3P&()9(D<!4.8@ *[ P<?9PX\:W;K&?I0T:M3)8F43<?M
MP^A:\Y9R>9EK=">$&F,8?_1S87[RMO?O,1&([!,<92#4S]YCVSN0.W12%UF8
M':X%#J+E6 @CIUF:CP_D#7.FE''S5FJOVLY CBU6=WK73VK]GE:A3E]7(2!Z
M?"BM0[LDDQ>=VNQ*C0"M>EO.64L<IBV339Y&W$PW$.&IP'TUN_.SB-(IQEMJ
M?TUS6(8]8J2@+H?T5LS?.XC'X[2Y3E;J*5DFT*VQ#'E7"12BFFJ;<*,$"FL?
M5J 9DH\.'$*Y\Y4%.>MY3P0<!C.S_1S71/,,JE/1\T:Q>8J1]LZ86IJ0@&;'
M,0!( .GI>B(6%'2H "00]H<OR5WIRUE9C0*4CMRE+:/[-<2\T9B-37YTQ?#-
M5/;4_(J(E4KJFT_N#[ J:EEY#,2+'N[QP5K5F#3 V/\ 2J(F8DCF06!X(E05
M;)@0P6L.E54X>!_$*I<V=G3*I_-A^T"J\OP_[I3A+?(_S)!;EWR/C1^6_+U@
M]LU=!6SW>7.6Q@5^[$Z"$VW;**$.H )?=IJW'@/,*^;WG9EO^\T\P/KU,Q9]
MV5/Z5WUY39@RTCP;&A2R_MC)_<O7:(A\9W+EGS7.6)(EM!%)AL8Y_5E>-DDV
MXE. J%> 8;,!\P 4O#E6DO +B(</T6;5N&G5VAKG/58NY^I&S>W_ $B,F:&Y
MA#):&XLWI;IE6:F.;J&,*/ZOK_TWA^<: 9R[NLG2J2$M@A[5%(N#/L)Q7&P:
M)/=PFN0XX_<HM4'"8-2Q;MJJIUE5CBW-K4 ?=5^R-25,EX\0(Q.-SM'Q4N:E
M+&"_88J<Y$VD=U6N-8*[@5TX^$RIM)S"X 4ABF282[<1*990Z9B_ZU\"FO\
MGJ@--K-A +/<X5OBC&T-<JQ2VVRC.BIGS5JE%HP(@K >C6;";JI_>$N'JI$;
M:U!\"5,-(JF.)I$=,5(:L8%AWBJC9;-DETG<EDCYTZD5R())E,9"R*+0%@3
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MXDDLVPN.-]ERJOY.^$1VX'>5@4A+-YEXUBF6197(>DQQU/1[$S_#,MB615Y
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MYJB*-(?5'J"AXLNO;Q7:")@$PG.4^KD )@32'&P#YC:K7JWS%&)PL +[AT*
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M+BWQ7?MQN#%[DX+BNY$(Z.>"RG',=FVY3-'C%5).6BV\BL+Y&100<:44W1;
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M #I OE'4 U$';8_I>I2U]K>SIX?2K%;XR>X&S?<- 3&/3.Y$]AN\V+NL#_"
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M=BH%C@^)QCN)EF.,QC-UCHR4-! W9-VIHQBY%HU!$@(:2J%,BQ2 !4UF+T^
MW$;Q0W/M5>V1,ETP_JADO./L$37,(_:X")[T.\6HXVV!3NI%,K<[H8%B^YN+
M2N#YC'A*X_D<1,Q$K'A*2\4JZC))D9C(I).(9VQ= )VC@Q;@J02W#2(#Q"M1
MK3HEX%K0]@^/IO5&M1C6#2 -A:TB_H6*L!V:;*L7L65O'O9=GBCU!^WQ>8S#
M-Y2,82+=NJWC%2-Y"?>$ Y(IX<.("%E3<[WJ[^=J.7=]E@W>G!68R-( $82
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MY>6!W\,<?K\5[3D"%.IK5",[8FJ>'U#N6H#NP5 =W-T0*D5-0N=92"@JNW:
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MJ_[A5IU*; &3DWW,U[[UBUW(=M&";\09XZ>B&B;@SALHPFS.Y)%R3IL%VY1
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MVTO\6G6$;,;>..V? \A;0;"/^,JY=C\1 0N2N8L%0327=3LM%J&;IK*())G
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I!IT]&WY;\/WZC8R@7==]044HB41*(E$2B)1$HB41*(E$2B)1$HB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2226999d1-fc_working4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-fc_working4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"3@'\ P$1  (1 0,1 ?_$ 0$  0  !@,! 0
M       ! @,$" D%!PH&"P$!  $$ P$               $" P0%!@<("1
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M>]OV4R+C&E]P5\,>3AKT>WW*?;;==YN-VV!,S5MB;;[4ZXE2H2 4H\!S(!I
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M4/2SR+5&0TE/#JIDKDM16$$%3I.J$^WZ:@#8W8H<FT@[%QN![&;1[;76\W;
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M7_)VVK0<JR9=G<9;DW!1;,&+=(L7P='_  >G <.%=V[NX,HU]V4Z.8@/ [X
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MR)1$HB5&A$J1<B5!+(E2B41*(E$2B)1$HBT)\I^^[KZ/]:[_ #RKK[^JM_\
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M0P1JFF(L!('NCML>]:\4A+VKJ5*//[6H.FH/'B#I78]#,1E2#,2R[(H9*=:
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M0^M4FTG:KD01$ WLHU"E*(E$2B)4;+T2I1*(E$2B)1$HB41*(E0;PBT*:?\
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ME4[JOZUBN\5N(\E@_P#WDXQ_Q)[_ -(X_77_ ,S3_P"PE_EE=8?.JW<%<_\
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M=Z7J4J>81TJ.ORE:\?A-4F+F]3N,8JMMV ]H5?@6U>O74>/P55-S%AJ4[R+
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MO<5V1]EV$=J.&L6;'83,O))K")5YR1^ULLO/.*Z$<Q6 TA+K+*$PPKE4XO\
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M14%QH[BPXY'96X!H'%M(4L#CP"E)*@.)J02JQ4J1#1E(#:542VA/R4(3_>I
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M(7V:%HD--R@ E;RBESE0D %/,/EC0D'D!T\.-+K'4&T.RE2XTMQ;*%@J1J2
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M8P$3>  IJ*I*(E00Z)4W(E$6A/E_ZW=?_P 5NO\ \95U]_5?YGUKC[]W^/\
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M]#S5CQS,*1MN6;ORA6P '#$&1LZ-EB@$H:CJ<:9FR'EN-AWW9U[V$DG33D6
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MLI/5;2WS/N(:;^WJ(9!*ECAS:CTT.<IW V[0J/(J&P.^PJY=F0F'BTZ^T/M
M>2XE0<:65)2KD2ZWS-E7M>.NG"JOC(.P/I%BGX>LSVML51I]MQP-@: L]4K
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M%*>BI]N7?&PM/'F#J4H4 K0$#6KLJ<=0!;4%JQ.4IDER ;G]=ZCO>IIK:;
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M8XE.;=8M*^ZAVRW_ 'G[U&?NC2(LB^1]9O1?<2VIJ)<FE)Y&VEK4"I)T(2>
MKKJ)!@W.N?R>.9'-$]H5E.A8G)VT@^^7N7'MT2_W-N-)CQY&LN4;/;^=LH-M
M>6AM*'$GBA/'TU/>P6:2IQ1-7"+3A<]97,;CBTL;'61,U%PG6=O&,70PJ.6V
M7W&S9F@%:OQB$\S8'B@53]/2S"]5 Z+K3=I7&9A=[99NW_%I+-BMUPMRDR&H
M]OR%#LM+:ER[TYU@;?*@>WJA0\?!9X>J]*V('->M;$#SI2%[]"FWCOZXVV6
MRX\2W0&Y:H^C2&)*HC*520GE80F2MU!^%2E"L"LQ-ED5EY8@2D+R3;Z-2X/>
M:\72V;>;;FTS9T 76U6WYP$5;2$W)"X-DYD,AQM9;"A(6!SZZ<XU]-:R;7MJ
M]"VU'&3)S$Q!L T=:^QWT+DG#<*;<6AF7)MMM<3USSN:HMSK8ZBVR$%2QQ]%
M<N\R0IQ<WP%G4N/0IB569 [HE?KV;%\=O(^^]B^UR4(2DN.\CK2O:#3C'O#Y
M=YDK"3SI 3H"2-*PJU=S8="S<M0(=P+U8;B3%/7S%G'FE&.YA%@@EQK0$..V
MF$RYRZ\_$GPX&M=5KF=@T >A;+*Y;R\0 #2G(]97+;BOQ&L]Q-)DO*2NQ0&
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M<NM<M'Q2/;[RWM0TVX+,;K%>>N1=>>Z\65!7+5;E*?<6ZB4Z[<0XE2=%!#1
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M9+) WO=(FT='K7CKYT;^H;SWK'*Q(C2AF9"7=<N8L&-C%R+=2WV^37M<=O\
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M1KFM])L2I2C*Y>9@*4G4EW0)]E &H4?5Q]7C6+*< >\67*\N*=*F#5%K:0K
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M&@+1U /B>(UXZFN89CP=(6VSL8VE@]BK#P'Q5?CX1L4Q\(V*-5*4HB@$@>
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MKQ/NG@/ARAN7<T1*,15[]P(^D2+[6UZ=B]!;BW>,IEAE],@2>NP=1M67@
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MX)U.OXU<?W[G?A<A5(-IB#=HQ!9>?>G!YNPCUVKR4]U^_LSN=WJNF5R)LG^
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MAMQZSS8K>L4I+:U/.ZJ!"F2KQ7Z/;%;SA[,?";SH5YD2AC?4S.%O=P[QR0S
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MU(['(RVMQ*5.:<G44 IWE'$(4XH<Y2"20-=-36V) &$>'5H5\2,2T"0%7]!
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MXON$@;^^59O7V@2]JN^?<KN9QO=[<9C;_-=G]U6]K;GD3;%PBW&&F\6-[;W
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M<7?S'XN&9%;[+C\2S8YN=?[RN7-M/2:<28C^LA21TP=$5# /S*H'FM/-RO\
M2MJN^7:3WSX'W0=OW?/V7XCA.Y&3N=M5@V:W"PS<6\V+&)B(YN=SR!4Z.]?\
MIQZ27V5(A#I])TD<Q_O<J4A-VU6E1 @>+3=^-?(;+]A/?I?-U/,!WJ[A'<7@
M9WW8=IV0[/X#8+,_ G6S$[J<4WK:;M3TQC+[JT&A+W'9:2XI<5GV=0=-=)(
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MTI 0R(S;?,LE 5UR^@G@>7E/KHQPL+]:"XO>JD9I3+00[(>>7SZ\4M<G* -
M2$)63P^+U5)%MERG;>JI\3IP&OA4J$HB41*(E+D2B+0II_UN>(_"M^'_ -L_
MBKK[^J_S/K7'^;_K_I+81Y=7X&7;7_%T/S5VK>[N\0_*/8LJ%T=A["LV&/T"
M+^E-?F$5R@?LQL65E?"-@597B?H?6K%G>MA&Y5:O*VE$2B+KK<20(^"YQ<;1
M(EQ9[N'9B]&GM)=85$D0,:N,YMY#G(A2=%- >((]=4W"VUM#A2#]&SVKR4]@
M6 [XYSM%W%^8YO-W.[TW2S]J6\_<YF. [=6/+[G&PF[X]L'E&0Y5DMIS:&\[
M>1,@2+?B-O88; B\K2Y 2'.;1$FTM*[UA5E@018?5I6)>UW<Q8NYC;O.NX#>
M?N?\S/$>X++LFRF3M<_LG8-\KKM/C%JLV37G&['%BR;#MKDD%]L6.S1E.]*[
M, 2.H-$D%*9 &&RP*)7V6+NO<?NP[T-^-G>RO</N;Q3NUVU[=KO8)C?<WE?;
MA:MR,3W(M>618>43K7)O.'Q\9S7*_<3>G\>0HO6]P=-2_M@Y"42]G)U)B!:Q
MQM9JY[.M9]]@.ZF&/X-WQY%L=WZ9[OYMS:]GLW<PW:C>?'LVM._VW*L>Q;<*
M?9;A*D97/LUT>4(7N;;JVL?BZRK=((*2>1J@VVMWKS[=J76&[1[%T-V4]H'<
M/W>=DV4=RVYO>QW/6/=!64[HSMDA@6[DG&,>Q1C#\QRVT6QJ_L3_ )X>3TDP
M8!6GWF 4EM?A]A4"YM)NZM2IEHN#+XG$>_ONB[Y\2\O_ +1[%NEDVVF7[V)S
M>?N]NAC-POF-7^^V+#,DWDLR(UCNLVXM(>FR?X%P2XHNS.?E<(1IIRFB'D;]
M:J%M]W*Y=U]R,?<SRANX78-C;?N-W]W9[>^XZS;LXK?L$WOS2ZY_DMCS/%\/
M2;3?L3:ML:R?-1DW'*X2GEKMCW,(:='$\NJ8M?";QTCH5,1BZ>075':=VS=P
M_>CV?[\]QVY7>?W/XGF%JW(WU=V49V^WAD8U9L0@XWN'G]LALY-$F)NTAAB(
MBU00&U/6\A+:]--/9JLTW:%5WO"]@/)N=<3N;W4=Y^\OED=DVZ2;MN[?[2_G
M.36+N1R39YG+[SN)>,;LF0;K6.)+@NV$9#=9+@7 M)</NLT'D5P T* (N%]^
MM+,6*XLW+G63WEO;P[*83G._-^[<N]K>#=':?&]L<GSASM3[H(N7VC=[&,GP
M7%<UR>9<<>M69QL*N4F%.9M\1I\1L=4IKYM65.> 1269SWI;%2TFML>^U:SL
M&[N;%W@QM[=\^XWN8\Q+;?/KEN!F]BV)QWMGVU[@+]MGB+.,Y-DN/6H71_$\
M S&VONH8M,!3P1,@?;0Z-$G4(F+1LN4FP ,X7I"\G?N-WJ[ENS6VWC?O'LQQ
M//L>R"\X^Q.RRV7^S7>]6R%<5.VZZRV,BCL3TO2X3Z0KF/R@?#PJDMBQFT:?
M:H)Z#VK;0EQU9074(!+#2BXG116M7-S@K!(/+H.'B-?AH&>Q02^IG4]5*%)I
MZ4GC\/'7X_"H#B]3S%"D.<K;T=EZ,MQI,A+X2IH K')J%$#4J/#U&HF6\)+H
M+^=<;%#[$M+BX[3*E*N*)4B/RCDAQY26[9SJ25:I1"TT&O@.&E4MTW7H^C2D
MIB!=0D7$19L!,?WZ+;I<?J7IF0V^J/[Y'ZAZH:"0H:AGTGC5ICK[SJ,0<EGY
MO6JZ6P\$R)!CRF#$$UI,I ]XDA*%NL+E-N+#@4RM 4"I(]K7TU2;1:+"JG&B
M_P!+*$9( <]X<9<F*7';MKRD:+MQN2%2-&5*42E 4E.@!3J$BA#GF4 D!V%_
M6CA#TD(=C,<I68124!UR,M#1F\[G*=>57+KX#Y7C62 T3J ?:+K.E'N(V6"X
M\_0K=+0><:G*;MJ9CT1U,?(FTM\L9<QE;26D$.E?/S*&@#@UYJ@@-S W<M"E
M[QRY!22(;Q>B3)<6*Z68QM]S>>:#KEQCJ#2>8HYRXM+[<?4)]K@=*,X8'NFT
M#5^)4VD6W\K>E7:XL1Z7#7*+'48?3!2M7*ZY/94VJ2&6U ZIY2O3E]KY'A5I
MK"H=I F_2?8H+ER(T9^9)"7X\M0>?0G5Q4=J<6[?[FCE*SHDGF\/L_"J;"'Y
M;4>0L-_+2N(R/&;;DV/7O&9H7'L%QQ"[8P]&2R6WE6Z]6AVUO( 6CE)]U.@]
M@C4\12TC7[!<IL$AH]IOM6AR^^3?NTJQ9#LKC7?%O/;^U#+6<HE.[5%R]KR)
MJ]9/E+^3SX";VW=8]F;LZI]UN2V4JM'*AM;*2M125.9,;K>G8KCZ3>W*Q;I-
MB]J,0[==L,7V0V^MQBX+@=O18;#;8D(-QXD!!YT]9^(PW #Z5.D\J4((T3PX
MC6@B,F(O94]Y[6 ;EL7<7(MAI0;FN+BI!;Z,GF<'22"E2"QJA3K03PT TT^.
MJK#>.]RZE2S'#HL7"RF(\:WP&T0H\%RQ.2;Y'BQ@AFUI)DR07E :LI6\;D5J
M'.%<RU:^FK# 'E8DBX/)^;9S:U<7&,S)D\LP-/1$+6_-8N+?4AL-1$&3"]Q+
MA0TN7[^TG7E*B$Z<!XU26#2%W+T*2[$'7RZ5/%<CS%F<ZIYEZ[0W%MPY!(MR
M8D1KF;E-MK0A#+BVI7,M15Z >&E"S Z;&_#L4$EVD[6ORY]**B)<;66U$IC#
M6USM0OHO*/,XL*3IRI0XIQ(.H&GI]>5^5>;^?F50Q/B!Y:V]"FE,-37(\@-P
MIY:; Y9@;?+DH%9DMLK4M(YVXB@H  FJ;K"XES:!K*AM5WIZ-2@6F"M3R6E!
MM#:#;OG-E71MEP0DF.J.'4LAIIM\(.H( "!QX:TT83KM;2%!  OMMOT:K5;.
M>ZR8;4@L(GNM%TKB24=*[-%+KB'9,53XZB&%.\4$-J!0M)!(T)ER"PL#6:G_
M !*1H.A^G:KGHMN75,J0U:'7"P&VYCC30N3:T*>6IEYQ3W42CE5P)2D:J(\:
M@@,UOX%+Z=)T*];6\^^^XN2VIF,%<K+1XM%!5JI:PM2=/8'H'A4V1# "T=:6
M$8K>UMBJZZ\?'7CXZ^/P^FJE3LN2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M5!N1*D7(M"FA^^YX?]JW_/.NOOZK_,^M<?YM/G_IK8/Y=7X&7;9_%W^/=:WF
M[O&-I[%E0NCL/85FS'_0(WZ4C\RFN4_\L;%EY7P] 557B?Q>BL6I>L^-RK5>
M%RMI32B41?$979Y=[P7-L=@SF&Y%QA9%8(K[P2$I5=[$FW-JY0%\B0N8==/$
M520#(.+"%(9GB.\+?4M:G8EV$W78;M(W>[8-W9;>38MO%NOW'7+(K-:VI+<:
M[XMO;>KDB4B?,YHLR-";M5V=2ZE',V^AQ0/!(U$AW&BT]/XE59>[DV>U:],-
M[%/,P[2=N-Q^V_MSE]J&;;'-W+)KG@NXFY^2(QC--K8V69)-S-=N5:?O2YP+
MTF#-R24RS[S=D:QT(("1HA+%AMM8J 8DMH/JL7;][[ ._?9''^WV?VZ]PMEW
MWS+;S UX!N%M?OG>;EC^W.=3"K+5R,ER7GM^YD2;>&8>3M.)7)M3[I7;8XZ@
MY4*;JL(<V-<=!"K$O>TOV>A=?;8^7EO=@F:]W7>9O\=A\%SJX]JN=88O9[MW
MN2(^'294'"-VW[E=;Y/LV'[>-/W%<S,G$)==M3KKGNJ25 G1,&1PXB" =*HB
M0&B+[OQ+!WRX-H?-@S;L21@O;GG.UENV1WCSS?ZP2KWE\D(RS;2-/W3RZ#-<
MQ]I>!7UR^.MO3'W&RY<(2CT$<4\QY8>.D]YE4\;S<"MB.X?DZW[ MG^U>7VM
M[KV[&.YWM%N5S>PO<C*;2+/CFZ*,CD9Y<<@L4R F9?K?;88=W%F@.(C35%R&
M%<B2H\@.0Q#GE>HQM;]%^E2([ .^7N\W[P[=WOXR#9/%H^S&/9I)VHVUVOS"
MX9ZS_"[<W'I]@GWK(ID[!]NG8,9F3!MRHS)8F-M*CK4V$*)YH$Q<Q8)8-3@M
MT>U9G]E'91GG;GV4Y[L-G=ZM;UVO&Y>_66A^WI=*)]GSG<W.<HMD::MYB*_(
MBHMN0-(Y5<[8 T'#2JA*):+=[VJ+'=W#^E8-8CY<'>EL]V7]K^%["[V8##W@
MV!R',+K?L,F9#/B[*;BP<ES+<>YM6[(\@%EN84^S;<UC*/6LDHI>B(2. 2H(
MS(+,VCG*!C:+?5R[5];L/Y:F_&9]YR^\3NUQS8W:N7'VUR3;=C:#ML8BWZT9
MFG<+'<RQ;+KOD>>Q<+VJN[HM<'*DO(#D"5SAM6JF^<FD9=V]B+%,FU6ZEU1A
M?87YCG: -[=JNSB^]L.X>PF79QF6?X9D>\%Y9QK)-GYN4Y%D.37&UI@G;'<<
M9.S;[KDSZ F7<64J1"1["0HI1#W&USHY7J7&FZY[EN,[%^W?-.V;M]M.W6Y&
MXJ]Q,O=N$^ZWF]O./2>>3<IKDU3$)V8^\][JP%A#>G3 0  D#A0'O,053*W4
M+>M9JJ6TI]26FG6TAMM8Y]0@A16!RIU*>;AQ/B:1=G*@\UQT*:JE"A1$/$%)
MXI.FH/@=#J-1X'0^%01:Z)H-%#0:+&BQZ%#U*'V0^.C(I.DUUDR.FW[PAKHH
M?Y$]9+/,5=)+NG.EKF.O*#IK1AJ18E][.:Y3@.PU\ON$;L;?[*Y3\[XK MF>
M[D2+7&QN S+R.V1)4!\WB'.A.+N4:2J.TE39^V.ITXFE@+"P[%5$.;0X7QT_
MO3[=]E<-PR'O]W';2XWF,7 ,;S3);E,R?'XL;,([&/6RX3+QCK<Q^WH3 N+=
MR0^P64-MH;>0$Z)TJ)1[I(%NCV[$87BV/HZUVCL!W5[!]V%LNUZV!WBP_<Z#
M:9:TWAC&;A9)D^.&FHJ5.+<LTV<X !+:25%0U"P#P-8V(D^A,+!UU-YA^[F?
M]O?9)W"[K;87:/C688UAF3Y3B5SN-GMMWC6&=&MKDF"\]:;LQ*MRX[3K*>5*
MT%"2DD"JK3:[D*DE[#=S<VM:C.W+;KSL>X+8K:7N!9\P_ $C<3;;'MP;;9U]
MOVU\>VPG)%EMDZ+ FR(MHZ+Z F:$K6ID\W*24DFJ097!U4!$-;[%WGY>??\
M]R&^."]U6UV]K&*VON&[6\N>MDG+<>;MEYL.0Q',?PJ\1+G"@N8W88\5TIS-
M+:D",0DM$<QK)P@V-:S,VGG0F-]A!-^A80=@#'G6=Z/:7MIW0XEWZX=C3>XU
MK-ULF'7787;6]M.2>G'+S-PG2;0HQHB(KI4VXAES1U&H2#[5.Z+ SI>Q-ATZ
M.I=H;9>:3W8.=L?FQX-O2_CJ.Z?RY=M<^AVK<.S1;0U8<TOUHQ/?Z-#R1-A;
MQNTVUM'SSLPW*#:XSZ&Q*Y0=->:(Q%LHMS_@51(NT7^Q<EVT[;^<_P!Q^Q6V
M^^47S$\*Q&TY_:&[K:K-]X?;6YJBNOR)[7NKUS>MT9YWI&$X->4Z:::<.%9O
M86V=6U467NRW:]GNWW<OMCM7+P[NOW=M&[VY<[)9U[>SNP6*VXO;VK&+/8FX
MD)5ML\:%##J;I:9:E'E!*) !)  JDR$AC!#J6%HU:]?K7=6XNZ^W^U>&W[<+
M<K-;!M]B=EA/I>S3))D*)9VFQ&D+1)2BX.L6Y82TP7-5+'.--35)O %^E0'(
M)OLY?@6/VR/?EVA]S$J=CVQ/</M!O+F5DAS+S=,%VVS:Q9E?IUMM=PCV24IV
MUP9+CT:*9URC!U 26VWW$)XG0U9LQ$'2@Q$/%F':K3=GS >S?9'/E;3;N]Q&
MU.%YXPXZEVR7?-;%[Y8(S[<F/%7?X%TG0W6)$F;%=9;ZB%$N% !U\(>P%[.6
ME&+M>.6C2L->\OO7SO;WN3\KG$-D-Q<;NFT'=/N-)QG(;U#M]@OT?,,??RKM
M]M3;=HDR8LT,,S+5N!(Y3%?1HF0C0\$Z0;) !F540\3(N[O;8I.P?OAS+<JZ
M]]5X[F\RL..8CL)O7:\8M-QNCELP^PX_8CB[4F*),B%$ML?ED1E!U:'00M:B
MLDD:G+ # L21TJ)N2PTZ5F7LWYA/8[O_ )R,$V5[GMD]U,S:B+ZEMPW<+'Y[
M[;B6)CZ@BV6B;)"9'0:45.! 66] >"14$,"1=ITH"9:+/3U+--];K$*&W<6T
MK(N"0$17ESTED/- AXO):*]4>L'TU'B),;VV=2IN%K-UOMU*X*&RZ9"6TATI
MY YR)#H:]G1OG'M!("1[.N@T'JJKZ-J/J4I9:*BLM-E:OE**$E2OC41J:E%%
M*$(Y^1"4=34.<J0GJ ZZA>@'-KS'Q]=$<J;PX#@!X"H)9%&I1*(E.=$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41:%>/WW/3^%;\/A_#.NOOZK_ #/K7'[&_C_I
MK/\ \N=\+[-.VM(0L'[WAUUTT&GSKQ/'TZ5N]W'OC:>Q9$#X1S'L*SA8&D:*
MKUM)X>D:)0?BXZURD%X :@LW*CN@ZXA55#56GXO"L:I>ZSXW*K5Y6THB5!+(
MK-;3SDJ*\M,?HMLK1(93U=%O%+X2\WQU)"EH^4?!/A0. 6\1*-Z+E:OVXRX[
M\:9TY+3R914TI;K:'7 D_-_56R6W4H9*E<_(02#Z>%"'+B_DZJ<&]7#D3J*@
M**65^ZRXJU(<!+8ALQ'&7&4 #[:LO%)27.;V1Q-1A%O./2H!L;0IUQW-9I+Q
MF-R4(+468E#;++P<"E*ZD1#,CEY$C[,G7X*C#:^E2]NH!?/7[#K1E%GN-CR%
MLW:QWRU)M%ZQR0>A:'XDAIV/<TMR80C7@^\1WU(',_X)3KH2HFIC;SZ=/LVJ
M'[>7X%\=M5LG@.S.(VC!L!L,:RXQ8[UD-[M%M9DSU-VN3?KY*O;JHI=DN+>*
M9$M9/6+@U]8J&)#&ZQ^A"298M*[1,52D)"I3RGF=0Q)4A@NEM14HH=1TNB-%
MK5H4I!\./C48=!N-X]GX4=46[:TT4GG6^HO>\N./\O4+Y*5>R6DH!;YDC0'P
M]%5]0/,FWDURN2RLS79A#2BXP& VHK* @I0'$E.OR72@$^GU5#=W#H0&U^3J
MV]U?:7*=;4S($Z6A]Z#*1R08K:&&FM(7NR&Y'4)9!^V*4-5'X*@1 L#BR_23
MSZ$L?F"ILV]R)(N,J,M/4G3'W%(=*RV[#D'E5'>T',VIAI2BV6RG52O:)&FC
M""V+5Z4DQ\(;E?M]"@NUJU^US7^FV>LPPMN,&?>$\6DN\K/.MAK4@:DJ(\=3
MQJ=#$"WE8C@7?CVKE&VF"^MY^*P?8')TR]KU D)YE!2^4#XJ@X[@;E 9NT:/
M:HME[I);=*#RJ/+R Z!)"0$\>)TTJJQW4!Q9H4U%*41*(E0 B5*+3IY[4AV'
MY=NXLJ/':?D,YWL[T_>5*3&;"]T<42XITM.-OZ\GR>0^(X\*D7'4JX6GG6KK
M;C9?$-[/-K[7[=N/9DYACT+RY<$O4/%[I(4U83=FMN>V,)7&3;WHDQW7KN#1
M]P\%FJ8W8KHJJ1-AC8762/:;MKBNRWG@]U6W&UUCAX=B5S[3K3E%OQ>QR9[E
MMA7U6XNW=NE39B+G*F.)6[ C+2 THCVTG3QK$ [UEZIE(WRTK81YS"UM>6YW
M7.EQV"V[MG>VERF^@XEB"F)(YF4A8>_RIQM:DI]DIYB-3I51(5(#DDWKS\XC
MY<WF"M>6YMCO9VP]^6[TO(K?L)AV;6+:FYV[:E.-.8W<,"B7UK$K,L;4-W94
M])]VC(5(G\G!6KW@JJ2VE5.27MYEG_Y2*^UU[R[MR\RV"M.0P,]O"<@A[\.9
M7+2]GS&>1;G 8F2;HRY-D6I%O7;8< M>[C3E4CAKS5EN+ ;A=S_A]2!Q(8;2
M=&A:]O)Q[2_,BW0[!MCKOM=WZKV4VSO&-S(</ (5@Q:;<8-B-N0N%TY=QVBR
MEM*U7%[E4??5+Y&S\&ICAM"##81:5G?O!Y<MB["_*T\S[(Y>4W;=+>C?OMVW
MERW>?<W)9$5;F3W9K:K>6[NO6J/;+;8(D5)N6;7-P)]S9'VY TT&@&]@=89#
M-]C/M72_89Y563[B=GFQ>66?S".Y##8.:6%N4<9QY[91-IQM"KA?&EQ&!?\
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MXB>(J&&I%#[)*_LT:\BOLDZ@I/*KQ3J"0=/0:80;P$<J 2E*E+2E*5KY@I0
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MUCVI\9E_<I]8]BCR.?=<3]NH'^,:?$TM$H]8]J?&9?W*?6/8G(O[KB?MUO\
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M?G?53K>89]E8NRL^K7<C?(?_ $3IY6=T5:7I^HF',^]2_.^JG6\PK]P.RO\
ME)WR_F3J/)SW[VEU'ZB8<Q[U+\[ZJ=7S"?W"[+/Y1]\/YDZ>5GOWE+\[ZB8<
MQ[U+\[ZJE+OF%>BQ=EG\H^^/XVR=/*SNFK2]/U%&',>]2_.^JH=7S"_W#[+/
MY1]\OYDZ>3G?WM/T_43#F/>I_G?54_5\P[]PNRS^4??+^9.I\K._O*7I^HIP
MYGWJ7YWU4ZOF'?N%V6_RC[Y?S)T-+.::E+T_43#F?>I?G?54.KYAW[A=EO\
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8 '7T*E4Z%<Z'DTUX\FG-IZ=/'32B+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2226999d1-lc_correlat4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-lc_correlat4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!F 'X P$1  (1 0,1 ?_$ ,T  0  !P$! 0$
M       $!08'" D* P(!"P$! 0$  P$! 0$           $" P0%!@<("1
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M0CS2;ZM*%2B).F!^:+=-$P/2F(H<NY@J;===/<^X?2U#^V_Q6_OL9,>/#FM
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MA--)L8>":2:+RPH%A+4V%A_U4X5=-B]<TAN;MKANF'T^H;5NNT$2^FM]=^W
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MC_)%A9N,A\6\Z0*U=GXJXRT.6:G;"XQ3",[)6$LL4@*E1I($74--F:)N!=G
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M>)V :C"W*'K>/U8,<G)N761&1WTN]L]EB95NVBG+2P2S^>>R22"B<?L8&[P
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MP"80 0#T JT5KE<IR[VVVDF5GX!\-[QG N?K%Q\@Y;,4:<%TLC.I>V1R:JI
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M+NLJP>CT_P 5U\\7U<EE_&E+::E+7R)-E#D%BW#!$ R/=2UI11H5B@LJSDW
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M);8! 0'?XD]=>A_N'0EY8Y5['\#C_@SA)JFW$^@67,8#@*!^I,P#VRF(9/8
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MEPE*O5I*^Q<-,5)F[BV&/'SHR'NQ,8O8 1("Q3Z)K2SVN5T<N^VAF;E7QFY
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MW*.OLI$B&.\ALI"]1[64<,6[V/D+/&28R#IZ@@=-LA&(0KLXE414*8%!^H@
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M*[C'KQUW6UUQOD:+KE;=S$;8L^.HVP2+AXXD@AD7"=H>&44;#'+E6(0[8A1
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MZY'X_J\%9ZXM(@=1[:T)",LDE*1JC99DS5@%8U.&;IF4ZG@G,ZW$A.WLI?\
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MH_@=C_HW'#/*K>*QF?X[W47+GPG+*^/\U9\Q@9M$ PQI4TI.NR[,4B[+F9W
M[]TNQ2;@!2N303<Y0[X]O80W'XZ\[K?W+UJSRA9N.;_U'\*&\?Z?TGT<,WER
M\R3C^/5Q2Z^9C# <X\\'QQ0,M3C=,T19LP3..4(3W*Z!2)Q[_(;8LO\ =S-#
M$<E.6E#_ '?VY0+W]NX/;^ORNI_<_5MU75I_\N7_ -ISX_T["4N=3/\ [:_^
MXN=E;F]E2.MW(JO5-C&4]M@AM%.&K*7;E5D+X#^=CHI0&+9=M&KQ?:1D!. I
M@_ZNP8OIN(E^H_W?K/)XSECP635>P\1?B5_'CU,5SXM2GR\R\3/;C??;%DW#
MN,\B6%5XG(72C5BTK,CPKB*^VN;+7XV7>1YC**]4H6/6>=LJPIH]SIZN@G5T
MAZ/IO6=;*/N[FZ]^IYGJ?3+I99<T4T]E-)+<<TZCFK(N%0J6&6\<XLD[/)M3
MGEW?VHK)J#&>*=R/6FJ*VRQ4@Z-R ('WZO3U]-9^H?1QKD\6W2LIR]3H-8+-
MMM2E/;;0UI\;;Q*X7DLO53(.&,6XAR[7,5/+&RGJ1'5R@1LRT<!,1K9G#,XN
MLQ(/%VSI@Y4[B*Z@J%$$^DO3U#^;X>I]5@VXZG-VM'ZUZGTGI?4=-8)]-8-I
MT2<PYAU457O/7C-FT^+ZYBBY7*BQ\^_Y)W$KAUE%S)(-Y]E9)B4@UXV$>P*\
M&_?N/=R-V.0KD\BD)Q3,8$A$1 NL?4^JPJUFZZM^SB9ZGI/3==OI<RQ2QBB5
MW10TU;7W&,TS9[/=<*<UY^UFD#6TF3&,G&/G#QVQ7@FD/7EX&,,"BQ3+ H:,
M!$R:8&2ZDC=1?I -^-]?U;?_ *GB_([&/I_3XI8OD<*+*7Q]T&]K%F3+"ZXU
MLKW*.7!K$^@'LVLX<MEDUXH[=N10&2HK'%9QUBW$ 4'M;=W^$>GZON/^K\_X
M6WS5?_N6MK!^:=/^L<OJO]-].-)7T0W?2>'$UD!Y".04=CB:S8E%1JU:JU_=
M4HL#)39@):O<S#B/;.T)=>+.G'BV+'"(I V=;^Y .H.D!/P_]89K+5I;^K-N
MX]KI_P!.QR4MW7_M;_\ Q&6.&.6.0;1R1LN*[4>/=LF.%6.64DR3)4VZAWO^
M&0A )LQ;J))F3+>#?WH!'?L#^2'<^CDP_MW43>33YE6/Y;__ ,>)S=;^IX+#
M##IMM=3/DG^+[:-S>MHNKW+,5+FOF:V5;!-T/(0<;&9=N#R'L$5%1"4O'4YD
MPA4Y=)Z^M391FV>ED' %:@11NS HF*;J,)@)KR?3_D>MEFH>2K_B:7@=+K_C
M%ABWRMPMU?$O\WO+VH<XZK5HQZ9)CFBKVF0>J(-3-8AT3'81"C&08G35%I,_
M?2W113Z!+[0 +]2W= 0^C]'U^J^I]+?W*L\?8?.>IZ+QP3R44=U5=KU@V/-#
MN#-61$_KZGBPKJE#HW3*JZ*.Y0ZOGM\1U]/Z;#JY88W56]=[/)ZCB%K/855K
MU@- - - 2Z0 3 F7<5"F!4AFW27I5ZP(4%3J?VJ96^^XB4=]C? ?352DC<$D
M3(D13NE(W!N4HB9P"BK@[18A@( [.0,!2; ;T =MQ#TU=.+\UKYDUC3V/3R)
M65-NX<'0'\UTB8B#Y=JFFJUBO:&!Z5$[5?MMNL3" =7:$X H&P^@;-)XV*J-
M-[B&91BAY21>@V8)D=JBJRDF#Z1=J=PRBYTGCV,?%)%(+K"H4X"D0^YNH!]
M#>1ONE["J(^FTV[0Y06[P-42Q[ZNJ-5V+I!![(-IEQ(N7!'9P; V3033$1(K
M_"X3V]/3\+K&I*Q$TCQ.*C]TGC_BFZ<3MZL'+:]UGDQ6,3X0@Z3Q$82"OZ9R
M'55.2DB"][>QIY5-JL]02G)DW69(1VKZ?K](;>;Z3UN?5SAO*[NL593H<OJ&
MTH>ZYU;>-E4#\ >$!$TG+11/ACQ:.=!P1(@%44PC3A.)>VHKN83%^K?X>FVO
M4R?-TU-4Z^.AU>E7J1JDOU[S)6^4BO9%JSVKVZ*0E(U905126%4"=1063 P"
MBHB?J BY@VWV]1UY/J_Q_2]1BUU$KWE[CV_2=7+H=;'J8.4U#6W8:]L3>-+C
M]C^^,+Z2ODF'*R2KIO'N'\XHR!P#9X0IDTU)3H$Y!,!@#IVW*&OS'\1^$Z?3
MZF&36+3;<)Y3]NL_$^U_+_V'J=;I]7I=/FQRQA-M8Q]R=+[]4;,JTQ;LF0E:
MLE(U!/H8HL#"/;;(1X&11*B4550*3H';X[B !OK]-]!Z7^+I?2H4*DM^T_/?
M4^H?6ZCRR<OF=82FO J4@COZ_A\/]&NUFX.!$N6W]LNFUW[IB&*F80+L!A#T
M'Y_\FNIU.@G@U@OJ?:59Q6YAK<N.1<DP68JSD!)-[&WV/.C%@*SHA45B-K&D
M)SF;E:J$ !E4O4HF$-O\F_A^H_"8=:>=8I.=<M3T>A^8]1T(KDFH_;B[=ICU
MR X#$S!@[%N ZE:(VM1.);O'6N25=K/B]TYX:YB1#OIQTD[5*);KN '$I=B?
MR!KS.K_5NEU87)T_I5?JSKQ]QZ72_LOJ.CGEDL\YR:?VX4A09026*\@3F2*8
M]EG]8<0=>][+/X\AW.QR/(Z6CFVQ0@D@,)'8D-L)RA]/^;787X+'FA+%N\SE
M$6,_[ACATW+RK2B4EA<J<.YR[\C:3R&Q]8XFKNZC+*,9UHR.Z*:7(RE(<YBN
M6XQ+MFI[4(]8"[B7^V'_ #5?A$\IP6-_\65SN]'\ET\.FNCU^:%@KI5452A[
MMY*Y7AI:/_%(MGYE:HTQU(A@VE04%8%C&;1]::#LD$.9J'_^' 0V,7_ETR_
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M)1KE(R4%D^ KL1'-7D>P=)%1.TMK8A6A7$$[!L44IP@&,D8IC!T[[B ;3/\
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M7_CDOR+R8\JD9CYW'N&R2[MM:D!2>3OLW#IV+<4V=4E4E0*")3 !E"[F*/\
MG\OIK++J3E>:\:7_ $W'T67H>AT_3X]/HPNFDHJZ*;5OWEY8BN<B<MRO'/(I
M)8^/HJL6-O6I^G5HB*<(HR9R5,9D*= 8A,GMQ;L%BIA]&Q!$-@U]5Z#H=3J<
MO'E2T]A\KZWI^EZ;ZBQ2E+++*K;K+K.^M++0SWS[0,FY)J;>LXOOD;3K'$.V
M#YW(R6Y$3]J+=H'()TH&;4*915^F?8$@#Z1_R#];AZ)Y1BGC11$OMFQ\?S88
MX<_*WS-U\5%]U:$D<\=6L[)2=PO+"!F+Q/T,],GG)3O4XI-(ZTTL"T)V&C(5
M5.Y,'V[C9#UU\N_P>/.\\UAWO)5MH>YT_P V\>DNCT<LL<%$0L<G''FGVLQ\
MKG!_[<7$\3)RS!:G8:MZ=LAHE==\$F4QY6OR2:[XI60$[<>2LI"@'N5 ]3 (
M!\\?[)C;-8I)5KE1:ON.?+\]G.672>3ZF5J8PVOM\^!3^1N!S>V+9'KZ$M]F
MIN9[; W6\KMU71!8,JQ5/T4C',S B91'[DD*3LQ4SI%,<!,)NKXG^$QLUC%[
MY:4\[EQ_.-QE.?/9T57>E8IW&P25H,0ZI#ZF,00C(N:@WL*T3;@;M-A<(+ 4
MX"8#*%+N8/4!$?Y-:Q_JF#Z?)E_&L&O\6=U7=V'D+\_FNOCZN<OY9<.%9IJU
MM7H:PW/C6L!L*RF%T;I"]J1R.%Y:F?.I0A#HQTRO).$R*I0BS@1,1R0!#;I^
M'KKB?]/3_;TX_P"+/7N/>Z/]N>.O55OVX1.NI?&E<4I"CYXE,W*3-;<L%\1Q
M^-3 5U)B?JCD\?HJ"9,\2FAVQ4I1O7JZ_4-P]1VN/]2:?,OX9_XL_@=E?VKI
MYXK!KK-3*^G"4ZU^[B_$UTX7F^1]1A:Y/.JYC*VL_P!31L1)$A$#'EX SQS%
MM7"[&KKT^*J1=D) NYMRG HF$/4A->'Z3HX_R8M4RE^P]OUO0P?2>&7VM5J_
M:JFR"CX_E,D<LD\QRT0JU@<15^2J<,_=B+-X]D90I&=B*,5'F-"MDF:U6;](
MIF 3 IL)0V -?=_B?2_RYK+./VSI[#X#\ICCT.E&-FW%6Z=]?$V%@":!A:)'
M HJ-U7"7KOL!U2&$?7<0'J5U]AT>EAT\5RJB9\GU7DVWJU0G^L'.- - - -
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M!\YC'&J\VO&L<O.<E_?$2QZ"A$@EIRKN,9UMO7RK&ZS$26EC 9,"G X@<-K
M3DZY".>_T':@DX0.']L1<H@ ^H[ !2G ?E\_GI&\21!#&'?J*!?7TV-U;_'^
M0-M0I]Z : : : I\\\4H=SVQNRBZ,U>JF4$I6YA(F*9T=T=G1#JK%*(@)0*
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MR,PLLJYF'$@L;N&54^H3B8PF,)Q'1J(M8JK.^3.#4*- - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - 4G<Z_"6R#>
MU>RP\58ZW96CNNV6MV"+:3E=L%<FT#1L[#3D-(I.(V3CI.-<*(*HN$U$E$E#
ME,4Q3" HD3'>:1JY^WX\6M'S<[SNCQR@)!Y$V0UO:UN89UJ2H*<JJB4JT<]H
MCJM*0BD L=PJK[<Z8(]72/2([#K23<;FNXQ]-7=I]K-UR!D&A7$=&GCTDVB2
M*24='G0#V21U@*=+VK<0Z$D2&$_5TE ?4-@VWU=R2IV#5N:VN3=FZ%N"A?[R
MY3(BF5($FZJB9O;%.!U45"B<I_<^@@4 ^GT#<=]9NVC2HM8/?[TAVD5C%!N1
M9?L;/S@P.!@!7?8JY0$P_E"(!\P]=(VXB:2OT6][B<ZA2&7<@BHDET',98%#
M ( /;(5+HZQ44 ! GH<-M_CZ_AH)(8\B0BG0*9ND!#K4,(E3* E WH<2])C>
MOPW^&K&_;;>2NA9W+O(7%> <?R64<QWFAXWH$''.7\Y9[A>*_7(QJHF0$F,>
MQ>3CB-92DG+R2[=FT0*J11PZ<II)@90Y2F7KQ#W*(@Y/[_SKYK^=BZ6[B]PF
MH^2>,_"]A;9ND9<Y<(OKC*.\KT*SS#NMM&E781L#C5K6VXU6&E5)5HC9I1,0
MDD$UOI2*9:RC,.U:G0=X]?&SQJ\=F+#4'"]28*6N0:K$O.37T7'!?[W(R,@>
M:D5Y.S DYGW#$[]0@ W6>.B$!NB'4/:)M&OJG]L:FE,-*_ V&?:W ).D2OQ3
M354*+8$4!2.S1 4Q%%(Y7 #Z])O4.G^+X?B3CB^-2<M;N".9,RLD^T4YE V+
MN8^XJ'. #UJJG$QC**JF'<QA]1'U$1U-MMJ&MMO>]2,T T T T!C9GK!]!Y%
MXGN.&,LP:EAQE>$X1G)5TDG,1LA(I0UCB+(BE]QAI&*E2(IO(E$X]#T@B!#
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M*2.B8\$HIT]&9J<'68N)0=#/N69FZ*VP*=:9R5T2DN/++EU\ME8Z;]9*- -
M- - - - - - 8YY\O^2\?8XFKCB'%A\VW>)38N8?&1K>O09&41>RC&->JA)I
M5:ZO%@81SEPZ!,(Y3NBV%/<G4)R5V,XM3!R^\H,+<!.=V9D\U^16B\K^*>5T
MV$;CN%<SLC?<785QY/10DB+-,IYOL,31:M(5Y2439K/'96S%%BT:%65.8BA1
M):Q+%,7%4H\-O,V2^,[Q:\">+>5Y[DOPJRW9LJ0=SP]8,269T;,'^.-/LQI:
MZT>RNYVO6EC-R,./VN0QZ#!4B*:W0L*I#*D,4R8YUXE[.^?&YO:]Z(&,0R(
M<I ,  KU 8PB(=(&Z _#XZL383%Z4/9!P*QC$,GVS$30.8.KJV%8IA$F_27U
M()=M0)R1.A1H!H!H#E#_ '07"+%<_P +LL<W7LYD F9<+USCK0*,DUM\NVIQ
M8B:Y6TR&=KV"L$<^PGWY6>4I+H55 IRG*@8!W2+K5U)AII..!OC\;;5XAX_>
M#ZSR17D5GW#WC(]<*+@H)O?.<+4Q9^JF*BZYDVZZZFY$@'9$H=(".LQXFYGL
M,V= - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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MF4B1TO:+-4ER)N&"@GZSHCL0ZA2F$-P#6FY,K&)B(? J?630T T T T T T
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M,G0HT T T T T T T T T T T T T T T T T T T T T T T T T T T T
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MY7?]K\7_ /SA8#TQL]M"NYLI\<__ *?'!/\ ^S?C'_\ 12D:R:=S,K0@T T
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M"LO$#3,C(Y6ND^5I*Q%'D3P3YQ&R2'8+/%,XL;ALHGU]DQ58Q)8W3U%#U<?
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M>Y>UF,7+>RR5&X_Y7N\0W46D:CB;)UC8KI <3I.X2GOY1LW(5--0X'>K,RE
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ME'^)/4\SI^BZRJTVVVZ8QI9=CKQ5#::AL8Q4VZ2":G]W=,W!$R=M0CH14<E
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M,I;*>.\*>.RCIQT@G*/TW$A<\SJM4I9-HFP+6KQB&Y4DB#],OO.H)0IP[20
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MBFN*:J:;PJ0=/<%4YNR9-58QB?4'\0_#;67N*M^A.]0HT T T T T T T T
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MFX"(#W#>OIK,:ZFE;@9OZ : : : : : : : : : : : : : : : : : : :
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MF4]_ _-/7=)==9<V'-+40TG;_,R;X*XX80XVUA6KX+QE5<4UI14RIXZMD5%
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M25)+<YS&( >I@THFYIM3;0B;=E.U:^S>>XSA@5;HBU3(9VBJ+4ZCL"(K.R+
M1./*L9#H%VJB!E.@-SEZ#!TCL(@]A::,BRR9C. 1!N )E$W<6.OT%[?2/;4;
M@*6SDAU Z=RB !ZCOZ;:@<*]H(1Q8FR:2BC8A'IVKPC9^D@N!U&2/=,FNZ6*
MF14Q2($3,80,!0'I'U#U'5C?0CR42?+6>%RH^$J#55LGVU(M1G(IOG$FV!),
MKQP+-% #M09OS&0$ ,J B7<1*(](2DPK"J7$_'ED09H-G ,)-^F[7!%+[2Q<
M29DRFZ *NZ*U3/[5 #&^HQOI*4!$1U;B40:5N;"18RR;4.B:&"2.TD4G[99Z
MJ\.R9("Y21(FF[.L7I<(_4=J80*;J'2"23-&<(X4!%)LIWNDYQ15$R2W:2."
M*JI$C)B<Y"K"  (!L(" _/;2-Y9I*JMK[CS+8$CE#9LKWE'2K1!ON;O'4;MR
M.E@43[76B<B!A-TB CZ?RZ0K:J_;PW]HEQ,=G9[NPB8V5&27>$(BB1NV(U B
MI7A%7)G"G?!T@Y9 D4[/VQT@ HF,;N[CZ%Z1WE4$Y)QH4: ^#'Z!+OML8>G<
M3;#U"( 4 #;UZA'_ #: @3/S%6%(6RH@4AC"H4#F+U 8H 3<$]OJ*;?X_+52
MWNI&XVKX%+RMJAJW&2LW89*'@(J(;.)1S)2\NSC8UO"-D>XYEY!\]%NVCF;0
MB:IUCJ&[:2:0G,8 WVVNHVXRI\JG!R<JYE[-]#ESY:>7[D!S1S<\X->*&C*W
M@BLM(T?)_,FL3;RVXRH[.7DDZJ%AJ\K5*VXKD\R:(MY1^@Z1L[(CI%HF<JA"
MF Y+T_4='#-MO%S:6O9KP*EU,DE55BGN,Z/'7X<<"\&K,OG&\R#S.7+6]LG1
M[CFJ]0Y%%32TA),9(8V"?3TK<7\*=DUAVC=+M2)A%)F(@4I1Z2<^7Y#I/"<7
MTTK-\RG;AP.3#\=U>OE;+)I2URO*%:8[[\3=.>/*H=DJJY41*DB<H->LRS<Y
MC$7*4RY.LB;DY!.!@$Q=_I#\ UUO]R]/FHYNF\LG,\RE<%X>9PY^ARP<_4\,
M5#7*X;T<=K0A&ZK47(G=J.#*NCDV!,S=JFDFJH"0(->ZJFD;I/\ 68H[GV#?
MX!K&6'2ZBG&-^CO:IU^AS]-M9-SS1:+/1:%6#ZIE_P#S?#U^&^N!=/ERX'J=
M+*24%9MRG^E)$B?:!,$TT2$(4P"814 "[% =C 'P^7QUT5^%](OV])4TPQ0?
MK^MEE+RS;WO)OS/LS)%0HE[:!NDB9=Q;D,<_1N B<P^IP-\P'7-AZ/I=%_2L
M(I;%:&,NMU.HH;<<7-SQ6C4W"8HJ;II;?21H7V@E';81ZDA]=Q$1'T^(Z[>/
M4>./+/T\*'7RZ*S?UPUV1YDQ^VD)L1O[=!O\VY&A.V(?_NE.0@&_EV^6N63G
MC>1#9FDT,J*1E=E1*(D.H8Z9.D3B )$$>E,OU_ /D ?AHVW5W"445B+U"C0#
M0#0#0#0#0#0#0#0& '-[*RF"^*N1;D$^O%2:$E0*FPM!:U5)MVTOMWR52*35
MGAJS8&CBIN$PG[/'ALH@?IW$Q4S'*0!T]^L0NPBY8>,0IG;:#G*\M'DJYH\/
M,8\3^">-,T.KQY!^3TO5HZ?R,>A8MC@IDO/K8YAJY!I5AE3$:L5>Y3M\=)D$
ML 82&8;%,0/04:/[2-IIMW=WV[NPVG\ J;S&P;DBE8<Y4<AS<@&\SQPL.;8=
M6T5"C4Q[C_)@Y HK1Q77DMC^@U68DH]1"[RJB:#I5XAT F(IE,FF"<6.HE)=
M_P"GD;Y=0T- - - - - <B_[G3#G"]UQER=E>V-HU3F#6J]@J.Q].GL%K;3
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M8<J^01^UG2Y[PW!X!QI6G2;R(*T7@)?D]4HMPJ+12"5DEE2H9;D]S)NR$
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M)5Q,IG+NL(9&0Y5Y,K&3'2^17\UBYQ"4LE56CZ"JM)F9U=^E^I[*>4<()/$
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M"NVR2@*$2[A%#M4VXM@$1<"0%CG[G>ZA5 /J'^?\M-)C4-Z<"$74(RCT2?D
M1!%)N_3>**%63C&J94Y%X1PF"JXK(-@$Y-S@&_Q$/CHWNXA;\MNT_!=+%=LF
M)?MIO<E*X,W(LY[GV0  IY(%Q0!?W*;A1$@!U=/2H/KZ!J.M%8JO)/@(=1'V
MZ)E-S% !>[$$NP?4(;CN8-]OP^>K*T)6EF>)&R:>R9RN#&Z-CO0-LF':#8HF
MV4+N/J(^I1#1WK4J<55'O(-X#9XS.D^1=/FI!,/?:+JM3")1,0 %1LX:*?2
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M^ING%78K-573.0F(69.D8%%3I@B9>#1,.Q0'K( _CHFK*7\"Q6L5U,NM9*-
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M1;OL/1T"Q$#D5]BW,H()-#D,?<70E$Q/7L!L/;*?X;Z4TN2'62+*=07*Q0.
M$3#< $ 'Y#Z@(E'1JDLJ>A+0(FNX[AG!CK'*X,1KZ;.01V$2[>@;!U '^0VC
MH2K4NQ$MQ54*HKTB@J4IB$;EV#8 , ;]/J7UZ=_\^BO,? )J.73S(U-,@AU"
M(BF ;@?K/Z_Z]297$*]/M/C8_4*A04.D0IOH((&%8#?@!Q /I /Q#XZ5L[EA
M75CPZ$E%3'$5MC%V%D.P&#;I#^$#[>NV_P ?GJ]YF$^P]#@D&Z*@+?S2]P##
MM_%OZB"@#\?Y--)5S36_[3]=&2;D;&]?5=H@!Q'XE4.4GQ$=_4/CJ340HI8@
M512*JZ*N8"(.FIUECE]#F,BHB@F/4'2.Y4PV#U^&JXT(E6=#Q$J1S)M!%0B;
M=F605$IS )RBHL3ZC ?J$=T/QU7J%,1["9M3=[H<E ?:F;-EFH%$>L063$YA
M/ZAN80Z?B(ZSPU+W."(*0IP.3LJ)=0B.XB( (_CZ'$=_75[&2FXERBA$C"T3
M(*PH-"OA4,8VY@,=1/U$#;B/Y.BXAKQ(=%,"[S(&,/4P]R" G,( *R/>+L C
MT[G^>CJ6RDB$#$.*J!$@10;.&YQ('H4 <M1<J"&PB.XJK;C_ "CHIFA)IN@B
M%5VY7"":IMW@E$Y4RG.'T[*!_" E*(?2/RTB.P<=3\4*BZ$Y?S$UB )C*%,(
M@D!]Q+U;GV#JZ1^ ?+2JH*2?92D1*"8BKU](A[L0*)! 1 =O4V_I_D^6DZZ"
M$Z+M(L4A$H)]S;IV]   _P"0-2:\2PX_RGJ3;;I =Q*  ;_-Z:A=.!]Z : :
M : PPY-YLA>/F!\@YAE896S,F<2T0DX1@LG$Q\E8K;,1U,K:9HZ6,E+G--6&
M<8LQ.4_04! 3&(4ISAJ4K[[?.QF7INOHGV7.>+)'G\SSPTQ6E2N37!Y7&6=L
MEUV'@^%E#C;C3[S%9&&7BOM]3>VJ.QWDJZOJM#U9S/5D7L=+/Z[)RB,DHDP_
M.;N1;)U24WV[192VXMV[<>XSE\7_ #_Y$\KLIIUKF+Q-4X^YR=X7M%QJ$[%J
M(!3I[%3+(-,AI$S%M^M;X^@^J9F(TRC61?(O%UDE%DDNQZE+E[0IF'V+AKH=
M ^LFB22[A-([4BAE@ Q'*Q2I%$P*'; B8J9A!,X )Q-L&^WQU5,-JY'$PY-/
MGGH7;_\ _(SG-[U4&;AMAA^^KY#.&X+N),)"+(1)-/<QSF%)=8=@ H^GQ_&J
M.]7,N4^WO]A0'BUS7C' _ALXIY@S#.Q-(Q]3\'5 )&T-6DH_;(0,M>U8&!27
M1B4)UZ8Z]IF2I;$1W)W0,8I2;GUFEJS$[2:GP6TFL7G6^BKEYI/$AR7@0);,
M(YPC62^/;0U,4#2B3N6XX/FHIM%^Q)(HK-;.T-VUFB2H ?8=C (!5NU9,KJD
MTJ2WP68JRA/<\_*GG.M2Q6]5?VI]B^+G2@5"():')\923-=Q!.5D[.[^V1]-
M=M#JHD!#K((=7U$WF7+;@$FG6QJZ\U]0SGQ3Q1;>-O*3S#9/SQF6\06([I4.
M*D_5;2]C\AXTDLY1,*T?2]WB</M,>1SVO3%-FY0J+J>CUQ-$)[(&[R!7%4M:
M0*+&)AH[C/&>1%#QZ\'H]NFN@A#\0N-,(5NY !41-$X8I;(Y05(0B"Z?Y0 4
MZ>Y# &Y1$!#43;N:II\MMYG%H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"D7>Z
MCE9,PN(T%3)G0D&ADS+N.E0#F2(4I'(I)&*00'K('H8?7X;5)OC[NPCA6OY/
MM,!?('Y(>.GCRQ,]R-F>V(O)M5K-MZ/BV 0E)RZ9$LL>T0%K!-F5>BYM2/5?
MR3QHV]R[(V:('=@=50I ,8M32HJ^[YF:PVZ17;AV'/S3.-W/_P \<DTRYS =
M.N,?!&;4=2F+<!1#F*;SF1TX5V:H(R<\RD)W(CR';G(A+F51>LXIPZ56(X0#
MVQB]<4>!7_AT>FBX[;SJCP7@#'G'+'T'B?%%;3KE,A$@501%1 _2/2F3<_8*
MW*=P8K-,NY4P#;;T^.K5.I9Q:3QN7YC7/NB+&W$>A8Z0;E,!NE,YREWW  $1
M /EJ-+0*=29:A1H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H#$#E#@NK<E\&Y!PO:EUXM*V1\69G/D5]M8ZY*5FP1-OQ[-%
M RK5^H6.R#!-%@*"Z'<$ABE4*8=PTTHC@9F)FB;[*:>9R^43]NSREM.5,FYX
MY6<Z)O,>9:;59%+BA)7N F+.TKE]A6<XM3K2FQL^;)X]><4>QQ\ Z;%0.11,
M2;)JHBF4^E?@$L9K,]FF^-YLX\:'&;FYCCD79<A\^>3\/E7(2N$;'C''F(81
M)4T?$44UYQT^-<W::V0;$07"JM3; (?;4NV,J)>^.WYR**M4]Y=6MZM[SH*U
MDI*)6+/)>Q$CU=F+-ZW=&% R@>X226345:J="J7T+E3Z1$>H  ?@/PU4X(U)
MCER.XA8CY6424QKF=&>L5)GFYV<Y7TIA=".E&1Q5W:N62H.6:A/S WZTS@(A
MOMHWN+Q=X+;(^.OC8GQ+5X1+U@S_ (Z#'P4(TI$@5J]08P%:LD+;H:);@X04
M9)H-+#!I. Z6Y2=0CL0!^K2?';RX$Y?#:O;Q/>R>.[C-8<6X/Q.2GE@8KC:[
MJ;K!=KKA6D-D?%A:D%;*V:42]Q[5O/5)E)%IT4#Q*.4:D<_;FW6!NRET)$/O
MVGQ+LX2XL8?XZUI6KX?K,?36LC./;+9IB*CV+*VW><D7LE(.Y.\6B/092=L>
MG<2B@%5?&64*F5,G5L0-3M*Y;DY.OW10VM"D6AFCX]<>WVL2N,,#F1\@$E18
M5[E#$,BCR<%9SC.-R"XQ)*V&M-Y5HW2;@FG:V #^K5@]L?O&*ZU.NFW@82W1
M?;M.F3QO21T_'YPA1!-PHLTXB\8&ZK1^^45?L6?^#5.3 SQ9=,7#Y9NDF/4Z
M.1,7ABB<0+\LI:NE"IZ&<(O"[E$@)F3$Y0,H*Q2E(02"8Q_X1 1*8-MMP_RZ
M5U-4<15DK<6)HRW.^[;- 78MD7+AP1)N<IB)@W5465*FFB#EPIVB (CU*;
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M>5P()!V ACBJ1/T+JW5)L3[;]A?G+Z.6>)G#OF)SFXN\G7T_5<D\3*0-"PG
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M$O&-F4PA>K)!)U/  3T$XKZR[R:;$=P<[+$ZE13*;K.4HB8! 9#79[RY-?\
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M-=I)14A!,)NVR+EF15PJV2?B"B>ROKI*JF5*7*1J;\CG NBS_"'"50X!5+&
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MZDW,K1,>6/)+S2K1A%-%7[X$C*G,DU0(910X@0H;%".YI1"WQ/"O"Z[S+;4
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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M;AL$9M.2I-0HT T T T T T T T T T T T T T T T T T T T T T T T
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M7:JS(RS=%-9)N";>)2KI5G'4LY2#J P; 81V^GU=U22HEM06KX4<Z_W#'/C
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MD(_<(<\,.H9QP71^+:U'D)Z=K,0I9IZMP,D]EZ[89^LR2*[!S7A49)$E*P\
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M',%:DIIU,1KA&"LK \2%6?./T0JWDCS1G9^\P7$%&Y=O0QM:B*;EX&4YOO\
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M?4+**)GJQ"VF$DJ[9(YE/P\LS/'ST;)) HRDFAQZCIN6H!V1+U;#Z  [E#\
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MYRW5]B[+>\O9!D.3W("=R!"@@D+=RV:(&!PCWBN7W4V$QE#R1]CFZC" "7T
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MH!H#%/D]&1H<5^1)0!DHT)A3*Y54TV:*C+W1:%,F9+M6Q3"BDZ1>"D8AR[F
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M(CQ1.'?%PJC]KW[ON1,43 <=B=(=(!N.I,FHCL*NT T T T T T T T T T
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MAYTQ]B!S5XO)=HC*(E:WQH^)F[3.1:23F46!ZZ)&$.@;85#MV:ZA1$ *!$!
M1W^.I^K?3:XKR[LIUK[/TTN7L<=T1(D8P%$!,5$6RR).D0(([+%5.H)M_P"3
M;4W[4):-7[R%<*G:BT7<%3,9!LX[CH'35%! 2)HB0'/>5W,=;I'82B ?2/\
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M\%U,1)D%UWV_2#K?M&[6RDC5S)%D^:B^F.PPBBO.?Y#X6%PCE:W.\<RE/?\
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ML3Y>,Y<?&?%:W\KAKV8,6<UN$]NY<5J'J6-4:@\Q2_K.'L<96'%SN;0-</\
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M<[>1U^5PID'%>'I6D+X_QI!0C.)CBO8[**0NFK%O P$>B<#9/6 2@F0.A$!
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AN@@EZM_S%?0VLVIMV=J-)S7>;6M"C0#0#0#0#0#0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm2226999d1-lc_evidence4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-lc_evidence4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#% +, P$1  (1 0,1 ?_$ 0<  0  !@,!
M       #! 4'" D! @8* 0$! 0 # 0$! 0           0(#! 4&!P@)$
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M0568\X?ZTM^A+]WI!)'G#_6EOT)?N]($CS3#X)JA]<@?=Z4+5YG/F&_,*?H
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M>+P-.)H2S;'4<LJ9)Q:<O,4T%SMP=.,L7DP/3E2.GW"DA:EA:$%P'<43;;[
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MWZ!OJQ21-8**&1*>633A5YQBWF5H=&P(Q9UBF=.H9RN[;-'[$J7>21(Z59*
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M&3!P<QDB^6"S5)RGYI#F\U,1*N4-A #;CX;==(&<,U4>I%ZB+7B$ZQEA;&L
MA?>3'(E_&5/$-)!N9PF2=N5B:4BJV:RG4;K(I4UG8'IE9!1(%G!&C-<Q4CF
MI365CF,:9%,I/$;GR=FYN%W]1>Y-[U,2+6;8U6-Q!A)6C0IS(D.-/<"MC9%P
MI$>=L07 H*.NP1'NW -3*62LPC'=KS-Y4X X(\H.0'+2BU5WEK"F2\@03>OU
MME'HUAW6$I]:-JC^2%*&ATG]+02;^8P,1!Q)>7WB[2(.V]KC^.W=@*.BQ\-H
MXX\2D5>C>IFYXMI\L<?>H TR%?[SA6#RNUQ$XQG@(V'(5I;JY&Y!8,ZG;8[&
M1YV391\-W1\4L03_ !J:Y%#F-OWA'*=0E.VWH+C<J,E<QQ]*U+DYCK/0X)Y#
MTKCY 99NT@UH&);8PDY<&D9.ST2[@\@TR>@$7A(I=5 A08$3*Y*&W:.QM,*.
MJ]6W$M&I5'OW^SP["Q'#_'7JF<F^*F,L_P IZLUQJE@OE&L$X8H\4^&Q8Q@H
MC8;)#1SIXN7!/P0-V18Y,YP3 VZ9-Q*81'>\,O$RZXX&VK@K$<GXGCM3X[EE
M9&MQS)&2-H;VJQ1K>/8,["S4D3'@7\<A&14$FD4T<8OF +9 "J;@4!*!1U-E
MP-4CAZ]N!/\ )S&V6;NYPK]&F=&F%RUV])2US*L+ Q\@P"30R9JVU*_C)$RC
MI-8_?^LEV/U/OL&CX"LQ@9,-Y>*AE(\9&612<.2+QQ". :,UI:2.!':RWD%!
M$YW223-03"4O:("/41VU6G@LV1<<5MW]W=0J<7<J_,K2J49(-W_S,Y;,WXL%
MDGYV[MR4@_"N6[(Z[EHZ0.?M426(10@E,(@ %$0D%G;;U8GJ=0HT T T T T
M T!+N4U54A*BH":@&*8!,0IRF /$A@.4^Q3^ B ;A[-4F53RT]46=C8NV$PB
MRDV+AJ=((M\U25C2K& Q2KF3\K<3I@/NCMN Z2@D]]2S>!XV7K<//4J6?*RI
MJ9;I*-AW"JBAEBUTXO/FKSCJ@4YB'1:% -Q-U'QT;9:3.9D;Y@_#>;Y8]WD=
M_D].[N[.[RO'M[M^GU]0DJ"$X4.*:Q$MTSD()B&,78H]N_=L(AL/:'C\FM*.
MXCEJF)S'F[V:"@=@@J0%0,F)1(H"OO@H42^Z8%.[?<.@[ZCQ+;,5)S4*- -
M- - - - - 45^@B"_P 0=,RG1NJJ42F. @S.H=(R)0Z@J05C=2]>H?4UI3$Y
M+V_D2%*K#?L/EQ]4Q\;_ /#B>B&5([0[%>XY*2:+(*)*'5;.4JHH;L.0QC*
MIY11 0WW .FC48XDA/XEA!]!7)8[(O'+-RQ4RN3_ $'99AR*#YB@*$#'\^Z<
MI',F;S/+%>-*4_:(#W" ;@.VCE-[PJI;CY6*5PCI$_Z'-2Y56*^9:D,WXGPB
M\R+A^RQ%\N5(@\7?,=RD5/FUA0(>4A,=WB*18)&9*GG8J85#N,<5 7#S S3O
MV[BUB'A.RW\2\OK 2]HM7H14;DC*66TMLK5VOX#DD)>IV.<K_P \'E[M6(0K
MA6)KC]A$NP>>8(*@\;JH"<3>[V;%"N7N%,'^&T8>\SL]1V;S[0,9\+LS8^P_
M?>1.)<7R,19^0^,L;DL3^^R<.VA*;(0,LRC:DL25?+P2B3]4S<B2K)450!\B
MLD*90K40\C*;JL^[\CKZ3U^XA94RGR6S)Q0O\](Q>2(C"T!;,(7"RWZ2N&([
M3C=;+;F:LTY7\G2LE,5 +HUR R1;-6:3%BX&)5,BB)TEC!E.'!IJE'MMN,@O
M5[Y"6_CGPS>S-%>MXVPW[)>,\.+S"IT1^8&]YE'#%>2:"Y$R*;M-)J(IB(#[
MO<.P@ ZKHX0JU+B9-7_JL<',28F](QS<(@UJE+M593BK/W>XO,AY'DAO%NM&
M<<.P-@FUXM[:7%;:,)N?L2C\B+1H@R1*8I6Z::12%"=@PVV1Z/U1\;R!./'I
MDYP@;79JI9:'EKA=6[">%M-H1A_Q1GK;B]DK&+5B+E2TJ97DPEE1!668O#F%
M8"$, E(!=-SV$221>GU.,MYHPKF/C9EU3CQEGD/Q!BJ596N9([&</<I67HQ)
MIVBFXO<W"XX*E;8V,A89HN[,^=D^!0!$YD!3$BFIC7NVVJ*VN'CMGMZS&FQ*
M<;LE>CYZ@V0.*^;KW<:@I$9(S/6X=CDJRL+;BF6;4P3U:GRLE(RR5\A'@2,,
M[.+99RFJ(%\-*Q1T*XFJK/Y%EH7TV%<P^DY@7EQ"9US.ER=J7%?%MFI\TXR;
M85ZA'N82KLW+6O.XEG(EBIEI%H]Q/CCD5F773XIVL8PB*$\,25M]FV9>#FOF
M.V9R]%/@)ES)CQ*9NF0\G<*U[*JW9&A4I^Q2;$DC*SA61DVRD8]?+(KNEV9
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M;.TQ2<HD63$Z*@E.&X"=NLFX1-TVZIK)%,'U0TEB$PFU;I&5.FD0AEU/-6$
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M^08.#X\95QU0ZQ8JV7YFFF#!"=Y#L&IXIH@FPCH9M*%ABF5;1YBHH_#D!0I
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MY?/FX\WL2\*:AZBM5Y6ST-=J_#5>YR6(H2$C6N&WJ4FD9=>&"./'MW\PL@+
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MTP9%F7!_6?V/]3J_J[QD2[C[17^PNOTA=!F2T%^\D/\ P6P_!4M0I5= - -
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MAZM^R+>>FOQZY3\?>9WJKYGR=@Z1K-5Y>Y3KV1<2_#W*K69\$36I[,3^6++
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MT\M,1*82$[B?:#VEW)OX]H[;EW^IH#D2$$1,)2B(E$HB)0W$H^)1';?M'Y-
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M8 *  &_4=@ -@W'QT !-,#&."9 .<I2F.!2]QBD[A(4QMMQ*3O'8!\-Q^70
M$DP 0!,@ 8PF, $+L8QAW$P].IA'Q'0')B$-N!B%, @("!B@.X& 0, [AX"
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M^IU?U=XRDEU_M5/["Z_2DT#)>#_>6'_@N/\ P1'4"P*IH4: : : : : : :
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M,;<MN)%!(XN;9GD*$S--341%RXD:R;7&V%,GW0&KLPS#8'+HQZB4Q"[&$Y@
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M<J*/VF>]2P*MC?U"LB95A*G/.8&VX4Q^U";>*HK1I;@$];U"L6HI(IG(G%H
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M8DQCB_-V4OQBB;G'X3QQ;<C6>OU^39'?MT<>UJ5N;U%=4ZBA""^91GEE,!#
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MDOSQPC99AE 0D-D2>;QEG=UXM[0Q^G-U^-L\.#ANY3%0)<'"*JI?- JIDR@
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M0ADS13([<" S.@0\>5-,Z()QQP S!,R2A"'3.FT$@&*(!L(;:/&2I0H*KJ%
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M CNN<3[!OMHFHVQ*Z[9$Z[J#!>293*T3&R+]B=N>(D'C5,LM%"!]E&C1^@"
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M[<F6,P5Q%Q%Q[F)J=Q[!2;&8GXMO%O%I2QR4\1JU1435(VBR2"JP1Z)#)AW
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M$XF'SFR  F=N9LL0Z!!!854CB)TC *@ )1Z@.KC4F%$5S630T T T T T T
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MGJ#9;GH7%G#BN9C,T7R16LX8<LU];P[=6-CPM_T7WYO-@FT67E%4?+DY98!
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M='2;E]A,%5#H7IM_TQU-._FH6[X74Y.(![P>&N8MMO,R.'@&AD: : : : :
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M@RL-5A6!01[^AP#8X) !?O9!$"&3,;N+N/B/7?1J,3HJ^R_Y%1>DFM0HT T
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M?%+CQP_H:N-[#FODKAV#J]TQE,,;/,9(CW;=*O/K3DV:M2S9SC*K056G$FK
M2RDHW:.#2Y1(W7,0IT6?</&#<APUXSSW'7%415LC9-LN4\LV08^S9"OSF35=
MQ"EE32*DG 4BM,F$56(7%E68K&BX%((ENX-%H-E'HJOP.L+%<0IYJTVVX[ZF
M?&H:&@+09N$AJ.]0.O%MRK'#<\JD_50 "!N/:$>DLJ4X=WB(;:JWDH7(:J=J
MR2?V_G"\7*HD&R1"=Z'N& X%, F[PVV#V#H]Q%[_ ,BKZAH: : : : : : :
M : : : : : : : : : : : : : : : : : : : MS6@_CQD0?^)6 _[6E='[
MB+-<2X7ZU^Q_J=7/O*2[C[13^PNOTI=-Q,R7@_WEA_X+C_P1'1XA8%4U"C0#
M0%NK4A(.6TXS8%=LUWD3+(QZR)FP-322[,4D7YUCD,+9TV6,F! .8"G PCL/
M8.S*I)<QEM)IHXH8-7P1QYO&!^1V%,L6'*&;+E9+-D^9K%8R'DB(R0^<.596
M.F[/DRHH35/JR4@Z,=8$$G<>5LJ8J(D()RD&I4E;<"9QMMQ,M/3%PGE# /'_
M .CW*,:O6%FV3,N2M I3B75F5*/B.4R#9GN+:2=\[>R+Y<U>HKN/;B99918!
M;['-OOIE.0HG$FRC4-''<40W P"'7KN&W3QZ_4T!I1]2BALLZV9GB^:Y%0>.
ML87FO-*#8!DH(7<?5+)9G;EA#N83)!&"M:Q]>;,83D8#+.R*KJL0,S* HN!&
MPW&.?L&$^LP0F.'^#<MN,U0%@Y2-F^ <2-,O1L%)N8KYHJ]">72]4N82)=LN
M*QC:K%7B7=41:L&X2"3U0%U"J>:H)1+8N>5.\D0Z3V&RGC%QWQ+D:IY4;Y<F
M:[EZ\WW+;BP91AXU2WT=:IV6L2%X8T6*D:D\E(K(-7G$ZU)/4URR IIN3(JB
M!! 2[2&EAQ(G7@958IX=<;<%V 9K$F-F-1DT&TL!V47,V=4ZCBSS:DM,O@;R
M$X\*8CA])KF5.)1[3J&Z@/@C;NJ*89>DS!9(E;M442)BD4A1 $S*&5$NYC&$
M/,.8YC=1]HCJ&D1C[[DV ?;N(!OMX>.F1JV(<[CS-E(N:+EO*9+/S?-[X2-$
MDU3&=F!N82M2^5L?N<"'8&P@.YNFN/4;=D+<=2^V[FPI^1JSY'\(&/.[BQA/
M&UW:VW#H1$K5<ER-88&!61J:C6I6*&&@N"RC>2<F%$]E\PZRO>L!F0 *GO"!
MNF]"_426%V,O"N7M[N)]Q]M^;]-Y?&MU,.Q)+DE*ZB^:72%A&/Q3D6:IGHJ8
M1985;82M4M;;K6$;RXN391^<(Y=F=5&323+YZ+-@1P*:,B)-R;]P]0W#7C7]
M!J_5:=M[^-UAQMQ/KNH_='K/_+=-SKI[+>6V>1PDURPXJN51B]YG'@K@7@SC
M]BY/$M;J:4U3HV8=6-NVL<6TGW*<@N\,_4(S%ZT<*B10NP=I-]S"(?;;Z[%G
METIVNUQV;9>D^3Z[[FZGS'46KJW?UCIBDHQK%,9[BMY9X:8&SC&PM<R/BJ+E
M(:I_.;VK-TV:D/',CV)!LW<)*-HHS AET58XIQ 0$2 <-^@AK3\HTKE#M<=_
M@=3I.ONZ/J%UNEJ6?4K;%)WM]CFG90\W:?3_ .+UJIE5HDUB&+>5NDIN6U:9
M+/9DQ&S)\9H:23$/G0!*=46*7;W]?=Z:YK/*.GY5%KE=LOM.W=]P=7?>UJ:B
M:>3B$\HWIYXEUJGQTQ3!4ZN4TF*:ZI!4N':UBM1TQ 1\PO'5YHBFBV,@^?-W
M+HSMTFV3\_[X*@&*'=MKOV=#TZ232CO]/'T'D:NO]2YJZ^V6YF:3N_H[O61+
M?Q5P;?\ YH>6_%=5E%(YB2)8H*0+,P0S-%N((M6:;9 B9$(Y) &Z)MAW)L "
M._5?TF@[I5JPX^/:<"ZS4T/ZNR[X5AA7\\7N91)WB'@F]OTT[IB"I3,?"14%
M7*T5["J(*-ZS%Q,<JW;).&9FHMW2$PFH.YA X!N Z/HM%UA;4);YAK66\JNE
M5?>W/:7'4Q)3'HL/B\;UU0[&.:0:C=6)8JI)1$.X,X@O)=/$U0=F:*E(<2"=
M03;=I@$.FM?RFCC"PXF=+K-2V]-W?JF7Z<,B _POCV9GS6"9Q71IA\I%LFAY
M.7I\:^F7.SI^)FBKAPS.1N@W*J!B]H$[3*&$1V$-N.[I[6^96T]?:<G5=7=R
M1;?+3<)52PP><S26\#UKG'M7?*M7,E4(AP[1."I'RD-'K2!GBG4[I=R@U]Y0
MPD 3&'IOK+Z9168])TM#K.HLOW8;N)*NL<U%Q(%E)2DP<A*(KI/!D@@P%XHH
MV$2M5BKMDB *R *FV />Z].F^E_1V:MRNOMM=\9S[(1Z%W4/5M2LU.73W-JD
M]M3T@0R13"]&*.KVK.9$!\L@*N@>F4.+-PU4+\1NW%QW@!@W Z8>W6/Y#2F8
M4R]^9U+NIU;/AMN=%'A10UP7>>0=XFH#^40F7&/(!Q)-WGSJA(&A&:,C\<*9
M'B8G>>017O3=CMN8=@,&WLUE>7:4RTH[S/\ BG76KD5US41@L(G=W%=-6FZP
MJ>=#&\T".BIBHS:&(15-(CA)4BJ"!1ZG7["CW;B*>P>&NU_(]-2BGL/5L\WU
M[>7XH4VS%SPP>+X%J6?%7!3&R&M#?$U/)8W4B:9+-?B\BH\2=IB@("=PJF?R
MSG4 #  [;B7</ =<*\MZ-*58DYWOCQ.U=]R=?=;R7:K=JMA_*IG/ G8_CCAQ
MHJE(H8QI+%ZD4I"OT*JWC'YP(DHB!%%V[=NX.!RJ"(E$1((@ B&X!MB[RCI7
M;RVV)M/>_?@;O^ZNNLF-6ZU//X,X>[&A;ZD<(>-N/K4%RKV+ZVSM7FR)E9I-
MBX*(E>N!>+J?$>:")!,HF7KN&P^.NI;Y5T6E_:<O,M[:]IS:OWEYIK*-.]JU
MYKE;]4>@O=+T"KR]?D(9_$1CB,F(^4C7[)8KDWQ3>1%T/DG=M5B&V<IK!V['
M 3 8-O$-;_DNC=G*OIPTZ3GE@YW'67W)U]NM]6[4U%J)VN4[8I:K6H:C?D8F
MTSTS>']*?2D]6L*0+20GT7#"3.C)V@2+)2('!Z?WIPPB41=' W78! 0Z;:ZG
M_P!L]'J7/4O5K=RSGLR9ZC^_O-[;59I:EUMEKR5LNLUE-$]6O39XE4\TX> P
MY$1SBR-%8F;40>V8P2#)R"A?+4,,P?L33%=01$HEV[NNL+[4Z)5^%TXT])R/
M]Q/.&U%URM496UWS0I]3],/B-1XVW1]1P]$0:%V8I0]D;IR=G4^<6*!EU")B
MLK-JBF03.3]2F+]?6K/M7H=.Y7*&U7/WA_N+YS_$TN"M]J*=1_2UX>8WB['!
MTO"L56XFYM"15H9H3-M>DF6::Q'A?/.K/NC-RBLV ?=$G4P!KMV>3=-IN;4\
M-H_$U;^XOG'(U<W,TA+#*97J+Q8*X7\?.,\C*26&\3M*DYG$?A7SED]DG G1
M2 A2 8KQ^[4$#>27J;<WRCOKGT^F>A?_ %=K:P_$^<\T^Z_-O,5RZK^%NO+%
M:F6D."@)N!5261$5P "*I"F/:1),A>P1*7O)L7QZ_7UWM%7I/GQD^=MU=35E
MZDS+Q*QKF-#0#0#0#0'10.Y-0O<)-R&#O#MW)N40[@[@$NY?'KTT0<Q3$QUY
M$8:KO(K%&0<(VU%\-8R'49JOR<C'N@0DXP7C)1NDZ9)IC\1\2'GF$@]IB;AU
M#5BG$SZC3W!^C!:4++5&&8^:O(;->#ZC+,Y.!P/.&J!:M)'8[C\!;9-G3&$^
M_B" FD8#NWX[G3 1.(CUK6>18RS6R[#?55FK5DP(V:%,")&S(4Q46!0_E&0'
MRB^44W:D0A V*(% I@\-P#1DMW[]O ] Y XHG\M,JQ]R"5,P]I1$JA1W$=P^
MU -_R-18E9YFRMIUS#2#: 72;3;A WPR[EN95FF<2;%(83 *(["'MU:$-%.<
M>17+["L5R]Q:A 89S=ERL85LF=J0CCBE6"38UU<D;-QT'3<@Q;9X],:P3HU(
MIX]NN4BCU917M(JEY9"Y<)<"UE<=I,;L.>HIS0S=4L)8OE<3<>L99ZM67[-5
MI2G9.I.4X5I3ZRQK]8=4F3C*.>RQ=XA7TJ]>S13JN?[G?E0 &I?[G<:M<R-+
M+';9FSNO<W,03O$ W-J]Q%:Q["#37I#.Y^4J\782/$4VDF\KM7L#TZ*CIFY<
M,2#\.1145_**H0!*D80?#=CWE5SM5.X]SP%O^9,]8G@N0V4Y*/C8C/T56\T8
MDHT.DFF&.\>7R(:V6D5L7QA6-(R*],F6ZDH=959!P_!19B"37RR%J3CN#BCX
M[;8&R#62C0%E.03Q['XKN$@T2CS$85^7>K+2*J2*3?X=H*B9RJ+*I$*81 ?;
M[-,AF719+'4,0RA"B7M;BDJA[Z"AERJ&/Y:A!,0Z8=@=0';PUJ=QF,&5K630
MT T T T T T T T T T T T T T T T T T T T T T T T T T!;JM?Y[Y$
M_.UC\&E='[B+%EP?UK]C_4ZN?>4@+?:G_L3K]*71D1+0?[RP_P#!<?\ @B.C
MQ"P*IJ%&@&@/(S:[X@.0C!*5^DFX%ND=([YJ9=5, ;+OVJ!VS@$?,3$-BJD$
M0WZZJPKZ2?T?1MB?/_R1YE<^>.EW7J>3,Z^F9AYK/OY*3J3&^1>282X34"W,
M)DW+TCWDHT;NF*"*Y <*(-42E543\.X %+3JE,[(DRDK6XC+UP;,/3RSI8.2
MF!8')]DNN!\BN_GZVPA+%QT7E'.-/.KDY*UU96+<RURO3I9PJ#,Q5 %^<"F,
M;ITZ&_$J36.!G]J%)(5-SE*8WEJAW;)=Y0*;J/9^5'<#:L4)VXFG;D/@_E1D
M3F-C7)\C4:)/X"Q&T86NKT_\;4:DYD<APDH,FK.6[YU3FV\NR8 T8"R,@@S%
MH(N14,L"I 2YM-KD:X_E^!,^)A_D_P!*[-&6+G=&#]3'&*:^CA_*-":!B>*G
MXV-R_)W2]XSMK&9N-:L5MM+@6D<:AB0Q$7"*J'QH@*H[]>1W6W?&_P BT3C=
MW]YG7B?AU/6N Y+I\JVD$YEN6%X@W]ZIU*DUF$'66=2>V)_!'@IURXE5WJSU
M,R!5$1'S$/,,4QS"41'-S^!.U42[WVEEYXM;06-]+#BW@^C8RFLRQK%5A;ZW
MF7E'CR&<3$X]EHN!BJMR=R]CJNMW:)UT%W:IHV%:D 062+WF[2E#IMUU/"/3
MQ),3*X<.XWG1G?\ -[43BD8XI 8YD$U$D3F,(F,=)-5590B9Q'< $YA !\=0
M(G]"E(L ;P<N7L\SNCGA?* W8*W<@<OD%/L/8=??L =AV$? = 6HQ&W2B,;4
M-H-:7IX,:?"1P5&7?B_E:L9-JB(P$H^!NR!Z]:^1N=4$4>[R1]P-^E2,W8UQ
M+THF[T4C@8A^]),W>F&Q#=Q0'N(&YMB&WW#J/34>)HBZ Z'\/M>[J'3_ (?R
M-"K'<6:R7F.DXI2!U<))S'('(<X"DD"@=J8D P^]MX=X:TL)H<W+S9GNJ_/Q
MMKCDY:.5540. "!# !-]PW !W 1U,$1IX+Y3U" ;)@ I@EU-[@#W;=1Z[[!X
MZF)Q/'>11'8-QT"4DN*NYRE^4Q0^R.VD')R1;.<$SH<0T T T T T T!)/@$
M4B ']=+^E/\ \.N;1I<^PZ_4?(NWWD$Y# BH & @B10"G,&Y2CL( 80Z;@4>
MNO&Z]8W+?[&=GIU%#5UPRSID#*/(CE;0[9,MI.$QW>',9!II$7*)4&C>G'0$
M/-=N$R@7XXQ?=*&O)Z-MZCKW]YWNHTW;8J/'#N-J+8G8B0NP!MW="^ ;F,/3
M[.OI=*EB//2A01]<A1H!H!H!H!H!H!H!H!H"$OMY*W=V@7RE.X3CL0 [!W[A
MW#8NWC]30%HLJ4=7(-*EJDA8K94E)ADZ;(SM.^%3>L_.2["JB=ZPDDP$@FWV
M[0U7)%'K/CIY%U6L80S-:<%1O)_U3<HS5">MI*RS6/W%#<0S*RNRO_B*HPF$
M\(2K6$BP.T7[$717:_:VV%01(819Q^(R4]V1]6O J4:3O$_!D]&V"]6>,G,5
M8YEV4SDQ]&2EY=IR5+A'G?89*'@ZW&.WPD6**ADF+<OFB<>T $  ]Q57L,P]
M0#0&E;'_ *4<31+3R#FW')ODC=HKD2\NK7(%*L-QQVK1FX6]@A'(69HQ9XP9
MV-K*TF-*1..15E%4=D@,8AQ,.]4JFW89;M>>6.946GI0XX(V;V(^=.0DAF%M
M>V]VD,UMIJAJY#<.8>-5C*S4GA4\<?-Z5)B&[]ZHV;%;$>E6<*&.Z.4Q2E0S
M5)W/*/:1LL<%>/=-X;TNDV6%E+)3N+F/COZM%V!9G&Q-LDVM6>0["6N++YM
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M  &'RS  " F.8QAV#I[QAW_)T>)5@36H4I$_U@Y<!;INP&->@+980!)<!;J
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M)?B5$G)G D RZRI2(>>F1380[""*R2*ABB!A\P!* ''M'V:/<%.9Z/4*- -
M- - - - - - - - - - - - - - - - - - - - - - - - 6YK([WC(GU"U
MC\&E=5XHB4%POUK]C_4Z?J[QE!+N/M% _P#@77Z4N@)>#_>2'_@N/_!$=0+
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M0I2#L;RC]Q2[CN ;)[[=!#?ZNN_;_56)/(^,UK^;4=Z<J=Y."Y*8/+%0@F.
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MM3M@*#@1#8X*K%$QA'H4=^T?#5D$,(IPGV>4= #F="9RNH!E5EFHIJB)1,)
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M-MC"95+['A_6F*0YAG. H@4IC" 7+,&X@ "(@'_H[!U';0M"PD1E3U=Y7/\
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M(YPTE5UFQX&_V>A6R9249H.56Q2&D<<,A[CE*("'3Q'56)&LEB7>4;F KOM
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M-MO29"RTHPB(N3EI)ZSBV$2R=NWDA*N"M8UHW:H**K.GSE0Y2(LT$R"=0XB
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ML/*N,.35MJ$CD*M,'L;6\BPV-&$@3Z1(MP_?23-Y%V9!H*J:[4Y&ZJBR8$
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MPI5Z?G>0EY2(F0P%FZ>CHZL9'PS,5N"@9F/:(25FDT#R+LZDB= R*3=5>.W
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M\ $YS1[10>YJ8PN&1DQ-V"FKL?<N_@(:@2*QH4: : : : : : : : : : :
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M-5/*>4,69"H]AX^\@L@5V?HS"M95Q_0*W9)QQ4+,M&PDNL=1HJWC"A*NBJ-
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MU-/W1)[A?<'Q)[H>Z/U2^&CQ*L#OJ : : : : : : : : : : : : : : :
M: : I,LB=PB5$A"F\T3)*"<W:0J*G:"H]"F$5.W[7V;ZJ(S2CE?EMS>IG,W%
MO%ZMX:P+(Q.8H#*M[QQ.2>0+#%OJ[2<22F,F,_#V&/1H<BDM.2B.4XTY!163
M2 [)3<!W+VHBF7N(JU>/O]9<^+]1_%T$2ZMLO+Q 2;?->8,0P!,=K+6-2V2N
M'+C=8%[#O"/VD*9K;(6'I;IXN3=9(/@'0%/T()BC&LE?P[HR]7M\3V>/O52X
M<Y(:"O7<FOFM=CZU:+9^,DVP%FSE6]!0>.[I'H*'<@8S^ 4BG23DNQBE4;G
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MD5-/QSPVXF["/'=FAOYFX%$HBMV"H8Q3F*8YNQ14OWPP=WVP]!Z]=&:Q)S4
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M#WF('@(^&G',$7R$.GWE+H8IP^]DZ')N!3ATZ&* ]!\0T !! -P!%( $3"(
MF3J)A 3"/3J)A#K\N@'D(" @**6PE$HAY9-A*(=HE'IU*)>FWR: X^'0 A4P
M01[" 4"D\LG84" !2 4O;L %*  'R!H"(0A$R@1,A4R!OL0A0*4-Q$1V*4
M-Q'?Z^@.V@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@.!*4WVP
M/00Z@ ]!\0Z^P= =?+((=HD)V@': =H; 7ITVVVVZ:88 A_"MN\ROPZ'F&#8
MRGDI]Y@$P&$#'[>X0$Q0'ZX: ZD9M$P[4VK8A>]13M(@D4/,5,8RI]BE .]4
MQA$P^)A$=]!PR.YFZ!BE(9!$Q"'(H0ADR"4JB9P.0Y2B78IR' ! 0Z@/709S
MF"-FZ?G>6@B3XA057'8D0OGJBF1(5%MBAYJ@I)E+N;<>TH!X &@.WE)=?O2?
M4-A]PO4/D'IX:LL0CK\.WW(/D([IF Z8^43<AP*8@')[ONF AQ#<.NPB'MU
M<F11,42F22,43=XE,F02B??N[Q 0V$W=UW\=]662$0Q9,S#W&:-A, G$#"@D
M(@*J0HJ#N)-]U$1$AOE*.P]-)93DK-H50ZI6K<JJJ)&RBA4$@44;I"H*:!S@
M7N.BF*IA*41[0$P[!U'4 ^$:["'PS?8507$/)3V%8-MEA#MV%4-@][QZ: [?
M#M^GWA'HH*P?>B=%1WW5#W>B@[_;>.@.2H($ P$12(!S',8"ID*!C*")E#&
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M4/BVG[J;_MR?W6D,2A\6T_=3?]N3^ZTAB4/BVG[J;_MR?W6D,2A\6T_=3?\
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MEFFW*JT2(J?S""<7!7 FZG.!3" HAMM\NN:[RCJ;=%:CMNEIM[J1[SCT_/\
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M'_P0X_QY8/\ *NDL#Z+J/_@AQ_CRP?Y5TE@?1=1_\$./\>6#_*NDL#Z+J/\
MX(<?X\L'^5=)8'T74?\ P0X_QY8/\JZ2P/HNH_\ @AQ_CRP?Y5TE@?1=1_\
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MNP\S1^=]WM.VN0[0U2#KJ%4Y#KH'.9S[=,BOYCC5,C0#4*-4@T!4X7]\X/\
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M +6_^E[SMK9VT-4@U"H>P= L&-4@T T U"C0#5(5*!]^3AN@#VRQP'ZWSG&
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M T T T T T T T T T T T T T T T T T T T T T T T T T T T T T!
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MP-W 8?XI9'#W=C!_HL'M'6NG_:3[QZG4>GT_1\^HE+7U>G5*5EZJ6+1XW_\
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M!^K,FTS=Y"F #!OOT,&P]!$.H;!\FHPL#OH4: : : : : : : : : : : :
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
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M_0,5JY IPV04$H%.;?H?V:^[^V?OSS'RGJ+;]/XK(CE:4)<RP;?#<?E?WO\
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M N+/IXX\P^@SFI<Z%CLZ907.[7!42HJN6ITU!;G71\T=@6$-Q*7IK^5_N/\
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M/Y:J/_>.@'TI\A/]V0G\M5'_ +QT!R&4N0?^[(3^6NC!_/8Z [!E'D%[>,I
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M $] .W\[^A_IZ =OYW]#_3T%3G8/D#[ : ;#]3[']/00AM\NP_D?TQT V#Y
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M/^GH!L'R!]@-*@;!\@?8#2N]@;!\@?8U98..WZA?T/\ 3U <]H>T"_8V_HZ
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M% /:.@.AETB"4IU"E$X")0$?M@#;?;[.D9C!QF<&71(!1,H4 .&Y1WZ" B
M("'LW,&@XD;0%!E8YN\6345( F!(J8&%,#[%\PQA#J8O3KKI:O\ -KJ[+]!W
M_35M8<*:^DX-?0Z?5MG55O-O:EP8UY?XWT3+4,]@['#QSU)Z!!*Z-'I*.VJY
M#JBBX2,*I3 = 3[AL8!^KK]#\F^ZO-/++%9IZNK;;NYVLEP/S'[E_;WR/SYN
M[J-#0OU7'Q/33:J^-<=Z+/8(X!XMPF>3<L&;>?E9-8J@3\E%$*^9D((F(@B1
M5\].*93'WZ*EW$H=-<WF/W_YWK)6/4UGIO%/5;GL^$\WR;]H/MSR_4>K]#I[
MM5?+<M%6\O&.9^LS,C:U&L0%3L:@@*8"5(C<I>T#&*(&#WMMNGR:^;U_,-34
M4)W<ZSD_1^E\AT^G;^"WDW*U+VGM&:S5)(4BK(^X=8.TH]NPD.;N*!1V$1)M
ML.V^O+U;G?=S78L]K2TUI+DMPGUU(J;UH<PF(N0Q1VZ[B'4QP( =0 >IQVUP
M6IIMLYB9!=(1 H'+N)Q( ==Q.4H&$H?*(%'?6P1= 0S*IE 1,<  HB [^P0'
M8?J]!T@DHZF<(E,0IE"@90_ED 1^V.)3G[0^KVD$?R-!*(:;YHJ&Z:Z9P\U1
M -A'JJCW^:F'3J8GEFW^MJPQ*(H+I#V^^7W^_L_XW9OW[?G>T=0LG3XMMN<O
MG$W3^W#?;MZ /M#KT'5AMQF,IR(Q#D/OV& W:82CM[#  "(?8'4$S@=M !'8
M-Q\ ZCH"%YR6PF[R[ )2B/R"<2@4!^N)@^SH"(4P&#N*.X#OU#Z@[#_-#0'.
M@&@&@&@)9P\:M0W<+IH^XHI[YMOO:11.<^WCVE*41_(T!P@]:.CK)MUR*G;J
M>4L0HCW)J>4DMVF 0#Q26*._AUU8:!-:@&@()G")#BD90I5 )Y@E$=A[-P+W
M?6W, :#.#J+ML7Q6*'0QNN_@4!$WL]@!JM-8A-/ Y3<H*]_EJ%-V*%2/MO[J
MAB$.4H]/$2*%'\G4@)S@1] - - - - - - - - - - - - - - - - <#X#T
MWZ#T^7IX: LY28AM&VK(C%JDHB166B; [ "@!%74PG*.7"1"@;[9)4@;C[?D
MU9\3,4X%V/+-Y'=WG_JWQ6VWO]OF^?Y&W=M]K[GCMIF7(+^!_P"PNOTI- \"
M6@OWDA_X+8?@J6H4JN@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@++9YMUUHV
M-+I;:%7HRT6"K56;L3>&DY9S#)O BXYV\%(CI*+DT1,8&X]#E -5..T-2HR,
M5_3)Y3WCF5QBK^<<@U6*IEBEK+=X5>!BIL\R5NE6K(^@4U'*P1,.B8ZGP(]N
MR9A  \='/=MMWF4JSG&WN[C8CJ&AH!H!H!H!H!H#$3DK9>2<)<L%,<%T.OVN
MLREZ4)E:6E)UK'2-=K*</* 1Q&1KR(?I2'FNSI]YBKH*)B4 #<##M:Y"5-3)
MUDH07ID1#S!(=PJDZ4-W'$RACBL@3?N$ 2,82]![>TO31^GV"9[/:5[4 T T
M T T T T!*.3JD.EV]@(B57SQ,)N\  "]GED A@.(COXB&JO21^@UY^HWR3R
M?Q#XDY*Y"XZI+7(_T85]_:+ QE))E%O$HMNM'-2D:DDF;]NH8RCT1ZB3;LT=
M4%C0OGQ'RI-9YXJ\<,W2T:G$2.8,'8GR4YB5'"3HC92_4&NVXZ1G":1$Q\L\
MF)=B$ O3H&VKG6IF$\*9>E&4*0"":8"!2B!" ($ZD 0*&X$Z%]T!\.@=-9-D
MJY2%0Y??$H 7;8 W]H]?$-5=1IZ/PWNK[3BU-*[4<K E@;$W^WW';Y-OYN^I
M_B&A,*[UF/Y.[%D8J1R_:CN&WR#_ $]:74:&HJM,?2U+'0Q"Y56'D35L?D?<
M:JO!7/("EOBB3$79Y="*9L:<HPFCNS-5GT1--?-*_(T "IIE$P"(]P;;#PK5
MI*P.WU6NK+?@BBWT[6L/>>HN658K&]2A+;DR3:Q\L^_%:/;1HH1QUVUAFUXY
MC*-(I_YB3MTW2>O%B]")E  ]P-MM<[K;3/?4\VS7=S57S3E'?7&#!CF/S<S[
MQTY+\5L71>(*Q+8CY Y;BL<-,DGNGG6$))Q5[/:W$<^K<K6>YLU10KAQ!9!Z
MHIW@!0*!1$0C2X1MZ#UM335N@M7]7-'9LL^XVZ->Y0R1U.TZA%=S@)>X4!.B
MF/8B<P )B 8WB&WB/34='3,ZZ3SDK&H4P"]13FA3^!W&RWY_N2[@PPS]C UF
M+;E;*KS5EG%C+,(XA'BI&Y2C'1CM01'NZ$^U'V522DJ3([#^5:SFS$F.LO4Y
M=-_5\D4NJ7^ONTE"F4!E;X!A8F2)"@/8846$D &*!MOS.X=0*(E4J'.==O8:
M^.47,[,F#.:/$3!;+'44KB3D+<)6M.[H>:C$9B-DHVCVJW%.TAE8T[U<7SZN
M_"J^4X()4EC&'<H"45$Z;=P4-*??Z3;("A!'[Z7L\A0Q!\.@KI ;Q >FX*Z1
M6@E8LQ8Y)Y#RCB?"5SR5B>CP64[?3X1]-MZ38;9,5MD^2:KR*JJI+'^+DY)D
M+Y3<A?)%GV%$![.X!W&J4FMNWO\ 82DK?O\ 93=[2W?IE<I+?S)X?XZY 7JO
M-*G9[DO+_.5<8O49)K$*,7!$/@TI!)C&"]*F._WPZ"2AO:4.FHW)5Z3/W4*0
MU3 5)0P] *F<PC[W0 *(C]J F^P&^@,,*?<>44AR/R_5[KC:FQ?'& @JM*8N
MR#&W>2=6&SR3V!B74HR?P(5!BX9@UG554% 5>JAY11$@&#M*-F:>!'C*Q\?7
MM%#,>/$XLFXJ 0#F3[S FH=8A1.(F$I5%")G,!=]NI0$/#;481.:%&@&@&@,
M/.;^6\I8*P+<<G83PBIR R7#-6+>&QLVF8FNKSH/)!)L0%YJ8*+)JP8J+F74
M\S<O:4W0=]54[2.N&WX$/A%R+3Y8\?<8<@U:!9<62N08F:;2M&MHQ[B=A'-8
MLDU#*LG3F(?RL<*97#8ZR1RK;G26+T#;8#:R%9@S'U"C0&L7U1^7&6.$_'R<
MSYC[%]>R+#5B;QI"6165M0P#R%2OF4Z70DG+9!6 ED'(%5M!!V[R#UW#KK2;
M2<8QB8N2;4NFX]QE/)7)*8PKA6\X#Q_6[;.Y!<8EL]Z:35YDH)*N5*1D*?.6
M%S&@:LR:<DK\T'=I&*!$!$ $P#X:GS*"_+7!^)F=!KR*Q4EGJ+-"1<*-5Y!L
MC)OW#1J=5NV%5!HJX9-Q7.FE["IE(8=MQ#<=CF(%)D]IJ&AH!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H"W-:_P ^<B?G*Q^#2NEQ%@^TN%^M?L?ZG5S[RDNO
MX'_L+K]*30CP)>#_ 'DA_P""X_\ !$=0JP*IH!H!H!H!H!H!H!H!H!H!H!H!
MH#![U#;?R8IO&*\/N(T;7GV=7Z/S127=IEZ_!P=?E)!)5%K9)*0MKMA5"LH9
MP)552/UBH'+T$#!OJJ".8-.<QS5M>!/4!X-8'JO*6T9ZQ3R<;92IEP6-46,U
M%QV08Q3'[NN2<#>8.,?0MJ:O&#UZ5X6NOY%K"^2B+SX47[;XEZA*[RB63D'Z
MAUQ]8K-?!^C<AJ?6Z1'\2&.4G#N:J\:M(TIFXNF.XE6:I[6-KDBSE;0DZL*+
M=J$H9)BLP7=BLJ#T&22J*PPG\/Y?D7\X3<GN06.LV<^>,G*/)DSF=GQ@KT9E
M&OY:-7F%/7<5IU6XJZ1L(\CH9G$K_.4A&R*:ZY 0$B)R&;B8/M!-O%8[=P5:
M9;=Y)<<,@<G_ %!^&]^YN0F?_HP@,P0^>8+#N-6,#!2<1#T?'URR#BV*&?4E
M6"B*MAM\_3W$EYAC*JHM9!) QR"EY*9X1 SX[1P/?>@6:R(>G=5D9PZ)I%GE
MG,["2EC.88@3A6=T=I/EFJ44Y5^!.>1!R0A.U(2F#NV ! 1)(-O(D?6MSSRP
MXV8HQKD3C[E0M/C)3*M7QK*UDE5C;!+39[9+1+-)VWDG<3(.&I6R:B@;BLGU
M/O[-]%67D1TIE4L-FC)7J/\ #CDQQ3R1ECD/!Y;H>?LEAB:W8EBJ;$Q%,Q^K
M945)5-VSD(JN,+;*F9%A%$DW!TE (4P[F+W]3H^(3YE3\=NRAEO:.5.8N2GJ
M%Y&X,8@L"6+,3X&Q8E?,TYDBY&HV"RV:Q2#:FA"8QJL M(/[$QC%F%["4>SC
M5HB9D\A 8*N$SNQ05K4O@570IVV])CIB;E%R=PYZ@\]Z7.;<ODM]5S5B>SWC
MBCFE!G6#9'21<P;ZXO6-DB@(E(&DZNVA9XJ!GQ!*JQ9HG[Q.8@:B3F%MXDG/
M;T;^&$UAR>4X7\A>6MWF?4FXR<F.52]?S;Q^F)YSB^Z+T2GPRE7Q"ACF!GH/
M(LE$PL.2+FT(B7<NE7'<FY573;F*<I]^T;*SHAC$8SMMO*7Z>?J,7W,G 'E3
MF;,.5+!;>16);3<<>6*N?BR>D3+Z3KU/KL[5$X"HI1T(QB%KBZL"R+59NBB+
MA5$Q2F$4Q L@LO#,WB<5*=GJB89KT)R$R2CE'+A6[4]SGTHII Q:D^DP:IS"
MD*C',8Y$T8N^[CI%(F5(I?M0#<=55J1PC79ZBF;^16%^3G B+H65_A<?9OY"
MEQ]=Z$O36("Z9$Q7DRUI.6EQ)"G>-6S4U7$JB'Q:97!U"&,4PD*)95?#D50U
MS&-O-_.W.NI>K7PRXJ8,Y!4R&Q]R7H&<+ Q@[K3H^-8UDM;QGD!ZLLE.Q-8>
MNYF0AV\:=TP3754\]XBB"NP"80.56XE'@77XCY(Y:X7]0S)7#+D-R#4S]77F
M&([+=?L"]0:UZ6B!F%9$7,<W=04&QAB1+5PS4006<KD7$A0$P .KG&V\*ENV
MT&XC* WXF.K6..[8%=N!*[-2=<GY&-83$>C((Q"X,4G3%RW?IJ)-W3=(QA\H
MQ50$>WO'N#4269?SRJ?.'Q4L7JS\^>(8Y0I7+BA8SMU2R%=BUIJ>GQH(9#M4
M"DP*S3R.^=5$ZE6HD(<Z96B,48ZDE\>\%R@;X1L.F[)=XKBOFVVH5?&_K69N
MM? +'F29:I,V/+#('(AGQ81@4H23>UJ/N\E7+K9(BQ.PCXMTW?-7,-C^35,>
M-3=LD%BII.3)*+-R*,7#)E3;;B7QOMT]0'"V=\'7+CQ)9AY.8RMMB:T3/-2O
M%.KE#\]6;6<NG^8:F6\FK"L*MWQ!7Q8=B*$8U8/ED2)$6200%[=MLRM^"VKW
M>DO5 <A,T<U>6_);#>-<N2^'L%<=6SO'#N9B8&J2-@N67G=#KSIU),GI2.Y>
M.B*I)W7S"HG.@#I_$>0":B*P"I*=^V0:=*T_#AP+!\<^9/+" Y$<K?3CS/DA
MQ,Y0PQ1_I5POR:"CPZY[%0I6O-EV#)_5(2'7A74U SD++'6)*-"J*$$@&$R?
MEZJIAM(QQV2]ICWQ+O?J[\ZN*%BRQC[E-2,>Y2H63KU&UDTW1JH]3R3:J]7J
M?*MQG&#&K2M,@Z5Y4BV(@BD=,%' N@42  *)I&#$PZ]NV?L)&T\ZK]S_ /\
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MFA*[&,57$L[DED3"U**)$3=R0*E !V+]<=:::H\0FG5&#GITX=\CCTS=YLP
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MOTM+-Q:?>G]F2O9Q8QF 8^V6>59E2@[=,XWRQBZTR$U68V23-(/D9>3JGGJ
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M^4<Q?<^%$AD#G .Y(1#?QWZZ4%2,9@\.041 A^TH%3<.A36W4(@4R;DZ**:
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M-LL/:3"\$HNT024.<';=87I'C90J)R2!N\B[E%-4BZ12N$W"P=BA5 *4^WB
M&!*SQ@8*%\LOM\2!'UQ:-14305%,IW!G!4FA_+$#J.1>K*+*//C0.NY6,8I^
MP$T^U0W80ON]M36"I :GM(HPJK<3BS0)V \0,BBJL02HHKBD=^Y2.5,B@K$5
M44,4JIE2F$.@ 4=M1/>54H301KM1(^YP:'45(;^Y1(*A$2=#(BJN5PF(J#N8
M3 4/MMMNF^DU[#+ME05AJ@1NF)4TP2 QQ4%,#=Q2F,  (%'8-B^[J&B9T T
MT T T T T T T T T!;JM?Y[Y$_.UC\&E='5D69<']9_8_U.K^KO'Z>XEU_
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MSME2@813. (;P$HKQ5DC&$A54S' 1 2E.43 )0 3 )0'<!*!@W^3?0'<! 0
M0$! >H" [@(?* AXZ YT T T T T T T T T T T T T T T T!;JM?Y[Y$_
M.UG\&E=,^XBS+@_K7['^IT*2[C[17^PNOTA=4F9+07[R0_\ !;#\%2U"E5T
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MFE$V^PUQ2R6[C*A/6!NJT(X""G([D*6],U!,P(51O N:_"J$,)B@0TB?< W
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M%!*F4!.BD*IDDC" =2$,L<0#V=P_+H,,";T T T T T T T T T T T T T
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M5%0!,0"  %,81#81'=*F8"4*/53U$S\V !3]BI"'4$3G4(W3*)EC" F6, "
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MO*&_XNK,5Q:EG,=<6]\C'<BJUDH**.:!)7[,@Z0%:=.BW$IY%=J;8![MR_(
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M(R0(;Q*!P'KO^NGV'?ZH:]ZVY7KF6#/E^HO6IK.]8/W$]JG"- - - - - -
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M(L67!_6?V/\ 4ZOZN\9=Q+K^!_["Z_G$T!+P?[R0_P#!<?\ @B.H%@530HT
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M[HE-LH;?I,L!7)F)N3E%5_5LXMO%-T$FG%;DZ1(5$B]ZYU;AQV%1+RRK&$@
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MF(BF0NQ !,-BDV* =-O9KV-+2AS->_>?%S/<54 V#8-=RU0H#.=:(AH4: :
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M'%H:N%K&)$$(Y=\6(=&^&$13F"E Z"C8 Z@!Q -]7$SGF7LU#0T T T T T
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M_3CMZ2[5.HU>J<<#:*8B05S?$NG;DRJL@^<J@4ZSEXX5-YIE%C^\8GNIE$1
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M#MUJ,LOC'D$IUCG3!-4Y4Q5*414*4WO>Z"WN@;;\SVAM^3JL)%3UDT- - -
M- - - - - - - - - - - - - - - - - - - - - - - - 6ZK7^>^1/SM8
M_!I71U<$69<']9_8_P!3J_J[Q^GN)=Q]HI_877Z4N@)>#_>2'_@N/_!$=0+
MJFA1H!H!H"0> <3I  [$$#E$05,0W>/:)2E*4H]^Y0'VAX:J,W&G7U8:,_>8
M=&V3_(*.Q#08FS4]P^!+&C.QSSF2CKK!NH%FP<#8(Y1436%LU\X!$O>@"@>W
M;5R%,\RSGI=Y!C\F9MSCD1SF:2RI-RE-JE7>*/L:Q^-FD=%Q4FWAD2MV\=:+
M*=XX6E&RAN\Y41,F<N^VLQ..)<'1U-^A%4$R@EYA=TD@W 1Z@0I?$?R"Z5*!
M=MP,D052@98#"D [[G G;W;=/9W!]G5AO DHB"<INXH& 3% !,'R=P#M]G;4
M#]IJSY<]>>'IN;?Z;93_ )F,++O]C51?>;4-0#0$!;?8-Q[2=I^\Q3B50H;!
ML)-@'?5(RT=P:RKRTXW6C654=13*P&5?.[ Y[9MLF9N( >N)F9+BH]$0Z_?$
MO=]NF0S+QZA1H!H!H!H!H!H!H /0!$? /'0%/75(;N A@$2EW-]3;Y?#6;FF
MN)+M*_%(MI?;M$U.)/(.5BGD3).$XF.1$5'3]T0I1!--( _+&,'CMKHZWU$^
M9*8R/2\OT;KM3EUD[=.57LGT&FW$64^7.3>9<K5LEX]L$7AMJV?+,R/$ *R!
M8[E 60G+WB3N,B4XAL [  ZSTUNM=<WJ)X^\^XU.J\JZ7HGIZ>IIVZKMIQP-
MX;-L=JU09HM#MFS-'X=NW2 I1*F5+RRAV@)2@'9]77==CB$OA1^==9<K];ZB
M<S+<=IJ5]1CD7RIPI9L<17'V@+7!C(+M3S1TT#*%9E6<F,H*YBI*[]I1W$-8
MY=6E(7K/H_(M?R[2M?\ -W66S..2Y3:_CR3FYFDU>3L3(T?-2%?AGDDV, !Y
M+YW&-5W:8%Z; FY4, >'AKLS@SYO6Y?K7\GR<SCLFA[),# 4>[??<?'1XF%@
M=]0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0'S6>L-B?$5)O%6M[?B?!\@LK9FC
M\CSL@M9;:XB8&O0.+GE 07D"*A5IP&4W)&R(F*:8$ 3I-UMCCV" UQ%21/;M
MLS+#T5)>K/,%9/&MXWHN*V">69MFG 8ZG7D]453)OYKREXAR[K=8,+84DA\M
M0&Y?.3[3"!1Z:0X&%#<PH^:)*D147(550O<0@[[F+W@3<-@$/MS &H63L#QJ
M8-P6)MWE3WZA[YC^64O4/$3]-6'@25$Y$454PVW. ;B!0$?#N'P#?ZND,IJG
MRN<I_5VXE"4P& >*G*@NX?+^./&WIJ14KR[3:JA]H7\X3^<.J9(^H4: QYR$
MZ:I9CQ2DM.6..443L*98QJ0XP,IWLMB$D#D<D*3<P]H[IFZ;:THDRV7V9ID*
MHL9(=DQ A?+((&1!0-Q,<H@/]4, @ ] Z &LY&BH: : : : : : : : : :
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M?CW7(\M7D&$U,*(P4'8:DTN"KUXBF"2;YM%.F#\YFD6E(%*X7(F8J'Q*93B
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M#0#0#0$(X'WZ#T^OMKCNU.5P<EO+%<22=G43*F<5#E(!_OA" )C*!VB!0 0
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MO:!>W8NX#L'CJ9*<1F]Q7-0HT T T T T T T T T T T T T T T T T T
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M=W.YX%=3_J9/SA?YP:Z[Q9W[?E78=]0T- - - - - - - - - - - - - -
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MR_RP&^S_ /BZ]!779;C/T.=238;;!MX;!M];;61$4.= - - - - - - - -
M- - - - - - - - :&/4MYC0D'F'%&!(+-,MB!=O(7:;R+:HJ">3DO!.8E&L
MM:4SB8I,&C202FVTM+^<8[Q$4Q03Z#W#MJ<"1LS,[TU9N#F,-RA:WF.R9DAF
M\C'JLY*TUTM:E*R1XV<J!5#LR2,FFX+#$(5#SBJ%!04M^TN^VH]Q>)L9U -
M- :K[C_[8+!O_P!YKG__ ,><(:!8FTAO]H7^QI_SAT&1,: XW#Y0^SH"PUP4
M;&RYCU(9";;+^59P!BDDD:-?$&()U\T1[TP4ZD'<!\-:4P3?B7GCTR) <2;I
M$,!-FYQ 13/[VYNX-@'O^3ZFHV5)X5*EN'RA]G4+#&X?*'V=!#.="#0#0#0#
M0#0#0#0' " ^ @/UM <Z X Q1\! ?K"&@&X?*'V="PSG0@T T T T T T T
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M&,!B^\([&-_/U;5"KB?1Z'56ZR33;7X%53'81ULYM2WFJ3FH<(T T T T T
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M%]XPF'8"[=3"(B/UQUG,UI*VRF0;D[._ZHA[=_#?0Y-6Y71!,Z'$- - - -
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M;=S+-'4^W/M3_!M7ZDVM<J6+=.\VOMCMQ;%406(0.T"B41$QO,* E  [PW\
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M#HH\X/3I.FFJL#3)&3#JBBF94"F^BBYD\LPI@8"CWFVW'H ZCHI)^HV7FL;
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M4=_*2[@$#>63N P]Q@'M#<##L&X@/B.P:R:+-YUH\KD?'-NI,2N^9.K/ 2$
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MUPS%Q>J]ZO4G\^6XEIR9 +2G81-61)6+=8()DZ7;H]J)57R$>0^R92$'N]P
M#8-7?)(PC$SR8J@LB4X@4%1*GYX%_*K>403E$-Q$IB;["'B AJ/T&D3FH4:
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M_FI+)&$A56PM$UT ,8ZC=91@U7.FL<Q2]YQ%7N P>)1#P'H!SBPHP16M0HT
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M\MJP1N@C41(F*"B)2%0 I$P,J*R@@!0#N'N*7M*8"]/EUF[&3DMNN5$RK 4
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M7I.0\LWB;Y\V\5G,N\RK-!7Z:DVJD?!03>?G'1%37 CM5I\SJBHJ?L*<4C"
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M4 ("0>:(@4!4, @(!]J'7IX:KJ9Q36WI)99H<5$ER=Z JJB+DR!4'1W* AN
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MHD$ #[8PCTU&%.1743@;N* B8" 0/,Z=IQ[>HE$.@]0ZZ->)4WAD1]0HT T
MT T T T T T T T T T T!P(@ "(^ !N/UM 62HLDUL,[D>88+% %+(>L)F
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M"G&X?(/Z$?Z&D"1TZ=!W#P]T>GUNFA!O]0?L#_0T$O</=#?8OCX^[X_7Z==
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M_F'^[_C.W;RFWSCW>7V]GD?>/B.[V_#=WC^4[M:^*:<=F8I'&G:8QH_\V_\
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MF_%CIO\ 3A_:-7XBJ,H. _%C?_[.']HT<E>&1V_BS_MO_M&LF:'7^+7^W/\
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MG;4<\"5S._\ %G_;?_:-9)0Y_BS_ +</[3J_%Q%.!T-^+&_7Z</[1JU-*,H
M?BQOT^G#^T:.0XX';^+/^V_^T:R9H0_XL?[<O[1K=>!JO$?Q8_VY?VC2O 5X
MG8OXL]?_ "X_D^3J.2/B=A_%G_;A^1Y._P"1]73XN)*'7^+7^W3^TZM2G'\6
M/]N/Y/D;ZE2^ _BQ_MR_(\C5J.P!^+&__P!G+\GR-M1S!.W [_Q9_P!M_P#:
M-9)0?Q9_VW_VC04.H_BQOU^G#^T:TI-*.!Q_%C_;C^1Y&E1V /Q9W#;Z<]]P
MV_J'C[-*\"5XD,_XM>=[WT\>9O[/*V^ZT^+B9^&>)&-^+>X]WTZ;]-]_)W\
M_P"#2N<24Z_Q8]OTY?D^1_,T\#2 ?BQO_P#9P_M&H'AD=_XL_P"V_P#M&H9H
M0Q_%C<?_ "Y?VC5J6N1W+^*G7O\ IKW]GG>3W;?4V]FJN;(ET?J)*4^B;X%?
M\=OQY_%[L'XS\=O@_P 7]]A[/B?B/O7F>/;O]74<YX&5R_IQX%X<=?1E\R-O
MHN^9OQ>\TV_XI_"?-OF[%V^*^#^]]W;X?4WU5,4P-/\ /\2Y0^1WH[[=_P"M
@^&_AU_F:E2*)XP<_>^W\MMY_U/M_-_2]_P#,U#1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm2226999d1-lc_indicate4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-lc_indicate4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!,@.. P$1  (1 0,1 ?_$ -D  0  !@,! 0
M       !!@<("0H"! 4#"P$! 0$! 0$! 0$           $" P0%!@<($
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MX#XUJDUOMH92I3?K5^*A>1]"*JHF4,!DA8) '<FFW65D1-U PJBFJ)1[PM\
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MJ/;T\:U?L,Q'%[?F8V?4A]0[5OI_:A'.<O&#R7,71)!KB.J%,E:14KD[MC'
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MSFWRKX9KZ:7P%?C%L#(L$7SDN7)33+*G.-91*8N],FS)$-D")23B-%8H).%
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M * 4 H!0"@% * 4 H!0"@(?PVH#CW]>M@  Z]1[@&_3I:UA^NJ#D'4 &H"-
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M4#A\-BEZB"@TT(E#D]8  H  > 4*1H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M6-UB-""@% 0_=^2@%_JO_4H2I&A10"@(7^D/H_=>@^($1]@7_+:@'6W4+5
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M$P 5" /Q$N!1#N#PO8P5GI]7'J-I71A98Y?:SLB(  B(] \1]U=2G$%"& !
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M".*%BD0!=1I_',W4,=-/K;P\U,1\/95AQRT^1)U7W'OUDHH /@- =8"%$0Z
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M"@VVE]R M")ZQ2PM5@0XN)I3,9&99>0P;K-CNG33\*@YGYM=%IYA@36[$C&
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MQ3U=ZA^,<L-AO-V91R DX3(L RC/,L5UT_8.W61Q2FM(C "N)'$4I*+9HIO
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MJVM8^':6J\AN*NE^7.KIW4.YHDTYB&4O&KMTFHX(VFD74<9,R#F#=J(G2BI
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M-E51E%S@!DRC9$ MUO1*M$S5H;>*4Z[O$S$>C5ENX\]T3LF<W=OG!.1>>/\
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M2/4!>C$N'8JBB!TQ5$.ABUOIS/IW;0>;W3Z;Z+75GEGZ^/$P]M]_\_X;$4]
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M\Y%S>':!XA--?+! ::P32>E)[&-R?+S&:)R4GF*F8XO%R4;*]BS)LDDQ?&0
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MW37@8I?V:I<#>G#$"10BID]D9MW"F-P$?QM]X7*7V#5B<WMH<L(QZ&,;O_\
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M.1?%/<\0?"N)NP<-R* UCY:<_'8*DJMC[!G9(GRK=3YIV13RE7R)1 BQQO\
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M33SS];C6\?4S],W[>7C&$NP$7,%*MV[YND1JNU<K$5$JB*JQ5KJ(C<""(&(
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M1P(W&TQF0405TZ5'?#UL=13YB6CM)QDYFTK!,%2I.55I*>;Q8H-BJG13.H8
M.JD%S :3I51YK0<SAQ#R>G$M?T#H_.>0G)7A3SAP\(!/3&-<%@TW+1TV^EF.
M8,<_:9SF3I7Y=I%1DE%*,_EW)2F$\F4_Q&^Z\!%5Y26V+AROF=_3OI:Y)E&"
M[1PW?><95K]_-\C=J[3Q-71FR]F8D^?8WL7)22I6$^K!2.O5%#,VK! E@,Y
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M-2.CFB#5 S^2>*OGK@4VY$DQ,NX7,<WPW$PW$:OQ#<WW$YBV2'N#M(!1 P6
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MOI;DEC/J$<A\RUYZ:>N.4N*2D,S1;9OMG"&,Z_:H*Q6.HNR1#R1(T/YR8IJ
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ML5Y'RC#M,V5:F$2@X$QSI&[>\MN@#UKCF7)1VFN](."!^TB8V=13R3(\6BD
MAP*)E[0&[A^ /B"PWMXA3]:I-ZEZ?JY]]#,'N_GQQ1XXY*AA>ZMOXW@>1O$4
MG",7+K*)*%27;HNDA.*13& 56[@B@6O\)JT\L5=J3T8^UZN:G%?5E.-;^J)P
M;W)D\#A^M=]8OE65Y6Z>,<;@V*EG<N]:-R.%6+6UNY4J:I?$0OW=1KP=3+IO
MK-*O9J^#N=E[3K8X+)I)?"+RK6+M,JW!K["(F3F,RR-MCS:";).99.0-Y:D=
MWI)*$*IY0J%,8R2H&"YAZ#7JZ>6.*]7XR>;+HY.&E^7P,<N5>IMB6:OGL#Q-
MUCL3?\_WBVE,FQ"(Q=WA^(*+J&3;OLE=O\P8R24<B!555A38NC%13,)2&-\(
M^E3-4XVDX-I-K]7"O9?S*/RN1<KMB+L0W9RLUSQJQ^0!RZ;L-"@7,IQVDDY4
M:H1T\79.K(-* E1;F,HZ_#')BINDA(FH=,1,-I9O;MN(AVTDGC%]$<68YPWR
MMIQYVAR+>(2[2'6R39DS,[K1!Z@Y1*G+PB&WMIY*UQ$BRSP%A3BD6:0]I?@L
M4H!'BIX;? LS2$8Y/7[UMO/)N,6G,K_H]B(CCS@VVXF6V%K;$3+MY<<;:8EM
M!B5WDN.?A\=C@IH*.TR%3+('((+)B/Q"/;84M*F[:Q.:'CDX<.7Q6Z;[J6+1
MO4>Y$<*.6K#A1J[@XKAF7[LG=W8KDVK)C54:U@,@P;$VF7:VF'24G(Q*D:[9
M1:\#%N" FB#TA"$5 H%N(F]F;PYN9431B,H_C=<TU5^?<9"/08Q)GE&K.4PY
MG"X]E4O'<A9."R!KD#<KU%D+1;)6LDN!U&BBKQRJ_: 8?.+U\PPB(" !7G>3
M::F$_'QOYG7.F2R5_)&8W<W"[06\F,,QRK 8=GD6*-R-L)SC%I&?PG/<&^1,
MDM$.(#-\*D<?RU%FS=(%/^'&>C'."E.BLD=%98AV62>+GFE]E]_82T<MM7P>
MG<67OMA\P.&YT1V6Z/S#XRED1CXC8>/0F.?TQZY2**R[M[E\(;'\#Q5>%A%6
MC]G\Z:7DY!0HM3'*8ZJXI<G2\VJ5)/&\.3);I_?>JMT8<PS#6>9MLEA'*#,B
M2S<""Y SU-(6B+H $Z9%3"L7[*AKB/B-%#?I4(C32KZGX?#>5@&88MEB-SK*
M"[4 ")H"!1,J82@8Q" )_$.ON\*:TE)^7';>)U<3M0^B&01ZR:RGWB*;8!!4
MRX% "&+>X?"HIX4Y7H3F4S5HY'G6HI@JGYAT1()B+E GE&,!@+V]3@-_'V>R
MG*YL%DH;9;GRKWCKW4VH,O4S2268!E>,9?CL(1,B!S/))W#'8($^^=(=J8N)
M-(!$HB-A'H/0!EJ;RK[IW-%H?IU<B]5O<-QS2S.:5<9R[4S3(6K$J;;R?D1S
M&;>F#O\ FO/\T4)5,UO*$.H]?"^DZ6JC*4MOC)E.0DVZIR( "I%E4@< D<"_
M$4X")1N!S"%A(/A4=^!9;."[AN!C*@<QDP,4BH 4A^TPEL 74&X=0]EJJ7IT
M7Q(XYJRVO E+*,+PW*4A99! 1K]-=(Q5%7R0A)HHA<5%8^42-^)1KDI;B59N
MLDJF8 ,0P& !"):T_/?^%Q+6VBNU/SM=%"1P/:.KYX[O LJ)/8!Y:ASXEFTG
M)2+M,10*N"<#,NH^=G'"A%B'[$UGR28%,)0L4I  Y[_@7A--G4GC7?(/$LY7
M3A'C*8Q'-"LCR#G#I]NQ;37RI"7%=!)A)R3=1LNH0Z9#&5*?N(/0/$8MU W9
MUWE<B/C*-4W)6K@P*'&R9BI]Y"@)R]YK*"%K%]XCUJKM$D/Q1F/F^6L"GD]5
MP"P"B 7[C&ZAX  _FI#$TG<<T9!)=82$*84Q3[TUNEE!"UR@/=>X=?S4A]R$
MJ#L).DUB&4 # !#"7V7_ 'C"%(W!GT%0I>X;" %L(^'4!"]_'V7H(W(\<TT@
M(/3))JJI,DQ.JH3M_B@<3B ^86]BDOUI$=I%DFZ)TU.9IMB#8KDZO8FH)2D
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M5SE,43'*80$%P\0"MY1S4.6&4]+&]$_BS8;:KI.42+HC\"I"F+?W"'<%PN(
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MNL4CA5-5HJN10# 0PE$H"4+T^Z7=1^<\"4QC%4<_&T;(T>]N<?O58T+N+>6
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M_2O?_7^YQSZ?/KE3OC:QY_>^VRPY>G-,4GYF;-FV%N0"&#XBB8MA$1LF8PF
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MF.0W#7&5CD.!15)D.2B0X@(_9[FQ/&WN"I/!G18J*L^I>4/J+"8;\+L= /\
MW_D?T?\ 04ECEPWU/K_XGO44O_Y,<=  ]@3^1#?\HH4G@3EQ?ZCF/)[U$ "Y
MN&>. 'O&?R/]_P"XI++RX:LZ$AR:]1/Y43)<*\:<JG'L,A^L.3 'EF"PCT0
M 'J/A19/O')AJSF7D-S\4C$6ZW#'$R IWBZ9/9S(G#80$YU 3 JS9?O$36-8
M0M>DMW)R8+[<JE!\AE.;+F81RW$>&,/AF9+O#/EY.'RS- 9K."J$<M?Q"*66
M4AR-RNA,(E(U,4Q1$!*);!36#32BKG=VDJ;Q]2SECP^T3D&TN5'%U$&, 9HP
MC7N..U3+S\W)SK=I&M!1<N,6:D C%V ")3%$13N(&$1$=U</!5.+2ARYC1?(
MUNO5HV7SQVOQ^S3D?R"XSR.#:-V+^I^?8(_P_(9V$S#"!A%LAR)%?) B'6/-
M70,4YEHH('DI(ET% L(&'S,P^--=*V[2V3CPU[]W<RPWC1Q8U-S*V]P]UEQN
M<YB&9[,G'&6[6R:4SG.8Y1O"XG%9$W>1F2KP^5SBQ4W,C%("W%%$XF*"7<8E
MS%"Z?ZMOD<TIRA?;K5RU^#IV'ZA&'8M#X-BV/X=C:*C6!QN+:PL2@N[>/EV\
M<S13;LT_FY!P\>NRE3)855U3JFM<1$:E-;0=7EDVWQ\-Q.0> ?4%"$: 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * \:34!)5#XDP,M9$05,8" 7XE.X *!@$
MX&+TZ>-.VPXKQ-<+]H3C'<QAW$6-C-10.YLKD-^1$;CF-YQ+3\)ATF\D,UU<
MVCXR<6Q98[\T;(.#I(N3 U74*B)A*4PC8:U#2>W B;:;Q2YJ7M34M]])77>S
M\%Y7D6R3B'H;C="3\-*-OF]8Y1L3(I:? &I#'15#-HE!-DU.NS-<6ZQ#W1#I
M\1JOIMBH?$F/\CKU.5J-/R1EI]8K4\?M?T_]RX'+;':ZBC)!K"&+GCZYFV-E
MCT)$"J&/^'RJH@S*H%U!14./;<;C67S32&Y-++IK%O.5BE5[MM338Y >G5H#
MB[KG6/('=WJ6[89,,S32@L7F8X[1WL6:6>+R\>8<1:2(Q<(ECJ2#)P50WSS9
M4/)5$$A'J95.&DXW-R1X]-R\<LEC>MNZ_:;2_H=:1PS4G$6;4P[?3/?NO]AY
M'%Y)AV9+.'*N2-/FC34B5GL QHQFG^L"J,RW!TFDXDVX.4U@*J8MCJ6O-5I)
M1W$Q4=-<DY-S7]W9P^IGT8IG2:()G$@F*0 $4[]@]1$.VY2C:WT!4-5UN=H?
M ?J&@.)^I3%$+W(- IN:M'[1LFEC&-<.,VV,U5E>.>$\AVV4;D2$?O&,.&2Z
M[>(.>\JK%0S)JW:O!,47B)1*  )3>RN(7-:+KS,X3S^EJ9MQT\2T#TK%5][^
MICZH&P.&>00N+87E&D8''M?;)0;('P,V:EC-$$.[;-%HO(DE56S!%5%0#QYR
M@HF<P$$P <2^V7?\2K_R/&?U6U^TJWOCA+Z[>*:0WI*Y_P"H'IB1UVWUOE;S
M+DX_',<6DI#'A8.5I!G%?,<6HXJ#H6@& #$<M1N)?O M<)DXK*KVDPQ>627J
M<.EB;O0]UYR&RST=4,7XT;#@=:[6=[==.8O-LB13EHZ0C8_-F3K*060EL2S9
MNBM(1#-ZBF"; 0 3%L9/[1;7'-E2671Q;6TLS@;FUKS9G8+BJRU#NO#,3D\)
M?8^7E$ZDX:'<FV<LSB\:;22N,@YUE/ECTCR;*74 $"P91*\3N4 *4J-7/*;I
M(;P;BKJJ?(F7/-=\J,HY+ZCSC"-GXQC'&B)P.6A=RZQE8]@.7YCEBJ.4DBI:
M(>A@DP[:H-W[N*5'RIV.^[:G#RS (D5RFW70[^V>&'4YH?-'IW+MKVK4[&NM
M;<HX/D/M7+,KV=B;_C]-8_CL-J[7:3)HME../8%Q-IO9&9?+8(V>KINF#QH6
MQYI^!SIF$Q0'XC+4TBG:>KK9=%PU+SH\FK5O'Y(EG6&I^9\7A.X&^X-SXAE>
MR9>=EW6ELHA(Z/90N&1CS'6,=&-Y]BSUOC;)X9"4*N<?-CY0?O 'N,( !=Q&
M-&I@\'4AY2OM1)F3:>]15]Q4PS!H'DGK>+Y2LI!H.8;64QS'3XA+QC:)!J]C
MV;!32[IDB\6EC J10D W4$H#=0OV1Q+>,7:V9G'&'Z]=?@5(W!K#EI+9AIJ0
MT?MS%-<8?CLDFKO!C.1D;)O]A$&'4;J%@!E-?98+(J[\Z0 "#B)  *(A8>@J
MM/&C6_\ (4E/)-</J?>6USR_<<J&V=I;<PQ/B>7&?P]SJ)&)BBY\XR,SV/5!
M?\8#7)94C?Y!%PD8"Y*4 4.403N &+I<T\M(VJ(37,ZM;1W'WU3K?EGC^X-^
MY'M;;>)9?JK-6C!#0V'PL;'-Y?7:C:)CTG;K(W".OL=<.05EV[A0 4D)<!(<
M $ #X"G,RK?$J2=)J[\$2GKS5G.Z/U1R.QS9>\]>9)LO+9/+?_#=ET3#1+-C
M@$6]6G/U/;Y0FTU/!)/3QC9PR!85F4T(BB:YE;B)XY?J_4$L5Z:\NW$E[)].
M^H/)<<->8;CG(?74;R(ALGC'VQ-CKPD,&+9%C3?+F$A(1<:S#3[MJDY5Q1%9
ML4Q85F85S@/FE_2@EW5P^1TK!.^X-6\O<HV1H);6^Z,0Q73N.1_S7(*$=Q<8
MO/YO.$7QX6[_ !MROKF8<,456B<I\",C#I]RZ?P?" I2L4OJ%RRWIH4,><)N
M0&2;^;YSEV_$W&EX;'3R&+XA'%(EET=M.22R" E)M1XEB<>N,&OCR\8F"1I=
M5(#(JB#4IC"=6J9Y58RX?J?<5ZT7J'E5@37<\=M3<,)G"DO*D;Z'?QT;&)!A
M<*)ILC5')Q2P:!&1>-D#,04.N67,)DCB*AA$14.6KJ&:],V;C:D7CB2/%:?Y
MO1G$3+M<Y+OW"WO**6G%GD+M]M$1*>+QT6ZR2!.PC/EB:N9MQ41AV;E$]X)3
MXW #WF'XRQRZ[+AMO)Z4TJ_7CMN/)V-I'U$W^H.-F-ZMY%ZTQ7;F$(X<RY!9
ME-0,'(0FS$HN*9M,G/ MW^F,B0;+23] ZB)DXV($"G\4OL@;A&J-J9:3\2JF
M4X%RQG>46F]@8-M#$XCCACV#.(C;FN)&-CC9)E><!'9^B$U'NOU!E'*3(7LK
M"*%*298E K(_W(7$JUOZG$?$QK#F9\#KX-KOEG%<K-J[$SW:N)Y7QBF8@J.O
MM7QC-HCE&*2+=-BGWR#A' 899<$/)7+\<V\[NX!$!'J%4S-%0.(>M3H:3UOS
M.Q>"WJQW7NC$-CSF:2&4+:,?04-#,&N!QKS#X=C )Y"##6V*"NHQR)H]5,!T
M94!*J2YC_8(7,EZM/$/^-OT37X;O+S)&B]7<^F_#A]KM?>N#R/*#\$<LTMGI
MQ$0&/-GK1I)M!;"V#52+8Q_G%FX@<84QK(&Z]1 ^6I].I>9+U0^6([&3AL/5
M7,UX;CR&J]UXAB:F)2II?D43)(R,?DV!#KPKJ/!EBY7NM\F!HL,L5)2R00P%
M*41 ]_A&SG*@OH_5/+M\R<)#7O*!_P I839#79V*QW'!#'9.*=:G.Q9'R5^^
M>.<:.E($<'P598062C7@_P"&R=HN2@4H!]@Y5-I'IB7/-Y1HCS]::XY88_NG
M>^6;0VWBN6Z6RB'3)I3"XZ,C4)S )TSM0OS$XLA@$&JY0!N*9;*2<H%[_![1
M2U70RDL'+3;^1+.KM4<UXC4&^<7VGNW",LVIF!\D<:,RB'CH]M%8$D_<9 K
M$G4V^LL?(X,Q;OV!5 482H7;GZGO=2-M+=-#6...JYH<G7RC4/-]UP\@=6X=
MO3"HSED@RQLDWM]_',%,0='C\PB96>3;M%-8R3<AG^,,WC5,0Q]+[UP7J2WF
M$U"@PI;EWW_*+%\&O(S(HC!\1C,QD6TQF4?C./L\LG62::,?+Y.RBFS>=?M4
MDF4:DF@[E2+*% K5N':8/NR?9#+KW&W&/>3X7P#I;Z/=0$: 4 H!0"@% * 4
M H!0"@,+7K98MK>?T+KMYF.W9?4641FS6HZ[DH7!\DV*XFLD6Q3+K0[C%<2,
ME-NF:C$BRQCD43(4Z)2B/<<M*0Y*N;F7+$WKMY&OQZ66HR9AZB.&1W)3GABV
M[,TXS1SV+PS4&KX]XSUKBDS(QN2KH-&&5'S;/<1>J.9 $3%!FLF*OED('Q"4
M:LIU6O=0F2::5(2LM[II<W#.3>P9C4V@MK;1B(U[(Y!A^)NYIK#L4W#ER\73
M>,T4BHE9)JKK*^4MT["B-J<T*=)V[B\O,XHG'A]&:H.+?M2&Z5,<@W4WZ;/(
MIVN#0@KS#/#=EJ-EG(',*AD%B:K<$.BL02$$04, ]0O1988T)R]7-2TJF1+T
M;^6LOS5Y,<GM_9EI;,^/^83.'Q+!?6F6P<[%JJP34, 0A\D(M,0$")UI".9M
MU3%\H3?WP/N&I"E/%U";>#62]*=^XR?\V>(O&[DQK:/<\BM5QNY8[1<-G&=0
M.*R#:(<G,Y_!6T@[;-&LM$31O/D1QM$B1DDA$%"@-C6 *U;U+RL1OFHU*=YJ
MZ&HK!37!['4^2V?<A^+W"/7>.85B&02&D\:BU=6K9LLT@,EQV"C\>R6&:OGD
MRGECB/577= 9BS5,L@H(H%O8$NS9'CT_TXQ6AN;\&<CP7+.,^JI_6F,#AN%2
M^-IOH?&_DCL@B0477(JW!(6,<4I0!,H@'DDM>H]VI4M5]K+N5S^4DH<""J)"
MC]V V$W4.@=!_@J%B#67]=G7_#-QAN)[BY13;Z6EL=QS*(346A$I:.(AF>PL
MM;-(&+F)**=0LRH3\%FW<:Z^<,@FD0$.X5"@F)BU.-:OQ1AK'-*DI.VCG>2)
MQ]S3GMPA]-KB)!<6]+X_R>FLQF<BR/*X1+,X*8:ZVP7-LPVQF\/ LW,9*.&J
MR^/L92)8+"F)0;K =%1)-0HD(;M-C>&%'"KNMW3N103@_NOD;OCU[8[+N4>C
MAT%GC#CX:/Q_%BR*4@$I $QO<)B2)_*(4Q5#*++%$1M]@.E1L8J.9NF3CCYF
MY*'4 &@% 0$+^T0^J@(=H?OWO[?W=* XF(4P@)NO:;N*(_Q1L/Q![A !M]5<
M^=IM%HT>:_(!R>4DJFFYL90@B6YQ]IA+8P#W& /&IDWDH=]K&6I?IHRD&<:Q
MPS./,6E&QRRX(%3"=0(DFLU["D3[B.#MU!34(!0+;NN(!7'J8K^+)6H_CJPJ
MN<5V_7B?GO<QMY;6]0ODCMO -K[.RO1./\0BRJ>I-?.)61@,R"<Q=[//F6PY
M^7F5V38[5HYQABNJ5-@V.L5BH4JQ3& R?YGIYX]/#IY8I\R4/FLW%8M#7T/Z
M'_Q/I?S]#/HY9-8YXI^FF4)-P[^EV>]2I-E7T5/4;WCR5XGX\?<NI\BS*=PY
MY/X:CM6*CIUE#YQ&8UEN28_'RA"R3&:.LLE&Q:"!U0>*E540,<O:4P%+];'J
MY98QFN;*56-(L]Y\/^^Z'1]OUFO;SCTOVMZZPJ0G5\9,R+?D1#MP3/*81DT(
MV;&[3G_#91ZITL B"#>&*J:W0.@>VO4NI@NER\I\_H]'+/H9]7F7+.VIZZ?)
M[7QAM\CF-S7$O_W*RN]@]HA^#=:Y\\O[:'%]"DK)'25Y:ZD04%%93-$U27 Q
M UQFRP7"X"'<G"B7H(5M+%JKCN9S_C:I?O@^C?E=J5\?L0?98B8.HBXU_F+8
M+= Z&6B4P#J(5QZO5712R;HW%F;PZ56GC/>CT4^2^K%3 49;(2]P=@".'Y,4
MOQ7#J<T<!0\?&N./O<%^JO>7^*;8J>U'MLMVZU6+8F3G1[[F(:29O&)""(_V
MSM)$I#=?S5?_ .A@OU-[;B/IMJJ4=J^)X.>[OU/C.-2N39)L[#8> @(.6R*5
MEOQ>.!['1./,%9:6<E3*^%P55-BW,)0 HF$P6 !'I7?#J_\ L8Y/+)*)KN79
MJ<?X'GU,>7%NRKJW2]D:.7.KU@=[\EMP9GOSC?JI#(^(6F<9R32SQG+NW;22
MVDRE5X\D[FD>C($BE'B$#L"'7:@9..=%["A]Y_&'YGN5T^IUN10ECOUIKQK*
M/W7]7_7Y^V]GSOFSRR=8T5;7I2.TV._V>C(8.4]+?0+B'.R4.=A%J&@DG" O
MHXCC$<. 4E40$%4RLR@(B(IE#X1\+#7WO8\V."667-DLOIY'Y/\ N>EC_+SX
M]/+'I/"9>+2UK5*&]US.9#H?+LP(985+J+G^$;C]XNJH!>T!,( 3N[?I$+U[
M^OZNI/!'P?:X/#I+"9R3?FV_F>K\(]H^\ $ , @8U^O4!ZA;Z0Z5S@]$D1\+
M?3<0N B'N_>J2+W("6_0P=X7#H/0"B ]#  WO;V4FI#Z 4H> !^:J   %[>T
M;_GH"(]?>'U4!P @!;J(B'M$>H_6-J >67Q +#80Z>RXW&WUC6<EZ0?$Q"$#
MO*4 [>H@%@Z>(]+=1^CVUPZ>+F=#4[S%#ZN7$#,.:G$S,-5X*^*RSZ%F,=S/
M!U@<-&X/I>"EHV1&,7.[=LR%!5F18Q1\TG4H %QZ#[^DTLE"B3.34.;? P!9
M/NCU#/4OA&7I_P ]Q3R/4TK*Y?@&"\R-SS;]5_$M,!?R[C')J=AV3E"'(J\5
MA5LD7[/GWXK"DF4"C;[ST>YZV.?2QQW.C\+;CFL>I7'QKINX_+O*V^A;QMUK
MHWU _4?C\7BD RC!X;4F#PKDZ+,C5&%C=?ZC;2CYJFDW3%JYE9%J+@X KXK&
MN C<:\6[B;<+++&V.+7PDV[$2I"FD*)@43[0[3 8!$Q1 .VYO: AX^^I7Q+"
MW<.P[= * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * ER=%VF4ZK14XG!% H-
M0*<X&N\3%18I2B'WA4;]?<%5;]"2IC4QS^HOZ>NG_4<P?"-:;I>Y3%XQ@^3-
M<N8'QL4#+RKL[V$?JINB+QDB5-0IH)( $Q+W4-[JMM4W]-J#[EJD^YU^"WKQ
M*%<(O18XS<!-L*;6TM(Y:ZG7$6O'.6L^YC'#0[5T*)E!*9G#1HIN"B@40 3"
M/3P\*EUPVT(L<<,D\9E[7+A/4+UOF.X>+&W,?UU Q613<:LSR%MC$HS)+_KF
M[@#2;A7'CMBN6?R1GR@^60ZH* 7S!^$UAI>EW3P-)M/F7'Q-:#17"WG3S"YN
M2_J-<^-!*XY@?''$Q:Z1XQJ':23C+96!BFD;%QT8X=.Y4D.JZ=33YV"P18D*
M!!+;N-W5*NCL:RB?3]WPUJ9^?2V@=@DQSDALW9.D'VBW>Y-OO,OC=6RZB)W6
M-14IE&?3;<KF1*QCF\A\HWR)-,3%;H7%,1L'<  A<U#$Y/&,J9&8U#]$GX_9
M#Q'NZ>SJ'0>E(BA3ZT!\U! I3',(V +#;W#^0>M!<I;LS5.OMQXN\PG9&(PF
M;8C+(*(OHJ>9LY%J9)8A2J%,B\261^(O00$H^%7]4ZF8;QAV)=U)H#4&@L<3
MQ/2NN\2U_#I.5G0,,=B(^)1.LY*)7"XD8HM4A7.4;":U^T+56H4D432=MQ('
M--,I.(W) Q266+IO.!6,0P 4RHP;H144_MSE, V&_M'WU,HC2LF^DYS5+-&)
MC]F?[3>G'$"8"B8=DYN(G,("(F_&7H=0O<?A]M7*)CC\B8O_ &\5P?\ ]F;"
MX)E$3>-^MC %A[3C?M ;?9"U9H:3?+&C/IV!<1ZW$+7^C\U"#L+T\?A"P![O
MJ^F@./E%N ]?$1-U#XQ$+!W]/B[?9[J.MRJAR!,H>_PMX^SW![@H0X>0G>]A
M#W '@'U!:BH5MNAS\LHA80N'N'V6\+?502SCY)+6M[;^SQ"UA\/9:EZZD5%"
ML<@( 7\1$;]1\>OTT \LON]EOR7O;ZKT! 4RB-QN(];"/6P#X@'3H ^V@.)D
M2&"PB8 $2B( -@N4P& ;6\>GYJ%FLD3HD.-QO</"UN@^\.G0:3H363EY9;WM
M8W]L'0WA;QH63AY! ZA<MS 8W:(!WB'CW]/B PCU]]".IS%,H]!\+W$/88?I
M#VVM14[00\HE@+;X?[7I;Z;A;V^VA98\HEQ$;B(@ #?W -P]GLI<2]!Y1+W"
MY?M?9L'4X]PCX>-Z? CK>X\LH!;K:][7]M 1\LMQ$0O<;B ^%P]MO?27$!4J
M@) &W4W0+=!_=UI30$#)$.7L,4!*(6$H@%C![0$+=0&I"'  D4H6"_OZV$;V
MM?P\;=*H(>23PZVO]GI;KXA:W@;VT%3Z %@M_#0$: 4 H!0"@% * 4 H!0"@
M-?#]HH7@([BEKJ6<)9W$Y@VVXQ1PC/\ "FL*_3PB76PK.E!D)UCD,]&12D:H
MB@8O<9J_.53M $["80CA*=2PWZ<;SY_0DKAWZ..@.&>2::8ZQWMBLICN-Y*[
MS+*(M>682^8;-V4Y:1<<WEG.2*)RN5$9,FT#&>4P1D4(X%$U3?+ *ZYEJNST
M^9(A3?->'Y&=#8\".8XMF&&N9A5E^LL4HT7>$:M5RP*?FM[.5$W")D5D_@ .
MTQ5 ^,.G3I4HH]D2=5/,S6OV)S&]4'@I(,-.2OIXXAR^PJ+'M@=I8#"-"3#F
M.,J#0K1W$(0N P%DET!7*I8ZA@6, FL4A0SEB[J(-8/FA.>TN3XF;1]1;G/F
M#3)\RXXX_P !]5P[XCK)#N(MF&T,Y"**2'81*;9QCN3QY(L[%V9;M)*M@ S-
M+X?<QQ3O]Q<W%GZ5MMX&<_84PGC.);$SA"$4FE,9P'(I<K..[GC^:_!826D!
MAVC!XLA'N'#P$_**4YB <R@ )@#J&F[-;=UC,0I=4?GZ\C9S3W(OELFCIKB+
MK?*-T,G4QLK<>799F&V8;5FOX,90C%.&S&-AI22C$,B%7)8XTDBE!.$4GA%B
MHK*I !U)2^VW +%RH?KT>XWP^&FP6FU..FK,Y98K&8.WG,80<CA\+YWX9CZP
MN')#M&9W5GBJ8% !$5;CUZ57%E03#X[RZ>W2P]?I#I^?PJ Q=<\O21XE^HED
M>#9/R%QJ>EI?7S2090#B(S?8>,IIMI(J)7!56F(9GC3-54@(@*:ATU%"FZ@8
M+ -+--%]+QY6J;;;RZ3BKQ3U=PXT[C>DM.,Y1EA6)IOB1J,U/9%DLCY;^7DI
MI=-25RJ:R&7.F+V54$ ,Y,    %B@4 MZ$HJJ4V85'XG-^TE8D4P6$O%=,J9
M1$1 "A ;P$3]XW.!A]P=.E3+2+$Z='E/ V30\ ^JA2- * 4!Q'\_LKEJRGP4
M024.!S$$3E*) -<0L @(#X" VZUJO 0=([-(B:Q!( I' 1,0!$?"P" ]0OW#
M<;B-ZY9K''I9*-)#<W=#6W]8#TR] \CL[XV9]^#-<0RS)=EL(#8T[#2V20#[
M-<;+DN)K&A948*2;).$1)*OBJ'[4U52NC%.<P6 OYK!]/#I8=;IUS;::>ZE8
M<PZZ'ZW_ (ME_,NIT<WE_%ATYQBC4)M*5#:HKMT,]>H-4Z^U!K3&-9ZTQJ-Q
M3#L6C6D=&1<4D=%$"E*HN[644.HJY76>2#A58QU%#F$5!$1]E?933Q73Z:C!
M+QFI\+^T_FSZV74]SES=3)Z:)46ZRA/CXE6?PU@L8OF,FJ@!T$%&Z1Q&WO 2
MB _77IZ>-%CJO!GEQZC73:Q;J=@L3&E'I',?H_O1OT^B_E]UJ]'*UN9RYGO/
MB,'#'$PC#QO<-[B9DU&X^\3>6(U>5ZQ YGO9\E,>AS% OX3%B-^MXYGX=>@B
M"-[=:\'ON@^KACCCIE;Q-XYPSJ#BT(8MAAXL/H*R0M]75(*^:_Z_-Z+Q9T_E
M@\M]@&*/"=KC'8Q8##8Q10[ M80N/EB6P?5UIC_7Y)I-)^(75W%(-C\>]39K
MC,[A^08+$2D#EL%.8O.QY3/4%E87)XY:%E?+<M739VD8K!VH/>14ARVN40'K
M7IZ'0QZ&#QSQ]+:HF[[W.FT'J]MULEU9Q<9JL[]R2M+[-U31\YS^DQO[C7M[
M+- \8,PCXCB5MO%<DV0W5=J.Y62PAA%N8Z0RF'3>Y#C4_(@M)["=.U$R!(*E
M\E3[:8 "1?G^XPQ75YHYGH]'V]EK:']"_JO>K/V[PSRY%$98TE.Z2?\ J7JO
M]#.5Z'.,9]C?IGZ"E]19.T-Y<>T3-BD]#Q"*.7N&N(X@=PW?3+>$EYN+!T@J
M!!%JLF)!-<MAZU]O^MPC"6X7-]+'Y;_D'7Z/4ZV6#EY+"_>])@S5XQOIQ&HH
M16TX5OA<LD*A7\ZR%R[PA=4RAU&S:'DW0)S#AVFV.0BQ5F2) 726 #&*4AC^
MKK]1]+K/!NBB7VI6TU/S/1Z?\O3_ )%#OVT<?B5RC<MC)U%-U!2;239@ '47
M;J)'6=$ H'$&Z8= $Q/?Y?C7'_V,4SH^AFKJQZJ4@Z6.812(BW.4?(((]STX
MEL!N\EC(@/<!K6./PV^JJNL\K47F9?3Y76_D>T@IYB29^TY>\ &RMBF#H ]0
M*8Q0\:]&+34G!S/$[%:(* 4 H!0'S5 1(-K>R]Q$+![1+[S '@ ]!I0'0.R;
MG."IDRF^(%#=PF$PJ%+Y936$;% "=.E24I>\K6_N+&>.1Q<\H>9B*MA(V?:F
M4 $R)HJ&.:9W/V]QD2IF4 !2Z]QAO[:RNH\LGCNMV?4-)I1M!B?]( J;CU%/
M5'0<(HF!ME^%"DH03"<2J85KXPD.L/:L<.Y3[)A$H"'3P"MIM8IKC\3+Q3ZF
M<[U_]4;**29$R%3(4I"I=I"E*81^$G@%S=1Z?71U-)1VG8H04 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4!(N:/G<>@5RA)(L4T6D@J=(4B+.7QR1[TR39$J
MC98"_>E*8! Q!N6WAT&Q2=0G6-#3EYE^I7EG&;0O*3)(7<\OEW*G=^^-M\>M
M#ZM:(Q2CS4 ,LNRG!H;*U8<S1N1^15WF$6N(N&TKV?A@^40W<<JIY:NY.7).
MC7+IKW_A8O+]+G"N4'%K9VJ])[/Y,R7(C)MR89(Y[O##I1:)>N=/SCM624AY
M:'?ACL3-G8'C82*2,V6.DW!61./DCT.,5-KE<RU-^PV/3F38^7()=B+XJ8IS
M*DD9-J64!J!2N'8(-C*LVYE#&.>X%1#X^MK=*VX?#R(JM1,.O;V<3'EOSU"8
M'2W)G ]'-8[&\PA,OTYF6T'.9ER&.*TBY+%66;NDX(?EY9!(%W/ZI$)V^6)_
MO_'W9EXT-XK')/-4V^)6KAUR=4Y;<?<#WV3'5,=+E N1/$-11=,C"JVC722?
MGKNG"QRI_,B%[B( /2M89+<N'=<SGA%*P[\9+Z6X&!%,#  &[0N!1$0"_6P"
M/6H#[4!Q$H" E'J ^-Z#4^0()@4R?;8AAO8#F 1$1N/6]P_(-620>6]5.11)
MNU.T3.!BF$JQU .! O?M'RC@(B'2UZJXDRF5$%K7-)VF;BAR3\QH[*1+3N?%
M7-\ ).3)PSDIQ1^_[A ! ;="]#!^29)I12IOIO'G3XF)3]FL74:^G'"]Y^Q5
MQL?/!:)."))E6$DI)'[2F1 XC8$S>/NJO[G-C"KT\8O#^+-AB)<NG30JKM--
M)7H42)F,-C%"Q[W*7V^ZLLU,U/3H!0"@% * 4 H!0"@% * 4 H!0"@% * 7#
MPH!0"@% * 4 H!0"@% * 4 H!0"@% * 4!TRO$#B4I#@('$0*8O4/A ##U\/
M"K:XNZ&$#UWM;<7MJ\3H%ARIS?9F.ZXBMA-Y%*#T\A(O,^S>90Q?+F1,<AFT
M3CN6OC**,73E83%CW  9  M<0IQU$S"_3-=MY@(]&'2WI]L>6>'Y%CDAR=T7
MMU@[.ZUUA/)4\NCA&8QRT9()N1PF5GM8ZYB$GYO+71(BBY<*J. 2*!1,8I32
MN-WY%<9*-5IKLC=FS?(8_%X>:R7*73./QC'V:LC.J/[(1J[ BJ:1?F'JQP:%
M'[XM^Z]Q#PJVUA&8EVE[? LO@/4J]/DD:T,GS&T61N= JR#)?;.$-DRI$$P@
MBD1::)YBJ9BB8Q2A<H" B 7"]5':GP(YO-2J.A^8G'OD]EF2P6D-KXSLQ;"^
MUR_?X;.LI".0;W9I*-#/6BKIJ_[5Y%(#^4I]L.H7#I.'X_EVE4Q,N)O->_?V
M%<]BY &%X)F>8?).Y)/$,4RC+2X\P$S61R$V.0CJ87CFX^2Y.L9VFR!,"E14
M,(GL "(VK3R<S-=^XF*4=M/S-!?D3Z@'-EN_W\EBVE^!FNL&VL[RO()G*W3[
M!U,T>8J7(R(Q<)D\DAM*+59[28M%6Q%8]VV3D52MG*@-"$34\O,OA)7C"C]*
MN;SW"YZK,<>M7SKY?&GLK)XLU.Z>XB5!3'56Y'#SY=.*7:/9)L#=,XG'L!=3
MM$WTT<65C3G]5R[&X!U]E0AUC.$B'!,36,<.X!]G_%[K6OTI$58FL;CB)BF[
MS%&_3M,'T]+#^8*JNC+L^TUP9#__ &3\3_\ ^52?_P O[QJ.R+A?/N^)LE4*
M* 4 H"%8Y0*D,I\5[@D;M]P_OB%<^MZ.DVY4*0D\G&-V8T.=J\<8>/";Y,4W
M"FST$8\Q4S#VN@F,. MQ AK!YAB^T/KK\=E[OI=7H898SRO)UXPC]A_QW_\
M+UNI_)'_ (U3_N1D+B 4_!V"1S +DC9 %!"X%'[N]QZCUL(>VOT72?\ (D]8
M7R/SW]AAS=?/+I_:V>VBH0%"IB/QB%P^L+_1]%?2PZ66/JT/FKJK_P ?ZCO]
M?=7:A?4.M*$]1Q-W>P/W?GHECJ'S'"ZWL*6WT^/\-(P'J%U0M<I;#TZ>-[#]
M/T4:P:@>LE^5<B@O%IG\LB[E0Z1#F ;%  3"YAN'0._WA7D]S":B(^!'F\7B
MLM680_4TX\Y/RRV!IG0N);9F]49+DT+DT@.P<52>)+(P,<[E4I""^6;/6S@Z
M+Y=RD)S?, 03H@(E&X6_-=;-/KX8O)Y95[$JN.)^V_K<L\/8]3J\J6*ANJJZ
M)/A0^'IT>EAN?@K.Q;(G,':>?Z1C\93AV.G)Q_(K0#.:5B9&)7G6Z!)96-:F
M=D69]X_*W[61;GL =OW/8>YZ>#7\E,9LC\U_=?R=?)K&N55S.\&;(N/M'<22
M,>H,W[+M4(9)PFFX;K"*QS"*H"82"<#"/4?;7J]TLO<=9]3"O3<7X)(\7L8Z
M/M\<,OO4U3XME&IGCU#I*B_P21D\!F2H'%)SBSA**BUG@%.*7XNQ;I)J/F0G
M&RB0+)B=,QB]P7N'E?MNKS2E7@_B>_'W&+495Q6^O@>&O*[TP)K'IY'$Q^;Q
MJ+D?-R#$CEQP6*%G $-(PKF0GG\N<_< '.F9,!/[ \*CZ'NL7RI+LX[W7<7^
M7VV<YYMJ5&_N*HXSN[7\ZX",/.EB94HD0^4R%B\QA1\J8?+_ .KFTX1FJ\*9
M3H I>8 W *UC_9^T3?3RR_W<:.CB>&_N.#]MU77%>EV*JHOFJX%.BLFM\(G+
MY8@H!R /;W%,2X>WZ:]?3]QT>I_XW)S?2ZB<9*/@<A?-R@:Z@]Q0OY8 8#@'
ML 0L(^SW5WO<+I9O11Y'V^83ND FL*H? 7Q$.E[C[0Z!5C=9')XM)Z,^H*%O
M8!^ST'QZ?7T^BH7E;4G/N#Z+>^HW AZ@>H=.OM\+^'4*5=M3,H\QP\03.9,R
MAP,! ,80 0*6YB^VP@%[UC/')2TE$G;#HY]53@J,Q7Z^WYK#2O*SEJ.Q\D3Q
MTF4/=9%AG#AJZ<-+1\YMTKM=R^03,V9((C)HB(*F)\-QO8!M\?+^P]M[/KY/
MW&48S$PW7N/K+^@_M.IT,>OCTT\,E*]6*IXW,8'I2[AU'@?J%>H5)9MM#7&(
M);;R7$'VN&>3YOC$ _S)!EB>"L71H"/E9-J[DA(Y9*B)42'&Q!'P"]?1]M[S
MV_NL9Z+M/Q/F^Y]C[GVW6R_E4<SQBLVQ7@;2_<2YP$#7 Q0 H]2@81&W:-@!
M/N$/&O5-3R[>!W \ ^KZ_P!^B:=@1J@4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * E.?9"=R1YYRR0$:"B"IG::+1H8%3*@Y%(X )UC_HC6, F3,(4T(ZN(G6
MMO#>6 S7IM<%M@[V8\KIK1FL<EW9 RY)I//$\;QI^X0S.+DD9A2:$X1SF31F
M(J?:@X[A<@J5;K<#!>CXW6W>$X36DKNCX06#\>-<S/'KU0\BB<IP/2,FVVUB
M;I]B&W\7Q5A';#=BF@WOC\O()3\O(%01+CRXV531*)2$Z>%ZU%%MW?(MUI.V
MOS[C._*XQ&9#$2\/(L8X\9.L7$?.M3H)&2?$>IG3<@HH<PHG((G/WD,!N[NJ
M/%1J1-ITWFO'R/\ 1'U;/\JM4Y9J7C9J$^EL;TSL9EE3-S"X<U7DMIST5LMK
M"2JC14[$Z[Q)6>C@3=?+'!,4RW.'8-HYG@;3QY/5>/F9*O3+T%FO%KAKJO3V
MT().!R/$E?PY:,_$H^91CTBLHEBU*@O&*+-5DD_DA OEFL4"A[!"KC*O2Y,V
MI],Q"\C)BD%DR!<!Z>)0L%AZA8+C;I0A]* 4!QOX^X+];W]ON#K4!X,HFN95
M$3HI.T!-8J94[+)'$# "H*B)RE[?;\/ATO6D1S;0PH>KUR^W-Q[U-FNOL'XF
MYMR$@L_UQG$=,YK 9.CCT3@+ T3'E.O()NL9G$Y$.V1-=,BR C\J;W_"IE+[
M9&/I:WIJ.'9VE&?V:%NQ)Z;$,Z; _!-YL/,'J$?,D4%:*<+R;I-9F4546OV3
MF-80(6_=2>9N"I<O2QM,.W:S8H8@8J)2F*4ABD(!@*%@ P!8P6N/@-&-#NU
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M&*80&]KU.I[E9=)S*?%A=+)Y<N%4]K%:$7;=\05FTBR>MS$,(F:"59,# '<
MF<)K*)%+U\1Z6ZUT]IUM9E*#R>X]OU5]RA0Z-0=Q%NBIY#@Q$SJI%4!)0!*:
MQ>\Q3 !@$;A[+@-;]YU$US-4FW<9Z'2B&_NB_>6)^H"!PU3#>4F92^618'L;
MP36>L@4-VVO]DOAXC:OP/]ID\L^5.DG[/_CD?^QED_V4>ZY>%@R4<GBF+*$;
MI K^KN/7*0@"(J?@S0OQ"!>H]OY:_7_URZ::Y4E113_2IGO/A>[R]QGGESY-
MXIY?_9E02A:P%L'P^ = "X>U/Q]E?;9\Q-S4^P5C&[*R-:5B"J!0"@% * 4
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MP&(-P"XE'Q]E2D<.-PVYEW\O [+1VD= ASE504/W)>8NF<@@8#&.'QG*2P&
M+![Q&U15[=M#6M;;:EL7-1;S.)O)%!1N< +IG.A\T?T:P?@CD $WPV*?I?M$
M;]:C22E14WTYYU5RFJF)S]F>(D3TWX@I2%*7^DC.!L4  0O-O@&Y?>(#5=<G
M!C#_ ,>+>Y_%FPTB4A0$"%$H6+[+ (=>T? /&H7@?:@% * 4 H!0"@% * 4
MH!0"@% * @/U?EH#Y&(6]Q !&WVC!T +#^:K+L(39TCMR'*)5 *<JA@ Q!M;
ML"Y2=X=>X@%'P]M2=8#4J#%SZ3Y$T] YPH4B9#_TWYJ)E0+8![H'#" ;NZ!<
MWAX_16NS;;>1PG",IQ;F,4!MX@:Q@M<2].Y,HC\/4?I\:S$&J';H04 H!0"@
M% * 4 H!0"@% * 4 H"0<D*X_5Z9:Q1>R6_ )E*#2(4J[@CE2.<$;*D.X!3N
M$K@0&QA, V\!K3;5-]WV&$DVI[NQFFNAZ-OJQ<SMP;EBN2?+M_K#C,GM:>G,
M9P^"6-B^33\!-S61K10QC_%=80KY08F'<^4KWS"?WBQ1[E!^,N:R=)7++WTC
M@9_^!GHX\,?3[,TR/4.%SC_:("L21V=D6:[#>3<NBK'FCP)*PLAF\OC3PQ$G
M"XE44;'4 RPV$.TMBQ3[/B,VIE>5?B95RHIE,82AVG4-U\TQC (VZF(0PG('
MQ![@JRV^!(4U-5?U4>8?.?6_-V#BN-V^M3Z(P+7>KF^19EB.[VS)!ULLK/(<
M]<N_Z/P1U/M$9"2DXJ,!B@19U%D%T4@=Q+BJ!6ET[3.2S=%ZK6BWE:Y84Z]3
MODSMCU'<.R'&=]M,,UEANEM>365Z@<0&.-V.?90MC6 ?K22$<_J4^?*R\C.R
M+EPDB=XR1!$%+>7VE3&4;;5X-<^26.-ZU2N_'ZFYGG&92+#7&3YMCD>N7(3X
M/D,UCT7+I-B*'EH6(D'[*.<D[WC=$[ETF0GB8/C#K54K&'?X;R4YJ2L7>=5H
M:4,ES?\ 5VV=DN>3V/\ -SB5JZ&<9[F\"UUYF3J.9Y5C+7',GDX4D8X3:\:\
MC1\Q,&(6-^(+"8 N)Q$:)JR'+GE9KE-PG@+D>29/Q;U')YGDQ<QRY?&$E)[)
M6X(BPE'HN' &79J(M(XJB/8   _+I=0'X:.)XP56L7F' I@[3A<!_('YP&]0
ML.Z+8>0G%G3W(O')G&]D:[Q'+/QK')O%1E9]@*LG#Q<]'KQKI:&>H%^;(\:H
MN3J$#S$RB<"_%81$-?$Q'-I0\3B7Q6P3ACQ_P?C]J43!C& +9>K&JODA0<O2
M9=G.3YRJBZ.51ZLJ#-UDQT43'.8Q44R@ @'PAG%I.(IKO-Y)M+).-VZG:8:)
M$JH_M)V(B=P*I4N*WP? F4X%-CV\ $A0*0I3@6WB(WZT;F#.-\IO0V4B^ >(
M= Z#X^'M\>M"D: 4 H!0"@("%P$/>%549&I1TF[8Z2ACF. @-^@=??\ 0%7-
MXMT5#ETNF\&WDY/H9$QCB(C\/L"_4>GN\*Y/&76Q[%U,5A$>HX@V,58IRF^
M+]/X/965@UE,T/-R^J58[@?U_P"&NIL4 H!0"@. E#N WNH6:0SB<@GMUKSY
M]'GN).1"=@?773IX<B@ASKH!0"@/CY9KB(&_/X_P5Y\>GU%DW-"LY@4WM-^[
M\H5Z%15N9:>AQ,03 (7$!MT-[OZE3*&FMZ*I1YXL5#$6*HX-93H';8!"Q@$
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MJ^@!KZC22[#Y2<M/>=@IKUPPNV=&<ZZ$% * 4 H!0"@% * 4 H!0"@% * 4
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M L T["QO/F42*D[TC$43 3 FHF8#!\(B4Y0$HCX' 0_)52:8>2?;!K@R-O\
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MZ?)AC@OM2IWUVX'PO[#J+J=7/.[YO&*4[+/B; P 8W4P 42EOWW "C_<CU
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M1"PC;M]UO"]>QOT]Q\Q+U5WG83\!^O\ J!7EP?J:.^A]*ZD% * 4 H!0"@%
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M6W%*"GB1.3X;&"]Q*%@L(6 P&Z@/3V?FJ<=2EKG-LI0XB\D>WM3,;3V=%'M
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M: 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * @(7"U5."-2</+
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M!UQ^\4W1F*@D%LHV.D 0^'&!,Z:HB<3AVWOT\?#I3%10N?4>=7>GQ,J!3 8
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M;CO#'FL.03[2B,:],G.NVT5!R*DHW5^7!-FBUE,8R!F"CDB!CF4$$3$,%@.
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M0C0"@% * 4 H!0"@% * 4 H!0&%CU^' MO3AV>N5 CKR95BH=(RAR=Q @<F
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MP.28=1$0Z^^_3Z_HK*Z?3P<XJI9?<<E$DU+=Y0-[0N82_1XE&NAC+''+[CX
M4A!^ "A;^4<1_? ?"CQ30QQY:J(.@X6<IN"%35:HM5$Q[A.8XK"M<WV2F1.4
M0[0_M@J1%%?Y&F[-OT_,XHK. 48I^890/O 74.4A0-;R0+V]H=?;[O&M0J[M
M#/,Z)_=J>Y<+"/N_L?UZAHC0"@% * 4 H!0"@% * 4 H!0"@% * 4!*.2R2;
M%9DW.0ZQI(3-$R=GW"1@377\]=0@^>4H B(!8!ZB'2_6JMVI'9[+ZFMWSX]
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M4_*$J1")=H>29 HFL*?8;I:X6M1O77:X2T4\OP[#NHL5!3(DJLZ*($,43%6
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MO^NRG=YBJ_5CX?B/P/\ :3_\7Z'_ ,Y87_793N\Q7]V/A^(_ _VD[_%^A_\
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M+J1%:P=+ -P  ,/C?W=MQ"H(FQP*X*H%@]H":_2W8%[C81OX@/2KVV(H:D%
M#  D,'<<.XI@$1+V%^R';;L 0*/NJ=IIQI1'8*4"E H> !T\?ZMQJF3E0"@%
M * 4 H!0"@% * 4!1O>FH,/WG@;S7F<1S*5@Y%<CA1F_:H/&YUDD'+8IA1<$
M43$02=G#P\!JPXX$>[>3<W. JOF"* @R;)H.&R@_ W646.JF4B9^WRS$1% I
MA !&W=]-&Z\7J1)1:-W!=A+N6ML7>8U/QNP$(YYB*\:=7(E9_P"7#'C,?,1*
M*+Y9]9B+9(3E#M.8 Z![JKAUA;A7&FO::R_*SUX?33T"P>:JXS:H@>2FP(Y!
M!O'8QI_%8O),;AW(O130CWPXB7)@;@N4ACA?R[%ZV$*BGL--J5#F51JJ+N_1
MLW)RYY#YSM?<7(KC.WXW8?E>,L'>KH1KB60X\$GCYAQ/\*</7$RR8H.'YXXH
MB)4TPO8PAT :G'4>J*[]I^7 V!: 4 H"%@"]0'P\DA;D*2R9@ # 7VWZ"(]+
M?76DVK"C541%$AR&3,F44S!V"40"PD#Z+>VP5-!J?-1("H>6D!"% .T OV !
M1\0N(6\!JJ-29<SJKF!7]H.W=M'2G!_$D=/Y2.%3NU^0N)ZAR#(6*[IM(M<8
MF]:;=RMZE'/&+UB=.04E,.9G+W"<HD*;X!&PA-;TFHF$X7JBCW?C/D4>]$;-
M]JX!L_G%P<S+866;-A>,.\9/%<!SK)%9.07_ %:BY.1A$8R1D7#E9J1X9KC
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MP3R#9^2P&AU\@G,^/DV/8IKV4BMTYP./_K"X+KW&W#95\\77:))@V1<C\ZD
M&.68I/16)U&U1/*KBG=<GWE$7=6T^!?$/DIF/.'*YW)&.#Y1#Z8UCIV1E!SC
M;FV&FZ)['6RDW!M<KR"8F4L)P:.D8YX9!L91)RQ$#"D!3)E*7NEO6Q<DE,-K
M%*J5YVKYFWWPE<[U#B5H _(YDX2W6.N,0/L1J\9R;:1;Y $,P&8)*M)8ZDFW
MDR/O- _GV4 P?$%P&KZ7MJ12E6_#<79-Q(N!Q**:K>_PD&PB0_3O 1N(=#"/
MLHZ=I<=YVA12.!0$A!*6PE#M^R/B-N@^X/S5"Q4^@!8?HM:U!2.)RH!0"@%
M* 4 H!0"@% * 4 H!0"@% * I_E[9V\5<LV+@C19_!2#%=PN @0B#ANZ31,W
M/WI@5PF\,0QNH_= ;H'B%7"YEWV\N)HU\Z-"\W-IY!F'I[:7X[M&ZNZ^1>Q)
MG:W*3"PE#H9SIC*M@^1)14R\BH==%V7$L2GY 95)=^LFB#\05*D4P]T=7._P
M\3=7*F(B(OQE<?,R_<'-#8MKSF!@. <>N.<YIK47'7!5(C,]]1V,N(:$W]E#
MUFX=/,?E)-CCL7%NS,ELI14*F=XZ/W1!#=O0.PD[K\R992X:_#N-DB. ?E@,
M(&#S%#JAW?:,"@]P&,(@%Q->XC[:3/$1!WJ A0'Q\E(0 OE@(6$.I>EA$1MX
M>\:3+)$6(?+I!?M3*4PD*F)BA\0$( E* #;^* ]/=2=2G S=,RB:ADRF.B83
MI&$MSIG.F9$PD-;I=(X@-O8(T5.TJM&AS$EC /8 ^PQNT1$P?Q  ?8 >VD(*
M7.X F4YKJ$ QBC]HQ>A1M</+N'V>OYZJ;,M*9@^UK^(!<0OX>[V"/Y:C4]A?
MB<J 4 H#K#\(AUN(@;O,3[0CTL4A0N(A_!0L4,-^S.?^Y=%;FWFYW+IIU%<:
MM1LL*BFF80D;++Y%FF0YY.0.-Q;7'UC-/DY-HC.9<R34% JW:8JI>ABC8UR]
MI.99*L[;>)=)I;G%J/;VIMC[*AT9R!;ZG6?LLUQ#*.V'RR"^0-+)1_XA%O4F
M[YBA+A!/ ;'60(5;Y<_9W=IK5S$NI*S^J6]Q)W&_U)-&<J\\+K;6JIW$\BUD
M%7 K2+)R1F9BTD7JW>" =P&^4CS"%^WJ(4R3[V$\,K?:E/':2P'E!ZJ^Z,&V
M;LUUI#&< F=%\8]G0VHMZR^5$7<Y;(9@^=Y6@JSPY!M),R B1/ ),!,*;@0.
M*73K8<-M*FE#IBL6US2]=Q=SS#YO9[J;+]4:5T9C\%/[WW!KG(]GPQ,X643Q
M?'\0Q#$\ES.==OBD6:K&44B<+DTTA\U(OG"F%QL(#N8I-O,YQP;5IW%D:7JZ
M;[_H@XYS,)QR<9UF>YMK0V"93DT$XD0PUO'?=M<ME8)NA$28G9M9%TF9,_SB
MB94CE[A&X".9RRM!U>.&+]<Z>._L*]YERTY^Q/-3 ^..'XWHG*L8R%N3)<B<
M-1=NLAPW!28S(R2BN3+-9]<D%-'F(E<B2+I%(5$3I& /O"T;<PG0SR+EM7?.
MWYE?.9//1[QPD)*$P[%@S1?7.N9O>.Z,@0<'=0^%Z^QY%DZ6:.#M$E4XZ7R5
MH^47CA<K)@9)FL)2J@4QB;R>]5,+FMBZ;7^9YV9<I.3F(>GVMR._HE1EMW#&
MLI=3 \<CIB891C64SV-A$)8C5BDL_5B8_#GP2+H@=@ "2QA4*2XEGZ:2]I$=
MB[[:;/N)3].'E]R$Y&NU&^SU]8Y7!/\ $V64&RS7+LQ387DDDBR=!A6:0(S6
M0N,==/!=K?AS9TX06538K@0I_+.)58G>5I_:[+Q?Y:EONOO6 DY;,/4!AMB8
M=#8IC/%AW#L-<)0\VDQR39,I,1NOOEVT<9P0PR2@S&7F3.5LBJ8$D3@(7*(A
M)]4ZLTEC%+)U\$25QZ]>;5.0:_UP[WX$#CV<9=DD]&S^,XWE$7^.ZO:QV1.(
MV'C\U@W"JTHMD*<4)/G$U2,#D<HJE$A1&Q:O]1AQEERXONW=I=W+^KCQHB-Y
MKZ5F,B8QJ"[&3!IL=YED(AC[Y_&80]SMU$IQ:YT@5D31"!$4^UZ)A76('8-N
MTQ^5JE2GT+[I^%3U>-'J8:0Y%;.)J/&,9V=#IRYI1Q@N8Y*V<L,>S=> E6T)
M)F@5G,6W;?*DDI),"G17<E.0P&]UY$)*C2M'"W8*O)W65:/S[44LYL^K+#Z.
M9[%QG2V'SFQ<[P2>UGBS?,6D6^E=4&R3(\[PYOG>,/IF)36CA=XWJW)C2?F?
M.E$KE9,ITB@%SII2R\]OB5+?5O3;SX%C^\O6]W?K=PU8ZRT_&YO"XY";"SS9
MN4':2;J'C,2Q"6CRNW\49IYK=LRBFTD)#KJ+&2/V@:Y &U:3YO .,?3BI<[Z
M+BBZ?2'K5:\3B\'QGDV[P3%<\EVY'6=2>-9="LV6$OWR"OX3$RF.OGB[\KQP
MZ2;D.95R@($>$'L^'XXGRJ\DR:=U'?;=V5*B9IZU'%_#E7B$I'3?ESF73>+8
M,^>2S&$B]C!BTL]@)*?QY\]:*-E\:!XFD(.$#.D2I.DA$]C%[IZ5V(B>4_ZG
MMLR:9;UC>,R,3"2^.QV<9NW<X!![,E QQD>4;XSA,[DTMB*4[DJD>W?)LHXD
MG"NB(NUO)0663!,INX!I,V="M:-2]MNPZDEZN.@D<J:KL8'9LQJB*C<8F,SW
MQ$13PNK,'B<UB6F1P@9CE*3%WC;3MA174.#B0:@F#-8!Z%,)6M"J&UBZ-)OA
MXZ$\\2O4^T;S&V*XU[A+C]7<F63D9+#(QWE,5,+YWBC1@^=*9%&LFR3%R@FJ
ME%O^I <D[69OC\>VKR>WB9:3='+6U.'XF4N(; V:BD"PJ$[A4[1,!E$P.)CB
MD< ^R(=UK6#PHU+@JM)[05 * 4 H!0"@% * 4 H!0"@/@LB5;L[K@)3=P&#Q
M#H(6_+>DQV#XG419)HM?(,4!*"0%$UQN;J8;7N AXT+$OB>5,8_%9!&/8>9;
M$?0SU J+MD8ZR9%DR 4OE',@=)8Q!M<?B\0JK<[F=93HC!5NOT)^.#>=S#:?
M$J&Q;1FZ\F_ VRTY,J3V4XTBA'RCARY D;EI=@QJ+AVPDG" *$C . B00,42
ME,4GEW%R6+I9Q\/(O.X.2O+]KE.4ZUY$8#B6+85K#%HC$<"R7''[)<<[/!ML
M=C#Y09JSC(X[%&8\APX*B8B)4P.!02(  4MC)+@S*Y'1?<NWQ,EU9-"@% *
M4 H#@H7O(8OO"@,>'J/<#,6]0/C=(:&R*3/CLC'Y.SV#@63HOI1JMCN?1</D
MF.1TT<L><2.D&\+E\@EY2Z;A 15 11$Q2F)'5INH46=$RE/I?>FLZX'8'L<V
MP=D*;@WAN7,E,^VQLTZKL#9'/NRH+O5T6_X?!L&:*\C\PJ";9@T3#SK 0H6
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M#T"B:=T(R4U*Z(-P0"Q;  B(FM_;#U,(7#VC4+0[/A0"@% * 4 H!0"@% *
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MXX:#RB]_?<;CX]0L8/$H#TZ@2XV]UQH).=OR?50*A&@% * 4 H!0"@% * 4
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M;?Q^D/S4KW"@ H!8 "P -[!T /R!8!H#E0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@.FN90"J]@7$"F$G:!.XIP 1*<O?8@F 0_C=.G6@T-:KUN>3_+;4
M^Y.!^F.+VZ"Z%D]\;6;XYD>6.,1P3+E4VJS/8 "4S#+<0S**,116.;J!9,#!
MY8!TN8!<5H1Y1BEE/-EE'D^[3M*3:H]2/EGP@YE;VXL<\MS!R2P[$=53.UL&
MSC%];X%B$W&QV+Q6QY08!6,PO ,%))2$S^IJ")#G*Y3*=6YE"EN:K]Q.S3:L
M[N!6"*_:*^/)I7-HS)- \A<#GL,Q!#8(XQ+EU;*DR?#G&1XABI<N8/,?SN<"
M+:(/LX8W;/56;D?-_0B #:2IJ7D>*_TOO;\2_+'?4STSGG)/0_&*"ALWR7,-
MX:Q@-S0&0,$(%*"Q_$\K:S3N+;Y"5"3;F%=)/&G J@5%8P /B-55I4CQ:2AJ
M:^7D94F"2I$B)J',H!>\Q+E13*F)3F)VE\@ [K@(CUO3*]"X_;\CUJA10"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@/BH41&
MX  AV@ A8!O\5_:%  *8;6#M* C<!L)N@_"(>(6_+X5>T4W$!3$1M8 Z7[K%
M$1$!Z%&]^E..I.&A]2A8H7"PCU'K?J/C;Z*A3E0"@% * 4 H!0"@% * #0'3
M50$Y3)F 3%5*8AS 80,4#6L)0 0 H6OW6Z^%J2Q28@LAPCA/QYUL_P 53Q'
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M7]%]@?TO\CW_ $5"ZF$+U+?^]SA-_P##P_[W&7_FT_[<?HLX_P#+[_\ C?\
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& 4 H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm2226999d1-lc_retina4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-lc_retina4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!G@*6 P$1  (1 0,1 ?_$ ,@  0  !@,! 0
M       $!0<("0H" P8!"P$! 0 " P$! 0            $"!P,$!@4("1
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"#=JBF!>(B F P!80#_>3\
MB(@-@"_^FJN.1'.S,P]=OOFVZ5=+]V/M";=RG-TMCQ$7&3#Z(Q/$DLI4^SE&
MB$@@ ,OUB*6L+9T2ZHG "#_NC2)"9>%U#[>ZX[J:0B-Y:0?Y&[Q*7E)7%&:F
M<0A,>D%IK'CHIS2RL2B^D?Y::)S'*7W@YB%A$OK5<1.V>WX$VQLCM^)JP=C>
ML^Z.OGSM?&7E&>=H\[W[-;?V?N.=C<<S=RM"X_KG%8EQABQ,?QENU?R**S,
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M_:-8!_F 6_#P/XVKC>HL4X2I[U^)FK%VK-1]R'%XV$3_ ,U$0(8"";F17R(
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M34FE54EXR8?]S_(7.+9DYP+0&MY/:>0@=XP?F!XMCL;#RR*WVQ2 Z3BI0\H
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M=\ESS!6&AS]:M=GAY#/\CRC'(=?*B:YP[]&71<XDJA(&D&S@5/93,;VCB'U
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M5@^ A!%P1KS2#^$5'1$#G10]0\*K !1_ ;VKXO4K3JLU*G.''?#P\3ZF@O\
M)>HJKRG'@FU+->?)=V=Y<4RR=5B]#.V\>UG)5)B[;X.Y.W<,TI!P#==-ZT3
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MAX>3044%;[<% .4 ,82" ?'LWF^5-+.',/'>MV[P/B:'K-S5Z6W56J*G;O\
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MP^WR/Q$3 -_(W'S49DB,H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M7%7D&H.=<A!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MS&[829;WOW'< S'7.68]L\L6;$)1N\C90\@LV29M6A&PJ'>+JN1%-LX2*<1
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H"#=@(\! RP>%"V3 1+<Q0L8]@&W&WC]]5$<[#24[<9KW9P/^XEWB]Z#
MZ;U=N_=:W637;%_C.UI]ICD(G .];8260DB2CS)<63_5&20)F;("Y$5CB( 0
M_I5;(LU'Z3=(BE0>$*H1)4!67LFL@=,O)F@H55)8CY$ ,\:+"0 Y\S@H VN(
M#1\&H[; L,UCVVGKZQ,A0"@% * 4 H!0%L'9/LKJ+K-BLAFVULPC<4CDTDDD
M"R#I)NI+.%"'!)BP(J("X<*6'PF F"N*NFF>9Y\.V!\7K7N+2]'TSHU$3BTH
M;;P<Y&(%I\\G4LLX*9X_)V[$%ER#(';R@L42%%,H/5%!;B@5!</X1\!](U%3
M0GE*C>:P?\G=)MZKD=-?+.ZK<C+]UQ[*ZJ[(XG!YMJO)X[)HB614.=PT< Z4
M;G*U!<6QS<C"D=+D &#Q7)330E-&>W(V/T3W/I>MVJ*=-4FVL:<94*9\2Y^L
MCT1*C"=0Q2 %B7"YOR\U=.U;M^;/$ZUSGKK2_MP+ /D.9O)#KOFD6UF4HL@'
M.X?+**J( O$>UP<M$S$ 1.L<M_'H/YUK;W[J*:])53*YHJ_]IM3^/M-'4*:D
MO+Y?_=^1C>T_A/0V1UOCA9F0Q)M)-8MJE)I3I6Q'Q'@&$ZZEA(J8"+.#"8/-
MQY7K\\:>UI:M4ZJV^>:N[-Y<(/T!U#J?6M#2K&FIH_9U44O!P_TK/+&4]^!D
MXZKXWUCQ^7R971;[%WCYPW;)2WZ%[/N%8@XY *QDTRB*0N )Z_C6_P#VKJ-%
M12_3AIO<O\D?GWW1?U^H5/[JGE<8XSC&'W+Z@01%=NJ'#D7P7UY6'U !MZ>*
MV+;=%;5="V[D> JO<M%5NK-DSKMG5% * 4 H!0"@-4#^X%Q1AF7:?XE\=DQX
MP^2]GY3"I1 P#[JR3_&IGV5"D"XBB"K4.0_D/I7F_=&F_>]#U=FW^MV*DHG.
M(V<&SZW3KOH=<TNI?Z?6MU/N52<%IVV]?R^F=AY5@\K'*B$#*JA&(E3/>43?
M)(BP>,B&*!E&Z;42)"-@ #D$*_G9[C]H]6K]S5>:X[?J)8U7(_13LY8/ZS?Q
MK[YZ!I_X[ILWJ;7[C]L_[;,R[M;SJK3RC8;#/QE:$6UCHN/GLA9%#),L=#D+
MA42""I&TJQ:.$&JASD*<2ID.'T_P@-?J'^,/9&I72:+MR/[=M?\ ^NG']!_/
M_P#G7W)IM?[MO?MTN3FN3"IPF]<JC!M9,R8)%Y&$"I\.7Y#Y$H"'_9 1M7Z+
MZ9TK]A1YH;[V_JD?G>]?=ZJ$H[<":-VH)G(83W$#7 .1A_SN 5]*NZHY3.UI
MZEYWDB9UP'9% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * XG_A'_#_6% :N>O@
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MI#;_ -)9K%:JWSA$0,9&9)*B=E$SS-Z1)H=O(OB.!4*K&L2J&0!,A YC8X'
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M1N).'$O_ "/5Q<^T=,@)^ZY)< /SXI*)D3/Y&WU\_/BU(P+./ FM0I+7:@)
MH)@$2\>0\?XO(_AZ_A7)2\#K76J9-9CY FNPNZ/?&+Z5'V([USI?$L#B=EY4
MK"OACIK(??CE#*Q*1U%#^])&<+E,U(1(;D(?D!@ ;?"ZBIU$3LV]S9JCW+JO
M^PZJND5M4V71/-M4TMM+B_[8S<+$M:[(]$E_CSQC$^R763<F>1$O!9=!M,C8
MY4YCQB<E@#@^.2(?1K*.CB2KU1P10RY'0+%!,41*4!N)OFU<U+I>5-3PV>'Q
M7P:/(7?:-OH^JM]2TNHU-3]185-1EAA";JSF=D&T3U[RLN=8!KO,5(QO#*9K
MA<#D#ABT1(U3_4)&$:OWC@6R(%3]U0ZHAS.45!* %Y6 *])IM-;5M:J6J]V"
M4O-I);C=O0]=5J=':MUVZ*'70I:4-M+%^+4[\=Q<B"10 0N/D+?A^=_R_978
MG"#[_(H@A@)[(@)_Q_[/G_96--KF4;2-\CEY'@]C;$QS6^/NLEREZG%1#4JQ
MEW:X7 "(I^X)N).8V$M[?CXKS76M6NGVW6^/RCNWGV^D:&KJ%[TZ.'SG\#'8
M]^5_K4T?.&Z09FY!JJ5%*01@(X6#[D[,S,HQ,><*Z5124 1,8R1  H#:X^*U
M/U'^1['3M6M-6FVZ6\J-[6VM;CW^C_C;J&NNTU454*B/^<Y3LH97SKAW*P/L
MW*Y)"XE!Y;&AC35-9T[G8Z)8M%E'"PMR)-58Z<E5#G3&XF Y4[!^=>ZZ![]T
M>NKCEKCNH_R7_,^1[P]AZOH5E57*Z:I>QU;:6]M*+QF:9$E$27Y7 PE]1L(#
M81N-JV'1J[>KIY[4I<8V]S9K_3Z>JS;JYN&\G54ICY^0/K]LGLEU]>ZQP+?F
M5=<FTA/MYG8F58;'(S&49)KV @\A>Y'K"'0469-V1,T#VFZST7"9V:)#'3*<
MUB#<L41XQ/;\36$^+"4D-/? C\H<MA3]^C+8EV<[+0L1*#[IIU=2*Q73$<P.
MZ?%.Z6/(E;'545.<B90%;P(^M'&,]H(I\/Z=OZ%D3;0>F>L^D_[;CM!IG#6>
M+[TW[VNT(AOS/XR0DGTYG3.<S;&);($\D."[A!=(CJ1735,B4Z8D()#"(@8@
M51F3%XYMDCUUU^UEVZZ?_,_W%[ Q22_9O66X8[-->[1?NI1KDVL9\,^DIV0C
M($QEFC4"Y$YBDH\"J%(0 5 H 6]JD;9+GCG/]?G!>+IN+Q_Y+N^W0C4'=#$$
M-@ZVQ7X8\AW,QUUD[F4+'%V<'8G.<##,)$GM1"J\VOB6&QG$B7OH>UQ'W.0B
M%6/B10L-F9D.^!W<3+0?0+OED$TQS'+];=2.RW;U3!L)PMBA/YA,:SU2C+Y-
M'XGKB DY.+:2TQ(0\:+2*;.W[-%5T=--1=(HBH$S1<MIC1[P?*7JOY$._/Q-
MPVMNO7;G2BFL^T^+Y!*N^RNJ,9U]'3R$J\;L"L,4>8SL7/4Y63:&<>XN0_LD
M*D0PE.80 !X='1R-U)J,?F=AZAZ3RPY:^INM;9V=ANJL9?9IL')V&,8JU'@K
M*22*_P!@B17D4B:QDTE%2F.J4WJ2W[:^+[HLTW=%R-PTJOG&Z<#Y-?4/V-UZ
MN[7RVTU#C=]Y-6";S34FV^^F:QF2["PUO@2&8M<B<2I7CEM"2F,+H-YA;'T5
M!9)&4FW*IU&2Y# 1(B@B *F*'*OS%U;V11U#JW[FI4N%4IFK:ZG_ (<3W_0?
M_P#2=?3]'5TBN^^:AI3RVX\M*6VZJMG^.9G5TQJCI+O1X[RO6Z6)9Q*XB^AQ
M>Y/#E?(JI.CMWB;0IA,LF"@*E0-[@<>(&3+Y&MO^W.B4:*RJ;;32E;=K3G%<
M,? Z>M][U>XJJKU5Q5TMSA$999[/N73[PZYX/O6'BH;*U9UJC#D*C&.<<R1[
M .F_$2B4P"S15]SB 6"X^E>OU6FNU4)I)PL\?I'W/FV+U%-7CEA^),=)Z'QS
M1N/N<>QJ2R&1:NN/-7(I=U.+DX@:P%4=%(;R)O(^+UUK5%VA-/:N)S7:Z*VF
MLUX?B6XHZ)[<QFP$)E#LHPF</":,[5@9/&S,UPBS <?MB"W2>)F6)<"@ G H
MAYY!Z5P.B^GA]SL*NQRXE(OD>T!FVY==M3X@U@I28PA.0R2:4<N'+*1>)IH(
M'0BH!NW8NTU9 Q&(G%-91NE=4O\ ,\CQT]_+GM[J74NDU7K3ICT[D_J6'+2H
MA4M81OVF^OX)]]=%]N=>HT_4W4J*KUI4I*AI-55-MNJNF&^9+'# PL=7=,2^
MS]Q,XYS'N_ML*:MLUG63% 71S2V/I-G#K'S>4T1?.7!3IB0QP3%3_>MYK0'\
M=>S^K6^JOFCD5=63KF'2Y>-"V'Z^_D_^6_9]_P!OTV=,V]1Z=N%_HAM54YQ=
M;AO.$S/+ION5%CET+KZ8TSO.&<2@K0T1(/,.QY&$8%:@F<32#IOEZWLMUBHF
M$HI$6/X\E"OV=[>IU^AN<VI:=OTH43OIWI;C^;WN?6=/UUYO0\RJ=?,YC%^:
M8:;R^Y>EGV]=7:O6BT,]REOCAY=$Z[(7+5\X(8A#BG90S!L[!(PG*(!RMZ>;
M5ZQ]0>&<,\GZ7 ]/C6Q,-S*%_J'%IYE-0]@,+UL<4DP*(7 3?>?:B0+?G:LE
MK6U-,M=M[)Z? FL=G&)S!A3B<AAI)8!L#=G*1ZZXC>P\4BN>8\1#S7TEK*6L
M']/N<;M5+,GBD@DDF=02*FX'*02I@0YQ$Q2C<"E4'P C8?VA5_>J)_#\2>F]
MN"\219)D49 QLK-RBYD(R!CEY.36*FHJ=)DW)[BZY$42J**^R3R)0#D-O #7
M/3KK5.GKNO'EC=]V*-#>U6HHLVX3JE8SG#W)EC4I\D74Z.=(-3[) QW#A1M;
M]!G#>RJBFJJH"P Q$Z=@3L V\B(?X:SZI[]T.EO*T[D/_P!/'_D;8Z=_#GN7
M7Z>K46[*="6^J7$8+R<9*A:O[I=>MLY+%8SA6:!*Y!(*7;Q@14R@X I5S(D5
M4]UD5%--4Q!$HF. <?6U=_I/NG3:ZNAT5)S5PWQOVGG.O?Q]UCH7/<U-"5-M
M)O&K)TJK;2LIQXEXR+M-8+D _I<0$O$0_P QKV]K64W<IGN_,\4[;IS(F_B]
M=U.5)QQL/OK5 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4!#KK%2 @& P^Z;@7B #]5N0 /D!#D >*0#2C[5=Y<&
MZ!_W(.V-PY_J7?VY(B7ZRX-B:6+]<L$AMB9PT>R^"XC[#Y]"S&7X<T0BT )=
M54'1SD 0L0;UEFC"8>)M$=,.\VO>\G7^/W_AFL]Z:;QZ;G\AQ=MB/8' XO#=
MC-G4&X19&D7F-8UE.;,THF15<E%JI]X)CE 14(G:G*\RJI/8S6%[3]/83KS\
M[WQ?9T3.,XVKL;?FV=VY9L3.,RG/MVI(Q@GKL^+8G 8B5V]2AHC'TY=V') >
M3@3EYE#@%1C:7D%Z^=?.UOS9?(EBW:7$,:V=B6!=7=!-<099@=TTC,<Q[+,&
MPT<N=PZ-TDT/U(TN],N8IN9#*')8!+RHTY@LX8XHUT^G^09-V&ZW_!EI#?#]
M_E&DY#NGO*,=PN2HIHPX,M<XF<^IL2/(O';$DQ$N'0%*W3$0,;@  4QQ*43P
M4DQ;QXEW?9IL]ZZ=HO[A76W7IJ3!M9_^#G3F6NL5Q>-7&!B<V9,OL(HS7VSJ
M?I+\K&3D# B $^Y!P8XB )EY5P^X?@>ZS#3^HM-;#_MJ\QT5B^+8CF6?S?6^
M+V%+84FH62EXG+)&%>9JGDAU%B*J)?>S#Y1T<2&/]R*M@ O&I*F5D'$89_D;
MV!5#@N'NDL);E + )3""B9%! W\5A,8!+</(!YM38/[I\":U#(EK@Y /R.03
M<A]L"^+B)3"%Q\_PC^%<M.1U;C7-CE^9K\?)MU<4S/<F-[_T/MS =3=D,*CD
M8TY\FREO%MLCQYU'.&().V)B.E3/8QN83,P.@"2AA'DH3UKXG5K;GG4+QX;O
MN:7]]](NW=;_ -AH*Z*=7133*=4<T8KEG!--;<&IQ,>N&]>.V_:#)L=C>Y?:
M;4\?IK'9ULJZQJ+R^.4E,M?LU#*,'8HLVK=LW55(X63,4SD $A"#<1$0+Y^P
MJZ[TUN%.US\/D>=Z%3U;7ZQ/JUZA6J6HYJZ9<S@E2ZL>^$\,3;/UI%P<#CN)
MPF.(E&'B,<AXJ/,V.DX03CX^(;MF*ZK@JHIB+ALD4/Y(JAR'UMYKV5AQ95*R
M27T1^A.FV;5&EH].(IH23G/!>$[7B54KD/H$ [62 "W.4//YUS6L&Y.M?JIR
M+'^^.$9!L3KUF,7C;-U(OHP$9<K6/("KJ1:HE5^[8($.8H'.*1?3\AK77ONF
M]7HZO03JK7-EQY?P/?>Q=7H[74;:U-=--JJ$YWJ8^,F(S+(7!,"8:)V[_P O
MRFQ=A .\,S*&DXX$PC%#LWRBC]PF"95/>"6?F 36/Y+XK\F]<Z5K-1U2B_?M
MU)*FI14L\:L<&O _4?1]?I^5V--=I<I5*JC9Y5@Y3QPQX%TWQAY+'YADVW)K
M$,><16#R9F$LS.Z;&16),O'CE1>/34,"?)-NF8W(O#P(!YK<7L;H<75/Z75N
M_P"2XFMOY@ZC578HI2;KE*9S\E4X1O@S0-3* LF55$Y/0"&$0L-Q-?\ #S:U
M?HC2Z*SI[*Y&ICCO?$_-]O47Z^:FJA\N&)/*YRGBLBA'$]!S,.!UV3B1CI)L
MT?$3!7[%>3C7D=[XE$0*J9(KP1$/'@*KQ7;$BE=LC$IT&^*U#JGU/['=5=HY
MJ[V?BO87>FU]MR[B/CF<.[C(/8\1B44KBX+D!V@^526Q?[DJPI@H'O<!N!0I
MLX]LOOX$24Y8=NR7>68]<_[?:6U1OG3&8;([79]N+K7U$RG^LNEO6R6QK',?
M;:@=#.NLVCV65Y:U8*/LY1B<PDW"X%$C104>*/,"E"KFL8'+G&6PE79'^W--
MM[=^YIG67<#9^H>JW;+8$5LCMKUK:PF.2R6Q)O'<N:YQ M\.RPT6V>8/$MY]
M PJMQ3>G53,4HJ6*/)S.<8DG+A&PNH[I_#]D.]YG0&R.JF^9GIOOCKIJE]U^
MQ;:L7CL1L <DT<Y&*D$\2R&!D$F;11PE-)/%R*E%,0.Y,(@-PM)+"3PR[=F7
M;_']\?N#?'OUY@M(:YE<GS!RZ=&S'867Y8:/7G,ZV9,-VQLSFG!DV"#.&BLD
MD$E# W]E7[=)42\S"'(7CAV[=Y6ELS^OY;N!J>_(>7:H_,)TN99=WLP_L9AZ
MW>YXA@_6V*U^PQEYU<,K+O!3@9*>A7S:2R)>(:E%G=P80,8G+UK"A<CE9S)U
MNK>IJ*U383=*5.*X-)_#XFY_V.U-B6\M)9KJO,XQ.7AYW&'"9T%3JI*DD"BJ
MW8ND/J,<@?<)F, &,;]M=3J&FKU5ITI-ISD=/J]BQ?Z+=TU57^UT-1MX/Q/S
MO-T:@S'1FR<YU%EC9P$UB63+XPX2=M5CK2 RC[[/^HVKEJY(L964:N@<LB )
MB@8Q!$!"X5XC4=.>GO*FY3%37'#>\]A_/OW%I/>VE]UWU;TNH_;J[J*J6N3S
MKGKY$I4Q5"<\3<"^&O%&6I^G)LGE862@)P)25<YLHK"'0<.2Q;A3@DR9&.HH
MHU(DX*9,]S"/GSYKT?2;5BFV^9\KE? _8'\=T]3M]&];J%%=&IYL4TLN$;\&
MWP+N]7_)UU>VKM1IJ2!G\AC,OD908B(:3F+RK%&4>$34,=-NZ.Q! E@1'R)@
M#Q7K*[.A_:.I7*,L5BMO?B>W76K:U2M5S2VXV;N"+F-L=J>O^BUX9KMW:^+X
M"OD*!W,*G/.%T32"!"E,=5 46:P<2E. ^1#UKY+M:)9U4_,^I5U*U0XJKAM3
MX/$]7A>[=7[(Q5+.\%S.#RC#U5GB">0Q:YE8XRS AU'A 5.BF("V(01-</PJ
M*UHFN954QXE_[&AI5)^1[?F:\?R[]E]H8K+X?M[K)V230Q) 4,.R+"X F-OT
M%IV0>KD3F5SNXU1\+4Z"Q$1$3"!3-S>0KS'O-6-5TJC2:7SU<EQ-+-<R6S;)
MJ/W9[NU7M_JM?4-)?:LI)M>5150IVTO"&L7.W<8+M7]O^V#O*&&'ZHVQ,8Q/
M;/>MHMS(0[+$@-*2D])-UE)U91] ^X1,6JQUB@59( 3'TO6N?;'2WT_5\]5-
M2JJ;X1-+49O?!JZY_-W7^M=5_P"OM7ZZXJJISMX-/#*VMN$&]-U_B).%U1AK
M?(,O)G.1,<?;C)9,"::[J3>*BT!^*1D%1CBE0 _U\$BG+?P:PB [;LV;M[.F
M*>69SQW? _570+UAZ&W=NW57=K3;QR44_?ZE6I/&,#R<H)3$1 S9 3$R!'Z*
M$@N9(XC]Q9,YQ.4@* 8!M:PWKF>@HQ:2A=^._:?=_<V<$JU+F<<MVP)8CAS*
M#=XRQBHB/@':1D7#&*:*-#"50.-P$K@3 (7JO14<KI22IGC/U,5JK$RZYJXO
M#Z%KN&](](X+G$7GF._U9$2<;]VH6/'*%G,>]%PH0YSJH';"/%,WFP'#UKX?
MHZCGQIJ5/S.>K4V<%S4RU\C[OO3N_,UGV,YICL$75#)!L1NYCS8XTG4UUC+*
MF]SF^6"YE -:]O%JCLZJ?*G\2+6:14RZDUXP>W+%;8QG2DO NYR,V3M.)QM^
M=B_<-2136>ETVYU$V$BQ!0Z:Z#X0&_ Z8  UT^J?]G;Z5>_;T5.XN7*/\Z=Z
M<R=SIG4>GV.KV?5=+TZ=4XM8\M4/?@\<#4/RO.DLPS'.YEZU6B\GC)Q0V28Y
M#IM$8QFY0551X,@69N%R!Q74,8HF,(@0!K\*^[;ONE]6IIHM7%0XE^7"'4]V
MW)']/_X[]X>QZ>@/]QK-/36E5A-7^-'#M!=UTC[&89I'9N8/)C#)O)9!%+%Q
MF)F'>$>R&,X].1"$LFHDQ:Q9A^[/&OR*ID\B/@!"]PK:_P#&=[W KEAZJS=5
MKG2JGEP3KJEX+8C\\?S;USVYU2WJ--T_4VZKCI\JI;\S5JB$Y6*;PCYFS_CF
MXL0D\#8[#6E#0F*+-".%G&2)J1[IND8> ?<W*GQ,)QM_"'K7Z<TFJ=#7.WR<
M<\N"/R&]*VLGS[UE\SU^.;5U_F7N$Q?+H2;.@!!53CGA5U$P.'TB8@!S ! !
M_"O3V^HZ/E_^2F3K?M+E+ETL]ZD[;\"@*R8&'SQ$P7^H;E\?M :["U>F:GGI
MAG7KLW.9M4OE.X7"!;W5(%BB8;CZ%#U']P5/WFE7]])PNFI9H^%<H' HE5(8
M# )BB ^H!8!$/W7"K1JM/<<45IL--*7D%'*"10,HJ4I3& H"-_(CX / #:]<
MW/3O),*=AQ4>-42<U%R$)[A$N0CX]PY@(0OIZF.8 IST;R2LSM!5,?0Y1M^T
M*SAA5)GP%DC!<#@(7$/Q]0$0'_(0J\E6XG-3O.93%-_"-[?E4::S*FGD?1$
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MM,=).N?8#:.,XB_[S+;/>JOVCL,<D71E5)\S97W&MH]S)&^Z0; 4X$,4AO\
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MSDKT_J*6D_DSP6[]!P6X]6.M1&D\BQ.%D#LSHRV)/$T748=B)3-@3$KEFH
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MX@%[>:[-J_4K:.*NUYVB>D(01,<@E^NUS>;FM>PB ^EKUV/4JCRLX73'>=Y
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M+FCL)_ZTFDLL9<+:YC'/!(N-S#=.N\!<MV.8[ QS&'+H0*V+.2K!H*XB41
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MN:X^1_WO7S>]8LY$15 * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% ?! #!80
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M*$'P/GSXKLZ?76W5YG+^)C=T=?I^HE%+GY'?]^4HC8AO(E BITU?8,)KB-E
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MPQPNS490.7/,L9.&:2)UONTC?I&+RR(^^10G&Q_4HWM7PNJ:;JJHY::J&_\
MU?@<NAO=,5WGOT5NWM22W=^<F.7Y+>M&4%B(7>HEA!FV$<R8["CHH\@9L\DW
M*BYCR40=6/147:-AY7,O[!P* ?2(WM^?_P"4^D=;N=#KNV:[:NN]1,\_^3RA
M91'C)^JOX!]S>W?_ .EHZ;J;=_TZ;%UTO_7C2J*/U35^J92237*EC,HM%^/C
M0IMP[QQ3(#,DRX]@J;3)U72YG!4'3LID5F)&0IMW!554WKA,3@I[0 !36$1
M+^:_C[HW7GK+=.IKM<DJ8=<_K6^E'NOY>]T^VM'TR\]+3=JU#44SZ<2Z&ME<
MX3/@;4K)G]A&-F)12*DW;E22 @FY )1\WN4/'D*_:?MC37:-+2KD1333OX[S
M\ =<U-&IOU7E/-54W](/4H>$40'U]I.__H!7WJOU/O.K1/(ISA';4,A0"@%
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M)8D"MT(\7!+ F!BJ'('D!,(?-UMRY0_)LR[X-5^Y==KK6I;M4)NG%33.,/\
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M[6V;<76^&EL=U_KC&L@>+J3>/8=CS!X5-8SHJWVF+,&)@DW#D7')RFJB(_\
M#_;$Y_[MK@/I]$HLTIOS)+Z;<?H;Y]N\]O2VK5[_ .54+C"Y5"<SCP4+@7/U
MW3U! &2 @E_^3^'[:ZUC246UAGX=YA<J;J,?OR%QDUD>A<J@L5QZ1RZ8=+*
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MR-/CY,-(=CLFRQSOS;76!'42\;&P6+[0SG&=BL,RQ[.':#R1X9%#0J6/0\G
MME06,84G)E%"EL F&UZZG4K5VJP\^9M=N]GY3_E7I75[UJK5Q5:J]2ARJVUS
M*JK%*FEPHC!XMR>(^)SK3.]A.VN#3#[B.-ZESA'9&QY!=N=5G-9! O%',#&Q
MX F*?$V5G9K' ]B^PF;Q7!H+%;N4TSGW[SI?QE[<UEWJEI7:JW;IJ53;;?EI
MJ55,II9PEXY&^; 1Z#**;LR$(DDU(F4H%(4I2@'(+%   "@'[*]92G12J4S]
MD=(MJU:Y$E@E'S/9)VX$X^2\"V'\PL%O]%0[57ZG.<G.A!0"@% * 4 H#@H
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MJLU357*)%3"IR*9(R AQ5.4MTCF.8MR@'X^?7\:A5D1="B@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!
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M'\+U4\ TY-I,! P7*(" ^@AZ>/'^NL2GV@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0'4J<I0^HP!<IA"X_@42\A_<%Z#8:NNO5$Q_NG=WB!RB =/,5
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M?_5DKG$_@P<A*)? ', %L/FQ \ /X@%ZCX'(R*H04 H!0"@% * 4 H!0"@%
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M"%-&LCI+(&1$4U_N?=#W5@,/W9U%''%0% 43]PRQOX1"P#8+    0@E&LD2
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M$1./DPB7U'\:Q,SOH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M5D7Y_&!$:[A-B[XQ_7387,; C%M6LW^IR<D#Z',]> Q20.]?NTC)(%1#D8H
M("(!?S6U/9>FY;J5*;2?RYD:N_F#4.YIJ'7"J=2PF<>2K">!FS8C90?/@Q2@
M #^/\5Q"M_Z:/0I6V#\VVE+K>S#[DVKF,A0"@% * 4 H#4<^:K3VIL+^1'XA
M\HU]K#6V'YUL7N$VF<\R#&,(Q*.R7,SD!1Z^=Y1.-X@LC-J LH*@G64./,1/
M_$ "%B"83+-MACQ^U2 IN10 X (&*8+ H8.("0 +8OH%O2U&4BZ@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M$:>V(@0"V(-P"U&U,)_T"XYGL*Q,A0"@% * ^&_A-^X?]5"K-=Y"%.()G'\
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M(I2Y3F*H*(G/Q*"JA01,942J FF4WHH-Q'\?'^-%/R#Q>.9I<=I^M>P>U/\
M<7[KUUK+M'M[J9ET5U<P*54V+I=VM'92LDVUOA9Q@E7J1DP+#2WNE(Z^J_ H
M42>P-)?JS-S=@D1!=;VRIJJ'='5L18#*F.LL7WRJK'$J JMRB)CD*81"PV :
MDM=Q5@N[:>JJ%% * 4 H#X;^$?W#_JH59D.5,#$,%_(_Y54X9;WGP/.OX8CP
M4P5(D)RJ&]KD!!&W,PD]?-[4N7)2GMB?+NZ+U<:DIEF#+NEH;Y'\HW=,3'7C
M;$?AVKC0<,BSAE\@>L!3ET&SD)5Q]JU.*8 N<0&X!<;5Y?J#U#N/TY\#7_N#
MIO65SK0NOFC"*DED][6TQ=;L)\I'7QC%97M#<LG(X M)IPV33N&Y2H$AB2#Q
M9J=&8<(24@Q5<->*)R&% JQB?[P!<+_$IOZRF[_LJJB8Q;-4*GW9HM?35K[E
MZG3U5JE?[*6L5N53W&UWH)4Z^ Z\?/<A_JM[(X+BRR63MTUUV^2,SXVP61FU
MW?M>R1R_*;W#\C <QC>GFO;:.Y559I=3ENE8^$X\=A^C.@VJWH+.HNU*JZ[5
M&.]<JB9QG?Q+@J[A]T@Q)8P"8 '^$+"%P\B #4LTMTRWO.*X\<<RQSOA@V1[
M T1G6/8H"PR2K4'B:%[$=J,"G5!F4I+"9)8#V$!N'[*UO[[IN?M*^28BK_VF
MS?8%>FIZE;_<*CGPB5WF#V*[0.,0RK4#S(=2R..2^MFKC'W3-%X#-.8=_I2[
M KMLDA K FBX46\B(B/(!_?7Y3ZH];<ZU;N45U+DIJ4*IJ6G5GF?J>UHM%7T
M2]IX478QY4W3--*A983B9&?CGQC.);--T[7R;#TL 8YXYA1B,<3?G>C[:+A^
MX7=!_P"QX@I"""A0-8!N(A</Q#]#>Q=#<CFK;;EYM_Y+@?GSW[KZ*FK>>"V*
M,GQ>)F);D!+VR"(W]+6_(/Q\UNRS;Y;1I:[?55?+2LR/K,P% * 4 H!0"@-0
M;YFMY:LV=\D7Q-ZVPC8<)D6;ZT[EJQ.<0V/R!%)3#G#?W6BC>>341,5%X+E(
M4[%$ Y7_ '5EA\NW<8X]NV/R-C79^M]UY7N[26?X/O=Y@FLL$3GD]EZL6P<9
MY+8HNE6WVRK_ "I/,X,L "2"903(6,?<OJ-R+?C4>"G(JSY<^W?\B6OM3;S<
M]G8W<3#L9((Z+9ZY0Q%MUL0UZ9>$#*UE9-5ELUWFQL\0</SQXR#8%&GZ4CS2
M9<?= 3<@L0Y&.6$+/AVR/48IA>VX+:FY,PRC;R^4:VS%+#BX/K9;#S1O_+B2
MAVS]E..VT\7+WHRC;)WS]NY GVC;A]IQN;E<(X>695AGCQ)3H;6&[<%2VZEL
MG>LGM8^:;-F<FU_*2V*%@QP+#E\1Q&(:XDV13RF6"1:,<ABG[LJET!$78AQ\
M7&S&!(3Q(?4>M-W85J[,]?; WG*;"V%.36T7V.[=<8B6.6QR%S'*9^4Q* CX
M0,K?%D'.N8*3;-4U#.D??,R >*8&XEF:[?$-0^[/\B1,]2]A8WJPWTR_[&3<
MSO#^G%L?2[*#@"99U684F DR94\U_P#UT5NQ;(L4@8B4)M<PBH4]P\DJ\-HE
M? F^V]4;LS?0[76^"]@WN#[7;P$&S<[>1Q,S\TTYC42(/2.8P,KCQ;+2TBBX
M4.)5S"0BQ2_5QY&G_CBABECG!%]@==[QV)_R<=:EWJZT^; MKXAGNQBM-?\
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M5">.1):<*9[?3(AV6N]OLNT2VWG.Y'[O0RNH)'7\?I9Q&"DV99TZR7"WK38
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MCL;Q*/FNQ#+$$GS]ZXQIH:/R:77Q8^3-R1Y\HE4%U01"07]@EB^XI;D,QG/
MR>4'OMV:YVAL=;34CK;;4II0<,VEK+,\[91\:6;1V#A6.93#266:EE%32,::
M))DT4V6CSNRE<"F4XC[1@^FD3@IDDOAW]MAW;/UIMG)-GZ-R_"-OJ:^PK6>3
MY3(;#URRQ/\ J)'<D1/X^6+@(-W*'R:$''CX5*D4? <$'OW7W/'BE[8&.:PS
MP(L\%B2K(M=[I>]D<.W VWB]@]&8OKR6Q#--(&P@IF.5Y@]E9%_'[&')?ZO
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M7$:22%,G6K#1JRB:IVW\Q)<CE,Q%G"7!<B@+>Z4$E2% RJ@75\?S0$0/R 1
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MD2(@"-T4_P"%,YU%"^0,%C <YO<"QQ_BO0D'!2+CU0(51JD<B90*1(0'V"@
MW*((7]GF6_@W'D7\!JRQ"\#L48,U12,HW3,9%0ZJ)K"!DE52G(HHF8! Q3J$
M4,4PAZE,(#X$:2RP=9HQB95-;[<H*I)F2*H0RA#>T80$2'$AR^X6X> ->WFW
MJ-00<OTYD)S']@.9TP2$W-2X$ 3" E^OZ#_5;D%C<0 +V  "R\]I&DU#.#F*
MCGA!3<M$EDQM8AN7%,Q;<5$0 P @J00N4Y.)RB%P&]0H2BV")N22' 1%$?\
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MS 80$!O<!H#I"(CBE A6Q2IE.90B8'5!-(YQ*)A13!3@CX+8.(  %$Q0\&,
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M;B &*?B:X@8@F()B&,0P" V$0N%8]QD=M * 4 H!0"@% * 4 H!0"@% * 4
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M7KZGMKIW5Z-33<KL75;YE+=/'N.;^1>M=/U6FITVENVZ[LIQ2TX4-1AWF7Q
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ML0.HF+M #I'.DH3W"\B*)D144(8+W Q$W*8B'Y'#\Z0)1S6>-$"B=9PBD4#
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M)*./;XEVR^W;\2$Q#4^<0_:[9.X9'>F83^L\JP>"Q/&=".X661Q#")[&_P!
M^[RJ(EU7)XQW(29H)<3%31(8PNS?4/F]VL+=N)5K'56VL3W)V(R^<[!Y;G&&
M[5>0K_7^OYZ 280VCA8-9]M*P^,/7>2+(3+"6<R3!4[EHDF0JK1,AP 3%&F#
M>.*[<"IU4XK!D%HK1^Y=5:GS_!,P[%9?M;-<RSG9>3Q6RYR'0CIS (3,Y#[C
M&H2(B7&3/%)6,PLQ56J"ZCAF94$;)I^T"9SLW&?;(F4[WNR[^V9)([KCN.%Z
M.2G7!QV=RB?W;_RWR+#HOLN\AEV>41&2FC731'*6N/QLW+N4Y"*2*:R#=XH<
MP%$"F$; -[NRV$A-9=MOW/NR>ON[,TZLP>B8/M+L#$]GQ7])^]V"9PTHEE.3
M'BG:CZ9;R,<TEC.H]%Z@V*455'1@'EQ]1M42W=NXKRY7EVV$P[!:#W-MG56I
M]?Z_[-YMIG*L/DL)>9%LO'8][*2^=,\608HSZ<I%(2\<H0V0.6ZIS@NOQ4%0
M>0^M&GL[?B)415D^WA@52SW76>Y7MC4.<XON#(L4Q/7LWELAEFMXINL_@]I-
MYO#LKQB,B9Z6/(L%,?:8Y(SS>;;G!H\346BTDT_)RF"*-I7GAFR"D=59LY[-
M83MMMM_* P'']<9SA;W3(I.AQR7G,CD\-?1^9_>'>DCEG$(W@7" "=,%/^+L
M7U-:X[>VX9=_:>VT[8'5V91_8/;&SI7<622N#9CB&&XEC^IGK=TT@<#>8TW?
MKSDY$/EWHQ[PT]^K)KK&0(7B<!3,/(@VD)YXEQ7=VC=APW'9JK66:X'L7>F?
M9CMW)L]Q[9N5PV581ALRU<M66K8ME!I0CC$X0'3Y9%1*0>G]TOME2**I@"UQ
MJQC"Q<_U,9W_ *?B230FH<[UOB.WH#*-Q93L*0RW9.89WBT],1\BS?8-C66,
M6C:*Q*/(\<JG<$QIS'JK$*D8I1,<H%"XU%*\2X98P>3P70&V(CJME&AG'9O/
M)'9<X3;R$-V,<LW1,Z@'&R,]S',<9E&D(YFB/4G6NXG*&L8R05=MS+)1R9B"
M0IB@%A)03/%XL^9EUIW!DO4)#KW =E,RPW<Z&*X%C#CM-&095<W6>8;D..S<
MO.@V)DC9Z9SDC.#7:J7>>2NS7,(7 7&1PV'SL+H;;>T=+X5K7"^P>5ZSS'%)
MC")J;V=%1$DZE<U-CL:O'SS*4;QS\%6HSRWMN52F64#F<?XK7HW&1%/]RP/1
M[KU'L+9.5Z/E\.W'/:[C-<[+C\YS6)QMFZ;J[7B8]NT.WQ*;<JO(J/(D^=M_
M9$BBJI  >(_5<H&L-Q5$8O\ H378VFMD9=O_ $1M3&=W9+A&#:E3S@<WU PB
M57V/;:<YKB<A 14AD3@95BU4=XD]=?=M^*+L0-<;D$ $6$^)9:@EV/:'VI#=
MG<OW1*;^R7(M<Y+KR%Q*-T1^E?I^'P,U$R,F]6RX%C3BI?U-P@_*D0I&?U@!
MQ,H6Q0-(;QE\V_Z#;"4T[OKVS)+J+2NQL%WCV)V)E&]\PV+C.V)?'9?#]7S,
M7+1D%JO]'Q#&(Q=O$RRCIZS,=V\AU%KH)E"Z]O6]%$PL^W;YDAM3BY\)[9=Q
MVZ,T+N#5Y-QM,^[0YSN1UG>:Y!/X*ZFX9Q#):JAY=";2C("/*I/22.1(0BC]
M!0"&.S*!FA3!8;6D+-;NWY&2;:A[W\/&,=L=Y*-1==]QZOT;E>N,_P"U>8[C
MV/*2^=ST/N.?QCWLJQR+S)5JC#PD0P-DTDY%GBOZ:8$S X3(('\ 7CYRAO!9
M&$I;^W9DC8Z W/C721/KLZ[2YP[V] Z7G,76[7L6;QUGHY"LWF?L,M;P4?,N
MY0Q\?;ND%&P%=BLL5N0"@4X\ D8XY&;J<<>W;YE7NPVI\WV]A^)P. [;R+3$
MACVT<!SA^\QN/;9(KFF+:_F2Y)(Z\?-%9V!CXZ$SIM'@@L^<.031L6Z9S&*4
M;"VLF*A<2%W'JO9.PLQTE,XGN:?U;"ZRS<F9YYC,*W0?--P0CZ*%@AA>4/VL
MXU5QQG&.T#+ J1!^@IS "W$!L4K%21P\&?<KU+L&>[ ZIW"QWKD^.:YPB!R*
M$S'1<<R?*8KGSY\RF?MI^7G47I# :!4D4E&Z#AA9Q]H0"G#F%D8<J$_W;9^2
M.F-U?GY^U$IM]?<D^[U6IJ1[@/\ R$<1$@EBT?F+7*<)E&VP(Z8.Z&+5DS-H
M-RV*F*2:XE?&$!X@<05-P%NV^/W1VXMJ784#V*V_M><W5DV6:^S_ !'#\:QK
M44I#(1F/ZRDL,<S,I*/HG('60'<2Q<M3RA$%!18)H)'9B4Z@B 4Q1,'GGP^6
M/B^R.G26N-C:YE]U368;DRG;W_,[;61['Q!I+Q47'%TK@&0D;K1.KL<,YRMV
M2:QK&3 <B3]O[22X&$P)%&Y:L*<,MGX!3$[<R!TOIO:&LM$YGKW+NP&7;2S*
M?EL\D(W9N10J\=.XXEE*3A.)81C9>8?.'".&&7(JV5]U(%3I%(0 $X5%O+&2
M/.8_HK:Z'31QH*3[29\^VB&*R4"7L\YQU^.PEY-YD+R6;Y4XQQ>:)(JOFC%X
M2-!JH](?[=L103 0Y0I. C?&1";$Z];>S7J3&=:L9[299K3:),2Q/"E>QL-C
M<6\S%Q)8>E'-\FG0Q%#-6K05\K:QRYW($ESK-Q<&YE$2B QI^(G#'\29[IT+
MMO<O_AW6P?LGF.HB:LS.,S'.DHK'V\DYVM$1..3..'Q^<*.519\?3E'4N5X8
M2@\)=&WDW&Y2LC*IK:NW;YDRW#I+:6:=@-);0PC?F1:RP;6ZLTIGFLX6/?/X
M[;2ZXQKANVGUVKYLU8D!HD"1SN"*&]LX<2FL(!8^7;,QR6&3?;@C[(:8VLZ[
M6XOO8F^,O:ZNB]:2N.2G6M!LN&)N\GG1:$;Y8284ED(AQ*PZAC@@B*(*G WT
MC^%.*S[=MV\L+)]O#@_'<F1V(Z>VAC_8_:FV97>TSDFMLGQ*#@\=TJ^9JACN
M%Y!&S17TIE+/( DW LYF99+)ME6J3+ZR)%$ZH?2 R9Q$>#.>E]$;*U]G?8#+
M<UWYD>UHK:^9GRW#,3F\9''V>I8@T+'1;/%8B0+-RZ<XS;.&"CCW03:GY+"
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MK F(;;USL/(&F/I.5!V)#8WFD//R.MY=!I(-OTV)R[[7].=+J HBB58PJ%$
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M_=0'P$TP&X)D 0"UP*4!M<1M>U[7&@/A$4B7 B29 ,  / A2W H6* V +@4
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M@FF'*R9 Y#R-8A0Y&L!;F\>1XE /W!0 4TQL ID&QBF"Y2C8Q! 2&"X>#$$
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MQ.\8?/VK.3?PK\5H.>WQ'RS$&\Q%N$2>\B05")@H6Y#E,*-PYNX\GV7^6/\
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M66?[!U_C679AIZ7?9#J[(9V(:/I;!Y:5;MV[Y] NG*1UXYRX1;$*<R8D,(%
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M8ABL4TQ_%\4@8C&\;@8U!-I'0D#!Q[>+AXA@U0 J+9E&Q[5-%),@ 4B9  /
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M0A<'GIJ&BG&03T1#3<CCF,ME@:GRC(6D._6A\=5<A_-*A*O"E2$""4UQ UP
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MU[K["=:EPO$,V+E;K",.E#9?DV/P^5#%MLFCIZ20GHN.:2+4IWP@E]UQ,!R
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MI ($]T.1/<5)>'S-B)@B"#1%(#*B4"F,4%O^\3*H<RA41"P<2H%/P*%OI*4
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MVS8A4R$ /P*0I2E"P?D%%,<28>!'AY !_, ]:AD?: 4 H!0"@% * DTNQCI
M&R,DU:O$2J&531=,TWA/?)P%,Y 4*;VSD_ 0#_550[SB+9LX3,BH1JH \454
MQ2(J((6#@W4;F"Q4Q((!8? !5<9(Q6?&3BRC6<:5!"-:-(^.0-;[1!N1FB"A
MQX@8A$R@037$+>*G?F/H3VH9"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4!\L ?@% !*4P"!B@8!]0$ $!_> ^!H
M     '@ #P !^0!0'V@% * 4 H!0"@% +!Z?A0'SB%^5@Y"%A-8+B'Y7];4
M$I1&XE 1_,0 1H#[0%%]^[QUUUOUAE6Y]NY(UQ#6N$1I7^49$\$QV\:@[D&,
M6V5403(!SE%T_(43<R\0'T$;6$9Y+J_V8TYVVUM%[JZ_YRPV'K'(G4HDSR..
M.H1J=]'*-F"[9-%9(QS%25;G\@H'$1&X#<+48Y;"Y6H44 H!0"@/@@ A80 0
M'U ?(#0   +6  MX"P %@_(/RH#YQ+:W$MO6U@M?\[>E <J 4 H!0"@% * 4
M!\$ 'P( (?D/F@  !0L4  /R   /]% ! !]0 ?Q\^?(>E ?: 4 H!0"@% *
M4 H#X( -K@ V\A</0?V?E0'P"$ 3& I0,:W(P% !-;P'(0"XV * ^B #X$ $
M/ V'SZ#</\AH#[0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@,/?SV/$6OQ-]RRN
M7 MV[C7F.H*G37:HK@5?:&!(F%(KODD>Y5!*;Z1$"F$0L-AJHQ>>9JK?%CWS
M^6GK?\4L5E74_J5I'-NM&BI',IF9V)L#('QIZ88JSBKB80;0[+/(=PN9)TX
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M(J<O>]H0NOS$0 UP L@\\<X^94M/ES4_A]OZ/;M^=AYW_P ;4P\3+&3NJ 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
'% * 4!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm2226999d1-lc_study4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-lc_study4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!L@)N P$1  (1 0,1 ?_$ -0  0 ! P4! 0
M       )! <( @,%!@H!"P$!  $% 0$!              $" P4&!P0("1
M  4$ 0," P4$!08+!00+ 0(#! 4 $08'""$2$S$)02(446$R%0IQD2,6@4)2
M,Q>AL<%B)#3PT7)#<[5V-QBX.>'Q4R49DF.STS:"1E9FUB=(6)@:$0 " 0(#
M!04' @4"! 0' 0$  0(1 R$Q!$%1$@4&\&%Q(A.!D:&QP3('T13A0E)B(_$S
M<B05")*BTA:"LL)#4V,T)1?_V@ , P$  A$#$0 _ /?Q0"@% * 4 H!0"@%
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MX^X-IK#/>>8[V1^/\SQ9X7>Y?S'U['YKB.L-E8OFDUQNB,E?+2$T[UGAT1D
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M:R[++MXQKZ+S!&*?.B/5"+%B)$C,#]B(I^(3I@F?YJ$;3SA^[%^F]9:_XWP
M<#F_+7?^Q$)_\M4P/8VY,=R'$8.&,#1NI(PT7(,(5BP 43*%0(FJ90H%+W"
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M1L(0<<V,=1%$2'4<+NCG\AS&%5PL==7\0B %%0XV#X!TI7Y"GSJ:U8=@L/\
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MX?C>OH_HNP^%>I6K:_\ F6PX3U3?E+4M+A44MF.SO,SVQ!(*P 8?&)P\9+
M)E MNTMO@(UUR$%""2W&D1JY2;RJ555%8H!0&RY7(V06<' PD13,H8"]O<(%
M"X@'>8A;_M$ H#I8[&Q!":CL:D9^$B,FEQ L7C<K,QK.=DS@D1=4D7%JN0=R
M7A24*8WA*?M >MJFA%<:'>J@D4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M/MJU"<-/"ERK\*?4B]&[;=:KWLCZY^8HCDNJFLRJ1(8W&,LC9J=8_6':JR$
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M8]NW@251I@,P:&#S=4$A_P!I%,70") &SKPW3^J#_G.T1#OOUH\R5D5U02*
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ME3S<F/';M1=2;K$XH'$AB0-%4RAXI,&:P]X]I3 %Z)O:4K*AZA*%0H!0"@%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MP!\P6M7U+T[JYZK1<,W7TZ1KX+P7U/DSF*C^ZG<@J*;;INKL]AV*M@/"* 4
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MG'3.</FQ&X(.\E?MTB+RKA(%3=IE1,(=PU*S(V>X]&]02* 4 H!0"@% * 4
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MW'R]_;BVZ;?,L'B79P?D%R;VQ)126N-:1F'P:SP@SDWE;>[=K&)K)_4'9*I
M1LHZ*CW")3%&PVKJO3^NG;<7)4Q7=M1I_4/*^3\OLRCJ&YW$GG-UKPMK:2<P
M;A19N<BBX.S(BF0SHI"$37.) %0Z92%*';WUU30ZF.IM5C_+15WG*;LK$[C>
MGCPVJX8U^)S=>TMB@% * @0YL_-[S_M:W_\ W*W6/](I,A'_ "C1NGO&VA/?
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M#<.M69!J?0>L<)R,5E9K&,6CXJ17<I/2NEG2*2)E3N5'YSNW*WDN'D4$1$
M/0*RVD5]02O[MU-WTJ?1W2_+;VCY;:A<C2\HJN%,:+%K?59F7!;^,Y_Z]P'T
M^/< ^G[:]F%:?RFWOBHOZJ4./=L4C$,03*B HD0#YBW*4@?*8MB]#C;]GW5Y
M[J3B^+(L7(J3IW''J-FRJ2J#M-F=$YU#^%4I%0,8XB)A,"H&&YA,/ITK7=3;
MTCDU-1HWE2/UJ9+0SU%N7%;;36U-]QU,,5Q9%TJY1@8TJZ@]RBA&+103&*4
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MJR1_P"=5J5@!4"D=?2F'S :X&"]OL&E&W056PG]J"10"@% * 4 H!0"@% *
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M1D:J 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MCNG-C<WI.%' #X =-95NI%AE H$ S-5=HFD1\\!-,2F3,D( :U_FKDG+E?\
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ML%^O0/A5^/FR#NP>3Q*LO4 Z@/WAZ4+A]H#X(@'K4TJ  @/I2C0/M0!0"@%
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M&9NI*%'M50$ ,F:U^X+_ 'UYM1*='&&9IO4<=6].UI'2[GA]S4:5?LKB>/B
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M^IO1Q%8E(-P-<H_*)P/Z"(6$!&PY0V5H2NL]$VZS:QRX9?H<8O[L7%67%H:
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ME:?K]?.,E.:?#C]*''/RQS;JBWH5KK-F]:X(M2G27!2L>&GB^)/^!BMP9VM
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MZF=_27]3;]1)4C-F\APEY1ZZ0\6FN<FY!,HH;S)[<7<[:8I)&ZG:-6N02/\
MLQS&(7L4(("F4# 'XAKT*.-8S;]C_4C_ -M\]TTJZ;7ZAJF3DVO<W2O>;*N.
M^Y_@::CEAL;36SE6EC)DR/&\@Q0[RX^,2F6B,S120$2J"("!+7* ?&H3O)TW
MGCCINL-%?5V5YW+4=DI4KLV8[=Y2?^+?GSK[L3V-Q*'-TQ$H*2.L<X5(S23
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MW\2?CE"C]YWG'_=>X]+J@3-CY_K GC$!6SS!9J(1,[ Z8 Q238H2YQ<G)WG
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M!0"@()_U&+DC3V=>93D"'=+)CQY(**+4C]5,9#E9H]JV;I(@LQNB*W41[@,
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MQ!I/,<.VQKK+)?*3XGALIE.LYH^)9M)@82I?E.009YA%BR6$  KA^5J7NZ"
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M&,(B)C&$1&H)*B@% * 4!8KDVXEVG'[<#F !09E#7V4J1H(G437^J)$NC)>
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M/'*/\O$OF4B2"G?W 82A]@"%K /VWO56JI*TUM:?R/-9C)3367B8&<Y,RRC
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MF[5/%#E^ENW)<,FXYK#?EWG7^-W,' .3K"8>X6CD<<$([61?L\KQZ4@5TVZ
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MEEFJ["?GV^912=XMZ>EE6*,8N\Q!BNM'-RIIMVIP1;IE(BFF(@F0Z92FL-A
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MFNRC.?%%41O4+8H!0"@% * 4 H!0"@% * 4 H!0"@-'9_P .O_'4X$>;>#$
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M *^TG+[\X+63E"TI2>"2JE)[EM=<VZF%F=9E[9N8XL]QE'(-6Q4C-P[DOYC
MQ2#1Y%I&6%8)1(KB-7%)X4JG881,>YRB-NM8^\M+;NR@DXS5/E7+^/N.5<\Y
M=T/S'E7H7E&%R["24XIUCYDZTEQ8Y)YJJR)+>"W&;0>&X1A.;ZQB8^:=M8/P
MP>=^,6<A.-%DT"GD7IV[=HFY4724'U3[1KUVHP2XDVWV[;3K_P",>F.4\JY7
M;N<O7'Y:<>*4OL;DXX)-T62H2:D(M],JEYOXP&*'E["V PG+\O9:UNEOZ:]E
M,#KJ>+\2H _C'L[>TM_Q#U_S5%FU'AI;%R48XU,;N1>%X%FVN)N(V.^0B\=4
M56?GEG2@I*13]L@N#=R@8@F,<?I2]X%+UZ>E^E<]ZZM67IWQ./#AL>#\W>;5
MTW>UW[M?LH2E=X<DTO*FMZSQ(LWW#/$(;'8[94MR DF^M'1G#5-PFQ>!^9,)
M$B*44S7<^4%E4Q=D7$![.TO< #:N%<RY!=GHK>MBJZ>7%1[\4M^]'6+//K]U
M_P#2)6[BYC"/F58TSKFMR:KAM)=M%87A^O=?0N,X:N5S#1K2S9R7YS.O(;RG
M<G.0ZI1.H8W7YKU] =!:>U:Y6H6VG*KK[T<BZEO:MZFNKBX2I@GLW;"\3 PG
M(H8;W%01&X6_9;[:WEVE:G*FUU-7M.3@G(KZ%P4 H#2<Y4R&.<;%* F,-A&P
M!U$;  B-2DVZ+,B4E&+E+[40 <XUR#[QOM?K%-<B>$;D()K"4.YTDV!N'S6_
M&"8_\GXVJXYQM2I<='Q?4M:VXIZ*,;+KYHOZEP>'4.3.^;W-?;P%*^90N9X/
MJ?&Y(IB^ QX+$GLMED>@8QRCWQ;Z>;E4N %$RGRB:PV\;N1NWI7+;JZ_,Y-T
M_I+MWJ35:J:HE))98UC)/&NSA^)-XB7M22+_ &4R%_<4 J_E@==C]J\#<H5"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#8NK_8_R
MA4E?!:WFX FL%RC>WVA4$4CL>!\$3WZ%Z?T?\=5)1ICF6VVGAD;9Q7O\I0M;
M[0#KUJI*&UE#<]E3;$SD/^;$W[#$_P!(#5NY%/".),7-*M,2@6(^4"Q43E#^
MMVG3N8/L#TM5EP;P(E<O[%@C0LR.N"0"BJ4$['MYP3_B%_" G)WF$/M"UAJI
M6U@GEV[R["[>4D]G?3]#29@8P+E,U'^,3QG$JQ3 <AQ[3%*55,Y"_P ,;#<H
MW"J_2M+%9]N\OO43E%1>2.F$UEB$?)KY/'X;C;/(4D!;)23*)8-'ZS4ARN.Q
M1ZW10,'E63"XB0UK>@^E6KEFWP/A7FX73Q#U=V$72K6.%<_;B8H;B]OK0.[L
ML5S_ "'$Y>#S=TCWOLJQ;*9F(D'Z9S&4.R!9-V9%,YCG_']. 7^'PKQ::Q>A
M'A<:/QS,II.H-3;MJ-U55*+'!;OY:X$ _O;:NV5 [,P;+&T;*SNO83"H_&S.
M#-'"Z:4@R0<BNY=K(%71*=JG8QA/8/OKD'7>AUMZ;5J+DDE3)?RK>U\S]*O^
MS7JOI*US"V^:7K=FX[R<DU-YZAO'ACN,,O:ZUYLO+.5FKYS$&"ZS+%LE2>YI
MD(-'J30\.!6;8&XJJHHH+&23:I!\@G^%KA7DZ+Y?J[6JAZL.!>S^VNVIT?\
M[P.;]%7>4W;V@U$+MUQB^%0N1JW+59.6&U9T/=6R!4K=$!1.D4P&N14P"I^,
MW<)A X_B-U#[AKOBHX4CD?C_ '8VW.7"T^]5W=YRZ)0*2Q0L%Q_S_P!-46HR
MA&DLZGCHEED;M7 * 4 H!0"@% 0A?J,?_1KYC_\ 2\>O_-5HJI*?U)@]7_\
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M?R]IS[\A<@ZAY-II*>HG*,52G!%-^:"PI*3KM]A.\W33*V $B6(! ZDL!;
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MO\I%BF]# (^+F-ZCBY4JDGNVG OR_P#D'_V#;A?G"4[491<HQI6G'.-%5K#
MX?VQ.:F'-L]RO3Z4+FDAFVY]X[$V/YD(U!>/BV\RB,B*,L]36.DP_+F+1FBH
M!Q*)#+)E, "<M_+I-9%N5%YIRKGX_4Y3^#_RXNI];J=).W=_<7=9QIT@DHW%
M-QCA)UE%6W7<I+>>H% 3&01,<.TYDDQ.6X#VF$@"8+A<!L-97Q/M&%7%-YT-
MVA4* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M;QC;M!#*$P05%:.4*!KJ"F4GC,%AZURSK]TAP[<_9Y_D= Z#4OW/$_MX<O\
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MJT:0P,W7>Y*H)W?U*8B%DB $+Y"BR/4BT$WD5*<W4MBD*81,H!0MW")S")C
M)A#]E"5CB5]"2S^_9" B=-;&D\IC6\QCL?BDP\F8MWXOIG[!NT457;+>=N[1
M[%2EL/<D</NKR:^*EH[D7DXFR]&6-5J>J=#8T4W;U4KZ49)5H\<:55?>>29U
MRVXLSI'S[&/;:Q;(6(2/T$=-!BV-R:<N[8H2'E>%.IKM9(0N(? P#?KTZ5RG
M6WI::58P37@GO[F??').C>I=39_S\VX*)U2MQA@^''"2IM55CWG?N.ON>O\
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M5I@3FD<-?RQ9R!_X(E(4YN^_4!*0/CV@-S5[O3_D_E^AW;]Q%V./#A2*Q7T
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MY9/$"+)*  '35(4Q1 P - ??HF39G]*W:M6S5)(4TD$6I2MT26L!4VR )@!
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M-2"=.Z?S56E7,-4\:%V_8#:XEE^XO<YR;=J+#(^7+7F!F;3-D\D06FLYQS#
M?/F41&MDY1)RYCHI+/6V0L"HE,!2+,E4; 9$P!"IMWDXY+=M+F<=58_&/U%_
M+G#M$K,8K4\[Q:USDG(*!QQJH3&7&X6#>.:X4X?,&)48P,CC8=S('$>TRACO
ME3B("<;EYF0MYEA^HC.</9WYF.2*G<F;DT$0J1+ ";M/D[I10D>H41NV!ZN*
M9#J>J13";^K4[,0\>W;LC*CV\-C\R<]UB]7YC:$P;14I",<5CM9%P_*T\Q;Y
M3AG\IHNCS<NZ2=O#1CD7")!40$2=@]+4V=P2>PDC8IG2:I$4$1.!?F[A Q@$
M?ZIC@(^0Q?03>IAZ_&H>>.94LBKJ * 4 H"T6^L05SS36R\0;'.D[R#"\@B6
M9R%,H8KI]'+MT+)D^8XBJ< #[QKP<U@[O+KUN.<H&:Z<U$='SW2ZJ2K&%U/-
M+?M>!Y4-:<YGG!##6/%_;>GI<<OPQ].)1BZ+IDW+D,6YE7"J+T4G!%%7;PP&
MN1,!%0W0"A>N61NW]'Q6^"K;>>_+'W'U]H-!H.H86];^X=OA@EY9+**4DXOO
MXG7>J;C/KVJ=9[)R/;.]^3^980YP&"V2=@KA;%V8J;F09O#'<(B-S%4:'4%0
MA  2E_$(?$:RW)=)?E)WI5JL<*]YS7\M\ZTD.'0VVI8\+JT\$X8M;:M$_P 6
MX(E$?4!&_6_7X]?C72-/DD?.3RDUN9$5[G'*/!N.<'C<'GVL3[)@]AHY"LNS
M31;@U;HPSEJ*@.1?(+-S***/+W'[*M\RN1C:X:)X+/Z'(?R#KK.BM.SJ+,;M
MJ>+3W.3W^&9 MAG+SAI"9:3*L5XH.)"6,^:-FS9M(XN=<%[N'G8Q8':@+Q5%
M%XE<Z0"*8!V>H5B-)*"M)N.W;L57@?-EF[T]IN9+FRY==E;GDY23CY:IT35&
M\8QJMR6P];7&S-2;"U1B67?R\\Q)><:MY,V/OTA;NX]-1!L1-)5$Q$[&*F)0
M$0#M&U9RVI27'PT36X^S.BN9:?6<FA<C%0XXUI[(_P"FXR'3(< <"/\ 6<IF
M+_R04((_Y KT2:I'_A?R,[%-2D]\T_B=/R1FY?P,L@V.9%TJP=M412&PE*HD
M<A5 $;_. FO^VM0ZNY7'4:63A.XFX/:OZ3,].:I6M;;G<C'AA<3]B>TB$XDY
M)C&H=M;7PC8!VT)F+_))B2CI:<( .'C!VZ31;'17(4B8 NDB4_VB(C7&= I\
MKU4E5M5>,O&FRF[XG7N<Z=<TT$78^["JC155*YM/>9;<GMS:V9:JR5G-2L.Y
M3E<?E&T:W'QNU9)W]"*)2H% IS Z$P !?@ #>LEU+SK4<ZY;'EO!"$8Q:4HU
M3Q<7X?R[C#].\BN<LU3UUYM)O%.F>*7BO-[&47MU8K-P?'S%TYI-PT,]D9J3
M9ME1'N3CGCXIVA3@83"!NTH_9^RKOXXY-=Y=J5-7;LUQ92EA]\7N6XPG6=VU
MJKO%7S42^#7U)"6Q1**H#>W<6U_N* ?YZ[W*7%LH:'Z4;:7"VZHJJI(% * V
MUC 1)0PB!0*0PB(WL%@]?EL- >7_ '[N+96>>^_PKPG,='Y9J_']91&WXC#,
MYE<B;2D-MN+<-FZBDQ!,F3!B>) OC P$%13Y3@ W$+T7<1_=O/3)^>E%L*A$
MRG7!?Z<$P$0()A("P*7$!$$Q;#Y;?9\M[U53'N%<.\WR29CB4$O&O=,>SL(<
M@+JV[Q*D8QS=H%2(81 P7'[:BF.."%?D:DY(ZINB/B**A4R>;Y3*]Q1 QBEO
M\I2J"%A&_=Z=!I3,-M.A2?GAS]ID6P"D+8C@QSF$ITCJ$!8K51$;""QD3E'\
M5@O0-[C7^=E%(JQ"=R1CJIB8"F$Q3I*@W'N2[BF( .$U2^HC8@#Z#4$X@TJ[
M*5L7Z4HK*J^-?M QTFQ#&6%%50P'#HL5#L /4#J%^ " RU3(A,UMY-RL("HW
M*AU#R)* 8#I]RI"C=7O[3"D01[OE#J(4H*[7D;+:964(":R1".TP1(NGV'33
M%59,%0,B8RIA\)2&N-^M31"INH31%TBF[3$-Y':*@J(F(4BK!R9HY(<HJ"9/
MR*D$R0B(]Q.M13W"IM*S2A 2,5,IP.[%#L(D<ZJMB.SBFD4%0 IP*DF('$1*
M(&$+7M3#:,:5*@)4X6%1$"E."8HCW?,IW&$%2"01 2*-R]1+<1-Z!2F%2*[^
MW^A5_7% >M@"QA,/:(E("754#CW /<%NE@I0<11*RQDC@GV%.8QS)E[2'[#*
MF.<B: *=_0Y#)B!QM:_I:B6..");=*HVS30E* &333,FD0SI0XF$B!U#"F0"
M$+\RX"N0Q!L(#<*4VO(5]Y]-+N1*04FG<!FBZXJ"-^YPW42$&2:0& 3*NF_D
M,0>ZQ1)80&F&P)L!+.@:%>?1*JE,4RQ6Z*)A=B4X61;BD*H]K@IA#O&]K7L%
M02?!E'94C **1E2J$0!P0BAFJAA1(95QV>4%$D&ZXF*8!,(CV^M30BIK3E%U
M'(H&0!(O:4P&.0PE%01,4S3R@H!?J$P("@C:W8H4+7 1%05-)I@0!S_=)@W0
M.M]0H4YD.@*=MP(<%! GB.)O2X%&PT:H^X5JN\VF\RY4.L*S=-%$JXII#8PG
M%!$G>JZ,('$/&O< 3"P"'QO2@QS>14(3 K)G/X;*I)D%9J41.L@H<G>!#G 0
M(:_W4P%6^WP-P9-4I2B=L &$%#&3!2ZI"%$>TXDMZB2PF+>Y1&W6E$'7=M-A
M::,BDFH*0&!4MQ,D4RA&]RB<#K?,0PE%,0'M#KT'^B:"M$?$ID5E3)D%(Y/"
MD=)QV'(@JHKY/EN=7N(0ADP((B V,H6H>#P%<*GT)1X8X$(W144\8*"EW&2^
M8;W0!4PG**B8?,(VL)>GWT:IX!.IN-I%PX( ^),ES'(52QQ34$@B!#IE[P,)
M')0[R!>X%, #<>M*+;F*FRK-*%;JKD;*&,4X^-J*0_5G23.@FNH"7EL()',<
M?7TM]@W4%3<-*J@B8_C(0Y2%,<#@(@CYDG)FXJ$!0HCWK)D+V@-_F'K4T69#
M=#;3G 6*!B@0H';'735,0YB 0! OU*A>\AB($ >XQ;]W: ]:BGN)J:"S3@AV
MQ72*20N3) <@ <?HCF;)'%LNKWB"JRRYC 0Q2E*!;7 1N--HKA@5Q)+NN(@4
MI"E$_D,4P$.4Q>](2?,)NB?4UP]?2IX17"J*1&:6.CY5&Y2=H'%4X&$2IV$1
M1$I+]RGU"?4 N A\:B@3WFY^:K?(F9-)-510X%N(FLF1([CYT@.!BJ'12-8.
M[UZ_=14!H+-&,8"BCVV()ER]AA,U,8O<F13Y@!2X#:X6_94M4"=?$U*2RI/$
MGX0^H5\@=I0%5)$$C@(JKG Y.Q-1 Y# 'J'=U'I3A(JRH7?KD!$4$2N 4()P
M H&L?M'M%(A^ZP**]W<2X"':F;[0M3W%61MED'8IE.*!"$*=4'"B@&*1%)-!
M17ZD [Q,HD!R@6P6$;#4KO'@? DU>Q,@E2%P803$0[@3[^\"&4!+O,<J1+]P
M@)KV"U014TDDG8(NU%T4R%24*9NH4IA*JV6(11,PI^43"JAW^-2Q@ 3E$0L'
M2IP>&TG'V!.4<&*:Z2:AP,/R-P,IV%\[M(AE#=X !3%;=3!^$UPL-&DB*FH)
M-3R>(Q2=W<?O,5)0R38H)]Q065\@ :Y[!<H  B(!TIA["5CEF;/YL]\:8BS
MJAC)BI<#>)))4P$$?(!OXBC4#=Z@  7*40"WK084-E6;<D<JM@30*8@@!>\B
M@W3.'<*]RJV$C8![5"]!$Y1M:E*K @I')4':+H#)B1)PBX8J)'(F7QF<%!==
M$I#$-?ZM)41&XB "(^@U*(V=Y U,_I^^'N5;O?;E=9SR!-K=QLN%V\EQ?C=@
MKQNCO\2(TJ[)?(5L6;-TG3]VLW7=%5!VNNF9)\X3(!2*G*91=NVT)X8Y&4_/
MSVLM+<\/\+<AF\]V1H_86H&.1-,'VSI%Y$X_GC-CDT4G R3-[*O(Q\HM#)18
M"51(0N':':(!>\9XDXF5'$[BCJ7AUH;!]!:3CU([%<(BEF4?*ORM#3612RJJ
MRCO*)^1:(- ?S<VY6,X54$@?C&U@Z5*5,D4UWY&(@>W##S&@.3^K\PV9D#W8
MO(_=&1;GG-FD9Q3N:Q#+%<@_-L&C8TSYJ[CY=A@L5'M&S1%TDJF#=$.@''NH
M^_;V_@5>&?;_ %1<[A7Q!E.+N5\A=VYWMB=W3NGD6]U%%[*V'D<<QA6*\+J2
M$R=GA7Y5#Q)4R%;&=YY)&4,H8ZZCMV<.\$$T4DXP3H%6AJY&\ , Y&\M^)W,
M?),VS+',SXJN,@7Q#%X=O JXWEA,C*B5ZRF"R,8]EFDD0K8#-7+5R@= W\0M
ME"E.50A=QU'E-[:&L^2_(_CQRU0V#M#6NYN/#U-2+F=;2$?$N<YBF;PKY/%\
M[!RR<*3"0B!D2*'/W)IJ"1/M*-J9[@U[BTW,_P!FK2'+W;4?OZ%W%N+C=N=6
M$9167;%X]ST?A<GL6/2;E00=Y2"$>8SQTFF0Y"W-W%[C"%A,(C-$UVJ3\S)C
M@/[>^A?;]UYDN :F4RW)9[8N0AFNP=J;!G#Y!L79$T@U;-B2&09()$'2HL"+
M%221&Y"$N%NM*85>!%=ZQ[?P]YB5^HF,L/L^<PD3%55*HUT.W3 I_&G]4\Y1
MZ/;-6IB)&+Y57"Q@!%0_0ANX3=Q0$*IV=Y.->[M0R>]NCDEMGDAK!^[W!Q)R
M_BL]P5CBN*XQ!YQDT9DJF?0JN*H/CY(S4C(6'9LV+H[8/D.DH<"C83#4MNA3
M[%VV$E[(JA6R?F&ZA@[A^4"F#N'N #@'R]X /6P 6_H !TJ"LJJ 4 H!0%N-
MNSF1XWK3-)S$(<N091%X^_>P$(=NH[)*2R"7>Q9*-T7#155-=P!2F JA#=HC
M8P#5,[<;L7;G]K[;3(\HM6KW,K-F])QM2G1M9I4>1YN\HY:>Y$_7=.LDX58J
MV5!51P5T>)R4[=:9^O5;_2J%#,S'3BDHT?-9450*>XC<MRUH'.XRTERMJWQK
MBK5KQW4V)8'U[T+R+IJYIO1GS'4VI^DH\*<<5Y,56.#;JJK%;#,GV[.9V\>0
MV59[B>S=>X+@J.))HQRT7CI9<)%O,-A.9$KM-Y*NFR30YT[?PTB#_K5E.G=5
M'5?[E$Z+!+#!/8<Z_*G1/)=%_DTNIU,Y1DWYG%MKCA6KI6M*TQSH37$[?&0H
MF]0 1$/M, 7MZUMJAZ>1\[.=I*44WN(Q^=_*36'&I3%%L]QB=EU,J=3B$0XA
MXPC@8]1NHQ!PHJH1LNH4KLRX&$;E[J\>KO<24)Q66?:IS?JR_IK%7.WQ3Q:P
M2S>.-'GF1'<A?<FT/MC6LS@4)J>=R.9=_G,-!!+P1U5&4PHLV3*];*.(XWT!
MVX(%,D*)B (#<;B-6H>G<@I)4E\/9[$<2Z@ZDT?.(SY%<T>$<KC:<H\7#)M>
M6JI1))-+:\2<G@<UR%GQUU&3*Q>H388;&@[0=*J**D_A->P%15,8_< )  @(
MUEX1;LJV]BP.U] 6'H^4:>TYSE%0HJ[5@9U%./:<W3^J</V7#[ZM\#^TZ5ZD
M'YE]J13^ O;8?4U^X;>H#\+7]+5YM9:_=VZ?RT(T[5A_W&(F\^(&L-W2A9C*
M8]TG+ D1$DM#O31SXJ:?E*D J$ W]V!@_=7-N;<@:NN:V[O%]YO/*^H78TZM
M3JXQR^'=B6;POVV-%X[*Q$E-/\RRL8.7_.8]ED$^L\9).C)D(4AD2D*)T0 @
M7*)A ?NK&Z7E=KU%"]L\?U&LZCOW>)6?+'9D]U?Y42(PT4PA62#&-;(MFK8@
M)((MTQ212(4>A")]QNTH!]]=$Y5H+&E2E'Z^.]FHZK57;S?%B<XG<0,(_$?L
M^ZL^Y1E]IXXUVFY4%0H!0'PW0HB/V#]_^2@//AS,E(AU[SWMA((2K=ZXAL3W
M2QE6;*0(8(V1419>(BT00[DS=R"0!ZF[0MZ>M2ZU(2_0F#<\<8QUR$8<AC[.
MVVE(Q^L%-6$U@WRAFEI]S'*92^RT<N>XG^3F?K[!*\?F:A(@_*D$<FFA]/<O
M>*K%%6I783H-OA&R-J;)0V3LJ?=;5=-UG6*Y)-LW^&8@FW)V%+A,2WC6;J'<
MG 3=RBCE<H@:W9\:#'V=NWT/N!Z%3P'%\RQ5OLK8V6(9KF&:Y@[FLZE6$[D<
M"KG#HZ[B!Q62:1T0A$8]BY%1+"(G0749&*0RBCCM$IE13'93MWG$RO&]M,\>
MB<>7>TMHHQQ-90^L3[/83S9IMYTUB,>:0/\ -SS* 8J1BV<2)VHNG+TL>1(Z
MYQ[42E  HV*/VFWLSC6WV=':FBG6U]K8FAJ7*<8RMJ_PR?:14YFSK&8U:*",
MSY^[CY)I.0TLW%)1TBDV;'.X*=0#@"G:6*[A0[=FVEFF=9WJS/'>>;!QU?5<
MIDDHAB^(33.&P[.39'',8\6VQ(A>-D7,^VA@8@LQ*BY:>%=50P]P& "S4DVF
M6DF['<\WNL,_V$\D9O"FN$FU_(S#1SJN-0:R#"0"?B\63CF\@WR5<S $U7!Y
M!0ATSG#QA?HKNP(2H4V%:*1PK)=JY$38>?903:DJE)K0^823*6C<,!.-_+C1
MV%$;,8Y2+CE!'R"145S -@[NEQ5PIL)VU*+'^/K> U#*ZB'9VSII"61V$@KG
MLY,QKO8R1<^R:?R%,Z,^A$-&J2V'(3@1\08C4O@9-DBJ J<!/4$4.F3O$>-G
M^-L9QI5W=ON(BHZ(QZ)-M?'\SB8[=CDN-SK"?:.5,Q7QI_%E</7#,R#L_P"6
MBHLU4%/O+:XS4G)X;CN69\>8_-HG442]V3M*(#4.983FS22Q[((^-ELX?X(X
M:.8^-V&Y-#.$)V$FU&8%ED$4F@O4SG+W)W 05(H<Y/:80GML8=MLV=YW'/\
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MTJ<W0C#9F>F>H)% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M)4K3V.BP?RK0DHYF;,SM&;R;6D_QXF76C&>M8S)&N_6.>0)(T=HS62OL=)K
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MVA /(^'D7&4QF+(HM @$8Q^NHQ.A("HL)VXG*;L$@!POKOFGJ6Y)MUHVJ/\
MX,,8KWU]AT7H3IW4K50C:X90<XJ54\$E<JZJ==V'#[3@^'.J-;Y!K*6V&SQ%
MIG.T<#=Y%D4!%IY)*P;V?GH:%*KB$$LNJFO$1ZLTX=.4P52*=+N+T P -K?X
MMT$N9<N>IF\5J)KQIZ=%7#?[=]:&:_*MO_I',8:2U'RRL6VW3)2]1-TJWL6.
MSO521O,,^W(SX[PV<P7'MYD^UY2-PU24T<?/FT,HUD)1_'ER:&3SAO%OT?\
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M!\RBA[  6Z=YC6^_[:O;*;"%%+%&H"E*(B 6OZ]1'_.-"IR;S-5"!0"@% *
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M/:^S)36^7YREGBS 6>JM20.'J1AY?(,]=-I3\PD!<M'*B3!NV6;'5?'1()P
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M*=*544$;ID $CIE6[0.HH!E! H)$(%BB<ACAWF[A O7UJ:8$5.1^K+_\,_\
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M2I:2)KA7M\CDF;Y19LBJN@)%5"]RB9!(4J1A$1%&ZJI#J"C^ 3]I04$.X"E
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M/%@AT(MDZ,J905$SV$2"/0!I1T%:LRL-^G>XI"4P?^*+W%>I1_\ [K'0_#[
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M")N0/]0Z70Y6OD5$R%,F)2N#N<6N1%,I5A(/8 =HV$0&P#5FB%79V[5+ O\
M]/!CBO(?4ZN(\L^6L/QN;X3EK#9L+.\GLC=;>R69,W<N<5DL+FH_'7F.@T2F
MTVJCPKE,AQ9%6 EC]H53B3389.._T\/$PC5<Z_)_W$U$BI',<A^53XY3E +]
MIBHX2"I@'["]:E!K>8Q8/^GI@O\ '[>)]B\P>5TEQN79:X)H;&,6Y,Y,3:V.
MOS8XV_Q95V2^5QM:-?MY7-0.M$ T3 4&8E*I<;C4)*H=:;#*#_\ YV.*'_\
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MS!J5D86)8ZY1$%.@I/T!XMPD[C(YTB04T7+!FX23,/<8B2S=-1,AAL%Q*4P
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * \G'N[\NV/$SWJ?;ZS'8VT,FP?1<;H=[-Y]&12\C(1,@0N>[%9J.)+%X5
M1Q)/E%"E;IE5%J=/Y #NN40!L&-3/3BQ[[/"#EMOV-XV:ZF\WQ_8^1_4FQAA
MG&.J8H$XK'QQIA](M&<NLWG4XY>*!+Z<Z[9,JA;^/N[3VJ6);;]B.V<N_>MX
M<<*M^2?'7=DCG<%FL;@QM@@[CH7ZB D(?QR[@K"/>F<) ZDUDL>=*$1 .XR*
M2AO0!I4JI[C,S@IS0U9SSTTSWWIMIE26%.IV9QI!?+(I6)>*NX7QD>G;I&,H
M"B8JJDZW^-1L[B?F9MU!(H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0%,X^'^[?@4_P!X_8'I_J?VJJ63SV=OT'\>WZFE+^Z)_NG]VC_=?W7];\'_
M -W_ &/Z:C;M(/CO_=S?[G^-#_>_]W_WA/\ %_K_ /P__O+5!)4%]0_N_C^'
MU_H_TT!N4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
1 * 4 H!0"@% * 4 H!0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm2226999d1-lc_treatmen4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-lc_treatmen4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!4 ), P$1  (1 0,1 ?_$ ,T  0 " @,! 0$
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M4/IE5A]EJK/SNP#_ %N\0Q.X^_3&K_M56?GB/_7,0)9\^F56_:JL_.S'];Q
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MF!,]GK!Q$0*!?E-L4QA$0 "AW.O$1''.29A0>F!1$AP;BF8I0#XIN@B7^@0
M0^#)7J6SL<OH/3IU#M_T]/\ 5BG40>9F+-%UR*>2\RNWC(]DDF9=VZ<I)(I*
MK+$;)(F46\E,ASK*D*'40$1. =/9U-5$T*PNJ[-\F%))A85I.K:TB'2J2*#)
MV[>I;'CY158B;I)T08EO$ECF4>!B="R &!_X"0"?E;QXD^'B?L;A!I$S L=Y
M=M3;ICU0\BSO4%$NO>)NAR%ZCU.H(_!DE6P6'!S?N5Z1_1K5^\[O\WB6('W*
M](_HUJ_>=W^;R2('W*](_HUJ_>=W^;P('W*](_HUJ_>=W^;RRQ!\'A5I$?\
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M?O.[_-Y! ^Y7I']&M7[SN_S>! ^Y7I']&M?[SO/S>! ^Y7I']&M?[SO/S>!
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M?]:W/1*A:Z VL GOFLK8_GD786?2+AE8)ZA6089TV!][F!4O/7#RDU$S%4,
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M^":DU6+U*;2UMKOY8116C8V56K,2O*D[3IIE1%TM'*K*I@9J3M\PQNT"@ =
M\,J6%<4O@[2%H%&J#Y9U4JI!U!W(#Y;X8&MP<<#I82$.==4&R"8',9-$I1'I
MU$"Y,5AEGU/<CNYBK1,Y$NX^6CXV3:/78"LD\CV:S=9D91,5T3D.@("51$#
M/A\/MRJ?5"N1QZ:V^)YFOZIUA4)!96JT*GUE\IY*K=:(BF\29T< [Q6<>X()
M@Z5(H8! R@'$O</0?$>I=P?>24D#T"_&]P5<]0_'45*4I.H>P"H? '\F1Q8N
M=Z.ZR%& , 8 P!@%?MA?;KQ^_FVE]5&F5V74P[OD6 ^#_E^',XZ&OB5SY7_8
M+>O]^L?6^NYOX!>9)&G_ +)=7?PZI/U:C,R4D7 & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8! &P_MSX]_XJ?5-
MGAV[3/\ (G_)@T5QY7C_ -PMZ_K*R'_:^NYOX$L23I_[)=7?PZI/U:C,R4D7
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8!7_80_P#?IQ\#\']Z?U39X=NTF2P&3!2N'*[[!KU_6UGZWUW-Y([D
ME:?^R75W\.J3]6HS([E)%R 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@%?MA?;KQ]_Q3^J;3#LNI,E@<F"E;N5_
MV#WG^MK7UNKF:>.1$29I_P"R75W\.J3]6HS#N4D7(!@# & , 8 P!@# & ,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# .M)(]XKE! P*(NA;E()A 5"
M<"^< ^7X!T$1Z>/L]N6"2<XAQ,<Y1+T G9T'KU[NX.HA[ Z=H^&0I^F , 8
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M I?^KAA.3GY"C & , 8 P!@%?]A?;GQ__FVE]5&>57)JL6 R%*W<K_L'O/\
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MASWISA9DU8CY ;TJ:XSIV!(\B\4;QJI"P:P2)(JP+)>[MFY0!)\)%$2&-U,
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M#W@#!U,)A\?^9CCMYF8;?EQQW$]Y#8P!@# & , 8!PW92" '$P%,D14Y>O\
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M$OR6Y(:CU-Q9V'L,M0L<KN3=FLZE9#PJBB(KU_8&IMB;&"2.T+6X)BVD(#Y
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MO9IHT-(2DLP!^K=9U19)&3FD&TJ[*@H)B]RQ"F#IF32,QN"C & , 8 P!@#
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M6GU-RHMO6Y>,WQ8]AH_5.@S>JWRVJ<%2Z A!0_&[C)&5J-C8E$RD!L&E; Y
MR4ZJU36;%*$A!D"/6< *AR*$3*4P'+U*/G4>X\^JM?N7.>XKU*PR5AXU<PJC
M#)$C%4.44PBOM.2C(U*'TL=Y/;D%]O:QQ[=)\PFJG0G)A7<,WC"39F36*46"
MQ0 A:ZRHEBU6ZIW/ MZG.0/IRPK392\=;+_&;D@TO[[X=@S9U#>YCR[-5M:=
M?5AI'0%9K0QT0J$2L$?!00*'BW!C%4.JHJNAT:$WF"Q7*O9/%B[<U]8ZC4<5
MB.NU*V56+K8;>T;$2VJE8AN39Q7Z!2RI'(P?P,#/5DWTG2>.F964.],HR(\6
M,9#*TE2*SM!)<4W;3NZ&P755SK,U0,B[*05 <IN5VS-L@\!X91P95E[H<?-0
M 3>!SE(<P" B'41S/CM!4>IP4K]L+[=>/W\VTOJHTRNRZF'=\BP'P?\ +\.9
MQT-?$K?RQ^P2]_UM9^N%<SDT_D@[DF:?^R75W\.J3]6HS,NY21<@.O3$G>Z!
M,1%0%0\SPZ!U_)@/P!\'\N7$D<3&8-:3U[%M.P,_QVDFW(G8>@^3+^4O;/4C
MNC:DVUM9NY1<O-:)VZWR;;56I]@N8IYKMPK%.V7O3ICYYG*GE)._+4*B<M)L
ME+<>\EOT.'&N6VE]UV2+VSO3<&R+#?8Q;>>V=WTRSTN>LUHBHQS#5=>GU6T:
MHU?:ODB/I3)HS+YC%^80;%'S0 Q0$][_ "@*JX=Q??EER^V+I9>!U_IKC5>N
M3.V+=$*RC2EP%EIM2BX!,II0(U],VV\2U7IQ$R/H14YTOE1-;M(   "HF)C6
MV\JE[41532//[G3"2<&SYP>GW9./M>FYUM"I[9K.SM0;J@41%^BSD&;^B:.V
MKM_8PKH%=I"1P#0C9'J<5!$/Q5[V)]JEP9?HR9*_;-)A*34&*602?17Q3@]D
M&[HA5P*Y0%(%D.TR@@"!TD7! *!3AW%-E43"5"_<D]Y(V9*, 8 P#JY'MZI
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MN08HRB1^H*E,(@7%;Y$>FF-W.W79F;HZC@Q9--DX%R[ A/(3E$U!8J+=B7B
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M7=J]<MRG(555A<IMKV'*=10P*(=@E-X]!'V>&1E7>9?<A1@# & , 8 P!@#
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ME15HP1:B8%P>K#Y1$3=6JHBN'<<!$3& 3>TW@3K.K<5IQ"^![',FCB.W96A
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M0\4@P-'$9%58BS%05A>N?.[>Q/ND-9)I9M6D2*DHH(JB8%7*'0!'_A_V8?\
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M67:S4[AION>KM,K&Q!BZJFE.5ZTU&YW&N),54$' OYRF4B4B;U=V)#E1(+"
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MSND_0DB4Z:)_=G8"JF53I[NJ($ZE*82F-V>'03=/$ S.8*Z*3D"X'H'Q.@B
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M45'N]8M-[U$,4G>X*NV*'G7]?<R\- SC5I+LXMTY=Q3I1C8FQR)KD(8Z9P.
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M+95J9/J91$%!2$Q!$AR".FXZ*20[NS<</CVEB\R:& , 8 P#"7ZX'V3\-/\
MQ^ZU_P#</R/RNR)DS:9"C & 8CO5"X>:KY6\?+W*7P5VMMTA6K3M37%SC!10
MFZ%8JQ$*3:\K#.'T;)M#O+,QBCQ$L8$52N(9RHBW!!P)7!/%_P >O5.G3-76
MU>?'E%8+J],KTRX\2-/0^XA:UTOQ(H/(:)DY&T;AYKZ<X_\ ('<MR?IE23E%
M[E1G6Q*S 0Z)H>,=-:Y576S)9)@W<J.WC=NN!5UU%.IS:?LP_0IC2^%-MZIN
M(E-<[;(S:%3!,O0/8 >W-_XWHM<VF<C/5,# & ?F/_$'_=)_Y8X)DU_JE_\
M,-[K_P#"CJ/ZL7K R; "?^W_ ,O@#+A!^1^N0HP!@# & , 8 P!@# & , 8
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MZBW<O%[]8%'9T#]I2G2]Y$W00$P=.GB/M&,J[MO S"Y"C ,-'KI?_!9#]?\
M_.5#^K]WPFU8&6^ECUJ-4_\ [9@__P -:XN#U& , 8 P!@# & , 8 P!@# &
M , 8!7[87VY\?O\ %/ZJ-,KQR9EV+ YG!HK;RR#IH6\_UE9'_M?7,VKHA)NG
M_LEU=_#JD?5J,S+N4D7 .I(CU\TQ#J=S@X+!W*&14* =O1(/$3]O5/\ F\1\
M,U14P9EN=YJ-_P"8?L\)4>4? Z?MUFXYZV;G@>4S1I8>1.GM?[]I"S)L''DD
ML60I^P9ZGPQB*HJ)"L0[H05(;M-X!U&5H655N%&TE^?0LLD)9=-;QLS&X<<+
MBDYV'7@<3W&;2VO=#ZN=@WKJ[5D8*GKFQV6M)+(,FY4EU/>3"+HBIC=#G,4"
MB7N#4Q'Y)[C-PI,Q[@S.3,JQ0%?N1:%EDD&TVW=$3.HK#ECW1@>%?H('\T4P
M$#]BOB0 \1OJI%5RM\R167#6<OY%25^3%HG.6LYQ==:BL]>IK*@0-U@M]JS$
MJVBK'8G;!^\F("-K1ZHS9F>4IX@W))$2G%E"F=IE630'M \]-*=Q7KGB^.$7
M.1BP(=V8[J11*LDT0%5&1<$04'W-N*CAJR(($CUE3IB8QBF,)C&,(CU,.2ZK
M8L[8/8X P!@'3!+#U4,9N4$D%U472@. -Y $1(H4_;Y0=PF.< $.H=H#W=?@
MRP2=]BE49ZC'&.3W(?21+@1"T'OTAJIC(.#LTJZZV3%6,*BZI:DR=R5FVL#B
MR*$:,VG<=T\6$Q")=Y1*,[V&ZQMR*2>MQ*(.-1\+A!S%-577/O7A699*7:QZ
M+YVCH_DD@$8Q<.  KR46*F=0C=,#*F234, "!#"%=5*KX]@57QVR9P <D$ -
MX=AB 9,>O4RG41#H4G3J(^'P=<1C(KTVH?B$@@906Z9B&= GYGNXJ%*J4.G4
M 5)T$Z7</@'4/'H/X,1OL$Y5+[O$^#(I)^9YY3MP1*!E%E@%-J'4"CT]Y.!4
MO8;_ %X@2IX%5N51F:7''D*B<K=,1TKM5%HF\*FQ+)$3HDZJ9HW,MU"3]S+W
M..TH&[^G3H7\;.J_:IZ4L9ITZ77$4ATHB*_2SD"?_P#-CT^VHN$%7A.$O%0R
M;0S$D(N5D.B:%Y'9'"JLH+=%(.A5 #M,'B'0,O\ B<4G;X%TO==E]!EFIB^8
M*K8C5,#>\.E7::23<Q#=@E,8P=@^(#[3!FE[4_03XG&6LK!NX%HN(HN2MDG0
MIK""7>FNLHW2*W$X%%PJ99,0[2AU /'.>'@C:5Z,Y7RMU\@2M5BE5.DF?S^]
MN=$53%*'F)G2ZAUZCV]>G=T'IE>F,HGJX?+GN/X2FT514$A4S()."HF<D<%.
MAV>6855?, GE_D52^68.O@;KU$!#IDC<6N[.S.,2<%R1RJQ:D>=@)G:&2= 9
MN]:&4*4'";HB*B91[A/\4 /X$Z]?'POI<3@DUI+<8,!M->.U?\PSND?DI^3K
MQ/TR)W"C=P2- Z]7O0K)HR1D ;KJ-1#H8 Z#XAUZ=<RDIX%M7)G]+*)B/1%,
MSOO354[V@BY;@9%4$3)"X1(=,% -UZA[0$!#IX9K!,P?T29:G216*=%5)?IY
M;A!<B[,>H^P79 \D#=/8'7Q$0#X<B4\RMI7MOQVG),\[ 45,F MRE(9-1-3S
M#*=P&$P D4G4!#H'3Q'NZX2D.55JA_ 2*7;YABF22#VJK=4B 7IXF$QR@7H4
MW@/C[<1VB>P['(48 P!@# & , 8 P!@# & 8;_4.]1NT<()G5-%U+Q/VWS)V
M7L=:68-:3KQ&V.9E:+CXN:D7QG5CK6MMHR!%(V/BG;U03,_C(I=INPIA.6*4
MLTVZ\^AFD0XE]L;OD2#Z>',O8O,"-V4_VIQ:MG%6>UR2A-XRA7NV3-DDG*,N
M6VD%,(:P:TUF[@)&(^CB1' @U54456#N!,4@ ^JMSJSLOD(2M"CPW+=QW'B_
M68GI.I>GION9AW>SXJ3BX!0Y)K6\W9:U>P(Y*Z=&&.N5= )R,:H'.5, 3[B@
M)4P\.TH97%^ X+ZF!#TAXR,^_5IUQ&\-N9''LGO&S)<ECW+RUVSO>"6,_P!-
MWJ+)[[2+9I77+)K+'.D"9WYW9E5""F02]$B]9.^VV!';W\I-U>$3\E%9$Z3,
MCHJHBY4:))(^]J&,?J^633#JFL[.!CF*83"41$.XWMPYR516-^TG=Y"C .MD
MI$(U/SSI=Z)4G"BA_,[3 9(A3)I$)V&\Q1<1$  ! >H> #UQX@XBTV"2*;CW
M17RSJHE,103).!340,J(MVXI"=TN4P  )%Z"8O4W7PZ9615N5*YO:PJFY.,.
M\Z7;'JS2.>4"RJF,VE?DHPEK3#Z5-D4^AR Z*=W&%#J AV@(CT'IT$M\B<-4
M*?>@E%,(3TR]&Q4.GY$,P>7MI'('6!TN!&]UG4E5UGO:F9V9V<OF <2AUZ]>
MH]>N(R$V[F9/(4_D3?@#KG#_ )D[%@PO>NT[3;\*8@ZQ3E+_ 'X47H<"B8A1
M^C]W\53] !%(/A./@&9U^ZDMW45Z&6"F32 5*M 5%=3W>OP"2G:0X@KWQ+(X
M&9B!1!YVBH "!/8 &'_9'"]U9QQ)ZE,9)#SL 8 P!@# & , 8 P!@# & , 8
M P"O^PP_[\^/O\O]Z?U49X>.IEV:+ 9,&BMW+/[!;S_65GZWUS-*Y%YDF:?^
MR75W\.J3]6HS#N4D7(#KNI5%$U2=5B@EX'(/0!_'\  !*'PYI.D&<R:V'KA[
M[?ZSN&A*O'[?XK<:7UP;[B>-]L\L:;7KO H?1#^[0YXJLL++IK>C%L$L,X4'
MXECFXG &_B?M#L:K1O(K^I<2ROHP[0<[1T?;DU+5QTVL>KV(T<\VOQOCQA*G
ML/Y3</Y4S\E9::XU;7&RD*98(T12B6P][0P_&$QCGS.^^[A]32TK%/C\"N'K
M@^G+*[VC+5S#IUXY#K[(U)1];TB*TSH2YV6)0GZ>CN%1U=[B$0C=J9"N+JA2
MMA3 G,J(%]VBF_Y<!*'9JK5+]Y&EQO?'7C\BE/H5TXJ?*78-ZU%6N7+344#6
M31&PI'EI+DEW[]59*RHUWZ$G+MO<7NDJS29R/RZ0KF,3\U1F!#.P+U0D\1&-
MOH;A21C-A45\PRR<BJU(P2[2"*/>S*<O?UZ>P$A^$WMQ1E;Z_ ]-D*, 8!']
MC;R2U5FRQ28,Y-[$3!42"(G,$LYBUF[ 1[RK!U][%+P\0Z![!]@ZQ6K,NZF3
M5,@7-?5T#3JXT1B?O(M/7<IT38'ZY1"0)/TSF:U9V68!R5-10(FNS"AUG: (
M%162,!5$%"@"892K2Y7J^U^K&S.R]9NC^H_%GX[22VP]$R6EH[EK0'VK&DFD
ML26J^T%=-[<4);9<Z&F#F<QC9JO/M_)5?/T>KU(?=1$I3(5]7W"*Q@S?6ZM^
MI XX\1D;7;%QU;<F6SQL=T\/-VLVHCL4W44=?OFCZ=<68AQ;$>@4"P8 )Q2
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MB;+*Q5S(V?%LM?O^NK'Y+YP[115*,B &0*<.T0,8IZDV\1;F83E._8OJ64]
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MARWJMQ']M'ET/2YDT<1T!%1(W4()DUB*]Q@#KV=H% /P^)N[_1E4S*(XLS^
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M]@KNJZ+M6B4B Y%L=AUS8'*6*XU0Z4Q<6^FTZ%,(V2:I-U8.W$8O79)0""U
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MZ!Y#Z1WFZB8&*7LI=0[6H6RU&D@@QCVBS:U25,L$V8KUNFNB8$G92G3*9+P
M (.'"?7DB:7JU*5NZEORPR)!*)%5.B8"8I3]5"JKF#H+EX43@#QQU ! Y_C
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MQE&A?,'M2,(D+W&_". T<MJV3:(D02\$DPZ)D .A4R_ 1,H>!$RAX%*'@4H
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M<W5[&1_RP><L560HX,DIT[3:7P:& , 8 P!@# & , _/_P Z/^X'^L<N#/\
M(U_JE_\ ,-;L_P#"AJ/ZL7K)D8-@%/\ %'^<<N0OQ/TR&A@# & , 8 P!@#
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MHP%58'4.= Q4Y->#C(QT9R*9$_ "' >A0$>GLJB;X[>2L5SE9MNYNY.>9-#
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M<T(H$""07"K@OG%5(+H3.#D I#$["G54,(=1-UZA[/9EFO"!$Q-TSMLA1@#
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MX622[TTR (-7@'(!A$>\/'H'LRE3DS&9"C & , 8 P!@# ..X0\\G9W% /A
MY 4*(#[0$@F*'CE3(T<5>-371%$WDG()0*!7#8CDA>A@-U BA@+U ?9^#$N^
M1Z5;!^"L059N1LLX.H5(K<R)S (G(NW."A5C&%01/W&*7J7P]GM\<BO+#W8[
M^TY[1J#5/L\PR@F'N.)A$"B<1$QS%()C 0#F$1Z .5N0E".5D*, 8 P!@# &
M 5_V%]N7'O\ FVG]4V>6*=IE_DT6 S.(-%<N5_V"WK^LK'UOKN:5R+S)(T_]
MDNKOX=4GZM1F'<I(N0$?NGP@!C*)^<S%5)M),TP SAH],HF#5<W=V!\5THCW
M!W].THB "/@.X6)IWF8:RDO,K'NCA=QKWO9X*T;6TAK2\V" E$G;2P2;!RV>
MC*%>,G"Y9-2,!B5\61>,$Q4\\%@'M-X?&-W-344O\2:;_<Z>$$UT"FTJCP3.
MFTRM5^N4Z/46=UB)JD<V8Q<*HBX<)RBB1"(M3@H:7>.3&,/F&$RAAZ^/3(U#
MA?0)IKU.S>,\B<<R;& , 8 P!@# /,6-JLZ%D1$&9Q_M(+D>%["D9&\@'CIL
MZ305=(/FJ("9$""0AS].\P= $$-V(]7IYF"KUKZE"/*=PUOCJNHN)Z-YRZXK
MWRLXAXHEQB*8KH[D ZDH>N3"0>_*)RLS&M'O:LZ2\2A\<H%*7*TUN%/3,-\\
M[,S^9"C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & :LVW.4
MO/;TTK]M/5\1Q V)RIU;>=AFONCMXT2&K":48RG&]?JC;5]T<+S%&<2,VW<5
M)5VHNJE+K>3-H='9NPJ:%JDIN9I,IT[S(YZ9@\G]B%WGRCY.:WAM+7/>\A0H
MB*U,!U4IBE,-?+WX56LZT0BTXY275)=D$A5]Y?*++-E!55$>ASEA[;;A><>'
M7S[C]O6#V7MC37!K?>S-97S8E)FJM6R+,GE*I&M;.Z(H9L*AQ1+=T543(&5+
MW',;XQ%  I0[.N:?!KSVY!3NS2;=,]IKT^C/R!?7/G?K"M-^5G*_:B$_$["G
MEZIOFB:<K3=1DTU5L%TBG_\ P#8)Y4"HN(852=#!U5+XCTS$B%,F[=7_ '51
MM[X@D=%600:OUTSKKJ]GO9#N$RE(JJH1$"^88.A.A?@]@!@J._P48!U<H0%"
MMB]BQC X24*9 I#"3RU""(J]YR #?_K^T>T/8/LQX$<6R0FZU;2D;*SM_P!#
MZU'/D&SYF8T95X$YX^8=/R.VMD6%=FD!W@,4#D\PW></>1#H("(A5?>R74]Y
M_.^&S9?1^Z%TTDRD_NLV3(I"W<.4BO%34N73 R@$,F'0PI '3V>&5\*M_41T
M6>I07T+#J&]-G2'GMF[-=1Y>G:K9N=53L]]N<VY*90RI2F[U /U'V^/7,E5H
MW&7S!1@# & , 8 P!@# & , 8 P!@# & , 8 P"O^P?MRX]_S;3^J;/-*QE_
MF6 S)HKARN^P6]_UM9^M]=S64"2M/_9+J[^'5)^K49D=P2+D P!@# & , 8
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MB->+,,[;.-YLU>:"JYD&,>I)%.)2.5UE.WM^.(@(B81F:R%& , 8 P!@# &
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M%9HK%-%I"_V!VJ@U!B4C9,"**B E*4O00Z=/##M(43&86W7?FYEYR%& , 8
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M?!_C&SX@<<J/H5E<YO8)*<21!>Y6.!KU9F9][)2+J1>R#V$JJ*$"P,X<N3&
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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8WL/YG=^-T#\/M_FZ9)?JB>H_C,4W9/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tm2226999d1-lc_volumetric4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-lc_volumetric4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!Z@'* P$1  (1 0,1 ?_$ 00  0 " @(# 0$
M       '" 8) 04#! H""P$! 0 " P$! 0            $"! ,%!@<("1
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ML[M'H]=\EVF%*$R!J>H<X@5L,@^;419IZX2QX)3H"2TZTG0E&SPV;^D]>QO
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MW,-:S"%AAB-60F5 %I6G+/TVAT[Y$DG\%=,S7F+FGDB7]0]6R:I>2+09;9I
M;X^5,Z3&.O\ %OCOH@S.$I75,>K?(?$-.BDMN;U(!A3IC )?;VE3IB"0V42Z
MC=RVIE*-O1)5J\YU6)DB8A4YJ"4Z<]P4E$@+/6G)T99*0@Q6:'9@@%  6#8O
M0(=!UK6 >[@# & , 8 P!@# & , 8 P!@# & <;WZ:WO^9K>_P"A@&G>QO,'
M2M6<P]3=WR9/\5R;0D^DE)5RM8M#7V!T%;D*DX8')!PTM2K0L#-$55E:41]K
M&?LXU7IM5NAIB9&$DLX*[*F9Q&X_)^[<[QCH-WIGFDZ42]HB4R%RVR*[5#8$
M&B$L,:5BEN7VPH5K&2<65#X\Y#4+6A/%6=$K6IC$2=PUK8%0WS%V4[I<ASZZ
MYG9;7)HMUO"MD-M&2!BAHH0JE3:4[)YS*6-3)XK %Y@C/@&ZPI9&$*AS:6%0
M<4\.;<G-4I4QI!1@PB$83CR3\#UI(Y'#[!Z\Y^ATLATX9ZVF$:D%G1AM?HC-
MW\>RV=AE32H7 71LY=O6MA-6@(3A 86(1F@F V(#OFGO[BI]:+N?VCJ&CW%C
MYK,9]7X\I+$CI[34R>0 ]XQNDV<0+-HV9B=M!,T0X&#^!-&0>$)NQ$': !W]
M-=K<E]#S%VK^CNB:@M69LD/9K"7QR#SIBD#I] Y (HMJF:).@5F[=8N>H4%D
M&+TNSDR=28 @T8#1!!L#V:Z[(Y9MMU?66MK[JV8.,=C;S-7 MHE[4:G/@L<?
M%<7D<_9%YAQ:"35_'I0WJ&M>^MIJMI1N:<U(<H H+&4$"IG6/D?@<,Y(M>].
M6+<Y<E,W@Q-2J6D[H2T3ZGI<AOMF5-R>,/$UFJDI <QLLXA!#BX11:(12*0F
M:1B1GG)U9)A@&4P'R?<S3KLM7PDUSJ+N%X1:HF6P9V-J?RU,602]^.0C;ZQB
MKJI1I-S*1%L6EKJL$GT *!$40$[7Q!IQ*4-[H6EJ;J3G>]GY^C%/7)7UC/T;
M;"'US;8I)$#LH%'%+V\1E/*VKW!FRW^'GR>/.+6!X0"4M@G1N5H_?_$ICR@
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M-SA?M4M\ECS"Z6!7HAGSNJ;"KJ3OTR<XXK*:34JEK>$;PN(6FJRDQB8@P6Q
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M8C?NRO8+UH. 9TXNK<TD&J7%64D))(4J1C,%\ON4:<U6I$ L/J:;LE,2(8M
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MK)-+'1.XJD32F4*2DA)AJ9I1.#B=[Q2> &@E$F"WL7V, Z>"<V4/6-G6;<\
MJN'Q2T[E6IW&SINSM9:9[E[@0A:6T:UQ.]H192IP1L#>%<80 H3@)O2C5;.&
MF)$ ";M[T'6][^QK^9@&"0*S(59I4L.A3N8[EPB<R:MY.(QI>6GYNF</5 12
M)H %Y;V\3@!O4F!#I4FT<C/UOU)-,#\N 9N>>4F*&>>8 HDH C#33!! 646
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M0C<96&-:7M1;U1\"6EQQ&;&8Y&PJFAH]YL*8U>%8Z& %[2I8I,W[>"?"; ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"OUN<LT)><CCL
MTLRN6E[G,0;7)DBU@-JQZB%B1]@>AE&O<<:K!A;I'IFCC+T<0 :QM NTA5#
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M36!.I79DXYAIJ63R<2N&SJ5R5_A34Z+WF9P'3,"+2@_XLLPDI[1$QY"2>H*
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M2(9H2P#&4A0%%%;'HDDLH.]^NP$E%E!]"RP!"(2I@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M]D M 'L(E56ALEP48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MT822-F'"+$<8'S&N*>Z]/RDZ@_\ LC[2%]G?V=]-)=;W_0UEZ#']HWSY#(8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P"'KVO^G.9*T?;AOBP&&M*VC8D)+M)W\T_W 5KHM(;6EJ;D"$A8[/;
MX[N*DLA(@0IU"Q4</0"BABWZ9QW;MJQ;E>ORC"S%5<I-))+>VWL272V<MC'O
MY5^&-BPG<R)R48QBG*4I/8E&*JVV]B25621')$P2]@995%7MIDD9DC4@?(_(
M6%Q1O#(^,KHF+6MCNSNK><H0.38XHS@&D'DF#*-*'H01;UO6\Y#B.YP"M72_
M75#\B,T ?+UD4K9"+3GQ%75VV0BIK=NB5R^?*8S)ID5&V2$4K!;"F2M5N,0Y
MS6",T@]P I(/VAZ%L.A 0(W^5;AA6QV^^.=L2N#[H:N4]P6I%[6H/HFG;)CE
M5JGG<=3V&DJ>U:GAUG2F'#?M:1;<&AH7I@*MZ*$+0]Z#L.FAL%0+4SDB1N*,
MSWJ1>E3K$IOL#+V8F5%!.(,]V:$!I?ME#UOT$'0M?8WK6\ ]O 'K@$35M>-7
M6\_VY&*\D^I ^458IE3VHA^9G]K^BT_*C$;F1C!M2]-3<D>MAC4N;E/Q3<8K
M1[TH]CWWO0&  &XEG & ?-OY97+H-I[0J_=;\?,=@_2*MN:H90?:ZOA=BZV/
MY$N&3=/S=KN:;.SPDT3,F F'5*J9G=F2*5*-A*<Q&*AG@,]L)@?.;'_&9:G5
M%B5]>T8ZI6+9R^4?TA85*0"_G"D'#G%1T3#82E9"7&Q2Z@6O,@2,S<VSM2\,
M2-R;58VM]2-):Y.$/O1^H=)LIP!@# & , T,SW_O)U!_]D=:7_2;39>@Q_:1
MOFR&0P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MQV=+15$FNI1SP:A5*7-'&PO!3:0N.+)!H(?,;:< 8!I4\\#/U\HX(ON5\S]
MM?/,(K;G[H>Q;V>FEA4.EO3AEB5:J76(5Y6;^(PA%7R.2N*=86^OA1@79(CT
M6%!Z&F#,+![OB-=UGE37K.S_  5<*S>X[T@%)7'X]9ET';3G4=L3"L9O9]DP
M?GZL4D -?Y]%W!OE*\N"/CTI?1)1*QIEZ\\LU:4=[HOT$ZNJA._CZ\E/3K;X
M?>!^@9%S'TQW_;%DH+.@,W74>DC3Q,TR.HK2L&N8[.YZKE;TPA7*9,Q0Y+H]
M9[1JE8O$8<;L0C!#V956B(;YNZ?L/JC\H1JN8V/R/?\ Q\Z1WQ>VK&4,'Z%0
M1E!)I,@!T$Q.NI4R%QA[?$HV/9[B-)[1@P&?$)C->S[/IO;H(_I(^JG!1@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# /&<24H*,(/*+/). ,HTDX 3"C2S [ ,LPL>A & 8=[UO6];UO6\ \F
M , Q61P:&3!=%7.5Q.-R5R@L@U+(2X/[$U/"V'RD+6YL89+%E3DD4GQ^0!9'
MM8CTM2")4Z2JSBO;]V:,(@/),(7$;!C+O"Y[%X[-H?(40VU_BLM9&R21M];S
M-@$8A>6)Y2K6MT1C&6'>RCRAE[WK7KKY-8!"DFXXY(FL]76K,>7N=Y9:#G'%
M,/<K(DM)UH^SUPB2U@.BJN,+9>Z1E5(%<>4Q=0-M,1&*!)C$ Q)Q V2+8-@>
M]+>3.6I_(Z\F$[YOH::RVHD;4WU/*);3]>2.15@@8CBU+(BKQ[>(XL<H8D9U
M)03$I;::F G&'0B]!WK6\"IYY3RMS+.;3C]YS;G>C)C=<2"A!%;@E-20"06E
M&@M@AC;@L%@.T?5RMH"WF&"$1I.K+T2(6]@]-[P-AX'ODOEN2V RVS(^;Z&?
M[4C<G/FT=LMZI^O'2P&&9*B&E*IEK-,ET=/D37)U"=A0@,7D*0*Q@1$:V9O1
M)?L@>W..6N:+-L.*6]97/=(6';$$VBW"+/G-3P*66%#_ )M6&.#=]%IF_,"^
M1L'P"\T9Y'PBDKW)PMC!Z"WO> 3OZ?Z'I]C!#6'Y0V_QJLU/-%A^2"F*SM>&
MIGY-#8"FDE(KKILA=*W5 \OH8U5[1%(O)+#"Z',K"X."K37HHLA B4*50RTY
M)I@1:;*O<?OQI1+QF%PJ;RCQW4E4%6I&23"KRRSH?38:QL$E^3,[)+43/,UK
MU'VJ8OR!;'9(WNC<I-4+&]8C6%')31A%ZZ5J*4-G6 , B2_*3@W25)6QS]9I
M#DJKJZ*^EE93A,SN)K0ZJ(K-&58P/I#<Z$!$<W+36Y<9HLX.MB+'O0M:^3 *
M4])^*#EOIZJ><*ME;A<L /Y,C&X31%J4S:K[6URPN%KJ_;ZPE43*GK2 Q2M8
M)["FA*C>TYQ(@K@$!]=AUL6A!0NI0U%5;S-3E<4'2L620NJZGBC5#(/&4AJE
M6%L9&DGW97Q+@O.4N+JYK3MC4+%BDTU4M5FF'G&#-,$+8&G:>ZU^<G4'Z:UK
MU\1UI>O\_P#^TVF^SEZ#%O:C?-D,A@# & , 8 P!@# & , 8 P!@# & , 8
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M0[<7+$I"5BX[7CM0\:,I4?BT:6S>67SZ$?'A@# & , 8 P!@# ,=E!,K/:C
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M 8 P!@# & , 8 P!@# & , 8 P"$(%^_'??^V:S_ .)FL\;H7]5Z[_BXO\+
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M@*8QT-=_,0S=$ >OIKMQ^C?S2(X6@:4?$^ZV/>@^UZ_)@!KN"IWRN]V\RV;
M'>IPLZZ0BL]LF$>7UZ%@:]J-.CV*9I7 V.!:6W:0W2A1M3HDGW0_;%KV1>@'
M85]95>6S%V^;U;.X?9$,=MJ=-<N@DE9I=&7(2-08D6!0OS M<&M6)*K*$49H
M!HM@,#L._3>MZP#-L 8 P!@&B7\H'8:^<N0*]?)_UC"^0PQ"\0N$7G,\K6?6
M^RR"0RBC[OK@]I;J]K(0YDYS&'QB:N,P8UJ9.J*9W.-$K3RPDD#/)![$>EX
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MVMJA00$*?>SB"## >H0"WH2FWXB5(%^_'??^V:S_ .)FL\;H7]5Z[_BXO\+
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ME\4+T]G8=[$-J&"C & <>FM_+O6M_P"=@'. :&9]_P!Y.H+_ +(^TO\ ._\
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M D1=E3Z5MI2R22!O(,6$Z,]!ND-T53]>*?O24^0"FK(L>2,M=:30>TB(+'+
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M'S<[$#^)3)SDWM"V#WGM@$'5Z#%OQDOA/J/R&0P!@# & , 8 P!@# & , 8
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MOZJUW_%Q?X6!]'YG_H#EC^QJ'\63AGLCYP, 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M#)+M>+!,L,+Q'@L:1Q36,,3$"*FL(W42D8/]DZ5%IM _2;,P#9U@# & , 8
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MXJNY4ODX)8":ZDJ@;H-V&OV3M#MJ3Z(T'V_?C]?9P"^6 , 8 P!@# & , 8
MP!@# & 4NHSD$-+]:]L=3!L <C,[',YX,/A HP%I!7NZ#KY]@96BI%I^<12G
M4I"]?%"]4+=\%LOW?]W]KVPR@+HY0, 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8!0+JNIO(G/+!8WCD/L"B^>Z[2PY$W/T1M#E99>CXZS0MZ?U*Z2(Y2FN
M6N@MK2I8U;>E W[1G;+.2&'>^W[[V"Q&CJN .1+QYB4]/S/HN]X7T!;?3]VM
M%Q2F5P&I5--1IM,8ZCKJHF]G11)3.[ %K86BNDYPSM+ Z&8:+^YZ^SL4V)8
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M^,R6=%5ASE3S@]+H'#V5KZI' X:^R=Q==FFRRZ)%$HRH4.:].6!(D+= MZ8
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M4[D+A+9W8,W>BTZ4#E(Y/(W4\XP6BP@**]V2#6BR@ZP"V& , 8 P!@# & ,
M8 P!@%.-\70 ?=SQWN?(Y*IL![Y'1\>K8*H SFP0<$26RKMSZ0;*$W;>3)&>
M\+!)!Z$IVDVDUZ>Z]OU%@=-37A0?@:I"B[*A<@UTGU).Z?HUDZ 8N4.?)#.6
MYNAW+Z;I9A=8K9*FNI='FELL14Y)8V^*TK&I6N9A[-LWWY(]J->]P-Q.W$/B
MFC?(5RN'0,XZ=Z)Z\MY!3+5S?5TRZ(>X^[+ZDH1I?4\C^@<;U'V9HTZ.#T[-
MZ,US>G#:AR7"2 V(8?>'>] VP8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M^GR;]-^OIO .< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M(IZ_3(W1(65H/]Q<P!'^F!O(9=!M\P!@# & , 8 P!@# & , 8 P!@# & ,
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M  UK ,LP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MI*W**I&E=KZ=NXVA9V![H_D.Y\O/YTC)L;[H&4# &1[@,4V@90,FS<!DHUN
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M4N&<4^*.UI5<:>-';XRK3[-*G2>8&/F!86<\P6M7=!TUTG)4T9+K"]W68LT
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M2??29XLP^#<08^$'.7H RU R;:]P##50,= &%M0&*=/2!E!QF+W@YS(#(Z]
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MP_BVKNH)U3H;!E#Y8!S(X("CK*G492S5?(3E+&QJG5+[3>:[@7[)UL25,?\
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M_P"-!/\ AY7GK-'7_P"K:S_W/_C2-NR_^4O_ /X_]ID:G &:4:6 X:<9A8P
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M>;KN=',6)=M<-BW;X:2ELMQX4Z\*>U=&WX35RKD\BXIJ#5$ETEOQ,[O[(O\
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M<&V<=JBU)1W5BZ.L6;<5O;!N\HN-=M*/K5-_QFV73,[ZUZ?-;E\G\U"J]?\
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M[J@CSP'7'>NXZX(8W:=(5/:L1KQ2XE ?'"5W6TQ?5=U26\&(2D?SZ_3B8M[
M6M$0!)I0?I0+V2-;%H*$!7%VW<L!D_34'A[! 9;*N&^3H9U/T&%8VR1 UV"K
ML-1:CXPU%5ROZ0D[B"@B$4D_FB>W+3OZ*EK9L2'8-*@""J++]!]5DUS5O/\
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MTP^+GROBX?M7 6_YR+*U[LEW-6:0?"B/$(H*K0/TSM;7UH]]%JMNTK95O/\
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M?29U?NB_U,']@'^EFGP0ZEWCCHNI#W17ZF#^P#_2QP0ZEWB4CU(>[*_4P?V
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M-C[6CD9<GF.RZO8++(C"51Q#2\.4ILQT8(I#((Y.0TRLAI4JI[)T;4J6:(/
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M!^?Z[?\ 4_UW^CO[/\_^;@,_/Z._];^SK['_ +K^J_T\ X#]C^L^QO\ J/\
M2_\ :_Z7KE8 ?\[[.OL?U7Z'V/\ P_F9&4_7\W_6_L;_ /%_S_Y^ <:^QO\
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2 8 P!@# & , 8 P!@# & ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tm2226999d1-ph_anatomyclr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-ph_anatomyclr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!: ,( P$1  (1 0,1 ?_$ 0(   $"!P$!
M       ("0$"! 4&!PH#"P$!  $% 0$!              $" P0%!@<("1
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MT1&B(T1&B(T1&B(T1&B(T1&B+S5,8I2B4IS;G* ]@ (@41ZFV$!W -%!?))
MS-DFY6F:2Q/@AXR-:5S&<7FVD\#YC1*\(@T!1TF43F6F9)P\3.R:([O'"2*R
MR1#)(+&+/4[HMPXVPM4\:0?W=%M$I&:7;BA,W.4[W-OM"PB!E)"QSXF"0?/'
M*I?*(=X)('V! J9"D*51WS1BS+9J<4F1%%(5EMT _8G3543%,^XF 1[#%]3L
M8>HK>03_ !-N(B.CH!FD7\CZXMB^9H.:*.R9)3K.WQ\->3)M8V+9S5-EG: 2
M3RQ"T19&F"UY(%ED$.XSE0RYP2 3"(:D>A,]I7IR2YGX6XM0T?(9(G7QYJR2
M+X],Q[ H*3F1+$A'I*A,+,J?'-W]A6@HIZX:-WBOI118.7;9)<Q#K)E-2<'S
MZ='0$.Q#A<T_*'EKF[DB_F9;*US=X/P+#V1:6@<31\^WQVY3@F;U19,^4[>+
MF-L]E8N6Y>\D&61"M2RATVYV"Z*A432Y>F'3I5#05VK'<)X0SMFI,I.,^%+.
MYJLBH9>*NCZ%)CS&Q57BAE6TN=FJTKK61K\D=4KE99@("Y(J<Z"@ 8@A!V)A
M48,G9L&>S%'3,,WF^3F<[/>)QTX4&8H.,#PE!Q]$;$2,$0QFJ?$PN0'1T1,;
MR+.9APN8#!^TZ!M. K]2"N&"<4Q][;?!S&I!) \;\?2XBEXO-D-"6RRX#ZTU
M!63<92E+BL@Z[DPV6(8JH%$Q0-VF, PIP%$I>NX<Q342)I53&]%JZ2(%! E;
MJL+!%1[-NSQDBF;0B8$VZ=H!MJ74 ,L_*U A 1(!?!ML("=83]=]]C>3?Y_;
MHZE8I-XWH=E241LE-JEB15 043GZU"315-PV'R?>;%T97</CW".HWHD\7+@-
MPUO27CFN-^)V@F*J"CFIU1C0)%85=NY1:5H85N455)_ ,981((B)=AT"A-_Y
MF]E?#SJ,G)7 62\GX<GC-EPAH92?D\D5-=X\,#=./F$;^6ZV5&#=%6%)P9@Z
M;.44#&.DJD8H'*IFIQ#=/2FC\O<1>7& (22B,T8>:WVA,HV09/KOBB,&[5^8
M@E".03;NJ*LI:<AK$<,U *Z26 QC*&4!(")]A2B*OT*C<#3V;]W7@M>8,Y$Y
M;P:NA;.,.5#RM?<NDB3F);%,(6"C.VK40%S2X**DE7#["TZNF<2&0C%84I14
M(94G0!T"FCT./9V_'!/:X]YC8:YQ9+PO4E9Z?I0UY*<R3.X4LBB,)/N\C5Y[
M"5JL5EV\!K'A=*(YA;C,+ HV,NS?KM6ZQ5#^,HZFN]NF&U4TH2*],?8GB:\?
MUCIZ[0535: 4S4AB(,$B^I05*DZ9JE:H)/&BL0LF9J=NX$%"F(/<7N 1TW;$
M;/IN]"O[A@F<AS=R3?<IA4.1NW^':.XB=1(QPV#Y[]-'4$'%(SS)1YO'4VMG
M#&\:Z!Z=9%+*E(CC@>)OD6D(G9V=Q$@)VK*Q0Q3KB#EN5 )$#$3D =)(($2'
M+9NZ>M35WSZ=*)5%7NM?L=?@)J >A*1,ZV04A7B2OG!Z@JEY43G4W,*2AD@W
M,538Q1Z#UT959K,45BK=XD >TAS)]P].XR8B4X=H]0[3@(=?CJ$7MHB-$1HB
M-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HBMSJ0!LKX01.H;PG5[A,5%+<OZ
MB?F5[4^]0>GQZ?/4@;<%#KU0>HN#&*0Q=R%(90>\H@05.I"@(#L?N !'<.G3
M1BC]RJ14( "/< [ ([ .XCM\@ -Q$?R:,4<*4JI3!OVJ%#_;)G*/[@E =&R1
MZ.H"L4/X*OZ$51#] @40'1CN53(\Q?XJOZ450_KET8HW4H^8O\57_%*?W.C%
M0:51Y2_Q5?\ %*?W.IX3M'>J>(;^XJ7SE_B+_P"(5_N-.$[N\)Q;CW*/F+_%
M5#\Z2@#^^74,RK ,@X4?,7^*I_BE/[G4*>$[D"L4 $>U7H C_>E/E_S.J+DO
M#MRN,_""6Z@Z<)VA2%<%-_ 4_20W]K6!;YB)EO#F%)@1FI_,'\13_>&_M:SH
M7.,.Q'6J#3:5#S 'Q(M^39)0W3_F2CMJZ0IB./"G73UH!8H].Q;]**H?URZA
M5<!VCO"F\I?XJG^*4_N=%' =H[PI07 ?X"H?^U'_ +G1U)AL,3VA1\I?XJO^
M*4_N=1Q4S3@.T=X7DJZ!("CX7!]QV^A%0=ORC]/PUCWM3X3?),OL!4&/#4MV
M50FZ _\ T)<OY3)*  ?G$2@&EO4>(0.&0ZPJ:= O7S%^Q0?S)G'^L4=93=2(
M\Q?XJO\ BE/[G5+J'1Y-_@100_*42_O" #HZ/UJ/DZ["0X?EV$?W@ZZ/UHZC
MWA]A_P#>&_M:.CKS%R@7XK)!^=5(/ZY]352X42K%.'<3M,F/P4*H02CL.P["
M!AWV$-M0Y=B"ZASV*(*D'H ]P_,"B B&_P /@/ST-%*]= 71&I1&B(T1&B(T
M1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B*0RA""4
M#F*43B(% 1 .X0#<0#[>FB.V*T1G3+!J'54V=428V'(UL(Z94*KG="49=XB4
MA7#]R5 Y7!8*(.ND9\N00!!,X")@WTW%4DT<*U84P^AC&NBT5D'-AL\TM^(K
M#9WS4&SF9LCD>YY(KD+U;HD.X4]*V$QCH)J' YU!V,$[U+!FV)1^H4JF.\:I
MJD04<)$64,<I$C'*!SF31]0H!2B.XB1#ZQ^PO73 /DF;9IG[W@N5T'@K"]&K
M$/%.+SD'(EQ8N:S3H1<32;V+KSEN:6DQ\":ZD>Q:^M*!GZB:K=J("91-0.FF
MY1O!K[5SNVJ>O&2<P/;Q8T+#F?DEF)Z[?5JK4UJZ=J)P#ETDY>-L?U\XS,LV
MJ#*169(CWN':HIJI]RPF #"&# U"A^+J]2>QXA^U#Z![4,\<LV067(:"[*V5
MK!-5:%CL08S66;BX91IXZ>"T661G:>FL!DC*2I4EGS8H"B!3=@,*CIV*?7T*
M?28Q3)FQ00CX\S)%--+PMTV:+0I *0H)$4;-T40)XP  $H; &VVJLWHH+Y.^
M+Y].Q7UD@9NCXS D!N\QA%%(4BCN =1*8YQ$W3J.^H)=2 RK-0I1HB-$1HB-
M$5%(IG59JIID44,(HCV)J%1.<I5DS'+Y#IJ !1(4=PVW$-P 0$=PD8J#@K5]
MSI"DJB+=NFU<$ 5$?!YU2J&*'?\ 4L*B1MS?[3;1@^],(TPQ31G+WVHL;9JD
M)C+F&VO\T/(8RG8:WP+5LWC,DN2]RC5CEN.50,$U3FBIQ[4HI6%=@"Z_<Z-W
M)^.%+#:7VKG>OF,LGT',U;@LF,IO!W*'#]B3N=%M]>5!-W:W,,1Q$^OJ:;UJ
MMZJ@SHRY5G2N[CQ&*W("H"H C.X.J78>E=-GMO<\XOE?!3]3O,;"T;D!2B.P
MO%)@G*Y:M*-X62) /KWC]E).7\P2GSTF9-PEYWC\Z7JB$,X4'ZC14J:/L3GX
M.VC@Z[9-PB=5,W@63*<ICIJ*-R."IG* [@8S=4I]OXI@'12X5A*FL^31568J
M$,]*+5ZU<H'\?ITS#N"A3;" "50>W<=AU4Y-#@"J68N,62%F9F_%#*;F#DGZ
MPX0S)8"Q=?D';@GBI-_<BZDBP9'!$TF;1B[CFSPR29T_*(-MP.(%-O33%32K
MI?,6X2!NEWK!W'$K=,3B!1<';I& 5D_DH5P1(5 $/B4=]20<U$2X[%=053$_
MB Y14[ 4[ $!-V"82@?;^*)@$/SZA5+TT1&B(T1&B(T1&B(T1&B(T1&B(T1&
MB(T1&B(T14OK6G9Y?4H^/<2]_D+V]P*BB(;[[;@J42_G#;4L437G(;W(:#CK
MEYA?AGCFO/LSY>R%9JNWR17:V9210P[19F6%@G>+:$:116%9F\;LPJNA*B!6
MAA^0Z-++%066XN8'.G 'M^8]JV5>3%GEJ[7KG=(?%\4E"PIY]Z[N4C7K/9V;
M=M'HKMEP9C$T]^851,8 ,4I?X6I(#4P?HZ@5KGF_L3?1O]9']L,I1-^.\F#L
M4A]OYKI(-P4.1-/8?O,?[XHH4H?E$-4J6ZE3C_K(GMF'/V'LV6.T?B8<8R12
MA_\ 5NE-J'%V4X?ZQO[90]"6W*&WR#^;23_][]7HP)#B5%D0@3$&BG#_ %C3
MVS?G;<I!]FV,Y+K^Z^U/AG:JN C!E$/]8V]LHH[FM^40#_;8SD0#_M[4>&3@
M5!B2&HO0/]8Y]L<?A;\G#_\ VTDO_>_3P9[53X,EXF_UD3VOR#VFNN2RC]@X
MXD ']]]J/#N;4\*:G#_6/O;#./2XY-,.V_3&TB/3[?\ AWPT\.>U3X<U(;_6
M0O:^(;L-=,E%-_%'&[\!_<%]IX4]JC@GM4JO^LA^U\B0QU+KDDA0*)MS8X?@
M&P (B/\ P[X!JF5B4XF!-"&[U!C(!R5X*_ZR5[7B!D"K7C)*)G @"!38W?E%
M81V /'W/_JW$?EJQ^0A:%8@=A]ZMB7&6&/6KL;_6,_;-(X3:&MN4BNU4O,1N
M;&4D"ID^@B<I/7 82!N'73CM6L9 *]'2SG](4A/]8U]LQ05"DMV3CF1-V*@&
M,Y'=,W\0P>N'8=OEH-58/U7(A52TUZS1L5 ?]8V]LH!V&W9- ?L'&DC_ .]V
MI_,:;^+%4\-[(%'_ ,L;>V7_ /#=DS_Q:2/_ +W:C\QIOXL.G:HX;^P].Q50
M?ZQ5[9/Q"ZY-W_\ !L_#]_UVL./-='.@N0[U5P715E4E_P!8=]M=0@*IVS*)
MTQW % QI(F*.W0>OK=N@ZR8:O3S'RW(]ZGAN[%Z(?ZPU[:ZRY&Q+;DX7"A5#
M)I#C61[SE13,JJ)"@]W-XTRB8?L -7 +5^@E&3;U5&Q>NX##<JM/_6%/;<5*
M0Q+;DTQ% ,)!)C.2,!P)MW]NS_ZNW?KJN-H#Z>'O5$]+<@'(++R6_P!89]M)
ML"OGN.3$O3MO6+>3&DD3Q-!70; X/N_^E+U#I,G=\.XX!\]7?#N8A8_$U"JD
M/]80]MX2"<MOR7V%Z"/\VLCL7Y;&_E_00T\.YL5P6N(<61W+U2_U@WVW52&4
M_&V0TTB$<JG.KCM^F!4F;<SIVJ(B_P!O&W;$$YQ_@E 1'4>',Y*19.2NA??S
M]MX%$"'R!<F:KA KE 7E%>(E4;J;@10O>_#N(<2B!1^8AIX5S,44&U,9*K6]
M^WVXVX *^3K$B4P@ &4IKA,O7_;&D=M3X4]BCPKG8LF8^][[=CIL5X.8ET&I
MU$$BN'L6DD@*CI9-!L3O%V4O<LLJ4A0^9C &GA3&2GP926<Q/O%^WO*IIK)9
M\JS1%0QR =\[8L^TR:IT5 4*H]W3[5""'73PI]J>#,"HHLZCO=3]O9^593^E
M?A:-(EX@,:8O$!& 851,!"D%9]^T-N7J'RU'A306Y%7".]T?V[)1-HLQYH\=
M'*3XJAVBB64JL<C@B/;Y3I&*^V.5/O#?;X;AJ#;G$.1108&(<X)16'.2> >0
MS::>8,S#CW+#6N.&[2><4.S1EC2B'+M(J[5!^>.76!LJNB<#% VPB4=]4*A;
MMT1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B
M(T1:AS)=66/*E+VY\95RE$1+YTC769DRREPD44%E(FK1/E5134?S4B";=)(Q
MBD6.J!#F(41,$C:HZ= M,<?<7RJ5BM&6<DHI2%\N"R9(]J4RSB/JE31;INF#
M%BH[0;JF=.)!^\*NL"1/(!"D$-B (B2[NE#5*^ QP 1/XRE^6P_#\GP#1AG4
MI4KWU"E(YYF\D:1Q4Q18\KVB+2M$ZU:HL*-2VRK5"8NEN,J0:O58X[M1)(74
MA85T2HF$W[-54#"  &^I9\V*@D#$.&KTZER;2%LSSGG.*-B>M%<N\F<OV5%K
M4HYNN[:L\?5RI+)S3"+AG?IG3Z#K%"D[4Z?E<(-^Y1R_7 J("3N/ 8!14G;T
M]'4NGC@?POQQP]@)V/ABGMF4+A))2&2\DKQB"$G991R9=TY76,HX479L$'H#
MLW!14K<QRE()PW, TPV*14.<.G3<G%]%*-$1HB-$1HB-$1HB-$1HB-$1HB1S
MR^XKXQY;4AUCK)54B;*9HD:;ITI+-4RK4:S(MEV#>SUJ1*B\=,K8@UDEDVRR
M::9B-U5R>0 4'>6#.>H=?N1ZL,<>SW[.U<J&4\79QXK9XKU7D9J0B\UXW\ME
MP%E)X#EHCF2@QZX1$M!VA0@J.64K+U%XX923-,7S=N_,<4UG"28*GC-0U,GZ
M>GVKI[X(\I(SEE@^F9"7C6D'<V*TE3+W355T5IFLVRC6:3K<BD\(EN 1LL$.
M6<CU#"4YV3Y$1(0PB4*AA1J]/2HSSI]GH]B7UJE5+5=YIL1<X^<@Y^.CY..F
M8YY#R"3Y$KD/NITJ@X4:II*D$A45'C1!4X[_ -]13V ?B6IJ.52#7!)MPY=;
M?3[.CQZR/VKV6+CW;3'U\.JHYC;126#DKF+CY=1V1LZ_'+6G( G(@0BZ0OTU
M1*LH790T/530=72J6#%J%.LFNCWF054<,RI^,A/3_=X';K&4V.;8B[I YB;;
M[@8-]M*X)1WS]:R74*4:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$T![C7/
MN5XW)53"G'Z!/DWF!R6ED:-A*G,11%A25)I4M75RC?D2G6D$82KNP</$BH-7
M1GOHP04\*9O*62QCTZ?%0Y?IZ=^S<RS'V\N"9.(E"L,I?[0WR9R0R5,260LS
M96=(.7$G.72Q-&;>2:QC^233DDX=HUCD2)$4 G:;O^D-^LC)\3THJ3FS,.E4
MT1_K7RKQ+A[QA=M'KB.5_IDT5!55H?\ :G%?"6?U01,4QT=TOV&XCOOW%#I\
MP@@-O50.6(Z8+B"_^#)8),Y[1/"G]WL!)VC\ &1CP "?RS;?;X:I0NJEFG8P
M$//8;2/7J&X=?W7^CJ!M5Y2:2YS=P61V&X@.SI$QE_ET5,"QP$X?G'67;^@.
MLR'TA5BK>;+VHI6)0YU0$2B#=3Z>WIM^OO\ $VJU7@O;[GL"+10'$^J)S=HE
M $%-^JA!'XG#KMH-BKM 2N 'I14?W7,?->5=_E0;&'?]U8-%F"T$!%SB_P"T
M^\9< +\O0#T /E_PGXAMJ5/@QW((RL(G[T'4@=3]3O5KK-U^J/0/,O*(J" ?
M9V[!J"3V+$O1$;C;E<Q@+R"0.W;YKZ8=O$#NLL$@ _ZP;&^\C@)^T!U#JUU*
M*$=9G"Z/;(P*0IJ)B"KB&:-T$A P#Y%G"#APN@D00W,<B:AR@ B!3"  -42T
M@3M5J[_@S_HGU+-(6FY,F/4+04A$OX]N'=(HLXYE*K+D#<3E9!+NX8@F$H#M
MW"76%S#5>';)&]8FD/%(=B>(XN>UOA?DCC&*N47S.&ASSF(CEK=C^^8UKJ#J
MNS3I(IG\%'.(V_RR3@L:Y 4P-LF!@#?8/AKSGFO/)VIF()S^\=HW+K]#8$@"
M1L2MF?\ J_E;<L&B#7F2D\042[V8M,11KPJ*1OJ$IEOQF41 PCN7I\->><V\
MZ7='>$.*I!^^1FVQ;D<JC?CQ-AN563_5Y8-(-AY?G!<W4ICX7CMMNHC\;IOU
M+K4__P! NYR/_P!P^Y2.20->'_='O7I_\KU17^F$7_Q+QW^>FI__ *#<_&?_
M +DO[JG^2P_#Z![U6?\ ROS"F_4YB627'^*KAZ*('Y]QOQ]<E:_4BY(M$R'_
M /ED?_"%2.2-]0_W1[U3K?ZOVU0 3M.2Q_*780!YB*.,IOTZF$EN5#8?EU^&
MNHT7GZ](#BF?]L[>I5_R.)PCZ![U9'OL+6!1!5J/(FJN&@]BKG[]QDWBFP,V
MQP7=E]6A,R"A"K($,4P]G0H[]?AKKN6>=[AD1QFK??.WJ5/\JA9!) #[D@CF
M/P5=<0Z:VNTEF[",LV=R!&$#!8[?S,K<&#9,2 H\1JDC7(*$EG0"H D;*R2"
M2I@[3*D#ZM=YRKS#/53$27=J\1(J33!:776(Q!;"N(KUC<FPIB'G8AZ^8U.W
MC9*G7I)RZK=E=5MC79"T5^1.8(DH(1,M.E5(LR(+D0%42[H[@([:](Y>/S$!
M+&@7':HD$G $E6E099\0SZ-N" %!852G=5-JZ,Y*8_<"JCH\D55T94![A4.4
MICB.X@ CMK,E8 )&];O3VA+3VSMA'U+;U1O2$A6LA4&TM8*1?R&'\Q6:MV<M
M;:1CZMS%$QQ8[8V<L5T5G*PNEUHDI"@42CN(:"UL&2ORM@8CT).95; **SLF
M6;P 3?I7S9:(O%B44DETR]KQLO$+,VC-M]TI@F<-ESB'FZ!]L"S&FQ1X(Q.*
MJ&UMMT68I$\Z9B[]P*"!)=^Z(4=PV 4SRJ13EWZ" [ (=-3X3)X0 ICU+,+>
M\9S,;C*Z,(]K0[W8Z_D:GSUF:1*,$A?;76<A.8)K<O##G?+1MZ?5*+7,NJ/D
M S]4Y?.8IO(,>$ V^GVJDV8YYCOZE@ZA6KM85@R ]F7.R:*TIZ5Z[(NX:D*V
M6*HY=BW<*KM54A15$Q _:IFV$Q=C#,;<2*"BGPXF+C!7>&DI2NS$?,QEY=)R
M\:91]&E9KR4,[/Z7L47!-1L@X36V+V[@H=,"_(1W'9X050M1=EE5DBI^9M]\
M<Q3E$KE*V6 YI%E"-0,$%*2'J&'WK+G>(NO$86I W226W4[0VV$3!:U%MK,C
ML]X6/J+8C8D1L]H76Q_JLS.1CZ_RZC95X+P[:UT9;]B)Q .VN1YAV[^W^$.M
M0'?<M2!FNOHH@)2B&^P@ AO\=A#Y_ET4J.B(T1&B(T1&B(T1&B(T1&B(T1&B
M(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B+45SR)!X_B;9:[A9F<)7:N@L^</GI'
MQ44$05(U*W4:M6RKN0DG+Q<C1@Q:IKNY)=5(&R2RITP-+$HV:31C^ M?("]U
M_-MZ9/(K&$8HUDL.TVR%7;33ES&2!W,;>I&MO0#[AE95^EZR.%P1&2;QIFI7
M!$'!#HIJ/TZ8JFN)WI:T:9,PJ@!5TER 4%$UA-L0@B;M!'J8G8([[]NJJ$U5
M->&F/38KN*1#$$%  2!]0@( )0V#X[#TW#42K@J@Y6MK3<X^HPTY9;'8&-?J
MT+'NY65F7[QNBA Q#)L=<9:067.!O3NB$+V%^I43*E*!>[IK$GI;\SPQG(#"
MA^*R+<2<1MQ]G5CV+D8YQ<GC\JLT3N4T#35IP]C($:EQMJY7ZQXN\V]LY&N.
M;G$5]9T1C^/[CDSUD)&JN$DW9(I)DZ(8B(I*:S+=KP;0A<<S&+EWSQ54K)!<
M 'L[$][[8?"R4P)5)[*^9F<7-9_OYV@KS93M9!3']")'MG$7CF#F![EE6K"6
M?23QPZ1.;U)G_B.H<$"E);N7K4'XF#;O8RHX69L"G5EG230@G2\7B*4I4A*W
M[4$Q2 2D$3(ICV$(0P@'V;[?/6OO\STUJS*7$0PQ:7N4BR9$ #YB=R1]F/F[
MA_$$T%."T&OV3W!CI,<4T-K)6V^/%@'HD[95YJ^A*0@5,.X[NQN8EJF4/J5*
M(E >>U'F&R \9_VMN3>UBKPT=S876EAY%\WKZJHXI6#<>8GBUD>Z/5S-??O>
M5,@<HF;N57&)'^0*2U<*IB!A0=O$ED3#V*D(<#%#2ZKS'<!^2Y('=*?J%%4=
M),"@KTRS6@\V<X.6W$W&\[F#/<+AG(.-*N^CQMD/ANPV>-RF$.H=4STU;4NT
M73:(X5*W2-V%^]"O7)OI:D5.4P%WG)>9WM9I/&N3)^<C$Y-VC%7H:;Y X'$'
MR'I&?4G4\(9>KN;\<U'+5$GCV6DY(KT?;JO+C&34,+NOSC=)] NVD9.QT4Z;
MH+LE1$WE136 >T#E ==-8G(AY.>MO4L.]",9,!3=7TK-Y6UQ5435=VVU1<$P
M WTKSTC$1;<A!']<SDK@HD3('4QCB!0 -Q'68!GETVK%)[UAJO([ :!_$MG/
M#I/D.V2ZD)_A_&"7WZC^72F*.RR>OY*IUO(J:EW"J6],#?LS5BSQ,NIX]@V,
M)B/C)*==^I#&#2F*$G#)55F>2C)JV>A*OHE%DMZM]X6C%Z=W'D16!=JJF;R@
M@B*AR'%9/]L42 4H[', XVHUEK2A[@<$';WTR]"N1IBWK315.]QC*O*3*><,
M?\0F.'$X# -ZL.+;;9,QVRVMYZ5MU2FW$)+K0=-I+"RVB,@0D(Q9,CZ=81R*
M@"7Z]U"@;F^8>9[6EB21%VH6G6H%&&"S[$;=#<B#N8;%N+^>KGY66IG$M5N/
M%]6#N,6(J-BNC>14^.R:$O+0$14VPFVZ"^?("7^'VZX_5?J%"U,L12GW]NQE
MGQTVCD*Q9^OT+(8OW$86NHJ$S[B?*>"W+$NS]]-1\3=JZ41#^_24[BZ6O435
M66Y1$%I19BF!>HB  ;;<:7S?8N$"<CA^W[118TN4WR.* H=\?4[I:51R#7,E
M58EFHUMK5XAGX).(^:@YR'DXP[=R0ZG@))5IT\(!VP=I1,<P%-W?$==IH^9Z
M;4!XR&>1.>\+7SL3MEIBN_V)*/.7B16^66%9N *=K7\F5 H6G%]L(T(T?0%N
MA6QTT&OWBW1!T\K\K&"O&.R&,HV79.E$U ,F8P#LC*V?EBWL5FXQBPH<=_<N
M:[CKG:Y\(^0KC)]O^_X!O1K VH/+VD1PO%R2U9*R9P,?F>1AXL5DK$K6JVNT
MFHT0(NZ0@6C-LB0$T4D"4$%V'3IM5J(&));IT9=?U3MZ5UAJ[:X"Q-IR!GXY
MC,)N(%T#R*6;O=SM9*,EBCXGK4I _E#4BACD$NWCW-UI,);3ATZU60<J5Z=B
MVLBDW7;IF,5)T51-,PJG(FIYMB_2<PB!@-T$=OSZJJ*'%  0M&YMQA&WB"8,
MHYRC6+/&2)YFE66/3!HZK-L,*PDF?(V(43)O2+*MU4U-TG0N!34 Q5# )L@A
MVE:^Q/EJ:B[%_,YF)XA#Y1AP0,C(E0.2%R/$F(1PVL5>ERH V,Z4;F_[HQZQ
MT'C=\FX%) 8_TRZM89G4'&O3I\$J_P AE%ED>\Q2F3 4SE,(; .^PE$!Z#J!
M3'%,2KAJE5(T1&B(T1&B(T1&B(T1&B(T1&B(T1>+DRA4%3)%[E ((E+W 3<?
MG]9A*!>GSW#1$UY[@/N"PO#>E1-=J[22RAR<RO)MJMQ^P?!HJNY^V3[UP"29
MY+M\;-G -&B2RKB3=K)MT4TQ4.J ==2:4IUJ,3OZ=GN6B_;5X%Y%P[8;GR^Y
MEV%;+G-G,K9](6"7FGB5K7PS2-UF=;QG0K$_5=)P;%E4VS=L[;Q:Q$%5U5SG
M[_(<Y@#X=.FU& H:Y].W'<GJT$RE+Y!/OV@?O _;N4IBD$B9S!OW@GUZCO\
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M;+.8J,D'!TEG,><A#N2")CCN F.8=_CJJY=_=RB,2" <U(,G<DF.8R69/O\
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M9XEF=_'F>IJ&DFRR3Q(_<JF/+<U\RV+>MG$$< (%'?Z <.W%7)V"Y$<<?C\
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MOW].GI5\:V!1T5(Z+%54GE21<G$!;"W.+KTJPJ(N.U5,$B@*X 8-S(B AON
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MA]BC1V09'CP Z=Z: QM@"*I$]8\DVIY*WW+UF8$E<P9;M0IR 24F;U"C-Q%
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MAH+OA+SFN+"K8:QY7$)QCA.USCARXB*TFW>N'EJCH)M#VY=TH0I@=-&;%(X
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MD*(E*/3ZMQV"16GH]JIPEO;'V=ZYU,$XSS'[Q>?67*;D"FVA/;]QA8%OZ/N
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MK=BAF$K SD7)PTQ$.$0!A(Q\P@LVDDG3=(4TU572#@Y16$/,4##VG#5$(BV
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MDV\I@[A, GW#;IKBM+R?Q+P\1G,F%)#'*F9=^U:+BN"5 TNIDTWQV:M#X/\
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M"*Y(""6S53J%*-$1HBH'KT61%5#-U%$TT!5 Y/@90!-LB/TCVB.P=>OQ^&I
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M>\?#V*#MY%3()H*+B&^PG\:BH&$OY1Z;ZJC*9Q=42M2#4*].H"(!ML8/B'P
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M+:PRT9*4T/4H"@^4D$WA^Y4#,B=I1/5(B8>1 )S*-9M1XA(#9TV)://#W?\
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M/_-IS*6S7Z%PZH^5J+6KY(2\:012D)K&<"UI&1ZP4$=E".)/&&/O")M@ 2+
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M:J$%]VH=R8J[0[#;TV^]&B[Q%0.@&0[%I;W!^0^)\G^W5POQK@>"FW','".
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M2<AYQY1XUSM6.&>2ZI7;7+T*@\S:0G3[PFGGR?I,M!VU>H/@CV2T?:ZM3AI
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MIQNQ5BPL5EK$6=N/9\@\2K D[9P-\9M+"H[D8:+/.F2I&1FMQ0W;GE =.VI
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MPBYFR\><<\?9V#M=E;T6W2###$M,IN6=F6;TY*"5M$C7AC8YL,HK QK]D1)
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M1&B(T1&B(T1&B(T1&B(T1&B(T1&B*TO (57O+OZC=04>XP>/R^C6(03AMN!
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M]J#X7+P[Q0Q0W("1T#(@40$1$2CN ; (]== _+TP<+RV!)TAE^W7N#*H_-K
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M=F!KL]:Z;_;N6DZPYY-X?44.\CJMDE[>8-0@B(-&>7'\K.&BX\I^TVR(01/
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M$R(.H:99OF8&(HH(O74>Y4(B&P)F.8 ,<H"(@-JE5:E?!'R@OTHG;\7/VO\
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M>H+'*/KDZ]NY;J/W8=V[-R0>Y:N"6IPU\PG?MUA #& P )2G[3 0VPF'??[
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M5_"6RB&CW+<PE(OY5Q(HD381UG0YQ"98/Q'&@]ZJE>,/E+NNINO2_IZ]''6
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MS-YZ_P!1(_M3]078<H+3@1B"%D?*:6>O^7CX$7'=^ \#W%N;;M'QC;;3CV7
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M$Z$;X_H_LZSK1_>]BXW3TY:?^)[ I##L'3[=9:L"JB/0?S]-M3BBE$1 =0I
M#*7<1_+M^31U+ +T >FV^F"IKV*.I4(T10$ '4)4(  #1*E Z'! C5#E2C58
MP4*.I10'H&H4C%2=P_U!I55,%-]7Y/W]&5--ZC^?;4$M11U*'0/AL Z NI4
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M\6^(,F%R2J5>#EG(Q=R8&;RT=$/'+-G7%;*U93SN5=%4,7[W;^H/Z4^Y"D3
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MB"&@T)EV93H"KQ:<21W#M*(N-@#<0UA>>-5"<9PS/$,?VHK;^0A+BMMLB_\
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M"9P)";"(=#;_ )!!V<X+5^)^\X!@[.D,>YO=H_'W KE7(.SG,>PX+R128\R
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MF@Q2<F,BJY5("9M%SOG1OV[D9@1AP2<O@#!CE6BZGE7+;&GM @<1RIC\WO\
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M</$.\G?@J7^78?1TWK':E[ILUAK$,+G_ #%CS)]KO+?A[Q+O:-<A,H1$O'Y
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M)LE5N4V^J75*-2"Z('H&I*D5*D[A_)HZGA"G  #X:*EW1\-Q_)_6WT3<H#\
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MCCTK(SV$XQ9TX_9:A+(^,,VHYD)JV5[!:<<JN< /YI(QC")=QU%6;O'39FC
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M3LS%[#F8OJPG*U3+MY,XD)^+FU6H(F3],DY5#]J)2=X\GSFU.<3&+-\"LFP
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MR>0R!A!P<AU""4!*0P;_ ).NI(;J1^Q>X.DS!WDW.GMOWD$I@W^(E "B)A,
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MK:LF5N/%0$.?97?3K[4LFLW:AU^*R>:.@J]:6KRNFD[Y!3]*BXNU$EG\.D5
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MGOK3'BFZJR)(4Q15("G:?67N9::R/GD ]*/Z6&'IV4==]RKRSK=5$3MP<@.
M>$,Y#?4?J]54WW?N3!)'"<!Q:X<4JS\4^+<:@P;RTNDHSJ>4+R$"JD*<_?)"
MKR"UPBD+D[:@_4>)JC/O3+@1VGXEW6W'\\Y];A8$;<B 9_M#(KWC]-?)(CS*
M=WFUJV9"R6>,)UXHX8D4?91)S8LFK%B=-F_>%:)D0(\F/63KA)^]9J M]](1
M92J6)ZB+POJ7QSM!<2#@5EE"JJK&$_&W>9&^3%Z=9SIFOH'3\JY=H+)E;A
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M7NP-*P:1CV:H./76RO1D\D\92 @!6B;=!J*Z238")=3:TP-DD#([/L7$F_J
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M6>./;"YS\1G<!D+B]D7"MJR,_2SK4[S&Y*96)O0UH'*V9I7*$+:81A6INN.
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M;+H@4%!7C8=V[ [\/(@ H%+N<GQUY]S[4\)R>GH)RZ.O</).E-P $$@F0;K
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M"P.>P[F+.SL%CD:/,.6R3)NX'Q'8$-U =NFNUTMRUI-/"S7Y(@99=J#52@!
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M%R_/M#I8Z$W(@\?$,RM9V@5"U@@(++-1;1BJZP,%E&*ZBX*-D0,Z6:F25<;
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M;<F4,Q=B4K9Q?<,]JQMD^A"K"1/_ '2@:.RIDV15T$H Z>ME#>#=J4XJ. %
MI%!=MS$0."O8)5#F$"AO\QUL+L0+$9?L#V*EZL$F?CZW=(9'Y).SIK(^'-56
M*]30$KE06A\(XP*4A@1!3Q&.4>\-P >TP#JSH]2+=UGV[-BFC56F>9=+3:N\
M69DCG[=J_P ?V'\*2[9)9,I',#<EV;927?1QS"N*$ 5FHHHH)0 H*?'7IW(N
M9@7Q4.QS&P+4<ZAXFA(RXHI*5Q360JLZ)&[_ -4FP51.H6.>+)E,D_9$6)XR
M(F'?<=>T:O6"?*ZD'YCL_#+8M'H].>)OV?:$ZE@E)P;".%B"B9NFIBJA*F5>
M"5D"8!CMBIVF(Z\9^X0#X?+7R=SSY^9DG;'U!=?I+!(&WXK%;NZ+_/\ <19
MQ'"B+;*$PU(+!LO)^=<8$"E(GZ B^WU' /R:P+D1XA;Z0K\QX<^$XA*OS1')
MO+156,B@H:-DH^8;+)+'-'*N =$;D51 QC(/6JB)=A$2F(;Z@U23F**@U*;M
M/[=7$=114KVA7+R>K,Y4.AF[.2"3ARJI^T,*3+)*,<1,""80*).T!VV#< U7
M;^L,HSJSIR7VT_:9X"9@POD:9NN'KE+OX_.^:*XW4:<D^3,,A]V0>4K3&09R
MI5_,T8GZA*.9) X,(;*J@8?GK+IW*6SW)Y;C9[;'$[B)8)NS<?:+9Z7)ST89
MB^^]\TYVR.T,J<ZHG6(QR?DNYLDNXAP#8B8  AN !J7[D;8M2^ZWE/..'>/-
M"6X\9++B7)=[Y'8/Q:UNQ*?3;B,>PR'9%H:3%K W2M6B!7>G33+XSJLU!(8.
MFV^I?8C >W[$UU&7CD]?LL\VL'!SHL.#(7@A3<=J4II-5' P2MYL;]O8&<GE
M>YR&0\:RTN_B)$(KT2)62K>#2<S"13H^H,S$D&M$KLZ>I)KQ1RAY1>XG@'-<
MGDWDV\P(XQ9[?-&R#-U"NP.%H4^:;)<^.E:R?9KS9&MFI3^:BH!S./UU7GW&
M>+: 0XD1!-,2EU #X]/?1226RKT[%IVGYWY/XTXX\9V.,[OD-WAVF\9LE9!L
M#3C>GAFYW[%]Y1S-F1]_.=F_'LY4;Q?F&&W3=NV?#,"S:0WHA,'G[DU!"6KN
M5)(PIW].M=B7%^]M\G<?,27]M<4L@(VJFQLH6YH1+>"3L)U/(FJ_"(:,8QLP
M$54S$,0C=(O<41 H;ZA5 N'6^=$1HB-$1HB-$1HB-$1HB-$1HB-0<$5,I^M^
MX;]S_P!36+>P54<4F/!Q3%R+G/<0$!O*@!L'VKRIO[&M?I_]4!O]ZS;H_<]G
MN2I=;M8"-$1HB-$1HB-$1HBE.<B91.H8"$*&XF,.P 'Y1'4@$X*"0*E2'53*
M ]RA2_+XA\1 1#](@&H4[&Q*;XYV\I_Z*&"9ZUP;>.E<N6IZI7L3U1=7N+9[
M&],H9NJZ1*/F.TCJZDY?N@)MV$;',(@ #JX(RF/E#E. QJ06]+_;BN8.L#/R
M,BXM-WD"R]LL\W+Y(R&J0PG>JV>R+KR+IB@43*'^Y:RT62AF0CN -V"8;CMK
M&UD]38T\ISC,6@)5P&%<LE?T(TQUD(W)0$C*./6-^Q(KRQ:W>2; KCZ'FA_!
M]"?'C[G)L"^L;SU^>*>3[L4%(Y2N'T;$ Q.=KW>0Y'!.I=PUY1S[G%@$VS<C
MXA=AQ"J^E/(OE'7<RMQO:'37+UL"!)C D!R6P6L<T.)@8AA5:L/II&XSC.G1
MCEH<7+V*KQF[UT[>B"?9YDH]9@W067 "D<'<$, $VV'G.5V];J.:VKL;<S8X
MZR9XM[BNO\U?DN3\CU&@OSA:YF;9$+4OEN&42' B2[CJ7C18Z(;V^[V$C1%O
M'4]Q_-%59!$X&<1\?2FWH\@O$TMMB A>ZVJDH(; FV$Y1W'ZM=-S'4:>S=\&
M<XQFYH2-K>I8?DW3PNZ :C4  \$*G&L ?6E,\5F3Z;K-YR6[127D;]=9/T2Q
MX]0KEE#45X6@MG:!P6Z(.F%1"12, ;&47[@W =;[DFDE= N"+VSFU/I<+R/]
M1^;1M7I6K,PPR!%6N'W)4$P*C-51=NUAXT 7%JB]E8QY(Q:Z)"IF!-JDWD&'
M<N!E1$=E!^(=-=;+E&AU)%P\&#=W:O'--?E<MF4S424IX]BFJ#==CX1.W,X[
M7H-!(H<#)E$[6MN&BD@W2_:?W\7)R$W @@(G 0H_D.@8?X?=\5E$AR7 .Q6P
ML"Q<."BI&QJB0*%$PA'H(J"GW )NP */U]OP_+J?Y#H&_P M^KXJ.-A1EH_D
M54Z['8+SG.,X&.:K16*<D7%)[WD%TJ:%JDTD1H1MVAY%7"T5V 0.ICFVU0.1
M:(?@?J^*L>/=J*JDXKUZ+7X[8<4,A'/U@J#11:0.Q;F67,=RZ.)U4^T>TP=V
MVV_RT_D>BQ^0GJ^*J_,712J4,9K"@"QRQ3!PV0,0CE=%LBW,W6,!Q2W8(D(N
M^(8A#"(E4)V[;?PNEFYY>T,R#\G=\5@ZJ]JC.)@)$!W95Z/KG+806.U79_&/
M"%9JQB:*0' Q2R,>X<2+AP)4@_@JI[&V-\ V&C^1Z:U](BXV ^]7]->NN#,2
M'V*@?SD=6VOKIR<BH5@0!$SMRW[5"  CW=QE')0W  U6-"(?3%^Q;FWJ@ TI
M+6/G)GZ$E,<XNQI?^14%=T2P\XAB=D=S'H+/3+-5GJ[].,L*;0J29P[S& 0*
M ;ZZH2LL&(=@N?XKAD2V?0K!^/W#3-/%7E1$< N762:[@NHWB*F;_P 7;K95
M!N+F[)PUBK,#(4JH7]M(5J!CK1$QUP3.+4S%Z<I4S")-B#JR;D!ABZR&)#EP
M"_=1=?O&7V\^-7&!6:L&.:6YG;];&[M.T9'R(X0G[Y.K.7 .7(.Y$&,?&LS)
MOR%,0B#-(Q2D -]M][,YF0Z'[>M5"AK5+1BH)VW>1[DSV0(5DF=!9@L[;NF?
M9L=)$"E3:('*<A!*)/JV*&P;"("(VB&0%]K=*+.=%*-$5*N0XF*< ,)0*(#X
M_P"^;B/\'H;I^C4@]Z@ODK2O%E5<HK^$XK@4_P#W0!7M70 2F[4_")1*J4WZ
MIOAT'1T9NMDF;D)PPXW<HZ\O6LXX2H]]C#)G[3RT4F#KRF#8R@KQXLI XFV#
MIY0^&I8 J"Y#"B:C+[.F>^*QE93VU.:.0\3(@D(/<59X04R[C*7;)F*X(RCV
ML8]H,A#+*.D4P\IW;@"I=Y>T1$#!!*J%%C,U[H'-O@_XH3W#>&-IEZ3%&!.9
MY(<=5'EMI/IWFR[66=5YM"29X!%(BA"+IJR:HHGW*)]PU(+%\U22V-0G0N'_
M +B'#WF7#M9O >:J?:7SUJGZJH+RC)M?(AUZD[95K.0(/%7;1<CHAB;&(4>[
MIJ,5(2\E5DBE$#&((B)2%()@#O.?<"$#\IQ^&H4]>"M1T4>QP=),J:RQ!%17
MN\7<(&+W;"?O*4>X?LT-&"BI6,25'K%C;K(6&#AIYJ=)=HX:R<:P?I+%4(=N
MLDZ,Z;K"H8I3#WF)V!W!N !\-5$X/@HW#)-C9_\ 9']NKD(=U,3F VE/M:QP
M6+<<42KFCVHBI=@!9*1%.59$71$NY/Y,/P#0]R#=@DV-/9VY*8)(JCPJ]Q?/
M6+J[N5=I2,L"URC$B*'4C5RY8ITU<I#]"@.X;!]NH4LH(VWWX<"&,XN.+^.G
M*FL,3>)$^.T9>BWJ122'RBL[2>V6[$547;HF*':@794Y1Z_ 3G/%.&C*V-_?
MNH6.; K6.:?#WDKPZEA6.U^^KE6)6V4QN<=^Q=Q92UNILTV6X 'DZ!U#6/KP
M(VR*$?!7=+&4YM&DDK'AOSIXEYQR5E>VXXS[C.S1F1K=6BTXS&?C6[B>5C*%
M4*X^08QPOW2QG#29BG#90H',/F2-\/@'.V(3&J/RMAEM"V>H!_+Y^O#%.Q,C
M% H[B'ZA#?\ ,F$XE'\PAK?Z:,HQ^8$46HQDPQ95QCD(43',4I0#<1$0  #[
M=92* J$ HF$Y>T W$=PV /M'[-$4"+)*?J*$-\_I, _UM$=1\J?\<O\ "^8?
MP0 3?N .B)N'W0)I*!X^UN?]&E)?A_+%<E5$#'V.BD%4O#<7*8  B90A7 [!
M]@CJU>^FNU2(RE2()*YB^:7+O'6.<JX&G5DG$FT>/;K4>Z64*S8J(!7[3+QR
M[%<Z8E7%\6-3!MMOY14+M\0U9$92)X06^*7(R'U.%K ?<AP^5%0654M:QD-D
MW1U6JA:ZW=G("B:#I_Z7QHB8IRB.XA^MJY'2ZF1>,)'L5@WK4:&40G!O:\Y7
M5:V82S=;HJ$D$T9;D';)-,[1^0T&0[B J""9&CD&@E4;J&;;%'NZF VH-F]
M\)C(2SI55\49Q^0@@]U4U'BKGAC.B.\@T>8J[\7%>R3;VS<D,Z"4D%60R*GI
MERH)-0,1)=) 3$'80-MTU3X-T#Z3W*>(+#>4ON)8YG,/S$9"4Z24.Z>T:PL/
MQ )F,R[;UZ[5FV>>-9';E4=)BSB14,)0$ 1 QO@&H,)P^8@B.]4R/R'A^I;W
MI?N5XG5K$"1U5K [[*V-H?J0R1WA&KJ*27=%9K&(V/V.%$6)! H]?K#[=7_$
MM$4D%E:&U*4QQ1('M9)@SESVH=NRSCE.+K:[!M7ZE<9"2 LND=['C=FS*/3.
MZ3%D!FYQ"#$0 ?LUQW.-'<O?X43*@P&\KV3R]J86(CQ)"(<Y[@E@>WID^F9Z
MY,Q\TZ@)=K4./:)<D,V\R[(B\=9#*X;PC9$Q%&9 _D,3,2( 7M$?J_)K3\KY
M5J;<?GM3CC]T[0L[S)S[3\9M^-#BH6XA@Q3L-PY'TU3*%D,6*?\ IIZ/J1Q%
M:52%X9JZB(M-D+8?1%'N>(*D<)=![D>H=.NO1=%&-JVTF$J[LUX3S.=^_J.*
M E*W3T#:FA+3SFQA3N37)".5B7JS22M^,W1$6DBFO-_>!\:8YJ2C?TI6?D56
M\$>50$]@$Q# /P'5=PO< %0X[EEZ6(&GD+E)<!8;ZLL RS[D>,GF*IZ.952=
M4>R$38VL>C))*(JNQ=,TD&J:!!;E,H9TJ0Q2 'ZPE$-7<%A,2[*;"ON*8N9X
MRHD6]ILP"K6J1J IT\#RCT!9-4$W 2""390S=1$3 "@#^J80 =,WR0@C*J]&
M//3%-YY6\0T()BYC'=9NU]M*"DH3SK2#6Q82R=C\&AHL"-U3.' 6T!(<#[%-
MM](ZJC,1B7*R;!#'C(!W]2?8PMGZKP>3YE$(UVZCF=.CV#)%$_KS*.)R<>.U
MFY#$2($<*[^3.CV& XF-]/Q'6OU4/$#1KT]BP^9<$K7#$AZ>M,&<E,Z5/CQR
M-R-0E("0;5>U1Y+?0GE53/(.4UK*XD64?&MT$DS@9RQ?11SB4O4!5#H&M#<T
M5V1I MU%>.<[Y;J[UPFU9G(,, 3F4L#@URSH\_C2]%AQ35EHF]6IR\A$G!%)
M!%";!^B^(JV*3R$!@X%,I]P^DQ@ =4<KTVHM3_>0E&F8WA>B\OL7;?UQD"Q-
M:9A(QPO[@.+L?Q5PHLG772[6EY3R?6U'<"<7<YLRO\ZP9BY9$14,FDX*0GB$
M0^M,P"'QUW-N[:%MC(/L73F</#9P_759E<^=V,KS.X=K$-7)5(9S.F$5&ZDT
M46LHLHURO62M$V#4Z!#N7+B2;^!,H=3*; '76#J#&9^6JP+=+DB<&^WT)V2Z
M\B:M&! /%$7JS%W?8%W)'GC!'GC9*/6;&)'%,HGL20$#AV$$.X=PZ:QF/:LC
MB&620GRWY<8_H&;\!O9N/69H6#&62:0W=N99%!$[!6:H%K6?@=1IL= KNH-T
M>[?8#KE#XF#4 %W(4$Q%5KAI[EF('QTBO:M8T_O>'>S;QX^3.E'-!;K@O'@5
MV9J4AD'KPJ*:!_@J*A=OU@UM[PXM) 0K(0C['3;U_8DR8)]QBAMKYGB3FJ:N
M8EUOU?G4182I2SB2#"ATVBL0;0PLU5G)'*]> $S ( =0W:'76CC:U$9_1+AK
MDCL<0ZV!R(YZ8?MN&<D53\/3"2<I2YLJRUF9GA%8M91DL1L^/(.$Q31!$^XE
MW( F$!V$-M=9RC4FS=!N'AB <:9+"U]LW;!C$$DR"0-9.8%0L5,F1)4+.G/S
MS95O'P[%SWKN)]:082+B$21"/,H+Y!DQ<*&3 .XJ:)QVV*.O8[OF'E7\N,/S
M-KBXC03#X%8.DT\^(/$BF83A^(_<8Q?7,28UC9JHSS";C*15J\H:/,::1:3$
M'4&\9+1:R:31$0=Q;QHJ@N3<#$43, @ AKP;F,)7->;D \/EJ,, ZZ?32LQB
MTB '61Q/,JH98Y5<7:Y$0<P9:)L%DN*SMI_)GIS1=3=._ \B3-E561O Q#M[
MCCWD$I_@;;6/>M3-PM$D45J_.$KLC$CA<=5 $J/ECS(I^++EC8\K7?/'OV4@
M\>NG$F11X"IC(%.U\0-RBBLD4@"(#N/UAJUX5W\)96#*(/#FD^I^Y5AQZR,^
MAZU9&3!X0JJ#J12,G%.DU"'5353=F;$(*1RE[BB [#IPRM_O+ORP&;, @D*D
M+I&]C*\0>1^%BU]AT4DD[1F?-LNJHFL"A#@YRC;W#<_<  ':NF8#%'Y@.X:R
M+=VW=#VY"0W*KA)(8%_6GIBF 2@.X=0#YAJI201BM&9KPO2LULZ]'7:L1]D3
MJ-H@+M5#O4%EDXBUUYV+R/E!\:R93G:+D3,0.@[@.P]= Q#J'V8I('(;VQ.)
M?*/(3#*^8,--+#:6OAC'2K-T^A/Q=7B!ZEM$7)!$YSO6T<_9METQ,) !5(.G
M74Y#: HH22<SVJ@S?[4O#WD',4N2R-B9(X52LLZ"SC(9=>-A'6/H))LM!4N:
M;,2I*/(*)+#,V29!4**K-$$]P[M]*8(W>L0R#[0_#++%=KL!/X6?0+;'\&O1
M86(JEA6KR3ZBO)F2LKBENY@S-XC+4Q^^GW2ZC<4@.DLZ51%0>W?2AK@4W8],
M$Z32*C 4&HUZF5:,0AJ]6HIK$Q$4V*!4&+)J3L2;I@4"AL0/GL&X]=0I64Z(
MC1$:(C1$:(C1$:(C1$:(C1$:@X(J97];_F=OT]>FL2ZJH_4DS81_Y1<X_P#'
MH_\ [K+:U^G'_-CM6==_P3U>T)46MXM>C1$:(C1$:(C1$:(J*1(91FNF0""=
M0@ID!01 HF-T -P*8=Q'\FCL742#AEK>]9#JF+ZS/W.W/48*NP$>JO(/79DD
MP5.W147!)(RBB:9CBF@?M 3!N/V:JX>+>5,6%, N/S+F:K)RWS#9>0-BD9+\
M'S]ED87C_0'I?#^$*>RE%'%<?2R:2[AHBMD4(YO+N3-Q6!$'9TMU?UQHEJ1I
MZRI\/<*+<:;2^-'AB'[.STI(_([(3QDU8XQCA<,+9<W@+24I$.#(NJ;'QKD1
MMMB;JI=B[4&$,R7&ON" !U9U(B2H-40]4'*^8O,\8Z:>EXPT8R8<1SAL;?5=
MWR+]/[G,38U<;9XIW :0'W9M4ON]BUO"1#2#;OXB/:E3BB,):$CD$DRE75BW
MS%L!'**8"!&2R3I190$4S*)E4.8X*"8Y@+X5(?G^8B57,QOH5]J_I[I8^6>2
MF,_E(LQ'X:Q,CD^U:;E+(HZN62[Z]<H*0M$7L5'A5$C 9%P<DFV-.SC<QNQ/
MPK2,4U! V_=V*#N!?@/LG*.6C2\H.J.$(1.&Y?._ZE:D<U\YVYVV).HO8%\9
M [E<XN*-%X4D6ZQ^R4EJ#8+"[==0,-EM,$\GIM03#]8J*3#Y41'XB(Z\VYK/
M\SS5X_BGZS[%W/*]/+3\G!D&'#;]02]<311F&(,91A#)H(?S9U\O[#<IEI"7
MCBN7:Q@V+N=5X].81^(B.O:O+FG,>6Q.Z/\ 9"^6/U&F)<RG'89?^Y(I1O$S
MBL]YK9"SK'IY2E\35/#\#7HM*>@83SS+FT+*3BK\KI\A)LAD(ULB1N(MCG+V
M=QA_AZV>C#VR_P")<+9'#;;K2P9CV8^4\ \,AC_EGCV\1;LA'*C*U8?'&3%N
M<H"!'(NZK*7U>2?B"@E**B*7<0QS"8! "FR,U?#C8&5K_P#1,\]68AM8.*D^
M@00%163R=EZ,,9(O4YAAFV Y-F]$2 /\G.N1-7]0QR@(F PQ2LJ)-?*SVT><
ME XJ\B[1+_T1QK=-X_YSLLRO6,IY<BYXT,RJ%QLRQ$JP/'Y"%.HW(<W[,\BF
M0=OUMM2V2C?TV#N5HX0^VSS8R1Q0P5>:_(<:EJW9Z.QD8S\1Y3RPA.-VJCET
M0OK(%G@N4B&JY13$?&D_6)ML/?N(@$,^*.6:I2PHSV<>6LF^3-9N4V(Z2U(0
M04:5?'LM>'*0*&*)BM)*>:TY5EV 7IVD'R#L(]O:&[A'8I=A7%*1H_LK8IC
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M4]*HHXL5AU*D.6%HJE.+>*;(VZRR$C3F,S%V517-%U@"Q<9!J/F[1PL2OQB
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M1PNNWBJ_5[#9*J^6K.0VL05H_;SJ[L^4I.V2,BLQ382$DWC7"BEJ5*)%10*
MA\AU3+GYU-!(\0K][I@@\O6P&$(XT+1S5_;<,\.8[N.(L5U&K2QZWD"C9RB+
M<_<@ R$TUDJY4XYY#I@=R8\(FF4AS)G;BEX#K&,00,(CJG^9R;$]Y4'R_"IX
M W5'O^U7='VN.-3B'<4V1;C>ZY(.L?/JQ6WMGFHIM4;3C:'L$6RGV5M,]:+V
MF=E8&?D"+IKNES+@83& P@ ZD\UD26DP../3V*?^GK8/T"FZ/K64_P#H^..4
M=??Q_!QDC&OSNLIN)6$FE9$I+0WS!4KG5KB1^1)1<\,DUK5V?O$X],$V[-1
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MSN?5%.83>4QQ2[MD^P * 4C1V7_Q)OTW+.M:3F$\;< >L>]+#Q_9/Q'5FTH
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M=/RNJR [Q[U0-/S-JVH=X]ZJTUBHK Z  3.F?S&4$QC% I0+N'C6,= =NW<
M[?GJB>GU8#\(QV^XK&U(YCI[7B>%;9]K^U)&JZ@K<SKD4@'2D:IARM0Z3Y,O
MF]4\M+B.E").X]P"T2'D9UY<X"F@0P"3<!UC^%K3]V/?\5B6]7S&1K:M@#U]
MZ56HLN<J:2ARG(#51FJ(H)B9=$R9BHE54\?D_DP=O9L(?JAOOJ?#UA^Z.\>]
M9D#K)X6X/U_'-6Z5DHV(BG#F4$J,<V;@82JE "&42'N\P+&#U!E!* %V[Q*
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M,=[=V'B6^!!<\*7$/JP2.9>42;,I2;4(=NU5>R,XY&03,V,Q;IE54CQ=E/\
M\'2%!4Y3&'H4XE+_  M8NJU@T]O=\%T7(^4?S"\)4(9\6P('M3>U* DX29R,
MZ2,=_D:9G+H<ZPB59K6G9WQJM"E*8!,!2P+ENU4)_P!#'<W\';7A_F_FGB.
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M$%1NLR763.8NPD 1^S4@?+TZ;T+NXPZ>K!-E^V]Q%S9PO#/N(G-UB[IQ;>W
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MS)BVK6+[RF4LC.8^/=HN(]>'I4A)%$B1B*?6**@ 40. ZYS3:8RED.M95_\
M[F>7ZGY1*I_]"?5^-+#KG-? ]G,4J<W/0VY2]Y[3!+00DV "_MP=K;IF#;<0
M'X:Z&SS;3:6V-//ZH!L']*P)_K?I-0/%B2TJ_P"%+^\KE8>8/':"155"_1MH
MD_2KDB(BH*(V.;9RP"F=O*#$,E_4*M44B*-SB':!3.2]?D-T<[TT@X'R_P!'
MVK67OUJTN<F?_P!*7]Y)KXS<FX:J*7QIF$B-&@[;DV[Y,A9%Z?:(B$KS9Y>Z
M_=LK)*^!"/<0*4J,07OZO%@*< )W@0+5[FVFU-LV(?46R;"OL5K1?K1I)ZV
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M /4KTZ]F;-*J JN[=B1,A>T5$4H^PR:AOK+L!6+JKLVZ^Q]A^I0O;MW!N(
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M(R=2]Q*.Y@3*!I^[R,8XQ^28H3MM OG;S'[9VXL")*<[_9F;^E)YB@"X[F$
M.>,DX:;NF22CBWV#<\8WRC7H$MAXWR_'3'^5,IWBO7V^?C*PYL5AK=!S\-!P
MU?H[C'"U1A'CAQ+(&?2Y+.*ZR"9R^$W>( ^7>REI?UO0E&<<?:'SY@J%X*-[
M);,:*)\7>3O(O.EUBJW(6N0C92J9GJ^=H2H4^H_>5-AC'?P;+*S&-=).4V;8
M5T5 (H<G:8TMB!TWA*@5%/A0+#JG[1/-/&\#AB0QU=.-<O<<'\[<F<N']:O%
MSRA 5"P5FRJHV6CT9U8X?#5HF*]/-'P(B\60BW:,>!A6;G=*%!,P!X[U%7IA
M[?>JMM[/W*VSS5(R[E>U86E,Y37/" Y5Y-C8*UW]WC^&KZ#ZCE?U:H2TAC*-
ME[*[.QJAOK?1<4D8QB )@ 3"47R*99JV>X7[3O.?ESEWD0_')&&;IAS+A:8I
MAB3RO?LGM'_'N K]H9V.XXZ;XMB<3VZI 2YO&$8!9IK-^H'[M IVH%6$R9F[
M%)>I&)*IU_94Y%26'N?]#;6S U<G^6Z7&I7&K4TE>&S2IML,W'$-SE<?6^TM
M<<+2T7"F)CI9JQ.P8R/K$02.NDV$YR)TERVQ0& /3IT*LN;?8_Y0V[-62K73
M;;QY>XLS=4^/\#D2-R+?,H'D*27%N*L:8UR.6FUYCAN=AKFUG8BBNEHQ5\^A
MU&CIT502%,GU2B<**8D&1D7Z=.]=0=4@@KD/#P8BS24;Q+5J[:QOE6!V=HP:
M,_*V6709F(1$B " "4!^K6-<#4H0W;V+(@3]0<;UJ3!N_P#.7FW\EG$/S#ZI
M]TUKM/\ ZL=JS]61^6#?B]Z51K=+4HT1&B(T1&B(T1)]Y'T-IE?&%_Q/+3 P
MT+E3'ESQG(OVY8IU)QK2_P!>E:F^EHB)E%"H3+Z-9RQEBMCE.*O8!4BG5$"B
M];IO."Y<,Z<1.27$BP2;J?IDCE["L*#>,J>9*4PBUY.(A8TZJ[=AD;'B!VDO
M$.%%'1U$E(*->0)04-YW!#@H!;EL\,G.%5CW@\*;1]NY-=3\W$7_ #1.N:_/
M#--<<8Q%&./'J*.1:RMSEZ^_ED5:^J 5)NJ56"*!Q'90!#8.F^O$?.^AGJ),
M!]Z.1_#+8"OK+])^:6](/F+?)-JC\=O%SZU7B(NG9XM<PD,:/&(\YA$" + A
M3"/?\-@])KR32>7[L;K\)8[I;>I?3NI\V:;\NW%%ZYPV'>M.0ABV+(MJGI)!
M%8E>C&F,ZA-G$ITB"LW3-)NP6-N#=J9Y*KL7"@]I2IIF[A[ WU[MY(N'06+=
MB=#'VW"<^M?%WZK><+FM\VZKEEGBE%[0H($?/8M U!)S[UY8Z<I7FPW#(IP<
M#%IKMJ%7073. 2\36Q6FBVE),_44I!Y:%FH*" &-Z+;X &M?^I7,XRTI'_$V
M?ABO1?T8\N:^[J(:W@DW[H_3+\4MS+=)WARF#NW49E$050 !^L!*)2AVA]AQ
M ?T:\-Y%&5_F,"WWQ[5]8\P\Q7>7:/\ E]ZD3'A/RQ'TTQ+%4F(*R_D<UV6W
MO''JXO'=)A*4MLIY1=W>[_<CAQ))E 1.HI&QSYTB=0/U.H;Z^@/+NG,3$MZ_
MPE?'OZN\PAJHW>&5*M]/\>)R*5+>8F3G(!UC*.:%<25_F*YAZ**7M%5VGE>1
MCZTZ3+OU'SGM"@#O]H[Z].LQX;8?8/4OD*[$_GY'/BEZRNV6EPZ-3I%1K1DR
MHHPE9C&1"I=%"&CV" *E(4/L$>NVKH(R6TG63C BFU-!^YAPFR#RYY$8)5C8
M1D]QQ"89S-4;7-NI!HP^Y9"T6?%DS#KE57<(+=P.ZL.P)[C\1VV#?484S5#C
M')-5XZ]L?W$'D#Q2RAEV @Y3D=2,T6EQDFRR5NKL^6$J.).*69N,V%)8Z1Y5
MZWFDK65U 2KINB1P<_F.5PGOY"A :JFM!GU=!3I58VGP8]QV2M7$B8O& <Z2
M5SP[RTFLFY3L*O*;"2>(R8Y>9DDYYG;,"X'-R#)4ZK+1^.EF\RY2^X8F9^\1
M6/XC.3!W2'9013?ZTX/Q'QES]QGB?C-Q$M?#N$953"5^C9&QYNMEYP)9*PXK
M5<M"UF0M6-8R,O\ /7^NWV;2EE46CIK%LW<8Y: J51 3E.8:5Z=.JJ5>@<].
MQ)3HW#3W#5JK[:_'J;XP1]4Q;P)R0B_OF3/YT,1R+*_1=6Q==<<5^W8MJ4'?
MY*5@5S_B<_JQD8^)F6XN4R-4C-S/A3'N*E^Y8QC[@O[@&*<?86I$IB/-E@KL
M/Q]S#17<;@?DSC;&=CK^2[Q?%YZEDR[DAKFZCV&Q4Q)NN1S+-(1_,QZZ)#(*
MIJ'-XA,>G3XJ/7T=_C3:GI/:FQ=FWCSPFQSA[.N-9''V1J-=,R#8&+W(E3O<
M<^87[-F0LH1UPB[/'7"QD=LDH6ZHK/#+KEDO,FL I&,!>Z11/5Z]O5V=B=A(
M.Y"B @8!*4>X!W VX!U ?F ZI52MSU(%54"  ]PG!4QOXH)D43 P;_9Y?W]2
M,%!30_/S W)!OG;BKS)XK8TK68<CX%6LU*M^*)ZV0='<WS%MUKEDK\TPAK%9
M): KS6=CE9I*09)OG[1JNZ:$244 IQ 9H_[*BK5QSS2/.2N,O=#YOTSF77IO
M#[KCKB6V\/LHX<PUQOE<K8>L=KR-E6_8AGZ^HMDEUCW(EOQ_4HTMOL)ABW)9
M5,#LDVZKH4A,KVP#UNI-0^2UUS1]L[D1R"F\.P4)46T%7*_P1Y 8/OUDC9;&
MY@IEIO=&AX.I5YE6$IX7,B0\FU="+QDT72#NW.J'31L37L4$M3HWP6;V_C?S
M YD9RXU7G,'&-UQ@-Q8PWD<@LW64<5V2O7S*-I_![)"F04?AS(EW14J;YJQ?
M.4QG4F90!HGY2D4$I=-_I^U-Q63USC-R8PC5/:)R[#X%>9EL/%_BM1<!YPPK
M5;)CJ(M5$F'7'I6FR4O25;U:ZKCA=:AY!,A'BNTD_4?=A%?3^1(=C2!4,[GV
M=>W/N4.],N[U5Z.D[W'VV>5>?VL]9K+1X?%<QR.Y&\B+CD"JHVJD@^P#3;5Q
M^;<;Z;.3CFG3TE"FM4_6JHRM$@M".'[OU$F<QC"Y[RA&-1C7IT[%.%.G3/UU
M7M2^-_/BWJ^UUB6[<-D<=0G"'-M9N^2<A.LN82L<+.1%<L\+(LYG'\/3,GV2
MV _F&<6<50EX]@;<I.[Y[2V8VJ*X8=,UU;ZI5:-$1HB-$1HB-$1HB-$4#?JC
M^8?ZVI&*@X*W)_\ !Q_,;_YH=3K/I/3)4:/ZAU^U)5Q3_P"<7R6_^SN/O_)=
MC_7.V_\ 4'K'L6_O?Z>/4?:E9IB '5W_ (^MS%WHM.< O43EV'<>FVJB9,J<
M*KR[TOR?O?V]6_F4\>]>O7^,7^K]&LD&BIX4;&_C%_J_1HZCAW+P<(^8@%-V
MG # ;;\H 8-^@?EU;NVQ=CPG:HE$-4*C]"3_  8?O_VM6/RD=@[U;X8[%'T1
M?X@?^N_M:?DX;!WJ:;UX&C41,(BEU'X_WS^UJH:.VV ]*MF,7P4OW8W_ ,%^
M\I_:U/Y.WL'I4<,-B@:,;]H_LOL^1_M_*&VH.CMM1O2AA!L%X_=C8?@C^\.J
M?R<.C^Y4<$-A1]VMO\ /^]-_:T_*0Z.I\..P^CWJZ-6B":(% G:'<8=A$0^(
M_9N&J3I([O2LBU$"+ %5'IT_X( '_-#_ &QT&DCN]*NBF2@9N40$ [=Q 0_6
M'YAJ?RD5))94_HA^P/W1U'Y,;0K7>H_=R8]1^(]1ZFT_)QVJ>%>J;5-$!#M$
MW<._3<=OWPU7&V+-!FG"%/XB#T A@'[1WV_KCJIW4B(1X _J$?[6CD;>Y3PA
M4WHA^S]\=7/"CT)5G@ZU'T8_8'[HZ>##H2G 5*9B(_(/W=43T\9"C>E2(J7[
MO#^$ "7YA^3Y_+5O\H,R&[5/"]%+Z!M_@P_=-_:T_)P57A#8IO0!_!  +\@_
M)\OE]FH_*;"&[53PLC[O_(']7Z-3^4WCTIPJ(,1+UV_<_P#4U,;'AGB<'O3@
M>B/2#]@_U?HU6^Y1X:CX3_Q/WM.()P%1["!T.D83?,0((_FZ_FU/RG()P[BH
M>,IOU4Q+M\=RF#?]P-02!@$X5.DCLH4>WX"/R/\ 8/VAMJ8R^92(UJJ_M+]@
M:O<6]5\(4=@T=.$+Q4*7NZ[_  _MZG'!5QGP!E)VD_-^G1BI\9':G]O[XZ,=
MR>.H_L?ZC?[.H[N]1XIVJ/['[0T4>*5 02'X"']7YM2Q4B\V*AVI_;^^.C%3
MXX1VD_J'1BGC#:H]A/M_K_VM&.Y/&4.U/[?Z_P#:T8[D\=':G]O[XZ,4\<([
M2?U#HQ3QAM1VD_J'1BGC#:O<I2]H= ^ :AU06D7VJ;8 ^6CJ&"@;X#M\=031
M2 U0J0PK=>@]?AU^6L>Z<\U,0262<,*I 7(V<S[_ /[<'V^/_7$KTUKM./\
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MWY6T6@C;G=TXF+5L5OQ&$I9&;]JGDGD1'-EY%-9OX$455SN GH:1:)BF0R@
MX28KJ."%4,7L -P'N,&W76A\H\AF;D=1*)(B8G"6P]BPOU-\R\I>[=TEVUQ#
MQ"&N0EF,G*VSQH@"HX]+:'C>1;RN2CN;]+MGD7+HJ50D^X/:J_" FJF3RC'0
MSA*(3%<%5C"8#&,9?937NW)=$+9B0&/;^%?&WG+G)UUN;R=_Z/\ $!HP3@?"
M/"TAGSF/CU9R#\F/^.,I6LMW<4$#BZMUP0<-IK%L,N<$C&9A6;,G&.%4&P(&
M6;);.P53.H!NKG#@@!M;W+Q>0_?F?[1]>"ZU(Y%J_(VD3E\RB(N :J=RI.U-
MP5(BI54 ,5(3CXP#8Q>FW3;?5J$N(.-JS!4"KJ699J"R%!GZ0GJ%P!P+WSJE
M%$2*'/X0*J @MY"E$-]R; .X?#5;E&?MZ=B1QC/E;6LA<C<P<;8"+L[ZUX60
MC92PV]Q7IA"@KN)Q*.,G!L;F+%&K/+>@G,@J[BRNCN020<';HIII@)&?#C3O
M0$LYH'ZO2:;MZ4>E+K.ET!(S^\7XO9%D5-O'.TD(M=J=<L@I)J/2&7BW#R-+
MNU,[.5LZ3.EXBG Y>X)'+[>]2Q:O3K7LK,M%4'"2AG2C=NJ[;.$FL=(C+%32
M21.V>Q#1%,5W[$RBAP,Z2(HW,)-@-N4VCDG"JI;AHZJU7Y3]FR:**[9]ZTXE
M?(?=_HQ!5))XJ[*KZ<@27F Z:*QQ4,4HB ;%'9CU(2&?-7YBX(X>G:';IHF1
M56260(+979,Q5%4O,@W 3-450 IR'5 ._H "/<&\F@9*DY,KR>+8*&,8[8A^
M[?N*83BF("B5N8OB$WC AD2@42[;"'Q#J.J753LJX            /@ !T
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MS?\ MZ<<<B.]/RXV2[B@'WVF3$/_ &9 /^>U!D#0,_6ATXR$GZBH^O+]J?\
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MUI[L)\4KCC8RG^8:;^"/]KX*7^BM</\ 2CY*?Y:5C_,C63PG\2G^8:;^ /\
M:^"G_HKV_P#TH^2?^659_P R=1PG\15/\PTW\ ?[7P1_17M_^E'R3_RRK/\
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9HT1&_P"0?W-%+*.BA&B(T1&B(T1&B+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tm2226999d1-ph_bindingbwlr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-ph_bindingbwlr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!1 ), P$1  (1 0,1 ?_$ ,     & P$! 0
M       %!@<("0,$"PH" 0$! 0$!                  $" Q   00! @4#
M @,""0<'"  7! $" P4&$0< (1(3"#$4"2(503(642-A@4(S)-47&0IQD5)B
M)958H;&B0[,T&,%RLF-T)G8WT9)3<S5%@H-D-D97\:-4Q&6%M59F*"D1  ("
M @$$ 0,$ @(" P$    !$2$Q D%187$2@2(R0Y&AL<'P0N$3T0-2<B-B_]H
M# ,!  (1 Q$ /P#W\< #@ < (08EXB"K.EBT257O/L#7PRD<HG=#)$'A9]+I
M6L1?W?\ *7^*P1%&OF!\I&^GB-YL^,NPV8;?[4TFROE5N_#M5MGN?=5N261K
M"ILZP'$9$*EH=P%BI2CV;B .:785PP([FK),K8V/1O3UUCF3,O@C]>_+_NYM
M+\M='\<VZ&+;'!8OD5[B0&VF\8='FL]O:5N=8)B>XUC7S>UW$LX!K,>VR<B,
M<N:M&"48+FDCI(Y'H7<6/QEWG_Y+V^!>;V1;=4&P]G6>-.[%3LQM3+=V+]NZ
MW+-RZNSVGO\ ) &Y7N+NOBV+ET3\)W%A6$R$@8.4GKA85)*UT+4+O)+P1^WA
M^7W>[9#?3XM=KMP=O-N\8F\[;7;$/<6LH5/W.!PC=2>RV-$W);C]QM;GV74M
ME3KDV[<R!E13V@KH16R>YGC7N2(27=EMNL%B_P @?R,8MX;[";K;D8YD6UE[
MN;MOB;\G*VW*-*;E#Q9U#(':5BK,AK<C9$>/8BD,^EBJR9BZ_4FL27,EED4M
MI_FVVSM/CPVQ\M?(.OQ#!LLW;,I)*;;"C"R*OAEG6YQEKNE]C8Y(@\L"$2R?
MOC6\H$_:G5?28?!)XY+!<*\]/$_*,$HLL-WIP[";7<.@H+]<<OLOI89<=7<&
MMBL??Q)VV(DS'&]3VK)(YJQ)U-1>2QZM/L6?U'GB\C-AZ2\NZ<K<_$JDK&,0
M@R:]HY,AKD8=0F-H21LK<4U7"3P3PWHNB1RK)H6FK.3NF1LT)2<"4Q?RK\9,
MKR*FQW"]_P#:N^RN\MS0:98<IKBRZX42J=8345:3#/"%,8@\)#TB:LKT0C54
MT5.$..PGH+7<3?K9C:/*:G$L[W.Q/$;C(R ;("L-M(0[TF ><>6UMKR25)1&
MQ.2QBDB^@=5ZI.3_ .22;4H2D.3$>,2+5E12R-JK:K-.KZQ2Q+*F/?+8HX)\
M,M:DB32VH;G%-1LVNCW(J(J*B0,IM\\OF!VU\)_,_P //%*_'$<_?:,G*-RK
M=P=S,+04V5A;BX=B4AA0.H4!=KF^%0ANB?W9HFS-?)''&YLO&H3SD2^"4ORC
M>>%'\<GAGN'Y/5^'MS27&JZJQ[$ZH<<VP$)NLJJ;1F&QE_:B!Y),6&,!C:6]
MDT*(*[7W$6J2)E1R7P5\?'[\N6_GDUY?5WCKNI@>WIK;?8$;?5V7[3BW2X'A
M0<YNU8-?6G/L,[S*1+Z.OW%C0B-"'/4ADZI&QJ*QFWKJE63,M^"^O-<YI=MZ
M<_-<QR?'<;Q6O.-CRW)K;W%9#1CE P!5'VUQ<K'R337IH\6K8RFN[O2B(NJI
MA77)9Y&>3R+VYS+9[<S/=E\UP?<^YV]PEV3!$$V"6KK#(*.@O+6DBOJ:O,IK
MNM@FL*E4CEF:'%(U9%9)HQSF:6K]H8FI13!MS\S'D9NGX-9GY'XIM%LZ#N[0
M[QY-LIC^%93E]'CNV=Y8@7FY+8"RY[_>"CE'/G%P!'(LEZ/&C9)45J+IT7T1
M/9EVF=>1VUFR>/T%MO%N#C=-<9"DID%>5> 6!T@;(Y&RD4(5.^P+)JQD%FDD
M>U)T;'%,O4B-56Q:O9P@VEDU*[RPV!LL*N=Q*C>;;0[;[':JMRJ[M:D\B!H2
M9($;<8XX@\R5P@I9<580I$,C$FA='I(R)W)9ZOY+(94/D1L9DE!E&0TF[V'6
M=!@E5%=WT%':1Q8[75UFT&P4G(+$MDHDTDDEM&JN@(8UJR]*HCD70]6)0@0?
M,[Q$L[8B@$\C]J";:5Q]MWER^K>,8CJZ2*SK8'->U)"(:L&27H1ZN^M.2ZHB
MO5_ H<3;'?K9C>@8X79;<G#,L9B+PP,A%H;P$V>G!%4H>J!M!VRQSB06T-84
MR?J:WI2!VJQ:<(:R)G!I8YO]L1E&9%X'2;O8O:9C8#&V(NW\>1U5BZD^R&BX
M_82UM0#']RE=-83)(]J2S.ZR7<D3DT]=D!$.\R?%8<JM&_\ $'M%+D-59)CK
MHY+6>&>64YC!0@EBEDC>R=QEHFCUTC^M$_!>$,2*JP\IO'JBS /;W^U[&I\]
M+L:0)E"+DU1$XG+;@OVN/XB,5-$H'N\PN%<) BSJBO;S>U/J5ZN)>!*GN/0$
M\J0*!IH4M!&<'8L)QBT)$O012I[1T\$DTF.231R//%:I#4;,JHV;1=%142#S
M@>#C)H'  X '  X '  X '  X ' "1R>2=DU:H\<;9&,.)>7+^1HXR"R3URZ
M2,55M6?0B?ZOX<5$9Y<_(GYQ=W_#CSU!\9]^MLL,J?'RIW$Q>CO]XQ![<BQ@
M'S7 A=Q <;E]AF]OH9.!;23-5*E6(P+1WU:=71ZZF5*)%?+S\R%Y\>-_B&#[
M5X%19]FF8KCUUDMW>QV)M+C(63925AX SZ6JR'&[WOQGU*O5B/E>Q)VO<B,1
M5XBUJ669P61;2>7>$F[=>/MYOGG>UN,;L;T;>;99344@,Q]0+?6V;8YCMH&"
M"!;V]L? 14V%]%&YLY**JD-375'*AZ])A">N1<E>8OC158QFV=A[SX7<4NVH
MA[\R,'L)"8<<)B/B9/'.V ?O:12R=*]*2<U]>(M'@>U$>O![Y'_'[S3V7/WE
MP3,8,%Q+$R"7 DY7915$$M(X"J]I^HI+4&M65[CKAS61PH/*Z3H1&JJHCJ]8
M2:PQ/#HDWM[Y1^/V> 91;X+N[@N0C8>':6^?RUEG]JGHRVPG&6IX(M[[4I]7
M+)6%R=QK"FNCA:J/7DKH]=ED3(F:SS5\8!KC"L>3R%VZ*O\ ,K(ZIJ@H<\QJ
MS%^X/-L9H!K9:V69H$SA@G.Z9Y1W:)P]6YZ">I%S?#Y0-@MB?+SQU\/[?-8I
M=V-UV9;!?O,;822TE+687G]Q2-R#)A:QF(-/*R#$IHHG(0UG=DB16<T5U6LJ
M_@E\%E=%8'3 0&3 PS1E%XZ&-(\H2QN9A0Y)(B,C,LZTI]0;"Z*9I JP1MU1
M7JK7ZM1,M%GJ5+8K\MNSV1?*7N)\<5_="@WN*X969)57T=9D,8>59?85>U=C
M5[< W<HA&/6'W"BW"(-(2!_[HBL?&^:*1CX5TTHK[B+O@P_*)\C62^")?CGM
M]M_0TF49GY%;B0X2W<'=&"Q_0F*R (MP]<B?77.$31(^"N<R/4IB+.1$G/\
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M]Q(XH!U1S(XT1&IHJ*GHB?L3C!>YD[J]/=ZV^V]-.7Y?RZ>FOK_#P*;O  X
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M1*]N)88;(XR$JG?]+D148,Y%;KHO#TV$K*$IC/R_> F83;A!X]O>3DY&T1E
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MDW9[,\HI<HO[W'O(&IAQ]Y$F.E 4U??%9I6P23-<0V>.7J6-Z1HU>\2OA?\
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M$)E\N361I$$>H)184$Q+1T8Y_3'2MUP/BSVT<<3H#@ < #@ < #@ < #@ <
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M5N#?YG2TV2;<YI@% 3)(!A%'#$#16M#3@/9(&$]W<C:J*]KOIU15X/[?D<_
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MB2:AHXGPD(W61LJ0A=),Q+IG.>^3J<UR+TKS75(@-R189XXW^W@('@T8/6*
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M2U=W*)(&),U4MX1FK4Q3=VDD163%/T31&Z(BZN3UXBVWQ)?77H3NV<SKS'W
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M>OH[G_!IQG?[F37[1\ZUO3%SG29ZMC5VG\A-':-_B_\ )Q@T@RX%!P . !P
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M:G):]6D$TV0W?\T7RHF,QBR?Y=;O5WWZ^( J<3@O,?DKS\.@J[">6]+(8'/
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M/PCS=NC2Q%FIZ;&+R;NRO_I\YN.-+K4HWNF*<Z(:-Z0*L;E54B=KT<2;DL5
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MG5]+](!M58PT3)[6*UP0BL;U:3UMI26MDJ=*Z-2I'D2?J5')RZ]5U_@X%#'
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MRR&8IK5;T=][Q!GQ*J-A5K9517*B:+6B#&RBLA"LR)TC"LG6L4!AE/"VL86
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M!Z=M-Q,EV9W0K\G#:RPKY:U BW:]?2U[ZXA5:D1$3NI'!Z:Z*FB^G!/U<O!
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M=_:!7UH,T;3$8CU,/DLG#M=VT55?(/$KT:U_I]/IQDH0%BE!Q2 ]V,O[D,^
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M\993M)^,_P#\B=G_ /X;;_SF\/\ V?>S&N$2"3T3_(G_ #<8-G[P . !P .
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M9 QFOB*>38K3W=NLE?+&_P"N3V(#(458X8VKU+HJ_@W<TG@FJA65<5 F24%
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MU[KNOZ3A..0(LMXO<3& K,&LM3#C:IL\*P4ZXV(\I\,]D.?'.QR,<[HE5&K
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MC:GY%U_!/7BI\<CN2+W?W5R3!K&\PW;JVIQP:/;+(=K%+5K")L6@I\>?BQQ
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M\R/T].,Q-@+\?:^L]B\946O DCDQSFBKJSI[74B:*GTLC]49PQ920%#9XC=
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M;K&CR(.V9D57E([.?6@=93%TLVBH2YO1[@]->6NO"6EW(>T_X'/&+QR^27P
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MQAA\L\LD4#9(HI5B5[2D5&0NU7J<B\1(H:R1[?U+WUPMM5Y%DT5%+8-C+O\
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MD$R4M@\:2%1XI8WHU7NZW:MU337C2T;O@RWP&NU5=2ROKJ@JXLP[+!C1B(;
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ME@1(N* $D)B]J:FX>VSYIBBXH Z]8H5#:L?4-(CU;R5.*[CR2(DZ$': _P#
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ME$73VM9AYFUD"Y XZ.&!KK;%!U&/RR5R?;BF.E!K:!CFJYK519E^MOKQI6_
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M5/QO'<&2CQC&;PU<A;D3\2N)5^@57MCCED^EC&*YX<R(V5^B+^\3_*G"$[Y
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M7KJNFBWP#3EN(>EPR$I<6\;<+<T%D2"B.5]R]"FH6CRV.Z&,7J_=\T1-=$X
M='"L]K[6UJ:8C&Z.(JDRQAQ"E!@SN#G%/(:++'82A1N2+MR*KN347ESY<)N
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M',IZ\N7)ZESSIZHD<-\A44Q1DI0YD@D4Y[W2"P$/@UZT5R+KJFO3QAE%Z34
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MKJTUYZ?AQO\ ,<Y__.#GH>*?C#LY2>%-7O)/NB%)O;F&YF2C;<TI'=?_ +&
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M\@KZ&\RBVLZ_'H,)%9560@98=^$3[IL*1L5&1]EW>:]NHEV86T8P44>-=)C
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MB/<QR:EX1&KEGH8^.GR_'SG(L=V0V9H:"QO:MI-]G^>7%;=V3K FI=!+BM0
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M=LS_ +KM_P"N>'MMU!])\.7QBM_+X8[-MU]=*RWY_L_^W*\3V8/W^YU^,?\
MX,]G/]V6W]<<)8,7]SI\7W_!=LW_ +JN?ZVXOMMU /[G3XQE_F/#79Z'_2Z*
MRV3J_P!'7JM5UTY_Y^'ML(!_<Y_&=_P>;0_[NM/ZTX>S) /[G/XSO^#S:'_=
MUI_6G#V8@_4^'+XR%_GO#79Z;_1ZZRV=T_MTZ;9NFO+_ #</;8L _N<?C"_X
M+MFO]U7']<</;;J#)_<Z_&/_ ,&>SG^[+;^N.)+!@G^&[XP9NGO>%>S1'3U=
M.M;:IT:Z:^MRGYM$_P W"6#7_N9_BZ_X(MF?]W6G]=\)8-_^YU^,?_@SV<_W
M9;?UQPE@QR?#E\8+M.[X7[-OTUZ=:NW73TU]+=?7EP]F#'_<X?%W_P %FS7^
MZKG^M^+[;=0#^YO^,O\ X.=H/]VVG]:<262#]3X<?C,;^7PZVA37UTKK3^M.
M'LQ!]?W.?QG?\'FT/^[K3^M.+[,0#^YS^,[_ (/-H?\ =UI_6G#V8@Q2?#;\
M8DO3[GPOV=+Z=>CN5UI^[UTZM/\ :[/SZ)_FXGLRF+^YG^+K_@BV9_W=:?UW
MPE@L1QW':?& '"4<$G8<[J5'].JJK8V+K^[AY=+$_#@W+LBI4'PC(6NF[<*0
MO7H67]KE7K5->:IR55_S\0IN\ #@ < #@!".DDB,1#X2(:X.)GVR_9,/.7/)
M(^2)S'1C]]Z(]C^E?W+>3UY_LO\ ).2!6YOQ-?'KY![CY7NMO9XL8-N1FV4D
ML.L,HRZ%Y)1Q!))YI4L$0904PZRSEJZ1)6JKM6Z::.XK;>1 BO[C#XE_^!K9
MC_=MG_6W&1'D_?[B_P");_@;V7_W9:_UKP$>3]3X-/B8B]/!392?J]>NMM$Z
M=/V?[89^;7^'TX _?[CKXFO^ S9'_=UI_7? I\?W&'Q+_P# ULQ_NVS_ *VX
M$CR?2?!K\3$?IX)[*3=7^G6VB=.G[/\ ;+?77_DX _?[CKXFO^ S9'_=UI_7
M? IK?W$_Q)?\#>S'^[;3^M.++!]L^"OXE8]>GP:V8YZ:_P"S;3\-=/\ [:I^
MWA)(/O\ N,/B7_X&MF/]VV?];<01Y/S^XU^)7_@)V/\ ]VVG]=\664_4^#+X
MEG>G@CLF/I_]3K;3Z_\ +_MEWY?_ "\220#^XP^)?_@:V8_W;9_UMP$>0?W&
M'Q+_ / ULQ_NVS_K;@(\GP_X*_B4DTZO!K9A-/3_ &;:?C__ #5>++$'Q_<3
M_$E_P-[,?[MM/ZTX2R@_N)_B2_X&]F/]VVG]:<)8/MOP6_$G%KIX)[*3Z\_W
ME;:<M/P3_;#/7A+ '?!G\2SM>KP+V177U_V=:?UWPE@^O[C7XE?^ G8__=MI
M_7?"6 ?W&OQ*_P# 3L?_ +MM/Z[X2P#^XT^)7_@*V/3^'[;:<OX?_LWPE@R?
MW&GQ-?\  YLS_NVS_K;B$CR8Y/@M^):;3N>#>S'TZZ?[-M/Q]?\ [:K^SBR(
M,7]Q/\22<_\ P-;,+_!]MM.?\'_V5X2RF7^XU^)7_@)V/_W;:?UWPE@']QK\
M2O\ P$['_P"[;3^N^$L _N-/B5_X"MCT_A^VVG+^'_[-\)8/W^XP^)?_ (&M
MF/\ =MG_ %MQ"1Y OP9?$LWU\$=DY]?QDK;3Z?X$_P!LM]>$E@_%^#7XED15
M;X$['ZIS36MM--4]-?\ ;G[>++ 54OPK_%3A^4@YGCWASM;A>7@R,E@LL<J[
M5723-<YS5<KB;/EU2.3\R<G<5;-$:DL _LFP#]"?V;_I;&?[.O9_;/T[]HNN
MC[?V.UVO^\:=W3\>GI_@XOMM,S9(J.!^^,&@< #@ < #@ < 8_W7_J_^CP!]
M-Z.?3T_P].G\6NG 'UP!C_=?^K_Z/  _=?\ J_\ H\ #]U_ZO_H\ 9. !P .
M !P . !P . !P . !P . !P . !P . /GZ/]7_DX _4T_#3^+3@#]X '  X
M' &!NO4SM=OL_CTZ?Z*_L_BX UA>KW9VO5TZP].NNGK/KIKRT_R< &'  X '
M  X 1T?<[3?:^U^V?3['WG;Z>K5.GI[OT^NG3I_*XI% ;U>ON3N[[_W'0)W_
M ''?]AU?TC_[&]S]STZZ]?;_  Z-?PXA0ZX ' 'XNG\/\6O_ ). /SE_K?\
M3X ^N /Q=/X?XM?_ "< ?G+_ %O^GP!]< #@ < ?/+_6_P"GP!^II_#_ !Z_
M^7@#]X '  X '  X ^5]4_-^/IKI^'KIP!B7MZK^?^+73^+@#+R_UO\ I\ #
ME_K?]/@ <O\ 6_Z? 'UP . !P!\\O];_ *?  Y?ZW_3X '+_ %O^GP!]< ?B
MZ?P_Q:_^3@#Y731=-?1?7JT]/Q_@X 32=[_KNQT=2_\ <.GO_P ';[/U]7^3
<BDK@_/Z/T?\ Y4_SW_\ $NO7_G[/_)P_0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tm2226999d1-ph_blocks4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-ph_blocks4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!>@*X P$1  (1 0,1 ?_$ /     & P$! 0
M       $!08'" ,)"@(+ 0$  04! 0$!            !0 ! @0& P<("1
M 0,# @0#! 8%!0D)" @7 0(#!!$%!@ 2(3$3!T$B"%%A,A1Q0B,5"0J!D:%2
M,['!T2068G)#4[87-W<:\.&"DC0EEB?7\:*RPF-$&!G2<Y-4M-0U12961V>7
MTV15=96U-J8Y@W2$A497A\<H$0 ! P($ P4&!0,"!0,"! <! !$"(0,Q01($
M46$%<8$B$P;PD:&QP3+1X4)2%&(C!_$S<H*2LA6B0U,D%L+B8W.#L]((DZ-$
M_]H # ,!  (1 Q$ /P#OXTDD-))#220TDD-))#220TDD2FJ2E )!JD+="@*_
MP@%%)X$T7IQ^7O3'Y5]R19CS4)[YXR&(399$N>Y+<2B,W&:2VQN6X5(2CB4<
MU>/ZG.%>*3U<!J*C-L]=WI+8QK++K*]0V%,XUA4F'"SB<6,@^Z;!=+E,M=LM
MMJQ>8+2IBX!FYW:$XH,+N);0^I:E)0"I"<8G+V]Z@/VY^WRQ5L<3R['<PP_'
M\RL5[?R#'<ELEFN6.WYEYLQ+OCUV@,3+-DT$KBLNNJOENDMR@WMZJJI :2KR
MZ=B*T *D\<*N*'Z]WQ58\C]=7II[>Y1?<4RCO-A\#-,5D,([BMP[?DT^P8_%
MEQ(]PLAN%YMUNN%G&0.6";!7\HF:N44N.GH -N!II4'%($$L<<^??A@GBYZQ
M?3=<.Z\7T]PN]%DA=Z+@[*,/"'8-_C9;,%C@SLAN:F!)LK<$H^Z+'+WFM%(:
M6E/FII@'D!P]ODD26?#YM[46>5ZOO3]&L_<O)Y_<6UP;;V>OTK'^Y*;DBX6]
M.-S8DV]PWA=OG+:PIY+;N.3=I8WI2&5[B:IJG!QPP28XYL_/O[.&*8EN]?/H
M^O.5XSB=I]26%S[QW2VL8-98\^4TQ,Z2>A*^4N4BU(M;#R9L-P'KOHXE7#A4
M.,:L9?3V9-A'A'+MY_%2-E/JV].]A[O6ST]W/NI9;5W@R6%<KM PQZ'?&[B_
M QFV7O)[U,94;4J&ME%EQ.>3]MN/04$U- 6J:''V[E,MC1D<[8>JKL!WO?[A
M1NU'=*S9DOM5-AVKN3:;;'NT=[%+A<G[[%M$*Y_>5KA)C-S'\9N+;JZK;2(J
MB5( J50ELWR3 D#5GS^"84#UO^ENX=R(G:NU=Z,71E]S1)7&L\X71FPW6/"D
M1X5Q5:+Z[;(UAN<VWW-Y,9UMB>ZM#B74E%6U['<$N6U9\3P^'<E6-&\/:&&9
MICBM,GI+]>7J4R+\83U8>CK.,GQFX]B^R,A]#3+T2[+S#);T];[DW'N\J2W?
MW+6EJ+(:@N+5]VL)"(R^(YI;/'/%,!3Z+=Q&]8?IHO\ W(:[3VGNYB5U[CHR
M*5BJ[)/BWV+#.8X]=46:39;?DDJWP,7FWB'>W.@(C,UU^0Z4I92LGBCP<L_P
M]L>.27N=OB,/R6OKMKZE_4GE_P"+5WD[9P,^[2.^E#%>V=J>M&)/-79/<Y>6
M&U]E57?_ )B7F35RQV"J[76]%J;<;$S"=;6RM#RTR&%ON37%_HFJ:@9Y'$\^
MS!6HF?B7^B2U6R5=YGJ"Q:.TW/#.0VM#UQD?<+MQ$2VLHN)C61X1VQ(EM;2I
M5-ZAQ/+38EZZOPJGHU&;O5L\.SO$.X6+VG*,-R.T99@-\L-F=L-\LDINYP,B
ML-ZMZ'75N,1"N8E^+;765 *;9VE\[D'DF7W'G]4J#\/HHS[N>H/LUV">M<_O
M%F,?%I&37"+BV.XW;6YEYD9S(D0)-Q@OQ,3L-NR#*RNWVZRKC+=6VVSO01P*
MVP8U)I3-.6Q)=N'M[%44_$E]:-^PK\.[OKZL/2AW*Q7('NW&/]O)>-Y&B>+U
MB5RO%U[N818+S:[W;+1<;3D*'3C>2531Z( MYHE2@%(+EFIAC_HHU..7M7O6
MM.9^(;ZW>Y?X<OHK[LX/W![%]O>_/>"5C>;YVYD,#)L9QJ5C$^!VTO[,/%[G
MD7<:V05W 1L@F)>;7<YKA4MD!M)J'&>E, Z<O0EG<>\X$K?%=O5AV>[.X/@D
M_OAW+Q>W9QD=CQ"XW"S8Y;LANN0Y)>WL69<?DVO&K3&R6_WRW.(W$.0V7DDE
M'VAJ-T@>.'T_U3G.E?K^"DG#/5%Z=NY-NN5S[>=WNW.01L4MR[M=)T3(H,ZU
MX]#(4W(,IR,^UTST%$!.\JW.)X&H!;)_;V9,&< X?E1,[MYZP?2CW:RY.$X5
MWEQ7),KCSF)T6USV+U8F;O<XDI2U(PJ=D%JLUOR534ML!8@OS=G48J1U6RX@
M<:4R^A[4O@?9PLN1^LOTPX%G=_P',N]V+8_?L/M*[GDV,7B<ZY=8$>X*M-RC
MN"VQ("ID@.1+Y'6@-)=);=&HU9R:G'\.U.0,#@/B]7[,N*BM/XC_ *(O\U$+
MN<QZG,&;[>W.YP[0[DLO[[>NTF^N2K6);-S@1[(BX1.O N45LK=A,H^T^*H-
M)D,"V/'+W8J+N0_V\,_?@K07/OEV8B]GV>\MPR[%F.S4;'+=G%BS9RX(D66?
MC[=I_M!9IMNB15+NSTQZTI;=8BADRG%+"$M%SR:AXA53=Z'#VP4<X5ZMO3;E
M&+YEGV)]U[1>[1B$9F?F%]N4*^1)6.09#45V*Y<[),LUKOH@&/)8Z3J(RF^F
MINJB5I*I"N..:B6[\DTK)Z]/1[(C8>] ]26"W:-W)R.Y6'#I:U7</W:^"R(D
M(CSUJM3"+=%?;*$,2)2(L:3)5\NRXM_[/3$\,$@*L?N3ED>M'TV6S.O\T3G>
M7&4=T8=RM/;]ZPBVY+(L3&?WF:YCEBQR[7>-:7+/%GRLBCN1NBNX-+0I*PLI
MH2$2"7XIP_VY-\,U9Q(;3)C*;3\Z[/N%O^;^36A+%JFBV+")D8.E2A'6T@D
MJ<*NJ"#33U%#C].'O3  E\N?'+X)^ZBI(:22&DDAI)(:22&DDAI)(:22&DDA
MI))IY9<8MJBM7.YW 6:RVE$F\W>].2XL-B%"M*6IK[<MR5N3\G)CMN=7:FNQ
M!\R>>F/P]J=Z3$X8^U53!GUU>DFW6[(,DE]^<;L^/L3Y,)]]=Q6+3;4PW78M
MPD6IY-J6)SRKC"67&V5R%]1;GE 2H)GJ<5J7?L]@H < =(<9<?Q5H<9OV)9+
MC4?(;!,BW?&<D;:R'[Y99DB/>Y+KK<=J<E#K33Y<97!943L  ;'#@=(-W_1.
M7%?T_55OO'K6]-5GSN\=L'^[>-1<V%V1C$J7(@Y!-C1\P5/DVBUV*3-M]L5
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MCXUFET>NUOA@Q41;C*$AEM#QZBD?NY<<NQ^*43X7.+X9]K<.!XJL6?VWOSZ
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MS<)5RR/(+U<$?:0E*WE]=5ND[:UW,]*NZ3'Z/^:XG[#CEY]"_P"9FR+N%WU
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MNACMKCV-#MOF=-3%PF.D,Q"IL%3@:BQ'>E0Y5S_)6^_";] '?SL#E_J3[?\
M=C*>]O=KTG]U</M4W",,]5%MQZZYA"SIV[QF<BNESE,SLPEQ,;N&+V&!'C,Q
M[W(;9G-O.MQ67%&0ZAS8%+$\EL^[:_A7^B;MKGF&=R,<[**MV9X#.N]_PQ<G
MN9W@R/$,4O622[5<Y\;$K!DV>W.QV2 F?8XJ>C'MS#/2CLHZ>UM*$K*E3[?
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M]J2GY1@E33;"DI;"DJW)3I$$'"GMA^:8 %R*<CCW\.Y13VG_  @_P_\ T_\
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M90^A)W)/RR]A4"DCP=@2PQ2R ->S)3[WY].W9[U18&YVM[VV.5E^#7V'TI4
M7S(\83>XKW25.C2)&'7NPS=K[+" :.@C<:$5.D69Q4\$@2 8F@3 ],_H;],_
MHRL4S&?3/V\7VFQR5&EJ3!:[A=S\P2Q+:DN/"3&M6?Y=E5M;#LB4ZXJFVJE
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M81PUM-A'1:B,V/S492D#0E$96=Y4\>%]O(Y4H6Q_+'U>U')4SO>=%C.8Y,E
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M[BKPMR(# K!=;1DN,HDFZV%<$2P0AQI;+U2JJ:T8DR#S7^W7 &U=(:3D<?\
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M*+''V\_Y)E2.*O;0, 32A^:,Y%)G0Y[[48N0;>^ ?DHTQ:6FS57':TEIM7!
M^J.6A]N(O4Q/O1;L371<8O1=;D.KGQF.+L-ITPG-RMW3W24F054V'FC1*ULC
M23,:'!,PJ:)F*4Y)F+EAV:VVE=8S'S3R^@E("=I=&WJ5(K\*>>B,!Y09J^Y<
ML?%EVK-\D^KB%R.!Y?,.'_<=<O/;-9:$IR.:"XREJ:;=7)23N2@)?=6XY4I!
M#;0VJ6KE0"IJ::<7LP5<M6;D\'<MD417;2](,=M<QEX'X;DX];44H"#U'S0
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M GS5W%0Y\M>U>E;QOVHEV>!./]2^9_\ -6V_BWKQTN1N(T9O_:"[@/K'Z?\
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M#8<^*[ZOR8O^A3U3?ZUIW^27:75K]:S45V^CE^D_RG3*2_=))4._$Y3_ /\
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MUW0(UQ2DN+04B,XF&_\ 5''I*'$^PT]#M7HWHL"!7 8?7YKT+8[J,VD2(U+
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M"-DH1L4I#QWH2J)NHI,A"13Y(\QH:+9G)Q@"M7#J]B$*D.S"DE ,^4Z6@F,
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M''4+>"4[]H=DSJ55QX!/+53Q$^.O )&$< &2&M,1V8XJ<OH1XS85;%(6L$/
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M8A3V'7MQ9EIOZB-)!#1!%>7XYK4]W2]+N>]I)"FLOQ0VM?30H*7+GK("GEM
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M?<M5\M%G8BL--NO>82)R8Z@$JEN((*)BQQ3JEM;]R<HP))&KEP7+>].MP@2
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M0*(!AJ4FI4$'FP>5=4MO'SY@ Z=,?K^:&[.7FW(@&@'U58KG=IF2.DW!0*D
MD!(2D5J5'^&E'B-:2W$6S1UZ (DC$)I/SXR!(C2?@9.U)%.5#7C4&NB-L&A"
M<1*(VZ:RT[_4:_$=X50^4TW4W%?AJX.:0!RP2O)*?FF7;0-K$E0"ASX*/C7J
M?55J)Q5F6TCP'O*RR7!&+T@M!;D;ILGE_%?07$T!X?X,ZJ7 #X5SGMA!V;WE
M2'ATA-S:5B=T>4E,U#DB,E5  XA/40FJ:+'%HGA70ZY$"8G'!UP-LC@H^ND"
M7:IQ3<F$ERIXHKM-"H>*6Z\?=HF31ABN?3[HG,9BOR2]BZXPE./R6PEL%M2$
MT^(#B?K#V>W0_=.S!;G:1CY1DS4'R0N=X9=G.&/"H@@>8I2>7/ZRO9JGY+Q>
M1S03>[@PO& XC@L,AP"TQ7(O!#MSD5/,G_DA\=WMU.W$^9IF*Z?Q5#K,8Z9&
M&%/FK08;D;(]./<6T$%<@W& I!(2KIE4/)-VTE6X;E.#P\-7;5B!\;?->8[G
MS!U>$3]IF/HNMK\G!)>>S7U2Q2H@IQEQT':GE]Z=L0>-*\SJU;&D.MKL8MP8
MQ^J[R0SU&G4KJ-SM37V41Q_6-41$NW GY(M9EHEJ"^<W^:RBS+7Z]<=OMNG-
MQ56[M5;"ZAPC[;K6NQJ11(*%*V= \C];3%A(1' +1[/>1CMI"1 -<BN0V?+D
MW*;+F35%YU]>[J#@3M2E IN)-*)U8UQ 8&H0#?;B-VX9$T<9'@DM\+Z26XX)
MJ0#Q3XD>\#1B=P,RX;>1E( 8N?DG9:\)N\VRSKFPEI3,%IEV2%R(K:@EU#[B
M=B7'VUN&C"J[0K]HJ.O7 #[T=%L^37]OT2 PINBV7%NH4@J2>DA1(.X_6+:T
MGGX:HW(DR< %UGMU_N$CB/DC96PEA)<)*J\PD^-/[DZK:9&2A.P=*-1Y'D.U
MEI]H!()<!JW6O%/G1Q-/8>6EI8UQ0^]M9&H?X*2,/[G99A:M^-7A=N5M4-K:
M7#0*6%D#:H<U)!USE:$JR'B0N[T[S).0?>%M@].GX@*XMCG=I?4%!C]P>UV0
MSTO24.L3U3&0EN XTXD(DNI'2EVIE?&,KD?T9'?=(E >9MWIE3%\C@V'Q7G6
M]Z!*R]S;"9:I!,:=E G9ZD?27VG[N81D/>#T@.W"\,6"RR+OD6*@L1TXU!^0
M?N*$]*X6BPOK26(,E)V./&C'T;I],WEZU<%J_P#:X=\7.=$3Z)<O6K@MWM1M
MZHT)#@DK1;>(QB3[I;E17$M6EI<JZMKIN$EE3##Q%."BA<DIX!7Z=>C[&\/+
M#MA3WKU?I<@;8,F9C\TA--'>.'C[.'+^;37"&56]N!(5Q3BB37;?M5%5TI96
MR&G!0!"$J^V)XBO,>.J%P N^"X[8&Y= #.X4YWOL_ESN(0>Y=O;-_P ?6 FZ
MH:=BN.,*3\RVHAI+S<C@J&1\"N>AXG$2,#27%;?INSG. G5F-''%1!8IL1NY
M625(AB$\N4VB^*:!4$1>.]20E3Q/Q$?7^C4KX<2@)$VQAS5+8[.Y9,9R!=SF
M*4;)78LN3]J[WW"[?XYC]P>>M;<V"S-6\Q):*)DF7:FMB"[;8R5;G&U\DJY<
M_: O[:[&)G($>Y%MQO;=FRQ(?2<CD.2K9>,;N,CN%>[/!8=;BW*[W!R3U E'
M12Q)^7BJ*EEM(+T7:L5!)"O#1+SK<-H+LC6(8=]3\5@NH=0AKD20VH9'@K&]
MN<DQ+LQ>(4:TWD7C.(<86R)?74/&*V,H$C%9:%*;BQ!Y(-Q>5_$ &\$U' UY
MB=VZ;FE@2:=RUW0]IY=V)D/U',?M919WI[>9)V;RR3)G7&WW%.;RKG> _$E1
M9*2U*D(F/+(BRW%-%2;L" NA]QH=%-MX@(FA "WDYBUM3P,#\E6>^P(<.XH-
MN4757% =?I0[5K2@JXA*0/-[:Z+V[G@\62\IZ[<$MS,AFU1_[$EQ7G6"$*21
M]-*UI3P/NUTNT!*>X"1QHEV#;94],NZN14R;;;8KD><WU6&UUNC;B8ZD(==2
MM=!%7\*54\>8J,N[J,)>5'_=D:=V/S5_IVUE.X)&L00ZEC NR-[SK%W;]9WI
M,ZXVIY_Y?'8*4.OB/\Q( 6M/3434E')0^,:#[WK5K;7S9.D1+.2)<!@R])Z3
MTB=[;PN1U&47(#BGB/'M4U6'T?\ <2[8:Y>WK.AJ6SE\_$Y*;E-M41U%NLUH
ML^0-24-R)\=PAR3<EH! 4"10"NJ__DIFZ)0!T$$L* 2((./)OQ6-]4PT;>1Q
M(A$?^M+$*_\ ;WM/AF2VENW2+IW05,F6Z*I;3JV;0Y8E3(SI8=:BLL+3*D2$
MU(?6*,@BG,O&W>W<Q<N4MACB,"O$[]B]>Z@)2_VXW,7'[OR4*83W]RW&,N.1
MN9$]$AA13<HC+$I80DED@ -I=56C(\5<3J^=BP$+8.O$5"]2]-7(V;8C,^ 6
MY<?WJ/)_<6^1I.>-8K-3!M652V5.,E+B5*2T_!=4I 4XU2J8H'$'EJX+43H\
MT&@JW>JY,@[9)E-R(RGF>NP7YKT:,W)> YJ:0 E1X?6*U'3RA<9L( EDJ.^9
MQ7EY#<9_>@!O=X?2 ?I\-1 E.+%)P)41"XWJX7!Y*I:0I- . / 5/*JU>)T;
M$0%<%Z17E!9E($5++CTETIZ"4()V%/!=>%!4J'CX:9B[HG9G"4=.)+(Q:XZ'
M[LW$N+QC-(X*!%"#Y* ^5?-*O9I'"BOV9O<:1%!^"/9$S-7>W67)J9*;>D+:
M4%)\U%.<.?$_1352)B(]JS!W8N'$>XI)>FR)"FB]0%\]%39%.J04I0.*CRW^
M/MU, ##)3 -ZG$]F/:O4B$NWJ0AAPPW7AN7O*2DI4-W @?1XZB#K#D.RZGI=
MPL "YYA*.4VNUV*?\M;+HG(F@$D/=)YLI)6M-"76(H( 2#R\=3VDY3(,@!7Z
M(OOHVX1)!D:#$CCR"2&) @/IEJMD9YQ]!0@D[EM*X4^%\?$5_LT7_3W( *7'
M:CK"STE..J>0\VY(*ZLLMJ<-"H4VAM#IY :%;A]5, <^Q&]GI;Q."0<.WO69
MEQ'S"VW@06P=P((((!/OUQ& ,<%G)PJQX)/6^ MY;23L<<<36A\W34H5\.("
MM7+0PXT5.[%>FTI?%5'B#_O:MQ =5)!E] [\F3_H4]4G^MJY?Y']I-0.*O#!
M=MR/'_=[=,IE>].HJ@'XGD5R3Z"?4ZPAP(W=N7DGD. O%H5X_1K/7HST$%L5
M8A4A?(8O>-M,VK%T*D!UM<#^M *15&V/;Z<-OB%*]O+0PO R_<<$1M##N36>
MBX];D_U957B3NX$FIJ3R:'CJ$97Y'Q@ >W-7H@98J0,BR#&H^)0L<5:T6Z0A
MQ#BE-H6L@=1GB"@.I_P)UT@)^9Y@+GCQHO/=KTZYY@E($ESF."B&3:+2N0AZ
MWWETE]*B^T\E2 T7-I0&]\5FNXJ57BKD/T]M<S%I1PX?ZK;]*Z?)XR+_ *,P
MBKENDV5#B6U_,?,'<DBAJ%#=44*=+4+A#AF6WVVUT6Z.[',<4WV+;*NC3CT:
M0F&$UJV[1!/ $_&4^!I^C1K5&%"'*S-V<[H,HG33ZI*B2'[9/#+B@$J=2B0X
M.*7$H<VU!!(X!1/Z=2+2BXQ0JY=,"0>)2UEEIAN06)UND;R]3J)W)Y[5@TJA
M!YHU"U(B32P5&](&KIB] L)(((]M:>/#5Z,PFU#DBB !U5%SI@TX$CSTW'W\
MJZM0(3B0XI;C383$3[1I3IXU*03S*CX).K4)!ETUQ:J0FV7Y/VCJ:^'-(\*^
M)]^J?G05 ;:;8?$(]"0ZAZC+!)30=+RU>))  JH5I3]NF\^ JZ<;:X2P%>T+
MU)1/$G[2WJ@@BN]=!7A[>H>!TW\B!S3G;7 7(+=R/19RFF2D@5( Y'V4X<=<
M""2FEC5.#&'7W+GN0YY:>9CZSX*D^5(_9^G4)AAS5"]2B),6MV3<GZ6]V(HK
M)2IP!(2/+552?'CJ)^U59RTQ;$JQ?9&VK;SBQ-PY"%+^^UI3Q' _9"A)VCAJ
MAO)@0(RI\U@_4EJ5T'5$@Z89C]R=6;28.)]TKO>,FZCB&;A,5%4RDN!#PDH7
M1:6FGUU5MX<N6@\)^9'3;Q$B_O6Y]$6#&W")!<2APYJ"NZ,^Z9-<Q?;@\MF<
MYM3;6BVX08:6UI!5_$HHG=S4GZ-'-C-H".35]ZV/6K1B1PU_10VS;)!3UG04
MJ200"4_33F?'125R(H$(>J7[4X%NEM_ZE$HI7D3QIS\=4+Y84P3.C4ABD@!
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M:VW;I$0NA:D.OCK)D..*".GTB"D-FN[F*<0>VOPE/R@/%6K\^'YK3^D;]J$
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M>J/_ %KW+_(_M-J&8[%6CGVKMR3\*?[T?R:21Q7K225'?Q(.B?0_ZEBO@O\
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M56AV56DT%5#GM_9J$HDXT5&Z"4\\\M3SRHC\:,VAN0AM2J @T&^M: _NZB)
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MNZ6!YS[5$)U: D*!ZB8;"TU*FU)'F9&O/(6Y;?J\KAI+42.]W7DW3K4Q=TG
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MW@MN.W\K<4FW_><IQRU=,-1FFUO(<4VX\L*2MQM**E0%5?HUA]YN)VC+2<2
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M1S*NW=_Q*<N-<[5)2TA=$.28+\8*%"H* >0H'D?'5J%\7 X/B[5KMMU6U<B
M9-/AJJF/,4M,A+K<=72415?%.U->"OX=#6NIQEX:RJC^VW/FL,>].2ULRH<^
MTO)<4EJ6^AXMM[JN!IQ HI2%<."_8=<3>!!!RYHV=J96]0PT\.2/9HS&%Z?Z
M+!;5*9;6XM2Z*24H2.6P%=>F/$:5FX3%WSP0+=6S;F0/DC^*7-H6=QI::/1$
M.-J-:E?4:#85Q%4["DFG'37[9\RF!+K/[^W*5S&A;YJT-UNQD^FZ+;W$-R)-
MKNRY;4Q3B5NH8>^]WBP&2A2VDI"DBN^AV@T]@Z%-Z=(8.LK:G$=5(B&!D![=
MJZKOR=TB0YW#]4$1,A*VH6(NHW;*![J7CMHZ:#>0@I+U.9Y:U.T^VO#ZKT7I
MM;8<8Q/=5=X@<#@:6>!6A0\.-$+5J_'[3$J[N;;7'R;\5\]C\SA.B)]?6.Q9
MDUR*AOMU8RVE&VCI=A68+J20?)M'Z]>;>I 1*0'_ .HO9O\ &>\-B; D'5M\
MAQEQ6D>PXO;;U9651B7ZI4:J4L$T<6FOE4=>1]0NF%XXNX^2]MZIUR["V(@R
M^X91X%*-NQ"VX[+3'CS3)<56@6I1!JE2:>:O[NOJSTWZ>L @Z8@>9+]4_P!@
M03;>IKU[PF4V<_IAP=1+WXQ-]%D1=)+;:("!-6_L*MSB5)86*^1/':#XCGK4
M7?3FWN7K8TQ?5^Z>9"S'JGJ5RYM95E6W=RCG$)"[26%^X6EF&W':^ZGPX5!2
M!4CKK^ML4NM2?K:]Y_QUZ,VERQ RA GR;GZ[G_RKX_\ 6N^F-W,Q/A\R& '_
M ,?/FK%=E\HOGIR[GV;,+9-DVMVWS56ES$75(DPIEGN,61;)2E1YPD,+6AFZ
MO*J:*^R'FX"GG7JWTGMMOMI2C"%(0J)3H]QOBLCTPZ+@)(UF4N_P\TVOQ$NT
MGS.:0>^N$-M1\6[F!V]2+?"<?CJB76:N%=+]UVVD%A/S#]ZX!#JDIV$)"1S^
M=-_8M;3?3LR$0#<N9FC2YK>[7?3MV@'+:078<%KCO-A^]VC+M2([+]E9;?D!
MY2ZE26T(56B'ZDJ>!XTU#:3E;\,JF3^YURN]:N6[@A,R:184BF=<K5=8\*7.
M:DV\IB/,QE?;2"5!UYAORDQ#1/\ 6>/$<-3LFV;L01)R#\CS17;[Z3B(=S7
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MC=!8-)>7=;Z/;L2,(B(GXF8G(J_B;EA/J/Q6.U<82+5>(S2DI?0@,!YQHKV
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MQT_5=TC06$14[TDCJ;:5K_"57QIQU=NSB(R(S ^:LP)<-A^2^;Y^;"9F0_Q
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M(^+7GVZVT=M/S=)=RYI1E\?_ .9KMJW<C=@'U"^#2CZHLZG-VQ/6,2OO>.J
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MHG[FP6UM>E;=V(-U@&!_VGQ[PR85B[HY;'#D&?$NDCJ/@[E/3$)34HH-JF'
M* <ZZ]OZ'ZUEM-IHG+&!'^[I:O8J_4_16ROS$;6F(!J?*!>G:&^."N9W7R1Q
M':3MQ"1U8LB9OG;T2%O;A)8LP$;RI:*PWTCYJ\=W(>/F/J3K8WMB5EP8Z8_K
MU8%T)L?XSVEC<?RA&!N'4[;<1+D9D2.&*C##\ZNV$PA,>GS8BFG5OLR&+F_
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M4!Q*OBY:!7-I*=D$5O#'VS*^?_\ )W1HPA<AL(1\S1;;3'23XR^')6_S3MK
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MB*C>0" 2!4@%7N5XZV,6;Q+/[NW$2/:/DE[$<(R'*(MPF0$(:CV:RAU[<55
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M=TMN,O1(MQ@QK^EP)#:4L,77&G5$!^25[:0CX5U\U]$VW\+K$=M,B4H7F_\
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MXI#I:_#\]5$@)W=+ME-&RM-W4N5I:^*AI3?7EQII%+-?%[MH>;#"4%:E2R'
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M_P# &H7BQ$Q)3M@D:9#!,&C2)4IB(5/R$.*!0379Q2:)!) H2-=B9:09?85
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MMB[:<C&)4D-1X%^<#Z4_>9V%55E0#>RIW42H#RTKJ LM%A@L+O\ ;RM[@B!
M!D,SP3<-\N.,W*,(4U=P^\9")\5V*AG@R%I6I.Y3;)ITQ[]#?(MWH>*+$!LU
M+K/IZQ<V_E;L0:,&#&3.:<E8ONK?+A?^WV+Y>AN6TPU;7H#Q>7QZ\=IIAPMI
M#KC8W+AJ)XI^C4K.QA%@ ,1F:KR_HG1K6UZL8-$VC<88XB3!4MDWEY:BJ.RI
M94=SBU);)_=\2H^S1*&U>+T^*]UZ3TCSP'$3'3@Y&?)$5+2\^3(:JJIH:GVD
M^!'CJN+9$7%5LMKT:U"32C$'_BDO"I4YCJ-MN):8<(-%)0LD)!' K;6H4"O
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MKDA&R!^I_P 58;-^W^'7V[V6X(N\;!KK>,;C7V_P+>>LPF2]/NL5;86U'N:
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MX ]8'EX:?S8D:GJ,5<MSH.2:UQLCCDI#3(-P<;%%MM4)1P'.M!XC]>I"9 ?
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M##90#M6/,$D#FE1YKT>M2TP[EFKKDEL2?HL3$2/)4 LDNJ-$@4Y_J/CH<2]
MA$G&&"5$V"8VIM#[9"'SNCGRUVI-%4\QI\0YTT;Z3L9W[L2Q;5',*C>W$8AH
MXL74E1<,O,>W(?@HJ:AP'<UP4/'^(@\"->O]+Z//^/J:7V'./% KMR4ON^T%
M'KD&7X\"[S6G;G<X*DF_+:&X)ITRX:;22 >H>!5KS/U#LI^49-X@(YCBJ$HW
M(W3;M2,(R! YO0*?L>^Z^YO;7*++;7A%-G8B7.V13]FZ\N-#GH> #R #M><
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M%)N""4?:..44A8X53M"%<*&M==+6J%#@J-^\+E1B>;J.+E:V&9"D-*ZB7SU
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M#V@MVY2 B#(1S/ XKI"]+WJ]R3N\NVX]FSDIN\XE+<;ENMM0FT.1EONN-@=
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MI_\ )W4NI=0GO[)G:V=R[ 1A*%NH%O26($C4Q)Q7*%ZV9B=^.L U#D?(A/\
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MUY]$JT3;@6U.2(R%_'&=H=Y(Z?LUK-GNK<X"7B%^-L@"FEW#9\.2U6WWD[L
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MIYCOWRX8Y<VY]XBSH,:Y1HR&):A+,8%AZ2SMC,OI2%[QO'':GEH-MSMYR(N
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MB\/NW";UW9TA4H/==9+>QA56D-("RVG:%J!HE->%:^!*W$1:(P#?%4[<Y1N
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MDR+1D5MNL20 IIZ2 )2XT]+2JB'%6-CD1M50=8_J5F)V\K[-=BWS ^J[0+R
MKI(5X\9MK_>7LMEOI^5;D.Y5VY*LMLSJG7G$)M\-FY2Y;#;I*Y.WIV1D44T4
MD<R-92&YO;3<QW,3X)DC 9-J'#-6([6%\&!9Z9GN6NR_X]G79&]PI%W3]UNW
MJ<N0VF/YPY%A=:$6U"1';"=ZF$JX#PYZV5B];ZE:$H B48'&F=<"<U./2K=L
M^(18GB58WOQF=FS6T87W'[>6F\8[DMB@_=N1L=&(@/%U<Y#AZ*;C/C_P;P.2
M4'A]&A^VZ38V\9V)QCY4^<J,00W>!FM99ZE>N2C,&6L$C"-:)/\ 3'W/P?",
MEFY%W*L]_N$B9=K%,@EM,=<=3;TV=(NRYC*[U 94$AUHI\C@INY>,-SMH6Y
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M:H*;BJ8_)4AI0#:E43\J4_$FF_GKS[K>[G(3MVP-1C.N8IB%MK%R&VL@3-
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M1EZ+>JU"<TR544$%+E3]:G!^G&FA]O:6C<UU,7Y?@O2>G]1(VXC$AS C \5
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MBJZ?W*^BXJ'#S+@OL26R*@@E!8//AQT!(U6Y1&)I[UC?5M@7(7; %;DKL?\
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MJVZPE$=%H<>(16.(,$)*M[C=#SYA/T:N;*.C;RE"1 .(]@O0]KU6Q$1C<(U
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M:A%5;V_N1DSGW!*N038*G2+(DMQSNJ.?"O&E5N5\OOU5B#B5:EO;DPSENP)
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MFG-CUQA.6BX07*J6\EMQ%:4JVAY)^L#PZFG,*N$8#^6W)->WN)C.KDDFJ':
MU\*I]X'+37(TTL@VY#R(Y_16)M-S>N41F+ :3(5+*4%+@!KO"10\%GB#K,;B
MW&,C.9( 0(2E:F7+,4XY&$W.R17)LBUMM*DJ:4W)1N)9JA:E$52D 5(/+PU1
M&ZA<N .=(^*+[/=F9 !.(R"[9_RFF/FQ7+U 2I4U4Q4RT/40232LW *5!2@
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M846U<:*"4BA2ELGXB?'0G=B5P&,0&*"B$IR\(HG;<\DNSL9VY,*+[*MO%:5
M("$* H%*;-"$Z%PVUG7HE_N#XJ]8B8D# +MG_**Y,N_S?4.P\4E3-K?)2D*X
M$3.WW/<5?O:([2SIEIB[?FB]N30YKN&'-S_=X'6JS4#EV+YH'YN-LK_$/PL)
M^(=KK<0?9_S?C?LU5O$ E^:HW S]I7+[CL2W22\]=7VV$M!0#3B4*WD*2*[G
M%HH=H]AT/NN/#%4;IRBI8S*VV:]XI9\FA7%IV<ZE/WE#0PAU=M5O&U#TE,C<
MLK4Z!YD-_%IA=JWU0;:^?&]HEKD"6&/!U&6(V*XWR_M,6JWS[K/;65_(P(\E
MXB&VX#(F.N1VWE-H9;3N ***X^84KJ4KH$<0 M5LMF9-*0HX."0;_$#EXO*8
MJD!NW+2)"Y*@PI#R6F0ZQTUDE2VW%$'C7R\O9UA>: =W*T5J-JT-/A##-AFZ
M5,)ERX&4V"XQAT[C;Y[+EO6XV76W$44''@R=H2$-+<- 3\//V4KI(B6^TXK@
M-Y;<2.FG]04Y>I//7,ZOEF:=<9?F0H"D7>YL[0S)<>;@I;85"15+*HBV'14N
MJ*MW)-./*SX299Y*4MY:- 8^\*OL*,[*FQ6"@@H\L>$$%1E\O,'.!;'$\ A7
M/74R B6J3F^";^7;,@7BPYA2Y=KI97G[A<+:VF MRW)@N-F4B3U-KKSF_<&X
M]*]>FVAY<^/"!L%F. K@O/;=_<DQ$Q)GXFB8&.1'YURMORJ'G5M3[>8Z68SC
M_3E-24%I)V'A\ZZ  .!&WAN\(WI1C;.K%CG[8(AJ<5S&?-6AP#MQD/>;/V+:
M^PF3.F%FV?<SKBD*M[+#,5@W!QU:2H@F.GR%I%.O\7#S![F\%B&B!J:N^/+\
MWR3V[-D!AI8\@FEWH@QQF^<6FPRVXENQIQAAOH/)4S=4+E-H4\V&EMMQ]J'Z
M[1U:[*5X\+.RA&W;@34S)/93#G@H2O>%V=U$^+8*SE][MEAQZ7\Q>Y@8=<;>
MB]..@/J:ZRGI/74EM,52C51'$5/"FC$C(6R3@RGMM4KK' R'S5QO3-C_ &U[
M7]Y<=&<2HN=3[K+=M*\>LJ(TM5O<ZS3Q=6_'=NRE%*8.TI+".+O/AYL_OS.Z
M" &A$@GW9>];WIFW$K8+.X.6%4C>KF6U@69W'M<RW]T0[(MJ=<FX:OEULR#(
M=:3&=+262A1,)OS*XD*I3VT>B;74]PAYZB _8/Q0SJ.Q\L4&0_3S5!G)RWW)
MSS*R6)<J0\QN67%I2X\XL$N<UDA8X\*ZW5BRT #B 'IR6:G: GWG)8**<;VN
M+*N9\?"H]IU*Y; E^2LV2P8>U5X9#;<E;12DAP>512*#@>(3Q!Y>T:Z/FNGG
M.G#<7U)MULBLJ0L-"5UP@!O>%IC=,+"2KX=JN?MU$5)2;4FX'DLJJE(;<X^8
M&I]O, '4M+XI>3J%?DO$Q]H/;VT.$^%4*',GZU#[=2C@K2_&'%H+CCE'$N;*
M(W4H 55!)W5KN]@TLF"=P$>>;:6P'FT!!X\*!7$5^L FM::8$BB1+U"0R\8T
MEUUH5#O (W<$U!'.AJ>/L&KD@ZK>4<PGCB5]EV!QUZ,IM3,OI?/M+(3U$I+G
M3.X[@ V'5^!K7PU1W !^*A.T2:CX)\7:QMW:VJN]HZ,Z6^O<XQ'2@*:H%I(^
MR+JE$% ^J.>ANK3-I8)_*/!-]G,\ABPV[3%N"HR(Z]QC=%QHN) 3_P"=AY.T
MJV4^$\O?J'\6V/'(.^?Y*T[X?)6>[;V3#\_Q"Z7\28MJS7M]"C96[8W&&+G(
MS1JT1Y=UEV_Y]3L*1;42%6GI%WH3 GYK<4';M77(\J35TGN4LE7CNXINZY=>
M[Z8*;9;[_CK"X<!D!YFS3+>Q9;8Z&Y"&8S<IQ]R(ZX:-LE)<*>-"HW-O?B81
M$0#(3P?$,5&0XTHH@2X4FO$_I_5X>&BVE5Q1&4.I<"@H;2*;5$UYUKX#V:C(
M$*);-?J0D'SKZ@]A_P!\G42^29XK*-K9A= (;$6.6%[DAPOJ(>'4!.TMD=4<
M/-\//CPEVJT$H6"[-6:ZV>9<(XO$6WW47%R"X]\NB0V)<>0Y%ZBVI:6DK2UL
MW;%<Z[>%-(AQ2BNV2S9IR7F18\CR*[WZ%':QUBZ1V6F[:E;<Q$13,>%'4X)"
M6[>ETN*BE9 :13?2II4Q<@ (G:$2=0-63)<;5)=<?:8*D%(&P+-$\_,/)0\_
M8-5HD1:)-4-G6N2(/)2V@-THM/4W\:\Z4%/"E#].KELX'L5235 1;Q/^[P&K
M054XE&$FGAJMI2S=&$.U2?+R '/V\/9[M,0R1K1!M?%7#F5#G_O:;%,S57T!
M/R8S.SLIZI/-6O=:X>%*;<1[2J]IYTU9?Q=RN"J[>@:@'V@']>F27[I)*AWX
ME/2=]"/J82\H-A?;J6-YHH-?\Y6LUXE.X</:-<;C"V04H-(A^/T7Q[L^R1AF
MVVRPL/HEQT0HW7+:PSN6AAA+*EH27N1W$5/MT-G%R^&*[7K6JWW')-7";Y)M
MU_@SF7EB7&2L17@ZM*F:N(4 *5)I2G C56Z'B0,%ENH;/5$C)QER5N?6Q:VE
M=PTWJ$A"X5ZLL6X0E-)26W$FY79!2VZBJ'*)CD[A^KAJMM2#$QR=8KTIN 1*
M((?63CA0!5WAVZVGM]<5R5AF5(@B2PE2 A6X17W'V$E2DJ<&Y:4D@?H\-<YR
M(W#"H$LNU>M[:\VW8'] ^25L82G'[/=E1RCJWO'WH[:]H08:OFX)ZHH29%?E
MN54?%SX<6D=4P"' *SW4KW]QOZA_VJ"KT]\PZI1<WE033_C$^TZ*;2LA[9(B
M+6G))=IQJ;<IBNBUN:ZS#KT@A1^60EQ2AY:?:=1.[ZR:;?'P-&EK_E^BEH/#
MX*2[8FW+OL1AY0(B-%M2=J2'5 M5)%:(YGVZ ;LR#D<1\E V2!3Y)>[@*A+L
M5JBQBV3(:2]U4%/DHXH[=B?BX,\ZCGKET_4+AU8N?DJ%FVTGQ_T5>-ZT*4$.
MFJ'G6U 5X['-H/!7#QX>&M9:/@!Y?1%;=NG<%[CNE$A2UCJ42>!-*DE)YD*X
MZK7ZTYJS&T]%*N09-:KA:8]L@1F(Q9V[GP\V\X[185PVLM*14)I\1U5C:(+L
MMSNI[<VR 8.PX<5'C+#"I 3T#155./%TT\AX<"CD:GQUU,#[!8[?BI,,'E@G
M,PY&EPEI0R 633;UPHN<17_!BG!7OUQG:D'I\%G+@NB=-6/-.;"+HJQ7B/)B
M.%MI;R4KMI11)2JJ=O7W43P5_B_#0/>6([FR83^YL5SWURYI+F5!Q*VVX=8K
M!A?9J^]S7X89O%^MC;=M0A],1UNL28MYYN8&BXO8ZRBH2@5)Y\-86=N4KPME
MR!(@4YH+T[J&O=B$I!M8'W<UJAS>_P F]3_ZPI9?:D..&6Z\I]3P*7:!04$D
M;0Y3XCRUL-IMHVA3 C!NQ>U=!VUJ_MHS.E]!R!S*C]"1U6&U2-R72C>=M BI
MH:^<A5/T:*1(J6P5B6W(#.[\DXVXEC8,E+RFI#R4M%MPI;0?,@J6 "IPBAIQ
MKJS:E(@' (=>VL0]..2:%W<B[PDE(1N %2D\#[_'1&&%4+O60"?P1EAIB,HN
MQKLEI-/X(9''ARW"4GP/LU%\B%58Y%$GI,=Q;R%R ''%)HJ@\Y ()(WUYGWZ
M<!,[XI6G79R+:4,(D?*BH^U2:E52? +;IN'#GIA$$U3D^&J0K:^F>B2WN=9^
M722%*<4Z'*!1^$]/;\'M//3&PQ=J=BH^2U?HD]Z4J2M+2&@"SU$%97M^L #M
MV\:TKSU(6=./R2H.U8 A];NQUQ) X\%\J"M.?LTC  ?DEYIB0'^*7K8& A[<
MM*NIQ2#3R5!]Y)I7W:JSMDL4?Z=> F _%.IB]PX\ 0I+*'-BTEMPK34I&[<G
M:4*I\0\=<?XY,M0^2TTMS&-JIR2-*NMJ5*$EII+.ULHV H5Q((W;@A%#QY4U
MT%B0#<UE]_N(FX2,'^B0V[C!+726KKGEO)IQX>'GIR]NK9LU<#X(9;,2O+DB
M,KIH0FB>)YT\1[N//3^6?8*_:,: X)TP%69;&Q]A!50C<7$<^=:%%?'VZYFW
M)_R1: @8-R1G%I#<*\-EBK:4R6DATN%0!9<*DKI0<3]/#VZ';H.")8Z2O.NM
MV(>7*)8C3P6ZGONNQ9QZ5^U&0/4-TL-I:AIE,/I4IE+$ ,K2ZI 2JLE4)*A4
MC9MIYN>L/"<H;MHC&1'Q7E73YPL=2 CI<W"&I^Y4IPN2B_V!UEFP6VZ+L$AZ
M2?FUQW5R@MCH;=SD)Y3!;,O=7SUVTH*U!+RY6[K%PX[%[OZ<OVXV!$L^@YC]
MRJ;F#;HNSZI;"(+3>X]% "@ZGJ+J H)9">5.1T=A=. <GM1"]8L:2V@=P7BW
MKQ-"[>MN( IQ*W)9*D+W.,K;2D*^R%-P4KGIS=N5U'#F@6XLXZ>>258Z8$R[
M.76W16(+$1"@6U.-N!\I17X@VR$$[O8KEI"X68XODA4[5YPPDS\"HZE7^?=K
MG(F26$Q6'5$M)!W(;&Y:QQZ;25_$!R&KVZVXA%QBBPV;9,?^%/N%>GIN/7*V
M%M&YID/,O((!6A#;H4G8$UH2L<=QIH*;0%X7#B:)_)$#A\&7;+^3TA.V_*/4
MK&</6"\>>E]0@H"*W#MPULVG?7E6M1]&C.SMUU 9?52')=VHYN?[O Z,9ISE
MV+YH?YN-+O\ ZPO#7&^3?;"TA9]F^!CE/ _NG56\Q)':J5UG+\URRNH V-@F
MKP&ZA]HXZH'%P*JB<U(6%3&9:;QCZMRD9&CKV]*J;6EQ0W+6 =Q4D=.WG@*Z
MIWI2#$4:A5_9;&$[D:#4'S/!*/;7/KOVLSR1.MS3#I4AZPR@]'BOU2M;D)Q2
M1)9="20I7$;3^G2D\K;C[L5I8[>-BV7;[1F<@F[E5I3>K_<5QH+CB'7EW2\=
M%:VPCYG8[2C;J.%)2>'E T]NZ0 2:X#M6?W^]E;D0Y%1D."<';G#+W?LDCN,
M,-;+(ER-( *@2^XP^@;:-&HK*1SII[LO 1'$K.W>I:(TD7EA0(YF_;J]6#(Y
M8R!($20_*GD]1P*#,AXOQT ]-HT0A=.?Z]-"0,:??[.FAU.4H,"=5!@$Z\-P
MF)"Q6Y9?=&TJF,K<;LP"WB=J77$IJDEML\(YY[M<[DGEHB5"?5)@L"=(' *O
M\IXLQF"5+^W("AP-1^D^[1F[:TAJ8(@=N!56I]&^ I[G]Z\(PA$R/$-WRW#6
MTID[@)"W+XPRE"5-LOK W/4-*?%XZSO421;,AEJ56^3; .55;_+^V.5>F^1E
M<R*"_GF5/Y!'QA^,XXH1VX5\7%;6$R&66T41;4CRM+/'CS.LW<O1NWHV[Q$;
M,:/R-3\54&\\35 ?@%2:\X&Q9H$Z3F-U>&0WY*9/22XLEP)<00#7Y?ANC+Y#
MPT?V]_S9B-F)\J!^GYJ$]Q(R MB@&"AJ)E4G'7EHL+2XDE<@V=^XM$&0AMUP
MQ&W6E.%S8I *E<-M33]!DPU0)/[2?@B_3XF5R,I9RC3@K8>CW%'K9D3??*]2
M$1L1[;7M<W(+K=2J0X^X\MUW:EIYN3&4*.*X*6@ )T#ZE.Y<F(09RU!V>Q7J
M'1K4/(!.49<?W*".]V?Y#WFSG+<NBQU39%^D-S+BMUJ.EQ##+Z9"PA+*%-I&
MU!Y4YZZ]*L0L:8WBTS(D=NEE'JMD&W*40,!F>*KY)>CO2UJAH+49J+#C%I5
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MW[NDG7Y0I_K#:NFX"!Q]_"OM^MI*!+T2E*MZH[$.:Y+3)<GAQ2D)*3T.D&E
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MW+5IC+@G'P2]*_*F?B@NMA"<)QJH%./<7M"/;_\ 7*&F)3AN2:G^R;_BG_\
MTC8U_P#9%[/_ /:;J6H)F*SL_E-_Q2P%;\'QH'A3_K%[0>__ .N8=,9<$F(6
M?_9./Q2!Q_L1C7#_ .N+V@_[2],Y27M'Y4/\4P+2LX+C(%:\.X_9_E_]DT\M
M57F3A[>]/I?-/>T_E:/Q2;?"EQO[$8V%2.GQ_P XO:(GR(=3S3W+H/CU'3(U
MX)-DFR_^5/\ Q3'7BY_8C&N==RNXG:*@]Y'^<P*-/=QT[%F;Y)"-0E^!^5A_
M$F9+$F\8_AJT-K!6E&5X KAY:U">X3BN>A>YA<@7A$U')<.M6KDH2-MY2TC
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M220TDD-))#220TDD-))#4?<DAI>Y)?GZM+W)+'_[EKIEFH^Y?HY_X/GX<_\
CNZAGDG"_5_\  _X?Z=.%(=Z]Z29#220TDD-))#220TDE_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>tm2226999d1-ph_prevents4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-ph_prevents4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#K *2 P$1  (1 0,1 ?_$ 1$    %!0$!
M       $!08' @,("0H!"P$  @(# 0$!              4!!@($!P,("1
M 0,# @0#!00$!0H+#@(K 0(#!!$%!@ 2(3$3!T$4"%$B,A4)84(C"G&!D5*A
M,R06%['!T6)#4S0EE1CA<H*2E#765U@9&O"RTI-$5-1%M=4F)S<YHL)C<].T
M57561V=WURCQXJ.S9'1EI39&=K:#A*2%Q6:&EJ;&E[=(P^/$."EX$0 ! P($
M P0'!08$! ,&  \! !$"(0,Q01($46$%<2(3!H&1H;'!,D+PT5(4!^%B<K(C
M%?&"DC.B0U,6TG,(8X.3H[,D%\+BTS1$5#7C=)0EI-48_]H # ,!  (1 Q$
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M0T(0T(0T(0T(0T(0T(0T(2(M"9*9;3B>H/-(4V*>[1I3#H4">' IK^K6= W
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MY!;6>T/:MOM[A]MMDC(L@R>_SG%KR3(\H?7&NN3W1#TM*[@]9H$EZPXXI:>
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M98C@_9#.,\]>F?\ =+MA=>TO;VZ?T$3.Q7ISQZQ6V'>\3L\UJ,]FN,=N;+W
M+*(CO1<5\P6I*6]R25$DY9*!7'#VK6#^:@P3/LP]"W;[*,3A7'(\>PGU'8GF
M.01;.1;+1&L%G[8=Z,>FQKA>;;Y&_.MJN=S94I"E*1O\?=1H+AQE[O3BI[K
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M#=J[K8C <SJ/VF[VWMJ_]R>Q$6]XF>U5[N[D(-RY5VC?S0<N;CKLA3REE-U
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MN:9<)<E9,A)#J:@(*LB&_;XTU+( !. 'H5QSZ_?U04)K_G#7PUX?X=DGL_\
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M0:/[=;PT#_2$>/(!W/K3BB_6T^IT[%2[;O5)W(O#G&J#GF;L'@5 U(RB5Q!
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MU.>CSL#Z,<![83;+<O3\]\Q3D-[NML9*TWE>;7N8'IK\J!;7U-3NX01^"E-
MW0U(4=8Q(C*4WJ2'X4#>Y,(!BV-#[UE98OKDVV!*Q7U!]S>R-XE^IC"NR#W8
M6#EL2Z6^7VEAVA4C.9;64WC#8ESN'<6_9(\_W/N#"7;;=4QF>G$<<CAMF2IU
M&"7HH(%:5'V+\:<%GEV=[R=E)GI>]*D?NOWY[Y]K>\OJ S3+L_QW(NUGELEP
MZT/=^IG;F^72_7R'8>UO<>YX<W>)5[C2&8EYFQ)K*&G4/)+C+W3'!H5& [I(
M^U%K;[L=]>PGHG[<^MWT0XQ([I^HRR=[Y<#(I?=JV7[&+1D3K5[LEFOM]0MV
M]XI88;2HF07U<;:Y;=WX ^( K5#C"GM61-,P1QPXJ$?0']4?MEZ0?2EW([!9
M#V;O.7Y1W,[YXSWFN'<9E7RN7E6(V&Y]G)^)X2Z]<51HT.1;LV[5O3G$OLMK
MZ4OAM)2H&"UY7 :!B5F'D_UN.U&3>H[U$^H.\]A.X\&^^HSLZSV(N^/0\FQ6
MYVFQ-3L=S3$Y)A"VMW!Z(Z[_ #R6'3(EOH/120D!*MTN,NQ:\W-?MS]"Q[RO
MZK78]W%_13 NG9[N5&3Z4.[.0Y#%2;E:5*6QD=\[LY,5.!%K=+Z K-Z?@A)Y
M5X@UC%>(MR))JS4_8IKQ+ZIG9+/^Y7KOFVG"NXDQSULN7%N\VJ;=;/%CV-RS
MP['D;:K,9=GA[%K7C*$CK.2ZU('&E%]D&W6>!RR6MYFD8N(X:(]OSEO:M<7K
MX];N!>IWM?Z,^T=C[=9%BLSTB]H/Z 9MYR.1&ES,EBX7A_:O +4L^2:9;2NW
MH[>NJ6L--M.&35L4% QMR$@!3 !9^7I7)2)NOK:UF.?V.:UHV5VY1+B7+2X&
MDJK1)\![A/WT?>&O;\M.X' /'$+#S00YX^)'^0K)+O!F+U^Q_#[NS"Z%VO>,
MM,WT%*@$,JF77J%.Y9/PJ/WEZ7>!*-2].85>Z4YNQ!Q)/\JQ9E,-1V&+5"<Z
MEKM\**[$X$'K2V098-4H!XQT<DC]>O>$=-2NC['_ &^>D>Y*41P-PP#X5'+^
MV5KT<C!3N#[Q[E8MBY<OK(9 V1J[^0/!()YJ'@=: <FJ49U4ZX!?85G[7]WW
MW(ZUKNW\U,?4OIK*0]=6LM@MI&U/-2W33F-#H=0$MN:W"0S;WT,*CS?+J2KA
MM\RF1+H1N3SK74ODIH_-'F95N83MN*J/$T3P5[!3DA?WJ^.MVJ>,B,E06H*1
MQ9)5TO\ 2@C]'W2/#4%\U(1;0A*0D)BV<0B>*DL$#C_?V_U?<U.*7/1?3._+
M#$?\5MAB?%/<K/R?]5*A?V-&2R;W+H>T(5L<S^G^L-:8+D,LEJ)^N'*:B?31
M]5#CK0>_\5O<%*6MJBIRN"Y0"VG;R*^7'5LZ#9E>W]F XQ]X5?ZP8C;R?YG+
M+YB?:9=];6ZFUP5V02RDI<D !*DD(J!1U)]Y0W:^B_+W2;D[$6!^668_&N?;
MH-+5D0HWR&4NUWJ9;[31;+B#N]M#U ?%OP0/#56ZQ?B;$JU8<?Q*Q=-_W(OQ
M/\J8*GF&&76C'4[*??4MSD=BFUJ/AX$K/B>6N1]7N"5T]LU=;'^T/X1[DI,Q
MUWQUA?7$9$5-#4A--M$_>K7GI)"O:M#=CO'M'N5JYSXLB.%V5@M- I'O)4D#
MWD[J[@@_"=:MZ!9JIQ*1% U0JM\J=;$B,Z'A%0?/)% 6@ZD;."BFM>DOE7EJ
M=E:/C!_Q#WH$Y-5F1Z ^[&ACR)_&%:UISJHGQ3X_;KHW3+?<&.!]ZGQ"8X!G
M5DW%@VIF, :QU)41M5P *.?#[-52'39VRY$O6$L<^I7(L./<6)K_ ! =0P >
M">*4OUIN3_;:86CX#/DWL[%(<XXJXW $&+45V[CQ-#P)4? #6['J,(TD0_84
M!Q3-%VTVF^2'Y<R.I+[Z=K=$D5H"H<2A5.*CXZP_.6QF/45J?D+CX%^T)9MY
MFVF*[!5$87$50--OK0E;C8"A1L>8;J=A%>!YC1^=M\1ZBC\C<S!]811=YG6]
MPKM3KUC=-:N(;6I!Y$T*$KYD \_#4C>P%7]A1^1GP/K";R%0I@ZCA *>/LY<
M?$'VZKOYN.;>HJV^( KT>\(CJ7%92"AW:E1(/ )W)3QJ *A1T?FQQ'J*-8Q=
M7GF6_P"-21N7QH*>S_0U'YJ'I["I\4'L5A$-$A/4)X@<!2G+CXC[=(^F6I0N
MA^)_E5=/+!5PJ&8A,I*@A@+0RH#@0\0E7@KP0GV:OM@CP!']T>Y85)?)*]GB
MR+9+DIA E4HJ4D$IXA10>%"CQTFW]@W)%L''#@IP#494.OR[NDJ=*4T^Q2?^
M>4?;K2/3[HR+=H64+@Q!2$_#>2K:OB$$A) '@>->/V#6E=VLP7(]H3&Q,4+U
MHB)!;J.'CP(/M_3K3E9(.%>T)C":OOI]Y->/$>S6N(E*W"NC@4?:AS_TO]G6
M)@^*@EQ1=D?Y0X'^E_U([17_ ,7%P]G_ +5';+[=>D(D8X,I!JN\C6^I5E\T
M9=/@&G"?U)-- Q1V+2K^8!C1)7TPN^3<FM/+QE^Z.-?E5[ ^ZKA[VI)4-3DO
MFJIMTYS&UQ,AO6!LR$D*VP[)DJ_A4R11*+A+/Q(.L&66IC1,65?HR&K?:G,D
MA]"W>8;'R>SWVWA"7/+M_P H-T8?#_!CW.G3;0[N:=3DCQ"^2(P]TF?NLF=2
M&'.)*%)6D4]VM=\%O[U/'0IUGDB4A_()4K8Q(;%V(X D!-/>)XET#EN^]K?2
MYFJO;2]DMEND=V[.-NJDW>SF7LHH(2U,4>27ETJ'5>WEK'!33)2-DMQL]YL,
M=M@[GQ?6BL!*A[PB7%/WFQ[1XZ,E#UJD2S0\9MX0WDUH-F=+@(^3W6T2VN(2
M 5*B.79(JH$'B.'[=6KH,]%V).&J7\JXO>VTBX8D]H4\PVL3%JBMVBXR(Y?:
M+S9$B-*<D+C(;6T'TQ8I+&TN<G C=N-.1ITK\[ [32X_V^!_"JQONGS8D@L#
M+,)%Q[YU;LD5GAC1IIM ++!D.-IW)260"4&4RZ>#'A37,^MS$[\IG'4/Y57-
M[L;D[8M6@?F!Q' \>U+&==NK1?+R,FQ]#DWS[MJN#:PIH -R+JB)N"5M,KH
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M7M'IMLCY1ZY*759#'M%ZA6E&&24V;+(;LA.3/N...L.MM3'$E:W)[JDU5;T
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M;:?>C=#Q,8:@X[#Q&:<S^(S6TV&%"C-HM5VAIGHNIW=1P]-+M2X4+<!"4I/
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M W8EO(D69RGI_P#AEN.?%8G)=F0)RG69CR8T^0Y?H2FD%8;D7EWSTT.[6U%
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MW/5YYC&2VVQ8W<H]K:0P]=&'XJ7XUJML63.+GFHC"^E*M[J%(VCWEFJ@008
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M81K9/^1W:9/79FOY+;+=<;<\VFWV]6YE4(3)+RD.(+("-P;0/';X:3'<W(O
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MKAF*N/P\BKATKR_^8T0G_3M")[P(?YO3[D3MGJF[]1I(D7FZQ7U> )6JH((
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M>\\_(><;N348,3X^X.+!2KBH>\./MKL08WG;O:OBMCJ_1 -C*(%V(TSJ91(
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MU\D=<LBY=D=W=F80+QM7'<W&9Q(U&/93FLIHF=X+>4F0B]62KJ$(><9O%O0
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MYN!HE:B;YA(@/)J3 >GVJF5CMHR[#K=W$RZ2]%+5KB068RBA*EMF[W&%95E
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MCO-P"^C#^5]BR+;],+'+:XXEUAGNKW!F,K%">I<+@PY(2JAH-A;3PH#^G4C
MJV]+)T&!- (_%=&>L$W13[B_],/ZB=0%G9Q]*U*?6I=GL_3U]1ZK8T7ICW:C
MN7#:; W%1EX-?VA3WD<:D>.F>W_VQZ%S[SN"=G)N,E\N?)V,@ES)4=0#:KA,
MM,Q\**04?+[(BV*YO</>_23IA;PYJJ^5:]GAR]DP$DWB1$9M#CUY8-ZFXTZB
M%$7'2I=6GG&65'W0NNT3EDT(H-,(;VV#4CU%.[.QN$L' [0FF+Q=F9<:);)+
MEKM<UEF4ZT&UDN&8E#BFU;00GHA9%" ?>\=-=MOX1S&613:SL9Z0[O3,)NWV
MQOO2^M"#$Z0L@K+RVT$DI%3[[K'B!IQ:ZI;;&.'"2WK?3Y4?4W:$Y,?S69:3
M&AB-Y;RZ@HJ6A?N\*5)"P*<-=)V?5K8D"#'$Y2X+PE'.H*=66=P[BAABY,/-
MR>JS)"]J'5!DA#1 4$N C=N-/T:>3ZO'P@(F/R\)<%JF%DF7B$ZF+4_8FWC/
M=>],QY3#\MJ,W(*B!L>!-5CVNJ'\&J]NNKVM33D'<92X);N81-PBT'C3#L"?
M.9/J=@J\Q=F)(.RJ6U5K^*GA][QUI;R_$VR"<A[UX6"Y!R_8HFG-6Y4%OHQW
M'I!6C8:5&^J:'X .*OMUS7K=P'4:-_45DV+!N/=5MR'<52()E1*,$#;\-0*<
M/[HKP^S7,MZ'F1S'N5GL?+S;XH[:V(JY\XF,H+V*YIY^X?LTKA;*\77MJ2V7
M)Y6RIEQAQ/D]PX.DK>W4I7@DH1[.>F-F!]RA\DKH<>EGIW0!+*:[2 :^P>+G
M@3X:90MT0QP"(K-O7]\5/+W5?]#KWGNXW P;U%;8VP%0_L29)BM*<9Z 44%2
MNH4@  ;D;2:CC45UKZR[H.W#9^Q7GVO+(26:E5.7 \ZGPI[-;$-U&W\Q]Z@[
M89O[%:7R3_I1_7TI*]#@BL9U^.XN6S3:Q4.5_MB2C[P/W#H6+)]6RXQ+A:W8
M<Y6TOE1 H>)W* H2%CD=#*<$T[A;I4((Z=L6T@*!*O=H.-/!>F.P^<'F?<M(
ME@G6M<Q=ABLQI*6 Z_#$I"N!(JD) J1RW*]NK+3PO\OP6.&"MV-FUVJX7IZ6
MT9#BXK94I(W5);A'[J3X#5:Z@.^>T>Y9<#DF3J$P1R(]T-[@XD%%![?B)U!0
MNQ7\I!<7)OJ&[X)6F@1V'RRE 1R[F]I!XG[=>-ZD&'%&:[T=:ZA6GDA3:P?W
M%G]@T(;-:7OK^-I7],/OH@\C'CU/C_M7>_[.A\E'W+Y7LJW388HI/&OB4^/#
MP4.&G$.FS? ^L)WN.JV@#48<)<46A0Y[C_\ A(C!D&Y(35(+SEL/F&D\S6BC
M2G ^]IE9Z?(8B3TS"K.^ZI;D36/U923EEQ7KJJVY$XA3\JZ%5MFI2!1MF.7(
MZ5D&JA5-N1S)''3*WL+F#'UA5V_U* )+A^P\$K2%VV0BMKCD)Y&J5)Y&I^)+
M?AKUGLIU#'UA.#?C*M'["DV&RMJ8F2A@@,)6'VJ?Q_4(* GCQIL5^W2R_LI$
M8'/,+QE,&H96D7.XLR9<6VI%E<D*W=5^J0KW45H>H!Q)K^K2V>PD3@7[0O(O
M@4_863HN,(HOL SEJ- \A*B *)(^\YR5QUD2ZU+\93!9\.7%*4.=:K8B26K'
M'NYD6&^2(H?6A!MKL*$'&TI"GHU3)4\ >?\ %>'CYR@9U2>[:E"3D',XA&[#
M)OJ+5>#Y=-L1/Q>X9H&V?Q +C9+O QN'''3??_C(,U:Z?$:<P.&O$[>1-06]
M"P%X6XDD@,.![4E=LI!>NRKG=8+*?E./7BWN*"T40U\HNQAE7X[A_$G30FHX
M5/ASUIQLZ2YQ5BV%X2+%OF/N39:@-R8T-^8IJ"8\.-<6$)6@EURY,HD/I("G
M?XI3*1X<_'P]8]U6$G^D>)C\$2F78N5CH8,E*2 % 'C1-.9('CKWC< &*J/4
MK1E,XXCW*1,*R.[8O;8M^LAC6A$3)[D^ZR@[UANX62#:]VUJ05'=UMOV4UMS
M[HIAC\%\_=1V9O6S";F6@ 5& DZFRV8)>.[S$W)\?F%Q3#,^WYEYI;,7<;HA
M;<9$9,PQ%O*68TL'9UJ<*TJ-RO=6Q<[ST[P(]RIT;>XVMXVHVR9QN1G"3QH0
M23GF6]2:>>3[/;DVC"K)"ND6R6>X1;C?I;45]?\ *(T&3%>6E:(90I'5N!Y(
M5^G2^Y$1$81< 'X+:V&QW%WQ=W>[UV<9!B1CJ'P"<V*6W*+5=6[FF[6W$K&"
MM3SKLAE4(I4TML[<::ENY2LJW)2"&R :$\$JTTW,3)]%!2@PQYKRW?0KGY=Y
MPE.9&,I0,Q7B&'LXJ7VLJPZ)=H3=@N#MQN-U:6JYWKHR(\%4MM;*.I!M\F'&
MN4!I:W5$ID[EJH*'@:X;/:S.X&D5,@34*E[WIVXLV2;@D(0)&,:^KL3;N]M#
M]\6_<HSF4(6$]-,<I5M44^X2#Q]PZOO3MJ81$KD=7=-*<5J6MS.%@V]M,6)Y
MF3U5Z[7',<4LL_;<W,>MDYG8Z@(4LJ;-4F@:+Q-$N4Y'42VU^W"KQCVA:W0+
M6RWF^CHAXE\$OD#3FWO4/X?*P%-QE72XYO*4H*6JY..,24.-O+<*T".E5G"W
M 4)57:'.(%2*\=*5C$@O+-=CGTS=WMJ+9LF,-($1$QX9U*=&-/=NLIODNWVS
M-I<A3;;KS2+E'E1FU*92ET!*Y-F@H-5"@X\]+;FTA.1+DE^2K/4>@]6M2$K=
M@1TD5U1=O]7P3>E.7*]7+HRD1ELRF5W671Q VO(2Y)*#ND'FIGE0G47;<YC2
M1W?1]ZSO6(V;1N@R%V@'"M.'-/#!\AQ:&FY.Y#:E.P;BA5M6R\TZ]9E38REQ
M84B>W';5(*FV4+VD.(&U2OLHLG;=R0P)(2F[L]P+D8VY:I1:0P>M2V&92Q-D
M7"\2;5CMPC0[].M?4>L]PDOLC%;;;W!)6I@H,MF2AW;)<":R![Z^1Y:TIVI/
M5M2L?3>G7!<C*WK-MP"'CQ!]ZZ^_RQMKM%KP3U&-66VQ8<=62XZ%=!:7*@N3
MD\=CJJ5'#B.&O*!+/V+Z>Z!'3K89A=:VS^U'^U^S_P"%_1J?_$KK_P#FUS"_
MF>+??KMZ.,#M&-%UAZX=R&6%R8T]T.,,)G8RZ\\6F$H4M#;"%'XDB@/$:23(
MT!L'^"KGG2-J]L&N:2.[PRD#@N'G.K4UB7;O&L8M.8S;KE4!J[2HMVLUP>3>
M7;@&;8J39(UJA7&5.>=<E-I:*DOE6ZGX=2!KR->Q47H?3K/CSNQ$0\XGY12I
M.*C'M+98&;9581E+5XMN1P)KKN3M^;E6',KM;4NN-LQ),U:$7EB.ZR[%6-Z7
M4D(;(!]T@PQJ/6F?6IPV\)6AI,#(#( $Q=QP.27L_P NG9GD.57J:G(S<[9E
MC[=G5>+5<;C<KI:$Q+8NTV5JQ3"W)@)M%YDO3BZE;H<!4WTT4+FFG3=K:C,,
M( .?I'!5B)VNVD#(1,R'I( 1R((8L2 S4(<&JC;%['?KUG]FNTV/MN\7+K-D
MUR:M\54R2)EMO3=SNJ+S9F0A[&/YROI4$)>*RC8X*.])6KUM[YMV1&) E&,7
M:CL/8Z9V.H685 /@W'$09X'#%N]H<.&#\G1JZQKEC=\R"#+MD]FUW6YN7!^2
MT9#*=[J=_2+ 8"1M#Q%=_';RX\/#<]7NVY'299?6>'8MB,XWXZ34>NN">/9>
MTKN5^NEXL3^16:)9,8OJ%1YZK@LRA-LEW@I7UG%Q>D0J:.&U?P<^/#4GUX3#
M"7_S%C9M2M3+C"OI-&4*6ZW6ZY3HN-OW"Y2[L^\PT'I1?N3:'Y;B6G=K3KYZ
M"8[I%?>_$%/AII;?WIONU17-\58MCN9 ")>K#'T8*36,=C8SBS]US1QB;;V6
M9SK=G"$0E$Q;@[%;!D+7( +[*%.?Q)V[J<:5*V5K67&*LUBUX\1)L?3FR8]V
MSV^9'>6LBDW1N%'L3C=DCVN)$Z5ID16%*EMH5 ;D-1$$/7112-BMJD@\P-63
M8[_P)"K,3]39,J1;Z1*V=1B6-?D:JMY1B#LRW1LXLUB5;C?W,IESW'Y*EPW[
MC!,22E]@JB,-0Q<9$Y:B!N*13BJFK!_?(QM&,9#Y?^IC1-;5K08^)2,0!\N
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M9&^M-C'_ %!+EM0RNWNO[0?, !FO!8V!?O)2?>43O' 4XZLG]FN>%J:7RO\
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M\,N*CB\8%W$MC[<-:GX=QCE)L5YL3D>;B:HQ15(Z,9ZY34$;QNW2$>^A7 <
M  )WL_-NTLM'5$!CC&9./)-%%ENL1AF+:;%>;]Y<A1D7F*N.\@\*G\5FU T
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M2)K["U$*36@2*;N/,:$:2$W[SE=]EW@QI[CMICI"=B6&W'*>XV!Q097@2=
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MA+)T>DR8%NP:)BMR=_G1$M^0*MS!N1Z/X*X+EZZ@4XB"A73D.D"@^RA.M">
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MS DO;<]X4X?%:BOK3J5$^G?ZC[@N+YN/%[=YN[*AJ<Z")<8X=D2WHBG2V\E
MD-ME&XH52M=IY::6KITMA@J/YFL7)["9@^JOH<+YD]@SUNVY!B]FB6MO&['
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MTFZ;!+7#MX3&D T-V4?J;@4A=_L>;Q>1C<*-;[;*<JJYL-K4ZV%I)MTAYO\
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MOMB@39R\>DV2$(QC04./-%:W+B@!Q;+$]'%3]/C'+58@[TP3'I4OZC,Y)/\
M*L;G;4_'B/)<N+3+,V2]+B/LE*GIC:W"[OD(275(*4.I(W(;KN/.G!G:;N^A
M=#V-+0'[L?<J8T*V3)##DZ\O)$9!22$*IP4!Q_DJZ\-,;;MR7KN<*\?@I[M5
MOQ5[%?YWR+-&R2)$=@V''H,MQ#,A%ZMTZ)=;R"R\N(\.C8;COKM2.% 5'W=:
M$P-7H5/ZY"0M2; PB_\ K4]]O+OE=\Q'N+>['<(OSM_H0\3Q]UYIE-ALC:+Z
MB,RV7Y3"2I^*IA)'5-.B. UH7G'!ZKB_6(0-^1DY@)3P(=GYJ/>X,1RP6+M/
M:LFFO1+S;\>S%=\2P.L4.77.;E>&*+8:EMJ"XDQL\%*Y\>/#2^08Y-]OBJQ.
M)FXA%F/)W:GL4485F;^%2(SK,Z^JM,=Y:G<9DI QITJ9Z551Q"9F[OAI_*>:
M$_;7V\(@BG>XKM=V[*['2T<7?,^EV3ORQBU=Z+7D=]M5L=L$VQIBNM1''6&K
M7)<GIG.J-H:>K)2EM5O'4WO+-%HY<:VWH@:41S@M6%@BX+C$,0<N*;V']O<<
M^5IFY*F.Y+B]1OII?CD\'E[20.L3[B1X^.NT]%NM8B'PC+^9;4<W !4)7]]O
M!LIN$?&'O*LS6@GI.\2M2U/-J^ ,CBA(_9I#U;?QOP(</I&1_%S5RLR+OZ$[
MK9C3EZM,&YW1B2S(A^9>;Z+T5DS%3@RXLA+X=4X4F.*;:4W\>8U6]E8E=W8,
M1C<CF,RC>'^D?X3[D_+'VIDWZ ['$W(+*V^2I+B7(A"AN*?=(@/#C6NNW>7>
MESN;6,3K'<E@8_C]*Y_O[LK&Y-R,(R#C'^'M":V0>GRY8U9W;C;Y*E(:2EP[
MG8I^^A)% &U<CKRW72YVXFD@&&8XHL=0\208Q)<Y'@HBM5]4TBYPKDWYE<!3
M+;:DH6>D09*'"2"I)W=(<O9JA]6LR@9#,:U;.G3$Q$Y'3@EW9%NL-):D)8][
M=0@BGQIIQ2?$ZH>[O:)D%GI[E;;&U-R'=!]84V^GS+%V*\W>!,D)LD2_RC(L
MK+J5A2UMLL+;71'4("UP]OO!/+7??+V\C"\'(^>38_@^Y?/7ZA]+N&T3"$B#
M9@)5%/ZI8^M@GKZE<PN$F+;?G+R7)+$*YQ%S6 I1::2S!:;6 %O$JHDG@#Q'
M+5KZ]O[<MC&5/]N3T-.Z$O\ TKV$[6^OQD\2)V&#@N7N/AQHL<(E^:AXVPU;
MXG\Z79*E$Q[L#&2"5OG<A<A5J11)HD>\>!U\P^=I^+NYF+%[D/\ Z:^M^EP-
MG9QC(U /\Q2OBK]EG6QWYLP4/A"$H3L5^\@@UV.#XB?'5-%IJLJ/;?5R"^DI
M^6=BLQ_II6#R[90RON=GG3)I[R4S6:#A3X0H>'CJ;N$1V_!-MIA(]GQ70CKP
M6XO *:% #+4M]<5!7],CU2@4_P#)CG' ^/\ X#93]HT+TA(1+E?*!D6U;ESW
M;>;D<^'_ %J@>.@.R]A?$3DC=MGH\Y<(49 (RBPPI"200%3+1<I%Y;;!)2 2
MJVHY^W@=968]\-@7]RK-K?0CB0&-:%2-F,O;*L35Z9WVV_XCV@FWA*!N5'NB
MK8MZ6P0E3E"T_+6"-JCPY^VS;*# '^%*^K=3M2M2C AM,\I<$]>SC=HNG<>P
MQ.BIN9&N2!:E$;4]'I\*J4C:/C\2G5AM0!8'%<BZU=G*,C;;22/<LF/5/Z<;
M'AF*V3)L+DR&'K@F,EZ--7';*=TXMN I,2"H M+ISYZ5M;)'AL)+F/D[>[PW
MXC?$W+9E)B<1W/MDM>DN/(@39L>4N9"$1N,M2;0IIQ5S4[UBX)!#<X5:+7N_
M!_&'GX;,=K.]Q]8S[5].^7=Q"&TB0:&W;XY!%XVRZKZ4:T7J.I-29<J1":WT
M.VH#C+1XD^SPUZ_V:Y,/$$^F*;[O<1D6)^H>Y%57*;:Y*'YL1^'TZ*#=L;6\
MP>:1N+7G?$T/O#AJYWNC7 *B3]L5I63(2%$N3\N9ROY2A]MJ$++UTM+"' _+
M\WY4*+Z5+<*5-B$*>ZCXSS\*_N^GW;8-#GF$YV]P1(?&B;$^0AV=TV(ZY.T@
M52DC[B?;M]NJ_=VTXDDNW:.";0W( !<9Y'BC$RXK<FNR!RD !) 4 >*C[=4H
M;28JWM"WS>B?E9/BPRW'8T&*I@NH9N-M+O#BV'9":'B1S"#[>6O469#%>,R_
MM3>F2I<*X!5H=#+AO[06%J2*),2432JF^.X#7L(LO/1$XND+6FMQ#0A#0A>!
M>^B?:=#U63DU"K4UTZ'C[WM^S_X.A053H4(:$*D_$G]/]<:@K*.*N/?"/TG^
MIH0,"C%CO%RL\F*Q:QNB,K_$)!]VJ2D\EM\A3PU9=C*)D.T^Y:!!U53NRJ),
MGF!=K>>H)\N,J[4V^Z$.LJ;VU4@_W9W][E^VPB8\+_+\%G&@9=?OY2:)#1WZ
M]3'3X/CM<_O!]O\ .#M,?W0#^W57ZM-Z#'4/Y2L0P-,%W=Z1*50OX5?Z1?\
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M'M-H;N$U$1N1!M#J4Q$-LH>4I:$K;"TMI25  $,NE]R\!^]#E@58CT[^D)L
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M23;S+?A^<A*,7:%!;K/EU;BL#R\@K*'T_A\2D<!0^(TRL;?Q _9D^*G )$N
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MV%J41$2^G2H41F>;W-R:ZN]?*!(4I3;3*5&@!2D#@Y(Y@5UH3 =S@K1MQ 1
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MP([.Q#* /EC[3<L$4)4@5J.&L+<R>53[J^Q;OEO;SN1MWY&&B5R<222*"WJ
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M-W,.[E(;Z73V;=B]VZJ:9?W&T.Z2'/(K?LV]QN!XD(=V+-A4YYJRO(L4GO\
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M_,:?24FL/JD]BNYS(BD@!WM#V.3RX<-G=D\..LAO"#]1] 6A<ZAL9#OV@#R
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M41A/YC7Z1;:0MKLOW0D!WB?*]G.Q!V4Y;]W==KXMW#GR.H.Z#!W]B@ !5?\
M*.OI(?[QW=O_ /8WV%_]Z[J/S4>)]BR5AO\ ,9?1Z<X?T+]P?U=F>Q!_;7NE
MK?UQYK!T'?S%OTAFG64Q>R7<=Q#VX/%KLUV' 0$E&S>/Z5$UJ%JI^C4B8YH<
M98)/>_,6?1Z:D$L]C>XSDE7Q%79OL4D^'@GNN0/#1X@':HY9(V?S%OT@WG?*
M2.S'<,@^"^S?8DB@!('_ )4J\TZ8_E[T*ZAZRO7<V8PBQ#Q8>]$S^8?^CFF2
M8O\ 0WGJ-_O;1V;[%"H036M.Z/&@.L)7[D!4U8I.UCQ&$3\WQ[5Z/S$OT;VD
M.ROZ'L\2J,2G<>SW8T4_5_2D1R&M6YO)%ZR^P3?:67 TLS'CQ14?F-OH\3T"
M//[%]R2" "E79KL0!P.X<4]V H<=:EOJ)=QJ]GWKUE8(5;GYA[Z-,>.LH[)=
MPFFD%*5!?9WL8H#>2!\7===.1UN6]_.1QE[%I7+<,PZJ/YA?Z.M6(Z.S&?)C
MR4[@V>SG8RBBKC6G]*)\2?'6Y'=S,<2ZTI1MZWX*ZG\PK]&I7P]ELI/Z>S?8
MX?U.Y5=+O[B1]4_9]ZVP!P'M5P?F%_HX-$*'9S,63]T0^T'9$*70CXJ]S6^*
M?#CXG7F>JZ<[C>C[U-,2&"L3?S$7T<I#9:>[(]PI;8Y=3LYV+(Y>"AW5W^.O
M'^]$%P9^S[U($7XJA/YAOZ-T9;[#W8W/:QA4?^)OL433@/'NF-.)WKTBXD5Y
MV] I(57L?\Q#]&A32I/]">9Q^O7_  KLSV+ 46Z_Q>WN>]\._CRYC7B;LS24
MC1;=H&9&FE55_P HA^C13WNSF3<C_P"V=[( \36G#N3KS-QBSR6X+%R0H:_M
M[$8/YC#Z-B^']"W< CD1_0QV'_3S_I3J..MN6SW$ [Q^WH6D"O4?F*OHW)W(
M:[,=P4=6@61V9[$?: ?_ "I\*;CK4N3G:^8U#X<D$ *^W^8G^CW!JXSVJ[A,
M5_=[/]C4\Q7_ 'T33EK2N]0:G??T?>H]*MJ_,8_1WBD);[-=P&#7F.S?8GQ%
M#_[=(^&F)C)GD?:5K2WH.+^H*B5^8M^D<ZAA4+M5G(<2H/5D]INRL<M](H6%
M,B-W,<2LI\=U .%.9UKW;@CP:JP.\;Y=3]@65GHS^LWZ _59WC;[/>F[#NX5
MA[@9#!6](DC">W%JB+89D6F(M+ZK3W N[J1UYC! 3'(H*\^>C.Z\FB"Q68W>
MM@TG/!OO6^33!;23YG\=&)0^M*4OJHR$T"D](H*RI:#4'D.(/&NI!."@\5AA
MZV/4YV?]*G82]]Z._%@NMX[?6&XHA7>.S!M<TIZ\2[36W51+A>K1"<2EBWK'
MO.@^]RXD@/M0"ZTH.?F/OI'QB$_T&]W/"A'9SL-X\.->[HT/FZU!=AP/L^]7
M'/S'_P!)#H^97V/[OJ#22L[>S78/W13<:U[O <=NAQDI-ZV>WT)'9_,K_2(F
MN+91V/[P;DDB@[-=@OL'&G>#[=33&JQ-^.?N5F1^8[^DK"4 OLIW@I3P[-]A
M#SJ/'NZ-9N!4.E$=[MR>Z#ZA]ZN,?F2OI&!)([(]X3N J3V:[!_;_P"Y?^W6
M!D'6]:W-J0H#ZA]ZO'\R)](-?!WLCW@_1_0SV"X?L[P:"7J%M1E#&J7A^8V^
MCY2A[4=P3Q_WG^QGZ^?='6+A;%F<9%HBM>67)%I'YC?Z0=6VHW:7N&7' L=5
M/9[L7^#3: >/=$\]WL/+4@AW."][L)1MD\NW+FD.X_F&?H_W)18':;/[G<BI
M"@TYV@['G: W3B@=T @4W <M9:A@ JWO;NVB?Z@D9.*L&P[?@C+_ .8N^D9"
MCW"2>S'<D_*I;<0%/9_L8=G57&:VIW=U!S\U_#I="_%Z MV!;0W5EFA$@Y.!
M]Z]'YDCZ1D-[RZNR?==748C20(O9KL(0!(25@N;^[37%5>'/QUMPF) -R6U:
MOQD[CV!6I?YDSZ/[55/=C^\ )4#7^AGL$/N\. [P@:V8B;T-.U;L9DCN_!&H
M/YD#Z0,Q.X]G^X(I_P"X=[%GPK0C^E'[=>AMC(D+1%]L0E)/YC;Z0)2XI?:#
MN& T!6G9[L7QKNY?^-(<MNL/#(S=>GCPX*TU^8[^D%(441^T/<6H!K3LYV)K
MX?\ N4C[=2+?$^U8&^#\H]R0[M^8B^DVW&8EP.S?<@F4I"54[.]BCO)4 14]
MT5'B#X:7G?TS]B4;K=68Q>,29,,AQ[45>_,.?2EM/EW9'8KND/-IZ_\ (^SG
M8A050))+G5[KL@'W^%*ZC\^'H[>A:MG>;>4FT'4_ ?>C;'YDSZ2$=*4N]B>\
M*B!MJ.S'8'F55\>\ \-0=X)?B]0^]679R$X4%$MH_,A?2/<;WGL3WAX<3_XF
MNP9/$?;W@.MJB]9&,1A3L"27_P R)](YY[HI['=X6MJ5J/\ XF>P1"MI2*\>
M[ZJ4KKT$HX%+-QN;434'T )$/YDSZ2BFW'6^RG>#>VXEM%>S/8(<2I"1R[NG
MQ5J1(-S[ ED^I[<8B3CD/O3BD_F(_I=Q(QE2NR7=U0(J?_$UV$)\*\^ZZ1][
M09AL*I?#S!M2,)O_  P^])J/S(GTFXP2IWLQW;C*?%:*[,]@JKVT!/\ Y65?
M#N_AUCJB:L76Y;Z[MR PF/\ +'[T>3^9'^DHM)_\3O=I7 T']#78,5X<JCNS
M4$Z (\"MV'6;4LY?Z8K+'TK_ %MO1'ZA+]'QOL/VU[MV";-NF-613<O!NV-G
M97*R:X&UV_J.63N5=G7$,NJ)6I22JG(*Y:@F)#5I\4S\20K ,3DMYOS!_P#Z
MTN'^T/S#^)B_Q_\ UI_'?[8?VG\5_;:P8<_9]G]BV=4N!^5_2N?GZY-EBYMZ
M7EXY<(3+[AD6T-)11*RH9%:7 -SBUH^)O6KU&!C#!I,.'%EPC]2O,MOH&PAN
M;I@&85C,Y_NE\2OG6]Q>T%[PC);DJ1CK\:*Y=K]\M=+L1:76XDW\10#3RE)"
M4NMGW@.?#QI7?'$+PC,_5SXJM^4OU;VW4-M*.WN[:1M"W&0,+P:DA1R.!XIC
MX/:[9+RUP9?$=1 += I)0JA28R4CW42?N!7AJR]/W,3$ FC'(\5N^9O, ZA
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MY*WK32U&8TSRF\>+@33@3\.[V?Z?4A2%6J<XYQ'(FO(_USJ4(IU$_P#6;O\
MZ'^SH] 4_G8\DHP(C$OJ.N[HGEW&$IWT_$ZRE@TH%?#TQ^W0H_.PS;U%;\OR
MT49BT?4WQQ!E B1VQRA0!!43N[@]N5< A/+4@U90=Y T<>HKZ<JOA_9H7H,4
M1=14(/AUFO\ GQJ)8$!>XE7T%:0_S"EN5>/IH=Y(+8)49MO40*5H+!D::\>!
M^/6I>)$:\?@D?4Y 0_S#W%?,*FVVY2YB50GZ-\"K<MOB*J)/Q)\-([<QFN(=
M&ZO9V@!N@"ZYR)R;)"1&%O&QUT.F0DB5M(]WI\./Z>HKV\M;]B8=CR72MCYJ
MA+;@ P?0/IGP3;GN06/?@TZNX;MP5^Z:\0E%>.FEJY!F)2_?=8G>D3'002,I
M<.U>+-PF+"GJ;1[*>%3^^3K7<G%*.G[?O 1XGW(PMA#@::]H*7.%.>T#F*>W
M48*[[?;GP:_A'N5MZU(C4<;))5X53[#[ /9J0:)9O+!UUXCW*XVMUHU@<61Q
M57AX<>91X:W]9P*?6P'8&C_!&%/QY"0D$]9(H]3AQ5RYBE:@^)T:CC1,;(P;
MDB3D%#A)!\?LKR\>&C7(IE;9JXJ^AY/*IYUY:PKC19]5O"Y;.EOE'\R*R2E3
MC2E D(*R>'+B@TX5]FLPS5*YY?B1?,N,R?:C@$*2V$J50BO"AKS('W:>.L2/
M4G?3]P(1 )&!R/%$+<EF-0-$A6Y1%:>* /8->IF1VJL=,V\C=$I<3P_"E%X2
M7:=4U3]RA'+[U>)\*:PUE7_;0E"T*4TCW)-?CJ)K0_P>S^QJ-96MNB!(^CW(
MU&DL.QQ(<C+2X704@BI('3/L/C752M[&<"S'UA9^<?-,=S8E &W6W'Z9C";Y
ME947GO+;LG[-V? I< JEX]!$2*\EM\%E*X[B%[BK<W[Q2D\*<M.-MM2 /1P7
MS;N]Y?GU,R8:?&D0W\7:L8Y,ML6]EMQHW$-$T;;!);.]137E\-:Z:QL$!JX<
MEUSROU&0VXMR$096R,#G+M1 "8X.K1.Y.Y033AP /BK2O\KHJ0?6%O;WR;<V
MELRTS:F,H''L3BQ2.F\R9S5RD>57&B.ICA(/XO4*2:U2Z.!2/9SUB;\;68IQ
M?X+FO7;%C8@N2 =3\B.P*:>Q_:?^>V4V^W32XF(D2U=8NQT#:AMX\W4J]OLU
MY#JED'1(Q_TR7-.L]9L;:1EK B6<D'[DN]P;$SC]QR;%[>M+MNM*'O+NU22L
M-.2$#B @&J6!R2-:YW,2\,EI;7>6M[.W=C(2UR#%B.''M428S%L4RT35RI"T
MSRZI"8B4JJ\4J?3P_ 6.' ?$.>HA<MQ#9E6W=6KUB_"YN)R\.V 0<0 0#D"F
M;<\=N")2G&;3*A-;PM#CG32%T2!45(/$C6,MQ&(8D>HJT=,\Q[.W;%HWH2FS
M,1+]BVE_2+M613O5=V\F26'68D/NMV0>6XH)*0U:,];FN*44K4/=0*FGART;
M/<VH78@&A)XJQ;3S!LMMO;.VMS@;DY<)&AIB*<5]5GYM&_OZ/_H;^;?"O_!O
M[_R^#[.>K'XG/)\#]O1BNJ^/#B/]G5Z/N7/;]>3.,9[3=DL-G7Z2(C>0Y)#M
M"%*DHCMQU1[I;Y?F*K(2\5[]NSW:4KN-::\>H&'A^(Y$J ^M?/GZ_P#EG<;S
MRS.&RU&^(6Y "!)_WHN:%\ >U<D/=>WV/N1A,^Y69FWWA=OC7>7"NC(C/OE%
MV8#Q6[':#SB"1#202X:FOLU3]U)Y&3NTBU<&/Q7P-Y:N]4Z/YE\"<K\+9W<(
MS!UPU1\0@F43D ^+XG!:DIDM=FN]SA3+$):F'BCJ*=\J0"E"OA5#?H*'VZVM
MGO)6[8<N6/U<U]G[#:[&[MK>XC>BTX?*0,7XZN7!1BF?)2)3<>Z*9+"0I,=S
M=.6^20G:%E]HHX?VJN6GL=R30&G:K=/86A&,K@?5FVEE)&*/7.Q8A>;U*MS[
M:+XTSM4X78P6(+4M2ELE;!Z]1.!(%-M1QXZ96 ;C2SIZ4LW.PU2T6[G==@W^
M*B22_%GK>G)==<=+BJQG$*; I5/!]2E5^']WQUNQV0G4^Y90V6YM6Q;BYY@$
MJ<<0QZ?"[=Y)E5IR$1A;9+<:19O*D7+IO+M3*I 83/1("4)G5ITJ?AGCSI[1
MV]D91;L"\8[F5VXTBY):LG]J85NR"6VI-M=N#:X5]""F[.T:><5R>0_ 6ZI3
M1C^;'-X[B3RIIA8\.!#Z1%@V'V"9V[-N(U1)-S47&F@K1I/757(,V:2L@L,Z
M#(_DKR)41RBC/2UL0"I 41L2XZDD&H^/PTSAN;40P,7[0F=G>V[0TE@PXLFN
M+5;6UIDK6XI' B,XLK'&H^-1IP)K\/AJM7-WI#O[59MMT03(&J+.?I'#M1^7
M%:D,1RP6TFNR-'44MI(<* K\6M*)HG[NEU[J@B]>/U+9W'1]MM[>J4XT!^D#
M#TITXGA-WOUS9M=L,9R8ZVI9#CZ4,(&]M)'7JI)(+@\!_!K0EULPS_XU1>K;
MW:[*9E<N6X6P0Q,A%Z/FLN&?1)W2@O1+E;9J[FPZTY'E.-^8*5]1MY&\J1+D
M#W0\#0\Z:K_Y_<W^Z27_ (RZY3N/UMZ9N]M*T=#D@@QO"X*$%G$0[LV.;K(S
MLMZ6[)@+CDGN*]:[BH%+\6!=TQ(!6Z\77)++#D]^63L5TTJ4E'B"1R&O0"\"
M)%W?)Z+G/F;]4=QU:]*[M;)A 0([MYM0B,2T S^EGS2+GWI!9R7(Y5WL(L=O
MB3'$*B6YN)"DIV".TC<B0V]&2NJFR>#?C^W6W%_<P)E;G,$9:B%6^G?K!O.G
MP_*;K;S,-7S&Z3BYP-NN/%07</1GW3C7,MR6+1(AN$[FF&FT)2"E0%-CCB30
M@'EIWNI;F;F+$,/JYKI5S]3>DV-N"97X;F.9N2D_^5A[U+G;WTN7.PW&W_.+
M9"FP4N1VY+/EVW$QTJ6@+*BH.I;&VO,"NW[-5?>G=0?5J(KA(GW+G7F;]5[>
M\M7!M#=CN"2Q<Q.?+_!3).]-KMHR%#^+/>79F-I4I-NM_2+-4,E:5>4DIWT<
M3_:\=(9;V8)$H3<=M?2RI4?U5W\=C+;[RU.Y<C@=9<BO[I.?%2W%L_97$9(%
MW<M,F^,LEQ5Q1,MR51Y&UQ+;*6/Q5N%:DTW=1/\ &<N'&"=UJJ9"7I59&[\P
M;VR;%L;V6U(^6'BZ:%Z 4.7V"%T[MV*S6)RY7=;++*E24V:+(>;>:N$6-_=!
M)>2A$1*6UM<D. [^?#CF#NI$=ZX' SD/\5&UZ)UOJ>X&UL>-.09WC(Z7R/ A
MLVPR4;QO4BF?(3$MN/IDQE?"(-\#B3RK^''M2TCB3KUT;EO]R?K/WJQ7?T\Z
MA8L:]UN)0N?A-L^\S'N2J_E&40K4JY7>4S1/%;,:Y%UX)]P<TT4.*O9K<_ME
MUB9/3(15<CY/W&YW4;.PL;DVY.-4[,Z,":@^K%0#W ]3D"PVQ$7'2M4^3YIF
M]^;NQ:4TMD-MQ2RM4=2C5;KU1PY#4?D9BL1(C^$A=-\J?HG=ZAN?_P"[2$;?
M=D ++\20^L-D/@HOPKU%W6%?HTF3<"\)94:&[*0EH%2.=0L. !']KK,;.X*1
MC+_25<NL?I-TZYMM&UM"U.W)M7A@O0Y=W''$K89:LWQO/8"K1=8=KCMQ$/N]
M9VX1)9>K'-&PVY&8V'<G@=QY\M>.TE?E/3WS$D\3DOFRYTKJ/3-S"1\8:<Q&
M4>+8'CS74[]!W!<=P;M+F4G&X3$?^==^P^Y7!^*AIM+_ /*,HDQVU]! #O0^
M9.443QW$T%=638:PXCJIIXY.OT2_]/&YW5SI<Y;LS-PV=D>\2_RW.->U=%;Q
MW-I04\ KF>/'WO:/MU8K1N&(<' ^]?4-T1(<D5*/ZV4+3M]>1RGTPO4U'H:3
MNWN80BNO\4).%Y*QU2FGO[.I7;45I2HT.R]+=RW:.JXS.,5\J)1112%K*?E\
MR%& *?X_JV\O]0 D=.G*GO5YUU "WX]0V<0-7AN^9BBJW$)6$U6JM#7:>%:C
M]>DT+%XEP)-V%:5WKFR$2T[6 ^N/%*C#32$%?6W%P<$%%-M/MWGQ5[-,K&WN
MXD2RR*2;KKMD/X<H$5PF/@KAKN-4MTKP)=2*C:.'P^.F5O;W6?O8<#Q5>N]<
M)D=).(^OEV):M&'7V^)2]8F9!9!*%!$=Y8X)W$[D4 X*&K1:\BSN2!(ISLO\
M50-YU2\8F,KEU](^N7%3?AW:F>8THW:V!U72BAQV0DL%CW7^HH!UI97NYGB*
M;?V/MK^GUJ!$YB(P/^P/_$JQ+>;RY<:,KDAJ;YB6<JQ=<>PK%Y1>F&*XX3M4
MR$QT;24A5.I59/!/[HYZ>VO*NTL1:4K0[;<1F_%/]C?W4H@-<-#^+BFQ>^Z]
MRB1E0[&EFUM*I4I<#ZCQ%35"(Y%4I TI\;;'_I^L*P#RC(GO"1'_ )1^]-NR
M=U,BLRI#L>>'G)O15+ZY4\E1:+I1L0MQ09!+ZJ\Z\/9J?&V[5-OUA!\CFX.[
M&5?_ &)./I2HYW@R%;Y>W0PH^(81[!XT^S1X^WR-OUA0/T^GIK&7_P#3GCVJ
M5K%WNLEXALVW([!;: ^_+;=BLDIVI('3-OX>^G]_QU:;QZ=,/$V?^%4:WT[?
M6I5C,\Q$ILY;A^)Y3)1<,*ND%J4ZEU4RVOOQA[[VQ45MESS""?>Z@-&_9I%N
MMOMIDF'AXG!C[DVV\]U882C/+(A15<\&RBSN$W.SS$1R1LD0HTF>A?NU%.DR
MA-"D'[QY:2W=E$DDQ#/E%TSAO+P80N3$N9,1ZW2#(;7&7M<MTX'A\<5]'.O[
MS7V:0GID1]/_  *Q2\W7\A+_ .*?_"K18>6['4FWOD5)_BG"34H]C6L#T^(^
MD?Z5H7O-^Y%7F&?_ )I^Y*<RWR9#"0BV3!]J(;[G('Q#0U/]O ^E_P#*ET_.
M^X?3JF/_ 'Q^Y)D1.ULE$5QS^WD!40BH 'NN(7_5TMN=*NZ323_P%6.SYA -
M9#'_ *G+L1!Y]8+I=6$I;/P]4D)!*J@&HJ*)]FEU_8W;8=I9_2<E8MAUZU=(
MB91&'UA4[&'VNHT>LKC5(-/:.8W>SV:63M78_B?L*L]CJ=F4<8G_ #A6Z<OM
MUM,L65"TCXN>T$TIS^S[.6IP0S(Q#4APE*F:4KQ)KX^S:-!0_!'?/?VC?[!_
MT.I?L57:_P#O>U6Y#[;T96_W5)DQ-O35L)!<5NK0 D<!HH4?UQ^+VK?1^7$0
MTKZGF"]%A:C_ $5Y-O(=))_\/^W/.C>@ ";E>]KQ=0U:F?FOIY5"AP.I(96*
M,E9?]U"*)K^*U7]&X5/(\M8F@/8LGJZT?_7]R%K'?IM=ZKLY#3< Q+@MF(7Q
M'W;K'D"]_6Z$BE-E/@//6G?'<=\9?!(.KSB+3T?6/<5\TVRX)>;_ &MZ^6%2
MUQF 4N,E*]WNI0HG<E?'W7A]W55C?:6F6+\5PS=PVVR>-Z5O5$#@,2W%1W,M
MDL29 DM.-EA:TR$N-KHHA:@:*4!P!2:\#SUO6KM17AFO?:]4VT!"$;D#&1 #
M2 ]8]*;ERA0GATXJO+O C<6V@Y]WV(4W]FF%N^17+M5\Z5MK&[@)3E N"<CF
MW%4VM,GH]=R3U*'^+*2.8 ^(K5[?9K;#+0VF[M1O@  !SGR1]ZH;+O2"-P4K
M=NK2G'A[H]NI5RL[ZT+.,?E_$."2$SE[R "_0_"5%-.'*M%\M#9.EN\WUJ1=
MXXCZAP1N6DM-@6YPE=1UXZ$&K8\22E1)X>U(U'CN:^]:]KK5L,3(,?W^2.1\
M5R*3 <N\*U3)$%M*5RI;#$AU" 0I:2X6V5)0*)4157&A]FCQ_LZ96.N6@'U1
M8-]8^Y$&G>:6E%U])(7'6DM+21P-:E2O_0^.I-X\?:F=KK=O2"3%C^^$G]5P
M+2DH(KX\?M^P:W3Q7K+>^*&X_O/S2N@LL1G%+;$I3Z 4U_#+.T*J :.;]V_^
MU^']@&?DE>YMXS',X).CI8=>.Y[RPX\#[P\/[9L:R/&C)5+>FP3$$XC/B'1B
M0V%.@Q(P2@&O4"JCD>0#8'+[=:!OGC7M6>PW-J$P>[B<QP5UJ4\$.#:)'1":
MI*MNTJW<!4+)KM_@T&]S]JLXZI:A9QC\OXQD%0Z^^IHN"(YQ)]U.XTI4<PU]
MFH%]LPW:JWONN6M9B"'<?6."*3)GXT5N$\'D-[2H-M;0LU5Q]Q:@.%/;K;$;
M6)$6]"\M_8M;J)C*X"2 ,CF_%.RTW:-;7GG)Z"ZU<FFQY3H52@I2$E76.X)^
M+EL%:_9J/&LPP,!7B!@JI/H-@3$Y2B3$DU@,R^+I(*'VG7U6U B1Y"P0ZY^,
M$BJ=P"*-"IV^W1^>M1# Q?\ B">;'<['8L#<MDQ&&J,<WXE.:W8O?[LZOY7;
MKG,::)&YBV2WT+J#PW-)6E-0/MUJ;K?6!$B$H$TPD$O\S?JSLQ9:Z;=F!TU_
M,BG>_AC[UF-V%].S^33'#D%K7"6['9##DNVJ'3ZB@'2I#X:*]I J*C53W6_U
MDL6+2^I?)?ZD_J[9V1-OIVX_,"4IDM?H.&&KCR=9;6+T\S+ E4FQ7%NWO0BX
MRDQK. M_JU!5O9G-*1P=_MN U6KG4;HN:0)8XB1'P7$=]^J%_>ZO'L7+D9,S
M7C1F_</#EBHYO?I7R2[7"0'KTAN1* 3(=78E++H*UE6Y2KF@FM3S)YZ:6MU(
MGO28?Q)]L/UIV^WM0LVMC+Q(DL^X9J#/P<DBV+T3W*V7EF:](1):9=2Y1NQ4
M;-7$K5U")SB0%$>.ML;D?]0-_%7WI]U+]==SN>GRL"R1<E;;_P#279@P_P"6
MLMG^P6!KM,=O([/9Y3K:4MU<AP(NWBH@J#C;M:5.O._OHF #/_FK[EQJ]^H7
MF*75M>UO[J(E=B&%^X8@&(X,,5G-].SMKVML7<*&BSM8]'O43N'C(9?C/6HO
MN):O$?RJ4(9"74U<"MI"CSX<M8[ 7#>B.]CSQ7UAY5WW5+O4MN;\[TCXT0YE
M(#2X[7S7<=TWO;_[9+I_&?X[V_\ PW/5[TW/_DMZ5]K>D_\ [K^Q7-C^:4AL
MR_2CVODQ*O('<!+B7=ZZHWR[(V!4*\%&OZ]'5;<X;0RD.Z6#\W!57_4_?1GT
MW5]0MQC@,IO\5RB>F+'<F 95=;@M[&+G"@I?8*MP1'0TZ'$DEA"@2Q((X+\.
M>N?[BY*-PXD/+V+X.\\]4Z0-U"6UM2M[VU(ZY@ ZBX<UD10@Y9HQW'],EMFK
MON80DQ3:E2@@'S=Q0X5!G:?<0"V**CJ^]KPCNC  !WSP2CI_ZK[K9WK?3)B<
MQJ B1&#U#\NQ8 M]F;WYQ*G+:S!6[M 6M^4H"A)XA2'!S^S5EL;BYK$*X\!P
M7T!+]0+-VPUC<&Y"/",%*=Y[5Y8O%8L9Z?#DQ[1&?<BQ60I  D,LE:72F RI
MS<(J0-Q5X_;6X=/#@<>ZCI_G&5^;2,V,H_3#,K$NZPYJ)[]IN<-FWMM.4#S5
M4E1V@CCM2>(6?V:LNW$2&(JQ]ZZ#L^IBY:%P2E*AR'%2K=9\"U6F#B=JE=.]
M7>,9=\ON]:K<MMOJ.%/067&PHBWT%(R>*AQ]B [LQ:)U$GD%7>FSGN92OR$1
M;C)M+ER&'Q/%(?;C H&=S9-I3(+CS+TEFV7(.NML2WFW'&Y"F0T0$A"T-G^+
M'Q#AKR._E'!V[!DKD+,H1[PTZH"0' $./6$A7B'+L,Z[XG<)2EJA/%*%U)H"
ME#@HM24.4VOZ\I=4D"7,G?A'@EF[C<BUR [J0T0V9T3J[@G::4)(^$)5]VOM
MUK;C<#0\'9A[T\AYKW.VN^'=E<U:C]%O@I6[0X9CV6Y78K7DP6BQ>9B(N$EE
MY]M;#<A]E!(4T^PJI;0H_$.6JQO=X8/C5\@JSYQ\Z]2V/2;V\M7+GBQMS,(Z
M+1,NZ[5'9GFMEF/^D7!WI:;CB4A36/-1RHW5=QNX?W;F@ZFOF) %'POAN^[J
MJ;OJIM2(EJ(<# <'HOC3S)^N?5OS5RS<%R4HD'3*W9 '=#NW,J2<Y[IXQV;Q
MU$:YN79VYI2V\VVVM+C.YQ]N.$J+]P954EL\-M.6K#LC"T1KJ7(Y_*JYY/Z#
MU?S1O/!VD08@G432(:+_ $@E_1P6O?N/ZKLKR2[17(;*K9;XTR0J,N6W$'F8
MXD,$[2A$H^XVVFO$?$-/Q;E.R\8Q$=+NYK1?1_1OTOZ=+;-O91N[F41$QC*0
MTDAB"VGYCAB:'!.=7K/RZ6+2NSK@MJM3*6G*1X*RX6ZH)HN(X#[Q\::1;V-T
M2:@8CTT3&'Z(]%G(RWUILXM.[[M02M9O6SD5LE#SMN:F$E7%2(R^;9'WPGAK
M?.\O3/>$6]7P2>[^D\+VW-ZV-46&<N*E7"O6?!NMWD#(K48\526EH$=N*G?0
MNES<4R&"-HI2A\= @+[QN1#'F<\53NH?I19C,7+6B1&K4)2N"M&9@>?!-C(/
M6K-M60S)5C@3G+<RM*&Z1K<Z$IZ3*C0OR'#\:3X\-:MSI-F4G$($#C*8]R\=
MK^CFRW-O_P"XG"%^7"=PAGYC@V2@J;W?Q=;R)<B1<ILF[NM3(J7"W[K+3B75
M-JVSDBI3'7[>?/V-?[-8(<B))S>2Z)M/)>XL@V+=NS"U8CI+F='I4Z2<T3[K
M>I56=VRQX]CV..P8EC@3K<](6U%)6Z8\"*7PKS,E2JF&5<:<^6L_[)&3!HD1
MH*RRQ3_H?Z>[+973N+4+4-Q,QD?ZETN[EVDXSX)M=I>_,CMDF3=I]I^>EI3B
M0R['AJ#94Z'10*4RD[0BG'VZ@=#M/6,7_BDKGN/T_P!OU20N;B-N40!37<CD
MWTLF>[WISAJ45P)LR3$(HIF2F,XA5=PH0MMWVCQTPAL8DM&(;MDJYL/+W2X@
M'<@>*": GAVA,C(<GO\ E$MLW"&PR7%K6CIM,ME96I!<*RTRBM.%.?/7L>EQ
M.4/7)7+9;/9;6 G:C($ 9GA_$D]0N<8MR&TA/1X)( ]GVHIX:B72X@4 ?MDM
M:_=V^HVY@Z2?MFI2MG>7(;,"KYI+)<2*T8A T5[E#1 YTU4X;.((E$ >DJG]
M3_3_ &6XN>'.S;D 'H9\?1P7T&?RZ]T?R;TM_.9;SK[K_P#1^YN="$D=2)>5
MJV]/A4UU9MAM8QMNP^49G@NN_I5TFWTN5^W;CI'_ -N&<FD?$ Q72')4$) I
M]^G/^U4=,[,!AR7<+\F [4<2K=7A2FO-;!#+2U]?>[MV[Z9'J,#M?Q<1R)M/
M+QQ3(D^T?O#7I*($!+)(>L;J=G;D0_W#A0'WKY8[BHLF:A":@2IUM6K_ %-J
MV'[Q\=8/$28\?>N<;KS)NX$D3E0/\L,J'$)5BV.YO@J5':-*<:JX4H?!O[=.
M8;&V:,,>)58'F3=R+2F6_AAE7@E2)C%SN4@0@VTA:E;$$*6*;U;2:ANOL]NF
M5CI]M@&&696Y:ZO=O-JD2[91S4D,=N<=Q9A$O,)JD(< ]UMU\\5 K3\2XX'N
M).F5O86V8 >LK>C>G<.)]B<UN[F6+&[6H6&+[GQ#<VROBK8A7%QYT_"!J^;;
MK,0:ZZ'A'AVJ=UTN#-"(!IB9<?2FG>.[]UOS);C2G("FDNI<2VB.CK=8!* =
MB5?Q?3-.7Q:]=[YG%FP3 W'$)?3#(<RM+;]$C&_JN".G6#24N/H403Y,ZXR%
MN3I3CZ557[RJ?#1'W0D:YEU?]0;]F[*(E=<2&%NUG%\RKUTSHUF5H&$8LQ^J
M?XD1$F++150637B2$^ !_?\ ;JG_ -]W.<Y-_#'[E9(=3MN'$L> ^]6&A%)6
M$@^[3F:<]W*BC[-3_?\ <C&4O],$XVV_M%J2RR'WJ]MC^S^$_P#1:C_N#<?B
ME_I@G-K>63&HEARX]J,(W@44S3D*I-/ZE-;EGS7N+DFUSK^[!4NYY<L@$B,&
M_BFC+;CC2VW67)C"D*W=5A9 ;(4""Y5T>SAP/CJS;+J\]PSF3TRB,>Q(MWT:
M,'#1:N<OBI(LG<[*+6VEF'*CW9*$E(:FQXCZDC=4_P ;$=-0>'/5CLW#<BYX
M'W\DCN]+MB3$!@V!/!+\KNU8K^>I*QMJ*FG$I::12E5?<D#VZV/RL#_B4RW'
ME*,8&EK_ %W/N1BV]P, 4AXFWU=BAKW: T*M_MF#Q;T';0.('M56WGE<Q=M#
MDGZYI<A=X\>8)1%QM$A":@%3,=5>/]M)/CH_+6\ !ZRJU?\ *TG))@/\T_N3
MK91VDS]A33C*['.62AM"%.-I44@.@GISU\R2.7AK?N]*V\HG2(TYRXJNVNJ=
M0L3'B2D0WX8\.Q0AW&[1NXPEF;#>2];)?GG$.=5]:EM,=!:2>HCA5#_@=5O?
M=,A$&@;O9E6_I76I7#$N1/N91S43L(;=8,:W<'TDA1))' FO,K/,CPU6+_3[
M9.6/$\%==MU3<0BSER#E'BB]/X-5MEU-EZ@%2TI_>_L@?U] P= 2J8Z8[84!
MQ(-:?M_1HQ4HO\O7]O\ KC_8T4Y*/R5OA[T7D0G 6DU(!6%GB>/34D^S[='8
MH.R@[ #VK?E^68D(E?4UQI;HW>6[890@>T;>X7;GV$>&I#H&TA%Y,*<ROIS,
M%6ZA\/[!X?P:][@#.%Y6R797)"MJ14\ZC]?"G]77ABO6>"T;?7PL2K_]-[O?
M!/%*I,%0!4H#_:.^C[O'[^M*]\KG\7P56ZV2+/\ [P?RE?/4[4]O\B=MGE2^
MS%0\\M*F4//A*_P&30_R>O$I'[-4.5V1D=&*^*?/WZC[3IU^1C.[.&F-1&W^
M+F0I>OWI5EW#'WKI)CQ8Q;B2I"'1,N2%22MCJJ71#6U6PI!X\!NUL;>5Z4L>
M\X& SXT7*=E^MT-OU$=R^; F'U0MT8_2TJ\W;)8+Y9VWN&'760A+<=U =;0#
MU9"Q13"7/[JU]FF-K<%M,GU!^'%?3WE?]13U/9V]Q9N3A"4"W<M_B910Y;94
M*.0GAQ!X*4>9 \4_9I\THQJK1L^L6K]]H.[GAP[52L2E,QE*/X+0<+P/,@].
MG)/'@@^(UF'96.UU*8B8 EVX!$70S)JB -KP^(U/LX^*_$CPU$B#\N*U[N]N
MQ)E=)TN,AP2\S 6E<R>WMV3/<0"I1"2:<@00/BTO$Y'#-5^YUC3&&WDXNVSW
MJ14Y=N^XS^*X;D6,.VQJ?\R:BM*<6TRLL!MFX-)(6O:XG?YCF/W=9"<CCBB?
M66N/9,O#D>$?MFH.O$=+<N3<$-(8<D+4K8%+ %?#;Q3]W4&9?DG/3^K7+[6B
M9&;'*/%)T1")B:@<0>%33PY>[JPGFK_T^]*<@Y)J>'!7%QBU^&HUWU2FBB0*
M$#QI3XM8OGDGFXA_0?/0?<D"="=:45!5 >7$^ROLUDY:F"H>_N^'=D)8./Y5
M+[';:^+L#EV:V>7;/OU6X54'2K_<2/OCQU7M1](2+;]6GK%.Z2>'!,/HPG$.
MM%9;D1E!+NU:AO42H<?>XT4V?#QU!G+!,+O4+\(B0!,)1)P'!'F(DXQZ1FTK
M2*T)XUXGVI.H-R;/DJGN^J69[DC<7)0J,H\ A%L3K(HVW'*J"AW.'F"/O(/A
MK&>^D1C+U!;A\U$2K=.G^&"?F'=O\CRBXMVV)"BR52764H*U.CIA2M@ *(Y(
MW;OX-+K^^D' ,GKD$J\P>>-ET_8G>3OS&F)IIA6C_!9I85Z.)=S4Q$R)N+%6
M&R^I)EW)L;4JW5'290345THN=5E&1,M3/D OG3S!^NUS:W3;V0O&9+5MVFJ.
MTK.'!.TN)8#:(R[988EU;EIWKD.*DN;$])">'5=(/NJKKQEU4@:8F0CSC!_B
MN&==\W];ZI(SW.X>1:C1B Q>FF(=*-\[@8'V[+DEVV.HEK:<4EN,E.QLI2E:
MDG?/:H-Q%.!UK^)+<$AWX4 QXLJ]TWH?5/,.XTV!J,I]XDEJGL+#L98PW_UD
M-6J4^S;;5)+3C@^%B"YS2".+TI1X$:/R,#60!/:5VGH_Z*W]U:$]W*U%QE.Y
M_P"$)Q8?ZJ85Y=;1>($H+=7LWEJ(VYQ37ATI38YG6,[$@'@:I+YA_1W?])C.
MYM!9G;B'I.X3[8J6<P[HRHMCAS\:<D-(F1GW9!<1'<4E2$IZ03U520F@4KD1
MK7MRG*9A(FG(+G/2N@#<[_\ )[MHD7-)J>+%8+=Q._\ W!*WVFY\U*0H(JF/
M;Z %H\OPOM_3K>C:MN 6?F2OI[R=^COE?=QCNMQ&,KFE_GN8@\!(!96?2FR'
M+I7J!Q:=-N=PEQ)?<[LNTZRMP$%-XSEN(\" $CWD+H:']&K;T[91E= 8-VG)
M=LZ1T/:GJ-DVXQ M7 &>52X7TX?(M?WI7_DW\C\2_P"*_O7Q?%]O/[=6?PX?
M#$X?;/%?27@\A_\ H6G]BYI/S.V.VB=Z9NTMOR.X+M6/O=Q '74%"]I1(L[@
M(Z;$L@[D('P'7M>F;D1 _("ZJ/G+I-W<;0PM"08# QSDV:XN8N:8GVRN@:P#
M(DWE$!3 )F,R4%@L+(C](F):PLN[55IN^$<O%/N(&V3.RY/>I3]B^1/.GD2Y
MU:Y/;[Z-R$-=T"496WJ6?"51C@I_Q#U7VBY1%VN]VJ'.N:@L@JC3^/OD [^L
M6R-BQXZ6BX;DCXD9"3Y$?%UQ#JWZ+;FS/Q-C=G.P2/GE!\.0CGR65F+99A^;
M)Z,28T]N<6GI+WH)VM)<-"ZTVGEI!?(N=Z)+:1AVKE?7MAU3ITC#=V=$M(I+
M#'B"WM43]\NQ4K,XUN>PN*^FZVU-Z40S=++;TNF>();K\S6QUP%1#_%J]VO'
MF->,;<B' <T5\_3'S@.@[J=C>1M'97O!UZXS.G1K;3I(_$7H< S9XW=LO3]D
M=FSI#^78U=IEF2@BYAC(,45O5OB_!MD2"#M!XE*AKW\"<FC(4]"Z_P"9/U/Z
M1/I@CLKMD7X3^46K_P K2P)# NU7;DJN]WIGS&]99<;]B6+"%&D(;"8S<^T(
M2D==XFB7)Z5UVN#Q\-> W,':!<=A7MY2_6[H/@&SY@N" -PF,;=NZ0!IBWTW
M*N#FF;C?IC[K6=NP9$QCRHTZU7^TSB5S+43+7'G,20 E%Q"U!I;/&A'QZR\:
M4G%,'5GO?K%Y:O7IW+5W7M!$Q@3:O."7$:: >%69&<V[!9_F4F9DK6/R';_<
M+E&C+0A^WI;4J- 7$2E(<E[B=D)/WSHA>FP%!'#T^M:>U_5GH4-P8;V^^T <
MZ;=TUHP^0Y<E(G:7T=MMM*FYT)R+BTXMQM$E^W[7$=!L<T1W*"I7]X<M>H&O
MYJ1X1^Q50\W?KW/J=Z5GR\=O#9F( U6[P)(D26>46HV(63MGL/;CM\_$:C2H
MT"<%LH*5O-K2ZJ&I(H>BR  VI?[PYZ);>!+'UN'7&MYONM^;+OB2$KL8R-(@
MB,?$.6IZ'32IPJDWNMWVL^ 6V/<K0NW/RG'4A3P:EN@CHOJH PZVK^YCCRX:
M\I[4#B9]H3GH'Z6]3ZU>C&["Y:VTW).NWB#I9JGV9+3)G&<7?,[V[<KY<&G3
M(8#8V)<&XA;RP/>6Z?B7J[QUN3)W=?<GD;RI+;SMBS";BY-WE#_IJ- @)DMH
M=00E"U%CW:[@I22>5:"@'LUZ<@NH]2V-S;68B0(.F68. '!'&7YC<Y08 *:"
MG _NH_MAH.'I6[Y=A5O_ &<OYPK3*W:\92>?];1DO6[;.;H^GS;A;0Q*3L-0
M]4CD2 FE2/"OMT.WI2V] X*F=:V=@*Y84LGB 0?NG^U.H<^A+[D3$X)/0P(C
M@8>_CET"3S'/ARK[-,*/7%']^M7(]TQ(_ADCTFU76-Y5*GTL-W7?Y=W<V-@;
MZ>XJ]\TX24GEX:RJ*K'\W'<?*QXL",>U)\ZQS+2!(ER4WE#A_BFBEPBH)'!!
MK0!--8@47K+;FZ1I CV,JZ5'&O,?U1I=FZZ=NR#;(/+WKQM3[,EF8TFOENL%
M*I4)ZJD%-:$'CTSJ<*#!4#JT-0D.<T9@W%Z8^_%?FML=8J/$*'BGVUYUT.3C
MFJ5N]J8-.,' (?U*J_8I=+*M<>:AF,U%B05%;+\=TM*^8*%1TGW@> '('4F@
M8IAL?,&WNSCH(-PRD&(DWR_;-=[GY2R>N5Z=/46DRGI33.9X"AI3K3B$C^6]
MTDJV%;;854)'*O+7K9(+D<%T7H&X-X2!9P+9];KKQ13I _8H?M4?[&B0[Q5P
MB'#(B\=Z33Q"1_Z+6%FAJO&[WHD<@M,GUV[2)OTW>^;+S@997;I*5J)2."['
M?1X@UX5\-/MK,4CF2%4_,&PN;K8SMP!)?B![U\U^SVK%,6$U]RXHZGE%5]X*
MXJ<8<_N;%?#3^P P[#[URW=^6MU<DVB;./JAP5%T[IXO;D*8L<,MN*'NJ4S(
MYJ.T\>FT/A&GNSZC&W,$D8G(\%O;;I-PD"K.<QP4<RL\R1XO2(\MAAL[E;5[
M@5CWE) '7!]T'^'3B]UFSX)#Q?2<I<%:.G]+O18$%GCF,DP+A?I-Y=4BYJ0[
M[U2I 5Q-*5%5+\#JB]4ZC"=PD&+N,C^%6FQT^8&!]828E+DU04I/ 4K3ARX^
M-?;JHD536N26D,L1D-J</-/[*4KR&AD9HI+D17AL!J0?8?9_I?MU"*(J''_$
M']7_ ,'4G%;KD*VM*G2D*!]VOASK3]/LT(J4<99-.5/V?LT*0C,U\;N'C3]M
M2-"@MZ$0<7O2CVC=7]=/[&@J#[%:UBA#0A#0A>#Q_2=24%'DS-B&Y"E]&6VH
M%!4#3@!3E^D^.KY'J=HGYAZBN3=2Z?<$2!$D,,QQ4J6GNOE<*!&BW"/%O-H0
MVE&Q865,,I0A*P@":@U>;'[I^'6_M^J,1@U,BJ;>Z);E<,WE&8E0.*E^Q*^_
MM1FP"Y4Z1C,X^^]M:>Z6Y-6R!_BR56M0?B.F<.HVC'('L*:;+8WK(![Q !HX
MXIGW3M]D5A5*>EK9GM/H Z\5^*_MJHIX!F0XJH/V'GI!N-N3!F.'+BMV'4K1
M+Q.>8*C]YBVP@RV]*DR9;2G5(9>:6D15***I03&;!"U) /O'X1JH]2Z=.X"P
M/U9A/-IURW:Q,<LI9+Q;ZWA20*-#X>!Y4X5XJU4MQTB]&18'$9QX)_9\R[<!
MI2CA^&:O]< B@K6OL'@?MU:!9(KGZ$GZ7N(^, 6Q/'\*MNJWA'_JUH@<.-5#
MV:SB=)71]G,2LAOPQ]RZ /RT=#]3?%./_MK\F'_Z?]N-9SD# CDL;L3J!R?X
M+Z;#HHTK_4_\\-:5OYEE>+A$Y+9=C*:ZA;2XPM"J4XA2*>(/('7AN7KZ5 B9
M6F'X?@M2OU5[+#NWI9[PV^:E:HYM<5*U>Z*_XM/&I0H'@?9K1W+"V V"XS^J
M=B-SI5V!Q%V!?_W<OO7&4R,4LMU0+O,:BO;UK"B2L#<VM )Z33O-0(U0]UM3
M.!#'2PS'%?E?U?I]_>QE"T#*>D8<I.GL,OQ]P)A0IT:XEY"6V@E+P+7#8GBI
M#8JYO'^MU5-QTJ>LS+Z 3G%4/<= ZC8N'5;G$N34QRX52/>[!:\HCHB7J"L1
MBO>E310.25H!JI+PXA9\-8VX3V\GB2"!Z>*;=)WM_H<XW8$1N@$<<2^16).3
M>D>R7"?2!(FQT*  6IV&DUW+/-4,>'V:LGYJV?J'I!7>NF_K-U?I\=,O"G;X
MZ9_^/X)K'T7I86I3EYE.(!]VDJW$I )/$"+6I%-'YBV#B'["F]W]>=[<MB$+
M-H<2T_1]?:GEB?I+L,.3YFZ3Y@92E0WEV(:G>FE-L%7@D^&L?S=L&I'H!27?
M_K%U;J$/#'@Q@,S&X_\ .IQN':'";R#UX,MGD"$NQ? U\8J_;K1_,D#ND/R=
M4#:^:>I;$ZK%S0!VGW)EW'TX87+<9;A(FL<7.IO<B_B;BC93^1#X>/[= WLX
MCO%_6FUO]3NM[>3^-&7;&?WI"O/I7QR1&##:Y*E@CW2[$\4JY?R0>W0-_P 6
M(]*VMG^L_6]E?-^W=MZN!C<Y?O#@HP8]%L3>I,R5*6O:*-F7;%UH:CX(ZAST
MRM]3V^L:9#37Z9<.Q6&W^OW5+D--OPHQ? PN'W231O/HGFJ$]VV)F-AK>1_+
MK0CJ EPME(6A!--O\.F5KJEMJ3@P ^F2LVQ_76(MQ_."!+90N#MQ)48,>BO+
MILI;:D3U $TI.LZ>%0!Q7P//6S'J@_%!N.F2>7/U^Z%:M!M!N<-%W[F67KGI
M;4YC28=QG%;JRBB!(A%5 MDCBE"T\TZ56;]B7>,L32A^Y<<L?J_?N=2&XVT;
M,8$U!A=X']Y05<_1]/8NBA%DS6(JG]SP3*MNUY!<JCAT2:!)5^W7OXKN#(84
MH5T^Q^M5H;%KT+=R[&-.[<[I(RKG3C@LANVOIMQRP--+GV9RZN])Q*AYB"E1
M)?"ZJ*DH!X"FL?&M"AK)\\/8N6^8_P!3>M]4OF<;T8;9Z1A&8.&>HD*56>UF
M 3Y,8-PSYJ*YN* ]'(H$GG1@U_4=(/%OR[L3CP_:J)<\\]6E"<8W!$3BQ&F?
M'F4][G*L>'0T2)6RSQ(;!CQI12MS<VA":U#*'2" T#\(UY?D+ER3R!]<<THV
MO1=WUJ<3;$YW+DQ4&(/>K@:U4!Y)ZF<#MT.3;$7L7-]Q84A BW%7O^[M^&&@
M?$GVZ]H=- ()U4/+[ETCI?Z)>8MU&-X[:_;LD.YNV*UQ9W]BQ&S/NKG2V+W=
M8L,-0YK9#CQ:>"%!2W"3QE@\$N^SA75A&LER35=F\M?I]Y?L3LV;TYROQF":
MBI#8]SDL.Y-RNEXFH*GRN5+E.K,=I"RIQ2W2: 573BJG$^.O<0$<E]![;8;'
M8VI"W'^C",0)'+NY4'N3@GXEDENEQG9-IN$4.H!0MQL!*]VX )I7F1H'RZ5Y
M1ZAMA8E&<G+Y@\N2>]@[:9H)3%ZN-I?MD)UXJ5(>7&2G:L DT+ZE\ECP\=8S
M'=:+LJKUWS;TO<0G8LRC>NB+#2)!R'IW@MI.!Y%B.)]OK,F9?H\R0B$M,N C
MJ*7N%2A*MC!"E%-1P)&L8VH1Q9NT+Y"Z[T+J6YZK=WTK5QY7)G2&  U4=^7
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MH^SE4QMU_<B5Y+7&4G=YVVJ/ 53*CD@@UYA==([FYO6:][UD<DAM](LB3B,
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M#Z#9B +,3.4F+VA(A@^./H13!N].9PKY%0W<Y:?-383: [?I+E W)VDME5*
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M/>7A+J$IPBWRFP>69F/4RA1'JSRIIU)5=5+34$I_G(Y3_G"->AZ:'^27J*O
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M#U[QHL1;?IF[HE4A*RL&U6;FD-$4K</_ %(=%<4KW$ Y<#$YE%S],OU]\O\
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MJ"$45"/2[ZE;H2PCL]G */;9K".7#PEDUXZ&4N^*)?YK'J,Y?T-YO_D>Q_\
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M T[T\=\[=TX,SMM<9;T>0VF1'DNO-MM*+@2I*.BL%0<*"#N Y"GCJJ]0>/\
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M&ITN@EL549;(VG>BBO +25>/W>?AJ "@R 1K4*47D/%E(*6^HM2@E*-VVI)
MY[5>WV:$>I4.S$L[0XV\5J%=C3:G:?95(\/T:EGX*';BC>H15#0A#0AT-"'5
M)50@4)K7C0T%*<^'C74LAT%*V@D J^P5)_@!T (=5:A#JTX\VT 7'&T5K3J+
M2BM*5INYTKJ4.K?FXP34R(XY\.LW_5KH9#A&=0BJ&A"&A#JUUF?[ZU_TQ/\
M9U+*-0Y*I*T+KM6E5.>U052O*M.5::A2ZKT(=4A5>8H?8=""JO\ F_YN&A2A
MH4.O*Z$$JE3B$4WK0BO+>H)K3G2I%::&0ZIZ[/\ ?FO^F(_LZEBA^Q>>88_O
MS7^O3H8\T>KUKSS+ YO-#]+B1_7U"/5ZUX9" "4J:505X.II^LT--2R'HBT>
MXM/U'4B[QS2U,:?X?9M )_9H:G/[50_%']P_]#N_5J**:K'?NWW_ .UGI^MT
M.=W5R&S8E9KD\E#4EUQU:F^LL1FEN!U*!0R $FA.LGCZ5@"?0H6A?4<]$3#C
MS#WJ=[>N%IN,X(\B3)85#:=#I;2#&MI+BE)30[B:%/ \3J&S*D'((T[]27T&
M@4>]3G;1!Y4^87/]-/\ :[G30ZD,<52_]27T*,J2C_.:[:)Y<%7"Y^)/_P S
MCH?BAGX>U'V/J*>B24TM^#ZD.VKR6D)4^HW&Y[4!8445(MIX$(5X>&AW1@B*
M?J4>AQ"U-R/4QVQ;4*@I3/N7/]=K'@=%/\$._P"U5_\ &5>A7_A/=L?]GW'_
M +V:APL7/V=4GZD?H5=4A7^<WVR66SP_QE=$T)(/)-M 57;XZ-04U/V*4[;]
M0'T>7U\MVSU!=NIJ:$@M7&YBH!2FH(MZ?%5-31\V4X#)U:7]0WT/-BJ_4AVZ
M3^FYW7_L'4N3BHTHL?J*>AITD-^I/MLK9\5;I=Q2O+X8''X3J%([5X?J,>AE
M'!7J4[:I_P#OI=OZ]OT,$.O/^,J]"G_">[9?[/N/_>S4.%#KS_C*?0H?_P")
M[ME_L^XC_P#!FC4 C%#_ (R?T)_\)[MG_E"Y?][=&H*60_XR;T)?\)WME_E"
MY?\ >W0XYH^V)7BOJ4>A)#:W3ZG>V:4MCWE^?N)":UY@VVG&FI<850O#]2GT
M)=#S?^<]VT#9J.KY^Y;>%13;\MVU]WV:$9NR,ROJ(^B*U>Y*]2';F-7P5<;H
MLT)V\UP">8U(YJ**VQ]1KT*N;EL^I?MPLG;O/S.Z<.=.'D*"O'4(PP9&/^,6
M]#G_  E.W'^4KI_WOT,$/V*G_C'_ $/?\)7MM_LZX_\ >W112R\/U'_0[X^I
M7MM_L^Y#_P#!PU-,D,O/^,?]#G_"5[:_Y0N7_>[1ZT,%8D?4']%T*(Y<%>H'
M!516RD&,T3O6M:D(2$ PD ^\XG[PY:C)10U]BR*[0]W^WO>6SR<D[<Y%:,BL
MI;@/"3:U+*DM3D278JY*5-(0GKMM**-JE?"KEXA92"3B5+NH4H:$)A]PL[QK
MMS9',GRZZP[/8(+<EV?+EJ4G8TTVEU9;HDI.UI*B:E/AJ1Z5!?)8RL^N_P!(
MKZBM'?W#HK=5(<@OJ4%I4D[2%;8;OBDGXO'17!'= <X<$;_S^_1G_P (7MY_
ML^Y_]@:.[S0\^*K1Z^?1XJOE_4'VZ72F_=<+GPY[:?XN//CJ6&3H<_4J_P#/
MW](O_" [<?Y0N?\ WMT-VJ'")O\ U O1O&%9'J&[;M "I_QC=*TY<*VX>.A^
MU#]BL1?J$^BV;UO+>HOMU(Z&WK;;A<QTPO?MK2WCXNF?V:"R*9JT_P#40]$,
M<E,CU(]NV5 TH;A<CX5\8&H1@B"/J6^@]W@GU0]LUCE1,^XU_P"Y@T=W+%2\
MN2K7]2?T)Q]M?4SVU2'=U"NX7+WMM/A_Q<> W?9J7XJ,56GZD_H26 ?\YWMH
M*^ GW$_U;;J'"R '!''/J)^B%(_']2/;=(^RXW3E^JW#QU-<EBR+(^HQZ'%+
M"(_J3[=K*B O_&%R53C1--T TK4Z-1S4]T(^?J!>BK;N/J)[>*!XU%QN@K^R
M".&A0X]"/?Y]WI%_W_>W7^4[M_WOT.CNJT]Z]_1_%0IZ1Z@>W+3* 2M9N5U-
M !4GC;CR&AU%,D1B_4,]%4Y:F;?ZC.V[[PKN1\PN8I0@'E;CR)&AV4E\V5Q/
MU _1PI01&]0G;=TF@ ^8W3[>?^+?8-#E0&P#(P_Z^O1]#2TJ?Z@^W$9+X46#
M\RNOXFS:7.=N'P[T_MU%.:R=N"+?\81Z+/\ A&]N/\HW3_O?HIS0_8JO^,']
M%_\ PC>W'^4;E_WNU+E8N%X/J!>C%YQ+;?J,[>%10XO\.7,=&U 25;NM;JI-
M#PIS\=#G-2",DFP/J$^C*2W.<3ZCL#4F(XI+E5K210T(3MMU#Q]NH=&'%6F?
MJ8>@]\T3ZH.UZ_"B+A<ZUY^-K&C!9%CVJ^[]1'T3R&UR87J-P.0U%;6[)7%D
M2'PTC;O05^8@I"2H-JVTYT-=2*XJ&&2D?M5ZI.QO?5,A':3N?CV636"X TP
M#1IX1UK 1%<% \H)]O'48!1V+)[4+)%WZ50"VM8J5;D_<*2D@D[DTK_6U(4'
MVJ/LWSS&NW]I?R')KZFV0VE!M-6F5JW%"U!*0X$IJ4L*/Q>&IPQ"C'!8Z?\
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M2I6[9]\.SW=ICS':W.<=S-I*=Y<M"WEA*BT727"Y':(2EI.[A7AJ0>(]*FK
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M)N$QB;&CS(\F>4[GURD,N*4DB4^:_B)*O#B--+#4]"Q,9'%DAL6)-XOD*U7
MUB],*0FI '!L#BC8KDX?'3*W@HT$I'OCK%PB^8MD&3*N>3O-SHMM==<*$,LK
M;><X>8<":-0G#1->6F_4CHMDQQ '\RJ,/G D2PY#@O5HG7B*M:#+?^71HT*X
M6GK.!JR.QVU,K#82YRE*:6#4_P!Q&J'?W,S?,7/SG(<4RL$ !LV1-B5,@12B
MV3FH+P60I+Z4.$<5$C\5B2>)H=.]B=< ]:'WI@'&:=V6PE368\VSQ4H:>V!S
MAQ(WFO\ ?/ ^W6E;/>6O>MAFHZ3\6M\VY2I]FC69V[,,)C&ZV^.M;<A_J>82
MR&'$.L.()Z;HX.-\Q^II9R?DD]\,#IIBG!;G<(QU^2O)K/<6F8RE)&.(?>%Q
M2HD+KU_FC+U%"I_PC[X]G!C;9O0D]RY(%J]M.":\V\1+T5/7%];L%NZ*M%D2
M"$\6F8\E 5TU-[D[Y1YE6O/?0B($\A[TWG<D8L/0G7C;Z)L+(K9)AS4W*(;@
MU+DPDMU;L5C\VB6I94^R0H0ZE!":\#4CGJO"W_5<?B^*77>]1R4FY1C%K5!-
MOQ-R^SW$VU=WR%I8;52\)=::M2DE4UU2=MEF 4&Q/'B">.K%L[8T<V/O6N(
MD.S)WWA+$2/,O%[R +OJ9L?IXU%HVRX%/Q4"J$-1DDU<6?\ 4:\;D*-1*>G7
MS.X 7=SD."L.9O(C7-V1(QJ*AVX)L%EBMW%2QLD78OQ&%1MBGMIZBQN/ BB:
M5\%>X@*\*JV"!E8U 5TOZ&1U,:_9G:U-VW#HJD3;JG'AT)D]I)FN-2Y </24
MFE$P5BHX\>6E\[8!IBRJ?4-Q.$R _P PR'!-7)FY2I-OCRVV'X]QBF6MMAM#
M>Y:#*6#[C3!J%10>!\-(65PW&YFQ#Y<N*D['\?A6;M9=LP5YBW*O$J+;!U7G
ME%]J();*DMI4\XA ;3, ]VGQ#0"=2JN]L_F 8G$ZL>!Q4$S&G1=)\BV15RS:
MHJ9>XJ)-'$17#MJI7$JD?9H+#O,ED>A1NQ-N9 MRQK(44[R,LN607-2LAM3L
MBUXQB-F@3KN2G>I3N07!#)"DN-$J$B>CG3GXZW/%)DV38JM='\O;*W:C..GQ
MO%D"-4OET!CZW]29^1S[)%;E068+D<O0[O,B79:B5RF)K0<8)4J0X3Y9&T\J
M#?XZ#<76.D[&%FW$@"D89G(<UUK?E1D8^SWX[\N0K@Y.NZ^S,\/-J.Y*4*RS
MM,H<%.%(H$H'PZ(7(O455AM%KFG@*+NRUDFR)S!^&HUIM9?5_K4 _P!;4CCF
MO.Y\I/[I]RTK?7DF-I^FKWTZB:CRT8\?LM5W'M&LY@LE&YF90TYO\%\UONSV
MFQW#(.ZW3E/JVMJX./*%5/;*>^KV#6+D]BH'EWJ4O&@#*1.J64?PK'1,0J81
MO0 $I7L-34@@5K3Q%!K$.NQ6-[,[(%Y?[8R'X476"RK;X  <./, ^.I #*@=
M;ZI>A=E&)/S#*/X4IQK',F0]L.,D$D#C7G[I_=7X:T"0%J3OS.+^Q+4''KO:
MG(B);"5RI4>5*MS J0\Y;D,N*"JMHY+?;_>YZDES1:%V](.:MZ,U)OF\@L-C
MM%YR'$XS4:[R'8?72T@J6EMR8A%:I:^Y!]OAH89I9>ORJ 2PY!1I9<8LDY^5
M"OMP<@RHJ5+9CI<<"24IJDT2M)-5@\QX:W3R5\M79$L_N36R&VRH;3C"UM-P
M9,@,0IRP%+Z:7"VM8*FE$$(<0>9T1!-<TYV]?8ENZ6N5B\6SO6ZYL7,RVDJ6
MPZE*P-P6LFBXYH04T_7H%3S3>U:XX)1NUHFVRS1YT7+(MS:D*2EQ+3325+"E
M(24\(#5."J\QJ>UU0XS#T85^"11#LBF&U.QU(D; MUQ2UD.K4E))2"\0**!/
M #GJ,"F6VGSX)$E-MMG^2\$\0!4_I\2?'4%TRC,LO-2G:M._='Z?ZVL9*0K/
MC3P_T-1D^:RR?-*TFTJL2>BX:DT\5*YG;]X ^&LW=1S5F*Q0..D_QI21Q/L/
M\''04-Q5EUD;J@<>!IH=#<%[H6*M.@';^O\ K:QDI!5@D@T'+1BL@'5.I4H-
MNN-RF0AL+"@HDGP(**#]==2%!X):C=5<A2O*IH$UK3V)T#BH(8+O+_*/R5.]
MGO4?NX[<DQJG*OPS*?U-2%H''U+L7K]GW:_Z&L5FRYO_ ,P-.PR)V>[*O9<7
M13.'ODA"5+K(V1@WNZ4:00D+/CL_3IQY>G&-V#XZI?R+@_ZU[>>[\MW(6P=>
MFTS$8>-$Y^E<Z.-Y(FXQID!]AN4RZQ=DK<-1Y5HH4F,?>6![Z%'P/P^&NO[?
M>VX;0"1'^V,C^%?FKU7RYN)>892C&0'YR>,HU_J<EJV]=G>S+\0S.+A^.9.[
M:(QM3 1TF9*P&WX<.2M(4VDHXNOU_5JD=?ZA"5\PA*(=CA+$19?6OZ1>7[UO
MI$+]ZW(Z!.):4/E-TRICFRPF8]3><N,."\6SMME[E*"XY?CN8FXL@4/X/0R2
MSI]Q55#\)7O*/Z!SD76X'UK[#AT0ZFTW/]4$QKAWHRG)9BF9=Z0B&(5T3'M5
MBMUT@V^V2'FT",\P+IYM3C$5:004N+VI1[QX@D-QZX)E8Z+/\,LL3%,W(;M=
M+_,ER7+??K?969UH6'E*83L88L:(TZ I*F5K*KM<=TQ-$\4C1XH 9P_I32WT
M6X0^@D]L5E=V7SC#9UL&(=R2W(N.+(D6/%LB;0ZMI"I40,H"G$-2VZ%<]P5&
MP#?H-VC%5._M3TN?C&.D"O%@>[335,[^CG)>UO=.R,O(M\NPYG?EVR7?IKC3
M[4:Q=P;I$C2GF3$F,E!\A**O>0O;M&Y)Y'PD=6&"VNF^>]G8N> 9V]<3$5MW
M<!C@HFN2LO@Y^AF:U'BY([EH9@WE,:2ZU6)$EQ;"5K:D.I4E5@::((4!04-#
M[NO.5H$]UV;DNE=)\T[;>VA,2@Q!PC,4$FS2Y:<&OEQ0IUFU2&&$UW.W.TW*
M(\D;14I;D)BN'@1]P\=5F)N?4[]H2R.S,:A_6$H-86XJT9-$8N4B<E<5$2?;
M#"E6N0J3)9GM06K7=KM%C69@J<#B5EU;B?@-0 :L-N=)$C2H6S'^D*O_ ()C
MP;7F5DN&/QI-N%MO&/OKD6E*RV+D(CRWWT];)A*5BBPH2TD!*T* H"*I7IQ"
MY!G!HMB.]$0(DCU%-]Z),,]$5-Q0]<:"E[!'2 &\E._@*D!0_P!7I=N78ELA
M[TLV?2+MHB1! !.8X,GU:!=[?<+0J,T?/1ID*2YDT4H$Z.]&?9<97;WEN*80
MIUP%1WMN5*4TIQKH6I W&_>%/2F\YC;6CJH!$^P<E?FX0_$G2)DJ9\TENY##
MAHO#*FU946+O;)%YD!4D), MM24! _DPH$(!J02;CT\O 4R/O51W_7-O:GI,
MXNX'RR.(?)3/F6$.=K[]'R2[FQSCA1?P_&HP2XLRY#S$AN3;7^C+)\O9(F1K
MN#*JLH5(&U*G%?A%A>Z7>$"&+T^J/%5G:>8K,Y#O18D_1-Z!UC3=\AFJR!TW
M1EN*M,R?.4U"CR>K?6+K(#\>=)!7*V2I"&RM:#TE(4Z0I"3P%=WG3;A$@Q>N
M85[Z3U"%\0(/=.C(Y]M57(MSZFGI4EQIRU2J=.RNNM(D)44BJ]BW$J]XH4>7
MW](;FPN1- 1<!Q<*\[:,;D!F&/O7D:5DTVW7&-;G/ES%XML:4&'$E*W$M3"Z
M5"K@ &V)3B/#37N@UJJ]!W]*,*7/%N=:N%N9G.S+#CL-N0XI VFUP)#+A160
MGC_* 3S\-0]7'$IK88@>A%X4ZXVSI2X=]5:A']U;325.(3QKM_#;=)XCVZ@>
MU,8,S9JZY=I\$,,RY*#;(R@Y9RD%2BYQ"0K:I5.(_=3H9Z9K MCQ7D_*)-Q;
M<2](0FX/I#<X *HEH IBD'<H5HI?B?[(R*9*PS&5#A^8$M)*R22HBG$J/@ ?
M#6)J602BMRNJ[]=8CJQMV6I1 HI/'^7'[U3XZBW3'%UX7OE*^E3^5663]+ZU
MM'DUW9S\#]=QH?\ G=-MM@?0JCU3_<';+X+I4.MH)3+!>ZA9+4%]=MI3OTO/
M54E+G3_\5V=^\>7'!,JX_JT5R0OE%(C14,)#\G<K<S[P!/'H'^T5HJL.U+;$
M0VR72RJJGQW$#F% _P!Z^Z-!)-2LRX(=*MN>+TV0F[M"7%4IEN3#3Q6ZI:W0
MAU("EU#'O$\^>O.8,@M.[,"N;GBC\JUMVNX-+M-U;-PDIK"FJ(*+.A02>DX0
MEO;121S.O V#*@=O0M.6X@,?<4O958X=J#D7$9<BX69Z+ C;)+:D57 N1N"Q
M[\>"11I*3\.MF[;(%7=OBM WHD\TPUV6^FX)DKM[$2)=&;VJ.MI;:E/BY!I1
M4L)E.J20'$D5"?B\?#WZ?W;P)_$/>O"1$@P^96+#<4V!5M*P"NP8YD<A_P!U
M2MH=RIIZJMO,?RD<N.NE]+N1C:C$X,?YE,H3F[9MPR#)RY'<I%N3B4?%;FVW
M%CXPVIUA>ZJAYB\!7]X^Z!^S5:ZB7@>P>]/8UP3->O:9<F+<'9LFUQ6'+$<A
M$:-)6J[IWE3>UQ$>2TTF,E#]2OA^+]AU2[X_JD#\1]ZEGQHI/PK#4W^UW"#9
ML?R^1<;'<1DM@FLY]VTL"9 6AY*U!O(O+.)0EV\*%#L4:5Y<2PVKZ'S8^]9
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MI0)VBX].86P>1]Z^>/,?5=S;WD[;RBTH_41] *=>28RG,;Y=9>72,9@PQ?\
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M6V^VJU8+WH><D,R''XUGR!+<=+R6&94AM@..-.6]Q02PHCB%_"-6>Q&(B-3
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MH2*D'::@ZM73[8(#_NJB=4G($Z<6G[&3MQ(S+M[EIM]ZDW2BOYW%34;WK.'
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M2[6MH'CR!H:GVT]GV:G),-*LPHQ"7U*-:4I7]"OT:A P5NT-!^>ZD@< L?\
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M1J9\"O*SY%EN )Z;I'#7;J7;,+']Z]29#:D2)2/> % %<N'VJ]FM353%=@[
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M'7%-W%J#'=3$9<>6U)$5,$*(%4N;NH:!.WCEX&;>S[8+2GY5)I&6 /\ R_\
M\K-7XMY;R_+&B6H5RNL-ND7&9TMFWQXR4".VFES>;D)42E0/^#)_C/LXXBS5
MR/8M>7E3<#Y#,!L1:/WI8[B92C&Y$MZ/9[(^[<EH,2#!E0W56IA3B4+:;6Q#
M67ZI0ODAK@KEI@/:R]-OM+URY429S]).2BB._*RQZ<U:8D=#\"WKE2H+\-*
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M5E&S<U RC)NPA(5ULL.T]*,M8N5P>*0EAMD-.HXD5"0N0M5 DGD-;\W8JR0
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MP\-8@9*# 9JN0_=5MQWU*%G1(51;302-U?"G3/.H'/0X!XJ9 YX*M5V<@]6
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MAAZ568W1@DV1Q1[O)O<%_I/+^H=,;!P;DLA>#51NULQ9CB4$$**PD+H?=)H
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MJ%:(X+Y>[Q@6.''@K#"S8BSQ@VEB&%3Q?X<E,';!6,9+*RN%*CRD7698ID2
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M@$WF/$+V%_50_!6+W*CLY&S'BQJ/>>>+P)--DU;DY8IO4.*W0>0U=NGQC&W
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MJV6/MNVT]=5,42+C)M0A!T.*ZJG'@E5H<X+*1^(>'$ZC635ZKGENT+6[9O\
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M5K-ZU*$#%R!@)?B?-/2;@4UF/CS64Y#$M*+'<VX#MYM047KE&@2(;#;C3?\
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M/:BXZ2;HPT^^I:'T[B.F:,DA!VG\0A5 ?LTPVFX:%,AQYJ&HC,1)C-0%H=E
M/-K@%*9+J*?AN+ZU0?>/XM*4\.>M.%2_->%X4+\']J^EE^569#/TQHZ>HXX6
M^\G<>,5.+4LJ\M=W&PY51-"YS(_A.FNV+Q/H51ZF7N#@\O@NE<ZVPE,L%[J%
MDM0OUU05_3$]4+:FPZP[VWS-N0V3M"VUX3E"2DJ*5  I)!X&N@H=E\LABVPK
MBFXQ9CIK#CQ%V@NR>JW:EF)&*ELLK*4E2BZLU26S[QU"Q]R3\6DNQ[Q;IKK4
MEZXQ&YC*8SJ';5UO-0)<3<5K2\4=/S)5\)W;:<*U _%(8V!JY=B7\X<R.7-L
M$BX@M,(MC-O@Q(=X6HI3;F(;#SLHMM(W^8"D%*5)&RBA4UU"8V;. 9\,D7L#
M<-,S_&%]AV3@??EVUFYFM4&A+TZ%4D<:ZE,86"1Z."04J<M;"(-QK9+N[>'[
ME*N-S:-W=EQ'H<:,Q;PN48+C"69,93G4WJ!*R-@YG:A8(I7U*O6^GP>L7_RL
MDN<TME4I\R7'V7WI+[88NR^D\N6M3C[B(R-Z8202DA(W5K2ON\6NWL8>C),+
M-GP\F ;)L%8\H8%G=?" [YA2COD,^?Z/%?#W_C^'[-,K=@LWP6_"9B*(A,;B
M7/)8(N4=ZZ/R8<F0F4'%0TL+BQI\E#1;*).\N+8VUW)IOY&E"^O#NE5VT^.2
M7$2;K'DOQXCKX@S,;@B1#8F.LB*K(X#H4R\MNHD&UT4FJDH*^/!%=5W>X$?Q
M)E8K(<**[D4>(W_-M+$.(9$!EQF3(?2S*7*#SKLCWRML*;V[DIXE7P^&JS>9
MS]LDSAC5$VIE]0T^]9[C>$QGDT4F%<IL1I-: U$=90KW2/9K8Z=8'B \SER2
MTX.B4%+#:DOS[C)D3$)>7T)+CCSK[CE%*2IYUY2P0M-"=JB:ZNEJR/"H/I&7
M)8M1SBW!..U8I*>L\^\HD"*M:U]..I1W4WJ /5ZC9X].OP^.M#<V09,1PRY(
M8CL26BZRXT!4>?/?<EDBCZ^JM5 4$>XMTJXD'[WCJL^/S]JB#/R[4G+>-VCI
MB.L-25IW*1+?CA2FSP^%#@4:N%(K10Y>.CQ_LZ96F>)[%2B&F8S65)?MHA$I
M#3#BVP\$U -4+8V @UI16I\<' ^U,X#NLG#9)CT^?&OS$)M4&VR4O6QE,@,"
MV-!("FVU!@AP*0XH5"6Q1?+VXJO^"V'N3H[@9NQE%R@/V/(Y5EG.(:8O;%I?
M=BN 1^@C9)D0Y49<KS14\ 5I'3H>"MQT8H%DC)_0F>N\2H"Y"(5XNRGW&DIC
MOR;G+E>5=*6RIY+:W1N*E!1X*2?>Y^V5'@8EO8ENV.3G ZQ<[A<6H(B[(T)^
MY27+G\P!61/F7IU:'[@2-B=BFA_%_%QH&4P13)E'@F1J*]E/4JVYN:V\LW)V
M=?IUFL?E%4^8W*1;F'"=SCK$$J<C0EW7RM72DU7L%=VT:7;@4/I4^">'L1>R
M79Z'*2[D%D8RN7/CW!J';Y#28"W!,N0F,O==Z+<U5CL)Z5.G[U=U1\.EES#D
MH\%\CZD>#C,U5GM@D0L72]<S"<=:D,M%(0TA_J>12J!U2JNW;N'+GX:8Y\4"
MM5)&/V6WIR6]Q&<K@S8EB"6)7G;,Q:Q=%J7+;9<C2W;K)#RFC#45;0X4]1/'
MB*C BB,%UE?E4;ACK_?[U+LV3'Q:'V^WDD!^-)1/:<;1?>UR)* EF#$2E,J6
M0\3N(!X<3[VH(+5P60-6"[BV$N)X*)I]M?Z^O"^8F/-9V1(&N"$L@!H*0%-I
M2[(6LJH$"/L<I3:0=P/M%*:71LB=T9O+VNMJ<],7R ?U+3%]> X\/IP]ZI=[
M6TB)&;C22E2FU%S;:KRV!19 35*SQH=63INU-R9MM01-6S<45;ZMN+-NV+A;
M49!G+9%?-2P[(,L*Y=EB3ISMFR&:F3=$0I\IN+)D-)CO-+=984IEPH=@,J 5
M7BD?9I)U'RUO;,3W+K$#_ER&:^7?,G4X&U*[<(C*-L"IQ&HXGTIVYY&O]K:0
MKJ3Y<^XM0D1%(E2K7MC69(#;2W1Y@RDLHEI"3PZ?&@][5</3]WMKO?C<9_PD
M8)7Y3ZUM-S?\(3C&(G"NH38DE@U&=J*-%9*SB%A2;)YN+EZK@9DO)XU\<>DQ
M 4R_Y/Y5EEN0H@.->_YA/\7RX\'6VO7;,&!(.6+XJ[;W:PWUT&Y$SMZG,0&=
M@0^;4Y%-_'5IGR+HF^7B? 0PTM28U'IH?.S@ \J3'#55>.U7+6WM][=M3<F7
M^HC);5C9QB8>'VOI5^SXLJ\)<N-AGP[:JUO*47+K,;?7)ZZU*:5$;?=C*8*3
M&)6$%=2I->0K9=GUR[2,9%PP^<I\-O+PN\"1I!;T)R2W(DJT.63)7V7)6]2A
M<V-CNT#J )2SNXC8X/[H/A_98;>\N;BV\C+_ %$YI->LW+6XUVAG@W)*N3,W
M.*UA=NFVLX[:D6Y\RW&W%2VW'.C<MF]8CP4))<2V!4GPTGWMR]&&88#/FO+H
M-O:;G<XQE&4Y58&HB^"QS<A^1OK\Y^3)GVU=VN!BQU3'2E*4S*H=94I3R8Z4
MI4DT2GCPX\-5X;RY;O8R8R_$>*[/LNB;6YLXR,+;^'&HMQ&,<^/:GMA-QCQ<
MX:ERKF_-6628AD/KV0$UB^X X\Z'"-M*C9^C5CV/5;@B#J)+'ZSQ5:ZITO;V
M)&V! 1$AA$#)_BI2[X%^X=]<K+UXNXF.(C)M4F1'EA-_C"7**GF.I*'12$]7
M@E3P]P\>/#O'3K&N_IUGQ304]F/!4+9[/97+$;AM[>6T%R9-('2UL-(TP=N&
M&*RDMMHL]NL5CBOV2-=[A<,3Q%TRIJ6GG+,^FU),HM]:+(7_ "UQ\%5%-4Z(
MKN^[W+IWE"%_I\)W3'5X420;0+/'-Y+C75^OV+/4KL-K$2MF[(1E&0B"TC4,
M#0T+ TYKW.&NVV3XHWC [?VFS9$VNKF6Q40)\EQ(3( 28#5GA/)X/H_ZJ/\
M%CV\*SUCR7M(7"2;1[P_Y,?P_P 2V-CY@W) $(78EC43D<_X0M?;Z;G;&)#\
M7)+).DS/<ERGY<4.O(5M2I(2N8\L>[R]X\]?(W4+I%LUJPS_ 'E](0Z7:E(#
M0-(=AIY)#>9<:@0$Q'K8E59#CSJ'&%.!QSH**F7$D*!*JG@?9JF7K_\ 6/\
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MTN6D>Y30@=B<T.WR'KM'LTFZ+CQ)* L-)60.(;-"0@*'\8?'6ANH!\,_@@@
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M+*TYTP5(!V1'&@=S+C3G)]7WM7[HNVBVD@:]))J?Q,N3><.I7+5L3A(B(N1
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M>:X$D( H"W(?_JZ8PG2B>V;9@ Z6<5R&# N:8F:*%UN#JB+JMH%:4L%"A4%
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MA=-;QC*!X@+4""-P\%'6_MIR!XT^*];N\E',^H)/>D7*9(>;N83!,8;DLMT
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M%"X,5A3Y;0MNO4)VUX<SKLG1KGB6(&5.Y;QIB.2^=>L=:W.VZA<C;F3$7K@
MC&)=I4^8!-FW8U8[^5MH2;L_[RNC)4X*;3LK^&Z>5:?KT\-JW<#AI 8XIOTW
MS5O;(B+IN0E*!;N6^*D'++;@.%]I8<[([ [=)(R:]XV[("W2IL-8_;)-I<XW
M"-7;=[@DDTW'D:CAJA]?VUNU8G.C",<SG-E[]%W-^Y?A:@3J,Y<*-!SZ  _%
M81*N3"D095DD-V]J2N'8;I&F(;=>>N$4HA3S"6XB:IK>^ZO<4K:)JGAP%.,]
M4NQUEC37,$<P<%UOH\;GC"$P[Z"_$%V/8KY2U:;G=$AJ8E=KBM2TN2GG7(Y6
M\S#>);0Y(>2!64?N#QUHV(B873>GV8RMC4,C[U1"CW!I$>ZT$I,E6TH4 :[A
MMY; .&\>.M\]-M\!ZRD_>)Y)1%CN#EP=E2\=97''2<B7-=RNEO:M+[BEJ0ZX
MFVN-(D)<4$J/42X$AO@.)!Q_ML. ]94L0,0E23!F3TH9O60XWD>0(X6>VL7B
M^H7':X],.%NW0MQ0V0.._BKQU/\ ;HLXB >V2/2\5XF'8;-#)O33V33!Q:E0
MEK9:14I2G<AJ1;D&B@3\!YZVKEL-]N*Q ;' %)=WELWBW1XKTI$<DTLUO9"6
MW:+Z:7FY*D)2IP@!I(JMSQY5XIMR!$^M91XKVY.S(C*IQM*(D#,/*^1>2A.Y
M/R*(G'Y.ZM0DN2[<M7NE5>9H>&DUR<A(UH@N4WF0A33\)E1#5_?;N$<U)Z;+
M"V7EI!))%46]7 <..ME>LW,@%*DZWV->*LYE:'TQU8H;8_/:42?,7*U(+T0A
M*E.HJF1"<Y[0=W$'P,DMO.[#-PJI_<_,)EKM$?(!%@20^+M97VF(R=R6TRH[
M2E$1&R5=*4>84- )2NZ*]VC*- B7&DNF)*(M\)/43?2:O)4*^[N4A5:BG/\
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M=!M)*JIVN_+NWVUZ^(_TZSMBK%G)JJ-YJW=[9VC<EXFF$;I8/WM(!8GGAFW
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M""XE+DITK4@R7Z A8X%1_3I)MMR;<P9'CB6R2_=;/\Q#2V7X7P+IT2,K.,S
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M=M9FJ;:FE18^90U;E;NW#/PE=3SIK(6(@.=3]H50AYGV$03&<?$!H#&9; '
M9!SBM_'H-[/^F#L1V1C81Z5E,?T5,WZZ/6YYA*R%/EX)6PK_ !5:2!&00!^
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M<J?^R*0[&Y?U:H7)1)-7)'Q3+.1X_P!%* (R5MHVLLM6QED%20!M?D(5Q!(
M!*>''6A>Z!.%#$@U_P"6RO?2+I<:B]89OZU=*I+T=,F-$A+:-2 W(:4OF?NH
M9KX:72Z-<!PEC^ _>N@;2Y8T5,78\.*]2MYU_HJ"FAP]YYM30\?!=!X>W2JY
MTF\ [2_T%:G]/$:?8C+VYM;;;;D)0)*7.FMIY7 I"=X2:M\SSY\?9I;?V5Z'
MTRS^DJ"+;?3[%X^IYEL+::9637P2*\Z_=5[-+96KL2QU>HK$^$#]/L4B=LLP
MM>)9?9KIF41F>BWN+K;'PVAN7OC264 RGFGTLT<=K_%+^'[>&?\ 4 ;O>LKD
M<1<\0FWJ,!R*=7>^1"R?)9&;6",W9;9DC3BV;/ F)I#1%/5&Z7&:B)D[T3J)
MJRC;M-*UX'?SU>U,MN;E -34XJ'+$QC@D*^=7.?%510/4GNK%=R:<%NMCX=0
MUS][VIG W6S]27)TQ$*5(1#FMRQ(1M2E#:6@V37B-KKNZ@3]FMA@MZ#NR:3K
MLI.U#SCZ"A3BDN,/N1^KU"D^^E!][I[>%2>9U*96G[OH1+:XYN,J9<7ZUV_R
M^0@H\!0E2_#]&I=,;=0R-@,))VM%:>&U,ESS01_I0XD :'7EX!_#[%6@Q0E1
M5$92\?@?B[(BP>/\:6VRI[::;:D;>/MU#H-DGZ?8K"@MPT=DRUHKP1YIT ?K
MW'^IH=3X)_"?4KQF.J^)+9_U _T=2M+P_P!WV*V4IEMOL+=>CMAM4QQ$1Y<;
MS'DPIT-.%LIJ#N(!-=M3P.CT(\+/3EP77O\ E'(P5ZG/48RX'9*U=G)TN)*F
M.KEB$&\J[/,[&FW@>?4J5!2/T<=2&]*@P+@@,R[]V>:?T?UM:<>'-9!6+D%>
M6=<'$(8?"DC@HI6@5HL<4@!/'AQUNV6IZ%XWZ6Y']T^Y:COK#W:UXCZ$^\%P
MG0FYT5<%A3["Y*(9)5 GK!$E3$G:0E-/A\=,($F-<52NO6X6[$0'K,$_Z2N$
MFV8S8UY<A[$I5QCPWTN)\A9Y3T=A)+,D&OD5I;40DC[@J -/9=-C=-'J,&7Y
MS;7KW5=O_N"[I!Q>57#8LL%?5+B-QL^8NNS%71AE]=Y5&?D0Y0*NDZP5%4AU
MQ/5)ZB36OV^.E6ZZ;';R!D&$B<8M]L5W+R%YCN[F'>F]RWX+CQ'.>(RP^S+$
MJW0'),TIO4F3!M1-!<MSLE/W:5CJ<82!3=_=/#2^<O ?3AZE]/\ EKS1T[\O
M"W?E9%[1)Q*Y%_GYA\%E;<_33)N.+2,GQ>XW*\,QD[BV^N2"2"U7\3S4D<$/
M _#K6 (7%.G^8K]Z]&)) <_6^78L/[C'EP93T*8[-9DPW767HR'WX_24VLMD
M%RM7JJ01\(VT^W4R8LNQ>6M\;AB)%P?#SXH@K=Q_'N//_P!B,@\Q7^OK$+M/
M3(6968EH8'$#BE"$M3[6UYUHKK\99!/  ^*Z_P .L(V&E^Q:>X-BS$D::-P&
M:M2FG%+:+2&W$LE74*!T31930G:%;J!!Y\M,;%@EO1DJ=U3J8!,8'\6$DK*M
MULGQ$J1<VT2Z^]%VH6M.T*2?>$A"O9]WQTUA8#,>'!4W<2OWIF<=1<CB< R2
MH98MS*D)BVDN'^ZQ[;%AJ!( J V%GP]NJX2#3)=7M>#^Z_H2>$==]V7+4N6I
M@A4-A3BDQF"HJ4X'8ZNHW)2LH1P(30)/MX#^I:74J63H_#+#L4DV5^PWZ(F!
M>XEEMR$&O6A6R%"DJV[D^^^V&EJ)2OCQ\!K,&O)<LZMXWBG3J?7'B?I32NE@
M-K?Z3<I,Q/ [TIZ?,D?"'7N5*\]:!846]TSK!G,5S/U\D1HV M/4V[0G>A*S
M16[< % 'C2A\/'6/N5WL;XSL@@FH'U<0KT*-;EJ.^%;2JIJN1!CR%']/42#H
M2_=7B9$N07X\DIS7X$>1Y-E!0H_>:C>93][]S:!7;I=;NRQ!]J1W+\XQ,C1A
MF>:2IT.0RWUFXB9;2T[U+#?2+?"M%("':*()X$CEIC9O.S<LUL],ZC9E=$+D
MHOJ&)"(!3R&E+A.)94H4*.C[R:^Z=J@M)!IXTTPA>[HK7M74>F6-IN+&IK3Z
M3E$YH--R6(HC(ESW%4_C)4R1*'  <6W%4(X>W6+5=+_[=:%>Z/\ */O5X=4L
MH26HA6BH4XN$VM2R>.X5XI_:="/!M6Z=RG(!6"XXV:*XU%*M?@ 5^Q-="@RM
M#'3[%XVDH2$*"7T"E$R1UQPY5Z@(.H=']/!@WH2RU<Y'EUM*:MR$H 2R&;>P
MTL"BJA2TT*N0T44@VV^D>I%8_FGUDER2E)-2EIYUM! Y@I!I0^(U*@"W^[[%
M]#W\J*UYGT'=RS'%NB/H]065LH?CP6$*\FS9,++$0]-39(9W*VFM 5U"1XR.
M!P6M7$8KJJZ;O]]/\1T^1_C?[[\7/[/X=0Y4KE'_ #7ESN%M]$/;:5 GKMKK
M_<I";@$%*NK'5,QE*ZAQ#@]Y)(X4_3IALXO,BFEENQ8!C@OGIBXL/,LKA)/D
MTK=<9?.T*D/.E"I*U&JMQW)2>?CIAH"R X*^AQ4M.U7'F>)Y4X>'Z=2;8S0#
MP5GH#V#]IT>''@5#JH1TGG0?ZHZ@VQDARO?+)]H_UQU'AA#GDK'2;]BO]<K_
M *+66CL6]_;H<!ZRJ'8XZ2W4 _A"I]XU]ZI%.)_=U/A]B@]/@,AZRJ1&5Y7S
M0^+B/B->!(Y<N&W4&WQ1^0M\!ZRE@6V9>9?5;5MVU!K0<@I7W4*_>T"(2"YL
M86XN -7:>Q)LF+(B2U,R% E)VIJ:<E45R2.>LM(.&*T+MPV<,G]BI?4G9X<*
M^/V:@VP.Q:%SJURV6!+=D?BE6V10^V5D#A]IX< ?UZ1VG)8K=N;Z48EG;L"L
MOP_,OAM-/PUJ!!4K[R@/#[$Z=[6V"S\N*2[KJ4W+$YY!756]<- 4DTK7DI7M
M^T?9IQ;L1(H S<TIN=6N1E\QQX1X(J^S#"?V>)]O^FTH\,'!6(^;6K_4_P!,
M/O1>/&B*#S@X]/:KF>%=Q_>_M='A#@H_[M.+W&_AA]Z4(EW@,JZ;B2=M:\O;
M_IQ[='AA3_W9(XFZW\,/O5HW>W/@[4?H-3_67K>$%8!YKF,#<?\ A@K!>:J2
MR2FM-U3^SF5>TZG0,U \U2/_ %/],$.NK]_^$?V-&@*?^Z9?O_Z8(N]<($4"
M$PIRBB"!S%:_:X3]S3#P'K1EZ:2:JW-D)<A44\IE+*#MIM 5N KRYTV?PZ!:
M#X#VH$1FZ;,BY1VXFSS*U'<>5"?O>TC67@Q%2!ZRITL*LR>&$8FSF:[U:I#6
MYZ0Q;X&/+*ECIN+N#)'P&M*.*\%ZQE;C<A(2'<R]:Y=>\PG9W(&)D9YAH\U]
M0+\O7@M\[0?31[5X-D('S")?;_<26ZJ"F;BQ:%MJ*G6HZR5!K]VFJSOMM'Q"
MV(IZE:NE=;ENK(O!V)X1S6\+YFSXI=/M]UNG_/Z1W(2B:I['?D\?4$N))VJ_
M5J)8+?N4"TW?76R"-C7TYN]EZE+4E,.US5>[MJ:V*]+/!2DI/\7XZM/EEY]1
MM0.!N0?UJJ]:D(V3)\'_ &KYP%HS&S9"_;;@F=(:8=9?4XD)9YHDEOEU5#FG
MVZ^O?)VTVIVMOQ#!S">)D/\ F<ESW='<7'G:C,QR8!/"^8G"BD(N,)I_>D>Z
M0KD5$>!0>8U9I=)LS&F48L_&2KVWZ]?,@1*0)QI%1[>NU>+WEAMSY6U&Z:7"
MHAR2D+ZP017:\?AZ9_;KREY7VU\?+#_5/-6?8==O"0<S([N02<WZ>\'>BA;S
M*0H\^G)G#Q5_\D)Y:\_^R-G<CWH6_3*XK)8ZO.9#&3-P'%1H[V*QM3H<@H?+
M')?\JFBHH2?^J3X$:J4?+.VMTC&(_P TD\'592BQ)8X4"78_9_MI$C%4JVRY
M,E 0IQ0F3]K2DU*BL"YH!"U#Q!Y:]#Y=V^<8?ZI+S\25VDJDI=#_ &]Q2 EN
M(TU&VDI(<2'B*[UD$R'WCS'MUY3Z)L[?SB _S36(V4+M0'':4DIE]MKPH!V*
MI\< :E0K2JJ>Y-3XZSGTKITQ01?^*:3#H]VT=6F@YE$;[BG;J?!#%LM?06O>
M'I'4?!9*]H;5PFN>.X\O#5?W_0; <Z8MWLY+=L3-@@5! 'L3&9[&3BP9./7O
MKI65K$=:W2$IW*!'O1W>2OM\=5>]T7;QD>X'?\4N':G$.JW80[LB:<(IN3L6
MSN%**[A;69] "41TANHJH4]R-&\>.DVXZ/8TN!%NV7%;OY^X&<G#@$WGH90Y
M)=N5J>LBVP%-E3SJQ*(ZA<("WW .@0.0'QZJV^Z9;#@1# RSDI.^D "YKR"1
MS>+>A1;,A9VJV\D'PK^_JK;C86Q(T&/$\%C^?N?O&G );#\.9[[32IQX4?-*
MIIQJ*+'(?U=:W]OCBP]92:WL8 ,P /,JIU]Q\):<N+O2BBB(ZB*-)70%(X5X
MAL#GX:@[" Q ]93.QL;8+,,LRD][R[IVMLEY8YGV\/\ 3:/[?#$ >LII'81(
MR]91AB/OE;FE$D>TD_=5[:^W27$);;J>?[$4>,CS3Z'_ (4%/3Y>)6%> ]@U
M*96L(^A>>'ZS_7T9IC:^WK7F_P#3HTIEH'#VE>A5?;J"&1HC]BJM0IT17G#4
MU2WPNQ6RYTUN$&G^+KD32G@PGV_IU(YJ?#:E%U__ )1JY-_YT?J%95S5V/N2
M*@#F<P[-*]OL&I#+RN6WB3'%=_#/-/Z/ZVM../I6B%Y-(\L\@_?COI_7TZ#^
MKK<M8Q]"\KWR2_A/N6B[\P/(E6WZ9_?.XQUE*F(45*2* @_*KN?$$?=TSMMI
M]*I?F.$O!B>,A_*5\[3"N\F0XSD"'8%Z6\B.ZLT+45P\6%I(HZPH'@?'5XL1
M-N;O$CM*^2NL^2ME<VA M:)D4(E*E>!++/*R6JT>J"P!G*&FA.ML5E#$S;Y0
M@WI@B0I9MQ:W%2H"#Q2:>%*G6UO=M9W.U,F#",LSBRX;NNH]1\G=5\.S.0EX
MN($2"(2SU#@>'%8==X_2I?>WLIU-G$:X6IYY'22J3.<!"F"X0"[&4JH6".?#
M7*>M0O;64O#), 1@!^'FNH>6?U/L;Z4;6]E*WN3$U$85[W;\% 3/>'N'8[*[
M:&9ZX<1Q(JP6XA2H*+:34KBK5QZ?M\-><;MQOZ@8KINTV.UANA^5D3"N/85#
M<^Z2+W(7)ELA#W4<6Z\$H!D+=5N6H[0!P4DGD/BU[ ZHX59=5\NS-F<&DXU6
M\&X\T4+"36E?#^ :P(JNU=,ZA,68U+,<A^)5>1,<I -*GP4H\^'B-;]NV\F2
M/J?4Y^$0"<!D.*7&<:?E1G+CU=D:$A*I0W*JI+P4I/)-#M2RKQ'/32Q;H!3)
M4W\Q+<7VD23KX#,\DR78MKCRUS6)JQMW!2.HOA3;7@5E/-.F4+8+*U=.Z=;O
M6\J@YGBR4&HBG2 23QIX#PKX:I9#8*-AU*Y=F!(RQ.0X.KSEN6P4*'P&I<XD
M\J4YC[3J%8BUZU7\/O"J"8B_=W*0JBJT4I/(T\%#60+!5;J'3+<[AD0*D9RX
M<E(F!8U'OX<?N,E2]B5GWE+%0&MP^#;XG6A%S%W=<OV>Y(W@MAPQ/#\)32R*
MU6^+>9,:W+*]CRDOU6H@;75)12JE>Q7LU+C!=&Z=N)RLQ,L&CPX) DQUQ1N2
M:5-.9X"E?'[1J!P6Q>F9'DZ?V,7FU6M3D5ZVHNC[J5!#Z_>VE:-O-3J#P(KR
M\=(82D[F@=5KKD;ENS*Y$@ 1CQ_$DJ[6FZ!=PE,[41)BU.EC<HAA-%E*!5!H
M E7@=;UF9<<BJMM.L6XW80[PN1DSL./:FI+0VB/MCC\5*DA9J2.8)%"2.7V:
M80F0 778?+G6KG@QB\ODX1_$KOF6B>"?;X_Z.M_%6ZYN" 6.0R"-M%#R5;1R
MI7]8/VZAB:I/N=W*+U.>01)YE)K2O C0'>J2W>H3$Z$X\ KO0'V_MT+8_N$N
M!]B\$4K<13D*U_:*:,:('4)&E1Z EBB(K9!3Q(*:^PJX \>/#4560W\J"M3P
M"^@U^4P@F-Z#NYJ2^5_^_"9<JJE$D#Y#A8]GV:RQ3E\\EU;</:?A]OA[?TZA
M"Y=?S,_:]/=_TH=OHC]R^6FR9Y&GQW6G&4K<=N-RL%M> +K;Z5;6%D\ "/T:
MVH69Q,7'<)/N7+_/75#8Z>9/$OIHQ.$P<EQ70/0>JYV1V1"SY34_K/P(S<F5
M;VEJ%N*F6E-ER$RDUW"O'V<M/]C:$:DG5W?M@N"1\R7O[CJ\*SX?CFC2>LOX
MEC7W6]/4_MO=68D[.FG;D"TD /1W@$JCAQ()894GX=OWM6O;7HQMAS6OO7:?
M*WF0QM F-N/<E],OQ\BF;![.W.ZQT_+\OBLL[@%*7(CIH!M)/OA/@1X:\#>'
M$>U7K<><HZ3(FU_HN?>I6Q7TP/WAD-J[BX\\E*X_GH=Q9D32YU2K:&?(=+9M
MVKW;MU:BG(ZB5X&CAO2J-U/S9$ZI'0"\F:,_:Y3NR[TF9':;,T[9,FQ#)HY5
MPL$6UWA3R24O%2BCS;)IO!\?OZQ,Y'NQTZ>8/WJG7_-FUC<US)\4YQ!'O!3&
M;]*O<&#)"IR6KBM(KUDVFX*">"N92L\CQ_7K3%TN\C$^@J#YXV<J6V%?PS^Y
M(]T]..<RY!0W=;>TIE2DMP';5<T+=*U4+8W+2*C8!S\=2;QR(;L*9[7SKM(B
MNEV&4E3']+_<R@48<"&CC22JV3B%_:-LPGC^CPU'BEL1ZBF$?.VVQ&CTQFE>
MW>GC)W$J2S<GKU-0-Q<;MTM2 D"JA7H(Y)!//QU[SO@C$>HK6W/FNW>>/< _
MAGV\5>M7:+$W[A*M>47Z7;KU;&W+BAI,.5&1YNV=1X-$R+6^ARK[8%$K_7Q&
MD^YE&X6)&)59WG6+I$C98 QD,#4$88YK(W&8W8KM$A#&3PDY@TF$<C2@GJ*,
MH.--I:(:AM_W.<L4H#PYZ5W!'',*K[C\[<F=,(F)(/H9B,>*2.X&:^EW*;6X
M_;&)N.RTI2$18,>4MA:@XE7O*^22@*A1'QCEK8,HD9+?Z#T._"\"1<?5*FJ'
MX5CY8^Z6'X3(E+MN.P)[CU/DZIMNNLXSS$+M>N+<N/Y8_BMUZO1W;SM^%5(E
M<8A=)AT2]/9DB)I;&,H\%+F!=Z,5S!J6WW%8LV#0 I9;?M6/92^ZHI<"$ I9
M^?*]YI2E? .(_5K*-ZC&@7-O,/EVY*\3$$R,X_5'\'-/^"SZ>E/PV)C[O296
ME2R0H^Z*\32TJ\=8B5DA@SKGVPN=7C=%RX),27PX=J2N_-D].-PAX<WBTAUV
M1.;O#=P?HJD-0194QBHJM#(&XNN'[WP^'B2E$T+,KSM-SO;4!*#"8B,>SM3>
MQOT^]G'+&B=-RIM_JA2O+AYFJ:K<H"/E9/ #V^.@"V1R6MNNJ[^,]9 UOSX=
MJD'"_2#V4S!+KLK,[LQ-0%]-/F[>D$I:"QQ7CRP.*CXZ9^+MSWBWJ*5V_-O5
M(#0/# _AG_XDQ<B]'=@B7I^+ OEUGQFGG41$IFVDJ6D.E*?^UJ "M*4^ U/C
MV!5_8?N6U;\];VT-$A9!S.F?PFB;WHL>FMC9<KO9F_!YZ?9@%4!'A$//GR\-
M9?FK9# @>@K8M_J!<MR_J"Q+_)<_\24[/Z5\#L<^0]=,E$)4E*D(6Y(B* *D
M*0">G 7]XZ>V]UM[<GCI#\BM;<>>=_NXQMW#&4!^[/[TASO2'8ILUX6;N!YP
MO.+7Y6)-MZ%.=19+*%=:"!56X@<M82W5F<GC-NP'VT6U:\]W-O 1N6;,FS,+
MGL[P2IC7HSL<*>I>62KS%C$';)\]9UI7Q1M(Z=ODJXH!\/#1"]M8'42#+L/W
M+'=_J#U#<#PX>'&WPTS_ /$LE[]BO9CM%;[1!MMR(OMFFEZ[A:@L *0AE8JS
M;FTD;!X*5KG]L6[/R@"*H^RVN^WFZC/=&<IN7#BI;[9KNW^BQDMNRWT7=NK]
M8WTR+-)E[(:T)6D!3,6 7N#B4+J0XG[HU[2N&5IG>#%E]4>0-O<V_3+4+@(
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M]ZM/YF(L,X^7GP77I^4I80WZL/4L=P%>Q4M)W K '\Z.R)XA KX:9W>L?FK
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MWE8JJM13EQYZJ76>@CID?$+TF!6WHQB3BYX+.U(W9$AW]:^@]JN+<5IT @5
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MGI%8MQX ?%9^X%W3<>QF3;MOG%RVHB5E5P+P0I++S?%HLKKOZE:5'+3/8FY
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M@!H"3RW>!TQ/7ACW_5'[UX7;<8"@IZ4K6B.REXMK=Z^SI@[Z';4D&G+XMO\
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M3P/TP_$M<[6(I2B?%S8RVSML.WS('F5R=J:A0Y*5M%?Y,W][6U/SU-GU7?\
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M8A]NI "D>A>_\G,^F#_O5WW_ "ACO^Y#4L.:GTA5_P#)Q?I;?[TM^_RCC?\
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M7DKBB<0&@>NVEJ2V8J_Q!M2I4@*W<?AY>P%%)JE?4(5AUI;BVZ.[&@EP.-[
M5.;@D)(<W M[*'D#6OV:,*YJ"'[%;,44;(7[Z%$EQ20I:TU5[BE$[J $>/AJ
M7JAN",(04BA4%#V;:?USJ%/8BST5"@NBW4;^?3<4CQ\=I%:5UE$EUYS@#QKS
M2>[&JDM]>30>/7<K^W=7QU[LX? K5G%QH<MVJZU;$H(*E(6*D_Q*0KBG;\52
M>&O+4%Z"P!V=B/H82C;0)(  %4"HI]O/6)(*]A%L@W8KI0D\TI(H1Q2-8KTR
MHO:*_>_@_P!'0A>@'Q-?X-"%[H4,O*#V#]FA9.4*>R@_5_HC0H0X^T?L/]G0
MA>4_TO\ K?\ 1T*7*]H?L_9_HZ%"''VC]A_LZ$(JF(A/)V0?],\XK^J=9&1/
M!>7A '$^M>^41Q]]TU_><4JG^EJ> .C45/ACB?6O#%2 3U7Q0'X7EI^WD#31
MJ*@V@V)]:2 M)<"A(=2D"A2)"S7G0E5:^.M@VPU2'[%YC> AB/:CR765D;G
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M"EG<MCM/ERR $!0IL[IJYE.E72?TFORD(2A<TN?^;#AV)?N>KQC:<&(!Y%3
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MGT=, 1SS!XZQ%"Y5TV.SB2"!A[V2Q<\ZSK+,3ON!9.B1+NEAR&ZN.O1_+"'
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M4@.!"7=M.JBE:<SJT[&Y#;EYXAN>"\"9381 ;M3XLG="U)5Y6SPX3JD5HN4
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MD3X:"H=<1?<KN3;LZ[7HN#ELQNQ/-8%C-J2RJ(AO<ZSFK\L A;K)W'S@&L=
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M;SB_)NM[*2$0UIZ#B]SB%;20 4TKQU7S8\2[SU?%=]Z/M;=C:1E)A_3AB ,
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M\;=\K^FEVJMRF4-+MU[OMM'3">DMF!&M$9E3:D50I&U'"A(H=>\(]U.-L (
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MSNIDG0EH90VM!EX] @O*"DD[5.,2E)/'D=;VV?5(E+NO;:S';$3E $:>&)D
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M80L>L@P_+<5D2&Y[<L0D.+2VY!\PV%I4>H@T0ED"B/M.JWO]A<G.4Y F+A@
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MU'TJ#4=3GNM*XHIRXZ@D@.,54=_U';W#=!U>& ^L2+B@^EV-:8YK/=-T';?
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MBH*/O%2QQ"D<@K2RY<)-,5<.GW(BV*C Y\TKX#D4R! GVVU)+R;U(APY 4.
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MC4Y(;@CUK:BLV]+,U*U.NR;@P-H4?<AVU,YOX>0ZJ>'M.M%\V4$2YI,2A?\
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MX$>S6S(PTE\5TSHL3&1TM@/BNC#:O]T?X-MY_?\ W?T:UJ>U6EI?\/M7+O\
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M.6%/Q&2%R'GY!7Q)JP*TTKO1#/E7E1>4O+MZ1[XP&.H&HP4/X9W)R6T76SV
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M''(4]2KV_P"G:N^79Y'#TI_2&'CAUNS"T;D%R8_%N,>5'1+3##+UP9*TN/\
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MR!&CVM3[C"'43G:K;7&>*64J44EYL^^M"SR/PZXOUW;&-V3@TE/(\59>G7:
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M2V4^S@-6+K'1>F;JR1*5O5*(([Q?YN5%8^E>9>O=#W'B;2,YV;,VF (F&H@
MXD2P(Y8<U#-D]+5WQ:R6G+.W]VB75R2TTU-@NS$!TMQ4A##;[3[,>IV-E)H=
M<UW7E_;V+A\&495+U.170MIYWW'5+X&^MZ-4^ZS @S+U<D>\*!;MV'RR!W 8
MMS5GCS;K;(ZH[L!3[:HI4Z7+JNCG60V269',+^S7E8Z/;C,.(T#9\5T+9]?L
M7=EHE/3.1)=XO2C<,G61G;[LICCMVQ:YYGC;6*N3;S?,U#K<VK:8,6%#NK<?
M<F;,0DUB*2E)-254KJY[+H6S$HRG&W$ZB<3P'-<[Z[YLWL;=VUMKT[O].$&
MCD2"109%.V+A.-V[+[OD_;9QM[)E2YCMEEO.@LLR)TDRV0X'MK1J^VCBH%(I
MQTUO]/V-B,KEF4#/3Q-#]RH]KS=UZ<[6VW<+UO:^(,(Q>48ECQ:38.P6-_<B
MU=XLVN4B[9P_'D62Q>Y;#:8[39-O4DM[28L=*G%?-I;E>-:<>6N?[_>7K-^1
M=H"881;ASYKMG1NN['\G;A:G<.X-LB4IZ0TM1.3#Y6&"C>R]H>[DRRWZXV^
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MJZHYCBN=]2Z.P?0T8B3D$5.3^I2SDM]EY?A4G*'W\>=*;^ANYXP^VVF4]/\
M+7-%J=$=Z8'5D69D 'I*X+YCEKH_3+6FR!)L#SS5?M[.[M[C]\<) L0#4^HT
M3(QS 8N?9)$O\^T1L QF5'>F1(=G0P(HF1(\N4R%= )0%+=;:1Q2"*#4;3H=
MR+7#$B)+LXX,G,^NV;5Z5GQ/$NQ)#Z3@V7MS48W^_P!RM^:WRZIC1'Y5K%RL
M-MFR5H3(?=WO0[/*!4XES\); 6:<MW,:<V-A.),6:088BN+*W].ZA:G8MES(
M2$20 :"AD_8Z4+O(SZQ/FR6VY.MWG)<?7+S4P7UD&W//P7(B75,22E;?E%Q*
MA2E<0. I0,_[5?D8",<:FH5AV^ZLFV9@NS^_VH[9.R0DVI]J1=&E7@))0V"R
M2=O34>)>4?A"O'7MM/*=ZTPD"2YKJCP2/;@SN^)".B.HE@1P30M..SL-R*0Z
M]Y8OVYF8Z\Q*;"_/1HU5/H;HZFH"&R% ;OC'#V[.YZ'+;P\1CW82HX+T6OUR
MU<O[*>W()U L069AGZQPP6?W9R]X;W)NJ(U@MUCPY$7'G?G4MZ*U&;==;F6Y
MIQPESR(45+6%<U5IJC;W;VS>DT6%'.> HOF?SOY>ZC"X1<G*X]V!A'6&B/#(
M>IX]F*V-2X%A[GXA/P*]AN-)?;(9W*;%%MEB0G@ZG;[RHU.8T@Z;LFFTOEK3
MT+Y3\FV=QT7?VMW)XW(W)2<2=GAIJWJ6EOOMZ<\D[87^Y=>W7%VSJN5PD0%1
MF*L/Q8<HN/K_  0\A2>BZV>%.!U9?RIL6 :^'IBP'95U]P^2?/NTZCM8[,W(
M#=BW",C)PY((#.SU!P)R2+VRNRGH=X[<XICPD3<P8Z+H> 2H*2ME*_PU-,@G
M> .)TFO[..XF8VQ4M[F3SK9W$P-U?D]N,@S'D>96Z>3>/YE38V"P[FU'#$"2
MS;'#(2DM2I$>;& (0XA*"H( \.>FG3=O&R8VHA@"6')E\*^6=AO+O4/[AN!(
MWC<G*1U L90TD>KWK2%WCB93BW>'*X=ZNLH7B3DSKR^D72F7 N%XFJDE2TO.
MAQ*6E#CNI[WVZ]]Q*<;DHF1<MZBZ^[/*D-M/RQMA;MQ$([41)+$B<;<0#EB7
M61^,NS,CN5HEX'(A6^#B%O:ESY,EYIE3TM26#(%5O0JJ\Q,5RW'AJK]2L&=P
MD?B'\J6;WIYO$N"SN*@9,L8NY-OO>,9,]'R)A..*6VD[;"0\SQ6^D;C 7(0*
MK10U/+2RWM])P.*Z)Y4Z=<@0^&N68_ K\#'W[KCT6Z,/Q[C&8N5KC.KE+;$H
M?-'MC/N.NATK<#)J-O,<=-+5IHLW!+/.4?!D,0!XQ]6E;#_4]..-^GCLYC]Q
MD/0X\!(F*88WDI#YR60E73;W\TS:UIXZ:F0C9#O1<=Z/MKE[J<M(!)C+,?B!
M]RUN0[6W?\:F7JY9!:X"W;VM*&)L;I)60Q;2D?CS&JDJ<H-4-R]5]9["8-P-
MQ/N3,5'N4&!(EML6K9:[W<;>Q*M3;:/,1+S+Z,EZ1TI#Q);:B)5S ]XZEPK?
M:[UMOW1[DX;)C$!VV7'K79MARVH\_"25(W*??(=6$CJ5)W2U\N.H-2E6[@22
M!Q^"?^%6B?=V/D:KU9+-8\C8=G7!#C*6D]>.RN0A*MT]I!*EVYH<03_!K(GW
M*KV^A7;9&H$,?Q!-R2YC]N,FUL&PJNM@O#'D[R(S>UA%FENAI_J![W4N=!*@
M0X/AJ-8Y)I9L';FI^."4\P[BY!?FO(R&+0IJY0V8;.1)BK4E2F6F60@.>:.Z
MB6"/C^YH]Z80WT+0J<.13<Q>_7K%;TFZXNR]*1@]LA6:W!O>>LB=.D072@M[
M3P9O2C[O#AH+^U*;?7;<B!J&H\CP7T]OR\DRXR?IL]N)%VC*BS[EE>47F0VX
MA:%%V[BV2W =_$D+6?M]NL\DXVNZCN(B4>62WFK5M%=8IC$.57H6*U#_ %U_
M_-=>JW_W5N<__6)E>A0?@OD]._Q*/_5K _\ N=6@9+%U>:'$?M_@T T/:K+X
MHPHKDGDW^@_^EU!/%2)Q174.%.N*.+F..\J_L5SU'3H?U ,W/N2@$)/4ZZRZ
MAU3"G&@5)<4$J 0%%(&[@KX@#^S5VV]LFS_E'N7H:CDG,U_-YJT.-/Q-SDK<
MH^Z.-5K/]Y/AI9N[9$CVCW+ @OC1)1%#3V_8?9I+"V7<J&;#%7T-/RVD6]B%
M&E&3<[0I4B04),/I2%46WU"FI5U"30_<&F=FV:.."E_6E+'FWC/CQ;DU+ND.
M+?6ATX:''FT'RTH_<1(2 D*(_3IG"V?8AL.U//N%B([?7&V669<V\F%U8^93
MI+2D/I9?0J4$)46W9200NWH/$U][3#;VSJ^W!5_D*NHIN2G)#L*Z(7U7;C<4
MP&82:[DLVJ0TTRDIJ5#>B4 . '#AJT;#N@?Y5D78/P=.:$FQB?=6RZFP7E$)
MJKZREHJ"VX2Z;BEGGN2?B\-6C;W (ZN/WH+G#%1LX+K>99<?DIW)X"IKR!5]
MYWASUZ6^NV"1WO\ A*V?R,K8>(1RU7JY8_<:>81M+S52-P(#+BJ5*7#^]I]L
MNL0$@8RX9%:MVS(Q(F I<@9[(GNI:,Y)5MX@K5X$#Q73QU8[/6P0.\P;@5HS
MM6XC+4LJ<1=LT*QS[K=(5TN$EP+0S(0]5M)*&4I-3#>J07#]X<]7"Q>C&WJ)
MD9'CBN=7GG>\,",8@Y!F3&B9M(5>X,>0J5)@M2EIC1I+CCHBM./LI<2VDH"4
M[T(2#0"NT>S6O#J7]<VR^DD\:)U#8B-@77[P KQHF_W0?M+LLNQE&*5AHJ!&
MWCY=-?N(\1K7ZI=MS:6$TTZ5J(,1\@*QRQN2J%?HA@S_ # :62M(4>/X;H(X
M+_=U11.M"MF[,2M$R U)YY^S!;NEFNMLNDF!-O/F57-AA#BFY3C1A*:1(+00
M$H"Y;@&\G@H_;JF>8H:Q*;RI"[3(T&/VS*QL&@-*L.8[$S519,93K;\>! \T
M0I,R(MGS3M0/>5TW5.;C]H\-<$Z_;?<2(PU1_E36U2(.*+&/(E.=.%"EF.33
M^;MF;<=03SW.".T\BB10FJ. 1I5_;YFIQXN%:[@844CXGA^7LQKO>;' LK"6
M(@M3\2:_#:NUG5?6I;# ;:7,CR"Z\8ZJI2V"5- '4?V^;8%NT);<).H9576+
M^4WF729ZI^_C=SN+\V99_3ME<%V+)#O20I[N=V7DI2DNK4FG3(I0TH=90V)M
MDEL0V(6G;I,MBWW+O6C<Q_IC_P [KTR7O;Q1B<0([-14=9BO^N&MBUDW!97"
M!!RN6W\V.W+D_3Q[5)B C_W\?MT12O CL;Z@QPXBG/3&T-(;-57KLC*T#EX@
M_E*X6NR'8S+^Y5]38[+)FNP+#-\O<\R4A0A*B!E#CQ3)<=;9*2T]3@ZH>_J_
M['9FW( DTSSP7$_,'4(RMRF(1)E$=UF [W/[46P?+._5D]-EAD]D>W\A>5W)
MRVMM2;S"DJ"85P8BKBK+7EFG4%3LE]1X.<"V..K'/J-O9V1;C6>G@<AFN*WO
M*>ZZWNI[J_(PLFZ2"XPE(TB#P].2UY9IW][CRKZNY7^[Y"^@*!1%9?N#JFP&
MT)3P3UCP0*<O'5,W_6)BZ93D0'% _!7OIOD#97-N+.WM0G<(K*6D.Q:I+=B-
M]O;I:LF?R'+DWBP65<GSUO9Q9QE#;ZU6N B\35!A<MEVBX3ZDC\/FCQY:Y>X
M#GV*Z=-\H;JU.,)0.J,Y$2U1^4P8>UU&^:7O"'L8;3#@6]5VO3TBY1WX<9+2
M[$T[TY$4R#TUJ;ZXDU34M_Q)_5)Q73^E='N;:T'B7$8O49!-*3E$._0[5893
M(87$0#\^XE-!U $]0HVB@?I\?W-3R"97+9M@F3"OP4J8/;;+<L$8GWB]1&WV
M<XR=YO'V(JWFCYW#K3!;=<"'7$!)=<(Y#X-><,75!M0TR$(@AJ5QI5T9R2%\
MIPO&IL_(<:+L%:U8?CT)V*V&9MK3;U%R\MIN+_0?9>$;H;TL*W!S;4@[6, &
MB#A16;IXF 9DG46)XGCZU'_D;7DZ;;>Y]V,^-8HTR)W,FOK!FV^#-G*GQF+>
MATE]Q BF+38EX$#E[&,0PH0^:M6T)\,8UP]:D3'<,PK-LR<LG;2>B>R_:I;V
M49=?RU&+;[<6XO%I;\U%N!6I$=D %:C5W[::4;I@"W >]:W7NCW1MR*Z0(T<
M?B3S[8V:=:XM_P 1B7F.N'8\HMLE<EM]OR\MBSW&XE+K)3(+2VDMLDU2I0HH
M'6A8!-SGK'OJOF;S]MY>-*<H!Q;O1-1D  MBV5?/,D[-V"VV,V"8Y:IJ;FX5
M381=VM)O,<J<"IJ#MWS0.7LU<-M$SL 6ZSJ:X8KYFW$8[3JLI[P2CMI!N[\S
MD U8$M0Y<%A#VQQ3)^X;!GYM?G+':\?E2I-DM\-2ELRW!!;\K!;PT2G;K_BB
M4Z)IV_ E.ZB0@JUH7]R3#5,MV4'85]+[:_MK=PVMN(F)BQU#5($$DF,J49L
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M;OK=S5/D2I2I(?+E&["47*$OBXI.U;K)(X_HTWZE<A=MF /9ZUSKH/0]W8W
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M6[BDJ*)Z#3:#[NK+L;$9V@9D.Q=WXKU'6;UHZ+1D[L&T]N:Q!:2H><<0!'4
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M[NJ]' .3EP'%8['NQ%?LU]@7J/+C2K/#3>,>@-I?(<6F.X]+:VAAP!2I#R.
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M3Q'"AU:-G"U*D=/L50Z_M0($M7NY<UL=R"V9E/\ 2K@T%./6^1;BJ5$=R-Z
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MJJ[@$S/;\$"B2Y[L:'$@P8>Z'(:ER)+B*%*E)G14V\$A*4<%$4UUK97H6Y#
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MWF;*#G[?#VFOMUY'BO44#(-\OU_UM>DEYQQ6H'Z[[C2/I>^JCJUX]KL[(4/
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M#(2VL]%&T!' UH+%LMX-N=19PV?N2GJG3]WU';G;_P!01,2" [5'U,0K^/\
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M(FL-3*N/189<"9EUE@>^116C5(T*/S,3,"4@"<2JEX3>7\9PWN7=%V^SN7!
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MA:@ X=G]JDOM7V_;BP86>96D+QR.$26&G4)%=K274@!9=5QZB.2-=EL;3P<
M17BM#?=0A?#$B@X')7>X?="Y9K-7:L=;>MN-VI"F(Z&0^$R6W$(2542&4'9T
MSR3XZPW^[C9LD''2<E78;>6XN AVU\>:A5<AYF$Y-B0IDA;+FQQP,O$>\0E1
MJ&J\-VN7]8ZI#Q9!P[\#P5OZ;TZ?@@D4$>(XKZ27Y7N2J7].^A!'_C-O@_\
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MOMI+RP&W%ON./,@\E)84X!7G]@TLZGU!K9#_ $S^KDF=C@<:(PF AM\O,NE
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M^*9#*MS%JOEAR"S6&\R+I.V]5+$F#=)C2F4(<AK"U-35%22V2" *#3"UU*9
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MBV<V:<.Z\-=DOUJ6BW6MNWVFX*;=8=<CI2:B-+!3U9KU2% 4&ML2<5"9;?\
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ME=P'Z]9/!TACOME(M R<<_VH[;_79^7K<C/17+1Z9NDK\*1'&'=GGFE!(6@
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MH2G<4)*A[JU:<V.D;<P#Z>52M:]U2Y;F09$2_P JEF=VKL.)8O(ELW:;)F(
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M'\?8IWSJY6S*K8[<KAEBF)UO@@1V672LON.L$NI71Q1]Q<=('^F.MJW:E<8
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MQZG.Y,"49D<",5KTBW2\PU351,B<BP$O34R"R&T.3+FVM8NKBT^6ZA!?XIX
M>\::LG3]S(GYJ Q]>:Z/L+=N\+8O6I:YQMD/@(R#Q 8\,7P38D7.5&C2[C'D
M/3)"GO><6A>Y7NGCQ;;J*H&K1:W C#5$]YN(XJZ[7HVUO1 G;CI;C+CVK(_
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M2%*9ZSDCX(:/N#^,&@3#458O[.4I5 :F8&2QEN%XNM_R2XWJ>;80^TI%?G,
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M,A4JPOZ'OTSJI(]-&-5%>4RY&G+_ .2/LT"<\W]96M=VUJY\P<U]JH>^A_\
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MI^BF@BJAZ528N=+#:0W%;7)JDN-=900AHJ +F_I%1I[WAQ(T-F<%#U;-5NW
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M>'([%VM[B7/#;;:K*WD]ER['\CSJX2\B$2(%7=2KIBT3>7'"E2T@GB!0PQ4
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M?IXS[U.=Q>QE\N[<"\9=C.4]NY<S*\1M6(WAJQM3L;Q>=><8MK;K+0'4CQF
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MZW*W9+9KG=+@VW?V&5/3;/DSL=27$OC8@<>5(-2Y0 V"6[W]/O#[?WANO?\
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M95W*[O9&UV?R5628M=;KF.<B]V^W1XT4MV2VMKSAYV*I3[+Y7*2_U76Y*VU
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M>=Q>5<\7R'&[C>L>N-SGHFNQ)4AR,J1%846RIIM2#GF@U2[A'T\L#PSM;GV
M.]P,\S#(^Y&-3L-R3N/G5\R/,LD5C%R91&G6N K)\GN\FV]9AV4GJL26UI,I
M9!KS!0NCZ63'PWZ86!X3Z-KOZ';=W#O,OLO.Q5_!K?$NEC^97&V8C,QZ3BLN
MSN7"?D$JZ7,+L;K;+;KLGJ,=,J00I:CHH0QQ^V2@.,,/MFGX?0>(&-]F(>*]
MY\IQ7,NRUN-CL^9VZTK*+QC[4F>Y L=VQE.1,6J5;X<9Z*V6WU/H=5"0XI.X
M^Z!!#E\TZ,7]$.(6"%WMN$O++M/[B]^GWW\V[CVV([C5V476K2ALP(=HNZ6X
M#C#MJWI7'=955PCA3C.H_:BC2/0IZ[!]GXW8CM5B?:^-E.29JUBUO1;TY-EU
MTNEYR"YH;)V.7"XWFYWBXOK0D[4]22X0D4!IJ%DICT(0T(0T(0T(0T(0T(0T
M(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(7A(',@?I^SG^S0A#<GVCV<Q
MS/$#]8U#CBA#<DUHH<#0\1P/ T/VT.I0O"M XE20 :&J@./LY\]"'"&]'#WD
M\30>\.)(J ./$TT(7M1[1PXGB.&A"I#C:@"E:% \B% @TYT(/'0H<*K<GVC]
MH\14?P:%*]T(0T(5(4D\ I))K2A!K0T/[#H0AN3Q&Y/ T/$<#[#[#H0@%H4"
M4K20E12HA0("DFBDD@\%)/,>&A"&] (!4D$\AN%3^@5T(0WH'-2>!VGWAP5P
MX<^?'0A>U%:5%12HKQX\N'VZ$($A()40 .9)  _23P&A"%1[1RKS'+V_HT(0
M"DDT"@30&@(K0\C3V&FA")_,[=YWY;\PA?,>D7_(>;8\[T 6TE[RO4Z_2"G4
M#=MI50]HT(1PD 5) %*U)X4'$G] &A"\"DD!04D@@*!!!!!%00>1!&A"]*DB
ME5 5-!4@5/L'M/#0A>!:2 0I)!%00001[1QY:$+T*2H52H$>T$$?P:$+PK2.
M:DCB!Q(YD5 Y\R-"$"M !)4D 5J2H "G$U)-!0:$(A'O%HER7H46Z6Z3,C!"
MI$2/.C/28Z7-^PO,-NJ=:"^FJFX"NT^PZ$(^%))*0I)4.8!!(_2.8YZ$)#4A
MJ7TY+-9 ;6I*%*-$@%%-X"2G<D[_ !KK*F>/%8XT8D<.";-]PS&KR'7YN*XE
M=KPW'E/6]Z^6:%,BMSTMA;2I2UQW'PR](2@N%'O%*33C30?4$ D$=B)6^SPL
M=GN,V^RQ($B].0E3#:H\>+8!<8\!N.PCRZ.G*#7E&CR1S''GJ*  T]"G$D5/
M!V4H;D\?>' T/$<#PX'[>.H4JE3B$I4I2T)2FNY2E )33GN)-!2FA#A$H=WM
M5P6^W N=OG+C*")"(<V-)7'60"$/I9<66E$$&BJ'4L>!4..(5Z7.@P&5R9TR
M+"CMD!R1+D,QF4%2DI2%NO+0VDE2@!4\R-0I5UE]B0RU(8>:?8>:0^R^RXAQ
MEUEU <;>:<05(<:<;(4E0)!!J-"%<J.'$<>7$<?T:$+PK0#0K2#2M"H TX\:
M5Y<-"APO=R:;MPVTKNJ*4I6M>5*:%* 4DBH((]H(I^W0A>Z$(:$+RHX<1Q-!
MQYGV#VG0A"H]HX<_LT(0W)H344%:FHH*<ZGPIH0AN3^\.5>8Y>W]&A" (/$$
M$>T&NA"\"T&M%)-#0T4#0C@0>/ @Z$+TD#B2 /:3H0O-R>'O)X\N(X_HT(0*
MT J!6D%(!4"H52#6A5QX T.A"I4ZT@)*W&TA2@E)4M*0I1!(2DDBJB 33V#0
MA%(5UM=RZ_RZY0)_E7E1Y/DID>5Y=]*$.*8?Z#CG1>2VZE12JB@% TXC0A79
M4Z%!;2[-F18;2E)0EV5(:CMJ6H@)0E;JT)*E$\!6IT(5UE]B2TEZ.\T^RNNQ
MUEQ#K2Z$I.UQ!4E5% C@>8T(5N3-APT!R7+C14$D!<E]IA!(%2 IU:14#0A7
M&7V9+2'X[S3[+B4K;>9<0ZTXA0"DK0X@J0M*DD$$&A&A" ?8*RV'FBX"$E <
M05A1&X I!W D<?T:$*A^5%BHZDF3'C-@T*WWFV4 \.&YQ217CH0BC-[LTE8;
MCW>V/K4I24H9GQ75J4D@*2$H=42I)-"/#0A&I,V'":Z\R7&B,[@GK27VF&MR
MDE24]1U:$;BE)(%>0T(5N'<K=<&P[ N$*<T24AV'*8DME24A12%LN+22$D$B
MO(Z$(X""*@@CE4&HX<^7LT(7NA"&A"&A"&A"&A"&A"&A"&A"&A"&A"&A"&A"
M&A"&A"&A"&A"&A"&A"M-I"0?^;PU)+H,6KDHI[L=R<:[96!_*,JN9MMHA6^[
MEXB%+F!]:8S:T-UC)7TU>X0D%)*B>'+6O=D "_ K3W6]M;4:I%J'(GW8* [O
MZR>RMFN&,0;W<L@M\O(I=O590K#LHVS0_;7GD*:(M5'4E -*'B!I9*<20XKJ
M'N9+_P#N396Z3DPSH33-O2DS*/61V7PO+EX?-OF0/7]FVS,KG6F!AN4S)JX2
MHMQC1Y!:B6Q]887+LZTA5"*H.MW^X6W8D,W K4EUS:QN "4C&I/=D#4,!@^+
M)<8]3N"7?'L>R-EF^7*V9!CT#)TVVVXW?A=K0F5;HMU4]D$!-MD38BGTRJLI
M?9842TZ!N(5M@[^V"6J#R-.*@];VTHO\P:H (8C%Z'[.E#'?4?VTRG$'NX%H
MRB WC494X.2[K:IR7;7=;3<)-F<BO(?,1UJ1NAOD I2K:.'#CH_/P-00!V%9
MQZWMS SU !LXDL<@] :52=9O5)VPO>66_%(UZO=GO<T3&F;1E-COD1^ZLL0)
MDIT1V)\"VJ>7TF'.("N"#PX:F.^MFC^PU6U?\S;2X= (B</E/;[4W)'K$[.P
MFL]B19MS3)[<2+W;,C@P,-R1P6=VWKN492WG&+<MMMN2NSO;54VD-$U(&H.^
MA'.F&!]"71Z]M;DI1C23D-I(QIGQ4V]J.[V*=W\0L^=X3='+G8;K,=&\V6Y(
M=2Y:WY]FE(7UFVG 42[>XDU0.(U(WL)-6O84\V>ZC?MZXU<LS&GV9-7N3ZFL
M([8W&-:;W:NZEWG.MH7NQCMUG=X:"5.O- *7:,<N:#0LJ)][EK>&#C!;H+#B
M4TVO6'VFG.V]+MN[ZP%ID,NI;_HC[HLL*4IQI1;N;J\/2TU'!%%=0H!25<>!
MH,XJIU,RR<M-V@W6);+O9VY4>++C.=-$RQ7&))"93YD[G(TAN.^P5*34A214
MFOCHJ*G%9#)F;L^U%AO;O7AV#NT.RWJ!.SVZVS)9K=JLN86'M-W$O6 WZ7*+
M;-NNC%^ME@DV4L/SY+;069:DE24C=4C4T/9P^"Q#C@[X_'X)>P_UE=ALD[U7
MOTRM7O)[;WBM3<-_)<>D=O,SQZ&\_>'IS R"WW>YVAJU)B7B5"?>2X'GDJ0$
MJWJ%%$R;!2SGTM]@DK+_ %I=E<*N7=>RW"X93+G>GPVQSN!*=PK+%P&?G]FM
M636QA.8)LZ['QM&11C[JW:$$&A0H HU,&P;XJ!AWB\@<7]5,5C[#^KOZ*[AB
M':G,H679Q<,9[UQK//P/*KAVJ[CXWB5P<O5W>LK4V_9/=\939,/F;XA#,>Y/
ML/NO!EM-5R&0HI@</MGVJ 3G\PSYYTQP626;>LCLKV;R[',-RS*[WD>69E:<
MBR;";-AUGOF=Y+DMBMS-KG2Y;^*8K;[S?!!M$6\PS$D*0EJ8F0M3%0E5(;N]
ME/V\UD"YYFOKP'+X)MVOZA_I:OG9C/>_MOSF^7;M?VXN3UM[I/R\6R=-XPEZ
M,Y-CR&+MA#UI3DMO4EZ :%V.D*2I*AP<0288X\>:ESZ!ER_Q4)*^L!Z*A<\
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M5'ENQ\HD=_>Z\F*&;D]%$ME^?;W9$C<GWT;BE(*?>U)! 6#DEL_8I<]</?3
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ML^G;?[9V7R',^][V/%;-GNF%P,LP"T0G;D_;24+DKCW.S%"'6DH" :+X)W2
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M5V<M,;M5$NUER&)CC=SR I;N$)Q3ZF6KD;VY>K>PV4I0X8LAIS;0I5N2DB0
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MP)H>?LT!\78*6PI7#E]Z@#'_ *?_ *1,2P2\=LL7[)V2T]N[W#99DXNSDG<
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AH0AH0AH0AH0AH0AH0AH0AH0AH0AH0AH0AH0AH0AH0O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>tm2226999d1-ph_slows4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-ph_slows4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ F *\ P$1  (1 0,1 ?_$ /8    %!0$!
M       #! 4' 0(&" D*"P$  00# 0$               $$!08" P<("1
M 0,"! ,$! 8(#0H.# P' 0(#!!$% !(&!R$Q"$%1(A-A,A0)<8%"(Q4*D:&Q
MP=%2&!KPX3-#)-46UE>7UUB88G*"DI1&MA<H./%3-+3$U"96=H8G-W=(HK+"
MTD14)6:61XC8XF.39'2$-54VIGBHI$5UE;5GAQ$  0,"! 0"" 0$! 4#! ,
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MV_?^[ADX6C@RJ%*- 3P)Y8'"$8I(04Y>TBOV?TL#\T)4]V? <;Y+9)$)[<'
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M]E]W&7-9$I,YS/Q?<P@2 L5>QR^(??P#-*,U1SUL!05:GUD_"/NX!F$B=%4
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M"&P4_-UJ.5#Q/K#OQ'VL29/+/%.*6[RGA'3ZCP]*4N,1Y49,=P4?40XBG
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MFJMOVXQOY&=8B4]8S+Y1;CT6-NJ4ZX%A3B/07%N#MYUR]^)+R8 X >H*F"G
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M(2W%(X@.CUTI/('$U;]J4KJ E.$#Q^*8X]$_N?O]5[7N)6%&=U$0PPI6\OB
MD?CD^944[I;YS]=%:9"GJEM !+<8"GG*50Y#7MQ9;'8_(J"H0'!YGEU7EO[A
M_<6YW>WE SJ$&E 8PIC*IJ_:M89[SDA14HD!(=4DUI6M">7(\,6VVIQIY9N%
MPFG<5*U:50D_$^0XDE-K.5UTM+/).;F>S*.S^NQ)QGI#ICN-S4$S$'B. ^5%
M*SI[:?'\.')DF\:Q?%'Q\[A&3L\LFI[R>7/G3#6I5,5-6=/S2#PP]JE_3+!?
MC)2M ( /,GL61]_$=6NYQ)#GU!7:RVZE*D"0'8\3S0U3IQN+#2^A(!.2M"KM
M< ^_@C4/H3>-G"K$EAGS/)&Z,VY>U(ZA#3:%K5Y*@E3KZ!\X5$5+:2>-,)*J
M79678^V8[D=(T@#2"29?N?D_(K+[EM4NRRU1Y$9H+!3P\^6153:5@^( \CC7
M*K*+8D^@*VR^WE6GI,33-,O^Z?/P6P_2Y;[6_K2$W,2A2/.=4A)4M?SAA.CB
M5*!I0#%)[FN9TK>4HD_#'@/G7HG_ ,>MJV^M<B9&JM]15!QD,/IP>!ZE=(->
MZ+MLIA3D9EH9&9#BSXA0H0A1IEKW''#KG=J@NY1D3\<AD.:]B;]V[8?[0"(#
M_P"/,_%/Y!U6EB+M9EZDDZ;D(;"T.E(5E%*$-*];,%_KO=BVV=6YI4HUG/E&
M/(9Y\O%>=+VWV^%].VC#WPW$\AUZKH%KCHZLEYVPD:@C-1VW"@>+SIJ5<78H
M^0%)_7<06W]Q7 JQEKE@3^V/)<F[\[8MHV51HP;RH?NF?]7JN&^\VUZ=#71V
M"?+6DNW=(RN/JR^SN-))JXE)XY_M8[-V]O%2]I"9PD!!\!B[_P %XZW_ &FE
M0W&4  PK3XGA)0EI>UH<GE("?"TZ:%2Z?JS8]/?B^0KR88G'P3C9]NIU&B0&
M+\3S7;+9C8W2MKT[ GOK9?O$B4JJ?,DNI*2Q'!&5U03R*ODXXB-[K2J.\L>D
M5]7OLI]K=OK0A1-.E(_4U0YJ5@<*$3P4/=9EBLFG[7!8@0F6)BHU^4\M (J6
MVK?EH"HBM5'L'/$QMNXU:]S3I.<91? <2N6?^4'9=GL=B].G3'N;@,)U)9"F
MWQ+03;_:B=JJ'(NB&VUMYG?U1Q]JF5Y2.;*#RR=^++N.]&WJ"W@^ ' <OYKP
MGVKL<+JYD[ BF3F?FBNO*M-V^T;+ZA<F0V5+BL^ C-F"BY;D CBCM5B@[+?3
MJ7$8DG&4N ^5?1O<^T+.C:3.BG@ 2TZG,#BN(^XT9N5/<D-M)!>DW(\7' :>
M<V4@ $C@%8[!M4WHACCHA^2^>GW'L*0WR\C #1&ZN0,3A_4(1>E=&N7&%YF5
M)HR^4@.._)>/'ER%,2%6HTO2/R5?[?V$7-(B&D$4Y'.7S+%)MJ?MZ"'*%1%0
M05'M_JDC#V)YJL7VWB$2" ^'$\UBQ=>;6L.&H<5X.7 #@>STXR&*K$Z %1L,
M^JN;A*?\=1ZI)J30T^ 8#@5OI4 1A^J1KC*3P-/L\,:<ULK40,4IBL<% T]=
M%*J4.Q7=A"MMG;QE,>(4VZ.TPU<8B,S:59D+(.=V@RJX<J<<:OB,NBZAL.S0
MNJ8;2P',\U34%D7 0MYLCP%'AS+)/C ^4.[$::6DM)F*>;I9SL7&9;@HLN=S
MD20MIU3C2FO,0T"0 H5\7(^@8<6]M3A(&+%RN8;KN=Q(F!) &H9!)&&'%QRN
M4$KS J2HK6%<#3B$A([,3U"B-#X9*O\ F2JESFFM2P[P3WD?!7&A+B0RL\LM
M\^.;E\7^CA$8H#G@0,T:[V? <*7=$DG1S5^COP'() KQSPB49I7C-9JQ;J6Z
M \U<OB_T<(4AS01"\[QC@/23V? ,8EUCB2R^C!]3-13ICZD#W;FM#[$&/C0<
MTD3@R]I:%9A\ 'W,!#+)8!NT:;7;BGNT+JX_8T]<<+'-'$>*^&_IBQ.:BN*
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MHBK%> 3WXF]AOH7!'FDZWZ+E7<?>E>I<3I0G/,C&%/B/2H-T3MNYJJ2MM*4
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M>1/?BLVVZ"-4BJ<"<,U9.Y=FD*0$8D>[)\8]%JK)TM<8[CS<B"^'$DFCGE@
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M1"I=48QUR.KXI]3EEBND=P;")1E5C&)!+G&7BN^VO3I_>_99-Q@+0\YJ*/\
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MHRN5JA)2D<7/3C$6L!)V#^"GJE]*K0T GUIKB3"\^GVEMQ(]0A3RB"*$UXH
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M'ZB$Y1\KS.E#?MKGQRY0Y7D:TP2#Q(2-P7UJ<-D+Q1?75_\ -?Z,/^G;7'^
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MY;>!P'K*3J80P:$?#QKA'6'T41P'K*8T( Y=^,V4"07;@C'$A(32O&O/XL*
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M:)!2G_<$N(AZI?Q1T?ZFMI]3@4>JNYN9"DC)#8';7CFT+VY<*^D.764=[U'
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M2WVR1X[=TL3.]'34JZ65UAR4(3,J,>FEA;*?:8ZT\1S0KB*8W>9,#^IA%/Y
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M'5OQBBEMLZA!B)D$D81)Q <C#IBM/K;UL[;S.HZ^].D%=H<N]HM<:<+['UE
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MMMUX;A7S?>'L3K*TQ=,ZS>O9M+[,Y[/:9<,:9_="J=I^Z2K?;V=0.!0,<LL
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M9>[NZR(477.MY>L]<W-R[R(,B]2&Y$C2=XU?.T3'#<K4<IT^1 ;_ %0BE$(
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M_<IMSE2-3:U)C1[==6X-PN=UM]F:B60^SEFWB''41G4TI9*\98MSET6& .&
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5A@0A@0A@0A@0A@0A@0A@0A@0O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>tm2226999d1-ph_synapsesbwlr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-ph_synapsesbwlr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!+ ), P$1  (1 0,1 ?_$ +\   $$ @,! 0
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MQ3)G1B8QC$QA!VC6.#<$3%L&HQ&RT)(;SZ]2-BG+7EQ'DJ'OB 7 "X 7 "X
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M;_-'VZ)?8RQ<,0LDO:S(+NB8LX333$9QDCLF460VCCAM:Y6Z=R%2[0$GZ?\
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M^36..[M?6QQ;9_W8O1[#8&F]F.U)[0UD+<O<[$,6:FO[?>UU^RM)PX59XI*
MZZRMK>+U)ZE45PN7Q&KMT_[(\&L7;Z%C-Y^F"W]R0T@&FVOO KH-S02,ERF
M5/DUVY[.Z.<%G*K9"2GU9K+^,X@&ZXV2Z(HZ*NN4UZM=C3RC;+[@O9UAF=?0
MU]DWN8]JI.R]Y_:Q[8?;YO-F55@^8YQ)B9%6T&S&W^<[C%<5]G9?*P?KDP-[
MMMC'!G60X*D Z+P]N<0_@D<9HP]ZK2!OC]%WW4?4#&ES;";_ '\P;&TP4H]Q
M8I.Q_+-BZ(/;W<08L+\ROU#'SJTVKGV"B"NB:GUF(FJ@.O:H3T2+LHQM*<?
M]U_H2[H>WRZS.;O5O/[>>]ETS(LTRU^#F+2C[E$R"SSW#GK^_P +2T;QN*^3
M"QZYY$D1XZ]3?0CC<XIN&_\ B@KB^A/L=8SWW)^\3ZC];F>_^WFV.XNR'O\
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M(#!]M17\2*Q $.DNG3145-.7%A=;'P?!_JX_I=.R@D!4[N(J*V@&YME9NR$
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MJOXBIR14^/$GZE(E8Y'(&.X^U:.5<^Q1?4,O-L*J&.JB@*H/Z=LGRUTT_O\
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M)=0<5->E/^%>'D'SDN'XO-:KK#%KD&[>6,@9S)F*)W73;5I-"CL^"BJ?>7A
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M8['2,/N-,JXPVJ'UIU)% M5T3Q5?#@"6U>.X1<,D;F1BP^@D2 "D**8Z**:
MJ:HJ_;Q:!#9=)8//F8NLH@IU)RTUYDO_ )A>:_X<0#L  Q4O5DQIJ1*EBCD<
MA =6^V+@%JJB"IU$Z*^"\*^0-V,5]]?MO4,:,PB"1DA] H::**IH2,*?)2X
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M)8.24:4D0A#4@T31#U5 94?%>'<#5(8OP><JM4/LKVT/I'14+P5"[75KX>/
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M+,>EE!/"86G;$@12\JJJ)U/M> CKQJ&#GR2WN:QQG',@QQUQVG1Q"5 U_C*
M.$JB\X*HOI4TTX7@#MCLK:N4WI>TS[3JBO4G:=U0NOP_]#=\4Y\)6P1-^$KT
M]J/%E%7"6B*0J(Z:J>JCU"2=.B<30"255%Q&'5R)5FY;-W*+WV3-MW0HJ1U$
M0[+(=*.^L5%ZM==.7QXK46"94V[EPWCK^$8WV\;]3*4QDR!<;[@EWR5$,GFV
MO,<C7P\$XJ=0@59.KB!=]N>XKK>FN@:%U>5WER ]-%37C()+4E!CR+9:J$^X
MVSZ4GR0.0<Y:@JIT-KYNDM/'PX Y'I)6:DTU8.0E1=>A15-=$1%155M4\2X
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MC=-2,?\ =@T >L1NRH?, DO5U5F,EJJKHBZ=6G%?ZWU)OX.[UQS-"X 7 "X
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M*K9%C*A3"DM.*ZU,].,5U]Z78FX:MOHO60:Z)IT\9O922AA7RS'::-D66M9
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M3 BPW+GJ4[QOZ+PV2VL]T"*GF#/H1C_8K3"IRTY<BXG\_(V=ZGC)1< +@!<
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MO2XJR.KI[O22::MQ]41&^$@SP.1:MH!-MVJ, JH:OHSTZ(NA:]$C110OMY\
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M(B>455=9Y%88PEV!W(MRJ"33JT3U%&KUFO3"-M^>VRB&W-94?XO\)?#]Z/\
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MZ=VV<1<5?$0U7I<>?+30FTUYSBY\^(LE'''L<KLM?@,L33%H\ABR"%3,45;
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MH32R&I(9DDO$!PG;C',4JW[O(V;C)LGR1]TS)TH18D['?+N+.<- )FK-$%!
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MO'H60M1*RI%9#P(G:TU%%)PP%="?).?/X?#CFXT4%N1.65;) E:"!ZA"( $
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MS9#<2LQ7;]FEW.W R:\PP+++PA[LN5D"DDVE.3<"CLJ2GD4<'<)+[\1L'A!
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M#1S6Z3 ,8HIWHD8RS)#:5RP;;(T%AA.I#_\ *O*(K!%,P\G<=XY&A< +@!<
M+@!< >.W]:?#\KRCZL_OZK<8@-6,=S>^2[(G.:JXRK<*@<(!)&7211!I%_\
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M3W';7&<DMWF(+S#V%QBNH4R;CT08D:/8VCR$KQ@R@2S5L1_$7545<\85LK[
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M65,V=$=4)-!"J6X[41E'$?+MMBBJ?WEVJ7<SE]@"^YG*][=RY[6^T>RKAS7
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M6/>X.WQ.T]Q[D&L=PK$CA/;@8]09/39Q>N.%?(XU:6%^WD-3<U,I+16A9@0
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MZ-6)5U.+>\:MKB4A;S&@ZU\4ZW*>B=70D; 535S@X]:ZDW\'>*XP47 "X 7
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MS"0C[;?,>,R4^'MP;>EF#8U%S:U#+$@9-<$1Z8RU!)6R5T&E8>8!5-XS-5%
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MB4K!A;SAZ=BDRVN7WC<IJJ1;K*Z7NI\@N&9+M6^1K'-4=T%I/X7WT\4* /\
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MGZQA&>M!ZNG\3IZ]-5TU44D;D.1@$<%QEP+![D*H'\N2J2*X2Z-E)7[P\,8
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ME>60 N$L>"11.VMD*Z*CW\+Q37RG$ ^<+O\ #</NJ.YW#Q?YV+!-J-)*M@9
M5T1%ZW9-7,$T0S3DK*?=_;R+-D&[<J?A^=9T>3X)BH8C$BH*RZEN>U+8M#<"
M.4=QEQBLJ@91A(YHNC3NO<\4TYQN7**#*SSB;(EG63(WY>8 5%7W6UL1=T'7
MH%'&Z]!4T71%ZETXCR#GV^Q1O+?7O5E2ZD6!JIR%;)UH@0#)571D1#01U\5T
MUXJ4@L)L4]%P_=.JS+'V:ZXF;<B>37%7)C1VTDQJB9"DN5(R"27Z)R=V]/4=
MIQ6NG^&>O+7&F1X!UN%NMFFYF52KNU3%[)\\C<;??''()^JEA4N.-OIJ;GXS
M5>HQ4YDJ]'7JGW$RVRCQ9;=L5@4]]C]-+GEDN(4^46\1F(Z#F-.6 S'KFJ=<
M:9?*6[C\0%<(R".3O@H->/%CIAD*]YC>D)?+ZT)#45LW@DN2F7 28+J]33G:
M-!1H4#75.HT77QXRXBBD9H\HO,<:)^K?1@7G5!Q %4ZP44ZN8$/WD#3X\)A
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MA853M#MKGDU+;<+*,D.WO(V"2\NRD["_ERZ:NA0;*)0.LW,=]STT"IA1*Y#
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MQ*) 1(NJ*J<;]FT9A YPJ]PO(*/?.SRK()L/.69U.H!7UYS6KVPR!W,2G9!
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MUQ);73J:JNJ:#X<52#GEP[RH 7(5=+@#T59NM#7/NY2T%A*6,\A8J+;-FAQ
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MX \/VI:RC.X3E+-R*\CSYUH+&'[>0ICM7A]XK0PY*Q*1ZK<BV,YX0;=-!DM
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M\@9*(+;0]*(B@H]H(?)!U33[?\>(RF+CF>S\,]14I3C.CU$<ZB6\\TR?6_-
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MPERFJ(.N:JD=-416!+GU:?>^/%6 1F1?>FD45M629!G'F:.MQR<@*\#K\/\
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M#[;2T]K-QNENE:6<V1C^%7S^1RL;QFQD26*N/A]W)NWG6;>WC74F]IV!IGF
M;]"ZZJBAZDB@VJQ1/8.8)%[O*.)$A8GD^,S:*RPN?3-/553C#DA_2?5M_*:Q
MU,IG0H65L-)617D) EJ*F>JB2B)).7;!44<CF^HRQA5P1F*]%<4YHHZ@Z(/-
M.OU2\M?[^,=RC,_E#-]!:IW[*M_[1LX%)8&PRTCT&#8R/0S)@,)$;8=-ADR,
M2/S-J/E5%5>*G- G2[X;GR]O8V#%ELJVQO%\MCY%'CC>6EE(!^G@W='! \<L
MFOR[Z8H%N:J"Z@JJ)$*DJJB7@D(N%G^^F]7O0+%\2WZR.KR;-:Z)=,8A;!7U
M6(6>*[?T%-:90Q5UL7!:#'H,HGK)JV$O4 XI!*)%<44$1W+Y9R2%Q58*<[HK
M03L;H:C$W\F"_P <KG*[*H5]C^+TT((%9%@QL8L*B;0RYUA=I:M19AO.SQ;=
M1!;)%(G'.G+>ME!W7Y),G5,=Y=4=J>IHB40U50)P>6@Z<T^WC.BA9VMR2SHK
M;$9S5]7NU$B!D^&VZ_**>[GN2Z[%;FX;-I^\JWG15'+%A>3P*J(NJ:+STF0^
M=[LHP^RM, D8_5VDFVK,7P&NR*;95=1617YC%?7L-NUX5,YX"<?>8?)Y":9$
M/(@:HJH+E .\;^C3 Y>W_N_F"'IU=R^B31-41$&JI@Z>6J?N<-?(V=Y+C!1<
M +@!< +@!< >,O\ 7,*#_5D^H#Z#7O?YUNH>O-.YV,?5434CY].GP\.*\D6*
M-6=Y#LY$*F)TAZVV2*/HB)HO1%)%14;3Q41X%([:S[;I2-,>(P4!'35%31!1
M$3[@Z*B+P8+E[>^W>=E>W%]DHQHX/,@[VQ)V2AGVFX3Q((@T0<A>5?'X<:7&
MI9"ITN(V'3CTUCT\BOGS(S9B2Z.FKX,FNJDA+TDR.NJ?'C-X*3"11PJNA#UJ
MJ0JBJG4;B\U[JIIJ0\M.+H#C\RD)BA>EKQZB,?P%04312CIIHBKX>/#(&&?#
M>8H*NQF1 C+ZEAU1'7[J&PXNJ<DU%.'=@SKJVA7CE%$050@<;354%-=&713[
MI*NFA<2@%G +2XBUT>13(A0;=ZUCFA""KU5=;&F BJ3;FB#ZI%Y+X\53((?E
M=9=U&1M1+@Q5,D*+/KQ BT$3:;.3K^$THJIS!\.I.#H$TR&IET90#%Q!4V$Z
M212)14A=T7SCHFBIQ;1 .6]M*NG&JN63LQBE$9%N^1(/=<!>HM>VH:ZE&7QZ
M?'C+LI.\<WGSS$6D9PO-LBHJ^;"(6:NM*,Y'<]&@,HCB2^XK:B3BZ="K]Y=>
M-+D]40AJ0;[(QL<EN3L%R$G@?6Q?G2TD.=)L@A$@/=O[OPZ=-$XRK924%=G>
M2!"^N'9\I51$ZB1-5)>7\,6D74OV<7(,R?96=6D>I<$OD$X#?DQAT%N24;I;
M9-SDA%TM2#3[W[W%M*@8HW&5ULF+;T^.1IU>A"#0NMMN "ZDFI";3@Z(2:KS
M7B2U8':3E<N=?V%GF X<PK_7U(@&VB$9/:Z(U4,#HI'PFY 2\5R/'<,QS+9T
MJPGK7991S:.&>$BR25LZ>V?I[2U=F2*=T(D-&SU%M7Q+J\S9*B::4$'US(8&
MYFVM9?/5E!37F!8])L+,+1D83.XD0[V75,/U@5D:4VWZ9;5I2- AFKD(T55%
M54Y,KN"K>/[F28<(X\6I%QTA1!5&V54N6FO,OL_9Q)*?=EF60NX[<.S&#K3>
MF1%B=(-(CH=F9U+]W]U>G_'A+!RQ+&X[E>LB<I"XR2 JH*Z$0O(BK^$G+7AY
M!%H]8U+O4BWMZ8RT/440E%.M%-1Y"#2:=8_9QD#YD1W<)V%$:NG$BL-N!'46
MV7/(2MJJKW8ZK\$^WBV@8T2+9N_C/7SBIS5?P8Z<D3GJB1T1.7"6#B"/CEF\
M+Y6+W\L2$: 9B*]*]7W1=%%\/LY\5@=;(&K>(GY8>ZAKFR:G$2(A(9HG875$
M>U5$:+Q5.( 3"T*3R9M3<<,5T005?,:Z= ZJ32ZKKIP\@DOR.0^,MD*<ZJ?'
M))*N/O/&*"T2N<^MV1J2=M==15. +&8AFM?E>$NXAD$>)99'"ANLXP\Q'CM+
M$9;1QB8+IL!$-Q3D*PNI [IT^*?&S*!WW/T>%6L#V]>[P9TKL62>XD5T557H
M'_*W:A$'F/Q#]G!XCN39W3N,E%P!XC7M<V;R?=BP+/:3&<<L,0P=+.VR*2#S
M,":N54E,Y<5D:&U:74=XA2<=:JDC#HJA*B&BHJATXJ;T1N M91 ]SVX]Q491
MGL>]F8=E>58A9N8[*N<=+&0N[6U&9MQC\J,-BY8"Q8R);T=UQ7Q;9 55QUE-
M#6QR;EX%()&84VT&!-PL!PAB3(S*ZF1H]/O7D*B_DF$YM80W[25@N+E#KZEE
M:03.6:2B@S(K:P ;.7W"%':U%;(IRQ_WWM,B_P P/;?N=AE+A=CG!;&2<JLZ
M&76W,E:^1DCVZ^)+5W&4Q;N'BEZM6!>L:6MF*+#RBZZ1,H0J<RFHP"18A>9A
MA'MLW:WBR#>N[I<XAX?=8T_@&-LNSJQF7NKC]_%D%<7D.GNZ2\A+)KNFK2NL
M4*"VCRS2<[K)(5*9#S!1"NS)96**_)P/%DFV%+8T;MG4A(#)G8]I;C<29DA7
M[R4R@R)443)?3#YB'EQB64PLNQ"[PQM;][&_2FHCTN,V52^8(1]K5 C3GCU_
M$5/#EPPBAI]LEA:,[=^YW(8UO.:.ZVUDU3\66H-",JSQG/F(345399ZC[KYI
M]XT\-?VWCAM$92^!\RJ5@S\AB6/H8='?PW'V7HSCBG,R49XCTM#()1(!5?N?
M#C-E+F[I^VC)-LL+M\HL,%=>G8/.C56>RIEUC<QKOS)=;!8=!NNL0>5!DW3.
MJ"KJHB:KRY\:?&/")(.=M=M-T8.75VZ>(P\:E#MQ35.ZS,&-*BQ6WJ21'3+*
MRKL_67S)$[9PZ-6FU VNE4/JTU31Q35AEE?>B]MENED&VWN2QB%:T>8[SXK%
MEY)B;K1LTV#N;:L1MJ)[JN/U@%';O)N&MV ]R<^KJ3.L/PU1!URN&LLG&53*
M<8CD-=7T5"]%L;OILZO%TS%"'5&6?S4B<NFN'4>L0UT[BZ:_W8T4+M_C)9-F
MS^/;5C)R#%<IO%CO,63\6)$&R>L"9>$$F#2KVD=FDBHO5R1.?Q6O-8'D@F]^
MQN3;2YKB-)E;3&+2+UMDJ>PQR3"DO=3L9'T:<:C2KUQ/*A*JJ IJ*<^::SDO
M5A.21;8VV,WLN9C4*+.QFZR)[U,;+YO2%!BT/;X&MQ*RRPR.L9)O_;EI0G7-
MHX<XB<>5$%%T)*FL;!E[H>YG<?-\WVUSR1G;F43\#N7(SEUDD.Q9R"Q?GSZ#
MU-/:0S&JE U5NTG;9_EF->X?F/Q$^3<,0067NOD.Y.X#.1;AWM=#J(MU&6*R
M,><VRVXU7K''1'7ICFA #BK^U>)+;L -QZ/=P[6CJJW'Z;UUQ.B9IBPNKY*"
M? >&28R%2T:%EHX^/$*H9 7G^]S3B(ILQW:WRH=Y]C;*!*Q*%8;]%)V]QK-+
M. Q*&DDC0MSZYB6]8R)3T X5=(.48(,\B1LUU5=47CH^4\?_ &,I0^P&*++]
MS_;]FDYVPM\1W"O\HQ6#!=P:V;ELTD2R.+C\BAZ9BW53%ZF\<@B*DLXAU=+F
M/W1S+3[ER/6\&_V+^XHFK/.MOK"EDXS8-5< QD1NI5D.M X0H1V!.(@6Q\QY
M<OV+Q7R7+(2@"%YMUB^/36K2IF6Z5M)<XM:5(B4?0;^_F.2X$-S_ +.%7.J9
M! /*@H//4DU1>,M(!6]P>Y=AOKNKB>T+(.AA>$8?3UC-@**VL@+FJH[V[/NR
M")DG(U];/M>5I/NKR+[RZ;]G&@J*$RIN)("E IJQUU$\J>BGHG5KS\3#]U?M
MXYQT*<537R<A">ZM54Q JT86.A1Y(*XDE'U7[\Q=5!(HZZ:>/%AR#.@XQ,LG
M59D1*@1'5$567TY(J)KSEK]O$@!!P;<>RQ"SJF:!FZ[U[@L;&LQ4([I<DGWC
M[XJ(1FR%>S)#FO6G%3!-=UHM8V.)?Y=S1:BLXC3Q+UBT!QL$F1:J T@LH35;
MUOHXCR.]/<'733I^-?8%;)+8^M<.RC5,IU>1:,2C15T%-=1DE\$^WC,@/UC>
MQZ>]L+9J)"6D=9437T\M>HE[H^44=0U7SA^[QKOH GGY<>0G:LL-2(5=&K[<
MZOT">F%XI#!J22F9B//213LM]"-("HA%KJJII)D'?9_1T63Q8K[LK23*C,6&
M3W>)C!"72WC2NC38[C-(OF,6Q>\U?XBNG%C\9U)G^N\'>MXP:%P N %P N %
MP!X]OUI:J<OU</>9))Z'&OI6[\ZP8QFXD,6L"RJ9%;!BG+@V%)("O80$9D*@
MNRNO5C[NA#U:Q@A229L;D%=13\D^2S?EDOT=U5M'94IP(_YB21.L_E#3;R2&
MVD1&M4<)PND0YJJ+KKU< &$_:^F&]A4MC9WE8U<-"[)2,C3S8&0-*H];-7+!
M$T+7FJ\^)ZE.Z3[.< VM]JGTY]\Z;'-J,>W"R>D*1(E9KFAH]>1Z[+6\#PJ*
M78K['&')!^L><U[48M$=551!153LN/JJ='*9<'2AWHAE*SW)D@-XPZ+62Y*U
M-KX-3=PH]58I:O#.A)\QFIWB:D"K:DV;@_AZ]2HJ*O#E6#J";Y//%=0KZ1%T
MT75F1_T?SZ<N,X!S]FF__$<3_P#!9?\ \4XU*!FQ(+,@'OEU;5Q4;Z%?]1'E
M(KFO7VNWK(;UZ>DM?'Q3A3 R39MG5F7364SJ?=\L>4OPZD\)W[.("3885.U8
MVPV+@S)!HB-S8L29V6_PW$\W4RZ2:*NJ\_#A38#+&<K:QJKN4M*>ZFUZ/K6L
MNQYNM<+CH.N-.HA,+U..,A\4^ZO%79@AV?2I^3@-E+8II#PH@HP4>6+0B/6F
MHD<U$71%U^_X\'( CZ=G_P"Y*K_\&E?_ *QQ /=/Z9HR8(:Z,LTVX:*$28NH
MO=2$JJCCB)IHGCP!:O;>GG2I+FT\7(JN%6RJ^7:$KC,D#<<;9.0@(X1HRFJM
M)^[KIQI+0 <$&ZKH":SJ-7$Z4'6/,7IZ>E--1EH.J:_;QE4!AN9SSC<%+R'5
M6RB#R1RC1IOX(]3:&AJLIQ%4]$7X>'%0&C2I<%1#'8/<(5041B3JA+R'GWM$
MYKPKH"?5#MK;$L>%4U(QL7PVDJ<H]:JJ2I7I9=Y!(;!@7"5.K7H0_P!G"V ]
M[F9;!CT.+9!4L5+56YB]/#:4 D&3CU-3P(,D% 9/<!&GV2%$(4U3P5?'C3:@
MA62WS6;E;##;D*O.&DEGN&#$L2$!=3K5"<DJ"$@JO/14XS,Y*7'IZ+8>T85J
M)8;F4TEE$5^SH[[%HW=%$U-$>FXE-952$51$3_BXTEQ[R2R#YU5[,NQAA8!5
M9Q+M6!D!=VVXDFNGE8RBT2([3R*;'\;CDP"(:.Z][55#11YZQ^K%E7IF*S8#
M[K]@%3$8756Q('%147[J(@2C7123X\0I'Q"2BZC5T/\ :C,G_P#:/&09<.)8
M2'Q,*VD%&B'FC4C0NKGX?,%75.GBSU 7*NK1V/TO1:\25%0D;;=1%54\?,^:
MZ:+IP?? &MC'*^#-<<9@5G>1%73H<^P^?)].?C\>* =VL4G+*6OH*@]#T42:
MD%T+\-.F6B)U<1@9SCO(XC/RNEZ55%4D9E)IJNFO.;S73@"9,06(3!.,L4R(
MB*I=#,E571/BB2555X ><'RVW@3[J)1K10[#(:R3AARW*3(9DN-6WRAZR5".
M#)1IIU@XC>G<%Q"54T%=%XJ!Z(GZ2N8DW8WW$7#%HYD#%QO,4:R*Z$JN1V(N
M [=->K8C63-1)7HEPP;3R'JFNB*G--<L&=G<SXYFA< :2<%_H%?EVX_R7_H[
M_E+U:_FK_*?_ $6?+/6]$'U'K_RA_)]_TOINYW?-V>G7R]/&E[:DCC9GM_T8
M/R2_Z_\ I8?)?S?'^2_,_P#29\E]-\R<_P O^CU7\E\\[/\ ZGZ?QN]U>FYZ
M\:?MWC_LRHUD@E[_ +>WYO4_.OZ-'S'U"?(/F_\ HCZ?4=MSYG^7?6<_S!\R
M[W7Z;\?7OZ\^OB?E%FO!.!_H'_(<2[7])3\J?E>U_)'RG_1U\C_+WR^Z^:?E
MCTO\A^6OEWJ__1?Y;J[VO[_#\HV*(K _V_G^5DGM?TA_\F_0U'S'T?\ HS_*
M/:])(_+_ ,S[/_8GJ_3=[N]WS:]6OQX7%8)7R1ZN_P!MS\\?^7_T1O3_ "$>
MGY3_ *$/FO1K6:=?I/YGHTT\>7W?V<359*2FT_VZ'93Y_P#T?O3:I_Z]_P!%
M?IO%.G7U_P"%IU^&OQX.?@IS_P#L[WY9F?E?^C-^7_5TWYD^1_Z(?0^AZY'9
M^<>@_E^WZ?U'1W^6G<TY=7!3W(R&2O\ ;==X_5_T5?DG0FOJ_P#0OZ730.YK
MW?P=.YU:_MX7!0Q9I_1 ^5;C_G+^F1^4OS W_FI^=?\ 2I\J^9]5'Z/YG\[_
M )+7U_H.CO\ /N=.G/IXOY;G_G4RXT#R%_M[_D63?DO^D7\E_*^$_FO\J?Z,
M_P#Y _EEQ\@^:?*.7R3Y%ZOT_>_E^SW.CR=7!3H?8Y,I_H#_ )<8_-7]'C\D
M_(G?F_S7_19U?*?4M>G['K/)Z/M=ON:?A]W37GP?MW P0O\ ;:>AF_+_ .B5
MZ/Y95>N[7^A+L=GYPG8[O;_#[?J>GHZN77X<^(Y*B8XG_MZ/Y7\M?T<O_7LO
MY'^6_P#11W_F7K6^OL?+//ZGU/:^YY^K3XZ<+T#FW$_H"_FFH_S3_I"_G/MA
M^3_S[_HR]5T=H.U\I_,/\QU=GP['PU^&O!^T_D"%)_MW/F%1VOZ)/R[Y6'Y4
M[W^A3Y)\D[L[\O\ Y:ZOY'_Y).YIZ7EKKISX:"F1E'_;2_,9?S_^AW^<OS#5
M?FKYI_H*]9^9OF$CU_5ZS^9[WS7O]/5Y^K]O!Y[!'+=_[9/TH_._Z%/H_G;/
M5K_H Z>OTDO3JZ_+U].O[?'B(HXU'^VM^;KVOZ'WS+Y<]U=O_09Z[T7:F=ST
MG3^/V.CN:]/ETZM?CPL@\8[_ +=+\LY!^6?Z,WY9]3_VM^7_ /1!V^KJF]_Y
MQ\N_#UZ>YT][_P"$_P"MQ;T-#-DG^W4]4'YX_H>_.?EX>G_,7^@_\P>LZ(_R
M#3YG_P!H:_EOI[7_ ,#T]/DTX;W(LY9_^V_ZZ;YK_1>_CGZK7_0WV?5=H^SW
MNKR=_N=&G5YON_LX <;7_;S^@K?4?T7_ )5^=L8UU_T/]KU/S=/RUW]?)W^O
MK]/U>;JZNCX\+&C#D?[=GYC1?(?Z*GSKYP]\S['^AGYC\GZYWJ.YVOYGL^K]
M/][R_=_9POY#['"'^U[Z5]'_ $#^O7EV_P"GIX\M?N\]=.)93G@_[:GJ?Z/Z
M$?I_P]>S_H Z>G5SIZNCRZ=/AKP^Y!S+_;1\O2_T*>Y^S_0%K_=ISTUX7LO@
M;XO^W)^=3/R[_1 ]5WS^9]C_ $'=_P!/VDZ]>SY].G7QY::\4ESV.2Q_VS_;
M#YQ_0_[7J9W8]9_H+Z.ON-^IZ>_R\>C73B6&-['^UZU73^@SUZ+KW_Z>_7IJ
MGCU\]>(4^YO^VT]'%]7_ $*_EO4/?[_^@3T_BGCW?PO'I\>- PU_VQWK&O3_
M -!?TO8/T_I_Z?'J>CI'U'H.W^)U=/3U='/7IU^'$\@N[[0_Z?73D?\ H&_T
MC_+_ )Y ]?\ Z=?\FOE?I_EZ>H]/_E?_ "O9^8='5IY>[X^;C7Y1>#.^YLAX
MP:%P N %P N %P!HSW)_H)_YLYO_ *C_ .CY_GC^9+;\X?YU_P"B_P#S<T^2
ML]KN?GK_ +X]KU/<TZ^75W?CU\:Y=R>"55_] ?\ *E9ZK^DW^5?ET#Y7\X_T
M>?)?1^E;[/RWU?\ (^D]/V].UY.CI^&G%_+4@:GO]N=W0[W]%+U_3_+>M_T+
M^IZ=$T[?>_%TZ=/#X<3\NX\%A6_Z:'R[)O2?Z(_RI\IA?GWI_P A_P#+OTOS
M(?D/S?I_[O?_ "1^EZ.__P SM:>;HXV_>*F#/XR5-;_VUG?L?S/_ $._S)\U
MLOS/\[_T%>K_ #5ZIS\R=_U_X_KOFO<]1U_B]S[_ )N.;-(YO_9CO_F$/_SO
MSB%%_P"S'?\ S"'_ .=^< ?B_P"V._\ F$7]W]/[_P 7 &([_M@/^?\ T&=/
M_A?Z?/C\?O\  ''!_P!LGI)^0_T&_3Z+ZGY?_3ZZ/NKKW?2^73H_XN6G%K8.
M*%_MA.W+[/\ 0>[G7_.=K^GUKW/Q-.YT?O:]7CP8.9W_ &TW;_G?Z$ORS]S7
M_0#T?]/DTUU\.&Z!Q?\ LNW_ ,P1_P#G>O$!AS?]L+V@^7_T$^_WV^WI_3VU
M[NA=OHT\W7XZ:<^ '2+_ +;_ .<-_+OZ&'YE],7;]#_H'^:>E[9]SH['\YV^
MUU:Z>7I_9Q27/8:9/^V8^6CWOZ&'7RTZ_P#0)T_N:_>Y<0&96?[8KTK?<_H1
M]6G_ #_Z?OVKKT=S_IT^/%N* X_^S%Z%V_Z$'5HO\'^GYU^'+3HYZZ^'[>%[
M*1#_ -FL[,S\O?T.>GU"_G'J_P!!/7Z7K3K^9=//HZ>[_&Y>/[>*9N23%_MD
M?R_%]1_0O_+WXWH/6?Z _EFG67J_0][^4Z>[]_HY:^/&31QP?]K_ .C+T?\
M0:]-YNKM_P!/CM:Z<]>CR>'%!@,?[;3T3G9_H9?EG4>W\@_T#^/[FGH?)U:=
M']W%\$^Q,&?]N3\OK_4_T4/E_;<^2?./]"O\#J'U/H_5\NCN=/5T<O#7X<1R
M!ENO]LCVP_,/]"KQ3I];_H Z?^KIZCEKKKX<0,;1_P!KW^[_ $&]-?A_3ZT_
M^AP*.,+_ &Q/G]/_ $'OO#KV_P"GW^W37I^/ #P/^VCZ?P/Z&OQT['^@?QT_
MZO[. &2)_MI_7.>H_H7:Z+KU_P"@3J\#\=>?CKX\4AA1_P#;#^KL>]_0=Z^Z
MW_$_I]=6NAZZ]7/QX64S2_VOVGF_H+ZZ?'^GQK_=^WB 4?\ VP';7M_T&^C1
M.K7^GSTZ:+_=IIP!QQO]LW\P:_*O]#WYSUCZ;\J?Z"N[ZK4?3^I^4_B=WJTZ
M-?-XZ<53H%WO:=_H!Z,__P!%G^C?\K?/F/FW^G7_ "3^3?F'Y=1=_O?Y8_R/
9=]#V>KJ\W5TZ_#C3GU4F=FQ/C!H7 '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tm2226999d1-tbl_studies4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d1-tbl_studies4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"E -\ P$1  (1 0,1 ?_$ /0   $#!0$!
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MA'NFATUQ[F9*1,#J/"EZ1..WAW[=M3\+H?3I_BA^;U8F=7\F4$SQG0[I>/\
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M/UW5BW5_)F,XY 9S;=\/UYY=1*=W(,HX7>4+DS\O<,U0103,"LW_ $8SI0Y
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MS;G_ (9T_K.EAI_BA^;2WO$'/F=!VWS9F#L_\9UT_P ,Z?UG1PT_Q0_-S_\
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M#$4OF5W@RSEQ/"0K^YO+*T;MGSAPT8QJT\BND207(@@=9H@<X 15,IA'QAV
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MV',:OU>W@0SRVR63Z;8^IT/EJ!2$K-D$=^H ^R;[G5Z?H]76Z"U0VFIJUW_
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MBD[G3<5^KE:5M?E3S&AYCRR$R$\8SB-=3[E1$LPW6C:B3R=-VJS79$%PD*I
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M/Z1Z?VG5Q?!#[.DI] &1\/U$6OXPE/I)I_:]7'N1K["MB@H< )(?!@FUA_\
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M"&";5^Q)2WTCT_.ZF+X(OX>B]=[$] "2\Q%I^,)3Z1:GYG4Q?!#\'3AWL/0
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MIK)@=H.X"!HL0*,6?L -NMJ(#['V@\&K2XS+=I3H T : - &@$T "&X;:%5
M\.A! #;0K<E6A!/:V\&A=X>W^[H070!H T : 0/ 'V@T*[1 \)OV/[&@=B*M
M"!H T : - &@#0%/9V;^'^WH7=8+V]OM>QH070!H!!#?;[&A4X%T(4]G9OX?
M[>A=U@O;V^U[&A!= &@$T ?9#PZ%R=@NA!- 'V=OW.W0N0NA T : - *'W3;
M_HU#_P!=K+]A5:9^+/\ *PPU_P!D_P#Z%LFOEU/E9=/S+M.UFN8[#F-RG_R@
M6_\ R/0/_?A>-=?3^5;CBU__ $>\8-;[AO\ ^T)_ZPNOHB726-4": - +H!
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MPMD?%F"E<//*+8S5>5,IU6RGB0ZK0A>K8"@ CMI6TO5=MV 4=DTGO?$\#9.
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MP.;+]H,UO9VCHZ0M_)G39XNW1CG+)\D\!V"[87!5S%0(8$6VQ! %.HQ3!TB
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M&F*T/.3EZ@JZ>%2DI"':N)N=B:\U;.)AFW<*R4N^0CT&[5%404>J^4KE*4A
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MA0T : -!"#0!H T G;[8?M?Z>A:"Z$#0!H T : -2H#5 :$A!H4- &@#0!H
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MV8]I*W)7.>N8KC,[62=QW=!Q]@)K&*SU@;H1BBZBLE#0TR* ]_:6Y1*3X6.
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MFS[QO8M*4YK#"\EM97QI*I/3" QK00"0(/2  8=28OVVQ"4U:NX<;>PZI6#
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M5*N5>UR2<R)Q9Y*94Y7<O[P?%U@J6.LX\1J50L>Y%F<B8I<(1.0*MEF]WE:
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M#WII#$(/D/2_S1JOQ,P]Z:L,0@&BTL?#4*K\3L/>FI#O)*0I:'2AWWJ%7_\
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MQF'C!S/5?V=K6VM:L54J\77(AO8T&U2D*'/6JC72MBXDJ<O%.S I+/1*HX6
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MO3=\/B23F>4N,*_7L72869694SW"+7?&T:9N_D7<[2WC&O33]Y'QL;&A(BC
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M$98)9-/.<58)[%5@=TZ]-HB_M*U7++:)HZ<>YJ[>4B7+:"J+Q4I'_D9Q,D4
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M^'C;*ELHE_=I_9\&BFZX-5JHD?C4-!H T : - &@#0!H T : - &@#0!H T
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MXV\E(V(R)7<9L*T_:X&R0R=7 \5BK#T.]8MYLE<2,LHW?P"Z9SD\H'K;" E
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M7*YOG]0]*U4CR[0;!3D3Q[%2).]R)4VZAV3Q^1RJ=9XFYC&#\8U\GUO&JIQ
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MMW*#G&]338(NDSHKE Y?@I90S=)NU6,+LY=U5P(7I .H.]]@!WU:4:4Y>W;
MS+TJ>]>&V)0/&#CR=UY3(XDJJCHH)(NQ4(HJ=#NA$K1\T31>"<"/1ZS](]9@
M H;@ ^$H;MH@Y2LAX&W4XS<>P3[M;&]4(X$ABH+$1<>4)D,;J3*#?RDRP[DV
M'[C1*DHCMAX& GQBX]NW4HU5Q?75 ?+%=B!6SDR)CHBDJ3NERJF0V S4/"8?
M:UII)4JML2VN&HIO\#;%XO<?GRQCKXS@CJHM63<&ZB"Y4T"HIG(4$3&.4IQ.
M!?&V,;;I#P>S$\N/<*X\#))Q8X^]0E^JJM@ >R*:@^U_^D:=BCM(EO[BWZ*_
M'[S2US[W_P"5:06,A!XK<?A_Q2UT/M!_\IT@1D)Z*O'[S35[]K_Y3I"R[R07
M/16X^^::M_>&]\ZE34(Q'/%WCVAT";%E>(/CG*D0A]ES)](@4=EC!V".P=H>
M'57>(5EQ0CQ?P'W@+H8RKS-RZ.4KA%,INI-$I.@IS?AS[=0)D'M\.^HL\ YN
M-KZ+''[S45GW);WSJQIQ)Y@]%CC]YIZS[DM[YU(TCS!Z+''[S3UGW);WSI&D
M>8T7HO<>P(F=#%E<4-#R'=D.!3")%52((G*H'E #N"3C?LV\.K9;8'9"M-NE
MQ7P"!W(J8MK:QUG;AR8QDU!$!<JG4Z=@<@( 'V=15^855A>]%CC]YJ*S[DM[
MYU8TXCS!Z+''[S45GW);WSI&G$>8U[SC)@)DLU6;X@K:KLW>I)J$3.0R""HI
M%=& ZCLI"@)-A'?VM2RJ*I<K586$^,?'LBJC9+$M;*W$>_4= 4W=F7, "8A@
M\IZE#;JF^Y#^YTRO)??W&W]%?C[YJ*S[BM[ZU:#E#T5^/OFHK/N2WOG2@Y0]
M%?C[YJ*S[DM[YTIB.5%DO%KC^'^*:MB ^$1*8?[#K4:5UIU:NIJ:AQP9@N^+
MG'UJY:/2XHK2;EL5P9FOT'*":X]R8A!$SG_95"%]KP:JANL')U$X;TS,<36K
M<7\"'4.X^K>!:&D3@G)](" $3 FP*!NJ;[H$2#ON;[K6DD]+.+J:=+:F5I;J
M>F]%CC]YJ*S[DM[YUF-.)W>8/18X_>SBBL^Y+>^=*8B&[0]%?C[YJ*S[DM[Y
MTIB.5%/HL\?O--6O<5O?.LQI+&HQG7%[C\DF!_JIK1! Q1 W<K;!L("(]CD>
MT-5*72".GS5$<\9<!G%!4F)ZV\$I0 O8)">#M^[=D$1W#;PZ4+9;:9GHK\??
M-16?<EO?.K3$G*C ?<6L  '<AB2MG26;/ 4$$E0$IBID!,0W=?=>..W8(:0F
MLY0L?8S%/Q>X_BN*?U3UH3+1QF[I(H[J@W%1N(&,4'8CX$R=NVW;JQ.$$E7X
M&R]%;C[YIJW]X;WSK-34(MJ<6^.Z>W?8GJX;[]/6T=K^#;?;R=P/1X0\/A]C
MV=*BB+?HP<</-14_BR4_G]('$S_18X_>:BL^Y+>^=6-.)/,'HL<?O-/6?<5?
M?.D:1YA/17X^^:>L>XJ^^=(TB=8>BUQ^\TU:]Q6]\Z2LBQJ .+/'X?\ %/6@
M_P"8K>^=*,GF0OHL<?O-16?<EO?.D:<1Y@]%CC]YJ*S[DM[YTC3B/,'HL<?O
M-16?<EO?.D:<1Y@]%CC]YJ*S[DM[YTC3B/,'HL<?O-16?<EO?.D:<1Y@]%CC
M]YJ*S[DM[YTC3B/,'HL<?O-16?<EO?.D:<1Y@]%CC]YJ*S[DM[YTC3B/,'HL
M<?O-16?<EO?.D:<1Y@]%CC]YJ*S[DM[YTC3B/,'HL<?O-16?<5O?.IY1Y@]%
MCC]YJ*S[DM[YT\N(\P>BQQ^\U%9]R6]\ZL:<1Y@]%CC]YJ*S[DM[YTC3B/,'
MHL<?O-16?<EO?.D:<1Y@]%CC]YJ*S[DM[YTC3B/,'HL<?O-16?<EO?.D:<1Y
M@]%?C\/AQ16?<EO?.I"$-VAZ*_'WS45GW);WSI"$!Z+''[S45GW);WSJQIQ'
MF#T6./WFHK/N2WOG2-.(\P>BQQ^\U%9]R6]\Z1IQ'F#T6./WFGK/N2WOG4C2
M/,'HL<?O-/6?<EO?.D:1Y@]%CC]YJ*S[DM[YU8TXCS!Z+''[S45GW);WSI&G
M$>8/18X_>:BL^Y+>^=(TXCS!Z+''[S45GW);WSI&G$>8/17X^^:BL^Y+>^=2
M$(#T5^/P>#%%9]R6]\Z0A#5@>BQQ^\U%9]R6]\ZL:<1Y@]%CC]YJ*S[DM[YT
MC3B/,'HL<?O-16?<EO?.D:<1Y@]%CC]YJ*S[DM[YTC3B/,'HL<?O-16?<EO?
M.D:<1Y@]%CC]YJ*S[DM[YTC3B/,'HL<?O-16?<EO?.D:<1Y@]%CC]YJ*S[DM
M[YTC3B/,'HL<?O-16?<EO?.D:<1Y@]%CC]YJ*S[DM[YTC3B/,)Z*_'[S3UCW
M%7WSI3$3K%]%CC]YIZS[BK[YTIB/,'HL<?O-16?<EO?.D:<1Y@]%CC]YIZS[
MDM[YU(TCS%@_%GCZ5=%0<15<W3N'?'(H (@(E$>P7A3"([;]F_@T:TV%4IRR
M*%EQ]2L><RN/,?3*]$PQ%ZK*G I2G%3<RES$XD$JQ"=I4]O!I?4BB*2=.]0T
M1WCDR%Y06!$Z3<X_4)3E^\(@FEVFR%>2](E #;_<>'?V?!JMUE$2351WK"YB
MH.&DY:;<HMHB+;OYF0<+J)M&C5@T24>NW#U94X()-&C=(QE%%! A2 (CL&^C
M[R*%=3;N6)R%P#GO)_.FR9"O-*R WQ_@ZA6:4KU.KK! TB3)C&N/CUJT3ZUH
M:2U>:UX(RXQ[UF1'R22!8@ KWI-N[U855>$R3^+Y3/F.K?>%>25^@K?CEDQ1
ME:K<#4A.HM"-WJ_P8U3D6SRP3;6#=_""7BI'<F,<52%#M. C+'#E1;\3>KJ:
M7I\L3X[BJZ<C:MD3"_(5KA7*M-C,K8\H-VFG:<2O#3-PAFC:N6AW5)(]0CIM
ME.-T+ :%748.1.0J@H&%(5.D1"VOL.+J==<C4I4=KA[8X'.G)7(SD"S]6U@_
M-T+E12OVUYDBTP%I=/(AXVDYEO'V;,K H+*GL#5XB14E<;'[H_>@($*.X[ .
MHW"57)Y_4ZS^US328CB=\7-H:LFKYZ\0409LD#O#/!$19@Q3+N=TN[%,J#8C
M<"G.OU"((HE%0P]/@D;X/;4/"1AE>8_'1O/)UA;*M#4GW-=D[/&1S&XUM^K/
MQ<&R2?3BU8!&3!2PDC$'"(G,V(< !=(3=/>$W7"DQMVX%=?YA\>+5CVQY1KV
M4Z'-4>HJ.DK+98FY5N2@8!1D[78NRSDTSDEHV(,R>-S(. <*$[AP44C[' 0U
M>7"NVW:25MMLJE$[RKQ14F5==668)$!:6LA+1R1P0/(QU:81[UX:R6>-45;K
MUR-44BW215'&R/6B(=X([@"$WF53#D@]R;Y+V9UE3@M-X)S)7K#C7+N2&C6P
M)5=5G-Q-@K$U9\2$:R2TM"V%PP(:$B)]PHFW.14'GE E Z0%$3+41TW^_P!F
M)-K)?);"N(Y%!GDC(M,H81\C&K34I/VZ!K\-$(.H<SU-W;7LF^8-*HT=(N$U
M2F=GZ#D.0P"('*.E\.];2**76F7AB>VO4O)ITB]OJG+%)*LZY)SU6LJD:-IC
MBJMFJB@-F:(.VZ,FL)&A_%37*)>] VW9L-JRRE5V;>T^?:(YN<X'G"7-/*U?
M-6/S2N&,FY/JR&+)+"C.%E;J3&,G-HL8-]=G-T5=U,]M^!?)B*GB'XMA6,<$
MU^[$ATO382CH^S?M>=K,*<A*K9.-6*\UY0?U;%">1X1JG)DL,_%5:*+9ES2)
MCL6]@E20C9VLJC"N%4]DRG.D0Q@+L41U4Z09:[([.V>XS%.05&RA3\F,L67-
ME'7"EU62?+MG3%L:;KR(-C]S+&@2R3:0!NX4,=!,XBD45"F #")1+K,GS;;T
MMZ8YE3L]EXQ? _.\](\:G%XS+<R3JK3(%^A_E'*D&-?.VT') @U[EE(2+Y98
MSE/M[H%S=R(@7<W5OJO-U,=/J))V<DX3O)8XGY)X>S<G-!C6ZUFRRM:4<HV>
MI,9J(<WFJN$70(-DK13F;QU-UX95JHD\9^5)I>5,7"#A,#)K$,)*;-F?1]1)
M-KE=)I!ZN_9HHV-8A"9M<S%QS5WY'Y$5>59(JR8NWR;(4X<BQTQE5V8'%9<B
M/49)N4RAMB@(ZS9;8?;Q[T-0]Y-X?N>.<C7VIV-C9F6'0G)>Q1#%ZR/(H/ZB
ME*OVWEJ#99XNQC7ZT"X!!91(2."$.8H"!#!JJ(EU6\CM48_KVG.KA1D;)7-.
M(Q]R.JV:)*IA#Y3NRF5*&:DOI]K;:/4;G?*/'X_)8BV^$2B0EFL5$R O31[L
MJ(M!2\E4ZP6(TI32T:G2^-O89/)KEM+5OFY2N)%IR=4^-U+O.*V>08;*=]AX
MUM2LK7I>7R6R0KK&0GIVE0C"?B@H3!X5%.1D7+@3(I FGWI%-3)V9%E30U5\
MY59ZX=X[OSS,%JK^;[U=<E8VQEQLGU:DEBEG;W^0)VQ5Z+\C;N9._!9(JO.W
M\((OVZRJ;I)T539$%"]5<]D=A(BV9G9;6$F%<:\P9/%JUIA>0,.3,ED9L'=?
M&1PL?X%A9*19B]1@C)JY%*DY9,6Q03-(!W)3'1_D2BKL4W6"K2VDUQ(EW'DQ
MRSIW+KA+QP>WV*H=:SM4;=,VI*P8Y.68JDC6J7E^T-8QP9_/13F>,_=4-HWZ
MSBS%/RD3]!^CH.HWB27%*8^+CLO.EF&)+-#J]Y1=W;+=0RMCMO+14+2DZA0V
M5<?TRQ0[^RM+W7IYU'6RS&GUBNACVY3JE9G;&:*"*8BJ)4[5+N[4&M-V,KML
MWS<.;?\ /N.L:2!(FU6*NQ\P<B;KX%-.19; $4*)3K2IX-15.0(V17623$1+
MT"*Q!Z@$P *D5?ZB78C2LN5."9.AQ638K)N.Y:CSY2(U^Q1-VK,E&3TJ)TN]
MB89\TD%64D[9MG*3A<J"BAT6Q^],4"!N,E9R5)N\P$N77'X]0L=X<98Q?%UV
MDF<(WR2E\@U*-8TUPB5X*2M@>NY%)M%P[HT6[,D]<F02.BU44* E(?IM_P 1
M7M/$Q//[B9-/*TBQSMB ["W*+$@)Y3)5(3@)'R5==FZ3:S S0L%WGEC57N4"
M*&.LBF=4NQ2B )Q\0>QKG,7C9:8RT3$5FG%!V-)D'C"V][D.G)N8$6;%B^.M
M(MAEQ.T()9!(OX44P#???V-$YK<+J;=HW$?ZP+A_=9>FU^I<@L/34S<;5"P%
M7;L<B49TM/OI"58Q_DL&1M/K*2JH.'Z!#E;@H8HK)@(;G+NP]C#VGP&;Q+D[
M)SSUD.=L5S^04)BB1F)H^UP=4%L=NLQ.#3#")E6S \PZ*4JAK"N8'!$2]0+;
M[>/VYWV%EV14EJ/+C!0VU.DER)24)]TM*I0[&3N-?BW%O^!X=U./R4!NY>"M
M>'+:.9++*I, 4,D@BHH;8I#""%B3AEG\<CST5SCXU2[&RO&>4:4LK3K/7Z;:
M8A"V5UQ8*_:;;(RD35JW,PB<CY?%V.9DX1VV(P7*FY\I;J)%(<Y# %B^X8*]
M[;8$C6MPBE6*$@\=1D>W7,VZ3.)5J!42O6PO68.C* B#9=PSV4*F;M$H[AN
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MJ%(]LO\ *GL'_P"#[3/_ "BWW5,JQ[CVV6H!&WT*VTUVFH=I<Z;;*BL9-99
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M,<NA6O@%DNM9TY'\9+@?([J/X]VAKE.VUV8FO(*HHRH5G5I-<LL>I8DXL7L
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M2"/3VEVBG@:IIHB?:[))V<%#$;FVVV'NU?8W'?[O[.M2R<J>!D%[I,A4C=R
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ME!WI/;-[F?\ B:I)6(=\3VS>YJ?Q=0LH!73#PB;W-3^+H69$[]+VS>YJ?Q-
M'?I>V;W-3^)H!073'P";W-3^+H28#OD_;-]XI_%T$HI\H2]LWN2O\36N5DYD
M*"Z8^ 3>YJ?Q-1IHO,A>^)[9O<U/XNH)0=\3VS>YJ?Q=!*->^23<BW#I1.)5
MB;=^FKV"._W.PD]K[.J1P]Q C+#]%#FG@A=95,.[IKXNZ,=)J@'4YMI _DDU
M1\(^'P!H[9=HM435'0S4-$!LNX?N62^2,@TJ.7[#C$S7!E,.JM&-9.1,Y,GD
M:[JFW!G:*Z).\3 ">$VVV_;X-*S:2EAHE.).:F[@YF_,C(R;EZ]5#R8B=G9F
M4027_#K$*7*(F7!J5;?I /[K;<-]5]I=*788[OBOGA!P*8\SLDMD2K)$,NN6
MU)E!!1#O5'6Q\IE*)$E=B#V[;CX0\&B4J5,AT=82/0#Q!S:;[KF;E(?^86T/
M_P"*FH9@H#A[FHO:3F;E4@C]T)4[<7?;P;[94#P;Z%4H7T/\V_KH97^]N'Z5
M="U,CT2<X@/B\R\E%+[)186D?VA^M0-M"1B8SGA[FI<J)2\S,IMQ(_8.W!FZ
M-M1.X;M5^]79]2>5"BF5VF(D$WC 7??I-X-"FL+PDRLD!$VW+_)K1)20,_D7
M31K:6\Y(#LX(1(\ZEE CPA4TU@*&_6  F4    -A(Q-IZ(.< [$^9N2TR^T$
M?:OTJAI4I67B)G F_3S+R4!C!XQO@^U>-MX/\:OL;Z!U*3<1,["/B\T<EE^Q
M\&VH?_XL!H2,V6O0\S=^NGEG[VX?I6TC>(+A.'^;"E. \T,L&$P !3"%P\3;
M?MV^M0=]]_L>#0*AC$X<YQ*H)QYK97, COTBC<.SP>S]; [^#0IF&XA9M_V+
MF9E%(OM WMH_NAE0NDO(<2V3AYFH@F,',S*8G/L(F,C;3!N&XAXHY3]L=-Q*
MM05!Q#SF'AYHY0$/:!G; ']OZUAT*J%I+B!G8B0IJ<U<H*B/]WY#;"CMV=FP
MY8-[7MZ$@MK<0LV%!(BG-#+6_C=(MT[BB']SOU]&51W#VM_!VZ<O,R-\M2P;
MB'F4-@]-?+0''_8SN;@0?V>K*NG)O+.XL!Q2S@JD1(O-/):+G;QT$R6I99-0
M.T4A3+E5,^_2'L@'8/@U6HA_M=XE57[E=?P*O10SFFB"9N9V3#J])"D4%*UD
M BQ@V427'ZTS=R8I]@#<=S" ]G9I&J'02FTBUZ+>=T"N"*<Q\E&533[Q(RI;
M65NN'B;E!P;*!B )1/ML&_@'2/XB?+AJPVRX.A63BEF\YS$],/,1 [Q9,IE4
M;JF!NZ0[\#>-E   IQ\4/#V_M:0L1."H;%EQ,S8HF!R\S,GBJ9)%0R:B=L<F
M0%0HFZ! V4P$O;V> -^G[&E\7!]YE#Q&S:IV..9.2U"^T#*U)_N_6F;4$LU!
M.*6<571#(\T,GJD,GUF301MCE(AP!3<AE4\J](=@!MN =HAJQ2@E36"A7B1F
M\@.7*G-3*)0!(RW0!;:T31!,ISB5=;ZU1*4!W[!, ;;#J12M>_AB$ZUIM>8
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MW*H1#ZT1.H!S^+MV>SV]FVI!9R*2<5LU*)H*)\Q,R"5<%A#K;78@D[KN^@%
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M#'DCE?!CY[(5F+L[VB*.9M-J@NH]BXB#L*W=HQ\G--C"9K9T0*)E ,)AV$
M $=*JFXE&X9'W/'K#,?<>J]EK(5IX^<G']>Q1:58*S6ZMP-%?5Z2=UF0GFYE
MX4DOE^( S8YHA8_CMFHG(<G47V"RG8'5QMO'6Q5R\:9GO4%5HK"V;\>L[MBX
M,HP-[N=<I",8$:5[5XP@F!C?;()%@-8 W*5L=/\ !F'J$=MRP5;B9ZJ.:>!/
MW4-!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T
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MI%;!4O5K8#0](P$[-F\H<IVCECF#HRY:2FF6SU*YHNTFARK[LR'3OLB! 'O
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M,F\8J@,FY50>)[;.E=BI =/J,FM'0MNF71S9[L#IY&>K#X_*4+/>-Y*>S8M
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MOJX]8!Y[<9?%S']$>GF)R[R[]7WK$?/7B#\1;?H;U9U&Z8E)L>^L3-MTYMQ
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M G2(N$B;=VZ H@0#]74( .P![/;HW2MIF*;5,!L8K@Z@%>+@8@F3.=0.DAD
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M@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T
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M-#R/KE9"?87#U9#V$BRR;V1YOX6%2'^49J(_4=2N:,(&9"E;2L9%Q&IQJQS
MN0&QN^Z@ZNCI#>6NO<6BR5\K;M0ZV!^)69I3UB>4N=^7:PAB5%WB1#$\9C>H
MW57)XW)8HXA5C+O,V5C&4_RMPWB,;&;BT5BW)@\K /*0!+I453E6<"-TNIVS
MV>PA/ZJ2XY]K&*N=Q<48>A+]75>8-T")M(7HD;(N)A[BO #!W&_))&GSBO2W
MC3)+=CP>Q81$H 7J-%-G<5J9QCVCC^L=46;J>J893S2*BG:_+[CS+W:HLG#8
M6*69U,K8&<C#2W=HMTEG[.WF=( W7;E7=GZR=!# 8-5I45KC:MQF6DW<GWY8
MCG>O?KM1+ZNS)5O5;QU<O./A972@34(9I 6/Y?-H:>8,8M-VS*WE(],\/,/5
M ,0YA$$2B!-AW*RVWFK+:$>.0,UEQ?UB_JJ)E6EM[5EX<9Y85DL?W3)IZ>DM
M)#B'DR0IGSN8KTPJ^7C2B+LO>,NHQD"E#H'8Y341@U.<$F<93KOVOOL.U6 9
M/):]:MMDS31HFF9"+;[6R3-%@G+-6S)U)O2(K&LI8F(^$HAF!"B=QT$212\<
M=BG[([G/Z":N.S:\@USAY;7G!>;J2%ID;1C?CG/8SF&3K/=,K$ODFC1MN-/0
M:Q$+V>,<5NMT5FFU9R8"_?2X@46I"='](_!Z;:4YD2PBR-L#*@>0&>FO,OCC
MCE[F3'N0,794Q[9+2WBH^M1;%]9V["LY9>Q\I#WE&TS8D$DG4DC&;HMU]R-C
M!U_A1Z";LA3NDNI\+ZQ4BUECF'R0M-8Y6JU')+''>6\/\EY+'N,,:O8E6U2;
MJN0V0;Y!5][UFFJZ_50OC:NL^[*1B<J(%V*=P ZDNR]X#.Y;*=J#J3.2>;Y>
M6&!,-DY"558,DX%-E'),.AAHDRZJAXR5I%>.W&LDR"522%U\/I+F<'\DZ#*]
M'083=>F:N+#F-6W:>-P?RMY'7+BQR;.^R%7&^1<2\OOJR=9*N:J5&86BG,H;
MCW+J2S6,F)14L#-OCVY^V+#%D':AQ!/\,;R@"EZ^1+6M=%IB.VIR/7.AJUM^
MXW&!^5V3\IW7UD^%+<^F;#CK%N!*+/U:PKP$C37ZKW)E,SXM8EH:,66DS/H3
M>HM#GD4'(I=T*:I@ IBZ:DOFA<VT_ B;7EG5$>%GZ7GAR9;S1A;U9''Z]XFO
MB-:5A,O9#83B;RMJSRTRQ?9!SS)IC$SX34>>3<-P;H)G;)IG$#$/N("D(:S;
MKK&4OV%G4NG.F<XIMN]Q(+-U_P"7J_/BP\>,><A*Q4J=)\?F^:8YL\QVG/N:
M*HO-Y4BPB"-1OD3\,D*&/B#Y6 L@_I(_@OP6ZG.J6WXG5&IU\!EH3GSF]7@I
M*9*GY:-LL[1.8UBXQ9-RK'2/P(1C5*ID@^/I[)J\:B$F,3',HZ/>2CF/5D>Z
M;$+W1WO2 KZ55:WU]PRE89Q?^H_/'?+'(.X<ZLDT%ME> R?Q;C\+53(OE-5Q
MRG>(].RJ5_#"/R'G[C%VJ3C*?<IXMKDY-E'KE.\>1S=1RFB9(ISEDJFR---^
M6L=[.VVH T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H
M T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &
M@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &A'8<_,M_
MY<?'/_@A*?ZZZZ Z!Z%(WM/\J&Q_\@5-_P#*+>=?'5:]R\3G?_U?^J\6//.(
M/'+,&S"0&+=.4TFQ'Q&[9RLV*N7NCK(INT5T3*)=0& #!L(@&_9K+:5M]#I5
MSI*Q.76*/5R9%P1=<SW'$G,3(E+^N^WLK3/1T=BC#5E21=LX=M%&W/<:M+'V
M,9D!@$H^* [!L'9JK3#F9<'1S3IAI)+'.MQHI7U4>!K/A[*F/IZ=M<K=\I6:
M&OMPS7)OY-')R>0:_,TZ<C'$8#.<^#JJR1=T>/,9A$G9QZQ55R*('(NN57IC
MR]O Y94X-KCN'[XO\;LL87:=_FKDA>N04I%Q*<52)ZTT?'-)#&M.8-56TA$.
M0QY!UTEJ=3\45DF5_+IR+\#1HJ N159<ZLF7+N?Z9<20TDE8[?;FGDJ&3:N'
M&-K!S&J7,*10,K>*_BR5I,8DS=R3=*/G'4]3G\1?Y2.;NVL1)GBX*K"P(9RD
MY$A'H%!,0\8MH\2Q%(4KA[Y&ASYZORXY(SJQY#<>.2MHXU9,C8MM1Y^RUJI4
MJ[*J5EJ\FY)S7U:KD.!M5,EUY!"V.VYG3MH+M CH%4EBJH-S)\OI=*6J58K5
MGVW'1ZC4^6'#IW8[S;94X%M<F%P6C,Y=L+17#]K3LEF.^8QZKG+]LGY.I2$S
M(3R)FZ[>G)S<I4U5",X(6C)()!1--)--% I?<^YI^VJ3JY9<61%5V;CQ?M_^
MS_%:H6,S1]M]1IZQZLV'A,8VSC*TS39C<5\JFMX2U"+%1!Q&4L]Q?VFP0,?=
M56PY!:(O[#(23L>YED>[-XA.E,I"%\/UE7AI>I>![/I=26B=*3U)/Q]Y&?("
MB9_775"C8SRHYQ^M%<%JQ!V^L0M2I=C:6%B.0^3RD; QLA;(J3E8YU4Y1P29
M5,W,S,=!+I,HJ4QD1Z:S4YXI),C(/JSJ;?L)M,2062++2)&8Y"PG(B^7MG#P
MTM)7ZZ,;J%V.[>HS(/VL4SL,PZ=JD18IMFXE=&**1"$3*5"3K(ML7Z'L3\$I
MQMRAK?)V.SS:V$K5\.GPN,/\B*"8C"-4D*+)GE$TU(=9O_25:(DH8PCU@9P(
M &PCIITKMVVH-3OKMM>,Q%^J=J[3!67,+V/,]YNK_*F4&N7:C.R-;K%0FL93
M[(^.U&SA(E))&)6+R,^."*%3DQ?)*F6$ARB0-M11-+D*Q2*L]9!<$LSGP_D?
M&^5^9F2LR3ETHM@P_5;XIBK#,?+4JNVZOR].LA7=,B*I 4:Q@T8NV9B+R39\
MY3\E,)#%%57O-43LF;?:UE@%+4S"5%[$\\?:7K'ZMUO)Q7%!B;D'>H=WQ(M:
M=QB[BI2Z&X+<'@(W(@,I:)<,7$/%$1+=CD C1N4@%:%]L=\T6JFVR'F:B:H>
MS%_#E?%/(7*V>XK*MA*YS#9)6Q/ZDA#01F#A=>";L3'6(LT B2B9&)3@"0[;
MI%^SJQS*VJ+8YI#-7ROX1R'+*U<=;9)9JM-*#CYDBJY5C(9G4:4_8S4G#62F
MVE)-ZZ?1KAXV4:.*:0J8)CTF[\W5X"ZN=$29<Y5)P%B7Z-=&)=2;N9E&:":B
M#\B#9BZ>&2**9#F18D:-]P36 .G;I[-_#HN7FG$5C/+'M.8W&[U<=XXLQ628
MG&O*N\)%R7?)G(5C47H>.'+%I:YBM5JM.%&Z+ZO/2%,6/JS/L*F0@=@@4!W$
M6E)5ET]M":I='>>?R]ZM"TYJ:813GN7.56D_@O-<?GU&U1^+<.R2,W<X^X56
M\(L7*,E"D0:MV$S4P*0R3<HD*L;8O8 :BET:O-1%;X_1CJ7/@F.3K5"RG);,
M=ES=2F3QFK"8TE8&NU2+=SS:/%FV=F^0S*L+S2ZD>+SJ;OEE6P"X-L4>[2$J
ME4WYC+5R5(LOV_0S<V<$W>4.8&"^6XYEG*A,X-CI]JPID-7*S+-WK6UUR_TY
M0A'4U&*+D3 E\5$1[PIMD]P[?#83LFS9%K#;4/V8D]G[&0)%H-@<2) 08+*.
M%TV$8N[=/$FZ8B[=-G "T!=58HG*D7\ H83%.'2 :FFLIVN_ :_+#4M)V$&\
MP\5\@9,O%ILR.44UJ!=(!C2K-@VPTZFR%.BD%&$"X/>@E'-7D["PG>\KO0#1
MNL5B<DLL<P=X1/4B5GG["V_-?2F%M;!GZ=P!CL2Y.XXY*I&7+I6:KQIQ]-T6
M-H[N!KEL86Z*<0F1&R*D-;;B2<N2[M5Q?3%#OW;?<6X )MC&WUII57$<-+2_
ME:^/$Y&N\J04]GS-WP)ZRH^&\GO^0N4)='A]DKCWQI5EK(ZJ&19QU0HQ&YDQ
ME=KOW*KIZHT!4)9-4X. ,<3'V$LI&82=DL[,T'BADS)N4\!<KLI9;EX/(]-Q
MY.4!_18ZJU"-K=A@9BULI^.>?#49 QTX<SB.KC%3NS$3(7O# 7L(3>JBYK1+
M;2=%WC3K>J=:*XDRWCM#DODV-GLF\DD.3262%Z3C]*7H\\+3$<4>C(T])HM2
M+'$NVV)TR&/)-7*A EU3DV.BB)>F7"F.9N[#%96YG)&G5JR2K-*X4O/7T[U9
M$W Y,SEDY;D_D5Q8^0&,H>@7Q$,>XRC8A\6,@KC$1\S'LHZ(091SJ*&Z/%?)
M&K=JS$5"IF*9,I (;TI4^5/P*M&N^UI-;G[C<VSU9\I:.,&,N,"O):]IUW'-
MXFKB>5/0L<-7EO6FI;(4P,5*D9PX?!3-K\OCIE59"18Q6B8F[3J:BUJ9<1::
M>GRPTY=^)[^Q\*K)8.4B7(Y?D):6DXZP^3#"S,*10 4<,X]_D"><+'3+">3%
M3%&]*@ E$#[D\   #KFEHZ4E><[>2_'YCP9XL.Z/*9RGX.E9.Y8V',3_ #$&
M/\;V(^&%[ED1*T.[T\IUJB5J7<H6NA-FD)%I,M)%F9&/!(&RZ2RR9R6#3=O8
M&Y=4^ZW#<;_U>F0,FSE_C%L;<Z*'SSQ/94GT!:I*(Q+B#$4W6Y,)9N,?+6(,
M-8>Q^FLA%QT6HP3_ *4X[M-9(I2;% 4ZZUE032FE2W:UVGT3:R:#0!H T :
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M^WJLKQ1G[BP7!AZ:H>'ZG+/V_P#U@K/L?_#.S4^UJSXH?<R7!B^FM_XG+/\
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MP+L>4LL[;HQ;MP_*]6!JP9-2J+69RZ*!@61^2R*JDBGW2R*A=]S;])1V#K
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M4J[_ ':GNIM6-W L+,/*5!\)U?V%3AJ/2*!Y0I_#6]V/IRO$@"Y.&W:IV_\
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M<%P*!_N^E)4 Z ,.V^WW0Z0)@PW;YY'- 4@H DPIN.YUA*7<!ZA$=CN68_=
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M5<.E#[$Z-NK;M\.JFL:F6I45,CZT*0=!HS6?@=BB@)'+,C=-)%\X+WAD72Q
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M>P+Y7OXJ+.UU.[3!"6B8QNE*2#:0!-JXD;#86R*Y)'8S=5$'"3!0YWPK=:!
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M0$)2VSI:L$CWCJ0M#%9DG)(@M$JG("Q''<""@R9J[8L-45)ICAN]@T65.2E
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M0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T :
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MX8DGQ0DZOE&G33R70;(SDO:W6/E[A"3\( KNR/E"(."]T4 ,38#@6!&L3HU
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MY7.C9CM] :,Y.23F*IY<L+-9@J!V+8YU]SIG3VJJ'7#/=C[0Z.;%MPSP(M9
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M2D]CBZ>KSL&(4$(/C]D@L62X2>0.-U@=E<J,JZ\8R$RDM3)$I4S%*N"?6 "
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MW)K'=W05/3%<'&6_9E@G)KCQ(J@HWR+379(ARZ).N6YUUVM;<"S "]V5PT*
M"^,LDW'<G:"OL>'7%1)-V[V3F;;CY=R,YKR>P$1)P\)DVH.3-F!Y4A6SQ\'D
MD(Q0.Z454:"T2:(F9LP 0$@#X!W'L =6DSQWWDJE'#=<8I.1/'-'X-:GRI50
MCFC1Y/D57>OU7AA7?"H?O3JMU#BP \D8!**@E P$V+L ;28=2NJ35#*><F<
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M#TI^/WG7K/NJWO;2=. \P>E/Q^\Z]9]U6][:3IP'F#TI^/WG7K/NJWO;2=.
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M4K9MLC5CVX]I'3*5V-BGUM54LN?%2N<*7/CW,57$CM?I&,3O$C9<23!'"S0
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M"0M=83@T6GP9! YBA*"#=I&H];-7\!XYQ4ES4N3PEU.70W-85,:U[J]A]!F
M'KZY<&:!*XT^#YE[+\6J^TJ#XDA(N1E;0?$K!.NN4DG"3A!FS=R:Z1RBB4#
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MZ5+B.'%58/>P5%9(Q]U0+UF(4BI$RB3H.8H@ D,;J#</9'34H<#3529^H4-
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MN>O]W3.X/LDH08HLC&5#R<O5OV]VJ/A[?8-]C5;;)"12:#9'4!11FR$Q>T#
MDMN&V_L]X/MZS-U322B:,RB))J;HD*U$J&Q0**2Q>CJW#;QCE ?N/8]K5::(
MFG)<\C+_ 'MI]X?^=U(9:8&3UD_OBOWAOYO5G)$E8E)E$PVW56#[29A__-#J
M6EE"=\E_?E_<C_S.D,2B]UA[?_J#Z;6HG J*8!W^QMX"F#^SX="S%IB.F:3T
M *<P[!V]GM[;>R ^WJ_*+:&9N'^@H_O:D,DHQW"9U2@! 1$-C 8%4U!WWVVZ
M>DQ/L[^'3>591!@>0MD@$5TV0;^R":O]@5!UI2\3+2R,0("*.8%4F3(3%\!C
MHK;[_?E'P#J5F=4]A?FLCM-XV*9,G=B"0%(!2D*D10@%  VV\<QM_![&I!=Y
MD;_Z-AU!):[XGMF]S4_BZ"4:M]%QLDZ:NG+5%=PS*H5NHNF?=(%#)F-T=I?N
MC)A^UJBTL2$(PDD0)(-&C@J8E%,.A0!*8H[DZ1,?8! ?9\&DX@Y>H<,\GNN=
MUVY63%CQ).T6P4^JX_"F2M;MOR_:H4B6O$M&!\H"3[6L'."UR*!3 W%/K3,/
M@$-5*'E!F:19/LSL.E$$15R$@Q<I1Q&+8S=*/8$82*2S,HIJ X1>.%EC-7FR
MA0 AD-B@4!W$=P'2:WA*E4C>-HADQ,*A&K)$1_ND$5P,._VU%/:TG>6-QM>H
MO]]6^\'^:UDLHU;Z+8OEVSQRBDX49E4*FHY(<3) J8AC=WT]W]T*0;^'P:OB
M2US<8YX.)=J%649L5A)L)1%)8! 2CV#VJ!N(#JN8"2F78>@[XGMF]S4_BZR6
M4'?$]LWN9_XN@E!WI/;-[F?^)JDE8AWQ/;-[FI_%U"R@[XGMF]S4_BZ"4'?$
M]LWN:G\702@[XGMF]S4_BZ"4'?$]LWN:G\702@[XGMF]S4_BZ"4'?$]LWN:G
M\702@%=,/")O<U/XNA9D3OTO;-[FI_$T =^E[9O<U/XF@%!9,? )O<U/XFA&
M'>D]LWN9_P")JDE8AWQ/;-[FI_%U"R@[XGMF]S4_BZ"4'?$]LWN:G\702@[X
MGMF]S4_BZ"4'?$]LWN9_XN@E!WI/;-[F?^)JDE8AWQ/;-[FI_%U"R@[XGMF]
MS4_BZ"4'?$]LWN:G\702@[XGMF]S4_BZ"4'?$]LWN:G\702@[XGMF]S4_BZ"
M4'?$]LWN:G\702@[XGMF]S4_BZ"4'?$]LWN:G\702@[XGMF]S4_BZ"4'?$]L
MWN9_XN@E!WQ/;-[F?^)H)6(G?I>V;W-3^)H4U[Y,CD6PE(@H=-<G2+@BGB[]
MNY ZDQW[/LZ>!&DR!&69%!#FE@9RNL0H)4Y\4>XCI-</&<6U,/Y%);V3>'P:
MKMK:164BR.\Z&ZAHY_Y:Q/<LE<CIAK4LNV/&1H_"=*[U:+1E) SLP9'N2AC"
M#.SUT4A,F8">$_@W[?!HJ.A&\4C"<\0,U-U%7*7,?**?E+D#+>3M[8U(FD=0
MPF44%/*6QBH%.(AOM[/@T=;132BV;B1F]/O3K<S\K)H)[&*MWMO$ITA* F4V
M'*90#I,;;;<?MZB4UJ7:M#-]#S-WZZ>6?O;A^E;5C>2"HO#W-P;[\T<L#_Z6
MX?I5U("H5>A_FW]=#+'WMP_2KI#Q*!^'^;.Z030YFY11%$P"<QF]M5[S;V!+
M]:A.GL^R.K7$%I?B'G51;J'FAE$"&+L0B+>VM^@2^'J$F5A[WKW#;L#IV]G?
M0E2P7B#G02*&'F9ED#D$0*3JN(]?[/UIAT_M#I&\E3-]$+. #^#YFY-3+M]R
M#&U_VLJAJMMFJ9&(YXCYL1[OJYG9/3W!03J@6V-"^+T[=9@RIL;PCMN/9VZ0
M]1&X<%E/B1FPZ9U!YHY6 A!V Q5+><I@VWW*8,J  Z<F\3C:;%/B#F\B@&],
M[*(IA_L/DML G@$/.J(=GVM0JHH10ZX>9I=B83<SLM)?@'#<A6XW!%( <D A
MSG3)E,"J*)]("F(]I!WV\.@69B^AEF9!JI'L^9&2ACW"R2CAO*Q]IF#&*5$Q
M%DVZKC*B?DH+KF%01 H]HB&P[[Z@!7B+FXIAZ.:>5$R$'\)^ MWBE]@__P!U
M8-P$1VW\ :M74A6CQ#S4N3J3YJ92. "(=:'RM,!P_N3&Z,K; ([;[=NVEI<R
M]Z'F;OUT\L_>W']*VI&\%0\0L[#_ /?IY/#[3&V?I8U2.R"R/#G-Z@@*O-3+
M&P;[ @G<&^^^V_7T96-U^#LW\&@@N>ASF;;LYGY? ?;[^Y?V/K3#0IK%N)N;
M4$5E3\S\J%$JY$4"J+VY,KDIS)%ZR*&RGL _A![  V_3X>WL<M8J284F4VXE
M9L46<-@YHY2%5!)JHJ4?E:N9/R@%1* E'*@"0-TQV'^ZV^QI$8P7)VF:XXA9
MR60!)/FAE!$WLJ>1VPXB';V"'UK$]OV_8T)X& UXG9T32=;<QLFJ&1<B@F(I
MVLA54P(B;ONH<H& G\H/B]OW/A[>PZV%KD7$N(V;G"RO><SLGB*14C%!(ML,
M!#*]8F >G*G: "0-A[-]M5J"9T,T.(6;1_E.9F4CA[0H6T/W?K4'4N#1H5>*
M&<U6X.FG,7+ICB*!BLW?RR8+]VHL5-0ZA%,GG.D":9A,&Y1ZA+MV>$#:2"3=
MA2]XMYF(5("<P,V+ FY29K*,6]X7#OG"@) I^ R</6U;G((K*[]*)1W-L ZJ
M6)./ H/Q3S.519+TRLRI"W,D"BKT]U8M#E41*KNU=K91[IR<G6 &*7P"!@\)
M1U8D2]K-TF0'%+,_=]\MS0RTT3-T@3RT+BT5$YA "D%)?*A3%,(F  ]G<=9Y
M<RTKD \3\UE, *\SLLHE R13JJ#<")!WXB"8E4-E,I3[](^UJ\JN<LCW0BX3
MB3G'N@57YG940[%1, KV\Q2@542I;J#E(@?A4@ _V-]NWPZD;R<(-AZ'F;OU
MT\L_>W#]*VD;S4"#PZS8/W7-/+GV.@;B3]O;*H[Z" ]#G-?ZZ>7_ '2Y?I5T
M%0]#G-?ZZ>7_ '2Y?I5T%2V;B'FIL<I1YG9</WA3FZU4KBLDD"72)A.H;*G2
MB @?V?NMOL:;@XO,57BGGA G>>F+E Q>A0P)I(6U950Y5-DTTDRY0ZE3*)^-
MV!V>#8?#J[RNSRP64>*V<A4%$W-/)@K%( G;E2M2JA5=S *0[95 P;  "([>
M ?!HE+I:9YHNI[3-#B9FY4 *7F-E)%;NR]1BH6TY#JB'CIB8,HD  1/V;]N^
M_@#1UG!%E.(M*R\1\ZI;F-S0RD9, $#;L;;N!NSP!]:P]0;>SJ*M"MT-6;BG
MG4K(H*<RLIK#U"*RI&]N\I13Z2]V(,PRD910QU0V$.HO2 []NVVJD[+'O]I)
ME3=N+R7%'-YT4!6YF9710$B7=+J)7!JJ<RI2[D51-E/<O1L&VYAWW'4B:7DI
M;<]N\1#B=FY4NY^9&7TS "NY"IW10^Y%1(0 +]:11$%4]CA]@?9\.G+G0M,*
MFR5X<9G.("3FCE]/;;L[ZY&_=^M,NI!74QUN(N;VPI 3FCE@I1.0BBBQ;@N&
MQC%*!MSY4*"0%[1'M'?]C6HS,SP3+2O$_.H'5ZN9^34VR>W2Y*2UK"J(E*(A
MW(94+T["(A]T/@^SV3E<361*;:P-@'$#.OE'?#S4RB*?]X\CMO3[/L_6P(>S
M[7L:9&KY*_1!S@)SG-S.R:?JV[LIV-K."7:._3U95'[K<-]MO!H2!0XA9Q'<
M%>9F2E"^P'P=:0V_;RL;0081.*.=#B3HYD93Z#)@H<#-;<5=,!$Q0 6XY2Z]
M]R_8U;I$UA^XJ:<1\V+BL8W,G**:A5!*)!0M@*"F!C]TJ<@Y3*8@*AN( /V>
MT='.<"EQF>B!FS]<S*7N%M_2IJ<2U,+T-\Y?KLY;^\N/Z6-"07T>'F;T^KKY
MJ995ZMMNHMP#IVWWVWRL;P[_ +F@@O>B!FO]<[+'[5P_2IH(WEKT.<S_ *Z&
M7_=KE^E30U.\7T.LS@4P!S/R_N8.PW?7+Q?#_P"-/[.B(ZE@G#;-A3"8>:V7
MS /L==R#;P>S]:P^UH*%[T.LT?KHY?\ =KG^E30M"@W#O-X&**/-7+) #?K!
M4MP<=?@V HFRN7N]NW?P[[_8T)0J7X<YH<$ JG,S*8C[)NYMH[]@AX/K4^SI
M4D8%TW$'. ;=US/R@F'M>2VPW_\ %4NI% E#DI/P^S<J!>\YI98 2[AN@2WH
M .^WW0$RJ/4/9HE!2WZ'.:_UT\O^Z7+]*NJ2I=]#_-OZZ&6/O;A^E75DI67B
M#FPH"(<S<IF/_<F41MJG3]H#94]G[>I+!27B#F\Q3$7YG914(8! >Z:VQ X
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M!Z'^;?UT,L?>W#]*NH ]#_-OZZ&6/O;A^E70!Z'^;?UT,L?>W#]*NK(#T/\
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MRE=R1(,90&=G:H ^5=OY%L=A$/VSL&:"O3WJ37<P$ ""/88X419X$57?[T<
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MP=AC%\7L-OV5AJQR)FV(2JK_ (]A!?D;DG/C;EAS%A,;<H,\8UJE6Y0\)ZE
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MH T : - &@#0!H T : - &@#0!H T : - &@#0!H T :$=AS\RW_ )<?'/\
MX(2G^NNN@.@>A2-K5PH')V<<H-SJO3X%I;=9B?J1*@B3(MX.+D70D/U /68
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M?[0_O:%@-_M_M#^]H0-P^S^T/[V@#?[?[0_O:%@-_M_M#^]H(#?[?[0_O:"
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M70'0/0I'AH&_*2?'_P 1U3+_ /[Y=QW_ '=?9_\ Q#=4//(K%1*EN4A1,X6
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M5?2OE>+*%AV/Q7!R)GA(UDYG/K@;W=&K0;U0$'4>NK68DHG9D*1\F1+J  Z
MU?!;68A0VN:;5M-RS).<N>4\OC[DYQ?X]I\<X2\M<H6U)U'7V7RDUQ]-0*R,
M?-HJ? U(=8XL3N8,"BRA=T9)L/8(^SL!Y8T^)*36S#'<K_;:0CIULS%"^MWY
MECARB0N2I>(XQU)<K"=OB=;GH957(F2&[)TNS6KUC?RAU')BEZ#%1$>WQNS3
M3+;=Y-464SK?[?<=P<.(3)L54AQ?HZ-89)NU5K=AR-46LBBS)'668AV;^\"Q
M8>3)J.I2+EI!P!S@@DLNJ!>KNS#L%K=,1WWB<8E/LBZ/8<8N?G+SD)QUA>8N
M3*M>#+-L8DI3_%E3HT,[MQ69D\=5<K]G:Y&#E"@Q>NY-9TN5JNTZQ(<!V'IW
M&*REG<:<IW/5A\,,R54MGG+F?<]9)X_8@O$9C21QY@^%M\;)-Y4MI9W:3F+;
M;H-<K5-J_K"; [!E&@N90BKP3%1V$"AXP-5O,K=KB*R+MKR+^6:SR/5Y0>K+
MK%USBX\L6KV7HJ^QL09_(5^;D:*3CRS5-8Z\A:R,K"]M3AXZ\E1==2C0QEB$
M%<53B!-?/7/] TFZ1$6SX8#BW2U<WK!R/Y0X%QWG2D1[N"P_'6/#ZKRJ-H;X
M#=@QQ&1ZA98;Y9$^!&!I&RNS@Y54(0P"F/3^%+M;76GADM\%EJ&OBLSV^ >2
MUFY,T;CO*T7(2,*]DG$Y=>0,)/M1C;!)'-69!&LLX^/=2[1^H16U1<>#D@IG
M!FV!5P8IBE$NCJLPFT\R,6<N8/(S%U_Q6LXO$E/KW;U@=;QE(1-(CY.PX>A<
M<NL\P5=:TBQYRAY-S5(.Q0D#*J,I"/<,2*MU"'*JF3H,34OAV$<QF/EQTB,U
MSWK(.;S"2S)+,(2K?4^[:'?522/7'(63"&%[(1O!/7%N0C54(PDN9LH9#J*X
M52.J()F$Q"U5ETE+:!32X4\MG&M1J*QZP#,U-X.7;(N4+7$WC,COE%5\%4RT
M4J(+38N0+.RN!V+^PR[*->SY8IXUC<@/C^3G<*G4*BF05B@<!)YVB8ENK;7<
M+:Y#]9'S/R"XU<F<"X$F\KQ=TK7*FJY"1:V21@18L<56V@(41G8;#+2+JR33
M>7^%9+)Z3E!!5>+,/P8H4%3]8G1[]$I+!1W8%OAU;VV1 >U<P>=E,X9Y*Y=3
MN>*_)I8GRQ;Z_7*R7%QV#6UQ]?L6081LHE:!NSM)R04:\'W#)P!?N=QZ.WT-
M"TORPK)=+@X2YJJ[ ^@[D5F23Q!@7).6H]D=^]I]?&7*P9)G.F[4%ZS:$1:R
MR"#@#I"+GM6(B8"AN/3V#KG24QJNN?N&^:[6G+2[<JL^8VP+Q!YC%NL=:Z!R
M"LW'@;UB@& NEZ\GG1S3'S6$+=_A*0 [FIHV!XV<=4.W,Z,0!,1OMT!MOFHJ
M$2BW]5[3QE=K-_M'KLR/U,I2K6NK\(Y[)AHE%N_30B3I7GC;&MZYY$6Q)I.!
M<MITSCRCH2^XV[D>KJ"MI*4J%B7S7VQNI8=6>3M4@WO''(D6_P#@VQ0$^2-;
M3A%46QV"Z,G.0$>4L290SQM$LFBHD7(BF!R H!A#83B8.1]O-[,":9FD1-=\
M6^!Q#H<W:?513;"N7V;MMGX2<DJ:4];M4Y,S#BO<?IH8M,#1QEI%67@5("T)
MY ;E;) XA$8YO!B!"KD-_1YX;2:AKS7K;C@4>LO<,ISU*T-)T^&0L*MFR-:
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MH T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : -
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M9*Y?/LY6ZPSF2:<PJ-AQG(4RBPD4O"EDYU:',XGX&.;6!$6T]8#+?@E0W[@
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M0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T :
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M)?I1I45*?K/S%^K1:?ZQ\4?2G7P\V&W$T*&3\Q^QQHM7]9&* _\ M3K+;5J
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MKM-T7H*AU]1R 8X" %$-<W4?*ZV;;05.;:&]^$B'.*2'DZJP&#=/RHA1[H1
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M("< 6-T)"(E-L7V #QO#[<C:0FXG]=\"KSK-MY0HX.F@S:I&4=/EE2HM6@D
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MZA)B44.D3-@$3 /BCY_6:=%\L\<_8%.]CP6;UF] J'!NN<VD*?D>YP4Z\H<
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M]9!]7Y>Z9;,?EQSG[$N7,@9_PI#K3M7F50RE3)=Y=L:@XEX*PR\"X0=VV$8
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MYF?@_FZT8WM&,*MQVQ[8I>3:2UQQ]+(3DS?8G$LE%)UA"&DI%Y%(QCC'JH+
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M;=K6(6N+&D(7FEQJ!PBX&VV@P(G55.V&/<>1/EED#-SK2K07PHR2A4S )15
M1*8A!WW*&D]PAUB\/34XX=UW9+;/(G!5X!3M8)1N1%H^,7O&[=).0 $%4DR
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MGCF/@L$S\3&]\Z@J+Z?/'/\ +\U\2F]\Z"H>GSQS_+\U\3&]\Z%J)Z?/'/\
M."9^)C>^="55H>GSQS_."9^)C>^=!(OI\\<_R_-?$IO?.@J)Z?/',/#8)D/M
MPQO?.K J'I]<<OSAF/B8??.D"H>GUQR_."9^)A]\Z@J'I\\<Q\%@F1_[#&]\
MZ"HOI\\<_P OS7Q*;WSH*AZ?/'/\X)KXE-[ZU:8HH>GSQS_.":^)3>^=0@GI
M\\<_S@F?B8WOG02'I]<<OS@F?B8??6K#*'I]<<OS@F?B8??6D /3ZXY?G#,?
M$P^^=()47T^>.?Y?FOB4WOG4%0]/GCG^7YKXE-[YT*'I\\<_S@FOB4WOK4E
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M"(ZG U?>6?@Z!_($'[E_M6G 0LRGX/A/R% >X_[3J\SP+&3#R"$#_K#!#]I
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M5#Q#R6)#PQU<#VMVB([_ /\ ACJD<B^2Q/LQ]<_$T?>6E2">0P?Y @_Q<O\
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MP%+X.S*URY&0>4D25"3Q-=6LNJW=9AN+^"M+"O.H4LC;R'K\HT!(4TR HD\
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M[7]G02Q?#MV_M:$#0"Z 3?LW^QH6*P&A!= &@$T ;AMOH6*P+H0- &@#0!H
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ME2FKAR%[E"-VPR"KILG$>1HNRSBKI%.% '#@[5%-:4,(,D#*K@4I=S]ICE
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MS0=>@+8[Q_!R%DF*U(7QE1U'C"+AWTD]+&2RL)/G>&;G;@D<4VINDQPW !V
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M#A4C<WP@=5)'R9P"NPMNY47)WHCN*13;F#8-2%;<6>)?1N$8JHW*X<Q#(CH
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M2$,<G6&WOVO.B">2*T\7?IPC]C9"PZ9PFTJW(-IR2BW7A1:.(N-%RX(H<$U
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M(1TVZM* 7?(V2JO<'S&[W6J,;"RC,1W6>3:%2J=@C"MNER8IP,@D@??8!'8
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MU,,8(R2[FR5VU\#:_<X:'4>K(MI:=A5\ UM=^X6:R#=[WBYIIX;Q3&+^$'<
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MW;2$GJL6.]9OW6#4XZX^9 RKZOS.D?6W%M>N^,.;<TO^,SF8M5F(HZBJ'?\
M*,;'1 6!M)/K!;R",='D%2<.^5+T  '\8_4JE+^4BK2:^*[">_!W)%7YI6B
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M=A?LZ>P1Q,$O$_*YUGR"/+/+Z2:CE-TB@^=SRW<-TSHG*<Q%+J(+E,= Q>T
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M2%B<ND50!(NP*&NY#FW HCX0VT:49"'E.)MAX?9-,KY0IRZS(F=03'>%;/[
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M7.\H3X<Y(14;.4N6>6_A".;$91KY96:763:%(1(Y) 3W7KE%54T4^HZA@$1
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MA("*& 3 )2'$X%.8!(/8'M#[6H4N*N6Z.W?.$4M^P.]533W'['48-] 4>6-
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M JD("ID@63%0J8].RAB=74!!ZR]HAMVA[>I# '=-B"!3N$"&,82%*=9,HF.
M;B0 $P")@#MV\.V@%.Y;IG*FHX1(H8!$J9U2%.8 VW$I3& P@&X?MZ %'"")
M#**K(I$(7K.=10A"$)V>,8QC !2]H=H]F@#RAN"7?BNB"/3U]]WI.ZZ \)^\
MZNCI#;P[[: H%XT! CH738&JA2'3<BND""A%2@9,Q%A-W9RJ%'<H@.PAX- (
M+UF"0K"[:@B ;BJ+A($@#VQ4Z^D _9T!=(N@J&Z:R2@=0DW(H0X=92@<Q?%$
M?& H[B'A - --G3*%8POBN^98N#KR:NXVI=LR!) 5-155PTI<$\L;A%!-(!4
M764;QYBE3*(&4$0 O;JK%D8WW&;D50N4.(ZOFW'$D+N N"4NY09F1516(I 6
M"4JJY3HN"]:/])AU.P3;]N^E!RMNW(DLHY;D530461(HJ!A32.J0JJG24QC=
MVF)@.?I*01'8![ '4E%O@;V2OU8^&_DX639K/DB.B.HLCE/RP[G<J;-#NRJ
MHB*ZI3E#JZ0'V^P=K3&IF3PV,+ED6RN[.7(]'84<L4_5;51Z1\W41E(TIR]T
MJX%&:E.A90GC;&*F/9X TE(5=F Y%DG5$(1R\C6B,DL=F9Q&)"Y:I%5>E,(I
M)&.LZ;$\8Q"[ !NT1V#5IVI!-KM8T=,R_*1]2=63+T,TILJ:95B6W>/&1$9
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MGRE4*7K%,Y>DVP]FIJ5.9?,O8.[:TFR0Z@%C.\[1[]0#F[-^@$W !N([!]T
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MS$7K$:G#3ZU%F[!+XPY MXYW\)-@A9*O/XVB&>&A6!W"HER+D..$ 426*40
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M1[]5Z==G:!CJHR-KIT!:8VL3\^97NBK2+MHN\<-VK=!0XI-T2D3+J%2\=@>
M?'GZPK?DI.(L+>P7FB5[&]B*TM]H:,7-2J43+PE9C6[%O,ILF18:-G72:1DD
MR& %/"&P;"RI;Q]MNUUQX-YZK[BRYPQ#8&3C+VVH%?R$ZR9#$2R;D +%#69\
M>XK.W,%:@LI+#!%6<7J0/TM7*9 %7[GL#:<=O FWZXDIY7!=0GL:3N*9I:<>
M56PH>3/!2EY9E,HI=XS5V8SK:0)+L#@9D38R*Q#!N/;VCNI.1HB=:\!8SXHP
MD9EZCXTR5FN_8VH#?'N-*^Q=6'(%^95J-@4(@[*+=34M)RSHSIG%L4WCD3"L
MJ=),Z@G-L.K2943!EIPE<O9MVWFFXGX3;C=<Y\F+!CJ/QW;.23ZINI&M-RK-
M;53!I]/KE$2:STEY%'2,>>5;TI)\J0H !5%RAX^P'$G:HJ1J^;[CWD?ZN+C%
M'1V>8I!ED$6O)*Q.K-E@QLLY%%W.2#MI7&:HMWQK*9U%D.E56@&!L=(IBE,4
M0V.;=0M;U23R;[U7'% &>%VD/"7^")@6E.,<X[<UC+&1Z_+M*N_AZM7Q:V28
MAK,SD;D1C&T]D5O\)J.!;;+=V)1<+"=*[!#F6<NN>/J^:7B+'O'/&G&_#^<[
M)!H\O(#(ML<UMU=;Q8X])S0<W'F)2)M[Z>=V*$[Z<M("<S== I5%NG?P;Z=5
M2M24^9V^S->T[AUWBMBZ+5MDC+QLI8[%<ZZM4)FV2*S_ .50U=<'(GAFMA4D
M'$RS;=X_=&_!+DW\I4#^Z-OFRPUE#&8;>K1XPEQ$_P $&8Y,-BU]98VTK5M_
MEG)+CHD(=TY=12$>_<VE1['QB(N3D<M43D;O$^@BQ#%(0 ;B-N(N/+67U3W%
M.=R+!Y.C!RC2[+&*0:$L:D9AR=4V-MAX" ;5]C'VEA7;A%,IUV@SC6A4GKQ-
MPX01; B00((AI#++F2>K7'<,VB4((!5)%1AGR, U8D-&_ \9(,!CW$>FHS63
M.YW166$%3"!P%7LV$H#I(AS4:_#_ !;QE@I/("..2V2/3R5.R=ELGPM9;!8E
M1FI-[,2!W<>O-RKU6,[IW..#E(W%(O:4-@ A=DT#4N6-=6?5[<<:=GS(_)>L
MQ=XALNY::0K3($_'Y'O35K82U^!JU:BSN(=&P$BB&;P]-8)!TI (@CN/:8=Q
M;ZP;^,X-<?(W%,QA0U:DYC&\Y-QTZ_KEEL$]96QWD4_K\HP,!IN3>J$,@_K+
M10#%$!ZDPUQZ-.E2J.7L@TI3K0P,D< ^-V4[AAF]V:MSZ-BX^M8UMB-2#N5J
MKT;5O@@(H(M8\+#2[&+E7$<$(V!!1RF<Z12F*40 YM^O2U1NPE\JTKJ' OC]
M2<_V'D["LKPXS':*JG29B>G<DWNPQ2]:2>,I$L<6L3-@>P")0>QZ2@&(@!@.
M&X#OKZZ>KJTT5G LN*R.=FKC;CS/=;9U.^J6HT(SD8F3\G@;79:VJY<0<DSE
MHL'CF!EHY=VD@^8D,<JACE5+N4X"41 ?G)/;M._,U67^*6)\ZXDEL'9):V&2
MQK,5-&E/86)LUAK;MS DAO@-9L^F8.492C\Z[+LZU5!.41$0'<=]1J2^Z-O>
M;[#/';'F",8,<1T$MC:U"/!8C5.2LU@F)1!)8QS&31FI23>2J( )QV$JP;?L
MZ36;R)4A^[B-QA7A)@_ UOR-=Z0RM(S>4Y62D[B2:N5KG8F9&3!V"X24),S4
MA%R#Q0'ZW>NE$A66Z@ZA'H+M:7D=D#,Q7JK^+T)F64S/!)Y*@9&<L"%GFJ)!
M96R1"XDE)ALY%RB[=8HC;6VQZHH=1545Q&,'R@RZIE.H5#]1ZE@$FKS*N_JN
M.,=US"MF8A,D4:;>D;'EH;%>5,C8NKTP^:()-$GTC"T.U5^(=G49-TT52J-C
M@L0@ ??4F1#+>=_5E<8<W7>"R9*P]_I-UK]=C:H2:PU>[QBA[)UF&6>.(Z D
M_JYLM7^$8Y TDY(**_>)J)N5"& 2F, U<KK"*TZ6QM.UQ /DUQPG'G.GA*YH
MV(<YH8WQGC3(5/D[Q28BQ.6D!(KV+$)(67ML^SE&:CJ5>-()TY,=XL=5X<BJ
MASF,!C"<N+":4D]O ZC+\,\%2&/+IBZ;J3F4JF2G#.7NI2NI EHL4TV/%"WE
M96;(]":(HV2AFR92^4F H($$![  (DX6J_Q*Z.%9W(\U->KGXZ/ZA2:Q&-[=
M$2..)AO-4BZC=[?(W6!=$5B1?D0M#FPEL"B$RUADD'B9G?0Y1$Q50.4Q@&PY
MDLJ(,*U^K*XJW]FN2WPMYE)9_88*V35D:90R!#STU8:XV?-(AZ^E8VR)2"R4
M>A(K$00.L=)%,P$* %* !"71),]ACZ%C(AG#,W,N+=@P^#FIWTQ)R:Q6W28F
MZRCYXLHY7!(X@50YA.4=A =P#5EK@'5S?)'?#'"/!F![5D2Y4)I94IO*4D]D
M+I\,W*TV",G/+_*P<_"</-3+^-?OG!9!8%72B8KJ]11,(]!=N73RIE<74&<A
M/5<<9:KFY;.54)D. F)&?^4\[18C)^0V&(9J92?$>MWKW$C2T)8Y,N!Q5[TX
MQAA<&<*F4W%0_5'"U)F8=B=#U\5ZN?C3!S>6+!&0-M^%<Y;)Y3>RN1+Q.O;"
MU*RAF*2+%Y*3CA>O'11KS(I%&8I'*DCW8;%.8!>6;&::;K>>?;^J\XG,L=XC
MQ<RAKQ\D,#K5YWB6/DLH9 F35%[5UX=S"NDEY&RK+OC-5H!H;98QNKN0WWW'
M77$6*I)40Y@]E=^ V$;A?U,K,W-MIF2)&&CH2R6RDW"U55[:6\6P81S)>=3K
ML_$DD7K9O'$!)9;O54NH_28.LVY*%2TCKB/M7L 8LJN.V&)X"LQ,9CV.;2#5
MO5&K-!.'6+*F>JR(R+$H@WE/*W4BLN8%RG_#F!3[LH"%85'-9(Z63U</&ZRX
M)I/'=:"E8?'..YJDS--CZQ.3U95KZE"FH&;@B1+B"EV#J/50<UUN *I*E. $
M#P[ &HX?8%G/Z6&?B+U>7'_".3;CEJB'R,E=+TWBVMCF)_*.0K1(2;:*;@W;
M)/'M@LT@LZ!%,H%1Z]_)TPZ";%[-*1#0JW,M'OL$\.\1\;E+D&)PL\,TOMM4
MN%E:25MLUA*[DE8J/BS@@I-S#TS(IBQ:)_P0$#Q1#;QA$1:7$J^K_4F_:U"A
MU?8-^UH47?[ _M:" W^P/[6@@3J^P;]K0!U?ZDW[6A!=_L#^UH6 W^P/[6A'
M0-_L#H2=XG5_J3?M:%#J^P;]K0HN_P!@?VM! G5_J3?M:$#J^P;]K0HN_P!@
M?VM! ;_8'0S.\-_L#^UH55#?[ _M:%@3J_U)OVM"!U?ZDW[6@#J_U)OVM '5
M_J3?M: LN'!6Z1E#]@!V!U#T[F$!$ ]GVM%:'8<_LM.$2<W>/P+@L5Z2M2"3
M-NF0#INFYDK@J9<R@F*9,2G,8NP%,'B[[^T(="="G//,U7S;9N1$@VPK<XVE
MSZ6#J8>0>3*)%D#(?6-=1.78D7*!N*0&#L+X1TI,B78ZF"RQ-SR7%P13D70Q
M,BL)!$D6Y)VB<Y>D>NDE 1 2>QIX&8<76F<.'N=P=@\BZ, [;[#'J^ !V$?^
MTSP;CI+'*'U.\Y@,!!Y$48#"&X%^#U>H0[>T ^1NXAV:6V%YD74\/\XP PFY
M"48X;].X1ZVP&#<!#LIOAWTC5<.9%WZG^<7ZP%'^+U_H;IYE>)18##_. 1$
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M_:;X=@UT+7T8KI<D3U6%H</<[@ 1'D51@ !V$1CE=@'L[!_WF=@]NOA4QRF
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M-8Z;=RS]AUNNJ<BR]=1S#N73A=L6)</![Y(B!G9WKF95)\%K)'0,)2 F8#B
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M"(@7?79I4P50DL=KC/1[P')VADNHG>E5</7 @490YR=9(\14Z17%--3;?<P
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M1[E) PE*8HB?<>G?8=5N'6J9(\N:A;;AI>.7-/&/)^VWNMT2+DF,Y3&E)F9
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M#6(4UB1S5B\D_GY]RXXWQ?'IDTY6PN3[#/9.8Q]R7FL5T>,"9J\@+".^#6+
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M%U"%@HXCEN9!56WOC^4@OU_@PW3W4'IR]/ES> YE$X.N6;P.X6N0T&@#0!H
MT : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@
M#0!H T : - &@#0!H T : - &@#0!H T : - (/@'[0Z Y_9;#_SX^.8_P#U
M1D_[-U'5)-3H%J%&";B'I03G:'_W"*C[/_U_O&B,NT]]9S+G6BVZ+$'2;IU)
M('7<@4\4DLHJT3;M7Q$C@],J_,<2H]!3(^*;O1 .G?;\$GP(^Q-RN)SKB."Q
M\7Y3NV1L#97R)@B"O:GE^0<>0[6F2N-COQ3C".YR%&=J]IN2%C?NF/E'1Y6#
M#9VZW3 W<@24=4Q6$GCV=GC4]%E3@W0L[XEMV,<GS]NL,S:G\0M"95(Y:M,C
MNWM/FX&[PLVU:MF;6CM3MYF! W0K'D*8"G 4QW+OR>ET\MGRS1NU4/BM-(=K
M=,6:'"7!2U5O$]VHF3.3N;\T2UBA[C4("V7QIC)G;\;P\Y'/X:0B*PE4*)6Z
MR^%1JY;D5/)-GVYF"(D/L985/9U=5:=$*LZ4IPE;096CF<--/#&#17+U:E=N
M7%ZK\9)7,^548F%L4O)-[?&%IR=M 965N4J= 4UJJ-<$Q#V@X!NTZ>E(NXB.
MXF\?UFF=2=J;5.PBT-4OFL6]]"8N2</,,SX9O.(;9,VMPPM=<"FN;* 0K:Q2
MC5)ZA*(VAD1LS3B&YR.AVV4;IF$&YOP7:7J^>E-IVX?$[*-ITB#G'7?4_5&/
ME.-$V\Y,9LLKWC+39G&=6@I%&@I0MVQ\I%4*OS>/[:JUH+&22A;-!T1JP?.F
M"S*2*@NH=NY36 JA>O3^U.Q1/P(E>>=M/J:8ESC"Z8$QUR;SYBGC_>)J2M41
MC>HHXOEX;'UKEGLE(V!"$D;U0+-9G<1.V"?EY-8'SQ\<CEYT)"F@4B1.W3U-
M"I-9[O>%,\R7FL["70\%#J9QA\].L]9@7M 8Q3Q-9 59XY!M*PT>]NDW&.9<
M$Z859%RE,7,YB>0F23$Z9 ,42=YU<CM5Y*:E.WZC1S7JH\?RV#K_ (D?Y8RC
M+2%AS?/<C*A?!^2+*UT#*4G:I*\12M9!C6&4&LV0LSE XE?M78'!FEW@F 3]
M=BQ31;/@13??X7<3V5;X!V0F,Y.J6[E#G:[Y>GXL\-&9FMR.-FE[QW5$%P3.
MVK$=4Z-$X_>="[-D!#246^6%,@"81$3B,HGY;)-*;6Z]VXU=M]7-4LADS"$I
MDB^5/(68:S5Z78<@P"%60DT:I3;HUR"U?5Y@>M.JX5:9DD73!P=VQ,OY*J?H
M A@2.6+57**%Y;$K;\_CC=!Z.W^KBI<E#\7Y.K9!R%&7_B?"0L7CG(3(]<&R
M2L2S8T9O8V$JWD(-:#>.[NCCZ/!8%&A$45 -W(MRF-K3E_ZK:3$.K_=EX%F[
M>KPIUVQ;G:D.<B7IA/\ )>0A)/)645"5TUXF;%7:XWJ< 7R8M?<55K&PM7CD
MF'0FP("@LTCF YQ.H;,)+E3I)8<-LNR_J\F$SF'C#EJ8S#?GTYQI;VEE#$,2
MM)A)A.T^[5Q1)8J-72*J0J=S5, ]28[AX1 -AKJ:7E4/;>2<Y!8,J?(;$=IQ
MID>$G)N/L$8[BFDD=6/;O:E(2+!TP;W9D+15$AG=>65*] IDUP$Z)=D5.T@F
MU=1$APY==H(RT3BEE.OPD90ICD[DJV8[@G;"&K;FQ1M(:2>0F7D*ZXTFQFKE
M"BQ856+5,JW(X:E8R1@BVPF<&ZUC+7>2(2BS:SXFYN/#*O6KD'B_-2%_R92X
MS!=,GL=1%#@BU1U1K@TL,'?8-1Q*N)F$EKD,\@7))U 43>MF^S1OX=E0/P:-
M+E-6*F_<-6JCG$BQ/>J C9N!=PLIR(SRYKL/R3BN6./,=BCBQ.NPE^@+^ODV
M+K7PDA1B69U'O9E-HTD/*7RP]TB7N%BB)SF[M$J,H)-8V_4=2Q>K;8W>G3&+
M\E9:R%D"@7V:8SDW6))*I(J4YHUBW<<\KT%+L:M&RX5.3>NS/7AU';B3)('(
M5NH1H!DP[>GU$M+CY;O=M0KU57-1VCX9<X@FR5(9 7=9.MBE+R9&-X2UTMPQ
MK"S"';)R /6\C5EUJPM)MY-X][E!UWKDR1&:8F1*5;QQY8XOOV\0FE39+#C(
MWE+]7I6JCDK'E^1R%E)Q7,9X8@\ 0&)P^1JE;E:=7:M&4HSUZ_<006,1E(>)
M1V4"236.!C"H4#[;9AI3^Y;,-J52D[/M/ 8B]6*TPQ=)5E6^2N:%,#OI&<L=
M9XSD;T M-A7]BFS6"T+IS'R$0N'>/+7*R;C8TXH7>0/L %*0"9AO)P:>%UZ&
MTNGJD*G;(W-./UL_\BX/'V8,SUW+3;'L63%2L=$6^HS&.+0SM-9D7]+>2QXL
MZ^-6"2J$H]6,*;17I2 QRF/KP,9N*K:<B6U<X/*5;/M.Y'/,T95M%XKM6KU$
M6BUFF/D("RUZ-;,X]R_D6S6I1RK9_)-&W6\\F.V()E1[HI0  *>1:S56.R[W
MQWGH^7/#"K<LZE%1KFP6K%EGIMK96J@7FJ*12TS'S;:'G(Q0>[GH^Q1Y41&>
M<B.[;[HA=NS?>--N*,JCDLBM5[B/-R]7T;)&&$,>99Y!YGOF2Y21K,M 9L8-
MJ SO34E+L\%=F4)7XL*7%T$6+1]75UU#R<29P9)ZN4J@F*W*F4-*HAK4XLVK
MO[CS#'U3&/[38LZS.6,S9@R$SY'8QAZ)E2L6X*5'?*]&,K]PAAL<X\I-3A'$
M?+,D[P_7;DC73=MWKE0!2$I4RED5EXEK%KF(3+W^:XF5$<(Q,SS#Y$(0W''*
MT!>\)Q#*-PZNQBI"*JUPAH>/1<O,8KRCYG'Q%O>(_P"Z"R@B)0W..Q1T=:&5
MIBL5'5KWJZX>'](MBUSWF%Q'\F)R>E\D$4:8^_H\])0$%'/G381I9#$*>.KS
M,H=/6&X#K35ZN7P+;;>_"O&X;JZ>JK826)^-->H'(_,F+\E<2JLO2L,9NK;7
M'3FXQM/?P]$A#QZ\?/4.<JDD52/QO&;"[BE#IB0>D2]9P%RJB>WQ[B.;K<]K
M.\]7D?U<+'*M,H5-NF><X#+T#(5?R;/Y-1+CSX7NM@C*K9X%!:29C43Q;79A
M;S$,5DP9ANW+[9NN.&Y_?MV%5%%J\?@/_P B.&Y>1S3'S2P9:R+6W.-9YC8F
M,A!MJ60\T[8NTW::CL'M8?E#K.D!1*0B0;%#L[1$5)SN^(<]E_P^)X!+@@*>
M<,KYF7SKE=Y/YJI=5Q_8HU^UH0(%J]7C[1$O08@SIZ8)*N8^WJ@83J"8=B].
MP@.K8L;MQ*32E^^\<7BCQ#J?%O$Z6(Z7/SUQJ2$O=IR+6MC.OO!BI6V7NPW"
M4,VVAF2I3A*6)V ;D,7I,.VX;#J4L34H2[:P>2M'!J,G^5T5RT7RCE1M:6.,
MG.(HC'<<SQVWI$36W 7]0[A$?DP$]Y04<BO1W%\8/P1/%\/4=7=$77!*-,UG
MQ=\]@R!/5/UEE@_+^ V>=\TL:7EK+EKS/(*1B>.3RE>M5WL4[99E&M+2%-53
M69.7\R(+E?@Y$"H)=V/:H)JFHML;C;$/3+QGN^",G-'JUS9 >8JR'CCD)F7$
M6;<=U5OCN"R= M<;GD7\$Q!),K>P1<G2)VNJF5/!,U!.DP+VMR]O:8#*6NWQ
M$-T7RSP,W('JY:KD*#QW,_+:VTC->%[.^MM9SG7'35Q;W%\LL4G4+;.'C9R*
MEZBK$V6B/#Q (FBR@D9550J:1NE8.CF4I.S:F]6FM,U6GOMSRL-=4?5SSF/K
MGR0R1(\C\WW:S<I<70&-;V+QIBXDNQ&-KU]@TI:"1;46,A$7D*?(;M5L57O$
M#' @*)G( E%IU:=2:=FU<27[6&$IZK2/1Q1@G&L'R*S%#2W'ZY35^A,H AC\
M^0IA[89F^6!2$LS ]'<40T6Q/D-1%(64<DOW3!MUJ&,*YE*NHFE-I&KOVJN[
M:TU\1ZI:DAC_ ))X\E<Q9-LM5Y(9'@LC3KIV-5:RL%/5Z8QO/13FNJL*K'%Z
MT)3&[$XE> N0Q1.';N !S*'5W\2.:)6IUPVO/19C]62WOM8P,Z@,[YGKF9>/
M8JPM*S,S&@EN80LB6FM#+S[)6I.Z@_:0R5(:JI%+'&.8#*@<JG4!=9A1"F/>
M5.]TU>,%_)WJTJ[DK%U+J,EE#)Q<Y8[OD?E&D\FGRM7&[H9'80]KA(V6&,;P
M"M,!FQ@;DZ:E2&$!,Q4$C'(8_4<VMUV HZ,]GAC@W(T3E#/\F9_DAE*_W*T8
M[B:(X:ST=16S)2J14Y9YMBS4)#4.&,4A96PNS@(*=YN;VMM1U>?<%2B^(O-#
M@^VY)3F.<GUV\6O!^<L53-F:TG)E,/%N)1C4YA[61D9 [&P1%I@G3B.9U9HL
MW(NR.!C=0'(<!$NEJ["[VHF=MH/%Y.]6S7,LX6J55F<M9&E\K5R1/:8#D<H:
MO(7N*N[4\_',K*:++6T::"4=#SB[(J984Q3%*F84S&ZCC%5.M>[WE:Y76SO7
ML/>MN"]CE\"VK&.2N3.8+]D"X0D97[/EX6&.4+>\2B)N.L*:32.3H473$C'7
M:' 3?!9?%<'V$! @E[=?5JIMVP./EYICXFND> K:S53BY&O\X998H<1QK8U6
M5=-:&-EGU::2C@)K,DUJ"T*HJ8U!;B7R-) O4LKML'1T\FMIRKQ]JLOY5QI:
M/7RKXKQG*S"5OPK8;E/5:/M\0V8M[K6@9!=.M-J5%10Z$O%2573,HH<YO^<_
M[@O9VFWX>IIFM/:W=W'UU)-4J[5X$=,>^KG=4'E GR@?Y^R+<YZ0Q*GAF^5>
MQMJ@2KV2)3>WM^5830]+C9U)QW]],8IDW2)>I FX;=75W*.ZI]7*25WLNCMQ
M&IN/JD8MU$Y\QG3>0>7,>81Y$#:S6[$=?+2'42);T%F3L$?#R,Y2YB<:,Y1M
M:5T%SFD 7*GT"F<IP$VE(I9D%-NJ9F_NL/5\=_5=/N-$ED.0KO*'.EOMV2:Q
M 08V6X-,7*HQRU4AJM6*FX,WB<?QZ /*Q4:NWB6H=PH@JT3[QP55R/?#E*7D
M5V9NDFFDO5149K@G"6$J!FK+4)=^-RP1^+\P)EIWUAUF%7#R=ZT*@XJ2U'>)
MJL)*13-WD<J;H>J;#N"?3J'%#-KK3:T>]IPCFX"FPBL%R(S//Y4K]H8S=GR6
MHCC\UHR6[K;]N]=U*PQ+VFMJ0WKEF=I+H2)F,<R<=R[-Y.JF(%$BFV)5G3/?
M>9=5X046"Q]G.L5^X6&MV/DQ*Q:V2[Q%MXTMD6L,;#(1$:YB8IS!+TV-?Q4+
M$)LR]VP(T6(B*JP*+G%4TE)0IMR[BUYFW$Y>WX'CGGJWJ1)8RP34V&1;ZTR'
MQ;DG\CC3+;$*Z2VP-LE(M6#M!56CJO&J[]*S4J46BG!%(Y5NDW?**-P2<@58
MG2NII>K+Q1(:4J/;[H-1DWU8=:S2J:Y7?,.4&N4YJ[X<O%CO46C22R#J8P?,
MOYW'E57;+U-:,1AJY(33Q IV[8JRZ2HBLLJ)2& M:5-HNC)<1+5D5?=[QTH;
MA"WAN349RUC\H91D[LOC$<(N8=1O0R1;.HE=TQ[(214AK;=?OG4OC5FH806,
M/4X-L0"CL6/7IEJ$GVEB;:KVG2G7,4- &@#0!H T : - &@#0!H T : - &@
M#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T :
M - &@#0!H T : 0P@ #OV=@_V- <_P#+?^7%QT^Q4I,!^W_OU[-5F;SH#J&C
MG_FG,4UB7D:LZA\<S&0E9'"%-(N2"1='.B!\B7=,1'R:.DA#8 W[0]G57:3.
M@C?F7=$E'*).+F4P*58RG7T2PD.98YQ,!/\ >> !T]/MCX= Z&7Z9UV_5?RE
M]Y+?1#0DO(/3.NWZK^4OO);Z(:"7D'IG7;]5_*7WDM]$-!+R#TSKM^J_E+[R
M6^B&@EY!Z9UV_5?RE]Y+?1#02\@],Z[?JOY2^\EOHAH)>0>F==OU7\I?>2WT
M0T$O(Q?35O'ZKN4?<Y?Z(ZE\#F#TU;Q^J[E'W.7^B&J.87TU;O\ JN92^\E_
MHAI!.9B>FK>/U7<H^YR_T1TH7F+J7-*[GZM^+V4@VV_V.7]G?_ZH?8T$EWTS
MKM^J_E+[R6^B&@EY!Z9UV_5?RE]Y+?1#02\@],Z[?JOY2^\EOHAH)>0>F==O
MU7\I?>2WT0T$O(/3.NWZK^4OO);Z(:"7D'IG7;]5_*7WDM]$-!+R#TSKM^J_
ME+[R6^B&@EY!Z9UV_5?RE]Y+?1#02\@],Z[?JOY2^\EOHAH)>0>F==OU7\I?
M>2WT0T$O(/3.NWZK^4OO);Z(:"7D'IG7;]5_*7WDM]$-!+R#TSKM^J_E+[R6
M^B&@EY&-Z:MW_5<RE]Y+_1#2"<S+B?-*[GZM^+N4@VV_N)?V=_\ ZH?8T+++
MOIG7;]5_*7WDM]$-!+R#TSKM^J_E+[R6^B&@EY!Z9UV_5?RE]Y+?1#02\@],
MZ[?JOY2^\EOHAH)>0>F==OU7\I?>2WT0T$O(/3.NWZK^4OO);Z(:"7D'IG7;
M]5_*7WDM]$-!+R#TSKM^J_E+[R6^B&@EY!Z9UV_5?RE]Y+?1#02\@],Z[?JO
MY2^\EOHAH)>1C>FK=_U7,I?>2_T0T@G,Q0YJW<?_ +US*8_:)+_0\="IR+Z:
MEW_5;RG]Y+_0_4+)3Z:MW_5<RE]Y+_1#5@SS,N)\TKN?JWXNY2#;;^XE_9W_
M /JA]C0LLN^F==OU7\I?>2WT0T$O(/3.NWZK^4OO);Z(:"7D'IG7;]5_*7WD
MM]$-!+R#TSKM^J_E+[R6^B&@EY!Z9UV_5?RE]Y+?1#02\@],Z[?JOY2^\EOH
MAH)>0>F==OU7\I?>2WT0T$O(QO35N_ZKF4OO)?Z(:03F9<3YI7<^^_%W*0;;
M?W$O[.__ -4/L:0.9EWTSKM^J]E/W.6^B&D#F8>F==OU7\I?>2WT0T++R#TS
MKM^J_E+[R6^B&@EY!Z9UV_5?RE]Y+?1#02\C$]-*\?JN90]REOHCJ\20Q0YI
MW@/_ +US*(?:2EP_^R.HX-*1?34O'ZKN4?<Y?Z(Z4*9/IG7;]5_*7WDM]$-#
M,O(/3.NWZK^4OO);Z(:"7D'IG7;]5_*7WDM]$-!+R$],^Z?JOY1^\EOHAI#S
M).X YG74?!Q?RE]Y+?1#2"SN%],Z[?JOY2^\EOHAH)>1B^FK>/U7<H^YR_T1
MTH.8/35O'ZKN4?<Y?Z(Z4', <U;Q^J[E'W.7^B.D(<QE>F==OU7\I?>2WT0T
M$O(/3.NWZK^4OO);Z(:"7D'IG7;]5_*7WDM]$-!+R#TSKM^J_E+[R6^B&@EY
M!Z9UV_5?RE]Y+?1#02\@],Z[?JOY2^\EOHAH)>0>F==OU7\I?>2WT0T$O(/3
M.NWZK^4OO);Z(:"7D'IG7;]5_*7WDM]$-!+R#TSKM^J_E+[R6^B&@EY!Z9UV
M_5?RE]Y+?1#02\@],Z[?JOY2^\EOHAH)>0>F==OU7\I?>2WT0T$O(/3.NWZK
M^4OO);Z(:"7D'IG7;]5_*7WDM]$-!+R#TSKM^J_E+[R6^B&@EY!Z9UV_5?RE
M]Y+?1#02\@],Z[?JOY2^\EOHAH)>0>F==OU7\I?>2WT0T$O(/3.NWZK^4OO)
M;Z(:"7D'IG7;]5_*7WDM]$-!+R#TSKM^J_E+[R6^B&@EY!Z9UV_5?RE]Y+?1
M#02\@],Z[?JOY2^\EOHAH)>0>F==OU7\I?>2WT0T$O(/3.NWZK^4OO);Z(:"
M7D'IG7;]5_*7WDM]$-!+R#TSKM^J_E+[R6^B&@EY!Z9UV_5>RE[G+?1#02Q/
M3/NWZKV4_<Y;Z(:03F8!S.NOL<7\I?>2WT0T+.$ ',Z[^SQ>RE]C8DO]$-*7
M"7D+Z9UV_5?RE]Y+?1#02\@],Z[?JOY2^\EOHAH)>0>F==OU7LI>YRWT0T$L
M/3.NWZKV4_<Y;Z(:03F8>F==OU7\I?>2WT0T++R#TSKM^J_E+[R6^B&@EY!Z
M9UV_5?RE]Y+?1#02\@],Z[?JOY2^\EOHAH)>1C+\R+HX$4C\8LI)E[E13J$L
ML!>HG2  ;>H;#OU>W[&JG :E2[ADV&5)C*G,+#LC+4J2QZM%1#])NVL*3@%E
MB^26,1, N6<881/Y28 V+[&H\RWG6O4*1T0#O.3-C 2(B1MA"G%3(9!(^W5D
M&Y!U%$Q=RB'7[&JKIP(Z50_"RPQZ8B;J7%51=0##XH)B8P&#K'QNA!,3>,;^
MY*'@TML&^PUZLZ=%$ZX1SIX1%,QU?@\@NC*"!P "M0_!@L/2/C;].Q@$-2O:
M*76&0E,IJD=G*D( U=^2&(80!3O *@<X')V] E(L [=NKO=0XPIB6'LRLV2;
MJ)-453*R#=-0AES$[J*,N4KJ1W!(VXMFQN\Z>PH^ 3 ';H257;9%DMG:E)%
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M2(]R0IB=/8)NT0]O2'NWE[#-3E#*")Q:J-TA1 Q0=[HN!< 8PJH"CL< [M$
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M!V&<*"/08B*9S 0X["!3B :>*+$5=@+S"J*IFX)LS.2-$W1T1="!P**RA%1
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M+ZOLUCJ5G=9-I::,-*NW2K.RQ%3NV'+AD4\.G;CR4FP<6;&B3^,2*L=J!5
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M>:TM0*[?K9)XKE%&-;SJUP+CU1IW#@)1W*6J J*$FZ,6P&*1H(V9N<RQQ33
MH&-ML ZRDTXO-4:E[(;PWK(7JE>Y2,VV+G\WDWBDQJ<_8:ZP5CW2,BVL56G;
M,P,U6;V;R5RHBVC"$.4%B"!E-A 1[0LN:VDA=@]$+S'"VT'CG9H+'KV1L?(J
M3>,T:P#EB8D6VBPM:KET==.P DD"1J@?<1<*%W'IVZAV!=-HA6JCVJ=(-0T&
M@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T
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MO0NDH-WY4OC=@N+0Q$3M1<]R<!.W.8;#A8/;L*W+;=RVC'L'*L?'WE)9N57
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M5R1@:C83P?R&BZ1),2C?Z)/P=76J$&XBI>&=QD*Z;"L2>6E%G(O1(@@H" F
M#@H A<76("YI41,[=IL_5S<9YG'6<,XD1MBEJPYBVP.*KAB&E'*-EAH""GF5
M:NDHM0[*R=A7XE$UILTIUHMTA'J67W\8QATON*K*2GA?^AWGUDT&@#0!H T
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MLO"' 5WR'D'%L'GJ&L>4K$O;KJXE96P69&8L[UC&Q$A+N&L[?7K8574/#MD
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M49_A[0"_YP[C]_ O'Q#&_P"'M24#'6]8G@$@'(BC=U%@056(F:$C2 8$ND!
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MNR2]GP?['[.I+)Y6)\ P/C!\$06Y=NH/(D?%W !#J_!]FX#OI4L:3(^ 8#<
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M\DQ?Q:Q][Z@AXEGY-0WY+C/BUC[WU#<[S!>U^)*!4D8B+,NJ4P%$8UCL!0V
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MXN&;R*J#@P))HSLTR43*KT@=40+MN/;F8.'E;4&*RHV6",?72";!>>D&>?\
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MB_G;/&!\YXAAR/WV.Z7*VFS5625LU]12J^2V(K-VZ5<(NW8K*IN'ZZ:97QU
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MRT2< N"RT3,,4W2?:3K4* ;AX=:>F:NR"+4K+SFYZM[&&<:9"W@>0L2]F#X
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M0'%!?O+O6YUR>48+5NRD?.7:TLF@VK;98SES*'5Z7X_@]DRB>5M1J+KFY,+
M5%B8_E?ZP^RYQX79DL]8R%,P3['BDIAA&P5V<KD0\R&68*T),+D8JS$JG+LS
MIIID4[H!,4JFP^-4D[;#+E/PW8;AVO5087RW0I[/UW>4VPXFXZ9-O:LQ@#"\
MY$.X61QLR:0E1AI07D>JBDFP2DYR!F')>[.H79Z4/9'8U7"A?VI6N;CN[K)0
MT : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@
M#0!H T : - &@#0!H T : - &@#0!H T([#GYEO_ "X^.?\ P0E/]=== = ]
M"D:F[UFSY2SZSMVV:HC@"G) JY7203%4N0[X8R0**G*45"E, B7?< '6KD<^
MG_Z?_GVL>&:EHQRBR2:2L$HJ=9/K!Q)) 46?6EY8*8HKE 5.Z'LZNS?43:U9
M'WTQ";MN/.FLL [(A\'S,6@LY3<&04*Z: !UV+HS X..],/BE,F8"^V4 '2(
MHSIT:DZNNF:\#;.9J$42432E(X#MEN@JIGL?N@H'=F7,F(*B(=XW-T]GMZLO
MXG*TGV%PLU74P, R,1T"T!RD=5^V$'"@I"HH"A4UQWZ!V[! -^KV=-VR"K;.
M)8-.P38J2[B8@S"L[2(_*5X@(%(*"ID!('7XO2W(0-PU&[KR)7W,T"*["-V(
MC8(=^U.X*$"W,_;];5H?NR.B*F,9(5 %KWO\H8_A[.W;5<W4_4MW;3XF\:3E
M8<ED#,W,4B5)9_&*K)O&*9BJ,3*-^E$IEP[>K?QMNDW9X=*S%[GX"BKMF5-)
M"(05>G3F(T&[Q5OW" /H_P "34J2^Y14Z0 [@AC#OV]0^UI;AO%FJ*V68FK5
MDH9,[=+X:BTUW*R[1)TS>,50!JQ;#($0DB/3*)@4Z@'#=(N_CAL/M2'S\V5Y
MJG)%E9VSN+J\U!@]CGZ;ZOIG4CS(.549'I=*N>Y0*T;12 N/("$(H)RG%<A?
M"38?NMK93 D+MH8J<U'N5&BCEU$*RI$'CL[5Y)-RR I(/A;(*"+1V6+'9 Y.
MD!-OTB&X;@.E+</;4E9LHUQBA<9OH-X1T89^).19 D69@5VS3C4E$5?*55FB
M_B2NZJ2X$\=02[AX [1U(FMH>KEL,-20A=V:<5*Q+15FY;H"V._;&?/&]743
M(JU:*F54:B#E,W1U+'*)NH!$?".KNB*A.E9DB3B;B/2\8\C\R<AF^8;;.R>=
M'M?G+379QW1@BD'-3J]7I$=$H*1L*SD@9!%UE(1 SDXB8-^KP!J1G22T=E:<
M"7KQ:!19RZR<C7FYG,P5X11W(^4)JF=A'LE%3)%77 ".$B=V!>D (;Q@ H^-
MKZJK4IS%34NR:&29U%(D!LL_KR#!5!I''3:/T0 X.B"W6 A3+CL+4/N3#L([
M[B)M)TO&4VS*YIE19X&Q2?UI([<HS<.0Q=VD>HF\;BNB0=SG YSF$NQE4Q';
MM#P:<S;LI%=MPL5)DUA'5?:.'JK=Q#*2[TH-C.W<D@4DHR*/>*G$C9T1))0"
M"J("!4QW*'V-?"EBL8M:;B4N!>8+UA@*0-7+ 2"9P@0Q)&/,9JH_$A')#*N'
M(N#)H"  7M-V![.MK2HKP]A)I2W'/X&6U-7HM,!3E(ANDW7.N*OPHFJLJ90R
MB@B!3N%2=AE1#;8 [/!I.E=HU2]ZVH7"R<,AY.FO.02?2 HB)7J*H]8@;81!
M0RA.KJ.'L;:4B^77(BE4?RV$-LT<9JUF/*%,ODQFF^,X>H/'K.7QE$R%%0I-
M_:2+N& &MG47AU+$BPB48A1)+R!ZS4,B^6ZQ.8$Q(@K=E\1VP2T:24?#,UF4
M9)P2+!LP9M81%9^W&.CTV+5LS%)T8BHR!P Z1MA*)QV'M'4F=K2IQ5/RON,1
M)W7@[Y9])0*:3F&0:KH-WY00.<7;@2J"4%NL2N#*%3'^Z  [=@[=;AJ^^>W]
M#B4VM):8SE5IV-TQ[#4S+:#<5>1AUK#7J[&$AG"K5Y$NT_A"*<-F*OD+W\(5
MRFN,.;8Y"B54#" @)3[[#EVM6H[-'[6[<+F15X:<8,><,*;8<78_OKNT0MAL
M=KOOPK:GT(X0B+5>+9+W9PP:':,6#X2R"MJ=N0$Y%"IAN3K+L!-9H]JG6HU+
M3*F._P#2PF4V<QD8D9NM(-W23P$'+EP$G%B8KL[@B:B9A%R0Q4P20((] >SK
M<MN4Z[=F1RT5JE6^SNM,MVZKRRJWE#^'.8JB2[=)61;BQ3^"C'/'NA[MQY0"
MJ'7U#L/:/L#J4M1EK%;_ &L$)N'\J,@JYBCMG48NJ*X2+4&;8R;IND+4NSH'
MN[H1%;P#X![0[ T<T7>5>5/#PVM&MRQ2*QE&FY!I3ZSEK;R\TI]4Y*:K<G&@
MLQA97REM(.VB<F#UH+Q5FY72W,B?8!#8-P =+%,G0G8KL_ ;[BO@6J<6L%8[
MP=5[^]O%7H=4J]*K#^VO*RE(! 5J#85^+>/%8)C"]Z[7CF:1U#&((]91$ +N
M(#$H7+-+\V[2KJ)ZIL?@E9\20K6;0,1-$)V ^#&J3D)!XY=-ADRNP=F\G!F!
M-VQTTFIA* G*([ &_;I,/(FJ$Z6NI?4E8 CA94\K&^3#*'1?&:OV8D/NBW[I
M.4[]7OMRKG*)?)?$ZA+OV=>OKS42=*2?"(<W^)B.'4,L*O>S#)'N["Q<=ZF_
MCN\(P8OU%(I--/K,B5LFAN'87O!+MU"([:^;;==LR16)9=>/X5^3IEIZ%.C&
M22#E4&#Y-,5VXM5N[([4,8BQAZ'!=P2$ W#[&N+7#:3QNO-/EL5E^W>6AEX)
MPBW54?L8]199R55-1U$F>,%@:]2[-11)19)5%9OX@& RANI0?&#8-N[2J1D<
MVI1&3?@(RE(I5,IVSQBP,W,#9E'.I)@8R;)/Q%'[<Z+I4IBR*)"'(54XF*!0
M#I((B J.UT]UQE:6OE2YGW3:R^,O$N%U$E)N#=-#)]SWY'34DLT./0)S"812
M:BF4Y3 &W4;82_9T2<RJ.:%UNE7S:6HS]AE-Y>L>42'3)P2SU Q2NT"/P,FL
M3K)TB(.5NZ$Y3F$?%';L#2;E8S[V5GL*Y"59K),0C9J#17"0CUU2OGK7N4(T
MBY#NFB8MCF4[]1#Q2 .Y-R]H[:.B"<;VC#8S+!7OA<NHR/5&0!<J+Q]&E;.4
M4$U6_>(_!S@Z@]8F*8 5$![1U+4XP+1POW3MLRM22AU5A4?2<:=D1J1(%7+^
M/\J%]WJG]-%-JJ#=0@E.F'C%$=R#V;;:L*'RVSM 24^94C:8V["MG/0J(J]T
M^8NNE:/:JR/EL6BD\\=1)82ID6043\EV$5=B$ZNL.GJV[)NP%GS8F=\+U9-5
MPF62B%4D" H9$DB3R@%5 34ZA%1P"!DME!\ [[B'V=%*J[61I28362KQ"O3)
M.8>-36?.U>\,_:J"N!V2*:#Y5/REP45/*"@'W(;=V [:.BSCA4JAM1-_:X(,
M\CN(S3.E]IV1:7R6RYQ_O5?K\I%OK?B=?$DDC9&SUK"IJ,9:/R95+FU0^$/@
MTX)':-6Y@!=3O# ()B65L5X:5K6?:.MA?#E>Q4,?*3>8+#DO(LNR<0,AE^XC
M2&=BDHD'Q%1K#F.J4% 5TBAABFABJECB>(P#=7<QN\4L\"UM=KQ^!) )N-*#
MP?A#R KYR=^N961A%@0 J:7>)@ .' [+)MN@P  ]ANS8>W1I1-)G,RFZJ*&6
MO-UQQ%F7+)LO)CH)*)MT'D8F+ULLD)C,$1,J51'RM+9,1$4Q#J#Q@VW"N;+3
M22TY5<L\]'2L$:.(W2D6<$[(=PY)%.G[!PI&MRN%2 H=RFN][T'0JE6 H*J"
M *@&P;=)5K>[O,IRL*]WQM/4R,Q"JIG2"38)F K9=(Z3^-ZDA6=D14(EU+"4
MIN[*/7_J!';MUE3&9U):5%F? :G.=#HV;\7V?%]CE#!#6N+DJL[D(28CFDY$
M!),',.>>8J+N :*C%E="N!%B+%,)  4SAN43I9>%"K"W;8D+L=<*DJ$BRALG
M<N\EY[K+)8C*'HV3T<4,:F@J0%#03<KO'5 J=E.2-@"G:@=1T81 QA,)C=)M
M6(OMM/H]2:F(;LWJG Z6+6.";J-4?A:-[YT5= O3(-1#K005<B8!%;8HE NX
MB/8(!L';JRXB]V'%10KK^RIBEFJ^[0:KJ2,(Z28F777[M^D@J$@U%)0AP*5=
M BJIUDS"<1W*(@&W9OI5-Z;_ &WA0TM5V&3L-<,M'$02!I-1*SJ3>"L#>7>,
MC-T 3\H1#<&9]Q+L4-@,)NP>W1I/_5<9++5+=7= B4I#K"J!)B+,W<N7S<06
M=L"&BV_P> D;M3(&*H)05,/:(G^['M]KE2=BF&1-2HLL%C5X(HMCMK#&^3-6
M3:.$J3YF<[Y=@B"&SSRP3=(I'#Q#)] #UFW$>S9RI.5;MB:E?,IGN]]#<(RD
M(H"9U92*3725-U@>0:;*(@8X !P(L(;?<^#;P:TIM_<N/N)"=E&N!8)/Q!0:
MI+2L#WB:[M-SY*]1%$GDS(7)!(5RKON*FP=@;>UVZZ&ZP[/B92BBH*G-03XR
M7E,K G;*BV?I%)( 5P5RF/?M3&ZE@2 W6;P>#<.W5> 7+;N[8+;F7C$7)5S2
M*;PZ_P"#!$DA"=R0 V HF!1<FX=*8>'?PZC:NL*E&]]QI0=Q7E9I)"6CA58R
M3IG(=[(,MWZ:C%-- 4@!78B:3AV!P$O=CN4=]P[!6M)]@EI<RNM[=N!DNU(>
M1:+)HST:DZ25;N8Y19^R!-A,LR*D$R@IG%18BBRNX@;O">+X/;:G675L)-SI
ML6W<88I4T[WX0:N8+KD2IH3[P\JLF5ZT1$AR),&Z;PJ*"Y7[=(PCW:8"0INW
MM[4*K2J5NB4TM[!SOAV$_+,5\8-/Y[62A\.PGY9BOC!I_/: /AV$_+,5\8-/
MY[0!\.PGY9BOC!I_/: /AV$_+,5\8-/Y[0!\.PGY9BOC!I_/: /AV$_+,5\8
M-/Y[0!\.PGY9BOC!I_/: /AV$_+,5\8-/Y[0!\.PGY9BOC!I_/: /AV$_+,5
M\8-/Y[0!\.PGY9BOC!I_/: /AV$_+,5\8-/Y[0!\.PGY9BOC!I_/: /AV$_+
M,5\8-/Y[0!\.PGY9BOC!I_/: /AV$_+,5\8-/Y[0!\.PGY9BOC!I_/: /AV$
M_+,5\8-/Y[0!\.PGY9BOC!I_/: /AV$_+,5\8-/Y[0!\.PGY9BOC!I_/: /A
MV$_+,5\8-/Y[0!\.PGY9BOC!I_/: /AV$_+,5\8-/Y[0!\.PGY9BOC!I_/:
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2CP?=>QX-NW54S2TCS+NH4__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>tm2226999d3-bc_pipe4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d3-bc_pipe4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!C@.2 P$1  (1 0,1 ?_$ .H  0 " @(# 0$
M       %" 8'! D" PH!"P$! 0 !!0$!              $" P0%!@@'"1
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M*_[I93JPPNUJVT0H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH)"&_P!]FFS_ #"XU_?E5#C?2%4:CH_UY?XQ6[_+1"O^Z64ZL,+M:MM$*#5V
M8,QX^P3"%D_R2]7:&,E>ULC<F2(U;L_R:3OZTMLCD1B4?;BE#M))5(G,X"=$
MA2E&'&C%>^RP C&&C7<FU"/$#:8Q(Y[@W*$;CLIF$"AHEY*[&TB4PI;D&8L,
M(:E^14,?GCAX':$CK(B#%2IK,>TZ9. TPX9>Y!8PE7%9]2"B0Y9U08?9<825
M9)M-T$QE,4Q=WF.@'E%3E%HR.Z,3+&2@+#4[-<9V/KI0'.)Y(AG*[7,*) 7N
MS%!MW%$NDT]QM"IG,L?/&*93)8\WN[[CF0.#>ZO4.<595C#V1Q<&S8B5*$M[
M]T00EBV7M8998["+"5P\RS:68XQA,IQ!<9ON8Y;'&NRYDQG&G)N9WR7*KJTQ
M V]O<G6PD24PE.<,\5Q!,&(LD02P&&7  09ZT*U;@U-B]>V*&5<M;T2M8SJS
MDJA6TJU*8HY0V*E"$Y0B/4(#AW*&,DPPH0@7N 0@WM>\$C05\SUGQ-@I7A-*
MLASQ)R\T9R@N#TK@W.+0WH(JY3@Q;9*]/-EJB[DL3E$MYURR4B8ZY@P;DPPB
MUPCO46#J*4"@4"@4"@4&&3^8^044<).&-268GI%+,WH8M$"F8Z1OKG('QMCS
M4WMGE$]1Q@),/<G4K=G+5Z-(05NC#30  (5J*\H=6Z1SS=+-/:+!6;3\E0W'
M$=RF\(=_P<6V7BTI>7=A9Q)'8[-A:4]P.<F0\(R;[C>P[D5Q;+]Q0JL=!I65
M.8=&9@4ROL:\HV5 ['1J4)T*62QM6K3@,6QZ1)VIQ>&HI]8UEQI5=DBQ6E[X
M)'O)YQ6Y,$&5U H%!"D2)B4R)TB2=T1G25D96&1.S( ZPG!O8I0NDC9'7141
M_K%HWA?#W0D@=^X,:$ZUO]2]!-4"@4"@4"@4"@KKJ:U)1K2SCY#DJ80R>S&/
MJYA$82:3C\F&*7-O=IQ(&^+QTY8FF4TA1 T"M\=""!C3FGF%;O=C!8NPA6L1
M5)FB,C>JR".N>A::)5&IWBW,*V%&9%B<=GR*,709 AJ5:>WNCK"Y+"99-(VX
MJ656G'96WGJDSH25:YW>UR+",LIPJL[4"@X+FJ4(6Y<L1MJMY5)4BA0F:4!J
M A:Y'DE"&4A2'.JQN;"E"H8;  )0H))"*]KC&$.V]@IU!=6DERIIZTYZ@,7X
M!F4Y19ZEL,;'.)MDDCB5UQA!Y0X/"-TR-(ESEWHA<VN*@;"A*DR7^E&)4&P1
M6+ ,VUIIHE5TZBM0SC(4WC&2\.PN/8@DLYBF15DS33G)32\,B!CP\1&V$AU8
MEDE;7$TMR>"YBO-&C362=TDPD5QWN(119E&WJ@4%?(KGQ-*-1V5=.UX<\,[C
MB['>.,AFRE>XM!S?)&_(SQ-6A$4TMS<H6*DI* V%G7&8K&2<,0]F\!"$(QVF
MBJ5TT6#J*4"@4"@XB]2<D1J52= K=#R"AF%-R :$M8L&&VVR=,-S6MS>$TS\
MEKG'E%_Z16H.O%F[3'#JS!<'U-R;&>;\>8 FDN<84?E&6L^-5C)!W=NGCKC2
MZJ>MD&RG,Y2QL*F:,JA&!P+;U*, ][N:878XFYEIP)7A63QWJ 19!SWGO!1$
M1=F95@J/8:D)\H7.;.K;YDCS(FGRMM/9$34I6FHD+85!16N-48 \\2C_ .P4
M$%A&%6&J!0*!05WF.I2&0G4-AO38Z1^;&S+-[3D-YB<A(94Y4'(38QCZ612=
M,M>USBD5J7 E(Y(P@+1)59=AJ@V-,+N$5K5*Z:+$5%*!0*!0*!05SU):E(WI
MCC</E,KA.0)DVS7)$*Q6W @!4)4*D4IR [EL48\)E3*<0HLMM5NIP"AG$#/N
M3N["&&P+"%:Q%4F:-?N6MF!,LXR;B20P/),3S+CK$;MG!OQE*D\)1N.2<<L_
M?1*R08]D[/-W^"NQ29P2&)STY[FF7IQ%F"$GW)8[V4*_?;[PADU-FO"V(<RH
MVD]@1Y;Q? ,FI6)2K+7J65-/8HTRHAI4+BB4Q2P]M*=;$C-"66$P0+BL$-K[
M+%;1J!0*#!,EY"9L60IZG#ZB?75&TV0D)F.+M1S[*)$\O#DC98_&HTRD" 8Y
MO\B?7%.B1D[LL CSP[L98-T,-%:,%:UHQF#,$JT]RW$^7]/^;HU$2<B)<?YB
M9XTF.EV/3W,IG%+H=(85*9C%WQ"W.BDI,L+ L":2>,0 6-WD\12B1*Z512@4
M"@4"@4%/E>L%NMF+,N#F'!6=9C-\(1&(SB3AC1.'#$#Q'IN4Z'1\Z)>&,QL[
MJ[KE5F14&Z0Q(G5;LG<V+$(95AVFBJ58Q'=?&)\@HM*DAQ6V/<ZA.JK(,BQR
MR2RQB&/@@\ABL2FLG>VF6QYS-\IB7Y&;"%*428*4)&V]C;*;EB*WY0K"]%12
M@4"@T)FS-;YBE*67$,'Y:SS(K-BI_7QK%:6(%J6B/(C-Z-<E[K/)9#&,]<L-
M",M U(E"QX<3"C-X2#+*.,+HR+!>:(/J)Q'!<U8X/<CX9D%EL\LUGEO,:7A)
MO:I2W.+6[MQ@S>]'1G=41Z50 !AI6_$BN6887<(Q!MFH% H% H% H% H% H*
M\ZG]1T8TI8D=LT3>)3F60]@=HJT/1< (B*QY;C)E+&.$L:HQ%+9A#B%*0Z12
M-(29WN<<:6$=S+@W 1"M8TDZ&0DY<<BIA"XD_8@RE%BYTN>FIJE#J/&+G&D3
MNS1USE5FQZ,B.2Y,^-QKJSLBT24ZZ$201J:Y1AQ1AA 30W+4"@]1PQ%E&F )
M,4#++&,!!-R@FGB &X@DE7/-((L89>VY#<8P VW[HK6[M!2>)ZNY9D7#;?E?
M&VG6<S1>=J%D>#7J H91$TS_ !EJA^4'[&LHR(ZN)ZB[&:V,IK")6:E3'G[
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M\>)3*WIR6&V[],6)4Y"4RY04U[V 8%7@*::JEX*8';%,6[&+(,9R-E<]SS)
M,;XNR+'7G(TF<,<OL#<-'+[,V1B(QA9:1C]A'"GJ*HAMJUN;DCB=<L1C@H7'
MF&'"=U-5$S-,A28EKPIE_&F1YS,&R2=IG!\9*\ROLT?(Z;,X?+=13GC&:8EC
M6*6]2YQI=B"(M0U4=2G. FX2E:SB=DS?NS2' UQ'PMGR^73C"&>37+/R6?R+
M%63=4,9*PUJ;Q1DE^6,$#&_R-ABT=TW9OQ*3(4)3)#BI"B4LXEJ-.Z,RE>I
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M#59VA/2FH*Q02=B<@9>$V!7$,<A\L,@!\&0A<<0H50![N&5AO-\>&F)@?_\
M/OMW)F"':&R:P1"M=64I"0B.BO3;CYOBS9 (([P1+"W*:.<:'"LEY5B:YO,R
M&N;W*7H!NC!-V]S7L#JN:4Q@6M2<<VI;IR[)R"K!M:RLE(><]T5:7\F8XB>*
M)GB9K<89!']7+(<!"]RR/2B.2IR<%;N\R=JR!&W]HR ED4A=UYZMT76=.^G1
M4:(Y6,XP5Q4K*T;PQYCJ$XGA[/ L>1Y'&(FQ%G@;FE&-2?8)BM2<N7K5BY<>
MK<G5T<UZDQ0K6*CCE2I08,TXP9@A"N&,RG!F,9IDS'^89*PKW#(V*R)"FQ](
M2Y9,6^T73RY&F;Y22@9VQ_1L(RY$A1$%+;&I3+*@$%V,W5BP; VW4"@4"@4"
M@4&H<P8(Q;GII8F+*T>629HC4E:)BR(2)5+XV2AE+ H[[8GVWDH_,8SW)F5_
MTJ4PVX[D&VL,&Y%:UZHSJ0Q-DE44=X2^DKEL=?F15'79,!Y>D2]8T+D8D"Q.
M-];W!*_%FJD@Q &>!2%0+=7O<>V][T&HR-+N$$S7A5E3Q-S):].IJ0["R(N=
MY#"5 QM[(=&6^S=>TKW:XI!&5)K:06MNI+*;C1I@6L0,1=U2C5SAV>>CES42
M12LPL@$.49#0976$D2[(2-$S9#;W]))_*F#MZ.6IT&-U[F^H"3W(,>+:R7;>
MP@6@4%VW-*RE(;-;M+&#&M<6J21!RNB3Y ME-'%5D[R&Y8];L@ =CI GDS5C
M-QE:K'C2L02(^[DE F;"B$KB$"HD %!99@55HQE5HCTLK,TK-0AV(F@.5G)T
M:W]W>DSU+$3"^2-D$$QGE#_C]&_D8[?I4UJ !.3NBQJ/<"E 0G!.L;:P[*SJ
M*-Q99Q'C_.4$>,9Y18SY+!Y!='X;8"GV11\ET @5DKTR=:KC#LS.)Z,*Q.68
M(@1UR3! #NPBV6H-(X@T*Z4\"S=-D?%6)4D9FR)L<F=$_GRN>210A0/ 22W,
MI$GE<I?$*,U820$L9Q903MZN(%AV ,=A*I2(6VJ*4"@4"@4"@TW'\!8JB^69
M9G%CC[DDRE.FMM9)=)S)C-EUGUG90& 96U:R.$C51RZ-F"</O,L*0(4MS!W*
MW%QBO>B5G>&\=Y*D6/97,V5<Z/\ BJ0G2N +DTGE;(&.R)0W*V<]W)1,+VUH
M%RLUH<%"05U11]KI5)Q5[;V:8$0:PF&C73=D!-EU),\=#D1.=G:+O^4+N,RG
MYA[_ ""$IT*.'R! K!*@*HD_1="UIDZ!:S#;U25,G+)+&$L 0V5DH@"-!NE!
M(ND#LCQ39&]2M@AL>D4@1S?(Z21NQ>/W\R41*0*Y"GF!3V+(#6^G#4"D]C[2
M-5<8@J%QH!7#=64I#9!NFC""QDR-'GR")Y@W9=9&N-9*'/WJ2Y$=9A'6),K3
M,3&[O\Y>I"_&-+%X04G(4X%("D:Q2<I)"!0<8:)57&P-I?P7IF:7%FPK!_)1
M*[ ;R'!4ODTPFKVI0M % &9HO))Y()/(2V%E"K.[R;P*@HD>_&;R4"XQ[5:B
M1FNGG%T_R"TY3?DDT1SQFC)D-2OT-RSEG'-U47,7*W/P(^-F/9O%V>2H27%>
M<<4%Q3JKD&&7$7<-Z5&U(]'F&),31&(NS-D>CC WI6ED8F5$G;6EI;$)(4Z-
M WH$A929(D3$@L$  !L$-K=RU03- H% H% H% H% H%!J;,^#L8:@X4IQUE^
M.'RZ$+EC:X+XYY12A@0."MG<D;PTFN%HP],IR^S:[MY"H@!PQ@*4$@,#:PPV
MO:C9R!$2W(TR%.-680E* 24->O7.BP0 6V6NI<7-2K<%AM_Y3#C1F"_EO>H*
MAD=G_I#3*%)Y.'D@0G9$(RNC0BF&0C&:.STB06E?AN%,1DM&RP,I5)0 7*43
M*0@0*U119AY!@BR[AM92D-GBTT88&;FHX47<]]U$)$R',@[3F?AO-4B-@+B:
M4@_<RFUF<">*DEM@/!W>=PMY8$UOZ$ 06+1A\MT5::)NAQ*BD..U1IN"VLMA
MQ4^-4]R3&YA$XZ6E)0^3)<XC<P:9D[Q@Q$G 28VKURI":4&P1E"#W*52D/<D
MT7Z:&['9>)VK&9;-CPG(8<K$Q=DEDZ941,^*DXYFD?RCVJ3I%Q=VV5"LN1I@
MFV1HE "Q$%%[V78*I2&>)]/^*TDOR5/$K(])Y=E^.LD4R,]DSN?EJ)&P1I&X
M((\A&4"462MEV-([K I#D1:8]/=8>( PB.-N,KKVU#:.!II)AZ.032FTYKT[
MXNQ*\0&'1F*ZE)UA/,>-GMYD;>Y.9*&7K9$SJI!CA4S1MH3HVZTC3=XG$J1;
MP8"Y ;6)2GWEP-*F'I!B=ADWA)OE,,9I(K:5+#BJ3YXR+J+/A5V].L*<7*V0
M,F.+JZH5TH$J)LI9V]2H9T5T(#B#C#E2F]I)"U]12@4"@4$A#?[[--G^87&O
M[\JH<;Z0JC4='^O+_&*W?Y:(5_W2RG5AA=K5MHA0*"O>HO4 RZ?V''JE<E;5
M\CRWEN&X2QV@?7\$4C:N=34MV7(+2.4";GD;$T)6>/KE C"D2Q0>:26F))&<
M>"U6(J.:V9%R&T9$#"LDPV,,\7'CR73TG*K#+E*B.6M$7J(MS@R/S,]L34HB
MJPI#*^^K&C6K$QR=*,P)@;V-*()\;86.<@Q7*\%BV2(,XV>(=-&A,_QEW "Y
M93JR+K7,;W,@(K[JR5>GW)I5Q;!7+&&][6OMM8K-:@JE-M0+]&]5NG_ ;:SQ
M5SB688?G=\=I.6]+54D8W[#*2 *36+P0G2E-B$M6&?IAB,-4GG"L 0;DD[ C
M,M- M;4"@4"@4"@4"@4%1L+ZDY7E/49JEP*[8UCT62Z97/%C8JF#=D=RDY\Q
M,RM B\A-!I$:4XVC!;&!M:%)1*FPG%5?OFX[ W0 V&.I72M84XMYYQ28E<C.
M4'I1K22"E1!AQR,LT!!BLHH [C,2@.-""YEK7!80K6O?;>U157]:^H%^TQZ:
M<M9HB#/%9/+,?1)5)VV,2MZ6-*)Q3(U2-*L4;TUI5+DX6166!'<@NZ8)G^J)
M03ML*K$5E);+)>,T\O:M@51W'Q>GT6*RW9JE1<@<A904Y7*E)*1>R'1D:<#4
M&%IHN>$ZZL Q' 5C*!M%8RX2G K:H'%O&N-; +D8W(@@*DYO J($N)3#%8(%
M!J2P[J"R!B%:UAW#8-[W_+4'X6YMIJ\]K*<$)CFF* H4MQ:L@:].09N-P<>C
M"9=044/? [!"#:U]U;_3:J-,K<LGSV#9N/TZ'Q*?9'Q@Y2J -2%^=#T<(69<
M8XJSOY,:=GUJLH-[P0K9"E1N R;A$G5 /3B$684,00S^%O,@,QY$'[)(8PQ2
MU1#XXXSHF/.XUT.:I.J9T1TB3,#XX!3&KXZE>#32T:DX(!G)[ &*UKBO:@RZ
MZI-8DM1=019.==.$D^YI=B31*S"RDH2S;BW [J33@!+M:]]V(5K6VWO:H/%.
MK2*]_P"]%2=3WLH-2*>]SBSN]U9.YWY*?O8A;TH*W5MT 6P0=MMMJ#DT"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4$A#?[[--G^87&O[\JH<;Z0JC4='^O+_&*W?Y:(5_W2RG5AA=K5MHA0*"JF
MKW'FGO,V.&#"&I)L3.$,S'.VZ#QQ0<N SK&;((8[*)3&'1C?]])/8Y%LC*A,
MA-*N(2A2H"D$ TI084.Q\!*@&,()J&TQYE=M%V1,KK-7&F+)>G;+4^QLXY.;
MT3UEO#8,:K8XW CV07,)"DJ50]X'+4J1K5K @":M(L6B)1EHS"#;KT\+'5H:
M&AAF)VW05V2,E:[X^1*(WJ5T7JYR_-MHZ0>P/#HP/+8YJY8YI+!,:G!>> @A
M2:L&689<( F7OLM:R:UDX(3^>,LI81D7M?)[A]W1JEB3$^@L,J=L>+"37I-%
M;2S+$7SO)FI?'CP+KR*#XV<',\]:F,NK;5*0-]V XFU@V.!5A925II==?^@5
M9B2V'%[+,M.NK%K5@@PXD>UR&#'LF&K0-"L0,XA)5K$K2*W<" !A=RSB[*0
MW5BQA#."315[].N)"L7S_)'9XK,?IQ89A>3V[5-C%[,CQ8HPMP1,9:Z3EOQZ
MI<0DG)#YC!]03.)JWA=<PUPB)=]NP(+6NGNGP.WBL5*!0*!0*!0*#J4PXB;'
MG6)VRK8XID;FA4@TLE+$*HHE4G.+]4Y*&X#R#+# *UC2;[-MNX('^FU7N,>Z
MJ9B#%N/H3@+L4LUQ6*MC+EZ497P? I'DQ*$X4W?8)+M-N9CWR$.TE/..=5\.
M-$R)0IVLTT2%"65O:4HD A!%EPR1P,<SW.\5Y9[,W7BYY<,@P]4$9RIG9JR
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M0X]@+9*E\Z;8/#V^;NJ,IN=)BAC3*DE3DWDV+"2A7R$A$6[K$902@V"48<(
M;!MLMW+4&85 H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M!0*!0*!0*#L@H% H% H% H% H% H% H% H% H%!C43_JM5\I9G_;!]H,EH%
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M+O*2.R/O@8/ 8MJI7O&^GCV_TAPQ"V6V[*4*)OU:?I_U,]*OP#2A0]6GZ?\
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M0H>K3]/^IGI5^ :4*'JT_3_J9Z5?@&E"AZM/T_ZF>E7X!I0H>K3]/^IGI5^
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MI(Q2R(QB4,B!8A<$+-(F%J>VI$O:]O@Q<D;W)(I2)EC=M_H#0 L,G_8O:BH
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M]U@<'?3VI4]PR*/"EB<53NR*'6.M#@>SNRU0:K6.C4:K1G&-[BK5'#--/)N
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M4HA^LIVO;RY'@>-<>]-O_FK)[3$/PT.#>LQE?BE$/UE.U[>7(\#QKCWIM_\
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MI(97DJ"YU=,ZY2TE)I%(5[L[)LA8?S*[X3G.E:/O3V<Z+2@/I=X@^1=.:,0
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M3?\ FRAJUV\*!0*!0*!0*!0*!0*!0*#,LB_W@SOY92?W[75L=V?RW+_J,/\
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MPM-O@P"M85A[TN3L:KBGX]#D*#K"(K.&_&,H.2RQ@4%1O)3LMC[:UX]?C"7
M8&><.3C+6I.G:5%RUYQ[FD  JXE)-AAG% H% H% H,DAOG?%?E(Q^^:6@OY0
M5+SSYWMOR;1^^;Q0:3H%!J&882ATSEUIXI<)U'I?Y*EP@Y[A60YG#Q*XJ!S6
M.]FI<VL+TC95QI2YP/&G6FIAN*'?C.]%!%S!W$*,=CFEW!L/F\3R)%(<LC4H
M@N( X%B)C%,YXU,3!B0"AN5EPY!#T,G(B!:<E8TICRU5T%UQ9Y # GV';=4J
ME(8>U:+]-+1$<8XS:XI(4\8PAD\S.>.&(&8<Q&JHKD9U<Y.Y7E UQN03'MU2
MJG21.YA:)P/5->[5*+ 3VVCM5K)2&P1:<,,'*(4K7PP+VLQQE&4YI@:V22"4
MR9;$LFS1',T$EE#$LD#VY*6\UQ(R"[WLE .R(@U7OI))9I) RI5:,&C.#M,N
M*&9:O85@HNPPO-D^S.].2[-N0C6UAS1E)9('"?O4C<7S("H@A7)UV3%YI[6N
M,[PL-VV@2@W9=72E(A^*-+>EI$IQVA*B+1&C\?9DG6IR M4>G,KAQ:3+\Y+G
MADYR2)ICTJ:$\B/<4F27X!I:XI6WIDJ\919)9("@EJR4AR(KH]P-#S'I1%V[
M([<FE63EV9Y&VE:@,_JX[),A/$@1RMV?'N.+,H*8\\('QZ1%FK6P],8TK2MT
M2<F,(,&6)4I#T':*]-Q\2D4).@SR8QR;-GK'+3A9-RO>2-F<?*,N5WR5#YIY
M<>64!D8GL%QW&QKVXNY!IJ>X.]SC2AJR4A:%,G+2)DZ4H1XRDQ!2<L2E2I6J
M1%DEA+ )0L6&GJU9]PA_/--&,PP6T0A7%>]ZBO?0*#L@H%!U>]J?@&0ZC<;Z
M?8=C=_3Q'/,2U&7S#IMF!QUB01K/V'M/.H+(.+U3@'?T_?<4=9.Q$-C^F$*Y
M2MB7JR!VW)E6-"3^%1J.YI5ZN=:O8_ZN'",O^/$TX]::$P7'4O2N"!XA[FSZ
M1I,OSP6L:7/P6Y%.Z3,X%<476,2$A5$01*N3&&)5I9@KJB82M9B62QC4ADM]
ME.D7/DL*#F#*4)P3VV0FYDC;:WL2[)*C .?,90Z(1QG:&4DQ*0ZO;+ $"*^\
M%F"$I,N.]A#%?;/^A7^U(8CU!O#KK$C66<>3\G7),,D=FUC^;,>/\=RC3]"5
MF^R?.2)RDY,"5NCQC]E20=G2N%E:9%('!P?4J=.86<X+CAA""\'RD:^[H91J
M U5:LHW/=0+BQY'1XB18@1]EM)V_#<A@N,9B*/N.KO.SUB/+F.LFREN<7<<B
M;VYK1"&2HC[P@-L[D@-2.0D.Z(43037NLMBNJK-J;(Z+3;+\LN1B)S[0;*VE
M#UFC8OC)NF+<R1S2;'=2./(8I1$0P.'463YM+I&-C1+%$=NE6-;68E+0B=EB
M=66IPFG5\+0,RUBY=R=B#-^$<TY<8,(.K)IHUUO\.RTB98(QMVKENPQG/,&
M(M)(^T9";7QF0QA1CN*,DCDZ!@&0J6G3)O4,[FC;+%"57A2M=#RT[ZRLPSB6
MXWPCCC..GG%[?B)#H-A[/!)_+D2Z09XPCF73IA][DN2X/ D.*GV83-Y#.YM(
MH^PN#/,&IB0/4%, \)[I>_3!I@B>!,Q;5UGP6DO2AE&7ZM3!Y3U4XBFV4"6U
MN@VGB'-C0IQKBY:M<?)*0S=AM$6:&MTC?FA;)R'*TFDBY0'<L2=(D[[3IV@K
M--;32;M!,N1ULR-J9=,YH!ESO3!V/C\LBKV\P!CPKA5#JCR'/87J!RNW*",<
M2^4,+)B\PQS7GNKC=]1LRD)AKT2O;6TI$F4*\/Q.['1U.<AS7%TD<<FY5Q)F
M-6SY,FC3&\B8A?BI0P.,% ) \1M!)9<V0;&\*D\XC"5V&VNRZ/LZ%H&:DL&Y
M)*P"PDJ2RC5I?/#CQUA\I[(+L5(O@UR8'G7LT*] [IIH30Q8A<,@Q!,SS7'P
M-2KY+RF,P]^9<')=/Q\J1S02XOP*:!60F6 &><F *\,UU,='>QW7:IHQR_B_
M%^4>U_=Y[/(M&$[-VD+J\JT[F]("70Q"'0EH52$]X,]S[NCFJ7N"0Q*E(3E&
MG*E@=X*",W8"I/ RCA=5>JMY=N0#MYB$>2<'I(VU=H 3)WC&TE[\8L[2LV+:
M.]![JJ2Z<,F)94[)H9J ?1L'@O'IUX6\FIIF62()F[O:R>QP,9U3\;ZMXR\F
M2..1^0FM#O'C7UD:GDQ@D"6R%^8S'1 0M&T/:()AP4;NVB/WE2588K%G $';
M?9MK%FFZ#^:-KP_QBZC/^J$A_2@KUMT3_I[*_P!R?SKGZ@]6/]![M_4W?YEZ
MI5=B=\*!0*!0*!0*!0*!0*!0*"9CGG"Q>[+7^_$5H9G_ $V)_<N^:6SWC_+\
M?]3?^;*&K7;PH% H% H% H% H% H% H,RR+_ '@SOY92?W[75L=V?RW+_J,/
M\V'#]'?Z?R/^SP?\NUAM;YS!0*!09KCK'$[RY-HYCC&<4>IM.9:Y$M,=C,?1
MF+7-R6F[17L L&PLA*F) (Y0H-$6G3)RQFG# 4 8[;;-YO+9'+WYO.7VX>6P
MXK===-(B/NT1$:9G1%9;#>>\]W[FR&+O3>N-AX&[\&WOK[[YI;;']LS.B(BL
MW3,6VQ,S$/OH[);05,=!F 'F+9%F?E%/\F2!%-Y3'&E28HAT#6ELY#:4PL1H
M^XYNV\@MX3< !+)4F%E%E!$4G <=YDZ<=)LOTFWI;C93#[S*X-DV6W3].^*U
M[Z>Y'@VZXTS.F:1^=O7'UAY+K#Z1V9O=F!^BW=E<.<+#ONBF)BQWTW=_?X-M
M?H636;8F9F8FZ;;>U&NEOD90*!0*!0*"-=OV4KW29O?A#1)25%*!0*!0*!0*
M!0*!0*!0*!04YS5Y\G^YK=^C'0:EH% H% H% H-/ZA6*#2C .<8SD^3N,(QK
M(L/Y,8LAS-H=!,CM$8,[PMZ;Y;)VMZ 0I$T.+ P*%"LA58LRZ<PH)FY%N=ER
M3JTZG4]H_DT 6*LN85U((-,LZ<X.L?RHUJ62D1.V.,EL[SJ5S&GQ_%,O8R7K
MTC!#,B-L^9E+W'&!*YN:%8VK *VM0B.":4'*>[#&*<+QTOHU..Y+IL:\IQ'&
MV*<)1J5]IBA3G1-:8VZ>)/F229D@DJQ9-\=-TEN%!#XI),.NV5;,S7<\XI&D
M M*3GJ2!7/,3I6/P:5BX9'[O'979 C4_:]]BKWI^U(M3&QOME0"^1!XY3$^'
MV544XF=^D)2\,*F1. HT5C2BK!!>]A!J<*_DNM+4D=/V_0'JDT3Y%-D*Q+H1
M&UH5,^>PK0$93PQ:0P9VT6*%[NH$F22!TO%GHP#VH3GK#29/C@8E@"_"!-A6
M*5JQX*=Q>C6!DZ7NSCJSQ<_R!N60K'4K[+F60YL VMZ!3'E62]6B5%)2%KD5
M>ZUS X'0%&<5=0+^B$(82[!#?94CC92_'3)TOQ5*==LM@D@;V9Q4]KOV?>.G
M\*UM;W8IU@^:,-]E+A.>,]@K;WLVJE$6GBX9*LNUSDQZ>P@;+VO<+N?$G=^/
MB>YVU39\=V9DG\0EB- ^.NJC4YIGGN"5\7CBX.,8MBPG.1$3R4A5>#T\N33!
MGCN,H_,EXW9>MCKLROQP$J8LM2V* /C*S^%L71QG+,TYF^(VC)F2$\^29DT%
MX6U.JT5XK$XV5$YU(UZ%JD*>(WC3>A7F1)\3NY)PR'0]T/)6D"$G4%)S;)2D
MQ'X5B?F=F=12@4"@R2&^=\5^4C'[YI:"_E!4O//G>V_)M'[YO%!I.@4"@4'5
M,8'.*V0GM5G/)C>^.?:)SEKS>=!$RX:TK3.JQ5-[8@%X4:FQ<Y,$1#%3(5:R
MIL-2C*>#%9ES JPK# 5C]_6V7IBQQJNDN*=-.0LR9K>62=FXJP6[9JQQ(8%(
MF]\Y1&J#Q(O+;$Z*$.2V:/)ECM,D3E89J=D[PM<_=E$GD[FYB:+%::6$-S*I
MA48UL*I'@&0Y"#.-7KT_8UBCCB%]F3$](Y-@?$T"+GJV,!9S;NT';W)D>P.!
MI18QGE$C+*W1BI-<P-?XSTR9(APL?1.$-^04\:C\VT%.F+)C/[ 32>'Z?].F
M*D,'G$.F9@E9JMFELA1,+^4K;K LH/-R%>QA=K>%+(R47:T;!DP,..@'T*@#
M&#-FHT.*PJK;FX<(ASUD2V' MH0[" Q(./;(+1VQ7]%:.=X;GN4E8U+5U%*!
M0*#L@H%!$+X^PNBYN<W-D:'%R:#+FM+@O;42M<UFW&69<UN5J"3#T1EQE!%N
MBA!OM#:_\EJ#BN$1BCLN1NCK&(\YN3>((T#BX,K:M7(1@4B6 $C5J4QBA,("
ML8C;7 (-[&7N+_6OMH.(WP&"M*I&M:X7$VU:WB-&@5M\<9T:I"(\(@'"1J$Z
M,LU,(X [V%<%PW%:][7_ "T'Y'H#!8BK<5\3A<2C"YX5+5SNLCT<9V56ZK7)
M5W\XJW%0VHTQRY4O6_TQQAMQ#--_/%>XN[0?KA 8*[*EBUTA<3<EK@(H:]6X
M1QG6*EPB A 2)8H4(S#5(B0 M8-QW%<-K6M;\E!QUN-L=N3.^1YQ@,+7L$G$
M4.2,:V+,:IGD(R%%E9 GQL/0F(G81*JUC074 ,N$RVZMW>[0>U[Q] I*B8VV
M1PB(2!NC"@A7&T#W&F9U11Y4E2&-Z52QI5Z(\AI4)D!HB"QIPEB 2*X+7L&]
M[4'L402#JW-N>U<-BBIY:&17&6EW41YH.<VN..!82E\?;EYB,2M$R+2@V"<D
M*&$@P-K6$&]J#U*,>0!6D8V]5!H>I01AY+D<:1*(RRG)(](20J0E/S&F,1")
M:7DH*PZP52<)9X;&CV"_.%M#UI\;8[2$EITL!A:9.3#N3PHA/%F,DDJ 6[OD
M,646A" $.VW_ *LM:R+_ /;H)=%%XRVQU-$&Z.L2")HVX#.DC")H;TL=2M!1
M5B"VI,RD)RVTAN+(MN D!*L58'<L'90>+'%(M&.^O)J-L$>[^WCOWP&SMS3W
MYWMOW>W?7>"9/WQWOWP9N-WMW&[%LV;;[0B@8VQV6M"Y%P*%@<0*@K0+P19C
M"M M";8\*L*JR&QX503[;NQEA;NP^[MVT'N2X_@2%Q \(H1$$;N4H$K*=$L:
M9D[B6J'<0AJ0+BD0%(% Q#O>X["W5[WOW>[09=0*#^<?K>PSF!YU<:@W-HQ1
MDIU;5>3I$8D<&V"RA<A5%A46+$-.K2M9I!P+& N&]PBO;;:]OY*]5=%MX9##
MW!EK,3'P;;XLFL3?;$_2NX)E^EO5MOS<N!T'W=A8V<RMF+;A75B[%PXF/\2_
M7$W5A5CD&SES,97Z.I?P/78/6>[>48&TMXW>/:'<'+LGML/RCD&SES,97Z.I
M?P/3UGNWE&!M+>,]H=P<NR>VP_*.0;.7,QE?HZE_ ]/6>[>48&TMXSVAW!R[
M)[;#\HY!LY<S&5^CJ7\#T]9[MY1@;2WC/:'<'+LGML/RCD&SES,97Z.I?P/3
MUGNWE&!M+>,]H=P<NR>VP_*.0;.7,QE?HZE_ ]/6>[>48&TMXSVAW!R[)[;#
M\HY!LY<S&5^CJ7\#T]9[MY1@;2WC/:'<'+LGML/RCD&SES,97Z.I?P/3UGNW
ME&!M+>,]H=P<NR>VP_*.0;.7,QE?HZE_ ]/6>[>48&TMXSVAW!R[)[;#\HY!
MLY<S&5^CJ7\#T]9[MY1@;2WC/:'<'+LGML/RCD&SES,97Z.I?P/3UGNWE&!M
M+>,]H=P<NR>VP_*.0;.7,QE?HZE_ ]/6>[>48&TMXSVAW!R[)[;#\HY!LY<S
M&5^CJ7\#T]9[MY1@;2WC/:'<'+LGML/RCD&SES,97Z.I?P/3UGNWE&!M+>,]
MH=P<NR>VP_*2[!@K-Q3ZRFFX<RJ444[-QAAAF/9< LLL"PD0QC&)HL$  !M>
M][WOLM:M#,[RW=.7Q(C,8%>\N_+M[D_"VF\.D&X9R&/$9[)S,X-__O8?@S_W
M(CD&SES,97Z.I?P/6OZSW;RC VEO&W?M#N#EV3VV'Y1R#9RYF,K]'4OX'IZS
MW;RC VEO&>T.X.79/;8?E'(-G+F8ROT=2_@>GK/=O*,#:6\9[0[@Y=D]MA^4
M<@V<N9C*_1U+^!Z>L]V\HP-I;QGM#N#EV3VV'Y1R#9RYF,K]'4OX'IZSW;RC
M VEO&>T.X.79/;8?E'(-G+F8ROT=2_@>GK/=O*,#:6\9[0[@Y=D]MA^4<@V<
MN9C*_1U+^!Z>L]V\HP-I;QGM#N#EV3VV'Y1R#9RYF,K]'4OX'IZSW;RC VEO
M&>T.X.79/;8?E'(-G+F8ROT=2_@>GK/=O*,#:6\9[0[@Y=D]MA^4<@V<N9C*
M_1U+^!Z>L]V\HP-I;QGM#N#EV3VV'Y1R#9RYF,K]'4OX'IZSW;RC VEO&>T.
MX.79/;8?E'(-G+F8ROT=2_@>GK/=O*,#:6\9[0[@Y=D]MA^4<@V<N9C*_1U+
M^!Z>L]V\HP-I;QGM#N#EV3VV'Y1R#9RYF,K]'4OX'IZSW;RC VEO&>T.X.79
M/;8?E,MGV#LUJYU-%27#^4E*93+9&H3J$^/Y8<0H(.>%AA)Q)Q;0(LTHTL5A
M!$&]["M>U[7V5LMV[RW=;N[ MNS&#%T8-GY=O@Q\+B.C^_\ <5FX<E9?G<I%
M\93!B8G&PXF)C#MK$QWVMB7(-G+F8ROT=2_@>M[ZSW;RC VEO&Y?VAW!R[)[
M;#\HY!LY<S&5^CJ7\#T]9[MY1@;2WC/:'<'+LGML/RCD&SES,97Z.I?P/3UG
MNWE&!M+>,]H=P<NR>VP_*;FP+H1U5:BLEQ[&$$PW.$+F^'CNJD$PC+_%8?&F
MM-N!N+[))$ZMA*1 VMQ)EA7"'?5)XQ )3E''F%E#X_>?27<NZLG?G,SF,.;+
M8^C;=;===/!;;;$UF9^]&N9B(F7!](>L'HAT9W7B;VWAGLO=A8<:+,.^S$Q+
M[I^C999;=,S==/Q6Q%;KIMMB9C[D^SV[-/"N@:$6+CY!$WS/(4!!4_S [("B
MG5P%N0&'1^)I!B/O%8:0IM<04Q8Q*%8K!,5G'" 4$KSCTIZ7[PZ3YG_%F</=
M]D_B843HC_NNG\J_X=4:K8C37P+UD]:6_>L3/US,SE]QX5T_H<M;/XL=R_$G
M1^DQ9C\J8I;IBRVVMW?=CU=3?,"@4"@4"@4"@C7;]E*]TF;WX0T24E12@4"@
M4"@4"@4"@4"@4"@4%.<U>?)_N:W?HQT&I:!0*!0*!0*!08RCA4-;F53&V^)1
ME#'5J]<ZK&!&PM29E5N;HZ&/;FXJ6LA(!">O<7HX:P\X1=S#E0[FCO<R]Q4$
MTJ;T"Y+WBM0HUB+=)Q=YJDQ*A+NDAQ2A*+O<T RMTF4$ ,+OL_,& (K;+VM>
M@\')J;'E(8WO#<@=4!HBQ&HG)&G7)#!%#L84(Q,J+-)&(LP-A!O<-]E[;;=V
M@XJZ.1YS0DMCDQ,S@VIPIPD-ZYK1*T) 48!E) DI#R#$Y84I9H@EV"&VX"*]
M@[+7O019D!@IVZWV%1(W=E)B![Y'&<>[(1%%D(R1;I'?=%)""@@*#?N%@#:P
M=EK6H/8;!H2>%6 ^'18X"]86X+@FQYI,"M7E65V*7*PC27LI6%67GV":/=##
MOQFR_P">+:'F;"H:>\.<B.B49.D#VT@87E]-86HQX=V,L0!ELSFYC2W6KVD
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M;QRT9O+8>4G!FZ^W3CVQ-;+[K+M%/"MFGP/7^(![.WXRY6Z+G3V;6MV8=*_
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M0%:C=-V9'?).L2;Y$D,++;KIUDDQFU9$/D=W(3D)J<6!NE"(*)<L;N]TAF7
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MI4/=&B!^=<(=NY#;:+<VKC\3H-OK#^E.!XT^2X7&ZG.EN!7O[LGH[F)=Z/\
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M*:S-FLOM%D*)/'S4(VQO17[0'4PN:4:4IN%=*D2W9%J4Y.6"P0=ZFE#!;>Q
MO>2L:OE7OJ*4"@[(*!0=;4/P'E?31JFU<99@T'2YOP1K->8#D^505F?XRPY-
MQEFN(8P9,02@21!D1P88;.\89,B,+9%1MS7]O7L3F0I+)0+4RNPDE337X'7=
M#NS&U(02+XQB$ZQUC74?"9]@/-V!L]XV%JCS1B"/0];DO/V0LKQZ4KGR+L*)
M;F&"N>.YBWQ*5MQR,MP3EQIJ\& 5)DX0@M6-)6M=M(V6D-I?$9UX.7Q&/]H%
MCSM (KJ5;7)6YR9E@&,W> 3M\QBMB!A[ID4W(AC'#7'%Z(M)=V;E6,5X1&.
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M1\'=8LX]FMJ%%HK@NFYN@6.R92S=AOE;LYGX\F3,:>+*=2LTBV*&&/S<1H4
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MN8S5D:FL'C>5%%XM%ST"DY,T,D7"W W(RS]VDC\#L\J,B@_FX]I9_C^U??\
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MK7"4H% H% H% H% H,DAOG?%?E(Q^^:6@OY05+SSYWMOR;1^^;Q0:3H% H.
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M+;:4LCN<,ZYL]7$NL% H% H% H% H% H%!&NW[*5[I,WOPAHDI*BE H% H%
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M[.[,VB=D71P:#'SNR2;+[[(\F('ES/O=F;RVAB1)@'GJB+J3E=%"DUJK@1H
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M%_-2L=T[ZWNP;T;_ ,,S_<%_-2L=T[ZWNP;T;_PS/]P7\U*QW3OK>[!O1O\
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MX5U$H% H% H% H% H% H%!&NW[*5[I,WOPAHDI*BE H% H% H% H% H% H%
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LF3.J-*?F<PI,4VR4LQ08!P3B 06,]E*( ,X5K!M<8@@M>_=O:W=H+JT'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tm2226999d3-tbl_trials4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d3-tbl_trials4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!;@.2 P$1  (1 0,1 ?_$ /<  0 !! ,! 0$
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MEK:<L.\&5]Z7HTS1I C<?+-\LGO<OBN[R2.VN'B0F-SPX_HGECRTC2]E02'
M"HTT%#3+SGW>9_EV:S6&7Q2WEI$Z("9L9:VLT;98VO!-&287 .87&CM%35M<
M4$%!7(Z1Q9*FZO9 L:$,<<YF<$@@D3P;"&-P5-3Y.D$:Z_YR.D%8G) H(7/2
M9(<UHS4QP3CP;),[W>OS7+F3"!\S!(7AG8QN +6%W>A[@06L)#B"* U"YAF1
MYM);FYC@D,38S)H'=;-I+72!G?F-I!#I TL:0:N%#3CBU#W!-F,$BBD ?WQM
M4-;^^-8$1!.W:1LD2T?N7/,0CYAY;_,FB( 2FB=U+4F6$-8"AB5")" 6]3/F
MF7VTNQGE8UX<UIKJ:Y_>![N]87U& .(+JC#6JBVR3-;R';VL#WQEKG-IWSVL
MKC<QO?2-90XRP.#*'$119"5%Q?9G#CB^\L;/03)_K2/W5"*K/A]=RB*1&6KV
M5WB=C3&9S)/(I2PS%M2;C:. @2)4 VPPU<H7;,ZPHLCH.U.89W(S.&Y#9&-E
MZ^V?+CD:Y[ 0^-C&86N83B+ZEV+N0VE"3HWN5;MPR;OOWHS%LS\NCO(X3'$]
MC'EKF2R22![VR 8!%A#<!+BZM0&Z<;$L 5SN53,BI&F0NT+8EK@YI7B5C8V,
MR/P@Y^+:(V[6*^F+R(;%U2PQQ1)#C35I:,;DI 028,1A6A;EUVVU@C-^YC;E
MX (;B=B?AJX1MIC<!1Q  KA%2-!7/-L7WMS,,K9(^S820Y^%N&/%A8Z5U=FP
MFK6DEP;C(:":BL_<=^&EBW#R61\=IBU/E;O+8URR2S0EY0%H7ML8(?7<ALT8
M6]&YF$ 4'2UBC^BFI8'1Z,>EQ"O_ !J;?2+4YOO%9Y=DQS>W<V:-SF-90U:7
M/D;'I(KWCG5<-![DMT.6]R'=+,,VWA&0W;7V\K6O?)B%'!L<3IM -*XVMHQV
MEO=-=I;KH#;23'=5QTQ0_'J+6(TVC/G%M@\ICMERF(29I03M<\')_*C!+(G'
MHR$4,*8>K7*]*F[2A!WAP-&*@@":.Z_,I<MRZYS3-WPNL8@7M=&U[26 :G->
MYW=XNY%'4=H-&UH+$>3PYOFUIDF0Q7#<RG<(WLF>Q[1(74Q->QK/T>&CG8FU
M;I%7 5/<;HGQ)+N!%5CU+K4'#02PB'NG()$XQ1''=]#H%M5SE+5BB++W5/"-
M&]\8'OY&:X!;O\\V0([_ +.RE\^?G+S?1QP>D[/&("'%VJH89<0&/_\ S#<7
M<UIW:JCM=UAFHRV:6Y]#VHC-T"P-[ZAD$)87"/A_6EV'N\-?T:B*#T5;UE(4
MKA!8"_20AS5/+>P%("B-+Y<Z1U"F<Y RP5J4'D.<[?F)N6D'K$#,2N6)B5!0
MS"PA-+V+876:9?9N++J5C"T NKJ8'$AI>=3&N((#GEH)!H=!6KLLES7,&"2R
M@?(UQ<&TUO<P N;&TFLCF@@N;&'. ()&D*YZ_P"*?(^TVF.O\ IF>R5BETA<
M8I&'M&QGD,[[(FDI&8X-+:YKMI42I4F,<$Y.^]'WNU2@I/K>SS %BLW>>Y/8
MR/BN[F)DL; YS2[2UIK0D"I T$_ "=0)618[L[P9E%'/8VD\D,LA8QP:0USV
MTJT$T!(J!K[XAO?$!6C%Z3M68OSI&F*%.XWIEDJ*%NZ5U\%CA39-718N;FB$
MKETC4M3>FF;TX-:HA"TC-TXK3DIP""3!%&:#?GS*QMXFS2RMV;F%X(JZK  2
M\!M26 $%SZ80""2*A8MMD^9W<[K>&%^V9((W!U&4D<2&QDO+0)'%K@UE<3B"
M&@T*J<;X\7=+)2ZP=DK*5'31FDJ^$K(DN0>19*9/&P1P5U>MK&]F-SF]6(2)
M,9T,",H]X'U8^]3"[T711-F^600-NI9H_1G,#P\&K<!U2%S:@1__ '"0S_:5
MRWR'.;JY=9PVTINV2&,L(POV@UQ!KJ%TN@_HF@R:#W*NR#</.4EE(H^YPBA[
M+?VV5O#_ !^..">,KDR%X?(QM&6^-*%6O D3FN"%2X$)^J[[0S59H4Y>AG[Z
MO+%UO#D=DY[+FZA8^-K7.&(5#75PD@5T$ FO !4Z-*RK+=/>7,&1R6=E</CE
M>YK"&$!SF4Q-!-!4$@4X7'"*G0N-3Q6N%OH=]Y"N[ !FA4?M45/K4#JK2H)2
M3+6]G?':2DK(XI.*=FH$8$T%IE(%111PU"K02@#ZH_99N>Y>_-&Y1&_%<O@V
MH(!+<!+0VCAH.*M10D4&FE16';LYM'DC\^ECP6<=SL"'$!^,-<Y]6'NFX,(!
MJ :G0#1U+,IB!-$]E;D"4GNB*#PZ&3*P9NO9SD:1Q*8HDPJUZ-K0KW!(O0-[
MI,9.)N84!YR<\HMP=2-B+'KI#O)S*ZDM8&[ --U)(R-@-2,3W $D @D,;B>X
M @X6G2%B918Q7UTX7)<+*&&260MH#A8TD-!((#I'X8FD@@.>VH*D_A?3=5W_
M ,@8M4]QSIWJV"R)EGKJ\68V:;E)$'2P>O95/E+V\MCDF$4XLH2(P(I3WJA*
M(@HP1W?BT7W@L+>/,;[*<IDO\NB;/=,<P",U[LOD:P-!&H]U4:#4Z*::K9;H
MY3EF>Y[%E>;3/MK*1DKG3"A$8CB?*7.!&EM&4.EM :UT45)7\8YM%^3;]QDG
MRA)$)!"9M(([8$D5@-.8XO%H:!:[R^QMBZ"CG"*M4);%#X285K8EC>$ B="V
M8#6ZV9U;3Y*S.K0&2&6)KHVCOG.?0,C[#B\AAKJ=KU%6G[N7EMO&_=R^(BGA
MF<R5Y[UC(ZN?+V6-C!D!'?-I2M0I Y3\41U#RONCCI5(GZ7--/2$J.KI;+7"
M/,Q!PNK;BM/#V[*-,48BJ)R=7,I(D*5*=]8H&64$TPTT!>8N1YZ,PR*VS>_P
M1R7#,08P./'H:.Z<X@ DD#54T %5G;R[L'*MY[S(,LQRQ6DF O>6M'!W3G'"
MQ@+B&M!.DT )) 4 GT?;:&8RV O$"?XW+( , )XV2U.7$"X.$Y<A;$Q\R<Y.
M:TM,72+G)T2ITYZX\@E2>K(+*$,1Q6A[49G8/MX[J.5CX)>\+#CQZ"3@#:EQ
M !)#02 "3J*T;LFS1EW+8RP21W4'ZT/&#9Z0 9"_"U@)<T N(!+F@$DBN6\;
MX+RQYH&Z'9P@=K,_)FIN0E15"96J\#<W-8V6RX?8<I4N+PRN3 F=6P]N(A9!
MY3@-T VFH%>C_P""V S>@FWG@CS6VC9+ [)9[267:"I-8WQM #@X@UQD%N'$
M'"FO0NHM]R[J7([R62"Z9O%:W\$&Q- ,,T<KR7-+0X4$8(=CP%KL6JA6+J?C
MI=QTMG4'45T_,\EK!U3,5BHY-X%$T<(>U[OI@:FB3O4F5M+&S.3V]"TE;R#U
M(#' [?>IM&[S=G-\M$$5R)F.AG:71EM7%[0,1+0T%Q#1I<0*-&NBYMN09P;J
M>S=;O9<6S@V4/HP1N+L+6O<\M:TN=H:":N.AM55VKBER3>5,O2(*0LC9]?S)
M+7LXTKB[BVE1*;*S%P"XS(5#D4D3M3J2%M4&GEG"!X,G)&<=WA0=CRV_/<FC
M;&Y]S#26,R,HX'&P4[IM*U&D 4UDT%3H5V+=G>&9TK&6=QB@E$4E6$8)#7N'
M$T#7:"2#J )-!I7>:N/%D,;U>L>L&D;?.>*2A#VY3=(R:(CGZ*GL!S80R22Q
MU#M&)$E.B 3%P>^1DC0*7,)Y0DJP =;V.E^;V<L=K-:7-N([F5H83W6U;IQ-
MCHYIQZ-9Q!M#B:5<BR',(9KV"_L[LRV<+C(&T9L7: U\I<QXV>GO06E]1A>.
M&R@41;IL>)DZ:#.ZUK.!%#-DMPT+D^I29Z(K4#/<8L@5J).UIYR \!C*8I1E
M =B1Z,2;.+WH69/K3+Q-L#*T/[K74-.#OZ.(PG!^/0G"=#J%8?J7-3 +EL+S
M&<&JA<-K^K)8"7M$FN,EHQC2VHTJ2'3A-RU94KNL=./=HI"(_*4,+?\ OXPL
M&<R2-R$,I$B=TQ6C%+:0>I*,(\*. !(%2482(W1I8P!PV;RY!(YK67<!+V%[
M>Z'=-&LCCT::#30@TH0MA)N=O1"U[Y+"Y#8Y1&[N#W+SJ#AK K45/<U!%:@A
M0O9-93^GYBZ5_9T3>(5,F8MN/<8^^)O!UI*5X;$;TSK2^]$80J;W9G<"%250
M4,PE0G. 86(0!:WO8V=[:9A;MN[*1LMLZM'-U5!(([!!!!!T@@@K49AEU]E-
MVZQS&)\-VRA+7"AHX!S3V0YI!!%0000:*Q,REA)A$PB81,(F$3")A$PB81,(
MF$7U(^(?ZIW%_P#_ .=Z4_X;1K/Q#O!_GU[_ +W-^\<OI+NK_P!,9;_N%O\
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MD5&IW>8RI@8@^&K6IJ(6.*5)L)QI(2Q!%N[->VEOIGD:T4!J=0!- 7'4T$Z
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M$AT,+B,9T-J50E]*VBV0<-C.$07)8AY.9GDYP-4MNEB)DDB\ULC+ZY,6ENY
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M23''6GE/$ZBO*AK[M*SFZT.0-//<\67FQV!N K@6?')8R5G<TUA=OL4A@(3
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MM" <;TUH55?<4Y*T=<7)UH;YY+I5QXG%<\G9I#)JBK.=K*#A5@5LJKQ\0P^
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MXFB:=M-2C;E9RU.3$F79@QDL+("8[B.X(PE@+'RO+FL>[$"&4()#"6EY=7$
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M#%%FZ@5?)5SMYI2Q6UE2*MS+,L"9R*/(4R5J@CD!\"YLSLD*_P"QQ.(2M "
M\8= _)-[EU[)'F+(XG.=.(@PXF=W@:T'6X4H0>^IV%.8Y3F,T6;,BA<]UR(!
M&<4=7[-C0XZ7BE"#WV'L+%'LU+0K&B.>'':WK>G;;":TK&P=2>32P]DFC^1I
MM;V]Q3@"WLT0BTBDZM2O-/!HD.T(-:Z>DT171OHV>\%M<7N2SVMJPON)(Z!M
M6C22-9<0-'P_!5;C>JTN\QW=NK*RC,EW+%A:VK1I)&LN<UHIPZ?@JKNXM6K4
M7#%1;=RI;58+<N-UIVT*@I2(UY&K(2LK#)+4C2J$.UFV&]6;!:^1?-V-Q1W7
M"0-B$ES5N#B85I0!(26(P=K,K:ZS816AB=%:"5CY'.+*D,.(,:&.=I+@*DT
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M2>&GWWW:H^U_,?,VJ?0''L=NUT5G.?X2>P&Y_0F<Z3PT^^^[5'VOYCYFU3Z
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MWW:H^U_,?,VJ?0''L=NUT5G.?X2>P&Y_0F<Z3PU[ OM3W]ZQW/\ ^QE]J?\
M[LC_ /Y_>L?_ +H_[S_^F_[O_P#I\\L]6V/BQ_G.QUG]5R->KLZ^RO%/4^6^
M*'_4/H^MWZGD:]79[[LK1]SC_7#Y*_WRSO\ GU5GT5]UOV<Y)_+8/S OYZ??
MI]LF\W\ZNOWKEBMG>+RE,(F$3")A$PB81,(F$3")A%K&L[_S#F?]HW3_ *T9
MGA&??YU=?MW?*OV'N?\ ]+9?_ND?YH5B9J%TBF=KX^6ZZP1DLW43 S0*4.ZU
MBB,GE\BBL&;IH[-IQ"9T1P?<S?&$^:C:5*D!2L34!6!*:+O#=@%TZS7/S;+V
M73K+:8KIC0Y[6-<\L!T@OP-=@J-(Q4J-55MH\BS62R9F.RP6,CBUCWN9&)'#
M01'M'-VF$FCL&+"=!H54F[C%?+A^D 9];O$<152Y(6.S'J=JF>N8Y I&YF!)
M;HK+9//7*-QYAEZT\6RRFA2I+<AF ,#HC8BS-!H?G>5LV5)FO=."Z,,!D<]H
MUN8V,.<Y@X7@8=6G2%<CW<SN3;EUN^-EJX-F=(6Q,B>=3'OE+&M>=082'U!T
M:"J4_P#'J\(S9;'3CO5<V!9\J RG1&%H6)8\O,S1R0OK8XZ0LMF O)F#-("=
M;&A6M@U2167K8BC!AUO>JXLVRR:R=F,<\7H4=<;RX ,+>^#ZTP%OXS74(X0K
M<^0YS;YBS*9;:;UE+AP1AI<Z0/[PQX:[1KOQ7,Q-<-1*[$KX[6_#&Z9.[S%T
MBALKI2F16$NC,MA<V30)>L>4D=1MLU,ADB?PQ1T6/RP*0E*O\'4&J"S@ !L2
M<_1<09OE]R^..-Y#YA6,.8]A> "XEF-K<0#14EM0!0\(K5<Y!FMI'-++$#';
MD"4L?'((B7!@$FS<[ 2XX0'4)(( [EU.&8<>;I@3$VR26UZ^-#4Y.,<9@B%X
M$L<&M[F,=)ET/8Y,RMZM6]1!\ET5/"Y-2)U3HU3BAT(].686$0M3;YOEMU*Z
M&WF:Z1H<>$ ACL#W-<0 ]K'=RXM)#7:"053=Y#F]C VXNH'LB<YC> D.D;CC
M:]H)<QSV'&QKPTO;I:" N^\<9.0,>L&%51(*BG+!9=A,""51*"O;*H:)0Y1Q
MRV[;2O2AG</!UC,W>#L2Q08:N"F"0D3C4&]X1KK,ICSK*9K22_BN(GV4+RU[
MVNJT.%*BHT$]T  VM2:#3H5R7=S/;>^ARN>UF9F,[ ]D;FEKRPXJ.+30M%&N
M)+J4:"XT;I5QPKASR8L:R6JI()4<@E<[?8FW3QE;V54QK&AVA#P(HIIE[;+R
MW;YG+8RYJS@IB%Q:\28U9OP<(]GZV7JS<[PY+9V;K^ZN&1VK)"QQ(<"'C6PL
MIC#@-);AJ!II32K]GNGO%F&8-RNRM9);U\0D:&EI:Z-W>R!^+9EA.@.#J%W<
M@XM"A*<P:8UG+Y# +!C+U#IK$W12RR2,2% >V/+,YI!=Z<D7(E( &E#UK>A!
MWT;"86((P;$$0=[V5K=6][;LN[1[9+:1M6N::@@\((6GO;*[RZZDL;Z-\5Y$
MXM>QP(<TC@(/W$:1H5J9?6,F$3"+]!"(8@@ '8A"WH(0AUL0A"%OHT$.M=.]
M[WO?Y-837H&M3$X<>+Y:EB=N7TW9A#BJ?&^+%-_S*D)J_4N=CPIFV&G(B$!B
ME-,UAXPA T&! Y;[X.^HZ!:WO7,S?*Y&E[;B$L#2ZN-M, TE]:Z6#ECN>RMM
M)D.=Q/$;[2Y$A>&4V;JXW&@CI2HD/(/=]A4YUHVZV*;NU9OE/6DS60PM"J0/
ME?.M?2UNF[*PHFCYP+'MVBBMH)?FYH2,/^>FJ3DX"2TG^.$+1?[[*X\SRV6V
M;>Q7$#K-[@UL@D86%Q.$-#@<))=W( -:Z-:MRY-G$%X[+IK2Y9F#&%SHG1/$
MC6AN(N<PMQ!H;W1)% W3J5BM\>?79N?GAL9W)P:8LB1N,D<D:)0H0L*%P=4+
M&@5NRHHL1" A:\N2=*4(T0=&'G! 'I%OHS*?-%&]D;W-$CR0T$Z7$ N( X:
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M:&RODF,Z?16OE[2XL=C2N:1FHP/,P>&1B;K<&F=>I1$*31#95#\8:J 5I(N
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MN-&C0UM3H;4TX234KS3>_>:?>[/),ZGB9"7L8P,:2:-C:&MQ.-"]U!I<0*\
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MX,/:9:#3PC;S6_?4&"V6;KK/WHM]Z+HW^3(DO;*.782S1-GT=R7M#N,:":_
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MK'N:UI+@ XN-&AI)TEQ(#0-))T*U'9WDSWQPQ2/DB:YSP&N)8U@)>YP JT,
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MPMVP[T+->,SM'-$C2\P%X:'AKBPDD-%' 4I4]_WG^TM6,XL7-$K"]UNYX8)
MQY87.<&BC@*8:FF/]7_M+HL'&&W) 5!@ ;8XR/-IMR1VJV*2N;Q&*2ZQ&UP<
M5#2UKHU'GYY0.'@C\X)1DM)JP*0M\-UWC;M6/6PZJ?F-JS'I<61&CW-:YS6D
M"I!(!&@=]2N'\:BF3-K*,R:7.9":2.:QSFL(%2'. (T#2ZE<'X^%6^PT/93R
MT262.#.FA,5ATH%!Y-)K$<T,&:FN< (5*#826"0G(G-YF*0E&,:IJ;TZM>A)
MZ#E)1)'29JM][;L>V-IQRO;B :,1+>5HT!O$XD Z@2="NR9C:L>R)KC),]F-
MK6 O)9R^YJ TUT.<0"= ).A5H[C/;25\<F18VQQ.0RUZT6L]2H$ZA;A FFO)
M XMC,PR=9/6A]<(GM(\/KVB;4Y1:LQ4-T5EH>JTK[X@-(S"U+ \%U3(6 87!
MQ< 21A(#M !)T4PC%6FE6QFMD8Q(TN)=*8PW X/+V@DM#" ZH +CHIA!=7#I
M5W5OPMY!6E/'VKX]'(JU6"RR,Z$I(E.K/K.O'>93LH #2H/7!,VEC$78TF6D
M'$F$$,HEH#0K$?0/I7H=*+-QF]C;0-N9'.,!;BQ-8]P:WE/PM. ?E4U'DFEF
MZSW+;2W;=RN>;9S<9<R.1X:SEOP-.!HTU+J:G<EU+#:..=P/,:52A-$3DZ8@
MZP2$C.Z+FYIEKV*I&8N0VH-@B#BJ32-W)KME,\(=ADIA!3 +.UTB&F4A*ONO
M[5DFS+M/<Z14M&,T95PT#$=#=.G1QBN0_-+&.41%]2<&D EHVAPQU<.Y&,Z&
MU.G1QBM7%Q=MW]#3U>A"2&+X7%FZ-/LO:VRS:Y<K%AL7F;VV1N(2Z756BE!]
MBQV*R1]?$"9(N5-A9(]N*(8MA*6HS#Z/65KZ6+(EXF<2&DL>&.+02YK7TP$@
M D@'@/"#2CUO9>G-R\F03O+@TF-X8YS07.:V0MP.<T D@.KW+N%K@,><SULT
MPB81,(F$3")A$PB813.R4+8#O$(]/%NHK$(I,ESDV09WG\UBL'*FZYH5B;G/
M<9*DCJWJ%C*VN@!(U;R8 IB1+ #(4K230B!K$?>P,E= ,3Y6 %P:USL(.D5H
M#I(TAO?$:0"%@29C;,G=;MQOFC +PQKGX 148L(-"1I#>_(TAI"JY_&:VVU7
M/P25J8X>SUA/3JOF<NE,MC+7#4<^)$X:U&&.1^5#T$W<CB6TQ2$+")SUIOV%
M<+84(M*,H&8VK@S9DO?(S&UH:2[#HTD4JT::=U33W/?:%0,ULGMC,3G/?-'M
M&M:UQ<6:.Z+:58--.[P]UW/?:%U1\:[L!8*:L@P=0=*%D2#8*,Y.\1XZ(JJY
M$S&2'=E$V$!VW =UN4QDF*C7_;EIH(**,ZU0#98]!GUA9[ W&/\ 1AV'4<6.
MM,&&F+'71AIB/$JO6MAZ,;O:#8A^ Z'8L=<.#!3'CKH#,.(Z*#2J1**4F,6A
MY=@#70N0PL<K3P<Q_B,[BDD+12I2UK'DAJ=&MN=3'YG J;FY08F5JTA"%;I.
M=X*<=U)W>5QWD4DNPH]LV'%1S7#N:TJ"10Z2*@&HJ*@5"KAOX)I_1J2-GP8Z
M.8YM6U J"10Z2*@$D5%0*A70Y<7K?8K(9JMD3?$8Y(GF"PVSP.K[9==-\!;:
M[G\;9Y=$ID\V6;*/F VL;W'Y"@.3F#<N^/.6ITI01JSBB!VVYC:OMS<QE[HP
M]S*!CRXN:2US0RF(D$&NC10G4"599FUE):NNXB]T39'1T#'EY>QQ:YHCPXR0
MYI![G0 2>Y!*J4LXBWM!+"F%;S",M+"YP.%L=E262J)A$E=<)JVE>H[J'V W
MV4V/2Z$/\1F9\N:B&A8WKE0'%6X$IB._4"V5JF+-+*:!EQ$XN:]Y8!A=CQMK
MB:6$!P<W"XN! H 2=&E4PYUEUQ;,NH'ES))#&UN%V/&W%B86$!X<W"XN! P@
M$G1I5M,_&^XWN36S#4L4)32>D(C,9W93*ZR2+,Z]DBL#1F.$E=FXAS>DHY62
MD1@T:7IGTO$H),+.*T,D83-UOS"T9'%,7?HYG-:P@.()=H -!W/_ -5*:CI5
MU^:6,<4,Y?6*X>UC"&N(+GFC0:#N:GE4H:@Z="@W,U;!,(F$3")A%[V?_C8Y
MXI_Y OSK_P"5+5_SC_7#Y*_WRSO^?56?0?W6_9SDG\M@_,"_G7]^GVR;S?SJ
MZ_>N5K\67&T&6^J_?J7*2JK-C:A^D\6;EJ?:I*]'QJ*OCZXQXU*$90U'SC9V
M]0A" !A0QB4:T$PL6]##G;]PY%<[IWEIO*7-R.9L<4KFFA8))61MD!TTV;W-
M?4@@8=((T'5^ZJYWILM_\OS#<H,?O/;.EG@8X8FRF&"65\);H)VT;'Q  M)+
MP YI[H;)IE)N.UZQ%EY*QZJ]\;+VAG(2I(E9,..3IQUE;3G)))I:\:0,+PC)
M9ESTP^2E#JXE"0E'H@;_ ,^\)$>G4:\6RVQWQW5S&7<J\O\ UUNI<Y/=RVTP
M)])M&QQX68I&$O:R3&V*,AY:\_JL :]B_2^=9I[N=_,H@]YF793[,[^V6\67
MV]Y;D V5^^:;%)@BD:(W21;-\\S3$UT8_7[4OCD$]VE"D<]Y>]I6RS:MHI(W
M!LXB3J3U$4[5I%5$C.>FN%1TAIEL26[CVG]X?D;VXFID[J48>K":$M. [_$%
M%E\GD69R93[N]R;G++VXAA?O#!%=EES*(PQTTA?%*-ILV1EC0YT1#6$$O+>[
M<3WV]620[P>^'WFV6>99:7-Q%N?=3Y>)+* S&5EM"([BW=L=K)*V5[F,G:72
M!P;&'_HV-;T9#0=8$W.S-R2K80UV2V]E%^DN 0))!8VTII+R+)W,$WS@610I
MJ2M$AG;>(OK-%J2#%'?DA-WK_-=;+N6>]N>.W:DFDO[J3)7[_P#HUQ.9Y'F/
M+CL3LQ*7E\<#M56N#:.+?_<TV,Q]W^Z[-]8+:'*K&+>6/W2^FVEJVUAC;-G
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MV=G5K@(J#@_^,:M&D[/8";$-(IM0:G$J+4V1-A(!3(F[N7HD!((VA],%'$
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M3,79;:B$NUD-:[TAK2?_ '-IA,H&DC 34-%,C?499=Y*9]U #E#,XOG7 8-
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M(\ @%P;1@(P@VBZAJN\K&J(I58E+)XQQ1XUTQ6)Z:S9N&$1JY[&8-O<F?&!
MLV@<5SK F69R58@<EJ8LKRFSMNO SR!KTZDJZWTFS@E(CFVES<2/[AN(QL-
M"=( <6@$ ZG'2#A(-YGIF7VLQ$4YEO+J63]&S&Z)AHT$BH >6M!:#WKG=T#A
M(-^L-^1=\D5!J;HNJ*2":<9NT%M'E1<T_959[DBMZ)VP+C]+95)J\.4(FC4T
MES9+:.6-9* DI.-5M\0FD "WD+E:6P^QD9'.+2%S8;BQ9#&TZ,#F;5H#M>%I
M;(#733"X'NBT''DRZ:.*Y%A ]L%WEL=O$PBAC='MFM:_2<+2V4.))-,#@>Z+
M6G'R*VA&I+QE[0<]V>(Q');=%JT1-8E"U+\UI75S3L<[L^42XEE;E2HE:M3Q
MU)*$NNG0.D[O^]*[\81A#GRVTD>8V.$.=%#%(USJ&@JU@;4]G"?PK936DL6:
MY:&->Z&"&9KG4-!5D;6U.H8BT_!PK7QF\72IA$PB81,(F$3")A%(E0RUE@%L
M5?.Y(R?.6.PJQ(5+7Z.=!(OG RQN2MCRZ,G>J-Z3[\JH41A'09O0/\9^^_)T
MY8NHGSVLD,;L,CXW-!XB00#\1TK%O89+FSFMXG8)9(G-#N(N:0#\1-5E1S)B
M;D]\FKVO2(V1#)96]K6K8]OP6TFN?Q_PIXCU@R9YE[0F=&!(]*IO&Y^4B=PI
MW&/JT9;N@5!,":3HD/7;UF4RM9ET-G+&]MQ%$QCF%IT%H#30TPENBH<#A(U&
MNA:C(YFQY3;Y?-%(RZAA9&^,L=H<QH::.I@<RHJUX.$BE#70I6Y2)&OE/?=6
MW94EA0.)UY**;XP1IW6/<[C4/UQJ?:DJ*OZ<E\?DK6ZOK4^-2%B?X&I=F4]$
ME"!]2*RM-@5"SK2 8V6EV6V4MG=1O=.V68BC2[:A[W2-((!!J'!KJGN2#BH*
M%8>4%^49=-87L4C[ED\[@ QSMN))'RM+2 020\-<">X(..C:%9#=H+=]4<_X
MMN1\<5,=CCU7?*SEQ-7NKI.]QV!RNQX;?+]!'^'7=%6F0+F=-*WQ>CA9B&0M
M:0Y4^MVB$QPTYB/1JDK!R.SN<CEV=_B<R2V@:'@%S6.C#@Z,D5PCNJM)HTU(
MK6@.LW:R^\W;FV6:!SV2V=LP2-#GM8Z$/#HG%H.$ NJQQ 8ZI%0Z@-DV,\4,
MSU):G&FK!U="IO/N+W#*0NIB&W%+K$7.Z81,3I5>%;J+!L*S)+#(LZ!53H]Y
M,;R'1 S@5,1R8)>W(1!0[L#;UUU%F%SM'PLN9P.XHX1N;AC?A:P.<.Y#:T+J
M.![VI5^U9F+[V'-;S;26\=W= 5CHX1/;AB?@9&USAW ;4M+J/![RI'Y<RT]N
M<MY)R<J.9T(X)>/B/CM%*R:[)Y(\<Z*)L.WJ%H^L*[;+%+:+VM"NUSU5)<SK
M;;^M.3$GFO18T[:'96U2M<W&UM<K;EUTR<&<RN>612R8622/<6UC8X!^%^$5
M(PZ7:: .EA-EDK<IO8[D&Y,SI"R">7!'-+(\LK#&\"3"_ *D!NE^FC6NJE97
MA"&)]X961-K"A+F=PZ9>7L>NQ**8Q]S=["F3O85RVA%GN(MPW(+K9B&ZUEJ-
MT=3.3:F6DD[1&*7 9#>3UX:;FSF>R[MX8W@79@,?<D!K0V-A#C2C#'@+R"1K
M ;5QHJ+O+[B2.^M;>*0"^=;.B[D@,:&11N#C2D9B$;GEKB":T:"XT6(\0!!J
MSXTWI$[/8*G<7VVZTKB7TW85<72U2BU$DNU8<'>4]>SF(0>QY VLD/U#@/:M
M\99(P-JU&[MJ T9@5A3<$6TEVUQF$,MLZ4,BD>V1KXR&8<+AB:YS 2[%A#7,
M<06EPU%RW4_I%WFMO-:.F$<,KVRL?$6QEN!XQL<]@)=BP!CF/<"USA3"7+!/
M-TNA3")A$PB81,(F$3")A%L;Y)B;^151\/)M5#Q$3$5/<8HSQ[LN!.4SB$7D
MU?3N!SJPWQUD2F/2)^:UBV$6(CEY#\6_)"C&X"Y:J2*C2E2<81:#+\5A=7<-
MR'UEN3*QP:XAS7-: *@'NF82W"=- "!0KE\JQ99>WUO>-?BGNW3,>&N<U['L
M8 *M! >PM+,![J@! (*25Y;+HX0TI2T0E4=56YQ^Y"7P^32)*I*@:E5H1FZH
MS3Z:*6-%U\E6LJ>7G08RJ%C*O3$>$KT2 U*J"'P'9IA2-CK3.)KN5KA:SP1A
MKJ$X#&9,3"!7#BQAP)H":COJ511OL,_N+^=CA97-M"&N#2=FZ)TN)C@T'#CV
M@<": FH[ZE<R&B\:5<.."7@XLL""H[H,X!KZ?27PLEC"7 ";/5<RC>7*'CX?
M:XUY\21Q15 PDQH;\8Y@C*=\'M,-22BT-6'5.L[MM^<Y#'FT].$FSPG%@V&P
MVN"F+%B[O#3&6Z:%VA:-^7W[<T.\#8Y#8>LA(80TX]GZ-Z,9MG3$7!]7X,.T
M+-(!=W*P!DL"K^O^%BU'+&*#(>1[YR58TS0<DLYR>)4HIMMK^3F+WE3"X[8[
MA 2V5/-#BDB)X6,VCC0*5 $R@8>L$#=QSSSYN#$YYL!;FO< -VA<*#$6!U<.
MDM#N 5&I=)%<7-SGP="Z0Y6VU-:Q@-VI>V@Q.8'UPZ2T.IH%1J4P\C*_:N0?
M(F@HE%;7I-&T(^$/#-CEDM<;YHR/QEE<:PXOU9&Y]$]RF969$X(.P6J2LY[:
MG95CNA-.<B]!,,(3@.4DXMA.ZQL)Y98IB\WDY:T1R$D/F>6NHUCG82""7!IT
M<9H#@Y7<ORW++F::&X+SF%T6M$,I<1)<2.8["V-S\!:0XN#31NH$T!NN;S=R
M<XIRKH>:2FG6:7SJJ>*C91K;&^05-63!V2MN.4P*BC)3CG>,+F*VI-S$^!'E
MR=R,&Z)4[BXMAQ@R2'%4G1:M0PM;+;7L+93$R68R$Q2,<7RMQ&01N;CPXNX&
M@D!PTEH)5FWMV,FL\Q@9.Z".:X,I=#*QY?.W$91$YHDPX_T;>Y):UP%2T%RN
MQ#;=9SKE3S)D[-.((VQ8?9[2:A8S(I'+HQ"FNP)O7_%6N*0*/B@Y6ZLPGI38
M,J@:I8WDE=8J4EJ@"$'OAY:=:W$.6VD;V/,OIPD(#2XM:Z9TG=80:86N / *
M*RZRN[?)[&)\<AF]9MF<UK7.+&/N'R]UA!I@:\!QU"BTQ9UJ[I,(F$3")A%[
MV?\ XV.>*?\ D"_.O_E2U?\ ./\ 7#Y*_P!\L[_GU5GT']UOV<Y)_+8/S OY
MU_?I]LF\W\ZNOWKEBT6884+8BC!EBV PO8BQ" +99Q8B3B][#O6]@-*&((M?
MN"#O>M_DWG=EK7"C@"*@_&#4=HZ1V5Y4USF&K"0:$:-&@BA'P$$@\8-%57:1
M2!_TA"^OKP]!;$P43:%V<UKCIO1@T'04B'2P\[21,'0==!9?>@UT:_)EBWL[
M2T+C:Q1Q%[L3L#6MQ'C=0"I[)TK+N\QS#, P7\\TXB;A9M'N?@;R6XB<+>P*
M!<VY7*!.>WL4D?Q/(D>V\3OMX<=N>T&TGD_:':_:CPK:/:#_ !'5=_WG4_O.
MCO?R90+"Q$'HHAA]&Q8L&!N'%7%BPTI7%W5:5KIUJLYMFANO3C<W'IN#!M-H
M_'@PX,..N+#@[G#6F'N:4T+B)D<A3JVY>G?GDA<S]'DE82Z+BE;7T!T#7DY0
M \)R+H '6O\ %;#^371E3K*S?&^)\41BD[\%K2'?E"E'?'54LS+,8Y8[B.XG
M;/#^K<'N#F?D$&K?_IHKV@]D%1Z1^6)M%FVV6L4>DL?^;TU<7@Y,C^<30K;B
MWAH5IUFCVUZ9E*@*I(=K0PEGEZ%WO?Z",.LS3)77EEZ-E<[\OGVT<FTA:P$[
M-X=@>"*.8\ M>-%6FE:5!W>1;RLR[,O3,\M8LWM/1YHMC<OD+6[:-S!)&X.J
MR6-Q$D;M(#@#2M"+*D;\NE#\[2%RZH*QW7'K324VC (T@31[ZA @)--/&F;6
M\C02$Q/?BT206 &M] =9L[*TBL+2.S@KLXVAH)I4TUN<0!5SC5SC32XD\*TF
M99A/FM_-F-S3;32%Q J&MKJ8P$DM8P4:QM3A8 T: J)F2L),(F$3")A%K&L[
M_P PYG_:-T_ZT9GA&??YU=?MW?*OV'N?_P!+9?\ [I'^:%8F:A=(F$5W,\V?
M6:,R>&DFDJXM+CFA>[L:\ ST/EV/ <RHY)D80&DF(I$PIWQ>2F4@%H7@R]2G
M'H9"@XL=B2VBDF9<'1/'4!PUX74Q-/&UV%I(XVM(H0"LJ*\FAMY+0$&VE+2Y
MIU8FUP/'$]H<X C@<YIJUQ!M'+ZQ4PB817='9J]15JE+8Q"3H#9@T?-UX>"R
MS/+6HV<I)5.C"@5[.ZMN0OQB4D"X9185*A* 279NDJA40?8FMHYWL?+4B-V(
M#@Q4H'$<);4X:Z >ZIB#2,J"\FMHI8X:-,K,+G?C8*U+0> .H,5!4BK:X7.#
MK1R^L5,(F$3"*H-3LZ,3DA>61R<&9X:U1*YL=6I8H;G)N6IQZ,3K$*Y(82J2
M*B# Z$ PL81A%KIUO6\IDC9*PQRM#HW"A!%00> @Z"%7%++!(V:%SF2M-0YI
M(((U$$:01QA522S&73-UV^S"52.6/>]!#MYDKXYOKKL(!;& .W!T5*E>] 'O
M>]:[_P#)O?3EN&WM[:/96\;(XN)K0T=H !7+B[NKN7;7<LDLW*>XN=VR25WI
M-.;!G"=$9,IA,I@D9-^"MYDFD#W($[0)?H9NTR(3JK5EH-K HQ"[P'>=9HK>
M^C?>[Z*8;6TMB1;QQQN=I.%K6UIPF@%:5^^KEQ>WUZT&[EFE:S0,;G.#:\ Q
M$TK3XZ=A=U!:UHM<9,A399,^;H:<G6HSHD@F,B21DU(Y& -<4IC"G<2VH:=>
M:6$1P-E;":(.MBUO>LI=86+Y_27PQ&Y!!QEC2ZHU'%2NC@TZ%6S,\RCMO0X[
MB=MH01@$CPRAUC"#AH>$4T\*MYN72=:A'$&E8_*VUS<"7(R+MRAP/0N#HC3G
M%IUXV5,,:=6X)4AA@0&[*$866(6M;UK>\NO; UWI$@8'M%,1I4 \%3J!/!58
M\;[E[/18B\QN=7 "2"0-!PC02!732H"YE<EERR.MS OD$C51- J4":&56ZN9
M\=1K0 )$K$W-IQXFU.J"6H+V9LH&AZ"8'I_(+73#8;=LQE:Q@G(TD 8B."IU
MT^%2^XNGP-@?)(;5I.%I<2T'AH*T!TBM.-4]R>WIY W%O#NZ.H&=N(9VD#DX
M*UP&MI2['M*UMP51IND3<FV8+99!7>E V+?0'73O*V11QU,;6M+C4T %2=9-
M-9[)TJB2::8-$KW.#&AK:DG"T:@*Z@. #0N):Z.;F%$%Q<5S@%L0DM;<%:K4
M*PM[8G,--(;D6CS#-)4)!J@P0"2^]+"(8MZUK>]],M8QE<  Q&IH*5/&>,]E
M0^222FT<YV%M!4DT U 5U#2= T+H94J$PB81,(F$5Q'R^6*8\FB*F42)1%$2
MG:Q'&#WMR-CR16+9@A*DS*8I$VD*1"-%O8P%:%O8M_E_+O+0MX&S&X#&"<BA
M=08B.(FE?OJ^;NZ= +5TDAM0:AF(X0>,-K0'XERHY#,FV-.+*@?),@ASTM"%
MV:4;FZI8T[.*<HDP 7% 2>!K7K2"0EBUHT QA#H._P FNC(=#;OF$CVL-PT:
M"0"X#L'6 I9/=QV[H8WR-M'GNF@N#'$<8U$ZM>E=6.R>2Q!R"\Q.0OD7=P$F
MIP.L==E[*Y (/UH)Y 5S:H3*@DG!UK0PZ%WHM:_+K)F@AN&;.=C7Q\3@".T:
MA4P7-Q:R;6UD?'+2F)KBTT/!4$%5%I3SN:210J8B);+)>H\,>%2EI*>7V2'=
M6'9C@Z*#D853F9U8!;$<>+>^C6^D0LID-K;0ALICCMQ0"M&M[ TT'P!7(FWM
MY<%T(EENC5Q+<3G]DFE3\)7]C"6>^"OKQ"T\O\"9$12J3.D8)>?!6AN&,S9*
MA]7-0>J0(A#*'WHU @ WL.^C?Y-Y$[K7$V.Y,>)QHT.I4G_9!UGX$MFWV%\M
MH)<#!5Y9BHT<;BW4/AT*@&B=$A(B3Q."5.[%D+AE&[4$DN1(##O!5@BQ]Z!8
M6$WK.K,WH6M"[[HWT].7A@<:BA+='P<8["L':L%'8@UU#PZ>(]GAH5QGN"]4
MG1I%2U6I2MX#2T"8]2<<G0EG#ZTX",DP8BTP#3-=\+0-!T(7Y=_EP&,:2YH
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M1)')&=+7$N<'1QUV&'"W 0T?C$+=;V99E@]8MLG30QY1+;QVXQM,,L4HT/8
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M=+I&8^4A^CI^' X/^M3E9Y\5%]1N.MC>+Q-ES)?/)U%[I=(S'RD/T=5%G_\
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M9T?+O)S>?6Z+[!%/_P!9+*_4B^P1_P!\1?\ \G_ZR?\ @[_S*_\ K/\ NO\
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MA$PB81,(F$3")A$PBZ@7! /J>\6I!^$JU+>G[U22+KUZ+POPQ$3T#WUJM)X
M?UI8>D9?4F=]K7>"Z"+F&H( <2G&>2!0H":,@@9@ G'A([S9PB2MBT,P).C
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MVF@U,LXV6ANL&>N964HY9PFKXT^.T'6-UP">G\A"ULT:C,E&^KDK;$5R]^*
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ML#C#-=#=(G!=X48IU Y5#4$FA21,,!!I4QCAI70=X8G[RV9")0W1@.CX]?\
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MG@EH(+@0*:?QM6L*X'+M*H<THI*:HX_<AUCBQ6YQMJ-M1-L>A9;;+G7E0_\
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MCKG%7EDJR.MSK!['FMP1%>G$Y^$Q^U+)+>B;&L-L,&O'M/,; )DKF6^.&O\
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M!U'>&#")@;Q<%/BXDVC^/AK\?'\*ZPN%G%(=P1GD".A:Z'=T.C#=#HY:@F,
MIPVL#,W*&=C3ZD&S-KU2U@:%9J5N6GC-6H$Q@BTYQ8-[#D8&8L5!B4[1^'!4
MX>)2[6%4US2T130*JH@SP2%HG%Y=D<9CY DC.C<I&ZJWU_6)$6S!E)CGI]<%
M"Y5L&@Z/6*#CQ])II@Q5  "@U*DN+C5VDJWX?0-00&9.M@1.$(&J7.Y\X5&N
MOAKNO"VGV=+")Y9@XRVN;BM:HA^D>:I"':0::B$6GIQ3$*%FCC2"1 @-:#4:
MT+G$4)T?-J4PY4H3")A$PB81,(F$5A1^LX?%GFQ) R)7A*[VJ\)7^;K#Y;+G
M':]V0QYOBJ-4U$N;ZL310*9@:4R<!30!"2'1 !:#W^M"R  *GC4DDT!X%C?'
MNS[XFQ.,UK#XW7#\SQZG8E:D$JY"CMZZBS(+$;K1!;[+8XZOW8@G) DD",
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MHAJ%BU0:H.&8<8,8J@ T4&I4DEQJ[25?F2H3")A$PB81,(I.SG%UZ\././\
M7#Y*_P!\L[_GU5GU']UOV<Y)_+8/S OA7[]/MDWF_G5U^]<L5L[Q>4IA$PB8
M1,(F$3")A$PB81,(O6OV5?ZDM8?ZXL7_ (@2//G_ ._?[3;[]G;_ .'C7UQ_
MTJ?8AE7[:\_Q<RV)9X^OT4F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(I))_@2OXHO_!UG//[\_"5UD?ZMOY(^1<N4JM1RJ_TI3_'G?Y06=!'^
MK;^2/D7*3_KG_E'Y5U\K5M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB812=G.+KUX<><?ZX?)7^^6=_SZJSZC^ZW[.<D_EL'Y@7PK]^GVR;S?SJ
MZ_>N6*V=XO*4PB81,(F$3")A$PB81,(F$7K7[*O]26L/]<6+_P 0)'GS_P#?
MO]IM]^SM_P##QKZX_P"E3[$,J_;7G^+F6Q+/'U^BDPB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A%))/\"5_%%_X.LYY_?GX2NLC_5M_)'R+ERE5
MJ.57^E*?X\[_ "@LZ"/]6W\D?(N4G_7/_*/RKKY6K:81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PBD[.<77KQM<Q[Q?&'E7R#9B(+2R\ELMF:(B
MEKY35=O;PJ 0\J2PGN3NY,"A>XK#-:Z1G'#&8,7Y1;WO/I%[M]U[6[W"R>Y?
M=9DQS\OA<6LO+AC!5@T-8V0-:.(  #@7Q@]\V_5]8>]C>*RCL,DD9%F]RT.E
MRZSED<!*X5?(^(O>X\+G$DG22L:_M#R+U<T%] U7>C6=K['V?3,V_CKKSB\S
MZQ<Q^K=W_P#E5CYE/M#R+U<T%] U7>C6/8^SZ9FW\==><3K%S'ZMW?\ ^56/
MF4^T/(O5S07T#5=Z-8]C[/IF;?QUUYQ.L7,?JW=__E5CYE/M#R+U<T%] U7>
MC6/8^SZ9FW\==><3K%S'ZMW?_P"56/F4^T/(O5S07T#5=Z-8]C[/IF;?QUUY
MQ.L7,?JW=_\ Y58^93[0\B]7-!?0-5WHUCV/L^F9M_'77G$ZQ<Q^K=W_ /E5
MCYE/M#R+U<T%] U7>C6/8^SZ9FW\==><3K%S'ZMW?_Y58^93[0\B]7-!?0-5
MWHUCV/L^F9M_'77G$ZQ<Q^K=W_\ E5CYE/M#R+U<T%] U7>C6/8^SZ9FW\==
M><3K%S'ZMW?_ .56/F4^T/(O5S07T#5=Z-8]C[/IF;?QUUYQ.L7,?JW=_P#Y
M58^93[0\B]7-!?0-5WHUCV/L^F9M_'77G$ZQ<Q^K=W_^56/F5ZH^R\>?GOPV
MKV0.3+&6M4I?)^2)%%HZTQ9E) EFKT2#:9E8TR)M3#,T'OC! +ULPS>Q"Z1;
MWO/P;[]+<Y7[R+RS@EG?&(H#BED?*\UA8=+WESCQ"IT#0-"^K?\ I9O!GGN7
MR[,;J"UBE=/=C#!#'!& VYE PQQ-:QM=9(&DDDZ2M@_DM!XJ5[O=SR'TF?E%
M?H?T2VY#4\EH/%2O=[N/29^44]$MN0U/):#Q4KW>[CTF?E%/1+;D-3R6@\5*
M]WNX])GY13T2VY#4\EH/%2O=[N/29^44]$MN0U/):#Q4KW>[CTF?E%/1+;D-
M3R6@\5*]WNX])GY13T2VY#4\EH/%2O=[N/29^44]$MN0U/):#Q4KW>[CTF?E
M%/1+;D-3R6@\5*]WNX])GY13T2VY#4\EH/%2O=[N/29^44]$MN0U/):#Q4KW
M>[CTF?E%/1+;D-3R6@\5*]WNX])GY13T2VY#4\EH/%2O=[N/29^44]$MN0U/
M):#Q4KW>[CTF?E%/1+;D-3R6@\5*]WNX])GY13T2VY#4\EH/%2O=[N/29^44
M]$MN0U/):#Q4KW>[CTF?E%/1+;D-3R6@\5*]WNX])GY13T2VY#4\EH/%2O=[
MN/29^44]$MN0U/):#Q4KW>[CTF?E%/1+;D-3R6@\5*]WNX])GY13T2VY#4\E
MH/%2O=[N/29^44]$MN0U/):#Q4KW>[CTF?E%/1+;D-3R6@\5*]WNX])GY13T
M2VY#4\EH/%2O=[N/29^44]$MN0U/):#Q4KW>[CTF?E%/1+;D-3R6@\5*]WNX
M])GY13T2VY#4\EH/%2O=[N/29^44]$MN0U/):#Q4KW>[CTF?E%/1+;D-3R6@
M\5*]WNX])GY13T2VY#4\EH/%2O=[N/29^44]$MN0U/):#Q4KW>[CTF?E%/1+
M;D-3R6@\5*]WNX])GY13T2VY#4\EH/%2O=[N/29^44]$MN0U/):#Q4KW>[CT
MF?E%/1+;D-3R6@\5*]WNX])GY13T2VY#4\EH/%2O=[N/29^44]$MN0U/):#Q
M4KW>[CTF?E%/1+;D-3R6@\5*]WNX])GY13T2VY#4\EH/%2O=[N/29^44]$MN
M0U/):#Q4KW>[CTF?E%/1+;D-3R6@\5*]WNX])GY13T2VY#4\EH/%2O=[N/29
M^44]$MN0U/):#Q4KW>[CTF?E%/1+;D-3R6@\5*]WNX])GY13T2VY#4\EH/%2
MO=[N/29^44]$MN0U/):#Q4KW>[CTF?E%/1+;D-3R6@\5*]WNX])GY13T2VY#
M5WM:UK6M:UT:UK6M:_YM:_)K66->DK(  %!J7]PI72$VH1B$(28O8A;V(6]]
M/3O>]].][_+_ ,N\O"XF H'&BQS:VY-2P5*_/DM!XJ5[O=R?29^45'HEMR&I
MY+0>*E>[W<>DS\HIZ);<AJ>2T'BI7N]W'I,_**>B6W(:GDM!XJ5[O=QZ3/RB
MGHEMR&IY+0>*E>[W<>DS\HIZ);<AJ>2T'BI7N]W'I,_**>B6W(:GDM!XJ5[O
M=QZ3/RBGHEMR&IY+0>*E>[W<>DS\HIZ);<AJ>2T'BI7N]W'I,_**>B6W(:GD
MM!XJ5[O=QZ3/RBGHEMR&IY+0>*E>[W<>DS\HIZ);<AJ>2T'BI7N]W'I,_**>
MB6W(:GDM!XJ5[O=QZ3/RBGHEMR&IY+0>*E>[W<>DS\HIZ);<AJ>2T'BI7N]W
M'I,_**>B6W(:GDM!XJ5[O=QZ3/RBGHEMR&IY+0>*E>[W<>DS\HIZ);<AJ>2T
M'BI7N]W'I,_**>B6W(:GDM!XJ5[O=QZ3/RBGHEMR&IY+0>*E>[W<>DS\HIZ)
M;<AJ>2T'BI7N]W'I,_**>B6W(:GDM!XJ5[O=QZ3/RBGHEMR&IY+0>*E>[W<>
MDS\HIZ);<AJ>2T'BI7N]W'I,_**>B6W(:GDM!XJ5[O=QZ3/RBGHEMR&IY+0>
M*E>[W<>DS\HIZ);<AJ>2T'BI7N]W'I,_**>B6W(:GDM!XJ5[O=QZ3/RBGHEM
MR&IY+0>*E>[W<>DS\HIZ);<AJ>2T'BI7N]W'I,_**>B6W(:GDM!XJ5[O=QZ3
M/RBGHEMR&IY+0>*E>[W<>DS\HIZ);<AJ>2T'BI7N]W'I,_**>B6W(:GDM!XJ
M5[O=QZ3/RBGHEMR&IY+0>*E>[W<>DS\HIZ);<AJ>2T'BI7N]W'I,_**>B6W(
M:GDM!XJ5[O=QZ3/RBGHEMR&IY+0>*E>[W<>DS\HIZ);<AJ>2T'BI7N]W'I,_
M**>B6W(:GDM!XJ5[O=QZ3/RBGHEMR&IY+0>*E>[W<>DS\HIZ);<AJ>2T'BI7
MN]W'I,_**>B6W(:GDM!XJ5[O=QZ3/RBGHEMR&IY+0>*E>[W<>DS\HIZ);<AJ
M>2T'BI7N]W'I,_**>B6W(:GDM!XJ5[O=QZ3/RBGHEMR&IY+0>*E>[W<>DS\H
MIZ);<AJ>2T'BI7N]W'I,_**>B6W(:GDM!XJ5[O=QZ3/RBGHEMR&KOY862O#C
MSC_7#Y*_WRSO^?56?4?W6_9SDG\M@_,"^%?OT^V3>;^=77[URQ6SO%Y2F$3"
M)A$PB81,(F$3")A$PB]@_9%_J,5K_:*R/]^WW/G3_J&^U.]_8VW[AB^QW^D#
M[",L_P!YO/\ %2K9AGB2_3B81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA%X<><?ZX?)7^^6=_P ^JL^H_NM^SG)/Y;!^8%\*_?I]LF\W\ZNOWKEBMG>+
MRE,(F$3")A$PB81,(F$3")A%[!^R+_48K7^T5D?[]ON?.G_4-]J=[^QMOW#%
M]CO]('V$99_O-Y_BI5LF7+4C:B6.+@I)1H$"50M6JU PE)TJ1*4,]2I/,%O0
M2R2"2Q"$+?Y-!UO>>)+].+6Q1G(KECRQXN-7+BBF^D(_';68G:P* IBPH5-W
M*626N N:XJOU<UM)%:\28X[*;3BZ$EXTE+C8T<>-="D!RE?I,:X'2J0214+)
ME5S"X[(YRBKL^?J-R-VF4MK5C4D0FP5</DEGP1G='R6U5%K%210^O93:S(WL
M+EUL8;G12_"4-2].!()0@6%$0IJ%##7VH/"E\11]P8[*G#XFF-5S*Z8+MEXZ
M\E78^PZXKEX;V&Q'FMDC?4"E78KC7SF[)@OS2R 7O#,4> Y8E))%HS)HHQ!=
MB4=IWPAAZ UW>;B<36)/2E5\DU<C8*BN^71AOX\W3Y2_1U>;G)HG6[VP-E2.
MWD99I7(E"DMI9]I#M.)Z390^]43$%1J;YBN3C<//6(W"]1 ,*XZ<E*>J"FUT
M!A\K62.7,=O<7:$O5E:#6!H=YZ^3^;>6[;5)0&,J0D"I"CTH"B) $W82 Z37
M@7+'.TZXJ3*WH55,3DLI=B)54'(>WWV>*JZL6.1.KD7&:T:_J2SXO;ADHB3,
MOK*4QB5312!Y3/I3<*-^2MA=O Q+VS2M1,0JI62\YN,"DVQ$1MA.K0_58JJM
M',(;)JQMF)V$ ^\G';+3?S:KF3P5HG<])M"0 -;&(UA;G,IS=4RA"0(:M,>2
M7"FH5@\#.3LUY/H.5CE,0LP4]-<R+7H.%":H#-*S6FPB"16MW)L'*(C8#FY2
ME#+=.,G6!7#/TE":,.A%IB"^]!H4!KVUGGA2F$6&,CY)2J6\II+Q#HULC'SO
MK*HH1<MW6E-T[J_Q&LVNTI)+H_4T(10F.NL;=)C.I\"N9 N&4<]LB9I:T)2G
M8U@U):;"BNF@5V-W(%;7L9<U/*-#&JPE*::RR/1IOA2V1V$GL:*QEG2R0%@P
MQE;(]N<*&T,5.&X/J;;:8"+C3*RCU2I(D"Z*B5XU1I1SZX6PS2H<BY-T\D(0
M0VN+&<EJ:9-KLW-5>6ZI7IJWGSNYLYB]O:83+=-AQR9V4FE(-) :4F&@3B":
M)1,07:4<[>'"))(5[AR2J1K216Q('5#X>[2YN:0)9]:049M:,1'E$:43D&P4
MJXM0RJTNCD+FDT-0G.,)+,, 2H4-6'STC9\GX:;X_O-?VG >07-"1\0;2=#5
M#\FDM<26.T)>UON+<%B&6V*V.8,[G38$BY"\$%'$IG LT)(M& 'DT48M5.-7
MM<W:+<1J.AUJRZ56LW.1E20-38[O&8XC<'.1R>+)Y."!^5J]3B3)T$[9B[#.
M+CRMT;%"EI:7D?@K@J2&!'H,44EP"F-WY2<?F"00F+OEHQQI>K#>(I'(JG<?
M#TB93)IZ4J-K^*NKH>B U1B5V'I H#'FMT.1KWTQ.:! 2H&6,(25"QPD'.=I
M/YN<;.+M<JX9+XM;[!R>43*2@+DVG9HD?'8B+I7)NACJ).CALJ;VZ3OYS2^'
M(3W';2ZHC4*G294'8-2HKI 6PS(5281,(F$6*W+[DXDXM5K%I*FC(9S/[3N.
MI./5-0,QY#'$LPMNZ9BWP^*H760;;W<3%&F4I2J>7E8!(K-2L[8J-+(-, $L
M1031<Y<KOVLY&G>[PD-$.-#-M9SZ563:; SO]2&57((B7'7E J?D<ULR?-+A
M6ZN+%2 ]>[[6(36P]"ET80(D\TXDFD:]2I#ASNXGLI:KYR6ZBAZY!8%35@O8
M)Q%IU!Y:WS"]G!(TTZG7PV71=EE:%BL9T5^#M3R:C RJ3B5 -*^^3*-%$J%T
M(WV@/$65OD;C33;@2GR4V1**;1-S[!;+BIS3;\.;7EY>ZHFHI3#68JNK,\C1
MY:L1,+^)L=71(F&<B(4%Z[[%$Q!6^@[0'C59J!4PT=<D:D%A2:M[AFM2&/,+
ML ,+G*BF%*QDGI$;>G%OAL?GRVOY$26!^9FE["[(4Q@3C@D$F%G[FBC$.!6G
M1/:#U>[\/.)?(7DA,(I6TLO/B_Q=O6R2V!AF1]>ULOY$Q*-G-KE)W8DF6)ZG
MK5YGSDM:V9SE;HF1G;1'%[6G&)5(P*(': 2I(K_G=0]AN-U-S>.Q&TRE+W=>
M.JXMTJ2T2W.=64PPAIG+ZR5E'T\./D$]<FEM4N SD+6F5KP(&A0Y[)TUB)5F
M0IJ%"7+7M):FK'A-;_);CW8T'L:6L?%ZWN1E0(Q0ZP+%B;^EJYJ=A%$6*VP,
MUC>J]8GB;- XP>J>ES)MO>=*"#.^4(524,T4%P J.);$H2]*I)#(C(EQ:<I:
M_P 88'I84D 86E+5.C4D7*"TP#C3S@)P''[T#0AC%H.M=(M[_+D*I7/A$PB8
M1,(F$3"+7E6')F\.4;5?$_XTM=3((#3ERVI1L$06>BESDZ7_ #*B7Y5#[)5@
ME<=?F)NI:(N-D,[E'&ARVTS4S9*/RR8E&68!LW*I!)U*T:=[7GA#:M30"S7&
MT/T>+Y76-8V?+8+)(_*G%]J-IM"8N]8-N[+<XTP.\<CC(T6U'7",K7P]46R)
MW-, )JDL*E,(U1 X%9<2+E5Q]BDY(KA_LUF02\^Q&:H-(/ WM4@)MJ10Q)8S
M%5BR0HFM3'$%D.U>KR'XAB/5ENAC,:!;HCP86C<A34+@0<L^/+E,M0)+9;=\
MXCR;+,9O"&B2H6"7G4RO-:[=;*_F*UE3P^Q7VL'),>0_MS$O<5[0:E4!5$E;
M3GZ+)4:ECK'NTIXH1FI:YE=K<EJYD;R_<<V7D>^S"M*VM5MA3Q5 E#&T/]UL
ML0&78\FA-3(W9\)/..=W-5MG;1[4KE.DY)Z@$T48A]Y9&3;EEQUKN0@B\OM1
M@:WC;O7<>/"40[NS:VR"W-.VZM87I^9FUP8F%[L03*:%E2+5)"AR,,3 ( ,2
MQ)HZ%-0LB,*4PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB810=R:=KN8>.MZ/7&F.LDNY#-533]PI&,212G2,3]::6,.9T&:W4Y8
MI0HO U<B G"(!ZA,09T]X8>2 0C0%!K31K6J^KN?L,E/&3G!<3GR(Y,NV^.'
M&DIXO&B)35M$5?SZX@3>(Q2V)';TQ/@KY7=95PZ.)T0&T.4:-7H7J-+ET:5;
M1&.!:@2,4JFN@G3^%9%(^TCB3':7):(V%7\OB%7\<8#Q)=]6W(GNL4P9M,>5
MC@[,L$CIR$N;H$S HE3\K8VMO/4E(VXEQ.6C<3VY&!,<:HIQ:3Q+)7CMRTKG
MDG%+/E<499K&4]0SR05_,$,I01]S$<M865IDQ;_#Y#6LFL*#6'$GV.OB92B7
M,+LY!ZT1J)0$AQ3*D9$*0:J"V+M../K_ %I ;93MDI1PNX7*-M=)/CC*Z"(C
M=PJ9#")[89Q<0L N[CZP:E47B]:NHWA)('QD7-RL"=&81X6M1D'S11B%*K&U
MK[1IGD').H+F-G4^@/#E^[,CFMR8L.M;$A<:97>(37C7R-XQP%RD3D6W-3G*
MEDCCK7*Y,U!);GUUC[N 1*EK\*+.(5J%%&+37@HLI8-VCM+6 _2J%,40LPVP
MV.Q('647A"455205LR*PZ^F]I,XJLL.%6K**7?TK3!:LEB]Y+52= M928RLV
MM3DZ-0>&J*<0/PJ*WWM'UJVSOT8?9HY,0-C,X<7UR7F3](&:KH5;5?!J>S4-
M5*T#?!)]/"VU<H0K4[FL2N&M.30\EG-"QL$XM*HU6%1,6GXE?K;V@E3QRFXO
M+&I@OZYR(QP_I_EQ::YOC]:+;)@%$V5'WM;$[%MIG12J$L#I-)2WU_)EY[)"
M4KNM/-C[AI"W[") 2J43%\BI#9VJ-#/-D#@357]UN#&5R*H_C.9;B%GK5;5H
MIKR5J"&W;0\A2+DEIG3%U@]CPNP67J%:-E4*VU4X%!<TJ$KOC@J)B%5LQR%4
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+PX\X_P!</DK_ 'RS
MO^?56?4?W6_9SDG\M@_,"^%?OT^V3>;^=77[URQ6SO%Y2F$3")A$PB81,(F$
M3")A$PB]@_9%_J,5K_:*R/\ ?M]SYT_ZAOM3O?V-M^X8OL=_I ^PC+/]YO/\
M5*ME"M(E7I5*%<F3K42U.<D6(U9):A*K2J"Q$J$RE.<$9)Z<\D>PC +6PB#O
M>MZWK>>)+].+!3BEQKN3B55+#Q<ALQ@4EH6MB7-AI*=OZ>0%VU7U8[=7!=$J
MRDT3+(5Q&R%T#:%9;.W24+LQ=8WI4PU;0J4%'F+"@ C1P*((QV?,L82HO6#G
M-XY)J'JSG+/.>=6#5A>$%I$2^<6+9M[!J&1.!"-2U#CC%>]JN+B7)@G*7!9'
M0ELZAM$9LUQ,FJC#VJU4=4QV:MJ5(V<-6\=E5_(!\3N+7,CCH<>!KD;4&>+>
M5LGJ62I9:43OREN-)8,*H$Q)B+8UXW'3B:+1Z;P< 3U5 :='QK$6NN%MT1^X
MYQP:;))#C8PG["?A-P!F]VN$<E9+4<;!YER^KV52^OD DZMA>[ 9JWEK>\J8
M>N6E!2#DC<<<X;2E: Y/G44-:?[-%DO/NRBF;FV7V*NK)K-D>)!R=XQ<EJ":
MK*@*^U*\9C.,W%RL>)::L;SB:QP8C[#B5BUS7JHY:J;U;8M;%KP$:?K1MY9R
ME53A5PR[LPIW9K@U*IM/J:BK?87"'FOPNON,TA4RJLXDP1_E\YTLZ&2&@F(M
M\=#D#A$2:?"E--D*M<>X+'$YQZ2B]%-92JG#\BI#?V<G)Q;4L*#([3XD1GD+
M1]RTA;E4RBD.,*NJZRL=RH\^0IU2CD*Q)9LZ2AZ<+?CLK6I%Q3.M2H8NI$%8
MVDGF=\7M51A-."JS:X8\<;,X]ZY+.=G36"RQWY#<F)GR*+;X'&9 QMT--FD5
MA$=6Q<;G()$[*9(6C%#2Q%*M)&_>]"$(1>^_T J%4!3MK-;"E,(L"GSC?:=<
M\R)SRYX_@KF1_I]J*LJCY!UE9DKDL (6K*.>IVZ5':<)FL:@%HGA>VIGLY[9
MG1D5-1*1Q3&(E):U*:C-*6RJ:::A<EET7R!<N2_'[E?"%]8O,FK2M;_HZ94]
M+9;,(O"CZYO5^I2;!DL0GC7 IPXAL*)2R@6DH[9\<3)GIM<E!>S$0D9.E$*2
M#6H6L1U['2[FJC^4E(P::T\)MO?LT(EPGC;L\/<S9T\:L0NZ>55SRZ3#C[=7
M[T6V5BW+^4)S:PMZ=6H5DH&,D!FB]']">:JC!HIV%^NT+I2V:RG,YY'/ ZGV
MEO\ YS]B+J"1GY^R4D34^<<.5D0/E0IJ\*JW2EM4.,+?S%9SHC(<#D#6A/5'
M)-:#LL(*7 Z^R%D^I[/NY7"\(7R ,<JG:)&[=IBU\[;5A#7*9:=%8]%8AP6D
MO!J-PVOG4=;H5<NFLB9UR.6/CDX(6,@3D)0B+"86$I9M53A-:]FJQ6:NR1Y%
M?8_LOBP^QO@45*8/Q_6\>^.7)^+PQ[9[XN"*MLAA:V'CY)2<=2FNU6F*H]7R
M J5?-M?,/G*^"+=1]1I'M"M55.$TIH65KAP8O-TY>V+:\CKO@Y9E,\A)Y1%Y
MSA=;L4<K!O3C1;51UG5%:N[+Q\5/U3K(S8D7=4-+,S@PNKLLB2J,R12L>0-R
ML0](!*JK":UT45E\6>!/+FDYSV?S-/7B@Y96' :&\F*D;+%:;$L?=JW+!;:0
M0UDKZ:2:O7*FB8W%+":V>)!W(DX)6[IG%P.&I)5EZ'LG2J@-(IQ!;N\A5IA$
MPB818F<R>,!?*>KXO'6J4%P2RZEN&JN1-'SM2U;?VR)W%2\J2RF)*9#'=+&[
M<AB#\06K97I&!0G/.:'-3I.<0IT2<64$5'95H7[0MS<ON,-Q\?;8=8)1ZFTZ
MQ?(:&05+(I%:QC?*G$D@;-)Q'2Z%55K4<9')+HU4R;2GF.Q1FB1+TQ99@51"
M"118G7EP O?D99L1Y$3=QIB(7)'Y#V?Q2Z-Q*53IX@2^)\+>6CARWDRD,B=*
M_:'X;K:$B7Z96I <V&%15*6<J$N=!K#$Y,U5):2:\.A=HW@!<)$D-D9\JJTE
MO)[5H?:*G;-?906(J#EU3NN3*_-&.&:(+D9>];6B6;'I'H.NKW_^9BJG#\M5
MC#V?_&"R[UXT\2Y?(1P>-,_&"P.T%E-:(T[W(OG;,IW>,GY*TVSI+$;U4. F
M@,/88);;HX["B4/BA[.-:U@ HBB!$J15+02!V*J[X1V4MZUVCXZ,2)QX;VG&
MV/@QQ8X27NCY TXLM=3%1<56B61V.W=QQ"]- FLUQF;5-UA[E$Y&F UA7)48
M]K3PEG:/54X3HU:E>=E]FKR$<GBRY; Y/QMD#VA[0J5<XJEB=X1B43.K+ 9+
M4X^BH2PZDNV*)V?9\76QYO7JG&/2)F4/1NEP"##49(-&DF*IA/WZJAV?V9')
M-3#^3\8J&2\6F!NYL]GS*N'5PPU-#I%5, I::"=N3LGA,UH9E@D<?D[M!R5?
M*Z0-KNU.*=J7KU"9._G+5"TY6@/53">"FD+=A7C&[QF PF-OZAM5OD?B4=9'
M=4SEJB6E0Y-30D0K#6TM:,Q8%"-00+976[ZS8.C8M:W^34*M7CA$PB81,(F$
M3"+7G5'&2[N+#??D$XWO%4NU>W+=-J7O E-I*I6W./'V8WF[G2ZQVHF*1=A<
MT=TPE)9KHY25K;QO,,4@*<1LPE@"BB7 $JD C4L!G[L9I1%ZNN&DJ5G$,2P2
M:<!N-O#B+O4[<Y$.5'RRFN05V7_.K>F:=HBRMNVHLR0WJY#&A1&[ E5)N_"+
M12G1*151@X!Q*UPL,X<.<U[.T=B-52 QJYG0WD0R<;IW'^2-?SIYM6&<=J^X
MY*+SBCBEBS] )&WNT;)7%-,L--)A!I):!Q<D*!R1C5D.!1^-\:S%J#@%9L!:
MN*5=2N3P:4P+@E>UPWG14S2/<F;[*L_<VKZ^J[@$ M9";%%#="T,68N0Z\#X
M[-KF^CD2N/H%>T*0"I2B*550;2@X L6(_P!D=?#/QN;Z#-L.HSE*'L;+7[+7
M<G+7S+1!LFL;3:D2W!Y)%#]& 8FQ&W=:8T>$;4&&CZO2G0==;M51A-*=BBCN
M?P>PDG+FWFYDBM12"019[X6R\''RQ&+DK$%G(&WN*=;QV6U=:]:S=AB,@C<S
M:&6:N)#81)D1#>SM:Z)DEO[2:6TC4+2C35>E/(5Q,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$5@VC!U5DP"3P9!-Y?6RZ1-X4
M2.?0 ]F33>(*@*4ZI/((FHD;-(X\2_MIR?1B42]N<$6C=!V>F4%=\4,BPAM?
ML\F6^M<D7RW;*,<;&Y'</93P5=9S"(&T0P47H.;*9*IE1B%J5.\H,?;&=CY2
M<<!Q<%9S0WJ$Y(D+2E+,7E+IJJ2VNO72BMV>]F)#;',Y!@?+HLQF2\AJOXM1
M1X.A::-QY^@MH<.I%\[J,O&O9"H;W=6TRF*RI&@<PMZH"QM-7( ", ,D0B,5
M3"LOJ8J&Q:[K=WC=D\A9]>]ER'PPQXMZ51^"P]<0>-J)9VHJ+06O&".0F*MC
M.0F"IT00F&-0X'*%!QH]G: 7"D#C6OI=V1,7 ]O=I0.^)71_(PRRJSMN+W#1
MU=5Y"&1OL6NH-:U7O-@R^E5Z"2U5.9]>-=7*[M-AN&T#>GD9"-I$4E0C;"-[
MFJC#VU+]A=FQ"KD<TJVYK>LRS"W'A_R)X<V I>-,#5()U$^4,Q@5A6=.M/,<
M;FA)#YHBE]:M9D?*:$25F8D(3$A"'9>DPDJJ8:Z^)41Y[.RQ9E5$3CMC<[N1
M4YO>J+0@EKT7R66QJF6>4U9(JVCTZAC"7JOF& (*UFQ,IA%H2-HEQ[P@4K9.
MA>#2CCR0$(P)54PFFLU5PN79[*7F7-MAOW).TI5/W#BQ<O%JT)7+&""."NR&
M.Z)0VS-TE0&]I9&%G@Z^,/R'8&EO:4Y+8E;@$).I$ D0C54P_(N@T]FVP1)J
M;&V W%+HF:\<-:]X*7(M PLSF*UJ7J1JE#)5TJTA//);(E=L&;)Y("DCZ22K
M;30/:D*EI/+*0@1JIA^2BHI'9:UPT/;VNB=A/L58EW*7BKRE8XBW1UH,9(L\
M\/:BK.D*GKQL$H4C7&P-1 ZA8P.H3#=N)ZL"DQ.J2@. 40JF'Y5M)R%4F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+PX\X_P!</DK_ 'RSO^?5
M6?4?W6_9SDG\M@_,"^%?OT^V3>;^=77[URA:JZRE]RV'$JO@: MRELT=R6=F
M2GJ )$NC1@,/4*UJHSI"F0-Z(@U0>9T"V DH6]!%O6M;Z;/L\R[=O)[C/<V>
M69?;1E[R!4TU  #6YSB&M'"2-(UKB=U-U\XWTWCL]UL@C$N;WLPCC:2&MJ:D
MN<XZF,:'/>=-&M) )T*MO-5DH6:2/#+.8S)#8H^M\;>(^F1REHE&W!R5*T29
M:W,L@C[8:O9!JD)I>S=""J3F=6!4F3C.)T9BVV?.EN8;:YM9X6W$3I&2%T3X
ML+0'$.?'(X-?1P-*%KA4L>\-<1G7NZC(+*YO+*_M;E]I<,ADB:V>.?&]SFM<
MR.6)A?$7-<,51(QV%LL49>P.M2>0*65E*%T*G+,JCTI:DK,I=&1=K0%[9M\9
M&Z0(DC@1T[&D<"V]T*Z\@?0:G.[XLP(1@$'6?E.;9?GEBS,\KD;-82.>&O;W
MKL#W1DM/"TN:<+AH<*.!((*U.?Y!F^[&:R9)GL+K?-8FQNDB=H>S:Q,E:UX_
M%>&/;B8>Z8ZK7 .!"_<*KZ86&I?TD/8UKT9%H?*Y](S$Q>_!F6)0ID5O\A>G
M)4+H(1I$J%'L -F"#URDPH@OOC32P"C,\WR[)V0R9C*V(3W,4$==;Y9GB.-C
M1K)+C4TU-#G&C6DBK)-W<YWCEN(LF@?.ZTLY[N8M'<QV]M$Z6:1[M36M:V@J
M1B>6L;5[F@V9FR6E3")A$PB81,(F$7L'[(O]1BM?[161_OV^Y\Z?]0WVIWO[
M&V_<,7V._P!('V$99_O-Y_BI5LPSQ)?IQ,(F$6K&3<ZKLX^W#,X]RSIF QBG
M2>(G(CF0P3FH9Z]SB25S"^+ZJ "LB#W4SOD7CK(!_=&2RT"AH=6A<-N4KD:U
M& LT!/ANY5-2->JBF6D.5$\FMA(Z9LF$Q2-VU,>+D/Y8P%D9WUV P%Q^3/:R
M+26L),\*FUT<M/=6R50RIULA)0%IWDE["<F:TPDAQ X4@\'#18T_></(."G$
M?E[)8+$JU3\G;<A59S:2OSR\R6H.,#)-'R>-8+/LI\(1Q-T?(6UKXBB9=*#!
M1]*:\OJ(:M2VHNO.)FFE4XNYJLZ^)5V2KD)2+-:$NA9<,7.4KLN/M1J!0H41
MJPHG!['E,)AUT03;@ IW*KF[8Q'TLJCP%@=GZ9W9/O1JDK9:H^%4#4562F%*
M81,(F$3"+%KD)R344-8O$J$&0(4I;.4O((WCYJ1@DY+,."OHZ9MZYV]Z&RB9
M'0R2H5+133BD-+TH0[)/4)Q:&8$0] *":45-KODK)+"Y,<J>.::N&1M-XV1B
MG7Y'+S[!7J"YTJNMBE;Y&F]2Q%UZ6*))VT,04EKE %;J(&S"A%%'=(M )720
ML/1]I'>KYP:8^=%<\.F"70EOJJ:WM:D4=N208@[1ZKH,ODY3PFK1V4TBZMME
MVDF98>N<CF5SU$VHM-U  /)J@\).IIIHHQ'#BHI7L+M'8;#-VO)6^!.3C4_'
M"JZ-N#DI.I$^'0]WK2+7N!:^MB)GAYD:>@RJ2UQ6[>*42U&K<F33<UJT0$AB
M]4>:0G43%VE==G<N;=J/D/1U?R_C23N@.0%QK./L,N=GML#C9K39Y,)G$T;7
M&7T"*N4J%OJ>1I:\<@HGU#,G)P*)+ I7-*(@>A80D@]A2E5/)-197)?E+QT5
M0,4;-XUMM&.I4MW)RG@$Z17:R3=Z1F!8RF1#N-"8P0S8=A$L7"4Z4ZWO1.P;
M"*%(.DA92X4IA$PB81,(F$5H6!(72)0:72ED:6]^=8W''A]1,SH\J(\WN9K2
MA/7[1*GM(R212V%G@(V'K@(%6P[WK_%[PBU[I^T$E+AQK[,WD$T4FP+A]H4[
M\9&-QB[E:[BQAI]5R-IA9;Y:I$ZI:LD>[#3Q0AJ4H1 &G8A*QZ*,T(K0QA+F
MBIQ: >-2J\<JK,#RUN;BG$*.CDI=*VXR4SR%B\I47 K8=2U9=MHW-5+'%)"Q
MG56O*A;)&7:F%KB\/"9P?%1;4?H:1K6*@:2&0IKIIV%C[&>T3L]O<)W3=Q4+
M%HGR;C7,&JN'D0:H19KQ-J,LB1W#3S=R)99FRV$Y5W$Y>U$PFB_*K[(V-5'O
M#T@FH!91QI*\A47-%&+@.NJE@/*^_K,K&<N/&NBZQFUPT]:-RU+<$2M2[W.L
M*^CTNI5>A*&S,,Z9ZNL!V=G"UV-[;'B.F*V=N;T;2M&:[*D:I.%"I)4G5K5%
M+[052]4=V<M]1JFER>+\_IY1D/&R3:5GQJ85&FN^MGRS&AS&S(XB]H)P)"@C
MBA*,'AS. >CB%)0S0"V5I1,6@'C6R;(5281,(N%0)0%.>)(42<J"2:),2H/&
ME3FJ- %LDH]26G5F)R3#.C0AA*-$ .][T 6]=&R+77QFYFW-R)J*K;N'15.0
M>&V+8DXAJIM6\GWM=,6EEKFRIU 9?)6AK=..<6C\E5,[5 %S^-O$[(1;;"3=
M!.$<6$LV52"2*J<V/G+PPDNGD;#RNX[NJ:/0F064^+TEPP$QK:J[B<FW#91.
MEKMY=TVDQ&.2C9:)>X[-\$2'*$^C3 Z4I]F0IJ.-5,',?BD9"S;%)Y$T\H@Q
M#@[M9LI33V/*68M;'H\W2^1EB6$+C :+C<1=TSLY&_P3>UG!5J!%I]]9A*A8
M<\ENT.G%)O\ SQ0Q&M*]G;)Q,[-N)\_Z_>QV*[ITMI('Y;R4)<H\ZJ6R'N:1
MA1I$G'HXYO$B$Y <@K"MB4I0FBVFFB@NI7L"JRI^V[Q68R&QOL#D31D(F6PU
MBVR:*OEH1%L<(O+;91EFPF+O29>[$GLSK)E@^I;TZO1)RD1I&@AWM03HR%-0
MKV8N4W&Z4Q61S>+WI5<EB<2FBVMY&^1V;,+XB:K!0H4SJ=!U FM:K,%+#6A:
MG6D-X B5*D2@E02 PDTL8B5"L5?SWX1-:)I<E_+CCBF;WV+1><-2X=R0':-5
M"IL\$1^)S#PD#Z(DF+/[RH"G3.!FP)#!Z'_C.@L>PDJ.-7K N4-(6==]S<=X
M3.6A\M:@T\3-LR-IEJ+PEG/ES?Y53HTR<2K3@Y&,J!4A$YG$D"1HCG-,F&=X
M5UQ!)*BM.%=V0\G..D1F"N 2R\ZHB\Q0M4F>UK#(IY&F18E;H2THY!-#5&W-
MQ2D%'0^.N*9R=2=CT>VMJDE6H 6G-+-$2HU+J//*_B['8SN:/O(^B&F(_,>,
MV:"3+[;@2=C.KB;+CFR%SU.YF/\ I(IATQ<TXTK2Y%C$C<E(-E)C#3-=[A*A
M?EBY7<:)0PRN3QB^*ID;%!I?J 2QP8)LPO(&.<&-29^21%64W+5*C<C=&%82
MO1(P &>N0GEJ$X323 #$2H1QY7<96J%0>R7"_:B3U[9+80^P.<[G\:,B4ICR
MA<TM8)*TR$IQ,:CXP6ZO[>D-<MFZ0D*UZ4@PT!J@D R5"MB!\U>,=CGW<3&;
M<B!H./UK&4Q8IRQZ:TO@\]*9XTY:;6=&):-S=RU;G)=,Z,19&A.+RB5)D83]
MEA$82H[2C[D7STI"H>*\RY(P*SJ8L8)=,6E;M1MQMH-B".6JCJYF/6O@6F1,
M223J/)3>[^#MBQ64D-(1NJQ,B4#(/4E:PA(I4+**GILJLNHZML=<A3MBVP*Y
MA$V6-J0PPY*WJI7&6Q]4(4QIW0<:G2'+]E@$+]\((=;W^7"#2*J1L*4PB81,
M(F$3")A$PBP(Y:<A)U#+ZX3\5*S<R8A*.7E@6P5(+,,:FU]<(#5="U2Z6;.#
M8<T/:=?'5-@2MT&S,S<<Z)%[<WIERM88D5#3E)S)5).D <*Q?Y"<_GSL[^0;
MK7U_NUD<@Z4D?%:=<EHO)V>*U<"ZH@]U+:]<5U84,5ML93T[!)5#G5KN-B7,
MP@)"7E*I0N!1YRX*A*%,I50783IU+*!L[0^H5#I.(F_P:W(19<%Y6U_P[5U=
M)VF!CE;W:EIUU$KB@+@P.L9L21U\;#I!4<O*D6E*M[2+4J-*H3J4A+B$M$:H
MIQ#[ZY('V@U86?$ZS>H%6]OR28V]);]C,#J!.FJQ!8KJ=Q=E*ZO[Y=E2AXM9
MNKEF8J[LE%J.J5"R0D>$.BE-I*$].H)4#43$% +AVIW'P)<FO)EWR4DL#@?!
M*Z^6L@@C+&*B0QGYC4/:22$76!8U2N0QZQ4?(2I92RNC*K:#W-(QC*;UX"=*
MU?@@S%$Q#7V%,;9VE=)';LI%(X/<<#DM<SSBA7A4.EK#"=2"=O?-I[8(QQP.
MAAD;L&1L!2*:R=_T@4Z>US*J934B@QR)2)@!/,43$%D=QYY%Q7D@RV"]12-3
M.+:K*W;#I"5-LV)BI#D1/:M?#8Y,DB8$4EDM1G($+N2(LE0(X 51?>G$Z&2,
M!@H4@U60&%*81,(F$3")A$PB81?D8MA (00",V$(A:+!L&ACWK6]Z '9@@ T
M(6_R:[X6M=/[N]8180Q[M#.-4E2U\M;G>:B(LY+RF-B 05[*W!:O6\+YH]5_
MR)9!-#,WNCP!YA<G83R$Y04X@O0>]&VB5ZWOH448@K8K?M.^)UDQ=YFJ>03F
M&Q5JXO5KS(2/%AUO+HD5)^/MJI%XHO,H>E5MQKC(U1CRVFM7DU.2)Q5N(R H
M259*M(<?-%&(*!X#VB)T<Y-\UXGR"<7: 5_6B[B)%J.KN;1R&0B8&SJ[Z]MZ
M=N\8*DHY*9$9 <]M$' O\HK'\IG:$B!5X8>@$D< DJ)BTFJF&O>U0XJW JJ]
MII[=N6O)+:A4WGD:C<#J"9O2]"RU==\-X]6F7)'+:%/&&-=6EE39,4\A,<-E
MI4!8ENAC3'(S%2B8@=2N."=I7Q;L9+7BZ-/DMTDM6C+OY#P10^Q%?&"WRN^.
M4H10RYB=;D)C;X#.()(W9&0OCBCJGQ*%3UQR4L@A68G43$"KEEW/2EH1/T-=
M2%EM)*\K9]%:=\-*@:I0V)[RG-,J;]B%+[ZI;MU7S=^K-.%26>B2*F$E:>4@
M/<2EPO!]113B"OZD^6=1<AHI1\WJI1(W^,<@H;-)_ G(^/J6L2>*P)R965_7
M2Q XF)W**K"'J1(D6T*LD"\A8?U"@DDTLT!9 05DQA2F$3")A$PB81,(F$3"
M+#?G/R==>*],,$GB+&U22T+9N^B.,]--$B\.U%!6OR*M*-57$7B8B;5"):*)
M1,Z1&O#@04I1G+DS>)(4I3'*"SRR@F@[*B6Y^05G<-K;XI-]JS0ZY*?Y3VP[
M\?GEP+K],@GU:W4JJ6P;=@:Z L=<-IJN4UG*4]3/+.-C5H7:1(U:Q <%W5A
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MF7?Q,/AIU>[_ /U'G'\%<^;3[/M]^I&WOHUF?]"X]KMU/K3+OXF'PTZO=_\
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MGC4;\(;2$!D+KV-.LIC;4=OP!M.3R94J,#UHA:&9&6D$C@)/PE2^1K@0*Z2
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M6[?K^%,U>P]P;YU,8Z\O[<^O+2O#LLE.I0)-F[&H&4$P0LN/:2\$"HH5;C<
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MJ-FTZ6C3@!IP5K3[NRH/Y!]H!R_J+A^ALAQMVM@<C:_X!6)RXL2!0)BJYXB
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MMRN9TKRSJN6W%-*_C=#QUG_2.O04T3+/G!8ZQ5W\G:@-:0!KHO" IOHPDLJ
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3PB81,(F$3")A$PB81,(F$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>tm2226999d4_ex10-29img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d4_ex10-29img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -U M8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!W% "T4F1ZT9'J* %HHR/6C(]: "BC-)D>HH 6BDR/44N1ZT %%&1ZT9'K0
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M[,RG^1J5KZU5=QN8@I_BW"@"S^=&.U5/[3LAR;N'_OX*7[?9G_EZ@ _ZZ 4
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M1WH PH?"FD1Q "&9L#[WVB0%OR84K>%=-('E&ZC]TNG_ *FML#CZT=>>H[4
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M[/Q%;IB74+>Y?)&]H]F1] M07<6IW4#VFH:/;7T601B?:"0<]"OTZT 7=/\
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M_/\ ^N@ X]:,>]'//-+WH ,4F..QXI?_ *U)0 8&<\=<T8'3CTH.?_KT9/\
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M02N/\:LK?>)T'[S1K-O]R\Q_[+0!O>G-*<Y%<])?^*&N (='LUBQSYEUDY_
M=/P_&JWVCQJ\S$6>CI'GY59W9OS! ]>U '4^G;Z49YYKE]OC9AMW:*H;J0')
M'X=ZHWU_XKL+BQAN;S2@]W<B)/*B8@ CJ2?J.W>@#MLY''\J7O\ RS7+R6_C
M $E+O2'4'J\+C(_#-(5\;I]UM#(]<2"@#J/<@TIKEO-\;*<M;Z(V/1I ?UJ6
M.]\5HH,FE:>_'(CN"N/T- '2=>_%(<_C6"=6UY%D>3P\I"#@17BN6^G J/\
MX2>Y0 S^'=7V$X_=PASGZ9Z4 ='FDP.E<Z_BPQG:^A:TK;0W_'KN&"..0<9Q
MU';I3?\ A,K8#Y]*U<?]N9_Q^GYT =*<XZTTKD\C_"N='C.QR!)::A"O=I+1
ML#\JW;:ZCN[6*Y@;=%*@=#C&01D'!YH D*[N[?RJM<Z=:7J;;BWC?)R3CG\Z
M<NH6;$A;J D'!Q(.#W!J=) Z!U92IZ$'(/XT <^?!FEY)@^U6Q9MV8KAA^F?
MZ4^31-4B4_8]>G4$\+<1B0 >G8UOY[=:7OQ_.@#"0>([:,&:2UO?FP0@,1Q^
M1%0/X@U*!&>X\.7FQ>KQ2J_'KV-='D#(''TI#@]<F@#G$\9:<)&2ZANK0C&?
MM$048)]<UIP:WI=P?W.IVDF.RSJ<9]>?YU?:-7!4@$$\@]#6?<Z!I%Z&\_3;
M5V88+^2I;\\9H T58'!R/7BEW#GGI7-)X)TJ"4RV[W5N2-I\J7CKQP13GT?7
MH0@L_$+;!D>7/:(P([#(Q^= '1[AZTOXUS-M)XMB8"<:=<J.-R(4;]6Q4@\1
MW5LK"^TC4 P8@-!;EU_(')H Z*C/U[=JYZ/QEI#,4EEGM7_NW%LZ?KC'ZUI0
M:M87*@PWMO)D<8<4 7\FC-1I(CC(92/4$&G97ICZ<4 .HS]>W:D&,9P/PI0>
MF>#0 F?K^5+DT8]*,"@ S1FDP/2EP,T !/U_*C/-' 'I1Q0 9^O;M1DT<48&
M?ZT &:*3 ]*7IG'% "?GGTS1^M+TZ"D.3TH 44M(*6@ HHHH **** $-)^//
MYBE/6DSCK0 M)G/0Y'M1R!^'UI30 G\Z/Y9SS1]!2_A0 F!WZT$XYY%+CVHZ
M&@!.G/IQT_E0<=2!Q2]\4UN00O7M^5 '+:JZP>/=$F5#^^AE@8XQSPP_K74K
MQ\M>0^/]<\0V?BJVM8)K41P 7<.V,%@<NHR>O3C%9,_Q"\7N=JWMO&N.0MNO
M/XT >Z9/'R\]2*16&,=AZ5X(/&OBW;D:Q@X[QJ?YBFMXG\2SE6N-;D>15V@A
M$'\@* /?@<^_X<&EYW'CMTKYT.J:S+*9'UO4@V!@17+1]/\ =XJLUS>D_)JF
MH'=PP>Y9J /I'.-H]\<&FO*%!9B H&22>E?,\T4S%!]KN'[C,C#'ZTB6<8&<
MR;^^&.#0!]&_VWIJH7;4K106Q\TX'\Z9<>(=)M8EDDOXV5ON^4V_/_?.:^>3
M#;LFV0 H?X?4_7--CM+=CQ$N!W/:@#WF;QWX:MYS#-JL4<N,D,C+_3V_2J%Q
M\4?"5JRA]1+%LX\N)F'XX'O7C M[8/Q" 1WW4LBQ$+F*,]N5% 'KX^+'A9N5
MNYW3'WQ;/C/XBH)/C!X8VN(I;IGYVJ82N[VSVKRLI$HP(P!CH.*C+B/@!@#Z
M'^E 'I@^,FF&9E.DZ@5_A="K9_ D$5'_ ,+>A#8_LJ8#WP#C\#7G$:@,6(!P
M>:D<J>A.1[T =]-\9#'(BPZ"9$;^]=!"/P*G\J>?BZ[0AUT&:,C&3YX<8]L8
MKSIY&C.%QSQUI[$Y*%0,+DYH ] C^+N2&DT>7)[C'/ZU,GQ?M0V&TN<'/J /
MSKS16X4YY#&GHNXEM^5QG% 'HC?&6!;CR_[#G9.S)< G^7]:M1_&31VVB32=
M45FXPJHP_,L*\R53YBCKGM4K8"AMHZ]0* /4C\6M 0+YEKJ4>>?G@4?KNJ&X
M^+VCHP$%K<2H5R2>#^7->7NSD[EP<>^* [R?-)_#P.: /3D^,.B,<RVMZF.H
M1-_^%.C^,?AMW*20ZG 1T,D(P1^!->4H6+,V<@GBG$YE7<,\YH ]BB^*WA6>
M2./[9<(TCA5#6S\Y_"MSQ.Y'AJZ;)^<(G_?3JI_G7@\<7FWVDH  #>1@X';=
MBO;_ !J4CT 2.&.RXA/ )Z..P]LT =&",<'CU_\ KTN/;O7.GQSX>4A6ORC'
M^$P29_E^-3Q^+_#\L0E75;4*3CYW"'KCH<'O0!MX)S2#^M9:>)-&D4LFJ69
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MP@"P//MN8W\I&52^#G'/![<55>YN=3UK2R^DWUNEO(\K/.$"C]V0.0Q[G]:
M-C4FQI-ZV<X@<CM@;:KZ,!%X9T\] MI'R.<804_76V^'=389XM)2,_[AIB8A
M\+(<X"6(_1* /GQD87=XT=Q<QE[F7_5R%1]_/2K":IK%O$(;;7M4B5!A$%RQ
M4<Y[_C582;FN3U+3/SG(ZG_ZU,AW&-AU(/)H W8_%_BR-1&-:9F08W/&#^9[
M]ZT9/B9XKBXVZ=*<G[T)XX]FXKCRQ1MV?XL'/I4NXE\#\: .YMOBYJRLHNM'
M@88^8PN5/X YK6MOC#I+2;+O3+ZV'!R%5P/R/]*\OV_O>>W:I"=IVE0>W(H
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M[IAG&><YK7A\!^,9H?,DTN")@2/+:89X^A(J8>!O%ZLB?V2C$_W9EP/KN(H
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M-AZG-LG]16CV]3Z?TI>XYH R&\-:*_']FVP_W%Q_+%1/X2TAAQ#,GNEU(/\
MV:MSO1C(H YQ_!=BWW+S4HO]R[8_SS5&Z\%QV\33VUSJ%Y>+L,/VFX#%,."<
M' [9Z^E=A^?^?\_K2G .: ,DZG?X.-%N6XZK-%W_ .!@UC:MK^HB$:>^DS0W
M=\A2 1W*[E)'4D=,'Z]*W-8U6+2;)IV'F2,=D,0)S)(1PH],U0T#1IHKN?6-
M10#4KI1YB<,(0,X53].I]J ,[01KVBZ<EK<:1<W4SRN\LINXR03TQDY/ &<U
M/?\ B"_CM$M7T.;[1>*T<2"5&YQSG'0#UXKI;JYBM+66XG(2.-"[$^@K \.0
MRZA-+K]Y&0]P-MM&QR88NP!]6ZGI0!G^'](N_#LLR6>CR3>:J&266YB!SC[J
M@#I^-;#ZOJ%M9R3W&DM#L4DM)<QA!Z?,3G]*W"5"DY'K^%<DDC^+=2#^7NT*
MW;(W#BZDZ#CKM&<^AH SK:VO];UF#Q%<Z1(;?"&&#[2N,#/S$-CU!&, X%;R
M:GXA:1E;PVH0 [6-\G(^@!YKH54(H"K@ 8 '\J,#TX_.@#G-3DUO4-)N[)='
M6.2>%HPS72$#(QZ>]7-:B=/"5[#%RXM&08/?;CJ*V.G_ ->D*AU*L 5(P0>0
M10!\N6]U!''L=AO#%6!/?\:MQE#%O#ID\L PKZ#F\,Z',I631=-?<,$M;)_/
M%9%Q\-_"\L;J-)BCW# *?*1GTH \0\D2'(;J1T/6GK"5.2V3GKFO2I/@SI;$
M;-7U!/[N O/Z55D^$%U;P-]F\0.[DG:CVPR1]=U '!,<2 C]*;(3(V1P370W
M7P\\6VUSY<%I]JCVY,@>)>?3!;/XU2NO"OBB"7+Z!=L$ZE,,#Q_LYS0!F/$Z
MH,R'/T'X5 V]E([9Y-3S+=PS*EUI]W!A<XDB8'Z\BJYNH&<A9 /2@"8,RISS
MQTJ-'V*5(.2<FI#(CKMC8,^,[<T!%X((9N#P: (XR79EY!;CBI2P1CS\P[4D
M:KOW;L$GKVH4#+ X)H B.))22JD'G %,2U0RL0"I[$<&I!_K&W<+C/)Z?X4X
M;F<!>-OZT &Z\LW#VVH7D!(Q\DK+^.,UIVGBGQ;8[777Y'C0_P"KF"ON]CD9
MK.FW[E#]=V:' Y89P>V>E ':6_Q6URWVK=:?:3)GETW!C^N/TK2@^,EA$I&H
MZ3?JQX'DJK+CW)8<]?TKSH/C)/(QQS4<;J(U5\DYSSS0!['8_%3PQ?3&$7,U
MN^TE?/A(' YY&173:7KNFZP&-A=QS;" P4X(_P XKYXV1R#+H",^E=[\&K9!
M<:W=<A@Z1XQP .: /2K[7--TVZAM[V]MK>6<902R!<XX[U=CE28*T;(ZMR"K
M9S].:\B^,"1G7=$$K95HG!0CW'^)KC4$UM&!9:A- K$EE1F7'ZT ?270GY>A
M]*:P1A\ZY&.K#./SKP6Q\6^(]+@"QZH)T3D";YN,].HXK?A^+&LHBFYTBSGS
M@9BD*9S^>#0!ZE-I.GRJ3)96S?[T8XK.G\)Z0ZD16S6YSNS"Q7^5<WI/Q4L+
MF1UU:U.G!<X;<TH/M\J?SKH8?&GAJ4#;KEFH'3S7\O/_ 'UC_(H C3P[>6F'
MLM;NQR3MG8.O/UYI[)XMBWE)=)N!U7>'0GCVR!6Y;W=O=)YEM/',G]Z-@P_2
MI&<+DMP/<<4 <\-4\06RO)>:1"R #YK:X#=?8@4YO%]G"=ES:7T#8YW09'Y@
MFMU70L &4G''O[T\KD$$#Z8_*@#-MO$6F7CQI!=QN[L%"9PV3[5JU6%A:>8L
MGV:'>AR&"#(/UJS0 4444 %%%% "$9^GI1W'%!Y-'Z4 (,_C0.G'3MBE]Z0^
MXX]Z %^OX<4=?_U4?SHZ_E0 =.G ^E'?O2=_UHXZ<<=J %Q[8IK<YZ\=A2G!
MZXYI>.,_K0!YM=_"V+6/$.J:GJ%_<1F>?=$D# #9C&&R#5Z+X3^'5 \UKN4@
MYSYN ?P%=WUZ_P Z,CIQ0!QT?PQ\*)DOIAD!QP9G'\B*T(O!'AF%=B:%9,I_
MYZ0AC^9YKH?PYZ4@.1P0: ,N#P]H\'^JTJTC ' \D=*MPV%G;G$-I!'M.0(X
MP,?E]*M4AZXZT - SSGCCG-.P!Q^'%'<\_I10 %>AXS2;0#TIW;Y<>E(  30
M FT$=>,4;1FE[]/S_P _YQ2\T -"@'_ZU*. ,#CVZ4M)[_AF@  V_='L*.<Y
MYI>O;\*3Z_B: .2^)=N+SP'J%NZ3,'"D+$NXY5@P'?N*\,CD<6\6^.5>#UC/
MU[U].S0QW$925%=#U5@"#^=5?['TPJ!]@ML#H!&./TH ^;FO;10=[@.!GD'F
MD.HVJ%2Q;G':OID6T*0^0$3RP,;-HQ^55)M"TBX(\W2[&4?[=NA'\J /G5Y&
MP&,$Z \@^6V#3OMENJ;9)2G..5/)_*OHM=&TY5 6PM0 < >2HX[=!0FD6$<P
MD2R@5QP&5 "* /FYM0LQPLRL?0=::FHVH54,FTX[]Z^EI=,LKG_CXM+>;_KI
M$K?AR/K51_"OAZ3EM!THGU-I&?Z4 ?.RZA;>8&$P+'IP>:ZWX9+%<^/O/CE4
M^3;-\N,$D^U>L+X2\/1RH\>A:=&Z\J1;J"#^ J_!IMI:S&2WMHXF(V[D7!Q0
M!;]/7TH'3IC'Y4O7D?IWI"?\^E !CVR?7%+]!1WYI#^(H ,^ASGI2\'@_B*0
M\@CC/I2^] " _CS103W_ *T=3SS0 N/PJGJ5_;Z782W=U(8X8ERQ'I[>_85-
M'<12LZ12(Y3[P1@<'T-9M]JVD,_V.ZGAFWD(R8W!2>F>N.E &?HEK<ZK.FMZ
MH%)89L[8G<L*GOTY8COZ&ND\R,$KN4E1N()Z#UKG9?$JI8M<0Q1+!',L8DW!
M@!T/RCD<@<>]+%97$K:HT2P);WJ!H[DLQ8*5Z$>W44 2>(9-'NHX(-0O%"1R
M"8Q+(/WF!P&'\0.1Q]*HOXLNKE VDZ9)(A)17?N1CY0!TX((R:;9:!X?NI$O
M8[J.Y7IY2R!D+XZ#N".  #QBM71-0L2196MF]HPC$AB*!0<':?Q&/Y4 /T\7
M^H6U['JT/D"5RJ(C](RO]X8SU-:5K:06-M';VT:QPQ@*JC@ 5,..V#_.COTH
M  1SR,=>M';D].]&?\FCIG Q^% !^!'O1COZ\T'@<<?AR:!WP:  <8' _P ^
ME+CUHS_^JDV_GZXYH .,>Q_*@ %>!@4O3-(>/J3^= !U)!]*3 W9#<^E._.D
M)YZ_@: (I;2WF.98(I&Q@%T!/YUE77A'P]>*PGT6Q;=U86ZJQ_$#-;>>!SQ0
M.G'Z4 <3=?"OPK<;VBL'MW(QF&5E _#./_UUES?!^Q\M4M=6NX0/4!@3^=>D
MX_3I1C)YH \@E^$NLI'(+?6K63)X6:-E_/ /\JQI/ _BRS1S_9\,[)D?NF8Y
MQZ<5[Q@$=.U!49SB@#YKN=+\0VFPWFA7L,9/WO*;D\^U4?MT"7+1RYB=>&#\
M8/OFOI\J'P2!@^V:HW6CZ;?*4N;"VG4G<=\0.3ZT ?.2W,,L@9+I&7T'0"GS
M-M56!W G'!ZU[Q<^!?#%T2SZ+9[C_$BE3^AKFM2^$>ESNKV5Y<6C Y;'S C\
M?2@#S!E1!GOT(J/8&;</6NXG^#^IB,_9==C=^,><A _2J%[\-_%EI&3$MG=D
M?\\YMK'_ +Z '% '-EMZX53N'M7IOP9MU'AB_N60>=->L"WJ%1,?KFN#G\->
M)[*W/VOP_.'Q]Z*17Q_WR3BO5?AO:/:>#+56C,;M\Y4KC)(!H X[XQ6K'6=#
MN-WR -'CTSDY_05Q;.[,F58?,Q4X';-=M\8I&&LZ&@P5*NS9..__ ->N%PT.
MPALY!P/,H D5OD8. -R''RTA<[L* ?N]5_S[TH4!"X4OA5&=XI@>1)-J%U#$
M8(H GW;S&#Y;@EMP=>,]*406DB-NBA4[#P<CFF1+,0J#?PI/W>]*YP,$,N5'
M5>O^?Z4 *C7,#M'9WUS;IN4@QW# +QTQG'/!_"M.#Q;XKL3BWUS?&.<3HC9P
M/4C-9<DI23:2.6&,1^@XIH\L*#))$<JQ*E"* .NM/B?XCMV,=U865VF,DQ J
M3[]<?I76^&?B1%X@UZ+2&TN>TN'1F)=\@%1DC%>2;P7^Y%&-@[5T/P^_>_$>
M%P!\L$A)4Y/W: /=!TI::G2G4 %%%% !1110 AHZ4'K1T- "#&*7ZX_.D^II
M: $YH^IX_G0?H32_J* #G'<^M(./>C /./SH]\\4 +FD YR /RQ2YI,=1QSZ
MC_.:  ?4^E&?K2]Z3@CW'K0 =.?T%+0<<YZ4GZGVH #^'Y4O?O1^/UI.?3-
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MDNI]UI-YIEB:$*5 RH&< G.5/X5TT=M!#N\J)$W,7)"]23G/Y\U+C&?U/<T
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MPH'/&*3>_&[:5*<$K@"G"!,=8R0P/(Z8H <P8SAD$BX8X^8&F;)&BP#*2@R
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M>P+7)9T<N& *C)SC/KZ5Z'Y*=,$=\$D4R/9_PD>A-(ZCYI@=Q_O+Q^.5'ZT
M<9)\,_&!7F326SW61A[C^&I6^&OB8HK.U@7QDJ&88]O>O9STQW-1D8;/K@T
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M?&^L:C!JD&G0:)87UK+"9/\ 2"1[$ YKBY]"L+HL9O"%M$S@Y,&I.FT^O -
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M6JO_  A]N3&ZZA=L\2X0NV0O0D#TSZ4 ;_D2GYC<.,\@A1G^50R(\ =WOQ$
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M\_\ C] 'KB^'[$3FX9)3,(O+#!SP,YX]\TW^P+,D9>? & I<#/\ G^E>3?\
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MG(.*7Z=: $]<GCUS1W/<TOX?2DSP#QB@ _#'XXI311^-  >M'O2=/I1GGU-
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MM$0<]_\ /%7^ .#@?RH 7I]*,C';\:/Y]3[4O/O0 G\_04'UZ4II,\9'/TH
M#P,YZ>IQ2]L_RHY'2D/N<<9S0 O^>E!Z<9_ 4G<=!Z4O4]: $^GX>E' /_UZ
M7/'K1SCB@ Z=:"*3C\Z.,_UH 7''_P!?--=MJEL9QV]:7T]:9+@0L3A< GCZ
M4 ?.WPSM6M/B'IQG8@@R Y]3$P[_ %KZ+7<5]_7UKP+PA\_Q+A4CA;F3[W;&
M1^G%>]B14P"0"<GD\F@"OJ+;+*5CQC!Y],\URENVZ-1QD#.,^U=+K N3I5RU
MK"DDX3Y5=L#\3Q7'6<6N1VJF>RT[>1\R^:.!]0: (HI/LWQ#T92%.^"<G(Y
MVD_S%<CHVE2?V'9W']J7D8G#%(PV N&(.WFMJ'^U&^(^CRWZ110_8KA8/))(
M(VD'KWYQ6;HNG:M!HUOMU9! VXQPM:KE%W$8R/O=,YXH T3IN54B_O" P+9(
M_P #6SX%L_LVOZG()9)3Y2!=_?YCGG\!60L.H1QG-_"Y/K%@?I6SX(2[7Q'J
M#W,\,JF%=NQ-O.?\B@#K-7@U&5K$Z?,(U2Y4W"G^.+N*U&.,]OZUA^(X5F?2
MP^I"QQ>JR@GF8\X0<CK6XPY!!Z&@#S3X@6D=UXITPEV&+8[@I.>&XS^=9ITJ
MQ.Y9(99"<95I6  ]>#6EX^LY9_%>G7$5X8=MNR.-@8=01Q^?Y51-K=[QLU-
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M')]1^5'UHQ[\T 'T^F*,_C]*4<#]/2CK0 'O_C1_.BC- "=S1QUQ^E+S2<4
M!]\TH/\ DTF?K2GH>/PH 3KBEZ__ *Z3WS^5+]: $[Y_6EH^M'UH .O(-&>!
MBC_/)HZ=N?04 % _*D/3L:7V&,T '^?6COUI.GL*/Q H H7(']JVCDX!5E^O
M2KXSM&3SW-4-13-Q9. -RW&<]ONGK^E7P.O./>@!>U(,<8I>O_UZ09QG/:@
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M%:['OZ_2@#SOQN]T/%EE#!81W ^S,V&E"]3W_+]:SXY=320$Z/"(\=KQ>3^
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MRUJRFBM;6P%LC+F69G4Y.<Y5:Q'^%7B^!?DN='DYZ+(^?U45[B(\?=X_S_\
MJI=O)Z_G0!X.OPU\8LSK);V*KU!$P.ZF'X;^*HQQ;VI_W9,_RKWCR@>RCV%&
MSCKG\: /#;7X:^*KM2SK8PX_@F:0$G\$-9.O>%O$'A>T6?5!:?9IF\I&A<L0
M2I/H/2OH?;R.I_&O-_C.0/#VF1@#F]!X]HW_ ,: -WX8H5\!Z=SSMS],@<5V
M'6N)^%";?A]8G).7D_,,1_2NVY(_PH .^.:!0>E)^N30 O/X4'D?_7H[]*0'
M-  ?I_6CTSS_ "HSZTN3GVH 3&!_6C\?UI2!G/&:/84 )[8Q^E'3I],T?S_.
M@^N.: #G'%+^5)@8Z TH_P \T )_2E'MTI/3_"C/X]Z %^E'XT<_X\4=?>@!
M#Z<TOM2 THS_ /J- "#US2]SVI!G'M1]* #OG/%'7CG]12_B:0_4_K0 O7L:
M3OP1F@?2C)/% "_C^M ^F/:@G\Z#SP>GUH 3GIS^-' Z8'X4=1Z_0XI<\T &
M?\@4G>BES0 #T Q[4G;&>M+QC';K1DCZT '?/]:.HQ^AH_.DH 7_ #UI.O!Y
MI<\=<4F!C'8T 4-2.V-)3RB.I;\Q5]<A0#UQTJKJ*;[)^<8(;\B*LH08P!TQ
M0 H&!^':@\^G\Z./3OSF@^] !^&,=/:E''M2>PSQ1P.G&.!Q0 N??%)WX_7G
M_/>ES2=/7./>@ [YS_GBEQ1T_P#KT=J #G-'XT=>O(Z?6D_SS0 <$'ISUI?R
MYHS1^= !_AZU'+P"?KC\J?P?2F2 ,N&SM/IUH \ \,9F^*5LQ .+ELXX^Z,?
MTKUK4HY4^(.A3$ QO;3Q=<$-@,3^@_.O*?"IBA^+I1!A#?3B/G/\3?TKUC4Y
M ?'V@1$_=MKIS^/E@4 :>O1O+HTRQW$D#':1+& Q7# \ \5S$*W;Q*CZU<.H
M3=S:Q\_E75ZP0-+F)Z8QFN9B "@Y[=.U &)$UPGC[29I+F:<?9)S^\B5-H5&
M&./?'6LW1!91:+80QPV^_P HD[@,]>/\FNAO1O\ %>G1A03_ &9<N-QXST_K
M7):-HNG-IEM//:,9VC)9C(<,<X./:@#H'A2X7#&VR>I; K;\(-#]MO8D2!72
M-5;RMHW=?3G_ "*YP:+IQ*LUHP[+MY%;/@72K2PU+4I85=20%VDGA<^A]Q_G
M- '5ZH=1 L_[/V8\]//+C.(_XL>]7VR?E[YZUCZ]:-=?V6%NUMVCOHW):0KO
M SE1@\D^A]ZV"O&2,D?AGZT >,_$EH#\1( 2%=+)'R>_S-67YT3*P9XSNX.<
M#-;_ ,1$A?QO 0!YPM3G<>W/K6"88Y3_ *N,C[WS8% #(IH8D!>6,*&SCCK7
M:_">>&;^W6C<-_I*G*CC&./Y5R$(AB8$QP%3SMR"/SKL_AE!#%<>()(0 KW$
M8PJ\#"'C]: /1EZ=_P 3FG4@I: "BBB@ HHHH 0T<X]*.]&/04 &3Q2#L/TI
M>OTHP: $!]R12/G SZ].U*.?4_A0W2@#Y^\>Q"V^(VHP+\J,L4G3[Q*#/ZY_
M.NN^"]R'TO5;<?*8[@%0S>H[#\JP/BA:[/'\,^X%)K<+M';;T_G^E2?"9Y!X
MVOX"VV%K)V(XP3O09^N/ZT >N:/'=PP3_;G)D:YE=-SYQ&6RO.>!C''Z5I$9
MQQ]*R]-BM8-2U%(;AWGDE26>(D8C9EXQQT('OTK4;@=* ,S0[F>YLW\^R-H8
MY7B1""N44X4@'VQ6GCG.!FL/1(M3M[O5Q?R%XOM1>U)?=^[(!Q[ 9'XYIVI:
MZ^GZI:Z?%8S74UPC.HB91M S_>(]#W_PH VQFFEL#)/3K7F=Y\7/+DN(8M$N
M0\,K198AL,#@Y Z?3-8US\8-615-KI<)."&$T; =L8(;Z_I0![)QCG (_2EW
MJ!RPQ]:\4'QEUQXU1="M%?IO\YL?E@_SJ5/B]K &7TFVSWVG('ZT >R%E)Y;
MCM@?Y_R*\N^-4V-.T9,XW7$A_P#'1W_&LB\^+^N)'&UII=GG!WB:-C],%6KG
MO$_C/5_%]O:VU_IMO;BW?S5>'=Z>_:@#U[X8QF/X>:8I'+>:Q_&5S77?_K-<
ME\-&+>!=.#-N !VG';K_ %KKO\D4 '3_ /72'/;]:,CU'O2]_P#Z] !T' ..
MM'X]32'MQ^%*?K0 9..E'\_>@"C/2@ HQZ\D4G0>E' _SUH ,@]Z7/&3GCFC
M';FD^OZ4 +S2<BCZX H/0].GKB@!>_>DQD<<GIUI:3MSZ>E "^W]:*,9-':@
M!!R!]/7-'49./6@=.?Y8I>>.U ![_P Z3D__ %Z7_P#7THH 3@^_M2_3FBD^
MOTH /?(]>N:,C/;CWY_SS2YYHSSB@ ]L]*!FDSQ_]:E[_I0 FX=<Y^E+WI#W
M_4TM !GUXHZ#KTI,TN..] !_/M29&,\ ?6C/]>M+GK0 AZ' YQ2_G2=#WHZ'
MG@?RH 4?YYH_G[T=>#24 5]0.+"?/382>.@I]J0;6#!_@'4^W^?RHN%\RWD1
MOXE(]*CT\EK"$\_= H LCC QCZ=J7FDR#_A2CUZYH .,Y]12=S_C2\=N_I29
M&,Y_,T +VST'7TI,#IZTO3)STHQ^M !^&*0Y&3U[XH/TI<4 )FE[]3FD[?3K
M1ZXY(]Z %[]/I2'!P>,>]&<<\ >XQ0.1Q0 ON,TUCVZ^O>G<\TUON$GKCM0!
M\\>!@_\ PLRQFFRF^ZE;G@Y97(_/->NWT,B_$/1;@E?+ELIXE7G((*L3].0,
M5Y3H$4:_%"RCC4+&MT"H4 #@>@KU/Q#XATC1M<LS=6E]<W\$;/']FB+[$<[2
M3SC'R_I0!K>)KFWMM N9KB;RHE S(5+8Y Q@?A7)VFJZ=(BYU>T/ Y(* _G7
M43WMOK/AC[9!$)(9D#!)XL]QU4CL0?RK%C6'RT"6EF !\H$* #\AZT 8MSJ-
MO>^/+!+.ZAG*:7.'$+Y'?C^5<]H5LJZ;#Y5XZ,R>848 X/&>.W6NF=$_X6/I
M.+:",3V5PDFV, $8STZ=N_;/K7FVG^)=6M!]A@%D88)&B5Y(02<'J3WH [86
M+$!CJ.HK)TRC[5_E6]X$@9-5U5VOI[A-D8_>MNQG=_A^E>=R>)]=DA5V&G1[
M'W*RV^>GX_TKK_A9K=_JFMZN+YH6Q!$?W400<,?_ (J@#N==.F%M,_M.1PWV
MQ#;E"1F3/RYQVR:VB05'O^58^O7EM:1V/GVOVEWNHTBPN[82>7_ 9K7*Y))Z
M>O2@#Q[XDVEO=>-XGEB.Y;4?-N/.2<$>W:L3^SK06Y\Z,L23GYBO%;GQ$20_
M$*&3SBL:Z<@QUY\QNW:L4V[M)EKF7;QT- $<=C;I#LAM@%'4!R:[?X3QPVG]
MLVD,115N%;[W3*CC\ZX>2!X),+>3*A[G'6NU^$@*MKXDG\V1;M!NQR1MH ].
M%+0.@HH **** "BBB@!#UHZ=A0>O3/%'K_.@!/3^=';T^E''4BCMV_.@ /T_
M6E^O2D^F/3%+_GI0!Y#\8+93JFD7 8@JKQD8X.>>OX5A_#&40>/(B[MMEMW0
M+C.3P?Z5UWQFBSH>G7+%E6*[ //JO>O/?"MZNE^--)O9"2N\Q@'C.Y64?J1^
ME 'N27EM;^+);)8&^UW%HL[R9X*JQ7&/;-;A[8K)N)YH]<L(TM%:*59/-FQ_
MJ]N"!GMD^_:M7@=>._)H R;.WM[37M0*3$R7*QS/$Q/R@;EW#ZX _"L;7&$?
MCK0#N(5TGC.>/F*\'/?[QK4G>SB\86ORS&]FLW56! 38&!P??)JKXH1M^D7,
M:#]SJ$>Y@?NHP(/ZM0!X1>D0>(M:02[U%[+\P.>K$_GS3"VT'<2 3P<=*O:M
M;+%XHUA<*A%X_P HZ50G R<9VCIQ0 CN 0/XOXLBD=>  3D^M,1,L,<G%/;+
MCY,DCG% #B&"8&",]:9D);RL0,;"-WX5('8%<C&>V.G^>*9&%=)-_P#=(]NG
M% 'NOPT>.3P'IIC;(V;?Q& ?U%=;^/N,5QGPH39\.-,(& S3-_Y%<?TKM*
MG'_UZ,<<T@/O1TYZ<=: %[T44$XH 3O1S]:4^GX4=^E "'_/-+1S2<=>,4 '
M7D?H:7%)T[_G1C/_ .J@ Z<GM^-+CFDXQSW]Z44 ']*,4GX4O^>E "=!ST]Q
MTHSZ8_.C@?2CH.OYF@ X/(I:0_YYQ2G\/QH 3]#[48_+ISFC'UQ2GO0 G4#G
M/]:7-'?&>:0\#.<<=Z %_"BC!]/UH]* $)QUH/'KTI:.O:@ ]3S11^%)V/.3
MTH .W^/%'7WH_,4?7\J #T'7ZTOMU(]:*3/X4  YHXS[TM% "=N>G\J7K_\
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M?1=[>+:A(EB$DDGW8^GU_F*PM:TNQN;C3;;5+!;U9;CC "+&VTG) Z]#S[4
M0_#/$?@.P1V 5=VWMC)W?S:NO\Q.S USL&M^&K:U2SBFB@B0A/+$3*JXXP>.
M!Q5J[U+1]/G,=U(L;",29*$K@G YH V<@\9]NM+],?A67&=,G(,%W&-V0OER
M@YP!G\L\U+#>HXE$$Z7'E/Y<FSJI]S0!?'7^M'X^PID<BR?,IRO3/O4G)]:
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M -[MW%'&<<?3%<\OC+PX\IC35H Z'!!RO?W'UI\_C#P_#@/JL*D@$=<GT[4
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M$1#&MSJZHQ)V,(G?!'J56L^^\<>$]6T\:5+KAD69E;SXU\LIM8$$[L8(QZ4
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M+%@^Q(I?L@W$^?,<]MY_QH GST[YXIW7M]15,V<BAMMW*">Y)./UI!;W0/\
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M5CC<[@@/4#/XFI;I)E$4=K!<32@&1Q'&S?*.<X Z8S55)59?,*@9&0,>WZ4
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M.\X_2O;OAD@C^'NE?[7FOUSG,C'^M &IXD>*+1;CS)4B5BHWN<#[U<ZMS;;
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M)\,)C<>!;%]NW:6C ]=IQG]*[+O_ $KC/A:GE?#S3ACJTQ_'S7_PKL\Y/44
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M$>3VKH/AN;M/&VK1W%O&BO:B08/?<H7\#S0!ZVG2G4U#D9IU !1110 4444
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M60XX;H34XT&_9&#>02,89I1_C0!3!MXXPP!*KGK^?]*:'0IY@4E#G:<'!QU
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M*(M?CB2%F:72IMC =" V?Y5P>CEDTN''VI5*CY77@_3CI0!-'-(I(-JQ;!(
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M1?9(E1V R&)X- %XH$9@HXSU':LS4$U"RU)WMW?RR@175>#P,UL7PCMKATW
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M7!_"@ /KBD&?_P!1H QV'X#'^>E+^N: $ZGG%!.!GG\.]';/;ZTCE@,\'D4
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M^N:">.O3UH /;/-+U_.BD[]>E  21[?C2X]S11C- !^E'?!Q2?08S2T )^M
MZ^M&?K2GGCZ4 '6D[CTH(R.?I0"/QH 49[TUP"O/3!SD=J7'' Q[4IYZ8ZT
M9T#RVEP89%00,?W;>YYQ_A6@,X'457NH%NX=I^\.48'H:+.?S(0&_P!8GRL,
M=Z +/MC]*3&/RH!R31C P!0 O3\*.:3()Z9- ^]TYH /I1QZFC/YT9'4]!0
M>YX[G-+ZT=.U(3^-  .WY?2CMQC\:4<\C]*3H.] !W''ZT=L]*.YYHSCC@>@
MS0 N?R_E1Z=?I2<=<]OTHS],_7- "XR,9HQD?7TH/U^F:,?7- "=\_UH]!2Y
MP.:/;^M "9[YXZT'(';CN>*,]^@'K2]Q_6@!.GO^.:!^/%+]:3CN<_TH .V,
M?UI>_>DZ]<9QS1Z_UH 7KVHZFD_S[T$\=>]  <$<].N:.,]/>E_&C_/TH C>
M!)%VNH(]P*RY;:3STMHYY%C(WR+G&%X&/\XK7]LUGWB31W,%W%DJ@*R #JN<
M_GF@"KK-OLT^&"WMYY#YL8W0$!E .23GMU_.L35;7Q!;ZE?&R^TR6\I62$QN
MIVON!P03P/O# ]172WER9-+N)+57>8Q'RP/O;L<=?>L'^U=:MX[../3YG'EH
MDTDT+,Q;."P"GG !.* '7NI:V$L9+>QNVD>W)GC$8VJQ'!!Y^8$=#Z]JCBUG
MQ##;QO/I4LS,Y#%86#$!5_A'3DGD\<'C@9DN/$.IVMJQBTR:XE:5@H-K(BH@
MXYZY/TJ'_A)]2-E,[Z3B6*11M*.%93G!'&>,4 7([1_$<MU;ZS9JUI%)&UN6
M@9"3R3C=SUK75_M"W%M<%8V *%4_NXZC-60^V)=Z[3CD>G'_ ->J$,7VN]N+
MM3A63R5;&?QQ_GI0!S&ERK8_"_3)3#/(/+0[($W-RQ.<4J7>86633]8B '&Z
MTY/?U_SBMB33O['\)6FGK()&MT2(,%QNZ<XJL+FXX/VB7(]30!SEQ=PW?C"W
M,$DSM'I%PL@DC*$=P O?O7GFF^6NGVR-L+LA( ;)_'\J]3N+L/XSL?/7=)_9
MLW)R?[Q.?RKQS1W'V;=&'^Z-QQG)H Z11$/E\N(Y')KLOA.D*_VZ4*!A<C<B
MMTXKSGS")&W/)R1M ''3N<^_O7=?" 1?;M;D1&+,T>UB>,?-[]3D?A0!?\9:
M6TM[9V.KZQ=3V=[+,R".S0M 0,J!M4L1C ./3GU'3^#4CC\+V:6]Q)<PIO2.
M26+8VU7( *\XQT_PKGO%VHOK>MVFBZ1K+6%U$[B4LLBB1BH*H&48/0]3^9&*
MZCPMIMUI7AVVLKWYITWE]K%@"79L9[XR/RH \\\<"'_A/)"1&[I;1Y\T \'Z
M_2L9[96)/E1@?[.!6MX_LH9O&[-P[?98V<,W3[P&/RK'738&AV&U4]^&(H L
M16$3 NT&X<@X']:V/ *10^.;Q;552-[50X4?>ZG^8KFH[.. NJQNH(.0KL?Y
MUT?PY@V>,]1 W$>0F=QSZ_XT >MKR,\?A3J:O(S3J "BBB@ HHHH 0YSTH'T
MH/7I2?B/6@ ST/7Z4O.>](,\=:./:@!2?>DQS^M&>/\ "@]10  8.,#'L*1A
M\A_IQ3N,G\J9*P6-FYX!.01_6@#B+JSNK35]1GNM%T^ZCFG#6][<RQQA/E&Q
M>A)P?SKA_B;*;K5-#O2PE$]D6.QMR@C&<'OSFNKG@TR^BM9X=#0WVM3EUBN9
MW<;5R=YP>!S].?2N5^($\USINE2M;10&VN9K,I"<H H4@@_CT]J %^%%TEIX
MTN[5BHDN8/ESW R3^N*]8#6$/BD1"W(O[BU+F7U16 Q^;5XIX#=(_B-IP=@N
M^-P.0-QQT]^AKVF_OYK77=+M(;+SDNA()9@.8@ #UZ<D]/:@#889!!&<CD>M
M9%O&8?$EZ'U&29IHDD2T?/[H D%EYZ'Z=:V <C)_G61=/8P^*+4/$WVZZMGB
M64=-BD-M/XG/2@";5]9T_0K3[7J=REO SA [@_>P3CCOP?RK@KKXP6@N"ECH
M]Q>PJ?\ 6^;Y8(Z' *Y_/UJQ\9;5KGP="RM@17BRMQG("L/YM7E:X\C$2A1V
MH [NX^)]C+KEIJ#:/>KY$<D?$B=6P<^_3VK#\=^,+;Q7%9PVEA/$;=G8O(?;
M&,>M<VK,58<GUJ6([DF&T8'0GITZ4 >R_"92/AW8L>KO*3_WV1_2NUQ7(_#
M*OP\TM=P)Q(6YZ$NQ_ \UUWM0 ?F.]'4\BC'MUYHQQC'% !GKU-+SSUI#Z_E
M2^] !^!I 1TI>]'M0 &DX]O2E_KWHZ]* #\.OM2<^A%''M0<]: %SSU_#-'/
M/!I#R"/PYHX/!Y'?- !WSW[4M!Z=S]*.] "8[8XZ8I>:3)]#^-&* #&?7FJ-
MR&@G6XBC9MQVO@XP/6KQ^G>FNFX\C(Z'/^?>@ 5E89'3J".E.' ]/TJI:H]L
M[V[R94',>?3N*N9]_P 10 F<\YX_G1CMBCUZYI?IB@ _$TF/PI><]#1Z4 %
M.>E'THH #]*.>>M(.WK[T'J.E "\Y[T=>AH/3\?3WH[?Y- !2<\]3[4>XH/(
MH 7Z=:3_ #P*/SI>] !T%)GWH[=Z6@!,'UI3Z8XI!_GM01GTH 4T?G_A1W/I
M2=^<_7TH ,4IX[TF3Z&E^G% !V[TF.<\YH]Z7MVH 3C@$C\:/Y?2C\<4O\Z
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MF2,1X  PI^3/L,'OBNC\+/:2:!$]C#)!;-/)M621G+#>WS9;GG&<F@#S;QS
M6^(DS"65$-O'D*V#G!-9,EM\^X7%QMP.4D/^-:/CVUNW^)$LB7*)$+6-MI3V
M^G7([GO6:XGW%([L]!GY: "W@F?DSSNO&"YR:W?AI]HA^(6I0&1GB^QF0EAS
MD,@ _4U@_8[\$,E^@;UP*Z7X;^9'XUO?M+F29K144JN ?FR<_E0!ZX!TY[4M
M(.F:6@ HHHH **** $/7M10>M)@=/7VZT '4YYQ_G_/X4<X'/ZT>^.>O% Z
M9_6@ Z]N:/UH]NM+S^- ![?UI&4,IR.HQ@TOXTAX4C P!T[4 <];^'M*T749
M-1^T21_(4B$TH\J 'DA >@.3QS7"_$Y-,_X1&%]%\LBVU%3(86W8+HQ//N=O
MTKI_$=G=ZA<9NX-(MH+:9C#)>S9\Y2,=.@Y/0UR_C+S)_!6LP-?:9<?9A;RC
M['%L6/YCGD$@G:/7M0!Q?AZ:.+Q=H,TF.+J-2<XSN.W)_.O?]1CO9#:FTEV[
M)T>4%L;H^XZ'OCCBOFH.\+V,R@EQ+&^[/N*^D==1)='F+WGV6$&-VG&,*%8-
MZ]\8_&@#4&2#CCFLO5+AH-2TO;9K.)9S&9L F'*$Y'ITYK2A99(E=6#*P!#
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MM+1WH 3IVXI:._\ ]>D/(]O>@!:0\C\.XS2\"DQS[_2@!:/RI,=!P,=*7O0
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M&Y 1]*E]\\4@Z<<^E $ M86+-Y29;JVT'/\ C^-2!"%PH"KZ+Q3^,]LYI<4
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MN!_.O5_B=;I+X%O7* B)D?DXQ\P&:\=LI$BO]-NMRHT5Q$X>0_*I# @GVZ4
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M4./ZT :]S<Q6D#3SN$5 -Q/8&GQRB2)74C# $9K*\3HS^&M0PW*Q,X]L#/\
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M42PJ&=2?NAAD5R?AG;-X-TAVYWQL21GDAB*?;6ZCQ'K[2$-O@M"H/&/E8?\
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M ,$=*GO?'&L:GIMY;G0[5//#P&2.X+;3TSC//K0!WNC2;K;2ECSL$$2KDX'
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MY;&1IE^,\$" BND\3ZE9P^,)T9[A)5A0?*F0>OOSUJBNL1$Y!NMW=C&3G\*
M,Y;YMNTZ=>^N1"3^%=1\-;DW%WKW^BS0_O(GQ+P?F4C_ -E_6LTZWA<!;U1_
M=5",_P!*U_ ^H_;==U<CSD#+$-MQ%AQM&.H^I_/K0!Z".M+2#_/%+0 4444
M%%%% "'K[4F>/UYXI2,\>M)P#G_ZU "G]12=_?I2^F?YTG7/6@ &!TZ4<?\
MUN*,\]:,CJ".: %QS[^M'?/]:3N/6EY_&@ [>GUH]?7M1^E'7WXZ4 ,<C&&
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M+QX+\1WFH3Z8JZ?#+%""5DN2<JQ']U2?S J6Y\#>)(M0M[.22RC%T6*;)F8
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MG/1@:M^(<_\ "/WY7[WDOWZ#!H \ITOP5XAU'1[6[@N;)HYXPP#H20ISP?\
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M=#_[**(?A/81*P.I7#Y/R[E'R_D:]#SG/MVS2Y- '"+\+/#Y0*\MZ9 .620
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M'4RA\0:-A3DB9L]#QM_QJ3Q,RQ^&;YB251 QX[!@:MSV'GZK:7AD(^RI(H7
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M^/\ ^JE[C% ""CKD=QQ1_GK1D8SGB@ .<]Q1Z_RS2X%'UH "/K0:3H/PI>:
M$[=?UHX'<?UI<4G4^_IF@ ."3S2]Z,9&,_I2=N10 8Y_&@<#CFC/!R?K1^!H
M .OKB@\YXI1Q28/(H 6C%'?W]J0<Y_.@!<\TGTHS@XZ4?H![4 'X&E]\X'O2
M?09Q2\>_ZT &.G_ZJ.OM2#K[T=CC!H .V<CCOFE&/QI,CN1TS^%';(Y^M !R
M?;\:7.?IZTG8@9X]/I03C/(_.@ Z<9Y_6EZDXH/;TS]*3KV_ 4 <3\5#_P 4
M<RG^*>/MZ'-5?A./^))=,&R6D'\C_C5KXI(#X0+$_=N(_P"=4_A)%LT+4),
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M#*PZ$&O//C7)M\$VW^W?HI^GER&NA\#ZF-3\)6DA(W1?NN#Q\N,?IBN?^,L
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MW&!_]>GZRGFZMH:$=+AGQ]$)H OZE?Q:;8O<SAV12%.WJ<D ?J:L"0,H8="
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M!T,LI^]<3?HY']*Y(_%7>77^P;LJQP"7"D_@:IZ-\03I5I]D&B7#CS99-QE
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M^NHC5(?M42>0H,8QM.3]/7\Z<VN:E>&V=]14&)]RG  !&<'N* .DUZYB.D7
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MK'&T8B0C<<8X[56WW\0 6&V)7^_*>?Z_K0!'=6FIL5:/5X/-0AX_,ML#(YY
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MW6+=[7Q/K%FQY2=U!/<9R#0![7\/Y?.\":.X))\C;G&.C$=OI6OHSWK6)_M
M;9A+(OW0 5#':< ^F/>N2^$]T)_ ZPY)^SSN@7/;(.?IG/ZUTVC[XM1U2*34
MHKG]\)$A#9>!". ?;T'84 :SC(QZ^U8WAR6)].>.#3S8)!/)$(/3#<D?7-;)
MY[ @54M!<B6Y2X3Y/-S$PZ[2 <?GG\J /"/&44>E_$'5(%<*LJ+/G9G<7 )_
M#.?RJ -#&PWN8BLF"WE'IC.:UOBG9-#X\CGPP6YMHU7!Z,"0?PY7\JR)'8ML
M:.<Y)8DGVH N^$YH[;QEHT^(T;SI%=R"ORN@&#GZDUZ]-XR\/P/MDU.'<<C
M#-^' ]J\)O#)91V]QY4K+'@D2 ;,^^??VKZ*L[#3[6/-G:6T(< _N8U7</P
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MCJ;F/Q;H*;25<7*D^GRJ1].E7/$;;/#6JMDY^R2XY_V2* )-(&W1K09Q^Z4
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M":T53K=]*RH=MHBC)YQNZ?G273+%JNE#"C]X<X'?'6H[1V_M?4B(W/F6L!!
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M /6I/R]Z&^H_[ZQ2]_?WH 3/J.GI2XYH_#]:3MR10  ].,"@_P"<FEI/SS0
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M'#<MQTR36KDX&!DGUKY[CU?7ED*QZU*!V  _PJ0Z]XD>,QKK5R 3U#X/Z8-
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M>3UK:H **** "BBB@!#UQS2 GV_ TI/.,T=_\: #\Z3)/(SC\*7V!_6DR!0
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M \[7X0Z6KL6U?5 ".BRH/_9:;_PI[1\875-3!SG_ %B'/_CM>CTG?K^?^?\
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MI.!_CVHQ@_\ UZ %_$$_6@].,TG3)YHR.A/]* %/0XI.<T< YX^M'T'3IQ0
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MI_C0.G.:0$'D<TM !V[8H]J3W_K1QM.< =Z #Z#']*7ISP!0.G'Z48Y_^M0
M<"BBFMP#UY]!0!R'C72DU;4-$BW6TDZ7#2);7+,$F50"PX! .!W!Z]#TJQX?
MTV[T^_UK4KVXA:6]D5_(@<ND04' R0/FP1GUQFL[Q3"FM312/::9>:39NP>6
M6_:'RY.A!*\#MR?7WIFF60T?PIKEW:V]O!%.K20O;7;7&0%Q]YN^1VH \6T^
M02:5NY^Z3S[DU]!> $V>!-'''_'N.E?/5B,:46X'[LYQZU]&>#4\OP=I2_\
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M>@ _STI.?_K4?09I>_M0 #&!C\Z3Z?C2]Z0>^?J: %Y [FCV_2@#C_ZU'6@
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MV.\T77$NY)GO7MRT1D!!W$CY2&'&1W7ISR >FR>(])CL;:^?48$MKH@0R,V
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M@$X% #B>O3-)WQUI<_X4?C0 #\:3'M2]:3H<]?RH 44M(.E+0 4444 %%%%
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MU &0GCOQ3'*21:.#R=L7WCZ\55A\7:O93K/'HNA)..1(MH0XSUY!'_UZVO\
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M/XH'''XB@#U%?'^AL1^]P?=D_P#BOK4R^.O#[ ;KY!GIG!_D:\@<L,!])O%
M/(-HW^%([PLV6T^= 3WB/- 'LT?C'P]*0%U. -Z$_P"?6K2>(]&D/RZG:#W,
MJC^=>%JUN'^:%U _Z9L*0_8!RZ*3GKL(Q0![VNLZ8_W=1M#])U_QJ4:A9MTN
MK<_]M5_QKY]*6##Y7 ]>2*DC6PP#YB_]]XH ^@/MML1D7$1^CBE%U">DL9/^
M\#7@:Q1*1BX*@CJD^/Y5(P8#B]N!QVG:@#WL/&W0J?Q%*&YQC\1TKP9);J/
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MP\<?NKD?]MB?YU"_PRT5L^7+=*#V\S-=M10!P,GPOL'&!?SA>N-N?ZU&/AC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>tm2226999d4_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2226999d4_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  )<# 2(  A$! Q$!_\0
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M7F=W\*?^8I_VS_\ 9JM?%(G^S=/&>#,QQ^%8^C7.H>!M4O[>?2IYX92 KKD
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HM,T:.2/3;"WM$D.YUAC"ACZG%7JBI/GFY(QKU%5J.:ZA11169B?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
